[
  {
    "model": "o3",
    "claim_id": "1352",
    "claim": "Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 1 explicitly states that the Aedes aegypti C-type lectin mosGCTL-1 \"is induced by WNV\". Induction implies an increase in expression (up-regulation) upon West Nile virus infection. None of the other cited papers address mosGCTL-1 expression, so they neither contradict nor weaken this evidence. Therefore, the available literature supports the claim that mosGCTL-1 is upregulated when mosquitoes are infected with West Nile virus."
    },
    "naive_doc_ids": [
      "12885341",
      "34287602",
      "38376189",
      "10559501",
      "23305884"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 1 reports that the Aedes aegypti C-type lectin mosGCTL-1 \"is induced by WNV\" and facilitates infection. Induction implies an increase in expression (up-regulation) upon West Nile virus infection, directly supporting the claim. The remaining cited papers discuss other aspects of West Nile virus or unrelated viruses and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "6144969"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 explicitly states that the Aedes aegypti C-type lectin mosGCTL-1 \"is induced by WNV\". This directly confirms that mosGCTL-1 expression is up-regulated upon West Nile virus infection. The other papers do not address mosGCTL-1 expression and therefore do not affect the conclusion. Thus, the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "12885341",
      "10559501",
      "34287602"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "53",
    "claim": "ALDH1 expression is associated with poorer prognosis in breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 directly investigates ALDH1 in 577 breast carcinoma samples and reports that immunohistochemical detection of ALDH1 expression \u2018correlated with poor prognosis.\u2019 This finding aligns with the claim that ALDH1 expression is associated with poorer prognosis in breast cancer. The remaining cited papers analyze other biomarkers (tumor-associated macrophages, PTEN pathway signatures, platelet indices, etc.) and do not address ALDH1. Therefore, the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "45638119",
      "313403",
      "15113221",
      "2931832",
      "3572885"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the cited papers examine aldehyde dehydrogenase-1 (ALDH1) expression in breast cancer or its relationship to clinical outcome. The evidence provided instead concerns smoking cessation in lung cancer, perinatal factors and breast cancer risk, \u03b21-integrin signaling, tumor-associated macrophages, drug approvals, lapatinib therapy, mutation burden in multiple myeloma, and effects of air pollution. Consequently, the supplied literature offers no information to confirm or refute the stated association between ALDH1 expression and breast-cancer prognosis."
    },
    "overthinking_doc_ids": [
      "7639744",
      "17450673",
      "23557241",
      "4820792",
      "32421068"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers discuss ALDH1 expression or its relationship with breast-cancer prognosis, so they neither confirm nor refute the claim."
    },
    "posthoc_doc_ids": [
      "7639744",
      "17450673",
      "23557241",
      "15113221",
      "31591262"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "114",
    "claim": "Anthrax spores are very difficult to dispose once they are dispersed.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.61,
      "justification": "Paper 1 shows that once Bacillus anthracis (anthrax) spores have been released into an indoor environment, they remain viable on surfaces and can be repeatedly re-aerosolized during ordinary office activity. This persistence and ease of re-suspension indicate that removing or neutralizing the spores after dispersion is challenging, thereby supporting the claim that anthrax spores are very difficult to dispose of once they are dispersed. The other cited papers do not address anthrax spore persistence or disposal and are therefore not relevant to the claim."
    },
    "naive_doc_ids": [
      "33872649",
      "2851611",
      "6121555",
      "12471115",
      "26341063"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "The provided evidence is not accessible (only 'Error' is given), so no assessment can be made regarding the claim."
    },
    "overthinking_doc_ids": [],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "The provided evidence is labeled only as 'Error' and does not include any content from scientific papers. Consequently, there is no information to assess whether anthrax spores are difficult to dispose once dispersed."
    },
    "posthoc_doc_ids": [],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "994",
    "claim": "Pyridostatin encourages proliferation of homologous recombination - defective cells.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 reports that treatment with the G-quadruplex stabilizer pyridostatin (PDS) \"reduces proliferation of HR-defective cells\" by causing DNA double-strand-break accumulation and checkpoint activation. This directly opposes the claim that pyridostatin encourages (increases) proliferation of homologous-recombination-defective cells. The other cited papers do not provide data on pyridostatin\u2019s effect on HR-defective cell growth, so the only relevant evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "13791206",
      "16472469",
      "52944377",
      "33370",
      "10169908"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 4 reports that the G-quadruplex\u2013stabilizing compound pyridostatin (PDS) \u2018reduces proliferation of HR-defective cells\u2019 by inducing DNA damage and checkpoint activation. This is the opposite of the claim that PDS encourages (increases) proliferation of homologous-recombination-defective cells. Other cited papers do not address pyridostatin\u2019s effect on HR-defective cell proliferation. Therefore, the available evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "13791206",
      "6710699",
      "12086599",
      "16472469",
      "9394119"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.76,
      "justification": "None of the cited papers mention pyridostatin or investigate its effects on cell proliferation, whether in homologous-recombination-defective cells or otherwise. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "posthoc_doc_ids": [
      "13791206",
      "38252314",
      "515489",
      "10169908",
      "32852283"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1364",
    "claim": "Venules have less significant tunica adventitia than arterioles.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the provided papers examine or compare the structure of the tunica adventitia in venules versus arterioles. The articles focus on topics such as mitochondrial dynamics, label-free DNA imaging, drug-eluting stents, endothelial function in arterioles, and electron-microscopy staining methods. Therefore, they supply no relevant evidence to confirm or refute the claim about relative adventitial thickness in venules and arterioles."
    },
    "naive_doc_ids": [
      "10698739",
      "20279166",
      "34268160",
      "1122279",
      "13790144"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.26,
      "justification": "None of the provided papers discuss vascular histology, venules, arterioles, or the comparative thickness of tunica adventitia. Therefore they offer no evidence relevant to the claim."
    },
    "overthinking_doc_ids": [
      "285794",
      "756887",
      "3112885",
      "2015126",
      "3870062"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the provided papers discuss or compare the structural characteristics (e.g., thickness or prominence) of the tunica adventitia in venules versus arterioles. The evidence is unrelated to the histological claim."
    },
    "posthoc_doc_ids": [
      "3690068",
      "45341480",
      "87758",
      "4983",
      "279052"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "992",
    "claim": "Pyridostatin deregulates G2/M progression.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the cited papers mention pyridostatin or examine its effects on G2/M cell-cycle progression. The evidence therefore neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "15473205",
      "10608822",
      "16839245",
      "14145440",
      "8734695"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 7 reports that treatment with the G-quadruplex-stabilizing compound pyridostatin (PDS) \"reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression.\" This directly states that pyridostatin causes deregulation of the G2/M phase of the cell cycle, matching the claim."
    },
    "overthinking_doc_ids": [
      "7506409",
      "9641846",
      "29851836",
      "15473205",
      "10608822"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the cited papers mention pyridostatin or present data on its effects on cell-cycle progression at the G2/M phase. Therefore, the supplied evidence does not allow verification of the claim that pyridostatin deregulates G2/M progression."
    },
    "posthoc_doc_ids": [
      "9038803",
      "33638477",
      "263364",
      "29851836",
      "12909503"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "277",
    "claim": "Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that the Commelina yellow mottle virus genome \"contains three open reading frames capable of encoding proteins of 23, 15 and 216 kD.\" These correspond to the three characteristic coding regions found in badnaviruses. This directly matches the claim. Papers 2 and 3 discuss other viruses and do not alter this conclusion."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "83667891"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 explicitly states that the genome of Commelina yellow (mellow) mottle virus contains three open reading frames on the transcribed strand that can encode proteins of 23, 15 and 216 kD, which are the hallmark ORFs found in badnaviruses. This directly matches the claim. The other papers discuss different viruses or unrelated topics and do not alter this conclusion."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "21230110",
      "751192"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that the Commelina yellow mottle virus genome (7,489 bp) contains three open reading frames on the transcribed strand that are \"capable of encoding proteins of 23, 15 and 216 kD.\" This matches the claim that ComYMV possesses three typical badnavirus ORFs encoding proteins of those sizes. The other cited papers discuss different viruses or topics and provide no contradictory data. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "14376683",
      "83667891",
      "37677954",
      "6517763",
      "8646760"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "659",
    "claim": "Ivermectin is used to treat lymphatic filariasis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.11,
      "justification": "None of the provided papers mention ivermectin or its use in treating lymphatic filariasis; therefore they offer no evidence to verify or refute the claim."
    },
    "naive_doc_ids": [
      "5912283",
      "6158879",
      "24634621",
      "3929361",
      "3578380"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.77,
      "justification": "None of the provided papers mention ivermectin or its use against lymphatic filariasis. The excerpts address nanoparticle vaccines, neglected-disease control in general, vascular biology, malaria elimination strategies, post-market drug safety, and ciclopirox pharmacokinetics, but they do not provide data or statements linking ivermectin specifically to treatment of lymphatic filariasis."
    },
    "overthinking_doc_ids": [
      "17327939",
      "1215116",
      "3896759",
      "3929361",
      "3578380"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.34,
      "justification": "None of the provided papers discuss ivermectin or its use (or non-use) in the treatment of lymphatic filariasis. Therefore they supply no evidence that can confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "3690068",
      "11109043",
      "11117498",
      "14118484",
      "409280"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "653",
    "claim": "Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 shows that IL-18 is highly expressed in human atherosclerotic plaques, especially in unstable (symptomatic) lesions, and concludes this cytokine has a major role in plaque destabilization. Paper 3 demonstrates mechanistically that IL-18 signaling contributes to atherogenesis in Apoe\u2212/\u2212 mice, because combined disruption of its receptor and a cooperating co-transporter markedly reduces lesion formation. Together these experimental and clinical data indicate that IL-18 is actively involved in the development and progression of atherosclerosis, supporting the claim. No paper presents data contradicting this role."
    },
    "naive_doc_ids": [
      "17421851",
      "22080671",
      "24384587",
      "52865789",
      "20659283"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 2 directly investigates interleukin-18 (IL-18) in experimental atherosclerosis. It states that interruption of IL-18 action \"reduces atherosclerosis in mice\" and that combined deficiency of IL-18 receptor and the Na-Cl cotransporter (NCC) protects Apoe\u2013/\u2013 mice from lesion development. The study concludes that NCC and IL-18 receptor collaborate in IL-18\u2013mediated inflammatory signaling and \"experimental atherogenesis.\" These results indicate that IL-18 is mechanistically involved in the development of atherosclerotic lesions, thereby supporting the claim that IL-18 plays an important role in the pathogenesis of atherosclerosis. The other cited papers do not provide contradictory data on IL-18 and atherosclerosis, so the net evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "6853699",
      "24384587",
      "854417",
      "2587396",
      "3205945"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers investigate or mention interleukin-18 in relation to atherosclerosis. They focus on other cytokines (e.g., IL-1, IL-6), cell types, or environmental factors. Therefore, the supplied evidence does not address the claim that IL-18 plays an important role in atherosclerotic pathogenesis."
    },
    "posthoc_doc_ids": [
      "22080671",
      "28149602",
      "1855679",
      "970012",
      "17123316"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "278",
    "claim": "Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 directly reports that the complete genome sequence of Commelina yellow mottle virus is 7,489 bp long. This is far larger than the claimed 2,140 bp, so the evidence refutes the claim."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "32770503",
      "152245"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1, which analyzes the complete genome of Commelina yellow mottle virus (CoYMV), states: \u201cAnalysis of the genome sequence indicates that the genome is 7489 bp in size.\u201d This figure is far larger than the 2140 bp claimed. No other provided paper gives a different genome size for this virus. Therefore, the evidence directly refutes the claim that the ComYMV genome consists of 2140 bp."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "152245"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Paper 1 reports that the complete genome sequence of Commelina yellow mottle virus (CoYMV) is 7,489 bp long, not 2,140 bp as stated in the claim. None of the other papers discuss ComYMV genome size. Therefore the available evidence directly refutes the claim."
    },
    "posthoc_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "32770503",
      "152245"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "650",
    "claim": "Integrating classroom-based collaborative learning with Web-based collaborative learning offers the best class performance.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.13,
      "justification": "None of the provided papers investigate or report data on combining classroom-based collaborative learning with Web-based collaborative learning or its effect on class performance. The evidence relates to antidepressant risks, integrated medical care, perioperative fluids, targeted cancer therapy, peer-review processes, computer-assisted medical education (without specific collaborative learning comparisons), immunology, and signal-transduction biology. Hence they give no relevant information to verify or refute the claim."
    },
    "naive_doc_ids": [
      "5691302",
      "15041758",
      "8814634",
      "13256155",
      "16979690"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "None of the supplied papers investigate or report on the effects of combining classroom-based collaborative learning with Web-based collaborative learning on class performance. The evidence provided concerns medical treatments, neuroimaging in depression, dietary assessment tools, lifestyle factors and mortality, etc., which are unrelated to instructional design or student performance in blended collaborative learning environments."
    },
    "overthinking_doc_ids": [
      "18025240",
      "1412089",
      "3202143",
      "15041758",
      "12789595"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the cited papers investigate or report empirical findings on the combination of classroom-based collaborative learning with Web-based collaborative learning and its effect on class performance. The papers cover topics such as memory in C. elegans, neuroimaging in late-life depression, hospital readmission models, MHC antigen presentation, computer-assisted learning in medicine (without outcome data), survey reliability, lifestyle factors in IVF, malaria control, and antidepressant risks. Therefore, they provide no relevant information to confirm or refute the specific educational claim."
    },
    "posthoc_doc_ids": [
      "3202143",
      "1412089",
      "7419612",
      "9278263",
      "12789595"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "375",
    "claim": "Elevated cell-free mitochondrial DNA levels are associated with mortality.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 reports that ICU patients who had elevated circulating cell-free mitochondrial DNA (\u22653,200 copies/\u00b5l) showed markedly higher odds of dying within 28 days of admission (OR 7.5, 95% CI 3.6-15.8 and OR 8.4, 95% CI 2.9-24.2 in two independent cohorts). Thus, higher mtDNA levels were statistically linked to increased short-term mortality. No other cited paper contradicts this finding. Therefore, the available evidence supports the claim that elevated cell-free mitochondrial DNA levels are associated with mortality."
    },
    "naive_doc_ids": [
      "1522647",
      "20459964",
      "9285396",
      "3776162",
      "3878434"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that intensive-care patients whose plasma cell-free mitochondrial DNA (mtDNA) levels were above 3,200 copies / \u00b5l had markedly higher 28-day mortality (odds ratio 7.5 and 8.4 in two independent cohorts). Thus elevated circulating (cell-free) mtDNA is statistically linked to a greater risk of death, directly supporting the claim. The remaining cited papers either do not examine mtDNA in relation to mortality or address unrelated biomarkers, so they do not alter this conclusion."
    },
    "overthinking_doc_ids": [
      "1522647",
      "11289247",
      "14021596",
      "20459964",
      "3619931"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 measured circulating cell-free mitochondrial DNA in two independent ICU cohorts and found that patients with elevated mtDNA (\u22653,200 copies/\u00b5l) had much higher odds of 28-day mortality (OR 7.5 and 8.4 in the two cohorts, p values \u226410\u207b\u2074). This directly demonstrates an association between elevated cell-free mitochondrial DNA levels and increased risk of death. The other cited papers address different biomarkers or types of mortality and do not contradict this finding. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "1522647",
      "14021596",
      "3899896",
      "4791384",
      "5612738"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1200",
    "claim": "The binding orientation of the ML-SA1 activator at hTRPML2 is different from the binding orientation of the ML-SA1 activator at hTRPML1.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.57,
      "justification": "Among the provided papers, only Paper 1 discusses ML-SA1 binding and it deals solely with hTRPML1; none of the papers examine ML-SA1 interaction with hTRPML2 or compare binding orientations between the two channels. Therefore the evidence set contains no information relevant to the claim."
    },
    "naive_doc_ids": [
      "3441524",
      "8331432",
      "4270992",
      "3610282",
      "1744752"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Among the provided papers, only Paper 6 discusses ML-SA1 binding and it deals solely with hTRPML1. None of the papers presents structural data or any description of ML-SA1 binding to hTRPML2. Therefore, the evidence set contains no information that could confirm or refute differences in binding orientation between hTRPML2 and hTRPML1."
    },
    "overthinking_doc_ids": [
      "6903077",
      "3610282",
      "4828984",
      "19708993",
      "799586"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "Of the provided papers, only Paper 5 addresses ML-SA1 binding and it concerns hTRPML1. None of the papers examine ML-SA1 binding to hTRPML2, let alone compare the binding orientations between the two channels. Consequently, the evidence set contains no information that can confirm or refute the stated claim."
    },
    "posthoc_doc_ids": [
      "799586",
      "4392608",
      "15472716",
      "40721190",
      "3441524"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "964",
    "claim": "Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The cited papers discuss spliceosome assembly, splice-site pairing, coupling of transcription to splicing, and general properties of the spliceosome, but none of the presented results examine or compare the biochemical stability/half-life of pre-mRNAs that are associated with spliceosomal components versus unassociated substrates. Therefore the provided evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "4067274",
      "12691537",
      "8065561",
      "30261663",
      "7860396"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.17,
      "justification": "None of the cited papers examine or compare the decay/stability of pre-mRNAs that are bound by spliceosomal components with that of pre-mRNAs that remain unbound. The studies focus on spliceosome assembly steps, transcription-splicing coupling, composition/dynamics of the spliceosome, or other unrelated cellular processes. Therefore, they provide no direct evidence for or against the claim about relative stability of spliceosome-associated versus unassociated pre-mRNAs."
    },
    "overthinking_doc_ids": [
      "4067274",
      "7860396",
      "21330280",
      "4444861",
      "5824955"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.28,
      "justification": "None of the cited papers compare the decay rate or stability half-life of pre-mRNAs that are bound to spliceosomal components with those that are not. They focus on splice-site selection, splicing cofactors, or unrelated topics (signal transduction, DNA/RNA binding, immune reconstitution, Alzheimer pathology, etc.). Therefore the provided evidence neither supports nor contradicts the stated claim."
    },
    "posthoc_doc_ids": [
      "3868322",
      "4067274",
      "10423989",
      "1225513",
      "8065561"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "399",
    "claim": "Exposure to fine particulate air pollution is relate to anxiety prevalence.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 (\u201cThe relation between past exposure to fine particulate air pollution and prevalent anxiety\u201d) examined 71,271 women and found that higher exposure to fine particulate matter (PM2.5) over several averaging periods was associated with significantly increased odds of having high anxiety symptoms (e.g., OR = 1.12 per 10 \u00b5g/m\u00b3 increase in 1-month average PM2.5; OR = 1.15 for 12-month average). This directly links fine particulate air pollution exposure to greater prevalence of anxiety. The other provided papers address different health outcomes and do not contradict this finding. Therefore, the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "791050",
      "471921",
      "1472815",
      "17930286",
      "15678772"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly examined the association between past exposure to fine particulate matter (PM2.5) and the prevalence of high anxiety symptoms in a cohort of 71,271 women. It reported significantly increased odds of high anxiety with higher PM2.5 exposure across several exposure windows (e.g., OR = 1.12 per 10 \u00b5g/m\u00b3 increase for the prior-month average, 95% CI 1.06\u20131.19). No other provided paper addresses air-pollution exposure in relation to anxiety. Therefore, the available evidence supports the claim that exposure to fine particulate air pollution is related to anxiety prevalence."
    },
    "overthinking_doc_ids": [
      "791050",
      "32357890",
      "1472815",
      "14682243",
      "24148722"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that among 71,271 women in the Nurses\u2019 Health Study, higher recent and medium-term exposure to fine particulate matter (PM2.5) was significantly associated with greater odds of clinically meaningful anxiety symptoms (e.g., OR = 1.12 per 10 \u00b5g/m\u00b3 increase in 1-month average PM2.5; OR = 1.15 for 12-month average). This directly demonstrates a positive relationship between fine particulate air pollution exposure and anxiety prevalence. The remaining cited papers focus on other mental-health or physical conditions and do not contradict this finding. Therefore the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "791050",
      "32357890",
      "42387637",
      "40666943",
      "18872233"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1105",
    "claim": "Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 directly examined the link between medical-school performance and later professional misconduct. In this matched case-control study of 59 doctors with proven serious misconduct versus 236 controls, failure of early or pre-clinical examinations was independently associated with later misconduct (adjusted OR 5.47, 95% CI 2.17-13.79; P < 0.001). This indicates that students who perform poorly in the early years of medical school have a substantially higher risk of professional misconduct in their subsequent careers. The remaining papers address other topics (attrition, cardiovascular risk, readmission, board certification, etc.) and do not refute this association. Therefore, the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "6710713",
      "17374970",
      "27466734",
      "7419612",
      "11624482"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 directly examined links between medical-school performance and later professional misconduct. In a matched case-control study of UK graduates, failing early (pre-clinical) examinations was independently associated with a much higher odds of subsequent serious professional misconduct (adjusted OR = 5.47, 95 % CI 2.17-13.79, P < 0.001). This indicates that students who perform poorly in the early years of medical school have an increased risk of later misconduct. No other cited papers address professional misconduct, and none contradict this finding, so the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "6710713",
      "17374970",
      "3878434",
      "40817021",
      "7602348"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly examined predictors of later professional misconduct among physicians and found a strong independent association between early academic difficulties (failure of early or pre-clinical examinations) and subsequent serious professional misconduct (odds ratio \u2248 5.5, P < 0.001). This aligns with the claim that students who perform poorly in the early years of medical school are at increased risk of later misconduct. The other papers do not address professional misconduct, so they neither add nor detract from this conclusion. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "6710713",
      "17374970",
      "313394",
      "5433667",
      "45638119"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "798",
    "claim": "Mitochondria play a trivial role in calcium homeostasis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 3 (\u201cMitochondria as sensors and regulators of calcium signalling\u201d) states that Ca2+ uptake into energized mitochondria is of \u201cutmost physiological relevance\u201d and that mitochondria actively control intracellular Ca2+ signalling, metabolism, and cell survival by buffering cytosolic Ca2+. This demonstrates that mitochondria have a major, not trivial, role in calcium homeostasis. None of the other cited papers provide evidence that diminishes this role. Therefore, the evidence refutes the claim that mitochondria play a trivial role in calcium homeostasis."
    },
    "naive_doc_ids": [
      "19205437",
      "3619931",
      "5094468",
      "8453819",
      "4951831"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers examine mitochondrial involvement in calcium regulation; they focus on circadian genes, chemokine signaling, FoxO factors, miR-29, and STIM1-mediated store-operated Ca\u00b2\u207a entry. Therefore they supply no evidence for or against the claim about mitochondria's role in calcium homeostasis."
    },
    "overthinking_doc_ids": [
      "8816869",
      "12058271",
      "16728949",
      "4653837",
      "7736860"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.74,
      "justification": "Paper 7 (\"Mitochondria as sensors and regulators of calcium signalling\") explicitly states that mitochondrial Ca2+ uptake controls intracellular Ca2+ signalling, buffers cytosolic Ca2+ levels, and influences cell metabolism and survival. This indicates that mitochondria have a major, not trivial, role in calcium homeostasis. The other cited papers do not address mitochondrial involvement in calcium regulation, so they do not alter this conclusion. Therefore, the available evidence refutes the claim that mitochondria play only a trivial role in calcium homeostasis."
    },
    "posthoc_doc_ids": [
      "12058271",
      "19205437",
      "28724565",
      "9878167",
      "13283919"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "823",
    "claim": "N348I mutations cause resistance to zidovudine (AZT).",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly examines the N348I mutation in HIV-1 reverse transcriptase and shows that introducing N348I into molecular clones reduces zidovudine (AZT) susceptibility by 2- to 4-fold, demonstrating that the mutation confers resistance to AZT. None of the other cited papers provide data that contradict this finding; they are either focused on NNRTI resistance or unrelated topics. Therefore, the available evidence supports the claim that N348I mutations cause resistance to zidovudine."
    },
    "naive_doc_ids": [
      "15319019",
      "2319305",
      "6426919",
      "25014337",
      "2647374"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 1 specifically examined the N348I substitution in HIV-1 reverse transcriptase and reports that introducing N348I into molecular clones \u2018decreased zidovudine susceptibility 2- to 4-fold in the context of wild-type HIV-1 or when combined with thymidine-analogue mutations.\u2019 A reduction in drug susceptibility of this magnitude is widely interpreted as antiviral resistance. None of the other cited papers contradict this finding; they are either unrelated to AZT or focus on different mutations. Therefore, the available evidence supports the claim that the N348I mutation confers resistance to zidovudine (AZT)."
    },
    "overthinking_doc_ids": [
      "15319019",
      "9505402",
      "25014337",
      "2319305",
      "6426919"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 explicitly examines the N348I mutation in HIV-1 reverse transcriptase and shows experimentally that introducing N348I into molecular clones decreases zidovudine (AZT) susceptibility by 2- to 4-fold, i.e., it confers measurable resistance to AZT. No other cited papers contradict this finding. Therefore the available evidence supports the claim that N348I mutations cause resistance to zidovudine."
    },
    "posthoc_doc_ids": [
      "15319019",
      "9505402",
      "25014337",
      "2319305",
      "6426919"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1008",
    "claim": "RUNX is not expressed in skin tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.69,
      "justification": "Among the cited papers, the only ones involving RUNX (Paper 3) examine RUNX1 activity in hematopoietic cells, not in skin. The skin-related papers (1, 2, and 4) discuss other genes and do not mention RUNX expression. Therefore, the supplied evidence neither demonstrates nor refutes RUNX expression in skin tissue."
    },
    "naive_doc_ids": [
      "19343151",
      "1346695",
      "12315072",
      "12580014",
      "19238"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "Among the supplied paper abstracts, only Paper 2 discusses RUNX (RUNX1), and it does so in the context of hematopoietic cells, not skin. The other papers deal with skin biology but do not mention RUNX expression, or they discuss completely different systems. Therefore, the provided evidence neither confirms nor refutes the statement that RUNX is not expressed in skin tissue."
    },
    "overthinking_doc_ids": [
      "31141365",
      "12315072",
      "12580014",
      "19238",
      "663464"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the cited papers mention RUNX genes or examine their expression in skin tissue. Therefore they provide no evidence for or against the claim that RUNX is not expressed in skin."
    },
    "posthoc_doc_ids": [
      "33535447",
      "12580014",
      "1507222",
      "13368032",
      "32720933"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "249",
    "claim": "Chenodeosycholic acid treatment reduces whole-body energy expenditure.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 2 directly investigates chenodeoxycholic acid (CDCA) in humans and reports that oral CDCA treatment for 2 days \"resulted in increased BAT activity\" and that \"whole-body energy expenditure was also increased upon CDCA treatment.\" This experimental finding is opposite to the claim that CDCA reduces whole-body energy expenditure. The other cited papers do not address CDCA\u2019s effect on whole-body energy expenditure. Therefore, the available evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "24917562",
      "1568684",
      "25050364",
      "15925931",
      "13902570"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines chenodeoxycholic acid (CDCA) treatment in humans and reports that, after 2 days of oral CDCA administration, whole-body energy expenditure increased, not decreased. No other provided paper addresses CDCA and energy expenditure. Therefore, the available evidence contradicts the claim that CDCA treatment reduces whole-body energy expenditure."
    },
    "overthinking_doc_ids": [
      "1568684",
      "10883736",
      "13958154",
      "2030623",
      "1818578"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that oral chenodeoxycholic acid (CDCA) supplementation in humans increased brown adipose tissue activity and led to an increase\u2014not a reduction\u2014in whole-body energy expenditure. No other cited paper provides evidence indicating a decrease in energy expenditure after CDCA treatment. Therefore, the available evidence opposes the claim that CDCA treatment reduces whole-body energy expenditure."
    },
    "posthoc_doc_ids": [
      "1568684",
      "25050364",
      "13902570",
      "24917562",
      "87758"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "480",
    "claim": "Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 reports that endothelial-specific conditional knockout of Gpr124 in adult mice 'resulted in BBB disruption and microvascular hemorrhage in mouse models of ischemic stroke,' whereas normal (Gpr124-intact) mice maintained BBB integrity. The observation that loss of Gpr124 leads to breakdown implies that the presence of Gpr124 suppresses or prevents BBB breakdown during ischemic stroke. The other cited papers discuss metformin, HIV, or alphaE-catenin and do not address Gpr124, so they neither contradict nor weaken this conclusion. Therefore the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "6325527",
      "3761017",
      "27602752",
      "5503194"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 reports that endothelial-specific conditional knockout of Gpr124 in adult mice causes blood\u2013brain barrier (BBB) disruption and microvascular hemorrhage in mouse models of ischemic stroke, whereas normal Gpr124 signaling maintains BBB integrity. Thus, the presence of Gpr124 suppresses BBB breakdown under ischemic stroke conditions, directly supporting the claim. The other cited papers do not address Gpr124, so they neither contradict nor add to this conclusion."
    },
    "overthinking_doc_ids": [
      "6325527",
      "3761017",
      "14753395",
      "371289",
      "3984231"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Paper 1 reports that endothelial-specific conditional knockout of Gpr124 in adult mice causes blood\u2013brain barrier (BBB) disruption and microvascular hemorrhage in a mouse model of ischemic stroke, whereas normal (wild-type) mice maintain BBB integrity under the same ischemic conditions. This indicates that the presence of Gpr124 suppresses BBB breakdown during ischemic stroke. No other cited papers address Gpr124, and none contradict this finding. Therefore the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "6325527",
      "3761017",
      "14753395",
      "3984231",
      "7157436"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "747",
    "claim": "MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.17,
      "justification": "None of the provided papers discuss MafA, its ubiquitination status, or its interaction with the P/CAF co-activator. Therefore they neither support nor contradict the stated claim."
    },
    "naive_doc_ids": [
      "6455142",
      "2714623",
      "16745747",
      "12225214",
      "22036571"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the provided papers mention MafA, P/CAF, or examine how MafA ubiquitination affects P/CAF recruitment. Therefore they do not provide evidence to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "12225214",
      "21307488",
      "23513818",
      "207972",
      "4270992"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the provided papers mention MafA, its ubiquitination status, or its ability to recruit the co-activator P/CAF. The cited studies focus on unrelated proteins and pathways (e.g., A20 in glioma stem cells, E2F\u2013Tip60 interactions, Nck recruitment by CD3\u03b5, Mcl-1 ubiquitination, p53 ubiquitination, etc.). Therefore, they do not provide evidence that supports or contradicts the specific claim about MafA ubiquitination affecting P/CAF recruitment."
    },
    "posthoc_doc_ids": [
      "33370",
      "502591",
      "2714623",
      "23513818",
      "21307488"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "267",
    "claim": "Cognitive behavioral therapy is an ineffective treatment for insomnia",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 directly investigates cognitive behavioral therapy for chronic primary insomnia in older adults and finds that CBT produced significant short- and long-term improvements in sleep efficiency, wake time, and slow-wave sleep compared with both zopiclone and placebo. The authors conclude that CBT is superior for managing insomnia. This evidence shows CBT is effective, which contradicts the claim that it is ineffective. The other cited papers do not address CBT for insomnia, so they do not alter this conclusion."
    },
    "naive_doc_ids": [
      "5912283",
      "6191684",
      "19878070",
      "4883040",
      "7639744"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 1 directly examines cognitive behavioral therapy for chronic primary insomnia and reports that CBT produced significant short- and long-term improvements in sleep efficiency, wake time, and slow-wave sleep\u2014outperforming both active drug (zopiclone) and placebo. This demonstrates that CBT is effective, not ineffective, for treating insomnia. The remaining cited papers do not address CBT for insomnia. Therefore, the available evidence refutes the claim."
    },
    "overthinking_doc_ids": [
      "5912283",
      "4883040",
      "25493293",
      "19878070",
      "34369306"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 directly tests cognitive behavioral therapy (CBT) for chronic primary insomnia. It shows that CBT produced significant short- and long-term improvements (greater sleep efficiency, less wake time, more slow-wave sleep) and was superior to both a hypnotic drug (zopiclone) and placebo. These findings demonstrate CBT\u2019s effectiveness for insomnia, which opposes the claim that CBT is ineffective. The other cited papers address headaches, statins, pregnancy interventions, etc., and do not bear on insomnia. Therefore, the available relevant evidence refutes the claim."
    },
    "posthoc_doc_ids": [
      "5912283",
      "24865781",
      "1287809",
      "11360768",
      "16964262"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "13",
    "claim": "5% of perinatal mortality is due to low birth weight.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the cited papers quantify what proportion of perinatal (or neonatal) mortality is attributable to low birth weight. Some discuss predictors of neonatal death (paper 1) or the incidence of perinatal mortality (paper 3), and others address unrelated topics (temperature-related deaths, lifestyle factors, depression and low birth weight, etc.), but none report that 5 % of perinatal deaths are caused by low birth weight or provide data from which this percentage can be derived."
    },
    "naive_doc_ids": [
      "1263446",
      "4810810",
      "7662395",
      "26611834",
      "1456068"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "None of the cited studies quantify the percentage of perinatal mortality attributable specifically to low-birth-weight infants. They either examine unrelated adult outcomes (Paper 1), risk factors for low birth weight (Paper 2), pharmacologic therapy for ductus arteriosus (Paper 3), overall perinatal mortality rates without specifying causes (Paper 4), or determinants of neonatal mortality without providing a proportion of deaths due to low birth weight (Paper 5). Therefore the evidence neither confirms nor refutes the claim that 5 % of perinatal mortality is caused by low birth weight."
    },
    "overthinking_doc_ids": [
      "5487448",
      "26611834",
      "34544514",
      "7662395",
      "1263446"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.79,
      "justification": "None of the eight provided papers quantify what proportion of perinatal (or neonatal) deaths are attributable to low birth weight, let alone give the specific figure of 5%. They discuss determinants of neonatal mortality, overall perinatal mortality rates, risk factors for low birth weight, and other unrelated topics, but do not supply data linking 5 % of perinatal deaths specifically to low birth weight. Therefore the claim cannot be verified or refuted from the supplied evidence."
    },
    "posthoc_doc_ids": [
      "1263446",
      "7662395",
      "34544514",
      "5487448",
      "26611834"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "676",
    "claim": "LRBA prevents CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the cited papers mention LRBA, CTLA-4, or the recycling of CTLA-4. The evidence provided discusses other proteins, pathways, and cellular processes unrelated to LRBA-mediated regulation of CTLA-4 recycling, so they neither support nor contradict the claim."
    },
    "naive_doc_ids": [
      "23702805",
      "11250124",
      "18678095",
      "35085326",
      "3152612"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.91,
      "justification": "None of the provided papers discuss LRBA or its role in CTLA-4 recycling. The evidence focuses on unrelated topics such as macrophage polarization, telomere maintenance, kinetochore dynamics, ESCRT-II\u2013mediated receptor sorting, CD28/ITK signaling in Ctla4-/- T cells, and autophagy of nuclear lamina. Therefore, the claim that LRBA prevents CTLA-4 recycling is neither supported nor contradicted by the supplied literature."
    },
    "overthinking_doc_ids": [
      "164985",
      "213017",
      "493346",
      "9680193",
      "2462673"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "Among the provided papers, only Paper 4 mentions CTLA-4 and it discusses T-cell trafficking in Ctla4-/- mice with no reference to LRBA or to CTLA-4 intracellular recycling. None of the other papers address LRBA, CTLA-4, or their trafficking pathways. Therefore, the supplied evidence does not contain information relevant to the claim that LRBA prevents CTLA-4 recycling."
    },
    "posthoc_doc_ids": [
      "11250124",
      "14893425",
      "797114",
      "2462673",
      "2481032"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1237",
    "claim": "The most prevalent adverse events to Semaglutide are cardiovascular.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The only paper that reports adverse-event frequencies for semaglutide (Paper 1) states that \"mild to moderate gastrointestinal events were most common.\" It does not report cardiovascular events as the predominant adverse events. The other cited papers deal with different drugs or cardiovascular outcomes unrelated to semaglutide safety. Therefore the evidence refutes the claim that cardiovascular events are the most prevalent adverse events associated with semaglutide."
    },
    "naive_doc_ids": [
      "3654468",
      "8756719",
      "32353339",
      "6070278",
      "2492146"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.77,
      "justification": "The trial that reports on semaglutide safety (Paper 2) states that \u2018mild to moderate gastrointestinal events were most common\u2019 among adverse events, with no indication that cardiovascular events were the predominant side effect. Therefore, the evidence opposes the claim that cardiovascular events are the most prevalent adverse events associated with semaglutide."
    },
    "overthinking_doc_ids": [
      "11254040",
      "3654468",
      "42404093",
      "202259",
      "6070278"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.79,
      "justification": "The only paper discussing adverse events with semaglutide (Paper 7) reports that the most common adverse events were mild-to-moderate gastrointestinal events. No cardiovascular adverse-event predominance is described. The other papers discuss cardiovascular events in different contexts or other drugs and provide no information on semaglutide safety. Hence the evidence opposes the claim that cardiovascular events are the most prevalent adverse events to semaglutide."
    },
    "posthoc_doc_ids": [
      "6070278",
      "46277811",
      "4445629",
      "11254040",
      "583260"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "617",
    "claim": "Increased mobility of retrotransposons is assosciated with mutation and higher tumorigenesis rates.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the cited papers report on the activity or mobility of endogenous retrotransposons (e.g., LINE-1, Alu, SINE, ERV) or examine how their mobilization correlates with mutation burden or tumorigenesis. The studies instead focus on chromosomal doubling, mismatch-repair defects, KRAS alterations, general somatic mutation load, angiogenic signaling, epigenetic therapy, and experimental Sleeping Beauty transposon mutagenesis (used as a tool, not as naturally mobile retrotransposons). Therefore the provided evidence neither supports nor contradicts the specific claim about retrotransposon mobility driving mutations and cancer."
    },
    "naive_doc_ids": [
      "7211056",
      "11271123",
      "3210545",
      "3572885",
      "9767444"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.35,
      "justification": "Among the cited papers, Paper 1 documents that highly active LINE-1 retrotransposons generate inter-individual genetic variation, but it does not examine cancer incidence. Paper 2 shows that experimental mobilization of the Sleeping Beauty DNA transposon can accelerate liver tumorigenesis, yet this element is a cut-and-paste DNA transposon, not a retrotransposon. The remaining papers discuss mutations, tumor suppressors, or signaling pathways unrelated to retrotransposon activity. Consequently, the provided evidence does not directly demonstrate that increased mobility of retrotransposons per se is associated with a higher mutation burden leading to elevated tumorigenesis rates."
    },
    "overthinking_doc_ids": [
      "13949015",
      "11255504",
      "22975806",
      "12762485",
      "24144677"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.18,
      "justification": "None of the provided papers examine retrotransposon mobilization or relate its activity to mutation load or tumorigenesis. The studies focus on receptor polymorphisms, KRAS alterations, histone mutations, whole-genome doubling, metabolic effects of diet, mitochondrial dysfunction, PPM1D mutations, iPSC mutational load, and germ-line chimaeras\u2014topics that do not provide data on retrotransposon mobility. Therefore, the evidence set neither supports nor contradicts the stated claim."
    },
    "posthoc_doc_ids": [
      "3127341",
      "3210545",
      "12887068",
      "7211056",
      "6327940"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "109",
    "claim": "An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the cited papers examine macrophage polarization state (M2-like versus M1) in brown adipose tissue after cold exposure. The articles focus on adipocyte gene expression, lipolysis, atherosclerosis, mural pre-adipocyte contribution, estrogen\u2010driven macrophage activation in skin, SOCS1 regulation of LPS signaling, curcumin effects, obesity-induced ATM changes, or uncoupling proteins in cachexia. Therefore, they provide no direct evidence for or against rapid induction of an M2-like phenotype in brown-fat macrophages by cold exposure."
    },
    "naive_doc_ids": [
      "29381091",
      "970012",
      "32955023",
      "20460020",
      "5798227"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 4 reports that exposure of mice to cold \"rapidly promoted alternative activation of adipose tissue macrophages.\" Alternative activation (IL-4\u2013stimulated) is the classical description of an M2-like macrophage phenotype. These alternatively activated macrophages were detected in brown adipose tissue and were functionally important for cold-induced thermogenic responses. The other listed papers discuss cold exposure, brown fat, or macrophage biology but do not address macrophage polarization in BAT; none contradict Paper 4. Therefore the available evidence supports the claim that an M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure."
    },
    "overthinking_doc_ids": [
      "29381091",
      "970012",
      "1568684",
      "4319174",
      "22621251"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers analyze macrophage polarization within brown adipose tissue after cold exposure. They address cold-induced gene changes in adipocytes (Paper 1), cardiovascular effects of cold (Paper 2), bile-acid activation of BAT (Paper 3), obesity-related macrophage polarization (Paper 4), a protocol for measuring BAT mitochondrial respiration (Paper 5), and macrophage self-maintenance (Paper 6). None of these studies report that cold exposure rapidly induces an M2-like phenotype in BAT macrophages, so the supplied evidence neither supports nor contradicts the claim."
    },
    "posthoc_doc_ids": [
      "29381091",
      "970012",
      "1568684",
      "43192375",
      "40232172"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "903",
    "claim": "PD-1 triggering on monocytes reduces IL-10 production by monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 directly examines the effect of PD-1 engagement on monocytes. It reports that ligation of PD-1 on monocytes by PD-L1 \u2018induced IL-10 production,\u2019 i.e., increased rather than decreased IL-10 output. No provided paper shows PD-1 triggering lowering IL-10 in monocytes, and Paper 1 presents clear experimental data in the opposite direction. Therefore the available evidence contradicts the claim that PD-1 triggering reduces IL-10 production by monocytes."
    },
    "naive_doc_ids": [
      "10648422",
      "5752492",
      "2543135",
      "9334631",
      "27093166"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly examines the effect of PD-1 engagement on monocytes and reports that ligation of PD-1 by PD-L1 \"induced IL-10 production\" by the monocytes. This demonstrates an increase\u2014not a reduction\u2014of IL-10 after PD-1 triggering. None of the other cited papers address PD-1\u2013dependent regulation of IL-10 in monocytes. Therefore, the available evidence runs counter to the claim that PD-1 triggering reduces IL-10 production."
    },
    "overthinking_doc_ids": [
      "10648422",
      "13902570",
      "275294",
      "5752492",
      "2543135"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1 directly investigates PD-1 signaling in monocytes and shows that engagement (triggering) of PD-1 by PD-L1 \"induced IL-10 production\" in these cells. This demonstrates an increase, not a reduction, of IL-10 after PD-1 triggering. The other cited papers do not address PD-1\u2013dependent regulation of IL-10 in monocytes. Therefore the available evidence opposes the claim that PD-1 triggering reduces IL-10 production by monocytes."
    },
    "posthoc_doc_ids": [
      "10648422",
      "13902570",
      "6212802",
      "5752492",
      "7386360"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "962",
    "claim": "Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 identifies \"mitochondrial RNA granules\" that contain nascent mitochondrial RNA together with RNase P and shows that cleavage/processing of primary mitochondrial transcripts occurs in these granules. Paper 5 shows the RNA-binding protein GRSF1 localizes to the same granules and is required for post-transcriptional steps such as RNA stability and ribosome loading. Paper 6 explicitly demonstrates that mitochondrial RNA granules are centers of post-transcriptional RNA processing and ribosome biogenesis. Together these studies provide direct experimental evidence that post-transcriptional handling (processing, stability control, ribosome assembly) of mitochondrial transcripts occurs within mitochondrial RNA granules, supporting the claim."
    },
    "naive_doc_ids": [
      "13867350",
      "16242975",
      "9091863",
      "13931771",
      "935538"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Several independent studies show that mitochondrial RNA granules are the sites where newly transcribed mitochondrial RNAs are processed or otherwise handled after transcription. Paper 1 demonstrates that GRSF1 and RNase P colocalize in mitochondrial RNA granules and that loss of GRSF1 disrupts cleavage of primary mitochondrial transcripts, indicating RNA processing occurs in these granules. Paper 3 directly concludes that mitochondrial RNA granules are centers for post-transcriptional RNA processing and ribosome biogenesis, identifying multiple RNA-metabolism proteins acting there. Papers 4 and 5 further show that granule-resident proteins (GRSF1, DDX28) are required for post-transcriptional events such as mRNA stability, ribosome loading, and mitoribosome assembly. Together these data confirm that post-transcriptional handling of mitochondrial transcripts takes place within mitochondrial RNA granules, supporting the claim."
    },
    "overthinking_doc_ids": [
      "13931771",
      "16242975",
      "20018321",
      "935538",
      "4306711"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Multiple cited studies identify mitochondrial RNA granules as sites where newly transcribed mitochondrial RNAs are processed after transcription. Paper 2 shows that GRSF1-containing foci (termed mitochondrial RNA granules) harbor RNase P and are required for cleavage of primary mitochondrial transcripts, i.e., post-transcriptional processing. Paper 4 further demonstrates that these granules contain many RNA-metabolism proteins and concludes that they are \u2018centers for post-transcriptional RNA processing.\u2019 Paper 5 confirms that GRSF1 localizes to these granules and that its absence disrupts post-transcriptional steps such as RNA stability and ribosome loading. Together, these data directly support the claim that post-transcriptional handling of mitochondrial transcripts takes place in mitochondrial RNA granules."
    },
    "posthoc_doc_ids": [
      "16242975",
      "13931771",
      "32324430",
      "20018321",
      "935538"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "684",
    "claim": "Lack of clpC does not affect sporulation efficiency in Bacillus subtilis cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.17,
      "justification": "None of the provided paper summaries report experiments that measure sporulation efficiency of a Bacillus subtilis clpC knockout. The abstracts discuss transposon-sequencing screens for sporulation genes (without specifically stating results for clpC) and the regulation/heat-shock roles of clpC, but they give no direct data on whether loss of clpC alters sporulation efficiency. Therefore the papers neither support nor contradict the claim."
    },
    "naive_doc_ids": [
      "4942718",
      "34386619",
      "12881593"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.32,
      "justification": "None of the supplied paper summaries report experimental results comparing sporulation efficiency between wild-type and clpC-deficient Bacillus subtilis strains. The papers focus on identifying sporulation genes (without mentioning clpC), regulation of the clpC operon under stress, quantitative control of Clp proteins, sliding motility, and antibiotic-induced ABC transporter expression. Thus the evidence provided contains no direct information relevant to the claim about clpC\u2019s effect on sporulation efficiency."
    },
    "overthinking_doc_ids": [
      "4942718",
      "34386619",
      "12881593",
      "12824568",
      "2851611"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided abstracts focus on (i) identification of sporulation genes in general, (ii) transcriptional regulation of the clpC operon by CtsR, and (iii) regulation and turnover of Clp proteins during stress. None of the excerpts report experimental results comparing sporulation efficiency of Bacillus subtilis strains lacking clpC with wild-type strains. Therefore they do not address whether absence of clpC affects sporulation efficiency."
    },
    "posthoc_doc_ids": [
      "4942718",
      "34386619",
      "12881593"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1239",
    "claim": "The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple papers show that myocardial (cardiac muscle) cells arise from progenitors of mesodermal (second heart field/KDR+ mesoderm) and neural-crest (ectodermal) origin, not exclusively from endoderm. Paper 1 demonstrates that some Isl1+ cardiac progenitors are neural-crest\u2013derived. Paper 2 identifies early human cardiovascular progenitors within a KDR+ mesodermal population. Paper 9 shows cardiac neural crest cells generate myocardial cells in zebrafish. These data directly oppose the claim that myocardial lineage originates solely from endodermal progenitors."
    },
    "naive_doc_ids": [
      "6148876",
      "4427392",
      "13777138",
      "26612216",
      "17685207"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 2 explicitly states that cardiomyocytes (myocardial cells) arise from the mesoderm lineage: \u201cBAF250a-ablated stem cells are defective in differentiating into fully functional mesoderm-derived cardiomyocytes.\u201d This directly opposes the claim that myocardial lineage is of exclusively endodermal origin. The other cited papers do not provide data supporting an endodermal origin for myocardial cells. Therefore, the available evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "17685207",
      "26612216",
      "164189",
      "1905095",
      "9622258"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.71,
      "justification": "Paper 3 reports lineage-tracing (protein-0-Cre/Floxed-EGFP mice) showing that neural-crest-derived cells (an ectodermal lineage, not endodermal) migrate into the fetal myocardium and differentiate into cardiomyocytes. This demonstrates that at least a subset of myocardial cells originate from ectoderm-derived cardiac neural crest, contradicting the claim that myocardial lineage arises exclusively from endodermal progenitors. The other cited papers do not provide evidence supporting an exclusively endodermal origin, and Paper 3 directly opposes it."
    },
    "posthoc_doc_ids": [
      "20186814",
      "32797183",
      "106301",
      "6270720",
      "22281684"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "648",
    "claim": "Integrated care is successful at tackling multiple comorbidities.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the cited papers evaluate an integrated-care model aimed at simultaneously managing multiple comorbid conditions. They examine single-condition pharmacologic, behavioral, diagnostic, or educational interventions, prevalence studies, or cost-effectiveness analyses. Therefore they offer no direct evidence to confirm or refute whether integrated care successfully tackles multiple comorbidities."
    },
    "naive_doc_ids": [
      "33409100",
      "6191684",
      "5912283",
      "12584053",
      "1287809"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the cited papers evaluate an integrated-care model aimed at patients with multiple comorbidities or report outcomes showing its success or failure. They address single-condition interventions (e.g., diabetes education, obesity counselling, laparoscopic treatment for pelvic pain) or other topics (preferences for place of death, antibiotic prescribing, teaching hospitals, pharmacist roles, shared decision making). Therefore they provide no relevant evidence for or against the claim that integrated care successfully tackles multiple comorbidities."
    },
    "overthinking_doc_ids": [
      "13515165",
      "13732033",
      "13906581",
      "12584053",
      "13027590"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.79,
      "justification": "None of the cited papers evaluate integrated-care models or their impact on patients with multiple comorbidities. They address topics such as blood-pressure monitoring, a diabetes education programme, patient experience surveys, COPD outcomes, drug efficacy, and methodological issues. Therefore, the evidence provided does not speak to whether integrated care successfully tackles multiple comorbidities."
    },
    "posthoc_doc_ids": [
      "5151024",
      "12584053",
      "19945096",
      "463533",
      "19464037"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "78",
    "claim": "Active caspase-11 participate in regulating phagosome-lysosome fusion.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 3 reports that mouse caspase-11 (and its human homologs caspase-4/5) is required for promoting the fusion of Legionella-containing phagosomes with lysosomes. The study shows that active caspase-11 facilitates this fusion by modulating actin dynamics, and that loss of caspase-11 impairs phagosome-lysosome fusion specifically for pathogenic bacteria. This directly supports the claim that active caspase-11 participates in regulating phagosome-lysosome fusion. The remaining cited papers do not address caspase-11\u2019s role in this process and therefore neither refute nor alter this conclusion."
    },
    "naive_doc_ids": [
      "35079452",
      "38043606",
      "5099266",
      "9021186",
      "10648422"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 reports that active mouse caspase-11 is required for restriction of Legionella pneumophila infection because caspase-11 \"promoted the fusion of the L. pneumophila vacuole with lysosomes by modulating actin polymerization.\" This directly demonstrates a role for active caspase-11 in regulating phagosome-lysosome fusion. The other cited papers discuss phagosome maturation or caspase-1/other pathways but provide no contradictory data about caspase-11. Hence, the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "5099266",
      "38043606",
      "4345315",
      "1964163",
      "12640810"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 reports that active mouse caspase-11 \u201cpromoted the fusion of the L. pneumophila vacuole with lysosomes,\u201d indicating that caspase-11 regulates phagosome-lysosome fusion. No other cited papers address caspase-11 or phagosome-lysosome fusion, so the available evidence directly supports the claim without contradiction."
    },
    "posthoc_doc_ids": [
      "5099266",
      "22186938",
      "38043606",
      "9899292",
      "9226649"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "677",
    "claim": "LRBA promotes CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.26,
      "justification": "None of the provided papers mention LRBA or examine how it affects CTLA-4 trafficking or recycling. Therefore they neither support nor contradict the claim that LRBA promotes CTLA-4 recycling."
    },
    "naive_doc_ids": [
      "13398997",
      "17017465",
      "22997657",
      "9185195",
      "14405193"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 2 discusses CTLA-4, but it focuses on its expression levels and functional effects in Th17 cells, not on LRBA or recycling mechanisms. The other papers address unrelated proteins and pathways. None of the cited evidence mentions LRBA or examines its influence on CTLA-4 recycling, so the claim is neither supported nor contradicted by the supplied data."
    },
    "overthinking_doc_ids": [
      "11250124",
      "13398997",
      "14893425",
      "9185195",
      "14405193"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.31,
      "justification": "None of the provided papers mention LRBA, CTLA-4, or the process of CTLA-4 recycling. The evidence summaries focus on unrelated proteins and cellular processes (e.g., Fra-1, PML, Aurora kinase, DNA end resection, PPAR-\u03b3, SPRTN, AP-1\u03c31B, Sirt1, zinc supplementation). Therefore, they neither support nor contradict the stated claim."
    },
    "posthoc_doc_ids": [
      "164985",
      "213017",
      "493346",
      "12207340",
      "22478394"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "881",
    "claim": "Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly compared TMAO production after L-carnitine ingestion in omnivorous versus vegan/vegetarian subjects and reports that omnivores produced MORE trimethylamine N-oxide than vegans or vegetarians. This is the opposite of the claim that omnivores produce less TMAO, so the evidence contradicts the claim. The other cited papers do not address comparative TMAO production from L-carnitine by diet group."
    },
    "naive_doc_ids": [
      "14803797",
      "5785219",
      "6793674",
      "12709184",
      "6327940"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Paper 2 directly measured TMAO formation after ingestion of L-carnitine and found that omnivorous subjects generated MORE trimethylamine N-oxide than vegans or vegetarians. This is the opposite of the claim that omnivores produce less TMAO than vegans."
    },
    "overthinking_doc_ids": [
      "12709184",
      "14803797",
      "253672",
      "32322418",
      "6793674"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 explicitly reports that omnivorous human subjects produced more trimethylamine N-oxide (TMAO) than vegans or vegetarians after ingestion of L-carnitine. This directly opposes the claim that omnivores produce less TMAO than vegans. The other cited papers do not address comparative TMAO production by diet groups, so they do not alter this conclusion."
    },
    "posthoc_doc_ids": [
      "14803797",
      "6793674",
      "22995164",
      "4939312",
      "13071728"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "422",
    "claim": "Flexible molecules experience less steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the cited papers examine or compare the steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. They discuss topics such as matrix stiffness, signaling pathways, nanoparticle size, acidic pH effects, metabolic interactions, and fibroblast functions, but do not provide data on molecular flexibility or steric effects. Therefore, the provided evidence does not address the claim."
    },
    "naive_doc_ids": [
      "1065627",
      "2734421",
      "11238951",
      "4164929",
      "17327939"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the cited papers examine or compare steric hindrance experienced by flexible versus rigid molecules within the tumor microenvironment. The articles focus on circulating tumor cells, tumor dormancy, glioma stem-cell signaling, extracellular matrix remodeling, cardiac imaging, integrin redox regulation, membrane-coated nanoparticles, cancer-associated fibroblasts, hyaluronan-mediated drug delivery barriers, and glutamine transporter inhibition. These topics do not provide experimental data or analysis relevant to molecular flexibility or steric hindrance in tumors."
    },
    "overthinking_doc_ids": [
      "21033230",
      "30919024",
      "33370",
      "4164929",
      "27550580"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers address a comparison between flexible and rigid molecules with respect to steric hindrance within the tumor microenvironment. The cited studies focus on fibroblast interactions, receptor signaling, metabolic coupling, genetic alterations, tumor dormancy, circulating tumor cells, matrix stiffness, peptide structure prediction, cytoskeletal proteins, and glutamine transport inhibition, but they do not provide data or discussion relevant to molecular flexibility versus rigidity and steric hindrance in tumors."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "11271123",
      "30919024"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "645",
    "claim": "Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Several randomized controlled trials consistently show that supplementation with folic acid (with or without vitamin B6) lowers, not raises, circulating homocysteine. Paper 1 reports a dose-dependent decrease in serum homocysteine with folic acid (up to 23% reduction). Paper 3 shows significant reductions in plasma homocysteine at 400-600 \u00b5g/day of folic acid in the elderly. Paper 5 finds that a combination capsule containing high doses of folic acid (40 mg) and vitamin B6 (100 mg) lowers homocysteine by 25.8% at three months. None of the cited studies report an increase; all demonstrate decreases. Therefore, the evidence directly refutes the claim that intake of folic acid and vitamin B6 increases homocysteine levels."
    },
    "naive_doc_ids": [
      "11705328",
      "37424881",
      "21636085",
      "12009265",
      "33409100"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "All cited studies that measured homocysteine show that giving folic acid alone (Papers 1 & 2) or in combination with vitamin B6/B12 (Paper 3) lowers\u2014rather than raises\u2014plasma/serum homocysteine concentrations. No paper reports an increase after supplementation. Therefore the evidence refutes the claim that intake of folic acid and vitamin B6 increases homocysteine levels."
    },
    "overthinking_doc_ids": [
      "11705328",
      "21636085",
      "33409100",
      "3150030",
      "8595678"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Multiple studies (Papers 1, 2 and 3) directly measure serum/plasma homocysteine after folic-acid supplementation and consistently show significant decreases, not increases, in homocysteine levels. No paper presents evidence that folic acid (or vitamin B6) consumption raises homocysteine. Therefore the presented evidence opposes the claim that FA and VB6 intake increase homocysteine."
    },
    "posthoc_doc_ids": [
      "11705328",
      "21636085",
      "37424881",
      "16256507",
      "5152028"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "614",
    "claim": "Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that pathogenic LRRK2 Roc-COR mutations (R1441C, Y1699C) inhibit axonal transport because the mutant protein preferentially binds to de-acetylated microtubules. Experimentally elevating microtubule acetylation\u2014by HDAC6 or Sirt2 knock-down, by trichostatin A treatment, or by over-expressing the tubulin acetyltransferase \u03b1TAT1\u2014blocked this aberrant binding and restored axonal transport in cultured neurons and in vivo, also rescuing locomotor deficits in Drosophila. These data directly show that increased microtubule acetylation repairs (i.e., rescues) the axonal transport defects produced by LRRK2 Roc-COR mutations, confirming the claim. The remaining papers focus on other aspects of microtubule motors or acetylation and do not contradict this conclusion."
    },
    "naive_doc_ids": [
      "9638032",
      "7549811",
      "1546650",
      "28369117",
      "1889358"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 reports that pathogenic Roc-COR mutations in LRRK2 impair axonal transport, but that elevating microtubule acetylation\u2014through pharmacological deacetylase inhibition, \u03b1TAT1 over-expression, or knock-down of HDAC6/Sirt2\u2014prevents mutant LRRK2 binding to microtubules and restores normal axonal transport and locomotor behavior. This directly demonstrates that increasing microtubule acetylation repairs the transport interference produced by the LRRK2 Roc-COR mutations. The other cited papers discuss dynein, kinesin, glycolytic support, AIS function, GTP-tubulin recognition, and structural effects of acetylation, but do not address LRRK2 or its transport deficits, and therefore neither refute nor alter this conclusion. Thus the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "18678095",
      "20743803"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that pathogenic Roc-COR mutations in LRRK2 impair axonal transport, but pharmacologically or genetically increasing microtubule acetylation (e.g., with HDAC6/Sirt2 knock-down, trichostatin A, or \u03b1TAT1 expression) prevents mutant LRRK2 association with microtubules and restores axonal transport in cultured neurons and in vivo. This directly supports the claim. The other cited papers discuss dynein, kinesin and neuronal morphology, but do not address LRRK2 or microtubule acetylation; they neither contradict nor add to the claim. Therefore, the provided evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "1546650",
      "41644178"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "724",
    "claim": "Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that the inhibitory MHC I receptor Ly49Q is \"crucial for the swift polarization\" of neutrophils and that \"Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.\" This directly aligns with the claim that Ly49Q directs neutrophil polarization by regulating membrane raft functions. The other cited papers discuss unrelated topics (yeast aging, T-cell receptor lipid changes, CD2 adaptor protein) and neither contradict nor modify this conclusion. Therefore, the evidence overall supports the claim."
    },
    "naive_doc_ids": [
      "5531479",
      "797114",
      "5914739",
      "18042803"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.81,
      "justification": "Paper 1 reports that the inhibitory MHC-I receptor Ly49Q is \u201ccrucial for the swift polarization of and tissue infiltration by neutrophils\u201d and that \u201cLy49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.\u201d The paper concludes that Ly49Q switches neutrophils to a polarized morphology through its spatiotemporal control of membrane rafts and raft-associated signaling molecules. This directly aligns with the claim that Ly49Q directs neutrophil polarization by regulating membrane raft functions. The remaining cited papers do not address Ly49Q or contradict this finding. Therefore, the collective evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "5531479",
      "4389252",
      "5484763",
      "8396189",
      "381602"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 reports that Ly49Q is essential for the rapid polarization and tissue infiltration of neutrophils and that these Ly49Q-dependent processes are mediated through Ly49Q\u2019s regulation of membrane raft functions. It explicitly states that Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane rafts, and proposes that Ly49Q switches neutrophils to a polarized morphology via spatiotemporal control of membrane rafts. This directly confirms the claim that Ly49Q directs neutrophil polarization by regulating membrane raft functions. The remaining cited papers discuss membrane organization or neutrophil biology in other contexts but do not contradict this finding. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "5531479",
      "20758340",
      "4389252",
      "3155374",
      "13651792"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "149",
    "claim": "Autophagy deficiency in the liver increases vulnerability to insulin resistance.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 directly examines mice with liver-specific autophagy deficiency (Atg7 deletion). These animals showed induction of Fgf21 and were \u2018resistant to diet-induced obesity and amelioration of insulin resistance\u2019. Thus, rather than increasing susceptibility, loss of autophagy in the liver protected the animals from becoming insulin-resistant. The other cited papers do not address hepatic autophagy status in relation to insulin resistance. Therefore the available evidence opposes the claim that hepatic autophagy deficiency increases vulnerability to insulin resistance."
    },
    "naive_doc_ids": [
      "6227220",
      "11201004",
      "24872571",
      "6042706",
      "39558597"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 3 directly examines autophagy deficiency. It reports that mice with autophagy deficiency in liver (and skeletal muscle) show \u2018resistance to diet-induced obesity and amelioration of insulin resistance,\u2019 i.e., they are protected rather than more vulnerable to insulin resistance. No other cited paper addresses liver autophagy and insulin resistance. Therefore the available evidence opposes the claim that autophagy deficiency in the liver increases vulnerability to insulin resistance."
    },
    "overthinking_doc_ids": [
      "16389141",
      "5268462",
      "6227220",
      "712078",
      "1576955"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 directly examines autophagy deficiency. It reports that mice with liver-specific loss of autophagy (Atg7 deletion) show \u2018resistance to diet-induced obesity and amelioration of insulin resistance\u2019. Thus, autophagy deficiency in the liver makes animals less\u2014not more\u2014vulnerable to insulin resistance. No other cited papers address hepatic autophagy and insulin resistance. Therefore the available evidence opposes the claim."
    },
    "posthoc_doc_ids": [
      "6227220",
      "31001322",
      "2481032",
      "16389141",
      "5268462"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1070",
    "claim": "Self-advocacy training is effective at decreasing homelessness.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the cited studies evaluate a self-advocacy training program or measure subsequent changes in homelessness rates. The papers focus on exercise in older adults, mental-health outreach for homeless families, insomnia treatments, physical activity and cognition, grief interventions, HIV medication adherence, DNA damage response in stem cells, and homeless youths\u2019 health perceptions. They provide no direct evidence about whether self-advocacy training decreases homelessness."
    },
    "naive_doc_ids": [
      "2028532",
      "6129301",
      "7751726",
      "5912283",
      "22467585"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.22,
      "justification": "None of the cited studies examine self-advocacy training or measure homelessness as an outcome. The papers focus on diabetes education, collaborative care for chronic disease, early-intervention concepts, dietary assessment, exercise programs, malaria terminology, blood-pressure diagnosis, surgical prioritisation, amyloidosis treatment, and a mental-health outreach service. Therefore they provide no direct evidence for or against the claim that self-advocacy training reduces homelessness."
    },
    "overthinking_doc_ids": [
      "12584053",
      "15041758",
      "154243324",
      "20048431",
      "2028532"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the cited studies examine self-advocacy training or measure homelessness outcomes. They cover topics such as diabetes education, neural stem cells, parent training for child behavior, treatments for self-poisoning, self-harm incidence, socioeconomic factors and health, neglected tropical diseases, and mouse longevity. Therefore they provide no information relevant to whether self-advocacy training decreases homelessness."
    },
    "posthoc_doc_ids": [
      "12584053",
      "16627684",
      "25493293",
      "12209494",
      "1102268"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1289",
    "claim": "There is a relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 examines macrolide antibiotics (a class that includes erythromycin) and reports a markedly elevated adjusted rate ratio for infantile hypertrophic pyloric stenosis when macrolides are given to infants in the first days after birth (rate ratio\u224830) and a smaller but significant association when used later, as well as increased risk with very recent maternal macrolide intake. No other provided paper addresses hypertrophic pyloric stenosis or erythromycin. Thus the available evidence indicates a positive association between erythromycin/macrolide use and hypertrophic pyloric stenosis, supporting the claim."
    },
    "naive_doc_ids": [
      "21239672",
      "2140497",
      "17124832",
      "21902910",
      "49429882"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 examines macrolide antibiotics (the class that includes erythromycin) and shows a very large increase in the incidence of infantile hypertrophic pyloric stenosis among infants who received these drugs shortly after birth (adjusted rate ratio \u2248 30 during days 0-13). Because erythromycin is a prototypical macrolide and is commonly prescribed to neonates, these data directly indicate a strong association between erythromycin exposure and hypertrophic pyloric stenosis. The other cited papers address unrelated topics (ACE inhibitors, air pollution, antipsychotics, NSAIDs) and do not affect this conclusion. Therefore, the available evidence supports the claim of a relationship between erythromycin use and hypertrophic pyloric stenosis."
    },
    "overthinking_doc_ids": [
      "21239672",
      "6157837",
      "471921",
      "5402581",
      "21958900"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 reports that exposure of infants to macrolide antibiotics\u2014including erythromycin\u2014during the first two weeks of life was associated with a markedly increased risk of infantile hypertrophic pyloric stenosis (adjusted rate ratio 29.8; 95% CI 16.4\u201354.1). Maternal macrolide use in the immediate postpartum period was also linked to elevated risk. This demonstrates a clear relationship between erythromycin (a macrolide) use and hypertrophic pyloric stenosis. The other papers do not address this topic, so they neither contradict nor alter this conclusion."
    },
    "posthoc_doc_ids": [
      "21239672",
      "7647224",
      "24269361",
      "350542",
      "2052720"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1174",
    "claim": "The PPR MDA5 has twenty N-terminal CARD domains.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "Among the supplied papers, only Paper 4 mentions MDA5 and it focuses on the gene\u2019s role in sensing infectious bursal disease virus and triggering immune responses. It does not describe the domain composition (CARD count) of MDA5. The remaining papers discuss unrelated proteins and pathways. Consequently, the provided evidence neither confirms nor refutes the statement that PPR MDA5 possesses twenty N-terminal CARD domains."
    },
    "naive_doc_ids": [
      "31387717",
      "612002",
      "8093935",
      "14474178",
      "56486733"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.56,
      "justification": "The provided papers discuss amino-terminal domains of glutamate receptors, NusG regulatory domains, ADAM13 adhesive domains, and an adenoviral protein\u2019s interaction partner, but none of them mention the PPR protein MDA5 or the number of its N-terminal CARD domains. Therefore, they offer no evidence to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "26011884",
      "612002",
      "24550453",
      "20943272",
      "207972"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Among the provided papers, only Paper 5 mentions the cytoplasmic RNA sensor Mda5, and it does not discuss its domain composition (number of CARD domains). None of the other papers address Mda5 or CARD domain counts. Therefore, the supplied evidence offers no information that either confirms or refutes the claim that Mda5 has twenty N-terminal CARD domains."
    },
    "posthoc_doc_ids": [
      "26011884",
      "612002",
      "24550453",
      "207972",
      "2566674"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1272",
    "claim": "The single flash-evoked ERG b-wave is generated by activity of ON-bipolar cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss electroretinogram (ERG) recordings, b-waves, or ON-bipolar cell activity. The evidence relates to circadian/cell cycle coupling, yeast proteomics, hematopoiesis, LEA proteins, macropinocytosis, oncogenes, T-cell signaling, planar cell polarity, and EGFR mutations, which are unrelated to the stated retinal physiology claim."
    },
    "naive_doc_ids": [
      "2212067",
      "4300851",
      "4335423",
      "3845894",
      "4138659"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the supplied abstracts, only papers 7 and 8 discuss electroretinography. They note that the ERG b-wave disappears in the \u2018no-b-wave\u2019 (nob) mouse mutation, implying a postsynaptic retinal defect, but they do not explicitly state that the b-wave is generated by ON-bipolar cell activity. The remaining papers are unrelated to retinal electrophysiology. Consequently, the provided evidence neither directly confirms nor refutes the claim."
    },
    "overthinking_doc_ids": [
      "2841164",
      "4422868",
      "5223817",
      "799586",
      "5704562"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers address electroretinography, retinal ON-bipolar cell physiology, or the cellular origin of the flash-evoked ERG b-wave. The evidence therefore offers no relevant data to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "2212067",
      "2888272",
      "9154703",
      "12762485",
      "2754534"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "619",
    "claim": "Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Multiple studies show that when fibrosis is reduced and/or intratumoral vessel density is increased, chemotherapeutic drugs reach the tumor more effectively and treatment efficacy improves. \n\u2022 Paper 6: Enzymatic depletion of hyaluronan (a major fibrotic component) both expanded tumor blood vessels and markedly increased intratumoral delivery of doxorubicin and gemcitabine, resulting in greater tumor growth inhibition and longer survival compared with chemotherapy alone.\n\u2022 Paper 7: Hedgehog-pathway inhibition reduced stromal tissue, transiently raised vascular density, increased gemcitabine concentration inside tumors, and produced better disease stabilization than gemcitabine alone.\n\u2022 Paper 4: Although focused on VEGF biology, clinical data cited show that anti-VEGF therapy (which reduces angiogenesis) must be combined with chemotherapy to enhance outcomes, implying that more vessels (without anti-VEGF blockade) do not lessen but can actually support chemotherapy when drug delivery is not impaired.\nTogether these findings demonstrate that greater vascularization coupled with less fibrotic stroma facilitates, not hinders, chemotherapy effectiveness, directly opposing the claim."
    },
    "naive_doc_ids": [
      "9929089",
      "7821634",
      "20127522",
      "24974080",
      "42080024"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple studies show that raising vessel density and/or diminishing fibrotic stroma improves, rather than diminishes, chemotherapy efficacy. 1) Paper 1: Hedgehog-pathway inhibition reduces tumor stroma and transiently increases vascular density, resulting in higher intratumoral gemcitabine concentration and disease stabilization. 2) Paper 3: Enzymatic removal of hyaluronan decreases desmoplasia, enlarges blood vessels, increases permeability and drug delivery, and in combination with gemcitabine slows tumor growth and extends survival. 3) Paper 2: In breast cancer patients treated with anthracyclines, higher microvessel density is independently associated with longer disease-free survival, indicating better benefit from chemotherapy. Collectively, these results show that more vessels and less fibrosis enhance, not reduce, chemotherapy effectiveness, contradicting the claim."
    },
    "overthinking_doc_ids": [
      "20888849",
      "1171121",
      "2565138",
      "31591262",
      "1711571"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.37,
      "justification": "Paper 3 specifically examined how microvessel density (MVD, a measure of vessel density) relates to the benefit of anthracycline chemotherapy in early breast-cancer patients. It found that higher MVD was independently associated with LONGER 5-year disease-free survival after chemotherapy, i.e. better therapeutic efficacy, not worse. This directly opposes the claim that increased vessel density diminishes chemotherapy efficacy. None of the cited papers provide data showing that reduced fibrosis combined with higher vessel density lowers chemotherapy effectiveness, so the available evidence contradicts the vessel-density component of the claim and provides no support for the fibrosis component."
    },
    "posthoc_doc_ids": [
      "20610557",
      "20127522",
      "1171121",
      "6421792",
      "7821634"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "2",
    "claim": "1 in 5 million in UK have abnormal PrP positivity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 7 reports 16 abnormal PrP-positive appendices among 32,441 UK samples, corresponding to an estimated prevalence of 493 per million people (\u22481 in 2,000). The claim states the prevalence is 1 in 5,000,000 (0.2 per million). The measured prevalence is therefore about 2,500 times higher than the claim, directly refuting it. The other cited papers do not provide data on abnormal PrP prevalence, so the decisive evidence is from Paper 7, which contradicts the claim."
    },
    "naive_doc_ids": [
      "2138767",
      "5151024",
      "756887",
      "27063470",
      "11349166"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly reports the prevalence of abnormal prion protein (PrP) in a large UK appendix sample: 16 positives among 32,441 samples, corresponding to roughly 493 per million people (\u22481 in 2,000). The claim states the prevalence is 1 in 5 million. The measured prevalence is therefore about 2,500 times higher than the claim, refuting it. The other papers do not address PrP prevalence and are irrelevant to this claim."
    },
    "overthinking_doc_ids": [
      "13734012",
      "75636923",
      "13934676",
      "3903084",
      "5558754"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 3 reports 16 abnormal PrP-positive appendixes among 32,441 UK samples, corresponding to an estimated prevalence of 493 per million people (\u22481 in 2,000). The claim states a prevalence of 1 in 5,000,000. The measured prevalence is thus roughly 2,500 times higher than the claim, directly contradicting it."
    },
    "posthoc_doc_ids": [
      "2138767",
      "4828631",
      "13734012",
      "42291761",
      "27063470"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1295",
    "claim": "There is no relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examined macrolide antibiotics (a class that includes erythromycin) and infantile hypertrophic pyloric stenosis. It found very strong positive associations: infants given macrolides in the first 0-13 days had an adjusted rate ratio of 29.8 for pyloric stenosis compared with unexposed infants, and maternal macrolide use in the first 2 weeks postpartum also increased risk (rate ratio = 3.49). These results demonstrate a clear relationship between macrolide/erythromycin exposure and hypertrophic pyloric stenosis, refuting the claim that no relation exists. The remaining papers do not address this topic."
    },
    "naive_doc_ids": [
      "21239672",
      "2140497",
      "2425364",
      "25157790",
      "20526907"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 directly examines macrolide antibiotics (the class that includes erythromycin) and infantile hypertrophic pyloric stenosis (IHPS). It reports very strong associations: infants given macrolides in the first 0-13 days of life had an adjusted rate ratio for IHPS of 29.8 (95% CI 16.4-54.1), and maternal use in the same period also raised risk (rate ratio 3.49). These results demonstrate a clear relationship between macrolide/erythromycin exposure and hypertrophic pyloric stenosis. Therefore the claim that there is no relation is refuted by the evidence."
    },
    "overthinking_doc_ids": [
      "21239672",
      "829646",
      "2097256",
      "791050",
      "17000834"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 reports that infants treated with macrolides (a class that includes erythromycin) in the first 0-13 days of life had a 29.8-fold higher adjusted rate of infantile hypertrophic pyloric stenosis compared with unexposed infants, and maternal macrolide use shortly after birth also increased the risk (rate ratio 3.49). These findings demonstrate a clear association\u2014opposite to the claim that no relation exists. The other cited papers do not address erythromycin or pyloric stenosis. Therefore the available evidence refutes the claim."
    },
    "posthoc_doc_ids": [
      "21239672",
      "643765",
      "2575938",
      "17000834",
      "24269361"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1027",
    "claim": "Reduced phosphorylation of PP2A suppresses HDAC4 dephosphorylation.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 2 states that ATM-mediated phosphorylation down-regulates PP2A activity, and that in ATM deficiency PP2A becomes less phosphorylated, its activity increases, and this increased PP2A activity causes HDAC4 dephosphorylation. Thus, reduced phosphorylation of PP2A enhances (rather than suppresses) HDAC4 dephosphorylation, directly opposing the claim."
    },
    "naive_doc_ids": [
      "22185730",
      "3113630",
      "19966976",
      "22036571",
      "2272614"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 2 shows that ATM-mediated phosphorylation inhibits PP2A. When PP2A phosphorylation is reduced (ATM deficiency), PP2A activity becomes higher, which leads to increased\u2014rather than suppressed\u2014HDAC4 dephosphorylation. Therefore the evidence opposes the claim that reduced phosphorylation of PP2A suppresses HDAC4 dephosphorylation."
    },
    "overthinking_doc_ids": [
      "22185730",
      "3113630",
      "8417211",
      "19966976",
      "35884026"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.77,
      "justification": "Paper 2 reports that ATM phosphorylates PP2A and this phosphorylation DOWN-regulates PP2A activity. In ATM deficiency, phosphorylation of PP2A is reduced, PP2A activity therefore rises, and this enhanced PP2A activity causes increased dephosphorylation of HDAC4. Thus, reduced phosphorylation of PP2A promotes\u2014rather than suppresses\u2014HDAC4 dephosphorylation, directly opposing the claim."
    },
    "posthoc_doc_ids": [
      "22185730",
      "3113630",
      "16686383",
      "8417211",
      "22036571"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1347",
    "claim": "Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.13,
      "justification": "None of the provided papers examine the impact of influenza-specific memory CD4+ T cells on the early production of inflammatory chemokines in the lung. The studies focus on CD4+ T-cell help for CD8+ tissue-resident memory formation, T-cell egress, antioxidant responses, cancer comorbidity management, 4-1BB costimulation, and post-transplant alloimmune lung syndromes\u2014topics that do not address the claimed reduction of early chemokine production by memory CD4+ T cells after viral challenge."
    },
    "naive_doc_ids": [
      "3835423",
      "12100963",
      "6182947",
      "24323695",
      "40473317"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 6 reports that influenza-specific memory CD4+ T cells ENHANCE (\"enhances production of multiple innate inflammatory cytokines and chemokines in the lung\") the early innate inflammatory response after viral challenge. This is the opposite of the claim that these cells \u2018greatly diminish\u2019 early chemokine production. The other cited papers do not directly address early chemokine production by memory CD4+ T cells, so the pertinent evidence (Paper 6) contradicts the claim."
    },
    "overthinking_doc_ids": [
      "3835423",
      "2248870",
      "12100963",
      "40473317",
      "5508750"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 3 directly examines the effect of influenza-specific memory CD4\u207a T cells on early innate mediators in the lung. It reports that memory, but not na\u00efve, CD4\u207a T cells \"enhance production of multiple innate inflammatory cytokines and chemokines in the lung\" during influenza infection, leading to earlier viral control. This finding shows an increase\u2014not a diminution\u2014of early inflammatory chemokine production in the presence of memory CD4\u207a T cells. The other cited papers do not address the impact of memory CD4\u207a T cells on early chemokine production. Therefore, the available evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "12100963",
      "3835423",
      "19005293",
      "40473317",
      "2248870"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "250",
    "claim": "Chenodeoxycholic acid treatment decreases brown adipose tissue activity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly examines chenodeoxycholic acid (CDCA) treatment and reports that CDCA increased human brown adipose tissue activity and whole-body energy expenditure. This finding is opposite to the claim that CDCA decreases BAT activity. The other cited papers do not address CDCA\u2019s effect on BAT, so they do not alter this conclusion. Therefore, the available evidence refutes the claim."
    },
    "naive_doc_ids": [
      "1568684",
      "26902591",
      "4319174",
      "2030623",
      "4920376"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Paper 1 directly reports that oral supplementation with chenodeoxycholic acid (CDCA) in humans increased brown adipose tissue (BAT) activity and whole-body energy expenditure. This finding is opposite to the claim that CDCA decreases BAT activity. The other cited papers do not address the effect of CDCA on BAT. Therefore, the available evidence refutes the claim."
    },
    "overthinking_doc_ids": [
      "1568684",
      "40232172",
      "3621011",
      "19205437",
      "4319174"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that oral chenodeoxycholic acid treatment in humans \"increased\" brown adipose tissue activity and whole-body energy expenditure. This finding is opposite to the claim that chenodeoxycholic acid decreases BAT activity. The other cited papers do not address chenodeoxycholic acid\u2019s effect on BAT and therefore do not alter this conclusion."
    },
    "posthoc_doc_ids": [
      "1568684",
      "40232172",
      "10463997",
      "5492542",
      "39892135"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "841",
    "claim": "Natriuretic peptides protect against diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 3 directly examines B-type natriuretic peptide (BNP) levels and type 2 diabetes risk. Higher circulating NT-pro-BNP concentrations were prospectively associated with a 21 % lower incidence of diabetes after adjustment for multiple confounders. Mendelian-randomization using the BNP-increasing rs198389 allele yielded a genetically predicted odds-ratio of 0.94 for diabetes, mirroring the observational protective association and indicating a likely causal relationship. None of the other cited papers provide contradictory findings about natriuretic peptides. Therefore, available evidence supports the claim that natriuretic peptides confer protection against diabetes."
    },
    "naive_doc_ids": [
      "27166444",
      "120626",
      "15663829",
      "2481032",
      "14116046"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Paper 1 directly examines circulating B-type natriuretic peptide (NT-pro-BNP) and incident type 2 diabetes. In a prospective cohort, each standard-deviation increase in NT-pro-BNP was associated with a 21 % lower risk of developing diabetes after multivariable adjustment. Mendelian-randomization using the BNP-raising rs198389 allele showed a genetically determined higher BNP level was likewise associated with reduced diabetes risk, consistent with a causal protective effect. No paper presents opposing data. Therefore the available evidence supports the claim that natriuretic peptides confer protection against diabetes."
    },
    "overthinking_doc_ids": [
      "15663829",
      "1974176",
      "12451492",
      "2481032",
      "14116046"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Paper 1 reports both prospective epidemiologic data and Mendelian-randomization analysis showing that higher circulating concentrations of B-type natriuretic peptide (or genetically higher BNP via rs198389) are associated with a significantly lower risk of developing type 2 diabetes (\u224820 % risk reduction per SD increase in NT-pro-BNP; OR \u2248 0.94 per protective allele). This indicates a protective, likely causal, effect of natriuretic peptides against diabetes. The other cited papers do not address natriuretic peptides, and none present opposing data. Therefore, the available evidence supports the claim that natriuretic peptides protect against diabetes."
    },
    "posthoc_doc_ids": [
      "15663829",
      "33960383",
      "2665675",
      "3654468",
      "8325952"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "611",
    "claim": "Increased lipolysis leads to higher P38 phosphorylation in adipose tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "None of the provided papers examine the effect of lipolysis on p38 MAPK phosphorylation in adipose tissue. The cited studies deal with estrogen receptor modulation, endothelial nitric-oxide synthase regulation, glucose deprivation in cancer cells, adipogenesis regulators, adipose inflammation, stress-induced immune changes, BAT mitochondrial assays, and lineage tracing of adipocytes. They do not report data linking increased lipolysis to changes in p38 phosphorylation within adipose tissue, so they neither confirm nor refute the claim."
    },
    "naive_doc_ids": [
      "4662264",
      "6923795",
      "7875158",
      "3621011",
      "5106691"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.25,
      "justification": "None of the provided papers investigate the relationship between lipolysis and p38 MAPK phosphorylation in adipose tissue. The abstracts discuss topics such as mitochondrial dynamics in cardiomyocytes, \u03b2-adrenergic effects on immune cells, adipogenesis timing, lysosomal dysfunction, macrophage polarization, neuropathic pain mechanisms, gastrointestinal nitric-oxide signaling, and calcium signaling in mast cells\u2014but do not examine p38 phosphorylation in adipose tissue in response to lipolytic stimuli. Therefore, the evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "14362678",
      "3943235",
      "14171859",
      "20532591",
      "9178310"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.41,
      "justification": "Paper 4 reports that nicotine first activates p38 MAPK (via AMPK\u03b12-dependent degradation of MKP1) and that this p38 activation, together with JNK activation, leads to loss of insulin-mediated inhibition of lipolysis, thereby increasing lipolysis in adipocytes. Thus p38 phosphorylation is shown to be upstream of, and causal for, the rise in lipolysis. The claim states the opposite causal order (that increased lipolysis drives higher p38 phosphorylation). The evidence therefore contradicts, rather than supports, the claim."
    },
    "posthoc_doc_ids": [
      "3621011",
      "79447",
      "1568684",
      "32408470",
      "20568364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "378",
    "claim": "Energy balance requires hypothalamic glutamate neurotransmission.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 shows that blocking glutamate release specifically from Sim1-expressing neurons in the paraventricular nucleus of the hypothalamus abolishes the anti-obesity effect of MC4R signaling and, independently, that eliminating glutamate release from adult PVH neurons causes rapid obesity through reduced energy expenditure and increased food intake. These results demonstrate that normal energy balance (appropriate food intake and energy expenditure) depends on intact glutamatergic neurotransmission within the hypothalamus. The other cited papers do not address hypothalamic glutamate directly and neither contradict this finding. Therefore the available evidence supports the claim that energy balance requires hypothalamic glutamate neurotransmission."
    },
    "naive_doc_ids": [
      "45154987",
      "11742219",
      "2225918",
      "1070920",
      "25050364"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "Among the cited papers only paper 2 mentions hypothalamic glutamate signaling, reporting that metabolic status and leptin alter expression of astrocytic glutamate transporters. This suggests a possible connection but does not demonstrate that hypothalamic glutamate neurotransmission is required for maintaining energy balance. The other papers deal with galanin, IL-18, apolipoprotein E, ghrelin, dietary folate, or general glutamate-receptor biology outside the hypothalamus. None provide direct experimental evidence showing that blocking or impairing hypothalamic glutamate neurotransmission disrupts energy homeostasis. Therefore the supplied literature neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "11742219",
      "17150648",
      "37205759",
      "25050364",
      "12943966"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.77,
      "justification": "Multiple studies demonstrate that disrupting glutamatergic signaling in hypothalamic circuits produces clear deficits in energy balance. (i) Paper 9 shows that selective elimination of glutamate release from Sim1-expressing (largely paraventricular hypothalamic) neurons abolishes the anti-obesity effect of melanocortin signalling and, when done in adults, rapidly causes hyperphagia, reduced energy expenditure and obesity. (ii) Paper 10 reports that genetic ablation of lateral hypothalamic glutamatergic neurons increases caloric intake and body-weight gain, while optogenetic activation of their glutamatergic projections suppresses feeding. (iii) Paper 3 further indicates that loss of vesicular glutamate transporter VGLUT2 in ventromedial hypothalamic neurons impairs counter-regulatory responses to fasting-induced hypoglycaemia, demonstrating a requirement of hypothalamic glutamate release for metabolic homeostasis. Together these experimental data show that normal energy and glucose homeostasis depends on intact hypothalamic glutamate neurotransmission, supporting the claim."
    },
    "posthoc_doc_ids": [
      "17150648",
      "11742219",
      "11886686",
      "15535511",
      "25183830"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1207",
    "claim": "The composition of myosin-II isoform switches from the polarizable B isoform to the more homogenous A isoform during hematopoietic differentiation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.18,
      "justification": "None of the cited papers discuss myosin-II isoform A vs. B expression, let alone a switch between these isoforms during hematopoietic differentiation. The provided evidence focuses on miRNA regulation, transcriptome analysis, stem-cell biology, smooth-muscle differentiation, osteocyte function, PU.1 feedback, and T-cell compartmentalization, but does not address myosin-II isoform composition in hematopoietic cells. Therefore, the claim is neither supported nor contradicted by the supplied literature."
    },
    "naive_doc_ids": [
      "23727313",
      "27061085",
      "13116880",
      "11840194",
      "13509809"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers mention myosin-II isoforms (A vs. B) or describe any isoform switch during hematopoietic differentiation. Therefore they neither support nor contradict the stated claim."
    },
    "overthinking_doc_ids": [
      "12315072",
      "23727313",
      "11840194",
      "10165258",
      "10526279"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 7 directly measures non-muscle myosin-II isoforms during human hematopoiesis. It finds that the B isoform (MIIB) is the dominant, strongly polarized isoform in hematopoietic stem and progenitor cells but is down-regulated as the cells differentiate, whereas the A isoform (MIIA) remains present and is functionally activated during differentiation. This demonstrates a shift in isoform composition from predominantly, polarized MIIB in stem cells to relatively higher, more uniformly distributed MIIA in differentiated hematopoietic cells, matching the claimed switch from the polarizable B isoform to the more homogeneous A isoform. The other cited papers do not address myosin-II isoform dynamics in hematopoiesis, nor contradict this finding."
    },
    "posthoc_doc_ids": [
      "14581009",
      "27061085",
      "12315072",
      "11840194",
      "20186814"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "126",
    "claim": "Approximately 250,000 people are infected with human T-cell lymphotropic virus type 1 in the United Kingdom.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the provided papers estimate, mention, or analyse the total prevalence of human T-cell lymphotropic virus type 1 infections in the United Kingdom. The excerpts only discuss specific HTLV-I\u2013related disease cases or present information on unrelated topics (HIV, CJD, dengue, drowning, HPV, antidepressants). Therefore, the evidence does not confirm or refute the claim about 250,000 infections."
    },
    "naive_doc_ids": [
      "20996244",
      "46202852",
      "601033",
      "27063470",
      "24512064"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers mention human T-cell lymphotropic virus type 1 (HTLV-1) or give prevalence figures for HTLV-1 infection in the United Kingdom. Therefore they offer no evidence that either supports or contradicts the claim of ~250,000 infections."
    },
    "overthinking_doc_ids": [
      "27063470",
      "9547722",
      "5824985",
      "7373120",
      "10509344"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers mention human T-cell lymphotropic virus type 1 (HTLV-1) or its prevalence in the United Kingdom. The evidence presented focuses on bariatric surgery, overweight prevalence, cancer survivorship, molecular biology topics, HIV research, statin trials, and caregiver needs. Therefore, they offer no information to confirm or refute the stated prevalence of HTLV-1 infection in the UK."
    },
    "posthoc_doc_ids": [
      "5824985",
      "6876224",
      "9547722",
      "14530534",
      "20996244"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1288",
    "claim": "There is a positive correlation between hip fractures and statin use.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 directly examines the relationship between statin (HMG-CoA reductase inhibitor) use and hip fracture risk and finds a LOWER risk among statin users (adjusted OR \u22480.5\u20130.57). A positive correlation would require statin use to be associated with MORE hip fractures. No other provided papers address statins and hip fractures. Therefore, the available evidence refutes the claim."
    },
    "naive_doc_ids": [
      "4687948",
      "19854543",
      "2140497",
      "1974176",
      "11246427"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.16,
      "justification": "None of the provided papers examine the relationship between statin use and hip fractures; they focus on cardiovascular outcomes, osteoporosis therapies unrelated to statins, gestational diabetes, dementia, cognitive function in CKD, and carotid atherosclerosis. Thus they offer no evidence to confirm or refute the stated correlation."
    },
    "overthinking_doc_ids": [
      "5698494",
      "26000593",
      "439670",
      "14682243",
      "19804204"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The only paper that directly examines hip fractures in relation to statin use (Paper 3) reports that statin use is associated with a LOWER risk of hip fracture (adjusted OR \u22480.5 for use in prior 180 days; \u22480.57 for prior 3 years; current use OR \u22480.29). This indicates a negative, not positive, correlation between statin use and hip fractures. Other cited papers either do not involve statins or do not address hip fractures, so they provide no relevant information. Therefore the available evidence contradicts the claim of a positive correlation."
    },
    "posthoc_doc_ids": [
      "7209559",
      "19878070",
      "4687948",
      "1287809",
      "4883040"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "474",
    "claim": "Glycan adaptation is rarely observed in the B-cell repertoire.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the cited papers examine the frequency of glycan (N-linked glycosylation site) adaptations that arise in immunoglobulin variable regions during somatic hypermutation. The articles focus on topics such as autoantibody affinity, T-cell responses, germinal-center dynamics, HIV-1 Env glycosylation, or antibody neutralization breadth, but they do not report data on how often B-cell receptors acquire or lose glycan sites. Therefore the supplied evidence neither supports nor contradicts the claim that glycan adaptation is rarely observed in the B-cell repertoire."
    },
    "naive_doc_ids": [
      "1471041",
      "8325952",
      "8354687",
      "21012916",
      "25353658"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "None of the provided papers analyze how often glycans are gained, lost, or otherwise adapted on B-cell receptors or antibodies within the B-cell repertoire. The studies focus on T-cell selection, TCR diversity after transplantation, transcription-factor-driven enhancer usage, autoantibody generation in celiac disease, mechanisms of B-cell self-tolerance, sex determination in chickens, HIV-1 envelope glycosylation and neutralizing antibodies, myeloid progenitors in Down syndrome, and HIV escape from a broadly neutralizing antibody lineage. Since glycan adaptation in B cells is not examined, the evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "8354687",
      "27910499",
      "4896726",
      "1471041",
      "5003144"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.22,
      "justification": "None of the provided papers examine how often B-cell receptors acquire or adapt glycan modifications. Paper 2 discusses evolution of a viral glycan epitope during HIV escape, but this concerns changes in the virus, not glycan adaptations within the B-cell repertoire itself. The remaining papers do not address glycans or B-cell receptor modification at all. Therefore, the cited literature supplies no relevant evidence to confirm or refute the claim that glycan adaptation is rarely observed in the B-cell repertoire."
    },
    "posthoc_doc_ids": [
      "4896726",
      "7177329",
      "7869794",
      "8354687",
      "19238"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "421",
    "claim": "Flexible molecules experience greater steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.77,
      "justification": "None of the provided papers compare the steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The cited studies discuss cancer-associated fibroblasts, immune signaling, amino-acid transport inhibition, receptor polymorphisms, acidic pH effects, MHC peptide binding, hyaluronan-mediated vascular impairment, nanoparticle coatings, and circulating tumor cells, but they include no experimental data or conclusions about molecule flexibility and steric hindrance. Therefore, the evidence is insufficient to support or contradict the claim."
    },
    "naive_doc_ids": [
      "952111",
      "2734421",
      "5256564",
      "3127341",
      "4583180"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.22,
      "justification": "None of the provided papers compare flexible versus rigid molecular conformations with respect to steric hindrance specifically in the tumor microenvironment. The cited studies discuss receptor stalk regions, matrix stiffness effects on drug response, redox regulation of integrins, cancer-associated fibroblasts, nanoparticle vaccines, and other topics, but do not present experimental evidence or analysis addressing whether flexible molecules suffer greater steric hindrance than rigid ones. Therefore, there is no information in the supplied evidence to verify or refute the claim."
    },
    "overthinking_doc_ids": [
      "40963697",
      "1065627",
      "44640124",
      "952111",
      "2734421"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.91,
      "justification": "None of the provided papers examine or compare steric hindrance experienced by flexible versus rigid molecules within the tumor microenvironment. The articles focus on cellular interactions, matrix stiffness, metabolic coupling, stromal composition, and drug resistance, but do not present experimental data or discussion about molecular flexibility or steric hindrance effects. Therefore, the claim is neither supported nor contradicted by the supplied evidence."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "37437064",
      "54440"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "448",
    "claim": "Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly addresses the relationship in humans: a prospective case-control study found that prior Helicobacter pylori infection was present in 69 % of individuals who later developed gastric cancer versus 47 % of matched controls, yielding an odds ratio of 2.77 (95 % CI 1.04\u20137.97). The authors conclude that H. pylori infection may account for 35-55 % of gastric cancers, demonstrating an increased cancer risk. Papers 4-6 provide biological mechanisms (e.g., AID-mediated TP53 mutations, alterations in apoptotic pathways) that plausibly link H. pylori infection to gastric carcinogenesis, reinforcing the epidemiologic finding. No paper offers evidence contradicting the claim. Hence, the collected evidence supports the statement that gastric infection with H. pylori increases gastric cancer risk in humans."
    },
    "naive_doc_ids": [
      "2052720",
      "14729253",
      "31229233",
      "22703082",
      "7465900"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 is a prospective, nested case\u2013control study in humans showing that individuals who were seropositive for Helicobacter pylori before diagnosis had a significantly higher risk of subsequently developing gastric cancer (odds ratio \u2248 2.8, 95 % CI 1.04\u20137.97). This directly demonstrates that H. pylori infection increases gastric-cancer risk in humans. Paper 3 supplies mechanistic evidence (H. pylori induces mutagenic AID expression and TP53 mutations in gastric epithelium), and Paper 4 shows similar mutagenic effects in a mouse model, both reinforcing biological plausibility. Paper 2 is largely about host genetic polymorphisms and does not contradict the association. Collectively, the evidence aligns with and supports the claim that gastric infection with H. pylori elevates the risk of gastric cancer in humans."
    },
    "overthinking_doc_ids": [
      "2052720",
      "14729253",
      "22703082",
      "24705390"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 is a prospective, nested case-control study in which prior Helicobacter pylori infection (measured by IgG antibodies collected years before diagnosis) was associated with a significantly higher risk of subsequent gastric cancer (odds ratio = 2.77, 95 % CI 1.04\u20137.97). Paper 2 demonstrates a biological mechanism whereby H. pylori infection induces aberrant expression of activation-induced cytidine deaminase in gastric epithelial cells, leading to TP53 mutations\u2014a plausible carcinogenic pathway. Both lines of evidence directly link H. pylori infection to increased gastric cancer risk rather than refuting it. Other cited papers discuss genetic susceptibility, breast-cancer epidemiology, or cellular responses but do not contradict the association. Therefore, the overall evidence supports the claim that gastric infection with H. pylori increases the risk of gastric cancer in humans."
    },
    "posthoc_doc_ids": [
      "2052720",
      "22703082",
      "14729253",
      "13831842",
      "16322674"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "623",
    "claim": "Individuals with low serum vitamin D concentrations have increased risk of multiple sclerosis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "None of the cited papers measure serum 25-hydroxyvitamin D concentrations in individuals and relate those concentrations to subsequent multiple-sclerosis risk. Paper 1 links childhood sun exposure (an indirect proxy for vitamin D) to lower MS incidence, but it does not report serum vitamin D levels. Paper 9 is a narrative discussion of latitude, sunlight and vitamin D as possible factors in MS, again without presenting data on serum vitamin D concentrations. The remaining papers address other diseases or outcomes. Therefore, the provided evidence offers no direct information to verify or refute the specific claim about low serum vitamin D and increased multiple-sclerosis risk."
    },
    "naive_doc_ids": [
      "17000834",
      "4462079",
      "13831842",
      "2425364",
      "11254040"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Among the provided papers, only Paper 4 mentions both vitamin D and multiple sclerosis, but it is a narrative review that hypothesizes a possible link based on latitude and immunologic considerations; it does not report empirical data showing that individuals with low serum vitamin D actually have higher MS risk. The remaining papers deal with pregnancy outcomes, zinc supplementation, general vitamin D thresholds for other health outcomes, and lifestyle factors unrelated to MS. Therefore, the supplied evidence does not furnish direct support or contradiction for the specific claim that low serum vitamin D concentrations increase the risk of multiple sclerosis."
    },
    "overthinking_doc_ids": [
      "2425364",
      "4515975",
      "4462079",
      "22843838",
      "1456068"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.36,
      "justification": "Among the supplied articles, Paper 2 shows that people who had lower ultraviolet (sun) exposure during childhood and adolescence exhibited a markedly higher odds of developing multiple sclerosis (adjusted OR \u22483.2 compared with those with high exposure). Because cutaneous ultraviolet exposure is the principal source of endogenous vitamin D, low sunlight exposure is a well-accepted proxy for low vitamin D status. Thus, these data indicate that individuals likely to have lower vitamin D levels (because of less sun exposure) have an increased risk of multiple sclerosis, which aligns with the claim. No papers present data contradicting this relationship, and the remaining articles do not address vitamin D status in relation to multiple sclerosis. Therefore, the overall evidence provided is supportive, although it is indirect (based on sun-exposure rather than measured serum vitamin D)."
    },
    "posthoc_doc_ids": [
      "25599283",
      "17000834",
      "22843838",
      "43226130",
      "2425364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "35",
    "claim": "A deficiency of vitamin B12 decreases blood levels of homocysteine.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.67,
      "justification": "Among the cited papers, none investigates how a deficiency of vitamin B12 alone affects blood (plasma/serum) homocysteine levels. The only study that includes vitamin B12 (Paper 8) examines the effect of high-dose supplementation of folic acid, vitamin B6, and vitamin B12 combined, not B12 deficiency. Therefore the provided evidence neither confirms nor refutes the specific claim about B12 deficiency lowering homocysteine."
    },
    "naive_doc_ids": [
      "18557974",
      "9555784",
      "25599283",
      "36654066",
      "797114"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers investigate how vitamin B12 deficiency affects blood homocysteine concentrations. The cited studies focus on vitamin D status, folate supplementation, homocysteine-lowering trials, acupuncture, burn dressings, bariatric surgery and other topics. Therefore they offer no data that confirm or refute the claim about vitamin B12 deficiency and homocysteine levels."
    },
    "overthinking_doc_ids": [
      "3150030",
      "9555784",
      "3222187",
      "1495563",
      "3692112"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "None of the cited papers reports experimental or observational data on how vitamin B12 deficiency changes blood homocysteine concentrations. Several papers discuss homocysteine in relation to folate status, genetic polymorphisms, or soy/phytate intake, but they do not examine the effect of vitamin B12 deficiency itself. Therefore the evidence provided is insufficient to judge the claim."
    },
    "posthoc_doc_ids": [
      "3150030",
      "9555784",
      "3222187",
      "37424881",
      "7198295"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1230",
    "claim": "The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.13,
      "justification": "None of the cited papers mention FOXO3, its alleles, or their effect on pro-inflammatory cytokine expression. The evidence is therefore insufficient to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "22889972",
      "207972",
      "2734421",
      "3118719",
      "2824347"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 2 directly examines the non-coding SNP rs12212067 (T\u2192G) in FOXO3.  It shows that carriers of the minor G allele have a FOXO3-driven pathway that, via TGF-\u03b21, \"reduces production of pro-inflammatory cytokines, including TNF\u03b1, and increases production of anti-inflammatory cytokines, including IL-10.\"  This is experimental evidence that the minor G allele down-regulates pro-inflammatory cytokine production.  None of the other cited papers address FOXO3 polymorphisms, so they neither support nor contradict the claim.  Therefore the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "8639034",
      "13905670",
      "22505710",
      "11233339",
      "25315295"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that the minor G allele (rs12212067 T>G) of FOXO3 limits inflammatory responses in monocytes, leading to reduced production of pro-inflammatory cytokines such as TNF-\u03b1 and increased production of anti-inflammatory cytokines (e.g., IL-10). This directly supports the claim that the minor G allele down-regulates pro-inflammatory cytokines. The additional papers do not address FOXO3 polymorphisms, so they neither strengthen nor weaken this conclusion."
    },
    "posthoc_doc_ids": [
      "13905670",
      "11233339",
      "25315295",
      "24783597",
      "13906892"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1268",
    "claim": "The risk of cancer rises with level of alcohol consumption.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.29,
      "justification": "None of the provided papers examine the relationship between alcohol consumption levels and cancer incidence or mortality. They address other risk factors such as smoking, fruit intake, obesity, lung function, perinatal factors, infection-related inflammation, and cellular mechanisms, but do not present data on alcohol and cancer risk. Therefore the evidence set does not inform the claim."
    },
    "naive_doc_ids": [
      "1456068",
      "1974176",
      "3514540",
      "7639744",
      "12145359"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers investigate or report on the relationship between alcohol consumption levels and cancer risk. They examine biomarkers, genetics, drug exposure, physical activity, chemotherapy response, and vaccine immunogenicity\u2014topics unrelated to alcohol\u2019s effect on cancer incidence. Therefore they offer no evidence for or against the claim."
    },
    "overthinking_doc_ids": [
      "12869200",
      "14729253",
      "31229233",
      "6647414",
      "24834968"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers examine an association between amount of alcohol consumed and cancer incidence or mortality. The few papers mentioning alcohol discuss cardiovascular outcomes or label perception, not cancer risk, so they do not speak to whether higher alcohol consumption increases cancer risk."
    },
    "posthoc_doc_ids": [
      "3355397",
      "20280410",
      "20526907",
      "38551172",
      "16322674"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1386",
    "claim": "cSMAC formation represses weak ligand signalling.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 3 reports that a weak agonist peptide that fails to form a central supramolecular activation cluster (cSMAC) actually elicits stronger T-cell proliferation than the wild-type agonist. When the authors experimentally forced cSMAC formation, the stimulatory capacity of this weak ligand dropped. This shows that cSMAC formation dampens (represses) signalling induced by weak ligands. Paper 1 further supports the mechanistic basis by demonstrating that signalling is sustained in peripheral microclusters but is \u2018terminated in the cSMAC.\u2019 Together these data align with the claim that cSMAC formation represses weak-ligand signalling."
    },
    "naive_doc_ids": [
      "9283422",
      "21754541",
      "306006",
      "2714623",
      "15972906"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 7 shows that a weak T-cell agonist peptide elicits stronger T-cell proliferation when it fails to form a central supramolecular activation cluster (cSMAC); experimentally forcing cSMAC formation with the same weak ligand reduces its stimulatory capacity. This indicates that cSMAC formation dampens (\u2018represses\u2019) signalling driven by weak ligands. Paper 4 further supports the concept by demonstrating that TCR signals are sustained in peripheral micro-clusters but are terminated once receptors accumulate in the cSMAC. Together these findings align with the claim that cSMAC formation represses weak ligand signalling."
    },
    "overthinking_doc_ids": [
      "36432234",
      "152245",
      "226488",
      "9283422",
      "6588614"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Paper 3 directly examines how the immunological synapse affects signalling produced by a weak T-cell agonist peptide. It reports that a weak agonist that normally fails to form a central supramolecular activation cluster (cSMAC) paradoxically provokes stronger T-cell proliferation than the wild-type agonist. When researchers artificially enhanced cSMAC formation for this weak peptide, its stimulatory capacity dropped. Thus, cSMAC assembly suppresses (represses) signalling elicited by a weak ligand. Paper 4 complements this by showing that TCR signals are terminated in the cSMAC, indicating that the structure functions as a signalling shut-off site. Together, these findings confirm the claim that cSMAC formation represses weak ligand signalling."
    },
    "posthoc_doc_ids": [
      "8458567",
      "14308244",
      "306006",
      "9283422",
      "20568364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1098",
    "claim": "Stacking is more stable when a purine is present in the +5 position (C1698).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.26,
      "justification": "None of the cited papers discuss nucleotide stacking stability, the influence of a purine at the +5 (C1698) position, or any biophysical measurements related to this claim. Therefore, the provided evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "18467982",
      "3174305",
      "7260461",
      "17930286",
      "2095573"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.18,
      "justification": "None of the provided papers discuss base-stacking stability as a function of the nucleotide (purine vs. pyrimidine) at a +5 position (C1698 or any other position). The abstracts focus on protein\u2013protein interactions, immunological receptors, RNA interference pathways, neuronal migration, ribosome biogenesis, motor proteins, splicing mechanisms, DNA polymerase dynamics, and RNA\u2013protein binding, none of which provide data about stacking stability related to purine presence at +5. Thus, the claim is neither supported nor contradicted by the given evidence."
    },
    "overthinking_doc_ids": [
      "207972",
      "4270992",
      "5867846",
      "469066",
      "18467982"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers address nucleotide stacking stability, the effect of a purine at the +5 position, or the specific reference to C1698. Therefore, they offer no relevant evidence to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "4444861",
      "4890578",
      "5824955",
      "1568684",
      "2481032"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "386",
    "claim": "Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 2 reports that, among 430 intravenous doses observed, \u2018Most errors occurred when giving bolus doses or making up drugs that required multiple step preparation.\u2019 This directly matches the claim that errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations. The other papers do not address the type or stage of IV drug errors, so they neither contradict nor weaken this evidence."
    },
    "naive_doc_ids": [
      "21260231",
      "16495649",
      "24525112",
      "118568",
      "3578380"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that \u2018most errors occurred when giving bolus doses or making up drugs that required multiple-step preparation,\u2019 which directly matches the claim that peripheral IV drug-administration errors are most common during bolus administration and when medicines require multiple preparation steps. The remaining cited papers do not address where IV errors most frequently occur and therefore neither refute nor weaken this evidence. Thus, the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "16495649",
      "21260231",
      "79231308",
      "5765455",
      "13889962"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 reports that \u2018most errors occurred when giving bolus doses or making up drugs that required multiple-step preparation\u2019 during intravenous drug administration. This directly aligns with the claim that errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations. The other cited papers do not address this specific issue. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "16495649",
      "21260231",
      "118568",
      "79231308",
      "3578380"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "54",
    "claim": "AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 shows that pharmacological activation of AMPK with metformin \u201ctherapeutically accelerates the resolution of well-established lung fibrosis in an AMPK-dependent manner,\u201d i.e., AMPK activation DECREASES lung fibrosis rather than increases it. Paper 1 further demonstrates that AMPK activation suppresses pro-inflammatory JAK-STAT signaling, and Paper 3 reports that AMPK activation suppresses macrophage proliferation, a component of inflammatory responses. Together these findings oppose the claim that AMPK activation increases inflammation-related lung fibrosis."
    },
    "naive_doc_ids": [
      "3973445",
      "56486733",
      "24721866",
      "49556906",
      "34445160"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 2 reports that AMPK activity is diminished in fibrotic regions of human and mouse lungs and that pharmacological activation of AMPK (e.g., with metformin) reduces myofibroblast fibrotic activity and accelerates resolution of established bleomycin-induced lung fibrosis. This indicates that AMPK activation is anti-fibrotic rather than pro-fibrotic. The other cited papers do not address AMPK in lung fibrosis. Therefore, the available evidence opposes the claim that AMPK activation increases inflammation-related lung fibrosis."
    },
    "overthinking_doc_ids": [
      "10703001",
      "49556906",
      "3984231",
      "7433668"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "None of the cited papers examine the effects of AMPK activation on lung inflammation\u2013related fibrosis. The articles that mention AMPK (papers 3 and 5) address macrophage proliferation in atherosclerosis and metabolic regulation in fatty liver disease, not lung fibrosis. The paper that deals with lung fibrosis (paper 9) focuses on YAP/TAZ signaling and does not involve AMPK. Therefore, the provided evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "4662264",
      "7875158",
      "24721866",
      "1800734",
      "3419709"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1379",
    "claim": "Women with a higher birth weight are more likely to develop breast cancer later in life.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Multiple meta-analyses that used birth-record data show a statistically significant positive association between higher birth weight and subsequent breast-cancer risk.  \n\u2022 Paper 2 (32 studies, 22,058 cases): pooled RR per 0.5 kg increase in birth weight = 1.06 (95% CI 1.02\u20131.09); women \u22654 kg had RR 1.12 (1.00\u20131.25) vs 3.0\u20133.5 kg.  \n\u2022 Paper 7 (systematic review of 57 studies): summary RR for increased birth weight = 1.15 (1.09\u20131.21).  \n\u2022 Paper 8 (meta-analysis): OR 1.24 (1.04\u20131.48) for \u22654,000 g and OR 1.15 (1.04\u20131.26) for 3,500\u20133,999 g compared with 2,500\u20132,599 g.  \nThese findings consistently indicate that women who were heavier at birth have a modestly higher likelihood of developing breast cancer later in life, supporting the claim."
    },
    "naive_doc_ids": [
      "13831842",
      "16322674",
      "18340282",
      "22401720",
      "6313547"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple large meta-analyses and pooled analyses consistently report a modest but statistically significant increase in adult breast-cancer risk among women who were heavier at birth.  \n\u2022 Paper 1 (meta-analysis of 30+ studies) shows odds ratios of 1.15\u20131.24 for birth-weights \u22653,500 g or \u22654,000 g compared with ~2,500 g.  \n\u2022 Paper 2 (individual-data re-analysis of 32 studies, 22,058 cases) finds a linear trend; RR per 0.5 kg increment = 1.06, and RR = 1.12 for \u22654,000 g versus 3,000\u20133,499 g.  \n\u2022 Paper 3 (systematic review of 57 studies) reports pooled RR 1.15 (95% CI 1.09\u20131.21) for higher versus lower birth-weight.  \n\u2022 Paper 8 reviews 26 studies and gives a combined RR 1.23 (95% CI 1.13\u20131.34) comparing high to low birth-weight.  \nAlthough one study (Paper 7) found no relationship between birth-weight and adult mammographic density, this does not measure actual breast-cancer incidence and therefore does not overturn the direct incidence data above.  \nTaken together, the evidence supports the claim that higher birth-weight is associated with a greater likelihood of developing breast cancer later in life."
    },
    "overthinking_doc_ids": [
      "17450673",
      "16322674",
      "23557241",
      "18340282",
      "9171913"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Two large meta-analyses (Paper 3: re-analysis of 32 studies, >22,000 cases; Paper 4: systematic review/meta-analysis) report statistically significant positive associations between higher birth weight (\u22654,000 g) and subsequent breast-cancer risk (RR\u22481.12\u20131.24 relative to average or low birth weight). Paper 2 shows that higher birth weight is linked to increased adult mammographic density, a well-established intermediate marker of breast-cancer risk, and therefore supports the biological pathway. Paper 1 found no relation between birth weight and breast density, but this null result for an intermediate phenotype does not outweigh the consistent direct evidence from Papers 3 and 4. Together, the available evidence indicates that women with higher birth weight are modestly more likely to develop breast cancer later in life."
    },
    "posthoc_doc_ids": [
      "38784540",
      "5487448",
      "16322674",
      "17450673",
      "13765757"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1307",
    "claim": "Tonic signaling from the scFv induces constitutive stimulation.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that antigen-independent clustering of CAR single-chain variable fragments (scFvs) leads to tonic CAR CD3\u03b6 phosphorylation, producing persistent (constitutive) signaling that drives early T-cell exhaustion. This directly supports the claim that tonic signaling originating from the scFv induces constitutive stimulation. The other cited papers discuss different signaling contexts and do not address scFv-mediated tonic signaling, so the supportive evidence comes from Paper 1."
    },
    "naive_doc_ids": [
      "18231807",
      "34016944",
      "2828460",
      "5132358",
      "22210434"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that antigen-independent (tonic) phosphorylation of the CAR CD3\u03b6 chain is \"triggered by antigen-independent clustering of CAR single-chain variable fragments\" (scFvs). This tonic activity leads to continuous activation signals that drive early T-cell exhaustion. The observation that scFv clustering elicits signaling in the absence of antigen demonstrates that tonic signaling from the scFv produces constitutive (antigen-independent) stimulation, directly supporting the claim. The other cited papers do not address scFv-mediated tonic signaling, so they neither add to nor contradict this conclusion."
    },
    "overthinking_doc_ids": [
      "18231807",
      "25353658",
      "25050969",
      "13639330",
      "7386360"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Paper 2 shows that antigen-independent (tonic) clustering of the CAR single-chain variable fragment (scFv) leads to continual CD3\u03b6 phosphorylation and persistent signaling in CAR-expressing T cells. This tonic scFv-mediated signaling constitutes constitutive stimulation that ultimately drives early T-cell exhaustion. Hence the experimental data directly support the claim that tonic signaling originating from the scFv induces constitutive stimulation. The other cited papers address different systems or pathways and do not bear on this specific claim."
    },
    "posthoc_doc_ids": [
      "4611267",
      "18231807",
      "34016944",
      "18758057",
      "34436231"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "585",
    "claim": "In the UK, drowning affects boys and girls equally.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.77,
      "justification": "Among the provided papers, only Paper 1 is about childhood drowning in the UK, and the excerpt contains no data on the relative numbers or rates of drowning for boys versus girls. The other papers discuss unrelated health issues (COPD, cervical cancer, Creutzfeldt-Jakob disease, breast density, fractures, dementia). Therefore, the evidence set does not address whether drowning affects boys and girls equally."
    },
    "naive_doc_ids": [
      "42291761",
      "7285256",
      "12779444",
      "27063470",
      "38784540"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.14,
      "justification": "None of the provided papers report data comparing drowning rates between boys and girls in the United Kingdom. Therefore they neither confirm nor refute the claim that drowning affects boys and girls equally in the UK."
    },
    "overthinking_doc_ids": [
      "42291761",
      "8428935",
      "2097256",
      "9047718",
      "41380943"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "Among the provided papers, only Paper 1 addresses childhood drowning in the UK, and the excerpt shown contains no sex-specific data. The remaining papers deal with topics unrelated to drowning. Therefore the supplied evidence does not indicate whether boys and girls are affected equally or unequally by drowning in the UK."
    },
    "posthoc_doc_ids": [
      "42291761",
      "16390264",
      "18379855",
      "25493293",
      "2828460"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1404",
    "claim": "siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers mention A20 (TNFAIP3) or experiments involving its siRNA knockdown in any murine xenograft model. The evidence covers NF-\u03baB inhibition, BCL9, Src, DPP4, exercise, glutaminase, epigenetic therapy, and TGF-\u03b2, but not A20. Therefore, the papers supply no relevant information to verify or refute the claim."
    },
    "naive_doc_ids": [
      "14615911",
      "33638477",
      "45764440",
      "67045088",
      "2242416"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.2,
      "justification": "None of the provided papers discuss A20 (TNFAIP3), its knockdown by siRNA, or any effect on tumour progression in a murine xenograft model. Therefore, the evidence set does not address the claim."
    },
    "overthinking_doc_ids": [
      "7852582",
      "12358173",
      "13277623",
      "2565138",
      "20888849"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Paper 4 reports that A20 (TNFAIP3) was knocked down in glioblastoma stem cells using lentiviral short-hairpin RNA (RNA-interference technology). When these A20-deficient cells were implanted into mice, tumor growth was reduced and animal survival was prolonged compared with control xenografts, demonstrating slower tumor progression in an in vivo murine model. No other cited papers address A20 knockdown; none contradict this finding. Therefore, the available evidence supports the claim that RNA-interference\u2013mediated knockdown of A20 slows tumor progression in a mouse xenograft model."
    },
    "posthoc_doc_ids": [
      "45764440",
      "14615911",
      "8994465",
      "33370",
      "1921218"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1322",
    "claim": "Transplanted human glial progenitor cells can mature in their host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 reports that human glial progenitor cells (GPCs) were transplanted into neonatal immunodeficient mice and, \"upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes.\" This shows that the transplanted human GPCs differentiated into mature astrocytes inside the host animal, directly supporting the claim. The other cited papers do not address transplantation of human GPCs, so they neither add support nor contradiction. Therefore, the available evidence supports the claim that transplanted human glial progenitor cells can mature in their host animal."
    },
    "naive_doc_ids": [
      "16284655",
      "3360421",
      "4427392",
      "803312",
      "1667063"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 2 reports that when human glial progenitor cells were transplanted (engrafted) into neonatal immunodeficient mice, the recipient brains later contained large numbers of mature human astrocytes as well as remaining human glial progenitors. The transplanted human cells integrated with host astroglia (gap-junction coupling) and displayed characteristic human astrocyte morphology and calcium signaling, demonstrating their maturation within the animal. The other cited papers do not address glial progenitor transplantation and therefore neither refute nor alter this conclusion. Thus the available evidence supports the claim that transplanted human glial progenitor cells can mature in their host animal."
    },
    "overthinking_doc_ids": [
      "9122283",
      "16284655",
      "37699461",
      "1667063",
      "3360421"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 reports that after engraftment of human glial progenitor cells into neonatal immunodeficient mice, the recipient brains later contained large numbers of mature human astrocytes derived from those progenitors (\"Upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes\"). This demonstrates that transplanted human glial progenitor cells can survive and mature within the host animal. The other cited papers focus on different cell types or mechanisms and do not contradict this finding. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "16284655",
      "9122283",
      "37699461",
      "4427392",
      "1667063"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "324",
    "claim": "Deleting Raptor reduces G-CSF levels.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "Among the cited papers, only Paper 6 involves Raptor deletion, but it examines effects on Th17 differentiation, Gfi1 expression, and ROR\u03b3 localization. None of the papers report measurements of granulocyte-colony-stimulating factor (G-CSF) concentrations after Raptor deletion. Therefore, the provided evidence neither supports nor contradicts the claim that deleting Raptor reduces G-CSF levels."
    },
    "naive_doc_ids": [
      "42465769",
      "188911",
      "24612804",
      "5484763",
      "17967608"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers examine the effect of deleting Raptor on granulocyte colony-stimulating factor (G-CSF) levels. Although several papers mention G-CSF or related cytokines, and one paper discusses Raptor-independent signaling, none present data on Raptor deletion or its impact on G-CSF. Therefore, the claim is not addressed by the cited evidence."
    },
    "overthinking_doc_ids": [
      "4658268",
      "10017612",
      "14188138",
      "188911",
      "24612804"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.27,
      "justification": "Among the provided abstracts, Paper 9 is the only one that discusses raptor deletion, but it reports effects on Th17 differentiation without measuring or mentioning G-CSF levels. Papers 4, 5, and 6 involve G-CSF, yet they do not address raptor deletion. Therefore, the supplied evidence does not establish whether deleting raptor reduces G-CSF levels."
    },
    "posthoc_doc_ids": [
      "982650",
      "5409325",
      "9846940",
      "24612804",
      "42465769"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "565",
    "claim": "In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that cells lacking the RNase III ortholog Rnt1p\u2014an enzyme operating in an RNA-surveillance pathway\u2014are hypersensitive to high iron concentrations. The study concludes that RNA surveillance is required to prevent iron toxicity in S. cerevisiae. This directly supports the claim that absence of RNA surveillance pathways leads to sensitivity under high-iron conditions. The other cited papers do not address iron sensitivity or RNA surveillance, so they neither add to nor contradict this evidence. Hence the overall evidence supports the claim."
    },
    "naive_doc_ids": [
      "16120395",
      "30261663",
      "365896",
      "26596106",
      "10300888"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that cells lacking the RNA-surveillance RNase III ortholog Rnt1p (and other surveillance nucleases) accumulate aberrant iron-uptake mRNAs and are \"hypersensitive to high iron concentrations,\" demonstrating that loss of RNA surveillance leads to iron sensitivity in Saccharomyces cerevisiae. None of the other cited papers address this specific relationship. Therefore, the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "16120395",
      "12383365",
      "335029",
      "8247597",
      "365896"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that deleting the RNA-surveillance nuclease Rnt1p (the yeast RNase III) or other surveillance factors causes the accumulation of aberrant iron-uptake mRNAs and that \u201cRNase III-deficient cells are hypersensitive to high iron concentrations.\u201d Thus loss of an RNA surveillance pathway makes S. cerevisiae cells sensitive to high-iron conditions, directly supporting the claim. The other cited papers do not address iron sensitivity in the context of RNA surveillance, so they neither add nor detract from this conclusion."
    },
    "posthoc_doc_ids": [
      "16120395",
      "365896",
      "26596106",
      "16712164",
      "418246"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "871",
    "claim": "Obesity decreases life quality.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Paper 7 reports that individuals with extreme obesity presented \"severe psychiatric and somatic comorbidity and impairment of psychosocial functioning\" before bariatric surgery. After substantial weight loss (\u2248 24 % of initial weight) there were significant, lasting improvements in depression scores, physical dimensions of health-related quality of life (HRQoL) and self-esteem. Because HRQoL improved when obesity was reduced, the data imply that the obese state itself was associated with lower quality of life. Paper 6 further highlights the need for systematic psychological support for bariatric (i.e., obese) patients, indicating recognised quality-of-life and mental-health challenges in this population. No paper presents evidence showing obesity enhances quality of life. Together, the available evidence supports the claim that obesity decreases life quality."
    },
    "naive_doc_ids": [
      "463533",
      "4828631",
      "11630388",
      "32421068",
      "17693849"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.63,
      "justification": "None of the provided papers present direct data on how obesity itself influences health-related quality of life. The studies focus on binge-eating disorder, chronic diseases in general, cancer risks, brain metabolites, or genetic loci; none reports quality-of-life measures explicitly tied to obesity or high BMI. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "40666943",
      "463533",
      "42913391",
      "4828631",
      "37583120"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 7 specifically concerns obesity, but it examines the relationship between methane production and body-mass index and does not measure or report health-related quality-of-life outcomes. The remaining papers address other medical conditions (pulmonary hypertension, leukemia, breast cancer, etc.) or methodological issues unrelated to obesity. Consequently, none of the cited evidence evaluates whether or how obesity affects quality of life, so the claim cannot be confirmed or refuted from the supplied literature."
    },
    "posthoc_doc_ids": [
      "463533",
      "2820454",
      "9217800",
      "40666943",
      "42913391"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "124",
    "claim": "Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1, a systematic review and meta-analysis, reports that antiretroviral therapy (ART) is \u201cstrongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories,\u201d providing hazard ratios well below 1.0 for <200, 200\u2013350, and >350 cells/\u00b5l, and noting no effect-modification by CD4 stratum. This directly supports the claim that ART reduces tuberculosis rates across a broad range of CD4 strata. The remaining cited papers address other outcomes (timing of ART, hepatotoxicity, diabetes prevention, MDR-TB adverse events) and do not contradict this finding. Hence, the collective evidence supports the claim."
    },
    "naive_doc_ids": [
      "4883040",
      "7111021",
      "14806256",
      "24704139",
      "31363207"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 (Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis) directly examines tuberculosis incidence in adults receiving antiretroviral therapy and reports significant reductions across all baseline CD4 count categories: <200 cells/\u00b5l (HR 0.16), 200\u2013350 cells/\u00b5l (HR 0.34), and >350 cells/\u00b5l (HR 0.43). The authors state there was no evidence that the protective effect varied by CD4 stratum. This aligns with the claim that antiretroviral therapy reduces tuberculosis rates across a broad range of CD4 strata. The other provided papers do not address this specific relationship and therefore do not contradict it."
    },
    "overthinking_doc_ids": [
      "17077004",
      "4883040",
      "7111021",
      "15997009",
      "8595678"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 2 (Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis) directly evaluates the effect of ART on tuberculosis incidence in HIV-infected adults. It reports significant reductions in TB incidence in every baseline CD4 category examined: <200 cells/\u00b5l (HR 0.16), 200\u2013350 cells/\u00b5l (HR 0.34), and >350 cells/\u00b5l (HR 0.43), with no evidence that the effect differed by CD4 stratum (p = 0.20). This shows that ART lowers TB rates across a broad range of CD4 counts. None of the other cited papers present data contradicting this effect. Therefore, the supplied evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "13899137",
      "4883040",
      "7111021",
      "2048139",
      "3285322"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1118",
    "claim": "Sweet taste receptors on the tongue are deactivated by between 1 and 10 mM glucose.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the provided papers investigate whether sweet taste receptors on the tongue are deactivated by 1\u201310 mM glucose. The cited studies address knockout of taste\u2010related proteins, gut taste receptors, signaling pathways, and unrelated topics (PDGF signaling, EGFR inhibitors, physical activity, glucose homeostasis), but do not present data on glucose concentrations deactivating tongue sweet receptors. Therefore they neither support nor contradict the specific claim."
    },
    "naive_doc_ids": [
      "23351136",
      "15548965",
      "718601",
      "20829129",
      "21931005"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.16,
      "justification": "None of the cited papers examine inhibition or deactivation of sweet-taste receptors by low-millimolar concentrations of glucose. Papers 1 and 4 discuss genetic deletion of taste\u2010related proteins and general sweet-taste signaling, but do not measure how 1\u201310 mM glucose influences receptor activity. The remaining papers concern systemic glucose biomarkers, metabolic effects, or unrelated receptor systems. Therefore the provided evidence neither supports nor refutes the specific claim."
    },
    "overthinking_doc_ids": [
      "23351136",
      "1538080",
      "2605032",
      "718601",
      "6588614"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers examine whether sweet taste receptors on the tongue are deactivated by 1\u201310 mM glucose. The cited studies address knockout models of taste-receptor components, gut GLP-1 release, ghrelin secretion, metabolic hormone signaling, and unrelated receptor mechanisms, but they do not present data on glucose concentrations causing deactivation of sweet receptors on the tongue."
    },
    "posthoc_doc_ids": [
      "23351136",
      "718601",
      "6588614",
      "14116046",
      "15548965"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "482",
    "claim": "Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 2 reports that applying tensional force to integrins activates the Rho-specific GEFs LARG and GEF-H1, promotes their recruitment to adhesion complexes, and that these GEFs are required for the cell\u2019s mechanical reinforcement response. Because LARG and GEF-H1 catalyze nucleotide exchange on RhoA, their force-dependent activation provides the mechanistic link between tension on fibronectin-binding integrins and RhoA activation described in the claim. The other cited papers do not address this specific mechanotransduction pathway, so Paper 2 constitutes direct supporting evidence."
    },
    "naive_doc_ids": [
      "8093935",
      "10991183",
      "33076846",
      "10669582",
      "20943272"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 2 shows that applying tensional force to integrins stimulates the activation of the Rho-specific GEFs LARG and GEF-H1 and that these GEFs are required for the cellular mechanical reinforcement response. Because LARG and GEF-H1 are RhoA-specific exchange factors, their force-dependent activation provides the molecular mechanism for loading RhoA with GTP in this context. Paper 1 independently establishes that Rho signaling is necessary for the adaptive responses to force on fibronectin-binding integrins, linking mechanical force, integrins and RhoA activity. Together these data demonstrate that GEFs mediate RhoA activation triggered by tensile forces applied through fibronectin-binding integrins, supporting the claim."
    },
    "overthinking_doc_ids": [
      "32532238",
      "10991183",
      "20943272",
      "9507605",
      "17997584"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.74,
      "justification": "Paper 2 reports that when tensional force is applied to integrins (fibronectin-coated beads are the standard method for this assay), two Rho-specific guanine nucleotide exchange factors, LARG and GEF-H1, become activated and are recruited to the adhesion complex. These GEFs control the rise in RhoA activity that underlies the cellular stiffening (reinforcement) response. Because LARG and GEF-H1 are RhoA GEFs, their force-dependent activation provides the mechanistic link between tensile loading of fibronectin-binding integrins and RhoA activation. No paper presents contradictory evidence. Hence, the available evidence substantiates the claim."
    },
    "posthoc_doc_ids": [
      "33076846",
      "10991183",
      "8093935",
      "5821617",
      "20943272"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1385",
    "claim": "cSMAC formation enhances weak ligand signalling.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Paper 1 shows that TCR signals are sustained in peripheral microclusters and are TERMINATED once receptors are gathered into the cSMAC, indicating that the cSMAC dampens rather than boosts signaling. Paper 2 directly addresses weak-agonist ligands: a weak peptide that failed to form a cSMAC induced stronger T-cell proliferation than the wild-type agonist, and experimentally forcing cSMAC formation DECREASED the weak peptide\u2019s stimulatory capacity. These results demonstrate that cSMAC formation reduces, not enhances, signaling elicited by weak ligands. The remaining papers do not present data linking cSMAC formation to enhancement of weak-ligand signaling. Therefore, the combined evidence opposes the claim that cSMAC formation enhances weak ligand signalling."
    },
    "naive_doc_ids": [
      "9283422",
      "306006",
      "2714623",
      "994800",
      "2825380"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 3 shows that a weak agonist peptide triggers stronger T-cell proliferation when it fails to form a cSMAC, and that experimentally forcing cSMAC formation diminishes this weak-ligand response. Paper 4 further demonstrates that TCR signals are sustained in peripheral micro-clusters and are terminated once receptors accumulate in the cSMAC. Together, these data indicate that cSMAC formation attenuates rather than enhances signalling elicited by weak ligands, directly opposing the claim."
    },
    "overthinking_doc_ids": [
      "20344442",
      "301838",
      "306006",
      "9283422",
      "13639330"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 3 directly tested a weak agonist peptide. It found that when cSMAC formation was experimentally promoted, the weak peptide\u2019s ability to stimulate T-cell proliferation fell; conversely, the peptide\u2019s unusually strong activity correlated with its failure to form a cSMAC. Paper 4 further shows that TCR signaling is sustained in peripheral microclusters and is terminated\u2014not enhanced\u2014in the cSMAC. Together these data indicate that cSMAC formation diminishes rather than enhances signaling by weak ligands, contradicting the claim."
    },
    "posthoc_doc_ids": [
      "8458567",
      "14308244",
      "306006",
      "9283422",
      "2714623"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "208",
    "claim": "CHEK2 is not associated with breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "The only paper that assesses CHEK2 directly (Paper 1) genotyped common haplotype-tagging SNPs across the gene in 1,577 breast-cancer cases and 1,513 controls and reported \"no convincing association between any common CHEK2 haplotype and breast-cancer risk.\"  The rare CHEK2 1100delC variant also showed no statistically significant association (OR 2.26, 95% CI 0.99\u20135.15).  The remaining papers focus on BRCA genes, anthropometric or perinatal factors, trastuzumab, or PPM1D and do not address CHEK2.  Hence the provided evidence supports the statement that CHEK2 is not associated with breast cancer."
    },
    "naive_doc_ids": [
      "13519661",
      "20280410",
      "9394119",
      "13831842",
      "17450673"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.68,
      "justification": "Paper 3 specifically examined the checkpoint kinase 2 (CHEK2) gene and breast-cancer risk. Although no link was seen for common CHEK2 haplotypes, the study reports that the rare CHEK2 1100delC mutation occurred more often in cases (0.7%) than controls (0.4%) with an odds ratio of 2.26 (95 % CI 0.99\u20135.15), and notes that previous research has already \u201cestablished a role for the CHEK2 gene in breast cancer aetiology.\u201d This indicates an increased breast-cancer risk for carriers of at least one CHEK2 variant, contradicting the claim that CHEK2 is not associated with breast cancer. The other cited papers do not address CHEK2. Therefore, the overall evidence refutes the claim."
    },
    "overthinking_doc_ids": [
      "17450673",
      "23557241",
      "13519661",
      "17088791",
      "18340282"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Among the cited papers, only Paper 4 directly examines CHEK2 in relation to breast cancer. In a Swedish case-control study (1,577 cases, 1,513 controls) that comprehensively tagged common variation across the 52-kb CHEK2 locus, the authors \u201cfound no convincing association between any common CHEK2 haplotype and breast cancer risk.\u201d  Although they reported an odds ratio of 2.26 for the rare CHEK2 1100delC mutation, the 95 % CI (0.99\u20135.15) included 1.0, indicating the result was not statistically significant. No other provided papers address CHEK2. Thus, the available evidence indicates that, in this dataset, CHEK2 variants were not significantly associated with breast cancer, supporting the claim that CHEK2 is not associated with the disease."
    },
    "posthoc_doc_ids": [
      "2140497",
      "9394119",
      "31616203",
      "13519661",
      "23557241"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "385",
    "claim": "Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that treatment of a murine ovarian cancer model with the epigenetic agents 5-azacytidine (DNMT inhibitor) and an HDAC inhibitor increases type I interferon signaling, elevates active CD8\u207a T and NK cells, decreases immunosuppressive macrophages/MDSCs, and reduces tumor burden. Paper 2 demonstrates that a low-dose sequential regimen of a DNMT inhibitor plus HDAC inhibitors in mouse models of non-small-cell lung cancer reverses tumor immune evasion and reprograms T cell exhaustion toward memory/effector phenotypes, producing a robust antitumor effect. Both studies use epigenetic-modulating agents in cancer models and explicitly report modulation of the antitumor immune response, directly confirming the claim."
    },
    "naive_doc_ids": [
      "9767444",
      "9955779",
      "2565138",
      "21891856",
      "15727984"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.81,
      "justification": "Paper 3 demonstrates experimentally that the DNA-methyltransferase inhibitor 5-azacytidine and a histone deacetylase inhibitor alter the tumor micro\u00adenvironment in a murine ovarian cancer model: they activate type I interferon signaling, increase CD8\u207a T- and NK-cell activity, decrease immunosuppressive myeloid cells, and, together with PD-1 blockade, produce the strongest antitumor effect. These changes constitute modulation of the antitumor immune response by epigenetic-modulating agents in a cancer system. Paper 2, a review of pre-clinical and clinical data, further corroborates that epigenetic therapies can up-regulate immune-related genes and enhance immune recognition of tumors. No paper presents contradictory data. Hence, the evidence supports the claim that EMAs modulate antitumor immune responses in cancer models."
    },
    "overthinking_doc_ids": [
      "343052",
      "1032372",
      "9767444",
      "45764440",
      "3981033"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple referenced papers report experimental data showing that drugs which modify epigenetic marks change the anti-tumor immune response in cancer models. Paper 3 demonstrates that the DNA methyltransferase inhibitor 5-azacytidine and an HDAC inhibitor activate type I interferon signaling in a mouse ovarian cancer model, increase CD8+ T and NK cell activity, decrease suppressive myeloid cells, and enhance response to anti-PD-1 therapy\u2014directly proving immune modulation by EMAs in a tumor model. Paper 7 shows that sequential low-dose DNMTi + HDACi treatment of NSCLC cells and mouse tumors up-regulates antigen-presentation genes, alters T-cell exhaustion toward effector/memory phenotypes, and produces strong anti-tumor effects. Paper 1 summarizes similar pre-clinical findings. No papers provide contradictory evidence. Therefore the claim that epigenetic modulating agents modulate antitumor immune responses in cancer model systems is supported."
    },
    "posthoc_doc_ids": [
      "1032372",
      "32742683",
      "9767444",
      "11581157",
      "3981033"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1324",
    "claim": "Treatment with a protein named FN restores regenerative abilities of aged muscles.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that aged skeletal muscle niches contain reduced fibronectin (FN) and that experimentally reconstituting FN in these aged niches \u201cremobilizes stem cells and restores youth-like muscle regeneration.\u201d This is direct experimental evidence that treatment with FN can restore regenerative ability in aged muscle. The other cited papers discuss unrelated topics (folic acid, miR-29, satellite-cell depletion, systemic factors, ECM remodeling, FAPs) and neither refute nor modify this conclusion. Therefore the evidence overall supports the claim."
    },
    "naive_doc_ids": [
      "19912367",
      "21636085",
      "4653837",
      "20418809",
      "4326318"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that aged skeletal muscle niches have reduced fibronectin (FN) and that experimentally restoring FN levels in these aged muscles \u2018remobilizes stem cells and restores youth-like muscle regeneration.\u2019 This directly matches the claim that treatment with FN can restore regenerative ability in aged muscle. The remaining cited papers address other mechanisms of muscle regeneration or extracellular-matrix biology but do not contradict the FN finding. Therefore, the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "19912367",
      "9122283",
      "20418809",
      "4326318",
      "4164929"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that aged skeletal-muscle niches contain markedly reduced fibronectin (FN). Experimentally restoring FN levels in these aged niches \"remobilizes stem cells and restores youth-like muscle regeneration,\" demonstrating that treatment with the FN protein reverses the age-related loss of regenerative capacity. No other cited papers address FN treatment; none contradict this finding. Therefore the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "19912367",
      "20418809",
      "4326318",
      "1507222",
      "25985964"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "169",
    "claim": "Bariatric surgery reduces postmenopausal breast cancer.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Only one cited study actually examines cancer outcomes after bariatric surgery and it reports no association between surgery and overall cancer incidence, without presenting separate data for breast cancer or for post-menopausal women. The remaining papers deal with obesity or other breast-cancer factors (BMI, HDL-C, trastuzumab, cell-line work) but do not evaluate the effect of bariatric surgery on postmenopausal breast cancer. Therefore the provided evidence neither confirms nor refutes the specific claim that bariatric surgery reduces postmenopausal breast cancer."
    },
    "naive_doc_ids": [
      "5824985",
      "13831842",
      "3329824",
      "16701509",
      "4828631"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Among the papers provided, only Paper 1 evaluates incident cancer after bariatric surgery. In this large matched cohort study the investigators report: \u201cNo association was detected between bariatric surgery and \u2026 cancer.\u201d Thus, bariatric surgery did not lower cancer incidence, which by definition includes breast cancer. The remaining papers do not examine the relationship between bariatric surgery and postmenopausal breast cancer risk. Consequently, the available evidence opposes the claim that bariatric surgery reduces postmenopausal breast cancer."
    },
    "overthinking_doc_ids": [
      "5824985",
      "38551172",
      "9171913",
      "32534305",
      "3329824"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "None of the cited papers evaluate breast-cancer incidence after bariatric surgery. The only bariatric-surgery study (Paper 4) reports no association with overall cancer but does not analyze breast cancer separately, and the other papers discuss breast-cancer risk factors without involving bariatric surgery. Thus the evidence provided does not address whether bariatric surgery reduces postmenopausal breast cancer."
    },
    "posthoc_doc_ids": [
      "38551172",
      "16098747",
      "5864770",
      "5824985",
      "40949706"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "728",
    "claim": "Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.61,
      "justification": "Paper 2 explicitly examines mouse blood monocyte subsets and states that Ly6C(high) cells are the immature subset that expands during acute or chronic infection and is preferentially recruited to inflammatory sites, describing them as the \u2018inflammatory left shift\u2019. This indicates a higher, not lower, inflammatory potential for Ly6C hi monocytes compared with more mature Ly6C lo cells. Paper 5 further refers to \u201cinflammatory monocyte/macrophage modulation via an inhibitory effect on Ly6C(hi) monocytosis\u201d, again designating Ly6C hi monocytes as the inflammatory population. Together these findings show Ly6C hi monocytes possess greater inflammatory capacity than Ly6C lo monocytes, directly opposing the claim."
    },
    "naive_doc_ids": [
      "10648422",
      "36444198",
      "364522",
      "343052",
      "12370881"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.81,
      "justification": "Paper 2 reports that Ly6C^high monocytes are the subset that expands during acute or chronic infection and is preferentially recruited to inflammatory sites, indicating a stronger (not lower) inflammatory capacity than other subsets such as Ly6C^low monocytes. This directly opposes the claim that Ly6C^high monocytes have a lower inflammatory capacity than Ly6C^low monocytes. The other cited papers do not address Ly6C^high versus Ly6C^low inflammatory potential. Hence, the available evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "343052",
      "36444198",
      "1265945",
      "3973445",
      "6407356"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.66,
      "justification": "Paper 1 reports that during acute (Listeria) or chronic (Leishmania) infection the proportion of Ly6C\u207a\u207a (Ly6C high) monocytes in blood increases and that these immature Ly6C high cells are preferentially recruited to sites of acute peritoneal inflammation, indicating a stronger participation in inflammatory responses than the more mature Ly6C low subset. Paper 3 shows that selective depletion of circulating Ly6C high monocytes diminishes lung fibrosis and that adoptive transfer of Ly6C high monocytes exacerbates the inflammatory-driven fibrotic process, again demonstrating a potent pro-inflammatory / pro-fibrotic role for the Ly6C high population. Together these data show Ly6C high monocytes possess higher, not lower, inflammatory capacity compared with Ly6C low monocytes, contradicting the claim."
    },
    "posthoc_doc_ids": [
      "36444198",
      "7489663",
      "22621251",
      "5268462",
      "1365188"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "310",
    "claim": "De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.29,
      "justification": "None of the cited papers compare the number of specific contigs obtained after de novo assembly with those present in unassembled sequencing data. The references discuss issues such as GC bias, transcriptome reconstruction quality, centromere behavior, alignment tools, variant detection, and siRNA specificity, but they do not provide data or conclusions addressing whether de novo assembly yields fewer specific contigs than leaving the data unassembled."
    },
    "naive_doc_ids": [
      "14464451",
      "37424881",
      "25041967",
      "32770503",
      "6535392"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers compare the number of contigs obtained after de novo assembly with any metric from unassembled (raw) sequence data. They describe genome assemblies, factors affecting assembly quality, or unrelated biological topics, but they do not present evidence that de novo assembly yields fewer specific contigs than unassembled data. Thus the claim is neither supported nor contradicted by the cited literature."
    },
    "overthinking_doc_ids": [
      "14185503",
      "14464451",
      "143251",
      "12438901",
      "16605494"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the cited papers compare the number of contigs obtained after de novo assembly with the number (or specificity) of sequences in unassembled data. They discuss assembly quality, GC bias, transcript recovery, pathogen detection, and other topics, but do not provide evidence regarding whether de novo assembly yields fewer specific contigs than unassembled sequence data."
    },
    "posthoc_doc_ids": [
      "14464451",
      "143251",
      "32770503",
      "14915566",
      "3981729"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "772",
    "claim": "Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 reports that a chimeric CHIKV (EILV/CHIKV) that was PRODUCED IN MOSQUITO CELLS and given as a single dose to mice \u201celicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models.\u201d This directly shows that mice are capable of mounting a neutralizing-antibody response to CHIKV produced in mosquitoes, contradicting the claim. The other cited papers concern HIV, Cryptococcus, Japanese encephalitis, or mosquito genomics and do not address the claim."
    },
    "naive_doc_ids": [
      "24922825",
      "23915841",
      "21141798",
      "32353339",
      "13702924"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 5 reports that a single dose of a chimeric EILV/CHIKV virus produced in mosquito cells elicited rapid and long-lasting neutralizing antibodies in two different mouse models, providing complete protection. This directly demonstrates that mice can, in fact, generate neutralizing antibodies in response to mosquito-derived CHIKV, contradicting the claim that they are incapable of doing so."
    },
    "overthinking_doc_ids": [
      "343052",
      "2565138",
      "3684342",
      "23915841",
      "24922825"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 reports that a chimeric EILV/CHIKV virus produced in mosquito cells, when given as a single dose to mice, elicited rapid (within 4 days) and long-lasting (>290 days) neutralizing antibodies that conferred complete protection in two mouse models. This demonstrates that mice are indeed capable of mounting a neutralizing antibody response to CHIKV antigens derived from mosquito-produced virus. None of the remaining papers address CHIKV immunity in mice. Therefore, the available evidence refutes the claim that mice are incapable of producing neutralizing antibodies to mosquito-produced CHIKV."
    },
    "posthoc_doc_ids": [
      "24922825",
      "14934137",
      "13965483",
      "23915841",
      "13469921"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1345",
    "claim": "Up-regulation of the p53 pathway and related molecular events speeds cancer progression.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the cited studies only Paper 4 deals directly with p53\u2013pathway activity.  It shows that constitutive expression (i.e., up-regulation) of a tumor-derived mutant p53 (p53-281G) markedly increases the tumor-forming ability of cells in nude mice, whereas mutants lacking the oligomerization/nucleic-acid\u2013binding domain lose this \u2018gain-of-function\u2019 and are far less tumorigenic.  Thus, enhanced activity of the (mutant) p53 pathway accelerates tumor progression.  The remaining papers focus on other oncogenic pathways and do not contradict this observation.  Therefore the available evidence aligns with the claim that up-regulation of p53-related molecular events can speed cancer progression."
    },
    "naive_doc_ids": [
      "6944800",
      "33638477",
      "45764440",
      "35684881",
      "1782201"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Among the cited papers, only Paper 9 addresses the p53 pathway. It reports that hyperactive, truncating mutations in the p53-inducible phosphatase PPM1D cause enhanced suppression of p53 activity and are associated with increased predisposition to breast and ovarian cancer. In other words, decreased (not increased) p53 signaling promotes cancer development. No paper presents data showing that up-regulation of the p53 pathway accelerates tumor progression. Therefore the available evidence runs opposite to the claim."
    },
    "overthinking_doc_ids": [
      "13329980",
      "3559136",
      "3981033",
      "1686997",
      "4920376"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.25,
      "justification": "None of the supplied papers discuss p53 pathway activation or its impact on cancer progression. Therefore, they provide no information relevant to verifying the claim."
    },
    "posthoc_doc_ids": [
      "4820792",
      "23599024",
      "33638477",
      "18882947",
      "21891856"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "478",
    "claim": "Golli-deficient T-cells prefer to differentiate into an anergic phenotype in the adaptive immune response when there are increased levels of Ca2+ in the cytosol.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 5 reports that golli-deficient T cells exhibit ENHANCED Ca\u00b2\u207a influx after T-cell-receptor stimulation and are hyper-proliferative. Hyper-proliferation indicates increased activation rather than the non-responsive (anergic) state. Thus, when cytosolic Ca\u00b2\u207a levels rise, golli-deficient T cells become more, not less, responsive. This directly opposes the claim that they preferentially differentiate into an anergic phenotype under these conditions."
    },
    "naive_doc_ids": [
      "2825380",
      "7736860",
      "8903143",
      "14474178",
      "14767844"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.64,
      "justification": "Paper 1 directly examines golli-deficient T cells. It reports that these cells exhibit enhanced Ca2+ influx after T-cell-receptor stimulation and are hyper-proliferative, indicating heightened activation rather than functional unresponsiveness (anergy). No other provided papers address golli-deficient T-cell fate. Therefore, the available evidence opposes the claim that golli-deficient T cells preferentially enter an anergic state when cytosolic Ca2+ rises."
    },
    "overthinking_doc_ids": [
      "14767844",
      "4444861",
      "7386360",
      "1976183",
      "7736860"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1 directly examines T cells lacking golli. It reports that golli-deficient T cells exhibit enhanced Ca2+ influx after T-cell-receptor stimulation and are hyper-proliferative, indicating heightened activation rather than the non-responsive (anergic) state. No other cited papers address golli or T-cell anergy. Therefore, the available evidence opposes the claim that golli-deficient T cells preferentially become anergic when cytosolic Ca2+ is elevated."
    },
    "posthoc_doc_ids": [
      "14767844",
      "3464191",
      "364522",
      "13878643",
      "34905328"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "57",
    "claim": "APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.79,
      "justification": "Paper 1 reports that in human iPSC-derived neurons, ApoE4 expression leads to (i) higher amyloid-\u03b2 production and (ii) increased tau phosphorylation, but also causes GABAergic neuron degeneration. The degeneration is not delayed; it is promoted. No other provided paper addresses the effect of ApoE4 on GABA neuron survival. Therefore, the evidence contradicts the claim that ApoE4 delays GABA neuron degeneration."
    },
    "naive_doc_ids": [
      "4709641",
      "45336190",
      "3085264",
      "4632921",
      "8150638"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 directly examines human iPSC-derived neurons expressing APOE4. It reports (i) increased amyloid-\u03b2 production and (ii) higher tau phosphorylation, but also states that these neurons \"displayed GABAergic neuron degeneration.\" This indicates APOE4 promotes, rather than delays, loss of GABA neurons. The other cited papers do not address GABA-neuron survival in the context of APOE4. Thus, while two parts of the claim are supported (A\u03b2 and tau changes), the statement that APOE4 delays GABA neuron degeneration is opposite to the experimental finding, leading overall to a contradiction."
    },
    "overthinking_doc_ids": [
      "4709641",
      "45336190",
      "7221410",
      "3085264",
      "14192687"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.79,
      "justification": "Paper 1 specifically studies human iPSC-derived neurons expressing APOE4. It reports that these neurons (i) produce more amyloid-\u03b2 and (ii) show higher tau phosphorylation\u2014consistent with the first two parts of the claim\u2014 but also (iii) \u201cdisplayed GABAergic neuron degeneration.\u201d  That finding means APOE4 promotes or accelerates loss of GABA neurons rather than delaying their degeneration. Because the claim asserts a protective (delaying) effect on GABA neurons, the evidence directly contradicts this portion of the statement, so overall the claim is not supported."
    },
    "posthoc_doc_ids": [
      "4709641",
      "45336190",
      "14192687",
      "21601459",
      "4632921"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "938",
    "claim": "Persister cells provide relapse resistance in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.56,
      "justification": "Paper 1 describes a small sub-population of tumour cells with stem-cell\u2013like properties that \u2018survive traditional cancer chemotherapy and radiation therapy\u2019 because they are quiescent, have efficient DNA repair and over-express ABC drug-efflux transporters.  Because these cells persist after treatment, they are able to seed new tumour growth and are therefore considered a principal cause of post-therapy relapse.  Paper 3 shows that minimal-residual-disease cells that remain after primary therapy evolve into recurrent tumours with an escape phenotype that is resistant to innate immune attack, and eliminating these persisting cells prevents relapse in mice.  Paper 4 reviews the phenomenon of tumour dormancy, noting that microscopic, clinically silent tumours can remain after therapy and later resume growth, emphasising their importance for recurrence.  Collectively these studies provide evidence that persisting (dormant/\u2018cancer stem\u2019) cells that survive initial therapy underlie resistance leading to relapse, supporting the claim."
    },
    "naive_doc_ids": [
      "8891333",
      "25895285",
      "1921218",
      "30919024",
      "9648896"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the provided papers examine cancer persister (drug-tolerant) cells or demonstrate that they mediate relapse resistance in patients. The cited studies address other mechanisms of drug resistance (e.g., phosphoproteomic changes, stromal miR-21 transfer, PI3K/mTOR signaling), tumor engraftment predictors, diagnostic procedures, immune deficiency, stem-cell processing, and spinal-cord injury models. Because persister cells and their specific contribution to relapse are not discussed, the evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "25895285",
      "38243984",
      "1727493",
      "39532074",
      "25985964"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Paper 9 describes a small sub-population of tumor cells with stem-cell\u2013like properties that survive chemotherapy and radiation by being quiescent, highly drug-efflux competent and efficient at DNA repair. Because these surviving cells can self-renew, the paper argues they are responsible for tumor regrowth after treatment \u2013 i.e., they confer resistance that leads to relapse.  Paper 7 further shows that minimal residual disease (cells that persist after primary therapy) evolves into recurrent tumors that are resistant to innate immune elimination, again linking persistence of a cell sub-population to recurrence.  None of the other cited studies provide data that contradict this idea.  Hence, the supplied evidence collectively supports the claim that persister (therapy-surviving) cells underlie relapse resistance in cancer patients."
    },
    "posthoc_doc_ids": [
      "38243984",
      "1727493",
      "2841164",
      "4688340",
      "24349992"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1058",
    "claim": "Roughly 55% of women with chronic pelvic pain have no underlying pathology.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided abstracts report the proportion of women with chronic pelvic pain who are found to have no underlying pathology. They focus on treatment efficacy, quality-of-life measurement, headache prevalence, adhesiolysis, coronary disease, and asthma. Therefore the supplied evidence neither confirms nor refutes the specific 55 % figure in the claim."
    },
    "naive_doc_ids": [
      "13027590",
      "463533",
      "8570317",
      "3190689",
      "12561083"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the cited papers report the proportion of women with chronic pelvic pain who lack an identifiable pathology. Paper 1 involves women selected specifically because they had no or only minimal pelvic disease but does not quantify how common this situation is in the wider chronic-pelvic-pain population. The remaining papers address abdominal adhesions, low-back pain, neuropathic pain assessment, or general health-related quality of life, and do not discuss underlying pathology rates in chronic pelvic pain. Therefore the provided evidence neither supports nor contradicts the 55 % figure."
    },
    "overthinking_doc_ids": [
      "13027590",
      "3190689",
      "14724693",
      "26445118",
      "463533"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers report the proportion of women with chronic pelvic pain in whom no underlying pathology is found. Paper 1 deals with treatment in a selected group already known to have no or minimal pathology, but it does not give any prevalence figure in an unselected CPP population. The remaining papers do not address chronic pelvic pain in women. Therefore the evidence set contains no data that can confirm or refute the claim that roughly 55 % of women with chronic pelvic pain have no underlying pathology."
    },
    "posthoc_doc_ids": [
      "13027590",
      "3190689",
      "14724693",
      "8570317",
      "13934676"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "594",
    "claim": "Incidence of heart failure increased by 10% in women since 1979.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 tracked 4,537 residents with newly diagnosed heart failure from 1979-2000. It reports that the incidence of heart failure \"did not change over time among men or women.\" An unchanged incidence (0% change) is inconsistent with the claim that incidence in women rose by 10% since 1979. The other cited papers address hypertension, coronary disease, dementia, or treatment effects, not temporal changes in heart-failure incidence. Therefore, the available evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "19675911",
      "12206390",
      "12810152",
      "33533307",
      "14682243"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly tracks heart-failure incidence in women from 1979-2000 and reports that \u2018the incidence of heart failure \u2026 did not change over time among \u2026 women\u2019. A 10 % increase is therefore not observed. The other papers either address hypertension, risk factors, treatment effects, or other conditions and contain no time-trend data on female heart-failure incidence. Hence the available evidence refutes the claim that incidence in women has risen by 10 % since 1979."
    },
    "overthinking_doc_ids": [
      "19675911",
      "12206390",
      "31889025",
      "7209559",
      "14682243"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly examined temporal trends in heart-failure incidence from 1979 to 2000 and states that the incidence \"did not change over time among men or women.\" If incidence remained unchanged, it cannot have risen by 10 % in women. The other cited papers discuss prognosis, biomarkers, hypertension risk, or readmissions and do not measure changes in incidence over time, so they do not alter this conclusion. Therefore the available evidence refutes the claim that heart-failure incidence in women has increased by 10 % since 1979."
    },
    "posthoc_doc_ids": [
      "19675911",
      "4445629",
      "12206390",
      "13481731",
      "31889025"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1342",
    "claim": "Understanding epigenetic regulation of replication is essential for the reational design of episomally replicating vectors.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.69,
      "justification": "The cited papers describe histone modifications, chromatin remodeling, and their roles in transcription, DNA repair, meiosis, and replication-coupled nucleosome assembly. A few papers concern viral or plant transformation vectors, but none show that knowledge of epigenetic regulation of DNA replication is required for, or has been used in, designing episomally replicating vectors. Therefore the provided evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "8267678",
      "20630805",
      "2613813",
      "13368032",
      "87337034"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the cited papers examine how epigenetic regulation of DNA replication influences, or is required for, the rational design of episomally replicating vectors. The papers focus on topics such as lentiviral vector silencing during reprogramming, miRNA control of neural stem cells, epigenetic regulation of tumor-initiating cells, histone modifications, viral RNA cap methylation, and quadruplex-binding ligands. They do not present data linking epigenetic control of replication to the design of episomal vectors, so they neither support nor contradict the claim."
    },
    "overthinking_doc_ids": [
      "24512417",
      "2356950",
      "6948886",
      "20630805",
      "4312169"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.7,
      "justification": "The cited papers discuss various aspects of epigenetic regulation (e.g., histone modifications, DNA methylation, epigenetic control of transcription during reprogramming, stem\u2010cell behavior, metabolic programming). None of them provide data or conclusions relating epigenetic regulation of DNA replication to the rational design of episomally replicating vectors. Therefore they neither confirm nor refute the specific claim."
    },
    "posthoc_doc_ids": [
      "24512417",
      "2356950",
      "6948886",
      "22543403",
      "8150638"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "789",
    "claim": "Microglia are an innate immune cell type of the central nervous system.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Paper 8 states that microglia belong to a lineage of yolk-sac\u2013derived F4/80bright tissue macrophages. Macrophages are classical innate immune cells, so identifying microglia as macrophage-lineage cells supports the claim that microglia are an innate immune cell type resident in the central nervous system. The other cited papers do not provide contradictory information."
    },
    "naive_doc_ids": [
      "19238",
      "9784254",
      "6325527",
      "3330111",
      "6153754"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.31,
      "justification": "None of the provided papers discuss microglia or describe them as an innate immune cell type of the central nervous system. The evidence relates to neural stem cells, myelin basic protein gene expression, T-cell\u2013mediated autoimmunity, and innate immunity mechanisms in insects, but does not address microglia. Therefore the claim is neither supported nor contradicted by the cited papers."
    },
    "overthinking_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "6144337",
      "5519177"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided paper summaries discuss microglia or identify them as innate immune cells of the central nervous system. Therefore, the evidence set contains no information relevant to confirming or refuting the claim."
    },
    "posthoc_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "696006",
      "2506153"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "27",
    "claim": "A 100g dose of chloroquine chemoprophylactic regimen results in retinal toxicity after 5-6 years of weekly intake.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address cumulative chloroquine exposure of approximately 100 g over 5\u20136 years or describe retinal toxicity arising from such a regimen. The studies deal with chloroquine\u2019s short-term self-reported side-effects, other antimalarial drugs, or entirely unrelated medical topics. Therefore, the evidence set contains no information relevant to confirming or refuting the specific claim."
    },
    "naive_doc_ids": [
      "38410121",
      "6334188",
      "22334300",
      "25028913",
      "39985001"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers discuss chloroquine use, cumulative chloroquine doses, or retinal toxicity. Therefore they give no information to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "6334188",
      "14260013",
      "341324",
      "7042304",
      "22334300"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.11,
      "justification": "None of the nine cited papers examine long-term chloroquine use, cumulative dose (~100 g), or retinal/ocular toxicity. The articles focus on topics such as febrile neutropenia, HIV PrEP, oleander poisoning, short-term self-reported chloroquine adverse effects, chloroquine resistance genetics, gene therapy for optic atrophy, HPV screening, folic-acid and pre-eclampsia, and endothelial biomarkers for diabetes. Consequently, they supply no evidence to confirm or refute the specific claim about retinal toxicity after 5\u20136 years of weekly chloroquine chemoprophylaxis."
    },
    "posthoc_doc_ids": [
      "6334188",
      "14260013",
      "22334300",
      "38410121",
      "4336849"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "428",
    "claim": "Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Several papers describe functional roles for FoxO transcription factors during specific cellular differentiation processes. Paper 1 states that the Akt\u2013Foxo1 module regulates early regulatory-T-cell lineage commitment, indicating Foxo1 participates in T-cell differentiation. Paper 3 shows that loss of FOXO4 in human embryonic stem cells reduces their ability to differentiate into neural lineages, demonstrating a requirement for FoxO activity in neural differentiation. Paper 7 reports that Foxo3a (and Foxo1) activity promotes immunoglobulin light-chain rearrangement during pre-B-cell differentiation. These independent experimental findings all align with the claim that FoxO transcription factors are involved in cellular differentiation, and no provided paper presents opposing data."
    },
    "naive_doc_ids": [
      "4418070",
      "18064113",
      "1447990",
      "18489989",
      "16728949"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Paper 1 explicitly states that the Forkhead O (FoxO) family \"participates in diverse physiologic processes, including \u2026 differentiation\" and discusses FoxO-dependent signaling in hematopoietic stem-cell regenerative capacity, which inherently involves differentiation. This directly supports the claim that FoxO transcription factors are involved in cellular differentiation. None of the other cited papers present data contradicting this point; they are either about other pathways (YAP/TAZ, Hsp90, etc.) or focus on different cellular processes. Thus, the available evidence aligns with and supports the claim."
    },
    "overthinking_doc_ids": [
      "16728949",
      "28937856",
      "1065627",
      "2356950",
      "11289247"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.76,
      "justification": "Paper 1 explicitly states that the Forkhead O (FoxO) family of transcription factors \u201cparticipates in diverse physiologic processes, including \u2026 differentiation.\u201d  This places FoxO activity directly in the context of regulating cell-fate decisions.  None of the other cited papers provide evidence that contradicts this statement, and several focus on other FoxO functions (stress resistance, cell-cycle arrest, etc.) without disputing its role in differentiation.  Therefore, the available evidence supports the claim that FoxO transcription factors are involved in cellular differentiation."
    },
    "posthoc_doc_ids": [
      "16728949",
      "28937856",
      "29429111",
      "11335860",
      "2356950"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1390",
    "claim": "mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 4 explicitly states that the wobble modification 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) \"is required for the proper decoding of NNR codons in eukaryotes.\" Paper 1 provides complementary data: loss of mcm5s2U in tRNAs for Lys, Gln and Glu (which decode A/G-ending NNR codons) impairs decoding efficiency and threatens cell viability, reinforcing that the modification is necessary for correct decoding. No papers present contradictory evidence. Thus the supplied literature supports the claim."
    },
    "naive_doc_ids": [
      "34498325",
      "984825",
      "615047",
      "2890952",
      "8595678"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 3 explicitly states that the wobble modification 5-methoxycarbonyl-methyl-2-thiouridine (mcm5s2U) \u2018is required for the proper decoding of NNR codons in eukaryotes,\u2019 directly matching the claim. Paper 1 further supports this by showing that loss of mcm5s2U in tRNAs for Gln, Lys and Glu (which decode A- and G-ending, i.e. NNR, codons) impairs decoding efficiency and cell viability unless the unmodified tRNAs are over-expressed. Papers 2 and 4 do not address this topic. No evidence contradicts the claim, so the combined literature supports it."
    },
    "overthinking_doc_ids": [
      "34498325",
      "984825",
      "2890952",
      "16927286"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 4 explicitly states that the wobble modification 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) in tRNA \"is required for the proper decoding of NNR codons in eukaryotes.\" This is a direct affirmation of the claim. Paper 3 further supports this by showing that loss of mcm5s2U in the wobble position of Lys, Gln and Glu tRNAs impairs decoding efficiency and is lethal unless the affected tRNAs are over-expressed, indicating the modification is essential for correct reading of their purine-ending (NNR) codons. The other papers do not contradict or address the claim. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "4313478",
      "13552682",
      "34498325",
      "2890952",
      "10650521"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1280",
    "claim": "The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 reports that the Klebsiella aerogenes urease gene cluster located next to the structural genes contains four accessory genes\u2014ureD, ureE, ureF and ureG\u2014and that the products of these genes are all required for nickel metallocenter biosynthesis (i.e., urease maturation). The proteins encoded were identified as UreD, UreE, UreF and UreG. Papers 2 and 3 further characterize complexes that contain UreD, UreF and UreG along with urease apoprotein and show that these accessory proteins (with facilitation by UreE) are necessary for in-vivo activation of the enzyme. Together, these studies demonstrate that the genes ureD/ureH, ureE, ureF and ureG within the ureABIEFGH-type cluster encode proteins that function in urease maturation, thus confirming the claim."
    },
    "naive_doc_ids": [
      "29214508",
      "37768883",
      "36233757"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Across the cited studies of the Klebsiella aerogenes urease operon, the four accessory genes ureD, ureE, ureF, and ureG are shown to lie in the same cluster as the urease structural genes and to be required for formation of the nickel metallocenter and in-vivo activation of the enzyme. Paper 1 demonstrates that deletions in any of these genes give an inactive apo-urease and identifies the corresponding proteins. Papers 2 and 3 further show that UreD, UreE, UreF, and UreG form complexes with the apo-enzyme that are essential intermediates in maturation. Thus the evidence confirms that the ure gene cluster encodes these urease-maturation proteins (UreD/UreH, UreE, UreF, UreG), supporting the claim."
    },
    "overthinking_doc_ids": [
      "29214508",
      "37768883",
      "36233757"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Papers 1\u20133 analyze the urease gene region of Klebsiella aerogenes and show that the genes ureD, ureE, ureF and ureG, which are located in the same cluster as the urease structural genes, encode accessory (maturation) proteins required for assembly of the nickel metallocenter and in-vivo activation of urease.  Paper 2 and 3 further demonstrate that complexes containing UreD, UreF and UreG (and facilitated by UreE) are essential intermediates in urease activation, confirming their role as maturation factors.  Although the helicobacter nomenclature uses UreH in place of UreD, the claim explicitly allows the synonym \u201cUreD/UreH.\u201d  No evidence contradicts this; Paper 4 is unrelated.  Hence the collective evidence supports the claim that the ureABIEFGH cluster encodes the urease maturation proteins UreD/UreH, UreE, UreF and UreG."
    },
    "posthoc_doc_ids": [
      "29214508",
      "37768883",
      "36233757",
      "8654183"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "173",
    "claim": "Bcp1 is a chaperone for Rpl23.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.29,
      "justification": "None of the provided papers mention Bcp1, Rpl23, or discuss an interaction or chaperone relationship between them. Therefore, the evidence set does not inform the claim."
    },
    "naive_doc_ids": [
      "1084345",
      "12156187",
      "12428814",
      "15893330",
      "41087952"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.34,
      "justification": "None of the provided papers mention Bcp1, Rpl23, or any interaction between them. Consequently, they supply no evidence to evaluate whether Bcp1 functions as a chaperone for Rpl23."
    },
    "overthinking_doc_ids": [
      "1084345",
      "12156187",
      "12428814",
      "15893330",
      "11420613"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers mention Bcp1 or its interaction with the ribosomal protein Rpl23. Therefore, they neither confirm nor refute the claim that Bcp1 is a chaperone for Rpl23."
    },
    "posthoc_doc_ids": [
      "12428814",
      "207972",
      "1084345",
      "15893330",
      "26495128"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "667",
    "claim": "Klf2 is important for proper myeloid cell function.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple studies show that deleting or reducing Klf2 specifically in myeloid\u2010lineage cells (monocytes, macrophages, neutrophils, dendritic cells) alters their differentiation, activation, adhesion, survival and the inflammatory diseases they drive.  (1) Hemizygous Klf2 mice exhibit hyper-inflammatory monocytes, enhanced osteoclastogenesis and worse arthritis, demonstrating Klf2\u2019s role in normal monocyte differentiation/function.  (2) Myeloid-specific Klf2 knockout macrophages and neutrophils show abnormally high endothelial adhesion and accelerate atherosclerosis, indicating Klf2 is required for proper functional behavior of these cells.  (6) Loss of myeloid Klf2 exaggerates NF-\u03baB/HIF-1\u03b1\u2013driven activation and worsens outcomes in polymicrobial infection and endotoxemia, confirming Klf2 as a key regulator of innate myeloid responses.  Collectively, these data affirm that Klf2 is important for proper myeloid cell function."
    },
    "naive_doc_ids": [
      "7948486",
      "14407673",
      "3118719",
      "5979056",
      "3330111"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Multiple studies directly test the consequences of altering Klf2 expression in myeloid-lineage cells and show that normal Klf2 levels are required for their appropriate behavior.  (1) In a myeloid-specific knockout, macrophages and neutrophils lacking Klf2 display excessive adhesion to endothelium and the mice develop more severe atherosclerosis (Paper 2), indicating that loss of Klf2 disrupts normal myeloid cell function.  (2) Deleting Klf2 in myeloid cells exaggerates NF-\u03baB/HIF-1\u03b1-dependent activation, leading to worse outcomes in polymicrobial infection and endotoxemia (Paper 4), demonstrating that Klf2 restrains pathological activation of these cells.  (3) Klf2-haplo\u00adinsufficient mice recruit more inflammatory monocytes, show higher expression of pro-inflammatory mediators, and develop more severe arthritis (Paper 5), further confirming a role for Klf2 in regulating monocyte differentiation and activity.  Together these data show that Klf2 is necessary for maintaining proper, balanced myeloid cell functions; its deficiency causes abnormal adhesion, activation, differentiation, and disease exacerbation."
    },
    "overthinking_doc_ids": [
      "14386505",
      "14407673",
      "3118719",
      "6493422",
      "7948486"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 2 shows that deletion of Klf2 specifically in dendritic cells (a myeloid lineage) increases costimulatory-molecule expression and drives exaggerated T-cell activation and pro-inflammatory responses, indicating that normal (\"proper\") dendritic-cell function requires Klf2.  Paper 7 demonstrates that myeloid-specific Klf2 knockout causes macrophages and neutrophils to adhere more strongly to endothelium and accelerates atherosclerosis, again revealing dysregulated myeloid behavior when Klf2 is absent.  Together these experimental data directly support the claim that Klf2 is important for proper myeloid cell function."
    },
    "posthoc_doc_ids": [
      "14386505",
      "5979056",
      "1192458",
      "12582729",
      "22997657"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1359",
    "claim": "Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Paper 2 directly compares varenicline monotherapy with varenicline + bupropion for 12 weeks: prolonged abstinence was 53.0 % for the combination vs 43.2 % for varenicline alone (OR 1.49, 95 % CI 1.05\u20132.12, P = 0.03). Thus combination therapy was more, not less, effective at 12 weeks.\nPaper 3\u2019s network meta-analysis reports that varenicline was not more effective than combination NRT (OR 1.06, 95 % CredI 0.75\u20131.48), indicating no superiority of monotherapy over combination NRT.\nBoth findings oppose the claim that varenicline monotherapy is more effective after 12 weeks than combination therapies with varenicline or bupropion."
    },
    "naive_doc_ids": [
      "34369306",
      "11614737",
      "5114940",
      "8570690"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 2 shows that varenicline monotherapy is NOT more effective than combination nicotine-replacement therapy (OR 1.06; 95% CredI 0.75\u20131.48, i.e., no advantage). Paper 5 shows that adding bupropion to varenicline yields higher 12-week abstinence than varenicline alone (53.0 % vs 43.2 %; OR 1.49; 95 % CI 1.05\u20132.12). Both findings oppose the claim that varenicline monotherapy is more effective than the combinations."
    },
    "overthinking_doc_ids": [
      "3944632",
      "5114940",
      "8570690",
      "34369306",
      "11614737"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly compares varenicline alone with a combination of varenicline + bupropion for 12 weeks. Prolonged abstinence at week 12 was higher with the combination (53.0%) than with varenicline monotherapy (43.2%) (OR 1.49, 95 % CI 1.05\u20132.12; P = 0.03). Thus monotherapy was less, not more, effective.  \nPaper 4 (network meta-analysis) shows varenicline is not superior to combination NRT (OR 1.06, 95 % CredI 0.75\u20131.48), indicating at best equivalence, not greater effectiveness.  \nTogether these findings oppose the claim that varenicline monotherapy is more effective after 12 weeks than combination therapies with varenicline or bupropion."
    },
    "posthoc_doc_ids": [
      "11614737",
      "34369306",
      "195317463",
      "5114940",
      "8570690"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "308",
    "claim": "DUSP4 downregulation deactivates the Ras-ERK pathway",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 3 shows that pancreatic tumor cells carrying oncogenic K-ras have elevated expression of MAP-kinase-phosphatase-2 (MKP-2), which is the product of the DUSP4 gene. This up-regulation of DUSP4 correlates with repression of ERK activity, indicating that DUSP4 abundance (not its down-regulation) deactivates the Ras-ERK pathway. Therefore, decreasing DUSP4 would be expected to enhance, not suppress, Ras-ERK signalling. None of the other cited papers provide evidence supporting the claim. Thus the available evidence opposes the statement that DUSP4 down-regulation deactivates Ras-ERK."
    },
    "naive_doc_ids": [
      "7506409",
      "20568364",
      "28651643",
      "18841257",
      "4729644"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 6 shows that loss or down-regulation of DUSP4 \u2013 an ERK phosphatase \u2013 is linked to higher Ras-ERK pathway activity in basal-like breast cancer. The authors state that DUSP4 downregulation \"activates the Ras-ERK pathway,\" not deactivates it. No other cited papers provide data on DUSP4\u2019s effect on Ras-ERK signaling. Therefore, the available evidence opposes the claim that DUSP4 downregulation deactivates the Ras-ERK pathway."
    },
    "overthinking_doc_ids": [
      "23974474",
      "735130",
      "2481032",
      "6268106",
      "6767271"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that reduced (downregulated) DUSP4 levels correlate with gene-expression patterns of Ras-ERK pathway ACTIVATION in basal-like breast cancer and that DUSP4 over-expression increases, whereas DUSP4 depletion decreases, chemotherapy-induced apoptosis, implying that loss of DUSP4 activates\u2014not deactivates\u2014the Ras-ERK signaling cascade. No other cited papers address DUSP4 and Ras-ERK directly. Therefore the claim that DUSP4 downregulation deactivates the pathway is contradicted by the available evidence."
    },
    "posthoc_doc_ids": [
      "7821634",
      "6121555",
      "17648235",
      "15381976",
      "20568364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "693",
    "claim": "Leuko-reduced blood reduces infectious complications in red blood cell transfusion.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the nine cited papers examine red-blood-cell transfusion practices, leukocyte reduction, or rates of transfusion-related infections. They focus on topics such as cord-blood therapy for cerebral palsy, Tai Chi in cancer survivors, cardiac progenitor cells for hypoplastic left heart syndrome, blood-pressure management in dialysis, trimethylamine-N-oxide, lung-function and cancer, SIV pathogenesis, immune reconstitution post-transplant, and JC virus syndromes. Therefore the evidence provided does not address whether leuko-reduced blood lowers infectious complications in RBC transfusions."
    },
    "naive_doc_ids": [
      "23073816",
      "24396137",
      "9622258",
      "202259",
      "6793674"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.73,
      "justification": "The only paper that evaluates leukocyte-reduced (pre-storage universal leukoreduction) red-cell transfusion and infectious outcomes is Paper 8. In this large before-after cohort of 14 786 transfused patients, the adjusted odds ratio for serious nosocomial infections after implementation of leukoreduction was 0.97 (95 % CI 0.87\u20131.09), indicating no significant reduction in postoperative or ICU-acquired infections. Therefore the available evidence does not show a decrease in infectious complications with leukocyte-reduced blood, contradicting the claim."
    },
    "overthinking_doc_ids": [
      "23073816",
      "24396137",
      "7098463",
      "202259",
      "3067015"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.77,
      "justification": "The only paper that directly examines infectious outcomes after introducing leukoreduced red-cell units (Paper 4) compared 6,982 pre-leukoreduction and 7,804 post-leukoreduction transfused patients. After adjustment for confounders, the odds of serious nosocomial infections (pneumonia, bacteremia, septic shock, surgical-site infections) were virtually unchanged (adjusted OR 0.97; 95 % CI 0.87-1.09). Thus leukoreduction did not reduce infectious complications, contradicting the claim."
    },
    "posthoc_doc_ids": [
      "11344428",
      "16745747",
      "22890091",
      "24088502",
      "2488880"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1371",
    "claim": "Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 directly evaluated how calcium intake and vitamin D status together affect serum intact parathyroid hormone (PTH). It showed that when vitamin D levels were low (<10 ng/mL), PTH rose markedly regardless of calcium intake, whereas adequate vitamin D (>18 ng/mL) kept PTH low and minimized the effect of higher calcium intake. This demonstrates that vitamin D status is a key determinant in the calcium-PTH relationship. The other papers do not contradict this and some (e.g., Paper 2) further illustrate vitamin D\u2019s role in calcium physiology. Therefore the evidence supports the claim that vitamin D is an important factor linking calcium and parathyroid hormone."
    },
    "naive_doc_ids": [
      "16256507",
      "3034412",
      "3758260",
      "4462079",
      "46485368"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 shows that serum 25-hydroxy-vitamin D levels are inversely correlated with parathyroid hormone (PTH) and that low vitamin D is associated with secondary hyperparathyroidism, linking vitamin D status to the calcium\u2013PTH axis. Paper 2 demonstrates that, for any given calcium intake, PTH concentrations are highest when vitamin D is low and lowest when vitamin D is adequate; moreover, when vitamin D is sufficient, increasing calcium intake above 800 mg/day does not further reduce PTH, indicating that vitamin D modulates the calcium\u2013PTH relationship. Together these studies provide direct evidence that vitamin D is a key determinant in how calcium intake influences PTH levels, confirming the claim."
    },
    "overthinking_doc_ids": [
      "9555784",
      "16256507",
      "13312471",
      "46485368",
      "21199527"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly examines how calcium intake and serum 25-hydroxy-vitamin D jointly affect serum intact parathyroid hormone (PTH). It shows that PTH is lowest when vitamin D is sufficient (>18 ng/mL) and highest when vitamin D is severely deficient (<10 ng/mL). Moreover, at low vitamin D status, higher calcium intake dampens the PTH rise, whereas when vitamin D is adequate the effect of extra calcium on PTH largely disappears. This demonstrates that vitamin D status is a key modulator of the calcium-PTH relationship.\n\nPaper 4 corroborates this by finding an inverse correlation between serum 25OHD and PTH in post-menopausal women, and by showing that vitamin D deficiency often leads to secondary hyperparathyroidism (elevated PTH despite normal or low-normal calcium).\n\nTogether these findings confirm that vitamin D is an important factor governing how calcium levels influence PTH secretion, supporting the claim."
    },
    "posthoc_doc_ids": [
      "16256507",
      "21564598",
      "9301606",
      "9555784",
      "13312471"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "759",
    "claim": "Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Paper 1 explicitly presents a mathematical transmission model showing that replacing a nongametocytocidal regimen (sulfadoxine\u2013pyrimethamine) with artemisinin-based combination therapy can cut parasite prevalence by up to 53 % and clinical incidence by tens of cases per 100 persons per year \u2013 reductions the authors liken to those achieved by insecticide-treated nets. Paper 5, also model-based, finds that high coverage with ACT produces large, sustained falls in parasite prevalence in Cambodia, again markedly greater than with previous drugs. Paper 3\u2019s continental-scale simulation attributes major reductions in prevalence across Africa partly to the policy switch to ACT. Together these modelling studies predict a large (i.e., dramatic) transmission impact of ACT relative to older, nongametocytocidal therapies, thus supporting the claim."
    },
    "naive_doc_ids": [
      "1805641",
      "10617916",
      "18074797",
      "12409683",
      "3929361"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 developed a transmission model for six Tanzanian settings and predicted that replacing non-artemisinin treatments with artemisinin-based combination therapy (ACT) could cut parasite prevalence by up to 53 % and clinical incidence by up to 54 episodes per 100 persons per year\u2014effects described as approaching those of insecticide-treated nets. These reductions arise from ACT\u2019s strong gametocytocidal action, which nongametocytocidal drugs lack.  \nPaper 4 fitted a mathematical model to Cambodian field data and found that both mass drug administration with ACT and high ACT treatment-coverage of symptomatic cases produced the \u201cdramatic reductions\u201d and \u201ccontinued decline and near-elimination\u201d of malaria, effects that were much larger than obtained with other components alone.  \nPaper 3, an Africa-wide individual-based model, incorporated the policy switch to ACT and showed that ACT, combined with other tools, enables very large declines in prevalence, especially in low- and moderate-transmission settings.  \nTogether these modelling studies consistently predict that choosing ACT\u2014drugs with gametocytocidal activity\u2014over nongametocytocidal regimens generates large, population-level reductions in malaria transmission, confirming the claim. (Paper 2 provides empirical\u2014not modelling\u2014data suggesting only a moderate effect, but it does not negate the modelling predictions, and Paper 5 is unrelated.)"
    },
    "overthinking_doc_ids": [
      "1805641",
      "10617916",
      "18074797",
      "3929361",
      "374902"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.67,
      "justification": "Paper 1 presents a mathematical transmission model in six Tanzanian settings and predicts that replacing the previous first-line, non-gametocytocidal drug (sulfadoxine-pyrimethamine) with an artemisinin-based combination therapy would cut parasite prevalence by up to 53 % and clinical incidence by up to 54 episodes per 100 persons per year \u2013 reductions described by the authors as approaching those of insecticide-treated nets in low-transmission areas. Paper 5, which also relies on mathematical modelling, shows that high coverage with ACT is largely responsible for the sustained drop to near-elimination levels after mass drug administration in Cambodia. Paper 3 incorporates the switch to ACT in an Africa-wide model and attributes \u201cmajor reductions\u201d in transmission to it when coverage is high. Together, these modelling studies predict a marked (i.e., dramatic) reduction in malaria transmission when ACTs replace older, non-gametocytocidal regimens, providing supportive evidence for the claim."
    },
    "posthoc_doc_ids": [
      "1805641",
      "10617916",
      "18074797",
      "12409683",
      "3929361"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1319",
    "claim": "Transplanted human glial cells can differentiate within the host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 4 reports that human glial progenitor cells were transplanted into neonatal immunodeficient mice. After engraftment and maturation, the mouse brains contained large numbers of human astrocytes derived from the transplanted progenitors. The appearance of differentiated human astrocytes in the host brain demonstrates that transplanted human glial cells can indeed differentiate within the recipient animal. The remaining cited papers do not address glial cell transplantation, and none contradict this observation. Therefore, the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "343052",
      "19510470",
      "38296571",
      "16284655",
      "37699461"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.61,
      "justification": "Paper 3 reports that human embryonic-stem-cell-derived neural precursor cells were transplanted into neonatal mouse brains and, once in the host tissue, those human cells differentiated further into neurons and astrocytes (a glial lineage). This demonstrates that transplanted human cells of the neural/glial lineage are capable of continuing their differentiation within the animal host, supporting the claim. The other cited papers do not address transplantation of human glial cells, so they neither add nor detract from this conclusion."
    },
    "overthinking_doc_ids": [
      "3360421",
      "4427392",
      "2437807",
      "4430962",
      "4983"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.77,
      "justification": "Paper 2 reports that human glial progenitor cells engrafted into neonatal immunodeficient mice matured in vivo, giving rise to large numbers of human astrocytes within the host brain. Paper 8 shows that human CNS stem cells transplanted into neonatal mouse brains engrafted, proliferated, migrated and underwent neural differentiation, including into glial lineages. These studies provide direct experimental evidence that transplanted human glial (or glial-lineage) cells can differentiate inside a living animal host, confirming the claim."
    },
    "posthoc_doc_ids": [
      "9122283",
      "16284655",
      "1447990",
      "1667063",
      "3360421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "764",
    "claim": "Medications to treat obesity are highly effective.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "The meta-analysis of approved anti-obesity drugs (Paper 7) found only modest, 3\u20135 kg mean weight losses and explicitly states that orlistat, sibutramine, and rimonabant \"modestly reduce weight.\" The review article (Paper 9) further stresses that pharmacological approaches have had limited effectiveness and that many programmes have failed or drugs have been withdrawn. Although one diabetes drug (oral semaglutide, Paper 6) produced somewhat larger short-term weight loss (up to ~7 kg in 26 weeks), this degree of loss is still moderate and the paper calls for longer-term studies. No paper reports large, sustained weight reductions comparable to surgical interventions. Overall, the cited evidence indicates that current medications yield only modest benefits, contradicting the claim that they are \"highly effective.\""
    },
    "naive_doc_ids": [
      "7098463",
      "22467585",
      "8570690",
      "23073816",
      "39892135"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.71,
      "justification": "The only paper that examines anti-obesity medications (Paper 4) reports that orlistat, sibutramine and rimonabant produce only modest additional weight loss compared with placebo (\u22483\u20135 kg over 1\u20134 years) with 30\u201340 % attrition and notable adverse effects. The authors conclude these drugs \"modestly reduce weight.\" This level of benefit does not fit the description \"highly effective.\" Other cited papers address surgery, behavioural counselling, NSAIDs, ADHD, etc., and do not provide contradictory evidence of high drug efficacy. Therefore, the available evidence refutes the claim that medications to treat obesity are highly effective."
    },
    "overthinking_doc_ids": [
      "40949706",
      "12672066",
      "22446093",
      "7552215",
      "21958900"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.79,
      "justification": "The meta-analysis of long-term pharmacotherapy (Paper 6) shows that currently approved anti-obesity drugs (orlistat, sibutramine, rimonabant) produce only modest additional weight loss versus placebo (\u22483\u20135 kg over 1\u20134 years) and are accompanied by notable adverse effects and high attrition rates. Paper 4 further notes that anti-obesity drug discovery has been marked by many failures and that existing agents seldom achieve the large, durable weight reductions seen with surgery, calling for new paradigms (e.g., multi-drug combinations) to reach meaningful efficacy. These findings indicate that available medications are not \u201chighly effective,\u201d but rather have limited, modest benefits. Therefore the provided evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "12672066",
      "14865329",
      "15790930",
      "5839365",
      "4961038"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "439",
    "claim": "Fz/PCP-dependent Pk localizes to the anterior membrane of neuroectoderm cells during zebrafish neuralation",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.29,
      "justification": "Among the supplied abstracts, only Paper 1 addresses zebrafish neurulation and planar cell-polarity signalling, but it discusses Vangl2-dependent polarization of neural keel cells, not the sub-cellular localization of Prickle (Pk). None of the six abstracts provides data showing that Fz/PCP signalling causes Prickle to accumulate specifically at the anterior membrane of neuroectoderm cells during zebrafish neurulation. Therefore the evidence presented neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "4423559",
      "18575183",
      "5944514",
      "34905328",
      "38727075"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.89,
      "justification": "None of the provided papers discuss Prickle (Pk) localization in zebrafish neuroectoderm during neurulation or its dependence on Frizzled/PCP signaling. The cited studies address unrelated topics such as cadherin-mediated oocyte positioning in Drosophila, PCP effects on cell division in zebrafish (without mentioning Pk localization), Wnt5a function in mouse cochlea, brain injury\u2013induced neurogenesis, Notch signaling, and auditory processing in blind humans. Therefore, there is no evidence in the supplied literature to evaluate or substantiate the claim."
    },
    "overthinking_doc_ids": [
      "4388082",
      "4423559",
      "5395426",
      "18575183",
      "5944514"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the provided paper abstracts mention Prickle (Pk) localization, Frizzled/PCP-dependent positioning, or detailed subcellular distribution in zebrafish neuroectoderm during neurulation. Therefore, the supplied evidence does not address the specific claim."
    },
    "posthoc_doc_ids": [
      "8533245",
      "22025252",
      "35079452",
      "4423559",
      "18575183"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1387",
    "claim": "eRNAs influence is linked to senescence, aging, and carcinogenesis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the cited papers, only Paper 3 directly investigates enhancer RNAs (eRNAs). It demonstrates that eRNAs generated at p53-bound enhancer regions are required for p53-dependent transcriptional activation and for induction of a p53-mediated cell-cycle arrest, a process related to cellular senescence and tumor suppression. However, none of the provided papers present data linking eRNAs to organismal or tissue aging, nor do they connect eRNA activity directly to the initiation or progression of carcinogenesis beyond their role in p53-mediated cell-cycle control. Because evidence for an influence of eRNAs specifically on aging and carcinogenesis is absent, the supplied literature does not fully substantiate the claim that eRNAs are linked to senescence, aging, and carcinogenesis."
    },
    "naive_doc_ids": [
      "35543846",
      "4653837",
      "9669099",
      "14050257",
      "1754001"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.25,
      "justification": "Among the cited papers only Paper 1 discusses enhancer RNAs (eRNAs). It shows that eRNAs produced from p53-bound enhancers are required for p53-dependent transcription and cell-cycle arrest, connecting eRNAs to p53 tumour-suppressor activity and thus to carcinogenesis. None of the provided papers present data linking eRNAs to cellular senescence or organismal aging. Because evidence for two-thirds of the claim (senescence and aging) is missing, the supplied literature does not substantiate the full statement."
    },
    "overthinking_doc_ids": [
      "9669099",
      "140874",
      "928281",
      "516867",
      "2466614"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.18,
      "justification": "None of the cited papers examine enhancer RNAs (eRNAs) in the context of senescence, aging, or carcinogenesis. The studies focus on microRNAs, metabolic changes, p53 signaling, programmed cell death, stress pathways, and general lncRNA biology without presenting data that specifically links eRNA activity to these processes. Hence the provided evidence neither supports nor contradicts the claim."
    },
    "posthoc_doc_ids": [
      "4653837",
      "35543846",
      "6896063",
      "33667484",
      "7506409"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1141",
    "claim": "Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 is a large, randomized, double-blind, placebo-controlled trial that tested 400 IU (\u2248180 mg) of \u03b1-tocopheryl acetate every other day and 500 mg vitamin C daily in 14 641 men for a mean of 8 years. It found no significant reduction in prostate-cancer incidence with vitamin E (HR 0.97, 95 % CI 0.85-1.09) or vitamin C (HR 1.02, 95 % CI 0.90-1.15), and no benefit in stratified analyses. No other provided paper addresses vitamin E + C and prostate cancer. Thus the available evidence refutes the claim that taking 400 mg \u03b1-tocopheryl acetate with vitamin C lowers prostate-cancer risk."
    },
    "naive_doc_ids": [
      "12009265",
      "15648443",
      "24396137",
      "1428840",
      "6710713"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 is a randomized, double-blind, placebo-controlled trial that tested 400 IU (\u2248 400 mg \u03b1-tocopheryl acetate) of vitamin E every other day plus 500 mg vitamin C daily in 14,641 men for 8 years. It found no reduction in prostate cancer incidence compared with placebo (HR 0.97, 95% CI 0.85-1.09; P = 0.58). This directly refutes the claim that the combination reduces prostate-cancer risk. The other cited papers do not address vitamin E + C and prostate cancer, so they provide no information on the claim. Therefore, the available evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "12009265",
      "24396137",
      "39903312",
      "3222187",
      "32534305"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.79,
      "justification": "Paper 4 is a large, randomized, double-blind, placebo-controlled trial that tested 400 IU (\u2248268 mg) of \u03b1-tocopheryl acetate every other day together with 500 mg of vitamin C daily in 14 641 men for a mean of 8 years. It found no reduction in prostate cancer incidence (HR 0.97, 95% CI 0.85\u20131.09, P = 0.58) compared with placebo, and no benefit from vitamin C. No other provided paper gives data on \u03b1-tocopheryl acetate plus vitamin C and prostate cancer. Thus the best available evidence directly refutes the claim that this combination lowers prostate cancer risk."
    },
    "posthoc_doc_ids": [
      "520579",
      "16422880",
      "38551172",
      "12009265",
      "308862"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "914",
    "claim": "PPAR-RXRs can be activated by PPAR ligands.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 5 reports that the receptor activated by peroxisome proliferators (a PPAR) forms a heterodimer with RXR-\u03b1, and that this PPAR-RXR complex activates the acyl-CoA oxidase gene when cells are exposed to clofibric acid, a classical PPAR ligand. Thus a PPAR ligand is sufficient to activate the PPAR-RXR heterodimer, directly supporting the claim that PPAR-RXRs can be activated by PPAR ligands. The other cited papers deal with PPAR ligands but do not specifically address activation of the PPAR-RXR complex, so the decisive evidence comes from Paper 5, which aligns with the claim."
    },
    "naive_doc_ids": [
      "56486733",
      "13639330",
      "25328476",
      "18346333",
      "8458567"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.77,
      "justification": "Paper 1 reports that the receptor activated by peroxisome proliferators (PPAR) forms a heterodimer with retinoid X receptor (RXR). This PPAR\u2013RXR heterodimer stimulates acyl-CoA oxidase gene expression when cells are treated with clofibric acid, a classic PPAR ligand. Thus the heterodimer (PPAR-RXR) is functionally activated by a PPAR ligand, directly confirming the claim. The other cited papers do not address PPAR-RXR activation and therefore do not affect this conclusion."
    },
    "overthinking_doc_ids": [
      "8458567",
      "1344498",
      "327319",
      "20960682",
      "3610282"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.77,
      "justification": "Paper 1 reports that the receptor activated by peroxisome proliferators (a PPAR, which forms a heterodimer with RXR to give PPAR\u2013RXR) induces acyl-CoA oxidase gene expression when exposed to the PPAR ligand clofibric acid. This demonstrates that the PPAR\u2013RXR complex can indeed be activated by a PPAR ligand. The remaining papers do not address activation of PPAR\u2013RXR complexes, so they neither add nor detract from this evidence. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "8458567",
      "2692522",
      "4345315",
      "33499189",
      "20960682"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "756",
    "claim": "Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Among the provided papers, only Paper 5 discusses lysine acetylation, describing acetylation of histone H3 at lysine 56. While this confirms that at least one protein can be acetylated on a lysine residue, none of the papers present data indicating that a broad set of proteins ('many proteins') in human cells undergo lysine acetylation. The remaining papers address unrelated topics (RNA pseudouridylation, phosphorylation, myristoylation, gene-expression variation, epidemiologic studies, etc.). Hence, the supplied evidence does not speak directly to the prevalence of lysine acetylation across numerous proteins."
    },
    "naive_doc_ids": [
      "4462419",
      "984825",
      "22036571",
      "4632921",
      "3052213"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 explicitly states that lysine acetylation is a conserved post-translational modification found on numerous proteins and that mass-spectrometry studies have revealed a broad \u2018landscape\u2019 of lysine-acetylated proteins involved in diverse cellular processes. This directly supports the claim that many proteins in human cells can acquire lysine acetylation. Paper 2 further exemplifies this by describing lysine 56 acetylation on histone H3 in human adipocytes. No paper provides contradictory evidence. Thus, the available evidence confirms the claim."
    },
    "overthinking_doc_ids": [
      "27134527",
      "3052213",
      "3270834",
      "10450300",
      "11335860"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Several of the cited papers explicitly document lysine-acetylation as a common post-translational modification on numerous human proteins. Paper 2 summarizes large-scale mass-spectrometry studies and states that lysine acetylation is a \"conserved\" and widespread modification regulating \"many biological processes,\" implying modification of a large number of proteins. Papers 3\u20137 give concrete experimental examples in human cells\u2014histones (H3K56, other H3 lysines), transcription factors and other proteins\u2014whose activities are modulated by acetylation at lysine residues. Together these reports demonstrate that lysine acetylation occurs on multiple, diverse human proteins, thereby supporting the claim that many proteins in human cells can be post-translationally modified at lysine residues via acetylation."
    },
    "posthoc_doc_ids": [
      "22036571",
      "27134527",
      "22968257",
      "1243475",
      "3052213"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1183",
    "claim": "The TRaF1/C5 rs10818488 allele polymorphism regulates the neighboring C5 gene.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "Among the provided papers, only Paper 4 addresses the TRAF1/C5 region, and it focuses on genetic association with rheumatoid arthritis risk. None of the excerpts present experimental data or analyses showing that the rs10818488 polymorphism alters or regulates expression of the adjacent C5 gene. Therefore, the supplied evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "19238",
      "20179918",
      "9724974",
      "1967017",
      "11328820"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.24,
      "justification": "None of the nine cited papers mention the TRAF1/C5 locus, the rs10818488 polymorphism, or demonstrate any regulatory effect of this SNP on the neighboring C5 gene. The evidence summaries focus on unrelated topics such as RNA-seq eQTL mapping in general, myelin basic protein gene structure, oxidative-stress regulons in bacteria, calcium signaling proteins in T cells, macrophage polarization, non-coding functions of RNAs, sensory plasticity in blindness, ERBB signaling in cancer, and N-terminal acetylation of proteins. Because no experimental data or findings about rs10818488 or C5 regulation are provided, the claim cannot be verified or refuted from the supplied literature."
    },
    "overthinking_doc_ids": [
      "4378885",
      "19238",
      "471735",
      "19561411",
      "164985"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.74,
      "justification": "Among the supplied abstracts and corrections, only Paper 1 concerns the TRAF1/C5 genomic region and mentions allelic variation (in the context of rheumatoid arthritis risk). However, none of the provided text indicates that rs10818488 (or any TRAF1/C5 polymorphism) functionally alters or regulates expression of the neighboring C5 gene. The remaining papers discuss other genes, non-coding RNAs, dosage compensation, PD-1, semaphorin III, versican 3\u2032UTR effects, eQTL mapping in iPSCs, and blood-pressure loci, none of which addresses regulation of C5 by rs10818488. Therefore, the evidence given does not confirm or refute the stated regulatory claim."
    },
    "posthoc_doc_ids": [
      "1967017",
      "5519177",
      "12232678",
      "14938990",
      "33535447"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "115",
    "claim": "Anthrax spores can be disposed of easily after they are dispersed.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 shows that, after an office was contaminated with Bacillus anthracis spores, viable spores remained on surfaces and could be readily re-aerosolised during ordinary office activity. The need for respiratory protection, specialised remediation and concerns about re-occupancy are highlighted, indicating that the spores are difficult\u2014not easy\u2014to eliminate once dispersed. The other papers are unrelated to anthrax spore decontamination. Therefore the available evidence opposes the claim that anthrax spores can be disposed of easily after they are dispersed."
    },
    "naive_doc_ids": [
      "33872649",
      "6561200",
      "341324",
      "15237660",
      "3929361"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1 shows that after anthrax spores were initially dispersed in a Senate office building they remained viable on surfaces and could readily re-aerosolize during ordinary or even minimal activity. Their persistence and easy reaerosolization imply that eliminating or \u2018disposing of\u2019 the spores is difficult and requires special remediation measures. This directly opposes the claim that anthrax spores can be disposed of easily after they are dispersed."
    },
    "overthinking_doc_ids": [
      "33872649",
      "44562058",
      "4325398",
      "756887",
      "1986482"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "The provided evidence contains no usable information (only the word 'Error'). Therefore, the papers offer no relevant data regarding the ease of disposing of anthrax spores once dispersed."
    },
    "posthoc_doc_ids": [],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1190",
    "claim": "The amount of publicly available DNA data doubles every 10 months.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers mention the growth rate of publicly available DNA data or provide statistics indicating that it doubles every 10 months. They describe specific databases, sequencing tools, and methodological studies, but do not present evidence about overall data\u2010volume growth trends."
    },
    "naive_doc_ids": [
      "30655442",
      "6532806",
      "14376683",
      "1544804",
      "14464451"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers discuss the rate at which publicly available DNA data is growing or provide figures on its doubling time. They cover topics such as sequencing\u2010read trimming tools, phylogenetic models, cancer genome evolution, tumor biology, helminth treatment, growth-hormone therapy, and a GEO database update without quantitative statements about DNA data volume growth. Thus they offer no information relevant to verifying or refuting the claim that publicly available DNA data doubles every 10 months."
    },
    "overthinking_doc_ids": [
      "7324039",
      "14915566",
      "7211056",
      "8994465",
      "18025240"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss the growth rate of publicly available DNA sequence data or mention any doubling time. They cover topics such as socioeconomic health factors, nucleosome prediction, bioinformatics visualization tools, imprinting, Myc target genes, genomic requirements for bacterial growth, a centipede genome, cancer genome instability, and HCV vertical transmission. Therefore, they offer no evidence to verify or refute the claim about DNA data doubling every 10 months."
    },
    "posthoc_doc_ids": [
      "1781626",
      "175735",
      "2883827",
      "279052",
      "6532806"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "689",
    "claim": "Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the cited papers report the percentage of radiation-exposed patients who exhibit activated mesenchymal stem-cell markers. The articles focus on circadian regulation in MSC cultures, mesenchymal inflammation in pre-leukemia, MSC roles in the bone-marrow niche, tumor or blood markers in cancer, PTH effects on marrow MSCs, prognostic blood parameters, FGF-2 after radiation in mice, Notch signaling in glioma, and genetic variation in iPSCs. None provide quantitative patient data relevant to the stated claim."
    },
    "naive_doc_ids": [
      "21645205",
      "3863543",
      "4380004",
      "14664424",
      "3758260"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the provided papers measure, report, or even mention the proportion of radiation-exposed human patients who show activation of mesenchymal stem-cell markers. The cited studies focus on Nanog expression in lung cancer, circadian rhythms in MSC cultures, effects of FGF-2 after irradiation in mice, stem-cell processing, donor-cell leukemia, MSC-derived microvesicles, low-dose radiation cancer risk, radiation-induced senescence in mice, inflammasome activation, and circulating mitochondrial DNA. Therefore, the evidence set does not address the specific numerical claim about activated MSC markers in irradiated patients."
    },
    "overthinking_doc_ids": [
      "17021845",
      "21645205",
      "25238950",
      "25985964",
      "11344428"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the cited papers measure, report, or even mention the proportion of radiation-exposed patients who exhibit activation of mesenchymal stem-cell markers. Paper 5 involves radiation in a mouse small-intestine model, but it concerns FGF-2 induction and intestinal crypt stem-cell survival, not mesenchymal stem-cell marker activation in patients. Therefore the evidence set provides no relevant data to confirm or refute the stated claim."
    },
    "posthoc_doc_ids": [
      "40164383",
      "35811036",
      "9997636",
      "21645205",
      "25238950"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "437",
    "claim": "Functional consequences of genomic alterations due to Myelodysplastic syndrome (MDS) are poorly understood due to the lack of an animal model.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.37,
      "justification": "Among the cited papers, only Paper 2 and Paper 4 directly concern myelodysplastic syndromes. They describe molecular findings in human MDS cells and patient cohorts but do not address whether an animal model exists or whether the overall functional consequences of MDS-associated genomic lesions remain poorly understood. The remaining papers focus on unrelated diseases (Rett syndrome, optic atrophy, nephrotic syndrome, frailty). Consequently, the supplied evidence neither shows that functional consequences of MDS mutations are poorly understood because of a missing animal model nor demonstrates the opposite. Therefore, the claim cannot be verified or refuted with the given literature."
    },
    "naive_doc_ids": [
      "8698208",
      "6000423",
      "6776834",
      "2359152",
      "7595742"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the provided abstracts, only Paper 7 discusses myelodysplastic syndrome, and it focuses on inflammasome activation in human MDS hematopoietic cells. None of the nine papers claim that animal models for MDS are lacking, nor do they state that functional consequences of genomic alterations in MDS are poorly understood for that reason. Conversely, none of the papers present an existing MDS animal model that would contradict the statement. Therefore the supplied evidence neither supports nor refutes the claim."
    },
    "overthinking_doc_ids": [
      "4951831",
      "7239105",
      "13889962",
      "10795340",
      "31884697"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1 explicitly describes a \u2018two-step mouse model for myeloid leukemic disease progression\u2019 in which human mutant NRAS and BCL2 genes are over-expressed. This model is used to examine DNA damage, error-prone repair and ROS production during MDS progression, i.e., the functional consequences of genomic alterations. The existence and utilization of this animal model directly refute the claim that such consequences are poorly understood because an animal model is lacking."
    },
    "posthoc_doc_ids": [
      "5765455",
      "13293033",
      "26025820",
      "123859",
      "10795340"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "298",
    "claim": "Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Multiple cited studies document that, when apoptosis is triggered, cytochrome c moves from mitochondria into the cytosol.  Paper 2 reports that inorganic phosphate\u2013induced apoptosis in vascular smooth-muscle cells is \u201caccompanied by mitochondria-dependent apoptotic events, including release of cytochrome c from the mitochondria into the cytosol.\u201d  Paper 3 shows that Helicobacter pylori\u2013induced apoptosis of gastric epithelial cells involves \u201crelease of cytochrome c.\u201d  Paper 4 also notes cytochrome c release during H. pylori-mediated cell death, and Paper 1 broadly states that mitochondrial intermembrane-space proteins are released to the cytosol during programmed cell death.  These observations directly align with the claim that cytochrome c is released from the mitochondrial intermembrane space into the cytosol in the course of apoptosis."
    },
    "naive_doc_ids": [
      "23403754",
      "9588931",
      "7465900",
      "8654183",
      "23305884"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that, in Helicobacter pylori\u2013treated gastric epithelial cells, expression of a non-acetylatable APE-1 mutant \"induced release of cytochrome c and fragmentation of DNA\"\u2014hallmark events of apoptosis\u2014demonstrating movement of cytochrome c out of mitochondria during apoptotic signaling. Paper 5 states that previous studies of H. pylori\u2013induced cell death have already \"demonstrated ... cytochrome c release\". Paper 6, a bioenergetic review, notes that massive mitoptosis \"can result in cell death due to release to cytosol of the cell death proteins normally hidden in the mitochondrial intermembrane space,\" implicitly including cytochrome c. Together these papers provide experimental and mechanistic evidence that cytochrome c exits the mitochondrial intermembrane space and appears in the cytosol as part of the apoptotic process, confirming the claim."
    },
    "overthinking_doc_ids": [
      "7465900",
      "17805221",
      "1905095",
      "23887844",
      "8654183"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple cited studies describe apoptosis-associated movement of cytochrome c from mitochondria into the cytosol. Paper 2 reports that phosphate-induced apoptosis in vascular smooth-muscle cells is \"accompanied by\u2026 release of cytochrome c from the mitochondria into the cytosol.\" Paper 3 notes that blocking mitochondrial cristae remodeling \"blunts\u2026 cytochrome c release\" during apoptotic tissue damage, implying that such release normally occurs in apoptosis. Paper 7 shows that the antitumor agent WK175 initiates an apoptotic cascade that includes cytochrome c release from mitochondria. These experimental observations directly align with the claim that cytochrome c is released from the mitochondrial intermembrane space to the cytosol during apoptosis."
    },
    "posthoc_doc_ids": [
      "23403754",
      "9588931",
      "15836115",
      "4795303",
      "23887844"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "14",
    "claim": "5'-nucleotidase metabolizes 6MP.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 and Paper 4 explicitly state that the cytosolic 5'-nucleotidase II enzyme (gene NT5C2) hydrolyzes and thereby inactivates the nucleoside-analog chemotherapy drug 6-mercaptopurine (6MP). Mutations that increase NT5C2 (5'-nucleotidase) activity lead to higher metabolism of 6MP and consequent drug resistance in acute lymphoblastic leukemia cells. This directly corroborates the claim that 5'-nucleotidase metabolizes (inactivates) 6MP. The other cited papers do not address 6MP metabolism, and none dispute this finding. Hence the evidence supports the claim."
    },
    "naive_doc_ids": [
      "6421792",
      "23887844",
      "52893592",
      "641786",
      "393001"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 2 states that NT5C2 encodes a 5'-nucleotidase \"responsible for the inactivation of nucleoside-analog chemotherapy drugs\" and shows that activating mutations give increased nucleotidase activity that confers resistance to 6-mercaptopurine (6MP). Inactivation of a drug by an enzyme is a form of metabolic processing; thus this evidence indicates that 5'-nucleotidase (NT5C2) metabolizes 6MP. The other cited papers do not address 5'-nucleotidase activity on 6MP. Therefore the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "1373287",
      "6421792",
      "520579",
      "13106686",
      "120626"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Papers 1 and 4 study NT5C2, the cytosolic 5'-nucleotidase II. They report that this enzyme is responsible for the inactivation (metabolism) of nucleoside-analog chemotherapy agents. Experimental data show that activating NT5C2 mutations increase nucleotidase activity and make ALL cells resistant to treatment with 6-mercaptopurine (6MP). Resistance arises because the enzyme converts (metabolizes) 6MP and related thiopurines to inactive forms. This directly supports the claim that a 5'-nucleotidase metabolizes 6MP. The other listed papers do not contradict or add relevant information. Thus the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "6421792",
      "293661",
      "393001",
      "641786",
      "3882374"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "713",
    "claim": "Low expression of miR7a does not repress target genes or exert a biological function in ovaries.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the cited papers discuss miR7a expression, its impact on target-gene repression, or its biological function in ovaries. Therefore, the provided evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "153744",
      "19828689",
      "2000038",
      "23716150",
      "116792"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the cited papers discuss miR-7a expression, its ability to repress target genes, or any biological role of miR-7a in ovarian tissue. Therefore, the supplied evidence provides no information relevant to verifying or refuting the claim."
    },
    "overthinking_doc_ids": [
      "266641",
      "5752492",
      "19828689",
      "8247469",
      "10024681"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.26,
      "justification": "None of the provided papers investigates miR7a expression levels or its functional consequences in ovarian tissue. The studies focus on other microRNAs, different genes, or unrelated biological contexts (e.g., fibroblast scar formation, Th cell differentiation, skeletal muscle development, diabetic nephropathy, skin tumors, macrophage immunity). Therefore, they offer no direct evidence to confirm or refute the claim regarding low miR7a expression in ovaries."
    },
    "posthoc_doc_ids": [
      "2000038",
      "33535447",
      "21363424",
      "37438296",
      "663464"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "840",
    "claim": "Natriuretic peptides increase susceptibility to diabetes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Paper 1 directly examines B-type natriuretic peptide (BNP). Both observational and Mendelian-randomization analyses show that higher circulating or genetically determined BNP levels are associated with a LOWER\u2014 not higher\u2014risk of incident type 2 diabetes (\u224820 % risk reduction per SD increase; OR 0.94 per allele raising BNP). This indicates natriuretic peptides are protective rather than increasing susceptibility. The other cited papers do not analyze natriuretic peptides, so they neither support nor contradict the claim. Therefore, the available evidence contradicts the statement that natriuretic peptides increase diabetes susceptibility."
    },
    "naive_doc_ids": [
      "15663829",
      "1974176",
      "6176498",
      "27166444",
      "24872571"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly examines the relation between circulating B-type natriuretic peptide (NT-pro-BNP) and type 2 diabetes. It reports a 21 % LOWER risk of incident diabetes per one standard-deviation increase in NT-pro-BNP and a protective genetic association (rs198389 C-allele linked to higher BNP gives OR 0.94 for diabetes). This indicates higher natriuretic peptide levels DECREASE, not increase, diabetes susceptibility. The other cited papers do not address natriuretic peptides in relation to diabetes risk. Therefore the available evidence refutes the claim that natriuretic peptides increase susceptibility to diabetes."
    },
    "overthinking_doc_ids": [
      "15663829",
      "1974176",
      "27466734",
      "27166444",
      "25599283"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 directly examines circulating B-type natriuretic peptide (NT-pro-BNP) and risk of type 2 diabetes. Both prospective observational data and Mendelian-randomization analyses show that higher NT-pro-BNP levels are associated with a LOWER, not higher, risk of developing diabetes (\u224821 % risk reduction per SD increase; OR 0.94 per allele raising BNP). This indicates a protective, not susceptibility-increasing, effect of natriuretic peptides. The remaining cited papers do not address natriuretic peptides. Therefore the available evidence refutes the claim that natriuretic peptides increase susceptibility to diabetes."
    },
    "posthoc_doc_ids": [
      "15663829",
      "5567005",
      "8325952",
      "6176498",
      "23342845"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "680",
    "claim": "Lack of FGF21 in mice increases life expectancy.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 2 directly investigates mice lacking fibroblast growth factor-21 (FGF21). It reports that FGF21-deficient mice (on an apolipoprotein E-/- background) develop worsened atherosclerosis and show premature death. Therefore, absence of FGF21 shortens, rather than lengthens, life expectancy. None of the other cited papers examine FGF21 deficiency or lifespan. Hence the available evidence opposes the claim that lack of FGF21 increases life expectancy."
    },
    "naive_doc_ids": [
      "6313547",
      "9315213",
      "9513785",
      "2466614",
      "25050364"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.26,
      "justification": "None of the provided papers study fibroblast growth factor-21 (FGF21) or report on life expectancy in FGF21-deficient mice. The evidence therefore neither supports nor contradicts the claim that lack of FGF21 increases life expectancy."
    },
    "overthinking_doc_ids": [
      "4434951",
      "19521501",
      "30351165",
      "581832",
      "2481032"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.24,
      "justification": "None of the provided papers investigate fibroblast growth factor 21 (FGF21), its absence, or its impact on lifespan in mice. They address other genes (ApoE, TLR2, periostin, etc.), dietary interventions, hormonal pathways, or human population data. Therefore, they offer no relevant evidence to confirm or refute the claim that lack of FGF21 increases life expectancy in mice."
    },
    "posthoc_doc_ids": [
      "37205759",
      "52805891",
      "9513785",
      "21232018",
      "581832"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "516",
    "claim": "High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 reports that COPD patients with elevated C-reactive protein (CRP) levels have higher, not lower, odds/hazard ratios for frequent exacerbations compared with those with low CRP. Odds ratios rise as more inflammatory biomarkers (including CRP) are elevated (e.g., OR = 3.7 for three high biomarkers vs none). No other cited paper provides data showing that higher CRP decreases exacerbation risk. Therefore, the available evidence contradicts the claim that high CRP reduces COPD exacerbations."
    },
    "naive_doc_ids": [
      "3580005",
      "29564505",
      "18988265",
      "5558754",
      "21048969"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 6 (\"Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease\") directly examined baseline C-reactive protein (CRP) levels in 6574 stable COPD patients and followed them for exacerbations. Individuals with elevated CRP (\u22653 mg/L) had a HIGHER\u2014not lower\u2014risk of frequent exacerbations: multivariable-adjusted hazard ratios rose from 1.4 to 2.5 as the number of elevated inflammatory biomarkers (including CRP) increased (trend P = 1\u00d710\u207b\u2078). Therefore, high CRP is associated with increased, not reduced, exacerbation risk, contradicting the claim. The other cited papers do not provide evidence supporting a protective effect of CRP on COPD exacerbations."
    },
    "overthinking_doc_ids": [
      "25319221",
      "72933407",
      "20887554",
      "13843341",
      "19464037"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the provided papers investigate or report on the relationship between C-reactive protein (CRP) levels and the risk of exacerbations in chronic obstructive pulmonary disease (COPD). Therefore, they neither support nor contradict the claim."
    },
    "posthoc_doc_ids": [
      "72933407",
      "3868322",
      "4910408",
      "16256507",
      "2575938"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "398",
    "claim": "Exhaustion of B cells contributes to poor Ab response in HIV-infected individuals.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers address whether B-cell exhaustion occurs in HIV infection or whether it leads to deficient antibody production. The cited studies cover topics such as vaccine-induced immunity to Salmonella, general B-cell migration cues, HBV-related oncogenesis, antibody-production techniques in CHO cells, celiac-disease autoantibodies, inflammasome effects on tumor immunity, antigen relay in lymph nodes, and timing/targets of HIV-1 neutralizing antibodies, but they do not present data linking B-cell exhaustion to poor antibody responses in HIV-infected individuals."
    },
    "naive_doc_ids": [
      "18275697",
      "38587347",
      "3756384",
      "26108767",
      "1471041"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "Among the provided papers, only Paper 2 deals with antibody responses in HIV infection, but it describes the timing and breadth of cross-neutralizing antibodies and their association with T-cell activation and viral load. None of the nine papers examine or report data on B-cell exhaustion or its impact on antibody production in HIV-infected individuals. Therefore, the supplied evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "9705208",
      "13469921",
      "1554348",
      "3155731",
      "12966719"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the provided papers address the state of B-cell exhaustion in HIV infection or its impact on antibody responses. The articles focus on T-cell immunity, chemokine-guided B-cell migration (without reference to HIV), regulatory T-cell function, dendritic cell migration, nutritional support in HIV patients, and PD-1/IL-10\u2013mediated T-cell impairment, but none present data on exhausted B cells or antibody production in HIV-infected individuals."
    },
    "posthoc_doc_ids": [
      "18275697",
      "38587347",
      "11899391",
      "3930020",
      "14934137"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "18",
    "claim": "61% of colorectal cancer patients are diagnosed with regional or distant metastases.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the cited papers report the overall proportion of colorectal cancer patients who present with either regional (stage III) or distant (stage IV) disease. Paper 1 gives the percentage with distant metastases only (19\u201323 %), while Papers 2 and 3 discuss factors influencing stage or the share diagnosed at an early stage, but do not provide the combined percentage for regional + distant stages. Therefore the evidence supplied is insufficient to verify or refute the specific claim that 61 % of patients are diagnosed with regional or distant metastases."
    },
    "naive_doc_ids": [
      "10958594",
      "5641851",
      "22942787",
      "14315749",
      "2492146"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report the proportion of colorectal cancer patients who present with regional or distant metastases. The available data address socioeconomic influences, treatment patterns, survival trends, and preventive interventions, but they do not quantify the combined percentage of patients diagnosed at regional or distant stages (61% or any other figure). Therefore, the claim cannot be verified with the supplied evidence."
    },
    "overthinking_doc_ids": [
      "5641851",
      "10958594",
      "39903312",
      "16390264",
      "2058909"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.11,
      "justification": "None of the cited papers reports the overall proportion of colorectal cancer patients who present with regional (Stage III) or distant (Stage IV) metastases. The articles discuss gene expression, treatment trends for synchronous (Stage IV) disease, socioeconomic influences, screening effects, and survival patterns, but they do not provide a statistic indicating that 61 % of patients are diagnosed with regional or distant metastases. Therefore the supplied evidence neither supports nor contradicts the stated claim."
    },
    "posthoc_doc_ids": [
      "23830488",
      "10958594",
      "43334921",
      "16390264",
      "22942787"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "470",
    "claim": "Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 explicitly states that glioblastoma multiforme (GBM) is characterized by \u201cextensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis.\u201d This description matches the claim verbatim, providing direct scholarly support. The other cited papers do not refute this statement and some (e.g., on angiogenesis mechanisms) are consistent with it, but Paper 1 alone is sufficient to substantiate the claim."
    },
    "naive_doc_ids": [
      "12685434",
      "13329980",
      "195689757",
      "24974080",
      "42080024"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Paper 1 explicitly states that glioblastoma multiforme (GBM) \"is characterized by independent but interrelated features of extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis.\" This directly mirrors every element of the claim. The other cited papers do not contradict this description. Therefore the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "12685434",
      "9486930",
      "9600826",
      "42298280",
      "51706771"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 explicitly states that glioblastoma multiforme (GBM) is \u201ccharacterized by independent but interrelated features of extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis.\u201d This directly matches every element of the claim. No paper provided contradicts this description, and Paper 1 offers affirmative, authoritative evidence, so the claim is supported."
    },
    "posthoc_doc_ids": [
      "12685434",
      "7028976",
      "15570691",
      "1192458",
      "7795952"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "226",
    "claim": "Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.77,
      "justification": "Among the provided papers, only Paper 8 mentions cancer-associated fibroblasts, describing how IL-6 secreted by CAFs promotes chemoresistance in esophageal squamous cell carcinoma cells. None of the papers present experimental data showing that interactions between CAFs and cancer cells drive the formation or activation of CAFs themselves. Therefore the evidence set neither confirms nor refutes the specific claim."
    },
    "naive_doc_ids": [
      "13779605",
      "25915873",
      "20568364",
      "3848469",
      "24713020"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Multiple cited studies describe bidirectional signaling between cancer cells and fibroblasts in which cancer cells actively convert or activate nearby fibroblasts into cancer-associated fibroblasts (CAFs).\n\u2022 Paper 3 reports that cancer cells \"induce oxidative stress in cancer-associated fibroblasts,\" and this stress then drives a co-evolutionary process that activates the fibroblasts (loss of Cav-1, mitochondrial dysfunction, glycolytic switch). Thus, direct interaction with cancer cells mediates CAF activation.\n\u2022 Paper 7 shows that prostate cancer cells stimulate surrounding fibroblasts; miR-205 re-expression in cancer cells \"blocks tumor-driven activation of surrounding fibroblasts.\" This demonstrates that signals from cancer cells are required for\u2014and can hinder\u2014the formation/activation of CAFs.\nThese findings align with the claim that CAFs interact with cancer cells and that this interaction mediates the formation and activation of CAFs."
    },
    "overthinking_doc_ids": [
      "3376731",
      "10024681",
      "24349992",
      "13779605",
      "5483793"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 shows that prostate-cancer cells stimulate surrounding fibroblasts (\"tumor-driven activation of surrounding fibroblasts\") and that this activation can be blocked by restoring miR-205 in the cancer cells, demonstrating a direct cancer-cell\u2192fibroblast interaction that generates/activates CAFs. Paper 3 further reports that cancer cells induce oxidative stress in adjacent fibroblasts, triggering loss of Cav-1 and other changes that convert them into metabolically active cancer-associated fibroblasts, which in turn feed back to support tumor progression. Both studies provide experimental evidence that reciprocal interactions between cancer cells and fibroblasts mediate the formation and activation of CAFs, directly supporting the claim."
    },
    "posthoc_doc_ids": [
      "8702697",
      "10024681",
      "24349992",
      "20568364",
      "34016944"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "975",
    "claim": "Primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "None of the provided papers examine whether stimulation with primary pro-inflammatory cytokines results in the generation of secondary pro- and anti-inflammatory mediators. The articles focus on SOCS3 effects on IFN-\u03b2 signaling, TLR-induced monocyte differentiation, CRP effects on IL-10, PD-1 blockade, chemotherapy combinations, AMPK\u2013JAK interactions, lipoxin analogs, keratin/Aire regulation, and myelin basic protein gene organization. They do not supply experimental data addressing the stated claim."
    },
    "naive_doc_ids": [
      "5137019",
      "21498497",
      "9334631",
      "1454773",
      "37248765"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.6,
      "justification": "The papers give experimental examples in which classical primary pro-inflammatory cytokines (such as TNF-\u03b1 or IL-1\u03b2) trigger the appearance of other soluble or cell-associated mediators, i.e. secondary mediators.\n\u2022 Paper 2 shows that exposing human vascular smooth-muscle cells to the primary cytokines TNF-\u03b1 and IFN-\u03b3 markedly increases transcription and release of endothelin-1, a vaso-active, pro-inflammatory mediator.  Thus, a primary cytokine stimulus induces a new downstream inflammatory mediator.\n\u2022 Paper 9 reports that TNF-\u03b1 and IL-1\u03b2 up-regulate the expression of PAR-2 on chondrocytes; activation of this newly expressed receptor then promotes production of MMP-1, MMP-13 and COX-2\u2014additional inflammatory effectors.  Hence the primary cytokines initiate secondary inflammatory pathways.\nAlthough none of the cited studies explicitly documents induction of an anti-inflammatory cytokine, the evidence clearly demonstrates that primary pro-inflammatory cytokines drive the generation of downstream inflammatory mediators, satisfying the central part of the claim that they induce \u2018secondary pro- \u2026 mediators\u2019.  Therefore the available evidence supports, rather than contradicts, the claim."
    },
    "overthinking_doc_ids": [
      "1360607",
      "6397191",
      "12130690",
      "2391552",
      "3973445"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.38,
      "justification": "Several cited papers show that classical pro-inflammatory cytokines (the \u201cprimary\u201d cytokines) stimulate cells to produce a second wave of soluble mediators, and the induced mediators include both pro- and anti-inflammatory molecules.\n\u2022 Paper 5: Exposure of vascular smooth-muscle cells to the primary cytokines TNF-\u03b1 and IFN-\u03b3 markedly increased transcription of prepro-endothelin-1 and release of endothelin-1. Endothelin-1 is a vasoactive, pro-inflammatory mediator, demonstrating induction of a secondary pro-inflammatory factor by primary cytokines.\n\u2022 Paper 1: Conditioned medium from activated (inflammatory) T cells\u2014which contains primary pro-inflammatory cytokines such as TNF-\u03b1, IL-17, etc.\u2014up-regulated mRNA for RANK (pro-osteoclastogenic, hence pro-inflammatory) in stromal cells and osteoblasts, but simultaneously up-regulated mRNA for osteoprotegerin, the decoy receptor that blocks RANKL signalling and counteracts bone resorption (an anti-inflammatory/anti-osteoclastogenic mediator). Thus the same primary cytokine milieu triggers both secondary pro- and anti-inflammatory mediators.\n\u2022 Paper 4: IL-1\u03b2 (a primary pro-inflammatory cytokine) induced COX-2, PGE\u2082 and MMPs in synovial fibroblasts\u2014additional examples of secondary pro-inflammatory mediators.\nCollectively, these data confirm that primary pro-inflammatory cytokines drive the production of downstream mediators, and that the induced mediators can have both pro-inflammatory (endothelin-1, RANK, COX-2/MMPs) and anti-inflammatory (osteoprotegerin) actions, supporting the claim."
    },
    "posthoc_doc_ids": [
      "43619625",
      "2391552",
      "25315295",
      "343052",
      "6397191"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "224",
    "claim": "Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 1 explicitly states that cancer-associated fibroblasts (CAFs) are \"one of the most crucial components of the tumor microenvironment.\" Additional papers (e.g., Papers 2 and 5) further describe interactions between CAFs and cancer cells within the tumor stroma, reinforcing that CAFs reside in and help shape the tumor microenvironment. No evidence in the provided papers contradicts this. Therefore, the claim that CAFs are constituents of tumor microenvironments is well supported."
    },
    "naive_doc_ids": [
      "952111",
      "24349992",
      "313403",
      "22401720",
      "27647593"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 explicitly states that \u201cCancer associated fibroblasts (CAFs) [are] one of the most crucial components of the tumor microenvironment.\u201d Papers 2, 3 and 5 likewise describe CAFs as stromal cells present within tumors and interacting with cancer cells. These descriptions directly confirm that CAFs are constituents of tumor microenvironments, supporting the claim."
    },
    "overthinking_doc_ids": [
      "952111",
      "3559136",
      "24349992",
      "2734421",
      "27647593"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 1 explicitly states that \u201cCancer associated fibroblasts (CAFs) [are] one of the most crucial components of the tumor microenvironment,\u201d directly placing CAFs within that environment. Paper 2 also discusses IL-6 produced \u201cmainly from cancer-associated fibroblasts\u201d as a factor operating in the tumor microenvironment, again implying CAFs are constituents of it. These descriptions align with, and therefore support, the claim that CAFs are constituents of tumor microenvironments."
    },
    "posthoc_doc_ids": [
      "952111",
      "3376731",
      "3559136",
      "207972",
      "1522336"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "739",
    "claim": "MT binding domain drives amyloid structure formation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the cited papers examine or report on amyloid formation in relation to a microtubule-binding (MT) domain. They discuss microtubule binding by dynein, LRRK2, and other unrelated domains, but do not address whether such domains promote or drive amyloid structure formation. Hence the provided evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "1546650",
      "5914739",
      "7729656",
      "9638032",
      "15121114"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.16,
      "justification": "Among the cited papers, some discuss microtubule-binding domains (Paper 1) and others address amyloid or protein aggregation phenomena (Papers 4\u20137). However, none of the provided studies investigate or demonstrate that a microtubule-binding domain directly drives amyloid structure formation. Consequently, the supplied evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "1546650",
      "15655418",
      "35684881",
      "7042304",
      "15347087"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the cited papers examine amyloid (fibril) formation or relate it to any microtubule-binding (MT-binding) domain. The studies focus on dynein\u2013tubulin interactions, TGF-\u03b2 ligand antagonism, T-cell receptor lipid interactions, guanylate-binding protein in invasion, CPEB in memory, mutant p53 functions, glutamate-receptor ligand binding, and integrin signaling. Consequently, the evidence set does not address whether an MT-binding domain drives amyloid structure formation."
    },
    "posthoc_doc_ids": [
      "1546650",
      "40383969",
      "5914739",
      "12685434",
      "15655418"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "184",
    "claim": "Bone marrow cells don't contribute to adult macrophage compartments.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 and Paper 2 directly examine the origin of adult tissue-resident macrophages using parabiosis, fate mapping, and bone-marrow-transplant models. Both studies conclude that, under homeostatic (steady-state) conditions, adult macrophage compartments are maintained locally by self-renewal and receive little or no input from circulating monocytes, which originate in the bone marrow. This finding aligns with the claim that bone-marrow cells do not contribute appreciably to adult macrophage pools. The remaining cited papers address mesenchymal stem cells, embryonic-like stem cells, dendritic cells, or special genetic manipulations and do not provide relevant in-vivo evidence about normal macrophage maintenance. Therefore, the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "12827098",
      "7521113",
      "9412420",
      "35811036",
      "6446747"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Two independent fate-mapping and parabiosis studies (Papers 1 and 4) show that the main tissue-resident macrophage populations present in adult mice are seeded before birth and then persist by local self-renewal. They report \u2018minimal\u2019 or no detectable replenishment from circulating monocytes, the immediate progeny of adult bone-marrow hematopoiesis. This directly supports the claim that bone-marrow-derived cells do not contribute meaningfully to adult macrophage compartments. The remaining cited papers analyse in-vitro bone-marrow-derived macrophages or unrelated stem-cell lineages and do not provide in-vivo evidence that opposes this conclusion. Hence the overall evidence aligns with, rather than contradicts, the claim."
    },
    "overthinking_doc_ids": [
      "12827098",
      "24707550",
      "35811036",
      "7521113",
      "9412420"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.62,
      "justification": "Parabiosis and fate-mapping studies (Papers 5 and 7) show that most adult tissue-resident macrophages self-renew locally with little or no input from circulating bone-marrow-derived monocytes during steady-state. However, Paper 4 demonstrates that after infection-induced death of liver-resident Kupffer cells, monocytes recruited from the blood (i.e., bone-marrow origin) differentiate into macrophages and reconstitute the Kupffer cell compartment. Thus bone-marrow cells can, under adult inflammatory or injury conditions, generate new macrophages, contradicting the absolute claim that they \u201cdon\u2019t contribute\u201d to adult macrophage compartments."
    },
    "posthoc_doc_ids": [
      "10078024",
      "188911",
      "25985964",
      "5511240",
      "12827098"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "940",
    "claim": "Pharmacist attendance at ward rounds increases adverse events in wards.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.77,
      "justification": "Paper 1 directly examined the effect of having a pharmacist join the clinical team on ward (ICU) rounds. After the pharmacist began rounding, the rate of preventable adverse drug events fell by 66 % (from 10.4 to 3.5 per 1000 patient-days), while no change occurred in the control unit. This shows pharmacist attendance decreases\u2014not increases\u2014adverse events. The other cited papers do not report that pharmacist presence raises adverse events; they either describe pharmacist interventions without measuring ADEs or are unrelated to pharmacists. Hence the available evidence opposes the claim."
    },
    "naive_doc_ids": [
      "12258338",
      "39300105",
      "2276126",
      "42404093",
      "24575065"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Paper 1 directly studies pharmacist attendance during ICU ward rounds. It reports that when a senior pharmacist joined rounds, the rate of preventable ordering adverse drug events fell by 66% (from 10.4 to 3.5 per 1000 patient-days), while no change occurred in a control unit without the pharmacist. This demonstrates that pharmacist participation decreases\u2014rather than increases\u2014adverse events. The remaining papers either do not deal with pharmacist presence on ward rounds or describe pharmacists reducing errors in other settings, and none show an increase in adverse events due to pharmacist attendance. Therefore, the available evidence refutes the claim."
    },
    "overthinking_doc_ids": [
      "12258338",
      "583260",
      "42404093",
      "21260231",
      "38799797"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "The only paper that directly examines pharmacist attendance on ward (ICU) rounds (Paper 1) found that having a pharmacist participate reduced preventable adverse drug events by 66% (from 10.4 to 3.5 per 1000 patient-days), while a control unit without pharmacist involvement showed no change. No paper presents evidence that pharmacist presence increases adverse events. Therefore, the available evidence opposes the claim."
    },
    "posthoc_doc_ids": [
      "12258338",
      "583260",
      "6070278",
      "3578380",
      "11254040"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "643",
    "claim": "Insulin effects appetite via ventral tegmental neurons.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Paper 2 shows that deleting insulin receptors specifically in tyrosine-hydroxylase\u2013positive catecholaminergic neurons (which include dopaminergic neurons of the ventral tegmental area, VTA) causes hyperphagia and weight gain, and that normal insulin acutely increases the firing of VTA/SN dopaminergic neurons. These findings demonstrate that insulin acts on VTA neurons and that this action influences food intake, satisfying the claim that insulin affects appetite via ventral tegmental neurons. The other cited papers discuss appetite control through different hormones, cytokines, or circuits and do not contradict this result."
    },
    "naive_doc_ids": [
      "23869951",
      "15535511",
      "1070920",
      "12943966",
      "25050364"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 4 shows that deleting the insulin receptor specifically in tyrosine-hydroxylase\u2013positive catecholaminergic neurons\u2014which include dopaminergic neurons in the ventral tegmental area (VTA)\u2014produces hyperphagia and weight gain. The paper also reports that insulin normally acutely increases the firing rate of VTA/SN dopamine neurons, an effect lost when the insulin receptor is removed. These data demonstrate that insulin acts directly on VTA neurons to influence feeding behavior, thereby supporting the claim that insulin affects appetite via ventral tegmental neurons. None of the other cited papers provide contradictory or more directly relevant information on this point."
    },
    "overthinking_doc_ids": [
      "23869951",
      "4611267",
      "1281769",
      "15535511",
      "1084062"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 7 reports that deleting insulin receptors specifically in tyrosine-hydroxylase\u2013positive catecholaminergic neurons (which include the dopaminergic neurons of the ventral tegmental area, VTA) causes hyperphagia and weight gain. It also shows that normal insulin acutely increases the firing rate of about half of VTA/SN dopaminergic neurons, an effect lost when the insulin receptor is deleted. These findings demonstrate that insulin acts through VTA dopaminergic neurons to influence food intake (appetite). None of the other cited papers provide contradictory evidence regarding this mechanism. Therefore, the supplied literature supports the claim that insulin affects appetite via ventral tegmental neurons."
    },
    "posthoc_doc_ids": [
      "1576955",
      "3202143",
      "11414664",
      "23869951",
      "1084062"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1278",
    "claim": "The treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.5,
      "justification": "None of the provided abstracts report whether cancer patients receiving combined immune-checkpoint (co-inhibitory receptor) blockade experienced autoimmune or other immune-related adverse events. Therefore the evidence neither supports nor refutes the claim."
    },
    "naive_doc_ids": [
      "4468861",
      "21891856",
      "3559136",
      "25589047",
      "23912923"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the supplied abstracts, only Paper 1 involves combined immune-checkpoint (co-IR) blockade, but it provides no information about autoimmune or other immune-related adverse events. The remaining papers address bevacizumab toxicity, mouse cancer models, FGF19 therapy, and basic immunology of IL-1/IL-17 or regulatory T cells\u2014none of which report clinical autoimmune toxicity arising from co-IR blockade. Consequently, the evidence set neither confirms nor refutes the claim about absence of autoimmune events."
    },
    "overthinking_doc_ids": [
      "4468861",
      "25589047",
      "21891856",
      "38025907",
      "1855679"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.63,
      "justification": "Checkpoint (co-inhibitory receptor, co-IR) blockade is reported to provoke immune-mediated toxicity.  Paper 6 shows that eliminating or blocking the co-IR VISTA in mice produces chronic inflammation and markedly increases the incidence and severity of autoimmune disease in a susceptible background, demonstrating autoimmune adverse events following co-IR blockade.  In patients, paper 8 (pembrolizumab, a PD-1 blocker) records numerous serious treatment-related toxicities; these agents are well-known to induce immune-mediated (autoimmune) adverse events such as colitis, thyroiditis, and hepatitis, indicating such events do occur.  Therefore, the claim that co-IR blockade \u201cdoes not cause any adverse autoimmune events\u201d is refuted by the evidence."
    },
    "posthoc_doc_ids": [
      "11254040",
      "308862",
      "25589047",
      "4468861",
      "15128866"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "205",
    "claim": "CDK6 shows improved binding to loss-of-function variants of p18 INK4C.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers discuss CDK6, p18 INK4C, or their binding interactions. Therefore, they neither confirm nor refute the claim."
    },
    "naive_doc_ids": [
      "35684881",
      "3127341",
      "10698739",
      "47240151",
      "21164071"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.18,
      "justification": "None of the provided papers discuss the interaction between CDK6 and p18 INK4C\u2014neither wild-type nor loss-of-function variants. The evidence cited covers unrelated topics such as p53 mutants, GLP-1 receptor polymorphisms, Inpp4a mutations, c-Myb\u2013CBP/p300 interactions, adenovirus proteins, CTLA-4 mutations, a CDK4/6 inhibitor, yeast autophagy regulation, CDK2 knockout mice, and a hedgehog inhibitor trial. Therefore, the corpus supplies no information that confirms or refutes the claim."
    },
    "overthinking_doc_ids": [
      "35684881",
      "3127341",
      "6492658",
      "16745747",
      "207972"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.35,
      "justification": "None of the provided papers discuss CDK6, p18 INK4C, or their binding interactions. Therefore, the evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "3127341",
      "7717468",
      "1225513",
      "10698739",
      "207972"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1382",
    "claim": "aPKCz causes tumour enhancement by affecting glutamine metabolism.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.24,
      "justification": "The provided papers discuss glutamine metabolism and its importance in various cancers, but none of them mention aPKC\u03b6 (atypical protein kinase C zeta) or investigate its role in regulating glutamine metabolism or promoting tumor growth. Therefore, they do not supply evidence that aPKC\u03b6 enhances tumors via effects on glutamine metabolism."
    },
    "naive_doc_ids": [
      "27647593",
      "22914228",
      "24349992",
      "3831884",
      "25513319"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "The cited papers discuss glutamine transporters (ASCT2/SLC1A5), glutaminolysis, mTORC1 activation, KRAS-dependent glutamine metabolism, and related effects on tumour growth and therapy resistance. None of the summaries mention atypical protein kinase C zeta (aPKC\u03b6) or examine how it might modulate glutamine metabolism to enhance tumours. Therefore the evidence provided does not address the specific claim about aPKC\u03b6."
    },
    "overthinking_doc_ids": [
      "5256564",
      "27647593",
      "3831884",
      "10169908",
      "1196631"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers mention atypical protein kinase C zeta (aPKC\u03b6) or analyze its role in tumor growth or in regulating glutamine metabolism. The evidence therefore contains no information either supporting or contradicting the claim that aPKC\u03b6 enhances tumors by affecting glutamine metabolism."
    },
    "posthoc_doc_ids": [
      "5256564",
      "27647593",
      "3831884",
      "23599024",
      "20054396"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "813",
    "claim": "Mutations in G-Beta protein GNB1 are present in many cancers, resulting in loss of interaction with G-alpha subunits and concomitant activation of AKT pathway.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.22,
      "justification": "None of the provided papers discuss mutations in the G-beta protein GNB1, their frequency in cancers, their effects on G-alpha interaction, or any resulting activation of the AKT pathway. Therefore, they neither support nor contradict the claim."
    },
    "naive_doc_ids": [
      "21164071",
      "207972",
      "15113221",
      "14241418",
      "7736860"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the cited papers discuss mutations in the G-beta protein GNB1, their prevalence in cancer, their effect on G-alpha interaction, or consequent AKT pathway activation. The evidence provided focuses on PI3K/Akt pathway alterations (PIK3CA, PTEN, Ras, etc.), Wnt signalling, immune checkpoints, integrins, IRF factors, and other topics, but does not address GNB1 or its functional consequences. Therefore, the papers do not contain information relevant to confirming or refuting the specific claim."
    },
    "overthinking_doc_ids": [
      "21551568",
      "3590806",
      "5403286",
      "207972",
      "21164071"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 4 directly addresses the claim. It reports recurrent, patient-derived mutations in the G-beta subunit genes GNB1 and GNB2 across multiple human tumors (myeloid and B-cell malignancies and other cancers), establishing that such mutations are present in many cancers. Functional characterization shows that many GNB1 mutations \"affect the protein interface that binds G\u03b1 subunits\" and \"disrupt G\u03b1 interactions with the G\u03b2\u03b3 dimer,\" confirming loss of G-alpha interaction. The study further demonstrates that these mutations \"activate canonical G-protein signaling\" and that the resulting signaling is suppressed by the dual PI3K-mTOR inhibitor BEZ235, indicating activation of the PI3K/AKT pathway. No other provided papers contradict this finding or give opposing data. Hence the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "4993011",
      "16745747",
      "25479072",
      "33387953",
      "14819804"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "524",
    "claim": "Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 reports that in 2,595 human subjects undergoing cardiac evaluation, higher plasma L-carnitine concentrations predicted a greater risk of both existing cardiovascular disease and future major adverse cardiac events, but this association was present only in individuals who simultaneously had high plasma trimethylamine N-oxide (TMAO) levels. This directly matches the claim that elevated plasma L-carnitine, when accompanied by TMAO, is positively correlated with cardiovascular events. The other cited papers do not address the joint L-carnitine/TMAO relationship, so they neither strengthen nor weaken the conclusion. Therefore, the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "14803797",
      "6070278",
      "4445629",
      "6793674",
      "27466734"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.64,
      "justification": "Among the cited papers only Paper 1 discusses trimethylamine N-oxide (TMAO) and cardiovascular events, showing a positive association. None of the eight papers measure or analyze plasma L-carnitine levels, nor do they evaluate the joint relationship of L-carnitine together with TMAO and cardiovascular outcomes. Therefore the documents provide no direct information to confirm or refute the specific claim about higher L-carnitine levels in conjunction with TMAO and cardiovascular events."
    },
    "overthinking_doc_ids": [
      "6793674",
      "25822299",
      "4445629",
      "27466734",
      "1974176"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 3 reports that in 2,595 human subjects \"plasma L-carnitine levels \u2026 predicted increased risks for both prevalent cardiovascular disease and incident major adverse cardiac events \u2026 but only among subjects with concurrently high TMAO levels.\"  This directly shows that higher plasma L-carnitine, in the presence of elevated trimethylamine-N-oxide, is positively correlated with cardiovascular events.  None of the other cited papers provide data that oppose this relationship.  Therefore the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "6793674",
      "4445629",
      "14803797",
      "24408040",
      "24555878"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "899",
    "claim": "Oxidative DNA damage inhibits STING signalling.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that the oxidized DNA base 8-hydroxy-guanosine (a hallmark of oxidative DNA damage) \u201cpotentiated cytosolic immune recognition\u201d by making DNA less susceptible to TREX1 degradation, thereby enhancing STING-dependent signalling. Thus oxidative DNA damage was shown to increase, not inhibit, STING activation. The other cited papers do not address oxidative DNA damage in relation to STING signalling. Therefore the available evidence contradicts the claim that oxidative DNA damage inhibits STING signalling."
    },
    "naive_doc_ids": [
      "13106686",
      "19688024",
      "18358026",
      "5765455",
      "19922508"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 reports that oxidatively modified DNA (8-hydroxyguanosine\u2013containing DNA) is sensed more strongly because it resists TREX1 degradation and therefore 'potentiates STING-dependent immune sensing.' Paper 7 likewise shows that oxidized mitochondrial DNA released in neutrophil extracellular traps activates type I interferon signalling through STING in mice. Both studies demonstrate that oxidative DNA damage enhances\u2014rather than inhibits\u2014STING signalling. No paper presents evidence that oxidative DNA damage suppresses STING activity. Hence the provided evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "13106686",
      "13380011",
      "18358026",
      "6501747",
      "140874"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.66,
      "justification": "Paper 1 directly examines the effect of oxidative DNA damage (8-hydroxyguanosine\u2013containing DNA) on STING signalling and reports that such damage POTENTIATES (enhances) STING-dependent immune sensing by protecting DNA from TREX1 degradation. This is the opposite of the claim that oxidative DNA damage inhibits STING signalling. The other cited papers do not address STING in the context of oxidative DNA damage, so they provide no contrary evidence. Therefore, the available evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "13106686",
      "22059387",
      "213017",
      "14496749",
      "14972169"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "5",
    "claim": "1/2000 in UK have abnormal PrP positivity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 reports that 16 of 32,441 archived UK appendix samples were positive for abnormal prion protein, corresponding to an overall prevalence of 493 per million population (\u2248 1 in 2,000; 95 % CI 282\u2013801 per million). This directly aligns with the claim that roughly 1/2000 people in the UK have abnormal PrP positivity. The remaining cited papers concern unrelated health topics and provide no conflicting information, so the evidence available supports the claim."
    },
    "naive_doc_ids": [
      "13734012",
      "38784540",
      "5824985",
      "11349166",
      "27063470"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Paper 1 directly measured abnormal prion protein (PrP) in 32,441 archived UK appendix samples and found 16 positives, corresponding to a prevalence of 493 per million people (\u22481 in 2,027). This figure is effectively the same order of magnitude as the claim of 1/2,000. The other cited papers deal with megakaryocyte cytokinesis, cardiovascular risk, and genetic susceptibility to sepsis, none of which address PrP prevalence. Therefore the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "13734012",
      "7114092",
      "25355575",
      "2138767",
      "2647374"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports 16 abnormal PrP\u2013positive cases among 32,441 archived UK appendix samples, corresponding to a prevalence of 493 per million (95% CI 282\u2013801 per million). 493 per million equals roughly 1 in 2,030 individuals, essentially the same order of magnitude as \u20181 in 2,000\u2019. No other cited papers address PrP prevalence. Therefore, the available evidence supports the claim that about 1/2000 people in the UK have abnormal PrP positivity."
    },
    "posthoc_doc_ids": [
      "13734012",
      "13883546",
      "13989491",
      "75636923",
      "1606628"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "209",
    "claim": "CHOP is a general endoplasmic reticulum stress marker.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 shows that palmitate-induced ER stress in \u03b2-cells leads to a time-dependent rise of Ddit3/CHOP mRNA, and the authors explicitly list CHOP among \u201cmarker genes of ER stress.\u201d\nPaper 2 demonstrates that genetic (ARV1 deletion) or pharmacological disturbances that activate the unfolded protein response cause strong up-regulation of ATF4 and CHOP; CHOP elevation is used as read-out of ER stress in both yeast and murine macrophages.\nThese independent studies use CHOP induction as an indicator of ER stress in different cell types and stress paradigms, supporting the claim that CHOP functions as a general ER-stress marker. Other cited papers do not address CHOP, and none present contradictory data."
    },
    "naive_doc_ids": [
      "25510546",
      "35760786",
      "9752604",
      "9194077",
      "1748921"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.61,
      "justification": "Paper 2 reports that deficiency of the ER-resident lipid-transport protein ARV1 activates the unfolded protein response and specifically notes an \"up-regulation of activating transcription factor-4, CHOP (C/EBP homologous protein).\" Because CHOP expression rises in response to this ER stress, the study employs CHOP as an indicator of the unfolded protein response. This experimental linkage between ER stress and CHOP induction supports the claim that CHOP functions as a general marker of endoplasmic reticulum stress. The remaining cited papers do not provide contrary evidence."
    },
    "overthinking_doc_ids": [
      "9752604",
      "35760786",
      "1554348",
      "471735",
      "38944245"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Paper 1 explicitly shows that induction of ER stress (by palmitate in MIN6 beta-cells, in diabetic mouse islets, and in human type 2 diabetes pancreas) is accompanied by increased expression of Ddit3/CHOP together with other canonical ER-stress genes (ATF4, XBP1, DNAJC3). The authors use CHOP as one of several molecular readouts to confirm ER-stress activation, indicating that CHOP functions as a marker of the ER-stress response. The remaining papers do not address CHOP, and none provide contradictory evidence. Therefore, the available data support the claim that CHOP acts as a general marker of endoplasmic reticulum stress."
    },
    "posthoc_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "12909503",
      "19851614"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "434",
    "claim": "Foxp3 enables the expression of transcriptional regulators implicated in memory T cell development.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the cited studies directly examine whether Foxp3 itself induces or \u2018enables\u2019 the expression of transcriptional regulators that drive memory T-cell differentiation. Paper 2 shows that Foxp3\u207a Treg cells can elevate KLF2 in endothelial cells, but this does not address memory T-cell development nor demonstrate a Foxp3-dependent induction within T cells. The other papers focus on STAT3\u2013SALL4 regulation, Blimp-1 in Th1/Th2 cells, Foxo1 programs in Tregs, or general reviews of memory subsets, without linking Foxp3 to the up-regulation of memory-associated transcription factors. Consequently, the provided evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "20179918",
      "30908508",
      "37311371",
      "21363424",
      "20675284"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.21,
      "justification": "None of the provided papers examine whether Foxp3 promotes expression of transcriptional regulators that drive memory T-cell development. The cited studies focus on stem-cell histone modifiers, cytokine roles in memory T cells, FoxO factors, surface marker CD127 in Treg identification, and other unrelated signaling pathways. No experimental data links Foxp3 to induction of memory-associated transcriptional regulators, so the evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "6455142",
      "13636631",
      "16728949",
      "266641",
      "15803282"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the summarized papers examine whether Foxp3 promotes (enables) the expression of transcriptional regulators involved in memory T-cell differentiation. The references discuss memory T-cell development in general, roles of other transcription factors (FoxO, KLF-2, Tcf1, etc.), and functions of Foxp3\u207a regulatory T cells in endothelial protection, but they do not provide direct experimental data linking Foxp3 to induction of transcriptional regulators that drive memory T-cell formation. Therefore the supplied evidence is insufficient to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "5508750",
      "16728949",
      "18489989",
      "13048272",
      "15945975"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "744",
    "claim": "Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 shows that Ras-transformed cells actively internalize extracellular proteins by macropinocytosis, degrade these proteins in lysosomes, and release amino acids (e.g., glutamine) that feed central carbon metabolism and support growth when free glutamine is scarce. Paper 3 independently demonstrates that macropinocytic uptake of extracellular proteins supplies essential amino acids that can sustain cell survival and activate mTORC1 under nutrient-poor conditions. Together these data provide direct experimental evidence that macropinocytosis supplies intracellular amino acids via uptake and degradation of extracellular proteins, confirming the claim."
    },
    "naive_doc_ids": [
      "4138659",
      "3845894",
      "8460275",
      "23895668",
      "3831884"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that Ras-transformed cells actively internalize extracellular protein by macropinocytosis; the internalized protein is then degraded, generating amino acids (e.g., glutamine) that enter central metabolism and can substitute for external free amino acids. This directly demonstrates that macropinocytosis supplies cells with amino acids through uptake of protein, matching the claim. The other cited papers do not address macropinocytosis or cellular amino-acid supply and therefore do not affect this assessment."
    },
    "overthinking_doc_ids": [
      "4138659",
      "3845894",
      "4231060",
      "8814634",
      "253672"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 reports that Ras-transformed cells take up extracellular proteins through macropinocytosis, degrade the internalized proteins, and release amino acids (e.g., glutamine) that fuel cellular metabolism. This directly demonstrates that macropinocytosis provides cells with amino acids via uptake of protein, matching the claim. The other cited papers do not address this specific process, and none contradict it, so the overall evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "4138659",
      "3845894",
      "4231060",
      "4959368",
      "12207167"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "887",
    "claim": "Only a minority of cells survive development after differentiation into stress-resistant spores.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.14,
      "justification": "None of the provided papers measure or discuss the fraction of cells that remains viable after differentiating into stress-resistant spores. The articles focus on identifying sporulation genes (Paper 1), collective migration (Paper 2), cytokine effects on T cells (Paper 3), autophagic death (Papers 4, 5, 9), PD-1 signaling (Paper 6), microglial origin (Paper 7), and neural-crest BMP signaling (Paper 8). Consequently, they supply no direct evidence for or against the statement that only a minority of cells survive development following sporulation."
    },
    "naive_doc_ids": [
      "4942718",
      "12824568",
      "13636631",
      "2543135",
      "33667484"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "None of the provided papers quantify what proportion of cells survive the developmental process of sporulation or state that only a minority do so. Paper 1 discusses genes required for sporulation in Bacillus subtilis but does not report survival fractions. The other papers focus on heat-shock regulation, proteolysis, cooperative swarming, immunology, plasma DNA, imprinting, pancreas development, or innate lymphoid cells, none of which address the fraction of cells that become stress-resistant spores and survive. Therefore the evidence is insufficient to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "4942718",
      "34386619",
      "12881593",
      "4321295",
      "21878751"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.27,
      "justification": "Among the supplied papers, only Paper 4 directly concerns sporulation, and it focuses on identifying genes involved in the process rather than reporting what fraction of cells successfully complete sporulation and survive as stress-resistant spores. None of the other papers address cell survival rates after sporulation. Hence, the evidence set does not provide information relevant to verifying whether only a minority of cells survive development after differentiating into spores."
    },
    "posthoc_doc_ids": [
      "7875158",
      "7506409",
      "24044977",
      "4942718",
      "2851611"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "658",
    "claim": "It is not proven that moderate consumption of candy and chocolate reduces the risk of cardiovascular disease (CVD) specifically.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the cited papers examine candy or chocolate consumption or its relationship to cardiovascular disease. They focus on antipsychotics, statins, influenza vaccination, risk algorithms, antihypertensive therapies, gut-derived metabolites, gasotransmitters, and exercise. Therefore the evidence provided neither proves nor disproves the claim about moderate candy or chocolate intake and CVD risk."
    },
    "naive_doc_ids": [
      "5402581",
      "5698494",
      "11939159",
      "27466734",
      "40790033"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.31,
      "justification": "None of the supplied papers examine candy or chocolate consumption in relation to cardiovascular disease risk. Therefore they neither prove nor disprove the claim."
    },
    "overthinking_doc_ids": [
      "15984735",
      "6793674",
      "202259",
      "471921",
      "7454794"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.27,
      "justification": "None of the cited papers examine candy or chocolate intake or its effect on cardiovascular disease risk. They address statins, blood pressure, physician adherence to guidelines, dietary protein sources, and other non-related factors. Therefore the evidence provided gives no information relevant to whether moderate candy/chocolate consumption reduces CVD risk."
    },
    "posthoc_doc_ids": [
      "5698494",
      "1287809",
      "2138767",
      "409280",
      "4506414"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "917",
    "claim": "PTEN is a regulator for the transcriptional activity of SRF",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 2 reports that nuclear PTEN interacts with the N-terminal domain of serum response factor (SRF) and that this interaction promotes SRF binding to smooth-muscle gene promoters, thereby controlling SRF-dependent transcription. Loss of nuclear PTEN diminishes SRF\u2019s myogenic transcriptional activity. These data demonstrate that PTEN regulates the transcriptional activity of SRF, directly supporting the claim. The other cited papers do not address PTEN\u2013SRF interactions and do not contradict this finding."
    },
    "naive_doc_ids": [
      "20179918",
      "34071621",
      "2316374",
      "27822315",
      "1964163"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 7 reports that nuclear PTEN interacts with the N-terminal domain of serum response factor (SRF) and promotes SRF binding to promoters of smooth-muscle-specific genes, thereby controlling SRF-dependent transcription. This demonstrates that PTEN regulates the transcriptional activity of SRF, directly supporting the claim. The other cited papers do not address PTEN\u2013SRF interactions, but they do not contradict the finding; therefore, the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "6493422",
      "15176526",
      "19851614",
      "2316374",
      "14367469"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 4 reports that nuclear PTEN interacts with the N-terminal domain of serum response factor (SRF), enhances SRF binding to smooth-muscle gene promoters and is \"an indispensible regulator with SRF to maintain the differentiated SM phenotype.\" These experiments demonstrate that PTEN modulates (regulates) SRF-dependent transcriptional activity. No contradictory evidence is presented in the supplied papers. Therefore, the evidence supports the claim that PTEN is a regulator of the transcriptional activity of SRF."
    },
    "posthoc_doc_ids": [
      "14367469",
      "29429111",
      "2316374",
      "34071621",
      "6493422"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "615",
    "claim": "Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 directly examines LRRK2 Roc-COR domain mutations and microtubule acetylation. It reports that raising microtubule acetylation (via deacetylase inhibitors or \u03b1TAT1) prevents mutant LRRK2 association with microtubules and RESTORES, rather than worsens, axonal transport defects in neurons and in vivo. No other cited papers address the effect of microtubule acetylation on LRRK2-induced transport defects. Therefore the available evidence opposes the claim that increased acetylation worsens the interference."
    },
    "naive_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "7549811",
      "16056410"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly investigates LRRK2 Roc-COR domain mutations and microtubule acetylation. It reports that elevating microtubule acetylation (via deacetylase inhibitors or \u03b1TAT1) PREVENTS mutant LRRK2 from binding microtubules and RESTORES axonal transport and locomotor function. This is the opposite of the claim, which states that increased acetylation worsens the transport interference. The other papers do not address the LRRK2\u2013acetylation interaction. Therefore, the available evidence refutes the claim."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "7549811",
      "20904154"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that elevating microtubule acetylation (via deacetylase inhibitors or \u03b1TAT1) PREVENTS mutant LRRK2 from binding microtubules and RESCUES the axonal-transport defects and locomotor problems caused by Roc-COR mutations. This is the opposite of the claim, which states that increased acetylation worsens those defects. Papers 2\u20134 do not address LRRK2 or microtubule acetylation in this context. Therefore the available evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "41644178"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "350",
    "claim": "Discrimination between the initiator and elongation tRNAs depends on the translation initiation factor IF3.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.74,
      "justification": "Paper 1 describes how the three bacterial initiation factors (IF1-3) 'enable the selection of initiator tRNA' and shows that IF3 undergoes conformational changes together with tRNA to ensure proper accommodation of formyl-methionyl initiator tRNA (fMet-tRNAfMet) in the P-site for start-codon recognition. This demonstrates that the factor IF3 is directly involved in discriminating the initiator tRNA from elongator tRNAs during the initiation stage. The other cited papers focus on different roles of eukaryotic initiation factors or unrelated pathways and offer no relevant information. Hence the available evidence supports the claim that discrimination between initiator and elongation tRNAs depends on IF3."
    },
    "naive_doc_ids": [
      "16927286",
      "9505448",
      "22896970",
      "24521894",
      "4465762"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Paper 1 describes cryo-EM reconstructions of 30S initiation complexes and states that IF1, IF2, and IF3 \u2018enable the selection of initiator tRNA,\u2019 and that IF3 undergoes conformational changes that facilitate the proper accommodation of fMet-tRNA\u1da0\u1d39\u1d49\u1d57 in the P site for start-codon recognition. This shows that IF3 activity is directly involved in recognizing/accepting the initiator tRNA, a process that inherently discriminates it from elongator tRNAs. None of the other cited papers address IF3\u2019s role in tRNA selection, nor do they present evidence contradicting this function. Therefore, the available evidence supports the claim that discrimination between initiator and elongation tRNAs relies on IF3."
    },
    "overthinking_doc_ids": [
      "16927286",
      "9505448",
      "24521894",
      "4561402",
      "5116145"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.27,
      "justification": "Paper 1 describes cryo-EM structures of 30S initiation complexes and states that the three bacterial initiation factors \"enable the selection of initiator tRNA\" and that \"IF3 and tRNA undergo large conformational changes to facilitate the accommodation of the formyl-methionyl-tRNA into the P site for start codon recognition.\" These observations indicate that IF3 activity is directly involved in recognizing and properly positioning the initiator tRNA, a process that inherently requires discrimination between initiator and elongator tRNAs. None of the other cited papers address IF3 or tRNA selection, so the only relevant evidence supports the claim that discrimination depends on IF3."
    },
    "posthoc_doc_ids": [
      "16927286",
      "143251",
      "2099400",
      "24521894",
      "9505448"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "978",
    "claim": "Pro-inflammatory cytokines are up repressed during tumor development.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.62,
      "justification": "Paper 8 reports that in cervical-cancer patients the serum level of the pro-inflammatory cytokine IL-6 is elevated before treatment and that higher IL-6 levels have prognostic value for overall survival, indicating IL-6 is up-regulated, not repressed, during tumor development. No paper presents data showing systematic down-regulation of pro-inflammatory cytokines in tumors, and some (e.g., Paper 3 showing VEGF up-regulation) describe increased expression of other cytokine/growth\u2010factor genes. Thus the available evidence opposes the claim that pro-inflammatory cytokines are repressed during tumor development."
    },
    "naive_doc_ids": [
      "57783564",
      "8133180",
      "17844478",
      "9767444",
      "952111"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.25,
      "justification": "The only paper that directly measures pro-inflammatory cytokines in a tumour setting (Paper 4, NSCLC patients) reports that serum TNF-\u03b1 levels are significantly HIGHER in cancer patients than in healthy controls, and IL-6 levels are not reduced. This shows pro-inflammatory cytokines are not repressed during tumour development, opposing the claim. The remaining papers do not provide data on pro-inflammatory cytokine levels in tumours, so they neither support nor overrule this contradiction."
    },
    "overthinking_doc_ids": [
      "6270720",
      "21258863",
      "5236443",
      "39264456",
      "1780819"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.17,
      "justification": "None of the cited papers examine the regulation (up- or down-regulation) of pro-inflammatory cytokines during tumor development. They mainly address fibrosis, atherosclerosis, Th17-mediated inflammation, RET signaling, tai chi effects on survivors, splicing factors in breast cancer, and IL-1 signaling in cardiomyopathy. Thus they provide no direct evidence for or against the claim."
    },
    "posthoc_doc_ids": [
      "21258863",
      "22889972",
      "11233339",
      "8133180",
      "24783597"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "662",
    "claim": "JMJD6 slows the hydroxylation of C-terminal lysine",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.66,
      "justification": "Paper 1 reports that JMJD6 functions as an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that catalyzes hydroxylation of lysine 382 in the C-terminal region of p53. Thus JMJD6 promotes (speeds) hydroxylation rather than slowing it. The other cited papers do not address JMJD6 or C-terminal lysine hydroxylation. Therefore the available evidence contradicts the claim that JMJD6 slows the hydroxylation of C-terminal lysine."
    },
    "naive_doc_ids": [
      "37204802",
      "29788648",
      "12172346",
      "22036571",
      "2139357"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1 shows that JMJD6 is an \u03b1-ketoglutarate/Fe(II)\u2013dependent lysyl hydroxylase that directly catalyzes hydroxylation of lysine 382 in the C-terminal region of p53. Thus JMJD6 promotes (accelerates) \u2013 rather than slows \u2013 hydroxylation of a C-terminal lysine. The other cited papers do not address JMJD6-mediated hydroxylation. Therefore the provided evidence opposes the claim that JMJD6 slows the hydroxylation of C-terminal lysine."
    },
    "overthinking_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "19004126",
      "25915873"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Paper 1 reports that JMJD6 itself is an \u03b1-ketoglutarate/Fe(II)-dependent lysyl hydroxylase that CATALYZES hydroxylation of lysine 382 in the C-terminal region of p53. Thus JMJD6 promotes (speeds) rather than slows lysine hydroxylation. The remaining cited papers do not address JMJD6 or lysine hydroxylation. Therefore the available evidence contradicts the claim that JMJD6 slows the hydroxylation of C-terminal lysine."
    },
    "posthoc_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "2582169",
      "9334631"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "223",
    "claim": "Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that oncogenic mTOR signalling inside mammary carcinoma cells \"dictates a tumour\u2019s ability to stimulate MDSC accumulation through regulating G-CSF.\" Experimental inhibition of mTOR or its upstream activators reduced intra-tumoural MDSCs, and this reduction was partially rescued by re-introducing G-CSF or MDSCs, demonstrating that tumour-cell\u2013derived G-CSF drives MDSC recruitment/accumulation. Granulocyte colony-stimulating factor (G-CSF) is exactly the molecule named in the claim. The other cited papers discuss MDSC biology but do not address tumour-cell induction of MDSCs via G-CSF. Hence the provided evidence supports the claim that cancer cells can promote intra-tumoural MDSC accumulation by increasing G-CSF production."
    },
    "naive_doc_ids": [
      "2014909",
      "15435343",
      "2030623",
      "188911",
      "5836"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 reports that oncogenic mTOR signalling inside mammary carcinoma cells increases their production of granulocyte-colony-stimulating factor (G-CSF). Elevated G-CSF released by the tumour cells was shown experimentally to recruit and accumulate myeloid-derived suppressor cells (MDSCs) within the tumour. Blocking mTOR (or its upstream activators) lowered tumour G-CSF levels and reduced intra-tumoural MDSCs, while adding back either G-CSF or MDSCs restored their accumulation. This directly demonstrates that cancer cells can drive intra-tumoural MDSC build-up through enhanced G-CSF production, confirming the claim. The other cited papers do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "2014909",
      "15435343",
      "25726838",
      "42465769",
      "188911"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 3 reports that oncogenic mTOR signalling inside mammary carcinoma cells \"dictates a mammary tumour\u2019s ability to stimulate MDSC accumulation through regulating G-CSF.\"  When the pathway (or its upstream activator FGFR) was inhibited, intra-tumoural MDSCs and tumour progression fell; supplying exogenous G-CSF or adoptively transferring MDSCs partially rescued the effect.  Thus the experimental data show that a product of cancer cells (G-CSF) drives the build-up of myeloid-derived suppressor cells inside the tumour.  None of the other cited papers contradict this mechanism.  Therefore the evidence supports the claim that cancer cells can stimulate intra-tumoural MDSC accumulation by promoting G-CSF production."
    },
    "posthoc_doc_ids": [
      "15435343",
      "25726838",
      "2014909",
      "24612804",
      "188911"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "106",
    "claim": "Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 treats ambulatory blood pressure monitoring (ABPM) as the reference (gold-standard) test and shows that clinic and home measurements lack sufficient sensitivity/specificity when compared with ABPM. Paper 2 explicitly states that ABPM is more accurate than both clinic and home monitoring and is the most cost-effective strategy because it reduces misdiagnosis. These findings indicate that ABPM is regarded as accurate for diagnosing hypertension, directly opposing the claim that it is inaccurate. The remaining papers do not address diagnostic accuracy. Therefore, the provided evidence refutes the claim."
    },
    "naive_doc_ids": [
      "25515907",
      "5151024",
      "54490092",
      "202259",
      "10072941"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 treats ambulatory blood pressure monitoring (ABPM) as the reference (gold-standard) test and shows that clinic and home readings have only moderate sensitivity and specificity when compared with ABPM. This implies ABPM is the more accurate modality. Paper 7 states explicitly that \u201cambulatory monitoring is more accurate than both clinic and home monitoring in diagnosing hypertension\u201d and is the most cost-effective strategy because it reduces misdiagnosis. Together these findings directly oppose the claim that ABPM is inaccurate for diagnosing hypertension."
    },
    "overthinking_doc_ids": [
      "25515907",
      "3067015",
      "202259",
      "6137330",
      "13870943"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 treats ambulatory blood pressure monitoring (ABPM) as the reference (gold-standard) test and shows that clinic and home measurements lack sufficient sensitivity and specificity when compared with ABPM. Paper 3 explicitly states that ABPM is more accurate than clinic or home monitoring, reduces misdiagnosis, and is the most cost-effective diagnostic strategy. These findings indicate that ABPM is considered accurate for diagnosing hypertension. Therefore, the claim that \u2018Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension\u2019 is contradicted by the cited evidence."
    },
    "posthoc_doc_ids": [
      "25515907",
      "54490092",
      "5151024",
      "1727042"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1193",
    "claim": "The appearance of brown-like or beige cells primarily occurs in visceral fat, not subcutaneous fat.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Paper 6 directly examines induction of thermogenic (brown/beige) programs in white fat depots. In IL-15 knockout mice, genes associated with adaptive thermogenesis were elevated in brown AND subcutaneous white adipose tissue, whereas no preferential browning of visceral fat was reported. This indicates that browning readily occurs in subcutaneous fat. None of the other cited papers provide data showing that brown-like or beige cells appear mainly in visceral fat. Hence the available evidence opposes the claim that browning primarily occurs in visceral rather than subcutaneous adipose tissue."
    },
    "naive_doc_ids": [
      "3621011",
      "39187170",
      "14865329",
      "29381091",
      "33634749"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the cited abstracts compare where beige/brown-like adipocytes predominantly appear between visceral and subcutaneous fat. The papers discuss beige fat biology, thermogenesis, metabolic effects, vascular or mitochondrial differences, but do not state that browning happens mainly in visceral rather than subcutaneous depots. Thus the supplied evidence does not address the claim."
    },
    "overthinking_doc_ids": [
      "17973161",
      "19205437",
      "14865329",
      "4820792",
      "7875158"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the cited papers directly compare the prevalence or appearance of brown-like (brite/beige) adipocytes in visceral versus subcutaneous fat depots. Paper 1 addresses mitochondrial activity differences, papers 2, 4, 5, 6 focus on drug effects, adipogenesis, vascular or inflammatory aspects, and Paper 3 describes human beige adipocytes without specifying their depot of origin. Therefore, the provided evidence neither supports nor contradicts the claim."
    },
    "posthoc_doc_ids": [
      "39187170",
      "3654468",
      "17973161",
      "3621011",
      "79447"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "153",
    "claim": "B3-Galectin decreases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Paper 1 shows that formation of an integrin \u03b23\u2013KRAS\u2013RalB signaling complex downstream of EGFR promotes tumour stem-like behaviour and confers resistance to the EGFR tyrosine-kinase inhibitor erlotinib. Thus engaging this alternate KRAS\u2013RalB pathway increases, rather than decreases, resistance to TKIs. None of the other cited papers describe B3-Galectin or report a decrease of TKI resistance through KRAS\u2013RalB engagement. Therefore the available evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "4702639",
      "9929089",
      "34016944",
      "2272614",
      "3929361"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "The only paper that discusses the KRAS-RalB signalling complex in the context of tyrosine-kinase-inhibitor responses is Paper 1. It shows that the \u03b23\u2013KRAS\u2013RalB pathway MAKES tumour cells resistant to EGFR TKIs (erlotinib); inhibition of this pathway restores sensitivity. Thus engagement of the KRAS-RalB complex increases, rather than decreases, TKI resistance. None of the other cited papers mention B3-Galectin or show that engaging KRAS-RalB lowers TKI resistance. Therefore the supplied evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "4702639",
      "9929089",
      "1065627",
      "9225850",
      "16066726"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 1 shows that integrin \u03b23 (not \u03b23-Galectin) forms a complex with KRAS and RalB that ACTIVATES TBK1/NF-\u03baB and is both necessary and sufficient to confer tumour stemness and strong resistance to EGFR tyrosine-kinase inhibitors such as erlotinib. Thus engagement of the KRAS-RalB complex downstream of EGFR increases\u2014rather than decreases\u2014cell resistance to TKIs. The other cited papers do not address \u03b23-Galectin or KRAS-RalB\u2013mediated modulation of TKI sensitivity. Therefore the available evidence contradicts the claim that B3-Galectin lowers TKI resistance by this mechanism."
    },
    "posthoc_doc_ids": [
      "4702639",
      "9929089",
      "34016944",
      "7433668",
      "41650417"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1340",
    "claim": "Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 4 (Ultrasound imaging for lumbar punctures and epidural catheterisations: systematic review and meta-analysis) directly measures the effect of ultrasound guidance on technical performance. Across 14 randomised controlled trials (1334 patients), ultrasound imaging significantly reduced the mean number of needle insertion attempts (mean difference = -0.44 attempts, 95 % CI \u20130.64 to \u20130.24, P < 0.001). This demonstrates that ultrasound guidance lowers the number of attempts required, confirming the claim. The other cited papers do not address needle-insertion attempts, so they neither add to nor contradict this conclusion."
    },
    "naive_doc_ids": [
      "7751726",
      "4678846",
      "6549091",
      "15482274",
      "52874170"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 5 (systematic review and meta-analysis of 14 randomized trials) reports that using ultrasound guidance for lumbar punctures or epidural catheterisations reduced the mean number of needle insertion attempts compared with standard palpation methods (mean difference \u20130.44 attempts, 95% CI \u20130.64 to \u20130.24; P<0.001). This directly demonstrates that ultrasound guidance significantly lowers the number of insertion attempts. The remaining papers do not address needle insertion attempts, so they neither add support nor create contradiction. Therefore the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "5912283",
      "6191684",
      "16979690",
      "34338075",
      "15482274"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 directly compared procedures performed with ultrasound guidance to those done with standard palpation. The meta-analysis of 14 randomized trials showed a statistically significant reduction in the number of insertion attempts when ultrasound was used (mean difference \u20130.44 attempts, 95% CI \u20130.64 to \u20130.24; P < 0.001). This finding demonstrates that ultrasound guidance lowers the number of needle insertions required. The remaining cited papers do not address needle insertion attempts, so they neither add support nor contradiction. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "15482274",
      "7986878",
      "982650",
      "667451",
      "849771"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "34",
    "claim": "A deficiency of folate increases blood levels of homocysteine.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Multiple studies report an inverse relationship between folate status and blood homocysteine. (1) In a Norwegian intervention (Paper 1), raising dietary folate (via more vegetables, fruit and whole-grain bread) significantly reduced plasma homocysteine; lower folate intake was associated with higher homocysteine. (2) In Koreans (Paper 2), individuals with genetically lower folate (MTHFR 677TT) had significantly higher homocysteine, and low folate status further amplified this rise. (3) A large genetic meta-analysis (Paper 3) showed the MTHFR 677TT effect on homocysteine was much larger in low-folate regions than in folate-fortified regions, indicating folate deficiency elevates homocysteine. (4) A randomized trial (Paper 7) demonstrated dose-dependent folic-acid supplementation lowers homocysteine; by implication, inadequate folate leaves homocysteine higher. Together, these data confirm that folate deficiency (low intake or low circulating folate) leads to increased blood homocysteine levels."
    },
    "naive_doc_ids": [
      "10557471",
      "42441846",
      "8595678",
      "2565138",
      "6042706"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Multiple studies demonstrate an inverse, causal relationship between folate status and circulating homocysteine.  (1) In Paper 1 and Paper 4, experimentally increasing folic-acid intake (400\u20131000 \u00b5g/d) produced significant falls (\u224820\u201325 %) in plasma/serum homocysteine, implying that the pre-supplement (lower-folate) state had higher homocysteine.  (2) Paper 2 and Paper 3 used dietary interventions: raising folate intake from fruits, vegetables or whole-grain bread led to significant reductions in plasma tHcy (P = 0.017; P < 0.001).  Paper 3 directly compared a low-folate diet with a high-folate diet; homocysteine was highest after the low-folate period and fell 13 % when folate intake was increased.  These consistent findings indicate that inadequate/low folate (i.e., folate deficiency or relative deficiency) is associated with elevated homocysteine, while correcting the deficiency lowers it.  Therefore, the evidence supports the claim that folate deficiency increases blood homocysteine levels."
    },
    "overthinking_doc_ids": [
      "21636085",
      "10557471",
      "18557974",
      "11705328",
      "33409100"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Multiple studies show an inverse relation between folate status and circulating homocysteine.  \n\u2022 Paper 1: Subjects with the MTHFR TT genotype, who have lower folate concentrations, exhibited significantly higher plasma homocysteine than CC/CT individuals; homocysteine remained high unless folate levels were raised above a genotype-specific threshold.  \n\u2022 Paper 2: In populations with low dietary folate, the same MTHFR genotype produced a much larger rise in homocysteine than in high-folate regions, indicating that lower folate availability augments homocysteine accumulation.  \n\u2022 Papers 3, 5 and 6: Raising folate intake through folic-acid supplementation or diet consistently lowered plasma homocysteine, implying that the baseline (lower-folate) state is associated with higher homocysteine.  \nTogether these findings directly support the claim that folate deficiency (low folate status) increases blood homocysteine levels."
    },
    "posthoc_doc_ids": [
      "42441846",
      "8595678",
      "11705328",
      "5152028",
      "21636085"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1266",
    "claim": "The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.49,
      "justification": "Among the cited articles, only Paper 4 examines placental weight and subsequent maternal breast-cancer risk. It reports that women who had heavier placentas (\u2265 700 g in two successive pregnancies) experienced a higher hazard of developing breast cancer than women with lighter placentas (< 500 g). However, the study population was largely composed of women who were still premenopausal at the end of follow-up (95 % of the cancers occurred before age 50), and the paper does not provide a direct comparison between pre- and post-menopausal cases or state that the association is stronger in premenopausal disease. The remaining papers do not address placental weight. Consequently, the supplied evidence confirms an overall positive relationship between placental weight and breast-cancer risk, but it does not establish that this relationship is specifically stronger for premenopausal breast cancer as asserted in the claim."
    },
    "naive_doc_ids": [
      "13831842",
      "16322674",
      "25973484",
      "37480103",
      "16701509"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.39,
      "justification": "Among the cited papers, only Paper 2 examines placental weight and subsequent maternal breast\u2010cancer risk. It reports that higher placental weights in two successive pregnancies are associated with increased breast-cancer incidence (adjusted HR up to 2.05). However, the summary does not compare this association between pre- and post-menopausal disease; it merely notes that 95 % of the observed cancers occurred before age 50, without providing separate risk estimates for post-menopausal cases. The remaining papers do not address placental weight. Therefore the provided evidence confirms an overall positive relation between placental weight and breast-cancer risk but does not show that the association is strongest for premenopausal breast cancer, leaving the full claim unverified."
    },
    "overthinking_doc_ids": [
      "13831842",
      "37480103",
      "4828631",
      "16322674",
      "18340282"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.64,
      "justification": "Paper 3 directly examined placental weight in successive pregnancies and subsequent maternal breast-cancer risk. Compared with women whose first two placentas each weighed <500 g, hazard ratios for breast cancer rose to 1.82 when one placenta weighed 500\u2013699 g and the other \u2265700 g, and to 2.05 when both placentas weighed \u2265700 g. Thus breast-cancer risk increased with higher placental weight. Furthermore, 95 % of the 2,216 cancers occurred before age 50, implying the association was observed mainly in premenopausal cases, consistent with the claim that the link is strongest for premenopausal breast cancer. The remaining papers do not address placental weight, and none contradict these findings. Hence the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "13831842",
      "9171913",
      "37480103",
      "5864770",
      "16322674"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "411",
    "claim": "Febrile seizures reduce the threshold for development of epilepsy.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers examine febrile seizures or their effect on the threshold for developing epilepsy. The evidence focuses on fruit intake and diabetes, TMAO and cardiovascular risk, anthropometry and breast cancer, mTOR signaling and kainate-induced epileptogenesis, astrocyte involvement in seizures, GABAergic changes after kainate, and a GABA(B) polymorphism in temporal lobe epilepsy. Therefore, they do not provide information relevant to verifying whether febrile seizures reduce the threshold for epilepsy."
    },
    "naive_doc_ids": [
      "1974176",
      "6793674",
      "13831842",
      "116792",
      "1410197"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Paper 8 directly examines the long-term consequences of febrile (hyperthermia-induced) seizures in an animal model.  It reports that such seizures produce persistent changes in hippocampal circuitry, specifically a lasting alteration of neuronal excitability that continues into adulthood.  The authors state that these enduring modifications argue against the view that early-life febrile convulsions are benign.  A persistent increase in neuronal excitability corresponds to a lowered seizure threshold and hence a higher likelihood of developing epilepsy later in life.  None of the other cited papers address febrile seizures or their impact on epileptogenesis.  Therefore, the available evidence supports the claim that febrile seizures reduce the threshold for the development of epilepsy."
    },
    "overthinking_doc_ids": [
      "5691302",
      "829646",
      "2097256",
      "1410197",
      "27815697"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Among the provided papers, only Paper 1 deals with febrile (fever-induced) seizures. It reports that such seizures in immature rats produce long-lasting changes in hippocampal synaptic transmission, but it neither measures nor demonstrates a lowered (or raised) threshold for subsequent epileptic seizures. The remaining papers concern other mechanisms of epileptogenesis, chemotherapy-induced febrile neutropenia, ICU organization, dietary therapy, diabetes risk, or cardiovascular markers, none of which address whether febrile seizures change the propensity to develop epilepsy. Therefore the supplied evidence does not directly confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "14924526",
      "1410197",
      "116792",
      "6334188",
      "10577574"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1028",
    "claim": "Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 demonstrates that a Type 1 diabetes-associated IL2RA haplotype decreases IL-2 signalling (measured by STAT5 phosphorylation) in regulatory T cells and is accompanied by diminished FOXP3 expression and suppressive capacity of these cells. Because the haplotype is linked to higher risk of Type 1 Diabetes, the study directly connects reduced IL-2 responsiveness in Tregs with susceptibility to the autoimmune disease. The other cited papers do not contradict this and provide no opposing data. Therefore the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "11899391",
      "2388819",
      "33535222",
      "38830961",
      "9655347"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 demonstrates that a type 1 diabetes\u2013associated haplotype in the IL2RA gene reduces IL-2-induced STAT5 phosphorylation in CD4+CD25+ regulatory T cells, lowers FOXP3 expression, and diminishes their suppressive capacity. Thus, diminished IL-2 responsiveness in Tregs is mechanistically linked to a genetic risk factor for an autoimmune disease (Type 1 Diabetes). Paper 5 independently maps T1D susceptibility to IL2RA polymorphisms and shows that these risk alleles are associated with lower levels of soluble IL-2RA, consistent with reduced IL-2 signaling. Together these studies provide direct evidence that reduced IL-2 responsiveness in regulatory T cells is associated with autoimmune pathology such as Type 1 Diabetes, supporting the claim."
    },
    "overthinking_doc_ids": [
      "11899391",
      "16389141",
      "38830961",
      "24338780",
      "13940200"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.77,
      "justification": "Paper 1 reports that a Type 1 diabetes\u2013associated haplotype in the IL2RA gene results in diminished IL-2-induced STAT5 phosphorylation, lower FOXP3 levels and impaired suppressive function of CD4\u207aCD25\u207a regulatory T cells. This directly links reduced IL-2 responsiveness in Tregs with genetic risk for an autoimmune disease (Type 1 Diabetes). The remaining cited papers do not address IL-2 responsiveness in Tregs in the context of autoimmunity, and none contradict the finding. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "11899391",
      "2388819",
      "8790729",
      "35149431",
      "263364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "233",
    "claim": "Cell autonomous sex determination in somatic cells does not occur in Galliformes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.94,
      "justification": "Paper 1 reports experiments on chickens (a member of the order Galliformes) showing that male and female somatic cells have an inherent sex identity and that sexual differentiation is \u2018substantively cell autonomous.\u2019 Thus, cell-autonomous sex determination in somatic cells does occur in Galliformes, directly opposing the claim that it does not. The other cited papers address unrelated topics (SCNT efficiency, PRC2 in pluripotency, interferon signaling, dosage compensation) and do not affect this conclusion."
    },
    "naive_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "4085204",
      "5500086"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 studies gynandromorph chickens (a Galliform species) and shows that avian somatic cells possess an inherent (cell-autonomous) sex identity. This directly demonstrates that cell-autonomous sex determination occurs in Galliformes, contradicting the claim that it does not occur. The other papers discuss unrelated topics (human stem cells, chemotherapy response, IRGM in immunity) and do not affect this conclusion."
    },
    "overthinking_doc_ids": [
      "4388470",
      "3360421",
      "5500086",
      "13651792"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 investigates gynandromorph chickens (a galliform species) and transplantation chimaeras, demonstrating that chicken somatic cells have an inherent, cell-autonomous sex identity that drives sexual differentiation. This directly shows that cell-autonomous sex determination does occur in Galliformes, contradicting the claim that it does not. The remaining papers address unrelated topics (stem-cell reprogramming, chemotherapy, glucose sensing, etc.) and add no relevant information to this claim."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "3360421",
      "5500086"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1216",
    "claim": "The extracellular domain of TMEM27 is cleaved in human beta cells.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.61,
      "justification": "The only relevant excerpt (Paper 1) reports that TMEM27\u2019s extracellular domain is cleaved and shed from beta-cell plasma membranes, but the experiments described involve mouse models (Tcf1-/- mice, transgenic mice). None of the provided papers present experimental data specifically showing this cleavage in human beta cells. Therefore the supplied evidence neither confirms nor refutes the claim for human cells."
    },
    "naive_doc_ids": [
      "24142891",
      "19756935",
      "27588420",
      "4361990",
      "25510546"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the supplied papers, only Paper 7 discusses TMEM27. It states that TMEM27\u2019s extracellular domain is glycosylated, cleaved, and shed from the plasma membrane of beta cells, but the abstract does not specify that these experiments were performed in human beta cells (the study mainly references mouse models and transgenic mice). The remaining papers contain no information on TMEM27 cleavage. Therefore, the provided evidence does not explicitly demonstrate that the extracellular domain of TMEM27 is cleaved in human beta cells."
    },
    "overthinking_doc_ids": [
      "19756935",
      "27588420",
      "43661837",
      "16527698",
      "6144969"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.45,
      "justification": "Among the provided papers, only Paper 1 addresses TMEM27 cleavage. It shows that the extracellular domain of TMEM27 is glycosylated, cleaved and shed from pancreatic beta cells, but the experiments described involve mouse models (e.g., Tcf1-/- mice, transgenic mice) and do not specifically examine human beta cells. None of the other papers mention TMEM27 or its processing in human beta cells. Therefore the supplied evidence neither confirms nor refutes cleavage of TMEM27 in human beta cells."
    },
    "posthoc_doc_ids": [
      "24142891",
      "1905095",
      "19756935",
      "27588420",
      "1044552"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1068",
    "claim": "ScPif1p has reduced binding ability to G-rich ssDNA compared to non-G-rich ssDNA.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.74,
      "justification": "Among the supplied papers, only Papers 4 and 6 discuss Pif1 family helicases, focusing on their ability to unwind or suppress damage at G-quadruplex (G-rich) structures. None of the abstracts (or the information quoted from them) present quantitative or qualitative data comparing ScPif1p binding to G-rich single-stranded DNA with its binding to non-G-rich single-stranded DNA. Therefore the evidence set does not address the specific binding difference claimed."
    },
    "naive_doc_ids": [
      "799586",
      "1914588",
      "10874408",
      "4429668",
      "6386930"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.77,
      "justification": "The provided papers discuss Pif1-family helicases in the context of G-quadruplex unwinding, genome-instability suppression, and helicase activity stimulation, but none of them report comparative binding assays of Saccharomyces cerevisiae Pif1p to G-rich versus non-G-rich single-stranded DNA. Therefore they neither confirm nor refute the specific claim about reduced binding ability."
    },
    "overthinking_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "23664875",
      "25787749"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers measure or compare ScPif1p (the Saccharomyces cerevisiae Pif1 helicase) binding to G-rich versus non-G-rich single-stranded DNA. Paper 7 discusses Pif1p\u2019s ability to displace telomerase from telomeric DNA but does not quantify Pif1p\u2013ssDNA binding affinities or compare sequence preferences. The remaining papers deal with unrelated proteins and processes. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "posthoc_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "16217855",
      "29851836"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "182",
    "claim": "Bone Marrow (BM) transplantation is used to treat acute myeloid leukemia (AML)",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the supplied abstracts, the only study that mentions both acute myeloid leukemia (AML) and transplantation (Paper 2) focuses on the rare event of donor-cell leukemia occurring after allogeneic stem-cell/bone-marrow transplantation. It does not state that the transplant was performed to treat AML; it merely reports AML arising as a post-transplant complication. The remaining papers address transplantation for \u03b2-thalassemia, mesenchymal-stem-cell therapy for cardiac or renal disease, or basic/diagnostic AML research without discussing bone-marrow transplantation as a therapy. Therefore, the evidence set does not directly confirm (or refute) the claim that bone-marrow transplantation is used to treat AML."
    },
    "naive_doc_ids": [
      "10128893",
      "11344428",
      "19510470",
      "12130067",
      "40164383"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 6 evaluates outcomes after allogeneic stem-cell (bone-marrow) transplantation and explicitly states that 42 of the 69 transplanted recipients had acute myeloid leukemia. This shows that bone-marrow (hematopoietic stem-cell) transplantation is indeed employed as a treatment modality for AML patients. Paper 2 likewise analyzes complications occurring after allogeneic bone-marrow transplantation performed for various diseases and includes AML among them, further confirming clinical use. No paper presents evidence opposing this use. Therefore the provided literature supports the claim."
    },
    "overthinking_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "10128893",
      "10526279"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 4 describes a cohort of 69 patients who received allogeneic stem-cell (i.e., bone-marrow/hematopoietic) transplantation; 42 of these patients had acute myeloid leukemia. Since these AML patients actually underwent the transplant procedure, the paper demonstrates that bone-marrow (hematopoietic stem-cell) transplantation is indeed used as a therapeutic approach for AML. Paper 2 further mentions allogeneic stem-cell transplantation in a large series that includes myeloid leukemias, reinforcing the same practice. Thus, the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "24795767",
      "10128893"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1225",
    "claim": "The locus rs647161 is associated with colorectal carcinoma.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 3 reports a genome-wide association study in which SNP rs647161 (located at 5q31.1) showed a genome-wide significant association with colorectal cancer (combined P = 1.22 \u00d7 10\u207b\u00b9\u2070 across East Asian and European populations). This directly demonstrates that the locus rs647161 is associated with colorectal carcinoma. The other cited papers do not mention rs647161 and therefore do not affect this conclusion."
    },
    "naive_doc_ids": [
      "43334921",
      "520579",
      "9650982",
      "2095573",
      "15155862"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports a genome-wide association study in East Asian and European populations that identified rs647161 (chromosome 5q31.1) as one of three new susceptibility loci for colorectal cancer, with a highly significant combined P value (1.22 \u00d7 10\u207b\u00b9\u2070). This directly shows that rs647161 is associated with colorectal carcinoma. The other provided papers do not address rs647161, so they neither contradict nor add to this finding. Therefore, the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "9650982",
      "520579",
      "2058909",
      "2492146",
      "14315749"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports a genome-wide association study in which SNP rs647161, located at 5q31.1, shows a highly significant association with colorectal cancer in both East Asian and European-ancestry populations (combined P = 1.22 \u00d7 10\u207b\u00b9\u2070). This directly supports the claim that locus rs647161 is associated with colorectal carcinoma. The other cited papers do not address rs647161 and therefore do not alter this conclusion."
    },
    "posthoc_doc_ids": [
      "9650982",
      "14315749",
      "23665162",
      "520579",
      "15648443"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "68",
    "claim": "Activated Cdk5 regulates DNA damage-induced neuronal death.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 reports that DNA damage activates Cdk5, which then phosphorylates ATM. This Cdk5-dependent activation of ATM controls downstream signaling (p53, H2AX), neuronal cell-cycle re-entry, and ultimately neuronal apoptosis. Disrupting the Cdk5-ATM pathway protects neurons from DNA-damage-induced death, demonstrating that activated Cdk5 is a regulator of neuronal death triggered by DNA damage. The other cited papers do not address Cdk5 in neurons. Therefore the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "21295300",
      "18956141",
      "864491",
      "16630060",
      "3863543"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 reports that DNA damage activates Cdk5, which then phosphorylates ATM, leading to downstream signaling (p53, H2AX) that promotes neuronal cell-cycle re-entry and expression of pro-death genes (PUMA, Bax). Blocking the Cdk5-ATM pathway diminishes these DNA-damage-induced events and protects neurons from death. Thus, activated Cdk5 is shown experimentally to regulate neuronal death triggered by DNA damage, directly supporting the claim. The other cited papers do not address Cdk5 in this context and neither refute nor weaken this conclusion."
    },
    "overthinking_doc_ids": [
      "21295300",
      "1103795",
      "5572127",
      "16630060",
      "13001323"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.77,
      "justification": "Paper 1 reports that DNA damage activates Cdk5, which then phosphorylates ATM in post-mitotic neurons. Disrupting this Cdk5-ATM pathway decreases neuronal cell-cycle re-entry, lowers expression of pro-apoptotic p53 targets (PUMA, Bax), and protects neurons from DNA-damage-induced death. These results show that activated Cdk5 is a key upstream regulator of the signaling cascade that leads to neuronal death after DNA damage, directly supporting the claim. The remaining cited papers do not address Cdk5 in this context and therefore neither strengthen nor weaken the conclusion."
    },
    "posthoc_doc_ids": [
      "21295300",
      "1103795",
      "5572127",
      "7157436",
      "17231273"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "672",
    "claim": "L3MBTL2 binds to H2AK119Ub marked chromatin to form a PRC1 complex.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 1 reports that L3MBTL2 recruits an \u201catypical PRC1-family complex\u201d that contains the core PRC1 subunit Ring1B. Genome-wide analyses showed that loci occupied by L3MBTL2 display H2AK119 ubiquitination, i.e. they are \u2018H2AK119Ub-marked\u2019 chromatin. Thus the study links L3MBTL2 binding to chromatin that carries the H2AK119Ub mark and demonstrates that this binding is used to assemble a PRC1-related complex. None of the other cited papers address L3MBTL2 or H2AK119Ub, so they neither contradict nor alter this conclusion. Therefore the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "15635366",
      "23244529",
      "19572798",
      "1744097",
      "12225214"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Paper 1 reports that L3MBTL2 \u2018recruits a Polycomb Repressive Complex 1 (PRC1)-related complex\u2019 and that \u2018the presence of L3mbtl2 at target genes is associated with \u2026 H2AK119 ubiquitination.\u2019 Thus L3MBTL2 is found on chromatin regions bearing the H2AK119Ub mark while assembling a PRC1-family complex, which aligns with the claim that L3MBTL2 binds H2AK119Ub-marked chromatin to form a PRC1 complex. The other cited papers do not add contrary information."
    },
    "overthinking_doc_ids": [
      "15635366",
      "1791637",
      "140874",
      "2603304",
      "3829232"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Paper 1 reports that L3MBTL2 occupies chromatin regions where histone H2A is monoubiquitinated on K119 and that, at these same loci, it recruits/assembles an atypical Polycomb Repressive Complex-1 containing Ring1B and other PRC1 components. Thus the data show (i) binding of L3MBTL2 to chromatin that carries the H2AK119Ub mark and (ii) formation of a PRC1-family complex at those sites, which aligns with the claim. The remaining papers do not discuss L3MBTL2 or its interaction with H2AK119Ub, and none provide contradictory evidence."
    },
    "posthoc_doc_ids": [
      "15635366",
      "502591",
      "24311787",
      "23244529",
      "23195302"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "316",
    "claim": "Decreased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.32,
      "justification": "Paper 1 shows that the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which oxidizes PGE\u2082 to 15-keto-PGE\u2082, is markedly down-regulated or genetically absent in several settings (colorectal-cancer cell lines, human tumors, ApcMin/+ adenomas). Genetic loss of 15-PGDH \u201ccompletely blocks production of the urinary PGE\u2082 metabolite,\u201d demonstrating impaired conversion of PGE\u2082 to 15-keto-PGE\u2082.  Because PGE\u2082 degradation is reduced while its synthesis is unaffected, the paper states that tissue PGE\u2082 levels depend on this balance and implies their increase when 15-PGDH is lost.  Paper 2 independently establishes that 15-keto-PGE\u2082 is an endogenous ligand for PPAR\u03b3 and that situations in which its level is low (Cftr-deficient mice) are characterized by reduced PPAR\u03b3 signaling, consistent with diminished conversion from PGE\u2082.  Taken together, the papers document (i) decreased conversion of PGE\u2082 to 15-keto-PGE\u2082 and (ii) the consequence that PGE\u2082 is not metabolized, leading to its persistence/accumulation.  No paper contradicts the claim. Hence the available evidence supports the statement, though the link to actual PGE\u2082 build-up is mostly inferential rather than quantitatively measured."
    },
    "naive_doc_ids": [
      "21181273",
      "712078",
      "27615329",
      "58006489",
      "153744"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.62,
      "justification": "Paper 4 shows that the enzyme responsible for the first step in converting PGE\u2082 to its downstream metabolite 15-keto-PGE\u2082 (15-PGDH) is markedly down-regulated in colorectal tumours. Loss of 15-PGDH activity \"completely blocks production of the urinary PGE\u2082 metabolite\" (i.e., prevents formation of 15-keto-PGE\u2082 and subsequent products) and thereby reduces PGE\u2082 degradation. Because steady-state PGE\u2082 levels depend on the balance of synthesis and breakdown, inhibition of its catabolic conversion leads to its persistence/accumulation in tissue. This directly supports the claim that decreased conversion of PGE\u2082 to the PPAR\u03b3 ligand 15-keto-PGE\u2082 results in accumulation of PGE\u2082."
    },
    "overthinking_doc_ids": [
      "3113630",
      "3930020",
      "13573143",
      "21181273",
      "1686997"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "The cited papers do show that conversion of PGE2 to its metabolite/PPAR\u03b3 ligand 15-keto-PGE2 can be reduced (e.g., through loss of 15-PGDH or in Cftr-deficient tissue), but the supplied abstracts do not report measurements demonstrating that this reduced conversion leads to a build-up (accumulation) of PGE2 itself. Because the key outcome (higher PGE2 levels) is not documented in the provided text, the evidence neither confirms nor refutes the claim."
    },
    "posthoc_doc_ids": [
      "712078",
      "5503194",
      "7005276",
      "21181273",
      "22478394"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1041",
    "claim": "Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.77,
      "justification": "The cited studies that address H2A.Z report the opposite effect to the claim. Paper 4 shows that H2A.Z is deposited in promoter nucleosomes of inactive genes and \u2018configures chromatin to poise genes for transcriptional activation,\u2019 implying it facilitates, not retards, subsequent induction. Paper 6 directly examines activation dynamics and concludes that H2A.Z \u2018promotes full gene activation\u2019 and that H2A.Z-containing nucleosomes are unusually labile, being \u2018susceptible to loss, thereby helping to expose promoter DNA.\u2019 This indicates that H2A.Z destabilizes, rather than stabilizes, the +1 nucleosome and expedites, rather than slows, gene activation. The remaining papers do not provide relevant data on H2A.Z\u2019s effect on activation kinetics. Hence, the available evidence contradicts the claim that replacing H2A with H2A.Z slows activation by stabilizing +1 nucleosomes."
    },
    "naive_doc_ids": [
      "365896",
      "9724974",
      "18895793",
      "15778034",
      "9451052"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.3,
      "justification": "None of the cited papers report that replacement of H2A with H2A.Z slows gene activation by stabilizing the +1 nucleosome. Paper 1, the only article that directly examines H2A.Z, finds that H2A.Z is deposited in promoter nucleosomes of inactive genes and \u2018poises\u2019 those promoters for subsequent transcriptional activation, implying a role that facilitates rather than retards induction. The remaining papers focus on SWI/SNF-mediated nucleosome removal, HDAC functions, transcription-factor motif distribution, RNA processing, SIRT1 relocation, or general histone structure, and do not address the kinetic effect of H2A.Z on gene activation. Thus, the available evidence does not support the claim and points, if anything, in the opposite direction."
    },
    "overthinking_doc_ids": [
      "15778034",
      "18895793",
      "43156471",
      "5116145",
      "4162857"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.34,
      "justification": "Among the cited articles, only Paper 3 directly addresses functional consequences of incorporating H2A.Z at promoter (+1) nucleosomes. It reports that H2A.Z is preferentially deposited at promoter nucleosomes of inactive genes and that this incorporation \"configures chromatin structure to poise genes for transcriptional activation.\" This implies that H2A.Z deposition facilitates or primes, rather than slows, subsequent gene induction. None of the other listed papers provide evidence that H2A.Z stabilizes +1 nucleosomes or delays gene activation. Therefore, the available evidence opposes\u2014rather than supports\u2014the claim that H2A.Z replacement slows gene activation by stabilizing +1 nucleosomes."
    },
    "posthoc_doc_ids": [
      "9451052",
      "43156471",
      "15778034",
      "23604601",
      "25462689"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "705",
    "claim": "Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "Among the cited papers, none report clinical trial or cohort results on wheeze or asthma outcomes measured specifically at ages 3 or 6 years after long-chain polyunsaturated fatty acid (LCPUFA) supplementation. The available studies either examine only the first year of life, focus on other atopic outcomes (eczema, food sensitization), analyze different fatty acids (short-chain), are animal or metabolic studies, or provide general narrative reviews without age-specific data. Consequently, the provided evidence does not confirm or refute the claim about wheezing or asthma at 3 and 6 years."
    },
    "naive_doc_ids": [
      "22442133",
      "24269361",
      "20672596",
      "8529693",
      "20148808"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the cited papers report outcomes for wheeze or asthma specifically at 3- and 6-year follow-up after long-chain polyunsaturated fatty-acid supplementation. Therefore they neither confirm nor refute the stated claim."
    },
    "overthinking_doc_ids": [
      "22442133",
      "24269361",
      "20672596",
      "5691302",
      "25816994"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.35,
      "justification": "None of the cited papers report data on the incidence or severity of wheeze or asthma outcomes at 3- or 6-year follow-up after long-chain polyunsaturated fatty acid supplementation. The available studies focus on infant eczema, food allergy, biochemical markers, metabolic effects, growth, or other unrelated outcomes. Therefore they do not provide evidence to confirm or refute the specific claim about wheezing or asthma at those ages."
    },
    "posthoc_doc_ids": [
      "22442133",
      "24269361",
      "20672596",
      "4515975",
      "12584053"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1227",
    "claim": "The mean suicide rate in women is higher after miscarriage than live birth.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.17,
      "justification": "None of the provided papers report data on suicide rates following miscarriage or compare suicide rates after miscarriage with those after live birth. The articles focus on psychological distress, depression, pregnancy complications, pharmacologic treatments, and other health outcomes, but they do not present findings about completed suicides or suicide attempts in women post-miscarriage versus post-live birth. Therefore, the evidence set contains no information relevant to the stated claim."
    },
    "naive_doc_ids": [
      "22467585",
      "356218",
      "5691302",
      "22815457",
      "26611834"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 3 (\u201cSuicides after pregnancy in Finland, 1987-94\u201d) directly compares suicide rates in women within one year after different pregnancy outcomes. It reports a mean annual suicide rate of 18.1 per 100 000 after miscarriage versus 5.9 per 100 000 after live birth, indicating a substantially higher rate following miscarriage. No other cited papers contradict this finding or provide contrary data. Therefore, the available evidence supports the claim that the mean suicide rate in women is higher after miscarriage than after live birth."
    },
    "overthinking_doc_ids": [
      "17682477",
      "12438901",
      "25641414",
      "5691302",
      "829646"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 2 compares suicide rates in Finnish women within one year of different pregnancy outcomes. It reports a mean annual suicide rate of 18.1 per 100,000 after miscarriage versus 5.9 per 100,000 after live birth. This indicates that the average (mean) suicide rate following miscarriage is markedly higher than after live birth, directly supporting the claim. The remaining cited papers do not present suicide-rate data comparing miscarriage with live birth, so they neither add to nor contradict this evidence."
    },
    "posthoc_doc_ids": [
      "22815457",
      "25641414",
      "5145974",
      "881332",
      "25806385"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "236",
    "claim": "Cell autonomous sex determination in somatic cells occurs in Passeriformes.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Among the provided papers, only Paper 1 addresses cell-autonomous sexual identity, and it does so in the domestic chicken (order Galliformes), not in Passeriformes. The remaining papers concern stem-cell reprogramming, chemotherapy responses, or immunological cell-autonomy and do not discuss sex determination in birds. Consequently, there is no direct evidence in the supplied literature about cell-autonomous sex determination in somatic cells of Passeriformes."
    },
    "naive_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "5500086",
      "13651792"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "The only paper discussing cell-autonomous sex identity is Paper 1, which studies chickens (order Galliformes), not Passeriformes. None of the other papers address sex determination in Passeriformes. Therefore, the provided evidence neither supports nor contradicts the claim for Passeriformes."
    },
    "overthinking_doc_ids": [
      "4388470",
      "5500086",
      "13651792",
      "29641682",
      "1471041"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.91,
      "justification": "The only paper that addresses cell-autonomous sex identity is Paper 1, which studies chickens (order Galliformes), not Passeriformes. None of the other cited papers involve avian sex determination at all. Thus the provided evidence gives no information about whether somatic cell-autonomous sex determination occurs in Passeriformes."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "7426741",
      "5500086"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "985",
    "claim": "Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 2 directly investigates the interaction between the PTEN tumour-suppressor mRNA and its pseudogene PTENP1. It shows experimentally that expression of PTENP1 elevates PTEN protein levels and exerts growth-suppressive effects, and attributes this to competition for shared microRNAs (i.e., PTENP1 acting as a miRNA sponge/decoy). This is precisely the mechanism stated in the claim. The other cited papers discuss general ceRNA or miRNA concepts but do not specifically refute the PTENP1\u2013PTEN relationship. Therefore, the evidence overall supports the claim that PTENP1 regulates PTEN expression by functioning as an miRNA decoy."
    },
    "naive_doc_ids": [
      "18421962",
      "6828370",
      "13290521",
      "13964633",
      "11271123"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 reports that the PTEN pseudogene (PTENP1) \u2018is biologically active as it can regulate cellular levels of PTEN\u2019 and that the investigators modeled this regulation on the ability of RNAs to \u2018compete for microRNA binding.\u2019 This describes PTENP1 acting as a competing endogenous RNA/miRNA decoy that modulates PTEN expression. None of the other cited papers address PTENP1 or contradict this mechanism. Therefore the evidence supports the claim that PTENP1 regulates PTEN expression by functioning as an miRNA decoy."
    },
    "overthinking_doc_ids": [
      "6828370",
      "11771811",
      "22901758",
      "42662816",
      "1191830"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly investigates the PTEN pseudogene PTENP1 and shows that its transcript can bind the same microRNAs that target PTEN mRNA, thereby protecting (de-repressing) PTEN and increasing PTEN protein levels. This is exactly the mechanism described by the claim (acting as an miRNA decoy to regulate PTEN expression). The remaining papers discuss other ceRNA or miRNA-decoy examples but do not address PTENP1; they neither refute nor weaken the evidence in Paper 1. Therefore, the provided evidence overall supports the claim."
    },
    "posthoc_doc_ids": [
      "6828370",
      "11771811",
      "7281161",
      "13964633",
      "18421962"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "1375",
    "claim": "Weighed food records (WFR) result in poor completion since they're costly to run and impose high participant burden.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "Among the provided papers, only Paper 2 involves weighed food records, but it merely reports that 98 of 150 volunteers completed a year-long protocol that included a 4-day weighed record. It does not analyse completion quality in terms of \u2018poor\u2019 versus \u2018good,\u2019 nor does it attribute drop-outs to the monetary cost of running weighed food records or to participant burden. None of the other papers mention weighed food records at all. Therefore the cited evidence does not confirm or refute the claim that weighed food records lead to poor completion because they are costly and burdensome."
    },
    "naive_doc_ids": [
      "2048139",
      "21623140",
      "8298120",
      "13770184",
      "2659805"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "Among the cited articles, none measure or discuss completion rates of weighed food records in relation to their monetary cost or participant burden. Paper 1 reports that 98 of 150 volunteers finished a protocol that included a weighed record, but it does not analyse this attrition or attribute it to cost or burden. The remaining papers address other topics (dietary accuracy, birth size and cancer risk, cataract DALYs, nutrition interventions, portion-size tools) without mentioning completion, costs, or participant load for weighed food records. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "21623140",
      "16322674",
      "457630",
      "2659805",
      "11748341"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Among the cited papers, the only one that involves weighed food records (Paper 2) simply states that 98 of 150 volunteers completed a protocol that included 4-day weighed records repeated in each season (\u224865 % completion). It does not discuss why the remaining participants did not complete the protocol, nor does it mention the financial cost of conducting weighed food records or quantify participant burden. The other papers do not address weighed food records at all. Therefore, the provided evidence does not confirm or refute the claim that weighed food records have poor completion because they are costly and burdensome."
    },
    "posthoc_doc_ids": [
      "2048139",
      "21623140",
      "11748341",
      "21993510",
      "2659805"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "574",
    "claim": "In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "None of the provided papers discuss the prevalence (or lack) of segmental aneuploidy in domesticated Saccharomyces cerevisiae populations. The articles focus on yeast domestication history, transcriptional regulation databases, RNA-processing kinetics, maltose metabolism, and cancer or bladder tumor copy-number changes, but none present data on segmental aneuploidy in domesticated yeast. Therefore they offer no relevant evidence to verify or refute the claim."
    },
    "naive_doc_ids": [
      "10300888",
      "365896",
      "1256116",
      "8909176",
      "2402323"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.54,
      "justification": "None of the provided papers address the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae populations. The abstracts focus on RNA processing kinetics, transcription-factor databases, calorie restriction and lifespan, general domestication patterns of beer yeasts (without discussing aneuploidy frequency), rDNA copy number in cancer, and epilepsy genetics. Therefore, the supplied evidence does not confirm or refute the specific claim."
    },
    "overthinking_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "10300888",
      "14019636"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the provided papers contain information about the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae populations. The excerpts discuss topics such as RNA processing, transcriptional regulation databases, calorie restriction, chromatin structure, histone dynamics, stress-response signaling, ribosome biogenesis, industrial-yeast domestication (without specific mention of segmental aneuploidy), and rDNA copy-number variation in cancer. Therefore, the evidence neither supports nor contradicts the claim."
    },
    "posthoc_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "335029",
      "406733"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "368",
    "claim": "Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 directly examined extremely preterm infants who either did or did not undergo early echocardiographic screening for PDA. Screened infants had a LOWER in-hospital death rate (14.2 % vs 18.5 %; OR 0.73, 95 % CI 0.54\u20130.98). An instrumental-variable analysis also produced an odds ratio < 1 (0.62), again indicating lower\u2014not higher\u2014mortality, although with wider confidence limits. Thus, the available evidence shows early PDA screening is associated with reduced or at least not increased in-hospital mortality, contradicting the claim. The other cited papers do not address early PDA screening."
    },
    "naive_doc_ids": [
      "27099731",
      "9967265",
      "34544514",
      "21884059",
      "24323695"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly assessed early echocardiographic screening for PDA in extremely preterm infants and found it was associated with LOWER, not higher, in-hospital mortality (14.2 % vs 18.5 %; OR 0.73, 95 % CI 0.54\u20130.98; instrumental-variable OR 0.62, 95 % CI 0.37\u20131.04). No other cited paper demonstrates an increase in mortality attributable to early PDA screening. Thus the available evidence opposes the claim that early PDA screening increases in-hospital mortality."
    },
    "overthinking_doc_ids": [
      "27099731",
      "25612629",
      "9967265",
      "11880289",
      "36355784"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 specifically examines early PDA screening (echocardiography before day 3) and reports a LOWER in-hospital mortality in screened extremely preterm infants (14.2 % vs 18.5 %; OR 0.73, 95 % CI 0.54\u20130.98). An instrumental-variable analysis also trends toward lower mortality (adjusted OR 0.62). This directly opposes the claim that early PDA screening increases in-hospital mortality. The other cited papers address treatment modalities or unrelated topics and do not provide data on the effect of early screening on mortality. Therefore, the available evidence refutes the claim."
    },
    "posthoc_doc_ids": [
      "27099731",
      "9967265",
      "34544514",
      "33740844",
      "1456068"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "661",
    "claim": "JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 reports that JMJD6 functions as an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that hydroxylates lysine 382 of the tumor-suppressor protein p53. Lys382 lies in the C-terminal regulatory domain of p53, fulfilling the \u201cC-terminal lysine\u201d portion of the claim. The same study shows that this hydroxylation antagonizes p53 acetylation, promotes interaction with the negative regulator MDMX, and consequently represses (suppresses) the transcriptional activity of p53. No other provided papers offer data that conflict with these findings. Therefore, the available evidence supports the claim that JMJD6 catalyzes hydroxylation of a C-terminal lysine and suppresses transcriptional activity."
    },
    "naive_doc_ids": [
      "37204802",
      "29125354",
      "38009906",
      "19238",
      "935538"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 4 reports that JMJD6 is an \u03b1-ketoglutarate/Fe(II)-dependent lysyl hydroxylase that hydroxylates lysine 382 of p53, a residue located in the C-terminal regulatory domain of the protein. The same study shows that this modification antagonizes p53 acetylation, enhances its interaction with the negative regulator MDMX, and consequently represses p53\u2019s transcriptional activity. Thus, the evidence directly demonstrates that JMJD6 catalyzes hydroxylation of a C-terminal lysine and suppresses transcriptional activity, supporting the claim. The other cited papers do not address JMJD6, so they neither add nor detract from this conclusion."
    },
    "overthinking_doc_ids": [
      "29788648",
      "18895793",
      "4455466",
      "37204802",
      "2316374"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 reports that JMJD6 functions as an \u03b1-ketoglutarate/Fe(II)\u2013dependent lysyl hydroxylase that hydroxylates p53 predominantly at Lys382, a residue located in the C-terminal regulatory domain of p53. The same study demonstrates that this hydroxylation antagonizes p53 acetylation, promotes binding to its negative regulator MDMX, and results in repression of p53\u2019s transcriptional activity. Thus the evidence shows both (i) JMJD6-catalyzed hydroxylation of a C-terminal lysine and (ii) consequent suppression of the substrate\u2019s transcriptional activity, directly supporting the claim. The other cited papers do not address JMJD6, and none contradict these findings."
    },
    "posthoc_doc_ids": [
      "37204802",
      "2316374",
      "14367469",
      "10443642",
      "18895793"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "935",
    "claim": "Peroxynitrite is required for induction of T cell tolerance.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.67,
      "justification": "Paper 1 reports that myeloid-derived suppressor cells induce antigen-specific CD8\u207a T-cell tolerance by producing reactive oxygen species and peroxynitrite, which nitrate tyrosine residues in the TCR\u2013CD8 complex. This nitration disables peptide\u2013MHC binding and renders the T cells unresponsive to antigen, establishing tolerance. Because peroxynitrite-mediated nitration is described as the mechanism responsible for the induction of tolerance, the data support the claim that peroxynitrite is required for T-cell tolerance. The other cited papers do not address peroxynitrite\u2019s role in T-cell tolerance."
    },
    "naive_doc_ids": [
      "5483793",
      "7399084",
      "8629328",
      "2686003",
      "6650933"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Paper 1 reports that myeloid-derived suppressor cells induce antigen-specific CD8\u207a T-cell tolerance by nitrating tyrosines in the TCR\u2013CD8 complex. This nitration is said to be \u2018induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite.\u2019 Blocking or absence of peroxynitrite would therefore block the nitration step and the resulting tolerance, indicating that peroxynitrite is necessary (i.e., required) for this form of T-cell tolerance. The other cited papers do not address peroxynitrite in the context of T-cell tolerance. Hence the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "5483793",
      "37182501",
      "1744097",
      "26495128",
      "7386360"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "Paper 2 reports that myeloid-derived suppressor cells render CD8\u207a T cells tolerant by nitrating tyrosines in the TCR-CD8 complex. This nitration is produced \"through hyperproduction of reactive oxygen species and peroxynitrite\" during direct cell\u2013cell contact. Thus, peroxynitrite is a necessary intermediate for the biochemical modification that produces the tolerant state, indicating that peroxynitrite is required for the induction of T-cell tolerance in this system. The other cited papers do not address peroxynitrite or T-cell tolerance, so they neither contradict nor add to this conclusion."
    },
    "posthoc_doc_ids": [
      "1855679",
      "5483793",
      "20524091",
      "18429416",
      "37182501"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "939",
    "claim": "Persistor cells are one reason for incomplete responses to Tyrosine kinase inhibitor (TKI) therapy in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.63,
      "justification": "Several papers describe a sub-population of tumour cells that survive or are intrinsically insensitive to EGFR-targeted tyrosine-kinase inhibitors.  \n\u2022 Paper 3 shows that glioblastoma tumour-initiating cells (a stem-like, drug-tolerant subset) differ in their response to erlotinib/gefitinib; some cultures (e.g., GBM 2) are completely insensitive despite EGFR blockade, indicating that the presence of these cells leads to an incomplete overall response.  \n\u2022 Paper 9 identifies integrin-\u03b1v\u03b23-positive carcinoma cells with stem-like properties that are \u201chighly resistant to receptor tyrosine-kinase inhibitors such as erlotinib\u201d both in vitro and in patient-derived xenografts. Depleting or pharmacologically targeting this subset restores TKI sensitivity, showing that survival of these persister/stem-like cells underlies resistance.  \nThese findings support the claim that persister (drug-tolerant, stem-like) cells are one reason why cancer patients often experience incomplete or transient responses to TKI therapy."
    },
    "naive_doc_ids": [
      "9929089",
      "34016944",
      "40710501",
      "33535222",
      "80522346"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.81,
      "justification": "None of the provided papers discuss drug-tolerant persister (persistor) cells or link such cells to the incomplete clinical response to tyrosine kinase inhibitors. The cited studies address other resistance mechanisms (matrix stiffness, secondary chemotherapy, detection of EGFR mutations, signaling pathway alterations, microenvironment effects, etc.) but do not investigate or demonstrate a role for persistor cell populations in TKI therapy outcomes."
    },
    "overthinking_doc_ids": [
      "1065627",
      "9929089",
      "20738970",
      "711256",
      "46127781"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers discuss drug-tolerant persister cells or link them to the incomplete clinical responses observed with tyrosine-kinase inhibitor therapy. Although some papers mention acquired resistance to TKIs, they do not identify persister cells as an underlying mechanism. Therefore the evidence set does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "9929089",
      "17876040",
      "20738970",
      "34066665",
      "9197092"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1043",
    "claim": "Retinoic acid receptor-related orphan receptor gamma (ROR\u03b3) is a therapeutic target for castration-resistant prostate cancer (CRPC)",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that ROR\u03b3 is frequently amplified/over-expressed in metastatic castration-resistant prostate cancer, directly promotes androgen\u2010receptor gene transcription, and that pharmacological ROR\u03b3 antagonists suppress AR (including AR-V7), reduce AR chromatin binding, inhibit growth of multiple CRPC xenograft models, and enhance response to enzalutamide without overt toxicity. These data demonstrate that blocking ROR\u03b3 has therapeutic anti-tumor activity in CRPC, thereby establishing ROR\u03b3 as a therapeutic target. The remaining cited papers discuss ROR receptors in other contexts or unrelated mechanisms and neither contradict nor add to this conclusion. Hence the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "17671145",
      "37256966",
      "14116046",
      "8512633",
      "14131683"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that ROR\u03b3 is over-expressed/amplified in metastatic castration-resistant prostate cancer, directly regulates androgen-receptor transcription, and that ROR\u03b3 antagonists diminish AR signaling and suppress growth of AR-positive CRPC xenografts while sensitizing tumors to enzalutamide. These results demonstrate that inhibiting ROR\u03b3 has therapeutic benefit in CRPC, substantiating the claim. The remaining cited papers do not address ROR\u03b3 in CRPC and neither contradict nor alter this conclusion."
    },
    "overthinking_doc_ids": [
      "17671145",
      "8512633",
      "14131683",
      "37256966",
      "14116046"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that ROR\u03b3 is over-expressed and/or genomically amplified in metastatic CRPC and that pharmacological antagonists of ROR\u03b3 (i) down-regulate androgen receptor (AR and AR-V7) expression, (ii) globally reduce AR chromatin binding and target-gene transcription, and (iii) significantly inhibit the growth of AR-positive castration-resistant prostate-cancer xenografts while sensitizing them to enzalutamide, all without overt toxicity. These data directly demonstrate that blocking ROR\u03b3 produces anti-tumour activity in CRPC models, establishing ROR\u03b3 as a viable therapeutic target. The remaining cited papers do not present information that contradicts this conclusion. Therefore, the available evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "17671145",
      "37256966",
      "14116046",
      "9967265",
      "341324"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1030",
    "claim": "Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 reports that pharmacological inhibition of the H3K4 methyltransferase MLL1 (which deposits H3K4me3) converts mouse epiblast stem cells to a naive embryonic-stem-cell state. More than 50 % of treated EpiSCs acquire naive features within three days, reactivate the silent X chromosome and contribute to chimeric embryos, demonstrating both induction and high efficiency. This directly supports the claim that reducing H3K4me3 methylation efficiently drives EpiSCs to naive pluripotency. The other cited papers discuss pluripotency regulation but do not address H3K4me3 reduction in EpiSCs, and therefore neither contradict nor add additional support. Hence the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "13955536"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 2 reports that pharmacological inhibition of the H3K4 methyltransferase MLL1 (responsible for H3K4me3 deposition) drives mouse epiblast stem cells (EpiSCs) back to the naive pluripotent state. More than 50 % of treated EpiSCs exhibited naive ESC characteristics within three days, including X-chromosome reactivation and contribution to germ-line-competent chimeras, demonstrating both efficiency and functional completeness of the conversion. This directly supports the claim that reducing H3K4me3 methylation efficiently induces naive pluripotency in mouse EpiSCs. The other cited papers do not contradict this finding or provide alternative data on H3K4me3 in this context."
    },
    "overthinking_doc_ids": [
      "3882374",
      "6441369",
      "4462419",
      "23418635",
      "11390393"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 1 reports that inhibiting the H3K4 methyltransferase MLL1 with the small-molecule MM-401 (a manipulation expected to lower H3K4me3 levels) converts mouse epiblast stem cells to a naive pluripotent state with >50 % efficiency in three days, including X-chromosome reactivation and chimera contribution\u2014hallmarks of efficient induction of naive pluripotency. This directly supports the claim that reducing H3K4me3 methylation efficiently induces mouse EpiSCs to naive pluripotency. The other cited papers focus on different epigenetic marks or pathways and neither contradict nor add relevant information, so the net evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "15803282",
      "3882374"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "361",
    "claim": "During the primary early antibody response activated B cells migrate toward the inner-and outer follicular areas where oxysterol accumulation is generated by stromal cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "The excerpt from Paper 1 notes that activated B cells are guided to inter- and outer-follicular niches during the early antibody response, but it does not mention oxysterol accumulation or its production by stromal cells. The remaining papers deal with unrelated topics (tumour cell killing, dendritic-cell functions, T-cell homing, viral infection, cellular reprogramming, etc.) and provide no information on oxysterols or B-cell positioning. Therefore, the provided evidence neither confirms nor refutes the specific portion of the claim concerning oxysterol accumulation generated by stromal cells."
    },
    "naive_doc_ids": [
      "38587347",
      "1196631",
      "2248870",
      "1071991",
      "40365566"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.34,
      "justification": "Among the provided papers, only Paper 3 discusses the early migration of activated B cells to inter- and outer-follicular niches, but it attributes this positioning to the receptor EBI2 and does not mention oxysterol gradients or their production by stromal cells. None of the excerpts supplied from Papers 1-7 describe oxysterol accumulation generated by stromal cells or link such a gradient to B-cell movement. Therefore the evidence neither clearly supports nor contradicts the complete claim."
    },
    "overthinking_doc_ids": [
      "22874817",
      "24879055",
      "38587347",
      "11721286",
      "34615397"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.72,
      "justification": "The cited papers describe that activated B cells use the orphan GPCR EBI2 to migrate to inter- and outer-follicular regions during the early antibody response, but they do not present data showing that this migration is directed by oxysterol gradients produced by stromal cells. No evidence in the provided abstracts mentions oxysterols, their accumulation in these follicular areas, or stromal-cell synthesis of these lipids. Therefore the specific claim about oxysterol-mediated guidance generated by stromal cells is not addressed by the supplied literature."
    },
    "posthoc_doc_ids": [
      "38587347",
      "30369606",
      "42065070",
      "7869794",
      "24879055"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "776",
    "claim": "Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.14,
      "justification": "None of the provided papers investigate DNA polymerase m-deficient mice or their response to ionizing radiation. The cited studies concern other genes/proteins (p53, ATM, DNA polymerase \u03b2, periostin, FGF-2, etc.) and do not supply data regarding Pol m or IR sensitivity in Pol m-deficient mice."
    },
    "naive_doc_ids": [
      "31293581",
      "5572127",
      "11569583",
      "25238950",
      "118568"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss DNA polymerase \u03bc (pol m)\u2013deficient mice or their response to ionizing radiation. The evidence given concerns other genes (ATM, pol \u03b7, p53, TLR2, etc.) and other stressors (UV light, DSS-induced colitis, metabolic perturbations). Hence the papers neither support nor contradict the stated claim."
    },
    "overthinking_doc_ids": [
      "31293581",
      "52805891",
      "5572127",
      "43014661",
      "21878751"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "Among the provided abstracts, only Paper 8 discusses DNA polymerase \u03bc, describing its association with Ku/Ligase IV and its recruitment to double-strand breaks after ionizing radiation. However, none of the papers report experiments on pol \u03bc-defective (knock-out or mutant) mice or measure their sensitivity to ionizing radiation. Therefore the supplied evidence neither supports nor contradicts the claim about IR sensitivity in pol \u03bc-defective mice."
    },
    "posthoc_doc_ids": [
      "31293581",
      "5572127",
      "11569583",
      "1365188",
      "10017612"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "389",
    "claim": "Ethanol stress increases the expression of IBP in bacteria.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.91,
      "justification": "None of the cited papers mention IBP (inclusion body proteins) or examine how their expression changes in response to ethanol stress. The evidence provided therefore offers no direct information that supports or contradicts the claim."
    },
    "naive_doc_ids": [
      "471735",
      "30184745",
      "24185667",
      "1148122",
      "6669242"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.17,
      "justification": "None of the provided paper summaries mention Ibp (inclusion-body binding protein) expression or its regulation under ethanol stress. Therefore, the evidence set contains no directly relevant information to verify or refute the claim."
    },
    "overthinking_doc_ids": [
      "471735",
      "21602220",
      "6669242",
      "26886351",
      "30184745"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the cited papers discuss ethanol stress, IBP, or changes in IBP expression in bacteria. The evidence therefore gives no information relevant to the claim."
    },
    "posthoc_doc_ids": [
      "471735",
      "9194077",
      "25817686",
      "1507222",
      "4632921"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "141",
    "claim": "Auditory entrainment is strengthened when people see congruent visual and auditory information.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that when auditory speech is accompanied by temporally and contextually congruent visual speech, the cortical (auditory) tracking of the speech envelope is enhanced, whereas incongruent audiovisual input suppresses this entrainment. This directly matches the claim that auditory entrainment is strengthened by congruent audiovisual information. Paper 2 further shows that lip-reading (a congruent visual cue) boosts low-frequency brain coherence that facilitates speech comprehension, providing converging evidence. The remaining cited papers are either consistent with cross-modal entrainment (Papers 3\u20135) or unrelated (Paper 6) and do not contradict the finding. Overall, the evidence aligns with and supports the claim."
    },
    "naive_doc_ids": [
      "14437255",
      "10624000",
      "18379855",
      "6955746",
      "23331269"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 directly reports that when the auditory speech signal is accompanied by temporally and contextually congruent visual speech, cortical entrainment to the auditory speech envelope is enhanced, and that incongruent audiovisual information suppresses this entrainment. This is exactly the pattern predicted by the claim. Papers 2 and 6 further show that visual speech (lip movements) modulates low-frequency neural oscillations and strengthens coherence/entrainment, consistent with the idea that congruent audiovisual information boosts rhythmic neural tracking. None of the cited papers present evidence that contradicts the claim. Therefore, the available evidence supports the statement that auditory entrainment is strengthened when people see congruent visual and auditory information."
    },
    "overthinking_doc_ids": [
      "14437255",
      "10624000",
      "6985854",
      "25942757",
      "8122346"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 directly tests cortical entrainment to continuous speech and reports that when the visual speech signal is temporally and contextually congruent with the auditory stream, the neural (delta-/theta-band) entrainment to the auditory envelope is enhanced; when the two streams are incongruent, entrainment is reduced. This is exactly the situation described in the claim. Paper 2 further shows that low-frequency phase in auditory cortex simultaneously tracks visual and auditory dynamics during naturalistic audiovisual movies, demonstrating cross-modal phase modulation that can strengthen auditory tracking when relevant visual information is present. No papers present contradictory evidence. Thus the collected evidence supports the claim that auditory entrainment is strengthened by congruent audiovisual information."
    },
    "posthoc_doc_ids": [
      "14437255",
      "6955746",
      "313394",
      "6431384",
      "29429111"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "946",
    "claim": "Physical activity level is associated with the difference in maximal oxygen consumption between black and white youth.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Paper 2 directly tested whether the ethnic difference in maximal oxygen consumption could be explained by habitual physical activity. After adjusting for both total energy expenditure and objectively\u2010measured activity energy expenditure, African-American children still exhibited ~15 % lower VO\u2082max than Caucasian children (P<0.01). Therefore the VO\u2082max gap was independent of physical activity level, contradicting the claim that activity level accounts for the difference. \nPaper 1 speculates that a \u201cmore sedentary lifestyle\u201d might contribute to the lower VO\u2082max seen in black children, but provides no adjusted analysis demonstrating that activity explains the gap, and its conclusion is inconsistent with the controlled findings of Paper 2. The remaining papers document lower activity in black youth but do not link this to VO\u2082max differences. Overall, the strongest evidence (Paper 2) indicates that physical activity level is not responsible for the ethnic disparity in maximal oxygen consumption, contradicting the claim."
    },
    "naive_doc_ids": [
      "18537148",
      "26112696",
      "13230773",
      "13083189",
      "8428935"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 measured both maximal oxygen consumption (VO2max) and habitual physical activity in matched samples of black and white pre-pubertal and pubertal children. Black youth had significantly lower VO2max than white youth, and the authors report that this difference \"could be attributed at least in part to \u2026 more sedentary lifestyle in the black children,\" indicating that physical-activity level is linked to the racial difference in VO2max.  Paper 2 shows that black children engage in fewer bouts of vigorous physical activity than white children, and Paper 9 shows that higher activity is positively related to aerobic fitness (VO2max) in children.  Together, these findings demonstrate that physical-activity level varies by race and is correlated with VO2max, supporting the claim that physical activity contributes to the observed black-white differences in maximal oxygen consumption in youth."
    },
    "overthinking_doc_ids": [
      "18537148",
      "8428935",
      "11201004",
      "12205576",
      "1642727"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Paper 1 reports lower VO\u2082max in black vs white children and suggests the gap could be partly explained by a more sedentary lifestyle in the black group, implying an association between physical activity level and the racial difference.  However, Paper 4 measured activity energy expenditure objectively (doubly-labeled water) and showed that the ~15 % lower VO\u2082max in African-American pre-pubertal children remained after adjustment for total and activity energy expenditure; i.e., the VO\u2082max difference was independent of habitual physical activity.  Because at least one well-controlled study demonstrates that physical activity does not account for the racial difference in maximal oxygen consumption, the overall evidence provided refutes the general claim that physical activity level is associated with this difference."
    },
    "posthoc_doc_ids": [
      "18537148",
      "8428935",
      "11201004",
      "26112696",
      "13083189"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1072",
    "claim": "Sepsis related mortality has remained stable between 2009-2014.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 explicitly examined U.S. sepsis outcomes from 2009-2014. Using clinical (EHR-based) criteria it found a statistically significant annual decline in in-hospital sepsis mortality of \u22123.3 % per year (95 % CI \u22125.6 % to \u22121.0 %; P = 0.004). Hence mortality did not remain stable; it decreased. No other provided paper reports sepsis mortality trends for that period, so the available evidence contradicts the claim that sepsis-related mortality remained stable between 2009 and 2014."
    },
    "naive_doc_ids": [
      "4824840",
      "9167230",
      "3716075",
      "1456068",
      "21009874"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1, which specifically analysed sepsis outcomes from 2009-2014, reports a significant yearly decline in in-hospital sepsis mortality (\u22123.3 % per year, P = 0.004). A declining mortality trend means mortality did not remain stable. No other cited papers address sepsis mortality over this period. Therefore the available evidence refutes the claim that sepsis-related mortality remained stable between 2009 and 2014."
    },
    "overthinking_doc_ids": [
      "4824840",
      "27240667",
      "12224536",
      "1102268",
      "5596332"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1, which specifically examined U.S. adults from 2009-2014, reports that in-hospital sepsis mortality fell by 3.3 % per year (P = 0.004); thus mortality declined rather than remaining stable. Paper 7 (2011-2015) likewise notes significant risk-adjusted improvements in sepsis mortality over time. These findings oppose the claim that sepsis-related mortality stayed stable during 2009-2014."
    },
    "posthoc_doc_ids": [
      "4824840",
      "663464",
      "1456068",
      "4791384",
      "3878434"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "165",
    "claim": "Bariatric surgery increases rates of postmenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "The only paper that compares cancer incidence between patients who did and did not undergo bariatric surgery (Paper 1) reports that \u201cNo association was detected between bariatric surgery and \u2026 cancer\u201d (overall hazard ratio \u22481). None of the other cited papers examine breast-cancer incidence after bariatric surgery. Because the available evidence shows no increase (and therefore contradicts the claim of an increase) and the remaining papers are irrelevant to the claim, the overall evidence contradicts the statement that bariatric surgery increases rates of postmenopausal breast cancer."
    },
    "naive_doc_ids": [
      "5824985",
      "13831842",
      "3329824",
      "38551172",
      "16701509"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.25,
      "justification": "The only study that actually evaluates cancer incidence after bariatric surgery (Paper 1) found \u201cNo association \u2026 between bariatric surgery and \u2026 cancer.\u201d Thus the available evidence does not show an increased rate of postmenopausal breast cancer after bariatric surgery; if anything it suggests no change. The remaining papers discuss diabetes, anthropometrics, pregnancy, or perinatal factors in relation to breast cancer and give no data on bariatric surgery, so they offer no support for the claim. Therefore the evidence contradicts the assertion that bariatric surgery increases postmenopausal breast-cancer rates."
    },
    "overthinking_doc_ids": [
      "5824985",
      "32534305",
      "15512462",
      "13831842",
      "37480103"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.4,
      "justification": "Among the ten papers, only one (Paper 10) examines outcomes after bariatric surgery, and it reports no overall association between bariatric surgery and incident cancer; the study does not provide separate results for post-menopausal breast cancer. The remaining papers concern breast cancer risk factors or outcomes (eg, diabetes, BMI, platelet indices, drug treatment) but do not involve bariatric surgery. Therefore, the supplied evidence neither supports nor refutes the specific claim that bariatric surgery increases rates of post-menopausal breast cancer."
    },
    "posthoc_doc_ids": [
      "32534305",
      "2931832",
      "3329824",
      "12438901",
      "2140497"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "345",
    "claim": "Differentiated E2f-1, -2, -3 TKO cells in the intestine do not exhibit apoptosis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the cited papers examine apoptosis in intestinal cells lacking E2f-1, E2f-2, and E2f-3 simultaneously. The articles discuss roles of E2F3 in DNA-damage responses, Wip1-p53 signaling, Bcl-2 in crypts, celiac-related antibodies, FoxO factors, and caspase-mediated cardiac apoptosis, but none provide data on differentiated E2f-1/-2/-3 triple-knockout intestinal cells. Therefore they neither support nor contradict the specific claim."
    },
    "naive_doc_ids": [
      "28697248",
      "5254463",
      "30580263",
      "27772649",
      "16728949"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.23,
      "justification": "Among the cited papers, only Paper 2 analyzes E2f-1, \u20112 and \u20113 triple knockout (TKO) cells in the intestine. The summary provided states that E2f1-3 act as activators in progenitor cells and as repressors in differentiating cells, and that their loss affects cell survival in progenitors while suppressing Rb-deficient phenotypes in differentiating cells. However, the excerpt does not report whether differentiated E2f-1/-2/-3 TKO intestinal cells undergo, or fail to undergo, apoptosis. The other papers discuss E2F3-mediated DNA-damage apoptosis or unrelated pathways (Wip1, Dnmt3b, Isl1, FGF-2, inflammasome, SAA3) and do not address apoptosis in differentiated E2f-TKO intestinal cells. Therefore, the supplied evidence does not confirm or refute the specific claim."
    },
    "overthinking_doc_ids": [
      "28697248",
      "4394817",
      "5254463",
      "11915280",
      "26008063"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.6,
      "justification": "Paper 5 directly analyzes mice in which E2f-1, E2f-2 and E2f-3 are simultaneously deleted. It reports that loss of E2f1-3 triggers apoptosis in the dividing intestinal progenitor (crypt) compartment but not in the differentiating/villus compartment, where the factors switch from transcriptional activators to repressors and their absence is tolerated. Because apoptosis is only observed in progenitor cells and not in the differentiated intestinal cells lacking all three E2Fs, the evidence supports the claim that differentiated E2f-1,-2,-3 TKO intestinal cells do not undergo apoptosis."
    },
    "posthoc_doc_ids": [
      "5254463",
      "30580263",
      "37205759",
      "29423324",
      "4394817"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "657",
    "claim": "Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.71,
      "justification": "Among the cited papers, only Paper 1 deals with intramembrane proteolysis and ER-associated degradation, but it focuses on the rhomboid protease RHBDL4, not on signal peptide peptidase. The remaining papers discuss topics unrelated to intramembrane cleavage or protein degradation. None of the six papers provide direct data on signal peptide peptidase or its role in degrading proteins with complex membrane topology, so they neither support nor contradict the stated claim."
    },
    "naive_doc_ids": [
      "8533245",
      "6386930",
      "37643601",
      "600808",
      "11200685"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "Among the cited papers, only Paper 1 discusses intramembrane proteolysis that facilitates degradation of membrane proteins, but it focuses on the rhomboid protease RHBDL4, not on signal peptide peptidase (SPP). None of the eight papers mention SPP or provide data on how SPP cleavage influences degradation of proteins with complex membrane topologies. Therefore, the corpus offers no direct evidence that verifies or refutes the specific claim about signal peptide peptidase."
    },
    "overthinking_doc_ids": [
      "8533245",
      "1044552",
      "8677721",
      "23180075",
      "25001628"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.79,
      "justification": "Among the cited papers, only paper 3 addresses intramembrane proteolysis linked to ER-associated degradation, but it involves the rhomboid protease RHBDL4, not signal peptide peptidase. None of the provided studies examine or report on signal peptide peptidase activity or its role in degrading proteins with complex membrane orientations. Therefore the evidence set does not confirm or refute the specific claim."
    },
    "posthoc_doc_ids": [
      "37643601",
      "6788835",
      "8533245",
      "28644298",
      "2543135"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "19",
    "claim": "7-day-old adult Caenorhabditis elegans exhibit approximately 5% of the learning capacity seen in 1-day old adults.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.69,
      "justification": "None of the supplied papers presents quantitative data comparing learning capacity of 7-day-old versus 1-day-old adult C. elegans, nor do they state that 7-day-old animals retain only ~5 % of the learning seen in 1-day-olds. The articles discuss age-related cognitive decline in general, neuronal morphology, or unrelated topics, but they do not report the specific 5 % figure or an equivalent measurement. Therefore the evidence provided is insufficient to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "3202143",
      "13072113",
      "7042304",
      "11992632",
      "17050065"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "Among the provided papers, only Paper 4 directly examines learning and memory across age in C. elegans, but the abstract supplies no quantitative comparison of learning capacity between 1-day-old and 7-day-old adults (let alone a figure of ~5%). The other papers discuss neuronal morphology, protein aggregation, endocrine effects on lifespan, cytokinesis, olfactory adaptation, or studies in rats\u2014none of which present the required quantitative behavioral data. Consequently, the supplied evidence neither confirms nor refutes the specific claim that 7-day-old adults retain ~5 % of the learning capacity of 1-day-old adults."
    },
    "overthinking_doc_ids": [
      "13072113",
      "7042304",
      "16267205",
      "3202143",
      "6333347"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Among the provided papers, only Paper 2 discusses age-related changes in learning in C. elegans, but the excerpt gives no quantitative comparison between 1-day-old and 7-day-old adults. None of the papers state that 7-day-old adults retain about 5 % of the learning capacity of 1-day-old adults. Therefore there is insufficient information to confirm or refute the specific numerical claim."
    },
    "posthoc_doc_ids": [
      "13072113",
      "3202143",
      "7042304",
      "20418809",
      "28530299"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "264",
    "claim": "Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 2 demonstrates that neutrophil extracellular traps (NETs) contain citrullinated histone H4 and that sera from rheumatoid-arthritis (RA) patients possess autoantibodies that specifically recognize this citrullinated NET antigen, indicating that NET-externalized citrullinated proteins serve as autoantigens. Paper 4 further shows that NET formation in RA releases multiple citrullinated autoantigens, that the presence and titre of anti-citrullinated protein antibodies (ACPAs) correlate with the extent of NETosis, and that these ACPAs can themselves stimulate additional NET release and inflammatory cytokine production by synovial cells\u2014constituting a feed-forward inflammatory cycle. Together these data support the claim that citrullinated proteins exposed on NETs perpetuate inflammation indirectly by driving or sustaining autoantibody responses. Other cited papers discuss NETs in autoimmunity but are not needed to establish this link; none contradict it."
    },
    "naive_doc_ids": [
      "1800734",
      "30041340",
      "1049501",
      "11328820",
      "28149602"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 2 demonstrates that neutrophil extracellular traps (NETs) contain citrullinated histone H4 and that sera from patients with rheumatoid arthritis contain anti-citrullinated protein antibodies (ACPAs) that specifically recognize this NET-associated antigen. The authors conclude that \u201cNETosis can generate antigens for ACPA,\u201d establishing that citrullinated proteins externalized in NETs are immunogenic and drive autoantibody formation.\nPaper 4 further shows that (i) NETs from rheumatoid-arthritis neutrophils are enriched in citrullinated autoantigens, (ii) ACPA levels correlate with the degree of NETosis, (iii) ACPAs and rheumatoid-factor\u2013containing immunoglobulin fractions can themselves stimulate additional NET formation, and (iv) the resulting NETs augment production of inflammatory cytokines and chemokines by synovial fibroblasts. Together these findings outline a feed-forward loop in which NET-derived citrullinated proteins trigger autoantibodies, and those autoantibodies, in turn, enhance NET release and inflammatory mediator production\u2014thereby perpetuating inflammation indirectly through autoantibody induction.\nNo paper presents evidence opposing this mechanism. Hence the provided literature supports the claim."
    },
    "overthinking_doc_ids": [
      "14853989",
      "30041340",
      "29399239",
      "11328820",
      "1191830"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 2 demonstrates that citrullinated histone H4 present in NETs is recognized by anti-citrullinated\u2010protein antibodies (ACPA) from rheumatoid-arthritis (RA) patients, indicating that the citrullinated proteins released during NETosis serve as autoantigens and elicit autoantibody production. Paper 4 further shows that (i) NETs from RA neutrophils contain citrullinated autoantigens, (ii) NETosis correlates with ACPA levels, and (iii) these NETs enhance inflammatory cytokine and chemokine production by synovial fibroblasts, thereby fuelling ongoing inflammation. Together, these findings establish that citrullinated proteins externalized in NETs drive or augment the generation of autoantibodies, which in turn amplify inflammatory responses\u2014precisely the indirect mechanism of perpetuating the inflammatory cycle described in the claim. Other cited papers do not contradict this interpretation."
    },
    "posthoc_doc_ids": [
      "14853989",
      "30041340",
      "1049501",
      "11328820",
      "5836"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1212",
    "claim": "The deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.19,
      "justification": "None of the cited papers report data about monocyte-specific activation or describe deleterious consequences that are explicitly attributed to deregulated, prolonged monocyte activation in chronic infections. The articles focus on B-cell exhaustion, systemic inflammatory response scores, general immune activation in HIV, hepatitis B/C pathology, archaeal viral responses, colitis in Atm-deficient mice, and IFN-\u03b3-mediated macrophage activity in tuberculosis. These do not directly address the claim, so the provided evidence neither supports nor contradicts it."
    },
    "naive_doc_ids": [
      "20261352",
      "26314743",
      "44562058",
      "21700295",
      "25124117"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Paper 1 demonstrates that in chronically HIV-infected subjects, continuous exposure to microbial products up-regulates PD-1 on monocytes. Engagement of this deregulated, persistently activated PD-1 pathway drives high IL-10 production by monocytes, which in turn \"impairs CD4\u207a T-cell activation\" and causes reversible T-cell dysfunction. Thus, prolonged/abnormal monocyte activation produces harmful (deleterious) immunological consequences in a chronic infectious setting, directly supporting the claim. The other cited papers do not contradict this observation, and some (e.g., Paper 3) further associate sustained immune activation with pathogenesis during chronic HIV infection, but Paper 1 alone provides clear experimental evidence that deregulated, prolonged monocyte activation has deleterious effects."
    },
    "overthinking_doc_ids": [
      "10648422",
      "20261352",
      "44562058",
      "21498497",
      "25606339"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Paper 4 shows that during the chronic infectious condition of HIV, continuous stimulation by microbial products up-regulates PD-1 on monocytes. Triggering this deregulated, prolonged PD-1 pathway causes monocytes to secrete IL-10, which in turn impairs CD4\u207a T-cell activation and expansion. The study therefore documents a harmful (deleterious) immunological consequence that arises specifically from sustained, dysregulated monocyte activation in a chronic infection, directly supporting the claim."
    },
    "posthoc_doc_ids": [
      "5035827",
      "12631697",
      "13934676",
      "10648422",
      "20261352"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "606",
    "claim": "Increased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.79,
      "justification": "Paper 4 shows that the enzyme responsible for converting PGE2 into its catabolite 15-keto-PGE2 (15-PGDH) is DOWN-regulated in colorectal cancer, and this loss of conversion is associated with elevated PGE2 levels. Thus, reduced (not increased) conversion leads to PGE accumulation. No paper reports that higher conversion to 15-keto-PGE2 drives PGE build-up. Therefore the available evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "712078",
      "3882374",
      "15879931",
      "21181273",
      "5775033"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.71,
      "justification": "Paper 4 shows that the enzyme responsible for converting PGE2 to its catabolic product 15-keto-PGE2 (15-hydroxy-prostaglandin dehydrogenase, 15-PGDH) is DOWN-regulated in colorectal cancer, and this loss of conversion is associated with higher (accumulated) PGE2 levels. Hence, when conversion is increased (i.e., 15-PGDH activity is high), PGE2 is degraded and does not accumulate. Therefore the evidence opposes the claim that increased conversion causes PGE accumulation."
    },
    "overthinking_doc_ids": [
      "7548577",
      "9178310",
      "14637235",
      "21181273",
      "27615329"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.74,
      "justification": "Paper 8 shows that the enzyme 15-hydroxyprostaglandin dehydrogenase, which converts PGE\u2082 to the downstream metabolite/PPAR\u03b3 ligand 15-keto-PGE\u2082, is DOWN-regulated in colorectal cancer, and this loss of conversion is accompanied by elevated PGE\u2082 levels. Paper 1 likewise reports that Cftr-deficient tissues contain REDUCED amounts of 15-keto-PGE\u2082, implying diminished conversion rather than an increase. Together these studies indicate that DECREASED (not increased) conversion of PGE\u2082 to 15-keto-PGE\u2082 is associated with accumulation of PGE\u2082. Therefore the claim that \u201cincreased conversion of PGE\u2082 to 15-keto-PGE\u2082 causes accumulation of PGE\u201d is opposite to the published evidence."
    },
    "posthoc_doc_ids": [
      "712078",
      "3127341",
      "31564409",
      "5572127",
      "56486733"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "1351",
    "claim": "Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.66,
      "justification": "Paper 1 examines Drosophila neurons in which dynein function is reduced (mutant neurons). It shows that when dynein is absent, axons lose their normal uniform plus-end-distal orientation and instead contain both plus- and minus-end-distal microtubules \u2013 i.e., more microtubule plus-ends now point back toward the cell body. Thus dynein activity is required to KEEP plus-ends pointing away from the soma. This implies that increasing (up-regulating) dynein would maintain or even strengthen the distal (away-from-cell-body) orientation, not increase the number of plus-ends growing toward the soma. No other cited papers address dynein up-regulation or plus-end orientation in Drosophila neurons. Therefore the available evidence opposes the stated claim."
    },
    "naive_doc_ids": [
      "28369117",
      "36111909",
      "34498093",
      "1889358",
      "23702805"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Paper 1 shows that when dynein activity is reduced (dynein mutants) axons gain microtubules with minus-end-distal orientation, i.e. more plus-ends point toward the cell body. In wild-type neurons, where dynein level is normal, axonal microtubules are uniformly plus-end-distal (plus-ends pointing away from the soma). Thus dynein activity suppresses, rather than promotes, the presence of plus-ends growing toward the cell body. This implies that increasing (up-regulating) dynein would be expected to maintain or further enforce plus-end-distal orientation, not increase plus-ends that grow toward the soma. The other cited papers do not address dynein up-regulation or microtubule orientation in Drosophila neurons. Therefore the available evidence opposes the claim."
    },
    "overthinking_doc_ids": [
      "28369117",
      "36111909",
      "1546650",
      "1371440",
      "16090672"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.79,
      "justification": "Among the cited papers, only Paper 4 examines dynein function in Drosophila neurons, showing that dynein loss disrupts normal microtubule polarity. None of the papers test or report the effect of dynein up-regulation (overexpression) on the number of microtubule plus-ends growing toward the soma. Therefore the provided evidence neither supports nor contradicts the specific claim."
    },
    "posthoc_doc_ids": [
      "36111909",
      "18126445",
      "2727303",
      "28369117",
      "1889358"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "181",
    "claim": "Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Paper 4 reports that wild-type and mutant TDP-43 localize to mitochondria where they bind mitochondrially transcribed ND3 and ND6 messages, impair the expression of these respiratory-complex-I subunits, and trigger complex-I disassembly and neuronal loss. The study further shows that experimental suppression of TDP-43 mitochondrial localization \u2013 which blocks its ability to associate with ND3/ND6 \u2013 \u201cabolishes WT and mutant TDP-43\u2013induced mitochondrial dysfunction and neuronal loss.\u201d  Thus, preventing the TDP-43/ND3-ND6 interaction eliminates the neuronal toxicity driven by TDP-43, directly supporting the claim."
    },
    "naive_doc_ids": [
      "33911859",
      "41913714",
      "4425507",
      "16966326",
      "6492658"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.2,
      "justification": "None of the provided papers discuss TDP-43, its interaction with mitochondrial complex I subunits ND3/ND6, or interventions that block this interaction. Therefore they neither support nor contradict the claim."
    },
    "overthinking_doc_ids": [
      "3127341",
      "6492658",
      "25479072",
      "13380011",
      "6386930"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.71,
      "justification": "Paper 3 shows that wild-type and mutant TDP-43 accumulate inside mitochondria where they bind mitochondrially encoded complex I mRNAs ND3 and ND6, resulting in complex I disassembly and neuronal death. Experimental suppression of TDP-43 mitochondrial localization\u2014which prevents this interaction\u2014\"abolishes WT and mutant TDP-43\u2013induced mitochondrial dysfunction and neuronal loss.\" Therefore, preventing the TDP-43\u2013ND3/ND6 interaction blocks the ensuing neuronal loss, directly supporting the claim. The other cited papers do not address TDP-43 or its interaction with ND3/ND6, so they neither add nor detract from this conclusion."
    },
    "posthoc_doc_ids": [
      "10698739",
      "13380011",
      "16966326",
      "20675284",
      "6690087"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o3",
    "claim_id": "71",
    "claim": "Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.34,
      "justification": "Paper 1 establishes that SRGP-1 is a GAP for the Rac1 homolog CED-10 and that loss of srgp-1 increases CED-10-dependent engulfment of dying or sub-lethally damaged cells. It does not report that CED-10 activation itself kills otherwise healthy (viable) cells; rather, already damaged cells are cleared more efficiently. The other cited papers do not address SRGP-1, CED-10 or their effects on cell survival. Consequently, the provided evidence neither confirms nor refutes the specific claim that activation of CED-10 kills viable cells in srgp-1 mutants."
    },
    "naive_doc_ids": [
      "1127562",
      "7036529",
      "5002665",
      "1576955",
      "4373445"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.29,
      "justification": "The only cited article that deals with SRGP-1 and the Rac1 homolog CED-10 is Paper 3.  That study shows that loss of the RhoGAP SRGP-1 (which would be expected to increase CED-10 activity) accelerates the engulfment of (i) cells that are already dead and (ii) cells that have been \u2018brought to the verge of death\u2019 by sub-lethal apoptotic, necrotic or cytotoxic insults.  The authors do not report elimination of completely healthy, undamaged (i.e. viable) cells by CED-10 activation.  Thus the evidence indicates that hyper-activation of CED-10 promotes removal of dying or damaged cells, not killing of otherwise viable cells, contradicting the claim."
    },
    "overthinking_doc_ids": [
      "10648422",
      "34436231",
      "1127562",
      "7036529",
      "5002665"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.27,
      "justification": "Among the cited papers, only Paper 3 discusses SRGP-1 and the Rac1 homolog CED-10 in Caenorhabditis elegans. It shows that loss of the RhoGAP SRGP-1 (which would be expected to increase CED-10 activity) enhances the engulfment/clearance of cells that are already dead or are \u2018on the verge of death\u2019 after sub-lethal damage. The paper does not report that CED-10 activation itself kills otherwise viable, healthy cells, nor that this killing specifically occurs in SRGP-1 mutants. The other papers are unrelated to CED-10, SRGP-1, or cell killing in C. elegans. Therefore the provided evidence neither confirms nor refutes the specific claim."
    },
    "posthoc_doc_ids": [
      "10648422",
      "34436231",
      "1127562",
      "2686003",
      "15425958"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "154",
    "claim": "B3-Galectin increases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Among the cited papers, only Paper 1 discusses increased resistance to EGFR tyrosine-kinase inhibitors through an alternate KRAS-RalB pathway, but it attributes this effect to integrin \u03b1v\u03b23, not to B3-Galectin (galectin-3 or galectin-3\u2013binding protein). None of the five papers provide data linking any form of galectin (or a \u201cB3-Galectin\u201d) to TKI resistance via KRAS-RalB. Therefore the supplied evidence neither supports nor contradicts the specific claim about B3-Galectin."
    },
    "naive_doc_ids": [
      "4702639",
      "34016944",
      "9929089",
      "14819804",
      "17648235"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Among the cited papers only Paper 1 describes increased TKI resistance that involves activation of a KRAS\u2013RalB signaling complex, but this effect is mediated by the integrin subunit \u03b23 (\u03b1v\u03b23), not by B3-Galectin. None of the provided papers investigate or present data on a molecule called B3-Galectin or link any galectin family member to KRAS\u2013RalB\u2013driven resistance to TKIs. Therefore the supplied evidence does not confirm or refute the specific claim about B3-Galectin."
    },
    "overthinking_doc_ids": [
      "4702639",
      "9929089",
      "1065627",
      "19752008",
      "14819804"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Among the provided papers, only Paper 1 discusses engagement of a \u03b23-containing complex (integrin \u03b1v\u03b23) with KRAS\u2013RalB that leads to resistance to EGFR tyrosine-kinase inhibitors. None of the papers examine or even mention B3-Galectin (Galectin-3) in this context. Therefore, the supplied evidence does not address whether B3-Galectin itself increases TKI resistance via the KRAS-RalB pathway, so the claim cannot be verified or refuted with the given information."
    },
    "posthoc_doc_ids": [
      "4702639",
      "9929089",
      "1065627",
      "3831884",
      "4729644"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "730",
    "claim": "Lysine histone demethylase inhibitor JIB 04 is inactive against KDM5A.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.55,
      "justification": "Paper 1 reports that the small molecule JIB-04 \u201cspecifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours in vivo.\u201d  KDM5A (also called JARID1A/RBP2) is a member of the Jumonji (JmjC) histone-lysine demethylase family.  If JIB-04 inhibits Jumonji demethylases generally, it is expected to inhibit KDM5A rather than be inactive against it.  The other cited papers do not address JIB-04 or KDM5A.  Therefore, the available evidence conflicts with the claim that JIB-04 is inactive against KDM5A."
    },
    "naive_doc_ids": [
      "13400643",
      "18841257",
      "15215393",
      "4387494",
      "26491450"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.61,
      "justification": "Paper 4 reports that the small-molecule JIB-04 \"specifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours in vivo.\" Paper 9 identifies KDM5A (also called RBP2) as a member of the Jumonji (JARID1) histone-demethylase family. Because JIB-04 inhibits Jumonji demethylases and KDM5A is one of those enzymes, the evidence indicates that JIB-04 is active\u2014rather than inactive\u2014against KDM5A, contradicting the claim."
    },
    "overthinking_doc_ids": [
      "864491",
      "17338543",
      "36991551",
      "13400643",
      "18841257"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.35,
      "justification": "Paper 5 reports that JIB-04 \u201cspecifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours.\u201d  KDM5A (also known as JARID1A) is a member of the Jumonji C-domain lysine-specific demethylase family.  If JIB-04 inhibits Jumonji demethylases generally, it would be expected to inhibit KDM5A rather than be inactive against it.  None of the provided papers present data showing that JIB-04 fails to inhibit KDM5A.  Thus the available evidence opposes the claim that JIB-04 is inactive against KDM5A."
    },
    "posthoc_doc_ids": [
      "18841257",
      "3230361",
      "4387494",
      "4547102",
      "13400643"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o3",
    "claim_id": "306",
    "claim": "DUSP4 decreases apoptosis.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.74,
      "justification": "Among the cited papers, only Paper 3 discusses DUSP4/MKP-2, describing its elevated expression in pancreatic tumor cells and its role in repressing ERK signaling. None of the papers report experiments measuring apoptosis as a consequence of DUSP4 expression or activity, nor do they state that DUSP4 decreases apoptosis. Therefore the supplied evidence provides no direct information to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "19079491",
      "935034",
      "28651643",
      "14241418",
      "17648235"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 5 directly investigates the effect of DUSP4 on cell death. It reports that over-expression of DUSP4 \"increased chemotherapy-induced apoptosis,\" whereas depletion of DUSP4 reduced the apoptotic response. Thus, DUSP4 activity promotes \u2013 rather than decreases \u2013 apoptosis. The other cited papers do not supply data on DUSP4 and apoptosis. Therefore the available evidence opposes the claim that DUSP4 decreases apoptosis."
    },
    "overthinking_doc_ids": [
      "24190159",
      "3840043",
      "4323425",
      "1711571",
      "7821634"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines the effect of DUSP4 on apoptosis. It reports that over-expression of DUSP4 \"increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.\" Thus higher DUSP4 levels enhance, rather than reduce, apoptosis. The other papers do not address DUSP4. Therefore the available evidence opposes the claim that DUSP4 decreases apoptosis."
    },
    "posthoc_doc_ids": [
      "7821634",
      "17231273",
      "3765739",
      "3840043",
      "4323425"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1272",
    "claim": "The single flash-evoked ERG b-wave is generated by activity of ON-bipolar cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.05,
      "justification": "None of the provided papers address retinal electrophysiology, ERG b-waves, or ON-bipolar cell activity, so there is no relevant evidence to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "2212067",
      "2888272",
      "9154703",
      "22483580",
      "1275505"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers address retinal electrophysiology, ERG b-waves, or ON-bipolar cell function. They focus on topics such as circulating DNA in cancer, intestinal stem cells, bacterial chromosome replication, diabetes and cardiac prognosis, NPY knockout behavior, and LIMK-1 in neurons, none of which bear on the single flash-evoked ERG b-wave or its cellular origins."
    },
    "overthinking_doc_ids": [
      "2841164",
      "4422868",
      "5223817",
      "5884524",
      "10017612"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers address retinal electrophysiology, ERG b-waves, or ON-bipolar cell activity. The topics covered (circadian cycles, histone modifications, single-cell gene expression, immune regulation, dendritic cell generation, osteoclastogenesis, stem cell heterogeneity, and DNA methylation at enhancers) are unrelated to the claim."
    },
    "posthoc_doc_ids": [
      "2212067",
      "2888272",
      "9154703",
      "9500590",
      "188911"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "585",
    "claim": "In the UK, drowning affects boys and girls equally.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers present sex-specific incidence or mortality data on drowning in UK children. Only Paper 1 addresses child drowning in the UK but does not break down cases by boys versus girls, and the other papers cover unrelated topics."
    },
    "naive_doc_ids": [
      "42291761",
      "21495419",
      "27063470",
      "2360905",
      "7640792"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "Only Paper 1 addresses child drowning in the UK, but the excerpt provides no gender\u2010specific incidence data. None of the other papers discuss drowning or gender differences in drowning, so there is no evidence here to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "42291761",
      "16390264",
      "18379855",
      "9976969",
      "43226130"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers include gender\u2010specific incidence data on drowning in UK children. Paper 1 reports total numbers of child drowning deaths but does not break them down by sex, and the other papers address unrelated topics."
    },
    "posthoc_doc_ids": [
      "42291761",
      "16390264",
      "18379855",
      "9976969",
      "2048139"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "658",
    "claim": "It is not proven that moderate consumption of candy and chocolate reduces the risk of cardiovascular disease (CVD) specifically.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided studies examine moderate consumption of candy or chocolate in relation to cardiovascular disease risk. The papers address gut-derived metabolites, migraine, diabetes, HIV/tuberculosis, fruit intake, risk scoring algorithms, antihypertensive therapies, and vascular stiffness, but they do not provide data on candy or chocolate consumption and CVD outcomes."
    },
    "naive_doc_ids": [
      "6793674",
      "15984735",
      "4883040",
      "1974176",
      "27466734"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies address the effects of moderate candy or chocolate consumption on cardiovascular disease risk."
    },
    "overthinking_doc_ids": [
      "5698494",
      "11939159",
      "15984735",
      "27466734",
      "409280"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the nine provided studies address the effects of moderate candy or chocolate consumption on cardiovascular disease risk. They focus on statins, ASCVD risk thresholds, general CVD risk factors, alcohol, antiretroviral therapy, suicide prevention, physician knowledge, B-vitamins, or genetics, but not on candy or chocolate intake."
    },
    "posthoc_doc_ids": [
      "5698494",
      "1287809",
      "2138767",
      "3067015",
      "4883040"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "115",
    "claim": "Anthrax spores can be disposed of easily after they are dispersed.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "Paper 1 demonstrates that viable B. anthracis spores remain on surfaces and reaerosolize under common office activities, indicating they are persistent and not easily disposed of after dispersion. The other papers do not address anthrax spore disposal."
    },
    "naive_doc_ids": [
      "33872649",
      "6561200",
      "341324",
      "1495563",
      "2825340"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 7 demonstrates that Bacillus anthracis spores persist on surfaces and readily reaerosolize under normal office activities, complicating their removal and remediation rather than allowing easy disposal."
    },
    "overthinking_doc_ids": [
      "17682477",
      "301866",
      "371289",
      "1338283",
      "1542437"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 4 demonstrates that Bacillus anthracis spores remain viable after settling and readily reaerosolize under common office activities, indicating that disposal and decontamination are not straightforward or easy."
    },
    "posthoc_doc_ids": [
      "14700857",
      "15512462",
      "22023404",
      "33872649",
      "17626822"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "789",
    "claim": "Microglia are an innate immune cell type of the central nervous system.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 7 explicitly describes microglia as the brain\u2019s resident tissue macrophages that respond to innate stimuli and mediate inflammasome-driven IL-1\u03b2 secretion, confirming that microglia are an innate immune cell type in the central nervous system."
    },
    "naive_doc_ids": [
      "22647695",
      "43990286",
      "19238",
      "20960682",
      "24707550"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss microglia or present data regarding microglia as innate immune cells in the CNS. The listed studies focus on peripheral innate cells, translational fidelity, iNKT cells, T cell\u2013mediated CNS autoimmunity, CNS metastases in breast cancer, and BBB integrity, but do not address microglial identity or function."
    },
    "overthinking_doc_ids": [
      "3672261",
      "1748921",
      "2506153",
      "22647695",
      "3329824"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers specifically discuss microglia or their role as innate immune cells in the CNS. The studies focus on CNS stem cells, myelin basic protein gene expression, T cell mediated autoimmunity, innate lymphoid cells in the lung, macrophage responses to viral infection, macrophage metabolism, the STING pathway, or cell\u2010delivery strategies, but do not address microglia."
    },
    "posthoc_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "696006",
      "14474178"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1190",
    "claim": "The amount of publicly available DNA data doubles every 10 months.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers report quantitative growth rates or doubling times for the overall volume of publicly available DNA data. They describe data repositories, tools, and specific genomic studies but do not supply evidence for or against a 10-month doubling period."
    },
    "naive_doc_ids": [
      "15617300",
      "30655442",
      "5650232",
      "27768226",
      "24896957"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report or discuss the global growth rate of publicly available DNA data doubling every 10 months. They focus on specific methods, genome analyses, and reference standards without quantifying overall data deposition rates."
    },
    "overthinking_doc_ids": [
      "7324039",
      "8352137",
      "14915566",
      "4432763",
      "25121903"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.05,
      "justification": "None of the provided papers address the growth rate of publicly available DNA data or its doubling time; they focus on specific biological findings or methods rather than data volume trends."
    },
    "posthoc_doc_ids": [
      "1781626",
      "175735",
      "2883827",
      "8352137",
      "29334259"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1008",
    "claim": "RUNX is not expressed in skin tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report on RUNX expression in skin tissue or include data regarding RUNX in skin. Therefore, there is no information to support or contradict the claim."
    },
    "naive_doc_ids": [
      "12580014",
      "4380451",
      "4417177",
      "1669173",
      "11844826"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers mention RUNX expression or its presence/absence in skin tissue; they focus on other genes and tissues, offering no relevant data on RUNX in skin."
    },
    "overthinking_doc_ids": [
      "11238951",
      "79447",
      "1568684",
      "29429111",
      "7688110"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.05,
      "justification": "None of the provided papers mention or analyze RUNX expression in skin tissue; they address unrelated genes or pathways, so there is no information to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "14408200",
      "3150030",
      "11238951",
      "12580014",
      "39763465"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1322",
    "claim": "Transplanted human glial progenitor cells can mature in their host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 demonstrates that human glial progenitor cells engrafted into neonatal immunodeficient mice survive, differentiate into mature astrocytes, integrate via gap junctions, and exhibit functional properties (size, Ca2+ signaling) of mature human glia, directly supporting the claim."
    },
    "naive_doc_ids": [
      "16284655",
      "4427392",
      "1905095",
      "5633876",
      "10795340"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 1 directly demonstrates that human glial progenitor cells transplanted into neonatal immunodeficient mice survive, differentiate into mature astrocytes in the host forebrain, and integrate functionally (gap junction coupling, enhanced Ca\u00b2\u207a signaling). This confirms that transplanted human GPCs can mature in their animal host."
    },
    "overthinking_doc_ids": [
      "16284655",
      "9122283",
      "4427392",
      "3360421",
      "40087494"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly demonstrates that human glial progenitor cells engrafted into neonatal immunodeficient mice mature in vivo into human astrocytes (retaining human morphology, integrating via gap junctions, and exhibiting functional Ca2+ signaling). This confirms that transplanted human GPCs can mature in their host animal."
    },
    "posthoc_doc_ids": [
      "16284655",
      "4430962",
      "7492250",
      "1905095",
      "4427392"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "680",
    "claim": "Lack of FGF21 in mice increases life expectancy.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 shows that FGF21 deficiency in ApoE\u2013/\u2013 mice leads to exacerbated atherosclerosis and premature death, indicating that lack of FGF21 reduces rather than increases life expectancy."
    },
    "naive_doc_ids": [
      "2466614",
      "9513785",
      "25827024",
      "9315213",
      "14615911"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers address FGF21 or FGF21-deficient mice or their lifespan. Therefore, there is no information to support or contradict the claim regarding the effect of FGF21 deficiency on mouse life expectancy."
    },
    "overthinking_doc_ids": [
      "4434951",
      "19521501",
      "30351165",
      "21232018",
      "35062452"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.09,
      "justification": "None of the provided papers report on the longevity or lifespan of Fgf21-deficient (knockout) mice. Although Paper 4 discusses the metabolic benefits of increased Fgf21 expression, no study here tests whether lack of Fgf21 alters mouse life expectancy."
    },
    "posthoc_doc_ids": [
      "37205759",
      "52805891",
      "9513785",
      "6227220",
      "6313547"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1340",
    "claim": "Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 2 is directly on point: in a meta-analysis of randomized trials comparing ultrasound guidance versus standard palpation for lumbar punctures and epidural catheterisations, ultrasound imaging significantly reduced the number of insertion attempts (mean difference \u22120.44; 95% CI \u20130.64 to \u20130.24; P<0.001). No other provided paper addresses needle insertion attempts with ultrasound guidance."
    },
    "naive_doc_ids": [
      "33409100",
      "15482274",
      "34338075",
      "18670",
      "3093512"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 (systematic review and meta-analysis of 14 RCTs, n=1334) directly addresses ultrasound guidance versus palpation for lumbar puncture and epidural catheterisation. It reports that ultrasound imaging significantly reduced the mean number of insertion attempts (mean difference \u20130.44, 95% CI \u20130.64 to \u20130.24; P<0.001). This finding supports the claim that ultrasound guidance reduces the number of needle insertion attempts."
    },
    "overthinking_doc_ids": [
      "34369306",
      "3944632",
      "4678846",
      "15482274",
      "14729253"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 is a systematic review and meta\u2010analysis of randomized trials comparing ultrasound guidance versus standard palpation for lumbar punctures and epidural catheterisations. It reports that ultrasound imaging significantly reduces the number of insertion attempts (mean difference \u20130.44, 95% CI \u20130.64 to \u20130.24, P<0.001), directly supporting the claim."
    },
    "posthoc_doc_ids": [
      "34369306",
      "3944632",
      "4678846",
      "15482274",
      "1256116"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1183",
    "claim": "The TRaF1/C5 rs10818488 allele polymorphism regulates the neighboring C5 gene.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.04,
      "justification": "None of the provided papers mention the TRaF1/C5 rs10818488 polymorphism or its regulatory effect on the C5 gene. Therefore, there is no relevant information to support or refute the claim."
    },
    "naive_doc_ids": [
      "12232678",
      "12580014",
      "14938990",
      "29429111",
      "778436"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers address the TRaF1/C5 rs10818488 polymorphism or its regulatory effect on the C5 gene. The studies cover general eQTL methodology, various gene\u2010expression analyses, and other specific gene polymorphisms, but do not investigate or report on rs10818488 or C5 regulation by TRaF1."
    },
    "overthinking_doc_ids": [
      "15286783",
      "4378885",
      "28928964",
      "6948886",
      "8496132"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the cited papers provide functional data showing that the TRAF1/C5 rs10818488 polymorphism alters expression or regulation of the adjacent C5 gene. Paper 1 reports only genetic association with rheumatoid arthritis, and the others address unrelated loci or general epigenetic mechanisms without examining rs10818488 or its effect on C5."
    },
    "posthoc_doc_ids": [
      "1967017",
      "13906892",
      "21641088",
      "11578459",
      "13964633"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "5",
    "claim": "1/2000 in UK have abnormal PrP positivity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 1 reports 16 PrP-positive appendices out of 32,441 samples, a prevalence of 493 per million (95% CI 282\u2013801), which corresponds to roughly 1 in 2,000 individuals. This directly supports the claim of 1/2000 abnormal PrP positivity in the UK."
    },
    "naive_doc_ids": [
      "13734012",
      "5824985",
      "13900610",
      "1583041",
      "5548081"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 reports 16 positive appendixes out of 32 441 in UK hospitals, corresponding to a prevalence of 493 per million (95% CI 282\u2013801 per million), i.e. roughly 1 in 2 000, which directly confirms the claim."
    },
    "overthinking_doc_ids": [
      "75636923",
      "1606628",
      "2138767",
      "13734012",
      "5558754"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1, which surveyed 32,441 archived UK appendix samples, found 16 positives for abnormal PrP, corresponding to a prevalence of 493 per million (95% CI 282\u2013801), i.e. roughly 1 in 2,000, directly corroborating the claim."
    },
    "posthoc_doc_ids": [
      "13734012",
      "42240424",
      "23124332",
      "17930286",
      "27158570"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1227",
    "claim": "The mean suicide rate in women is higher after miscarriage than live birth.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 reports that the suicide rate in women within the year after miscarriage (18.1 per 100 000) is substantially higher than the rate after live birth (5.9 per 100 000), directly supporting the claim."
    },
    "naive_doc_ids": [
      "7662395",
      "25641414",
      "881332",
      "26611834",
      "4550036"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 8 reports a suicide rate of 18.1 per 100,000 after miscarriage versus 5.9 per 100,000 after live birth, indicating a higher mean suicide rate following miscarriage than live birth."
    },
    "overthinking_doc_ids": [
      "14700857",
      "829646",
      "7662395",
      "1958440",
      "9513785"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 reports a mean suicide rate of 5.9 per 100,000 after live birth versus 18.1 per 100,000 after miscarriage, directly confirming that women\u2019s suicide rate is higher following miscarriage than after live birth."
    },
    "posthoc_doc_ids": [
      "22815457",
      "25641414",
      "5145974",
      "881332",
      "9976969"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "34",
    "claim": "A deficiency of folate increases blood levels of homocysteine.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 2 show that folic acid supplementation dose-dependently lowers plasma/serum homocysteine, implying that low folate (deficiency) yields higher homocysteine. Paper 3 reports that individuals with genetically reduced folate status (MTHFR TT genotype) have elevated homocysteine, and Paper 4 finds larger homocysteine increases in low-folate populations. Together, these clearly confirm that folate deficiency increases blood homocysteine levels."
    },
    "naive_doc_ids": [
      "21636085",
      "11705328",
      "42441846",
      "8595678",
      "1538080"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "All five studies consistently show an inverse relationship between folate status and plasma homocysteine: low folate intake or status (deficiency or lack of fortification) is associated with higher homocysteine levels, while folic-acid supplementation reduces homocysteine. This confirms that folate deficiency increases blood homocysteine."
    },
    "overthinking_doc_ids": [
      "8595678",
      "11705328",
      "42441846",
      "37424881",
      "21636085"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Multiple studies show that lower folate intake or status is associated with higher plasma homocysteine. For example, the randomised folic-acid trial (Paper 3) found that increasing daily folic acid dose from 0.2 to 0.8\u2009mg progressively lowered serum homocysteine by up to 23%, implying that folate deficiency would raise homocysteine. In the MTHFR meta-analysis (Paper 2), the genotype\u2019s effect on homocysteine was much larger in low-folate regions (Asia: +3.12\u2009\u03bcmol/L) than in folate-supplemented regions. The Norwegian dietary intervention (Paper 5) showed increased folate intake led to reduced plasma total homocysteine. Gene\u2013nutrition data (Paper 4) likewise found that low folate status in TT homozygotes yielded higher homocysteine. Reviews and cohort data (Papers 7 and 8) also identify low folate as a cause of hyperhomocysteinemia. Together, these findings confirm that folate deficiency increases blood homocysteine levels."
    },
    "posthoc_doc_ids": [
      "2481032",
      "8595678",
      "11705328",
      "42441846",
      "10557471"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "648",
    "claim": "Integrated care is successful at tackling multiple comorbidities.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 reports that a 12-month integrated \u2018treat-to-target\u2019 program for diabetes, cardiovascular risk factors, and comorbid depression significantly reduced social role disability and improved global quality of life compared with usual care in patients with multiple chronic conditions. None of the other trials directly address multi\u2010condition integrated care, so the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "15041758",
      "13027590",
      "5912283",
      "439670",
      "2425364"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided studies evaluate an integrated\u2010care model addressing multiple coexisting conditions; they each focus on single\u2010disease or single\u2010domain interventions rather than coordinated management of comorbidities."
    },
    "overthinking_doc_ids": [
      "12672066",
      "13515165",
      "13732033",
      "2425364",
      "11360768"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers evaluate integrated care interventions for patients with multiple comorbidities or report outcomes demonstrating that integrated care successfully addresses multiple conditions simultaneously. Most studies focus on selection assessments, treatment preferences, quality of life in single conditions, service utilization, or methodological issues, without examining an integrated care model across comorbidities."
    },
    "posthoc_doc_ids": [
      "4833016",
      "6767133",
      "28017005",
      "463533",
      "19464037"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "126",
    "claim": "Approximately 250,000 people are infected with human T-cell lymphotropic virus type 1 in the United Kingdom.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers present data on the number of HTLV-1 infections in the UK population. They focus on HIV-1 biology, ATLL treatment, global burden metrics for other diseases, or unrelated epidemiology, without reporting UK HTLV-1 prevalence estimates."
    },
    "naive_doc_ids": [
      "20996244",
      "46202852",
      "601033",
      "581832",
      "3716075"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers address the prevalence of human T-cell lymphotropic virus type 1 infection in the United Kingdom or give relevant epidemiological figures for HTLV-1 in that population."
    },
    "overthinking_doc_ids": [
      "5824985",
      "6876224",
      "9547722",
      "20996244",
      "46202852"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report or estimate the total number of people infected with HTLV-1 in the United Kingdom. Only Paper 6 discusses HTLV-I/II case diagnoses, but it does not provide an overall prevalence or infection count approaching 250 000."
    },
    "posthoc_doc_ids": [
      "27063470",
      "80522346",
      "5824985",
      "6490571",
      "8298120"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "350",
    "claim": "Discrimination between the initiator and elongation tRNAs depends on the translation initiation factor IF3.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that bacterial IF3 undergoes conformational changes to facilitate selection of the formylmethionyl initiator tRNA over elongator tRNAs at the 30S P site, confirming that discrimination between initiator and elongator tRNAs depends on IF3. The other papers do not address this specific function of IF3."
    },
    "naive_doc_ids": [
      "16927286",
      "9505448",
      "24521894",
      "2479538",
      "22896970"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly demonstrates that bacterial IF3 undergoes large conformational changes together with the initiator fMet-tRNA and is required for proper selection and accommodation of the initiator tRNA (fMet-tRNAfMet) in the 30S P site, thus supporting the claim that discrimination between initiator and elongator tRNAs depends on IF3. The other cited papers do not address IF3\u2019s role in tRNA selection and are therefore not informative on this point."
    },
    "overthinking_doc_ids": [
      "16927286",
      "2890952",
      "6368017",
      "9505448",
      "24521894"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 4 directly demonstrates that initiation factor IF3 undergoes conformational changes together with the tRNA to ensure proper selection and accommodation of the initiator fMet-tRNA into the P site for start-codon recognition, indicating that IF3 is required to discriminate initiator versus elongator tRNAs during bacterial translation initiation."
    },
    "posthoc_doc_ids": [
      "40473317",
      "1122279",
      "4411760",
      "16927286",
      "24521894"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "267",
    "claim": "Cognitive behavioral therapy is an ineffective treatment for insomnia",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 is a randomized, placebo\u2010controlled trial showing that CBT yields significant short\u2010 and long\u2010term improvements in sleep efficiency, slow\u2010wave sleep, and wake time compared with both zopiclone and placebo in older adults with chronic insomnia. This directly refutes the claim that CBT is ineffective for insomnia. The other studies address unrelated conditions."
    },
    "naive_doc_ids": [
      "5912283",
      "19878070",
      "34369306",
      "15997009",
      "1759213"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly evaluates CBT for chronic primary insomnia in older adults and finds that CBT produced superior short\u2010 and long\u2010term improvements in sleep efficiency and wake time compared with both zopiclone and placebo. This evidence refutes the claim that CBT is ineffective for treating insomnia. The other papers are unrelated to insomnia or CBT."
    },
    "overthinking_doc_ids": [
      "5912283",
      "4883040",
      "25493293",
      "16979690",
      "27150276"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly evaluates CBT for chronic primary insomnia in older adults and finds that CBT produces significantly better short- and long-term improvements in sleep efficiency, wake time, and slow-wave sleep compared with both zopiclone and placebo, demonstrating that CBT is an effective treatment rather than ineffective."
    },
    "posthoc_doc_ids": [
      "5912283",
      "24865781",
      "6191684",
      "26016929",
      "3690068"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "677",
    "claim": "LRBA promotes CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.05,
      "justification": "None of the provided papers address LRBA or CTLA-4 or their recycling; they focus on unrelated proteins and processes."
    },
    "naive_doc_ids": [
      "9304312",
      "14893425",
      "11250124",
      "32101982",
      "35085326"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers mention LRBA or directly address CTLA-4 recycling; they focus on unrelated proteins and pathways (e.g., AP-1, torsinA, ARNO, Th17 CTLA-4 expression) without providing evidence for or against LRBA\u2019s role in CTLA-4 recycling."
    },
    "overthinking_doc_ids": [
      "11250124",
      "14893425",
      "797114",
      "9185195",
      "13398997"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers discuss LRBA or CTLA-4 or their endocytic recycling; the studies focus on synaptic vesicle trafficking, autophagy, receptor endocytosis for other proteins, and cell migration, but do not address LRBA-mediated CTLA-4 recycling."
    },
    "posthoc_doc_ids": [
      "11250124",
      "14893425",
      "797114",
      "17017465",
      "5531479"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "205",
    "claim": "CDK6 shows improved binding to loss-of-function variants of p18 INK4C.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.06,
      "justification": "None of the provided papers report on CDK6 or its interaction with p18INK4C loss-of-function variants, so there is no information relevant to the claim."
    },
    "naive_doc_ids": [
      "3127341",
      "7717468",
      "1225513",
      "23938319",
      "40721190"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers address CDK6 or its interaction with p18INK4C variants. Therefore, there is no information relevant to the claim."
    },
    "overthinking_doc_ids": [
      "3127341",
      "7717468",
      "1225513",
      "41644178",
      "20937018"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss CDK6 or the p18 INK4C protein, let alone any binding studies between CDK6 and loss-of-function variants of p18 INK4C."
    },
    "posthoc_doc_ids": [
      "3127341",
      "7717468",
      "22874817",
      "10698739",
      "38830961"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1268",
    "claim": "The risk of cancer rises with level of alcohol consumption.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies examine alcohol consumption levels in relation to cancer risk. They focus on lung function, perinatal factors, oxidative stress, obesity, lifestyle factors excluding drinkers, glycemic markers, and flavonols in CHD, without assessing alcohol\u2010related cancer risk."
    },
    "naive_doc_ids": [
      "12145359",
      "17450673",
      "23557241",
      "24349992",
      "4680262"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided studies address alcohol consumption as a risk factor for cancer."
    },
    "overthinking_doc_ids": [
      "12145359",
      "12869200",
      "14729253",
      "2140497",
      "16098747"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report on alcohol consumption in relation to cancer risk. The studies address SIDS, cardiovascular events, comorbidities in chemotherapy, lung function, H. pylori and gastric cancer, PTH/vitamin D, HER-2 and chemotherapy response, type 2 diabetes and breast cancer, and physical activity and mortality\u2014not the effect of alcohol intake on cancer incidence."
    },
    "posthoc_doc_ids": [
      "20240998",
      "20526907",
      "6334188",
      "12145359",
      "2052720"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1070",
    "claim": "Self-advocacy training is effective at decreasing homelessness.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided studies address self-advocacy training or its impact on homelessness; they cover topics from self-harm in prisons to medical interventions, but do not evaluate self-advocacy or homelessness outcomes."
    },
    "naive_doc_ids": [
      "13900610",
      "2242416",
      "5691302",
      "7751726",
      "12584053"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.04,
      "justification": "None of the provided studies address self-advocacy training or homelessness\u2014they focus on medical treatments and clinical outcomes unrelated to the claim."
    },
    "overthinking_doc_ids": [
      "5691302",
      "24088502",
      "5824985",
      "40817021",
      "22467585"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies evaluate self-advocacy training for homeless populations or measure its impact on homelessness outcomes. They address unrelated interventions in health, education, or other domains without assessing self-advocacy or homelessness reduction."
    },
    "posthoc_doc_ids": [
      "12584053",
      "16627684",
      "25493293",
      "13097856",
      "14843502"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1225",
    "claim": "The locus rs647161 is associated with colorectal carcinoma.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 2 reports that rs647161 at 5q31.1 reached genome-wide significance for colorectal cancer risk (combined P=1.22\u00d710\u207b\u00b9\u2070 in East Asian and European-ancestry samples), directly supporting the claim that rs647161 is associated with colorectal carcinoma."
    },
    "naive_doc_ids": [
      "43334921",
      "9650982",
      "8595678",
      "2095573",
      "15155862"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reports a genome-wide association study in East Asians and Europeans identifying rs647161 (5q31.1) with a combined P value of 1.22 \u00d7 10\u207b\u00b9\u2070 for colorectal cancer risk, directly supporting the claim."
    },
    "overthinking_doc_ids": [
      "9650982",
      "14315749",
      "23665162",
      "520579",
      "2058909"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.08,
      "justification": "Paper 1 reports that rs647161 (5q31.1) shows a genome-wide significant association with colorectal cancer risk (combined P\u2009=\u20091.22\u00d710\u207b\u00b9\u2070), confirming the claimed locus association."
    },
    "posthoc_doc_ids": [
      "9650982",
      "14315749",
      "23665162",
      "520579",
      "2058909"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "306",
    "claim": "DUSP4 decreases apoptosis.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers mention or study DUSP4 or its role in apoptosis; therefore, there is no information to support or refute the claim."
    },
    "naive_doc_ids": [
      "52873726",
      "6121555",
      "3765739",
      "19683625",
      "20738970"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 2 directly tests DUSP4\u2019s role in apoptosis: overexpression of DUSP4 increases chemotherapy-induced apoptosis and DUSP4 depletion dampens it. Thus DUSP4 promotes, rather than decreases, apoptosis, refuting the claim."
    },
    "overthinking_doc_ids": [
      "24190159",
      "7821634",
      "7165938",
      "3765739",
      "238409"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 2 shows that DUSP4 overexpression increases chemotherapy-induced apoptosis, whereas DUSP4 depletion reduces apoptosis. This indicates that DUSP4 promotes rather than decreases apoptosis, directly contradicting the claim."
    },
    "posthoc_doc_ids": [
      "2841164",
      "7821634",
      "8563659",
      "7869794",
      "10015292"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "250",
    "claim": "Chenodeoxycholic acid treatment decreases brown adipose tissue activity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly tests chenodeoxycholic acid (CDCA) treatment in humans and reports that CDCA increases, not decreases, brown adipose tissue activity. None of the other papers provide evidence that CDCA reduces BAT activity."
    },
    "naive_doc_ids": [
      "1568684",
      "1507222",
      "29381091",
      "26902591",
      "40232172"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly tested chenodeoxycholic acid (CDCA) treatment in humans and found that CDCA increased brown adipose tissue activity and whole\u2010body energy expenditure. Thus, the claim that CDCA decreases BAT activity is contradicted by the experimental evidence."
    },
    "overthinking_doc_ids": [
      "1568684",
      "40232172",
      "3621011",
      "4319174",
      "13902570"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.98,
      "justification": "Paper 1 directly examines chenodeoxycholic acid (CDCA) treatment in humans and reports that CDCA increases brown adipose tissue (BAT) activity and whole-body energy expenditure. This finding contradicts the claim that CDCA treatment decreases BAT activity."
    },
    "posthoc_doc_ids": [
      "1568684",
      "40232172",
      "3621011",
      "12280462",
      "14105446"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1364",
    "claim": "Venules have less significant tunica adventitia than arterioles.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address the comparative thickness or significance of the tunica adventitia in venules versus arterioles."
    },
    "naive_doc_ids": [
      "23862975",
      "87758",
      "602760",
      "27550580",
      "1122279"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers discuss the histological layers (tunica adventitia) of venules versus arterioles or provide comparative morphological data relevant to this claim."
    },
    "overthinking_doc_ids": [
      "87758",
      "3690068",
      "3692112",
      "2389574",
      "6957332"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss vascular histology or compare the tunica adventitia of venules and arterioles."
    },
    "posthoc_doc_ids": [
      "3690068",
      "9658390",
      "20457190",
      "24082820",
      "8290953"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "224",
    "claim": "Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "All five papers describe cancer\u2010associated fibroblasts (CAFs) as key stromal components within the tumor microenvironment. Paper 1 explicitly calls CAFs \u201cone of the most crucial components of the tumor microenvironment.\u201d Paper 2 details oxidative stress in CAFs driving tumor\u2013stroma co\u2010evolution. Paper 3 lists fibroblasts alongside tumor cells and immune cells as constituents of the tumor microenvironment. Paper 4 isolates CAFs from lung tumors and shows their paracrine effects within that microenvironment. Paper 5 reviews CAFs\u2019 roles in tumor\u2013stroma interactions and immune modulation. None of the studies contradict the claim."
    },
    "naive_doc_ids": [
      "952111",
      "24349992",
      "313403",
      "9648896",
      "32742683"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Paper 1 explicitly states that CAFs are \u2018one of the most crucial components of the tumor microenvironment.\u2019 Papers 2 and 3 likewise describe carcinoma-associated fibroblasts operating within tumors (e.g., recruiting immune cells and driving tumor\u2013stroma interactions), confirming that CAFs are bona fide constituents of the tumor microenvironment."
    },
    "overthinking_doc_ids": [
      "952111",
      "3559136",
      "24349992",
      "2734421",
      "3391547"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Multiple papers explicitly describe cancer-associated fibroblasts (CAFs) as key cellular constituents of the tumor microenvironment (Papers 1, 2, 3, 6), noting their roles in cancer cell growth, invasion, chemoresistance, and metabolic crosstalk within that microenvironment."
    },
    "posthoc_doc_ids": [
      "952111",
      "3376731",
      "3559136",
      "207972",
      "2734421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 1.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "470",
    "claim": "Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.99,
      "justification": "Paper 1 explicitly states that GBM is characterized by extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis, directly confirming the claim."
    },
    "naive_doc_ids": [
      "12685434",
      "7028976",
      "15570691",
      "9600826",
      "13329980"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly states that GBM is characterized by extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis, directly matching the claim."
    },
    "overthinking_doc_ids": [
      "12685434",
      "7028976",
      "15570691",
      "13329980",
      "9600826"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 1 explicitly describes GBM as having extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis, directly matching the claim\u2019s features. No papers provide contradictory evidence."
    },
    "posthoc_doc_ids": [
      "12685434",
      "7028976",
      "15570691",
      "6673421",
      "13329980"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "643",
    "claim": "Insulin effects appetite via ventral tegmental neurons.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 shows that insulin receptor signaling in tyrosine hydroxylase\u2013expressing midbrain dopamine neurons (including VTA neurons) acutely stimulates their firing and that loss of this signaling causes hyperphagia and weight gain. This directly supports the claim that insulin modulates appetite via ventral tegmental (dopaminergic) neurons."
    },
    "naive_doc_ids": [
      "15535511",
      "13322804",
      "23869951",
      "4611267",
      "3202143"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 5 directly shows that insulin receptor signaling in midbrain catecholaminergic (VTA/SN) neurons acutely stimulates their firing and that loss of this signaling causes hyperphagia and weight gain. This provides in vivo evidence that insulin acts via ventral tegmental dopamine neurons to regulate appetite, supporting the claim."
    },
    "overthinking_doc_ids": [
      "23869951",
      "4611267",
      "1281769",
      "1084062",
      "15535511"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 2 directly shows that insulin receptor signaling in tyrosine\u2010hydroxylase\u2013expressing midbrain (VTA/SN) dopamine neurons acutely modulates their firing and that loss of this signaling leads to hyperphagia and increased weight. This provides in vivo evidence that insulin acts via ventral tegmental catecholaminergic neurons to regulate appetite and energy balance, supporting the claim."
    },
    "posthoc_doc_ids": [
      "13322804",
      "15535511",
      "23869951",
      "1084062",
      "4709641"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "428",
    "claim": "Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 5 describes the FoxO family of forkhead transcription factors as mediators of processes including differentiation, and paper 8 shows that Foxo3a promotes immunoglobulin light chain recombination\u2014a key step in pre-B cell differentiation. These data directly support the involvement of FoxO transcription factors in cellular differentiation."
    },
    "naive_doc_ids": [
      "18489989",
      "20183360",
      "20310709",
      "13779605",
      "16728949"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers demonstrate that FoxO transcription factors regulate differentiation. Paper 1 explicitly lists differentiation among FoxO functions. Paper 5 shows FoxO3a promoting immunoglobulin light\u2010chain rearrangement during pre\u2013B cell differentiation. Paper 6 demonstrates that FOXO4 is required for neural differentiation of human embryonic stem cells. Together, these data confirm that FoxO factors are involved in cellular differentiation."
    },
    "overthinking_doc_ids": [
      "16728949",
      "28937856",
      "1065627",
      "20524091",
      "3748310"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 explicitly states that FoxO transcription factors participate in diverse physiologic processes including differentiation, linking FoxO function to the maintenance and integrity of stem cell compartments. This directly supports the claim that Forkhead O (FoxO) transcription factors are involved in cellular differentiation."
    },
    "posthoc_doc_ids": [
      "16728949",
      "18489989",
      "1065627",
      "14225271",
      "28937856"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "935",
    "claim": "Peroxynitrite is required for induction of T cell tolerance.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 demonstrates that myeloid-derived suppressor cells induce CD8+ T cell tolerance via hyperproduction of reactive oxygen species and peroxynitrite, which nitrates TCR\u2013CD8 and blocks antigen recognition. This identifies peroxynitrite as a required mediator for inducing T cell tolerance."
    },
    "naive_doc_ids": [
      "5483793",
      "7343711",
      "18207615",
      "24612804",
      "3848469"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 demonstrates that myeloid-derived suppressor cells induce antigen-specific CD8+ T cell tolerance via hyperproduction of reactive oxygen species and peroxynitrite, which nitrates the TCR-CD8 complex and prevents pMHC binding and T cell activation. This provides direct evidence that peroxynitrite is required for induction of T cell tolerance."
    },
    "overthinking_doc_ids": [
      "5483793",
      "3848469",
      "7399084",
      "37182501",
      "1744097"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 demonstrates that myeloid-derived suppressor cells induce CD8+ T cell tolerance via hyperproduction of reactive oxygen species and peroxynitrite, which nitrates the TCR\u2013CD8 complex and abrogates antigen recognition. This provides direct evidence that peroxynitrite is required for induction of T cell tolerance."
    },
    "posthoc_doc_ids": [
      "5483793",
      "26495128",
      "37182501",
      "1855679",
      "20524091"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "659",
    "claim": "Ivermectin is used to treat lymphatic filariasis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.05,
      "justification": "None of the provided papers discuss ivermectin or its use in lymphatic filariasis; they cover unrelated treatments and conditions."
    },
    "naive_doc_ids": [
      "341324",
      "3654468",
      "6158879",
      "22029384",
      "29107180"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the nine provided papers mention ivermectin or its use in lymphatic filariasis. They cover topics ranging from malaria, HIV, cancer, tuberculosis, diabetes, and antiplatelet therapy, but contain no information on ivermectin\u2019s use in lymphatic filariasis."
    },
    "overthinking_doc_ids": [
      "3929361",
      "3578380",
      "26461066",
      "1986482",
      "15541119"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers discuss ivermectin or lymphatic filariasis. They cover HIV treatment guidelines, cancer response criteria, bisphosphonates, neural transmission, tuberculosis regimens, SIV vaccines, cancer survivorship, MDR-TB trials, and organophosphate poisoning, but no information on ivermectin use in lymphatic filariasis."
    },
    "posthoc_doc_ids": [
      "1986482",
      "15541119",
      "24916604",
      "306311",
      "341324"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "53",
    "claim": "ALDH1 expression is associated with poorer prognosis in breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 directly examines ALDH1 expression in 577 breast carcinomas and reports that high ALDH1 activity identifies tumorigenic cells and correlates with poor clinical outcome, thereby supporting the claim that ALDH1 expression is associated with poorer prognosis in breast cancer. None of the other papers provide conflicting evidence on ALDH1 in breast cancer."
    },
    "naive_doc_ids": [
      "42731834",
      "4820792",
      "20886584",
      "45638119",
      "313403"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 5 directly demonstrates that ALDH1 expression in breast carcinomas correlates with poor clinical outcome, identifying ALDH1-positive tumors as having worse prognosis, which supports the claim."
    },
    "overthinking_doc_ids": [
      "7639744",
      "52180874",
      "17450673",
      "313403",
      "45638119"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report on ALDH1 expression in breast cancer or its association with patient prognosis."
    },
    "posthoc_doc_ids": [
      "10024681",
      "21439640",
      "22401720",
      "4820792",
      "13069283"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "421",
    "claim": "Flexible molecules experience greater steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers address the relative steric hindrance of flexible versus rigid molecules within the tumor microenvironment. They cover topics such as fibroblasts, signaling receptors, metabolic targeting, extracellular matrix components, and immune checkpoint blockade, but do not present data on molecular flexibility or rigidity and steric hindrance in tumors."
    },
    "naive_doc_ids": [
      "952111",
      "2734421",
      "14434123",
      "12866641",
      "44640124"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss the relative steric hindrance of flexible versus rigid molecules in the tumor microenvironment or present experimental data on molecular flexibility and microenvironmental diffusion."
    },
    "overthinking_doc_ids": [
      "952111",
      "2734421",
      "21033230",
      "4164929",
      "4435369"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address the relationship between molecular flexibility/rigidity and steric hindrance within the tumor microenvironment. They cover CAF biology, signaling pathways, metabolism, ECM redox regulation, extracellular acidity, and matrix stiffness effects on therapy response, but do not report data on diffusion or steric effects comparing flexible versus rigid molecules."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "21033230",
      "44640124"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "27",
    "claim": "A 100g dose of chloroquine chemoprophylactic regimen results in retinal toxicity after 5-6 years of weekly intake.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.13,
      "justification": "None of the provided studies report on long-term retinal toxicity from chloroquine chemoprophylaxis (100 g cumulative dose with weekly intake over 5\u20136 years). The papers cover adverse effects of chloroquine in travelers (Paper 1) but do not assess ocular or retinal toxicity, and the remaining papers address unrelated drugs and endpoints."
    },
    "naive_doc_ids": [
      "38410121",
      "22334300",
      "5433667",
      "12438901",
      "20606520"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers report data on long\u2010term chloroquine dosing (100 g total over 5\u20136 years), weekly intake, or the development of retinal toxicity. Therefore, they offer no evidence to support or refute the specific claim."
    },
    "overthinking_doc_ids": [
      "17925632",
      "38410121",
      "8593263",
      "341324",
      "3613041"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address long\u2010term chloroquine dosing and the development of retinal toxicity after 5\u20136 years of weekly intake. The closest is Paper 3, which reports self\u2010reported general side effects of chloroquine prophylaxis but does not examine retinal toxicity or cumulative dosing over years. Therefore, there is no information to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "12438901",
      "25789730",
      "38410121",
      "301866",
      "20606520"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "106",
    "claim": "Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Both Paper 1 and Paper 2 treat ambulatory blood pressure monitoring (ABPM) as the reference standard and report that clinic and home measurements are less accurate in diagnosing hypertension. Paper 1 shows that clinic and home measurements have only moderate sensitivity and specificity compared with ABPM, and Paper 2 finds ABPM to be the most accurate and cost-effective diagnostic strategy. None of the papers question the accuracy of ABPM itself; instead they support its superior diagnostic performance, directly contradicting the claim that ABPM is inaccurate for diagnosing hypertension."
    },
    "naive_doc_ids": [
      "25515907",
      "5151024",
      "54490092"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Both Paper 1 and Paper 2 treat ambulatory blood pressure monitoring (ABPM) as the reference standard for diagnosing hypertension and report that it has better diagnostic accuracy than clinic or home measurements. Paper 1 shows that clinic and home readings have suboptimal sensitivity and specificity when compared to ABPM, implying that ABPM itself is more accurate. Paper 2 likewise concludes that ABPM is the most accurate and cost-effective diagnostic strategy. These findings directly contradict the claim that ABPM is inaccurate for diagnosing hypertension."
    },
    "overthinking_doc_ids": [
      "25515907",
      "5151024",
      "54490092",
      "34873974",
      "7639744"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 treats 24 h ambulatory monitoring as the reference standard against which clinic and home measures are compared, concluding that neither clinic nor home measurements reach adequate sensitivity and specificity if ambulatory monitoring is taken as correct. Paper 3 similarly states that ambulatory monitoring is more accurate than clinic or home measurement and is the most cost-effective diagnostic strategy. None of the studies provide evidence that ambulatory monitoring is inaccurate; rather they affirm its superior accuracy in diagnosing hypertension."
    },
    "posthoc_doc_ids": [
      "25515907",
      "54490092",
      "5151024",
      "45447613"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "398",
    "claim": "Exhaustion of B cells contributes to poor Ab response in HIV-infected individuals.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided studies address B cell exhaustion or directly link exhausted B cell phenotypes to impaired antibody responses in HIV-infected individuals. The papers focus on neutralizing antibody kinetics, epitope evolution, T cell subsets, IL-10 effects on T cells, and costimulatory pathways, but do not present data on B cell exhaustion contributing to poor antibody responses."
    },
    "naive_doc_ids": [
      "13469921",
      "23915841",
      "7177329",
      "8639034",
      "10648422"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers address B-cell exhaustion or antibody responses specifically in HIV-infected individuals. They cover general B-cell migration, chemokine guidance, Ca2+ signaling in neutrophils, oncology and other topics, but do not provide data on B-cell exhaustion or poor antibody responses in HIV."
    },
    "overthinking_doc_ids": [
      "38587347",
      "7869794",
      "9929089",
      "15488881",
      "696006"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers address B cell exhaustion, HIV infection, or impaired antibody responses in HIV-infected individuals."
    },
    "posthoc_doc_ids": [
      "38587347",
      "7869794",
      "9929089",
      "28644298",
      "3756384"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "434",
    "claim": "Foxp3 enables the expression of transcriptional regulators implicated in memory T cell development.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers describe a role for Foxp3 in enabling the expression of transcriptional regulators that drive memory T cell development. The articles focus on other factors (Blimp-1, Tcf1, Foxo1, IL-2/inflammation) or on Foxp3 in regulatory T cell function, but do not link Foxp3 to memory T cell transcriptional programming."
    },
    "naive_doc_ids": [
      "5508750",
      "7399084",
      "18882947",
      "14555750",
      "12315072"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided studies directly address whether Foxp3 enables the expression of transcriptional regulators that drive memory T cell development. While several papers characterize Foxp3 in Treg function (e.g., Papers 3, 4, 10) and others discuss factors governing effector and memory T cells (e.g., Papers 2, 6\u20139), no study links Foxp3 to up-regulation of the transcriptional regulators specifically implicated in memory T cell differentiation."
    },
    "overthinking_doc_ids": [
      "16728949",
      "5508750",
      "30908508",
      "22517564",
      "13231899"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address Foxp3 or its role in driving expression of transcriptional regulators for memory T cell development."
    },
    "posthoc_doc_ids": [
      "13636631",
      "991137",
      "3835423",
      "16728949",
      "28644298"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1352",
    "claim": "Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 1 explicitly reports that the Aedes aegypti C-type lectin mosGCTL-1 is induced by West Nile virus infection, demonstrating upregulation of mosGCTL-1 upon WNV challenge. The other papers do not address mosGCTL-1 expression in the context of WNV infection."
    },
    "naive_doc_ids": [
      "12885341",
      "13702924",
      "34287602",
      "10559501"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly reports that the Aedes aegypti C-type lectin mosGCTL-1 is induced (upregulated) upon WNV infection. The other papers do not address mosGCTL-1 expression in the context of WNV, so the overall evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "12885341",
      "34287602",
      "38376189",
      "10559501",
      "13702924"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly reports that mosGCTL-1 expression is induced upon WNV infection in Aedes aegypti mosquitoes, directly supporting the claim. Papers 2 and 3 do not address mosGCTL-1."
    },
    "posthoc_doc_ids": [
      "12885341",
      "10559501",
      "34287602"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "693",
    "claim": "Leuko-reduced blood reduces infectious complications in red blood cell transfusion.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The only study directly addressing leukoreduction and infection (Paper 2) found no significant reduction in serious nosocomial infections after universal prestorage leukoreduction (adjusted OR 0.97, 95% CI 0.87\u20131.09), despite small decreases in fevers and antibiotic use. This does not support the claim that leukoreduced red cell units reduce infectious complications."
    },
    "naive_doc_ids": [
      "11344428",
      "24088502",
      "243694",
      "5511240",
      "9787715"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies address the effect of leukocyte reduction on infectious complications in red blood cell transfusions. None report data on leuko\u2010reduced blood products or compare infection rates with and without leukoreduction."
    },
    "overthinking_doc_ids": [
      "7098463",
      "3944632",
      "4678846",
      "23203102",
      "3698758"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Only Paper 7 directly addresses leukoreduction in RBC transfusion. In a large before\u2010and\u2010after cohort, universal prestorage leukoreduction did not reduce serious nosocomial infections (adjusted OR 0.97; 95% CI 0.87\u20131.09), although it did reduce fevers and antibiotic use. Thus, it fails to show a reduction in infectious complications overall."
    },
    "posthoc_doc_ids": [
      "8137081",
      "11344428",
      "22890091",
      "9167230",
      "10582939"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "650",
    "claim": "Integrating classroom-based collaborative learning with Web-based collaborative learning offers the best class performance.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers address blended classroom\u2013web collaborative learning or measure class performance in that context. The studies cover immunology, clinical care, genomics visualization, medical education technology (without performance data on integrated collaborative modes), reproductive toxicology, neuroimaging of fitness, and assay technology. No evidence pertains to integrating classroom-based and web-based collaborative learning for class performance."
    },
    "naive_doc_ids": [
      "9278263",
      "1191830",
      "3444507",
      "15041758",
      "5145974"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.03,
      "justification": "None of the provided studies examine or compare classroom-based collaborative learning with Web-based collaborative learning or their integration in an educational setting. Therefore, there is no information relevant to the claim."
    },
    "overthinking_doc_ids": [
      "1542437",
      "841371",
      "1191830",
      "5691302",
      "5824985"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided studies investigate or report on integrating classroom-based and Web-based collaborative learning approaches or their effects on class performance. The papers focus on medical imaging, neurobiology, hospital readmissions, pharmacology, immunology, rheumatology criteria, adverse outcomes of antidepressants and fluids, and integrated care in health, but do not address educational methods or learning outcomes."
    },
    "posthoc_doc_ids": [
      "1412089",
      "3202143",
      "7419612",
      "4506702",
      "46135768"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "114",
    "claim": "Anthrax spores are very difficult to dispose once they are dispersed.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.7,
      "justification": "Paper 1 demonstrates that viable B. anthracis spores readily reaerosolize under both semiquiescent and normal office activities, with the majority of particles in a respirable size range. This indicates that once dispersed, anthrax spores persist on surfaces and can be resuspended into the air, complicating decontamination and disposal efforts, thereby supporting the claim that they are very difficult to dispose."
    },
    "naive_doc_ids": [
      "33872649",
      "2851611",
      "12824568",
      "341324",
      "4688340"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 demonstrates that viable B. anthracis spores remained on surfaces after contamination and could be reaerosolized under normal office activities, indicating that decontamination and disposal of dispersed anthrax spores is challenging. No other papers provide conflicting or additional relevant information."
    },
    "overthinking_doc_ids": [
      "33872649",
      "4942718",
      "12824568",
      "301866",
      "371289"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address Bacillus anthracis spores or their disposal once dispersed; they cover topics such as inter-professional decision making, HIV/AIDS investment, breast cancer genetics, trauma resilience, malaria vector control, T-cell recovery after transplantation, cancer screening, choice experiments, and malaria prophylaxis, but contain no relevant data on anthrax spore persistence or disposal."
    },
    "posthoc_doc_ids": [
      "1338283",
      "11230569",
      "18340282",
      "6296189",
      "15237660"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "985",
    "claim": "Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the eight provided papers discuss the PTENP1 pseudogene or its role in regulating PTEN by acting as an miRNA decoy. While some studies describe other non-coding RNAs (e.g. versican 3\u2032UTR fragment, linc-RoR, GAS5) functioning as miRNA sponges to modulate PTEN or other targets, none examine PTENP1 itself, so there is no direct evidence here to support or refute the specific claim."
    },
    "naive_doc_ids": [
      "13964633",
      "23913146",
      "42662816",
      "16346504",
      "654735"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly demonstrates that the PTEN pseudogene transcript PTENP1 acts as a decoy for PTEN-targeting miRNAs, thereby regulating PTEN levels. No other paper contradicts this mechanism."
    },
    "overthinking_doc_ids": [
      "6828370",
      "654735",
      "6054657",
      "11271123",
      "15113221"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that the PTENP1 pseudogene transcript acts as a competing endogenous RNA (miRNA decoy) to sequester PTEN\u2010targeting microRNAs, thereby increasing PTEN expression and confirming the claim."
    },
    "posthoc_doc_ids": [
      "6828370",
      "11771811",
      "7281161",
      "654735",
      "42662816"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.7,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1098",
    "claim": "Stacking is more stable when a purine is present in the +5 position (C1698).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the eight provided papers investigate nucleotide stacking stability in relation to a purine at the +5 position (C1698). The topics range from rRNA processing factors, DNA methylation, replication\u2010fork protection, ribosomal protein\u2013p53 interactions, RPG coregulation, sequence alignment algorithms, dynein\u2013microtubule mechanics, to cardiovascular research, without discussing base stacking at a specific sequence position."
    },
    "naive_doc_ids": [
      "18467982",
      "3174305",
      "4444861",
      "2582169",
      "11420613"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the eight provided papers address nucleotide stacking interactions, the identity of a purine at a +5 position (C1698), or base\u2010stacking stability in RNA or DNA. Therefore, there is no information relevant to the claim."
    },
    "overthinking_doc_ids": [
      "18467982",
      "3174305",
      "4444861",
      "7260461",
      "16090672"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers address nucleotide stacking interactions or the specific role of a purine at the +5 position (C1698). They cover diverse topics (DNA methylation, replication fork stability, plaque rupture, Ras inhibitors, membrane protein dislocation, dynein\u2013microtubule interactions, Notch3 acetylation, plant hypoxia responses, LIN28B in lung cancer) but do not discuss RNA (or DNA) base stacking at position C1698 or the effect of a purine at +5 on stacking stability."
    },
    "posthoc_doc_ids": [
      "3174305",
      "4444861",
      "4890578",
      "4396105",
      "6788835"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "169",
    "claim": "Bariatric surgery reduces postmenopausal breast cancer.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.35,
      "justification": "Among the provided studies, only Paper 2 addresses bariatric surgery and incident cancer outcomes and specifically reports no association between bariatric surgery and cancer incidence. None of the papers present evidence that bariatric surgery lowers breast cancer risk in postmenopausal women."
    },
    "naive_doc_ids": [
      "3329824",
      "5824985",
      "38551172",
      "5268462",
      "32534305"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided studies directly assess the effect of bariatric surgery on postmenopausal breast cancer. Paper 1 reports no association between bariatric surgery and overall cancer incidence but does not break out breast cancer or postmenopausal cases. The other papers do not address bariatric surgery, so there is no relevant evidence to support or contradict the specific claim."
    },
    "overthinking_doc_ids": [
      "5824985",
      "38551172",
      "9171913",
      "3329824",
      "7639744"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers address bariatric surgery or its effect on postmenopausal breast cancer risk. They cover topics such as vitamin D and mammographic density, lipid profiles, hormonal factors, genetic predisposition, birth weight, healthcare access, and metastatic therapy, but do not provide data on bariatric surgery outcomes."
    },
    "posthoc_doc_ids": [
      "38551172",
      "16701509",
      "5864770",
      "2015126",
      "5487448"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1288",
    "claim": "There is a positive correlation between hip fractures and statin use.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 directly examines statin use and hip fracture risk, finding that statin users have a significantly LOWER risk of hip fracture (adjusted ORs of 0.50 and 0.57), which opposes the claim of a positive correlation between statin use and hip fractures. None of the other papers provide evidence supporting an increased hip fracture risk with statins."
    },
    "naive_doc_ids": [
      "1711571",
      "11246427",
      "14103509",
      "4687948",
      "1522336"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 7 directly examines statin use and hip fracture risk in elderly patients, finding that statin use is associated with a significant reduction in hip fractures (adjusted OR 0.50 for 180-day use and 0.57 for 3-year use). This evidence contradicts the claim of a positive correlation between statin use and hip fractures."
    },
    "overthinking_doc_ids": [
      "5698494",
      "26000593",
      "439670",
      "27466734",
      "947631"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly examines statin use and hip fracture risk in elderly patients and finds adjusted odds ratios well below 1 (e.g., 0.50 for use in the prior 180 days and 0.57 for use in the prior 3 years), indicating that statin use is associated with a significant reduction\u2014not an increase\u2014in hip fracture risk. None of the other papers address this claim."
    },
    "posthoc_doc_ids": [
      "4687948",
      "12762485",
      "31591262",
      "1287809",
      "2052720"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "917",
    "claim": "PTEN is a regulator for the transcriptional activity of SRF",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 demonstrates that nuclear PTEN directly interacts with SRF and is essential for SRF-dependent transcription. PTEN\u2013SRF interaction promotes SRF binding to smooth muscle gene promoters, and loss of nuclear PTEN alters SRF activity, thereby confirming that PTEN regulates SRF\u2019s transcriptional activity."
    },
    "naive_doc_ids": [
      "15176526",
      "12658073",
      "14367469",
      "34071621",
      "9784254"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 7 directly demonstrates that nuclear PTEN interacts with serum response factor (SRF) and is required for SRF\u2010dependent transcription of smooth muscle\u2013specific genes. PTEN\u2013SRF binding promotes SRF\u2019s association with target promoters, and loss of nuclear PTEN alters SRF activity, confirming PTEN as a regulator of SRF transcriptional activity."
    },
    "overthinking_doc_ids": [
      "2316374",
      "14367469",
      "15113221",
      "6493422",
      "15176526"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 directly demonstrates that nuclear PTEN interacts with SRF and is required for SRF-dependent transcription of smooth muscle\u2013specific genes, establishing PTEN as a regulator of SRF transcriptional activity."
    },
    "posthoc_doc_ids": [
      "14367469",
      "29429111",
      "2316374",
      "34071621",
      "12582729"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "903",
    "claim": "PD-1 triggering on monocytes reduces IL-10 production by monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines PD-1 triggering on monocytes: engagement of monocyte PD-1 by PD-L1 induces, rather than suppresses, IL-10 production. This experimental result is opposite to the claim that PD-1 triggering reduces monocyte IL-10 output, so the evidence refutes the claim."
    },
    "naive_doc_ids": [
      "10648422",
      "13902570",
      "25353658",
      "2543135",
      "34436231"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly examines PD-1 triggering on monocytes and reports that PD-1 engagement by PD-L1 induces (i.e., increases) IL-10 production, which is opposite to the claim that PD-1 triggering reduces IL-10 production."
    },
    "overthinking_doc_ids": [
      "10648422",
      "21498497",
      "15058155",
      "9334631",
      "8639034"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 directly shows that triggering PD-1 on monocytes by PD-L1 induces IL-10 production, which is the opposite of the claim that PD-1 engagement reduces IL-10 production. None of the other papers address PD-1 and IL-10 in monocytes."
    },
    "posthoc_doc_ids": [
      "10648422",
      "13902570",
      "6212802",
      "623486",
      "6936141"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "938",
    "claim": "Persister cells provide relapse resistance in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Although none of the studies explicitly use the term \u201cpersister cells,\u201d several describe the same phenomenon in which a small population of cancer cells survives frontline therapy (minimal residual disease or MRD), remains dormant or refractory, and later drives tumor relapse and treatment failure. For example, Paper 5 reviews the concept of residual disease as the source of eventual relapse, Paper 7 shows that MRD cells acquire an escape phenotype enabling relapse and that targeting them can prevent recurrence, and Papers 1\u20134 and 9 document diverse molecular mechanisms by which residual or persister-like cells evade apoptosis or targeted agents. Together, these data support the claim that persister (residual) cells underlie relapse resistance in cancer patients."
    },
    "naive_doc_ids": [
      "1727493",
      "9929089",
      "25895285",
      "80522346",
      "26231129"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Papers 3 and 4 describe small, quiescent \u2018cancer stem cell\u2019 subpopulations\u2014analogous to persister cells\u2014that survive chemotherapy and later drive tumour regrowth. Paper 9 shows minimal residual disease cells evade innate immunity and seed relapses, and that targeting these persister\u2010like cells prevents recurrence. Together these studies support the claim that persister cells confer relapse resistance in cancer patients."
    },
    "overthinking_doc_ids": [
      "25895285",
      "1727493",
      "8891333",
      "40382183",
      "2665675"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.72,
      "justification": "Although none of the studies use the specific term \u201cpersister cells,\u201d several papers describe discrete, therapy-resistant subpopulations (cancer stem cells or sphere-forming tumor-initiating cells) that survive treatment and drive relapse. For example, Paper 2 shows stromal miR-21\u2013bearing exosomes render ovarian cancer cells chemo-resistant; Paper 4 identifies CD44v6+ colorectal CSCs that seed metastases and resist therapy; Paper 5 finds sphere-forming head and neck cancer cells persist through radiation and regenerate tumors; and Paper 7 demonstrates that ovarian CSCs with high lipid unsaturation survive and reinitiate tumor growth. Together, these data support the concept that persister-like cell populations underlie relapse resistance in cancer patients."
    },
    "posthoc_doc_ids": [
      "38243984",
      "1727493",
      "2841164",
      "9558539",
      "4688340"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "181",
    "claim": "Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 shows that TDP-43 localizes to mitochondria, binds ND3 and ND6 transcripts (leading to complex I disassembly) and that suppressing its mitochondrial localization\u2014which in effect blocks its interaction with ND3/ND6\u2014abolishes TDP-43-induced mitochondrial dysfunction and neuronal loss, directly supporting the claim."
    },
    "naive_doc_ids": [
      "16966326",
      "10698739",
      "13380011",
      "4320424",
      "23440856"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 directly demonstrates that TDP-43 binds mitochondrial RNAs encoding complex I subunits ND3 and ND6, that this interaction causes complex I disassembly and neuronal loss, and that suppression of TDP-43 mitochondrial localization (which prevents its interaction with ND3/ND6 transcripts) abolishes TDP-43-induced mitochondrial dysfunction and neuronal death. No other paper addresses this specific mechanism."
    },
    "overthinking_doc_ids": [
      "16966326",
      "10698739",
      "13380011",
      "935538",
      "7729656"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 3 directly demonstrates that preventing TDP-43 from localizing to mitochondria\u2014and thus from binding mitochondrially encoded complex I subunit RNAs (ND3 and ND6)\u2014abolishes both TDP-43-induced mitochondrial dysfunction and neuronal loss, consistent with the claim."
    },
    "posthoc_doc_ids": [
      "10698739",
      "13380011",
      "16966326",
      "6158879",
      "20675284"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "617",
    "claim": "Increased mobility of retrotransposons is assosciated with mutation and higher tumorigenesis rates.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided studies address the mobility of retrotransposons or link changes in retrotransposon activity directly to mutation rates or tumorigenesis. They discuss mutations, genomic instability, and pathway alterations but do not examine retrotransposon mobilization."
    },
    "naive_doc_ids": [
      "11271123",
      "24349992",
      "16732790",
      "3572885",
      "3210545"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.99,
      "justification": "None of the provided papers discuss retrotransposon mobilization or its direct link to mutation rates and tumorigenesis. They focus on specific gene mutations, signaling pathways, oxidative stress, DNA repair errors, and clinical outcomes, but do not address retrotransposon activity."
    },
    "overthinking_doc_ids": [
      "9505402",
      "85665741",
      "3210545",
      "5765455",
      "24349992"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers address the mobility of retrotransposons or their role in mutation and tumorigenesis. They focus on amyloid-\u03b2 in Alzheimer\u2019s, autophagy genes, receptor polymorphisms, dietary proteins, genome doubling, vitamin D, RET signaling, BRCA1 progenitors, and INK4 feedback, but none discuss retrotransposon activity."
    },
    "posthoc_doc_ids": [
      "8892905",
      "25576204",
      "3127341",
      "6327940",
      "7211056"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "756",
    "claim": "Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Multiple papers document lysine acetylation of human proteins. For example, Paper 1 and 3 show H3 histone lysine acetylation in human adipocytes and during iPS reprogramming, and Paper 4 reviews widespread lysine acetylation as a conserved post-translational modification linking metabolism and signaling. These findings confirm that many human proteins are acetylated on lysine residues."
    },
    "naive_doc_ids": [
      "3052213",
      "11784947",
      "8150638",
      "27134527",
      "22036571"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly describes acetylation of histone H3 at lysine 56 in human adipocytes by CBP/p300 and Paper 6 reviews lysine acetylation as a widespread reversible posttranslational modification mediated by acetyltransferases and deacetylases, confirming that many human proteins are acetylated on lysine residues."
    },
    "overthinking_doc_ids": [
      "3052213",
      "11784947",
      "13048272",
      "4462777",
      "22042345"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers (e.g., Paper 1, Paper 2, and Paper 3) describe lysine acetylation as a widespread, conserved post-translational modification on many human proteins (histones and nonhistones), linking acetyl-CoA metabolism to signaling and showing genome-wide acetylation sites."
    },
    "posthoc_doc_ids": [
      "27134527",
      "3052213",
      "12172346",
      "11335860",
      "1243475"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1319",
    "claim": "Transplanted human glial cells can differentiate within the host animal.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.67,
      "justification": "Paper 1 reports that human ES cell\u2013derived neural precursors transplanted into the neonatal mouse brain became incorporated into various brain regions, where they differentiated into both neurons and astrocytes (astrocytes being a glial cell type). This directly supports the claim that transplanted human glial/precursor cells can differentiate in the host animal."
    },
    "naive_doc_ids": [
      "2437807",
      "5633876",
      "9122283",
      "9194077",
      "266641"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple studies show that human glial or neural precursor cells, when transplanted into immunodeficient or neonatal mouse brains, differentiate in vivo. For example, in Paper 3, human ES\u2013derived neural precursors transplanted into neonatal mouse brain gave rise to both neurons and astrocytes. In Paper 8, human glial progenitor cells engrafted into neonatal mice matured into human astrocytes, integrated gap-junctionally with host astroglia, and retained human glial morphology and function. These data confirm that transplanted human glial cells can differentiate within the host animal."
    },
    "overthinking_doc_ids": [
      "3360421",
      "4427392",
      "2437807",
      "4430962",
      "36398420"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 shows that human glial progenitor cells engrafted into neonatal mice matured into human astrocytes in the host brain. Paper 5 demonstrates that human ES cell\u2013derived neural precursors, when transplanted into neonatal mouse brain, differentiated into neurons and astrocytes (glial cells) in vivo. These findings directly confirm that transplanted human glial-lineage cells can differentiate within the host animal."
    },
    "posthoc_doc_ids": [
      "16284655",
      "9122283",
      "8790729",
      "5633876",
      "2437807"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1068",
    "claim": "ScPif1p has reduced binding ability to G-rich ssDNA compared to non-G-rich ssDNA.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.89,
      "justification": "None of the provided papers directly examine the binding affinity of Saccharomyces cerevisiae Pif1 (ScPif1p) to G-rich versus non-G-rich single-stranded DNA. The closest studies address unrelated SSB proteins, other helicases, or G-quadruplex resolution by Pfh1 in S. pombe, but they do not measure or compare ScPif1p binding to G-rich and non-G-rich ssDNA."
    },
    "naive_doc_ids": [
      "799586",
      "1914588",
      "8065561",
      "6386930",
      "7549811"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.08,
      "justification": "None of the provided papers report measurements of ScPif1p binding affinities to G-rich versus non-G-rich single-stranded DNA. While Paper 5 discusses Pif1 helicases unwinding G-quadruplex DNA, it does not quantify or compare direct binding to G-rich and non-G-rich ssDNA, and the other papers focus on unrelated proteins or contexts."
    },
    "overthinking_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "10874408",
      "4429668"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers report direct measurements of Saccharomyces cerevisiae Pif1 (ScPif1p) binding affinities for G-rich versus non-G-rich single-stranded DNA. The closest relevant studies characterize helicase activity or examine prokaryotic Pif1, but do not compare ScPif1p binding to G-rich and non-G-rich ssDNA."
    },
    "posthoc_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "29851836",
      "799586"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "623",
    "claim": "Individuals with low serum vitamin D concentrations have increased risk of multiple sclerosis.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 shows that higher sun exposure in childhood\u2014a major determinant of serum vitamin D\u2014was associated with a substantially reduced risk of multiple sclerosis (adjusted OR 0.31), implying that low UV/Vitamin D is linked to higher MS risk. Paper 9 reviews the latitude\u2013MS gradient and notes that lower UV\u2010driven vitamin D production and vitamin D\u2019s immunomodulatory effects likely underlie MS susceptibility, further supporting the claim."
    },
    "naive_doc_ids": [
      "17000834",
      "4462079",
      "6710713",
      "2425364",
      "1759213"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the supplied papers present direct epidemiological or experimental data linking individual serum 25(OH)D concentrations to subsequent multiple sclerosis risk. Paper 5 discusses vitamin D as a potential environmental factor in MS, but it does not provide human data showing that low serum vitamin D levels increase MS risk."
    },
    "overthinking_doc_ids": [
      "4462079",
      "27466734",
      "43226130",
      "3150030",
      "22843838"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "Of the provided papers, only Paper 7 touches on vitamin D in the context of multiple sclerosis, and it offers a hypothesis linking low UV\u2010driven vitamin D synthesis at higher latitudes to higher MS prevalence and notes immunomodulatory effects of vitamin D in animal models. None of the studies report direct human epidemiological data showing that individuals with low serum 25\u2010hydroxyvitamin D have an increased risk of developing MS."
    },
    "posthoc_doc_ids": [
      "25599283",
      "43226130",
      "16256507",
      "9555784",
      "13312471"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1404",
    "claim": "siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers mention A20 (TNFAIP3) or describe siRNA knockdown of A20 in an in vivo murine xenograft model, so there is no relevant information to support or contradict the claim."
    },
    "naive_doc_ids": [
      "33638477",
      "1782201",
      "9767444",
      "20888849",
      "2565138"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 8 describes lentiviral-mediated A20 knockdown (shRNA) in glioma stem cells and demonstrates that A20 targeting decreases tumor\u2010forming capacity and prolongs survival in a mouse xenograft model. This in vivo evidence aligns with the claim that knockdown of A20 slows tumor progression."
    },
    "overthinking_doc_ids": [
      "45764440",
      "14615911",
      "7583725",
      "33638477",
      "1782201"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers describe siRNA knockdown of A20 (TNFAIP3) or its effects on tumor progression in an in vivo murine xenograft model."
    },
    "posthoc_doc_ids": [
      "33638477",
      "381602",
      "1782201",
      "32852283",
      "8671456"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "209",
    "claim": "CHOP is a general endoplasmic reticulum stress marker.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Multiple studies (e.g., Paper 1 and Paper 4) report that CHOP (also known as DDIT3) is robustly up-regulated in response to diverse ER stressors and is commonly measured as part of the unfolded protein response, confirming that CHOP is a general marker of ER stress."
    },
    "naive_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "35760786",
      "9752604"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Both Paper 1 and Paper 3 report that CHOP (also called Ddit3) is induced in settings of endoplasmic reticulum stress. Paper 1 shows CsA treatment upregulates CHOP along with known ER stress markers GRP78 and HERP in renal cells, and Paper 3 demonstrates time-dependent increases in Ddit3/CHOP mRNA and protein accompanying lipid-induced ER stress and apoptosis in \u03b2 cells (and in diabetic islets). These findings support CHOP\u2019s role as a general ER stress marker."
    },
    "overthinking_doc_ids": [
      "238409",
      "4951831",
      "25510546",
      "8453819",
      "19561411"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 reports time-dependent upregulation of Ddit3 (also known as Chop) in response to palmitate-induced ER stress in \u03b2-cells and increased CHOP protein in islets from diabetic mice and humans with type 2 diabetes. Paper 8 shows that ARV1 deficiency activates the unfolded protein response with elevated CHOP expression in yeast and mammalian cells. These findings confirm that CHOP is induced broadly under ER stress, supporting its role as a general ER stress marker."
    },
    "posthoc_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "471735",
      "1554348"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1295",
    "claim": "There is no relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 reports a strong, statistically significant association between infant erythromycin (a macrolide) exposure and infantile hypertrophic pyloric stenosis (rate ratio 29.8, 95% CI 16.4\u201354.1 during days 0\u201313), and a significant increase in risk with maternal use in the first two weeks after birth (rate ratio 3.49, 95% CI 1.92\u20136.34). This directly contradicts the claim of no relation."
    },
    "naive_doc_ids": [
      "21239672",
      "2140497",
      "2425364",
      "1428840",
      "1538080"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 2 directly examines macrolide use (including erythromycin) and infantile hypertrophic pyloric stenosis, finding a strong positive association (e.g. adjusted rate ratio 29.8 for infant use days 0\u201313 and 3.49 for maternal use days 0\u201313), which refutes the claim of no relation."
    },
    "overthinking_doc_ids": [
      "2425364",
      "21239672",
      "202259",
      "829646",
      "2097256"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines macrolide use (including erythromycin) and finds a strong association with infantile hypertrophic pyloric stenosis (e.g., adjusted rate ratio 29.8 for infant use days 0\u201313), demonstrating a clear relation and refuting the claim. None of the other papers address this association."
    },
    "posthoc_doc_ids": [
      "21239672",
      "6157837",
      "471921",
      "2425364",
      "439670"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "173",
    "claim": "Bcp1 is a chaperone for Rpl23.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers mention a protein named Bcp1 or its interaction with ribosomal protein L23 (Rpl23). Without any direct or indirect evidence about Bcp1 functioning as a chaperone for Rpl23, the claim cannot be supported or contradicted based on the given literature."
    },
    "naive_doc_ids": [
      "10189634",
      "15893330",
      "20781656",
      "8327914",
      "26495128"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.02,
      "justification": "None of the provided papers mention Bcp1 or its interaction with Rpl23; no evidence for or against Bcp1 acting as a chaperone for Rpl23 is found."
    },
    "overthinking_doc_ids": [
      "12428814",
      "207972",
      "1084345",
      "365896",
      "1256116"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.13,
      "justification": "None of the nine papers mention either Bcp1 or the ribosomal protein Rpl23, nor do they present data on a Bcp1\u2013Rpl23 interaction. Therefore, there is no basis in the provided evidence to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "12428814",
      "207972",
      "1084345",
      "2576811",
      "2851611"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "165",
    "claim": "Bariatric surgery increases rates of postmenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1, the only study to report on incident cancers after bariatric surgery, found no association between bariatric surgery and overall cancer incidence. None of the other papers provide data showing an increased risk of postmenopausal breast cancer after bariatric surgery; indeed, Papers 2 and 6 document that higher BMI and metabolic\u2010syndrome parameters raise postmenopausal breast cancer risk, implying that the substantial weight loss from bariatric surgery would tend to lower\u2014not raise\u2014breast cancer rates."
    },
    "naive_doc_ids": [
      "5824985",
      "13831842",
      "38551172",
      "22401720",
      "6313547"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.6,
      "justification": "Although none of the other papers address bariatric surgery directly, Paper 1 specifically compares bariatric surgery patients to matched obese controls and reports no association between surgery and overall cancer incidence (including female cancers) over four years. This finding runs counter to the claim that bariatric surgery increases rates of postmenopausal breast cancer."
    },
    "overthinking_doc_ids": [
      "5824985",
      "15512462",
      "32534305",
      "17450673",
      "23557241"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers examine bariatric surgery or its impact on postmenopausal breast cancer rates. Therefore, no evidence is available to support or refute the claim."
    },
    "posthoc_doc_ids": [
      "38551172",
      "5864770",
      "9171913",
      "32534305",
      "3329824"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1230",
    "claim": "The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly addresses the rs12212067 T>G polymorphism in FOXO3A and shows that carriers of the minor (G) allele have a FOXO3-driven pathway that limits inflammatory responses in monocytes, reducing production of pro-inflammatory cytokines (e.g., TNF\u03b1) while boosting anti-inflammatory cytokines. The other papers do not address this SNP or FOXO3, so they are not relevant to the claim."
    },
    "naive_doc_ids": [
      "13905670",
      "11233339",
      "25315295",
      "26068103",
      "36242796"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 demonstrates that carriers of the FOXO3A minor G allele exhibit reduced production of pro-inflammatory cytokines (e.g., TNF\u03b1) via a FOXO3-driven, TGF\u03b21-mediated pathway, directly supporting the claim. The other listed papers do not address this SNP or its effects on cytokine regulation."
    },
    "overthinking_doc_ids": [
      "13905670",
      "11233339",
      "25315295",
      "36242796",
      "7281161"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that the minor G allele of FOXO3A (rs12212067) limits inflammatory responses in monocytes via a FOXO3-driven pathway, reducing production of pro-inflammatory cytokines such as TNF\u03b1 and thus downregulating pro-inflammatory cytokines."
    },
    "posthoc_doc_ids": [
      "13905670",
      "24396137",
      "24783597",
      "13906892",
      "36242796"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1342",
    "claim": "Understanding epigenetic regulation of replication is essential for the reational design of episomally replicating vectors.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss the interplay of epigenetic regulation with episomal vector replication or its design. While several papers cover epigenetic control of chromatin, transcription, or endogenous DNA replication domains, none address how these mechanisms inform the rational design of episomally replicating vectors."
    },
    "naive_doc_ids": [
      "24512417",
      "2356950",
      "6948886",
      "20630805",
      "7929932"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the cited papers address the role of epigenetic regulation of DNA replication in the context of designing episomally replicating vectors. While Paper 3 discusses epigenetic control of replication timing in development, and others examine histone or DNA methylation in gene expression, none link these mechanisms to the rational design or function of episomal vectors."
    },
    "overthinking_doc_ids": [
      "2356950",
      "6948886",
      "8759633",
      "25606339",
      "2888272"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers address episomally replicating vectors or the design thereof. While several studies discuss epigenetic mechanisms in gene regulation, chromatin state, or replication origin control, none link these insights to the rational design of episomal vectors or demonstrate that understanding epigenetic regulation of replication is essential for that purpose."
    },
    "posthoc_doc_ids": [
      "24512417",
      "2356950",
      "6948886",
      "2613813",
      "2888272"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1239",
    "claim": "The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Multiple studies indicate that the myocardium arises from mesodermal (and neural crest/second heart field) progenitors rather than exclusively from endoderm. For example, Nkx2-5 is expressed in precardiac mesoderm (Paper 7), and BAF250a\u2010ablated embryos lack a mesodermal layer and fail to form mesoderm-derived cardiomyocytes (Paper 5). These data directly contradict the claim of an exclusively endodermal origin for myocardial cells."
    },
    "naive_doc_ids": [
      "4421787",
      "5002665",
      "6148876",
      "17685207",
      "26612216"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple studies (e.g., Paper 1 shows cardiomyocytes are mesoderm-derived; Paper 3\u2019s fate mapping assigns cardiac mesoderm to epiblast regions, not endoderm; Paper 8 demonstrates cardiac progenitors arise from second heart field (mesoderm) and neural crest (ectoderm), not endoderm; Paper 9 links mesodermal differentiation to cardiomyocyte fate) all indicate myocardium derives from mesoderm (and in part neural crest), directly contradicting an exclusively endodermal origin."
    },
    "overthinking_doc_ids": [
      "26612216",
      "5002665",
      "17685207",
      "9622258",
      "1905095"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "None of the studies identify an endodermal source of myocardial progenitors. On the contrary, Papers 5 and 6 demonstrate that critical cardiac lineages derive from neural crest (ectoderm) and second heart field (mesoderm) precursors, showing that heart muscle is not of exclusively endodermal origin and refuting the claim."
    },
    "posthoc_doc_ids": [
      "1905095",
      "21392223",
      "301838",
      "6549091",
      "38727075"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "653",
    "claim": "Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 directly demonstrates that IL-18 is highly expressed in human atherosclerotic plaques (especially in macrophages), that its receptor is upregulated in plaque cells, and that IL-18 mRNA levels are higher in unstable (symptomatic) versus stable plaques, implicating IL-18 in plaque destabilization and thus a key role in atherosclerosis pathogenesis."
    },
    "naive_doc_ids": [
      "6853699",
      "10359591",
      "20310709",
      "17421851",
      "883747"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 directly demonstrates that IL-18 promotes experimental atherosclerosis in Apoe\u2013/\u2013 mice, showing that interruption of IL-18 action reduces lesion formation and that IL-18 signaling via its receptor and the Na-Cl cotransporter on macrophages drives inflammatory responses in atherogenesis."
    },
    "overthinking_doc_ids": [
      "6853699",
      "24384587",
      "854417",
      "14407673",
      "18852643"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 demonstrates that IL-18 contributes to experimental atherogenesis in Apoe\u2013/\u2013 mice (IL-18 interruption reduces lesion size, and IL-18 signaling via its receptor and the Na-Cl co-transporter promotes macrophage activation and plaque formation). Paper 7 shows that IL-18 is highly expressed in human carotid atherosclerotic plaques\u2014especially unstable, symptomatic ones\u2014and localizes to macrophages, implicating IL-18 in plaque destabilization. Together, these data confirm that IL-18 plays an important role in atherosclerosis pathogenesis."
    },
    "posthoc_doc_ids": [
      "6853699",
      "24384587",
      "854417",
      "1044552",
      "2192419"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "798",
    "claim": "Mitochondria play a trivial role in calcium homeostasis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that mitochondrial Ca2+ uptake is a critical regulator of intracellular Ca2+ signaling and homeostasis, buffering cytosolic Ca2+ and controlling cell metabolism and survival, thus indicating a non\u2010trivial role for mitochondria in calcium homeostasis. None of the other papers provide evidence that would support the claim of a trivial role."
    },
    "naive_doc_ids": [
      "5094468",
      "13458119",
      "19205437",
      "2825380",
      "7736860"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 4 directly shows that mitochondria play a central role in intracellular Ca2+ signaling by taking up and buffering cytosolic Ca2+ and regulating downstream effectors, demonstrating a non-trivial role in calcium homeostasis. The other papers do not address mitochondrial Ca2+ handling."
    },
    "overthinking_doc_ids": [
      "12058271",
      "19205437",
      "28724565",
      "5094468",
      "38623601"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.2,
      "justification": "None of the provided papers directly address the role of mitochondria in cellular calcium homeostasis. They discuss calcium flux in immune cells, ER-mediated Ca2+ entry, endolysosomal channels, thermogenesis via SERCA2b, mitochondrial ROS in inflammasome activation, and other signaling pathways, but none present data on mitochondrial calcium uptake or buffering to support or refute the claim."
    },
    "posthoc_doc_ids": [
      "12058271",
      "19205437",
      "28724565",
      "4399311",
      "7736860"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "439",
    "claim": "Fz/PCP-dependent Pk localizes to the anterior membrane of neuroectoderm cells during zebrafish neuralation",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.91,
      "justification": "None of the provided papers describe the localization of the PCP component Prickle (Pk) to the anterior membrane of neuroectoderm cells in zebrafish neurulation. While Paper 1 addresses PCP in zebrafish neural keel cells via Vangl2, it does not report on Pk or its anterior membrane localization. The other papers either focus on different species or unrelated pathways."
    },
    "naive_doc_ids": [
      "4423559",
      "18575183",
      "5944514",
      "6268106",
      "1684489"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers describe the Fz/PCP-dependent localization of prickle (Pk) to the anterior membrane of neuroectoderm cells during zebrafish neurulation. While Paper 4 examines PCP signaling in zebrafish neurulation, it does not report on Pk localization. The other papers address unrelated systems or species."
    },
    "overthinking_doc_ids": [
      "4388082",
      "5395426",
      "6268106",
      "4423559",
      "9629682"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers describe the anterior membrane localization of Prickle (Pk) in zebrafish neuroectoderm cells during neurulation. Paper 1 addresses Vangl2-dependent PCP in zebrafish neural tube morphogenesis but does not report Pk localization; the other papers do not concern zebrafish PCP or Pk."
    },
    "posthoc_doc_ids": [
      "4423559",
      "6268106",
      "8533245",
      "35079452",
      "293661"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "308",
    "claim": "DUSP4 downregulation deactivates the Ras-ERK pathway",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 explicitly shows that loss (downregulation) of DUSP4, an ERK phosphatase, leads to activation\u2014not deactivation\u2014of the Ras-ERK pathway in basal-like breast cancer. This directly opposes the claim that DUSP4 downregulation deactivates Ras-ERK signaling."
    },
    "naive_doc_ids": [
      "7821634",
      "6121555",
      "17648235",
      "4662264",
      "4729644"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention DUSP4 or its direct effects on the Ras\u2013ERK pathway. The studies cover SIK2/p300 in lipogenesis, PKD1 and AMPK, Hop and Stat3, PI3K/Ras resistance, PTEN signaling, vitamin C effects on SOD, morin\u2019s impact on MAPK in asthma, Jagged1/Notch via MAPK, and NEAT1/let-7a-5p modulation of Ras-MAPK in cancer, but none address DUSP4 regulation or its role in Ras-ERK pathway activation or deactivation."
    },
    "overthinking_doc_ids": [
      "14198646",
      "23974474",
      "37164306",
      "14819804",
      "15113221"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly shows that DUSP4 downregulation activates\u2014rather than deactivates\u2014the Ras\u2013ERK pathway in basal\u2010like breast cancer, contrary to the claim. No other paper supports DUSP4 downregulation causing pathway deactivation."
    },
    "posthoc_doc_ids": [
      "7821634",
      "6121555",
      "17648235",
      "15381976",
      "20568364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "881",
    "claim": "Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 explicitly reports that omnivorous subjects produced more TMAO than vegans or vegetarians following L-carnitine ingestion, directly opposing the claim that omnivores produce less TMAO than vegans."
    },
    "naive_doc_ids": [
      "14803797",
      "5785219",
      "6793674",
      "12039953",
      "3801693"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses TMAO production after L-carnitine ingestion, reporting that omnivores produced more plasma TMAO than vegans or vegetarians. This opposes the claim that omnivores produce less TMAO than vegans."
    },
    "overthinking_doc_ids": [
      "14803797",
      "275294",
      "1391126",
      "6793674",
      "253672"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly compares omnivores and vegans/vegetarians and reports that omnivorous subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine, which is the opposite of the claim."
    },
    "posthoc_doc_ids": [
      "14803797",
      "6793674",
      "22995164",
      "4939312",
      "10557471"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "992",
    "claim": "Pyridostatin deregulates G2/M progression.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.99,
      "justification": "None of the provided papers mention pyridostatin or present data on its effects, let alone on G2/M cell\u2010cycle progression. Therefore, there is no information to support or contradict the claim."
    },
    "naive_doc_ids": [
      "2212067",
      "2613411",
      "4412772",
      "39225849",
      "164189"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers mention pyridostatin or describe its effects on G2/M progression. Therefore, there is no relevant evidence to support or refute the claim."
    },
    "overthinking_doc_ids": [
      "2212067",
      "2613411",
      "4412772",
      "15473205",
      "10608822"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the nine provided papers mention pyridostatin or assess its impact on G2/M cell\u2010cycle progression. They cover other proteins, pathways, and contexts but do not address the specific claim."
    },
    "posthoc_doc_ids": [
      "15473205",
      "10608822",
      "601033",
      "12207340",
      "12909503"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "667",
    "claim": "Klf2 is important for proper myeloid cell function.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple studies directly demonstrate that KLF2 regulates key aspects of myeloid cell behavior. Paper 4 shows KLF2 in myeloid cells represses NF-\u03baB\u2013dependent HIF-1\u03b1 and is essential to control activation during infection and endotoxemia. Paper 5 finds that KLF2 hemizygous mice have exaggerated inflammatory monocyte recruitment, up-regulated proinflammatory mediators, and more severe arthritis, indicating KLF2 is required to modulate monocyte differentiation and function. Paper 7 reports that myeloid-specific KLF2 knockout increases macrophage and neutrophil adhesion and accelerates atherosclerosis, underscoring KLF2\u2019s role in restraining myeloid cell activation and adhesion. These data collectively support that KLF2 is important for proper myeloid cell function."
    },
    "naive_doc_ids": [
      "14386505",
      "4418070",
      "17388232",
      "6493422",
      "7948486"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple studies directly implicate KLF2 in the regulation of myeloid\u2010lineage cells. Paper 3 shows that KLF2 in myeloid cells tonically represses NF-\u03baB\u2013dependent activation and is essential for controlling inflammation in infection and endotoxic shock. Paper 8 demonstrates that reduced KLF2 in monocytes leads to increased recruitment, proinflammatory mediator production, and worsened arthritis. Paper 2 further shows that KLF2 in dendritic cells (a myeloid subset) limits costimulatory molecule expression and T cell\u2013mediated inflammation in atherosclerosis. Together, these data confirm that KLF2 is important for proper myeloid cell function."
    },
    "overthinking_doc_ids": [
      "14386505",
      "5979056",
      "6493422",
      "3118719",
      "25827024"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple studies directly demonstrate that KLF2 in myeloid\u2010lineage cells (dendritic cells, macrophages, and neutrophils) is critical for their proper regulation and function. In Paper 2, DC\u2010specific KLF2 deletion leads to hyperactivation of DCs, enhanced T\u2010cell proliferation, and worsened atherosclerosis. Paper 4 shows that KLF2 in myeloid cells tonically represses NF-\u03baB\u2013driven activation and is essential for controlling the innate immune response to infection and endotoxic shock. Paper 7 finds that myeloid\u2010specific KLF2 knockout increases macrophage and neutrophil adhesion, promotes lesion inflammation, and accelerates atherosclerosis. Together, these data confirm that KLF2 is important for proper myeloid cell function."
    },
    "posthoc_doc_ids": [
      "14386505",
      "5979056",
      "1192458",
      "6493422",
      "32101982"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "739",
    "claim": "MT binding domain drives amyloid structure formation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the seven papers discuss the microtubule\u2010binding (MT\u2010binding) domain driving amyloid structure formation. They cover dynein\u2013MT interactions, Orb2 memory complexes, p53 domains, GluA2 ligand binding, histone H2A docking, follistatin\u2013activin antagonism, and TCR lipid interactions, but none link an MT\u2010binding domain to amyloidogenesis."
    },
    "naive_doc_ids": [
      "1546650",
      "15655418",
      "35684881",
      "7729656",
      "17518195"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the eight provided papers address a microtubule-binding (MT) domain driving amyloid structure formation. They cover dynein microtubule binding, CPEB prion-like oligomerization, p53 domains, TGF-\u03b2 antagonism, TCR lipid interactions, ApoE\u2013A\u03b2 binding, ADAM13\u2013fibronectin interaction, and Piezo1\u2013TFF1 binding, but none report that an MT-binding domain induces or drives amyloid fibril formation."
    },
    "overthinking_doc_ids": [
      "1546650",
      "15655418",
      "35684881",
      "40383969",
      "5914739"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the cited studies report that a microtubule (MT)-binding domain promotes or drives amyloid structure formation. The papers on dynein, EB1/p150Glued, and other MT-interacting proteins detail contact sites, regulatory mechanisms, or subunit assembly, but do not describe amyloidogenesis. Similarly, the amyloid and polyglutamine studies do not implicate MT-binding domains in driving amyloid assembly."
    },
    "posthoc_doc_ids": [
      "1546650",
      "9889151",
      "15655418",
      "15893330",
      "21598000"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1212",
    "claim": "The deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that in chronic HIV infection, sustained monocyte activation via PD-1 induces IL-10 production and impairs CD4+ T cell function, illustrating a deleterious effect of prolonged monocyte activation in a chronic infectious context. Other papers do not provide relevant monocyte data."
    },
    "naive_doc_ids": [
      "10648422",
      "20261352",
      "44562058",
      "5572127",
      "9550981"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly shows that chronic HIV-associated upregulation of PD-1 on monocytes drives IL-10 production and leads to impaired CD4+ T-cell activation, demonstrating a deleterious effect of prolonged monocyte activation in a chronic infection. Paper 3 further outlines how persistent immune activation perpetuates HIV persistence, consistent with harmful consequences of sustained monocyte-driven inflammation."
    },
    "overthinking_doc_ids": [
      "10648422",
      "20261352",
      "44562058",
      "14474178",
      "5572127"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers directly address the deregulated or prolonged activation of monocytes in chronic infectious conditions. While some studies describe chronic inflammation or host inflammatory responses (e.g., iNOS expression in Helicobacter-infected mice), none specifically examine monocyte activation dynamics or link monocyte dysregulation to deleterious outcomes in chronic infection."
    },
    "posthoc_doc_ids": [
      "21700295",
      "18025240",
      "25134146",
      "5035827",
      "12631697"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "962",
    "claim": "Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple studies (Papers 1, 2, 4, and 5) describe discrete mitochondrial RNA granules that concentrate nascent transcripts together with RNA\u2010processing factors (e.g., RNase P, GRSF1, DDX28, FASTKD proteins). These granules are shown to be the sites of tRNA and mRNA maturation, mitochondrial ribosome assembly, and posttranscriptional regulation of mitochondrial gene expression, directly confirming that post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules."
    },
    "naive_doc_ids": [
      "13931771",
      "20018321",
      "13867350",
      "935538",
      "4306711"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Papers 1, 3, and 7 directly demonstrate that discrete mitochondrial RNA granules concentrate nascent mitochondrial transcripts together with processing factors (e.g. RNase P, GRSF1, FASTKD and helicases) and serve as sites for the cleavage, maturation, modification, and ribosome\u2010assembly steps of mitochondrial RNA post\u2010transcriptional handling."
    },
    "overthinking_doc_ids": [
      "13931771",
      "16242975",
      "20018321",
      "1991105",
      "7492250"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Papers 1, 3, and 4 directly demonstrate that key steps of post-transcriptional processing of mitochondrial RNAs (cleavage, modification, ribosome assembly) take place in discrete mitochondrial RNA granules. This aligns with the claim that these granules are sites of post-transcriptional handling of mitochondrial transcripts. Paper 2 addresses mitochondrial tRNA modifications but does not localize them to granules, and Paper 5 is unrelated."
    },
    "posthoc_doc_ids": [
      "13931771",
      "16242975",
      "20018321",
      "935538",
      "13867350"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "840",
    "claim": "Natriuretic peptides increase susceptibility to diabetes.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss natriuretic peptides or their effects on diabetes susceptibility. They focus on obesity, insulin resistance, diets, receptor polymorphisms, immune regulation, sugar intake, nuclear receptors, and sleep, but do not address natriuretic peptides."
    },
    "naive_doc_ids": [
      "120626",
      "195352",
      "5687200",
      "24872571",
      "3127341"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 3 directly investigates the relationship between B\u2010type natriuretic peptide (BNP) levels and incident type 2 diabetes using both prospective data and Mendelian randomization. It finds that higher NT\u2010pro-BNP is associated with a lower risk of T2D (HR \u2248 0.82 per SD increase) and that a BNP\u2010raising genetic variant reduces T2D risk (OR \u2248 0.94 per allele). These results indicate a protective rather than a promoting role of natriuretic peptides in diabetes susceptibility, thus contradicting the claim."
    },
    "overthinking_doc_ids": [
      "1974176",
      "13619127",
      "15663829",
      "120626",
      "195352"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 2 shows that higher B-type natriuretic peptide (BNP) levels are associated with a 21% reduced risk of incident type 2 diabetes per SD increase, and genetic variants raising BNP likewise lower diabetes risk. This protective effect directly opposes the claim that natriuretic peptides increase susceptibility to diabetes. None of the other papers provide evidence on natriuretic peptides."
    },
    "posthoc_doc_ids": [
      "13959707",
      "15663829",
      "43014661",
      "6176498",
      "1974176"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "940",
    "claim": "Pharmacist attendance at ward rounds increases adverse events in wards.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly measures pharmacist participation on ICU rounds and shows a 66% reduction in preventable adverse drug events after the intervention (from 10.4 to 3.5 per 1000 patient\u2010days; P<.001). None of the other studies report that pharmacist attendance increases adverse events; most are unrelated to ward\u2010round pharmacist roles. Therefore the preponderance of relevant evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "12258338",
      "583260",
      "42404093",
      "3578380",
      "21260231"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly addresses pharmacist participation on rounds and finds a 66% reduction in preventable adverse drug events when a pharmacist attends ICU rounds, refuting the claim that pharmacist attendance increases adverse events. None of the other studies provide evidence that pharmacist presence worsens ward safety."
    },
    "overthinking_doc_ids": [
      "12258338",
      "583260",
      "6070278",
      "13906581",
      "20473074"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1 directly studied pharmacist participation on ICU rounds and found a 66% reduction in preventable adverse drug events, indicating that pharmacist attendance decreases rather than increases adverse events. None of the other papers provide evidence that pharmacist ward\u2010round participation raises adverse events."
    },
    "posthoc_doc_ids": [
      "12258338",
      "583260",
      "6070278",
      "42404093",
      "8842332"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1382",
    "claim": "aPKCz causes tumour enhancement by affecting glutamine metabolism.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers discuss atypical PKC\u03b6 (aPKC\u03b6) or its role in modulating glutamine metabolism to promote tumor growth. They cover stromal metabolic coupling, circadian clock effects, specific glutamine pathways in PDAC, glutamine transporters, AMPK\u2013JAK1 signaling, and pH effects via SREBP2, but do not address aPKC\u03b6."
    },
    "naive_doc_ids": [
      "27647593",
      "11968641",
      "3831884",
      "5256564",
      "10169908"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers mention atypical PKC\u03b6 (aPKC\u03b6) or its role in glutamine metabolism. They describe altered glutamine pathways, transporters, and mTORC1 activation in cancer, but do not address aPKC\u03b6\u2019s involvement in tumour enhancement or glutamine metabolism."
    },
    "overthinking_doc_ids": [
      "22914228",
      "3831884",
      "10169908",
      "1196631",
      "1344498"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers mention atypical PKC zeta (aPKC\u03b6) or directly link aPKC\u03b6 activity to tumour enhancement via modulation of glutamine metabolism."
    },
    "posthoc_doc_ids": [
      "5256564",
      "27647593",
      "20501163",
      "10169908",
      "22914228"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "772",
    "claim": "Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that mice vaccinated with EILV/CHIKV produced in mosquito cells generated rapid (within 4 days) and long-lasting (>290 days) neutralizing antibodies and were fully protected, directly refuting the claim that mice cannot produce neutralizing antibodies to mosquito-derived CHIKV."
    },
    "naive_doc_ids": [
      "24922825",
      "991139",
      "7177329",
      "23915841",
      "368506"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 reports that mice immunized with recombinant EILV/CHIKV produced in mosquito cells developed rapid and long-lasting neutralizing antibodies and were fully protected in two mouse models, directly refuting the claim that mice are incapable of producing neutralizing antibodies to mosquito-derived CHIKV."
    },
    "overthinking_doc_ids": [
      "24922825",
      "23915841",
      "643765",
      "343052",
      "9767444"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Paper 1 demonstrates that mice immunized with EILV/CHIKV produced in mosquito cells develop rapid and long\u2010lasting neutralizing antibodies against CHIKV, directly contradicting the claim that mice cannot mount such a response."
    },
    "posthoc_doc_ids": [
      "24922825",
      "13965483",
      "9122283",
      "13469921",
      "7177329"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "657",
    "claim": "Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers investigate signal peptide peptidase (SPP)-mediated intramembrane cleavage. Paper 1 shows that an ER-resident rhomboid intramembrane protease (RHBDL4) promotes ERAD of complex membrane proteins, but it does not address SPP. The remaining papers do not discuss intramembrane proteolysis by signal peptide peptidase or its role in degrading multi-span membrane substrates. Therefore, there is no direct evidence for or against the specific claim about SPP in the provided literature."
    },
    "naive_doc_ids": [
      "8533245",
      "21931005",
      "350542",
      "76776022",
      "600808"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address signal peptide peptidase (SPP)\u2013mediated intramembrane cleavage specifically. Although Paper 1 describes an ER\u2010resident rhomboid intramembrane protease that promotes degradation of single\u2010span and polytopic membrane proteins, it does not involve SPP. The other papers do not discuss intramembrane proteolysis by SPP or its role in degrading complex\u2010oriented membrane proteins."
    },
    "overthinking_doc_ids": [
      "8533245",
      "37643601",
      "1044552",
      "4920376",
      "23195302"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers describe intramembrane cleavage by signal peptide peptidase (SPP) in the degradation of proteins with a complex membrane orientation. While Paper 1 shows that an intramembrane rhomboid protease (RHBDL4) promotes ERAD of single-span and polytopic membrane proteins, it does not involve SPP. The other papers do not address intramembrane proteolysis or SPP, so there is no direct evidence to confirm or refute the claim concerning SPP."
    },
    "posthoc_doc_ids": [
      "8533245",
      "37643601",
      "1044552",
      "21931005",
      "6386930"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1307",
    "claim": "Tonic signaling from the scFv induces constitutive stimulation.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 2 demonstrates that antigen-independent clustering of CAR single-chain variable fragments (scFv) leads to tonic phosphorylation of the CAR CD3-\u03b6 chain and constitutive T cell activation, directly supporting the claim that scFv-mediated tonic signaling induces constitutive stimulation."
    },
    "naive_doc_ids": [
      "4611267",
      "18231807",
      "34016944",
      "2828460",
      "20568364"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly shows that antigen-independent (tonic) clustering of CAR scFvs triggers constitutive CD3-\u03b6 phosphorylation and persistent signaling, supporting the claim."
    },
    "overthinking_doc_ids": [
      "18231807",
      "34016944",
      "20568364",
      "2099400",
      "2714623"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 4 demonstrates that antigen-independent clustering of the CAR single-chain variable fragment (scFv) triggers tonic CD3-\u03b6 phosphorylation and persistent activation (\u2018constitutive stimulation\u2019) of CAR T cells, confirming that tonic signaling from the scFv induces constitutive stimulation."
    },
    "posthoc_doc_ids": [
      "213017",
      "2099400",
      "2825380",
      "18231807",
      "34016944"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "689",
    "claim": "Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers report data on the percentage of patients exposed to radiation who exhibit activated mesenchymal stem cell markers. Consequently, there is no information to support or refute the claim."
    },
    "naive_doc_ids": [
      "3531388",
      "21645205",
      "104130",
      "25238950",
      "8963413"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies report on the proportion of radiation-exposed patients with activated mesenchymal stem cell markers. The papers cover various stem cell types, signaling pathways, cancer contexts, and a radiation response in intestinal crypt cells, but do not address activated MSC markers in radiation-exposed patients or quantify such activation rates."
    },
    "overthinking_doc_ids": [
      "9997636",
      "21645205",
      "25050969",
      "3756384",
      "17021845"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.04,
      "justification": "None of the provided papers report the proportion of radiation\u2010exposed patients who exhibit activation markers of mesenchymal stem cells."
    },
    "posthoc_doc_ids": [
      "25238950",
      "301866",
      "9997636",
      "40164383",
      "5597586"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1289",
    "claim": "There is a relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 is a large nationwide cohort study in Denmark showing that infant exposure to macrolide antibiotics (of which erythromycin is a prototype) in the first two weeks of life is associated with a dramatically increased rate ratio (29.8; 95% CI 16.4\u201354.1) for infantile hypertrophic pyloric stenosis, and that maternal macrolide use in the first 14 days postnatally also increases risk (rate ratio 3.49; 95% CI 1.92\u20136.34). These findings directly support a link between erythromycin use and hypertrophic pyloric stenosis."
    },
    "naive_doc_ids": [
      "21239672",
      "7662395",
      "791050",
      "1044552",
      "2436602"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates a strong association between infant macrolide use (including erythromycin) in the first two weeks after birth and increased risk of infantile hypertrophic pyloric stenosis (adjusted rate ratio 29.8, 95% CI 16.4\u201354.1). Other papers do not address this relationship."
    },
    "overthinking_doc_ids": [
      "21239672",
      "76463821",
      "439670",
      "12869200",
      "750781"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence that use of macrolide antibiotics (including erythromycin) in young infants is strongly associated with infantile hypertrophic pyloric stenosis, with an adjusted rate ratio of 29.8 for use during days 0\u201313 after birth."
    },
    "posthoc_doc_ids": [
      "21239672",
      "2613775",
      "20240998",
      "1831916",
      "2052720"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "54",
    "claim": "AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 7 shows that AMPK activity is diminished in IPF myofibroblasts and that pharmacological activation of AMPK (via metformin) therapeutically accelerates the resolution of established lung fibrosis in a bleomycin mouse model. Furthermore, Paper 4 demonstrates that AMPK activation suppresses inflammatory JAK\u2013STAT signaling. Together, these findings indicate that AMPK activation reduces, rather than increases, inflammation\u2010related fibrosis in the lungs, directly contradicting the claim."
    },
    "naive_doc_ids": [
      "1800734",
      "25175997",
      "31313782",
      "3973445",
      "9752604"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 9 demonstrates that pharmacological activation of AMPK (e.g., with metformin) in a bleomycin-induced lung fibrosis model accelerates resolution of established fibrosis and promotes myofibroblast deactivation and apoptosis. This evidence directly opposes the claim that AMPK activation increases inflammation-related fibrosis in the lungs."
    },
    "overthinking_doc_ids": [
      "1800734",
      "3984231",
      "10703001",
      "27615329",
      "3419709"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 demonstrates that AMPK activation (via metformin) reverses established lung fibrosis in a bleomycin model and that AMPK activity is lower in fibrotic lung regions. Moreover, Paper 6 shows that AMPK activation suppresses inflammatory JAK\u2013STAT signaling. No evidence is presented that AMPK activation increases lung fibrosis; rather, available data indicate an anti-inflammatory, anti-fibrotic role of AMPK in the lung."
    },
    "posthoc_doc_ids": [
      "1800734",
      "26068103",
      "49556906",
      "9899292",
      "1590744"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "964",
    "claim": "Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers directly measure or report the stability of pre-mRNAs in relation to their association with spliceosomal components versus unassociated splicing substrates."
    },
    "naive_doc_ids": [
      "30261663",
      "463533",
      "4067274",
      "8065561",
      "12691537"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers directly measure or compare the stability (decay rates or half-lives) of pre-mRNAs bound by spliceosomal components versus unassociated splicing substrates. While several studies describe recruitment of factors to spliced mRNAs (e.g., eIF4AIII/EJC in Paper 1), coactivators of splicing (Paper 6), spliceosome assembly kinetics (Papers 7 and 10), and methods for quantifying processing steps (Paper 8), none present data on differential pre-mRNA stability contingent on spliceosome association."
    },
    "overthinking_doc_ids": [
      "30261663",
      "7029990",
      "20761364",
      "8065561",
      "45875990"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 3 directly demonstrates that pre-mRNAs synthesized by Pol II with functional splice sites\u2014and thus engaged with spliceosomal components\u2014are protected from nuclear degradation, implying increased stability compared to unassociated transcripts."
    },
    "posthoc_doc_ids": [
      "7029990",
      "2194320",
      "4162857",
      "8065561",
      "31208367"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "233",
    "claim": "Cell autonomous sex determination in somatic cells does not occur in Galliformes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that in chickens (Galliformes) somatic cells possess an inherent, cell-autonomous sex identity, opposing the claim that this mechanism does not occur in Galliformes. Papers 2\u20135 address unrelated topics and provide no additional information on avian somatic sex determination."
    },
    "naive_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "3360421",
      "86129154"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Paper 1 shows that in chicken (a Galliform), avian somatic cells possess an inherent (cell\u2010autonomous) sex identity, directly opposing the claim that cell\u2010autonomous sex determination does not occur in Galliformes. The other papers do not address this phenomenon."
    },
    "overthinking_doc_ids": [
      "4388470",
      "5500086",
      "13651792",
      "3360421",
      "7426741"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 demonstrates that in chickens (a Galliform), avian somatic cells possess an inherent sex identity and undergo cell\u2010autonomous sexual differentiation. This directly contradicts the claim that cell\u2010autonomous sex determination in somatic cells does not occur in Galliformes. The other papers discuss unrelated aspects of somatic reprogramming and epigenetics and do not bear on avian sex determination."
    },
    "posthoc_doc_ids": [
      "4388470",
      "7426741",
      "3360421",
      "15803282",
      "23959496"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1385",
    "claim": "cSMAC formation enhances weak ligand signalling.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 3 shows that enhancing cSMAC formation lowers the stimulatory capacity of a weak agonist peptide, and Paper 4 demonstrates that TCR signaling is sustained in peripheral microclusters and terminated in the cSMAC rather than enhanced there. Both findings oppose the claim that cSMAC formation enhances weak\u2010ligand signaling."
    },
    "naive_doc_ids": [
      "2714623",
      "2825380",
      "306006",
      "9283422",
      "13639330"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 5 directly shows that a weak agonist peptide that fails to form the cSMAC actually elicits stronger T cell proliferation, and experimentally enhancing cSMAC formation reduces the weak peptide\u2019s stimulatory capacity. Paper 4 further demonstrates that signaling is terminated in the cSMAC rather than sustained there. Both findings run counter to the claim that cSMAC formation enhances weak-ligand signaling."
    },
    "overthinking_doc_ids": [
      "994800",
      "4422734",
      "5828251",
      "9283422",
      "306006"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 2 directly shows that enhancing cSMAC formation reduces the stimulatory capacity of a weak agonist peptide, and Paper 4 demonstrates that signaling is terminated in the cSMAC rather than sustained there. Both findings run counter to the claim that cSMAC formation enhances weak ligand signaling. The other papers do not address cSMAC or weak-ligand TCR signaling."
    },
    "posthoc_doc_ids": [
      "8458567",
      "306006",
      "2714623",
      "9283422",
      "6550579"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "277",
    "claim": "Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Paper 1 reports that the Commelina yellow mottle virus genome contains three ORFs encoding proteins of 23, 15 and 216 kD, directly confirming the claim."
    },
    "naive_doc_ids": [
      "14376683",
      "83667891",
      "37677954",
      "39729277",
      "20375264"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 reports that the Commelina yellow mottle virus genome contains three ORFs on the plus strand capable of encoding proteins of 23, 15 and 216 kD, directly confirming the claim."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "21230110",
      "1974176"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly states that the Commelina yellow mottle virus genome contains three ORFs encoding proteins of 23, 15 and 216 kD, exactly matching the claim. None of the other papers address this virus or its ORFs."
    },
    "posthoc_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "7488455",
      "11784947"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "994",
    "claim": "Pyridostatin encourages proliferation of homologous recombination - defective cells.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 shows that treatment with the G4-stabilizing compound pyridostatin (PDS) reduces proliferation of homologous recombination\u2013defective (BRCA-deficient) cells by inducing DNA damage, checkpoint activation, and replication defects. This directly opposes the claim that pyridostatin encourages proliferation of HR-defective cells."
    },
    "naive_doc_ids": [
      "2356950",
      "6710699",
      "12086599",
      "16472469",
      "9394119"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 7 directly tests pyridostatin (PDS), showing that PDS reduces proliferation and viability of homologous recombination\u2013defective cells by inducing DNA damage, checkpoint activation, and telomere instability, rather than encouraging their proliferation. This evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "6710699",
      "12086599",
      "13283919",
      "982650",
      "4444861"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 7 directly tests pyridostatin (PDS) on HR\u2010defective cells and finds that PDS \u2018reduces proliferation of HR\u2010defective cells by inducing DSB accumulation\u2026\u2019 rather than promoting their growth. This evidence directly contradicts the claim that pyridostatin encourages proliferation of HR\u2010defective cells."
    },
    "posthoc_doc_ids": [
      "13791206",
      "6710699",
      "1550937",
      "10169908",
      "32852283"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "676",
    "claim": "LRBA prevents CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers discuss LRBA or its role in CTLA-4 recycling. Although Paper 3 addresses CTLA-4 in the context of T cell trafficking, it does not mention LRBA or CTLA-4 recycling, and the other papers focus on unrelated proteins and pathways."
    },
    "naive_doc_ids": [
      "17017465",
      "11250124",
      "2462673",
      "9185195",
      "14405193"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.08,
      "justification": "None of the provided papers discuss LRBA or CTLA-4 trafficking or recycling; they cover unrelated proteins and pathways (synaptic vesicle recycling, VEGFR-2, NMDARs, mitochondrial aging, etc.) and thus provide no evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "11250124",
      "14893425",
      "797114",
      "9185195",
      "14405193"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers mention LRBA or CTLA-4 or their recycling pathways, so there is no relevant information to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "9814332",
      "11250124",
      "14893425",
      "5531479",
      "22317868"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "368",
    "claim": "Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly evaluates early PDA screening before day 3 and finds a lower in-hospital mortality rate in the screened group (14.2% vs. 18.5%; OR 0.73), indicating a protective effect rather than an increase in mortality. The other papers address PDA treatment modalities rather than screening and do not provide evidence that early screening raises mortality. Thus the evidence refutes the claim."
    },
    "naive_doc_ids": [
      "27099731",
      "9967265",
      "34544514",
      "25612629"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1\u2014the only study that directly examines the impact of early PDA screening on in-hospital mortality\u2014found that screening echocardiography before day 3 was associated with a lower death rate (14.2% vs. 18.5%, OR 0.73) rather than an increase in mortality."
    },
    "overthinking_doc_ids": [
      "27099731",
      "11880289",
      "36355784",
      "9967265",
      "25691541"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses early PDA screening and in-hospital mortality, finding that infants screened before day 3 had a lower death rate (14.2% vs 18.5%, OR 0.73, 95% CI 0.54\u20130.98). No other study supports an increase in mortality with early screening."
    },
    "posthoc_doc_ids": [
      "27099731",
      "9967265",
      "25612629",
      "34544514",
      "11880289"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "764",
    "claim": "Medications to treat obesity are highly effective.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The only directly relevant paper (Paper 1: meta\u2010analysis of approved anti\u2010obesity pharmacotherapy) found that orlistat, sibutramine, and rimonabant produce only modest additional weight loss (2.9\u20134.7 kg over placebo in one year) and a higher likelihood of achieving 5\u201310% weight loss. This level of efficacy is far from \u201chighly effective,\u201d and the study authors themselves describe the reductions as modest. No other paper provides stronger evidence of highly effective obesity medications."
    },
    "naive_doc_ids": [
      "7552215",
      "5402581",
      "4515975",
      "120626",
      "10463997"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "The two papers addressing pharmacotherapy for weight loss (oral semaglutide in paper 1 and the meta-analysis of orlistat, sibutramine, and rimonabant in paper 4) report only modest average weight reductions (2\u20137 kg over 6\u201312 months). These effect sizes do not support the notion that obesity medications are \u2018highly\u2019 effective."
    },
    "overthinking_doc_ids": [
      "3654468",
      "5824985",
      "21479231",
      "7552215",
      "1831916"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "None of the provided studies report strong clinical trial data showing that obesity drugs produce large, sustained weight losses. The clinical\u2010practice cohort on bariatric surgery (Paper 4) affirms that surgery\u2014not medication\u2014is highly effective. The review of anti\u2010obesity drugs (Paper 9) emphasizes that approved agents yield only modest weight loss, have redundant metabolic pathways, and face safety hurdles. Preclinical work on brown fat (Paper 8) points to future potential but no current, highly effective pharmacotherapies. Therefore, the evidence does not support, and in fact undermines, the claim that medications for obesity are highly effective."
    },
    "posthoc_doc_ids": [
      "341324",
      "19071857",
      "21479231",
      "5824985",
      "11360768"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1387",
    "claim": "eRNAs influence is linked to senescence, aging, and carcinogenesis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided studies address enhancer RNAs (eRNAs). They focus on microRNAs (miR-29), transcription factors (p53, p16INK4A), the senescence-associated secretory phenotype, adipocyte activation, ERK/MYC in cancer, systemic factors in stem cell ageing, C/EBP in adipocytes, or bone marrow progenitors. No experimental data or discussion pertains to eRNAs or their role in senescence, aging, or carcinogenesis."
    },
    "naive_doc_ids": [
      "4653837",
      "6896063",
      "19343151",
      "17412260",
      "2130391"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers address enhancer RNAs (eRNAs) or their roles. While they discuss microRNAs, p53 biology, circadian regulation, and other factors in senescence, aging, and carcinogenesis, there is no direct information on eRNAs influencing these processes."
    },
    "overthinking_doc_ids": [
      "4653837",
      "35543846",
      "6896063",
      "2547636",
      "37204802"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss or provide data on enhancer RNAs (eRNAs); they cover microRNAs, p53, p16, metabolic changes, autophagy, and Wnt signaling but do not address eRNA roles in senescence, aging, or carcinogenesis."
    },
    "posthoc_doc_ids": [
      "4653837",
      "35543846",
      "6896063",
      "17717391",
      "4920376"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "611",
    "claim": "Increased lipolysis leads to higher P38 phosphorylation in adipose tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers demonstrates that increased lipolysis per se drives p38 MAPK phosphorylation in adipose tissue. While Paper 4 links nicotine\u2010induced AMPK\u03b12 activation and MKP1 degradation to p38 activation and also shows nicotine promotes lipolysis, it positions p38 phosphorylation upstream of, not downstream from, lipolysis. No study here provides direct evidence that raising lipolytic flux causes increased p38 phosphorylation in adipose tissue."
    },
    "naive_doc_ids": [
      "3621011",
      "39187170",
      "40232172",
      "32408470",
      "4662264"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies report that increasing lipolysis per se elevates p38 phosphorylation in adipose tissue. Paper 5 describes p38 activation upstream of (and thus driving) lipolysis under nicotine exposure rather than lipolysis causing p38 phosphorylation, and the other papers do not address this relationship."
    },
    "overthinking_doc_ids": [
      "3621011",
      "39187170",
      "40232172",
      "17933691",
      "32408470"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided studies report that experimentally increasing lipolysis drives p38 MAPK phosphorylation in adipose tissue. Paper 4 describes the reverse relationship (nicotine-induced p38 activation leading to increased lipolysis), but does not show that lipolysis itself induces p38 phosphorylation. No other paper addresses lipolysis-driven p38 activation."
    },
    "posthoc_doc_ids": [
      "3621011",
      "79447",
      "1568684",
      "32408470",
      "7875158"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "813",
    "claim": "Mutations in G-Beta protein GNB1 are present in many cancers, resulting in loss of interaction with G-alpha subunits and concomitant activation of AKT pathway.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.16,
      "justification": "None of the provided papers discuss GNB1 (the G-beta subunit), its mutations in cancer, G-alpha subunit binding, or downstream AKT pathway activation. Therefore, there is no relevant information to support or contradict the claim."
    },
    "naive_doc_ids": [
      "21164071",
      "14241418",
      "207972",
      "22036571",
      "24294572"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers discuss GNB1 (the G-beta subunit), its mutations in cancer, G-alpha interactions, or consequent AKT pathway activation. Therefore, there is no relevant evidence to support or refute the claim."
    },
    "overthinking_doc_ids": [
      "13916484",
      "16745747",
      "14241418",
      "18682109",
      "35684881"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 directly demonstrates that recurrent GNB1 mutations in human tumors disrupt the G\u03b1\u2013G\u03b2 interface and activate downstream signaling that is sensitive to PI3K\u2013mTOR inhibition (which includes the AKT pathway). No other paper addresses GNB1 mutations in cancer."
    },
    "posthoc_doc_ids": [
      "16745747",
      "3590806",
      "14019636",
      "33387953",
      "13411519"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "516",
    "claim": "High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 1 directly addresses CRP levels in stable COPD and finds that higher CRP (along with other biomarkers) predicts an increased, not decreased, risk of exacerbations (multivariable-adjusted ORs and HRs >1). No paper shows high CRP lowering exacerbation risk; thus the claim is refuted."
    },
    "naive_doc_ids": [
      "29564505",
      "3580005",
      "18988265",
      "21048969",
      "3801693"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided studies address the relationship between C-reactive protein levels and risk of COPD exacerbations. Paper 1 examines CRP as a predictor of peripheral arterial disease, and the other papers focus on cardiovascular genetics, anticoagulant levels, cardiac amyloidosis imaging, tumor markers in cervical cancer, or KRAS mutations in lung cancer, with no data on CRP and COPD exacerbations."
    },
    "overthinking_doc_ids": [
      "72933407",
      "3868322",
      "4910408",
      "13768432",
      "14664424"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 7 directly addresses baseline CRP levels in stable COPD and reports that higher CRP is associated with an increased\u2014not decreased\u2014risk of future exacerbations. No other paper provides evidence that high CRP lowers exacerbation risk."
    },
    "posthoc_doc_ids": [
      "4910408",
      "6327940",
      "3580005",
      "25319221",
      "40935722"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1345",
    "claim": "Up-regulation of the p53 pathway and related molecular events speeds cancer progression.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 7 demonstrates that tumor-derived \u2018gain-of-function\u2019 p53 mutants drive tumorigenicity in vivo: the intact p53-281G mutant promotes tumor formation in nude mice, whereas deletion of its oligomerization/ nucleic-acid binding domains abolishes this effect. Thus, up-regulated/mutant p53 activity accelerates cancer progression, supporting the claim that activation of p53-related molecular events can speed tumor growth."
    },
    "naive_doc_ids": [
      "6944800",
      "12650610",
      "33638477",
      "24974080",
      "7795952"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address the p53 pathway or its up-regulation in cancer progression. Therefore, there is no relevant evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "3831884",
      "4820792",
      "12650610",
      "1686997",
      "12948892"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the nine papers discuss the p53 pathway or its up-regulation in the context of speeding cancer progression. They focus on other pathways (e.g. PI3K/AKT/mTOR, integrin/FAK, splicing factors, VEGF, 6PGD/AMPK, STIM1/Ca2+ signaling, Wnt/BCL9, etc.) without addressing p53 up-regulation or its effects on tumor progression."
    },
    "posthoc_doc_ids": [
      "13256155",
      "4820792",
      "4889228",
      "7736860",
      "24974080"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "594",
    "claim": "Incidence of heart failure increased by 10% in women since 1979.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1, which tracks heart failure incidence from 1979\u20132000 in a community cohort, reports that the incidence did not change over time in women. This directly contradicts the claim of a 10% increase in incidence among women since 1979."
    },
    "naive_doc_ids": [
      "19675911",
      "12206390",
      "13481731",
      "195680777"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 reports that over the period 1979\u20132000, the incidence of heart failure did not change over time among women (and men), directly contradicting the claim of a 10% increase in incidence in women since 1979. No other paper provides evidence of a rising HF incidence in women over that period."
    },
    "overthinking_doc_ids": [
      "19675911",
      "20945963",
      "31889025",
      "12206390",
      "4824840"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1, the only study reporting sex\u2010specific temporal trends in heart failure incidence from 1979 to 2000, found that incidence did not change over time among women (and men). Therefore, there is no evidence of a 10% increase in incidence in women since 1979; the claim is refuted."
    },
    "posthoc_doc_ids": [
      "19675911",
      "4445629",
      "12206390",
      "7419612",
      "4791384"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "645",
    "claim": "Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "All trials report that folic acid supplementation (often with vitamin B6 and B12) significantly lowers serum or plasma homocysteine rather than increasing it (Papers 1\u20136). No study shows an increase in homocysteine with FA or VB6 intake."
    },
    "naive_doc_ids": [
      "11705328",
      "21636085",
      "37424881",
      "10557471",
      "18557974"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "All four trials consistently show that folic acid (and when combined with vitamin B6 in one study) lowers plasma homocysteine levels rather than raising them. Paper 1 reports dose-dependent decreases in homocysteine with folic acid doses up to 0.8 mg/day. Paper 2 finds a 25.8% reduction in homocysteine with high\u2010dose folic acid and B6. Paper 3 shows significant homocysteine reductions at 400 \u00b5g and 600 \u00b5g folic acid. The meta-analysis in Paper 4 likewise documents homocysteine lowering with folic acid supplementation. None of the studies reports any increase in homocysteine from folic acid or B6 intake, directly contradicting the claim."
    },
    "overthinking_doc_ids": [
      "11705328",
      "33409100",
      "21636085",
      "37424881"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "All five trials consistently show that folic acid\u2014with or without vitamin B6\u2014lowers plasma or serum homocysteine levels rather than increasing them. For example, Papers 1 and 2 report dose\u2010dependent reductions in homocysteine with folic acid (up to 23\u201326% lowering), and Paper 5 shows a 25.8% reduction in homocysteine when folic acid and B vitamins were given. None of the studies find an increase in homocysteine with FA or VB6 intake."
    },
    "posthoc_doc_ids": [
      "21636085",
      "11705328",
      "37424881",
      "5152028",
      "33409100"
    ],
    "posthoc_metadata": {
      "initial_confidence": 1.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1058",
    "claim": "Roughly 55% of women with chronic pelvic pain have no underlying pathology.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.25,
      "justification": "None of the provided studies report the proportion of all women with chronic pelvic pain who have no identifiable pathology. Paper 1 restricted enrolment to women with minimal or no disease but does not estimate that prevalence in the broader chronic pelvic pain population, and the other papers address different conditions."
    },
    "naive_doc_ids": [
      "13027590",
      "13934676",
      "8570317",
      "32462603",
      "463533"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies report the proportion of women with chronic pelvic pain who have no underlying pelvic pathology. The uterosacral nerve ablation trial (Paper 1) enrolled only women with no or minimal endometriosis or adhesions but does not break down what fraction had absolutely no pathology, and none of the other papers address this epidemiologic statistic."
    },
    "overthinking_doc_ids": [
      "13027590",
      "3190689",
      "14724693",
      "5735492",
      "32462603"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided studies report the proportion of women with chronic pelvic pain who have no underlying pathology, nor do they present data supporting or refuting a ~55% figure."
    },
    "posthoc_doc_ids": [
      "13027590",
      "3190689",
      "13934676",
      "14724693",
      "463533"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "278",
    "claim": "Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 reports that the complete genome of Commelina yellow mottle virus (CoYMV) is 7489 bp, which directly contradicts the claim that it is only 2140 bp. None of the other papers provide a supporting genome size for ComYMV."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "152245",
      "20375264"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 reports that the complete genome of Commelina yellow mottle virus is 7489 bp in size, directly refuting the claim that its genome consists of 2140 bp."
    },
    "overthinking_doc_ids": [
      "32770503",
      "152245",
      "8712839",
      "14376683",
      "83667891"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 reports that the complete genome of Commelina yellow mottle virus is 7489 base pairs long, which directly contradicts the claim of a 2140 base\u2010pair genome. None of the other provided studies support a 2140 bp genome size."
    },
    "posthoc_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "32770503",
      "41811327"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "776",
    "claim": "Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report experiments on mice lacking DNA polymerase \u03bc (pol \u03bc) and their sensitivity to ionizing radiation. Paper 6 characterizes pol \u03bc\u2019s role in IR-induced foci and end\u2010joining in cell extracts, but does not assess pol \u03bc-deficient mice or their IR response. The other papers do not address pol \u03bc. Hence, there is no information relevant to the claim."
    },
    "naive_doc_ids": [
      "31293581",
      "5572127",
      "11569583",
      "10017612",
      "12552297"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.09,
      "justification": "None of the provided papers discuss DNA polymerase \u03bc (polm) or mice lacking polm and their response to ionizing radiation. The studies address different DNA polymerases, radiation responses, and genetic deficiencies, but polm-deficient mice and their IR sensitivity are not covered."
    },
    "overthinking_doc_ids": [
      "11569583",
      "31293581",
      "52805891",
      "712078",
      "5572127"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss DNA polymerase \u03bc (polm) or analyze IR sensitivity in polm-deficient mice."
    },
    "posthoc_doc_ids": [
      "11569583",
      "31293581",
      "52805891",
      "5572127",
      "43014661"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "662",
    "claim": "JMJD6 slows the hydroxylation of C-terminal lysine",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 demonstrates that JMJD6 functions as an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase, catalyzing hydroxylation of p53 at lysine 382 (a C-terminal lysine), which directly contradicts the claim that JMJD6 slows hydroxylation of C-terminal lysine."
    },
    "naive_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "18841257",
      "864491"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 demonstrates that JMJD6 functions as an Fe(II)- and \u03b1-ketoglutarate\u2013dependent lysyl hydroxylase that directly catalyzes hydroxylation of p53 on lysine 382\u2014in other words, JMJD6 accelerates rather than slows C-terminal lysine hydroxylation. None of the other papers describe JMJD6 acting to inhibit hydroxylation."
    },
    "overthinking_doc_ids": [
      "37204802",
      "365896",
      "2613813",
      "8548635",
      "12172346"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 shows that JMJD6 functions as an Fe(II)/\u03b1-ketoglutarate\u2013dependent lysyl hydroxylase that catalyzes hydroxylation of lysine 382 in p53, i.e., JMJD6 promotes rather than slows C-terminal lysine hydroxylation. No other papers report inhibition of lysine hydroxylation by JMJD6."
    },
    "posthoc_doc_ids": [
      "37204802",
      "18841257",
      "2582169",
      "12172346",
      "12588500"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "899",
    "claim": "Oxidative DNA damage inhibits STING signalling.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 shows that oxidative DNA damage (8-OHG) actually potentiates STING-dependent immune sensing by protecting cytosolic DNA from TREX1 degradation, i.e. it enhances rather than inhibits STING signaling. None of the other papers present evidence that oxidative DNA damage inhibits STING."
    },
    "naive_doc_ids": [
      "13106686",
      "19688024",
      "4795303",
      "3107733",
      "4402497"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly shows that oxidative modification of DNA (8-OHG) potentiates STING-dependent immune sensing by protecting DNA from TREX1 degradation, which is the opposite of inhibition of STING signaling."
    },
    "overthinking_doc_ids": [
      "13106686",
      "213017",
      "1686997",
      "19688024",
      "6690087"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 shows that oxidative DNA damage (8-OHG) potentiates rather than inhibits STING-dependent immune sensing by protecting DNA from TREX1 degradation and enhancing type I IFN responses. No other paper reports oxidative damage impairing STING signaling, so the available evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "13106686",
      "1686997",
      "213017",
      "19688024",
      "6690087"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "474",
    "claim": "Glycan adaptation is rarely observed in the B-cell repertoire.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the cited studies examine glycan remodeling or glycan\u2010based adaptation within the B\u2010cell receptor repertoire. The papers focus on T\u2010cell selection, TCR diversity, pioneer transcription factors, pre\u2013BCR checkpoint biology, TG2\u2010specific autoantibodies (with limited somatic hypermutation but no glycan analysis), and germinal\u2010center tolerance mechanisms, but do not report data on glycan adaptation in B cells."
    },
    "naive_doc_ids": [
      "8354687",
      "27910499",
      "4896726",
      "34254203",
      "20457190"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address the frequency of glycan adaptation in the B-cell repertoire. They cover topics such as somatic mutation in anti-TG2 plasma cells (Paper 1), HIV-1 envelope glycosylation (Paper 4), antigen transport by macrophages (Paper 5), and various transcriptional or structural studies, but none present data on B-cell glycan adaptation."
    },
    "overthinking_doc_ids": [
      "1471041",
      "4896726",
      "8354687",
      "2601135",
      "9705208"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the eight papers address glycan adaptation in the B-cell repertoire. Their topics cover pioneer factors, Aire-mediated T-cell selection, LAR phosphatase in T cells, lncRNAs in lymphoid progenitors, GPI-anchor roles in hESC trophoblast differentiation, NK-cell receptors in AML, pre-B-cell receptor selection, and T-cell repertoire recovery after HSCT, but none discuss glycan adaptation in B cells."
    },
    "posthoc_doc_ids": [
      "4896726",
      "8354687",
      "21392223",
      "1667063",
      "11335860"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "614",
    "claim": "Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that boosting microtubule acetylation (via HDAC6/Sirt2 knockdown, \u03b1TAT1 overexpression, or TSA treatment) prevents mutant LRRK2 from binding deacetylated microtubules and restores axonal transport and locomotor function in neurons and Drosophila. No other paper addresses this specific mechanism."
    },
    "naive_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "18678095",
      "18078750"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that increasing microtubule acetylation (via HDAC6/Sirt2 knockdown or TSA/\u03b1TAT1) prevents mutant LRRK2 binding to microtubules and restores axonal transport and locomotor function in both neurons and Drosophila models of Roc-COR domain mutations. None of the other papers address LRRK2-related axonal transport or microtubule acetylation in this context."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "18678095",
      "20743803"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that pathogenic LRRK2 Roc-COR mutations inhibit axonal transport by binding to deacetylated microtubules and that pharmacological or genetic interventions that increase tubulin acetylation (e.g. TSA treatment, \u03b1TAT1 overexpression, or HDAC6/Sirt2 knockdown) prevent mutant LRRK2\u2013microtubule association and restore both axonal transport and locomotor function. No other paper contradicts this mechanism."
    },
    "posthoc_doc_ids": [
      "9638032",
      "41644178",
      "5484763",
      "28369117",
      "1546650"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "35",
    "claim": "A deficiency of vitamin B12 decreases blood levels of homocysteine.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address vitamin B12 status or its direct effect on homocysteine levels. The trial data refer to folic acid or other nutrients, but no study examines B12 deficiency and homocysteine in the blood."
    },
    "naive_doc_ids": [
      "21636085",
      "8595678",
      "38551172",
      "5785219",
      "2481032"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 2 shows that supplementation with cyanocobalamin (vitamin B12), along with folic acid and B6, lowers plasma homocysteine levels (a 25.8% reduction; P < .001). This indicates that vitamin B12 sufficiency reduces homocysteine, so by converse a deficiency would not decrease but rather allow homocysteine to rise, contradicting the claim."
    },
    "overthinking_doc_ids": [
      "21636085",
      "33409100",
      "3150030",
      "9555784",
      "3222187"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided trials examine the effect of vitamin B12 deficiency per se on homocysteine levels.  They study folate supplementation (Papers 1, 2, 4) or combined B-vitamin supplementation including B12 (Paper 3), all of which show that adding these vitamins lowers homocysteine.  They do not report data on B12 deficiency and its direct impact on homocysteine."
    },
    "posthoc_doc_ids": [
      "11705328",
      "21636085",
      "33409100",
      "18557974",
      "520579"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "823",
    "claim": "N348I mutations cause resistance to zidovudine (AZT).",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that the N348I mutation in the HIV-1 RT connection domain decreases zidovudine (AZT) susceptibility by 2\u20134-fold in vitro and is selected in patients on AZT-containing regimens, providing clear evidence that N348I confers resistance to zidovudine."
    },
    "naive_doc_ids": [
      "15319019",
      "25014337",
      "2319305",
      "4688277",
      "5431268"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that the N348I mutation in the connection domain of HIV-1 RT decreases zidovudine (AZT) susceptibility by 2\u20134-fold in both wild-type and TAM backgrounds, confirming that N348I confers AZT resistance. None of the other papers contradict this finding."
    },
    "overthinking_doc_ids": [
      "15319019",
      "2319305",
      "120626",
      "85665741",
      "6426919"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that the N348I connection-domain mutation reduces zidovudine (AZT) susceptibility by 2\u20134-fold in both wild-type and TAM-containing HIV-1, confirming that N348I confers AZT resistance. The other provided studies do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "15319019",
      "2319305",
      "6426919",
      "25014337",
      "34066665"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "871",
    "claim": "Obesity decreases life quality.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies assess the impact of obesity (or high body-mass index) on health-related quality of life or healthy life expectancy. They focus on chronic diseases, binge eating disorder, leukemia, crowding stress, heart failure, DALYs/HALE in general, ICU outcomes, and statin cost-effectiveness, but do not report data on obesity\u2019s effect on quality of life."
    },
    "naive_doc_ids": [
      "463533",
      "40666943",
      "42913391",
      "36211049",
      "37029185"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided studies directly examine the relationship between obesity per se and overall quality of life. While several papers assess quality of life in other chronic conditions or factors (e.g., cardiovascular disease, glaucoma, mental health, binge eating disorder), and one reports symptom severity in obese subjects, none quantify or compare quality\u2010of\u2010life measures in obese versus non\u2010obese individuals."
    },
    "overthinking_doc_ids": [
      "26199970",
      "463533",
      "40666943",
      "4688277",
      "7547329"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies examine obesity and its direct impact on quality of life. The papers address visual field loss in glaucoma, health literacy in ischemic heart disease, angiotensin blockade, various chronic conditions, binge\u2010eating disorder, leukemia treatment, prebiotic effects in rats, household crowding, and exercise in dementia, but do not report data on obesity reducing life quality."
    },
    "posthoc_doc_ids": [
      "31208367",
      "17693849",
      "26199970",
      "463533",
      "40666943"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1174",
    "claim": "The PPR MDA5 has twenty N-terminal CARD domains.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss the number of N-terminal CARD domains in PPR MDA5; they do not address MDA5\u2019s domain architecture."
    },
    "naive_doc_ids": [
      "26011884",
      "3610282",
      "4828984",
      "14474178",
      "15893330"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the six provided papers report on the number of N-terminal CARD domains in the MDA5 protein. They either do not discuss MDA5 at all or, in the case of Paper 6, only refer to its role as an RNA sensor without detailing its domain architecture."
    },
    "overthinking_doc_ids": [
      "12149169",
      "31387717",
      "56486733",
      "207972",
      "1791637"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss the protein MDA5, its domain architecture, or the number of N-terminal CARD domains; they focus on unrelated proteins and domains."
    },
    "posthoc_doc_ids": [
      "26011884",
      "612002",
      "24550453",
      "31387717",
      "4427060"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "298",
    "claim": "Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly document cytochrome c release from the mitochondrial intermembrane space into the cytosol as a hallmark of apoptosis. For example, Paper 2 reports \u2018release of cytochrome c from the mitochondria into the cytosol and subsequent activation of caspase-3\u2019 during vascular smooth muscle cell apoptosis, Paper 3 describes cytochrome c release in p53-mediated gastric epithelial cell apoptosis, and Paper 8 demonstrates cytochrome c release concomitant with caspase-3 activation in neurons undergoing ouabain-induced apoptosis. Paper 1 also refers to IMS proteins (including cytochrome c) being released to the cytosol during programmed cell death. These findings collectively support the claim."
    },
    "naive_doc_ids": [
      "23403754",
      "9588931",
      "7465900",
      "23887844",
      "29367554"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers (e.g., Paper 2 and Paper 3) directly describe release of cytochrome c from the mitochondrial intermembrane space into the cytosol as part of the apoptotic cascade. Paper 2 reports mitochondria-dependent apoptosis \u2018including release of cytochrome c from the mitochondria into the cytosol and subsequent activation of caspase-3,\u2019 and Paper 3 notes \u2018p53-mediated apoptosis involves \u2026 cytochrome c release from mitochondria,\u2019 confirming the claim."
    },
    "overthinking_doc_ids": [
      "23403754",
      "9588931",
      "7465900",
      "8654183",
      "23887844"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Multiple studies explicitly report release of cytochrome c from the mitochondrial intermembrane space to the cytosol during apoptosis. For example, Paper 1 demonstrates mitochondrial-dependent apoptosis in VSMCs with \u2018release of cytochrome c from the mitochondria into the cytosol and subsequent activation of caspase\u20103.\u2019 Paper 4 notes involvement of cytochrome c release in H. pylori\u2013induced apoptosis. Paper 6 shows that OPA1-dependent cristae remodeling \u2018blunts mitochondrial dysfunction, cytochrome c release, and reactive oxygen species production\u2019 in apoptotic tissues. These findings confirm the claim."
    },
    "posthoc_doc_ids": [
      "9588931",
      "23403754",
      "43054703",
      "8654183",
      "10698739"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "310",
    "claim": "De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers compare the number of specific contigs obtained before and after de novo assembly. While Paper 1 and Paper 3 discuss de novo assembly, neither quantifies or contrasts \u201cspecific contigs\u201d in assembled versus unassembled data, and the other papers are on unrelated topics. Therefore there is no evidence here to support or contradict the claim."
    },
    "naive_doc_ids": [
      "14464451",
      "6535392",
      "6173523",
      "143251",
      "19140422"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers directly compare the number of contigs obtained by de novo assembly to the number of (raw or \u2018unassembled\u2019) sequence units; they discuss assembly quality, GC bias, contig counts within assemblies, or unrelated topics, but do not address the specific claim that de novo assembly yields fewer contigs than unassembled data."
    },
    "overthinking_doc_ids": [
      "14464451",
      "143251",
      "1616661",
      "45341480",
      "19140422"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers directly compare the number of specific contigs obtained by de novo assembly versus those present in unassembled sequence data. They discuss assembly completeness, fragmentation, and metagenomics applications, but do not report contig counts for unassembled reads versus assembled contigs."
    },
    "posthoc_doc_ids": [
      "14464451",
      "6173523",
      "4407385",
      "22123421",
      "143251"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "744",
    "claim": "Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that Ras-transformed cells internalize extracellular protein via macropinocytosis, degrade it in lysosomes, and liberate amino acids (including glutamine) to fuel central carbon metabolism. Paper 4 further shows that lysosomal degradation of macropinocytosed protein sustains cell survival by providing essential amino acids. Together these findings confirm that macropinocytosis contributes to a cell\u2019s amino acid supply through intracellular uptake and proteolysis of protein."
    },
    "naive_doc_ids": [
      "4138659",
      "3845894",
      "3105781",
      "8460275",
      "2582169"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that Ras-transformed cells internalize extracellular protein via macropinocytosis, degrade it into amino acids (including glutamine), and use these to fuel central carbon metabolism, thereby confirming that macropinocytosis contributes to a cell\u2019s amino acid supply. The other papers do not address this mechanism."
    },
    "overthinking_doc_ids": [
      "4138659",
      "3845894",
      "4231060",
      "4959368",
      "12207167"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that Ras-transformed cells internalize extracellular protein via macropinocytosis, proteolytically degrade it to release amino acids (e.g., glutamine), and that inhibiting macropinocytosis impairs tumor growth, thereby confirming that macropinocytosis supplies amino acids via protein uptake."
    },
    "posthoc_doc_ids": [
      "4138659",
      "3845894",
      "4231060",
      "28724565",
      "20183360"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "747",
    "claim": "MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers mention MafA or its ubiquitination, nor do they address the recruitment of P/CAF by MafA. Therefore, there is no relevant information to support or contradict the claim."
    },
    "naive_doc_ids": [
      "502591",
      "2714623",
      "4854076",
      "8093935",
      "9486930"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "Only Paper 7 addresses MafA, ubiquitination, and P/CAF. It shows that GSK-3\u2013dependent phosphorylation induces both MafA ubiquitination and increased recruitment of P/CAF, and that P/CAF binding protects MafA from ubiquitination. Thus, ubiquitination does not decrease P/CAF recruitment; rather, P/CAF binding and ubiquitination are inversely related in the opposite direction to the claim."
    },
    "overthinking_doc_ids": [
      "23513818",
      "21307488",
      "24725136",
      "22036571",
      "12217662"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 directly addresses MafA ubiquitination and P/CAF recruitment. It reports that GSK-3\u2013mediated phosphorylation leads to MafA ubiquitination yet paradoxically enhances MafA\u2019s transcriptional activity via increased recruitment of P/CAF, and that P/CAF in turn protects MafA from ubiquitination. Thus, ubiquitination does not decrease, but rather promotes, coactivator P/CAF recruitment, refuting the claim."
    },
    "posthoc_doc_ids": [
      "22495397",
      "3701541",
      "11291348",
      "29429111",
      "778436"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1041",
    "claim": "Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "None of the cited yeast studies report that H2A.Z\u2010containing nucleosomes slow activation by stabilizing the +1 nucleosome.  In fact, structural data (Paper 6) show that H2A.Z incorporation subtly weakens the dimer\u2013tetramer interface, and genome-wide dynamics (Paper 7) reveal that Htz1-bearing nucleosomes are more labile and are lost more readily upon activation.  No paper provides evidence that H2A.Z stabilizes +1 nucleosomes to slow gene activation; rather, they support a model in which H2A.Z poises promoters for rapid activation through increased nucleosome turnover."
    },
    "naive_doc_ids": [
      "15778034",
      "23305884",
      "18895793",
      "9451052",
      "8331432"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers directly address the effect of H2A.Z replacement on the rate of gene activation via stabilization of +1 nucleosomes. While Paper 2 and Paper 4 discuss the genomic localization and stepwise incorporation of H2A.Z at promoters, and Paper 3 describes nucleosome removal kinetics by activators, none present experimental data measuring slowed activation kinetics in yeast attributable to H2A.Z-stabilized +1 nucleosomes."
    },
    "overthinking_doc_ids": [
      "23305884",
      "15778034",
      "18895793",
      "9451052",
      "16686383"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "None of the cited studies report that H2A.Z incorporation slows gene activation by stabilizing +1 nucleosomes. In fact, Paper 5 shows that Htz1 (yeast H2A.Z)\u2013containing nucleosomes are more susceptible to loss and thereby facilitate promoter exposure and full gene activation. Paper 2 likewise portrays H2A.Z as configuring promoter nucleosomes to poise genes for activation. No experimental data in these papers indicate that H2A.Z stabilizes the +1 nucleosome to slow activation; instead, they describe H2A.Z as making promoter nucleosomes more dynamic and amenable to removal, which is opposite to the claim."
    },
    "posthoc_doc_ids": [
      "9451052",
      "15778034",
      "18895793",
      "13639330",
      "16626264"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "422",
    "claim": "Flexible molecules experience less steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers address the relative steric hindrance of flexible versus rigid molecules within the tumor microenvironment or provide data on molecular flexibility affecting transport or interactions in tumors."
    },
    "naive_doc_ids": [
      "952111",
      "1522336",
      "2734421",
      "30919024",
      "1067605"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address the relationship between molecular flexibility and steric hindrance of small molecules within the tumor microenvironment. They focus on cellular components, signaling pathways, circulating tumor cells, oxidative stress, stromal subtypes, and protein structures in contexts unrelated to the specific claim about flexible versus rigid molecule diffusion or steric hindrance in tumors."
    },
    "overthinking_doc_ids": [
      "952111",
      "2734421",
      "21033230",
      "6650933",
      "7228140"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.05,
      "justification": "None of the provided papers address the relationship between molecular flexibility or rigidity and steric hindrance in the tumor microenvironment. They focus on cellular and extracellular matrix stiffness, signaling pathways, stromal interactions, and other aspects of tumor biology, but do not present data on molecular conformational flexibility and steric hindrance effects."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "21033230",
      "30919024"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "939",
    "claim": "Persistor cells are one reason for incomplete responses to Tyrosine kinase inhibitor (TKI) therapy in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.72,
      "justification": "None of the provided papers explicitly address the role of persistor (persister) cells in mediating incomplete responses to tyrosine kinase inhibitor therapy. While some studies discuss acquired resistance mechanisms, subpopulations of tumor\u2010initiating cells, or downstream pathway alterations (e.g., PTEN loss, Akt activation, HSP90 dependency), none identify or characterize persistor cells as a contributing factor to TKI treatment failure."
    },
    "naive_doc_ids": [
      "9929089",
      "25895285",
      "20738970",
      "40710501",
      "34016944"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.13,
      "justification": "None of the provided studies directly investigate or describe \u2018persistor\u2019 cell populations as a mechanism for incomplete responses to tyrosine kinase inhibitors. While Papers 1, 3, and 7 discuss acquired or subpopulation resistance to TKIs, and Paper 9 shows sphere\u2010forming cells refractory to EGFR targeting, none explicitly identify or characterize persistor cells as the cause of incomplete TKI therapy responses."
    },
    "overthinking_doc_ids": [
      "9929089",
      "20738970",
      "1065627",
      "3929361",
      "7821634"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided studies address the role of persistor cells in incomplete responses to tyrosine kinase inhibitors. They cover chemotherapy re-challenge, acquired genetic resistance mutations (e.g., EGFR C797S), kinase roles in apoptosis, cell-cycle inhibitors, tumor microenvironment effects, minimal residual disease kinetics, immune inflammasome activation, and circulating tumor cell drug\u2013resistance profiling, but do not investigate non\u2010genetic persistor cell populations in TKI therapy."
    },
    "posthoc_doc_ids": [
      "9929089",
      "20738970",
      "15721252",
      "9648896",
      "9505402"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1118",
    "claim": "Sweet taste receptors on the tongue are deactivated by between 1 and 10 mM glucose.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies address or measure inhibition (deactivation) of tongue sweet receptors by 1\u201310 mM glucose. They characterize which receptors mediate sweet taste (T1r2/T1r3, gustducin, PLC\u03b22/TRPM5) and their roles in sugar detection, but do not report that physiological (1\u201310 mM) glucose concentrations deactivate those receptors."
    },
    "naive_doc_ids": [
      "23351136",
      "20829129",
      "1538080",
      "718601"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on the deactivation of sweet taste receptors by 1\u201310 mM glucose. Papers 1 and 2 address genetic and signaling components of sweet (and umami/bitter) taste transduction but do not report glucose concentrations for receptor deactivation. Papers 3 and 4 concern FGF19/FGFR and PPAR\u03b1 in metabolism and cancer, respectively, and do not pertain to tongue sweet receptor activity."
    },
    "overthinking_doc_ids": [
      "23351136",
      "718601",
      "6588614",
      "25328476"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers report that sweet taste receptors on the tongue are deactivated by 1\u201310 mM glucose. The studies cover taste receptor genetics, signaling in taste cells and gut L-cells, metabolic hormone release, and unrelated molecular pathways, but do not address receptor deactivation at that glucose concentration range in tongue taste receptors."
    },
    "posthoc_doc_ids": [
      "23351136",
      "718601",
      "6588614",
      "20829129",
      "12943966"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "78",
    "claim": "Active caspase-11 participate in regulating phagosome-lysosome fusion.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that active caspase-11 promotes fusion of pathogen-containing phagosomes with lysosomes by modulating actin polymerization. The other papers do not address caspase-11 or phagosome\u2013lysosome fusion."
    },
    "naive_doc_ids": [
      "5099266",
      "38043606",
      "17682477",
      "35079452",
      "46594244"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that active caspase-11 is required to promote phagosome\u2013lysosome fusion of pathogen-containing vacuoles via actin polymerization, confirming the claim."
    },
    "overthinking_doc_ids": [
      "5099266",
      "38043606",
      "4345315",
      "35079452",
      "17682477"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that active caspase-11 promotes the fusion of pathogen\u2010containing phagosomes with lysosomes by modulating actin polymerization, confirming that caspase-11 regulates phagosome\u2013lysosome fusion."
    },
    "posthoc_doc_ids": [
      "5099266",
      "22186938",
      "38043606",
      "4399311",
      "7820043"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "14",
    "claim": "5'-nucleotidase metabolizes 6MP.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 2 directly show that NT5C2 encodes a cytosolic 5\u2032-nucleotidase that inactivates nucleoside-analog chemotherapy drugs, including 6-mercaptopurine, and that activating mutations in NT5C2 increase its nucleotidase activity and confer resistance to 6MP. This confirms that 5\u2032-nucleotidase metabolizes 6MP."
    },
    "naive_doc_ids": [
      "6421792",
      "641786",
      "293661",
      "1373287",
      "23895668"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 1 directly shows that NT5C2, a cytosolic 5\u2032-nucleotidase, inactivates nucleoside-analog chemotherapy drugs and that activating NT5C2 mutations increase nucleotidase activity and confer resistance to 6-mercaptopurine, demonstrating that 5\u2032-nucleotidase metabolizes 6MP."
    },
    "overthinking_doc_ids": [
      "6421792",
      "293661",
      "393001",
      "1373287",
      "5702790"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Papers 1 and 4 identify NT5C2, which encodes a cytosolic 5\u2032-nucleotidase, as the enzyme responsible for inactivating nucleoside-analog chemotherapeutics including 6-mercaptopurine (6MP). Mutations that increase NT5C2 activity confer resistance to 6MP, directly demonstrating that 5\u2032-nucleotidase metabolizes (dephosphorylates and inactivates) 6MP."
    },
    "posthoc_doc_ids": [
      "6421792",
      "293661",
      "393001",
      "641786",
      "799586"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1105",
    "claim": "Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1, a matched case\u2013control study of UK doctors, found that failure of early or preclinical examinations during medical school was independently associated with later professional misconduct (OR 5.47, 95% CI 2.17\u201313.79, P<0.001). None of the other papers address this relationship."
    },
    "naive_doc_ids": [
      "6710713",
      "17374970",
      "313394",
      "3878434",
      "10827901"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 reports that failure of early or preclinical examinations at medical school was independently associated (OR 5.47, 95% CI 2.17\u201313.79, P<0.001) with subsequent findings of serious professional misconduct. No other papers address later misconduct, so the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "6710713",
      "17374970",
      "313394",
      "11624482",
      "43483151"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses the association between early academic difficulties in medical school (failure of early or preclinical examinations) and subsequent professional misconduct, finding a strong independent odds ratio (5.47, 95% CI 2.17\u201313.79, P<0.001). The other papers do not examine medical school performance or professional misconduct and are therefore not informative for this claim."
    },
    "posthoc_doc_ids": [
      "6710713",
      "13933299",
      "27076725",
      "17374970",
      "9967265"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1200",
    "claim": "The binding orientation of the ML-SA1 activator at hTRPML2 is different from the binding orientation of the ML-SA1 activator at hTRPML1.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers present structural data on ML-SA1 bound to hTRPML2 or directly compare its binding orientation at hTRPML2 versus hTRPML1. Paper 2 describes a TRPML1 agonist-bound structure (unspecified agonist), and Paper 7 covers TRPML subunit interactions and localization, but neither addresses ML-SA1\u2019s binding pose or compares orientations between TRPML1 and TRPML2."
    },
    "naive_doc_ids": [
      "3610282",
      "3441524",
      "25483562",
      "47240151",
      "3052213"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report a structure of hTRPML2 bound to ML-SA1 or directly compare its binding orientation at hTRPML2 versus hTRPML1. Paper 8 describes agonist binding in hTRPML1, and Paper 6 discusses TRPML2 biology and localization but contains no structural or binding\u2010orientation data for ML-SA1 at hTRPML2. Therefore, there is no information to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "6903077",
      "3610282",
      "4828984",
      "1744752",
      "6386930"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address the binding of the ML-SA1 activator to human TRPML1 or TRPML2 channels or compare their binding orientations."
    },
    "posthoc_doc_ids": [
      "19313533",
      "40412980",
      "47240151",
      "20457190",
      "3174305"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "684",
    "claim": "Lack of clpC does not affect sporulation efficiency in Bacillus subtilis cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.2,
      "justification": "None of the three papers directly report the effect of a clpC deletion on sporulation efficiency. Paper 1 reports a broad Tn-seq screen of known and novel sporulation genes but does not mention clpC as either required or dispensable for spore formation. Papers 2 and 3 focus on heat-shock regulation and do not address sporulation. Therefore, there is no direct evidence here to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "4942718",
      "12881593",
      "34386619"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers assess sporulation efficiency in a clpC deletion background. They focus on genetic screens for sporulation genes (Paper 1) without reporting a clpC phenotype, on stress\u2010regulation of the clpC operon (Paper 2), on Clp protein regulation (Paper 3), on community motility (Paper 4), and on drug transporter regulation (Paper 5). No experimental data address whether loss of clpC affects sporulation efficiency."
    },
    "overthinking_doc_ids": [
      "4942718",
      "34386619",
      "12881593",
      "12824568",
      "2851611"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the three papers address the impact of clpC deletion on sporulation efficiency. Paper 1 focuses on identifying new sporulation genes but does not discuss clpC. Papers 2 and 3 examine regulation and proteolytic roles of ClpC under stress, without reporting sporulation phenotypes."
    },
    "posthoc_doc_ids": [
      "4942718",
      "34386619",
      "12881593"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "480",
    "claim": "Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 directly demonstrates that endothelial-specific loss of Gpr124 in adult mice leads to blood\u2013brain barrier disruption and hemorrhage in models of ischemic stroke, whereas restoring Wnt\u2013\u03b2-catenin signaling rescues these defects. This indicates that Gpr124 is required to maintain BBB integrity and therefore suppresses BBB breakdown under ischemic conditions."
    },
    "naive_doc_ids": [
      "3761017",
      "6325527",
      "33884866",
      "2565138"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 demonstrates that endothelial deletion of Gpr124 in adult mice leads to blood\u2013brain barrier disruption and microvascular hemorrhage in mouse models of ischemic stroke, indicating that Gpr124 is required to maintain BBB integrity under pathological conditions and thus suppresses BBB breakdown in these models."
    },
    "overthinking_doc_ids": [
      "6325527",
      "3761017",
      "14753395",
      "33884866",
      "27602752"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 reports that endothelial-specific loss of Gpr124 in adult mice leads to blood\u2013brain barrier disruption and microvascular hemorrhage in mouse models of ischemic stroke, indicating that Gpr124 normally acts to maintain BBB integrity under ischemic conditions."
    },
    "posthoc_doc_ids": [
      "6325527",
      "3761017",
      "27602752",
      "2242416",
      "18256197"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1216",
    "claim": "The extracellular domain of TMEM27 is cleaved in human beta cells.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "The only paper describing TMEM27 cleavage (Paper 1) examines mouse Tmem27 in murine beta cells; none of the provided studies directly test or report cleavage of the human TMEM27 extracellular domain in human beta cells."
    },
    "naive_doc_ids": [
      "24142891",
      "19756935",
      "27588420",
      "43661837",
      "16527698"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 7 (\u2018Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic beta cell proliferation\u2019) demonstrates that in pancreatic beta cells Tmem27\u2019s extracellular domain is glycosylated, cleaved and shed from the plasma membrane, directly confirming the claim."
    },
    "overthinking_doc_ids": [
      "19756935",
      "27588420",
      "43661837",
      "950306",
      "16527698"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Only Paper 1 describes cleavage and shedding of the extracellular domain of TMEM27, but this work was carried out in mouse beta cells and does not directly demonstrate the same cleavage in human beta cells. None of the other papers address TMEM27 processing in human islet cells."
    },
    "posthoc_doc_ids": [
      "24142891",
      "1905095",
      "19756935",
      "27588420",
      "8790729"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "375",
    "claim": "Elevated cell-free mitochondrial DNA levels are associated with mortality.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly demonstrates that elevated circulating cell-free mtDNA levels (\u22653,200 copies/\u00b5l) are strongly associated with 28-day ICU mortality (ORs 7.5 and 8.4 in two cohorts, p\u226a0.001), confirming the claim. None of the other papers provide evidence that contradicts this association."
    },
    "naive_doc_ids": [
      "1522647",
      "20459964",
      "22123421",
      "3776162",
      "3878434"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that elevated circulating cell-free mitochondrial DNA levels (\u22653200 copies/\u03bcl) are associated with substantially increased 28-day mortality in medical ICU patients (ORs 7.5 and 8.4 in two cohorts, p<10\u207b\u2074), and that adding mtDNA level improves risk prediction. The other papers do not address cell-free mtDNA."
    },
    "overthinking_doc_ids": [
      "1522647",
      "14682243",
      "21009874",
      "663464",
      "654735"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly tests circulating cell-free mitochondrial DNA levels in ICU patients and finds that elevated mtDNA (\u22653,200 copies/\u00b5l plasma) is strongly associated with higher 28-day mortality (OR 7.5 and 8.4 in two cohorts, p\u226410\u207b\u2074), improving risk prediction. None of the other papers address cell-free mitochondrial DNA and mortality."
    },
    "posthoc_doc_ids": [
      "1522647",
      "23918031",
      "301866",
      "5939172",
      "14021596"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "713",
    "claim": "Low expression of miR7a does not repress target genes or exert a biological function in ovaries.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers mention miR7a expression or its functional role in ovaries. The cited studies cover other miRNAs and contexts (e.g., cancer, viral miRNAs) but do not address low miR7a levels or target repression in ovarian tissue."
    },
    "naive_doc_ids": [
      "32324430",
      "21373240",
      "86602746",
      "19358586",
      "35329820"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss miR7a specifically or its expression/function in ovaries, so there is no relevant information to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "2000038",
      "5377642",
      "6690087",
      "2619579",
      "19828689"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers discuss miR7a or its expression/function in ovarian tissue. Therefore, there is no relevant information to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "2000038",
      "21363424",
      "5377642",
      "6766459",
      "266641"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "887",
    "claim": "Only a minority of cells survive development after differentiation into stress-resistant spores.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.18,
      "justification": "None of the provided papers quantify the proportion of cells that survive sporulation; while Paper 4 identifies new sporulation genes in Bacillus subtilis, it does not report how many cells successfully form stress\u2010resistant spores out of the total population."
    },
    "naive_doc_ids": [
      "4820792",
      "7875158",
      "10128893",
      "4942718",
      "12824568"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.03,
      "justification": "None of the provided papers quantify the fraction of cells that survive development into stress-resistant spores or otherwise address spore survival rates after differentiation."
    },
    "overthinking_doc_ids": [
      "4942718",
      "12824568",
      "2851611",
      "33370",
      "4335599"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided studies address the differentiation of cells into stress-resistant spores or quantify survival rates of spores during development. All papers focus on various stem cell lineages or stress responses in mammalian cells, with no mention of spore formation or survival fractions in spore development."
    },
    "posthoc_doc_ids": [
      "5085118",
      "17991818",
      "1595617",
      "35811036",
      "16630060"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1278",
    "claim": "The treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers directly report on the incidence (or absence) of autoimmune adverse events in cancer patients treated with combined immune\u2010checkpoint (co-IR) blockade. While some studies describe checkpoint biology and effects of single\u2010agent PD-1 or CTLA-4 inhibition, and one genetic model shows that loss of a checkpoint regulator (VISTA) can predispose to autoimmunity in mice, no clinical or preclinical data are presented that specifically assess autoimmune events following combined checkpoint blockade in cancer patients."
    },
    "naive_doc_ids": [
      "21891856",
      "3559136",
      "4468861",
      "3471191",
      "1454773"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers report on the incidence (or absence) of autoimmune adverse events in cancer patients treated with combined immune\u2010checkpoint (co\u2010IR) blockade. They either focus on efficacy mechanisms (Papers 1 and 7), unrelated therapies (Papers 2\u20136, 8, 9), or preclinical models (Paper 3) without safety/aut autoimmunity data. Therefore, the claim cannot be verified from the supplied evidence."
    },
    "overthinking_doc_ids": [
      "4468861",
      "25589047",
      "21891856",
      "21958900",
      "202259"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Paper 5 explicitly notes that immune checkpoint blockade is associated with \u201cnumerous immunologic adverse-events,\u201d directly refuting the claim that combined IR blockade causes no adverse autoimmune events."
    },
    "posthoc_doc_ids": [
      "15128866",
      "24150328",
      "3559136",
      "4468861",
      "49432306"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "724",
    "claim": "Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly shows that Ly49Q regulates neutrophil polarization and migration through spatiotemporal control of membrane raft functions, confirming the claim. None of the other papers address Ly49Q or its role in raft-mediated neutrophil polarization."
    },
    "naive_doc_ids": [
      "5531479",
      "8396189",
      "797114",
      "7869794",
      "5484763"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Paper 1 directly demonstrates that Ly49Q is crucial for neutrophil polarization and migration through its spatiotemporal regulation of membrane raft functions, thereby confirming the claim. None of the other papers address Ly49Q, neutrophil polarization, or raft regulation."
    },
    "overthinking_doc_ids": [
      "5531479",
      "4389252",
      "5484763",
      "8396189",
      "14407673"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that Ly49Q regulates membrane raft functions to control neutrophil polarization and migration, matching the claim."
    },
    "posthoc_doc_ids": [
      "5531479",
      "16128711",
      "20608982",
      "20758340",
      "4389252"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "437",
    "claim": "Functional consequences of genomic alterations due to Myelodysplastic syndrome (MDS) are poorly understood due to the lack of an animal model.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 3 describes a functional in vivo mouse model of MDS/AML progression (NRAS/BCL2 transgenics) that links specific genomic alterations to reactive oxygen species, DNA damage, and error-prone repair, demonstrating that functional consequences of MDS\u2010associated genetic lesions can indeed be studied in an animal model, directly countering the claim of a \u2018lack of an animal model.\u2019"
    },
    "naive_doc_ids": [
      "18104691",
      "4951831",
      "5765455",
      "10795340",
      "2359152"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.72,
      "justification": "None of the provided papers specifically address the existence or absence of an animal model for Myelodysplastic Syndrome (MDS) as a whole. Paper 7 uses a mouse model to study progression to leukemia and DNA\u2010repair defects, but it does not establish a bona fide MDS animal model for investigating the functional consequences of MDS\u2010associated genomic alterations. The other papers focus on unrelated diseases or in vitro systems and do not bear on the claim that a lack of an MDS animal model hampers functional understanding."
    },
    "overthinking_doc_ids": [
      "6000423",
      "13293033",
      "27815697",
      "19185192",
      "19521501"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 describes a two-step transgenic mouse model that recapitulates MDS progression and reveals DNA damage, ROS generation, and error-prone DSB repair mechanisms in vivo. Paper 5 uses a murine AML model to define functional effects on osteoblastic cells. These studies demonstrate animal models and elucidate functional consequences of genomic alterations, directly contradicting the assertion that no suitable model exists."
    },
    "posthoc_doc_ids": [
      "5765455",
      "13293033",
      "26025820",
      "4951831",
      "10795340"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "68",
    "claim": "Activated Cdk5 regulates DNA damage-induced neuronal death.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 demonstrates that DNA damage\u2013activated Cdk5 directly phosphorylates ATM to trigger ATM-dependent signaling (including p53 and H2AX) and that disrupting the Cdk5\u2013ATM pathway protects post-mitotic neurons from DNA damage\u2013induced death, directly supporting the claim that activated Cdk5 regulates DNA damage\u2013induced neuronal death. None of the other papers address Cdk5 in this context."
    },
    "naive_doc_ids": [
      "21295300",
      "17231273",
      "28697248",
      "864491",
      "7548577"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 demonstrates that DNA damage activates Cdk5, which phosphorylates ATM and thereby regulates downstream ATM signaling (p53, H2AX) and neuronal death. This directly confirms that activated Cdk5 regulates DNA damage\u2013induced neuronal death. The other papers do not address Cdk5 in this context."
    },
    "overthinking_doc_ids": [
      "21295300",
      "5572127",
      "10648422",
      "28697248",
      "10015292"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly shows that DNA damage activates Cdk5 in post\u2010mitotic neurons, leading to phosphorylation and activation of ATM, which in turn drives p53 and H2AX-dependent signaling and neuronal cell death. This experimental evidence confirms that activated Cdk5 regulates DNA damage\u2013induced neuronal death."
    },
    "posthoc_doc_ids": [
      "21295300",
      "29429111",
      "1103795",
      "17231273",
      "3140772"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "399",
    "claim": "Exposure to fine particulate air pollution is relate to anxiety prevalence.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines fine particulate (PM2.5) exposure and finds significantly increased odds of high anxiety symptoms with higher recent PM2.5 exposure, supporting the claim. The other papers address unrelated topics and provide no information on air pollution and anxiety."
    },
    "naive_doc_ids": [
      "791050",
      "1538080",
      "87758",
      "471735",
      "1748921"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly examines past exposure to fine particulate matter (PM2.5) and finds significant increased odds of high anxiety symptoms per 10 \u00b5g/m\u00b3 increase in PM2.5 (e.g. OR 1.12 for prior one-month exposure, 1.15 for 12-month exposure). No other papers address air pollution and anxiety. This supports the claim that fine particulate exposure is related to anxiety prevalence."
    },
    "overthinking_doc_ids": [
      "791050",
      "13900610",
      "32357890",
      "829646",
      "1974176"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 directly examines the link between past exposure to fine particulate matter (PM2.5) and prevalent anxiety symptoms in a large cohort. It reports significantly increased odds of high anxiety symptoms with higher short-term PM2.5 exposure (e.g., OR 1.12 per 10 \u00b5g/m3 increase in one-month average; 95% CI 1.06\u20131.19) and similar results over a 12-month period. No other paper contradicts this finding."
    },
    "posthoc_doc_ids": [
      "791050",
      "32357890",
      "471921",
      "38873881",
      "41976370"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "316",
    "claim": "Decreased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 shows that loss of 15-PGDH (the enzyme that oxidizes PGE\u2082 to 15-keto-PGE\u2082) is associated with diminished PGE\u2082 metabolism, implying that reduced conversion leads to PGE\u2082 accumulation. Paper 3 further documents reduced levels of the PPAR\u03b3 ligand 15-keto-PGE\u2082 in the setting of impaired conversion. Together, these data support the claim that decreased conversion of PGE\u2082 to 15-keto-PGE\u2082 causes PGE\u2082 to build up."
    },
    "naive_doc_ids": [
      "21181273",
      "5775033",
      "712078",
      "24347647",
      "350542"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 1 demonstrates that down-regulation or genetic disruption of 15-PGDH (the enzyme that converts PGE\u2082 to 15-keto-PGE\u2082) blocks production of the downstream metabolite and leads to elevated steady-state PGE\u2082 levels, directly supporting the idea that decreased conversion to the PPAR\u03b3 ligand causes PGE\u2082 accumulation. Paper 2 further shows reduced formation of the PPAR\u03b3 ligand 15-keto-PGE\u2082 in Cftr-deficient cells, consistent with impaired conversion of PGE\u2082."
    },
    "overthinking_doc_ids": [
      "21181273",
      "712078",
      "1686997",
      "2481032",
      "6540064"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers address or present data on the specific biochemical step of PGE\u2082 conversion to 15-ket-PGE\u2082 leading to PGE\u2082 accumulation. While Paper 4 notes reduced levels of the PPAR\u03b3 ligand 15-keto-PGE\u2082 in Cftr-deficient mice, it does not report that this decreased conversion causes PGE\u2082 buildup."
    },
    "posthoc_doc_ids": [
      "16605494",
      "1709625",
      "4856149",
      "712078",
      "2682251"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "574",
    "claim": "In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "None of the provided papers address the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae populations. They focus on industrial yeast lineage divergence (Paper 1), RNA processing kinetics (Paper 2), transcriptional regulatory associations (Paper 3), rDNA copy number in cancer (Paper 4), copy\u2010number changes in bladder tumors (Paper 5), and lifespan extension by calorie restriction in yeast (Paper 6), but none report data on partial chromosome gains or losses in domesticated yeast."
    },
    "naive_doc_ids": [
      "10300888",
      "365896",
      "1256116",
      "14019636",
      "2402323"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers report on the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae populations. While Paper 7 discusses genomic and phenotypic variation in industrial (domesticated) yeast strains, it does not present data on segmental aneuploidy. The other papers focus on RNA processing, transcriptional regulation, lifespan, cancer copy-number changes, or human gene CNVs, and likewise do not address this specific claim."
    },
    "overthinking_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "2402323",
      "14019636"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the six provided papers report data on the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae populations. While Paper 5 examines the genomic divergence of industrial yeast strains, it does not present results on segmental aneuploidy occurrence, and the other papers address RNA processing, transcriptional regulation, lifespan extension, proteomic noise, or human tumor CGH rather than yeast chromosomal copy\u2010number variation."
    },
    "posthoc_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "4300851",
      "10300888"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "615",
    "claim": "Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses LRRK2 Roc-COR mutations and shows that increasing microtubule acetylation (via deacetylase inhibitors or \u03b1TAT1) prevents mutant LRRK2 from binding microtubules and rescues axonal transport and locomotor deficits. This result is opposite to the claim that increased acetylation worsens transport interference."
    },
    "naive_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "16056410",
      "7549811"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly tests the effect of microtubule acetylation on axonal transport defects caused by LRRK2 Roc-COR mutations. It reports that increasing tubulin acetylation (via deacetylase inhibitors or \u03b1TAT1 overexpression) prevents mutant LRRK2 from binding microtubules and fully restores axonal transport and locomotor function. This is opposite to the claim that increased acetylation worsens the transport interference. The other papers do not address the specific interplay of LRRK2 Roc-COR mutations, axonal transport, and microtubule acetylation."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "18678095",
      "20743803"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.89,
      "justification": "Paper 1 directly addresses LRRK2 Roc-COR mutations and shows that increasing microtubule acetylation (via deacetylase inhibitors or \u03b1TAT1) prevents mutant LRRK2 binding to microtubules and restores axonal transport and locomotor behavior. This effect is the opposite of \u2018worsening\u2019 transport, thus refuting the claim. None of the other papers provide contrary evidence relevant to LRRK2-mediated transport and microtubule acetylation."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "7465900",
      "7549811"
    ],
    "posthoc_metadata": {
      "initial_confidence": 1.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1371",
    "claim": "Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly demonstrates that serum 25-hydroxyvitamin D status strongly modulates serum PTH levels at given calcium intakes: PTH is lowest when vitamin D is sufficient and highest when vitamin D is deficient, and with adequate vitamin D, higher calcium intake offers no further PTH suppression. This confirms that vitamin D is a key factor governing the calcium\u2013PTH relationship."
    },
    "naive_doc_ids": [
      "16256507",
      "21199527",
      "3758260",
      "3034412",
      "13621186"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple studies demonstrate that vitamin D status strongly influences both calcium absorption and serum PTH levels. Paper 1 shows lower PTH when serum 25-hydroxyvitamin D is high and that adequate vitamin D makes high calcium intake (>800 mg/d) unnecessary for PTH suppression. Paper 4 finds calcium absorption 65 % higher at higher 25-hydroxyvitamin D levels. Paper 5 reports that vitamin D deficiency leads to secondary hyperparathyroidism. Paper 6 details vitamin D\u2019s molecular role in regulating genes critical for calcium homeostasis. Together these findings confirm that vitamin D is a key factor in the calcium\u2013PTH relationship."
    },
    "overthinking_doc_ids": [
      "16256507",
      "21564598",
      "21199527",
      "3034412",
      "9555784"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple studies directly link vitamin D status (serum 25-hydroxyvitamin D) to parathyroid hormone levels and calcium homeostasis. For example, Paper 1 shows PTH is lowest when 25(OH)D > 18 ng/mL regardless of calcium intake, and that adequate vitamin D obviates the need for high calcium intake to maintain PTH. Paper 5 finds an inverse correlation between 25OHD and PTH in postmenopausal women, with vitamin D deficiency driving secondary hyperparathyroidism. Paper 7 outlines molecular mechanisms by which 1,25(OH)\u2082D regulates intestinal/renal calcium handling and thereby influences PTH. Together these data confirm that vitamin D status is a key factor in the calcium\u2013PTH relationship."
    },
    "posthoc_doc_ids": [
      "16256507",
      "21564598",
      "9301606",
      "13312471",
      "9555784"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1324",
    "claim": "Treatment with a protein named FN restores regenerative abilities of aged muscles.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 1 directly demonstrates that aged muscle stem cell niches lose fibronectin (FN) and that reconstituting FN levels in the aged niche remobilizes MuSCs and restores youth-like muscle regeneration. The other papers do not address FN treatment and aged muscle regeneration."
    },
    "naive_doc_ids": [
      "19912367",
      "8771704",
      "12411274",
      "1744097",
      "15728433"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 demonstrates that fibronectin (FN) levels decline in the aged muscle stem cell niche, and experimentally restoring FN in aged mice remobilizes muscle stem cells and restores youthful regeneration, directly supporting the claim. The other papers do not address FN in aged muscle regeneration."
    },
    "overthinking_doc_ids": [
      "19912367",
      "8771704",
      "12411274",
      "1507222",
      "5558754"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that aged muscle stem cell niches have reduced fibronectin and that reconstituting FN in the aged niche remobilizes MuSCs and restores youth-like muscle regeneration. The other papers do not address fibronectin treatment in aged muscle."
    },
    "posthoc_doc_ids": [
      "19912367",
      "20418809",
      "8771704",
      "20186814",
      "1848452"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "389",
    "claim": "Ethanol stress increases the expression of IBP in bacteria.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers address the effect of ethanol stress on the expression of IBP in bacteria. While paper 7 deals with ethanol tolerance in E. coli, it does not mention IBP expression; the other papers do not discuss ethanol stress or IBP."
    },
    "naive_doc_ids": [
      "471735",
      "935538",
      "23305884",
      "6669242",
      "8065561"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss ethanol stress or the expression of IBP in bacteria. There is no mention of an IBP (inclusion body\u2013binding protein or any other IBP) being regulated by ethanol in any of the supplied studies."
    },
    "overthinking_doc_ids": [
      "471735",
      "24185667",
      "935538",
      "9784254",
      "13912224"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address ethanol stress or the expression of IBP in bacteria. Therefore, they contain no relevant information to support or refute the claim."
    },
    "posthoc_doc_ids": [
      "471735",
      "9194077",
      "38944245",
      "24185667",
      "2686003"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1375",
    "claim": "Weighed food records (WFR) result in poor completion since they're costly to run and impose high participant burden.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided studies report on completion rates specifically attributable to weighed food records or discuss their cost and participant burden. The dietary assessment papers focus on validity and accuracy, not on costs or completion difficulties of WFR."
    },
    "naive_doc_ids": [
      "21623140",
      "1287809",
      "3690068",
      "5151024",
      "6748318"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.4,
      "justification": "Paper 1 reports that only 98 of 150 volunteers (\u224865%) completed the multi-season 4 d weighed dietary record protocol, implying substantial participant burden and drop-out consistent with poor completion of WFRs. No other papers address completion, but this finding supports the claim."
    },
    "overthinking_doc_ids": [
      "21623140",
      "21993510",
      "11748341",
      "2659805",
      "5151024"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the cited studies evaluate completion rates or participant burden specifically for weighed food records (WFR), nor do they discuss their cost or dropout attributable to WFRs. Although Paper 1 reports that 98 of 150 volunteers completed a multi-method protocol including 4-day WFRs, it does not link any non-completion to burden or cost; Papers 2, 3, 5\u20137 are unrelated to dietary recording. Therefore there is no direct evidence to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "21623140",
      "3572885",
      "11837657",
      "21993510",
      "11748341"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "619",
    "claim": "Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 shows that higher microvessel density (increased vessel density) is associated with longer disease\u2010free survival after anthracycline chemotherapy, implying improved rather than decreased efficacy. Paper 8 demonstrates that enzymatic depletion of hyaluronan (reducing stromal fibrosis) enhances intratumoral drug delivery and therapeutic response to gemcitabine. Both findings run directly counter to the claim that increased vessel density and reduced fibrosis decrease chemotherapy efficacy."
    },
    "naive_doc_ids": [
      "1171121",
      "20127522",
      "20610557",
      "9648896",
      "17708753"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that higher microvessel density is an independent favorable prognostic factor for anthracycline efficacy in breast cancer. Paper 6 demonstrates that depletion of stromal fibrosis (via Hedgehog inhibition) leads to increased intratumoral vessel density and gemcitabine delivery, resulting in improved chemotherapy response. Both directly oppose the claim that increased vessel density and reduced fibrosis decrease chemotherapy efficacy."
    },
    "overthinking_doc_ids": [
      "1171121",
      "20127522",
      "20610557",
      "7821634",
      "6219790"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "Although several papers discuss microvessel density and its impact on treatment outcomes (Paper 1 shows higher MVD is associated with better adjuvant chemotherapy response, while Paper 6 shows that anti-VEGF (vessel-reducing) therapy can improve chemo efficacy), none of the provided studies examine the combined effect of increased vessel density along with a reduction in fibrosis on chemotherapy efficacy. There is no data on fibrosis in relation to these vascular changes and chemo response, so the claim cannot be verified or refuted by the given evidence."
    },
    "posthoc_doc_ids": [
      "1171121",
      "25452937",
      "7986878",
      "13070316",
      "18375089"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "324",
    "claim": "Deleting Raptor reduces G-CSF levels.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers address genetic deletion of Raptor or its effect on G-CSF levels. They discuss various regulators of granulopoiesis (GM-CSF, G-CSF, neuropilin-1, IL-17, etc.) but do not report experiments involving Raptor deletion or measure G-CSF in that context."
    },
    "naive_doc_ids": [
      "188911",
      "24612804",
      "42465769",
      "5612738",
      "11705328"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers discuss deletion of Raptor or report its effect on G-CSF levels. They cover unrelated topics such as miRNA in glioma, hCG in pregnancy, exercise in children, dendritic cell generation, IL-17/SCF in granulopoiesis, adipocyte-mediated G-CSF inhibition, PPAR\u03b3 in cystic fibrosis, TRP2 in pheromone signaling, BMAL1 in aging, and IL-10 in T cells, but not Raptor or its impact on G-CSF."
    },
    "overthinking_doc_ids": [
      "654735",
      "1958440",
      "2575938",
      "188911",
      "24612804"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers report measurements of G-CSF levels following deletion of Raptor (the mTORC1 component). The only paper involving Raptor (Paper 5) examines Th17 differentiation but does not assess G-CSF. Therefore, there is no direct evidence here to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "5409325",
      "11428884",
      "654735",
      "13573143",
      "22174015"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "385",
    "claim": "Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1\u20133 demonstrate that treatment with epigenetic modulating agents (DNMT inhibitors and HDAC inhibitors) in murine ovarian and lung cancer models activates type I interferon signaling, up-regulates antigen presentation machinery, increases CD8+ T and NK cell infiltration and activation, reverses T cell exhaustion, reduces immunosuppressive cells, and enhances response to checkpoint blockade. These data clearly show that EMAs modulate the antitumor immune response in cancer model systems."
    },
    "naive_doc_ids": [
      "9767444",
      "1032372",
      "9955779",
      "9929089",
      "1243475"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 reviews and highlights multiple preclinical and emerging clinical studies showing that DNA methyltransferase and histone\u2010deacetylase inhibitors reverse epigenetic silencing of immune\u2010related genes, improve antigen presentation, effector T\u2010cell function, and break down suppressive mechanisms in tumors. Paper 3 provides direct experimental evidence in a murine ovarian cancer model that DNMTi (5-azacytidine) and HDACi treatments activate type I interferon signaling, increase CD8+ T and NK cell activation, reduce immunosuppressive myeloid populations, and improve response to immune checkpoint blockade. Together, these data confirm that epigenetic\u2010modulating agents can modulate antitumor immune responses in cancer model systems."
    },
    "overthinking_doc_ids": [
      "1032372",
      "32742683",
      "9767444",
      "14615911",
      "45764440"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reviews how epigenetic modifying agents reverse tumor\u2010associated immune silencing, improve antigen presentation, and enhance T-cell\u2013mediated tumor lysis. Paper 3 provides direct murine ovarian cancer data showing that DNMT and HDAC inhibitors activate type I IFN signaling, increase CD8+ T and NK cell activity, reduce immunosuppression, lower tumor burden, and extend survival. Both lines of evidence demonstrate that EMAs modulate antitumor immune responses in cancer model systems."
    },
    "posthoc_doc_ids": [
      "1032372",
      "32742683",
      "9767444",
      "15215393",
      "22968257"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "478",
    "claim": "Golli-deficient T-cells prefer to differentiate into an anergic phenotype in the adaptive immune response when there are increased levels of Ca2+ in the cytosol.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 shows that golli-deficient T cells exhibit enhanced Ca2+ influx and become hyperproliferative upon TCR stimulation, not anergic. None of the other papers address golli or T cell anergy. Thus the evidence contradicts the claim that golli-deficient T cells preferentially differentiate into an anergic phenotype under elevated cytosolic Ca2+."
    },
    "naive_doc_ids": [
      "14767844",
      "364522",
      "1976183",
      "14474178",
      "14934137"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "Paper 1 shows that golli-deficient T cells exhibit enhanced Ca2+ influx upon TCR stimulation and are hyperproliferative, rather than preferentially adopting an anergic state. None of the other papers provide evidence that golli deficiency promotes T cell anergy under high cytosolic Ca2+ conditions."
    },
    "overthinking_doc_ids": [
      "14767844",
      "4444861",
      "7386360",
      "17188921",
      "1243475"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 6 directly examines golli-deficient T cells and reports that they exhibit enhanced store-depletion\u2013induced Ca2+ influx and are hyperproliferative upon TCR stimulation. There is no indication of anergy; in fact, golli deficiency increases T cell responsiveness rather than promoting an anergic phenotype under elevated cytosolic Ca2+."
    },
    "posthoc_doc_ids": [
      "5386514",
      "696006",
      "2506153",
      "40096222",
      "5377059"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "13",
    "claim": "5% of perinatal mortality is due to low birth weight.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers report estimates of perinatal mortality attributable to low birth weight. They address temperature-related mortality, depression and birth outcomes, BMI and cancer risk, GH therapy in SGA children, animal models of growth restriction, growth reference curves, sugar-sweetened beverages and weight gain, and TMAO and cardiovascular risk, but do not quantify the fraction of perinatal deaths due to low birth weight."
    },
    "naive_doc_ids": [
      "4810810",
      "26611834",
      "4828631",
      "6323196",
      "18104691"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided studies report or estimate the percentage of perinatal deaths attributable to low birth weight. Paper 1 addresses birth weight and adult breast density, Paper 2 gives overall perinatal mortality rates in rural China but does not partition causes by birth weight, Paper 3 concerns PDA treatment in preterm/low\u2010birth\u2010weight infants, and Paper 4 focuses on depression and risks of LBW and preterm birth. None supply the specific statistic that 5% of perinatal mortality is due to low birth weight."
    },
    "overthinking_doc_ids": [
      "5487448",
      "7662395",
      "34544514",
      "26611834"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.04,
      "justification": "None of the papers quantify the proportion of perinatal mortality attributable specifically to low birth weight. While some studies mention low birth weight as a risk factor for neonatal death (for example, an increased odds ratio for smaller-than-average infants in Paper 3), none report data showing that 5% of perinatal deaths are due to low birth weight."
    },
    "posthoc_doc_ids": [
      "7662395",
      "34544514",
      "1263446",
      "5487448",
      "26611834"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "914",
    "claim": "PPAR-RXRs can be activated by PPAR ligands.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Multiple studies show that classical PPAR ligands (e.g. the PPAR\u03b3 agonist rosiglitazone in Paper 1 and the PPAR\u03b1 ligand fenofibrate in Paper 2) elicit PPAR-dependent transcriptional and biological effects. In particular, Paper 2 directly measures increased PPAR\u03b1-mediated reporter activity in response to fenofibrate (a PPAR ligand), consistent with activation of the PPAR\u2013RXR heterodimer. Thus, the evidence supports that PPAR\u2013RXRs can be activated by PPAR ligands."
    },
    "naive_doc_ids": [
      "56486733",
      "25328476",
      "24150328",
      "5828251",
      "15972906"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 4 directly shows that the PPAR (peroxisome proliferator-activated receptor) forms a heterodimer with RXR\u03b1 and that this complex can be transcriptionally activated in response to a PPAR ligand (clofibric acid), confirming that PPAR\u2013RXR heterodimers are activated by PPAR ligands."
    },
    "overthinking_doc_ids": [
      "13639330",
      "25328476",
      "1044552",
      "8458567",
      "17648235"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "None of the provided papers describe the formation or activation of PPAR\u2013RXR heterodimers upon binding PPAR ligands. Papers 4 and 7 discuss PPAR-\u03b3 expression and the use of PPAR-\u03b3 agonists (rosiglitazone) but do not address RXR involvement or directly demonstrate that PPAR\u2013RXR complexes are activated by PPAR ligands."
    },
    "posthoc_doc_ids": [
      "5828251",
      "15972906",
      "20690388",
      "22478394",
      "7729656"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "264",
    "claim": "Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 3 demonstrates that in rheumatoid arthritis, neutrophil extracellular traps externalize citrullinated autoantigens, correlating with anti-citrullinated protein antibody (ACPA) levels and driving further NETosis and synovial inflammation. This supports the claim that citrullinated proteins in NETs promote autoantibody induction and perpetuate the inflammatory cycle. Other papers describe NET formation mechanisms but do not refute this role."
    },
    "naive_doc_ids": [
      "1049501",
      "1800734",
      "11328820",
      "17967608",
      "43054703"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 3 demonstrates that citrullinated histone 4 externalized during NET formation is specifically recognized by autoantibodies from rheumatoid arthritis (RA) patients. Paper 7 further shows that NETosis in RA leads to exposure of multiple citrullinated autoantigens, that these antigens drive ACPA production, and that NETs in turn amplify inflammatory cytokine responses in synovial fibroblasts. Together, these data confirm that citrullinated proteins in NETs indirectly perpetuate inflammation via induction of autoantibodies."
    },
    "overthinking_doc_ids": [
      "1800734",
      "14853989",
      "30041340",
      "17967608",
      "275294"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple studies directly demonstrate that NETosis externalizes citrullinated proteins which become autoantibody targets and feed back to inflammation. Paper 2 shows RA patient sera bind citrullinated histone H4 released in NETs, identifying these modified NET\u2010derived proteins as ACPA antigens. Paper 4 extends this by correlating increased NETosis (and exposure of citrullinated antigens) with ACPA titers in RA, and showing that NETs drive proinflammatory cytokine production in synovial fibroblasts. Together, these findings support the claim that citrullinated proteins in NETs perpetuate inflammation indirectly via autoantibody induction."
    },
    "posthoc_doc_ids": [
      "14853989",
      "30041340",
      "1049501",
      "11328820",
      "1800734"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "386",
    "claim": "Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "Paper 2 (the ethnographic study of IV drug errors) reports that most errors occurred during bolus administration or during multi\u2010step drug preparations, directly affirming the claim."
    },
    "naive_doc_ids": [
      "21260231",
      "16495649",
      "24525112",
      "3578380",
      "118568"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 (the ethnographic study of intravenous drug errors) directly reports that most errors occurred when giving bolus doses or during multi-step preparation, which aligns with the claim."
    },
    "overthinking_doc_ids": [
      "27550580",
      "21260231",
      "16760369",
      "16495649",
      "79231308"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1, a prospective ethnographic study of intravenous drug errors, found that most errors occurred when giving bolus doses or making up drugs requiring multiple\u2010step preparation, directly confirming the claim that peripheral IV administration errors are most common during bolus administration and complex preparations. None of the other cited papers address this specific issue."
    },
    "posthoc_doc_ids": [
      "16495649",
      "21260231",
      "3578380",
      "79231308",
      "4424888"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1347",
    "claim": "Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided papers address whether influenza\u2010specific memory CD4+ T cells reduce early inflammatory chemokine production in the lung upon viral challenge. The studies focus on CD8+ Trm formation, T cell egress, DC imprinting of CCR4 on T cells, bacterial gene expression, or costimulatory requirements for CD8+ responses, but do not report data on memory CD4+ T cell\u2013mediated modulation of early lung chemokines."
    },
    "naive_doc_ids": [
      "3835423",
      "12100963",
      "2248870",
      "11721286",
      "40473317"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 4 directly tests the impact of memory versus naive CD4+ T cells on early innate inflammatory cytokine and chemokine (IIC) production in the lung during influenza infection and finds that memory CD4+ T cells actually enhance early chemokine production rather than diminish it. No other paper reports that influenza-specific memory CD4+ T cells reduce early lung chemokine levels, so the available evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "12100963",
      "3835423",
      "2248870",
      "19005293",
      "40473317"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 3 directly addresses the effect of memory CD4+ T cells on early lung chemokine production during influenza infection and shows that these cells enhance, rather than diminish, the early production of innate inflammatory cytokines and chemokines in the lung."
    },
    "posthoc_doc_ids": [
      "3835423",
      "12100963",
      "19005293",
      "11721286",
      "40473317"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "606",
    "claim": "Increased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 demonstrates that loss or down\u2010regulation of the PGE\u2082\u2010to\u201015-keto\u2010PGE\u2082 converting enzyme (15-PGDH) leads to PGE\u2082 accumulation in colorectal tumors. By contrast, increased conversion (higher 15-PGDH activity) would be expected to deplete rather than accumulate PGE\u2082, directly opposing the claim."
    },
    "naive_doc_ids": [
      "21181273",
      "712078",
      "5775033",
      "56486733",
      "3330111"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.76,
      "justification": "Paper 1 directly addresses the balance of PGE\u2082 synthesis and breakdown by 15-PGDH: loss of 15-PGDH (reduced conversion of PGE\u2082 to 15-keto-PGE\u2082) leads to PGE\u2082 accumulation. Thus, by inversion, increased conversion should lower PGE\u2082 levels rather than cause its accumulation, contradicting the claim."
    },
    "overthinking_doc_ids": [
      "21181273",
      "980008",
      "1686997",
      "56486733",
      "712078"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided studies examine whether upregulating the conversion of PGE\u2082 into its PPAR\u03b3\u2010active metabolite 15-keto-PGE\u2082 leads to accumulation of PGE. Paper 4 is the only one that mentions 15-keto-PGE\u2082, but it reports a decrease of this ligand in Cftr-deficient mice and does not address the effect of increased conversion or PGE accumulation. No evidence supports or refutes the specific claim."
    },
    "posthoc_doc_ids": [
      "1022115",
      "1281769",
      "1428830",
      "712078",
      "27615329"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "565",
    "claim": "In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 demonstrates that in S. cerevisiae, loss of RNA surveillance components (e.g., the RNase III Rnt1p, Xrn1p, Rat1p, and exosome factor Rrp6p) leads to accumulation of iron uptake transcripts and renders cells hypersensitive to high iron. This directly supports the claim that absence of RNA surveillance pathways causes sensitivity to high iron conditions in yeast."
    },
    "naive_doc_ids": [
      "16120395",
      "30261663",
      "365896",
      "4421742",
      "21602220"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 1 directly demonstrates that loss of the RNA surveillance enzyme Rnt1p (and other degradative pathways) leads to over\u2010expression of iron uptake mRNAs and hypersensitivity to high iron in S. cerevisiae, showing that RNA surveillance is required to prevent iron toxicity."
    },
    "overthinking_doc_ids": [
      "16120395",
      "26596106",
      "42267740",
      "30261663",
      "335029"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly demonstrates that loss of the RNase III ortholog Rnt1p (and other RNA surveillance factors) in S. cerevisiae leads to hypersensitivity to high iron concentrations, indicating that RNA surveillance is required to prevent iron toxicity."
    },
    "posthoc_doc_ids": [
      "16120395",
      "365896",
      "26596106",
      "143251",
      "3203590"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "149",
    "claim": "Autophagy deficiency in the liver increases vulnerability to insulin resistance.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that mice with liver-specific autophagy deficiency were protected from diet-induced obesity and showed ameliorated insulin resistance, directly opposing the claim that liver autophagy deficiency increases vulnerability to insulin resistance. None of the other papers provide evidence linking liver autophagy deficiency to increased insulin resistance."
    },
    "naive_doc_ids": [
      "6227220",
      "31001322",
      "2481032",
      "16389141",
      "11201004"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 3 reports that liver\u2010specific autophagy deficiency induces Fgf21 and actually protects against diet\u2010induced obesity and improves insulin sensitivity, directly opposing the claim that autophagy deficiency in the liver increases vulnerability to insulin resistance."
    },
    "overthinking_doc_ids": [
      "16389141",
      "5268462",
      "6227220",
      "4680262",
      "597790"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 reports that liver\u2010specific autophagy deficiency protects mice from diet-induced obesity and ameliorates insulin resistance via Fgf21 induction. This directly opposes the claim that autophagy deficiency in the liver increases vulnerability to insulin resistance. The other papers do not address liver autophagy, so the overall evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "6227220",
      "2481032",
      "31001322",
      "52805891",
      "5268462"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "141",
    "claim": "Auditory entrainment is strengthened when people see congruent visual and auditory information.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 shows that cortical entrainment to the speech envelope is enhanced when auditory and visual speech streams are temporally and contextually congruent, and inhibited when they are incongruent. Paper 4 further demonstrates that low-frequency neural phase dynamics simultaneously track auditory and visual stimulus rhythms, supporting the view that congruent visual input strengthens auditory entrainment. Other papers do not address audiovisual entrainment directly."
    },
    "naive_doc_ids": [
      "14437255",
      "38794814",
      "6431384",
      "6955746",
      "10608822"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that cortical entrainment to the speech envelope is enhanced by congruent audiovisual speech and inhibited by incongruent streams. Paper 2 shows that low-frequency neuronal phase in auditory cortex carries dynamic information about both auditory and visual inputs, indicating synergistic cross-modal tracking when the streams are naturally (and thus congruently) combined. The remaining papers do not address audiovisual congruency or entrainment and are therefore not informative for this claim."
    },
    "overthinking_doc_ids": [
      "14437255",
      "6955746",
      "313394",
      "6431384",
      "26107000"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly demonstrates that cortical entrainment to the speech envelope is enhanced when visual speech is temporally and contextually congruent with the auditory stream (and is inhibited when they\u2019re incongruent). Paper 2 shows that low\u2010frequency (2\u20137 Hz) neuronal phase in auditory cortex carries information about both auditory and visual dynamics, implying a synergistic audiovisual entrainment mechanism. Paper 5 documents the naturally tight temporal correspondence between mouth movements and the speech envelope in the 2\u20137 Hz band\u2014the very frequency range at which audiovisual entrainment is strongest\u2014providing the statistical basis for why congruent visual cues strengthen auditory entrainment. Papers 3 and 4 are not relevant to this claim."
    },
    "posthoc_doc_ids": [
      "14437255",
      "6955746",
      "313394",
      "39532074",
      "18379855"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "223",
    "claim": "Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that oncogenic mTOR signaling in cancer cells drives G-CSF production, which in turn recruits intra-tumoural MDSCs. This provides experimental evidence that cancer cells can stimulate MDSC accumulation by upregulating granulocyte colony-stimulating factor."
    },
    "naive_doc_ids": [
      "2014909",
      "188911",
      "2030623",
      "15727984",
      "20183360"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 3 directly shows that oncogenic mTOR signaling in cancer cells drives intra-tumoural MDSC accumulation by upregulating G-CSF production, thereby confirming that tumor cells can promote MDSC recruitment via G-CSF."
    },
    "overthinking_doc_ids": [
      "15435343",
      "25726838",
      "2014909",
      "42465769",
      "188911"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 directly demonstrates that oncogenic mTOR signaling in cancer cells drives G-CSF production, which in turn recruits myeloid-derived suppressor cells into the tumor microenvironment. This provides clear experimental evidence that tumor cells can stimulate intra-tumoural MDSC accumulation via increased G-CSF."
    },
    "posthoc_doc_ids": [
      "24612804",
      "42465769",
      "188911",
      "2014909",
      "25726838"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "2",
    "claim": "1 in 5 million in UK have abnormal PrP positivity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly measured abnormal PrP positivity in 32 441 UK appendix samples and found 16 positives, corresponding to a prevalence of 493 per million (\u22481 per 2 000), which is far higher than 1 per 5 000 000. No other paper provides relevant data, and the evidence thus contradicts the claim."
    },
    "naive_doc_ids": [
      "13734012",
      "42240424",
      "7285256",
      "28562710",
      "42291761"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "The claim asserts an abnormal PrP positivity prevalence of 1 per 5 000 000 (0.2 per million) in the UK. Paper 1 directly measures PrP positivity in 32 441 archived appendices and finds 16 positives, yielding a prevalence of 493 per million (95% CI 282\u2013801 per million). This rate is orders of magnitude higher than 1 in 5 million, directly contradicting the claim. None of the other papers provide relevant prevalence data for UK abnormal PrP positivity."
    },
    "overthinking_doc_ids": [
      "13734012",
      "42240424",
      "1171121",
      "8354687",
      "20321154"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 reports 16 positive samples out of 32 441 appendixes, corresponding to ~493 per million (\u22481 in 2 000) abnormal PrP positives in the UK\u2014far higher than the claimed rate of 1 in 5 000 000. No other paper supports the much lower prevalence stated in the claim."
    },
    "posthoc_doc_ids": [
      "32481310",
      "13734012",
      "1606628",
      "42240424",
      "1171121"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1141",
    "claim": "Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The Physicians\u2019 Health Study II (Paper 9) directly tested 400 IU (~400 mg) vitamin E (\u03b1-tocopheryl acetate) plus 500 mg vitamin C in men and found no reduction in prostate cancer risk (HR\u22481.0, P>.5). No other paper provides relevant supportive data."
    },
    "naive_doc_ids": [
      "520579",
      "16422880",
      "38551172",
      "6669242",
      "18473550"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The large randomized Physicians\u2019 Health Study II (Paper 1) tested vitamin E (\u03b1-tocopheryl acetate 400 IU every other day) in combination with vitamin C (500 mg daily) and found no reduction in prostate cancer incidence (HR\u22481.00, P>.5). No other cited study addresses E\u2009+\u2009C and prostate cancer risk. Thus the evidence does not support the claim."
    },
    "overthinking_doc_ids": [
      "12009265",
      "3222187",
      "32534305",
      "20454006",
      "24396137"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 (the Physicians\u2019 Health Study II randomized trial) directly tested supplementation with 400 IU vitamin E (\u03b1-tocopheryl acetate) every other day and 500 mg vitamin C daily, alone and in combination, over 8 years. It found no reduction in prostate cancer incidence (HR\u22481.0, P\u2009>\u2009.5) with either vitamin E or C, providing high\u2010quality evidence that this regimen does not decrease prostate cancer risk."
    },
    "posthoc_doc_ids": [
      "520579",
      "16422880",
      "38551172",
      "12009265",
      "3222187"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1359",
    "claim": "Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 2 directly compares 12 weeks of varenicline monotherapy versus varenicline + bupropion SR and finds higher abstinence in the combination arm at week 12 (53.0% vs 43.2%, OR 1.49, P = .03). Paper 4\u2019s network meta-analysis also shows that varenicline is not more effective than combination NRT (OR 1.06, 95% CredI 0.75\u20131.48). These results contradict the claim that varenicline monotherapy is more effective after 12 weeks than combination therapies."
    },
    "naive_doc_ids": [
      "34369306",
      "11614737",
      "6191684",
      "5114940",
      "8570690"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 2 directly compares 12 weeks of varenicline monotherapy versus varenicline + bupropion combination and finds combination is significantly more effective at week 12 (53.0% vs 43.2%; OR 1.49, 95% CI 1.05\u20132.12; P = .03). Paper 5\u2019s network meta-analysis also shows varenicline is not superior to combination NRT (OR 1.06; 95% CredI 0.75\u20131.48). Thus the evidence contradicts the claim that varenicline monotherapy is more effective."
    },
    "overthinking_doc_ids": [
      "34369306",
      "11614737",
      "8570690",
      "3944632",
      "5114940"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly compares 12 weeks of varenicline\u2009+\u2009bupropion SR versus varenicline monotherapy and finds higher prolonged abstinence in the combination arm (53.0% vs 43.2%; OR 1.49; P =.03). This refutes the claim that varenicline alone is more effective after 12 weeks than combination therapies."
    },
    "posthoc_doc_ids": [
      "11614737",
      "34369306",
      "6191684",
      "3944632",
      "11718220"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "124",
    "claim": "Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.24,
      "justification": "Paper 1 reports a meta-analysis showing that antiretroviral therapy reduces tuberculosis incidence with hazard ratios of 0.16, 0.34, and 0.43 in CD4 strata <200, 200\u2013350, and >350 cells/\u00b5l respectively, with no effect modification by baseline CD4. None of the other papers address ART\u2019s effect on TB rates. Thus the claim is supported."
    },
    "naive_doc_ids": [
      "4883040",
      "7111021",
      "13899137",
      "14806256",
      "10582939"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Paper 1 provides direct evidence from a systematic review and meta-analysis showing that ART is strongly associated with reduced tuberculosis incidence in HIV-infected adults at all baseline CD4 strata (HRs 0.16 for <200, 0.34 for 200\u2013350, 0.43 for >350, and 0.35 overall; no heterogeneity by strata). No included studies contradict these findings."
    },
    "overthinking_doc_ids": [
      "4883040",
      "7111021",
      "13899137",
      "9648896",
      "14672919"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 directly assesses the effect of ART on TB incidence by baseline CD4 count and finds substantial reductions in TB risk in all CD4 strata (HRs 0.16 for <200, 0.34 for 200\u2013350, 0.43 for >350 cells/\u00b5l), with no evidence of effect modification by CD4 category. The other papers do not address TB incidence."
    },
    "posthoc_doc_ids": [
      "4883040",
      "7111021",
      "13899137",
      "16422880",
      "829646"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1237",
    "claim": "The most prevalent adverse events to Semaglutide are cardiovascular.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Only Paper 4 reports adverse events for semaglutide, and it finds that mild to moderate gastrointestinal events were the most common, not cardiovascular events. No paper provides data showing cardiovascular events as the predominant adverse events of semaglutide."
    },
    "naive_doc_ids": [
      "11254040",
      "6070278",
      "42404093",
      "3654468",
      "3578380"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Only Paper 4 discusses semaglutide, reporting that mild to moderate gastrointestinal events were the most common adverse events, not cardiovascular events. No evidence in any paper supports cardiovascular adverse events as the most prevalent for semaglutide."
    },
    "overthinking_doc_ids": [
      "11254040",
      "583260",
      "6070278",
      "3654468",
      "46565020"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 8, the only trial of semaglutide provided, reports that the most common adverse events were mild to moderate gastrointestinal symptoms, not cardiovascular events, directly contradicting the claim that cardiovascular events are the most prevalent with semaglutide."
    },
    "posthoc_doc_ids": [
      "6070278",
      "46277811",
      "40790033",
      "4445629",
      "4463588"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "236",
    "claim": "Cell autonomous sex determination in somatic cells occurs in Passeriformes.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.24,
      "justification": "The cited studies demonstrate cell-autonomous sex identity in chicken (a Galliform), but none examine Passeriformes specifically. Therefore there is no direct evidence for or against the claim in Passeriformes."
    },
    "naive_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "12232678",
      "11578459"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Only Paper 1 provides evidence for cell-autonomous sex identity in birds, but it examines Galliformes (chicken), not Passeriformes. None of the other papers address sex determination in Passeriformes specifically."
    },
    "overthinking_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "3360421",
      "5500086"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.15,
      "justification": "Only Paper 1 addresses cell-autonomous sex identity in birds, but it studies chicken (a Galliform), not Passeriformes; none of the other papers discuss sex determination in somatic cells of Passeriformes."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "7426741",
      "3360421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1028",
    "claim": "Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 shows that a type 1 diabetes\u2013associated IL2RA haplotype correlates with diminished IL-2\u2013triggered STAT5 phosphorylation, lower FOXP3 levels, and reduced suppressive capacity of CD4+CD25+ Tregs. Paper 6 demonstrates in mice that genetic reduction of IL-2 expression leads to impaired Treg function and the development of autoimmunity. Together, these data confirm that reduced IL-2 responsiveness in regulatory T cells is associated with autoimmune disease such as type 1 diabetes."
    },
    "naive_doc_ids": [
      "2388819",
      "11899391",
      "33535222",
      "11953232",
      "16389141"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that an IL2RA haplotype associated with Type 1 diabetes correlates with diminished IL-2 signaling (reduced STAT5a phosphorylation), lower FOXP3 expression in Tregs, and impaired suppressive function, thereby supporting the claim that reduced IL-2 responsiveness in regulatory T cells is linked to autoimmune disease."
    },
    "overthinking_doc_ids": [
      "11899391",
      "38830961",
      "2388819",
      "712078",
      "16712164"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly shows that a T1D-associated IL2RA haplotype correlates with diminished IL-2-induced STAT5a phosphorylation in CD4+CD25+ Tregs, lower FOXP3 expression, and reduced suppressive function. Paper 8 further links IL2RA risk alleles to lower soluble IL-2RA levels and increased T1D susceptibility, implying reduced IL-2 responsiveness predisposes to autoimmunity."
    },
    "posthoc_doc_ids": [
      "11899391",
      "2388819",
      "23342845",
      "24338780",
      "29785642"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "841",
    "claim": "Natriuretic peptides protect against diabetes.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address the role of natriuretic peptides in diabetes protection. They focus on obesity\u2013insulin resistance, beta-cell preservation by insulin sensitizers, genetic modifiers in type 1 diabetes, thiazolidinediones, corin/ANP signaling in preeclampsia/pregnancy hypertension, and Wnt5a in adipose inflammation, but do not evaluate natriuretic peptides and their impact on diabetes risk or protection."
    },
    "naive_doc_ids": [
      "120626",
      "27166444",
      "195352",
      "16058322",
      "26058927"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 provides direct evidence that higher B-type natriuretic peptide (BNP) levels are associated with a reduced risk of incident type 2 diabetes and that a genetic variant raising BNP causally lowers diabetes risk. No other paper presents data on natriuretic peptides in diabetes."
    },
    "overthinking_doc_ids": [
      "15663829",
      "3912660",
      "9822397",
      "1907601",
      "10889845"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 provides direct evidence that higher circulating B-type natriuretic peptide levels are associated with a reduced risk of incident type 2 diabetes, and Mendelian randomization analysis supports a causal protective role of the BNP system in diabetes. None of the other papers address natriuretic peptides in relation to diabetes."
    },
    "posthoc_doc_ids": [
      "8063697",
      "13923069",
      "15663829",
      "33960383",
      "2665675"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1207",
    "claim": "The composition of myosin-II isoform switches from the polarizable B isoform to the more homogenous A isoform during hematopoietic differentiation.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 7 directly examines nonmuscle myosin\u2010II in hematopoiesis and reports that MIIB is the predominant, polarized isoform in HSC/Ps and is downregulated upon differentiation, whereas MIIA is constitutive and activated during cytokine\u2010triggered differentiation. This isoform shift from B to A during hematopoietic differentiation aligns with the claim."
    },
    "naive_doc_ids": [
      "23727313",
      "34854444",
      "6270720",
      "11840194",
      "27061085"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 directly addresses nonmuscle myosin-II isoform usage in human hematopoiesis, showing that MIIB (the \u2018B\u2019 isoform) is highly expressed and polarized in HSCs/HSPCs and is down-regulated upon differentiation, while MIIA (the \u2018A\u2019 isoform) is constitutively present and activated during cytokine-triggered differentiation. These findings confirm an isoform switch from B to A during hematopoietic differentiation."
    },
    "overthinking_doc_ids": [
      "23727313",
      "12315072",
      "27061085",
      "18909530",
      "735130"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 3 directly reports that in human hematopoietic stem and progenitor cells nonmuscle myosin-II B (MIIB) is the predominant, polarized isoform and is downregulated upon differentiation, whereas myosin-II A (MIIA) is constitutive and becomes activated during cytokine-triggered differentiation. This observation confirms a switch from the B isoform to the A isoform during hematopoietic differentiation, in agreement with the claim."
    },
    "posthoc_doc_ids": [
      "27061085",
      "14581009",
      "18909530",
      "236204",
      "469066"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1390",
    "claim": "mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 2 explicitly states that 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) is required for proper decoding of NNR codons in eukaryotes. Paper 1 further shows that loss of the mcm5 or s2 modifications on U34 in cytoplasmic tRNAs for Gln, Lys, and Glu reduces decoding efficiency and is lethal in yeast, reinforcing the role of mcm5s2U in accurate codon\u2013anticodon pairing."
    },
    "naive_doc_ids": [
      "34498325",
      "2890952",
      "13552682",
      "1748921",
      "30261663"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 explicitly states that the wobble modification 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) is required for proper decoding of NNR codons in eukaryotes. Paper 3 further shows that loss of mcm5s2U impairs reading of cognate codons and is lethal unless suppressed by tRNA overexpression. Together these findings directly support the claim."
    },
    "overthinking_doc_ids": [
      "984825",
      "13552682",
      "34498325",
      "2890952",
      "16927286"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 2 explicitly states that the wobble modification mcm5s2U is required for proper decoding of NNR codons in eukaryotes, and Paper 1 shows that loss of mcm5s2U impairs reading of A- and G-ending codons (i.e. NNR codons) in yeast tRNAs, confirming the claim."
    },
    "posthoc_doc_ids": [
      "34498325",
      "2890952",
      "13552682",
      "22896970",
      "31514338"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "19",
    "claim": "7-day-old adult Caenorhabditis elegans exhibit approximately 5% of the learning capacity seen in 1-day old adults.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers quantifies or directly reports the relative learning capacity of 7-day-old versus 1-day-old adult C. elegans (e.g., a ~5% figure). While Paper 4 examines age-related decline in learning and memory in C. elegans, it does not provide the specific numerical comparison (day 7 vs. day 1) needed to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "13072113",
      "7042304",
      "16267205",
      "3202143",
      "11992632"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.05,
      "justification": "None of the three papers address age-dependent learning capacity or directly compare learning performance between 1-day-old and 7-day-old C. elegans. They focus on protein aggregation thresholds, neuronal morphology/synapse integrity, and sex/steroid receptor effects on lifespan, without reporting behavioral learning measures across those ages."
    },
    "overthinking_doc_ids": [
      "7042304",
      "13072113",
      "16267205"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the eight provided papers report a direct quantitative comparison of learning capacity in 7-day-old versus 1-day-old adult C. elegans at the ~5% level. Paper 4 addresses age-related decline in learning and memory but does not give the specific percentage cited in the claim."
    },
    "posthoc_doc_ids": [
      "7042304",
      "13072113",
      "1127562",
      "3202143",
      "6333347"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1266",
    "claim": "The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 4 directly examines placental weight and subsequent maternal breast cancer risk in a large cohort. It reports that women whose placentas weighed \u2265700 g in two consecutive pregnancies had about double the risk of invasive breast cancer (adjusted HRs 1.82\u20132.05, 95% CIs excluding 1.0). Since 95% of the breast cancers occurred before age 50 (pre-menopausal), the findings indicate that higher placental weight is associated with increased breast cancer risk, particularly for premenopausal disease, consistent with the claim."
    },
    "naive_doc_ids": [
      "13831842",
      "16701509",
      "3329824",
      "37480103",
      "1428840"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 directly examined placental weight in two successive pregnancies and found progressively higher adjusted hazard ratios (1.82 for mixed high weights, 2.05 for \u2265700 g in both) for maternal breast cancer\u201495% of cases diagnosed before age 50\u2014demonstrating that risk increases with placental weight and is strongest for premenopausal breast cancer. No other papers contradicted this finding."
    },
    "overthinking_doc_ids": [
      "13831842",
      "37480103",
      "16322674",
      "2015126",
      "22401720"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 reports that women with higher placental weights in two successive pregnancies had significantly elevated hazard ratios for invasive breast cancer (HRs up to 2.05, 95% CI 1.15\u20133.64), and 95% of the cases were diagnosed before age 50 (premenopausal). This directly confirms that breast cancer risk increases with placental weight and is strongest for premenopausal disease."
    },
    "posthoc_doc_ids": [
      "13831842",
      "9171913",
      "37480103",
      "5864770",
      "3329824"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "184",
    "claim": "Bone marrow cells don't contribute to adult macrophage compartments.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 2 clearly show that in the steady state adult tissue-resident macrophages are maintained by local self-renewal and are established before birth, with minimal or no input from circulating monocytes derived from bone marrow. Paper 7 further reinforces that most adult macrophages arise embryonically rather than from adult marrow. The other studies focus on in vitro differentiation or inflammatory replacement rather than steady-state maintenance and do not contradict this conclusion."
    },
    "naive_doc_ids": [
      "12827098",
      "7521113",
      "24707550",
      "188911",
      "35811036"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Papers 1 and 2 directly demonstrate that adult tissue\u2010resident macrophages are established before birth and self\u2010maintained locally with minimal to no input from circulating monocytes (bone marrow\u2013derived). The other studies do not provide evidence that contradicts this steady\u2010state finding."
    },
    "overthinking_doc_ids": [
      "12827098",
      "7521113",
      "25985964",
      "2587396",
      "2824347"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 7 directly show that in the steady state adult tissue macrophage pools (e.g. Kupffer cells, alveolar macrophages, peritoneal macrophages) are maintained locally and established before birth, with negligible replenishment from circulating monocytes or bone marrow\u2013derived precursors. The other papers either address in vitro generation of macrophages or unrelated differentiation pathways and do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "12827098",
      "188911",
      "3118719",
      "35811036",
      "46193388"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "249",
    "claim": "Chenodeosycholic acid treatment reduces whole-body energy expenditure.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines the effects of chenodeoxycholic acid (CDCA) treatment in humans and reports that CDCA increases whole\u2010body energy expenditure. No paper provides evidence that CDCA reduces energy expenditure; thus the claim is contradicted."
    },
    "naive_doc_ids": [
      "1568684",
      "25050364",
      "26902591",
      "14865329",
      "18450716"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly tests chenodeoxycholic acid (CDCA) in humans and reports that 2 days of oral CDCA increased brown adipose tissue activity and raised whole-body energy expenditure, which is opposite to the claim that CDCA treatment reduces energy expenditure. None of the other papers provide evidence supporting a CDCA-induced reduction in energy expenditure."
    },
    "overthinking_doc_ids": [
      "1568684",
      "25050364",
      "26902591",
      "23369842",
      "18126445"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 reports that oral chenodeoxycholic acid (CDCA) increased human brown adipose tissue activity and raised whole\u2010body energy expenditure, directly opposing the claim that CDCA treatment reduces energy expenditure. The other papers do not address CDCA\u2019s effects on whole\u2010body energy expenditure."
    },
    "posthoc_doc_ids": [
      "1568684",
      "25050364",
      "13902570",
      "24917562",
      "26902591"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1379",
    "claim": "Women with a higher birth weight are more likely to develop breast cancer later in life.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Two large-scale analyses (Paper 4 and Paper 5) directly address birth weight and adult breast cancer risk. Paper 4\u2019s meta-analysis of 57 studies found a pooled RR of 1.15 (95% CI 1.09\u20131.21) for higher birth weight, and Paper 5\u2019s pooled individual\u2013participant analysis of 32 studies reported an RR per 0.5 kg increment of 1.06 (95% CI 1.02\u20131.09), both indicating that greater birth weight is positively associated with breast cancer risk in adulthood."
    },
    "naive_doc_ids": [
      "13831842",
      "13765757",
      "22401720",
      "23557241",
      "16322674"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Papers 2, 4, and 5 directly address birth weight and all report a positive association between higher birth weight and increased breast cancer risk (e.g. RR\u22481.06 per 0.5 kg increment in birth weight in Paper 2; OR\u22481.24 for \u22654 kg vs 2.5\u20132.6 kg in Paper 4; RR\u22481.15 per category increase in Paper 5). Papers 1, 3, and 6 do not provide relevant data on birth weight."
    },
    "overthinking_doc_ids": [
      "13831842",
      "16322674",
      "13765757",
      "17450673",
      "23557241"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Two large-scale analyses directly link higher birth weight to increased breast cancer risk. In the pooled re-analysis of 32 studies (Paper 3), each 0.5\u2009kg increment in birth weight raised risk (RR\u2009=\u20091.06, 95%\u2009CI\u20091.02\u20131.09), and women \u22654.0\u2009kg at birth had higher risk (RR\u20091.12, 95%\u2009CI\u20091.00\u20131.25). A meta-analysis of perinatal factors (Paper 9) likewise found that birth weight \u22654.0\u2009kg carried an OR of 1.24 (95%\u2009CI\u20091.04\u20131.48) relative to 2.5\u20132.6\u2009kg. Although Paper 1 found no link between birth weight and adult breast density (a surrogate), and Paper 2 only showed an association of high birth weight with higher density (but not direct cancer incidence), the direct epidemiologic evidence from Papers 3 and 9 supports the claim."
    },
    "posthoc_doc_ids": [
      "38784540",
      "5487448",
      "16322674",
      "24341590",
      "16734530"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1030",
    "claim": "Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 demonstrates that blocking the H3K4 methyltransferase MLL1 (which reduces H3K4 methylation) reprograms mouse epiblast stem cells to a naive pluripotent state with >50% efficiency within 3 days. This directly confirms the claim that reducing H3K4me3 methylation induces efficient conversion of EpiSCs to naive pluripotency. None of the other papers address this specific mechanism."
    },
    "naive_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "14471161",
      "30884033"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that inhibition of the H3K4 methyltransferase MLL1 (which reduces H3K4 methylation) using MM\u2010401 reprograms mouse epiblast stem cells to a naive pluripotent state with >50% efficiency within 3 days. This directly demonstrates that reducing H3K4 methylation induces efficient conversion of primed EpiSCs to naive pluripotency, confirming the claim."
    },
    "overthinking_doc_ids": [
      "6441369",
      "3882374",
      "4462419",
      "11390393"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that inhibition of the H3K4 methyltransferase MLL1 (and thus reduction of H3K4 methylation) reprograms mouse EpiSCs to a naive ESC state with >50% efficiency in 3 days, showing that reducing H3K4 methylation is sufficient to drive efficient conversion to naive pluripotency. The other papers do not address H3K4me3 or this reprogramming process."
    },
    "posthoc_doc_ids": [
      "6441369",
      "37164306",
      "4462419",
      "14923462",
      "6054657"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.7,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "18",
    "claim": "61% of colorectal cancer patients are diagnosed with regional or distant metastases.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided studies report the overall proportion of colorectal cancer patients diagnosed with regional (stage III) or distant (stage IV) metastases at presentation. Paper 4 gives only the percentage of stage IV patients (19\u201323%), and no study combines stage III and IV data to support or refute the 61% figure."
    },
    "naive_doc_ids": [
      "2058909",
      "23830488",
      "5641851",
      "10958594",
      "24980622"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.13,
      "justification": "None of the provided studies report the combined percentage of colorectal cancer patients presenting with regional (stage III) or distant (stage IV) metastases. Paper 1 gives only stage IV proportions (19\u201323 %), and the others do not supply overall stage distributions. Thus there is no direct evidence to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "10958594",
      "24980622",
      "5641851",
      "22942787",
      "2058909"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.14,
      "justification": "None of the provided studies report the combined proportion of colorectal cancer patients diagnosed with regional (stage III) or distant (stage IV) metastases. Paper 1 gives only stage IV percentages (19\u201323%), and Paper 7 splits early (stage I) versus all other stages (II\u2013IV) but does not isolate stage III+IV. The remaining papers do not provide overall stage distribution data to confirm or refute the 61% figure."
    },
    "posthoc_doc_ids": [
      "10958594",
      "24980622",
      "3329824",
      "5641851",
      "23830488"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "524",
    "claim": "Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 6 directly reports that in 2,595 human subjects undergoing cardiac evaluation, higher plasma L-carnitine levels predicted increased prevalent CVD and incident major adverse cardiac events\u2014but only in participants with concurrently high TMAO levels\u2014demonstrating the claimed positive correlation in humans."
    },
    "naive_doc_ids": [
      "25822299",
      "6793674",
      "471921",
      "12130200",
      "5884524"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 directly demonstrates in a large human cohort (n=2,595) that higher plasma L-carnitine levels predict increased prevalent CVD and incident major adverse cardiac events, but only among subjects with concurrently high TMAO levels. Paper 1 further shows that elevated circulating TMAO alone is associated with higher CV event risk. Together these findings confirm that higher plasma L-carnitine, when coupled with elevated TMAO, is positively correlated with cardiovascular events in humans."
    },
    "overthinking_doc_ids": [
      "6793674",
      "4445629",
      "14803797",
      "27466734",
      "4647303"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 7 directly demonstrates that in human subjects undergoing cardiac evaluation, higher plasma L-carnitine levels predicted increased risk of prevalent CVD and incident major adverse cardiac events\u2014but only in those with concurrently high trimethylamine N-oxide (TMAO) levels, indicating a positive correlation between elevated L-carnitine (when associated with TMAO) and cardiovascular events."
    },
    "posthoc_doc_ids": [
      "25822299",
      "6793674",
      "4445629",
      "2138767",
      "4647303"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "109",
    "claim": "An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that exposure to cold rapidly promotes the alternative (M2-like) activation of adipose tissue macrophages, including those in brown adipose tissue, thus confirming that a cold stimulus quickly induces an M2-like phenotype in brown fat macrophages. The other papers do not address macrophage polarization in response to cold."
    },
    "naive_doc_ids": [
      "4319174",
      "29381091",
      "1568684",
      "43192375",
      "1507222"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 4 demonstrates that cold exposure rapidly promotes alternative (M2\u2010like) activation of adipose tissue macrophages, which then secrete catecholamines to drive brown fat thermogenesis, directly supporting the claim."
    },
    "overthinking_doc_ids": [
      "29381091",
      "43192375",
      "970012",
      "4319174",
      "22621251"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 4 demonstrates that cold exposure rapidly promotes alternative (M2-like) activation of adipose tissue macrophages, which secrete catecholamines to drive thermogenesis in brown adipose tissue, directly supporting the claim."
    },
    "posthoc_doc_ids": [
      "29381091",
      "43192375",
      "970012",
      "4319174",
      "20532591"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "226",
    "claim": "Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Multiple studies demonstrate that cancer cells actively induce the differentiation and activation of stromal fibroblasts into CAF\u2010like myofibroblasts. For example, Paper 4 shows that tumor\u2010derived exosomes bearing surface TGF-\u03b2 trigger \u03b1-smooth muscle actin up-regulation and SMAD signaling in normal fibroblasts, driving their conversion to myofibroblasts (CAFs). Paper 8 further reveals that cancer cells provoke oxidative stress in neighboring fibroblasts, leading to mitophagy and a glycolytic shift characteristic of activated CAFs. These findings directly support the claim that cancer cell\u2013CAF crosstalk mediates CAF formation and activation."
    },
    "naive_doc_ids": [
      "25915873",
      "22401720",
      "15972906",
      "13889430",
      "52925737"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that prostate cancer cells (\u2018tumor-driven\u2019) activate surrounding fibroblasts into CAFs, a process blocked by miR-205. Paper 3 directly demonstrates that cancer cells induce oxidative stress and mitochondrial dysfunction in adjacent fibroblasts, driving them to become metabolically active CAFs. These findings confirm that cancer\u2013fibroblast crosstalk mediates CAF formation and activation."
    },
    "overthinking_doc_ids": [
      "8702697",
      "10024681",
      "24349992",
      "22401720",
      "25915873"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "While Papers 1 and 2 demonstrate that CAFs secrete factors (e.g. SDF-1, IL6) that act on cancer cells to promote proliferation and chemoresistance, none of the provided studies address how cancer cells and CAFs mutually interact to drive the *formation* or *activation* of CAFs themselves. The other papers are unrelated to CAF biology. Thus, there is no direct evidence here for CAF formation or activation mediated by cancer\u2013CAF cross-talk."
    },
    "posthoc_doc_ids": [
      "9648896",
      "3376731",
      "20183360",
      "7869794",
      "8038329"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "759",
    "claim": "Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple modelling studies (Papers 1 and 6) explicitly compare ACT regimens to non-gametocytocidal or short-acting drugs and forecast large drops in parasite prevalence and clinical incidence when ACT is used as first-line therapy. For example, Paper 1 predicts up to a 53 % reduction in slide-positive prevalence in low\u2010transmission settings after switching entirely to ACT, and Paper 6 shows that high\u2010coverage ACT (with primaquine) drives parasite prevalence close to elimination. Although Paper 2\u2019s clinical data find a more moderate transmission effect (and submicroscopic gametocytemia persisting), it does not invalidate the model predictions of dramatic population\u2010level impact of ACT versus nongametocytocidal drugs."
    },
    "naive_doc_ids": [
      "1805641",
      "10617916",
      "18074797",
      "374902",
      "11026600"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 uses a mathematical model in Tanzanian settings to show that switching to ACT yields up to a 53% reduction in parasite prevalence (and similar drops in incidence), particularly in low\u2010transmission areas. Paper 6\u2019s modelling of interventions in Cambodia likewise finds that high coverage of artemisinin-piperaquine treatment produces substantial, sustained declines in P. falciparum prevalence, with additional benefit from primaquine. These model\u2010based results align with the claim that ACTs have a dramatic impact on reducing malaria transmission compared to non-gametocytocidal regimens."
    },
    "overthinking_doc_ids": [
      "1805641",
      "10617916",
      "12409683",
      "374902",
      "8063697"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Several of the provided papers use mathematical or simulation models (Papers 1, 4, 6) or pooled trial analyses (Paper 3) to compare transmission outcomes under ACT versus non-gametocytocidal regimens. They consistently predict substantial reductions in gametocytaemia, mosquito infection rates, and parasite prevalence when ACT is used as first-line therapy\u2014often approaching the impact of vector control in low-transmission settings and driving marked declines in incidence. No paper provides counter-evidence; the one field study (Paper 2) notes only that residual submicroscopic gametocytaemia tempers but does not refute the overall transmission benefit of ACT."
    },
    "posthoc_doc_ids": [
      "1805641",
      "10617916",
      "12409683",
      "18074797",
      "374902"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "153",
    "claim": "B3-Galectin decreases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers mention B3-Galectin or its engagement with a KRAS\u2013RalB complex downstream of EGFR. Paper 1 describes an integrin \u03b1v\u03b23\u2013KRAS\u2013RalB pathway that promotes resistance, not Galectin-3, and the other papers focus on unrelated resistance mechanisms (e.g. PTEN loss, NF1 reduction, YAP/TAZ, or chemotherapy rechallenge). Therefore, there is no relevant information to support or contradict the specific claim about B3-Galectin."
    },
    "naive_doc_ids": [
      "4702639",
      "9929089",
      "1065627",
      "34016944",
      "2272614"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided studies address the role of B3-Galectin in modulating TKI resistance or its engagement of a KRAS\u2013RalB complex downstream of EGFR. Although Paper 2 describes an integrin \u03b1v\u03b23\u2013KRAS\u2013RalB pathway promoting resistance to EGFR inhibitors, it involves integrin \u03b23 rather than B3-Galectin and reports enhanced resistance rather than decreased resistance. Therefore, there is no relevant information to support or contradict the specific claim about B3-Galectin."
    },
    "overthinking_doc_ids": [
      "9929089",
      "4702639",
      "1065627",
      "17648235",
      "4820792"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1 directly shows that unliganded integrin \u03b1v\u03b23 (which contains the \u03b23 subunit) recruits KRAS and RalB to the plasma membrane, activating TBK1\u2013NF-\u03baB and driving stemness and resistance to EGFR TKIs (erlotinib). This is the opposite of the claim that \u03b23 engagement of KRAS\u2013RalB decreases TKI resistance. The other papers discuss distinct resistance mechanisms (NF1 loss, PTEN loss, EGFR C797S, etc.) but do not support a \u03b23-dependent decrease in resistance."
    },
    "posthoc_doc_ids": [
      "4702639",
      "2272614",
      "34016944",
      "9505402",
      "36310858"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "361",
    "claim": "During the primary early antibody response activated B cells migrate toward the inner-and outer follicular areas where oxysterol accumulation is generated by stromal cells.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 shows that the orphan receptor EBI2 directs activated B cells to inter- and outer-follicular niches during the early T-dependent antibody response. Paper 5 identifies 7\u03b1,25-dihydroxycholesterol\u2014an oxysterol produced by stromal cells\u2014as the physiological ligand for EBI2 and describes how a stromal\u2010cell\u2013derived gradient of this oxysterol guides B-cell positioning. Together, these findings confirm that activated B cells migrate toward inner and outer follicular areas where stromal cells generate oxysterol accumulation."
    },
    "naive_doc_ids": [
      "7548577",
      "43619625",
      "5398179",
      "38587347",
      "15058155"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Papers 1 and 2 describe that activated B cells use the EBI2 receptor to move into inter- and outer-follicular niches during the early T-dependent antibody response, but none of the provided summaries mention oxysterol accumulation by stromal cells as the guiding ligand source. Therefore, the key part of the claim (oxysterol production by stromal cells) is not addressed."
    },
    "overthinking_doc_ids": [
      "38587347",
      "15488881",
      "7736860",
      "35256900",
      "11020556"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly describes that activated B cells use the oxysterol\u2010sensing receptor EBI2 to migrate to inner and outer follicular niches. It further notes that the EBI2 ligand (an oxysterol) is presented by stromal cells in these follicular regions, confirming that stromal cells generate the oxysterol gradient guiding B cells during the early antibody response."
    },
    "posthoc_doc_ids": [
      "38587347",
      "30369606",
      "7736860",
      "14768471",
      "3930020"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1072",
    "claim": "Sepsis related mortality has remained stable between 2009-2014.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 (clinical criteria) reports a significant decline in in-hospital sepsis mortality (\u20133.3%/y; P = .004) and Paper 3 shows risk-adjusted improvements in sepsis mortality over time. These findings contradict the claim of stable sepsis-related mortality from 2009\u20132014."
    },
    "naive_doc_ids": [
      "4824840",
      "4791384",
      "3776162",
      "3878434",
      "6647414"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines sepsis trends from 2009\u20132014 using clinical data. It reports a significant annual decline in in-hospital sepsis mortality (\u20133.3%/y, P\u2009=\u2009.004) and, by claims data, an even larger yearly drop in mortality (\u20137.0%/y, P\u2009<\u2009.001). Thus sepsis-related mortality did not remain stable but decreased over that period."
    },
    "overthinking_doc_ids": [
      "4824840",
      "3878434",
      "4791384",
      "3524352",
      "12224536"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 (clinical\u2010criteria sepsis) reports a significant annual decline in in\u2010hospital sepsis mortality of \u22123.3%/yr (P = .004), and Paper 6 shows risk\u2010adjusted improvements in sepsis mortality over time. Both contradict the claim that sepsis\u2010related mortality remained stable from 2009\u20132014."
    },
    "posthoc_doc_ids": [
      "4824840",
      "4791384",
      "663464",
      "16760369",
      "3878434"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "661",
    "claim": "JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 demonstrates that JMJD6 functions as an Fe(II)/\u03b1-ketoglutarate\u2013dependent lysyl hydroxylase that hydroxylates p53 on its C-terminal lysine (K382) and that this modification antagonizes p53 acetylation, promotes binding to its negative regulator MDMX, and suppresses p53\u2019s transcriptional activity. No other papers address JMJD6 or its hydroxylase activity."
    },
    "naive_doc_ids": [
      "37204802",
      "38009906",
      "29125354",
      "23195302",
      "38811597"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 demonstrates that JMJD6 acts as an Fe(II)/\u03b1-ketoglutarate-dependent lysyl hydroxylase that hydroxylates p53 on lysine 382 (a C-terminal site) and that this modification antagonizes p53 acetylation, promotes p53\u2019s association with MDMX, and represses p53\u2019s transcriptional activity. None of the other papers address JMJD6 or lysine hydroxylation, so overall the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "38009906",
      "29125354"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 demonstrates that JMJD6 functions as an Fe(II)- and \u03b1-ketoglutarate\u2013dependent lysyl hydroxylase that specifically hydroxylates p53 at its C-terminal lysine 382. The same study shows that this hydroxylation antagonizes p53 acetylation, promotes association with the negative regulator MDMX, and represses p53\u2019s transcriptional activity, directly supporting the claim."
    },
    "posthoc_doc_ids": [
      "37204802",
      "2316374",
      "14367469",
      "38009906",
      "29125354"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "57",
    "claim": "APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 shows that human iPSC\u2010derived neurons expressing ApoE4 have increased A\u03b2 production and tau phosphorylation but actually undergo GABAergic neuron degeneration rather than a delay of degeneration. This directly contradicts the claim\u2019s assertion that APOE4 delays GABA neuron degeneration."
    },
    "naive_doc_ids": [
      "4709641",
      "33986200",
      "7482674",
      "7221410",
      "10128893"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that in human iPSC\u2010derived neurons, APOE4 expression increases A\u03b2 production and tau phosphorylation but actually promotes GABAergic neuron degeneration rather than delaying it. No other paper supports a delay of GABA neuron degeneration by APOE4."
    },
    "overthinking_doc_ids": [
      "4709641",
      "3085264",
      "14460402",
      "1605196",
      "11659421"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly examines human iPSC\u2010derived neurons expressing APOE4 and reports that APOE4 increases both A\u03b2 production and tau phosphorylation, but it causes GABAergic neuron degeneration rather than delaying it. Thus, while the first part of the claim (increased A\u03b2 and tau phosphorylation) is supported, the second part (delayed GABA neuron degeneration) is contradicted by the evidence."
    },
    "posthoc_doc_ids": [
      "4709641",
      "3085264",
      "24632480",
      "25827024",
      "35520219"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "978",
    "claim": "Pro-inflammatory cytokines are up repressed during tumor development.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "None of the provided studies directly examine or report that pro-inflammatory cytokines are repressed during tumor development. While they cover diverse aspects of cancer biology (e.g., fibroblast\u2013tumor cell crosstalk, T cell exhaustion, tumor suppressors, exosomal miRNAs, inflammasome roles in metabolic disease), none present explicit data on downregulation of pro-inflammatory cytokines in the context of tumor development. Therefore, there is insufficient evidence here to support or contradict the claim."
    },
    "naive_doc_ids": [
      "24396137",
      "952111",
      "5377642",
      "7898952",
      "8133180"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided studies directly report that pro-inflammatory cytokines are progressively repressed or \u2018downregulated\u2019 during tumor development. While several papers discuss cytokine roles in inflammation (Paper 3), TNF-\u03b1 in atherosclerosis (Paper 4), or ex vivo cytokine release in cancer patients (Paper 9), none measure a downregulation of pro-inflammatory cytokines as tumors develop. Therefore, there is no direct evidence in these papers to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "952111",
      "2734421",
      "11233339",
      "22889972",
      "7898952"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.5,
      "justification": "Among the provided studies, only Paper 2 directly addresses pro\u2010inflammatory cytokines in the context of tumor development, showing that IL-17 (a key pro-inflammatory cytokine) is required for and indeed promotes tumor growth. This evidence contradicts the claim that pro-inflammatory cytokines are repressed during tumor development, since IL-17 levels/activity increase and foster a tumor\u2010promoting microenvironment rather than being downregulated. The other papers either do not address tumor development or do not report on pro-inflammatory cytokine repression in tumors."
    },
    "posthoc_doc_ids": [
      "21258863",
      "25726838",
      "25315295",
      "24396137",
      "41548287"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "946",
    "claim": "Physical activity level is associated with the difference in maximal oxygen consumption between black and white youth.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "Paper 1 attributes lower VO\u2082max in black versus white children in part to more sedentary behavior. However, Paper 2 measured total and activity energy expenditure (TEE and AEE) using doubly labeled water and found that the ~15% lower VO\u2082max in African-American prepubertal children persisted even after adjustment for both TEE and AEE (P<0.001). Thus, a rigorously controlled study refutes the notion that physical activity level explains the racial difference in maximal oxygen consumption."
    },
    "naive_doc_ids": [
      "18537148",
      "26112696",
      "13230773",
      "8428935",
      "17914395"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 2 directly demonstrates that black prepubertal and pubertal children have lower VO\u2082max than their white peers and notes that this difference could be attributed at least in part to a more sedentary lifestyle in the black children. Additional surveys (e.g., Papers 1 and 4) show that non-Hispanic black youth engage in less vigorous activity and have lower cardiorespiratory fitness than whites. Together, these findings support the claim that physical activity level is associated with the observed VO\u2082max differences between black and white youth."
    },
    "overthinking_doc_ids": [
      "8428935",
      "18537148",
      "4449524",
      "13230773",
      "13083189"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 2 directly compares VO\u2082max in black and white prepubertal and pubertal children, finding lower VO\u2082max in black youth. The authors attribute this difference at least in part to a more sedentary lifestyle (lower physical activity levels) among the black children, indicating that physical activity is associated with the racial difference in maximal oxygen consumption. Additional data (e.g., from Papers 1, 4, and 5) document lower vigorous\u2010activity rates in non\u2010Hispanic black youth, reinforcing the association between activity level and VO\u2082max differences."
    },
    "posthoc_doc_ids": [
      "8428935",
      "18537148",
      "21274919",
      "13230773",
      "13083189"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "411",
    "claim": "Febrile seizures reduce the threshold for development of epilepsy.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies directly show that febrile seizures lower the threshold for later epilepsy. Only Paper 5 examines febrile (hyperthermia\u2010induced) seizures and finds a long\u2010lasting increase in inhibitory transmission in hippocampus, but it does not demonstrate an increased propensity for or earlier onset of spontaneous epilepsy. The other papers address different models or genetic factors in temporal lobe epilepsy and do not test the effects of early\u2010life febrile seizures on subsequent seizure threshold."
    },
    "naive_doc_ids": [
      "35520219",
      "1410197",
      "30534237",
      "29723642",
      "14924526"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.2,
      "justification": "None of the provided papers directly address whether febrile seizures lower the threshold for later development of epilepsy. Only Paper 8 examines cellular changes after experimental febrile seizures in rats, showing persistent changes in synaptic transmission but not demonstrating reduced seizure threshold or increased epilepsy risk. The other papers focus on unrelated topics, so there is no direct evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "23136735",
      "5691302",
      "44672703",
      "22711954",
      "32463364"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "Among the provided papers, only Paper 2 addresses febrile seizures, reporting persistent increases in inhibitory synaptic transmission after early-life febrile convulsions. However, it does not measure or demonstrate a lowered seizure threshold or increased incidence of later epilepsy. The other papers do not pertain to febrile seizures or their long-term effects. Therefore, there is no direct evidence here that febrile seizures reduce the threshold for developing epilepsy."
    },
    "posthoc_doc_ids": [
      "1410197",
      "14924526",
      "116792",
      "23670644",
      "42873134"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "378",
    "claim": "Energy balance requires hypothalamic glutamate neurotransmission.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.76,
      "justification": "Paper 2 demonstrates that feeding stimulation in the lateral hypothalamus critically depends on NMDA (glutamate) receptor signaling, and inhibition of NMDA\u2010R markedly suppresses feeding, indicating that hypothalamic glutamatergic neurotransmission is required for energy intake. Paper 3 shows that metabolic signals (e.g., leptin, fasting, high-fat diet) alter astrocyte glutamate transporter expression in the hypothalamus and thereby modulate downstream POMC neuron activity, linking glutamate handling in the hypothalamus to energy balance. Together these findings support the claim that energy homeostasis requires hypothalamic glutamate neurotransmission."
    },
    "naive_doc_ids": [
      "11742219",
      "4611267",
      "17150648",
      "15535511",
      "22545779"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 directly demonstrates that selective disruption of glutamate release from hypothalamic Sim1 (PVH) neurons reverses the anti\u2010obesity effects of MC4R signaling, leading to hyperphagia and reduced energy expenditure. This establishes that glutamatergic neurotransmission in the hypothalamus is required for normal energy balance."
    },
    "overthinking_doc_ids": [
      "10017612",
      "25050364",
      "2225918",
      "11742219",
      "45154987"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 3 and 5 provide direct experimental evidence that synaptic glutamate release from hypothalamic neurons is essential for maintaining energy balance: Paper 3 shows that loss of VGLUT2 in VMH SF1 neurons impairs counterregulatory responses and leads to hypoglycemia during fasting, and Paper 5 demonstrates that disrupting glutamate release from PVH (Sim1) neurons abolishes MC4R\u2010mediated control of food intake and energy expenditure, producing obesity. Paper 1 further implies that hypothalamic glutamatergic signaling is modulated by metabolic state. Together these data support the claim that energy balance requires hypothalamic glutamate neurotransmission."
    },
    "posthoc_doc_ids": [
      "17150648",
      "11742219",
      "11886686",
      "26735905",
      "45154987"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1386",
    "claim": "cSMAC formation represses weak ligand signalling.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 demonstrates that TCR signaling is sustained in peripheral microclusters but terminated when those clusters fuse into the cSMAC, and Paper 2 shows that enhancing cSMAC formation specifically reduces the stimulatory potency of a weak agonist peptide. Together these findings confirm that cSMAC formation represses weak\u2010ligand signaling."
    },
    "naive_doc_ids": [
      "9283422",
      "306006",
      "994800",
      "2714623",
      "15972906"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.91,
      "justification": "Paper 7 demonstrates that inability to form the cSMAC correlates with enhanced proliferation in response to a weak peptide ligand, and that enforcing cSMAC formation reduces the stimulatory capacity of that weak ligand. Paper 4 further shows that the cSMAC is a site of signal termination. Together, these findings directly support the claim that cSMAC formation represses weak ligand signalling."
    },
    "overthinking_doc_ids": [
      "4324278",
      "36432234",
      "226488",
      "9283422",
      "35395662"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 2 directly shows that a weak agonist\u2019s stimulatory potency is increased when cSMAC formation is prevented and that enhancing cSMAC formation reduces the weak ligand\u2019s activity. Paper 4 further demonstrates that the cSMAC is a site of signal termination rather than sustained signaling. Together these findings confirm that cSMAC assembly represses weak\u2010ligand-induced TCR signaling."
    },
    "posthoc_doc_ids": [
      "2714623",
      "306006",
      "2825380",
      "9283422",
      "7506409"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "208",
    "claim": "CHEK2 is not associated with breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 5 directly addresses CHEK2 and breast cancer risk. While it finds that common CHEK2 haplotypes are not associated, it confirms a role for the rare 1100delC CHEK2 mutation with an odds ratio of 2.26 for breast cancer. Thus CHEK2 is implicated in breast cancer predisposition, contradicting the absolute claim that it is not associated."
    },
    "naive_doc_ids": [
      "23557241",
      "17450673",
      "9394119",
      "1428840",
      "13519661"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 3 evaluates CHEK2 variation and reports that the rare 1100delC mutation confers an increased breast cancer risk (OR 2.26, 95% CI 0.99\u20135.15), and prior work has implicated CHEK2 in breast cancer etiology. Although no association was seen for common CHEK2 polymorphisms, the documented risk from the 1100delC allele contradicts the blanket claim that CHEK2 is not associated with breast cancer."
    },
    "overthinking_doc_ids": [
      "17450673",
      "23557241",
      "13519661",
      "2140497",
      "3222187"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Only Paper 4 directly examines CHEK2 and breast cancer risk. In a large Swedish case\u2013control study of six tagging SNPs covering common variation in CHEK2, no haplotype or single\u2010SNP association with breast cancer was found (and the rare 1100delC variant showed only a borderline odds ratio, 2.26 [95% CI 0.99\u20135.15]). None of the other papers address CHEK2. Thus the available data support the claim that common CHEK2 variants are not associated with breast cancer risk."
    },
    "posthoc_doc_ids": [
      "16734530",
      "2140497",
      "9394119",
      "13519661",
      "3285322"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "448",
    "claim": "Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 provides direct human epidemiologic evidence that prior H. pylori infection (IgG seropositivity) is associated with a 2.8-fold increased risk of gastric cancer. Papers 3\u20136 supply mechanistic and animal/cell culture data showing that H. pylori infection induces DNA mutations, inflammation, and preneoplastic changes in gastric epithelium, all consistent with a causal role in gastric carcinogenesis. No paper presents evidence against the claim."
    },
    "naive_doc_ids": [
      "2052720",
      "14729253",
      "24705390",
      "22703082",
      "26488879"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides direct epidemiological evidence (OR 2.77, 95% CI 1.04\u20137.97) that H. pylori\u2013infected individuals have a higher risk of subsequent gastric cancer. Paper 4 further supports a biological mechanism by which H. pylori infection induces mutagenic AID expression in gastric epithelium, promoting carcinogenesis."
    },
    "overthinking_doc_ids": [
      "14729253",
      "2052720",
      "12145359",
      "22703082",
      "13831842"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 provides direct human epidemiological evidence: H. pylori\u2013seropositive men had a 2.8-fold higher risk of subsequent gastric cancer (95% CI 1.04\u20137.97, p=0.039). Paper 2 further reinforces H. pylori as a gastric cancer risk factor by elucidating a mutation\u2010inducing mechanism in infected gastric epithelium. No paper presents data contradicting the association; thus the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "2052720",
      "22703082",
      "14729253",
      "39550665",
      "7465900"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "154",
    "claim": "B3-Galectin increases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address B3-galectin (galectin-3) or its role in TKI resistance. Paper 1 describes an integrin \u03b1v\u03b23\u2013KRAS\u2013RalB\u2013NF-\u03baB pathway driving resistance to EGFR inhibitors, but it does not involve galectin. The other papers focus on chemotherapy rechallenge, PTEN/PI3K-Akt, NF1/Ras-ERK, or anti-angiogenic RTK inhibitors, and none mention B3-galectin or its engagement of KRAS-RalB downstream of EGFR."
    },
    "naive_doc_ids": [
      "4702639",
      "9929089",
      "34016944",
      "2272614",
      "23420807"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.3,
      "justification": "Although Paper 1 shows that integrin \u03b1v\u03b23 recruits KRAS and RalB to drive resistance to the EGFR TKI erlotinib, none of the provided studies mention B3-galectin itself. Thus, there is no direct evidence here that B3-galectin increases TKI resistance via the KRAS\u2013RalB complex downstream of EGFR."
    },
    "overthinking_doc_ids": [
      "4702639",
      "9929089",
      "1065627",
      "16066726",
      "34016944"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly demonstrates that unliganded integrin \u03b1v\u03b23 (which contains the \u03b23 subunit) recruits KRAS and RalB to the plasma membrane and drives resistance to EGFR TKIs (erlotinib) via activation of the KRAS\u2013RalB\u2013TBK1\u2013NF-\u03baB axis. This finding confirms that \u03b23 integrin engagement creates an alternate KRAS\u2013RalB signaling complex downstream of EGFR, leading to TKI resistance, in line with the claim."
    },
    "posthoc_doc_ids": [
      "4702639",
      "34016944",
      "2272614",
      "9929089",
      "14819804"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "182",
    "claim": "Bone Marrow (BM) transplantation is used to treat acute myeloid leukemia (AML)",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the eight papers explicitly describes the use of bone\u2010marrow (or hematopoietic stem\u2010cell) transplantation as a treatment modality for acute myeloid leukemia. The studies focus on molecular profiling (P1), targeted inhibitors (P2), niche interactions (P3), thalassemia transplantation outcomes (P4), donor\u2010cell leukemia post\u2010SCT (P5), regulatory T cells in GVHD (P6), and acute lymphoblastic leukemia (P7,P8), but none present data on BM transplantation for AML therapy."
    },
    "naive_doc_ids": [
      "13205096",
      "4387494",
      "6374918",
      "10128893",
      "11344428"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers explicitly describe using bone marrow (or hematopoietic stem cell) transplantation as a therapy for acute myeloid leukemia (AML). Paper 2 discusses complications after allogeneic stem cell transplantation but does not present it as a treatment modality for AML, and the remaining papers focus on AML biology, gene expression, or unrelated hematologic conditions without addressing transplantation as AML therapy."
    },
    "overthinking_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "10128893",
      "10526279"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.64,
      "justification": "Several of the provided studies discuss the use of allogeneic hematopoietic (bone marrow) stem cell transplantation (HSCT/SCT) in the setting of leukemia. For example, Paper 2 surveys >10 000 allogeneic SCTs carried out between 1982 and 2003 and reports cases of donor\u2010cell acute myeloid leukemia (DCL) emerging after transplantation, directly implying that SCT was used as a treatment modality in these patients (including those with AML). Likewise, Papers 8 and 9 analyze T\u2010cell reconstitution and lung complications following allo-HSCT in cohorts that include pediatric leukemia recipients, further confirming that HSCT is employed in treating acute leukemias such as AML."
    },
    "posthoc_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "323335",
      "10128893"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "730",
    "claim": "Lysine histone demethylase inhibitor JIB 04 is inactive against KDM5A.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers evaluate or report JIB-04\u2019s activity against KDM5A specifically. Paper 5 describes JIB-04 as a broad Jumonji demethylase inhibitor but does not include data on KDM5A, and no other paper addresses this enzyme\u2013inhibitor pair."
    },
    "naive_doc_ids": [
      "36991551",
      "864491",
      "11256632",
      "4387494",
      "13400643"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.25,
      "justification": "None of the supplied papers report direct assays of JIB-04 against the KDM5A enzyme. Paper 1 characterizes JIB-04 as a pan-Jumonji demethylase inhibitor but does not list KDM5A activity data; the remaining papers neither mention JIB-04 nor KDM5A."
    },
    "overthinking_doc_ids": [
      "13400643",
      "18841257",
      "313394",
      "3230361",
      "4387494"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report direct assays of JIB-04 against KDM5A or present data on its activity (or inactivity) toward KDM5A. Paper 3 describes JIB-04 as a broad Jumonji demethylase inhibitor but does not specify results for KDM5A; the other papers do not mention JIB-04 or KDM5A at all."
    },
    "posthoc_doc_ids": [
      "4387494",
      "18841257",
      "13400643",
      "15563864",
      "16701509"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1027",
    "claim": "Reduced phosphorylation of PP2A suppresses HDAC4 dephosphorylation.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that ATM-mediated phosphorylation of PP2A downregulates its activity, and that in ATM deficiency (i.e. reduced PP2A phosphorylation) PP2A activity is enhanced, leading to increased HDAC4 dephosphorylation and nuclear accumulation. This directly contradicts the claim that reduced PP2A phosphorylation suppresses HDAC4 dephosphorylation."
    },
    "naive_doc_ids": [
      "3113630",
      "8417211",
      "26019505",
      "22185730",
      "14405193"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 shows that ATM-mediated phosphorylation of PP2A down\u2010regulates PP2A activity, while reduced phosphorylation of PP2A (as in ATM deficiency) enhances PP2A activity and thus promotes HDAC4 dephosphorylation and nuclear accumulation. This directly opposes the claim that reduced PP2A phosphorylation would suppress HDAC4 dephosphorylation."
    },
    "overthinking_doc_ids": [
      "22185730",
      "1964163",
      "3113630",
      "38811597",
      "1554348"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 2 shows that ATM-mediated phosphorylation down-regulates PP2A, reducing its activity and thus suppressing HDAC4 dephosphorylation. Conversely, when PP2A phosphorylation is reduced (ATM deficiency), PP2A activity increases, promoting HDAC4 dephosphorylation. This directly contradicts the claim that reduced PP2A phosphorylation suppresses HDAC4 dephosphorylation."
    },
    "posthoc_doc_ids": [
      "22185730",
      "3113630",
      "16686383",
      "28806780",
      "19966976"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1351",
    "claim": "Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided papers examine the effect of dynein upregulation in Drosophila neurons on the number of microtubule plus-ends growing toward the cell body. Paper 2 addresses dynein loss (not upregulation) and its role in maintaining axonal microtubule polarity, while the other studies focus on kinesins, katanins, Wnt signaling, or in vitro dynein interactions, and none report data on plus-end growth toward neuronal somata upon dynein overexpression."
    },
    "naive_doc_ids": [
      "1889358",
      "28369117",
      "36111909",
      "16090672",
      "7093809"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the cited papers report experiments in which dynein is upregulated in Drosophila neurons to assay the number or orientation of growing microtubule plus-ends toward the cell body. Paper 1 examines loss of dynein and mixed microtubule polarity in axons but does not test dynein overexpression or quantify plus-end growth toward the soma. The other papers focus on unrelated proteins or biochemistry of dynein and similarly lack data on dynein upregulation and plus-end orientation in vivo."
    },
    "overthinking_doc_ids": [
      "28369117",
      "36111909",
      "1546650",
      "11983390",
      "12737132"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies examine the effects of experimentally upregulating dynein levels in Drosophila neurons on the number or directionality of growing microtubule plus-ends toward the cell body. Paper 2 addresses dynein loss (mutants) and its role in maintaining axonal microtubule polarity, but does not test dynein overexpression or report an increase in plus\u2010ends growing toward the soma."
    },
    "posthoc_doc_ids": [
      "18126445",
      "28369117",
      "36111909",
      "16090672",
      "23160444"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "482",
    "claim": "Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 directly demonstrates that application of tensional force on fibronectin\u2010binding integrins triggers activation and recruitment of two RhoA\u2010specific GEFs (LARG and GEF\u2010H1) to adhesion complexes, providing molecular evidence that GEFs mediate RhoA activation in response to integrin\u2010applied force."
    },
    "naive_doc_ids": [
      "8093935",
      "10991183",
      "10530014",
      "38808600",
      "1782201"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 directly demonstrates that applying tensional force to integrins triggers activation and recruitment of two Rho\u2010specific GEFs (LARG and GEF-H1) to adhesion complexes, leading to downstream RhoA activation and cytoskeletal reinforcement. This mechanistic link between force on fibronectin\u2010binding integrins, GEF activation, and RhoA signaling provides direct support for the claim."
    },
    "overthinking_doc_ids": [
      "8453819",
      "10530014",
      "10669582",
      "10991183",
      "20943272"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Paper 3 directly demonstrates that applying tensional force to fibronectin\u2010binding integrins activates the RhoA\u2010specific GEFs LARG and GEF-H1, recruits them to adhesion complexes, and thereby triggers RhoA\u2010dependent cytoskeletal reinforcement. This finding confirms that GEFs mediate RhoA activation in response to mechanical tension on integrins."
    },
    "posthoc_doc_ids": [
      "33076846",
      "8093935",
      "10991183",
      "32532238",
      "24554740"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1193",
    "claim": "The appearance of brown-like or beige cells primarily occurs in visceral fat, not subcutaneous fat.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the eight papers directly compares the induction or abundance of brown-like/beige adipocytes in visceral versus subcutaneous fat depots. While some studies examine visceral versus subcutaneous mitochondrial function, angiogenesis, or adipogenesis (Papers 1,2,4,5), and others characterize beige progenitors or browning in white fat more generally (Papers 3,6,7), none report data showing that brown-like/beige cells appear primarily in visceral fat and not in subcutaneous fat."
    },
    "naive_doc_ids": [
      "3621011",
      "39187170",
      "17973161",
      "79447",
      "41790911"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "None of the provided studies directly compare the induction or prevalence of brown-like (brite/beige) adipocytes in visceral versus subcutaneous fat depots. There is discussion of UCP1 expression, mitochondrial activity, adipogenesis, and browning in general or in specific depots in mice or human cells, but no data explicitly showing that beige cells appear primarily in visceral fat and not in subcutaneous fat."
    },
    "overthinking_doc_ids": [
      "3621011",
      "33634749",
      "39187170",
      "29381091",
      "16939583"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided studies report that browning (brite/beige adipocyte appearance) occurs preferentially in visceral versus subcutaneous fat. Papers 1 and 8 discuss brite/beige adipocytes in general but do not compare depots. The other papers focus on visceral adipocyte biology without addressing beige\u2010cell distribution. Therefore, there is no relevant evidence to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "17973161",
      "12903921",
      "31564409",
      "39187170",
      "79447"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "728",
    "claim": "Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "Only Paper 2 directly compares Ly6C subsets in mice and their inflammatory responses. It shows that Ly6C^hi (and Ly6C^med-high) monocytes are preferentially mobilized and recruited under acute and chronic inflammatory conditions, indicating that Ly6C^hi cells have greater\u2014not lower\u2014inflammatory capacity compared with Ly6C^lo monocytes. The other papers do not address Ly6C^hi versus Ly6C^lo monocyte functions."
    },
    "naive_doc_ids": [
      "10648422",
      "36444198",
      "7489663",
      "343052",
      "9784254"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Although none of the papers directly quantifies cytokine output by Ly6C^hi versus Ly6C^lo monocytes, multiple studies (e.g. Paper 1) show that Ly6C^hi monocytes are selectively mobilized and recruited under acute and chronic inflammatory conditions\u2014hallmarks of a high inflammatory capacity\u2014whereas Ly6C^lo (\u2018patrolling\u2019) monocytes are associated with vascular surveillance rather than inflammation. This behavior is opposite to the claim that Ly6C^hi cells have lower inflammatory capacity than Ly6C^lo cells."
    },
    "overthinking_doc_ids": [
      "36444198",
      "7489663",
      "7521113",
      "2844490",
      "22621251"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.7,
      "justification": "Paper 4 directly implicates Ly6C^hi monocytes in driving profibrotic (inflammatory) macrophage activation and the progression of pulmonary fibrosis. That role as key inflammatory effectors runs counter to the claim that Ly6C^hi monocytes have a lower inflammatory capacity than Ly6C^lo monocytes."
    },
    "posthoc_doc_ids": [
      "36444198",
      "7489663",
      "13380011",
      "22621251",
      "21009874"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1280",
    "claim": "The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Each of the three papers describes the Klebsiella aerogenes urease accessory genes ureD (sometimes called UreH), ureE, ureF and ureG and demonstrates that all four are encoded in the urease gene cluster and are required for nickel metallocenter assembly and enzyme activation. Paper 1 maps and mutationally inactivates ureD, ureE, ureF and ureG and shows loss of urease activity; Papers 2 and 3 identify complexes containing UreD, UreF and UreG (with UreE facilitating activation), confirming their roles as maturation proteins."
    },
    "naive_doc_ids": [
      "29214508",
      "37768883",
      "36233757"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.89,
      "justification": "Papers 4\u20136 directly demonstrate that in the urease gene cluster of Klebsiella aerogenes the genes ureD (also called UreH in some species), ureE, ureF and ureG encode the accessory proteins required for urease metallocenter assembly. Deletion of any of ureD, ureE, ureF or ureG abolishes or reduces urease activity (Paper 4), and UreD, UreF and UreG form activation\u2010competent apoprotein complexes with urease (Papers 5 and 6). This confirms that the ureABIEFGH gene cluster encodes UreD/UreH, UreE, UreF and UreG maturation proteins."
    },
    "overthinking_doc_ids": [
      "4387784",
      "8654183",
      "13965483",
      "29214508",
      "37768883"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1\u20133 directly demonstrate that the urease gene cluster (ureABIEFGH in Helicobacter or ureABDEFG in Klebsiella aerogenes) includes four accessory (maturation) proteins\u2014UreD (also called UreH in some organisms), UreE, UreF, and UreG\u2014each shown to be required for nickel metallocenter assembly and in vivo activation of urease."
    },
    "posthoc_doc_ids": [
      "29214508",
      "37768883",
      "36233757",
      "7488455",
      "9217800"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "672",
    "claim": "L3MBTL2 binds to H2AK119Ub marked chromatin to form a PRC1 complex.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.34,
      "justification": "Only Paper 1 discusses L3MBTL2 in the context of a PRC1\u2010family complex and notes that H2AK119 ubiquitination is present at L3MBTL2 target genes. However, none of the papers directly demonstrate that L3MBTL2 binds to H2AK119Ub\u2010marked chromatin to recruit or form a PRC1 complex. No explicit evidence for binding of L3MBTL2 to the H2AK119Ub mark is provided."
    },
    "naive_doc_ids": [
      "15635366",
      "23244529",
      "19572798",
      "143251",
      "935538"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 demonstrates that L3mbtl2 assembles an atypical PRC1\u2010family complex (including Ring1b) at its target genes and that these loci bear the H2AK119Ub mark. Although H2AK119Ub is not dependent on L3mbtl2, the co\u2010occupancy of L3mbtl2 with this ubiquitination mark and Ring1b recruitment directly supports the claim that L3mbtl2 binds to H2AK119Ub\u2010marked chromatin to form a PRC1 complex."
    },
    "overthinking_doc_ids": [
      "140874",
      "169264",
      "799586",
      "15635366",
      "2604063"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 directly shows that L3mbtl2 assembles an atypical PRC1\u2013family complex (including Ring1B) at its target genes and that L3mbtl2 occupancy is associated with H2AK119 ubiquitination. Although H2AK119Ub is not strictly dependent on L3mbtl2, this finding confirms that L3mbtl2 localizes to and functions at H2AK119Ub\u2010marked chromatin to form a PRC1\u2010related complex. None of the other papers address L3MBTL2 or H2AK119Ub, so they are not relevant to this claim."
    },
    "posthoc_doc_ids": [
      "15635366",
      "22767022",
      "30835854",
      "24311787",
      "41620295"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "71",
    "claim": "Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 shows that SRGP-1 acts as a GAP for CED-10 (Rac1) in C. elegans. Loss of srgp-1 leads to hyperactivation of CED-10 in engulfing cells and results in the removal (and thus killing) of cells that are only sublethally injured \u2013 cells that would otherwise remain viable. This demonstrates that CED-10 activation in the srgp-1 mutant context causes death of cells that would otherwise survive, supporting the claim."
    },
    "naive_doc_ids": [
      "1127562",
      "7036529",
      "7042304",
      "935034",
      "2543135"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.1,
      "justification": "Only Paper 1 addresses SRGP-1 and CED-10 in C. elegans. It shows that loss of the RhoGAP SRGP-1 (which would hyperactivate CED-10) promotes engulfment and clearance of apoptotic or injured cells at the verge of death, but it does not demonstrate that activation of CED-10 kills otherwise viable (healthy) cells. None of the other papers address this pathway in C. elegans. Therefore there is no direct evidence for killing of viable cells in SRGP-1 mutants."
    },
    "overthinking_doc_ids": [
      "1127562",
      "10648422",
      "34436231",
      "1669173",
      "24185667"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.11,
      "justification": "Only Paper 1 addresses SRGP-1 and its GAP activity toward CED-10 (Rac1). It shows that loss of SRGP-1 (and thus elevated CED-10 activity) promotes engulfment of already dying or sublethally injured cells, not the killing of otherwise viable cells. No paper provides evidence that CED-10 activation in an srgp-1 mutant directly kills fully viable cells."
    },
    "posthoc_doc_ids": [
      "1127562",
      "7036529",
      "7042304",
      "10648422",
      "34436231"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "705",
    "claim": "Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.2,
      "justification": "None of the provided studies report wheezing or asthma outcomes at ages 3 or 6 following long-chain polyunsaturated fatty acid supplementation. Paper 1 reports eczema and food allergy at 1 year; Paper 2 is a general review that mentions possible asthma effects up to adolescence but gives no specific 3- or 6-year data; the remaining papers address unrelated conditions."
    },
    "naive_doc_ids": [
      "22442133",
      "24269361",
      "7098463",
      "3801693",
      "19278208"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.6,
      "justification": "While none of the trials report wheezing or asthma outcomes specifically at ages 3 and 6, the systematic review (Paper 2) notes that n-3 long-chain PUFA supplementation in pregnancy is associated with persistent reductions in eczema, hay fever, and asthma into later childhood and adolescence. This suggests that LCPUFA supplementation does exert a protective effect on asthma beyond infancy, contradicting the claim of no significant effect at 3 and 6 years."
    },
    "overthinking_doc_ids": [
      "22442133",
      "24269361",
      "10692948",
      "602760",
      "20672596"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.75,
      "justification": "None of the provided papers report on wheezing or asthma outcomes at ages 3 and 6 following long-chain PUFA supplementation. Papers 1 and 2 address atopic sensitization, eczema, and early childhood allergic outcomes (at 1 year), but do not include wheeze or asthma assessments at 3 or 6 years. The other papers are unrelated to PUFA supplementation or asthma."
    },
    "posthoc_doc_ids": [
      "24269361",
      "22442133",
      "20672596",
      "5433667",
      "7209559"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "345",
    "claim": "Differentiated E2f-1, -2, -3 TKO cells in the intestine do not exhibit apoptosis.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 4 directly examines the effect of E2f1-3 triple deficiency in the mouse small intestine. It reports that, although loss of E2f1-3 in dividing progenitor cells compromises survival, differentiated intestinal cells lacking E2f1-3 do not undergo apoptosis\u2014in other words, TKO cells in the differentiated compartment remain viable, supporting the claim."
    },
    "naive_doc_ids": [
      "28697248",
      "18956141",
      "30580263",
      "4394817",
      "8083310"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "Only Paper 2 examines E2f1-3 triple knockouts in the intestinal epithelium, but it describes their activator/repressor roles in progenitor versus differentiating cells without reporting whether differentiated TKO cells undergo apoptosis. None of the other papers address apoptosis in differentiated E2f1/2/3\u2010deficient intestinal cells."
    },
    "overthinking_doc_ids": [
      "28697248",
      "4394817",
      "5254463",
      "29423324",
      "30580263"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 7 directly addresses the role of E2F1\u20133 in the intestine. It shows that in proliferating progenitor cells E2F1\u20133 are required to prevent apoptosis, whereas in differentiating intestinal cells they act as repressors and their loss does not trigger cell death. No other paper examines E2F1\u20133 TKO in differentiated intestinal cells, so paper 7 provides the key evidence supporting the claim."
    },
    "posthoc_doc_ids": [
      "5254463",
      "30580263",
      "37205759",
      "27772649",
      "1595617"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "975",
    "claim": "Primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.12,
      "justification": "None of the provided studies directly demonstrate that primary pro\u2010inflammatory cytokines (e.g. IL-1\u03b2, TNF\u03b1, IL-6) orchestrate both secondary pro- and anti-inflammatory mediator production. Paper 7 shows IL-1\u03b2 driving pro-inflammatory outputs (NO, PGE\u2082, MMPs) but does not report induction of anti-inflammatory mediators by the cytokine itself. The other papers do not address the claim of primary cytokine\u2192secondary mediator induction in the required pro- and anti-inflammatory context."
    },
    "naive_doc_ids": [
      "9197092",
      "33030946",
      "5137019",
      "3973445",
      "6144969"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Multiple studies demonstrate that an initial pro-inflammatory trigger elicits downstream mediators of both inflammatory and counter-regulatory activity. For example, in Paper 1 the pro-inflammatory molecule S100A9 engages CD33 on immature myeloid cells to induce secretion of the anti-inflammatory cytokines IL-10 and TGF-\u03b2. Similarly, Paper 4 shows that T cell-derived pro-inflammatory cytokines drive stromal cells to express both pro-osteoclastogenic factors (RANKL) and anti-osteoclastogenic inhibitors (osteoprotegerin, TRAIL). These findings confirm that primary pro-inflammatory signals induce secondary pro- and anti-inflammatory mediators."
    },
    "overthinking_doc_ids": [
      "5836",
      "72159",
      "10582939",
      "43619625",
      "11233339"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.65,
      "justification": "Paper 7 shows that primary pro-inflammatory cytokines IL-17A and TNF-\u03b1 induce NETosis in neutrophils, and those NETs in turn drive production of secondary pro-inflammatory mediators (IL-6, IL-8, chemokines, adhesion molecules) by synovial fibroblasts. This directly illustrates that primary cytokines trigger secondary pro- and anti-inflammatory signals, supporting the claim."
    },
    "posthoc_doc_ids": [
      "2391552",
      "3973445",
      "12705056",
      "6153754",
      "25315295"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "o4-mini",
    "claim_id": "1043",
    "claim": "Retinoic acid receptor-related orphan receptor gamma (ROR\u03b3) is a therapeutic target for castration-resistant prostate cancer (CRPC)",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 demonstrates that ROR\u03b3 is overexpressed and amplified in metastatic CRPC, drives AR and AR-V7 expression via recruitment of coactivators, and that ROR\u03b3 antagonists suppress AR signaling and CRPC tumor growth in xenograft models, establishing ROR\u03b3 as a therapeutic target. None of the other papers provide contradictory evidence."
    },
    "naive_doc_ids": [
      "17671145",
      "37256966",
      "8512633",
      "14131683"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Paper 2 directly demonstrates that ROR-\u03b3 is overexpressed and amplified in metastatic CRPC, drives AR expression via recruitment of coactivators, and that pharmacologic ROR-\u03b3 antagonists suppress AR (and AR-V7) expression, diminish AR target gene activity, inhibit tumor growth in CRPC xenografts, and sensitize tumors to enzalutamide. These findings establish ROR-\u03b3 as a key upstream regulator of AR in CRPC and validate it as a therapeutic target."
    },
    "overthinking_doc_ids": [
      "37256966",
      "17671145",
      "14116046",
      "8512633",
      "14131683"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly demonstrates that ROR\u03b3 is overexpressed and amplified in CRPC, drives AR and AR-V7 expression via recruitment of coactivators, and that ROR\u03b3 antagonists suppress tumor growth and sensitize CRPC to enzalutamide. The other papers do not address ROR\u03b3 in CRPC. Therefore, the evidence supports ROR\u03b3 as a therapeutic target in castration-resistant prostate cancer."
    },
    "posthoc_doc_ids": [
      "17671145",
      "8512633",
      "14131683",
      "37256966",
      "14116046"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "324",
    "claim": "Deleting Raptor reduces G-CSF levels.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss Raptor or its role in regulating G-CSF levels specifically. The claim about deleting Raptor affecting G-CSF levels is not addressed in any of the papers. The evidence provided relates to various genes, proteins, and pathways that are unrelated to the claim in question."
    },
    "naive_doc_ids": [
      "5409325",
      "11428884",
      "654735",
      "25827024",
      "5979056"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information specifically about the impact of deleting Raptor on G-CSF levels. The papers discuss various aspects of cellular signaling pathways, hormone regulation, metabolic functions, and disease-related processes, but none directly address or provide evidence related to the claim that Raptor deletion affects G-CSF levels."
    },
    "overthinking_doc_ids": [
      "5409325",
      "11428884",
      "654735",
      "22174015",
      "26735905"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers explicitly mention Raptor or its deletion in the context of G-CSF levels. The papers primarily discuss topics such as cytokine levels in cancer patients, microRNA regulation, myocardial infarction in women, epigenetic effects of high-fat diets, effects of EBV infection, epilepsy models, dendritic cell generation, IL-17 and granulopoiesis, and the role of adipocytes in hematopoiesis. As such, there is no relevant information about the specific claim regarding the relationship between Raptor deletion and G-CSF levels."
    },
    "posthoc_doc_ids": [
      "39264456",
      "5409325",
      "6085365",
      "6042706",
      "23305884"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "789",
    "claim": "Microglia are an innate immune cell type of the central nervous system.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The claim states that microglia are an innate immune cell type of the central nervous system. None of the provided papers contain specific information about microglia or their role as innate immune cells within the CNS. The papers discuss a variety of topics related to CNS and immune responses, including blood-brain barrier integrity, autoimmune T cell responses, CNS metastases, innate immune responses, and immune cell variation due to genetic factors. However, they do not specifically address microglia or their classification as innate immune cells in the CNS. Therefore, the papers do not provide relevant information to verify or refute the claim."
    },
    "naive_doc_ids": [
      "6325527",
      "22647695",
      "3329824",
      "5500086",
      "1748921"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information about the claim that microglia are an innate immune cell type of the central nervous system. The papers discuss various topics, including human central nervous system stem cells, myelin basic protein gene expression, autoimmune T cell responses in the CNS, peroxisomes in antiviral innate immunity, neutrophils in immune responses, and the chicken melanoma-differentiation-associated gene 5 in innate immunity. None of the papers specifically mention microglia or provide evidence regarding their classification as innate immune cells within the CNS."
    },
    "overthinking_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "3107733",
      "3330111"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly address the specific claim that microglia are an innate immune cell type of the central nervous system. The papers cover a variety of topics related to the CNS and immune system, such as BBB integrity, autoimmune T cell responses, ILCs in innate immunity, and stem cell characteristics, but none specifically discuss microglia. Therefore, the evidence does not support or contradict the specific claim, leading to a 'NOINFO' categorization."
    },
    "posthoc_doc_ids": [
      "6325527",
      "22647695",
      "3329824",
      "24044977",
      "3672261"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1268",
    "claim": "The risk of cancer rises with level of alcohol consumption.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not directly address the claim that the risk of cancer rises with the level of alcohol consumption. Paper 1 discusses alcohol in the context of coronary events and not cancer. Paper 2 mentions alcohol consumption in relation to IVF outcomes but does not tie it to cancer risk. The remaining papers focus on other health topics such as metabolic syndrome, cholesterol, physical activity, breast cancer risk factors unrelated to alcohol, her-2/neu gene amplification, protein acetylation in bacteria, gene expression analysis, tumor engraftment, and glioblastoma chemoresistance. None of the studies specifically evaluate the link between alcohol consumption and cancer risk, which is essential to support or contradict the claim about alcohol and cancer."
    },
    "naive_doc_ids": [
      "20526907",
      "2787558",
      "16701509",
      "6647414",
      "24834968"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not address the relationship between alcohol consumption and cancer risk, specifically the claim that the risk of cancer rises with levels of alcohol consumption. The papers discuss varied topics including lung function and lung cancer, adiponectin and endometrial cancer, genetic susceptibility and gastric cancer, physical activity and mortality, HER-2/neu and breast cancer chemotherapy response, and immunotherapy in liver cancer. None of these papers provide experimental data, results, or findings related to alcohol consumption and its potential impact on cancer risk."
    },
    "overthinking_doc_ids": [
      "12145359",
      "12869200",
      "14729253",
      "6647414",
      "24834968"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically examine or provide data on the relationship between alcohol consumption and the risk of cancer. Paper 1 studies the effect of alcohol on cardiovascular events but not cancer. Paper 2 discusses alcohol's impact on IVF outcomes, not cancer risk. Papers 3 to 8 cover other factors related to various forms of cancer or health outcomes but do not specifically address alcohol consumption as a risk factor for cancer. Thus, they do not confirm or refute the claim that the risk of cancer rises with the level of alcohol consumption."
    },
    "posthoc_doc_ids": [
      "20526907",
      "2787558",
      "3355397",
      "23577867",
      "38551172"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "209",
    "claim": "CHOP is a general endoplasmic reticulum stress marker.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides specific evidence that aligns with the claim by mentioning that DNA-damage inducible transcript 3 (Ddit3), previously known as C/EBP homologous protein (Chop), is involved in the endoplasmic reticulum (ER) stress response. It describes how increased mRNA levels for Ddit3 correlate with increased apoptosis under ER stress, particularly in the context of beta cell failure in type 2 diabetes. This directly supports the claim that CHOP is a general marker of ER stress. Other papers listed in the evidence do not discuss CHOP or its role in ER stress, providing no additional information that would contradict this claim."
    },
    "naive_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "7373453",
      "9752604"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that CHOP (C/EBP homologous protein, encoded by DDIT3) is a general endoplasmic reticulum stress marker. Paper 1 provides direct evidence supporting this claim, showing that CHOP (Ddit3) mRNA levels increase in response to ER stress induced by palmitate in beta cells, and its expression is correlated with increased apoptosis under stress conditions. This paper specifically identifies CHOP as part of the ER stress response, thus supporting the claim that CHOP is a marker of ER stress. The other papers do not directly discuss CHOP or ER stress in a manner relevant to confirming or refuting the claim, so they do not contribute to this determination. Therefore, based on the direct evidence provided in Paper 1, the classification is SUPPORT."
    },
    "overthinking_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "7373453",
      "9752604"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly discusses the involvement of CHOP (DNA-damage inducible transcript 3, Ddit3, previously known as C/EBP homologous protein [Chop]) as a part of the endoplasmic reticulum (ER) stress response in the context of beta cell apoptosis in type 2 diabetes. The study shows that exposure to lipids, which induces ER stress, leads to an increase in Chop mRNA levels, further linking CHOP to ER stress pathways. The evidence indicates that CHOP is indeed used as a marker for ER stress, supporting the claim that CHOP is a general ER stress marker. The other papers do not mention CHOP or ER stress markers specifically, hence they are irrelevant to validating this specific claim, making the relevant information predominantly present in Paper 1."
    },
    "posthoc_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "13244602",
      "21093407"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "398",
    "claim": "Exhaustion of B cells contributes to poor Ab response in HIV-infected individuals.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not directly address the claim that exhaustion of B cells contributes to poor antibody (Ab) response in HIV-infected individuals. The papers cover a range of topics related to B-cell migration, calcium signaling in neutrophils, tyrosine kinase inhibitor resistance in lung cancer, IL-10 in T cells, immune responses to Salmonella, genetic factors in HCV immunity, T cell-mediated autoimmune responses, and cytokine communication. None of these papers specifically discuss B cell exhaustion in the context of HIV infection or its impact on antibody responses."
    },
    "naive_doc_ids": [
      "38587347",
      "7869794",
      "9929089",
      "8639034",
      "18275697"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information addressing the specific claim that 'Exhaustion of B cells contributes to poor antibody response in HIV-infected individuals.' None of the papers presented include data or findings regarding B cell function, exhaustion, or antibody response in the context of HIV infection. The papers discuss topics such as B cell migration, calcium signaling in neutrophils, cancer treatment, CD4+ T cell activation in HIV, endothelial cell dysfunction in diabetes, dendritic cell trans-infection by HIV, IL-10 production by T cells, and immune responses to Salmonella vaccines, but do not link these topics to B cell exhaustion or the antibody response in HIV-infected individuals."
    },
    "overthinking_doc_ids": [
      "38587347",
      "7869794",
      "9929089",
      "10648422",
      "2533768"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain specific information regarding the exhaustion of B cells and its contribution to poor antibody responses in HIV-infected individuals. The papers discuss a variety of immune system components and responses in different contexts, including T cell responses, the role of PD-1 in HIV, myeloid cell regulation, and vaccine-induced immunity, among others. However, none of them directly address the role of B cell exhaustion in the context of HIV-infected individuals, nor do they provide data or findings related to the claim in question."
    },
    "posthoc_doc_ids": [
      "40473317",
      "6493422",
      "9433958",
      "52095986",
      "301866"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1008",
    "claim": "RUNX is not expressed in skin tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss the expression of RUNX in skin tissue. The papers provided cover diverse topics such as angiogenesis, keratinocyte gene expression, cytokine expression in immune cells, circadian rhythm genes, miRNA activity during viral infection, sperm cross-over activity, CETP polymorphisms, JAK-STAT inflammatory signaling, and chromatin modifications affecting pluripotency. None of these papers provide information pertinent to the expression of RUNX in skin tissue, hence the classification is NOINFO."
    },
    "naive_doc_ids": [
      "9185195",
      "12580014",
      "14311986",
      "4587978",
      "5838067"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain any specific information regarding the expression of RUNX in skin tissue. The papers focus on different topics such as ARNO and VEGF in endothelial cells, keratin regulation in skin tumor keratinocytes, transcription factors related to cytokine expression, myelin basic protein gene expression, oxidative stress responses in E. coli, adipocyte transcription factor binding, yeast transcription factors, and KLF2 regulation of myeloid cells. None of these topics directly address or provide data on the claim that RUNX is not expressed in skin tissue."
    },
    "overthinking_doc_ids": [
      "9185195",
      "12580014",
      "14311986",
      "19238",
      "471735"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain any direct information regarding the expression of RUNX in skin tissue. The papers cover various unrelated topics such as keratin regulation in skin tumors, semaphorin expression in neural scar tissue, uncoupling proteins in cancer cachexia, AIM2 expression in colorectal cancer, T reg cell markers, gene expression in Caco-2 cells due to epicatechin, H3K56 acetylation in adipocytes, yeast transcription factors, and the role of KLF2 in infection response. None of these papers mention RUNX or skin tissue expression, so they do not provide evidence to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "12580014",
      "33535447",
      "1507222",
      "42731834",
      "266641"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "776",
    "claim": "Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided evidence from the papers does not include any specific discussion, experimental data, or results related to DNA polymerase m (polm) and its role or lack thereof in mouse sensitivity to ionizing radiation (IR). The papers address various other topics such as senescence markers, ATM deficiency, DNA polymerase \u03b2, autophagy, and interleukin-15, none of which relate to polm or the specific claim about its function in response to IR. Therefore, there is no relevant information in the papers to verify the claim."
    },
    "naive_doc_ids": [
      "31293581",
      "5572127",
      "11569583",
      "10017612",
      "6227220"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers specifically address the sensitivity of mice defective for DNA polymerase m (polm) to ionizing radiation (IR). The papers discuss various topics, including the role of different proteins and genes in response to IR and other stressors, but none focus on polm-deficient mice. Therefore, the evidence does not provide relevant information to support or contradict the specific claim about sensitivity of polm-deficient mice to IR."
    },
    "overthinking_doc_ids": [
      "11569583",
      "31293581",
      "5572127",
      "10017612",
      "10015292"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information specific to the claim that mice defective for DNA polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation. The papers discuss different topics such as the role of DNA polymerase \u03b2, long-term effects of ionizing radiation, gut microbiota and insulin resistance, Atm-deficiency, and immune responses. None of these address DNA polymerase m or provide experimental data related to its role in sensitivity to ionizing radiation."
    },
    "posthoc_doc_ids": [
      "11569583",
      "31293581",
      "52805891",
      "5572127",
      "25453683"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1382",
    "claim": "aPKCz causes tumour enhancement by affecting glutamine metabolism.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The provided papers discuss various aspects of cancer metabolism, including glutamine dependence in pancreatic cancer, pharmacological inhibition of glutamine transport, and general cancer metabolic pathways. However, none of these papers specifically mention aPKCz (atypical protein kinase C zeta) or directly link it to tumor enhancement through glutamine metabolism. Therefore, the evidence does not provide relevant information to confirm or refute the specific claim that aPKCz causes tumor enhancement by affecting glutamine metabolism."
    },
    "naive_doc_ids": [
      "3831884",
      "5256564",
      "14471161",
      "22914228",
      "7005276"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers discuss various aspects of cancer metabolism and glutamine metabolism in particular, but none of them specifically mentions the role of aPKCz in tumor enhancement through glutamine metabolism. Papers 1 and 2 focus on altered glutamine metabolism pathways in pancreatic cancer and Kras-regulated pathways, while papers 3 and 4 discuss glutamine transport in lung cancer. None of these studies provide evidence specifically linking aPKCz with changes in glutamine metabolism leading to tumor enhancement, thus the claim cannot be verified or refuted based on the provided papers."
    },
    "overthinking_doc_ids": [
      "22914228",
      "3831884",
      "10169908",
      "5256564",
      "11968641"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The given papers generally discuss glutamine metabolism and its relevance to cancer cell growth, focusing on mechanisms like glutamine transport via SLC1A5, and glutamine metabolism in pancreatic cancer influenced by Kras. However, none of the papers specifically address or provide direct experimental evidence on the role of aPKCz in tumor enhancement through glutamine metabolism. While the papers detail the importance of glutamine and its metabolic pathways in cancer growth, they do not specifically explore the involvement of aPKCz in these processes."
    },
    "posthoc_doc_ids": [
      "5256564",
      "27647593",
      "20501163",
      "6669242",
      "6718824"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "181",
    "claim": "Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about the specific interaction between TDP-43 and mitochondrial respiratory complex I proteins ND3 and ND6, nor do they discuss the prevention of TDP-43-induced neuronal loss by blocking this interaction. The papers discuss various other protein interactions, mechanisms of cell death, and effects of different inhibitors, but none mention TDP-43 or directly address the claim. Therefore, there is no evidence in the papers to evaluate the claim that blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss."
    },
    "naive_doc_ids": [
      "13380011",
      "24995939",
      "2832403",
      "4320424",
      "11256632"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers explicitly address the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6, or the impact of blocking this interaction on TDP-43-induced neuronal loss. The papers cover various aspects of neurodegenerative diseases, mitochondrial function, and cellular processes, but do not provide data or findings directly related to the specific claim in question. Therefore, based on the information from these papers alone, no determination can be made regarding the validity of the claim."
    },
    "overthinking_doc_ids": [
      "6492658",
      "6157371",
      "1871499",
      "13380011",
      "1991105"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers contain relevant information specifically about the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6, or about attempts to block this interaction to prevent TDP-43-induced neuronal loss. The papers primarily focus on unrelated topics such as mitochondrial dynamics, neurodegenerative diseases, nucleosome organization, and ligand-binding domains of glutamate receptors. Therefore, the claim cannot be verified or refuted based on the given evidence."
    },
    "posthoc_doc_ids": [
      "10698739",
      "207972",
      "1941721",
      "6492658",
      "6157371"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "19",
    "claim": "7-day-old adult Caenorhabditis elegans exhibit approximately 5% of the learning capacity seen in 1-day old adults.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers cover a range of topics related to Caenorhabditis elegans aging, neural integrity, cell clearance, reproductive pathways, protein aggregation, and hormonal effects on aging. However, none of these papers specifically address the learning capacity comparison between 7-day-old and 1-day-old adult Caenorhabditis elegans. The claim involves measuring learning capacity, but the reviewed papers do not present experimental data or findings about learning capacities across different ages in these nematodes. Therefore, there is no direct evidence in these papers to support or contradict the claim regarding the specific percentage comparison of learning capacities."
    },
    "naive_doc_ids": [
      "13072113",
      "1127562",
      "1576955",
      "36178047",
      "8425533"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers discuss various aspects of aging, neurobiology, and related mechanisms in Caenorhabditis elegans, including synaptic changes, insulin signaling, cell clearance, and protein aggregation. However, none of the papers directly investigate the specific learning capacities of 7-day-old versus 1-day-old adult C. elegans or provide quantitative comparisons on learning capacity that would support or refute the claim about a 5% learning capacity in 7-day-old adults compared to 1-day-old adults. Therefore, there is no information within the provided evidence that directly addresses the claim."
    },
    "overthinking_doc_ids": [
      "13072113",
      "3202143",
      "1127562",
      "285794",
      "756887"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers contain specific information about the learning capacity comparison between 7-day-old and 1-day-old adult Caenorhabditis elegans, as claimed. Paper 1 discusses morphological changes in the nervous system of aging C. elegans, but does not quantify learning capacity in these terms. Additionally, other papers focus on aspects such as cell lineage, gene expression, aging biomarkers, genetic characteristics, and various developmental processes unrelated to specific age-comparative learning capacity metrics in C. elegans. Therefore, the papers do not provide direct evidence to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "13072113",
      "5002665",
      "6333347",
      "7834603",
      "24864273"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1183",
    "claim": "The TRaF1/C5 rs10818488 allele polymorphism regulates the neighboring C5 gene.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not mention the TRaF1/C5 rs10818488 allele polymorphism or its alleged regulation of the neighboring C5 gene. The papers cover topics ranging from gene signatures in cancer, polymorphisms in the insulin gene with obesity, cytokine roles in inflammatory conditions, receptor functions, neurotrophin receptors, and lncRNA gene regulation, among others. None of these directly address or provide evidence related to the specific claim about the TRaF1/C5 polymorphism."
    },
    "naive_doc_ids": [
      "15113221",
      "21641088",
      "24783597",
      "368506",
      "471735"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain specific information about the TRaF1/C5 rs10818488 allele polymorphism regulating the neighboring C5 gene. Paper 1 mentions the TRAF1/C5 region in the context of rheumatoid arthritis risk, but does not provide evidence on the regulation of the C5 gene by the rs10818488 polymorphism. The other papers discuss various topics such as gene regulation by lncRNAs, sex-biased expression, PD-1 expression in SLE, host-parasite interaction gene expression, and eQTL studies, none of which relate to the specific genetic interaction claimed. Therefore, no relevant information is available to support or contradict the claim based on the evidence from these papers."
    },
    "overthinking_doc_ids": [
      "1967017",
      "5519177",
      "12232678",
      "14938990",
      "1852826"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the papers provided directly address the claim that the TRaF1/C5 rs10818488 allele polymorphism regulates the neighboring C5 gene. While some papers discuss gene regulation broadly or in different contexts, such as through lncRNAs or histone modifications, there is no specific mention or evidence concerning this particular polymorphism and its effects on the C5 gene. Paper 1 mentions the TRAF1/C5 region in relation to rheumatoid arthritis, but does not provide mechanistic insights into gene regulation by the specified polymorphism."
    },
    "posthoc_doc_ids": [
      "1967017",
      "5519177",
      "12232678",
      "14938990",
      "1852826"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "657",
    "claim": "Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically address the role of intramembrane cleavage by signal peptide peptidase in the degradation of proteins with a complex membrane orientation. The papers cover various topics such as viral protein maturation, ER-associated degradation pathways, signaling pathways, antimicrobial peptides, and HIV drug resistance, but none discuss or provide evidence related to signal peptide peptidase-mediated degradation of complex membrane proteins. Therefore, they do not provide relevant information to verify the specific scientific claim."
    },
    "naive_doc_ids": [
      "37643601",
      "8533245",
      "350542",
      "28644298",
      "11200685"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain any specific information about intramembrane cleavage by signal peptide peptidase and its role in the degradation of proteins with a complex membrane orientation. While some papers mention general mechanisms of protein degradation, such as ubiquitin-dependent processes and the ERAD pathway, none specifically address intramembrane cleavage involving signal peptide peptidase or provide data relevant to its function in degrading proteins with complex membrane orientations."
    },
    "overthinking_doc_ids": [
      "1044552",
      "6422576",
      "10207180",
      "28644298",
      "6788835"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The claim is about intramembrane cleavage by signal peptide peptidase aiding in the degradation of proteins with a complex membrane orientation. Paper 9 provides relevant evidence as it discusses RHBDL4, an intramembrane rhomboid protease, which facilitates ERAD (endoplasmic reticulum-associated degradation) for membrane proteins. It specifically mentions RHBDL4's role in cleaving single-spanning and polytopic membrane proteins leading to their degradation via ERAD, suggesting a connection between intramembrane cleavage and protein degradation processes. This aligns with the claim about intramembrane cleavage aiding in protein degradation. The other papers do not provide evidence refuting or concerning the specific mechanism described in the claim."
    },
    "posthoc_doc_ids": [
      "1044552",
      "6422576",
      "10207180",
      "28644298",
      "11200685"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "27",
    "claim": "A 100g dose of chloroquine chemoprophylactic regimen results in retinal toxicity after 5-6 years of weekly intake.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain relevant information specific to the claim about chloroquine causing retinal toxicity after 5-6 years of weekly intake at a 100g dose. The papers cover various medical topics such as the long-term use of benzodiazepines, aspirin and age-related macular degeneration, chemotherapy regimens for breast cancer, side effects of different malaria chemoprophylactic regimens (including chloroquine), HPV testing, forearm fractures, carbon nanotubes, stress-related immune responses, but do not address the specific chloroquine dosage and duration mentioned in the claim. Therefore, there is no information in the evidence provided to verify or refute the claim."
    },
    "naive_doc_ids": [
      "24346598",
      "24735908",
      "195680777",
      "38410121",
      "5433667"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain relevant information about the specific claim regarding chloroquine and retinal toxicity. The evidence focuses on different subjects such as benzodiazepine treatment for sleep disorders, aspirin use and macular degeneration, chemotherapy regimens for breast cancer, side effects of malaria prophylaxis, effects in the retina from different treatments, angiogenesis therapy, dosing regimens in osteoporosis treatment, immune therapy in melanoma, and a study on ciclopirox olamine for hematologic malignancies. None of these directly address the claim of chloroquine's long-term usage resulting in retinal toxicity."
    },
    "overthinking_doc_ids": [
      "24346598",
      "24735908",
      "195680777",
      "38410121",
      "15685921"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss chloroquine in the context of long-term usage leading to retinal toxicity. While some papers discuss the side effects of various chemoprophylaxis medications, prophylactic treatment for malaria, and long-term medication use and effects, none specifically address the claim regarding a 100g dose of chloroquine over a 5-6 year period leading to retinal toxicity. Therefore, the evidence does not provide relevant information to verify, support, or contradict the specific claim."
    },
    "posthoc_doc_ids": [
      "38410121",
      "1373287",
      "3613041",
      "2328272",
      "7650066"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1072",
    "claim": "Sepsis related mortality has remained stable between 2009-2014.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence contrary to the claim. It reports a significant decline in in-hospital mortality using clinical criteria from 2009 to 2014, with a reduction of 3.3% per year (95% CI, -5.6% to -1.0%, P = .004). The paper also shows no significant change in the combined outcome of death or discharge to hospice over the same period. These findings indicate that mortality rates have not remained stable as claimed. The other papers do not provide relevant data regarding this specific claim about sepsis-related mortality from 2009 to 2014, and thus contribute to a NOINFO classification. However, Paper 1 alone offers sufficient evidence to classify as CONTRADICT."
    },
    "naive_doc_ids": [
      "4824840",
      "4791384",
      "3878434",
      "1538080",
      "2211868"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct information related to the claim, indicating that in-hospital mortality from sepsis declined by 3.3% per year from 2009-2014 based on clinical criteria. Although there was no significant change in the combined outcome of death or discharge to hospice, mortality itself clearly declined. Therefore, contrary to the claim that sepsis-related mortality remained stable, the evidence in Paper 1 suggests that it actually decreased. Papers 2, 3, and 4 do not provide information specifically relevant to overall sepsis-related mortality trends from 2009 to 2014."
    },
    "overthinking_doc_ids": [
      "4824840",
      "3878434",
      "4791384",
      "3776162"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides detailed evidence that contradicts the claim that sepsis-related mortality remained stable between 2009-2014. According to this paper, in-hospital mortality using clinical criteria declined by \u20133.3% per year, which is a statistically significant decrease (P = .004). Similarly, claims-based mortality data also showed a significant decline of \u20137.0% per year (P < .001). Therefore, both clinical and claims data indicate a decrease in mortality rates, opposing the claim that sepsis-related mortality remained stable during this period. The other papers do not discuss sepsis-related mortality trends specifically within this timeframe."
    },
    "posthoc_doc_ids": [
      "4824840",
      "4791384",
      "3878434",
      "1456068",
      "663464"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "585",
    "claim": "In the UK, drowning affects boys and girls equally.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain direct evidence regarding gender differences in drowning incidents specifically among boys and girls in the UK. The available papers focus on various other topics, such as distal forearm fractures, deliberate self-harm, hospital-treated infections, and more, but do not provide information relevant to the claim about drowning affecting boys and girls equally in the UK."
    },
    "naive_doc_ids": [
      "42291761",
      "7209559",
      "1102268",
      "2360905",
      "2488880"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information specifically about the claim that drowning affects boys and girls equally in the UK. The papers address topics such as drowning prevention (Paper 1), cancer treatment disparities (Paper 2), audiovisual speech processing (Paper 3), gender differences in infectious disease outcomes (Paper 4), medical education on gender and health (Paper 5), healthcare service utilization (Paper 6), electromagnetic interference in medical settings (Paper 7), perinatal mortality in China (Paper 8), and the consequences of undernutrition (Paper 9). None of these topics directly relate to the claim about gender equality in drowning incidents in the UK."
    },
    "overthinking_doc_ids": [
      "42291761",
      "16390264",
      "18379855",
      "2488880",
      "38664102"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers specifically address the claim that drowning affects boys and girls equally in the UK. The papers cover a variety of other topics, including cancer screening, cost-effectiveness of drugs, child drowning prevention without gender-specific data, gender differences in healthcare utilization and outcomes, curriculum content in medical schools, differences in infection outcomes by gender, the treatment of hepatitis C, forearm fracture incidence, and hospital readmission rates for heart failure. Therefore, they do not contain relevant information to verify or refute the specific claim about drowning affecting boys and girls equally in the UK."
    },
    "posthoc_doc_ids": [
      "756887",
      "15048300",
      "42291761",
      "2488880",
      "38664102"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1272",
    "claim": "The single flash-evoked ERG b-wave is generated by activity of ON-bipolar cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss the single flash-evoked electroretinogram (ERG) b-wave or the specific role of ON-bipolar cells in generating this response. The papers focus on topics ranging from mechanosensation and microtubule stabilization to cell reprogramming and immune responses. Therefore, there is no evidence within these papers that either supports or contradicts the claim regarding the ERG b-wave and ON-bipolar cells."
    },
    "naive_doc_ids": [
      "1275505",
      "1684489",
      "7036529",
      "188911",
      "6477740"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information about the electroretinogram (ERG) b-wave or the activity of ON-bipolar cells in connection to it. The claim is specific to ophthalmic neurophysiology, while the papers cover diverse topics in immunology, cardiology, oncology, plant biology, and neuroscience but do not address the claim related to ERG or ON-bipolar cells. Therefore, the papers neither support nor contradict the claim."
    },
    "overthinking_doc_ids": [
      "266641",
      "1905095",
      "2559303",
      "4350400",
      "9498458"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers lack direct relevance to the specific claim about the generation of the single flash-evoked ERG b-wave by ON-bipolar cells. The papers cover diverse topics such as circadian cycles, histone modifications, immune interactions, embryonic development, and stem cell reprogramming. However, none of them discuss electroretinography (ERG) b-waves or the specific roles of ON-bipolar cells in generating these signals. Therefore, there is no evidence provided that either supports or contradicts the claim."
    },
    "posthoc_doc_ids": [
      "2212067",
      "2888272",
      "3531388",
      "8038329",
      "35062452"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1340",
    "claim": "Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "Paper 1 provides direct evidence supporting the claim that ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure. The study is a systematic review and meta-analysis that specifically analyzes the impact of ultrasound imaging on the number of insertion attempts in lumbar punctures and epidural catheterisations. The results indicate a significant reduction in insertion attempts when ultrasound guidance is used, confirming the claim made."
    },
    "naive_doc_ids": [
      "15482274",
      "2991954",
      "3308636",
      "1805641",
      "12409683"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 specifically addresses the impact of ultrasound imaging on medical procedures such as lumbar punctures and epidural catheterizations. It provides experimental data from a systematic review and meta-analysis of randomized controlled trials, showing that ultrasound guidance significantly reduces the number of needle insertion attempts (mean difference -0.44, P<0.001). This finding aligns directly with the claim that ultrasound guidance reduces the number of needle insertion attempts necessary for certain procedures. The other papers do not contain relevant information about this specific claim, focusing instead on different medical and biological topics."
    },
    "overthinking_doc_ids": [
      "15482274",
      "2991954",
      "3308636",
      "7986878",
      "982650"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence supporting the claim. The systematic review and meta-analysis of randomized controlled trials demonstrate that ultrasound imaging significantly reduces the number of needle insertion attempts (mean difference -0.44) during procedures like lumbar punctures and epidural catheterisations. This aligns with the claim that ultrasound guidance reduces the number of attempts necessary for a given procedure. The other papers do not contain relevant information regarding ultrasound guidance and needle insertion attempts, indicating they have no influence on classifying this specific claim."
    },
    "posthoc_doc_ids": [
      "15482274",
      "11718220",
      "34268160",
      "1456068",
      "1848452"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1352",
    "claim": "Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim by showing that mosGCTL-1, a C-type lectin in Aedes aegypti, is induced upon West Nile virus (WNV) infection. This paper specifically reports that mosGCTL-1 interacts with WNV and facilitates infection in both in vivo and in vitro studies. The paper describes mosGCTL-1 as being a critical component in the pathway that enhances viral entry, thereby supporting the claim that its upregulation is induced by WNV infection."
    },
    "naive_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "991139"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly supports the claim by demonstrating that mosGCTL-1, a C-type lectin in Aedes aegypti mosquitoes, is induced by West Nile virus (WNV) infection. It details how mosGCTL-1 interacts with WNV and promotes infection, providing experimental evidence of upregulation upon WNV infection. Papers 2 and 3 do not discuss mosGCTL-1, focusing instead on interferon responses and genetic diversity of WNV, respectively, so they are not relevant to this specific claim. Therefore, based on Paper 1, the claim is supported with strong evidence."
    },
    "overthinking_doc_ids": [
      "12885341",
      "10559501",
      "34287602"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that the upregulation of mosGCTL-1 is induced upon infection with West Nile virus. Paper 1 specifically discusses an Aedes aegypti C-type lectin, mosGCTL-1, which is upregulated in response to WNV infection. The paper provides experimental data showing that mosGCTL-1 is induced by WNV and facilitates infection, thereby supporting the claim. Papers 2, 3, and 4 do not discuss mosGCTL-1 or its regulation upon WNV infection, thus they are not directly relevant to this specific claim. Therefore, the evidence from Paper 1 leads to a classification of SUPPORT with high confidence."
    },
    "posthoc_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "9784254"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "115",
    "claim": "Anthrax spores can be disposed of easily after they are dispersed.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 discusses the secondary aerosolization of Bacillus anthracis (anthrax) spores in a contaminated environment, specifically a US Senate Office. It reports that anthrax spores can reaerosolize under common office activities, implying that once dispersed, the spores can become airborne again, making disposal and containment difficult. This contradicts the claim that anthrax spores can be disposed of easily after dispersal, as the evidence suggests that they can linger and reaerosolize, posing a persistent contamination risk."
    },
    "naive_doc_ids": [
      "341324",
      "4688340",
      "6561200",
      "33872649",
      "719812"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim that 'Anthrax spores can be disposed of easily after they are dispersed' is contradicted by Paper 1. Paper 1 provides evidence of the persistence and reaerosolization of Bacillus anthracis spores in environments like office buildings, even under common activities. This suggests that once dispersed, anthrax spores are not easily disposed of and can continue to pose a contamination and health risk, requiring robust cleanup and remediation processes. No other papers provide information relevant to this claim."
    },
    "overthinking_doc_ids": [
      "33872649",
      "1338283",
      "1542437",
      "437924",
      "2211868"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 specifically deals with Bacillus anthracis spores, reporting secondary aerosolization of viable spores in an indoor environment, which implies difficulties in containing and disposing of them after dispersal. The findings indicate that these spores can resuspend in the air during common activities, posing challenges for remediation. Although none of the other papers provide information directly related to the disposal of anthrax spores, Paper 2 provides relevant evidence that suggests anthrax spores are not easy to dispose of once dispersed. Therefore, the evidence in Paper 2 contradicts the claim."
    },
    "posthoc_doc_ids": [
      "17626822",
      "33872649",
      "39970500",
      "20101846",
      "7912"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "482",
    "claim": "Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides direct evidence that guanine nucleotide exchange factors (GEFs), namely LARG and GEF-H1, regulate the response to mechanical force on integrins. The study shows that tensional force on integrins activates these GEFs, leading to RhoA activation and their recruitment to adhesion complexes. This aligns with the claim that GEFs mediate RhoA activation in response to forces on fibronectin-binding integrins. Paper 4 also supports the role of Rho and integrins in the cellular response to mechanical stress, although it does not directly mention specific GEFs. The other papers focus on different contexts or GEFs and do not provide relevant information regarding this specific claim."
    },
    "naive_doc_ids": [
      "33076846",
      "10991183",
      "8093935",
      "32532238",
      "418246"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 provides direct support for the claim by demonstrating that the Rho GEFs LARG and GEF-H1 are activated by tensional forces on integrins, which aligns with the activation of RhoA in response to these forces. The paper explicitly shows that these GEFs regulate cellular responses to mechanical force applied to integrins, including their activation and recruitment to adhesion complexes, corroborating the mechanism of RhoA activation through GEFs in response to mechanical stimuli. While the remaining papers do not explicitly discuss RhoA activation through GEFs in the context of tensional forces on fibronectin-binding integrins, Paper 1 alone provides sufficient evidence to classify the overall claim as 'SUPPORT.'"
    },
    "overthinking_doc_ids": [
      "10991183",
      "20943272",
      "5321708",
      "33076846",
      "8093935"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 3 specifically addresses the role of guanine nucleotide exchange factors (GEFs), particularly LARG and GEF-H1, in regulating the mechanical response to force on integrins. It provides experimental evidence that these GEFs are activated by tensional force on integrins, leading to RhoA activation. This aligns directly with the claim that GEFs mediate RhoA activation in response to tensional forces on fibronectin-binding integrins. The other papers do not directly discuss this mechanism, so they are not relevant to this specific claim."
    },
    "posthoc_doc_ids": [
      "33076846",
      "8093935",
      "10991183",
      "7915836",
      "10669582"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "68",
    "claim": "Activated Cdk5 regulates DNA damage-induced neuronal death.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence that supports the claim by showing that Cdk5, when activated by DNA damage, phosphorylates ATM. This phosphorylation is a critical step in activating ATM's kinase activity, which then regulates downstream processes, including neuronal death. The interruption of the Cdk5-ATM pathway was shown to protect neurons from death, providing a mechanistic link between activated Cdk5 and DNA damage-induced neuronal death. The other papers, while discussing related topics such as DNA damage, ATM, and neuronal apoptosis, do not directly address the role of Cdk5 in this context, so their contribution to the specific claim is limited. Therefore, based on the strong evidence provided by Paper 1, the consensus on the claim is SUPPORT."
    },
    "naive_doc_ids": [
      "21295300",
      "1941721",
      "5572127",
      "21219071",
      "29429111"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides direct evidence supporting the claim that activated Cdk5 regulates DNA damage-induced neuronal death. It explains that Cdk5, when activated by DNA damage, phosphorylates ATM, which is essential for activating ATM kinase activity. This Cdk5-ATM pathway is crucial for the phosphorylation and function of ATM targets such as p53 and H2AX, ultimately regulating neuronal death. Interrupting this pathway protects neurons from death, highlighting the role of Cdk5 in regulating DNA damage-induced neuronal death. The other papers do not specifically address the role of Cdk5 in neuronal death, hence they don't provide additional support or contradiction to this specific claim."
    },
    "overthinking_doc_ids": [
      "10015292",
      "21295300",
      "3765739",
      "15600979",
      "15836115"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that activated Cdk5 regulates DNA damage-induced neuronal death. The study specifically shows that Cdk5 phosphorylates ATM, which is crucial for DNA damage signaling and regulation of neuronal death. It demonstrates that DNA damage activates Cdk5, which then directly phosphorylates ATM, leading to subsequent phosphorylation events necessary for ATM kinase activity and initiating apoptotic pathways involving p53 and Bax. This clearly aligns with the claim by demonstrating the role of Cdk5 in regulating neuronal death in response to DNA damage. The other papers do not provide relevant information regarding the specific role of Cdk5 in DNA damage-induced neuronal death."
    },
    "posthoc_doc_ids": [
      "21295300",
      "29422484",
      "34436231",
      "1084062",
      "5572127"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "964",
    "claim": "Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the papers provided discuss or present information specifically on the stability of pre-mRNAs associated with spliceosomal components compared to unassociated splicing substrates. The topics of the papers range from protein kinases, RNA editing, cancer gene expression, pain syndromes, infection-related cancer risk, Medicare policies, mRNA-protein interactions, viral protein interactions, and protein transport systems. There is no direct experimental data or findings related to mRNA stability in the context of spliceosomal association."
    },
    "naive_doc_ids": [
      "6333347",
      "7029990",
      "15113221",
      "26445118",
      "2052720"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not directly address the specific claim about the stability of pre-mRNAs associated with spliceosomal components compared to unassociated splicing substrates. The papers discuss various aspects of spliceosome function, RNA processing, and interactions with other cellular components, but they do not specifically measure or compare the stability of pre-mRNAs based on their association with spliceosomal components. Thus, the evidence is not sufficient to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "4067274",
      "7860396",
      "12643937",
      "40721190",
      "207972"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain any relevant information regarding the stability of pre-mRNAs associated with spliceosomal components compared to unassociated splicing substrates. The papers cover a range of unrelated topics such as cytokinesis, RNA editing, cancer pathways, pain syndromes, DNA repair mechanisms, circadian rhythms, and mutations in chronic lymphocytic leukemia, none of which address the claim about pre-mRNA stability in the context of spliceosome association. Therefore, there is no basis in these papers to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "6333347",
      "7029990",
      "15113221",
      "26445118",
      "4444861"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1225",
    "claim": "The locus rs647161 is associated with colorectal carcinoma.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 specifically identifies the SNP rs647161 at locus 5q31.1 as associated with colorectal cancer, with a combined P value of 1.22 \u00d7 10(-10) in a study covering East Asian and European populations. This provides direct evidence supporting the claim that rs647161 is associated with colorectal carcinoma. The other papers do not address this specific SNP or locus in the context of colorectal cancer, so they do not contradict this finding, but rather provide additional context on other genetic factors and mechanisms involved in colorectal cancer."
    },
    "naive_doc_ids": [
      "9650982",
      "14315749",
      "23665162",
      "43334921",
      "21181273"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim by identifying rs647161 as one of the SNPs associated with colorectal cancer susceptibility. The study conducted a genome-wide association study in East Asians and replicated findings in Europeans, with a significant combined P value of 1.22 \u00d7 10^(-10) for rs647161. Other papers do not directly mention rs647161 or refute its association with colorectal cancer, but Paper 1 offers strong genomic evidence supporting the claim."
    },
    "overthinking_doc_ids": [
      "9650982",
      "43334921",
      "520579",
      "14315749",
      "2058909"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that the locus rs647161 is associated with colorectal carcinoma. It identifies rs647161 at 5q31.1 as one of the significant SNPs associated with colorectal cancer through a large-scale genome-wide association study conducted in East Asian and European-ancestry populations. This SNP showed a highly significant combined P value, indicating its association with colorectal cancer risk. The other papers do not provide any relevant data regarding rs647161 or its association with colorectal cancer, therefore reinforcing the support identified in Paper 1."
    },
    "posthoc_doc_ids": [
      "9650982",
      "14315749",
      "23665162",
      "43334921",
      "9558539"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1322",
    "claim": "Transplanted human glial progenitor cells can mature in their host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence supporting the claim that transplanted human glial progenitor cells can mature in their host animal. It discusses the engraftment of human glial progenitor cells into neonatal immunodeficient mice, which upon maturation resulted in recipient brains exhibiting large numbers of human glial progenitors and astrocytes. This indicates that the transplanted glial progenitor cells not only survived but matured and integrated effectively within the host animal, thereby supporting the claim."
    },
    "naive_doc_ids": [
      "16284655",
      "1667063",
      "4427392",
      "18104691"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence provided in Paper 1 supports the claim that transplanted human glial progenitor cells can mature in their host animal. This paper discusses the successful engraftment of human glial progenitor cells into neonatal immunodeficient mice. These cells matured into human glial progenitors and astrocytes, demonstrating properties such as gap-junction coupling to host astroglia and retained size and pleomorphism. This finding indicates that the transplanted human cells were able to mature and exhibit functional roles in the host mice, aligning with the claim. The other papers do not directly address glial progenitor cells in a neural context, making Paper 1 the primary source supporting the claim."
    },
    "overthinking_doc_ids": [
      "16284655",
      "9122283",
      "4427392",
      "1667063",
      "3360421"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that transplanted human glial progenitor cells can mature in their host animal. The study describes how human glial progenitor cells, once engrafted into neonatal mice, matured into astrocytes within the recipient brains. These human astrocytes retained specific human characteristics and were functionally integrated into the host's neural system, enhancing synaptic plasticity and learning. This indicates successful maturation and functional incorporation of the human cells into the host animal's brain."
    },
    "posthoc_doc_ids": [
      "16284655",
      "1667063",
      "1905095",
      "4427392",
      "16939583"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "34",
    "claim": "A deficiency of folate increases blood levels of homocysteine.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1, 2, 3, 4, and 5 all discuss the relationship between folate intake and homocysteine levels. Paper 1 shows that the MTHFR 677C\u2192T variant's effect on homocysteine is larger in low folate regions, implying that folate deficiency is associated with elevated homocysteine. Paper 2 shows decreasing homocysteine levels with increased folate dosage. Paper 3 indicates that individuals with the TT genotype and low folate status have higher homocysteine levels, linking folate deficiency to increased homocysteine. Paper 4 reports that increased folate intake from dietary sources is associated with reduced homocysteine levels. Paper 5 shows a high-folate diet decreases plasma homocysteine concentration. These findings collectively support the claim that folate deficiency increases blood levels of homocysteine."
    },
    "naive_doc_ids": [
      "8595678",
      "11705328",
      "42441846",
      "10557471",
      "18557974"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The claim is that a deficiency of folate increases blood levels of homocysteine. Across multiple papers, there is consistent evidence pointing towards a relationship between folate levels and homocysteine levels. Specifically, Paper 1 and Paper 3 highlight the MTHFR 677C\u2192T polymorphism's role in raised homocysteine levels, more pronounced in low folate regions, which implies a folate deficiency can lead to increased homocysteine. Paper 2 shows that folic acid supplementation lowers homocysteine levels, also supporting the inverse relationship. Paper 4 also indicates that increased folate intake reduces homocysteine concentrations. Paper 5 reinforces this by showing lower homocysteine with folate interventions. Overall, these findings support the notion that folate deficiency is associated with, or contributes to, elevated homocysteine levels."
    },
    "overthinking_doc_ids": [
      "8595678",
      "11705328",
      "42441846",
      "10557471",
      "37424881"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers provide evidence that supports the claim that a deficiency of folate increases blood levels of homocysteine. Paper 1 discusses how the effect of the MTHFR 677C\u2192T variant on homocysteine concentration is larger in regions with low folate levels, indicating that low folate status is associated with higher homocysteine levels. Paper 2 shows that folic acid supplementation reduces serum homocysteine levels, suggesting that insufficient folate intake leads to higher levels. Paper 3 finds that individuals with decreased folate levels due to the MTHFR C677T polymorphism have elevated homocysteine levels. Paper 5 reports greater homocysteine reduction in non-folate-fortified regions with supplementation, implying higher baseline levels due to folate deficiency. The overall evidence from these studies aligns with the claim."
    },
    "posthoc_doc_ids": [
      "8595678",
      "11705328",
      "42441846",
      "20083834",
      "37424881"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "611",
    "claim": "Increased lipolysis leads to higher P38 phosphorylation in adipose tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information that directly links increased lipolysis to higher P38 phosphorylation in adipose tissue. Although some papers discuss topics related to adipose tissue, lipolysis, and MAPK pathways, they do not provide experimental data or findings that directly address the claim about P38 phosphorylation as a result of increased lipolysis in adipose tissue. Therefore, they do not provide relevant evidence to either support or contradict the specific claim."
    },
    "naive_doc_ids": [
      "3621011",
      "39187170",
      "40232172",
      "20568364",
      "32408470"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about the specific claim that increased lipolysis leads to higher P38 phosphorylation in adipose tissue. None of the papers explicitly discuss the relationship between lipolysis and P38 phosphorylation in adipose tissue. The papers cover a range of topics including adipocyte differentiation, mitochondrial respiration, inflammatory responses, stem cell self-renewal, and oncogenic signaling, but do not provide direct evidence or findings related to the claimed biochemical pathway involving lipolysis and P38 activation in adipose tissue."
    },
    "overthinking_doc_ids": [
      "3621011",
      "39187170",
      "40232172",
      "11360430",
      "12909503"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not specifically discuss the relationship between increased lipolysis and P38 phosphorylation in adipose tissue. While several papers touch on adipose tissue function, inflammation, differentiation, and certain cellular processes (such as autophagy or bile acid activation), none directly examine or provide data about lipolysis leading to increased P38 phosphorylation. Without explicit evidence or studies directly linking these processes, the claim cannot be verified using the given papers."
    },
    "posthoc_doc_ids": [
      "3621011",
      "79447",
      "1568684",
      "791050",
      "22942787"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "205",
    "claim": "CDK6 shows improved binding to loss-of-function variants of p18 INK4C.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss CDK6 or p18 INK4C directly or provide any relevant experimental data or findings related to the claim about CDK6's binding to loss-of-function variants of p18 INK4C. Therefore, there is no information available in these papers to assess the validity of the claim."
    },
    "naive_doc_ids": [
      "10698739",
      "7717468",
      "22198971",
      "1225513",
      "1546650"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss cyclin-dependent kinase 6 (CDK6) or its interactions with p18 INK4C, particularly in the context of binding to loss-of-function variants. The papers cover a range of topics including bacterial two-component signaling systems, dynein-microtubule interactions, Ras GTPase mutations, adenovirus proteins, MHC interactions, retrovirus and RNA interference interactions, GLP-1 receptor variants, fungal virulence factors, and follicular helper T cell function. There is no experimental data, results, or findings in these papers that confirm or refute the specific claim about CDK6 and p18 INK4C. Therefore, the classification is NOINFO with high confidence."
    },
    "overthinking_doc_ids": [
      "1225513",
      "1546650",
      "4396105",
      "207972",
      "4270992"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers contain information or experimental data specifically regarding the interaction between CDK6 and loss-of-function variants of p18 INK4C. The discussion in Paper 9 regarding p18 INK4C focuses on its role as a tumor suppressor gene in glioblastoma multiforme, but does not mention CDK6 or any binding interactions with it. The other papers explore unrelated topics such as receptor polymorphisms, fungal virulence factors, T cell differentiation, integrin functions, cancer predisposition genes, anemia mechanisms, and congenital malformations, none of which provide relevant information about the specific claim concerning CDK6's improved binding to p18 INK4C variants."
    },
    "posthoc_doc_ids": [
      "3127341",
      "7717468",
      "22874817",
      "16745747",
      "4414547"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "434",
    "claim": "Foxp3 enables the expression of transcriptional regulators implicated in memory T cell development.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the papers provided directly address the role of Foxp3 in enabling the expression of transcriptional regulators specifically implicated in memory T cell development. The papers discuss various aspects of T cell differentiation, cytokine roles, immunological memory, and transcription factors involved in T cell development, but do not mention or provide evidence about Foxp3's involvement in this specific process. Therefore, there is no information provided in the papers that either supports or contradicts the claim."
    },
    "naive_doc_ids": [
      "13636631",
      "991137",
      "3835423",
      "16728949",
      "39539647"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific evidence about the role of Foxp3 in enabling the expression of transcriptional regulators involved in memory T cell development. While some papers mention Foxp3 in the context of regulatory T cells and its immunoregulatory functions, and others explore aspects of T cell memory and differentiation influenced by different factors, none directly address the involvement of Foxp3 in upregulating transcriptional regulators specifically linked to memory T cell development. Therefore, they neither support nor contradict the claim."
    },
    "overthinking_doc_ids": [
      "15945975",
      "22517564",
      "30908508",
      "13636631",
      "39539647"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The claim states that Foxp3 enables the expression of transcriptional regulators implicated in memory T cell development. The provided papers discuss various aspects of T cell differentiation, regulation, and memory, but none of them provide direct evidence or experimental data related to Foxp3 specifically enabling the expression of transcriptional regulators involved in memory T cell development. Paper 2 mentions Foxp3 in the context of regulatory T cells and their homeostasis, but it does not discuss memory T cell development or transcriptional regulation of memory cells by Foxp3. Similarly, other papers focus on different aspects of immune responses, cytokines, and transcriptional regulation, but not on the specific role of Foxp3 in memory T cells."
    },
    "posthoc_doc_ids": [
      "5508750",
      "4418070",
      "7399084",
      "13636631",
      "39539647"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1342",
    "claim": "Understanding epigenetic regulation of replication is essential for the reational design of episomally replicating vectors.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided papers discuss various aspects of epigenetic regulation, including DNA methylation, histone modifications, chromatin remodeling, and their implications in different biological contexts, such as stem cell differentiation, tumorigenicity, gene activation, and cancer biology. However, none of the papers specifically address the role of epigenetic regulation in the context of episomally replicating vectors or their rational design. Each paper focuses on different aspects of epigenetics unrelated to episomal replication or vector design, providing no direct support or contradiction for the claim presented."
    },
    "naive_doc_ids": [
      "2356950",
      "6948886",
      "8759633",
      "8267678",
      "18694784"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Upon reviewing the provided papers, none of them directly discuss the epigenetic regulation of episomally replicating vectors or its importance for their rational design. While papers 2, 3, 4, 6, and 7 delve into aspects of epigenetic regulation and its role in cellular processes, disease, and aging, they do not directly relate to the specific claim regarding episomally replicating vectors. Papers 5 and 8 discuss DNA replication and associated regulatory mechanisms but do not link these processes to episomally replicating vectors or the necessity of understanding epigenetic regulation in their design. Therefore, the evidence presented across the papers does not provide relevant information to either support or contradict the specific claim."
    },
    "overthinking_doc_ids": [
      "24512417",
      "2356950",
      "6948886",
      "1848452",
      "11568270"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided papers do not contain specific information about the role of epigenetic regulation of replication in the design of episomally replicating vectors. While some papers discuss aspects of epigenetic regulation, replication, and the design of vectors, none directly link these concepts to the rational design of episomally replicating vectors. Specifically, none of the evidence presented in the papers directly addresses how understanding epigenetic regulation would be essential or beneficial for designing these types of vectors. Therefore, the evidence is insufficient to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "24512417",
      "2356950",
      "6948886",
      "1349033",
      "1848452"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "480",
    "claim": "Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence that Gpr124 is essential for BBB integrity under pathological conditions. The study specifically mentions that conditional knockout of Gpr124 in adult mice results in BBB disruption in models of ischemic stroke. This aligns with the claim that Gpr124 suppresses BBB breakdown in such models. Other papers do not directly address the role of Gpr124 in ischemic stroke, therefore they are not relevant to verifying the claim."
    },
    "naive_doc_ids": [
      "6325527",
      "3761017",
      "27602752",
      "18256197",
      "2825340"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke. It reports that conditional knockout of Gpr124 in endothelial cells of adult mice results in BBB disruption and microvascular hemorrhage in ischemic stroke mouse models. Additionally, constitutive activation of Wnt\u2013\u03b2-catenin signaling, which is affected by Gpr124, corrects BBB disruption, supporting the hypothesis that Gpr124 plays a critical role in maintaining BBB integrity under pathological conditions. The other papers do not provide relevant data on Gpr124 or the blood-brain barrier in this context, thus they are classified as NOINFO for this specific claim."
    },
    "overthinking_doc_ids": [
      "6325527",
      "18256197",
      "32328114",
      "3761017",
      "14753395"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly supports the claim that Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke. It describes experiments where the Gpr124 conditional knockout (CKO) in adult mice endothelium resulted in BBB disruption and microvascular hemorrhage in ischemic stroke models. It further demonstrates that Wnt\u2013\u03b2-catenin signaling, associated with Gpr124, can rescue this disruption. This evidence aligns with the claim that Gpr124 plays a role in maintaining BBB integrity under pathological conditions, such as ischemic stroke, and suggests its potential as a therapeutic target."
    },
    "posthoc_doc_ids": [
      "6325527",
      "3761017",
      "27602752",
      "3435889",
      "39776978"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "659",
    "claim": "Ivermectin is used to treat lymphatic filariasis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain relevant information regarding the use of Ivermectin in the treatment of lymphatic filariasis. The papers discussed topics like prostate cancer, tuberculosis treatment, substance abuse treatment, synaptic transmission, HIV vaccines, neglected tropical diseases in general, malaria parasite transmission, and leukemia, none of which are directly related to Ivermectin or lymphatic filariasis specifically."
    },
    "naive_doc_ids": [
      "308862",
      "341324",
      "485020",
      "306311",
      "1071991"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss ivermectin or its use in the treatment of lymphatic filariasis. The topics covered in the papers include prostate cancer treatment, tuberculosis treatment regimens, case management in substance abuse, cardiovascular disease prevention guidelines, WHO antiretroviral treatment guidelines, immunogenic cell death in cancer, electromagnetic interference in medical equipment, obesity, vasovagal syncope, and cancer treatment guidelines. As such, there is no information that directly supports or contradicts the claim regarding ivermectin."
    },
    "overthinking_doc_ids": [
      "308862",
      "341324",
      "485020",
      "409280",
      "1986482"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers mention ivermectin or its use in treating lymphatic filariasis. The papers discuss various unrelated topics such as androgen suppression in prostate cancer, tuberculosis treatment, case management in substance abuse treatment, and other medical and scientific topics, but do not provide any information relevant to the claim about ivermectin and lymphatic filariasis."
    },
    "posthoc_doc_ids": [
      "308862",
      "341324",
      "485020",
      "17327939",
      "3446400"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "470",
    "claim": "Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided papers discuss various biological and genetic aspects of glioblastoma multiforme (GBM), such as resistance to therapy, expression of stem cell markers, genomic alterations, and potential therapeutic targets. However, none of the papers specifically address or provide direct evidence concerning the claim about GBM's characteristic features of extensive invasion, rapid growth, necrosis, and angiogenesis. While these papers cover related topics like stem cell behavior, genetic profiles, and therapeutic targets, they do not explicitly confirm or refute the claim regarding these particular GBM characteristics. Therefore, the papers do not contain relevant information specific to the claim, resulting in a classification of NOINFO."
    },
    "naive_doc_ids": [
      "9486930",
      "11578459",
      "470625",
      "5123516",
      "7028976"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis is supported by the evidence provided in the papers. Paper 1 discusses the EGFR-driven invasion in GBM through GBP1, highlighting the extensive invasion aspect. Paper 3 emphasizes the overexpression of EphA3, associated with maintaining tumorigenicity and growth, aligning with rapid growth characteristics. The papers collectively describe mechanisms supporting invasion and rapid proliferation, indirectly supporting angiogenesis and necrosis typical of aggressive tumors like GBM."
    },
    "overthinking_doc_ids": [
      "12685434",
      "470625",
      "5123516",
      "7028976"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis is supported by the provided papers. Paper 1 describes extensive invasion into brain parenchyma and the role of EGFR activation in promoting invasion. Paper 2 discusses rapid growth through genomic alterations leading to aberrant cell cycle progression. Paper 3 highlights the involvement of EphA3 in maintaining tumorigenicity and aggressive growth of GBM. Paper 7 provides evidence for the requirement of Wnt/beta-catenin signaling for CNS angiogenesis, which is a characteristic of GBM. While not all papers directly address each component of the claim, there is substantial evidence from the papers that aligns with the four key characteristics of GBM mentioned in the claim."
    },
    "posthoc_doc_ids": [
      "12685434",
      "470625",
      "5123516",
      "7028976",
      "15570691"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "5",
    "claim": "1/2000 in UK have abnormal PrP positivity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 discusses a large-scale survey of archived appendix samples in the UK, showing a prevalence of abnormal prion protein (PrP) of approximately 493 per million, which translates to about 1 in 2,000. This aligns closely with the claim that 1/2000 in the UK have abnormal PrP positivity. The study's data support the claim by providing experimental evidence observed in appendix samples from a broad population sample, hence offering strong support for the claim."
    },
    "naive_doc_ids": [
      "1606628",
      "2138767",
      "2891825",
      "13734012",
      "23124332"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct evidence supporting the claim regarding the prevalence of abnormal PrP positivity in the UK. It reports a prevalence of abnormal prion protein in humans through a large-scale survey of archived appendix samples, indicating a prevalence of 493 per million population (or approximately 1 in 2000). This data aligns with the scientific claim that 1/2000 in the UK have abnormal PrP positivity, thus supporting the claim."
    },
    "overthinking_doc_ids": [
      "2138767",
      "13934676",
      "24510595",
      "13734012",
      "42240424"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 presents a survey of archived appendix samples in the UK, which found 16 positive samples for abnormal prion protein out of 32,441 samples, indicating a prevalence of 493 per million population. This translates to approximately 1 in 2,028 people, which closely aligns with the claim that 1/2000 in the UK have abnormal PrP positivity. The claim is specifically supported by the findings in this paper as it provides direct evidence and statistical measurements aligning with the claimed prevalence of abnormal PrP positivity in the UK population."
    },
    "posthoc_doc_ids": [
      "25355575",
      "1456068",
      "7662395",
      "13734012",
      "1606628"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "422",
    "claim": "Flexible molecules experience less steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not directly address the claim that flexible molecules experience less steric hindrance in the tumor microenvironment compared to rigid molecules. The papers primarily focus on aspects such as cancer-associated fibroblasts, tumor microenvironment interactions, thymic microenvironment and self-tolerance, stromal-epithelial metabolic coupling, safety of targeted therapies, tamoxifen effects, tumor necrosis factor administration, tumor dormancy, circulating tumor cell profiling, and molecular analysis of tumors. None of these papers specifically explore or present experimental data or findings that relate to molecular flexibility versus rigidity in the context of steric hindrance within the tumor microenvironment."
    },
    "naive_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "2492146",
      "12438901"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information specifically about the comparison of steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The papers cover topics such as tumor necrosis factor pathways, tumor suppressor genes, cancer associated fibroblasts, tumor heterogeneity, and therapeutic resistance, but do not directly address the claim concerning molecule flexibility and steric hindrance in the tumor microenvironment. Therefore, they cannot be used to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "207972",
      "5991309",
      "29366489",
      "11271123",
      "13256155"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain information specific to the comparison of steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. Instead, the papers primarily discuss cancer-associated fibroblasts, metabolic interactions in the tumor microenvironment, effects of substances like statins and green tea polyphenols on cancer cells, and other unrelated topics. There is no experimental data, analysis, or conclusion within these papers that directly addresses the claim about steric hindrance in flexible versus rigid molecules."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "1522336",
      "17450673"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "887",
    "claim": "Only a minority of cells survive development after differentiation into stress-resistant spores.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain specific information on the survival rate of cells after differentiation into stress-resistant spores. The papers discuss various topics including stem cell differentiation, apoptosis, stress resistance, and other cellular processes, but they do not address the claim that only a minority of cells survive development after differentiation into stress-resistant spores. Therefore, none of the papers provide evidence to either support or contradict the specific scientific claim."
    },
    "naive_doc_ids": [
      "16630060",
      "1595617",
      "5633876",
      "2460304",
      "9197092"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The claim states that only a minority of cells survive development after differentiation into stress-resistant spores. The provided papers cover a range of topics such as lipid droplet metabolism in nutrient-deprived cells, T cell survival and differentiation, microglial cell development, Bacillus subtilis migration, trophoblast stem cell differentiation, and adenovirus-EBV hybrid systems. None of these papers specifically address the survival rates of cells after differentiation into stress-resistant spores, which appears to relate to a process more specific to certain bacterial or fungal organisms not covered in the evidence. Therefore, the papers do not contain relevant information to either support or contradict this specific claim."
    },
    "overthinking_doc_ids": [
      "10482574",
      "13636631",
      "22210434",
      "35811036",
      "12824568"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers provided in the evidence do not directly address the claim that only a minority of cells survive development after differentiation into stress-resistant spores. The papers cover a range of topics including DNA damage response in melanocyte stem cells, trophoblast stem cell differentiation, resistance pathways in breast cancer cells, HIV-1 protein Nef's role in T cell activation, effects of FGF-2 on intestinal stem cells, embryonic-like stem cells for muscle regeneration, genomic imprinting, development of thymic epithelial cells, and a hybrid system for stable transformation of mammalian cells. None of these directly discuss the survival or differentiation of spores under stress conditions. Therefore, the provided evidence does not contain information relevant to this specific claim."
    },
    "posthoc_doc_ids": [
      "16630060",
      "1595617",
      "4820792",
      "6936141",
      "25238950"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "667",
    "claim": "Klf2 is important for proper myeloid cell function.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 3 provides direct evidence relevant to the claim that KLF2 is important for proper myeloid cell function. It identifies KLF2 as a potent regulator of myeloid cell activation, preventing uncontrolled inflammation and highlighting its role as an essential regulator of the innate immune system. This indicates that KLF2 is indeed critical for the proper functioning of myeloid cells, supporting the claim. Although the other papers mostly focus on other aspects of cellular function or myeloid cell interactions, Paper 3 specifically ties KLF2 to myeloid cell activity, thereby confirming its importance in this context."
    },
    "naive_doc_ids": [
      "14386505",
      "5979056",
      "6493422",
      "2014909",
      "26873988"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers explicitly discuss the role of Klf2 in regulating myeloid cell function, thereby supporting the claim. Paper 3 specifically identifies KLF2 as a potent regulator of myeloid cell activation, suggesting it functions as a tonic repressor of myeloid cell activation in vivo and as an essential regulator of the innate immune system. Similarly, Paper 6 highlights KLF2's involvement in monocyte differentiation and function in the context of arthritis. These findings corroborate the importance of Klf2 in proper myeloid cell function, affirming the claim with substantial evidence."
    },
    "overthinking_doc_ids": [
      "14386505",
      "5979056",
      "6493422",
      "41877386",
      "22997657"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The claim that Klf2 is important for proper myeloid cell function is supported by evidence from Paper 4, which states that KLF2 is a potent regulator of myeloid cell activation in vivo. The paper indicates that KLF2 acts as a tonic repressor of myeloid cell activation, playing a crucial role in the regulation of the innate immune system, especially under conditions of polymicrobial infection and endotoxic shock. This positions KLF2 as an essential factor in controlling myeloid cell function to prevent uncontrolled inflammation, aligning with the claim. Other papers do not specifically address the role of KLF2 in myeloid cells, so their information is not directly relevant to this claim."
    },
    "posthoc_doc_ids": [
      "14386505",
      "5979056",
      "1192458",
      "6493422",
      "2754534"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "935",
    "claim": "Peroxynitrite is required for induction of T cell tolerance.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that peroxynitrite is required for the induction of T cell tolerance. It describes how myeloid-derived suppressor cells (MDSCs) use peroxynitrite to nitrate tyrosines in the TCR-CD8 complex of CD8+ T cells, disrupting their ability to recognize specific antigens presented by pMHC and thereby inducing tolerance. This aligns with the mechanism described in the claim. The other papers do not discuss peroxynitrite or T cell tolerance mechanisms directly related to this claim, so they are considered irrelevant to the specific claim."
    },
    "naive_doc_ids": [
      "5483793",
      "3848469",
      "7399084",
      "22705234",
      "52095986"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides relevant evidence supporting the claim that peroxynitrite is involved in T cell tolerance. It specifically describes a mechanism by which myeloid-derived suppressor cells induce T cell tolerance via nitration of the TCR-CD8 complex, which is mediated by reactive oxygen species and peroxynitrite. This process disrupts the antigen recognition by T cells, leading to tolerance. The other papers do not address the role of peroxynitrite in T cell tolerance directly and thus do not provide information that either supports or contradicts the claim. Based on the evidence from Paper 1, there is strong support for the role of peroxynitrite in T cell tolerance induction."
    },
    "overthinking_doc_ids": [
      "5483793",
      "20524091",
      "1192458",
      "24221369",
      "92308"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 2 provides direct evidence supporting the claim that peroxynitrite plays a role in T cell tolerance. It describes how myeloid-derived suppressor cells (MDSCs) induce nitration of T-cell receptors through the production of reactive oxygen species and peroxynitrite. This nitration disrupts the ability of CD8+ T cells to recognize specific antigens, which is described as T-cell tolerance. This aligns with the claim that peroxynitrite is required for the induction of T cell tolerance."
    },
    "posthoc_doc_ids": [
      "1855679",
      "5483793",
      "20524091",
      "7399084",
      "18062308"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "250",
    "claim": "Chenodeoxycholic acid treatment decreases brown adipose tissue activity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly contradicts the claim. It discusses how the bile acid chenodeoxycholic acid (CDCA) increases brown adipose tissue (BAT) activity, rather than decreasing it. The study presents experimental data showing increased BAT activity and whole-body energy expenditure in human subjects after CDCA treatment. Furthermore, in vitro treatment of human brown adipocytes with CDCA led to increased mitochondrial uncoupling and D2 expression, further supporting the activation of BAT. None of the other papers provide information related to the direct impact of CDCA on BAT activity."
    },
    "naive_doc_ids": [
      "1568684",
      "40232172",
      "3621011",
      "22914228",
      "7005276"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that chenodeoxycholic acid treatment decreases brown adipose tissue (BAT) activity, while Paper 1 explicitly provides evidence that chenodeoxycholic acid (CDCA) treatment increases BAT activity. The study detailed in Paper 1 involved administering CDCA to human subjects and resulted in increased BAT activity and energy expenditure. This directly contradicts the claim since CDCA was found to activate BAT rather than decrease its activity. Other papers do not provide relevant evidence related to the claim about CDCA and BAT activity, making Paper 1 the primary source to evaluate the claim."
    },
    "overthinking_doc_ids": [
      "1568684",
      "40232172",
      "29381091",
      "313394",
      "5492542"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 presents evidence that directly contradicts the claim. It reports that the bile acid chenodeoxycholic acid (CDCA) increases brown adipose tissue (BAT) activity in humans. Specifically, CDCA treatment resulted in increased BAT activity and increased whole-body energy expenditure. These findings indicate that CDCA activates rather than decreases BAT activity, refuting the initial claim."
    },
    "posthoc_doc_ids": [
      "1568684",
      "40232172",
      "29381091",
      "14865329",
      "18473550"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "693",
    "claim": "Leuko-reduced blood reduces infectious complications in red blood cell transfusion.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence relevant to the claim that leuko-reduced blood reduces infectious complications in red blood cell transfusion. It reports a decrease in posttransfusion fever and antibiotic use following the implementation of a universal leukoreduction program, which suggests a reduction in infectious complications and supports the claim. However, it does note that serious nosocomial infections did not decrease significantly, which slightly tempers the strength of the support. The other papers do not provide information relevant to leukoreduction in blood transfusions."
    },
    "naive_doc_ids": [
      "24088502",
      "3698758",
      "11344428",
      "25134146",
      "1805641"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 discusses the clinical outcomes following the Canadian universal leukoreduction program for red blood cell transfusions. The study found that there was a significant decrease in in-hospital mortality and posttransfusion fevers following the introduction of leukoreduction, as well as a reduction in antibiotic use, which is associated with infectious complications. Although serious nosocomial infections did not significantly decrease, the decrease in fevers and antibiotic use indicates a reduction in infectious complications, supporting the claim that leuko-reduced blood reduces infectious complications in red blood cell transfusion."
    },
    "overthinking_doc_ids": [
      "202259",
      "3067015",
      "3698758",
      "26474812",
      "24088502"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 provides relevant evidence supporting the claim. The study presented in this paper evaluates clinical outcomes following the adoption of a national universal prestorage leukoreduction program for blood transfusions in Canada. The results show that the implementation of leukoreduction is associated with a decrease in in-hospital mortality and a reduction in posttransfusion fevers and antibiotic use, suggesting a reduction in infectious complications. Although there is no direct mention of infectious complications beyond these factors, the reduction in fever episodes and antibiotic use can be interpreted as a decrease in infections, thereby supporting the claim that leuko-reduced blood reduces infectious complications in transfusions."
    },
    "posthoc_doc_ids": [
      "3698758",
      "23203102",
      "24088502",
      "4910408",
      "14973286"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "439",
    "claim": "Fz/PCP-dependent Pk localizes to the anterior membrane of neuroectoderm cells during zebrafish neuralation",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the specific topic of Fz/PCP-dependent Pk localization to the anterior membrane of neuroectoderm cells during zebrafish neurulation. The papers cover various unrelated topics, including signaling pathways in yeast, protein translocation in bacteria, cardiovascular signaling, neural crest development in mice and zebrafish, Dishevelled proteins in development, Notch signaling, blind individuals' sound localization, and actin polymerization in epithelial cells. There is no relevant information pertaining to the specific claim regarding zebrafish neurulation."
    },
    "naive_doc_ids": [
      "4324278",
      "1320137",
      "1590744",
      "38727075",
      "4932668"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers discuss various aspects of planar cell polarity (PCP) signaling, neural development, and protein localization but none of them specifically address the localization of Fz/PCP-dependent Pk to the anterior membrane of neuroectoderm cells during zebrafish neurulation. While paper 1 discusses PCP signaling's role in zebrafish neural tube development, it does not specifically address protein localization to cell membranes in this context. The other papers focus on different organisms, signaling pathways, or developmental processes. Therefore, there is no direct information to confirm or refute the claim based on the evidence provided."
    },
    "overthinking_doc_ids": [
      "4423559",
      "15983148",
      "207972",
      "317204",
      "4932668"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information specifically addressing the localization of Fz/PCP-dependent Pk to the anterior membrane of neuroectoderm cells during zebrafish neuralation. The papers cover various topics such as Notch signaling, spindle assembly, microtubule stabilization, and other cellular processes, but none directly discuss Fz/PCP signaling or its effects on cell membrane localization in the context of zebrafish neuralation. Therefore, they neither support nor contradict the claim."
    },
    "posthoc_doc_ids": [
      "6268106",
      "1684489",
      "2991954",
      "13411519",
      "4999633"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "306",
    "claim": "DUSP4 decreases apoptosis.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The claim under review is that DUSP4 decreases apoptosis. However, none of the provided papers specifically discuss DUSP4 or provide experimental data related to its role in apoptosis. The papers included discuss unrelated topics such as the role of Bcl-2 in apoptosis, effects of other proteins or molecules on cell survival and apoptosis, apoptosis in different contexts, autophagy, and cell death. Consequently, there is no relevant information or data in the papers to support or contradict the claim about DUSP4 and apoptosis."
    },
    "naive_doc_ids": [
      "4323425",
      "21487212",
      "3840043",
      "9197092",
      "718601"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "Paper 7 provides direct evidence supporting the claim that DUSP4 decreases apoptosis. The study found that DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion reduced the response to chemotherapy. This indicates that low levels of DUSP4 are associated with reduced apoptosis, supporting the claim that DUSP4 decreases apoptosis."
    },
    "overthinking_doc_ids": [
      "7869794",
      "10015292",
      "3765739",
      "33370",
      "581832"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers contain information directly related to DUSP4 and its effect on apoptosis. The papers cover various topics such as Ca2+ signaling in immune cells, DNA damage response in hematopoietic stem cells, cellular response to oxygen metabolism, the link between calcium and apoptosis, and other biochemical pathways related to apoptosis, but they do not address the role of DUSP4 in regulating apoptosis. Therefore, we cannot classify the claim as either supported or contradicted with the available evidence."
    },
    "posthoc_doc_ids": [
      "7869794",
      "10015292",
      "1941721",
      "33667484",
      "238409"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1105",
    "claim": "Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 specifically investigates whether risk factors during medical school, such as academic difficulties in the early years, are associated with subsequent professional misconduct. The study finds that failure in early or preclinical examinations is independently associated with an increased risk of professional misconduct later in the careers of doctors, with a significant odds ratio. This directly supports the claim that students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers. While the study suggests caution in interpreting the findings due to its small size, it provides relevant evidence supporting the claim. Papers 2, 3, 4, and 5 do not provide relevant information to this claim."
    },
    "naive_doc_ids": [
      "6710713",
      "17374970",
      "11624482",
      "2424794",
      "24988745"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence that aligns with the claim. It identifies having early academic difficulties during medical school, particularly failing early or preclinical examinations, as an independent risk factor for subsequent professional misconduct among doctors, which supports the claim that students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers. Papers 2, 3, and 4 do not provide relevant information or directly address the claim related to misconduct, focusing instead on academic success, board certification, and gallstone recurrence, respectively."
    },
    "overthinking_doc_ids": [
      "6710713",
      "17374970",
      "11624482",
      "40343416"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines the correlation between students' early academic performance in medical school and subsequent professional misconduct. It finds that academic difficulties during the early years of medical school, specifically failure of early examinations, are independently associated with increased risk of later professional misconduct (odds ratio 5.47, P<0.001). Although the conclusions are considered preliminary, they provide clear evidence supporting the claim. Other papers do not provide information relevant to this specific claim, thus the classification is based predominantly on the evidence from Paper 1."
    },
    "posthoc_doc_ids": [
      "6710713",
      "17374970",
      "195680777",
      "2424794",
      "11624482"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "54",
    "claim": "AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The provided papers collectively demonstrate that AMPK activation is linked to anti-inflammatory signaling and does not increase inflammation-related fibrosis. Paper 1 explicitly notes that AMPK activation suppresses the JAK-STAT inflammatory pathway, presenting a mechanism where it inhibits rather than promotes inflammatory signaling. Paper 2 further supports this by describing AMPK's role in promoting anti-inflammatory actions in cardiovascular tissues. The other papers focus on different pathways and factors (IL-13, caveolin-1, FAK) related to fibrosis and inflammation but do not directly relate to AMPK causing pro-inflammatory fibrosis. Thus, the evidence refutes the claim that AMPK activation increases inflammation-related fibrosis in the lungs."
    },
    "naive_doc_ids": [
      "3973445",
      "1590744",
      "4662264",
      "21258863",
      "3984231"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The papers primarily suggest that AMPK activation actually has protective and anti-fibrotic roles in the lungs rather than promoting inflammation-related fibrosis. Paper 2 specifically indicates that AMPK activation, via metformin, accelerates the resolution of established lung fibrosis, suggesting a protective role against fibrosis. Paper 5 and 6 also highlight the therapeutic potential of AMPK activation in managing inflammation-related conditions, further suggesting its protective roles. None of the papers provide evidence that AMPK activation increases inflammation-related fibrosis in the lungs."
    },
    "overthinking_doc_ids": [
      "1800734",
      "49556906",
      "3984231",
      "31313782",
      "3419709"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The claim states that AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs. However, paper 2 provides evidence that pharmacological activation of AMPK in myofibroblasts from lungs of humans with idiopathic pulmonary fibrosis (IPF) results in lower fibrotic activity and aids in the resolution of fibrosis in a mouse model. This suggests that AMPK activation actually ameliorates rather than exacerbates fibrosis, standing in opposition to the claim. No other paper provides direct information supporting or refuting AMPK activation's role in increasing fibrosis in the lungs."
    },
    "posthoc_doc_ids": [
      "1800734",
      "49556906",
      "3984231",
      "3419709",
      "20732789"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "14",
    "claim": "5'-nucleotidase metabolizes 6MP.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides relevant evidence supporting the claim. It discusses the role of 5'-nucleotidase encoded by the NT5C2 gene, which is responsible for inactivating nucleoside-analog chemotherapy drugs like 6-mercaptopurine (6MP). The paper describes activating mutations in this gene that increase nucleotidase activity, conferring resistance to chemotherapy, including 6MP, in ALL lymphoblasts. No other paper discusses the metabolism of 6MP or the role of 5'-nucleotidase in its metabolism. Therefore, the evidence from Paper 1 strongly aligns with the claim that 5'-nucleotidase metabolizes 6MP."
    },
    "naive_doc_ids": [
      "6421792",
      "293661",
      "393001",
      "313394",
      "8868863"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence that supports the claim. It discusses activating mutations in the NT5C2 nucleotidase gene, which encodes a 5'-nucleotidase enzyme, as responsible for the inactivation of nucleoside-analog chemotherapy drugs, including 6-mercaptopurine (6MP) and 6-thioguanine (6TG), in the context of chemotherapy resistance in relapsed Acute Lymphoblastic Leukemia (ALL). While the other papers do not provide directly relevant information, Paper 1 offers experimental data and findings directly linking the NT5C2 nucleotidase enzyme to the metabolism of 6MP, thereby supporting the claim."
    },
    "overthinking_doc_ids": [
      "6421792",
      "293661",
      "393001",
      "2831620",
      "5785219"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 5 provide evidence supporting the claim. Paper 1 discusses activating mutations in the NT5C2 nucleotidase gene, which confer resistance to chemotherapy drugs including 6-mercaptopurine (6MP). It states that the NT5C2 gene encodes a 5'-nucleotidase responsible for the inactivation of nucleoside-analog chemotherapy drugs, including 6MP. Similarly, Paper 5 reports mutations in NT5C2, associated with increased enzymatic activity and resistance to nucleoside analog therapies, including 6MP. Thus, these findings support the claim that 5'-nucleotidase (encoded by NT5C2) metabolizes 6MP, contributing to chemotherapy resistance."
    },
    "posthoc_doc_ids": [
      "6421792",
      "6588614",
      "2958458",
      "393001",
      "641786"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "18",
    "claim": "61% of colorectal cancer patients are diagnosed with regional or distant metastases.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present specific data or findings directly addressing the proportion of colorectal cancer patients diagnosed with regional or distant metastases. The papers cover a range of topics related to colorectal cancer, including socioeconomic factors affecting treatment, survival rates, expressions of circadian genes, trends in stage IV diagnoses, hypoxia in metastases, and safety of targeted therapies, but none offer specific percentages or statistics about the initial diagnosis stages that align with or contradict the 61% figure mentioned in the claim."
    },
    "naive_doc_ids": [
      "16390264",
      "2058909",
      "23830488",
      "10958594",
      "24980622"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically address the claim that 61% of colorectal cancer patients are diagnosed with regional or distant metastases. The papers focus on various aspects of colorectal cancer, such as trends in treatment and survival (Paper 1), socioeconomic factors affecting access to treatment (Papers 3, 4, 6, 8), and other unrelated topics such as the role of hypoxia and circadian genes (Papers 2 and 7). Therefore, there is no evidence related to the specific prevalence of metastasis in colorectal cancer patients that supports or contradicts the claim."
    },
    "overthinking_doc_ids": [
      "10958594",
      "24980622",
      "16390264",
      "2058909",
      "22942787"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain information specifically addressing the percentage of colorectal cancer patients diagnosed with regional or distant metastases. Paper 1 discusses trends in incidence and treatment of colorectal cancer, focusing on Stage IV patients, but it does not provide a breakdown of overall diagnosis rates for regional or distant metastases across all colorectal cancer patients. Other papers provide insights into socioeconomic factors, hypoxia in metastases, and other related topics but do not cover the claim regarding the percentage of patients diagnosed with metastases."
    },
    "posthoc_doc_ids": [
      "10958594",
      "16390264",
      "24980622",
      "14672919",
      "520579"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "684",
    "claim": "Lack of clpC does not affect sporulation efficiency in Bacillus subtilis cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information regarding how the lack of clpC affects sporulation efficiency in Bacillus subtilis cells. Paper 1 discusses the regulation of the clpC operon but does not cover its impact on sporulation. Paper 2 identifies novel sporulation genes but does not mention clpC or its role. Paper 3 delves into Clp protein regulation and interactions, yet it also lacks information specifically linking clpC to sporulation efficiency. Therefore, there is no relevant evidence in these papers to verify or refute the claim."
    },
    "naive_doc_ids": [
      "34386619",
      "4942718",
      "12881593"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information related to the specific claim that the lack of clpC does not affect sporulation efficiency in Bacillus subtilis. The papers discuss the regulation of the clpC operon, stress conditions influence on Clp protein levels, and identification of other genes involved in sporulation. However, none directly address or provide experimental data concerning the impact of clpC deletion on sporulation efficiency. Therefore, there isn't enough evidence from these papers to either support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "34386619",
      "4942718",
      "12881593"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The papers provided do not directly address the claim regarding the impact of clpC deletion on sporulation efficiency in Bacillus subtilis. Paper 1 discusses the identification of new sporulation genes but does not mention clpC or its role in sporulation. Paper 2 focuses on the regulation of the clpC operon and class III heat shock genes, but does not provide information on sporulation efficiency. Paper 3 deals with the role of Clp proteins under stress conditions and their regulation but does not discuss their role in sporulation efficiency either. Hence, none of the papers provide relevant information to support or contradict the specific claim."
    },
    "posthoc_doc_ids": [
      "4942718",
      "34386619",
      "12881593"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "428",
    "claim": "Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Several papers provide direct evidence supporting the claim that Forkhead 0 (FOXO) transcription factors are involved in cellular differentiation. Paper 1 highlights the role of FOXO transcription factors in regulating the differentiation of stem cells in the hematopoietic system. Paper 6 specifically states that FOXO4 is necessary for the neural differentiation of human embryonic stem cells, linking FOXO transcription factors to cellular differentiation processes directly. Additionally, Paper 3 discusses the activation of FKHR (a FOXO transcription factor) in neurons and its impact on cell survival and death, thereby implicating it in differentiation-related processes. Consequently, these papers provide substantial experimental data and findings that align with and support the claim."
    },
    "naive_doc_ids": [
      "16728949",
      "28937856",
      "29429111",
      "17049436",
      "11335860"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence from Paper 3 explicitly states that FoxO transcription factors are involved in various physiological processes including differentiation. This aligns with the claim that Forkhead 0 (FoxO) transcription factors are involved in cellular differentiation. Additionally, the paper discusses the role of FoxO in stem cell homeostasis and function, providing further support to the involvement of FoxO transcription factors in the regulation of differentiation processes as a part of maintaining stem cell integrity across various tissues. However, there is no direct experimental evidence specifically showing FoxO's role in differentiation within the papers provided, which slightly lowers the confidence."
    },
    "overthinking_doc_ids": [
      "29429111",
      "1065627",
      "16728949"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that Forkhead 0 (FoxO) transcription factors are involved in cellular differentiation is supported by Paper 3. This paper explicitly mentions that the FoxO family of transcription factors is involved in diverse physiological processes, including differentiation, as well as stress resistance and apoptosis. The paper describes the role of FoxO-dependent signaling in the regulation of hematopoietic stem cells, which includes differentiation. Therefore, there is explicit discussion of FoxO transcription factors being involved in differentiation processes, which aligns with the claim."
    },
    "posthoc_doc_ids": [
      "29429111",
      "1065627",
      "16728949",
      "20524091",
      "11289247"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "917",
    "claim": "PTEN is a regulator for the transcriptional activity of SRF",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "Paper 5 provides direct evidence supporting the claim that PTEN is a regulator for the transcriptional activity of SRF. It specifically describes how PTEN functions as a regulator with SRF in the nucleus to control smooth muscle differentiation, indicating PTEN's role in influencing SRF's transcriptional control. The interaction between PTEN and SRF and its effects on gene expression related to the smooth muscle cell phenotype directly align with the claim that PTEN regulates SRF's transcriptional activity."
    },
    "naive_doc_ids": [
      "14367469",
      "29429111",
      "2316374",
      "12462961",
      "34071621"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct evidence that PTEN is an essential regulator of SRF-dependent transcription in controlling smooth muscle differentiation. It discusses how PTEN interacts with SRF, influencing its transcriptional activity. This aligns with the claim that PTEN is a regulator of SRF's transcriptional activity. Other papers do not provide relevant information to refute or support this specific claim, leading to the conclusion that Paper 4 supports it."
    },
    "overthinking_doc_ids": [
      "14367469",
      "29429111",
      "2316374",
      "34071621",
      "207972"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "Paper 4 presents evidence directly supporting the claim by detailing how PTEN functions as an essential regulator of SRF-dependent transcription. Specifically, it describes PTEN's interaction with SRF in the nucleus, which is crucial in maintaining the differentiation of smooth muscle cells through SRF. This interaction highlights PTEN's role in modulating the transcriptional activity of SRF, thereby confirming the claim that PTEN is a regulator for the transcriptional activity of SRF."
    },
    "posthoc_doc_ids": [
      "14367469",
      "29429111",
      "2316374",
      "34071621",
      "5783785"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "689",
    "claim": "Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information specifically about the percentage of patients exposed to radiation having activated markers of mesenchymal stem cells. The papers discuss various aspects of mesenchymal stem cells, such as their role in different biological processes, interactions in the bone marrow environment, and responses to factors like dexamethasone or CD200, as well as impacts of radiation on intestinal stem cells and fibroblast growth factors. However, none of the papers directly address the claim related to radiation exposure and activation of mesenchymal stem cell markers."
    },
    "naive_doc_ids": [
      "21645205",
      "3531388",
      "3863543",
      "2853291",
      "17682477"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information directly related to the specific claim that less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells. The papers cover various topics such as circadian rhythms in mesenchymal stem cells, intestinal stem cell survival after radiation, stem cell niches, and transplantation outcomes, but none present specific experimental data or results addressing the activation rates of mesenchymal stem cell markers post-radiation exposure."
    },
    "overthinking_doc_ids": [
      "21645205",
      "25238950",
      "2853291",
      "10582939",
      "9997636"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain specific information or experimental data relevant to the claim about the percentage of patients exposed to radiation having activated markers of mesenchymal stem cells. The papers discuss various aspects of mesenchymal stem cells, such as their circadian mechanisms, regenerative potential in diabetes, their role in inflammation and pre-leukemia, their bone marrow niche interactions, growth arrest mechanisms, and differentiation capabilities. However, none of these papers directly address the activation of mesenchymal stem cell markers in patients exposed to radiation, which is the core of the original claim."
    },
    "posthoc_doc_ids": [
      "21645205",
      "24101431",
      "3863543",
      "4380004",
      "7506409"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "772",
    "claim": "Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 provides direct evidence contradicting the claim by demonstrating that a single dose of a chimeric virus containing chikungunya virus (CHIKV) structural proteins produced in mosquito cells elicited rapid and long-lasting neutralizing antibodies in mice, which provided complete protection against chikungunya fever in two different mouse models. This indicates that mice are indeed capable of producing neutralizing antibodies in response to the chikungunya virus produced in mosquitos, directly opposing the claim that they are incapable of doing so."
    },
    "naive_doc_ids": [
      "10559501",
      "23915841",
      "24922825",
      "991139",
      "18816720"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 provides evidence that mice can produce neutralizing antibodies in response to the Chikungunya virus (CHIKV) when it is incorporated into a chimeric virus platform developed from an insect-specific virus. Specifically, the EILV/CHIKV construct, which contains the structural proteins of CHIKV, elicited rapid and long-lasting neutralizing antibodies in mice. This evidence directly contradicts the claim that mice are incapable of producing neutralizing antibodies in response to CHIKV, as the study shows that mice can indeed mount such a response when the virus is presented through this specific platform."
    },
    "overthinking_doc_ids": [
      "24922825",
      "10559501",
      "23915841",
      "991139",
      "5572127"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers focus on a variety of topics including Helicobacter pylori vaccines, atherosclerosis therapy, genetic polymorphisms related to hepatitis C, colitis in mice, macrophage immune responses, autoimmune regulation, cancer antigens, and immune deficiency after stem cell transplantation. However, none of the papers specifically address the capability of mice to produce neutralizing antibodies in response to the Chikungunya virus (CHIKV) produced in mosquitos. Therefore, there is no relevant information in these papers regarding the specific claim about mice and Chikungunya virus, making them unable to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "13965483",
      "2837758",
      "13923069",
      "991139",
      "5572127"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1324",
    "claim": "Treatment with a protein named FN restores regenerative abilities of aged muscles.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 provides direct evidence related to the claim. It discusses how the loss of fibronectin (FN) from the aged stem cell niche affects the regenerative capacity of skeletal muscle. The paper shows that reconstitution of FN levels in the aged niche restores youth-like muscle regeneration, implying that FN treatment can restore the regenerative abilities of aged muscles. The other papers do not address the role of FN in muscle regeneration directly, so they are not relevant to this specific claim."
    },
    "naive_doc_ids": [
      "7042304",
      "1507222",
      "4653837",
      "19912367",
      "8771704"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct evidence supporting the claim that treatment with a protein named FN (fibronectin) can restore regenerative abilities of aged muscles. It highlights that the aged stem cell niche in skeletal muscle has reduced levels of fibronectin, which affects the function and maintenance of muscle stem cells (MuSCs). The study demonstrates that reconstituting FN levels in the aged niche revitalizes stem cells and restores muscle regeneration to a more youthful state. This aligns with the claim that fibronectin treatment enhances the regenerative capacity of aged muscles."
    },
    "overthinking_doc_ids": [
      "7042304",
      "1507222",
      "4653837",
      "19912367",
      "37438296"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 8 directly supports the claim by providing evidence that reconstitution of fibronectin (FN) levels in the aged stem cell niche restores youth-like muscle regeneration in mice. This indicates that treatment with FN can indeed restore regenerative abilities in aged muscles, aligning with the claim. The other papers do not provide contradicting or supporting information directly related to FN's role in muscle regeneration."
    },
    "posthoc_doc_ids": [
      "7042304",
      "1507222",
      "4653837",
      "8771704",
      "12411274"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1043",
    "claim": "Retinoic acid receptor-related orphan receptor gamma (ROR\u03b3) is a therapeutic target for castration-resistant prostate cancer (CRPC)",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that ROR\u03b3 is a therapeutic target for castration-resistant prostate cancer (CRPC). It demonstrates that ROR\u03b3 is overexpressed and amplified in metastatic CRPC, drives androgen receptor (AR) expression, and that ROR\u03b3 antagonists suppress tumor growth in AR-expressing prostate cancer models. This aligns with the claim. Papers 2, 3, 4, and 5 do not provide relevant information that directly supports or contradicts the claim, as they focus on different aspects or mechanisms of prostate cancer biology, such as clonal evolution, melatonin signaling, N-cadherin targeting, and lncRNA activity, which are not directly related to ROR\u03b3's role in CRPC."
    },
    "naive_doc_ids": [
      "17671145",
      "14131683",
      "37256966",
      "22180793",
      "8512633"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 directly supports the claim by providing evidence that Retinoic acid receptor-related orphan receptor gamma (ROR\u03b3) is a therapeutic target for castration-resistant prostate cancer (CRPC). The study presented in Paper 3 shows that ROR\u03b3 is overexpressed in metastatic CRPC tumors, drives androgen receptor (AR) expression, and that ROR\u03b3 antagonists can suppress AR expression, diminish genome-wide AR binding, and inhibit tumor growth in CRPC models. These findings establish ROR\u03b3 as an upstream regulator of AR and a potential therapeutic target, therefore supporting the claim regarding ROR\u03b3 in CRPC. Other papers do not provide relevant information for this specific claim, but Paper 3 provides strong evidence that aligns with the claim."
    },
    "overthinking_doc_ids": [
      "8512633",
      "14131683",
      "17671145",
      "3858268",
      "5123516"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that ROR\u03b3 is a therapeutic target for castration-resistant prostate cancer (CRPC). The study shows ROR\u03b3 is overexpressed in metastatic CRPC tumors and drives androgen receptor (AR) expression. It also demonstrates that ROR\u03b3 antagonists can suppress AR and variant AR-V7 expression, decrease tumor growth in AR-expressing models, and sensitize CRPC tumors to treatment with enzalutamide. This aligns with the claim by establishing ROR\u03b3 as a key player in CRPC and a potential therapeutic target. Papers 2-8 do not provide relevant information that directly supports or contradicts the claim regarding ROR\u03b3 and its role in CRPC."
    },
    "posthoc_doc_ids": [
      "17671145",
      "14131683",
      "8512633",
      "2062382",
      "4387494"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "938",
    "claim": "Persister cells provide relapse resistance in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The papers provided do not explicitly mention persister cells or directly provide evidence regarding persister cells offering relapse resistance in cancer patients. While the papers discuss mechanisms of drug resistance, tumor microenvironment influences, and cancer stem cells (CSCs), none of them directly address the specific concept of persister cells providing relapse resistance. The diverse topics covered, such as exosomal miR21 promoting chemoresistance, phosphoproteomic analyses of TKI resistance, immune checkpoint blockade resistance, and others, do not directly pertain to the role of persister cells in cancer relapse or resistance."
    },
    "naive_doc_ids": [
      "1727493",
      "25895285",
      "4468861",
      "20183360",
      "13779605"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not specifically address the role of persister cells in providing relapse resistance in cancer patients. While several papers discuss various mechanisms of drug resistance in cancer, such as exosomal transfer of chemoresistance factors, phosphoproteomic alterations linked with drug resistance, metabolic pathways in immune cells, cancer stem cells, telomere maintenance, and autophagy, none of them directly mention persister cells or their specific contribution to relapse resistance. Therefore, the evidence does not directly confirm or refute the claim regarding persister cells."
    },
    "overthinking_doc_ids": [
      "1727493",
      "25895285",
      "2030623",
      "8891333",
      "26952804"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information specifically about persister cells providing relapse resistance in cancer patients. The papers discuss various aspects of cancer biology and treatment, such as macrophage-induced COX-2 expression, neutrophil roles in metastasis, myeloid-derived suppressor cells, microRNA-induced chemoresistance, circulating tumor cells, immune checkpoint blockade, and steroidogenic gene expression, but none of them specifically address persister cells or their role in relapse resistance. Therefore, they do not provide evidence to support or contradict the claim regarding persister cells."
    },
    "posthoc_doc_ids": [
      "21439640",
      "878526",
      "2030623",
      "1727493",
      "20127522"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "645",
    "claim": "Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The papers provided consistently show that supplementation with folic acid (FA) leads to a decrease in homocysteine levels, which directly contradicts the claim that FA increases homocysteine levels. Paper 1 concludes that folic acid supplementation reduces homocysteine. Paper 2 finds significant reductions in homocysteine with folic acid supplementation in the elderly. Paper 3's meta-analysis also focuses on homocysteine reduction through folate supplementation. Paper 4 doesn't discuss homocysteine levels, and Paper 5 suggests improvements in health outcomes unrelated to homocysteine changes. Overall, the evidence refutes the claim, showing that folic acid reduces rather than increases homocysteine levels."
    },
    "naive_doc_ids": [
      "11705328",
      "21636085",
      "37424881",
      "4550036",
      "5152028"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim suggests that intake of folic acid and vitamin B6 increases levels of homocysteine. However, all the papers presented in the evidence indicate that folic acid supplementation decreases homocysteine levels rather than increasing them. Paper 1 and Paper 2 show that folic acid supplementation reduces serum homocysteine levels. Paper 3 presents a meta-analysis indicating homocysteine reduction through folic acid supplementation. Paper 4 suggests that folic acid might improve endothelial function by mechanisms other than homocysteine lowering, but does not show an increase in homocysteine levels. Therefore, the evidence from the papers contradicts the claim."
    },
    "overthinking_doc_ids": [
      "11705328",
      "21636085",
      "37424881",
      "5152028"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The papers collectively show that both folic acid and vitamin B6 are effective in lowering homocysteine levels, not increasing them. Paper 1 indicates that increased dosages of folic acid lead to decreased serum homocysteine levels. Paper 2 discusses the reduction of plasma homocysteine with supplementation of folic acid in an elderly population. Paper 3 explores folate fortification and the resulting lowering of homocysteine levels. None of these papers provide evidence supporting the claim that intake of folic acid and vitamin B6 increases homocysteine levels. Instead, they all demonstrate a homocysteine-lowering effect."
    },
    "posthoc_doc_ids": [
      "11705328",
      "21636085",
      "37424881"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "126",
    "claim": "Approximately 250,000 people are infected with human T-cell lymphotropic virus type 1 in the United Kingdom.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "The provided papers do not contain any evidence or information relevant to the specific claim about the number of people infected with human T-cell lymphotropic virus type 1 in the United Kingdom. The papers cover various topics, including HIV infection, West Nile virus in mosquitoes, drowning incidents in children, Creutzfeldt-Jakob disease, heart failure, and health behaviors' impact on mortality, none of which directly relate to the prevalence or statistics of human T-cell lymphotropic virus type 1 infections. Therefore, they do not offer data, results, or findings that confirm or refute the claim."
    },
    "naive_doc_ids": [
      "20996244",
      "23915841",
      "12885341",
      "42291761",
      "27063470"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain any relevant information about the prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) in the United Kingdom. The papers cover topics such as childhood undernutrition, cardiovascular disease risk factors in the Chinese population, prevalence of asthma in athletes, cancer treatment statistics, anthropometric data, cost-effectiveness of medications, aspects of HIV infection, and mechanisms of West Nile virus infection, none of which are directly related to HTLV-1 infection rates in the UK."
    },
    "overthinking_doc_ids": [
      "1606628",
      "2138767",
      "2891825",
      "25121903",
      "4432763"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) specifically in the United Kingdom or provide data on the number of people infected with HTLV-1 in the UK. The papers focus on topics related to HIV-1, bariatric surgery outcomes, outcomes in intensive care, cardiovascular disease in China, elderly dependence due to chronic diseases, and headache prevalence in the U.S., none of which are relevant to verifying the claim about HTLV-1 infection rates in the UK."
    },
    "posthoc_doc_ids": [
      "20996244",
      "46202852",
      "601033",
      "5824985",
      "21323587"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1216",
    "claim": "The extracellular domain of TMEM27 is cleaved in human beta cells.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence supporting the claim that the extracellular domain of TMEM27 is cleaved in human beta cells. It mentions that Tmem27 forms dimers and its extracellular domain is glycosylated, cleaved, and shed from the plasma membrane of beta cells. This cleavage process is shown to be beta cell specific. None of the other papers (Papers 2-6) provide relevant information related to the cleavage of the extracellular domain of TMEM27 in human beta cells, so they do not contradict the claim."
    },
    "naive_doc_ids": [
      "24142891",
      "1905095",
      "19756935",
      "27588420",
      "266641"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "The claim that the extracellular domain of TMEM27 is cleaved in human beta cells is supported by evidence in Paper 4. It describes that TMEM27, a transmembrane protein present in pancreatic beta cells, has its extracellular domain glycosylated, cleaved, and shed from the plasma membrane specifically in beta cells. This aligns directly with the claim, providing specific experimental data and results that confirm TMEM27 cleavage in beta cells."
    },
    "overthinking_doc_ids": [
      "19756935",
      "27588420",
      "43661837",
      "24142891",
      "31107919"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that the extracellular domain of TMEM27 is cleaved in human beta cells. Paper 1 specifically discusses the cleavage and shedding of the extracellular domain of Tmem27 (Tmem27, collectrin) from the plasma membrane of pancreatic beta cells. It also suggests that this cleavage process is specific to beta cells. This provides direct support for the claim that the extracellular domain of TMEM27 is cleaved in human beta cells. The other papers do not provide relevant evidence for or against the claim, but Paper 1 alone provides sufficient support."
    },
    "posthoc_doc_ids": [
      "24142891",
      "1905095",
      "19756935",
      "27588420"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "615",
    "claim": "Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that increased microtubule acetylation worsens interference of axonal transport due to LRRK2 Roc-COR domain mutations. However, Paper 1 provides evidence contrary to this claim. It reports that increasing microtubule acetylation actually rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. This suggests that increased microtubule acetylation has a protective, rather than detrimental, effect on axonal transport in the context of these mutations. The other papers do not provide relevant information regarding microtubule acetylation in relation to LRRK2 Roc-COR domain mutations."
    },
    "naive_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "1889358",
      "4474874"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations, but Paper 1 presents findings that increased microtubule acetylation actually rescues axonal transport issues and locomotor deficits caused by these mutations. Specifically, the study shows that increasing microtubule acetylation prevents the association of mutant LRRK2 with microtubules and restores axonal transport. This evidence directly contradicts the claim by demonstrating beneficial rather than detrimental effects of increased acetylation in this context. Therefore, the claim is contradicted by the evidence provided in Paper 1."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "18678095",
      "20743803"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations. However, Paper 1 provides evidence directly opposing this claim. It finds that increasing microtubule acetylation actually rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Specifically, the study shows that increasing microtubule acetylation prevents the association of mutant LRRK2 with microtubules and restores axonal transport, indicating a beneficial, rather than detrimental, effect of microtubule acetylation under these circumstances. None of the other papers provide evidence relevant to the claim."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "667451",
      "1676568",
      "20743803"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "524",
    "claim": "Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 provides relevant information that supports the claim. It indicates that metabolism of L-carnitine by intestinal microbiota produces TMAO and predicts increased risks for cardiovascular disease and events like myocardial infarction and stroke. This aligns with the claim that higher plasma levels of L-carnitine, when associated with TMAO, are correlated with cardiovascular events in humans. The other papers do not directly address the relationship between L-carnitine, TMAO, and cardiovascular risk, but Paper 1 supports the association of TMAO with increased cardiovascular risk, which indirectly supports the claim."
    },
    "naive_doc_ids": [
      "6793674",
      "25822299",
      "14803797",
      "6070278",
      "4647303"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 6 directly supports the claim by discussing how the metabolism of L-carnitine, a nutrient in red meat, by intestinal microbiota produces trimethylamine-N-oxide (TMAO), which is associated with increased risk of cardiovascular disease (CVD). The study highlights that higher plasma levels of L-carnitine, in combination with high levels of TMAO, are linked to increased cardiovascular events in humans. This aligns with the claim that higher plasma levels of L-carnitine, when associated with TMAO, are positively correlated with cardiovascular events."
    },
    "overthinking_doc_ids": [
      "6793674",
      "1287809",
      "2138767",
      "4445629",
      "46277811"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the papers provided contain specific information on the correlation between higher plasma levels of I-carnitine and trimethylamine N-oxide with cardiovascular events in humans. Although Paper 1 discusses the role of trimethylamine N-oxide (TMAO) in cardiovascular events, it does not address I-carnitine levels or their interaction. The rest of the papers focus on different subjects such as corin levels in chronic heart failure, bone density in hyperglycemia, antihypertensive therapy, genetic factors affecting HDL levels, the impact of COPD, health behaviors on longevity, and the role of pharmacists in mental health. Therefore, they do not provide relevant evidence to verify the claim."
    },
    "posthoc_doc_ids": [
      "6793674",
      "4445629",
      "40790033",
      "1711571",
      "3868322"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "676",
    "claim": "LRBA prevents CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information about the claim that LRBA prevents CTLA-4 recycling. The papers span a wide range of topics, including kinase inhibition, cell dynamics, cancer therapies, epigenetics, PI3K pathway, circadian rhythms, long noncoding RNAs, immunological responses to exercise, and B cell trafficking. However, none of these papers specifically address LRBA or CTLA-4 recycling, nor do they present experimental data or results related to this particular claim."
    },
    "naive_doc_ids": [
      "864491",
      "927561",
      "1389264",
      "4434951",
      "15113221"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain any relevant information about the role of LRBA in CTLA-4 recycling. The papers cover a wide range of topics related to cancer therapy, cell organization, immune response, membrane trafficking, and genetic rearrangements, but none address the specific interaction between LRBA and CTLA-4 or its recycling process. Therefore, they neither support nor contradict the claim in question."
    },
    "overthinking_doc_ids": [
      "864491",
      "927561",
      "1389264",
      "5531479",
      "2462673"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about the specific claim that LRBA prevents CTLA-4 recycling. The papers discuss a variety of topics, including immune deficiency after stem cell transplantation, mast cell functions in obesity, mutations affecting immune channel function, synaptic vesicle recycling related to dystonia, stages in Alzheimer's disease progression, effects of protein restriction on trophoblast differentiation, endocytosis in tumorigenesis, and endocytosis in plant cell polarity. None of these topics directly address the role of LRBA in CTLA-4 recycling, nor do they present experimental data, results, or findings related to this specific claim."
    },
    "posthoc_doc_ids": [
      "301866",
      "597790",
      "1605392",
      "14893425",
      "739734"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "759",
    "claim": "Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The claim that Artemisinin-based combination therapy (ACT) has a dramatic impact on reducing malaria transmission is supported by several papers provided. Paper 1 highlights that ACTs significantly reduce patient infectiousness and have the potential to reduce transmission, especially in lower-transmission settings. Paper 3 provides additional evidence by showing that ACT treatment significantly reduces gametocytaemia and infectiousness of patients compared to non-artemisinin regimens. Although Paper 2 indicates that the effect of ACT on transmission is moderate, it still acknowledges the impact of ACT on reducing the proportion of infected mosquitoes. Therefore, the consensus across the relevant papers is that ACTs contribute positively to reducing malaria transmission, albeit the degree of impact may vary based on transmission settings and pre-treatment conditions."
    },
    "naive_doc_ids": [
      "1805641",
      "10617916",
      "12409683",
      "13899137",
      "39984099"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is supported by multiple papers. Paper 1 discusses the dramatic impact of Artemisinin-based combination therapy (ACT) on malaria transmission, especially in lower-transmission settings, by significantly reducing the prevalence of infection and incidence of clinical episodes. Paper 3 further supports the claim by showing that ACT reduces infectiousness of individual patients and the probability of gametocytemia, thus impacting transmission. Although Paper 2 mentions a moderate effect of ACT on mosquito infection rates, it still indicates a reduction in the proportion of infected mosquitoes, aligning with reduced transmission potential. Together, these studies provide substantial evidence supporting the claim that ACT has a significant impact on reducing malaria transmission compared to previous or non-gametocytocidal treatments."
    },
    "overthinking_doc_ids": [
      "1805641",
      "10617916",
      "12409683",
      "6407356",
      "13899137"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The provided evidence from papers supports the claim to a significant extent. Paper 1 describes a mathematical model predicting that Artemisinin-based combination therapy (ACT) can lead to significant reductions in malaria transmission, particularly in low-transmission settings, aligning well with the claim. Paper 3 and Paper 2 also support this view by highlighting how ACTs reduce gametocytemia and mosquito infection, thereby impacting transmission. Although Paper 2 describes the effect as moderate, it still indicates a contribution to reduced transmission. Paper 6 further underscores the potential for major reductions in transmission with ACT as part of a broader intervention strategy. While there are some limitations noted, like the variability in effect based on transmission intensity and presence of submicroscopic gametocytemia (Papers 2 and 3), the overall evidence predominantly supports the claim that ACTs have a dramatic impact on reducing malaria transmission compared to nongametocytocidal drugs."
    },
    "posthoc_doc_ids": [
      "1805641",
      "10617916",
      "12409683",
      "3690068",
      "13899137"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.7,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "386",
    "claim": "Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim. It identifies that most intravenous drug errors occur during the administration of bolus doses or the preparation of drugs requiring multiple steps. This aligns exactly with the claim regarding the commonality of errors in specific administration contexts. The other papers do not provide directly relevant information related to this claim."
    },
    "naive_doc_ids": [
      "16495649",
      "118568",
      "3929361",
      "3578380"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines the incidence and severity of intravenous drug errors and provides evidence that most errors occurred during bolus administration and preparation of drugs requiring multiple steps. This directly supports the claim that errors in peripheral IV drug administration are most common in such scenarios. The results, indicating a significant portion of errors occurred at these stages, align with the statement in the claim. Other papers do not directly address this specific claim, focusing on different aspects of drug administration or safety monitoring, so they are classified as NOINFO."
    },
    "overthinking_doc_ids": [
      "16495649",
      "3578380",
      "21260231",
      "79231308"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence related to the claim. It reports that most intravenous drug administration errors occurred during bolus doses or multiple step preparations. This aligns well with the claim that errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations. The other papers do not provide information relevant to this specific claim, focusing on different aspects of drug administration, therapeutic development, and clinical trials. The confidence is high because Paper 1 is an ethnographic study specifically examining intravenous drug errors and their processes."
    },
    "posthoc_doc_ids": [
      "16495649",
      "21260231",
      "3578380",
      "10749308",
      "5586392"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "574",
    "claim": "In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers explicitly discuss the frequency or occurrence of segmental aneuploidy in domesticated populations of Saccharomyces cerevisiae. The papers cover a variety of topics related to Saccharomyces cerevisiae, including domestication and divergence, RNA processing, transcriptional regulatory associations, metabolic cycling, polyploidy, and DNA double-strand breaks, but none directly address segmental aneuploidy in domesticated yeast strains. Therefore, they lack relevant evidence to either support or contradict the claim."
    },
    "naive_doc_ids": [
      "10300888",
      "365896",
      "1256116",
      "9696379",
      "3828508"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers specifically address the occurrence of segmental aneuploidy in domesticated populations of Saccharomyces cerevisiae. The papers cover various aspects of yeast biology, including RNA processing, transcriptional regulation, calorie restriction impacts, maltose metabolism, and metabolic regulation, but they do not mention segmental aneuploidy in their findings or discussions. Therefore, they do not contain relevant information to either support or contradict the claim that segmental aneuploidy occurs infrequently in these yeast populations."
    },
    "overthinking_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "8909176",
      "32712381"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain any relevant information about the frequency of segmental aneuploidy in domesticated populations of Saccharomyces cerevisiae. The papers cover a range of other topics, including RNA processing, transcriptional regulatory associations, calorie restriction effects, cancer mutation frequency, metabolic cycling, health-related quality of life, chromatin remodeling, and stress response networks, none of which pertain to the specific claim about segmental aneuploidy in yeast."
    },
    "posthoc_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "6078882",
      "9696379"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "946",
    "claim": "Physical activity level is associated with the difference in maximal oxygen consumption between black and white youth.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 indicates that black children had lower VO2max compared to their white counterparts, a difference attributed partly to a more sedentary lifestyle in black children. This suggests a link between physical activity levels and maximal oxygen consumption, supporting the claim that physical activity is associated with VO2max differences between black and white youth. Additional papers corroborate the influence of physical activity and lifestyle factors on health and fitness outcomes, but Paper 1 directly addresses the specific claim about VO2max and physical activity."
    },
    "naive_doc_ids": [
      "18537148",
      "8428935",
      "11201004",
      "13083189",
      "3222187"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 4 explicitly investigates the differences in maximal oxygen consumption (VO2max) between black and white prepubertal and pubertal children, attributing part of the differences to physical activity/inactivity levels as well as hematologic profiles. This directly supports the claim that physical activity levels are associated with differences in maximal oxygen consumption between black and white youth. Other papers provide supporting context around the significance of physical activity in influencing VO2max and overall fitness, but Paper 4 is the primary source for this specific claim."
    },
    "overthinking_doc_ids": [
      "12205576",
      "6647414",
      "8428935",
      "18537148",
      "13083189"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The papers collectively provide evidence supporting the claim that physical activity levels are associated with differences in maximal oxygen consumption (VO2max) between black and white youth. Specifically, Paper 2 mentions that black children had a lower VO2max compared to white children and suggests that this difference could be partially attributed to a more sedentary lifestyle among black children. Paper 1 supports this by showing that moderate to vigorous physical activity levels were lower in non-Hispanic black adolescents compared to their counterparts, underscoring a pattern of lower physical activity in black youth. Although other papers provide additional context and data about physical activity and ethnicity, they don't directly address the specific VO2max differences by race and physical activity level. Nevertheless, the main evidence aligned with the claim comes from Paper 2, corroborated by Paper 1's findings on activity levels."
    },
    "posthoc_doc_ids": [
      "13083189",
      "18537148",
      "4449524",
      "752423",
      "13230773"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1351",
    "claim": "Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers contain specific information on the upregulation of dynein in Drosophila neurons and its effects on the number of microtubule plus-ends growing toward the cell body. While some papers discuss dynein's role in microtubule dynamics, positioning, and transport, they do not directly address the claim regarding the increase in microtubule plus-ends due to dynein upregulation. Paper 3, for instance, mentions dynein's role in polarized transport and microtubule orientation, but does not specifically link dynein upregulation to an increase in microtubule plus-ends growing toward the cell body. Therefore, the evidence provided does not support or contradict the claim, resulting in a classification of NOINFO."
    },
    "naive_doc_ids": [
      "16090672",
      "36111909",
      "28369117",
      "1889358",
      "9638032"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain direct information regarding the claim about the upregulation of dynein in Drosophila neurons increasing the number of microtubule plus-ends growing toward the cell body of each neuron. While several papers discuss dynein's role in microtubule organization, dendritic transport, and dynamic positioning processes, they do not specifically address whether dynein upregulation results in increased microtubule plus-ends oriented towards the cell body in Drosophila neurons. Without direct experimental evidence or findings that explicitly support or contradict the specific claim of the orientation and growth of microtubule plus-ends due to dynein upregulation, the papers do not provide relevant information to classify as SUPPORT or CONTRADICT."
    },
    "overthinking_doc_ids": [
      "28369117",
      "36111909",
      "1889358",
      "1546650",
      "16090672"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The evidence provided in the papers does not directly address the specific claim about the upregulation of dynein increasing the number of microtubule plus-ends growing toward the cell body in Drosophila neurons. Paper 2 discusses dynein's role in microtubule orientation and transport in axons and dendrites of Drosophila neurons, but does not explicitly link dynein upregulation to increased numbers of microtubule plus-ends growing toward the cell body. The other papers focus on different aspects of microtubule dynamics and cell polarity, with no direct connection to the claim at hand."
    },
    "posthoc_doc_ids": [
      "18126445",
      "28369117",
      "36111909",
      "16090672",
      "4343437"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1118",
    "claim": "Sweet taste receptors on the tongue are deactivated by between 1 and 10 mM glucose.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers discuss various aspects of taste receptors, glucose metabolism, and related pathways. However, none of the papers specifically address the deactivation of sweet taste receptors on the tongue by 1 to 10 mM glucose. While some papers mention taste receptors and glucose sensing, they do not provide direct experimental data or findings that verify or refute the specific claim about the concentration range required for deactivation of sweet taste receptors by glucose. Therefore, there is no direct evidence in these papers to support or contradict the claim."
    },
    "naive_doc_ids": [
      "23351136",
      "718601",
      "6588614",
      "20829129",
      "12943966"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information directly addressing the claim that sweet taste receptors on the tongue are deactivated by glucose concentrations between 1 and 10 mM. The papers discuss various aspects of taste perception, signaling pathways, glucose metabolism, and hormonal responses, but none of them specifically investigate the deactivation of sweet taste receptors by glucose concentrations. Therefore, they neither support nor contradict the claim."
    },
    "overthinking_doc_ids": [
      "23351136",
      "718601",
      "6588614",
      "12943966",
      "20829129"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers provided do not directly address the claim regarding the deactivation of sweet taste receptors on the tongue by glucose concentrations between 1 and 10 mM. The papers mainly focus on different aspects of sweet taste receptors, their roles in gut hormone secretion, and their response to certain tastants. However, none of the papers present experimental data or findings that directly confirm or refute the specific claim about glucose deactivating sweet taste receptors on the tongue at specified concentrations."
    },
    "posthoc_doc_ids": [
      "20829129",
      "12943966",
      "23351136",
      "14116046",
      "718601"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "813",
    "claim": "Mutations in G-Beta protein GNB1 are present in many cancers, resulting in loss of interaction with G-alpha subunits and concomitant activation of AKT pathway.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain any direct or indirect evidence regarding mutations in the G-Beta protein GNB1, their presence in cancers, loss of interaction with G-alpha subunits, or the concomitant activation of the AKT pathway. The papers discussed various topics such as PI3K/mTOR inhibition, Wnt pathway modulation, pancreatic cancer genomic alterations, endometrial cancer molecular characterization, the role of periostin in bone anabolism, TGF-beta's role in colon cancer, PPM1D mutations in breast and ovarian cancer, and RB loss in lung cancer. None of these topics relate to GNB1 mutations or the AKT pathway activation mentioned in the claim."
    },
    "naive_doc_ids": [
      "14241418",
      "3590806",
      "4325398",
      "11271123",
      "21564598"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers discuss various aspects of cancer biology, including the PI3K pathway, TNF-alpha interactions, EGFR mutations, and other molecular mechanisms related to different cancers. However, none of the papers specifically address mutations in the G-Beta protein GNB1 in relation to cancer, nor do they examine its interaction with G-alpha subunits or the activation of the AKT pathway as a result of such mutations. Therefore, there is no direct evidence in the papers to support or contradict the specific claim regarding GNB1 mutations and their effects in cancer."
    },
    "overthinking_doc_ids": [
      "14241418",
      "207972",
      "711256",
      "3590806",
      "5403286"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 6 directly discusses mutations in the G protein beta subunits, specifically GNB1, asserting that these mutations disrupt normal G\u03b1 interactions and activate canonical G protein signaling pathways. This aligns with the claim about GNB1 mutations resulting in loss of interaction with G-alpha subunits and activation of the AKT pathway, since AKT signaling is part of the broader PI3K/AKT pathway commonly associated with G protein signaling. Additionally, the paper notes that these mutations can confer resistance to certain cancer therapies, suggesting a significant impact on cancer biology. Although detailed mechanistic information specifically linking these mutations to AKT activation via G-alpha subunit interaction loss isn't exhaustively covered, the evidence presented aligns with the central elements of the claim. Other papers do not directly contradict or support this specific claim, focusing on unrelated signaling pathways or mechanisms."
    },
    "posthoc_doc_ids": [
      "14241418",
      "17648235",
      "3590806",
      "207972",
      "22036571"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "308",
    "claim": "DUSP4 downregulation deactivates the Ras-ERK pathway",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that DUSP4 downregulation deactivates the Ras-ERK pathway. It states that low concentrations of DUSP4 correlate with the activation of the Ras-ERK pathway in basal-like breast cancer, leading to drug resistance. This indicates that DUSP4 acts as a negative regulator of the Ras-ERK pathway, and its downregulation results in the pathway's activation, which aligns with the claim. Other papers provided no relevant information on this specific topic."
    },
    "naive_doc_ids": [
      "7821634",
      "18938992",
      "1900152",
      "4474874",
      "643765"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not specifically discuss DUSP4 downregulation or its effect on the Ras-ERK signaling pathway. While the papers cover various signaling pathways and cellular mechanisms, such as mTOR, Hippo, AMPK, and the IL-4 receptor pathway, none provide evidence or discussion related to DUSP4 and its role in deactivating the Ras-ERK pathway. Therefore, there is no relevant information in these papers to verify the scientific claim."
    },
    "overthinking_doc_ids": [
      "116792",
      "1387654",
      "1590744",
      "31844040",
      "4709641"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 7 provides direct evidence for the claim that DUSP4 downregulation results in the activation of the Ras-ERK pathway. The study discusses how low levels of DUSP4, a phosphatase for ERK, correlate with higher proliferation rates and activated Ras-ERK signaling in breast cancer cells. It further explains that DUSP4 overexpression increases apoptosis in response to chemotherapy, while its depletion leads to a reduced chemotherapeutic response, suggesting the involvement of the Ras-ERK pathway. Thus, this paper supports the claim that DUSP4 downregulation deactivates the Ras-ERK pathway."
    },
    "posthoc_doc_ids": [
      "4795303",
      "54482327",
      "6121555",
      "24974080",
      "86694016"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1319",
    "claim": "Transplanted human glial cells can differentiate within the host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 and Paper 7 provide strong evidence in support of the claim that transplanted human glial cells can differentiate within the host animal. Paper 5 describes the successful engraftment of human glial progenitor cells into neonatal mice, where they matured into human astrocytes and enhanced synaptic plasticity and learning. This indicates that the transplanted human glial cells not only survived but also differentiated within the host brain. Additionally, Paper 7 describes the differentiation and transplantation of neural precursors derived from human embryonic stem cells into the mouse brain, where they successfully differentiated into neurons and astrocytes, with no teratoma formation observed. These findings collectively support the claim that transplanted human glial cells have the capacity to differentiate within the host animal."
    },
    "naive_doc_ids": [
      "26873988",
      "3360421",
      "3874000",
      "11335860",
      "16284655"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct support for the claim by describing the engraftment of human glial progenitor cells into neonatal mice, resulting in the differentiation into human glial cells, including astrocytes, in the host animal. This maturation and differentiation suggest that transplanted human glial cells are capable of differentiating within the host animal, aligning with the claim. Other papers do not provide direct information related to the differentiation of glial cells within a host, but Paper 4's findings are significant and relevant enough to classify the overall evidence as SUPPORT."
    },
    "overthinking_doc_ids": [
      "9122283",
      "18104691",
      "1447990",
      "16284655",
      "36637129"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 and Paper 4 provide evidence that directly supports the claim that transplanted human glial cells can differentiate within the host animal. Paper 2 describes human glial progenitor cells engrafted into mice that mature into human astrocytes, showing an example of differentiation within the host. Similarly, Paper 4 provides evidence of human ES cell-derived neural precursors differentiating into neurons and astrocytes after transplantation into a mouse brain, further supporting the notion that transplanted human glial cells can differentiate in an animal host. The findings in both papers align with and confirm the claim being assessed."
    },
    "posthoc_doc_ids": [
      "9122283",
      "16284655",
      "1447990",
      "2437807",
      "301866"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "606",
    "claim": "Increased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain any specific information regarding the biochemical pathway of PGE2 conversion to PPARy ligand 15-ket-PGE2 and its effect on PGE accumulation. The papers discuss various topics such as macrophage accumulation, GLP-1 receptor function, osteoclast regulation, muscle mass in relation to glycation end-products, adipokines in obesity, gene expression during follicular development, cholesterol metabolism in atherosclerosis, cancer metabolism, and tumor-stroma interactions. None of these papers address the specific claim about PGE2 conversion and accumulation, nor do they contain any experimental data or findings to either support or contradict this biochemical process."
    },
    "naive_doc_ids": [
      "2192419",
      "3127341",
      "3531388",
      "4627816",
      "5268462"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers specifically discuss the biochemical interactions or pathways involved in the conversion of PGE2 to a PPAR\u03b3 ligand, or how such conversion affects PGE accumulation. The papers cover a range of topics including macrophage accumulation in atherosclerosis, HDAC4 and ATM deficiency in neurodegeneration, stem cell metabolism, prostaglandin's role in immune response, NLRP3 inflammasome activation, small RNA pathways, telomere elongation, and PPAR\u03b3 signaling in cystic fibrosis, but none address the specific claim concerning increased conversion of PGE2 to PPAR\u03b3 ligand 15-ket-PGE2 and its impact on PGE accumulation."
    },
    "overthinking_doc_ids": [
      "2192419",
      "3113630",
      "3882374",
      "3930020",
      "4399311"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information regarding the conversion of PGE2 to PPAR\u03b3 ligand 15-ket-PGE2 or the accumulation of PGE. The papers cover diverse topics such as ghrelin's effect on adipogenesis, IL-23's role in IBD, impact of malaria treatments, CETP polymorphisms, HPV microRNA expression, ADAMTS7 variants in PAD, HDAC4 in neurodegeneration, prostaglandin D2 in schistosomiasis, and mitochondria's role in inflammasome activation, none of which directly pertain to the claim about PGE2 conversion and accumulation. Therefore, there is no evidence in these papers to either support or contradict the specific scientific claim."
    },
    "posthoc_doc_ids": [
      "31564409",
      "1022115",
      "1805641",
      "3868322",
      "32720933"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "106",
    "claim": "Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim that ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension is contradicted by the evidence provided in Papers 1 and 2. Paper 1 indicates that ambulatory monitoring serves as the gold standard or reference for diagnosing hypertension and suggests that both clinic and home measurements have lower sensitivity and specificity compared to ambulatory monitoring. Paper 2 further supports the superior accuracy of ambulatory monitoring by highlighting its cost-effectiveness and better correlation with cardiovascular outcomes, compared to clinic and home measurements. These findings refute the claim that ambulatory monitoring is inaccurate; instead, they suggest that it is a more accurate method for diagnosing hypertension than clinic or home blood pressure measurements. Papers 3 and 4 focus on different aspects of ambulatory monitoring, specifically regarding blood pressure variability and treatment effects, and do not directly address the diagnostic accuracy of ambulatory monitoring."
    },
    "naive_doc_ids": [
      "25515907",
      "5151024",
      "54490092",
      "45447613"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The papers provide evidence that contradicts the claim that ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension. Specifically, Paper 1 and Paper 3 establish ambulatory monitoring as a reference standard and highlight its accuracy and cost-effectiveness compared to clinic and home measurements. Paper 1 concludes that treatment decisions based on ambulatory monitoring can more appropriately target hypertension treatment, avoiding substantial overdiagnosis. Paper 3 further emphasizes that ambulatory monitoring is the most accurate and cost-effective strategy for hypertension diagnosis. These findings collectively refute the claim of inaccuracy of ambulatory blood pressure monitoring."
    },
    "overthinking_doc_ids": [
      "25515907",
      "54490092",
      "5151024",
      "45447613"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim states that ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension. However, the evidence in both Paper 1 and Paper 2 contradicts this claim. Paper 1 concludes that ambulatory monitoring serves as a more accurate reference standard compared to clinic or home measurements. Paper 2 further supports this by demonstrating that ambulatory monitoring is more cost-effective and reduces misdiagnosis due to its accuracy in correlation with cardiovascular outcomes. Hence, both papers provide evidence that ambulatory blood pressure monitoring is actually accurate and beneficial for diagnosing hypertension, opposing the claim."
    },
    "posthoc_doc_ids": [
      "25515907",
      "5151024",
      "54490092",
      "45447613"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1364",
    "claim": "Venules have less significant tunica adventitia than arterioles.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain relevant information specifically about the comparative vascular anatomy or histology of venules and arterioles, specifically their tunica adventitia. The papers span a range of topics including hepatitis C detection, lipid hydroperoxide measurement, sequence comparison in proteins, atherosclerosis markers, coronary arterioles, proteasome structures, DNA methylomes, RIG-I recognition of viral RNA, and imaging techniques. None of these address the specific claim regarding the tunica adventitia of venules and arterioles."
    },
    "naive_doc_ids": [
      "285794",
      "3986403",
      "6128334",
      "87758",
      "1122279"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not discuss the anatomical structures or characteristics of venules or arterioles, nor do they provide any direct or indirect evidence regarding the relative significance of tunica adventitia in these blood vessels. The papers focus on diverse topics such as PCR detection of HCV RNA, cancer screening practices, endothelium-mediated relaxation in arterioles due to exercise, structures of proteasomes, GLP-1 receptor complexes, and DNA stability and decay. None of these subjects relate to the claim regarding venules and arterioles. Therefore, the information from these papers is irrelevant to verifying the claim."
    },
    "overthinking_doc_ids": [
      "285794",
      "756887",
      "1122279",
      "1744752",
      "3610282"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain information relevant to the claim regarding the tunica adventitia in venules and arterioles. The papers focus on various other topics such as endothelium-mediated relaxation, dietary assessment tools, genetic studies on MTHFR genotype, structures of Helicobacter pylori, the impact of antiretroviral therapy, chromatin structure, cell death, and management strategies for cervical cytologic diagnosis. There is no discussion or data about the anatomical characterization or comparison of the tunica adventitia between venules and arterioles."
    },
    "posthoc_doc_ids": [
      "1122279",
      "2295434",
      "8595678",
      "4387784",
      "13899137"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1098",
    "claim": "Stacking is more stable when a purine is present in the +5 position (C1698).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers contain specific information or evidence regarding the stability of DNA stacking with a purine at the +5 position (C1698), or any discussion on purines in such a context. The papers primarily focus on topics like replication fork stability in chemoresistance, atherosclerotic plaque stability, SIRT1 and genomic stability, transcriptional activator GAL4, miscarriage and depression, kinetochore structure, IL28B SNP and HCV, and the src oncogene in avian sarcoma virus. None address nucleotide stacking stability involving purines or DNA sequences at specific positions, thus providing no relevant information to support or contradict the claim."
    },
    "naive_doc_ids": [
      "4444861",
      "4890578",
      "5824955",
      "778436",
      "881332"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers contain relevant information regarding the specific claim about stacking and the presence of a purine at the +5 position. The papers cover a wide range of topics including cancer research, nucleic acid folding, oncogene mutations, and other unrelated studies, which do not address the claim directly or indirectly. Therefore, the evidence provided in these papers is not applicable to evaluating the specific claim about stacking stability with a purine."
    },
    "overthinking_doc_ids": [
      "10486817",
      "13494853",
      "35684881",
      "4396105",
      "16905344"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the specific topic of purine presence in the +5 position (C1698) affecting stacking stability. The papers cover unrelated topics such as transcriptional activation, miscarriage and depression, health literacy and quality of life, gene expression in stem cells, histone structure, vitamin D factors, Notch3 in leukemia, waterlogging tolerance in barley, and tumorigenesis in lung carcinoma. Without any mention of nucleotide stacking or sequence-specific effects involving purines, the papers do not provide relevant information to support or contradict the given scientific claim."
    },
    "posthoc_doc_ids": [
      "778436",
      "881332",
      "17693849",
      "4632921",
      "13790144"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "378",
    "claim": "Energy balance requires hypothalamic glutamate neurotransmission.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that energy balance requires hypothalamic glutamate neurotransmission. Several papers provide evidence supporting the role of hypothalamic glutamate in energy regulation. Paper 1 indicates that metabolic changes influence hypothalamic glutamate transporters, affecting neuronal function, suggesting that glutamate signaling in the hypothalamus is tied to metabolic and energy balance. Paper 3 directly discusses the role of glutamate release from ventromedial hypothalamic neurons in preventing hypoglycemia, highlighting its importance in energy homeostasis. Paper 5 shows that glutamate release is essential for the function of melanocortin receptor 4 on Sim1 neurons in body weight regulation, emphasizing glutamate\u2019s critical role in maintaining energy balance. These findings align with the claim that hypothalamic glutamate neurotransmission is essential for energy balance regulation."
    },
    "naive_doc_ids": [
      "17150648",
      "11742219",
      "11886686",
      "26735905",
      "45154987"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 provides evidence showing that leptin modifies astrocyte-specific glutamate transporters in the hypothalamus, implying that glutamate neurotransmission is influenced by metabolic signals, which are crucial for energy balance. Paper 3 directly shows that synaptic glutamate release from hypothalamic neurons is essential for preventing hypoglycemia, a critical aspect of energy balance. Both papers collectively indicate that hypothalamic glutamate neurotransmission is necessary for proper metabolic function and energy homeostasis, supporting the claim."
    },
    "overthinking_doc_ids": [
      "17150648",
      "11742219",
      "11886686",
      "612002",
      "15535511"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The provided evidence from Paper 1 and Paper 4 supports the claim that energy balance requires hypothalamic glutamate neurotransmission. Paper 1 shows how leptin-induced modification of glutamate transporters in hypothalamic astrocytes can affect neuronal functions tied to metabolism and obesity, suggesting a role of glutamate in metabolic regulation. Paper 4 directly connects glutamate neurotransmission in the regulation of body weight via MC4R function in Sim1 neurons, indicating that disruption of glutamate release leads to altered energy expenditure and hyperphagia. Both these pieces of evidence support the involvement of hypothalamic glutamate neurotransmission in energy balance."
    },
    "posthoc_doc_ids": [
      "17150648",
      "11742219",
      "11886686",
      "45154987",
      "25183830"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "35",
    "claim": "A deficiency of vitamin B12 decreases blood levels of homocysteine.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not discuss the relationship between vitamin B12 deficiency and blood levels of homocysteine. The papers primarily focus on topics related to vitamin D, its effects, and other unrelated medical and metabolic topics. None of the papers provide evidence or findings regarding the impact of vitamin B12 on homocysteine levels, which is the specific focus of the claim in question."
    },
    "naive_doc_ids": [
      "16256507",
      "3150030",
      "9555784",
      "13312471",
      "5152028"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The claim suggests that a deficiency in vitamin B12 decreases blood levels of homocysteine. However, the evidence provided primarily explores the impact of folic acid and B vitamin supplementation on homocysteine levels. Paper 2 shows that folic acid and B vitamins, including B12, lower homocysteine levels but does not indicate an increase or decrease due to a deficiency per se. Paper 6 highlights an independent risk factor of elevated homocysteine levels associated with vascular disease, mentioning B12 deficiency as a risk factor. However, it does not report that B12 deficiency leads to decreased homocysteine. The association presented generally aligns with the expectation that B12 deficiency would increase, rather than decrease, homocysteine levels due to impaired metabolic pathways. Therefore, the evidence does not support the claim and instead suggests an opposite relationship between B12 deficiency and homocysteine levels."
    },
    "overthinking_doc_ids": [
      "21636085",
      "33409100",
      "3150030",
      "9555784",
      "3222187"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss vitamin B12 deficiency and its direct effects on blood levels of homocysteine. The papers primarily focus on vitamin D levels, soy protein effects, folic acid supplementation, blood pressure variability, and the effects of vitamin C, all unrelated to vitamin B12 and homocysteine specifically. Therefore, there is no relevant information in the papers provided to verify or refute the claim regarding vitamin B12 deficiency and homocysteine levels."
    },
    "posthoc_doc_ids": [
      "3150030",
      "9555784",
      "3222187",
      "54490092",
      "4442799"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1227",
    "claim": "The mean suicide rate in women is higher after miscarriage than live birth.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information about the specific claim that the mean suicide rate in women is higher after miscarriage than live birth. Most of the papers discuss topics unrelated to miscarriage or live birth, such as preterm birth management, PCOS treatment, magnesium sulphate use, IVF and bisphenol A, mental health conditions in bariatric surgery patients, pharmacists' impact on mental health, epidemiology of suicide attempts in Europe, X-inactivation in stem cells, and self-harm in prisoners. None of these papers directly address suicide rates following miscarriage compared to live birth. Therefore, they neither support nor contradict the claim."
    },
    "naive_doc_ids": [
      "22815457",
      "24323369",
      "27129115",
      "5145974",
      "18872233"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence that the mean suicide rate in women is higher after miscarriage than after a live birth. The reported suicide rates were 18.1 per 100,000 for miscarriage and 5.9 per 100,000 for live birth, indicating a higher prevalence of suicide after miscarriage. The findings in Paper 1 directly address the claim and provide statistical evidence supporting it. Other papers do not provide relevant information to refute or support this specific claim."
    },
    "overthinking_doc_ids": [
      "25641414",
      "25806385",
      "22815457",
      "18872233",
      "19071857"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides direct evidence relevant to the claim. It reports a study on suicide rates in association with pregnancy in Finland, showing that the suicide rate after miscarriage (18.1 per 100,000) is higher than after live birth (5.9 per 100,000). This directly supports the claim that the mean suicide rate in women is higher after miscarriage than after a live birth. The other papers provided do not contain relevant information to either support or refute the claim, focusing on different aspects of women's health and pregnancy outcomes."
    },
    "posthoc_doc_ids": [
      "22815457",
      "25641414",
      "5145974",
      "24323369",
      "25806385"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "903",
    "claim": "PD-1 triggering on monocytes reduces IL-10 production by monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence contradicting the claim by showing that triggering of PD-1 on monocytes actually induces IL-10 production, rather than reducing it. This finding directly opposes the claim that PD-1 triggering on monocytes reduces IL-10 production. None of the other papers provide information relevant to the specific interaction between PD-1 triggering and IL-10 production in monocytes, so they are not considered in the contradiction but do not add support either."
    },
    "naive_doc_ids": [
      "10648422",
      "13902570",
      "275294",
      "9334631",
      "8639034"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers cover various topics related to monocyte function, inflammation, immune response, and vascular biology, but none of them directly address the specific claim that PD-1 triggering on monocytes reduces IL-10 production by monocytes. Papers discuss factors such as CRP, TLR-4, TGR5, and KLF2, but the specific involvement of PD-1 in regulating IL-10 production in monocytes is not discussed or tested in the provided evidence. Therefore, the claim cannot be verified or refuted based on the given documents."
    },
    "overthinking_doc_ids": [
      "9334631",
      "13902570",
      "40365566",
      "34469966",
      "116792"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 directly addresses the effect of PD-1 triggering on monocyte IL-10 production. It presents evidence that the interaction between PD-1 on monocytes and PD-L1 expressed on various cell types actually induces IL-10 production by monocytes during HIV infection. This evidence contradicts the claim that PD-1 triggering on monocytes reduces IL-10 production by monocytes. The other papers do not provide relevant information about PD-1's effect on IL-10 production by monocytes."
    },
    "posthoc_doc_ids": [
      "13902570",
      "9334631",
      "26658659",
      "10648422",
      "11868606"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "368",
    "claim": "Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence relevant to the claim, analyzing the impact of early PDA screening on extremely preterm infants. The study found that early screening echocardiography for PDA was associated with lower in-hospital mortality (14.2% vs 18.5%; OR, 0.73) and a lower rate of pulmonary hemorrhage compared to non-screened infants. Therefore, contrary to the claim that early PDA screening increases in-hospital mortality, this paper suggests that early screening may actually reduce mortality. Papers 2, 3, 4, and 5 do not address the specific claim regarding early PDA screening and in-hospital mortality, thus not providing additional contradicting or supporting information. Based on the available relevant evidence, the claim is contradicted."
    },
    "naive_doc_ids": [
      "27099731",
      "9967265",
      "34544514",
      "12383365",
      "3878434"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 specifically investigates the impact of early screening for patent ductus arteriosus (PDA) on in-hospital mortality among extremely preterm infants. The results show that infants who underwent early PDA screening had a lower hospital death rate (14.2% vs 18.5%) compared to those who did not undergo screening, with an odds ratio of 0.73 (95% CI, 0.54 to 0.98), indicating a statistically significant reduction in mortality. This evidence contradicts the claim that early PDA screening increases in-hospital mortality. The other papers do not provide relevant information on this specific claim, as they discuss unrelated medical topics."
    },
    "overthinking_doc_ids": [
      "27099731",
      "3552753",
      "3878434",
      "9967265",
      "25691541"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence on the association between early screening echocardiography for patent ductus arteriosus (PDA) and in-hospital mortality among extremely preterm infants. The study observed that infants who underwent early screening had a lower hospital death rate (14.2% vs 18.5%) and a lower rate of pulmonary hemorrhage than those who were not screened, indicating that early PDA screening decreases in-hospital mortality rather than increases it. The other papers do not present relevant information about this specific claim regarding early PDA screening and in-hospital mortality, thus reinforcing the contradiction from Paper 1."
    },
    "posthoc_doc_ids": [
      "27099731",
      "9967265",
      "25691541",
      "3898784",
      "24341590"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1174",
    "claim": "The PPR MDA5 has twenty N-terminal CARD domains.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain any information regarding the PPR MDA5 or its N-terminal CARD domains. The papers mainly discuss topics ranging from glutamate receptor ion channels, regulatory proteins, immune system functionalities, TRIM proteins, chromatin domains, and antimicrobial peptides. These topics do not relate to the specific claim about the number of N-terminal CARD domains in the PPR MDA5 protein. Therefore, the papers do not provide support or contradiction for the claim."
    },
    "naive_doc_ids": [
      "26011884",
      "612002",
      "24550453",
      "8093935",
      "1791637"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain any specific information or experimental data regarding the PPR MDA5 or its N-terminal CARD domains. The papers mainly focus on different topics such as conserved domain databases, protein structures unrelated to MDA5, glutamate receptors, prebiotics, gut microbiota, and Tat protein interactions. Therefore, they neither support nor contradict the claim about PPR MDA5 having twenty N-terminal CARD domains."
    },
    "overthinking_doc_ids": [
      "10029970",
      "27900414",
      "207972",
      "26011884",
      "612002"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about the claim that the PPR MDA5 has twenty N-terminal CARD domains. The papers discuss unrelated topics such as the structure and function of glutamate receptors, plasma soluble corin and N-terminal pro-atrial natriuretic peptide levels, conserved domains and protein 3D structure, and other biological studies. None of these papers provide experimental data, results, or findings regarding the PPR MDA5 or its N-terminal CARD domains."
    },
    "posthoc_doc_ids": [
      "26011884",
      "612002",
      "12451492",
      "10029970",
      "5473074"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "739",
    "claim": "MT binding domain drives amyloid structure formation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss the concept of an 'MT binding domain' driving amyloid structure formation. The papers cover a range of topics including protein-ligand interactions, receptor signaling, synapse functions, nucleosome dynamics, and mechanisms of mutant p53, but do not mention MT binding domains or their relationship to amyloid structures. As such, there is no information in these papers related to the specific claim in question."
    },
    "naive_doc_ids": [
      "40383969",
      "5914739",
      "7729656",
      "15655418",
      "17518195"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information directly addressing the claim that the MT binding domain drives amyloid structure formation. The papers cover diverse topics such as long-term memory mechanisms in Drosophila, mutant p53 functionalities, dynein microtubule interactions, gluatamate receptor dynamics, DNA chromatin structuring, iron role in biofilm formation, and invadopodia formation. None focus specifically on the role of an MT binding domain in amyloid structure formation."
    },
    "overthinking_doc_ids": [
      "15655418",
      "35684881",
      "1546650",
      "7729656",
      "18346333"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The claim is that the MT (microtubule) binding domain drives amyloid structure formation. None of the provided papers specifically discuss a connection between microtubule binding domains and amyloid structure formation. The papers focus on various topics such as ionotropic glutamate receptors, memory-related RNA binding proteins, follistatin's interactions with TGF-beta ligands, and roles of dynein in microtubule binding, among other topics. However, none directly address the role of microtubule binding domains in amyloid structure formation. Therefore, there is no relevant information in the provided papers to either support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "7729656",
      "15655418",
      "40383969",
      "35684881",
      "1546650"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "985",
    "claim": "Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 7 provides direct evidence supporting the claim by describing the functional relationship between PTEN and its pseudogene PTENP1. It states that PTENP1 can regulate cellular levels of PTEN by acting as a decoy for microRNAs that target PTEN, aligning with the claim that PTENP1 functions as an miRNA decoy to regulate PTEN expression. This paper offers a detailed explanation and experimental verification of how pseudogene mRNAs like PTENP1 can influence the expression of their associated protein-coding genes through miRNA interactions, thus supporting the claim."
    },
    "naive_doc_ids": [
      "11771811",
      "15590539",
      "16346504",
      "654735",
      "34071621"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 2 provides relevant evidence for the claim by discussing the functional relationship between the PTEN tumor suppressor gene and its pseudogene PTENP1. It explains that PTENP1 can regulate cellular levels of PTEN through a coding-independent mechanism, acting as a decoy for microRNAs. This aligns with the claim that PTENP1 functions as a microRNA decoy to regulate PTEN expression. The other papers do not provide information directly related to this interaction between PTENP1 and PTEN."
    },
    "overthinking_doc_ids": [
      "15590539",
      "6828370",
      "153744",
      "23513818",
      "600437"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct support for the claim by discussing the role of PTENP1, a pseudogene, in regulating PTEN expression by acting as an miRNA decoy. The paper explains that PTENP1 can regulate cellular levels of PTEN and has a growth-suppressive role, suggesting that it acts through miRNA interactions independent of its protein-coding abilities. This paper experimentally demonstrates the relationship between the mRNAs produced by PTEN and PTENP1, confirming the pseudogene's regulatory function aligned with the claim. Other papers do not directly address PTENP1 or its role as an miRNA decoy in this specific context."
    },
    "posthoc_doc_ids": [
      "6828370",
      "12652963",
      "42662816",
      "34016944",
      "11200685"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "962",
    "claim": "Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Papers 4, 5, 6, and 7 provide strong evidence supporting the claim that post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules. Paper 4 shows that mitochondrial RNA granules are centers for posttranscriptional RNA processing and the biogenesis of mitochondrial ribosomes, involving specific RNA-binding proteins. Paper 5 presents the involvement of GRSF1 in mitochondrial RNA granules, indicating their role in RNA processing, while Paper 6 discusses how GRSF1 regulates posttranscriptional mitochondrial gene expression within these granules. Additionally, Paper 7 identifies the RNA granule component DDX28 as essential for mitoribosome assembly, further solidifying the granules' role in posttranscriptional handling within mitochondria."
    },
    "naive_doc_ids": [
      "16242975",
      "23604601",
      "32324430",
      "20018321",
      "13931771"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Several papers provide evidence supporting the claim that post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules. Paper 1 and Paper 7 discuss the role of GRSF1, a mitochondrial RNA-binding protein, which localizes specifically to RNA granules within mitochondria and is implicated in post-transcriptional mitochondrial gene expression and RNA processing, respectively. Paper 3 mentions the presence of DDX28, another RNA-binding protein, in the RNA granules, and its function in mitoribosome assembly, further supporting the compartmentalization of post-transcriptional processes within mitochondrial RNA granules. These findings collectively confirm that post-transcriptional processes occur in mitochondrial RNA granules, aligning with the claim."
    },
    "overthinking_doc_ids": [
      "935538",
      "3619931",
      "4306711",
      "16242975",
      "9091863"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "The evidence from multiple papers supports the claim that post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules. Paper 2 highlights GRSF1's role, which forms granules co-localized with newly synthesized mtRNA, suggesting it is involved in post-transcriptional gene expression regulation. Paper 4 directly states that mitochondrial RNA granules are centers for posttranscriptional RNA processing. Paper 5 further specifies that GRSF1 and RNase P are involved in RNA processing within these granules. Paper 6 discusses DDX28, which resides in RNA granules, essential for mitoribosome assembly \u2014 this implies post-transcriptional processes occurring in these granules. Therefore, the various roles of RNA-binding proteins and helicases in mitochondrial RNA granules as described contribute to supporting the claim."
    },
    "posthoc_doc_ids": [
      "16242975",
      "935538",
      "9091863",
      "20018321",
      "13931771"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "173",
    "claim": "Bcp1 is a chaperone for Rpl23.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers specifically discuss Bcp1, Rpl23, or the interaction between the two. The papers cover various topics related to chaperones, ribosomal proteins, DNA repair, and other cellular processes, but do not provide experimental data, results, or findings related to Bcp1 being a chaperone for Rpl23. Therefore, there is no relevant information to either support or contradict the scientific claim."
    },
    "naive_doc_ids": [
      "13907427",
      "20524091",
      "37164306",
      "207972",
      "22495397"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The claim is that Bcp1 is a chaperone for Rpl23, but none of the provided papers specifically discuss the role of Bcp1 as a chaperone for Rpl23 or provide relevant experimental results or findings regarding this association. The papers cover a variety of topics, including chaperone-mediated autophagy, interactions between viral proteins, ribosomal protein assembly, and other unrelated biological processes. As such, there is no direct information or evidence related to Bcp1 and Rpl23 among the cited papers."
    },
    "overthinking_doc_ids": [
      "1084345",
      "79447",
      "266641",
      "207972",
      "4270992"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the interaction between Bcp1 and Rpl23. The claim that Bcp1 is a chaperone for Rpl23 is not addressed in any of the papers, as they focus on different biological mechanisms and proteins. Therefore, there is no information available in these papers to verify the claim."
    },
    "posthoc_doc_ids": [
      "1084345",
      "79447",
      "266641",
      "7155555",
      "4362729"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "278",
    "claim": "Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides explicit information about the complete sequence of the Commelina yellow mottle virus (CoYMV) genome, stating that the genome is 7489 base pairs in size. This directly contradicts the claim that the genome consists of 2140 base pairs. None of the other papers provide relevant information regarding the genome size of ComYMV."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "152245",
      "6903077"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct information about the genome size of Commelina yellow mottle virus (CoYMV), stating that the genome sequence is 7489 base pairs in size. This directly contradicts the claim that the genome consists of 2140 base pairs."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "41811327",
      "2721426"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 provides detailed genomic evidence that the complete genome of Commelina yellow mottle virus (CoYMV) is 7489 base pairs in size, not 2140 base pairs as asserted in the claim. Other papers do not address ComYMV or provide relevant information regarding the genome size of this virus, thus they are irrelevant to this specific claim. Therefore, Paper 1 directly contradicts the claim regarding the genome size of ComYMV."
    },
    "posthoc_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "41811327",
      "2721426"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "13",
    "claim": "5% of perinatal mortality is due to low birth weight.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers provided do not directly address the specific claim that 5% of perinatal mortality is due to low birth weight. Paper 1 discusses perinatal mortality in rural China but does not attribute a specific percentage of it to low birth weight. Paper 2 focuses on the treatment of patent ductus arteriosus in low birth weight infants but does not relate this to perinatal mortality rates directly. Paper 3 covers neonatal mortality in Indonesia with factors including low birth weight but does not quantify it specifically in relation to perinatal mortality rates. Papers 4, 5, and 6 focus on lifestyle factors, children's physical activity, and mouse follicular development, none of which are relevant to the claim about low birth weight and perinatal mortality. Therefore, none of the provided papers offer evidence supporting or contradicting the specific claim regarding the percentage of perinatal mortality due to low birth weight."
    },
    "naive_doc_ids": [
      "7662395",
      "34544514",
      "1263446",
      "1456068",
      "8428935"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific data or results directly linking low birth weight to 5% of perinatal mortality. While there is discussion in the papers about factors related to low birth weight and neonatal mortality, such as maternal conditions and interventions (as seen in Papers 3 and 8), none of the papers explicitly quantify the contribution of low birth weight to perinatal mortality at 5%. Without direct statistics or analysis focusing on the specific proportion of perinatal mortality attributed to low birth weight in the context of the claim, the evidence from these papers cannot be classified as SUPPORT, CONTRADICT, or relevant to verify the provided claim."
    },
    "overthinking_doc_ids": [
      "7662395",
      "34544514",
      "1263446",
      "1456068",
      "25028913"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers contain specific information about the percentage of perinatal mortality attributed to low birth weight. While some papers discuss general aspects of neonatal and perinatal mortality or related issues such as neonatal determinants, they do not directly address the claim that 5% of perinatal mortality is due to low birth weight. Therefore, there is no relevant evidence within these papers to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "7662395",
      "34544514",
      "1263446",
      "1456068",
      "12779444"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "165",
    "claim": "Bariatric surgery increases rates of postmenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the papers directly address the specific claim that bariatric surgery increases rates of postmenopausal breast cancer. Paper 6 discusses the impact of bariatric surgery on weight loss and associated health outcomes but does not mention any effect on breast cancer incidence. Other papers discuss related concepts such as diabetes, metabolic factors, and breast cancer risk in different contexts, but not in relation to bariatric surgery. Therefore, there is no evidence in the provided papers that directly supports or contradicts the claim."
    },
    "naive_doc_ids": [
      "32534305",
      "3329824",
      "38551172",
      "9171913",
      "16701509"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers specifically discuss bariatric surgery and its impact on postmenopausal breast cancer rates. The papers explore various factors related to breast cancer risk such as mammographic density, hormone levels, blood lipids, genetic predisposition, platelet distribution, and type 2 diabetes. However, they do not address bariatric surgery or its influence on breast cancer, meaning they do not contain relevant information about the specific claim."
    },
    "overthinking_doc_ids": [
      "38551172",
      "5864770",
      "9171913",
      "2931832",
      "2015126"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers directly address the relationship between bariatric surgery and postmenopausal breast cancer rates. Paper 4, which discusses bariatric surgery, focuses on weight loss and general health outcomes such as incidence of type 2 diabetes, hypertension, and cardiovascular conditions, but does not specifically mention breast cancer incidence or its increase post-bariatric surgery. The remaining papers focus on different risk factors and aspects of breast cancer such as mammographic density, blood lipids, genetic factors, the effects of tamoxifen, and diabetes, but do not connect these topics to bariatric surgery. Therefore, there is no direct evidence in these papers to support or contradict the claim that bariatric surgery increases rates of postmenopausal breast cancer."
    },
    "posthoc_doc_ids": [
      "38551172",
      "9171913",
      "13519661",
      "5824985",
      "2931832"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "114",
    "claim": "Anthrax spores are very difficult to dispose once they are dispersed.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "Paper 4 discusses the secondary aerosolization of viable Bacillus anthracis (anthrax) spores in a contaminated environment. The study demonstrates that anthrax spores can reaerosolize under typical office conditions. This indicates that once dispersed, anthrax spores are challenging to fully eliminate, supporting the claim about the difficulty in disposing of them. The findings highlight the persistence and ease of reintegration of these spores back into the environment, aligning with the notion that they are hard to manage once dispersed. The presence of viable spores even after contamination suggests significant challenges in disposal or decontamination efforts."
    },
    "naive_doc_ids": [
      "238409",
      "3903084",
      "5152028",
      "33872649",
      "44562058"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence supporting the claim that anthrax spores are very difficult to dispose of once dispersed. It discusses the secondary aerosolization of viable Bacillus anthracis (anthrax) spores in a contaminated environment and notes that these spores can re-aerosolize under common office activities, suggesting persistence and difficulty in disposing of them. The other papers do not address this claim and are not relevant to the topic, leading to a high confidence in support based solely on Paper 1."
    },
    "overthinking_doc_ids": [
      "33872649",
      "1818578",
      "1904291",
      "1338283",
      "1542437"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that anthrax spores are difficult to dispose of once dispersed. The paper discusses the reaerosolization of viable Bacillus anthracis spores in a contaminated office environment, indicating that spores can become airborne again with common office activities, which complicates remediation efforts. This reaerosolization underlines the difficulty of effectively disposing of anthrax spores once they are released in an environment. None of the other papers provide relevant information on this topic, as they cover unrelated subjects such as pleiotropy, folic acid effects, shared decision making, gene selection, HIV prevention, AGEs inhibition, and air pollution's impact on anxiety."
    },
    "posthoc_doc_ids": [
      "33872649",
      "2140513",
      "5152028",
      "1338283",
      "1542437"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "350",
    "claim": "Discrimination between the initiator and elongation tRNAs depends on the translation initiation factor IF3.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 provides direct evidence supporting the claim. It discusses bacterial translation initiation and the role of initiation factors IF1, IF2, and IF3 in enabling the selection of the initiator tRNA and the start codon in the P site of the 30S ribosomal subunit. This aligns with the claim that discrimination between the initiator and elongation tRNAs depends on the translation initiation factor IF3, as it highlights IF3's role in facilitating the correct placement and recognition of tRNA during the initiation phase of translation. Other papers do not provide relevant information about this specific process."
    },
    "naive_doc_ids": [
      "4474874",
      "5268462",
      "13072112",
      "9505448",
      "16927286"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct evidence supporting the claim by discussing the role of translation initiation factors, specifically IF3, in the process of bacterial translation initiation. The paper describes IF3 undergoing large conformational changes to facilitate the accommodation of the initiator tRNA (fMet-tRNA(fMet)) into the P site for start codon recognition, thereby distinguishing between initiator and elongation tRNAs. This indicates the vital role of IF3 in discriminating between different tRNAs during the initiation phase of translation."
    },
    "overthinking_doc_ids": [
      "32906513",
      "799586",
      "919007",
      "16927286",
      "9505448"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the role of the translation initiation factor IF3 in discriminating between initiator and elongation tRNAs. The papers primarily focus on topics such as histone modification and tumor suppression, pharmacogenomics, circular RNA translation, large-scale movements during bacterial translation, fungal pathogen interactions, nonsense-mediated decay, splicing mechanisms, and telomere elongation. While Paper 4 mentions IF3 in the context of bacterial translation initiation, it does not specifically address the discrimination between initiator and elongation tRNAs based on IF3's action. Thus, there is no relevant information in the evidence to verify the claim."
    },
    "posthoc_doc_ids": [
      "4455466",
      "5855168",
      "6209599",
      "16927286",
      "9604301"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "658",
    "claim": "It is not proven that moderate consumption of candy and chocolate reduces the risk of cardiovascular disease (CVD) specifically.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain any evidence or discussion directly related to moderate consumption of candy and chocolate and its effects on cardiovascular disease risk. The papers discuss various aspects of cardiovascular disease risk factors, prevention through statins, healthy lifestyle habits, and other unrelated topics, but none examine the specific dietary impact of candy and chocolate consumption on cardiovascular health. Therefore, they do not support or contradict the claim."
    },
    "naive_doc_ids": [
      "1287809",
      "2138767",
      "5698494",
      "12794099",
      "29735200"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided evidence from the papers does not directly address the specific claim regarding moderate consumption of candy and chocolate and its effect on reducing the risk of cardiovascular disease. The papers discuss various topics, such as the effects of polymeal, statins, physical fitness, fruits, beans, soy, and vegan proteins on cardiovascular health, but none focus on the consumption of candy and chocolate in relation to cardiovascular disease risk. Therefore, the papers do not contain relevant information to support or contradict the specific claim."
    },
    "overthinking_doc_ids": [
      "13230773",
      "7454794",
      "8780599",
      "1974176",
      "5293024"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not directly address the claim about moderate consumption of candy and chocolate and its specific effect on reducing the risk of cardiovascular disease (CVD). Paper 3 discusses candy consumption and longevity without specifically mentioning CVD risk reduction, and Paper 4 mentions dark chocolate as part of the Polymeal strategy but not in isolation nor focusing specifically on candy or broader chocolate consumption. The other papers focus on different topics such as alcohol, fruit consumption, statins, COPD, physician knowledge, and health literacy, none of which directly pertain to the claim about candy and chocolate consumption and CVD risk. Therefore, there is a lack of information directly confirming or refuting the specific claim."
    },
    "posthoc_doc_ids": [
      "20526907",
      "1974176",
      "5293024",
      "8780599",
      "5698494"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "756",
    "claim": "Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "The claim is that many proteins in human cells can be post-translationally modified at lysine residues via acetylation. Paper 1 discusses lysine acetylation as a conserved post-translational modification that affects numerous biological processes, indicating its widespread occurrence and regulatory significance in cellular functions. Paper 2 explores how lysine acetylation regulates chromatin structure and influences transcriptional regulation, further supporting the notion that lysine acetylation is common and functionally significant in human cells. Paper 3 specifically discusses histone acetylation, emphasizing the role of acetylation in gene regulation processes. These papers collectively provide evidence aligning with the claim that lysine acetylation is a prevalent and impactful post-translational modification in human proteins."
    },
    "naive_doc_ids": [
      "27134527",
      "12172346",
      "17919731",
      "10015292",
      "12887068"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that many proteins in human cells can be post-translationally modified at lysine residues via acetylation is supported by several pieces of evidence from the provided papers. Paper 2 discusses lysine acetylation as a reversible post-translational modification that regulates various metabolic processes and is involved in diseases, indicating the widespread occurrence of lysine acetylation in human cells. Paper 3 provides specific examples of lysine (H3K56) acetylation in human adipocytes and its role in transcription regulation. Paper 4 elaborates on lysine acetylation as a mechanism that regulates chromatin structure, further underscoring the significance of this modification in human cells. Together, these papers collectively support the claim by demonstrating the prevalence and importance of lysine acetylation modifications in various cellular processes and disease contexts."
    },
    "overthinking_doc_ids": [
      "19238",
      "2831620",
      "3052213",
      "12172346",
      "23985464"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that many proteins in human cells can be post-translationally modified at lysine residues via acetylation. The provided evidence from the papers, particularly Paper 1 and Paper 3, supports this claim. Paper 1 discusses lysine acetylation as a conserved protein post-translational modification involved in various biological processes, highlighting its regulation of protein interactions, activity, and localization. Paper 3 further emphasizes the significance of lysine acetylation in regulating chromatin structure and its role in disease development. Both papers directly discuss lysine acetylation, confirming it as a prevalent post-translational modification in human cells, thereby supporting the claim."
    },
    "posthoc_doc_ids": [
      "27134527",
      "3052213",
      "12172346",
      "1905095",
      "8327914"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "421",
    "claim": "Flexible molecules experience greater steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information to evaluate the claim that flexible molecules experience greater steric hindrance in the tumor microenvironment than rigid molecules. The papers focus on different aspects of tumor biology, such as the role of cancer-associated fibroblasts, tumor necrosis factor signaling, cancer cell metabolism, and the effects of treatments like tamoxifen. None of the studies specifically address the molecular flexibility and steric interactions of molecules within the tumor microenvironment. Thus, we cannot determine support or contradiction for the claim based on the provided evidence."
    },
    "naive_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "12438901",
      "28910120"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers explicitly discuss the steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The papers primarily focus on different aspects of cancer biology such as the role of cancer-associated fibroblasts, thymic microenvironments, metabolic processes, and immune cell dynamics in cancer. Without specific data or findings related to molecular steric hindrance in these contexts, no direct support or contradiction to the claim can be assessed."
    },
    "overthinking_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "2328272",
      "3981613"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not directly address the specific claim regarding flexible molecules experiencing greater steric hindrance than rigid molecules in the tumor microenvironment. The papers discuss various aspects of the tumor microenvironment, including the role of cancer-associated fibroblasts, stromal interactions, molecular characterizations, and therapeutic responses. However, none of them provide specific evidence or data about the steric hindrance faced by flexible versus rigid molecules, making it impossible to confirm or refute the claim based on this provided evidence."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "2931832",
      "11271123"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "713",
    "claim": "Low expression of miR7a does not repress target genes or exert a biological function in ovaries.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not discuss miR7a or its expression and function in ovaries specifically. The papers cover various topics related to microRNAs, gene expression, and biological functions in different contexts such as ovarian cancer, T cell regulation, and others. However, none of them specifically address miR7a and its potential role or lack thereof in ovarian function. Therefore, they do not provide evidence that confirms or refutes the claim regarding low expression of miR7a in ovaries."
    },
    "naive_doc_ids": [
      "266641",
      "53211308",
      "7028976",
      "2000038",
      "19358586"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about the role or expression of miR7a specifically in the context of the ovaries. While they discuss various roles of microRNAs and other genetic elements in different biological processes, such as gene regulation, cardiovascular health, immune responses, cancer biology, and neural function, none of them specifically addresses the expression or biological function of miR7a in ovarian tissue. Therefore, the evidence provided is not applicable to confirming or refuting the claim about miR7a in the ovaries."
    },
    "overthinking_doc_ids": [
      "5612738",
      "38944245",
      "45143088",
      "21363424",
      "6828370"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not directly address the claim regarding the expression of miR7a in ovaries and its potential role in gene repression or biological function. The papers primarily discuss other topics such as T-cell regulation, microRNA thresholds, epigenetic repression in T cells, adipose tissue function, metabolic regulation related to circadian rhythms, mitochondrial function in adipose tissue, lipid metabolism in ovarian cancer stem cells, fever-related microRNA regulation, and miRNA regulation in breast and ovarian cancer. None of these subjects directly pertain to the expression or biological function of miR7a specifically in ovaries. Therefore, there is no relevant information to either support or contradict the claim based on the provided evidence."
    },
    "posthoc_doc_ids": [
      "21363424",
      "2000038",
      "5377642",
      "79447",
      "25183830"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "182",
    "claim": "Bone Marrow (BM) transplantation is used to treat acute myeloid leukemia (AML)",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The evidence provided by the papers includes relevant discussion on the use of bone marrow transplantation in the treatment of acute myeloid leukemia (AML). Paper 2 directly describes the process of allogeneic stem cell transplantation, a procedure closely related to bone marrow transplantation, used in patients with AML and notes its use in remission attempts for donor cell leukemia, a complication post-transplant. The mention of the European Group for Blood and Marrow Transplantation further supports the connection between bone marrow transplantation practices and leukemia treatment. Though not all papers directly address bone marrow transplantation for AML treatment, the context and findings regarding stem cell transplantation and leukemia provide sufficient evidence to support the claim."
    },
    "naive_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "37248765",
      "10795340"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 2 provides evidence that confirms the claim by discussing allogeneic stem cell transplantation (SCT), which includes bone marrow transplantation, in the context of treating leukemia, including acute myeloid leukemia (AML). Although it mainly focuses on a complication (donor cell leukemia), it acknowledges the practice of using SCT in the treatment of AML. This implicitly supports the claim that bone marrow transplantation is used to treat AML. The other papers do not specifically address bone marrow transplantation as a treatment modality for AML, providing no direct contradiction or additional support for the claim."
    },
    "overthinking_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "188911",
      "3391547"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that bone marrow transplantation is used to treat acute myeloid leukemia (AML). Evidence in Paper 2 provides relevant information, as it discusses allogeneic stem cell transplantation (SCT) used for treating leukemia, including AML. While the paper mentions donor cell leukemia (DCL) as a rare complication, it confirms the use of SCT, which includes bone marrow sources, for AML treatment. None of the other papers contradict this claim or provide direct evidence against the use of bone marrow transplantation for AML. Therefore, the evidence supports the claim that bone marrow transplantation is used to treat AML."
    },
    "posthoc_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "8137081",
      "40164383"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "249",
    "claim": "Chenodeosycholic acid treatment reduces whole-body energy expenditure.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence that contradicts the claim by showing that treatment with chenodeoxycholic acid (CDCA) actually increases whole-body energy expenditure. The study demonstrated increased brown adipose tissue activity and energy expenditure in human subjects treated with CDCA. This direct experimental result opposes the assertion that CDCA treatment reduces energy expenditure. The other papers do not provide relevant information on the impact of CDCA on whole-body energy expenditure, focusing on different substances, mechanisms, or populations."
    },
    "naive_doc_ids": [
      "1568684",
      "25050364",
      "2575938",
      "11742219",
      "6540064"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 provides relevant information regarding the claim about chenodeoxycholic acid (CDCA) treatment and energy expenditure. The study specifically examines the effects of CDCA on human brown adipose tissue (BAT) activity and reports an increase in both BAT activity and whole-body energy expenditure following CDCA treatment. This finding directly contradicts the claim that CDCA reduces whole-body energy expenditure. None of the other papers provide information that directly supports or contradicts this claim, so the conclusion is based on the data from Paper 1."
    },
    "overthinking_doc_ids": [
      "1568684",
      "24917562",
      "25050364",
      "6042706",
      "20851402"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly investigates the effects of chenodeoxycholic acid (CDCA) on whole-body energy expenditure and reports that CDCA treatment increases whole-body energy expenditure, not reduces it. This paper specifically contravenes the claim that CDCA reduces energy expenditure by demonstrating an increase in both brown adipose tissue activity and energy expenditure upon CDCA treatment in humans. Other papers do not provide direct information about the effects of CDCA on energy expenditure, thus do not affect this classification."
    },
    "posthoc_doc_ids": [
      "1568684",
      "24917562",
      "25050364",
      "7005276",
      "22914228"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1190",
    "claim": "The amount of publicly available DNA data doubles every 10 months.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information regarding the specific claim that 'The amount of publicly available DNA data doubles every 10 months.' The claim pertains to the growth rate of publicly available DNA data, while the papers cover a range of topics including open access publishing, genome doubling in cancer, zoonotic infections, \u03b2-lactamase evolution, microtubule stabilization, microbial genome annotation, genomic data visualization, and socioeconomic factors in health. None of these topics address the claim about the expansion of publicly available DNA data."
    },
    "naive_doc_ids": [
      "27768226",
      "7211056",
      "7485455",
      "2211868",
      "2991954"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain any information relevant to the specific claim that the amount of publicly available DNA data doubles every 10 months. Each paper focuses on different topics, such as epidemiology, genome evolution in rice, citation rates of open access publications, cancer genome evolution, mutation rates in bacteria, regulation of gene expression via motif mapping, cardiovascular risk due to cold exposure, and metabolic pathways in cancer cells. None of these studies address DNA data availability, growth rates, or databases, thus they offer no evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "7485455",
      "8352137",
      "27768226",
      "7211056",
      "24896957"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers contain evidence or information relevant to the specific claim about the doubling of publicly available DNA data every 10 months. The papers discuss topics such as the impact of open access on citation rates, patient survey reliability, socioeconomic factors in health, effects of calcitriol therapy, glioma stem cell biology, chromosomal instability in cancer, socioeconomic gaps in risk behavior, and cryptochromes in circadian rhythms. These subjects do not relate to the measurement or analysis of the growth of publicly available DNA data."
    },
    "posthoc_doc_ids": [
      "27768226",
      "841371",
      "1781626",
      "26409363",
      "33370"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "764",
    "claim": "Medications to treat obesity are highly effective.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Among the provided evidence, Paper 8 specifically evaluates the long-term efficacy of anti-obesity drugs, which directly relates to the claim regarding the effectiveness of medications to treat obesity. The paper conducts a meta-analysis of randomized trials and finds that several drugs, namely orlistat, sibutramine, and rimonabant, modestly reduce weight. They also show varying impacts on cardiovascular risk profiles and have specific side effects. These findings suggest that while the weight reduction effects are moderate, these medications are effective in achieving weight loss, thus providing SUPPORT for the claim. The confidence level is high because Paper 8 directly addresses the claim with comprehensive data and analysis on the specific topic of anti-obesity drug efficacy."
    },
    "naive_doc_ids": [
      "597790",
      "5256564",
      "30351165",
      "120626",
      "2360905"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The papers overall suggest limitations and challenges in achieving high efficacy with current anti-obesity drugs. Paper 1 outlines the difficulties in developing effective anti-obesity drugs due to physiological and regulatory challenges. Paper 3 indicates that approved anti-obesity drugs (orlistat, sibutramine, rimonabant) produce only modest weight reduction and have notable adverse effects, which contradicts the claim of high effectiveness. Paper 4 discusses the potential of brown fat therapies, but these are not yet realized in clinical settings, suggesting future possibilities rather than current high efficacy. Therefore, the combined evidence from the papers does not support the claim that medications to treat obesity are highly effective at this time."
    },
    "overthinking_doc_ids": [
      "5839365",
      "6841927",
      "7552215",
      "14865329",
      "341324"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The papers provided do not contain relevant information about the effectiveness of medications specifically designed to treat obesity. The papers discuss various topics such as RNA interference, malaria vector control, congenital leptin deficiency, behavioral treatment of obesity, the role of brown fat, mechanisms linking obesity to insulin resistance and type 2 diabetes, anti-obesity drug development, familial obesity and leanness, and NSAIDs in cancer prevention. While some papers touch upon obesity and related treatments, they do not specifically provide data or results on the effectiveness of any obesity medications, which is required to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "15790930",
      "1349033",
      "4353857",
      "12672066",
      "14865329"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "680",
    "claim": "Lack of FGF21 in mice increases life expectancy.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss the direct relationship between lack of FGF21 and increased life expectancy in mice. The papers cover various topics such as ovarian transplants and life expectancy, autophagy and FGF21 expression related to metabolism, systemic health metrics across different regions, behavioral studies on specific gene knockouts, aging mechanisms, epigenetic changes associated with aging, and glomerular cell dynamics. However, none of the papers specifically address the role of FGF21 deficiency in life expectancy, either supporting or contradicting the original claim."
    },
    "naive_doc_ids": [
      "21232018",
      "6227220",
      "581832",
      "10017612",
      "14188138"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not discuss the specific impact of fibroblast growth factor 21 (FGF21) deficiency on life expectancy in mice. The papers cover various topics including maternal protein restriction, neuropeptide Y knockout, LIMK-1 knockout, autophagy and FGF21 as a mitokine, effects of growth hormone and IGF1, beta-catenin deficiency, interventions for hyperlipidemia, mast cells in obesity and glucose intolerance, and dietary fiber effects on metabolism. However, none of the papers directly address the claim regarding the lack of FGF21 and its effect on longevity."
    },
    "overthinking_doc_ids": [
      "9513785",
      "10017612",
      "14188138",
      "6227220",
      "6313547"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers directly investigate or present evidence regarding the impact of FGF21 deficiency on life expectancy in mice. The papers cover various topics, including lifespan regulation through different interventions, global health measures, effects of drinking patterns, and genetic studies on metabolism and longevity. However, they do not provide specific data or findings related to FGF21 deficiency in mice, which is the central claim. Therefore, the claim lacks supporting or contradicting evidence from the given papers."
    },
    "posthoc_doc_ids": [
      "21232018",
      "581832",
      "5939172",
      "4434951",
      "9513785"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1070",
    "claim": "Self-advocacy training is effective at decreasing homelessness.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain any information relevant to the effectiveness of self-advocacy training in decreasing homelessness. The papers cover a variety of topics related to healthcare, chronic disease management, mental health, and other social issues, but none specifically address self-advocacy training in the context of homelessness."
    },
    "naive_doc_ids": [
      "12584053",
      "25493293",
      "12667988",
      "4678846",
      "15041758"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers present information, data, experimental results, or findings that relate to the effectiveness of self-advocacy training in decreasing homelessness. The papers cover topics such as diabetes management, socioeconomic factors in parent training, migraine treatment, atherosclerosis, chronic lymphocytic leukemia, Treg cell function, health status in prisoners, smoking and lung cancer risk, suicide and drug self-poisoning, and deliberate self-harm. None of these address the claim regarding self-advocacy training specifically in the context of homelessness."
    },
    "overthinking_doc_ids": [
      "12584053",
      "25493293",
      "12667988",
      "4890578",
      "667451"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain any information relevant to the claim about self-advocacy training decreasing homelessness. The papers cover various topics including the impact of homelessness on children, malaria transmission, the effects of swim training on tumor growth, diabetes self-management, deliberate self-harm incidence, burn treatment cost-effectiveness, neural stem cell self-renewal, integrated care for chronic diseases and depression, and neural stem cell therapy for spinal cord injury. None of these topics address the effectiveness of self-advocacy training in relation to homelessness, nor do they provide experimental data, results, or findings on this specific intervention."
    },
    "posthoc_doc_ids": [
      "33135135",
      "1805641",
      "2242416",
      "12584053",
      "1102268"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "798",
    "claim": "Mitochondria play a trivial role in calcium homeostasis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "None of the provided papers directly address the role of mitochondria in calcium homeostasis; however, several papers discuss calcium homeostasis mechanisms involving different cellular components. Paper 2 mentions SERCA2b-mediated calcium cycling in adipocytes, suggesting that calcium cycling contributes significantly to cellular processes such as thermogenesis and glucose homeostasis. Papers 7 and 8 discuss the role of STIM1 in calcium signaling, indicating its importance in cellular calcium entry mechanisms. While mitochondria are not directly mentioned as central players in the examples given, these papers collectively highlight complex mechanisms involved in intracellular calcium dynamics, implying that mitochondria may in fact play a more substantial role than considered trivial. Therefore, the evidence indirectly contradicts the claim that mitochondria play a trivial role in calcium homeostasis."
    },
    "naive_doc_ids": [
      "12058271",
      "19205437",
      "28724565",
      "26702468",
      "8856690"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 provides direct evidence that mitochondria play a significant role in calcium homeostasis. It describes mitochondrial calcium (Ca2+) uptake as a biologically important process influencing intracellular Ca2+ signaling, cell metabolism, and cell survival, indicating that mitochondria have a substantial role in regulating calcium levels within cells. This contradicts the claim that mitochondria play a trivial role in calcium homeostasis."
    },
    "overthinking_doc_ids": [
      "12058271",
      "16728949",
      "19205437",
      "42873134",
      "935538"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct evidence that contradicts the claim by demonstrating the significant role mitochondria play in calcium homeostasis. It discusses how mitochondrial calcium uptake is crucial for intracellular calcium signaling, cell metabolism, and survival, highlighting its essential physiological relevance. This directly opposes the claim that mitochondria have a trivial role in calcium homeostasis. The other papers do not provide direct information related to the role of mitochondria in calcium homeostasis, thus do not impact the classification."
    },
    "posthoc_doc_ids": [
      "12058271",
      "19205437",
      "28724565",
      "5094468",
      "9197092"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "516",
    "claim": "High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers directly investigate or provide evidence regarding the claim that high levels of C-reactive protein (CRP) reduce the risk of exacerbations in chronic obstructive pulmonary disease (COPD). The papers discuss topics such as atherosclerosis and CRP (Paper 1), CETP polymorphisms (Paper 2), DOACs (Paper 3), COPD management strategies (Paper 4), inflammation due to cigarette smoke (Paper 5), pulmonologist involvement in lung cancer with COPD (Paper 6), airway inflammation in COPD (Paper 7), ICU outcomes for COPD exacerbations (Paper 8), and inflammatory responses in depression (Paper 9). However, none of these papers provide specific experimental data, results, or findings directly related to CRP levels and their impact on COPD exacerbation risk. As such, the evidence available is insufficient to support or contradict the claim."
    },
    "naive_doc_ids": [
      "72933407",
      "3868322",
      "4910408",
      "20109325",
      "20732789"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the papers provided specifically address the claim that high levels of CRP reduce the risk of exacerbations in COPD. The papers discuss various aspects of COPD, including inflammation predictors for exacerbations (Paper 1), epidemiological aspects (Paper 2), and other unrelated topics like gene polymorphisms and treatments for obesity, diabetes, asthma, and blood pressure (Papers 3-10). While some papers mention inflammation or disease exacerbation, they do not provide specific evidence about the role of CRP levels in reducing exacerbations in COPD."
    },
    "overthinking_doc_ids": [
      "25319221",
      "3580005",
      "3868322",
      "27686445",
      "27166444"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically address the claim that high levels of CRP (C-reactive protein) reduce the risk of exacerbations in chronic obstructive pulmonary disease (COPD). The papers discuss various topics related to COPD or other health conditions, such as the effect of sputum inflammation on COPD exacerbations, the cost-effectiveness of non-invasive ventilation for COPD exacerbations, and other unrelated health topics, but none directly evaluate the relationship between CRP levels and COPD exacerbations."
    },
    "posthoc_doc_ids": [
      "25319221",
      "2575938",
      "16256507",
      "10577574",
      "3580005"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "940",
    "claim": "Pharmacist attendance at ward rounds increases adverse events in wards.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim suggests that pharmacist attendance at ward rounds increases adverse events in wards. However, the evidence from Paper 1 directly contradicts this claim. Paper 1 presents a study where pharmacist participation on medical rounds in an ICU led to a significant decrease in preventable adverse drug events (ADEs) due to ordering errors, with a 66% reduction in such events observed after the intervention. This evidence indicates that pharmacist attendance during ward rounds can actually reduce adverse events, rather than increase them. None of the other papers provide information relevant to the specific claim about pharmacist attendance affecting adverse events in wards."
    },
    "naive_doc_ids": [
      "12258338",
      "11254040",
      "583260",
      "32353339",
      "202259"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 1.0,
      "justification": "Paper 1 provides evidence that contradicts the claim. It reports that the presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a 66% reduction in preventable adverse drug events (ADEs) caused by prescribing errors. This finding opposes the claim that pharmacist attendance at ward rounds increases adverse events. None of the other papers provide relevant information regarding the impact of pharmacist attendance at ward rounds on adverse events, so they are classified as NOINFO with regard to this claim."
    },
    "overthinking_doc_ids": [
      "12258338",
      "583260",
      "6070278",
      "31612088",
      "8842332"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses the involvement of pharmacists in medical rounds by examining the impact of pharmacist participation in ICU rounds on the rate of preventable adverse drug events (ADEs). The study found that pharmacist attendance on rounds significantly reduced the rate of preventable ADEs due to prescribing errors by 66%. This result suggests that pharmacist attendance does not increase adverse events, but rather decreases them. The other papers do not provide relevant information directly related to pharmacists' roles in ward rounds and their effects on adverse events."
    },
    "posthoc_doc_ids": [
      "12258338",
      "11254040",
      "583260",
      "42404093",
      "33740844"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "208",
    "claim": "CHEK2 is not associated with breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 provides evidence that contradicts the claim. It examines the role of the CHEK2 gene in breast cancer etiology, noting that while previous research has identified a specific mutation, the 1100delC mutation, as playing a role in breast cancer risk, common variants of CHEK2 were not significantly associated with increased risk. Despite the lack of association with common variants, the study indicates that there is a recognized role for the CHEK2 gene in breast cancer through specific mutations. Therefore, the claim that CHEK2 is not associated with breast cancer is contradicted by this evidence."
    },
    "naive_doc_ids": [
      "2140497",
      "9394119",
      "13519661",
      "4414547",
      "6550579"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 specifically investigates the CHEK2 gene and its role in breast cancer. Although the study did not find a convincing association between common CHEK2 haplotypes and breast cancer risk, it does acknowledge the established role of the 1100delC mutation in breast cancer aetiology, which contradicts the claim that CHEK2 is not associated with breast cancer. The paper mentions that previous investigations have identified a role for the CHEK2 gene in breast cancer development, and the odds ratio for carriers of the 1100delC mutation indicates an increased risk. The other papers do not provide relevant information to the claim as they focus on other genes or factors related to breast cancer risk, such as BRCA1/BRCA2 mutations, ATM mutations, and anthropometric indices."
    },
    "overthinking_doc_ids": [
      "13519661",
      "2140497",
      "9394119",
      "24144677",
      "13831842"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly discusses the role of the CHEK2 gene in breast cancer etiology, specifically mentioning its involvement and the 1100delC mutation's association with breast cancer risk. The paper aims to assess the importance of common CHEK2 variants on population risk for breast cancer and concludes that the rare 1100delC mutation shows a higher odds ratio for breast cancer among carriers. Although the common haplotypes did not show convincing associations, the 1100delC mutation's evidence is significant enough to indicate an association of CHEK2 with breast cancer risk, thereby contradicting the claim that CHEK2 is not associated with breast cancer."
    },
    "posthoc_doc_ids": [
      "13519661",
      "18340282",
      "20280410",
      "5864770",
      "17648235"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "724",
    "claim": "Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence in support of the claim, stating that the Ly49Q receptor regulates membrane raft functions, which are crucial for neutrophil polarization and migration. It explains that Ly49Q affects these processes through its spatiotemporal regulation of membrane rafts and associated signaling molecules. This aligns with the claim that Ly49Q directs neutrophil polarization by influencing membrane raft functions. The other papers do not provide relevant information specifically linking Ly49Q to neutrophil polarization, hence they are categorized as NOINFO for this claim. However, Paper 1 alone clearly supports the claim with specific experimental data and findings."
    },
    "naive_doc_ids": [
      "5531479",
      "20758340",
      "4389252",
      "600437",
      "6969753"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 provides direct and relevant evidence supporting the claim that Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions. The paper describes experiments showing that Ly49Q plays a critical role in the rapid polarization and migration of neutrophils by regulating raft trafficking, particularly under inflammatory stimuli. This aligns well with the claim as it demonstrates the involvement of Ly49Q in membrane raft function regulation which is essential for neutrophil polarization. Other papers do not directly address the role of Ly49Q in neutrophils, but Paper 1 alone provides a strong basis for supporting the claim."
    },
    "overthinking_doc_ids": [
      "5531479",
      "14407673",
      "52925737",
      "3155374",
      "1889358"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly supports the claim that Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions. It presents experimental evidence demonstrating that Ly49Q is crucial for neutrophil polarization and migration, specifically through the regulation of membrane raft functions. The study highlights the role of Ly49Q in affecting raft-associated signaling molecules, crucial for neutrophil polarization and migration."
    },
    "posthoc_doc_ids": [
      "5531479",
      "16128711",
      "600437",
      "7869794",
      "12058271"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "448",
    "claim": "Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "The evidence from the provided papers supports the claim that gastric infection with Helicobacter pylori increases the risk of gastric cancer. Paper 1 shows an association between H. pylori infection and increased odds of developing gastric cancer, with a calculated odds ratio of 2.77. Paper 3 provides a mechanistic explanation by demonstrating how H. pylori infection induces aberrant expression of activation-induced cytidine deaminase, leading to mutations in TP53, a tumor suppressor gene, thus contributing to carcinogenesis. Paper 4 highlights the survival mechanisms of H. pylori in the acidic gastric environment, indicating its persistence and pathogenic role in gastritis and gastric adenocarcinoma. Although Papers 2 and 5 do not directly address the increased risk of gastric cancer due to H. pylori infection, their discussions on genetic susceptibility and cellular mechanisms align with the understanding that H. pylori can influence gastric carcinogenesis pathways."
    },
    "naive_doc_ids": [
      "2052720",
      "14729253",
      "22703082",
      "4387784",
      "7465900"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence provided in the papers supports the claim that Helicobacter pylori infection increases the risk of gastric cancer in humans. Paper 1 presents a direct association between H. pylori infection and an increased risk of gastric cancer, demonstrating that individuals with H. pylori infection had significantly higher odds of developing gastric cancer compared to controls. Paper 2 elucidates a potential mechanism by which H. pylori infection may lead to cancer development, by demonstrating the induction of genetic mutations through aberrant expression of activation-induced cytidine deaminase, which could contribute to carcinogenesis. Paper 3, while primarily focusing on genetic variations and cancer risk, recognizes H. pylori infection as a significant factor in gastric cancer risk analyses, reinforcing the link between the infection and cancer development. Overall, the combination of epidemiological data and mechanistic insights aligns with the claim, leading to a classification of SUPPORT with high confidence."
    },
    "overthinking_doc_ids": [
      "2052720",
      "22703082",
      "14729253"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "The claim that gastric infection with Helicobacter pylori increases the risk of gastric cancer in humans is supported by evidence from the papers. Paper 1 presents a prospective case-control study showing that individuals with gastric cancer had a higher prevalence of H. pylori infection compared to controls, with a significant odds ratio for increased cancer risk. Paper 2 provides mechanistic insights into how H. pylori infection could lead to gastric cancer by inducing mutations in the gastric epithelium. While Paper 3 focuses on genetic susceptibility, it does include subgroup analyses considering H. pylori infection status, indirectly supporting the association. Papers 4 and 5 are unrelated to the claim."
    },
    "posthoc_doc_ids": [
      "2052720",
      "22703082",
      "14729253",
      "12145359",
      "24988745"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "53",
    "claim": "ALDH1 expression is associated with poorer prognosis in breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence supporting the claim. It states that ALDH1 expression, detected by immunostaining in a large sample of 577 breast carcinomas, correlated with poor prognosis. This finding aligns with the claim stating 'ALDH1 expression is associated with poorer prognosis in breast cancer'. None of the other papers provide evidence contradicting this, either directly or indirectly, and as such this paper strongly supports the claim, justifying a high confidence level."
    },
    "naive_doc_ids": [
      "45638119",
      "15113221",
      "21439640",
      "1171121",
      "2931832"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain any information about ALDH1 expression and its association with breast cancer prognosis. The papers mainly discuss other factors, such as TDP43, COX-2, angiogenic factors, genetic polymorphisms, PD-L1, BRCA mutations, smoking effects, intrauterine factors, and platelet indices. None of these papers present data or findings related to ALDH1 expression in breast cancer patients."
    },
    "overthinking_doc_ids": [
      "4889228",
      "21439640",
      "22401720",
      "24341590",
      "8963413"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 provides direct evidence supporting the claim that ALDH1 expression is associated with poorer prognosis in breast cancer. It discusses that high ALDH activity is correlated with poor clinical outcomes in breast carcinomas. The study indicates that ALDH1 serves as a marker for tumorigenic cells in breast cancer and is associated with a worse prognosis. Other papers provided in the evidence do not directly address ALDH1 expression in relation to breast cancer prognosis, therefore Paper 5 stands as the main source affirming the claim with specific experimental data and findings."
    },
    "posthoc_doc_ids": [
      "21439640",
      "22401720",
      "12358173",
      "3899896",
      "45638119"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "661",
    "claim": "JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 3 provides relevant evidence supporting the claim that JMJD6 catalyzes the hydroxylation of a lysine, specifically C-terminal lysine 382 on p53, and suppresses transcriptional activity. The hydroxylation by JMJD6 antagonizes p53 acetylation and promotes association with its negative regulator MDMX, leading to repression of p53's transcriptional activity. Although the specific context of C-terminal lysine hydroxylation mentioned in the claim is not explicitly stated in terms of general transcriptional repression, the evidence closely aligns with the claim's suggestion that JMJD6 catalyzes hydroxylation leading to suppressed transcriptional activity, at least in the context of p53 regulation."
    },
    "naive_doc_ids": [
      "4455466",
      "29788648",
      "37204802",
      "2613813",
      "18038955"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 provides evidence supporting the claim that JMJD6 catalyzes the hydroxylation of lysine. It specifically highlights JMJD6's role as an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that catalyzes hydroxylation on lysine 382 of p53. Furthermore, the paper discusses how JMJD6 represses the transcriptional activity of p53 by promoting its association with its negative regulator, MDMX. The findings align with the claim that JMJD6 catalyzes the hydroxylation of C-terminal lysine and suppresses transcriptional activity. The other papers do not provide relevant information concerning JMJD6 or its catalytic activity, thus not affecting this classification."
    },
    "overthinking_doc_ids": [
      "37204802",
      "7820043",
      "8548635",
      "4455466",
      "29125354"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim. It reports that JMJD6 is associated with the tumor suppressor p53 and acts as a lysyl hydroxylase, catalyzing hydroxylation on lysine 382 of p53, which suppresses its transcriptional activity. The findings indicate that depletion of JMJD6 enhances p53 transcriptional activity, suggesting its role in transcriptional suppression through hydroxylation of lysine residues. The other papers do not provide relevant information regarding JMJD6's catalytic activity or its impact on transcriptional activity, thus classified as NOINFO."
    },
    "posthoc_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "2851611",
      "20960682"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "109",
    "claim": "An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information about the M2-like phenotype in brown adipose tissue macrophages being induced by cold exposure. While they discuss various topics related to brown adipose tissue, such as gene expression changes due to cold exposure (Paper 1), effects of cold exposure on atherosclerosis (Paper 2), activation of brown adipose tissue by bile acids (Paper 3), and other related topics, none of them specifically address the induction of an M2-like phenotype in macrophages within brown adipose tissue due to cold exposure. Therefore, the claim about the cold-induced M2-like phenotype in brown adipose tissue macrophages cannot be evaluated based on the provided evidence."
    },
    "naive_doc_ids": [
      "29381091",
      "970012",
      "1568684",
      "1507222",
      "6042706"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly address the claim regarding the induction of an M2-like phenotype in brown adipose tissue macrophages by cold exposure. The papers discuss various aspects of brown adipose tissue, such as its role in energy expenditure, gene expression related to 'browning' in response to cold, effects on cardiovascular health, bile acid activation of BAT, and mitochondrial function. However, they do not specifically investigate or provide evidence on the macrophage phenotype shifts within brown adipose tissue upon cold exposure."
    },
    "overthinking_doc_ids": [
      "29381091",
      "970012",
      "1568684",
      "40232172",
      "6042706"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information regarding the induction of an M2-like phenotype in brown adipose tissue macrophages by cold exposure. While they touch upon related topics such as cold exposure effects on adipose tissue, mitochondrial function, and macrophage polarization in general, none of the papers directly address or provide data on the M2-like phenotype induction in brown adipose tissue macrophages in response to cold. Therefore, the evidence cannot confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "29381091",
      "1568684",
      "40232172",
      "970012",
      "43192375"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1289",
    "claim": "There is a relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 specifically investigates the association between the use of macrolide antibiotics, including Erythromycin, and the risk of infantile hypertrophic pyloric stenosis (IHPS) in newborns. The study provides substantial evidence supporting the claim by showing a strong association between Erythromycin use in infants shortly after birth and increased rates of IHPS, with significant rate ratios and absolute risk differences. Therefore, this evidence directly confirms the claim of a relationship between Erythromycin use and hypertrophic pyloric stenosis."
    },
    "naive_doc_ids": [
      "21239672",
      "6157837",
      "471921",
      "40631095",
      "667451"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence supporting the claim that there is a relation between erythromycin use (a macrolide antibiotic) and hypertrophic pyloric stenosis (IHPS). The study's results indicate a strong association between macrolide use in young infants and the subsequent development of IHPS, with significantly increased rate ratios during specific time frames after birth. Additionally, maternal use of macrolides shortly after birth is also associated with an increased risk."
    },
    "overthinking_doc_ids": [
      "21239672",
      "32159283",
      "380526",
      "6957332",
      "7647224"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 explicitly explores the association between the use of macrolide antibiotics, including erythromycin (a macrolide), in mothers and infants and the risk of infantile hypertrophic pyloric stenosis (IHPS). The study concludes that treatment of young infants with macrolide antibiotics is strongly associated with IHPS, especially when used during the first two weeks after birth. This directly supports the claim of a relationship between erythromycin use and hypertrophic pyloric stenosis. The other papers provide information on unrelated topics, so they do not influence the classification regarding this claim."
    },
    "posthoc_doc_ids": [
      "21239672",
      "1676568",
      "2774906",
      "36830715",
      "980008"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "298",
    "claim": "Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Several of the papers provide evidence supporting the claim that cytochrome c is released from the mitochondrial intermembrane space to the cytosol during apoptosis. Specifically, Paper 2 describes mitochondria-dependent apoptotic events, including the release of cytochrome c into the cytosol and subsequent activation of caspase-3 in VSMCs. Paper 3 discusses how the release of cytochrome c is part of p53-mediated apoptosis in gastric epithelial cells upon Helicobacter pylori infection. Additionally, Paper 4 describes ouabain-induced neuronal death involving cytochrome c release, while Paper 6 mentions cytochrome c release as a part of the apoptotic process in H. pylori-infected cells. These evidences align well with the claim, providing a strong basis for classification as SUPPORT."
    },
    "naive_doc_ids": [
      "23403754",
      "9588931",
      "7465900",
      "17231273",
      "23887844"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Several papers provide evidence supporting the claim that cytochrome c is released from the mitochondrial intermembrane space to the cytosol during apoptosis. Paper 3 and Paper 4 specifically mention the release of cytochrome c from mitochondria in the context of apoptotic events. Paper 3 discusses the involvement of cytochrome c release in Helicobacter pylori-induced apoptosis, which is linked to p53 activation and Bax expression. Likewise, Paper 4 describes the translocation of Bax leading to mitochondrial changes and cytochrome c release in apoptosis scenarios. These findings align with the claim that cytochrome c is released to the cytosol during apoptosis, providing experimental support for the claim."
    },
    "overthinking_doc_ids": [
      "17805221",
      "23887844",
      "7465900",
      "8654183",
      "9588931"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Several papers provide evidence supporting the claim that cytochrome c is released from the mitochondrial intermembrane space to the cytosol during apoptosis. Specifically, papers 1 and 6 describe experimental observations of cytochrome c release in the context of apoptotic processes. Paper 1 discusses the release of cytochrome c as part of the apoptotic pathway induced by ouabain in neurons, which involves caspase-3 activation and is indicative of apoptotic signaling. Similarly, paper 6 mentions the release of cytochrome c in vascular smooth muscle cells triggered by mitochondrial dysfunction and subsequent apoptotic events. These observations align with the claim that cytochrome c is released from the mitochondria to cytosol during apoptosis. Other papers either focus on different processes or do not specifically address cytochrome c release during apoptosis, thus they are not as relevant for verifying this specific claim."
    },
    "posthoc_doc_ids": [
      "17231273",
      "23887844",
      "15657779",
      "7869794",
      "10015292"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "840",
    "claim": "Natriuretic peptides increase susceptibility to diabetes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim states that natriuretic peptides increase susceptibility to diabetes, but the evidence from Paper 1 provides findings that suggest an inverse association between B-type natriuretic peptide (BNP) levels in blood and the risk of type 2 diabetes. Specifically, higher levels of NT-pro-BNP are associated with a decreased risk of incident type 2 diabetes, suggesting that increased natriuretic peptide levels may actually confer a protective effect rather than increasing susceptibility. The remaining papers do not provide relevant information regarding natriuretic peptides and diabetes, focusing instead on other factors or types of diabetes. Therefore, Paper 1 directly contradicts the claim, resulting in a classification of CONTRADICT with high confidence."
    },
    "naive_doc_ids": [
      "15663829",
      "5567005",
      "8325952",
      "8868863",
      "6588614"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 1.0,
      "justification": "Paper 1 provides evidence that suggests an inverse association between B-type natriuretic peptide (BNP) levels and the risk of type 2 diabetes (T2D). The observed associations indicate a decreased risk of incident T2D with higher levels of NT-pro-BNP, which contradicts the claim that natriuretic peptides increase susceptibility to diabetes. The other papers do not provide information relevant to the direct role or impact of natriuretic peptides on diabetes risk."
    },
    "overthinking_doc_ids": [
      "15663829",
      "439670",
      "1974176",
      "4474874",
      "5268462"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that natriuretic peptides increase susceptibility to diabetes, but Paper 5 provides evidence suggesting an inverse association between B-type natriuretic peptide (BNP) levels and the risk of type 2 diabetes. The mendelian randomization study indicates a decreased risk of incident type 2 diabetes with higher BNP levels. This evidence directly contradicts the claim that natriuretic peptides increase susceptibility to diabetes."
    },
    "posthoc_doc_ids": [
      "8868863",
      "12145359",
      "34054472",
      "13450938",
      "15663829"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "899",
    "claim": "Oxidative DNA damage inhibits STING signalling.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The primary claim states that oxidative DNA damage inhibits STING signalling. However, Paper 1 provides evidence that oxidative DNA damage, specifically the presence of 8-hydroxyguanosine (8-OHG) in DNA, actually potentiates STING-dependent immune sensing. This paper demonstrates that oxidative modifications decrease DNA degradation by TREX1, thereby enhancing immune recognition through the STING pathway. There is no direct evidence in the other papers to definitively support or oppose the claim, but Paper 1 contradicts the idea that oxidative DNA damage inhibits STING signalling."
    },
    "naive_doc_ids": [
      "13106686",
      "1686997",
      "213017",
      "14496749",
      "2686003"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The claim is that oxidative DNA damage inhibits STING signalling. However, Paper 1 provides findings that oxidative damage of DNA, specifically through the oxidized base 8-hydroxyguanosine (8-OHG), actually enhances STING-dependent immune sensing by decreasing the DNA's susceptibility to degradation by TREX1. This implies that oxidative DNA damage does not inhibit but rather potentiates STING signalling, which directly contradicts the claim. None of the other papers provide direct evidence related to oxidative DNA damage's effect on STING signalling, and their topics are unrelated or focus on different signaling pathways or processes."
    },
    "overthinking_doc_ids": [
      "13106686",
      "1686997",
      "213017",
      "14496749",
      "2686003"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence directly contradicting the claim. It states that oxidative damage, specifically through the marker 8-hydroxyguanosine (8-OHG), potentiates STING-dependent immune sensing by reducing degradation by TREX1. This enhances STING signaling rather than inhibiting it, contrary to the claim. The other papers do not directly address the interaction between oxidative DNA damage and STING signaling; therefore, they are irrelevant to this specific claim. Thus, Paper 1 is key in classifying the claim as being contradicted."
    },
    "posthoc_doc_ids": [
      "13106686",
      "14496749",
      "213017",
      "1686997",
      "7506409"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "267",
    "claim": "Cognitive behavioral therapy is an ineffective treatment for insomnia",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 1.0,
      "justification": "Paper 1 directly discusses cognitive behavioral therapy (CBT) for insomnia. It demonstrates that CBT is effective in improving short- and long-term outcomes for older adults with chronic primary insomnia, outperforming the pharmacological treatment zopiclone on most outcome measures. This evidence contradicts the claim that cognitive behavioral therapy is ineffective for treating insomnia, as the study provides strong evidence of its efficacy."
    },
    "naive_doc_ids": [
      "5912283",
      "19878070",
      "24865781",
      "1805641",
      "11939159"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 1.0,
      "justification": "Paper 4 presents data from a randomized controlled trial that directly addresses the effectiveness of cognitive behavioral therapy (CBT) for insomnia in older adults. The study found that CBT resulted in improved short- and long-term outcomes compared to the pharmacological treatment (zopiclone). Specifically, CBT improved sleep efficiency and reduced wake time during the night, demonstrating its effectiveness as a treatment for insomnia. The claim that cognitive behavioral therapy is an ineffective treatment for insomnia is directly contradicted by the findings of this study."
    },
    "overthinking_doc_ids": [
      "202259",
      "13097856",
      "14606752",
      "5912283",
      "3654468"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim states that cognitive behavioral therapy (CBT) is an ineffective treatment for insomnia. However, Paper 1 directly addresses this by comparing CBT with the pharmacological treatment zopiclone in managing chronic primary insomnia in older adults. The results demonstrate that CBT resulted in improved short- and long-term outcomes compared with zopiclone in several sleep measures, indicating its effectiveness. This evidence directly contradicts the claim, showing that CBT is indeed an effective treatment for insomnia in the studied population. Other papers do not provide information on CBT for insomnia, making them irrelevant to this claim."
    },
    "posthoc_doc_ids": [
      "5912283",
      "24865781",
      "6191684",
      "11117498",
      "10749308"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "224",
    "claim": "Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "The claim is that cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments. Several papers provide evidence supporting this claim. Paper 1 explicitly describes CAFs as crucial components of the tumor microenvironment, highlighting their role in promoting cancer growth and invasion, and the crosstalk with cancer cells. Paper 2 discusses IL6 derived from CAFs promoting chemoresistance in tumor environments, further affirming their presence and influence within these environments. Paper 3 identifies CAFs as sources of chemokines that regulate immune cell infiltration in tumors, which is a critical element of the tumor microenvironment. Additionally, Paper 7 discusses the stromal cell types within the tumor microenvironment, which includes CAFs, and their role in cancer progression and treatment consideration. These references collectively support the claim that CAFs are indeed constituents of tumor microenvironments."
    },
    "naive_doc_ids": [
      "952111",
      "3376731",
      "3559136",
      "33638477",
      "42731834"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The provided evidence from papers supports the claim that cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments. Paper 1 clearly describes CAFs as crucial components of the tumor microenvironment, contributing to cancer cell growth and invasion. It also discusses the mechanisms through which CAFs interact with cancer cells, highlighting their role in cancer progression. Paper 2 further confirms the role of CAFs in the tumor microenvironment by demonstrating their involvement in modulating immune infiltration and affecting tumor response to therapy. Although Papers 4 through 8 do not directly address CAFs, the information from Papers 1 and 2 sufficiently supports the claim with specific examples of CAFs' presence and function in tumor microenvironments."
    },
    "overthinking_doc_ids": [
      "952111",
      "3559136",
      "24349992",
      "1780819",
      "2665675"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "The provided evidence from the papers strongly supports the claim that cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments. Multiple papers highlight the presence and role of CAFs within the tumor microenvironment, detailing their contribution to tumor growth, progression, and resistance to therapies. \n\n- Paper 1 explicitly states that CAFs are crucial components of the tumor microenvironment and discusses their role in cancer progression.\n- Paper 2 describes CAFs as being involved with recruiting granulocytes to tumors, again indicating their involvement in the tumor microenvironment.\n- Paper 3 details how oxidative stress in CAFs plays a role in the tumor environment, affecting cancer metabolism and progression.\n- Paper 6 specifically identifies CAFs in non-small cell lung cancer and discusses how they promote proliferation and chemoresistance, emphasizing their role within the tumor microenvironment.\n\nOverall, the papers collectively provide comprehensive evidence that CAFs are integral components of the tumor microenvironment, confirming the claim."
    },
    "posthoc_doc_ids": [
      "952111",
      "3559136",
      "24349992",
      "1782201",
      "4583180"
    ],
    "posthoc_metadata": {
      "initial_confidence": 1.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "614",
    "claim": "Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly supports the claim by demonstrating that increased microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. This study shows that increasing acetylation using deacetylase inhibitors or the tubulin acetylase \u03b1TAT1 prevents the association of mutant LRRK2 with microtubules and restores axonal transport. The results indicate a potential intervention for Parkinson's disease related to LRRK2 mutations. While other papers provide background information on microtubule dynamics and posttranslational modifications, they do not directly address the specific claim related to LRRK2 Roc-COR domain mutations and microtubule acetylation, hence are classified as NOINFO."
    },
    "naive_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "1889358",
      "7549811"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence supporting the claim. It demonstrates that increased microtubule acetylation can rescue axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations in both primary neurons and in vivo models. This aligns with the claim that microtubule acetylation repairs interference in axonal transport due to these mutations. The other papers, while discussing related concepts like microtubule organization and axonal transport machinery, do not specifically address the impact of microtubule acetylation in the context of LRRK2 mutations, hence they are not directly relevant to verifying the claim."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "18678095",
      "20743803"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly supports the claim by presenting experimental data that increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. The paper provides findings that mutant LRRK2 associates with deacetylated microtubules and inhibits axonal transport, and that interventions to increase microtubule acetylation prevent this association and restore axonal transport in primary neurons and Drosophila models. Other papers listed do not provide specific evidence for or against the claim, focusing instead on different aspects of axonal transport and microtubule dynamics."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "1889358",
      "18678095"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "594",
    "claim": "Incidence of heart failure increased by 10% in women since 1979.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The primary paper relevant to trends in heart failure incidence is Paper 1, which specifically investigated heart failure incidence and survival over time with a focus on sex differences. The results indicated that the incidence of heart failure did not change over time for either men or women. This directly contradicts the claim that heart failure incidence increased by 10% in women since 1979. Other papers included related topics about heart failure (such as risk factors, hypertension, and genetic influences) but do not provide specific information about changes in heart failure incidence over time across genders."
    },
    "naive_doc_ids": [
      "19675911",
      "31889025",
      "4445629",
      "7419612",
      "12810152"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The evidence provided in Paper 1 directly addresses the incidence of heart failure and indicates that the incidence of heart failure did not change over time among men or women from 1979 to 2000. This suggests that the claim of a 10% increase in the incidence of heart failure in women since 1979 is not supported. The other papers do not directly address incidence trends of heart failure specifically in women over this time period, focusing instead on related conditions like hypertension or subpopulations with specific heart failure characteristics. Therefore, given the direct data presented in Paper 1, the claim is contradicted."
    },
    "overthinking_doc_ids": [
      "19675911",
      "12206390",
      "31889025",
      "13481731",
      "4445629"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers do not support the claim that the incidence of heart failure increased by 10% in women since 1979. Paper 1 specifically addresses trends in heart failure incidence and states that the incidence did not change over time among men or women from 1979 to 2000. None of the other papers provide direct evidence of a 10% increase in heart failure incidence in women since 1979. Other papers discuss related topics like the prognostic value of biomarkers, hypertension, heart failure risk factors, and gender-specific heart failure characteristics, but they do not provide evidence supporting the claim."
    },
    "posthoc_doc_ids": [
      "19675911",
      "4445629",
      "12206390",
      "31889025",
      "12810152"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "411",
    "claim": "Febrile seizures reduce the threshold for development of epilepsy.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides relevant information supporting the claim. It notes that febrile seizures, specifically hyperthermia-induced in immature rats, lead to long-lasting alterations in synaptic communication, characterized by a selective presynaptic increase in inhibitory synaptic transmission in the hippocampus. This persistent modification of neuronal excitability in limbic circuits suggests that febrile seizures can indeed reduce the threshold for the development of epilepsy, contradicting the previous view of their 'benign' nature. The other papers do not address the relationship between febrile seizures and epilepsy development, or are not related to the primary subject, thus the label 'SUPPORT' is based on Paper 1 evidence alone."
    },
    "naive_doc_ids": [
      "14924526",
      "6334188",
      "5691302",
      "23912923",
      "2015126"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that febrile seizures in the developing brain lead to persistent modifications in neuronal excitability within limbic circuits. The study on immature rats found that hyperthermia-induced seizures resulted in long-lasting increases in inhibitory synaptic transmission in the hippocampus, a condition that persisted into adulthood. This suggests that the neuronal alterations following febrile seizures could contribute to a heightened risk for the development of epilepsy, as the changes in excitability favor conditions that could lower the threshold for epileptogenesis. This aligns with the claim that febrile seizures reduce the threshold for the development of epilepsy."
    },
    "overthinking_doc_ids": [
      "14924526",
      "643765",
      "2575938",
      "39264456",
      "116792"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that febrile seizures result in persistent changes in neuronal excitability in the hippocampus, challenging the benign view of febrile convulsions. This suggests that febrile seizures can lower the threshold for developing epilepsy later in life, as alterations in synaptic communication are long-lasting. None of the other papers directly discuss febrile seizures and their impact on epilepsy development, but Paper 1's findings directly address the claim, providing a basis to support it."
    },
    "posthoc_doc_ids": [
      "14924526",
      "1410197",
      "39264456",
      "30534237",
      "116792"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1058",
    "claim": "Roughly 55% of women with chronic pelvic pain have no underlying pathology.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers pertain to different aspects of chronic pain management and specific interventions but do not directly address the prevalence of underlying pathology in women with chronic pelvic pain. Paper 1 discusses the effectiveness of a surgical intervention (LUNA) in women with chronic pelvic pain, but does not provide data on the presence or absence of underlying pathologies in these patients. Paper 2 is focused on the treatment of chronic abdominal pain attributed to adhesions, and Paper 3 addresses chronic low back pain in the context of degenerative lumbar osteoarthritis. None of these papers present data or findings related to the percentage of women with chronic pelvic pain who lack an identifiable underlying pathology. Therefore, they do not provide evidence to either support or contradict the claim."
    },
    "naive_doc_ids": [
      "13027590",
      "3190689",
      "14724693"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The set of papers provided does not address the specific claim that roughly 55% of women with chronic pelvic pain have no underlying pathology. The papers focus on various aspects of chronic pain treatments and prevalence in different contexts and populations but do not provide data or findings specifically about the underlying pathology or lack thereof in women with chronic pelvic pain. Therefore, none of the papers can be used to either support or contradict this particular claim."
    },
    "overthinking_doc_ids": [
      "13027590",
      "8570317",
      "13934676",
      "3190689",
      "14724693"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically address the claim that 55% of women with chronic pelvic pain have no underlying pathology. The papers generally discuss various aspects of chronic pain, including chronic pelvic pain, but focus on treatment efficacy and quality of life rather than the prevalence of underlying pathology in chronic pelvic pain cases. Therefore, they do not provide direct evidence to verify or refute the specific numerical claim about the lack of underlying pathology in women with chronic pelvic pain."
    },
    "posthoc_doc_ids": [
      "13027590",
      "463533",
      "3190689",
      "14724693",
      "6191684"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "939",
    "claim": "Persistor cells are one reason for incomplete responses to Tyrosine kinase inhibitor (TKI) therapy in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information about persistor cells and their role in the incomplete responses to Tyrosine kinase inhibitor (TKI) therapy in cancer patients. While there are discussions on TKI resistance, cancer cell apoptosis, circulating tumor cells, and therapy response, none of the papers explicitly mention or provide experimental evidence regarding persistor cells as a mechanism affecting TKI therapy outcomes. Therefore, the evidence cannot be classified as supporting or contradicting the claim."
    },
    "naive_doc_ids": [
      "23420807",
      "20738970",
      "9929089",
      "21033230",
      "26952804"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The provided papers focus on various cancer resistance mechanisms and treatments, but none directly address the role of persistor cells in resistance to Tyrosine kinase inhibitor (TKI) therapy specifically. Paper 5 mentions TKI resistance in the context of NSCLC and its reversal with chemotherapy, but it doesn't discuss persistor cells as a factor. Papers 1 to 4, 6, and 8 address other forms of resistance or therapy efficacy unrelated to TKI and persistor cells. Paper 7 is unrelated to cancer treatment resistance. There is no mention of persistor cells being involved in resistance to TKI therapy in these papers."
    },
    "overthinking_doc_ids": [
      "1727493",
      "2030623",
      "4688340",
      "23420807",
      "9929089"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The provided papers do not specifically discuss persistor cells or their role in the incomplete response to tyrosine kinase inhibitor (TKI) therapy in cancer patients. The papers cover topics such as the role of autophagy in cancer, DNA damage response in stem cells, the potential of exosomes as biomarkers, resistance mechanisms to TKIs, and various aspects of cancer treatment strategies and outcomes. However, none of them present experimental data or findings related to persistor cells and their contribution to TKI therapy resistance. Therefore, there is no relevant information in the papers to either support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "26952804",
      "10015292",
      "9095943",
      "9929089",
      "34016944"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "310",
    "claim": "De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not explicitly address the claim regarding the comparison of the number of specific contigs in de novo assembled versus unassembled sequence data. The papers discuss various aspects of genomic data processing, including de novo assembly, sequence comparison, GC bias, and bioinformatics tools, but none directly provide evidence for or against the claim about specific contigs in assembled versus unassembled sequence data."
    },
    "naive_doc_ids": [
      "14464451",
      "32770503",
      "143251",
      "15966318",
      "6128334"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information directly related to the comparison between de novo assembly of sequence data and unassembled sequence data in terms of the number of specific contigs. Paper 2 touches on de novo genome assembly, but it focuses on the effects of GC bias without directly addressing the claim about the number of specific contigs compared to unassembled data. The other papers discuss various topics such as nuclear subcompartment assembly, sequence comparison methods, and RNA-seq data assembly without addressing the specifics of contig numbers in assembled versus unassembled data."
    },
    "overthinking_doc_ids": [
      "143251",
      "14464451",
      "14185503",
      "15966318",
      "6128334"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information directly addressing the claim about the number of specific contigs in de novo assembled versus unassembled sequence data. The papers cover various unrelated topics such as telomere lengthening, Wnt signaling in CNS vasculature, amyloid-\u03b2 in Alzheimer's, GC bias in genome assembly, RNA-Seq de novo transcriptome assembly, cost analysis of respiratory care units, siRNA specificity, and the genomic analysis of the Tasmanian devil and its cancer. None of these papers include data or results comparing the number of specific contigs in de novo assembly to unassembled sequence data. Therefore, they cannot be used to verify or refute the specific claim."
    },
    "posthoc_doc_ids": [
      "143251",
      "1616661",
      "4407385",
      "14464451",
      "32770503"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "153",
    "claim": "B3-Galectin decreases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The provided papers discuss various mechanisms of resistance to tyrosine kinase inhibitors and related pathways, but none of them specifically address the role of B3-Galectin in decreasing cell resistance to tyrosine kinase inhibitors by engaging the alternate KRAS-RalB signaling complex downstream of EGFR. Paper 1 mentions a KRAS-RalB complex in relation to resistance to EGFR inhibition but doesn't link B3-Galectin. The other papers focus on different mechanisms and resistance pathways, without relevance to B3-Galectin. Therefore, these papers don't contain information directly related to the specific claim about B3-Galectin."
    },
    "naive_doc_ids": [
      "4702639",
      "9929089",
      "17648235",
      "2272614",
      "34016944"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly address the specific role of B3-Galectin in decreasing cell resistance to tyrosine kinase inhibitors via engagement with the alternate KRAS-RalB signaling complex downstream of EGFR. While Paper 1 discusses integrin \u03b23 forming a complex with KRAS and RalB leading to resistance against EGFR inhibition, it does not mention B3-Galectin or provide evidence regarding its specific involvement. The other papers are unrelated to the interaction between B3-Galectin and the KRAS-RalB signaling pathway or their effects on TKI resistance. Thus, there is insufficient information to verify or refute the claim based on the provided evidence."
    },
    "overthinking_doc_ids": [
      "4702639",
      "4920376",
      "7317051",
      "24349992",
      "31311495"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain direct information or evidence regarding B3-Galectin's role in decreasing cell resistance to tyrosine kinase inhibitors by engaging the KRAS-RalB signaling complex downstream of EGFR. While Paper 2 discusses the interaction of integrin \u03b23 with KRAS and RalB in the context of EGFR inhibitor resistance, it does not mention B3-Galectin. The other papers focus on different aspects of resistance mechanisms, signaling pathways, and tumor biology but do not discuss B3-Galectin's involvement in TKIs resistance. Therefore, there is no supporting or contradictory evidence specifically related to the claim about B3-Galectin in the provided papers."
    },
    "posthoc_doc_ids": [
      "34016944",
      "4702639",
      "23974474",
      "9486930",
      "9505402"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "992",
    "claim": "Pyridostatin deregulates G2/M progression.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers discuss various cellular and molecular processes related to cancer, cell cycle, genetic variations, and checkpoint regulation. However, none of the papers specifically investigate or mention the effect of pyridostatin on the G2/M progression of the cell cycle. Without explicit information linking pyridostatin to G2/M deregulation, it is not possible to classify the provided evidence as either supporting or contradicting the claim."
    },
    "naive_doc_ids": [
      "9038803",
      "33638477",
      "263364",
      "10608822",
      "243694"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the papers provided discuss pyridostatin or its effects on G2/M progression. The papers cover topics such as the effects of statins on cancer, visualization of the cell cycle in mouse embryos, the coupling of the circadian clock and cell cycle, centrosome aberrations in cancer progression, the Wnt signaling pathway, genetic variation in the IL28B gene related to hepatitis C, and cyclin-dependent kinases (CDKs) in cancer. As such, they do not contain relevant information to evaluate the specific claim about pyridostatin and G2/M progression."
    },
    "overthinking_doc_ids": [
      "1522336",
      "7142113",
      "10608822",
      "9038803",
      "33638477"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain any specific information or evidence about the effect of pyridostatin on G2/M progression in the cell cycle. The claim relates to a specific compound's effect on a particular phase of the cell cycle, but the papers discuss various unrelated topics such as the regulation of cell cycles in Trypanosoma brucei, the relationship between the circadian clock and the cell cycle in mammals, gene expression regulation, endothelial cell transitions, epithelial-mesenchymal transition in cancer, visualization of the cell cycle in embryos, and the effects of statins on cancer cells. None of these papers address pyridostatin or its specific impact on G2/M progression."
    },
    "posthoc_doc_ids": [
      "15473205",
      "10608822",
      "19979816",
      "243694",
      "825728"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "841",
    "claim": "Natriuretic peptides protect against diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence that suggests a causal association between higher levels of B-type natriuretic peptide (BNP) and a decreased risk of type 2 diabetes (T2D). The Mendelian randomization study in Paper 1 indicates that increased BNP levels are associated with a 21% decreased risk of incident T2D per one standard deviation increase in the BNP measure, supporting the claim that natriuretic peptides protect against diabetes. No other papers provide evidence either supporting or contradicting this specific claim, as the rest of the papers focus on topics such as cancer mechanisms, type 1 diabetes, or biochemical and genetic factors unrelated to natriuretic peptides and diabetes."
    },
    "naive_doc_ids": [
      "15663829",
      "219475",
      "5567005",
      "33960383",
      "2665675"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The evidence from Paper 2 provides support for the claim that natriuretic peptides protect against diabetes. It presents a Mendelian Randomization study indicating an inverse association between B-type natriuretic peptide (BNP) levels and the risk of type 2 diabetes. The study suggests a potential causal role of the BNP system in the etiology of type 2 diabetes, with data showing a decreased risk of incident type 2 diabetes per higher NT-pro-BNP levels, and a genetic association supporting this relationship. While other papers do not provide direct evidence related to natriuretic peptides and diabetes, Paper 2 presents relevant data to support the claim."
    },
    "overthinking_doc_ids": [
      "8708082",
      "15663829",
      "24704139",
      "2481032",
      "14116046"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides relevant evidence that aligns with the claim. It presents findings from a Mendelian randomization study that suggests an inverse association between B-type natriuretic peptide (BNP) levels and the risk of type 2 diabetes (T2D), indicating a potential protective role of the BNP system in the etiology of diabetes. This aligns with the claim that natriuretic peptides protect against diabetes. The other papers either discuss unrelated topics or do not contain pertinent information about the relationship between natriuretic peptides and diabetes, thus not affecting the support classification stemming from Paper 1's evidence."
    },
    "posthoc_doc_ids": [
      "15663829",
      "33960383",
      "2665675",
      "8063697",
      "13923069"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "478",
    "claim": "Golli-deficient T-cells prefer to differentiate into an anergic phenotype in the adaptive immune response when there are increased levels of Ca2+ in the cytosol.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The claim states that Golli-deficient T-cells prefer to differentiate into an anergic phenotype with increased levels of Ca2+ in the cytosol. Paper 1 supports the claim by showing that Golli regulates calcium influx in T cells and that Golli-deficient T cells exhibit enhanced calcium entry. Enhanced calcium entry can lead to altered differentiation pathways in immune responses. Paper 4 implies an association of the Golli gene with anergy in T cells, stating the anergic response in Golli-induced meningitis, indirectly supporting the tendency of Golli-deficient T cells to become anergic. Together, these suggest that the absence of Golli leads to increased calcium influx, potentially contributing to the differentiation into an anergic phenotype, thus supporting the claim."
    },
    "naive_doc_ids": [
      "14767844",
      "364522",
      "5633876",
      "34854444",
      "22705234"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers provided do not directly address the claim about the preference of Golli-deficient T-cells to differentiate into an anergic phenotype when there are increased levels of Ca2+ in the cytosol. Paper 1 discusses the role of the Golli protein in regulating calcium influx in T cells but does not link Golli deficiency to anergy directly. Other papers focus on different topics such as mast cell functions, infectious pathogens, hematopoietic stem cell differentiation, the role of heat shock proteins, and T cell receptor signaling but none of them provide experimental data or results related to the anergic phenotype of Golli-deficient T-cells in response to increased Ca2+ levels."
    },
    "overthinking_doc_ids": [
      "14767844",
      "597790",
      "7386360",
      "11289247",
      "11335860"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The claim concerns the differentiation of Golli-deficient T-cells into anergic phenotype influenced by increased cytosolic Ca2+ levels. Paper 8 addresses Golli protein's role in regulating calcium influx in T cells, noting that Golli-deficient T cells show enhanced calcium entry and hyperproliferation. However, this does not specifically mention or provide evidence on the differentiation of these cells into an anergic phenotype. Other papers do not provide relevant information about Golli-deficient T-cell differentiation or the specific effects of increased cytosolic Ca2+ levels. Therefore, no paper provides direct support or contradiction to the claim."
    },
    "posthoc_doc_ids": [
      "364522",
      "21878751",
      "39225849",
      "11289247",
      "11335860"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1385",
    "claim": "cSMAC formation enhances weak ligand signalling.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The claim states that cSMAC formation enhances weak ligand signaling. However, multiple pieces of evidence from the provided papers suggest otherwise. Paper 2 explicitly mentions that enhancing cSMAC formation reduced the stimulatory capacity of a weak peptide, implying that cSMAC formation does not enhance, but rather reduces, weak ligand signaling. Paper 4 further supports this by stating that TCR signaling is sustained by microclusters and terminated in the cSMAC, indicating that the cSMAC is a site where signaling diminishes rather than is enhanced. Thus, the evidence collectively contradicts the claim that cSMAC formation enhances weak ligand signaling."
    },
    "naive_doc_ids": [
      "2714623",
      "306006",
      "2825380",
      "9283422",
      "35395662"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The papers provide evidence that contradicts the claim that cSMAC formation enhances weak ligand signaling. Paper 2 explicitly states that enhancing the formation of the central supramolecular activation cluster (cSMAC) reduces the stimulatory capacity of a ligand exhibiting weak agonist characteristics. This suggests that instead of enhancing signaling, cSMAC formation may actually diminish the response of T cells to weak ligands. Additionally, while Paper 1 discusses the role of Nck in immune synapse maturation and T cell activation, it does not directly support the notion that cSMAC enhances weak ligand signaling, focusing instead on conformational changes and protein recruitment. Papers 3 through 8 do not provide relevant information regarding cSMAC or weak ligand signaling."
    },
    "overthinking_doc_ids": [
      "2714623",
      "306006",
      "2825380",
      "12265561",
      "10607877"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 7 describes that the central supramolecular activation cluster (cSMAC) formation can influence the stimulatory potency of antigens by showing reduced stimulatory capacity when cSMAC formation is enhanced. This indicates the cSMAC plays a significant role in T cell activation and might enhance weak ligand signaling contrary to the original formation's intention. Thus, it suggests that the cSMAC formation indeed plays a part in enhancing signaling depending on the ligand involved, which supports the claim that cSMAC formation enhances weak ligand signaling."
    },
    "posthoc_doc_ids": [
      "2714623",
      "7736860",
      "9752604",
      "10607877",
      "13868795"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "650",
    "claim": "Integrating classroom-based collaborative learning with Web-based collaborative learning offers the best class performance.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss or contain experimental data, results, or findings related to integrating classroom-based collaborative learning with Web-based collaborative learning, nor do they address class performance in that context. The papers cover topics such as antigen presentation, patient response reliability, rheumatoid arthritis classification, collaborative care for chronic diseases, nutrition security for HIV treatment, computer-assisted learning, dietary assessment tools, and the neurocognitive benefits of aerobic fitness. These topics do not provide relevant information to confirm or refute the specific claim about classroom and Web-based collaborative learning integration."
    },
    "naive_doc_ids": [
      "9278263",
      "841371",
      "1191830",
      "15041758",
      "31562330"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The papers provided do not contain relevant information related to the specific claim about integrating classroom-based collaborative learning with Web-based collaborative learning for class performance. The papers focus on unrelated topics such as weight management, cost-effectiveness of medical treatments, rheumatoid arthritis classification, antidepressant use, perioperative fluid resuscitation, metagenomics, computer-assisted learning, hypertension prevention, and diabetes self-management. None of the studies included specifically address or provide data on educational methods or the integration of different learning approaches in classroom settings."
    },
    "overthinking_doc_ids": [
      "6841927",
      "13843341",
      "1191830",
      "5691302",
      "8814634"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.99,
      "justification": "The provided papers do not contain information directly relevant to the specific claim about integrating classroom-based collaborative learning with Web-based collaborative learning yielding the best class performance. The papers cover diverse topics such as computer-assisted learning in medical education, rheumatoid arthritis classification, gene selection methods in microarray data, gastrointestinal risks of NSAID drugs, patient survey responses for performance incentives, aerobic fitness in children, memory and aging in C. elegans, and the integration of expression QTLs with genetic associations. None of these papers address or provide data regarding the integration of different learning modalities in a classroom setting."
    },
    "posthoc_doc_ids": [
      "12789595",
      "1191830",
      "1542437",
      "21958900",
      "841371"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1230",
    "claim": "The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence from Paper 1 supports the claim that the minor G allele of FOXO3 downregulates pro-inflammatory cytokines. This paper explicitly shows that the minor (G) allele of a noncoding polymorphism in FOXO3A is associated with a milder course of Crohn's disease and rheumatoid arthritis due to its capacity to limit inflammatory responses in monocytes via a FOXO3-driven pathway. This results in reduced production of proinflammatory cytokines like TNF\u03b1 and increased production of anti-inflammatory cytokines such as IL-10. The other papers do not directly address the role of the G allele of FOXO3 and its effect on cytokines, thus they provide no contradictory information to this specific claim."
    },
    "naive_doc_ids": [
      "13905670",
      "11233339",
      "25315295",
      "1550937",
      "2844490"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides relevant evidence to support the claim. It discusses a polymorphism in FOXO3A (rs12212067: T > G) where the minor G allele is associated with a milder course of Crohn's disease and rheumatoid arthritis. This is linked to a FOXO3-driven pathway that reduces the production of proinflammatory cytokines, including TNF\u03b1, thus supporting the claim that the minor G allele of FOXO3 downregulates pro-inflammatory cytokines. Other papers do not directly support or contradict the claim as they are focused on different aspects of inflammatory pathways and cytokines."
    },
    "overthinking_doc_ids": [
      "2844490",
      "13905670",
      "883747",
      "24783597",
      "25315295"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence provided in Paper 1 directly supports the claim that the minor G allele of FOXO3 downregulates pro-inflammatory cytokines. The study in this paper identifies a noncoding polymorphism in FOXO3A (rs12212067: T > G), where the minor (G) allele is associated with a milder course of inflammatory diseases and demonstrated to limit inflammatory responses in monocytes through a FOXO3-driven pathway. This pathway reduces production of pro-inflammatory cytokines, such as TNF\u03b1. The other papers do not provide relevant information on the specific role of the minor G allele of FOXO3 in downregulating pro-inflammatory cytokines, so they do not contradict this claim."
    },
    "posthoc_doc_ids": [
      "13905670",
      "11233339",
      "25315295",
      "36242796",
      "8604837"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "662",
    "claim": "JMJD6 slows the hydroxylation of C-terminal lysine",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about JMJD6 slowing the hydroxylation of C-terminal lysine. The papers cover various topics including JMJD6 promoting colon carcinogenesis through hydroxylation of p53, the role of bromodomains in lysine acetylation, acetylation effects on nucleosome assembly, parasite-induced inhibition of immune cells, viral activation pathways, genetic variants and stroke risk, and histone demethylases. However, none of these topics address the specific claim about JMJD6 and hydroxylation of C-terminal lysine."
    },
    "naive_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "3930020",
      "7820043"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that JMJD6 functions as a lysyl hydroxylase that catalyzes hydroxylation on lysine residues, specifically on p53. This suggests that rather than slowing hydroxylation, JMJD6 actively promotes or catalyzes this post-translational modification on lysine residues. The evidence directly contradicts the claim that JMJD6 slows the hydroxylation of C-terminal lysine, as it specifies JMJD6's role in enhancing lysine hydroxylation. The other papers do not provide direct evidence related to hydroxylation of lysine by JMJD6."
    },
    "overthinking_doc_ids": [
      "37204802",
      "7820043",
      "8548635",
      "864491",
      "927561"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers contain relevant information regarding the claim that JMJD6 slows the hydroxylation of C-terminal lysine. Paper 1 discusses JMJD6 in the context of promoting colon carcinogenesis through hydroxylation of p53, but it does not mention slowing hydroxylation activity. The remaining papers focus on different topics including silver nanoparticles, high-fat diet effects, RNAi regulation, bromodomains, and viral activation of IRF3, which are unrelated to JMJD6's role in hydroxylation."
    },
    "posthoc_doc_ids": [
      "37204802",
      "719812",
      "6042706",
      "2613813",
      "12172346"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1387",
    "claim": "eRNAs influence is linked to senescence, aging, and carcinogenesis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The evidence provided in the papers does not directly address the specific role of eRNAs (enhancer RNAs) in influencing senescence, aging, and carcinogenesis. While several of the papers delve into related concepts such as microRNAs, cellular senescence, aging mechanisms, and non-coding RNAs in the context of cancer, none explicitly discuss eRNAs or provide data/results specifically linking eRNAs to these processes. As such, the papers do not provide information relevant to the evaluated claim about eRNAs. The confidence is relatively high due to the lack of specific mention of eRNAs across the provided documents."
    },
    "naive_doc_ids": [
      "4653837",
      "6896063",
      "3230557",
      "23934390",
      "35543846"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not mention eRNAs or their specific influence on senescence, aging, and carcinogenesis. While several of the papers discuss related topics such as cellular senescence, aging pathways, and molecular mechanisms underlying aging, none specifically address the role of eRNAs. Therefore, there is no direct evidence in these papers to either support or contradict the claim about eRNAs."
    },
    "overthinking_doc_ids": [
      "6896063",
      "4653837",
      "6040392",
      "275294",
      "3202143"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The papers provided do not contain specific information about the role of eRNAs (enhancer RNAs) with respect to their influence on senescence, aging, and carcinogenesis. While several papers discuss related concepts such as p53's role in senescence and aging, microRNAs in muscle aging, the epigenetics of aging and cancer, hypoxia in cancer, cytokines in cancer cachexia, methylation in endometrial cancer, and the role of insulin and IGF in cancer, none of them specifically addresses the function or influence of eRNAs in these processes. Therefore, no direct support or contradiction to the claim about eRNAs can be derived from the given evidence."
    },
    "posthoc_doc_ids": [
      "6896063",
      "4653837",
      "6040392",
      "21902400",
      "39264456"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1027",
    "claim": "Reduced phosphorylation of PP2A suppresses HDAC4 dephosphorylation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The claim discusses the relationship between reduced phosphorylation of PP2A and HDAC4 dephosphorylation. The papers provided do not contain relevant information that directly addresses this claim. Paper 1 focuses on the role of PP2A in tau phosphorylation and GSK-3beta regulation in Alzheimer's disease, without mentioning HDAC4. Paper 2 discusses HDAC4 dephosphorylation and accumulation due to ATM deficiency, linking PP2A activity to ATM, but not directly addressing the interaction between PP2A phosphorylation and HDAC4 dephosphorylation. The remaining papers are unrelated to the specific claim, addressing various other biological mechanisms and proteins. Therefore, the information necessary to evaluate the claim is absent in the provided evidence."
    },
    "naive_doc_ids": [
      "22185730",
      "3113630",
      "8417211",
      "13242763",
      "16745747"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 2 provides evidence related to the regulation of HDAC4 dephosphorylation by PP2A. It discusses how ATM deficiency leads to enhanced PP2A activity, resulting in HDAC4 dephosphorylation and its nuclear accumulation. While it does not directly mention reduced phosphorylation of PP2A, it implies that changes in PP2A activity can affect HDAC4 dephosphorylation. Thus, this paper partially supports the claim by suggesting a link between PP2A activity and HDAC4 dephosphorylation, although the details specifically regarding 'reduced phosphorylation of PP2A' are not directly addressed. The other papers do not provide additional relevant information."
    },
    "overthinking_doc_ids": [
      "22185730",
      "3113630",
      "3973445",
      "6157371",
      "8417211"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 2 provides evidence that links PP2A activity with HDAC4 dephosphorylation. It describes how, in ATM deficiency, enhanced PP2A activity leads to HDAC4 dephosphorylation and its subsequent nuclear accumulation. This suggests that reducing the phosphorylation of PP2A (as per the claim of its reduced activity) would suppress the dephosphorylation of HDAC4, keeping it phosphorylated and potentially maintaining its cytoplasmic localization. Other papers do not discuss the relationship between PP2A activity and HDAC4 dephosphorylation directly, thereby limiting the extent of direct evidence. Nonetheless, paper 2 aligns with the hypothesis that PP2A phosphorylation status affects HDAC4 dephosphorylation."
    },
    "posthoc_doc_ids": [
      "22185730",
      "3113630",
      "8417211",
      "849771",
      "21622715"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "264",
    "claim": "Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Several papers provided in the evidence address the role of citrullinated proteins and neutrophil extracellular traps (NETs) in autoimmunity, which supports the claim. Paper 2 specifically shows that antibodies in patients with rheumatoid arthritis target citrullinated histone 4 in NETs, indicating that these externalized proteins can perpetuate inflammation via induction of autoantibodies. Paper 4 discusses how NETs serve as a source of nuclear antigens that could lead to autoimmune responses, connecting innate immune responses with autoimmunity. Paper 3 also associates NETs with the generation of pro-inflammatory responses via oxidized mitochondrial DNA, pointing to a mechanism by which NET components could contribute to an ongoing inflammatory cycle. While not all papers explicitly mention autoantibodies, the connectivity between citrullinated proteins, NETs, and autoimmune responses is evident, supporting the claim."
    },
    "naive_doc_ids": [
      "1800734",
      "30041340",
      "1049501",
      "14853989",
      "29399239"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The claim suggests that citrullinated proteins in neutrophil extracellular traps (NETs) perpetuate inflammation via autoantibody induction. Paper 2 provides direct evidence that citrullinated histone 4 in NETs is targeted by antibodies in rheumatoid arthritis (RA), indicating a link between citrullinated proteins in NETs and the induction of autoantibodies. Paper 7 further connects NETs to autoimmunity, highlighting that NETs can serve as a source of nuclear antigens in diseases like systemic lupus erythematosus. These findings collectively support the claim that citrullinated proteins in NETs can induce autoantibodies, which could perpetuate inflammatory cycles."
    },
    "overthinking_doc_ids": [
      "1800734",
      "30041340",
      "1049501",
      "16550075",
      "2405259"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The claim states that citrullinated proteins in neutrophil extracellular traps (NETs) act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies. Paper 4 specifically discusses how NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis (RA), highlighting the correlation of NETosis with autoantibodies to citrullinated protein antigens (ACPAs). Paper 8 further supports this claim by identifying citrullinated histone H4 in NETs as a target for antibodies in RA, establishing a link between NETs, citrullinated proteins, and autoantibody production. These observations align with the claim, providing experimental evidence that NETs contribute to autoimmunity and inflammation through citrullinated proteins."
    },
    "posthoc_doc_ids": [
      "1049501",
      "1800734",
      "14853989",
      "11328820",
      "5836"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "236",
    "claim": "Cell autonomous sex determination in somatic cells occurs in Passeriformes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim of cell autonomous sex determination in somatic cells in birds, specifically Passeriformes such as chickens. The study on gynandromorph chickens indicates that avian somatic cells possess an inherent sex identity and demonstrates that sexual differentiation is cell autonomous. This aligns with the claim that somatic sex determination occurs autonomously in Passeriformes. The other papers listed do not provide information relevant to this specific claim about birds, thus reinforcing the reliance on Paper 1 for supporting evidence."
    },
    "naive_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "4380451",
      "29641682"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence supporting the claim that cell autonomous sex determination in somatic cells occurs in Passeriformes. This paper reports findings from studies on gynandromorph chickens, a phenomenon where a bird exhibits male and female characteristics on different sides of its body. The results demonstrated that avian somatic cells possess inherent sex identity that is cell-autonomous, leading to the conclusion that, unlike in mammals, sexual differentiation in birds does not rely entirely on external hormonal cues but rather occurs in a cell-autonomous manner. Hence, this aligns with the claim regarding Passeriformes, as chickens (Gallus gallus) are classified within this order."
    },
    "overthinking_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "120626",
      "238409"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that somatic sex identity in birds, specifically in the chicken which is part of the avian order Passeriformes, is cell-autonomous. The study describes experiments with gynandromorph birds and chimaeric gonads that demonstrate avian somatic cells possess an inherent sex identity, thus substantiating the claim of cell autonomous sex determination in avian somatic cells. The other papers do not provide direct information related to somatic cell sex determination in Passeriformes, thus reinforcing the focus on Paper 1 for classification."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "7426741",
      "3360421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1266",
    "claim": "The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not discuss the specific relationship between placental weight of pregnancies and breast cancer risk in parous women, nor do they explore how this factor might differentially impact premenopausal breast cancer. The papers cover a range of related topics, such as anthropometric measures, blood lipids, and genetic factors related to breast cancer risk, as well as the metabolic processing of tamoxifen, but they do not address placental weight as a risk factor for breast cancer."
    },
    "naive_doc_ids": [
      "13831842",
      "9171913",
      "17450673",
      "2015126",
      "13069283"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim states that the risk of breast cancer among parous women increases with the placental weight of pregnancies, with a stronger association for premenopausal breast cancer. Paper 2 provides evidence directly related to this claim, demonstrating that higher placental weight is associated with an increased maternal risk of breast cancer. The association was stronger in women diagnosed before age 50, which aligns with the claim regarding premenopausal breast cancer. Other papers do not directly address the association between placental weight and breast cancer risk. Therefore, the available evidence from Paper 2 supports the claim."
    },
    "overthinking_doc_ids": [
      "13831842",
      "37480103",
      "16322674",
      "25973484",
      "16701509"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 directly addresses the relationship between placental weight and maternal breast cancer risk, particularly highlighting the increased risk of breast cancer among women with high placental weight in successive pregnancies. The findings indicate a positive association between placental weight and the risk of breast cancer, with the majority of cases diagnosed before age 50. This provides evidence supporting the claim that the risk of breast cancer among parous women increases with placental weight and that this association is particularly strong for premenopausal breast cancer. The other papers do not discuss placental weight or its relationship with breast cancer risk, so they were not considered in this classification."
    },
    "posthoc_doc_ids": [
      "13831842",
      "9171913",
      "37480103",
      "16098747",
      "24341590"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "277",
    "claim": "Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides evidence that directly supports the claim by stating that the genome of Commelina yellow mottle virus (CoYMV) contains three open reading frames (ORFs) capable of encoding proteins of 23, 15, and 216 kD. This aligns perfectly with the claim made about the typical badnavirus ORFs in CoYMV. The other papers do not contain relevant information about CoYMV or its characteristic ORFs, thus they do not directly support or contradict the claim. The high confidence is due to the direct and explicit mention of the ORFs in Paper 1."
    },
    "naive_doc_ids": [
      "14376683",
      "83667891",
      "37677954",
      "18695970",
      "21108759"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence to support the claim. It details the complete genome sequence of Commelina yellow mottle virus (CoYMV) and identifies three open reading frames (ORFs) in the genome. These ORFs are capable of encoding proteins of the specified sizes: 23 kD, 15 kD, and 216 kD. This matches the claim that ComYMV has three typical badnavirus ORFs capable of encoding proteins of these molecular weights. The paper further explains the role of the 216 kD polypeptide, which aligns with the understanding of typical badnavirus ORFs. None of the other papers provide information relevant to this specific claim about ComYMV ORFs, so the evidence from Paper 1 stands as confirmation of the claim."
    },
    "overthinking_doc_ids": [
      "14376683",
      "83667891",
      "37677954",
      "18695970",
      "21108759"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "Paper 1 provides direct evidence supporting the claim. It explicitly states that the genome sequence analysis of Commelina yellow mottle virus (CoYMV) reveals three open reading frames (ORFs) capable of encoding proteins of 23, 15, and 216 kilodaltons (kD). This aligns with the claim that ComYMV has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD. The other papers do not contain relevant information about ComYMV or its genomic structure, so they do not contribute additional support or refutation."
    },
    "posthoc_doc_ids": [
      "14376683",
      "83667891",
      "25994317",
      "4362729",
      "7155555"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "474",
    "claim": "Glycan adaptation is rarely observed in the B-cell repertoire.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information specifically about glycan adaptation in the B-cell repertoire. The papers focus on various topics such as transcription factors, T-cell dynamics, receptor binding, lung immunity, HIV glycan-dependent antibodies, and autophagy-related immunity. None of these topics directly address or provide evidence related to the observed frequency of glycan adaptation in B-cell repertoires."
    },
    "naive_doc_ids": [
      "4896726",
      "8354687",
      "21392223",
      "8305686",
      "2248870"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information specifically about glycan adaptation in the B-cell repertoire. The papers primarily discuss topics related to T-cell populations, autoimmune regulation, stem cell transplantation, immunological synapses, specific immune responses in diseases like celiac disease, mechanisms in viral infections, and aspects of gene regulation and cell fate specification. None of these focus on B-cell glycan adaptation or provide experimental data that could confirm or refute the claim regarding glycan adaptation in the B-cell repertoire."
    },
    "overthinking_doc_ids": [
      "8354687",
      "27910499",
      "4896726",
      "4422734",
      "27555165"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically address the claim regarding glycan adaptation in the B-cell repertoire. The papers cover unrelated topics such as renal cell apoptosis, transcription factors, angiogenesis, T cell responses, autophagy, immunity, and diabetes, but do not provide information on glycan adaptation in B-cells. Therefore, they do not contain relevant information related to the specific scientific claim."
    },
    "posthoc_doc_ids": [
      "238409",
      "4896726",
      "6673421",
      "2248870",
      "13651792"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "648",
    "claim": "Integrated care is successful at tackling multiple comorbidities.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers provided do not contain relevant information about the effectiveness of integrated care in tackling multiple comorbidities. Each paper focuses on different aspects of healthcare or specific conditions, such as tropical diseases, diabetes management, hypertension diagnosis, and viral infections, but do not address the concept of integrated care aimed at handling multiple comorbidities. Therefore, they do not contribute evidence to either support or contradict the claim."
    },
    "naive_doc_ids": [
      "6767133",
      "1215116",
      "3308636",
      "5151024",
      "12584053"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The claim states that integrated care is successful at tackling multiple comorbidities. The evidence provided in Paper 6 directly supports this claim. Paper 6 describes a randomized controlled trial evaluating the effectiveness of integrated care for reducing disability and improving quality of life among patients with both chronic physical diseases and comorbid depression. The results demonstrate that integrated care can significantly reduce social role disability and enhance global quality of life. While other papers focus on specific diseases or healthcare settings, Paper 6 specifically addresses the application of integrated care for multiple comorbidities, aligning with the claim by providing experimental evidence of its success. The consistent improvements in patient outcomes in an integrated care setting for multiple conditions strongly support the claim."
    },
    "overthinking_doc_ids": [
      "5151024",
      "6841927",
      "12584053",
      "13906581",
      "5824985"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 7 provides direct evidence supporting the claim, showing that an integrated care program addressing chronic physical diseases and comorbid depression resulted in reduced social role disability and enhanced global quality of life. This indicates success in managing multiple comorbidities. Similar synergy of improvements, though in different contexts, is indicated in Paper 2, where a multi-behavior intervention improved outcomes in weight management, reflecting how integrated care can address various aspects affecting health. While other papers do not directly address integrated care for comorbidities, they provide a wider context that supports integrated approaches, such as improved monitoring and coordination in healthcare settings, as shown in Papers 1, 3, 5, and 8. The combination of these findings leans towards supporting the effectiveness of integrated care for multiple conditions, including comorbidities."
    },
    "posthoc_doc_ids": [
      "5151024",
      "6841927",
      "12584053",
      "15040589",
      "463533"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1200",
    "claim": "The binding orientation of the ML-SA1 activator at hTRPML2 is different from the binding orientation of the ML-SA1 activator at hTRPML1.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the binding orientation of the ML-SA1 activator at hTRPML1 or hTRPML2 channels. The papers cover topics such as DNA-PK activation, p53 binding to DNA, chromatin structure and regulation, Cdk5 activator proteins, global disease burden analysis, microbial genome annotation, and TRP channel functions in endolysosomal pathways, but none of these are relevant to the claim about ML-SA1 binding orientation at hTRPML channels. Therefore, the evidence provided does not contain the necessary information to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "15472716",
      "25682129",
      "140874",
      "16546131",
      "19708993"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers contain information regarding the binding orientation of the ML-SA1 activator at hTRPML2 and hTRPML1 channels. The papers discuss various unrelated topics, including MHC interactions, transcription factors, HIF-1alpha and p53 interactions, siRNA activity, hepatitis C detection, cancer screening practices, nanotoxicology, Kir channels, and cyclosporine A nephrotoxicity, but do not address the specific claim about ML-SA1 binding orientations."
    },
    "overthinking_doc_ids": [
      "4270992",
      "8331432",
      "10247314",
      "40412980",
      "285794"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the binding orientation of the ML-SA1 activator at hTRPML2 in comparison to its orientation at hTRPML1. The papers cover a range of unrelated topics such as non-invasive ventilation methods, DNA-binding proteins in bacterial transformation, ADHD medication, DNA methylation in stem cells, transcription factors, neuronal proteins, and TRPML channels, but none address the specific claim regarding the binding orientation of ML-SA1 at different TRPML isoforms."
    },
    "posthoc_doc_ids": [
      "474325",
      "799586",
      "2475059",
      "3174305",
      "14530534"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "149",
    "claim": "Autophagy deficiency in the liver increases vulnerability to insulin resistance.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly contradicts the claim by showing that autophagy deficiency in the liver results in increased expression of Fgf21, leading to resistance to diet-induced obesity and amelioration of insulin resistance. This suggests that autophagy deficiency does not increase vulnerability to insulin resistance in the liver, but rather provides protection against it. The other papers reviewed don't directly address or relate to the claim about autophagy deficiency in the liver, focusing instead on different mechanisms or tissues."
    },
    "naive_doc_ids": [
      "6227220",
      "5268462",
      "2481032",
      "33507866",
      "3202143"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 presents evidence that autophagy deficiency in the liver, contrary to increasing vulnerability to insulin resistance, actually protected mice from diet-induced obesity and ameliorated insulin resistance. This protection was linked to increased Fgf21 expression as a result of mitochondrial dysfunction due to autophagy deficiency. Thus, the findings in Paper 1 suggest that autophagy deficiency in the liver may reduce, rather than increase, vulnerability to insulin resistance."
    },
    "overthinking_doc_ids": [
      "6227220",
      "5268462",
      "2481032",
      "195352",
      "1084345"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim suggests that autophagy deficiency in the liver increases vulnerability to insulin resistance. However, Paper 1 provides experimental evidence showing that autophagy deficiency in the liver actually results in protection from insulin resistance by inducing Fgf21 expression. This suggests that instead of increasing vulnerability to insulin resistance, autophagy deficiency may offer protective effects against it in the liver. None of the other papers provide relevant direct evidence regarding the specific claim about autophagy deficiency in the liver, so the classification is heavily based on the findings from Paper 1, which contradict the claim."
    },
    "posthoc_doc_ids": [
      "6227220",
      "5268462",
      "2481032",
      "195352",
      "31001322"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "223",
    "claim": "Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers discuss various aspects of cancer, myeloid-derived suppressor cells (MDSC), and factors influencing tumor environments, but none directly address the specific claim that cancer cells stimulate the accumulation of intra-tumoural MDSCs through the promotion of granulocyte colony stimulating factor (G-CSF) production. Paper 1 discusses granulocyte/macrophage colony-stimulating factor (GM-CSF) but focuses on dendritic cell generation rather than MDSCs or G-CSF. Paper 2 investigates fatty acid metabolism in MDSCs and does not mention G-CSF or its role in MDSC accumulation. Paper 3 examines NLRP3's role in MDSC accumulation but not G-CSF. Paper 4 concerns a different molecular pathway in gastric cancer unrelated to G-CSF or MDSCs. Paper 5 discusses IL-17's influence on MDSCs, but this is unrelated to G-CSF. Thus, there is no direct evidence presented related to the claim."
    },
    "naive_doc_ids": [
      "188911",
      "2030623",
      "15435343",
      "22049489",
      "25726838"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the papers directly address the specific claim that cancer cells stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production. Although some papers discuss interactions between cancer cells, fibroblasts, and components of the tumor microenvironment, there is no explicit evidence linking cancer cells to the stimulation of granulocyte-colony stimulating factor for the accumulation of myeloid-derived suppressor cells. Thus, the papers do not provide relevant information to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "2030623",
      "3559136",
      "4688340",
      "952111",
      "27647593"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides direct support for the claim that cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells (MDSCs) by promoting granulocyte colony-stimulating factor (G-CSF) production. It demonstrates that mTOR signaling in cancer cells regulates G-CSF, which in turn stimulates MDSC accumulation to promote tumor progression. Although Papers 2-8 do not directly address the specific claim, evidence from Paper 1 aligns strongly with the claim, providing experimental evidence and mechanistic insights that support the role of G-CSF production in driving MDSC accumulation in tumors."
    },
    "posthoc_doc_ids": [
      "2014909",
      "2030623",
      "15435343",
      "24612804",
      "42465769"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "643",
    "claim": "Insulin effects appetite via ventral tegmental neurons.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides evidence that insulin receptor (IR) signaling in catecholaminergic neurons, which include dopaminergic neurons in the ventral tegmental area (VTA), plays a critical role in the control of food intake and energy homeostasis. The inactivation of IR in these neurons resulted in increased body weight, increased fat mass, and hyperphagia, indicating that insulin signaling in the VTA affects appetite regulation. Although the paper does not specify 'ventral tegmental neurons' in exact terms, the reference to dopaminergic VTA neurons establishes a connection between insulin signaling and appetite control via neurons in this region. Therefore, this provides SUPPORT for the claim that insulin affects appetite via neurons in the ventral tegmental area."
    },
    "naive_doc_ids": [
      "13322804",
      "15535511",
      "23869951",
      "5531479",
      "18375089"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers explicitly address the specific claim that insulin affects appetite via ventral tegmental neurons. While some papers discuss insulin signaling in neurons (such as Paper 6) and its role in energy homeostasis, they do not specifically address insulin's effect on appetite through ventral tegmental neurons. Other papers focus on different aspects of insulin signaling, glucose metabolism, and related physiological processes, but none provide direct evidence for the claim in question."
    },
    "overthinking_doc_ids": [
      "32611468",
      "1576955",
      "2481032",
      "4709641",
      "6313547"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 3 provides evidence supporting the claim by investigating the role of insulin receptor (IR) signaling in catecholaminergic neurons, specifically dopamine neurons in the ventral tegmental area (VTA). The study demonstrates that insulin influences food intake and energy homeostasis, highlighting the critical role of insulin in these midbrain neurons. Although the exact mechanism by which insulin affects appetite through VTA neurons is not explicitly articulated, the evidence aligns with the claim that insulin has an effect via neurons in the VTA, a region anatomically consistent with the ventral tegmental area mentioned in the claim."
    },
    "posthoc_doc_ids": [
      "26336593",
      "13322804",
      "15535511",
      "1576955",
      "1192458"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1041",
    "claim": "Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The claim that replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes is contradicted by the provided evidence. Paper 7 reports that H2A.Z localizes to repressed and basal promoters and helps facilitate gene activation by making nucleosomes more susceptible to loss, indicating it promotes transcriptional activation rather than slowing it. Paper 8 also suggests that H2A.Z incorporation configures chromatin structure to poise genes for activation, contradicting the claim. Furthermore, Paper 9 notes that the incorporation of H2A.Z subtly destabilizes nucleosome interactions, further enabling gene activation processes. None of the papers support the specific claim of H2A.Z stabilizing +1 nucleosomes to slow gene activation, leading to the conclusion that the claim is not supported."
    },
    "naive_doc_ids": [
      "9451052",
      "11615242",
      "18895793",
      "5116145",
      "9724974"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The claim is that the replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes. The provided evidence from the papers does not directly address or provide experimental data regarding the specific effect of H2A.Z replacement on the stabilization of +1 nucleosomes or its role in slowing gene activation in yeasts. Paper 2 discusses the role of H2A.Z in localization at promoters of inactive genes and its general influence on nucleosome positioning, indicating that H2A.Z could poise genes for transcriptional activation, which does not align directly with the claim of slowing activation. Papers 1, 3, 4, 5, 6, and 7 cover topics such as nucleosome exclusion, chromatin remodeling, histone modifications, HDAC function, histone variant exchange, and a focus on transcription repression and elongation, but they do not provide direct evidence supporting or contradicting the exact claim about the effect of H2A.Z on +1 nucleosomes and gene activation speed in yeast. Thus, the evidence does not contain relevant information specifically addressing the claim."
    },
    "overthinking_doc_ids": [
      "5116145",
      "15778034",
      "13790144",
      "18895793",
      "43156471"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not include direct information or findings specifically on the role of histone H2A.Z in slowing gene activation in yeasts by stabilizing +1 nucleosomes. While Papers 5 and 8 discuss aspects related to nucleosome positioning and promoter regions in yeast, and Paper 5 mentions H2A.Z's involvement in chromatin structure regulation, they do not directly address the specific claim about H2A.Z stabilizing +1 nucleosomes to slow gene activation. Therefore, there is no specific evidence in these papers to either support or contradict the claim in question."
    },
    "posthoc_doc_ids": [
      "11615242",
      "16745747",
      "23305884",
      "406733",
      "15778034"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1237",
    "claim": "The most prevalent adverse events to Semaglutide are cardiovascular.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The provided papers do not contain evidence to support the claim that the most prevalent adverse events to Semaglutide are cardiovascular. Instead, Paper 7 specifically discusses the adverse events associated with Semaglutide treatment, highlighting that mild to moderate gastrointestinal events were the most common. No specific cardiovascular events are mentioned as being prevalent adverse events to Semaglutide. Other papers (Paper 1 through Paper 6 and Paper 8) focus on cardiovascular events and treatments unrelated to Semaglutide, thus lacking direct relevance to this claim."
    },
    "naive_doc_ids": [
      "6070278",
      "4445629",
      "24150328",
      "12438901",
      "14584755"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about the claim regarding Semaglutide and its adverse events being predominantly cardiovascular. The papers discuss atherosclerotic burden in cardiovascular events (Paper 1), corin levels in chronic heart failure (Paper 2), adverse events in multidrug-resistant tuberculosis (Paper 3), amino acid toxicity (Paper 4), and the use of inducible caspase-9 in stem cell transplantation (Paper 5). Paper 6 is relevant as it discusses adverse events from Semaglutide; however, it specifically mentions that the most common adverse events with Semaglutide were mild to moderate gastrointestinal events rather than cardiovascular events. Therefore, there is no supporting or contradicting evidence for the specific claim about cardiovascular adverse events of Semaglutide in these papers."
    },
    "overthinking_doc_ids": [
      "6070278",
      "4445629",
      "11254040",
      "12207167",
      "17682477"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers primarily discuss topics related to cardiovascular fitness, cardiovascular interventions, prediction of cardiovascular events, and other unrelated concepts, but none of them directly mention Semaglutide or the prevalence of cardiovascular adverse events specifically related to Semaglutide. Therefore, they do not offer relevant information to confirm or refute the claim about Semaglutide's most prevalent adverse events being cardiovascular in nature."
    },
    "posthoc_doc_ids": [
      "4463588",
      "35495268",
      "37578311",
      "4445629",
      "6070278"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "677",
    "claim": "LRBA promotes CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the papers provided discuss the role of LRBA in promoting CTLA-4 recycling. While several papers mention CTLA-4 in the context of T cell responses and costimulation, none specifically address LRBA or provide evidence on how LRBA might influence CTLA-4 recycling. The available papers are focused on other proteins, pathways, and cellular processes unrelated to LRBA and CTLA-4 recycling dynamics."
    },
    "naive_doc_ids": [
      "11250124",
      "13398997",
      "14893425",
      "5531479",
      "2462673"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the papers provided in the evidence directly discuss or provide data related to the biological function or interaction involving LRBA (Lipopolysaccharide-responsive and beige-like anchor) in the context of promoting CTLA-4 recycling. The papers cover varied topics such as synaptic vesicle recycling, effects of mutations on vesicle trafficking, mitochondrial function in yeast, and others not directly related to the claim about LRBA and CTLA-4 recycling."
    },
    "overthinking_doc_ids": [
      "11250124",
      "14893425",
      "797114",
      "22317868",
      "799586"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers contain information directly related to LRBA and CTLA-4 recycling. The papers cover various topics such as synaptic vesicle recycling, mitochondrial processes, T cell trafficking, oncogenic signaling, and membrane trafficking, but none refer to or discuss LRBA's role in CTLA-4 recycling. Therefore, the evidence from these papers does not confirm or refute the claim and is irrelevant to the specific scientific claim about LRBA and CTLA-4."
    },
    "posthoc_doc_ids": [
      "11250124",
      "14893425",
      "797114",
      "18264714",
      "2014909"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "2",
    "claim": "1 in 5 million in UK have abnormal PrP positivity.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 9 provides data relevant to the claim about the prevalence of abnormal PrP (prion protein) positivity in the UK population. The study conducted a large-scale survey of archived appendix samples and found an overall prevalence of 493 per million population for abnormal PrP, with confidence intervals from 282 to 801 per million. This prevalence estimate aligns with the claim that approximately 1 in 5 million people in the UK could have abnormal PrP positivity. While the claim states '1 in 5 million,' which is equivalent to 200 per million, the study reinforces the concept of abnormal PrP positivity existing in the population. Therefore, the evidence in Paper 9 generally supports the notion of a non-zero prevalence of abnormal PrP, though the exact numerical alignment is not perfect, it still supports the claim of its presence in the population."
    },
    "naive_doc_ids": [
      "7285256",
      "5735492",
      "5850219",
      "1171121",
      "2647374"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 1.0,
      "justification": "Paper 1 provides specific evidence that contradicts the claim. The study found an overall prevalence of abnormal prion protein (PrP) to be 493 per million population in the UK, which is significantly higher than the claimed rate of 1 in 5 million. This prevalence estimate suggests a much larger portion of the population has abnormal PrP positivity than the claim posits. Other papers do not provide relevant information related to abnormal PrP or the specific claim about its prevalence."
    },
    "overthinking_doc_ids": [
      "13734012",
      "1606628",
      "2138767",
      "3828508",
      "7285256"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides evidence relevant to the claim by discussing the prevalence of abnormal prion protein (PrP) in archived human appendix samples from the UK. It found 16 positive cases out of 32,441 samples, indicating a prevalence of approximately 493 per million, with a 95% confidence interval of 282 to 801 per million. This suggests a higher prevalence than the claim of 1 in 5 million, supporting the notion that abnormal PrP positivity is not as rare as the claim implies. The other papers do not provide relevant information regarding the prevalence of abnormal PrP in the UK."
    },
    "posthoc_doc_ids": [
      "13734012",
      "1606628",
      "2138767",
      "4828631",
      "17415081"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1404",
    "claim": "siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers specifically discuss siRNA knockdown of A20 or its effects on tumor progression in an in vivo murine xenograft model. The papers cover a variety of other topics related to tumor progression, including different genes, signaling pathways, and therapeutic strategies, but none focus on A20 or provide data relevant to the claim."
    },
    "naive_doc_ids": [
      "33638477",
      "1782201",
      "9767444",
      "32852283",
      "45764440"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The claim involves the use of siRNA knockdown of A20 to slow tumor progression in an in vivo murine xenograft model. However, none of the provided papers discuss siRNA targeting of A20 or its effects on tumor progression in such a model. The papers focus on various other genes, mechanisms, and models related to tumor progression, such as BCL9, SRC, integrin \u03b1v\u03b23, KRAS, Bmal1, STIM1, FGF21, 6-phosphogluconate dehydrogenase, and physical training effects on tumors. Since none of these papers mention A20 or siRNA knockdown targeting A20, they do not provide any evidence that directly supports or contradicts the claim."
    },
    "overthinking_doc_ids": [
      "33638477",
      "45764440",
      "1782201",
      "3210545",
      "7165938"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers specifically address the effect of siRNA knockdown of A20 on tumor progression in an in vivo murine xenograft model. The papers discuss various other factors and models affecting tumor progression, such as BCL9, SRC expression, NF-kB, integrins, and other molecular pathways, but do not provide evidence or findings related to A20 inhibition through siRNA in the context specified by the claim. As such, there is no information available within these papers to verify or refute the claim directly."
    },
    "posthoc_doc_ids": [
      "33638477",
      "45764440",
      "1782201",
      "8671456",
      "17717391"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "154",
    "claim": "B3-Galectin increases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the papers provided contain specific evidence or discuss B3-Galectin's role in increasing cell resistance to tyrosine kinase inhibitors (TKIs) through the KRAS-RalB signaling complex downstream of EGFR. While some papers discuss mechanisms of TKI resistance or alternate signaling pathways, none directly address B3-Galectin or its interaction with KRAS and RalB in the context of EGFR. Therefore, the claim cannot be verified with the provided evidence."
    },
    "naive_doc_ids": [
      "9929089",
      "23420807",
      "1065627",
      "4702639",
      "34016944"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information about a molecule named 'B3-Galectin' or its role in the resistance of cells to tyrosine kinase inhibitors (TKIs) via engagement of an alternate KRAS-RalB signaling complex downstream of EGFR. Paper 1 discusses the integrin \u03b23\u2013KRAS\u2013RalB complex in the context of tumor stemness and erlotinib resistance, but it does not mention B3-Galectin. There is no mention of B3-Galectin in any other paper, and none of them explicitly link B3-Galectin to TKI resistance through the KRAS-RalB pathway. Therefore, the papers do not provide relevant information to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "4702639",
      "34016944",
      "9929089",
      "25895285",
      "2272614"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides strong support for the claim. It discusses the involvement of an integrin \u03b23\u2013KRAS\u2013RalB complex in driving tumor stemness and resistance to EGFR inhibition. This mechanism aligns with the claim that B3-Galectin increases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR, as \u03b1v\u03b23 is likely referring to the integrin \u03b23, which recruits KRAS and RalB to activate pathways contributing to drug resistance. Although the specific mention of 'B3-Galectin' is not present, the involvement of 'integrin \u03b23' and 'KRAS-RalB' complex activation directly corresponds to the elements of the claim regarding TKI resistance."
    },
    "posthoc_doc_ids": [
      "4702639",
      "6426919",
      "7821634",
      "2272614",
      "1386103"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "57",
    "claim": "APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 specifically discusses the effects of APOE4 expression in iPSC-derived neurons, stating that APOE4 increases tau phosphorylation and A\u03b2 production but also causes GABAergic neuron degeneration, not a delay as the claim suggests. This directly contradicts the claim that APOE4 expression delays GABA neuron degeneration. None of the other papers provide evidence relevant to the specific effects of APOE4 on A\u03b2, tau phosphorylation, or GABA neuron degeneration, leaving Paper 1 as the primary source of information on this topic."
    },
    "naive_doc_ids": [
      "4709641",
      "3085264",
      "13969173",
      "33986200",
      "16605494"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The claim states that APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation while delaying GABA neuron degeneration. However, Paper 1 contradicts this claim by indicating that ApoE4-expressing neurons had higher levels of tau phosphorylation and increased AlphaBeta production, but they displayed GABAergic neuron degeneration rather than delayed degeneration. This suggests a toxic gain-of-function effect from ApoE4 that promotes degeneration rather than delaying it. No other papers provided relevant evidence related to the specific effects of APOE4 expression in iPSC-derived neurons on GABA neuron degeneration, AlphaBeta production, or tau phosphorylation. Thus, the main relevant paper directly contradicts the part of the claim that suggests delayed degeneration."
    },
    "overthinking_doc_ids": [
      "4709641",
      "1605196",
      "11659421",
      "24632480",
      "25827024"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses the claim regarding the effects of ApoE4 expression in iPSC-derived neurons. It states that ApoE4-expressing neurons exhibited higher levels of tau phosphorylation and increased production of amyloid-beta, but also displayed degeneration of GABAergic neurons. This contradicts the claim that ApoE4 expression delays GABA neuron degeneration. The other papers do not discuss ApoE4 expression in relation to Alzheimer's or neuronal degeneration, making them irrelevant for assessing the specific claim."
    },
    "posthoc_doc_ids": [
      "4709641",
      "23076291",
      "33986200",
      "7482674",
      "14405193"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "565",
    "claim": "In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly supports the claim by showing that multiple RNA surveillance pathways, including those involving RNase III ortholog Rnt1p and the nuclear exosome component Rrp6p, limit aberrant expression of mRNAs related to iron uptake in S. cerevisiae. It specifically notes that in the absence of these surveillance pathways, extended forms of these mRNAs accumulate, and RNase III-deficient cells are hypersensitive to high iron concentrations. This evidence confirms that RNA surveillance is crucial for maintaining iron homeostasis and prevents iron toxicity, aligning with the claim that the absence of RNA surveillance pathways causes sensitivity to high iron conditions in S. cerevisiae. The other papers do not provide relevant information regarding this specific claim."
    },
    "naive_doc_ids": [
      "16120395",
      "365896",
      "13398997",
      "27889071",
      "301866"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that RNA surveillance pathways are crucial for preventing sensitivity to high iron conditions in S. cerevisiae. The study shows that in the absence of the RNA surveillance components such as Rnt1p and Rrp6p, mRNAs encoding iron uptake proteins are aberrantly expressed in iron-replete conditions, which leads to iron toxicity. Additionally, RNase III-deficient cells, which lack Rnt1p, are noted to be hypersensitive to high iron concentrations. This indicates that these RNA surveillance pathways help regulate iron homeostasis and prevent the toxic effects of excessive iron uptake or mobilization under high iron conditions. The other papers do not address this specific claim or the mechanisms related to RNA surveillance and iron sensitivity in S. cerevisiae, hence they are categorized as NOINFO for this claim."
    },
    "overthinking_doc_ids": [
      "16120395",
      "42267740",
      "8247597",
      "418246",
      "4680262"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence supporting the claim that absence of RNA surveillance pathways in S. cerevisiae causes sensitivity to high iron conditions. It specifically mentions that the loss of components involved in RNA surveillance pathways, such as Rnt1p, makes cells hypersensitive to high iron concentrations. This is attributed to aberrant expression of iron uptake mRNAs, leading to iron toxicity. This aligns with the claim that RNA surveillance is crucial for maintaining iron homeostasis in the cell, providing experimental data that correlates absence of RNA surveillance with increased sensitivity to iron, thus supporting the claim."
    },
    "posthoc_doc_ids": [
      "16120395",
      "365896",
      "13398997",
      "5116145",
      "8247597"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "871",
    "claim": "Obesity decreases life quality.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The provided papers collectively indicate that obesity and related conditions are associated with decreased health-related quality of life (HRQoL), which supports the claim that obesity decreases life quality. Paper 1 discusses the negative impact of chronic conditions on HRQoL, which can include obesity-related conditions. Paper 2 links binge eating disorder\u2013often associated with obesity\u2013with significant impairment in HRQoL. Paper 5 specifically examines the impact of higher body mass index (BMI) on brain integrity and suggests obesity is linked to cognitive and neurological compromise, correlating to reduced life quality. Furthermore, Paper 7 describes mental health issues prevalent in obese individuals seeking bariatric surgery, implying these issues could affect life quality. While other papers do not directly address the obesity-life quality nexus, the relevant evidence from the aforementioned papers aligns with the claim."
    },
    "naive_doc_ids": [
      "463533",
      "40666943",
      "42913391",
      "24988745",
      "37583120"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not specifically address the claim that obesity decreases life quality. They cover various topics related to quality of life in different contexts, such as the impact of visual field loss in glaucoma, health literacy in ischemic heart disease, effects of angiotensin system blockade on mental health, mental health support in bariatric surgery, and health-related quality of life among chronic condition populations. While some papers discuss quality of life more broadly, none of them directly address the relationship between obesity and life quality. Therefore, they don't provide pertinent evidence to support or contradict the specific claim about obesity's impact on life quality."
    },
    "overthinking_doc_ids": [
      "31208367",
      "17693849",
      "26199970",
      "19071857",
      "18872233"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not specifically address the claim that obesity decreases life quality. Instead, they focus on various other health conditions and factors affecting quality of life, such as visual field loss in glaucoma (Paper 1), health literacy in ischemic heart disease (Paper 2), the role of angiotensin blockers on mental health (Paper 3), exercise impact on older adults (Papers 4 and 5), chronic stress and crowding (Paper 6), chronic conditions affecting HRQoL (Paper 7), and training effects on pulmonary hypertension (Paper 8). None of these studies directly explore the specific relationship between obesity and quality of life."
    },
    "posthoc_doc_ids": [
      "31208367",
      "17693849",
      "26199970",
      "2028532",
      "17691617"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "914",
    "claim": "PPAR-RXRs can be activated by PPAR ligands.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.99,
      "justification": "None of the provided papers specifically discuss PPAR-RXRs or their activation by PPAR ligands. The papers cover highly diverse topics such as dystrophin-associated protein complexes, urease apoprotein complexes, peroxisome proliferator-activated receptor gamma (PPAR-gamma) in obesity and metabolic syndrome, and several other unrelated subjects. Therefore, there is no direct evidence within these papers that relates to the activation of PPAR-RXRs by PPAR ligands."
    },
    "naive_doc_ids": [
      "9164724",
      "36233757",
      "37768883",
      "22478394",
      "24150328"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information about the specific claim that PPAR-RXR can be activated by PPAR ligands. None of the papers discuss PPAR-RXR interactions, their activation mechanisms, or experimental findings related to PPAR ligands and their effects on PPAR-RXR. These papers focus on other subjects such as myogenesis, T cell activation, receptor-ligand interactions, and NK cell activation, among others, but do not address the interaction between PPAR ligands and PPAR-RXR."
    },
    "overthinking_doc_ids": [
      "5828251",
      "15972906",
      "20690388",
      "7729656",
      "22478394"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided evidence from the papers does not contain any information relevant to the specific claim that PPAR-RXR receptors can be activated by PPAR ligands. The papers discuss various topics such as Notch signaling in myogenesis, T cell activation, NK cell receptors, inflammatory responses due to uric acid crystals, neuronal activation by bacteria, RAR/RXR interactions, mitochondrial compound effects, and estrogen receptor activation. None of these are related to PPAR-RXR interactions or the activation by PPAR ligands."
    },
    "posthoc_doc_ids": [
      "5828251",
      "15972906",
      "20690388",
      "2692522",
      "4345315"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "389",
    "claim": "Ethanol stress increases the expression of IBP in bacteria.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the relationship between ethanol stress and IBP expression in bacteria. The referenced studies cover a wide range of topics including enzyme expression due to hypoxia, oxidative stress responses in E. coli, stress effects on immune responses, RNA editing in stress-induced apoptosis, hypoxia-induced stress, effects of nanoparticles, and DNA binding proteins. However, none directly address or provide data on the effects of ethanol stress on IBP (Ice Binding Protein) expression in bacteria, which is the central claim."
    },
    "naive_doc_ids": [
      "9194077",
      "471735",
      "3943235",
      "7029990",
      "14874811"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers contain relevant information specifically about the effect of ethanol stress on the expression of the IBP gene in bacteria. Each paper focuses on different topics such as oxidative stress in Escherichia coli (Paper 1), gene expression related to macrophage survival (Paper 2), stress response mechanisms in Mycobacterium tuberculosis (Paper 3), regulation of uncoupling protein 1 in brown adipose tissue (Paper 4), myelin basic protein gene expression (Paper 5), NAADP binding in T-lymphocytes (Paper 6), and protein binding to SiO2 nanoparticles (Paper 7). Therefore, there is no direct or indirect experimental data, results, or findings in these papers that address the specific claim related to ethanol stress and IBP expression in bacteria."
    },
    "overthinking_doc_ids": [
      "471735",
      "9784254",
      "19851614",
      "36838958",
      "19238"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The papers provided do not contain relevant information specifically regarding the effect of ethanol stress on the expression of IBP in bacteria. The papers discuss various mechanisms and effects of oxidative stress, hypoxia, shear stress, protein acetylation, and other conditions affecting gene expression in different organisms (such as humans, mice, and Escherichia coli) and different contexts. However, none of them specifically address ethanol stress in bacteria or the expression of IBP as a result of ethanol stress. Therefore, the claim cannot be verified or refuted based on the presented evidence."
    },
    "posthoc_doc_ids": [
      "471735",
      "9194077",
      "38944245",
      "266641",
      "4464565"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "375",
    "claim": "Elevated cell-free mitochondrial DNA levels are associated with mortality.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim, demonstrating that elevated cell-free mitochondrial DNA (mtDNA) levels are associated with increased mortality in medical ICU patients. The paper presents results showing that patients with elevated mtDNA levels had significantly higher odds of dying within 28 days of ICU admission. This evidence directly aligns with the claim that elevated cell-free mitochondrial DNA levels are associated with mortality. The other papers do not discuss mitochondrial DNA or its association with mortality, so they do not contribute relevant information to the claim in question."
    },
    "naive_doc_ids": [
      "1522647",
      "14021596",
      "3899896",
      "31591262",
      "5939172"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that elevated cell-free mitochondrial DNA levels are associated with mortality. It presents data from two cohort studies that show increased odds of dying within 28 days of ICU admission for patients with elevated mitochondrial DNA levels (\u22653,200 copies/\u00b5l plasma). This supports the claim that elevated levels of cell-free mitochondrial DNA are linked to mortality. Other papers do not provide relevant information to this specific claim, thus Paper 1 is the primary source leading to the classification."
    },
    "overthinking_doc_ids": [
      "1522647",
      "14021596",
      "30398773",
      "4791384",
      "663464"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses the claim by providing experimental data and results indicating that elevated cell-free mitochondrial DNA levels are associated with higher mortality, specifically in medical ICU patients. The study found increased odds of death within 28 days of ICU admission for patients with elevated mtDNA levels and showed that including mtDNA levels improved mortality risk prediction models. The confidence level is high because the evidence is directly relevant to the claim and statistically significant. The other papers do not directly address mtDNA levels or their association with mortality, so they do not influence the classification."
    },
    "posthoc_doc_ids": [
      "1522647",
      "14021596",
      "3899896",
      "31591262",
      "3572885"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1390",
    "claim": "mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 6 specifically addresses the role of the 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) in eukaryotes, indicating that it is required for the proper decoding of NNR codons. The paper discusses the necessity of the 2-thio group in mcm5s2U for stable and accurate codon-anticodon pairing, which directly supports the claim that mcm5s2U is required for proper decoding of NNR codons. This direct relevance and detailed mechanistic explanation provide strong support for the claim."
    },
    "naive_doc_ids": [
      "919007",
      "3033830",
      "13552682",
      "1456068",
      "2460304"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that mcm(5)s(2)U is required for proper decoding of NNR codons in eukaryotes is supported primarily by Paper 1 and Paper 3. Paper 1 describes the role of mcm(5)s(2)U in ensuring stable and accurate codon-anticodon pairing for decoding NNR codons in eukaryotes, highlighting its necessity for proper tRNA function. Additionally, Paper 3 highlights the requirement of mcm(5)s(2)U for viability in yeast and discusses its role in improving the efficiency of reading cognate codons, further supporting the claim that it is crucial for decoding specific codons in eukaryotes. None of the other papers provide contradictory evidence, and they mostly focus on unrelated aspects of translation and gene expression in eukaryotes."
    },
    "overthinking_doc_ids": [
      "2890952",
      "13552682",
      "34498325",
      "4313478",
      "30261663"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 directly addresses the claim by stating that the wobble modification in tRNAs, 5-methoxycarbonylmethyl-2-thiouridine (mcm(5)s(2)U), is required for the proper decoding of NNR codons in eukaryotes. It provides mechanistic insights and experimental data on the significance of this modification for stable and accurate codon-anticodon pairing, which is crucial for the correct decoding of NNR codons. None of the other papers provide evidence that refutes this claim, making the evidence in Paper 4 highly supportive of the claim."
    },
    "posthoc_doc_ids": [
      "919007",
      "3033830",
      "13552682",
      "2890952",
      "279052"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.7,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "728",
    "claim": "Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The claim states that Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes. However, Paper 1 provides evidence that under inflammatory conditions (acute infection with Listeria monocytogenes or chronic infection with Leishmania major), there is a significant increase in immature Ly6C(high) monocytes, suggesting their involvement in the inflammatory response. This indicates that Ly6C hi monocytes are recruited to inflammatory sites more in such conditions, suggesting a higher inflammatory capacity, contrary to the claim."
    },
    "naive_doc_ids": [
      "36444198",
      "7489663",
      "343052",
      "9658390",
      "32742683"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1 presents evidence indicating that immature Ly6C(high) monocytes are preferentially recruited under inflammatory conditions. This suggests that Ly6C(high) monocytes may have a greater inflammatory capacity, contrary to the claim. The other papers focus on related topics, such as monocyte behavior in inflammation (Paper 2) and monocyte origins (Paper 6), but do not directly address the inflammatory capacities of Ly6C(high) versus Ly6C(lo) monocytes. Therefore, the primary source of relevant evidence is Paper 1, which contradicts the claim that Ly6C(high) monocytes have a lower inflammatory capacity than Ly6C(lo) monocytes."
    },
    "overthinking_doc_ids": [
      "36444198",
      "7489663",
      "343052",
      "4394525",
      "5106691"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The provided evidence contains a paper (Paper 8) indicating that Ly6C(hi) monocytes have an inflammatory role, as it discusses the modulation of inflammatory Ly6C(hi) monocytosis. This suggests that Ly6C(hi) monocytes have a significant inflammatory capacity, which contradicts the claim that Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes. No other papers specifically discuss or provide evidence for the inflammatory capacity difference between Ly6C hi and Ly6C lo monocytes, leading to this classification."
    },
    "posthoc_doc_ids": [
      "36444198",
      "1265945",
      "7489663",
      "4394525",
      "7521113"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "975",
    "claim": "Primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "The claim that primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators is supported by the evidence in several papers, despite the absence of direct experimental results specifically addressing this claim. Paper 2 discusses how Th1 and Th17 responses in Crohn's disease involve interleukin-mediated production of interferon-gamma, suggesting downstream mediator involvement. Paper 5 and Paper 7 describe the roles of TNF-alpha and IL-13 in inflammation and fibrosis, indicating a cascade effect involving cytokines. Although none of the papers explicitly confirm the induction of secondary mediators by primary cytokines, the described mechanisms of cytokine involvement in inflammatory and autoimmune conditions support the concept of a cascade involving secondary pro- and anti-inflammatory responses."
    },
    "naive_doc_ids": [
      "2391552",
      "2844490",
      "25315295",
      "3973445",
      "12705056"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The papers provided do not specifically address the claim regarding primary pro-inflammatory cytokines inducing secondary pro- and anti-inflammatory mediators. While several papers discuss roles of cytokines in various contexts such as inflammation, immune responses, and diseases, none provide direct evidence on the sequential induction of secondary cytokines (either pro- or anti-inflammatory) by primary pro-inflammatory cytokines. Consequently, the papers do not contain relevant experimental data or findings directly supporting or contradicting the claim."
    },
    "overthinking_doc_ids": [
      "3848469",
      "11233339",
      "25315295",
      "3973445",
      "29509926"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The scientific claim is that primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators. The evidence provided in the papers suggests a supportive link, particularly highlighting how primary inflammatory cytokines like interleukin-1, TNF-alpha, and others can modulate secondary responses. Paper 2 discusses the effects of primary pro-inflammatory cytokines on neurotransmitter systems which are downstream processes. Paper 3 discusses Th17 cells which produce IL-17 and other cytokines after activation, indicating a cascade effect. Paper 4 details how T cell-derived factors (primary mediators) can induce secondary processes within bone marrow. Paper 5 shows downstream signaling pathways activated by inflammatory mediators like AGEs, which induce other inflammatory cytokines and factors. Together, these findings support the claim that primary pro-inflammatory cytokines can initiate a complex response involving both pro- and anti-inflammatory mediators."
    },
    "posthoc_doc_ids": [
      "2391552",
      "25315295",
      "11233339",
      "43619625",
      "9956893"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1295",
    "claim": "There is no relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 specifically investigates the association between macrolide antibiotics, including Erythromycin, and infantile hypertrophic pyloric stenosis (IHPS). The results indicate a strong association between the treatment of young infants with macrolide antibiotics and the development of IHPS. The study finds significant adjusted rate ratios for IHPS in infants exposed to macrolides shortly after birth, indicating a contradictory position to the claim that there is no relation between Erythromycin use and hypertrophic pyloric stenosis. The other papers do not provide relevant information regarding this specific claim."
    },
    "naive_doc_ids": [
      "21239672",
      "27099731",
      "2052720",
      "2774906",
      "6669242"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 1.0,
      "justification": "Paper 1 specifically investigates the association between the use of macrolide antibiotics, such as Erythromycin, and the development of infantile hypertrophic pyloric stenosis (IHPS). The study reports a strong association, stating that treatment of young infants with macrolide antibiotics was strongly associated with IHPS. Additionally, maternal use of macrolides during the first two weeks after birth was associated with an increased risk of IHPS. This directly contradicts the claim that there is no relation between Erythromycin use and hypertrophic pyloric stenosis."
    },
    "overthinking_doc_ids": [
      "21239672",
      "791050",
      "829646",
      "7647224",
      "24269361"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 1.0,
      "justification": "Paper 1 directly discusses the relationship between Erythromycin (a type of macrolide antibiotic) use and infantile hypertrophic pyloric stenosis (IHPS). It presents evidence from a large cohort study that the use of macrolides in infants, particularly in the days 0 to 13 after birth, is strongly associated with IHPS. The study found an adjusted rate ratio of 29.8 for IHPS when infants were exposed to macrolides during this period, a significant finding that suggests a clear association between the use of macrolides like Erythromycin and the development of hypertrophic pyloric stenosis. Thus, the evidence contradicts the claim that there is no relation between Erythromycin use and hypertrophic pyloric stenosis."
    },
    "posthoc_doc_ids": [
      "21239672",
      "643765",
      "2575938",
      "23862975",
      "38630735"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "233",
    "claim": "Cell autonomous sex determination in somatic cells does not occur in Galliformes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence contradicting the claim by demonstrating that somatic sex identity is cell-autonomous in chickens, a member of the Galliformes. The study with gynandromorph chickens shows that male and female somatic cells exhibit inherent sex identities, indicating cell-autonomous sex determination in somatic cells. The other papers do not address the specific issue of sex determination in Galliformes, focusing on topics unrelated to the claim."
    },
    "naive_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "23581096",
      "9513785"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence that contradicts the claim by demonstrating that avian somatic cells, specifically in chickens, possess an inherent sex identity and that sexual differentiation in birds is substantively cell autonomous. This directly refutes the claim that cell autonomous sex determination in somatic cells does not occur in Galliformes, as chickens belong to this order."
    },
    "overthinking_doc_ids": [
      "4388470",
      "5500086",
      "13651792",
      "120626",
      "238409"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that cell autonomous sex determination in somatic cells does not occur in Galliformes, while the evidence in Paper 1 specifically investigates sex determination in chickens (a type of Galliformes) and provides evidence that avian somatic cells possess an inherent sex identity. The studies on gynandromorph chickens showed that male and female avian somatic cells may have an inherent sex identity and that in birds, sexual differentiation is substantively cell autonomous. This directly contradicts the claim by providing experimental evidence that such autonomous sex determination does occur in somatic cells of Galliformes."
    },
    "posthoc_doc_ids": [
      "4388470",
      "5500086",
      "13651792",
      "1471041",
      "2608447"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "169",
    "claim": "Bariatric surgery reduces postmenopausal breast cancer.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information about the specific claim that bariatric surgery reduces the incidence of postmenopausal breast cancer. The papers discuss various factors related to breast cancer risk, such as mammographic density, hormonal influences, obesity, and type 2 diabetes, but there is no direct examination of bariatric surgery's impact on breast cancer. Therefore, they neither support nor contradict the claim, as they do not address bariatric surgery as an intervention."
    },
    "naive_doc_ids": [
      "38551172",
      "5864770",
      "9171913",
      "13069283",
      "2931832"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically address the impact of bariatric surgery on the incidence of postmenopausal breast cancer. Most papers focus on breast cancer risk factors and treatment efficacy related to chemotherapy and genetic polymorphisms, with one paper discussing outcomes of bariatric surgery on general health markers but not directly linking it to breast cancer outcomes. Therefore, they do not provide sufficient information to verify the claim on whether bariatric surgery reduces postmenopausal breast cancer."
    },
    "overthinking_doc_ids": [
      "38551172",
      "195680777",
      "24341590",
      "5824985",
      "12145359"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers directly address the specific claim that bariatric surgery reduces postmenopausal breast cancer. The papers discuss various topics related to breast cancer, including prognostic markers, mammographic density, genetic predispositions, hormonal influences, and other clinical outcomes related to bariatric surgery. However, there is no direct examination of the link between bariatric surgery and its effect on postmenopausal breast cancer specifically. Therefore, the evidence from these papers is not relevant to verifying this particular claim."
    },
    "posthoc_doc_ids": [
      "2931832",
      "38551172",
      "2015126",
      "2140497",
      "3329824"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1307",
    "claim": "Tonic signaling from the scFv induces constitutive stimulation.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that is relevant to the claim about tonic signaling inducing constitutive stimulation. It describes how tonic signaling of CARs, through antigen-independent clustering of single-chain variable fragments, leads to phosphorylation and early exhaustion of T cells. This implies a constitutive stimulation resulting from tonic signaling, as it describes an ongoing activation (phosphorylation) in the absence of antigen engagement. Although the paper does not use the exact wording from the claim, its findings align with the concept of tonic signaling inducing a constitutive effect. The other papers either focus on unrelated signaling pathways or specific receptor-mediated processes that do not pertain directly to tonic signaling or constitutive stimulation as described in the claim."
    },
    "naive_doc_ids": [
      "18231807",
      "32598644",
      "35660758",
      "2828460",
      "1044552"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that tonic signaling from a chimeric antigen receptor single-chain variable fragment (scFv) induces constitutive stimulation. It discusses how antigen-independent clustering of CAR scFvs results in tonic CAR CD3-\u03b6 phosphorylation, leading to early exhaustion of CAR T cells. This suggests a mechanism of constitutive signaling induced by tonic activity of the scFv, aligning with the claim."
    },
    "overthinking_doc_ids": [
      "18231807",
      "116792",
      "213017",
      "23078022",
      "1574014"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that tonic CAR CD3-\u03b6 phosphorylation, triggered by antigen-independent clustering, induces early exhaustion of CAR T cells, thereby supporting the claim that tonic signaling from the scFv induces constitutive stimulation. Though the focus is on exhaustion, it implies a level of constitutive activity due to tonic signaling. This aligns with the claim that tonic signaling can lead to constitutive stimulation within the context of CAR T cells."
    },
    "posthoc_doc_ids": [
      "18231807",
      "35660758",
      "2714623",
      "4611267",
      "34016944"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1288",
    "claim": "There is a positive correlation between hip fractures and statin use.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain information directly addressing the correlation between hip fractures and statin use. While some papers discuss anti-fracture efficacy of osteoporosis treatments (not specifically related to statins) and others focus on different aspects of statin use (such as cardiovascular disease prevention and anti-inflammatory effects), none specifically investigate the relationship between statin use and hip fractures. Paper 6 examines the association between statin use and hip fracture risk, but it suggests a reduction in hip fracture risk with statin use, which is contrary to a positive correlation with hip fractures. The remaining papers do not address this relationship at all."
    },
    "naive_doc_ids": [
      "26000593",
      "1287809",
      "2391552",
      "11246427",
      "1711571"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 specifically addresses the relationship between statin use and hip fracture risk in elderly patients. It finds that statin use is associated with a significant reduction in the risk of hip fracture, which directly contradicts the claim of a positive correlation between hip fractures and statin use. None of the other papers provide information relevant to hip fracture risk related to statin use."
    },
    "overthinking_doc_ids": [
      "1287809",
      "11246427",
      "22420524",
      "31591262",
      "42441846"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim suggests a positive correlation between hip fractures and statin use, implying statin use increases the risk of hip fractures. However, Paper 1 presents a case-control study that finds statin use is associated with a significant reduction in the risk of hip fractures in elderly patients, with an adjusted odds ratio indicating a lower risk of fracture for statin users. This evidence directly contradicts the claim as it suggests a protective effect of statins against hip fractures. The other papers (2-8) do not directly address the claim, focusing instead on topics like cost-effectiveness of statins for cardiovascular prevention, inflammatory responses post-surgery, children's fitness, and osteoporosis treatment, which do not provide relevant information regarding the correlation of hip fractures with statin use."
    },
    "posthoc_doc_ids": [
      "4687948",
      "1287809",
      "2391552",
      "643765",
      "2575938"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "730",
    "claim": "Lysine histone demethylase inhibitor JIB 04 is inactive against KDM5A.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the specific interaction of JIB 04 with KDM5A or its activity as an inhibitor of lysine histone demethylase in this context. The papers cover topics ranging from cyclin-dependent kinase inhibitors, effects of signaling pathways on differentiation, histone demethylase activities in unrelated contexts, and other non-relevant subjects. Therefore, they don't provide evidence either supporting or contradicting the claim about JIB 04's inactivity against KDM5A."
    },
    "naive_doc_ids": [
      "864491",
      "1595617",
      "45764440",
      "4387494",
      "18841257"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers discuss the activity of the lysine histone demethylase inhibitor JIB 04 specifically against KDM5A. The papers cover various topics ranging from cancer therapeutics, bisphosphonate effects, cardiovascular risks, depression post-miscarriage, KDM6B inhibition, demethylase Jmjd3, KDM4E roles in embryonic development, and beta-adrenoceptor antagonists, none of which directly address or provide experimental data related to JIB 04 and KDM5A. Therefore, the evidence provided is irrelevant to the claim."
    },
    "overthinking_doc_ids": [
      "10542877",
      "14819804",
      "18473550",
      "202259",
      "778436"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the papers provided contain specific information about the effect of the lysine histone demethylase inhibitor JIB 04 on KDM5A. Most papers discuss broadly related topics such as histone demethylase inhibitors, but they do not directly address the activity of JIB 04 on KDM5A. Therefore, the evidence presented does not allow verification of the claim about JIB 04 being inactive against KDM5A."
    },
    "posthoc_doc_ids": [
      "4387494",
      "18841257",
      "13400643",
      "4547102",
      "9929089"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "617",
    "claim": "Increased mobility of retrotransposons is assosciated with mutation and higher tumorigenesis rates.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain relevant information about the specific claim that increased mobility of retrotransposons is associated with mutation and higher tumorigenesis rates. The papers discuss various genetic mutations, pathways, and factors involved in different types of cancer, such as thyroid cancer, endometrial cancer, multiple myeloma, and others. However, none of these papers specifically discuss retrotransposons, their mobility, or directly link them to increased mutation or tumorigenesis rates. Therefore, it is not possible to assess the claim based on the provided evidence."
    },
    "naive_doc_ids": [
      "21551568",
      "3210545",
      "3572885",
      "21902400",
      "22123421"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information about the association between increased mobility of retrotransposons and higher tumorigenesis rates. The papers discuss various topics such as KRAS gene amplification, EGFR mutations, mechanisms of renal cell apoptosis, and breast cancer risks related to BRCA1/2 mutations, but they do not address retrotransposons or their mobility in relation to mutations and tumorigenesis. Therefore, there is no basis in the provided papers to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "3210545",
      "9505402",
      "11271123",
      "28334217",
      "238409"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not discuss the increased mobility of retrotransposons in relation to mutation rates and tumorigenesis. The papers cover topics such as dietary effects on cancer risk, vitamin D metabolites and cancer prevention, hormone impact on breast cancer, chromosomal changes in bladder tumors, Kras mutations in ovarian cancer, chromatin remodeling in glioblastoma, and other unrelated medical and cancer studies. None of these references specifically address the activity of retrotransposons and their direct role in genetic mutations or related tumorigenesis."
    },
    "posthoc_doc_ids": [
      "6327940",
      "520579",
      "5864770",
      "2402323",
      "3360428"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "124",
    "claim": "Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 explicitly addresses the relationship between antiretroviral therapy and tuberculosis incidence in HIV-infected adults and finds a strong reduction in tuberculosis cases across different CD4 count strata. This directly supports the claim that antiretroviral therapy reduces tuberculosis rates among various CD4 levels. Paper 3, while focused on the integration of ART and tuberculosis treatment, provides additional context on ART's positive survival impact, particularly in patients with low CD4 counts, thus indirectly supporting the wider applicability of ART's benefits in reducing tuberculosis incidence. Other papers do not directly discuss tuberculosis but collectively reinforce the beneficial impact of ART on HIV-related health outcomes, supporting the claim's validity regarding tuberculosis reductions."
    },
    "naive_doc_ids": [
      "13899137",
      "4883040",
      "7111021",
      "39984099",
      "40790033"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim states that antiretroviral therapy (ART) reduces rates of tuberculosis across a broad range of CD4 strata. Paper 1 provides direct evidence supporting this claim, showing that ART is associated with a significant reduction in the incidence of tuberculosis across all CD4 count categories, with hazard ratios indicating a lower tuberculosis incidence in treated individuals regardless of their CD4 count at ART initiation. Paper 2 offers indirect support by discussing the timing of ART during tuberculosis treatment, although it primarily focuses on AIDS and survival outcomes. Papers 3, 4, 5, 6, and 7 do not provide specific information relevant to the claim about antiretroviral therapy's impact on tuberculosis incidence. Therefore, the primary evidence from Paper 1 supports the claim."
    },
    "overthinking_doc_ids": [
      "4883040",
      "7111021",
      "20188586",
      "13899137",
      "13938878"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence provided in the papers, particularly Paper 1, directly supports the claim that antiretroviral therapy (ART) reduces rates of tuberculosis across a broad range of CD4 strata. Paper 1 presents a systematic review and meta-analysis of multiple studies, showing a strong association between ART and a reduction in tuberculosis incidence in all baseline CD4 count categories (<200, 200-350, >350 cells/\u00b5l). The hazard ratios provided indicate statistically significant reductions in tuberculosis incidence for each stratum. While Papers 2, 3, and 4 do not directly address tuberculosis incidence reduction across CD4 strata, they do support the efficacy of ART in reducing HIV-related complications and inform general ART policy and guidelines. Thus, Paper 1 provides strong direct support for the claim."
    },
    "posthoc_doc_ids": [
      "4883040",
      "7111021",
      "13899137",
      "39984099"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1207",
    "claim": "The composition of myosin-II isoform switches from the polarizable B isoform to the more homogenous A isoform during hematopoietic differentiation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information or relevant evidence related to the claim about isoform switching of myosin-II from the B isoform to the A isoform during hematopoietic differentiation. The papers discuss various topics including hematopoietic stem cell differentiation, mitochondrial regulation, microRNA roles in cellular differentiation, alternative splicing in myoblast differentiation, and cardiac fibrosis, but none provide specific data or findings about isoform switching of myosin-II isoforms in hematopoietic differentiation."
    },
    "naive_doc_ids": [
      "11289247",
      "13116880",
      "14581009",
      "27061085",
      "344240"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers directly address the specific claim regarding the switch in the composition of myosin-II isoforms during hematopoietic differentiation. Instead, the papers cover diverse topics such as mitochondrial phosphatase PTPMT1's role in hematopoietic stem cell differentiation, regulation of self-renewal and differentiation in general, Polycomb ortholog switching in embryonic stem cells, heat shock proteins in stem cell modulation, the prognostic role of RDW in rectal cancer, transcript assembly in cell differentiation, chromatin modifications during aging, and gene expression in cellular reprogramming. These topics are not directly related to the myosin-II isoform switch in HSCs, making it impossible to support or contradict the claim based on these papers."
    },
    "overthinking_doc_ids": [
      "11289247",
      "13116880",
      "14581009",
      "20524091",
      "3899896"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers specifically address the composition of myosin-II isoforms A and B or their switching during hematopoietic differentiation. The papers cover various topics including mitochondrial metabolism in hematopoietic stem cell differentiation, mechanisms of self-renewal and differentiation in hematopoietic stem cells, the role of myosin light chain phosphorylation in Drosophila oogenesis, and other unrelated studies on protein isoforms and gene expression regulation. Therefore, there is no direct evidence in the papers to verify or refute the specific claim regarding myosin-II isoform switching in hematopoietic differentiation."
    },
    "posthoc_doc_ids": [
      "11289247",
      "13116880",
      "14581009",
      "735130",
      "11721676"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1141",
    "claim": "Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 specifically investigates the effect of vitamin E (\u03b1-tocopheryl acetate) and vitamin C supplementation on the risk of prostate and total cancer in male physicians. It reports no significant reduction in the incidence of prostate cancer associated with supplementation of \u03b1-tocopheryl acetate in combination with vitamin C. The hazard ratios reported for prostate cancer were close to 1 (HR, 0.97 for vitamin E and HR, 1.02 for vitamin C), indicating no substantial difference compared with the placebo group. Thus, the evidence from this paper directly contradicts the claim that taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer."
    },
    "naive_doc_ids": [
      "520579",
      "16422880",
      "38551172",
      "12009265",
      "12074066"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim is that taking 400mg of \u03b1-tocopheryl acetate (vitamin E) in combination with vitamin C reduces the risk of prostate cancer. Paper 1 directly addresses this claim by reporting results from a large, long-term, randomized controlled trial that found no significant effect of vitamin E or vitamin C supplementation on the risk of prostate cancer or total cancer. During an 8-year follow-up, neither supplement reduced the incidence of prostate cancer. This contradicts the claim that the combination reduces the risk. Other papers do not provide information relevant to the claim about the combination of these supplements and prostate cancer risk."
    },
    "overthinking_doc_ids": [
      "12009265",
      "3222187",
      "12074066",
      "520579",
      "38551172"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 3, 'Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial', specifically evaluates the relationship between vitamin E (in the form of \u03b1-tocopheryl acetate) and vitamin C supplementation and the risk of prostate cancer. The study concluded that neither vitamin E nor vitamin C supplementation reduced the risk of prostate cancer, contradicting the claim that taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer. The other papers do not provide relevant information regarding this claim, focusing instead on other vitamins or cancer types."
    },
    "posthoc_doc_ids": [
      "520579",
      "38551172",
      "12009265",
      "12074066",
      "308862"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "71",
    "claim": "Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 1 provides relevant information that aligns with the claim. It describes SRGP-1 as a negative regulator of cell clearance and shows that loss of srgp-1 function leads to increased engulfment of apoptotic cells and removal of cells close to death. SRGP-1 functions as a GTPase activating protein for CED-10 (Rac1), and its absence promotes clearance of cells under apoptotic or cytotoxic stress. This suggests that in SRGP-1 mutants, activation of CED-10 may lead to further clearance mechanisms, potentially resulting in killing viable cells that are already under stress, supporting the claim. The other papers do not provide information directly relevant to the claim."
    },
    "naive_doc_ids": [
      "1127562",
      "16745747",
      "5002665",
      "34436231",
      "5572127"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides relevant information that supports the claim. It describes the role of SRGP-1 as a negative regulator of cell clearance in C. elegans and its interaction as a GTPase activating protein for CED-10 (Rac1). The paper discusses how the loss of SRGP-1 function, which involves CED-10 activation, promotes the clearance not only of dead cells but also of cells that are damaged or on the verge of death. This suggests that activating CED-10 in SRGP-1 mutants can lead to the removal of viable yet damaged cells, aligning with the claim that CED-10 activation results in the killing of viable cells in SRGP-1 mutant C. elegans. The other papers do not provide information relevant to this specific claim."
    },
    "overthinking_doc_ids": [
      "1127562",
      "5002665",
      "7036529",
      "1941721",
      "4795303"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that loss of SRGP-1, a GTPase activating protein for CED-10 (Rac1), promotes the clearance of not only dead cells but also cells brought near death through various insults in Caenorhabditis elegans. While the paper does not explicitly state that activation of CED-10 directly kills viable cells in SRGP-1 mutants, the implication that SRGP-1 negatively regulates CED-10 and affects cell clearance suggests that in its absence, increased CED-10 activity may lead to enhanced removal of compromised cells. This indirectly supports the claim that activating CED-10 can be detrimental to cell viability in the context of SRGP-1 loss. The other papers do not provide specific information on SRGP-1, CED-10, or their role in cell death in C. elegans, focusing on different topics or organisms."
    },
    "posthoc_doc_ids": [
      "1127562",
      "7036529",
      "4662264",
      "5002665",
      "935034"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1280",
    "claim": "The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim states that the ureABIEFGH gene cluster encodes urease maturation proteins: UreD/UreH, UreE, UreF, and UreG. Papers 1, 2, and 4 provide evidence supporting this claim. Paper 1 discusses the involvement of UreD, UreE, UreF, and UreG in nickel metallocenter biosynthesis, highlighting their necessity for functional incorporation of the urease metallocenter. Paper 2 supports the formation of urease apoprotein complexes that include UreD, UreF, and UreG, emphasizing their role in enzyme activation. Paper 4 further supports the claim by detailing the activation properties of UreD, UreF, and urease complexes and describes their contribution to urease activation. Papers 3 and 5 do not contain relevant information for this specific claim. Thus, the evidence from papers 1, 2, and 4 aligns with the claim, confirming it."
    },
    "naive_doc_ids": [
      "29214508",
      "37768883",
      "18467982",
      "36233757",
      "17240457"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Papers 1, 4, and 5 provide strong evidence supporting the claim that the ureABIEFGH gene cluster encodes urease maturation proteins UreD, UreE, UreF, and UreG. Paper 1 discusses the involvement of the ureD, ureE, ureF, and ureG genes in nickel metallocenter biosynthesis, confirming their role as accessory genes necessary for urease activation. Paper 4 highlights the presence of UreD, UreF, and UreG in urease apoprotein complexes, essential for in vivo enzyme activation, and Paper 5 describes the distinct activation properties of complexes involving these proteins. These findings align with the claim that these genes encode urease maturation proteins. Other papers do not discuss the urease gene cluster and are classified as NOINFO for this claim."
    },
    "overthinking_doc_ids": [
      "29214508",
      "18467982",
      "1964163",
      "37768883",
      "36233757"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "The claim that the ureABIEFGH gene cluster encodes urease maturation proteins: UreD/UreH, UreE, UreF, and UreG is supported by the evidence found in the papers, particularly Paper 2 and Paper 4. Paper 2 describes the sequencing and functional analysis of the Klebsiella aerogenes urease gene cluster, identifying that the ureD, ureE, ureF, and ureG genes are specifically involved in nickel metallocenter biosynthesis for urease activity. Paper 4 further corroborates this by demonstrating that UreD, UreF, and UreG are essential for the in vivo activation of urease and form complexes with urease apoprotein. Thus, the evidence strongly supports that these gene products function as urease maturation proteins, aligning with the claim made."
    },
    "posthoc_doc_ids": [
      "14474178",
      "29214508",
      "9283422",
      "37768883",
      "36233757"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1347",
    "claim": "Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The primary paper relevant to the claim is Paper 3, which investigates the role of memory CD4+ T cells in lung inflammation during influenza infection. According to this paper, memory CD4+ T cells enhance the production of multiple innate inflammatory cytokines and chemokines in the lung during influenza infection, which seems to counter the claim that these cells diminish inflammatory chemokines. This paper provides evidence of the opposite effect by stating that memory CD4+ T cells contribute to an early innate response, promoting the production of inflammatory chemokines and cytokines rather than reducing them. The other papers do not specifically address the role of memory CD4+ T cells in the context of inflammatory chemokines in influenza, so the focus remains on Paper 3 to classify the claim. Thus, the evidence from Paper 3 contradicts the claim, leading to the classification of CONTRADICT with high confidence."
    },
    "naive_doc_ids": [
      "12100963",
      "3835423",
      "19005293",
      "6182947",
      "10648422"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that influenza-specific memory CD4+ T cells diminish the early production of inflammatory chemokines in the lung. However, Paper 3 provides contrary evidence that memory CD4+ T cells enhance the production of various innate inflammatory cytokines and chemokines in the lung, which contributes to early control of the virus during influenza infection. This evidence indicates that rather than diminishing the production of inflammatory chemokines, memory CD4+ T cells actually increase their production, which contradicts the claim."
    },
    "overthinking_doc_ids": [
      "12100963",
      "3835423",
      "19005293",
      "2248870",
      "26030079"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 7 directly contradicts the claim by stating that memory CD4+ T cells enhance the production of multiple innate inflammatory cytokines and chemokines in the lung during influenza infection. This finding opposes the claim that influenza-specific memory CD4+ T cells diminish the early production of inflammatory chemokines in the lung. The other papers do not provide information directly related to this specific claim, focusing instead on other aspects of T cell behavior, such as tissue residency, chemokine receptor expression, or responses to different infections."
    },
    "posthoc_doc_ids": [
      "12100963",
      "3835423",
      "2248870",
      "11721286",
      "7666498"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "744",
    "claim": "Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein. It discusses how macropinocytosis is used by Ras-transformed cells to transport extracellular proteins into the cell, where they are degraded into amino acids. This mechanism reduces the cell's dependence on free extracellular amino acids for growth, highlighting the role of macropinocytosis in nutrient uptake and amino acid supply. The other papers do not contradict this claim or provide relevant data, so they are marked as NOINFO."
    },
    "naive_doc_ids": [
      "4138659",
      "3845894",
      "3105781",
      "23599024",
      "1889358"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly supports the claim that macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein. It explains how Ras-transformed cells utilize macropinocytosis to transport extracellular protein into the cell, which is then degraded into amino acids used for cellular metabolism. The paper also shows that macropinocytosis can reduce the dependency of these cells on external sources of amino acids like glutamine, confirming its role in amino acid supply. Although the other papers do not directly address this process, Paper 1 provides clear experimental evidence that confirms the claim."
    },
    "overthinking_doc_ids": [
      "4138659",
      "4959368",
      "12207167",
      "1145473",
      "3512154"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence that macropinocytosis is used by Ras-transformed cells to internalize extracellular proteins, which are then degraded to supply amino acids such as glutamine for cellular metabolism. This supports the claim that macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein. Papers 2-8 do not provide relevant information to confirm or refute this claim, focusing on different aspects of cellular metabolism and protein functions not directly related to macropinocytosis of proteins and amino acid supply."
    },
    "posthoc_doc_ids": [
      "4138659",
      "23895668",
      "2030623",
      "30303335",
      "35345807"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "881",
    "claim": "Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct evidence regarding the metabolism of L-carnitine and the production of trimethylamine N-oxide (TMAO) in omnivores compared to vegans. It states that omnivorous human subjects produced more TMAO than vegans or vegetarians following ingestion of L-carnitine. This finding directly contradicts the claim that omnivores produce less TMAO from dietary L-carnitine than vegans. Other papers in the provided evidence do not address the specific claim about TMAO production from L-carnitine in omnivores versus vegans."
    },
    "naive_doc_ids": [
      "6793674",
      "7230315",
      "26658659",
      "14803797",
      "34101101"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly addresses the relationship between dietary L-carnitine intake, its metabolism by the intestinal microbiota, and the production of trimethylamine-N-oxide (TMAO). It provides evidence that omnivorous human subjects produce more TMAO than vegans or vegetarians following the ingestion of L-carnitine. This finding aligns with the claim that omnivores produce less trimethylamine-N-oxide from dietary L-carnitine compared to vegans, thereby supporting the claim."
    },
    "overthinking_doc_ids": [
      "14803797",
      "275294",
      "1391126",
      "21623140",
      "4939312"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides direct evidence relevant to the claim, demonstrating that omnivorous human subjects produce more TMAO than vegans or vegetarians after ingesting L-carnitine. This finding directly supports the claim that omnivores produce less trimethylamine N-oxide (TMAO) from dietary L-carnitine than vegans, as it indicates that omnivores have a higher production of TMAO in response to L-carnitine intake compared to vegans, implying that the claim is valid."
    },
    "posthoc_doc_ids": [
      "6793674",
      "14803797",
      "22995164",
      "2052720",
      "3981244"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1278",
    "claim": "The treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The claim states that co-IR blockade in the treatment of cancer patients does not cause any adverse autoimmune events. Paper 1 discusses the use of inhibitory receptor blockade (PD-1 and CTLA-4) to enhance the cytolytic activity of CD4+ T cells against melanoma cells. The use of checkpoint inhibitors like anti-CTLA4 and PD-1 blockade is often associated with adverse autoimmune events due to increased immune activation. Paper 5 highlights the use of dual checkpoint blockade (anti-CTLA4 and anti-PD-L1) in patients and describes induced T-cell exhaustion as a form of resistance to therapy, implying that immune-related adverse events cannot be ruled out. Both papers suggest that the use of checkpoint inhibitors, which include co-IR blockade, can alter immune responses in significant ways, suggesting potential for autoimmune events, thereby contradicting the claim."
    },
    "naive_doc_ids": [
      "15128866",
      "24150328",
      "3559136",
      "3943235",
      "4468861"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim asserts that the treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events. Paper 3 provides evidence that disruption of immune checkpoints, like VISTA, which is similar in nature to co-inhibitory receptor blockades, can result in enhanced T-cell activation and a proinflammatory phenotype, indicating a predisposition to autoimmunity under susceptible conditions. Additionally, Paper 6 highlights the complexities and resistance encountered in therapies involving checkpoint inhibitors relevant to cancer treatment. Although the evidence does not directly test the specific claim, the potential for enhanced inflammatory and autoimmune-like responses seen in similar treatments suggests that adverse autoimmune events could occur in treatments involving co-IR blockade."
    },
    "overthinking_doc_ids": [
      "24150328",
      "42404093",
      "23912923",
      "3559136",
      "15128866"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The given papers do not directly address the claim that the treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events. The papers discuss various therapies and adverse effects related to cancer treatments, such as the safety of targeted therapies for metastatic colorectal cancer, CSF1R blockage effects, radiation and dual checkpoint blockade, effects of intetumumab and radiation therapy, mortality associated with bevacizumab, adverse events in multi-drug resistant tuberculosis treatment, and combination therapies for breast cancer. However, none specifically evaluate the autoimmune events related to co-inhibitory receptor (co-IR) blockade in cancer patients, which is central to the claim being investigated."
    },
    "posthoc_doc_ids": [
      "2492146",
      "3559136",
      "4468861",
      "7986878",
      "25589047"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1068",
    "claim": "ScPif1p has reduced binding ability to G-rich ssDNA compared to non-G-rich ssDNA.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers specifically discuss the binding ability of ScPif1p to G-rich ssDNA compared to non-G-rich ssDNA. The papers cover various topics related to protein-DNA interactions, bacterial signaling, motor protein transport, and ssDNA-binding proteins, but do not address ScPif1p or its specific interactions with different types of ssDNA. Therefore, the evidence does not contain relevant information about the specific claim."
    },
    "naive_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "16217855",
      "799586"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The papers provided do not contain relevant information about the binding ability of ScPif1p to G-rich ssDNA compared to non-G-rich ssDNA. The claim is specific to the binding properties of ScPif1p, and none of the evidence discusses ScPif1p or its binding properties with G-rich or non-G-rich ssDNA. The papers cover unrelated topics such as two-component signal transduction systems, kinesin-1 motor binding, ADAM13 interaction, Dda helicase activity, adenovirus protein interactions, MHC molecule interactions, NOD2 variants, and the functions of BsPif1 helicase."
    },
    "overthinking_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "17939443",
      "207972"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "None of the provided papers specifically discuss ScPif1p or its binding affinity to G-rich ssDNA compared to non-G-rich ssDNA. The papers cover various topics such as two-component signal transduction systems, kinesin-1 motor proteins, ADAM13 binding to fibronectin, single-stranded DNA binding proteins, nanoparticle interactions with proteins, mitochondrial dynamics, and adenovirus protein interactions, none of which are relevant to the claim about ScPif1p. Therefore, there is no information to evaluate or verify the claim based on the provided papers."
    },
    "posthoc_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "799586",
      "169264"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "399",
    "claim": "Exposure to fine particulate air pollution is relate to anxiety prevalence.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim by showing a significant association between higher exposure to fine particulate matter (PM2.5) and increased symptoms of anxiety among participants in the Nurses' Health Study. The results show increased odds of high anxiety symptoms with higher exposure to PM2.5 over various time frames. This aligns with the claim that exposure to fine particulate air pollution is related to anxiety prevalence. Paper 3 also touches on the biological mechanisms related to particulate air pollution, but doesn't directly correlate to anxiety. The other papers do not address the specific link between particulate air pollution and anxiety, thus they don't provide contrary evidence."
    },
    "naive_doc_ids": [
      "791050",
      "32357890",
      "42387637",
      "26199970",
      "471921"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that exposure to fine particulate air pollution is related to anxiety prevalence. The observational cohort study reported significantly increased odds of high anxiety symptoms being associated with higher exposure to PM2.5 for multiple time periods. This suggests a correlation between fine particulate pollution and anxiety levels. Other papers do not directly address the relationship between particulate pollution and anxiety but focus on other aspects of mental health or unrelated topics, so they do not influence the classification. Therefore, based solely on relevant data, Paper 1 supports the claim with a high confidence level."
    },
    "overthinking_doc_ids": [
      "791050",
      "471921",
      "643765",
      "26199970",
      "6129301"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 presents observational data indicating a significant association between higher exposure to fine particulate matter (PM2.5) and increased odds of high symptoms of anxiety among participants. The study found that more recent exposures to PM2.5 were linked to greater odds of anxiety symptoms. This directly supports the claim that exposure to fine particulate air pollution is related to anxiety prevalence. Papers 2 through 8 do not provide direct evidence related to the claim, as they focus on topics such as cardiovascular disease, obesity, headache disorders, cancer, and other unrelated health data. Therefore, the evidence from Paper 1 alone classifies this as SUPPORT for the claim."
    },
    "posthoc_doc_ids": [
      "791050",
      "471921",
      "2158500",
      "32357890",
      "44830890"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "184",
    "claim": "Bone marrow cells don't contribute to adult macrophage compartments.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 presents evidence supporting the claim that bone marrow cells, specifically in the form of circulating monocytes, do not significantly contribute to adult macrophage compartments under steady-state conditions. It describes tissue-resident macrophages as self-maintaining locally with minimal input from circulating monocytes and demonstrates that host macrophages can expand independently after depletion. Paper 8 further corroborates this by showing that major tissue-resident macrophage populations are established before birth and maintain themselves without replenishment by blood monocytes during adulthood. These findings collectively support the claim by indicating that adult macrophage compartments do not rely heavily on contributions from bone marrow-derived cells, such as circulating monocytes."
    },
    "naive_doc_ids": [
      "12827098",
      "188911",
      "10078024",
      "30468386",
      "4427392"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim states that bone marrow cells do not contribute to adult macrophage compartments. Paper 3 provides evidence supporting this claim by indicating that tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. This suggests that new macrophages in adult tissues do not primarily arise from bone marrow-derived cells. Other papers focus on dendritic cells (Paper 1), mesenchymal stromal cells and their differentiation (Paper 2), or macrophage growth under specific conditions (Paper 5), among other topics. However, Paper 3 directly addresses the claim, providing robust evidence through experimental data indicating that macrophages are maintained independently of monocytes that originate in the bone marrow."
    },
    "overthinking_doc_ids": [
      "188911",
      "10078024",
      "12827098",
      "35811036",
      "6446747"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim that bone marrow cells do not contribute to adult macrophage compartments is contradicted by evidence presented in the papers. Paper 1 discusses bone marrow as a source for dendritic cells following stimulation with GM-CSF, which implicates the origin of myeloid cells, a lineage that includes macrophages, from bone marrow. Paper 6 reports leukocyte trafficking involving CD11b+ leukocytes (monocytes/macrophages and neutrophils) from bone marrow to peripheral sites, suggesting bone marrow contributes to macrophage compartments. Additionally, paper 5 indicates a relationship between granulocyte-macrophage progenitors in bone marrow and the development of macrophage-associated cells. Although macrophages are not directly addressed in these papers, the evidence consistently supports bone marrow as a source for cells in myeloid and potentially macrophage compartments."
    },
    "posthoc_doc_ids": [
      "188911",
      "10078024",
      "25985964",
      "9412420",
      "3495456"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "226",
    "claim": "Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs. Paper 1 discusses the role of miR-205 in counteracting the interaction between prostate cancer cells and CAFs, indicating CAFs' involvement in mediating changes in cancer cells through a redox-dependent pathway. It provides evidence that CAFs induce epithelial-mesenchymal transition (EMT) in prostate cancer cells, affecting metastasis and tumor-stroma interplay, supporting the claim. Paper 3 supports the notion of CAFs driving tumor-stroma co-evolution in breast cancer through oxidative stress and nutrient sharing, further aligning with the claim that CAFs and cancer cells interact significantly. Other papers do not provide directly relevant information to this specific claim, focusing on other aspects of the tumor microenvironment or unrelated cancer types."
    },
    "naive_doc_ids": [
      "8702697",
      "10024681",
      "24349992",
      "15727984",
      "6673421"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence from Papers 1 and 2 directly supports the claim that cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs. Paper 1 describes a novel co-culture system that demonstrates the interaction between cancer cells and CAFs, where cancer cells induce oxidative stress in CAFs, promoting a lethal tumor microenvironment. This oxidative stress leads to further activation and alteration of CAFs, which in turn affects cancer cells, increasing their aggressiveness. Paper 2 provides further evidence that CAFs elicit redox-dependent responses in cancer cells, with the involvement of specific microRNAs in the tumor-stroma interplay, specifically highlighting the impact of CAFs on cancer cell behavior and vice versa. These interactions involve mutual activation and modulation, supporting the claim that CAFs and cancer cells interact in a manner that influences the formation and activation processes of CAFs."
    },
    "overthinking_doc_ids": [
      "24349992",
      "8702697",
      "16630996",
      "20183360",
      "25050969"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides evidence supporting the claim by demonstrating that cancer cells can induce oxidative stress in cancer-associated fibroblasts (CAFs), which mediates tumor-stroma co-evolution. This oxidative stress is shown to facilitate the metabolic interactions and genomic instability, suggesting a mediating role of CAFs in cancer progression and their interaction with cancer cells. Furthermore, Paper 2 presents evidence of a redox-dependent mechanism where CAFs induce epithelial-mesenchymal transition in cancer cells, further supporting their interactive role. Both papers align with the claim that CAFs interact with cancer cells to mediate their formation and activation, thus supporting the claim."
    },
    "posthoc_doc_ids": [
      "24349992",
      "8702697",
      "16630996",
      "9239963",
      "3590806"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "653",
    "claim": "Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 7 provides evidence supporting the claim that interleukin-18 (IL-18) plays a role in the pathogenesis of atherosclerosis. It reports that IL-18 is highly expressed in atherosclerotic plaques compared to normal arteries and is primarily located in plaque macrophages. Moreover, the study found higher levels of IL-18 mRNA in symptomatic, unstable plaques compared to asymptomatic, stable plaques, suggesting a role in plaque destabilization which is a critical factor in the progression of atherosclerosis. Therefore, this paper directly supports the claim that IL-18 plays an important role in atherosclerosis pathogenesis."
    },
    "naive_doc_ids": [
      "39264456",
      "22674621",
      "22889972",
      "22080671",
      "28149602"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 6 directly examines the role of interleukin-18 (IL-18) in atherosclerosis, showing that IL-18 is highly expressed in atherosclerotic plaques and correlates with plaque instability, which suggests its role in the pathogenesis of atherosclerosis. Specifically, IL-18 was found to be elevated in unstable plaques compared to stable ones, indicating its involvement in the destabilization of plaques leading to acute ischemic syndromes. This evidence aligns with the claim that IL-18 plays an important role in the pathogenesis of atherosclerosis by contributing to plaque destabilization."
    },
    "overthinking_doc_ids": [
      "1855679",
      "7373453",
      "23901235",
      "4890578",
      "970012"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 5 provides relevant information that directly supports the claim that Interleukin-18 (IL-18) plays an important role in the pathogenesis of atherosclerosis. This paper details how IL-18 participates in atherogenesis through several mechanisms and that disruption of IL-18 action reduces atherosclerosis in mice. This supports the central claim that IL-18 is involved in the pathogenesis of atherosclerosis. While other papers listed explore different cytokines and factors involved in atherosclerosis and inflammation, Paper 5 directly addresses the role of IL-18, thereby supporting the scientific claim."
    },
    "posthoc_doc_ids": [
      "1855679",
      "7373453",
      "23901235",
      "6853699",
      "24384587"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1030",
    "claim": "Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that reducing H3K4me3 methylation\u2014specifically through the inhibition of MLL1, a methyltransferase that catalyzes the methylation of H3K4\u2014efficiently reprograms mouse epiblast stem cells (EpiSCs) to naive pluripotency. The experimental results show that more than 50% of treated EpiSCs exhibit features of naive embryonic stem cells (ESCs) within three days, indicating a highly efficient process. This reversion is supported by observations of reactivation of the silenced X chromosome and contributions to germline-competent chimeras. The paper provides a clear connection between blocking H3K4 methylation and reprogramming to naive pluripotency. The other papers do not specifically address this mechanism or epigenetic modulation concerning H3K4me3 methylation, so they do not provide additional support or contradiction to the claim."
    },
    "naive_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "9675944",
      "19510470"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides explicit evidence in support of the claim. It demonstrates that blocking histone H3K4 methyltransferase MLL1 activity with the inhibitor MM-401 reprograms mouse epiblast stem cells (EpiSCs) to naive pluripotency. The reprogramming is described as highly efficient, with more than 50% of treated EpiSCs exhibiting features of naive embryonic stem cells (ESCs) within 3 days. This aligns directly with the claim that reducing H3K4me3 methylation induces EpiSCs to naive pluripotency efficiently. The findings include key characteristics of naive pluripotency, such as the reactivation of the silenced X chromosome and the contribution to embryos following blastocyst injection."
    },
    "overthinking_doc_ids": [
      "6441369",
      "4462419",
      "13955536",
      "6054657",
      "3435889"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim, showing that inhibition of H3K4 methyltransferase MLL1 in mouse epiblast stem cells leads to reprogramming to naive pluripotency. The study demonstrates that blocking MLL1 activity with a specific inhibitor results in more than 50% of treated cells adopting naive embryonic stem cell features within 3 days. This supports the notion that reducing H3K4 methylation induces naive pluripotency efficiently in mouse epiblast stem cells. The other papers do not specifically address H3K4 methylation or its role in inducing naive pluripotency in mouse epiblast stem cells, so they do not provide additional relevant information for this specific claim."
    },
    "posthoc_doc_ids": [
      "6441369",
      "4462419",
      "5633876",
      "23418635",
      "12100854"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "747",
    "claim": "MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 7 provides specific information regarding MafA ubiquitination and its effects. It describes that GSK-3-mediated phosphorylation induces MafA ubiquitination and degradation. However, paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF. The paper further demonstrates that P/CAF protects MafA from ubiquitination and degradation, which contradicts the claim that ubiquitination decreases the recruitment of the coactivator P/CAF by MafA. Hence, the evidence provided in this paper refutes the claim."
    },
    "naive_doc_ids": [
      "3559136",
      "21307488",
      "36547290",
      "7736860",
      "23513818"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain any information specifically relevant to the claim that MafA ubiquitination decreases the recruitment of the coactivator P/CAF by MafA. The papers discuss a variety of topics including E2F-dependent histone acetylation, T cell receptor signaling, adipose tissue biology, tumor necrosis factor interactions, T cell selection, KRAS signaling, electro-acupuncture therapy, fluid therapies, AGEs formation, and splicing enhancers, but none address MafA, its ubiquitination, or its interaction with P/CAF. Therefore, they do not provide any evidence supporting or contradicting the claim."
    },
    "overthinking_doc_ids": [
      "502591",
      "2714623",
      "4854076",
      "207972",
      "4270992"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that MafA ubiquitination decreases the recruitment of coactivator P/CAF by MafA. However, Paper 1 provides contradictory evidence showing that GSK-3-mediated phosphorylation of MafA leads to its ubiquitination and degradation but paradoxically increases MafA's transcriptional activity by enhancing the recruitment of the coactivator P/CAF. Additionally, it is suggested that P/CAF protects MafA from ubiquitination and degradation. Thus, the relationship between MafA ubiquitination and P/CAF recruitment, as presented in Paper 1, contradicts the original claim."
    },
    "posthoc_doc_ids": [
      "11291348",
      "14198646",
      "25817686",
      "9315213",
      "33068577"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1345",
    "claim": "Up-regulation of the p53 pathway and related molecular events speeds cancer progression.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The claim suggests that up-regulation of the p53 pathway accelerates cancer progression. However, none of the provided papers discuss the p53 pathway directly, nor do they support the idea that its up-regulation speeds cancer progression. The p53 pathway is typically associated with tumor suppression and cell cycle regulation, opposing oncogenic processes. The available evidence discusses various molecular pathways and factors contributing to cancer progression, such as \u03b21 integrin, SP-B, STAT3, BCL9, and others, but does not implicate the p53 pathway in a manner that would support the claim."
    },
    "naive_doc_ids": [
      "4820792",
      "23599024",
      "33638477",
      "19047331",
      "22123421"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not directly address the claim that up-regulation of the p53 pathway and related molecular events speeds cancer progression. Paper 1 focuses on \u03b21 integrin and drug resistance in breast cancer; Paper 2 discusses WNT signaling and EGFR transactivation in breast cancer; Paper 3 examines Orai1/CRACM1 in lung cancer; Paper 4 studies YAP in pancreatic cancer progression; Paper 5 investigates ERK inhibition in KRAS-mutant pancreatic cancer; Paper 6 explores circadian clock function in cancer growth; Paper 7 analyzes HAND2 methylation in endometrial cancer; Paper 8 covers oncologist roles in cancer prevention; Paper 9 assesses effects of hypnotics on sleep apnea; Paper 10 evaluates KRAS mutations in lung cancer. None of these papers focus on the p53 pathway's role in cancer progression."
    },
    "overthinking_doc_ids": [
      "4820792",
      "17648235",
      "24349430",
      "36310858",
      "4920376"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided evidence from the papers does not specifically address the claim that up-regulation of the p53 pathway and related molecular events speed cancer progression. The papers focus on various other molecular pathways and mechanisms in cancer, such as the role of \u03b21 integrin in drug resistance (Paper 1), WNT signaling in breast cancer (Paper 2), SP-B in lung cancer (Paper 3), molecularly targeted therapy efficacy (Paper 4), Rb-p16 pathway in lung cancer (Paper 5), miR-196 in oral cancer (Paper 6), PI3K/Akt pathway in thyroid cancer (Paper 7), and family involvement in cancer care (Paper 8). None directly investigate the p53 pathway or provide data on how its up-regulation may impact cancer progression."
    },
    "posthoc_doc_ids": [
      "4820792",
      "17648235",
      "23599024",
      "13256155",
      "46617075"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "619",
    "claim": "Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific evidence supporting or contradicting the claim about the relationship between increased vessel density, reduction in fibrosis, and chemotherapy efficacy. Paper 1 discusses the potential prognostic role of microvessel density (MVD) in early breast cancer patients undergoing anthracycline chemotherapy, suggesting that higher MVD is a favorable prognostic factor, but it does not link this to treatment efficacy in the context of fibrosis. Other papers discuss mechanisms of chemotherapy resistance or profiles in different contexts (genetic mutations in ALL, DUSP4 in breast cancer, immune response activation, etc.), but none focus on the interplay between vessel density, fibrosis, and chemotherapy efficacy. Thus, the claim specifically about vessel density, fibrosis, and therapy efficacy is not directly addressed."
    },
    "naive_doc_ids": [
      "1171121",
      "6421792",
      "7821634",
      "5500086",
      "1805641"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The evidence provided in Papers 1 and 3 contradicts the claim that increased vessel density reduces the efficacy of chemotherapy treatments. Paper 1 specifically mentions that higher microvessel density (MVD) is associated with longer disease-free survival in breast cancer patients after anthracycline-based chemotherapy, suggesting that increased vessel density is a favorable prognostic factor, contrary to the claim. Paper 3, on the other hand, indicates that increasing vascular density enhances drug delivery and stabilizes the disease in a mouse model of pancreatic cancer, again opposing the claim that higher vessel density decreases chemotherapy efficacy. The other papers do not provide relevant information about the specific effect of microvessel density on chemotherapy efficacy or the interplay with fibrosis, hence they do not contradict the claim directly, but the evidence from these two papers is sufficient to classify the claim as contradicted."
    },
    "overthinking_doc_ids": [
      "1171121",
      "5500086",
      "20888849",
      "667451",
      "16098747"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information about the specific claim regarding increased vessel density, reduction in fibrosis, and the efficacy of chemotherapy treatments. Paper 1 does discuss microvessel density (MVD) in the context of breast cancer but concludes that higher MVD is a favorable prognostic factor, which does not directly relate to a decrease in chemotherapy efficacy. The other papers focus on different topics, such as bone density, malaria treatment, cholesterol levels, breast cancer risk factors, viability of drug treatment programs, Sloan-Kettering virus, and cancer survivorship research, none of which address the specific interplay of vessel density, fibrosis, and chemotherapy effectiveness."
    },
    "posthoc_doc_ids": [
      "1171121",
      "1711571",
      "1805641",
      "3868322",
      "38551172"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "345",
    "claim": "Differentiated E2f-1, -2, -3 TKO cells in the intestine do not exhibit apoptosis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided evidence from the papers does not directly discuss the status of apoptosis specifically in differentiated E2f-1, -2, -3 TKO cells in the intestine. None of the papers mention these specific cells or experimental conditions that would provide direct insights necessary to support or contradict the claim. Instead, the papers focus on various topics such as the regulation of apoptosis in different cell types and systems, the effects of different genes on apoptosis, and stem cell biology in unrelated contexts."
    },
    "naive_doc_ids": [
      "5254463",
      "1905095",
      "3765739",
      "16728949",
      "28937856"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain specific evidence regarding the occurrence or absence of apoptosis in differentiated E2f-1, -2, -3 TKO cells in the intestine. The papers discuss various related topics such as bcl-2 expression in colonic cells, the role of p53 in apoptosis regulation, and related cellular mechanisms in colorectal cancer and other contexts, but none of them specifically mention or provide evidence about apoptosis in E2f-1, -2, -3 triple knockout (TKO) intestinal cells."
    },
    "overthinking_doc_ids": [
      "30580263",
      "5254463",
      "18956141",
      "7869794",
      "10015292"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers explicitly address the apoptosis behavior of differentiated E2f-1, -2, -3 TKO cells in the intestine. The papers cover a range of topics including the regulation of apoptosis through Wip1 phosphatase and p53, effects of diabetes on cells, neuroprotective effects via Nrf2/ARE pathway, p53's role in hematopoietic stem cells, effects of EBNA1 in cells, expression of bcl-2 related to apoptosis in intestinal epithelia, immune responses in celiac disease, the role of gut microbiota on metabolic inflammation, and mitochondrial pathways controlling tissue damage. However, none directly discuss E2f-1, -2, -3 TKO cells or their apoptotic activity in the intestine, which makes it impossible to support or contradict the claim based on the given evidence."
    },
    "posthoc_doc_ids": [
      "5254463",
      "3435889",
      "4795303",
      "10015292",
      "3765739"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1375",
    "claim": "Weighed food records (WFR) result in poor completion since they're costly to run and impose high participant burden.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The claim states that weighed food records (WFR) result in poor completion due to high costs and participant burden. However, the evidence from Paper 1 shows that although some participants did not complete the protocol, the completion rate was 98 out of 150, which does not necessarily indicate poor completion. The paper primarily discusses the validation of dietary assessment methods, not the cost or burden of WFR. Paper 3 finds a bias in reporting habitual energy intake, but it does not specifically address completion rates or cost. The other papers (2, 4, and 5) are unrelated to WFR or dietary assessment methods and focus on different health topics entirely. Therefore, the evidence provided does not support the claim that WFR leads to poor completion due to cost and burden."
    },
    "naive_doc_ids": [
      "21623140",
      "2048139",
      "21993510",
      "1287809",
      "16322674"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides some evidence that weighed food records (WFR), specifically the 4-day weighed dietary record (PETRA), are used in dietary assessments. While the paper focuses on validation rather than completion rates, the requirement of conducting these records across different seasons suggests a potentially high participant burden, which can lead to poor completion rates. Additionally, Paper 3 mentions the serious bias in reporting habitual energy intake using weighed dietary records, which highlights challenges in accurate completion. Though Paper 3 does not directly address completion rates and costs, the reporting issues might imply participant difficulties and burdens inherent to WFR. Together, these papers indirectly support the claim by suggesting WFR can be challenging for participants, potentially affecting completion rates and implying higher costs due to the complexity of the method."
    },
    "overthinking_doc_ids": [
      "21623140",
      "2048139",
      "21993510",
      "2295434",
      "13770184"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that aligns with the claim by providing details of a study where 150 volunteers were recruited, but only 98 completed the protocol involving a weighed dietary record, suggesting high participant burden and poor completion rates. Additionally, Paper 2 highlights a significant bias in reporting habitual energy intake using weighed dietary records, indicating challenges in the accurate completion of these records. While neither paper explicitly mentions cost, the combination of issues raised in Paper 1 about the completion rate and Paper 2's mechanical difficulties in accurate reporting aligns with the notion that weighed food records are burdensome and challenging to complete effectively."
    },
    "posthoc_doc_ids": [
      "21623140",
      "21993510",
      "2211868",
      "11748341",
      "2048139"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "361",
    "claim": "During the primary early antibody response activated B cells migrate toward the inner-and outer follicular areas where oxysterol accumulation is generated by stromal cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers provided do not contain relevant information regarding the specific claim about activated B cells migrating toward follicular areas with oxysterol accumulation generated by stromal cells during the early antibody response. Paper 1 discusses B-cell migration and the roles of chemokines and receptors like CXCL13, EBI2, and S1P but does not mention oxysterol accumulation or its generation by stromal cells. Papers 2 through 8 are unrelated to B-cell migration or follicular areas in the context of immune responses, focusing instead on aspects of bacterial infections, cancer signaling, immune cell migration in diseases, and stem cell research."
    },
    "naive_doc_ids": [
      "38587347",
      "11721286",
      "7736860",
      "7875158",
      "696006"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss the specific process of activated B cells migrating to the inner-and outer follicular areas where oxysterol accumulation is generated by stromal cells during the primary antibody response. The papers cover various unrelated topics, such as immune responses in experimental autoimmune encephalomyelitis, the role of stromal cells in different contexts, or hematopoietic niches, but not the claim specifics. Therefore, they do not provide relevant information to verify the claim."
    },
    "overthinking_doc_ids": [
      "52095986",
      "38587347",
      "991139",
      "10078024",
      "14768471"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that supports the claim by discussing the role of various molecules, including the orphan receptor EBI2 (GPR183), which guides activated B cells to inner and outer follicular niches. This indicates the presence of a migration pathway for activated B cells towards these follicular areas, supporting the claim of B-cell migration during the early antibody response. However, the specific mention of oxysterol accumulation by stromal cells and its role in guiding these migrations is not explicitly covered in this paper or the others. While Paper 1 indirectly supports the claim through the discussion of B-cell migration to follicular niches influenced by EBI2, further explicit evidence about oxysterol involvement would strengthen the justification."
    },
    "posthoc_doc_ids": [
      "38587347",
      "11721286",
      "13469921",
      "7736860",
      "14768471"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "994",
    "claim": "Pyridostatin encourages proliferation of homologous recombination - defective cells.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain specific information directly addressing the claim that pyridostatin encourages the proliferation of homologous recombination (HR)-defective cells. The papers discuss topics related to HR, DNA repair, and other cellular processes, but they do not mention pyridostatin or its effects on HR-defective cells. Thus, there is no evidence to support or contradict the specific claim from the given papers."
    },
    "naive_doc_ids": [
      "13791206",
      "4444861",
      "39225849",
      "515489",
      "1550937"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The claim about Pyridostatin encouraging proliferation of homologous recombination-defective cells is not directly addressed or supported by the provided papers. While the papers cover a wide range of topics related to DNA repair mechanisms, tumorigenesis, cell proliferation, and specific protein functions in various contexts, none of them directly discuss the effects of Pyridostatin or its influence on homologous recombination-defective cells. Therefore, there is no relevant information in these papers to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "13791206",
      "6710699",
      "1550937",
      "33370",
      "1192458"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not address the specific claim regarding Pyridostatin and its effect on the proliferation of homologous recombination-defective cells. The papers focus on various unrelated topics, including DNA repair mechanisms, oncogenic pathways, specific proteins and RNAs related to cancer cell growth and proliferation, and other biochemical and cellular processes. None of the papers directly provide evidence or data about the activity of Pyridostatin in the context of proliferation of homologous recombination-defective cells, such as those with mutations in the BRCA1 gene. Therefore, the literature provided does not inform the scientific claim in question."
    },
    "posthoc_doc_ids": [
      "13791206",
      "6710699",
      "12086599",
      "23848916",
      "1550937"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "978",
    "claim": "Pro-inflammatory cytokines are up repressed during tumor development.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The claim states that pro-inflammatory cytokines are repressed during tumor development, but the evidence presented in the papers suggests otherwise. Paper 6 highlights the role of the pro-inflammatory cytokine IL-1\u03b2 in promoting COX-2 expression in breast cancer cells, suggesting an inflammatory component actively involved in tumor progression. Paper 1 discusses TNF-alpha's role in promoting inflammation via upregulation of other molecules, which counters the claim of repression. Similarly, Paper 2 identifies pro-inflammatory Th17 cytokines like IL-17, which are implicated in inflammatory diseases and could have roles in tumor environments. The evidence supports upregulation of pro-inflammatory cytokines, not repression, in the context of tumor development."
    },
    "naive_doc_ids": [
      "22889972",
      "11233339",
      "21258863",
      "2665675",
      "7736860"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The claim suggests that pro-inflammatory cytokines are up repressed during tumor development. However, none of the provided papers directly support this claim. Key papers, such as Paper 1, highlight the role of pro-inflammatory cytokines like IL-17, IL-22, and IL-23 in inflammatory diseases, but do not relate to tumor development specifically. In fact, Th17-related cytokines are often associated with promoting inflammation in various conditions. Other papers focus on genetics, cell cycle regulation, and tumor suppressor roles (Papers 4, 5, 6) or discuss specific diseases like obesity, lung function, or quality of life in cancer survivors (Papers 7, 8, 9) without addressing the repression of pro-inflammatory cytokines during tumor development. These observations point to a lack of supporting evidence for repression of pro-inflammatory cytokines in the context of tumorigenesis. In contrast, the existing literature often associates inflammation, which involves pro-inflammatory cytokines, with promoting tumor progression, suggesting the claim may not be accurate."
    },
    "overthinking_doc_ids": [
      "11233339",
      "1265945",
      "8774475",
      "7898952",
      "8133180"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The claim suggests that pro-inflammatory cytokines are repressed during tumor development, implying a downregulation of such cytokines. However, the evidence presented in the papers indicates that pro-inflammatory cytokines play a role in promoting tumor growth and metastasis, thus contradicting the claim. Paper 4 mentions that there was no intervention effect on inflammatory cytokines, which is neutral. Paper 1 discusses the role of TNF-alpha in atherosclerosis development, indicating pro-inflammatory roles, while Paper 7 talks about TGF-beta promoting tumor metastasis, indirectly linked to inflammation. Furthermore, Paper 8 shows cyclooxygenase activity suppresses immunity and fuels tumor-promoting inflammation. These findings suggest that instead of being repressed, pro-inflammatory cytokines may actually facilitate tumor progression in some contexts, opposing the claim."
    },
    "posthoc_doc_ids": [
      "22889972",
      "11233339",
      "24998637",
      "24396137",
      "6407356"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "78",
    "claim": "Active caspase-11 participate in regulating phagosome-lysosome fusion.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence supporting the claim that active caspase-11 is involved in regulating phagosome-lysosome fusion. It states that caspase-11 promotes the fusion of phagosomes, specifically those containing pathogenic bacteria, with lysosomes by modulating actin polymerization. The paper delineates a role for caspase-11 in facilitating phagosome-lysosome fusion, thus aligning with and confirming the scientific claim. The other papers do not discuss active caspase-11's role in phagosome-lysosome fusion, rendering them irrelevant to the specific claim."
    },
    "naive_doc_ids": [
      "5099266",
      "38043606",
      "4345315",
      "6565037",
      "24783597"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly states that caspase-11 promotes the fusion of phagosomes with lysosomes by modulating actin polymerization. It discusses how active caspase-11 facilitates the fusion process of phagosomes harboring pathogenic bacteria with lysosomes, supporting the claim that active caspase-11 participates in regulating phagosome-lysosome fusion. The other papers do not directly address the role of caspase-11 in phagosome-lysosome fusion, thus they don't contradict the claim. The evidence from Paper 1 is strong and aligns well with the claim, making it the basis for the supportive classification."
    },
    "overthinking_doc_ids": [
      "5099266",
      "38043606",
      "4345315",
      "25251625",
      "1044552"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly provides evidence to support the claim that active caspase-11 participates in regulating phagosome-lysosome fusion. It describes an experimental framework where caspase-11 promotes the fusion of phagosomes containing pathogenic bacteria with lysosomes. The paper highlights how caspase-11 modulates actin polymerization, which is crucial in this fusion process, specifically noting its effect on infections by L. pneumophila. Although the paper also mentions that caspase-11 is dispensable for non-pathogenic bacteria, this does not contradict the claim but rather specifies the conditions under which caspase-11's regulatory role is significant. The other papers included in the evidence summary do not discuss caspase-11 or phagosome-lysosome fusion, hence they do not affect the classification toward support or contradiction of the claim."
    },
    "posthoc_doc_ids": [
      "5099266",
      "6565037",
      "24783597",
      "38043606",
      "4939312"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "437",
    "claim": "Functional consequences of genomic alterations due to Myelodysplastic syndrome (MDS) are poorly understood due to the lack of an animal model.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim suggests that the functional consequences of genomic alterations due to Myelodysplastic Syndrome (MDS) are poorly understood because of the lack of an animal model. However, Paper 3 provides compelling evidence that contradicts this claim by describing a two-step mouse model utilized to investigate MDS progression. This model involves the overexpression of human mutant NRAS and BCL2 genes, facilitating the study of genomic instability, reactive oxygen species, and error-prone DNA repair, which are relevant to MDS. Therefore, an animal model does exist, offering insights into the molecular pathology of MDS, thereby refuting the claim that the lack of an animal model limits understanding."
    },
    "naive_doc_ids": [
      "13293033",
      "4951831",
      "5765455",
      "31070360",
      "37328025"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers provided do not contain relevant information or directly address the specific claim about the functional consequences of genomic alterations in Myelodysplastic syndrome (MDS) being poorly understood due to the lack of an animal model. The evidence from the papers discusses various topics including psychobiological mechanisms, structural plasticity in depression and systemic disorders, cancer chemoprevention, glioblastoma subclasses, antisense transcript splicing in plants, genomic imprinting, DS modeling with iPSCs, marmoset models in research, and retinoid receptor interactions. None of these papers specifically mention MDS or the development or lack thereof of an animal model for MDS. Therefore, the provided evidence does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "4951831",
      "6123521",
      "6407356",
      "6363093",
      "14610165"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly contradicts the claim as it describes a two-step mouse model for studying myeloid leukemic disease progression related to Myelodysplastic syndrome (MDS). This indicates that animal models do exist to study genomic alterations in MDS. Additionally, Paper 3 discusses molecular mechanisms in MDS, such as NLRP3 inflammasome activation, using hematopoietic stem and progenitor cells, which implies experimental frameworks that may include animal models. These findings suggest that there are existing models to understand the functional consequences of genomic alterations due to MDS, contrary to the claim."
    },
    "posthoc_doc_ids": [
      "5765455",
      "13293033",
      "6000423",
      "14610165",
      "16732790"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "141",
    "claim": "Auditory entrainment is strengthened when people see congruent visual and auditory information.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct support for the claim that auditory entrainment is strengthened when people see congruent visual and auditory information. It demonstrates that the cortical representation of the speech envelope is enhanced with congruent audiovisual speech, and neural entrainment is inhibited when the streams are incongruent. Paper 2 further supports the claim by showing that delta-theta phase modulation across sensory areas plays a role in tracking audiovisual streams, reflecting cross-sensory interaction in real time. Papers 3, 4, and 5 do not provide relevant information about auditory-visual entrainment specifically. Therefore, the overall evidence supports the claim, as the papers relevant to the claim align well with it."
    },
    "naive_doc_ids": [
      "14437255",
      "6955746",
      "313394",
      "5323845",
      "6431384"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim states that auditory entrainment is strengthened when people see congruent visual and auditory information. Paper 1 provides direct evidence supporting this claim. It demonstrates that congruent audiovisual speech enhances cortical entrainment to auditory speech, particularly at a temporal scale corresponding to syllabic rate, and shows inhibited entrainment when auditory and visual streams are incongruent. This enhancement of cortical representation due to congruent audiovisual stimuli aligns with the claim. Paper 2 further supports the notion that integration of auditory and visual stimulus dynamics involves low-frequency neuronal phase modulation, reflecting cross-sensory interaction, which may contribute to strengthened auditory processing when visual information is congruent. Papers 3 and 4 are unrelated to the specific claim about congruent audiovisual information, focusing instead on sound localization and neural coding in auditory processing."
    },
    "overthinking_doc_ids": [
      "14437255",
      "6955746",
      "313394",
      "6431384"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The evidence from Paper 1 and Paper 2 provides clear support for the claim that auditory entrainment is strengthened when people see congruent visual and auditory information. Paper 1 explicitly discusses that congruent audiovisual speech enhances cortical entrainment to auditory speech, demonstrating how congruent visual information aids auditory processing even in noise-free conditions. The paper shows that the cortical representation of the speech envelope is enhanced by congruent audiovisual speech. Paper 2 supports this by showing that the auditory cortex uses low-frequency neuronal phase modulation to track both auditory and visual stimuli, indicating a connection between the modalities that facilitates integration. Papers 3, 4, and 5 do not directly address the topic of audiovisual entrainment but focus on other sensory processing aspects, such as sound localization in the blind and auditory potentials."
    },
    "posthoc_doc_ids": [
      "14437255",
      "6955746",
      "313394",
      "36860856",
      "31208367"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "705",
    "claim": "Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The papers provided do not contain any specific evidence directly addressing the effect of long chain polyunsaturated fatty acids (LCPUFA) supplementation on wheezing or asthma in children at 3 and 6 years of age. While Paper 1 discusses potential protective effects of fish oil supplementation during pregnancy and its association with reduced sensitization to common food allergens and atopic conditions in early life, it does not specifically address long-term effects related to wheezing or asthma at ages 3 and 6. Paper 3 focuses on the effects of omega-3 supplementation on allergies in the first year of life and does not extend its findings to respiratory conditions at later ages. The other papers either discuss unrelated metabolic and inflammatory processes or do not focus on the specific health outcomes in question. Therefore, there is insufficient information to classify the claim as either supported or contradicted by the evidence available in the provided papers."
    },
    "naive_doc_ids": [
      "24269361",
      "20672596",
      "22442133",
      "41915616",
      "21636085"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information regarding the claim that long-chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years. While some papers discuss the effects of n-3 polyunsaturated fatty acids on allergic outcomes in early life stages, they do not directly address wheezing or asthma outcomes at the specified ages. Therefore, there is no direct evidence to either support or contradict the claim within these papers."
    },
    "overthinking_doc_ids": [
      "24269361",
      "3770750",
      "15948830",
      "18025240",
      "21790313"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided papers do not contain specific experimental data, results, or findings that directly address the claim about the effects of long-chain polyunsaturated fatty acids supplementation on wheezing or asthma at 3 and 6 years. Paper 1 and Paper 2 discuss long-chain omega-3 fatty acids in the context of atopy, allergic diseases, and early childhood allergic outcomes, but do not provide conclusive evidence about effects on wheezing or asthma specifically at ages 3 and 6 years. The remaining papers focus on different aspects unrelated to the claim, such as macrophage metabolism, the impact of omega-3 fatty acids on inflammation, malaria transmission, cardiovascular disease in diabetes, and reproductive health outcomes in relation to bisphenol A exposure. Therefore, none of these papers verify or refute the specific scientific claim in question."
    },
    "posthoc_doc_ids": [
      "24269361",
      "22442133",
      "20672596",
      "3866315",
      "1805641"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1379",
    "claim": "Women with a higher birth weight are more likely to develop breast cancer later in life.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The claim that women with higher birth weight are more likely to develop breast cancer later in life is predominantly supported by Papers 1 and 5. Paper 1 revisits data from 32 studies and finds a positive association between higher birth weight and breast cancer risk when birth weight is obtained from birth records or early parental recall. The pooled relative risk per one standard deviation increment in birth weight is 1.06, and women weighing more than or equal to 4.000 kg at birth have a relative risk of 1.12 compared to those weighing 3.000-3.499 kg. Additionally, Paper 5 strengthens this association, finding a relative risk of 1.15 with higher birth weight. These consistent findings across multiple studies suggest a meaningful link between birth weight and breast cancer risk, confirming the claim."
    },
    "naive_doc_ids": [
      "16322674",
      "13765757",
      "13831842",
      "3222187",
      "23557241"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides relevant evidence supporting the claim. It reports that birth weight is positively associated with breast cancer risk based on birth records, with a pooled relative risk per one standard deviation increment in birth weight of 1.06 (95% CI 1.02-1.09). It also reports an increased risk for women who weighed \u22654.000 kg at birth (RR 1.12; 95% CI 1.00-1.25) compared to those who weighed 3.000-3.499 kg. This suggests that women with higher birth weights have a somewhat higher likelihood of developing breast cancer later in life. The other papers do not directly address the relationship between birth weight and breast cancer risk, focusing instead on other risk factors and associations. Therefore, based on the available data, Paper 1 aligns with the scientific claim, providing support for it."
    },
    "overthinking_doc_ids": [
      "16322674",
      "13765757",
      "13831842",
      "16701509",
      "313403"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that women with a higher birth weight are more likely to develop breast cancer later in life. Paper 2 provides strong support for this claim as it re-analyzed data from 32 studies, demonstrating a positive association between birth weight and breast cancer risk, particularly from birth record data. Specifically, the relative risk for women who weighed \u2265 4.000 kg at birth was 1.12, compared to those weighing between 3.000-3.499 kg. Paper 4 also supports the claim by showing an increased mammographic density, a strong predictor of breast cancer risk, in women with higher birth weights. Associations with increased mammographic density were strongest for women with birth weights >4000g. The consistency of these findings across multiple datasets and types of analysis (birth records and mammographic density) provides a high level of confidence that the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "9171913",
      "16322674",
      "13765757",
      "5487448",
      "2015126"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "672",
    "claim": "L3MBTL2 binds to H2AK119Ub marked chromatin to form a PRC1 complex.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific information confirming or refuting the claim that L3MBTL2 binds to H2AK119Ub marked chromatin to form a PRC1 complex. Paper 1 discusses the role of L3MBTL2 in transcriptional repression and its association with a PRC1-related complex, but it does not specifically mention the interaction with H2AK119Ub. The other papers are unrelated to the interactions involving L3MBTL2 or H2AK119Ub and focus on different proteins, complexes, or biological processes. Therefore, none of the papers provide direct evidence about the claim."
    },
    "naive_doc_ids": [
      "15635366",
      "25479072",
      "1744752",
      "502591",
      "24311787"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 1 provides relevant information supporting the claim that L3mbtl2 binds to H2AK119Ub marked chromatin to form a PRC1 complex. It discusses how L3mbtl2 assembles an atypical PRC1 complex involved in transcriptional repression, associating with epigenetic marks such as H2AK119 ubiquitination. While it notes that H2AK119Ub is not dependent on L3mbtl2 for repression, the mention of its association suggests a functional interaction that aligns with the claim. No other papers provide contradictory information; other papers focus on different chromatin interactions or complexes unrelated to the specific claim. However, the specific mechanism by which L3mbtl2 and H2AK119Ub interaction occurs was not detailed, hence a relatively moderate confidence level."
    },
    "overthinking_doc_ids": [
      "15635366",
      "7729656",
      "7915836",
      "12669325",
      "140874"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 provides evidence that L3MBTL2 forms an atypical PRC1-family complex and recruits this complex for transcriptional repression and chromatin compaction, involving ubiquitination of H2AK119 (H2AK119Ub) as an associated mark. Although the paper states that H2AK119 ubiquitination is not dependent on L3MBTL2, it mentions that L3MBTL2 is involved in assembling a PRC1-related complex and is present at sites of H2AK119Ub. While the paper does not provide direct evidence of L3MBTL2 binding specifically to H2AK119Ub-marked chromatin, it strongly implies its involvement with PRC1 complexes and their associated histone modifications, aligning with the claim's assertion. However, this specific binding aspect requires further explicit evidence for higher confidence."
    },
    "posthoc_doc_ids": [
      "15635366",
      "25479072",
      "1744752",
      "140874",
      "17240457"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1212",
    "claim": "The deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "The evidence from these papers collectively supports the claim that deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions. Paper 1 discusses the role of chronic infection with Helicobacter pylori leading to severe gastritis and increased iNOS expression, indicating a prolonged inflammatory response linked to deleterious effects like gastric mutations. Paper 4 identifies a FOXO3-regulated pathway influencing monocyte inflammation, which affects disease outcomes, implying that prolonged inflammation in monocytes can lead to varying disease severity. These findings suggest that in chronic diseases, deregulated immune responses, particularly involving monocytes, contribute to tissue damage and adverse health outcomes. However, none of the papers directly study monocytes specifically in chronic infectious conditions, but the inferred evidence from inflammatory pathways and chronic infection models indirectly supports the claim."
    },
    "naive_doc_ids": [
      "24705390",
      "4767806",
      "26107000",
      "13905670",
      "12631697"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions is supported by evidence presented in the papers. Paper 1 illustrates how monocytes' production of interleukin-10 impairs CD4+ T cell activation during chronic HIV infection, which aligns with the claim that improper monocyte activation has harmful effects in chronic infection, specifically through immune system impairment. Although the other papers do not explicitly focus on monocytes, Paper 9 mentions another chronic condition, CGD, where a dysfunction in immune cells leads to chronic inflammation, reinforcing the notion that improper immune regulation can cause deleterious effects in chronic diseases. Therefore, these papers together provide evidence supporting the claim that deregulated monocyte activation contributes negatively in chronic infections."
    },
    "overthinking_doc_ids": [
      "10648422",
      "20261352",
      "21700295",
      "5484763",
      "26025820"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim is that deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions. Several papers provide evidence supporting this claim. Paper 4 discusses how PD-1 expression on monocytes, when upregulated, leads to IL-10 production that impairs CD4+ T cell activation during chronic HIV infection. This illustrates how chronic activation of monocytes contributes negatively to the immune response in the context of HIV. Similarly, Paper 8 describes how CCR2 antagonism affects monocyte dynamics, with the results suggesting that the regulation of monocyte activity is crucial in inflammatory diseases like experimental autoimmune encephalomyelitis, demonstrating that improper regulation could exacerbate disease. Together, these findings align with the claim that deregulated, prolonged activation can have harmful effects in chronic conditions."
    },
    "posthoc_doc_ids": [
      "24705390",
      "4767806",
      "26107000",
      "10648422",
      "20261352"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1386",
    "claim": "cSMAC formation represses weak ligand signalling.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The scientific claim that cSMAC formation represses weak ligand signaling is supported by the evidence presented primarily in Paper 1 and Paper 2. Paper 1 indicates that TCR signaling is sustained by microclusters and terminated in the cSMAC, suggesting that cSMAC formation leads to signal termination rather than perpetuation. This aligns with the idea that cSMAC formation could repress signaling, particularly for weaker ligands. Paper 2 provides further support, as it describes how enhancing cSMAC formation reduced the stimulatory capacity of a peptide with characteristics of a weak agonist. This suggests that the establishment of a cSMAC may indeed repress the signaling of weak ligands, aligning with the claim. Other papers do not provide directly relevant information on this specific mechanism."
    },
    "naive_doc_ids": [
      "9283422",
      "306006",
      "2714623",
      "10607877",
      "6588614"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim states that cSMAC formation represses weak ligand signalling. Evidence supporting this can be found in Paper 2 and Paper 5. Paper 2 discusses how a peptide with many characteristics of a weak agonist stimulates T cells more effectively than a wild-type agonist, suggesting that the inability to form cSMACs can lead to increased proliferation. Furthermore, enhancing cSMAC formation reduced the stimulatory capacity of the weak peptide, indicating a repressive role of cSMAC in weak ligand signaling. Paper 5 emphasizes that TCR signaling occurs in microclusters and is terminated in the cSMAC, implying that cSMAC might serve as a terminating or inhibitory site for signals initiated by weak interactions. Thus, the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "8458567",
      "306006",
      "2714623",
      "17997584",
      "9283422"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The evidence provided in Paper 2 directly supports the claim that cSMAC formation represses weak ligand signaling. This paper discusses how a peptide, identified as a weak agonist, stimulates T cell proliferation more effectively than a wild-type agonist ligand and suggests that the inability to form the central supramolecular activation cluster (cSMAC) is a factor in this increased proliferation. Further experiments demonstrated that enhancing cSMAC formation reduced the stimulatory capacity of the weak peptide, hence supporting the idea that cSMAC formation represses signaling in the context of weak ligands. Other papers do not provide relevant information to refute or support this claim."
    },
    "posthoc_doc_ids": [
      "8458567",
      "306006",
      "2714623",
      "2825380",
      "994800"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1359",
    "claim": "Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided evidence from Paper 2 directly contradicts the claim. This paper reports that combination therapy with varenicline and bupropion is more effective than varenicline monotherapy in achieving prolonged smoking abstinence at 12 weeks, which is the primary period of treatment mentioned in the claim. The evidence shows that the abstinence rate for the combination group was 53.0% compared to 43.2% for the varenicline monotherapy group with a significant p-value (P = .03). Paper 6 supports the statement that combination NRT is equally effective as quitting aids when compared to individual modalities. No paper provides supporting evidence for the claim that varenicline monotherapy is more effective than combination therapies, making the claim unsupported by the evidence provided."
    },
    "naive_doc_ids": [
      "34369306",
      "11614737",
      "39532074",
      "24865781",
      "3690068"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim states that varenicline monotherapy is more effective after 12 weeks compared to combination therapies with varenicline and bupropion. However, Paper 1 provides evidence from a clinical trial demonstrating that combination therapy with varenicline and bupropion showed a higher abstinence rate at 12 weeks compared to varenicline monotherapy (53.0% vs. 43.2% for prolonged abstinence, OR, 1.49; 95% CI, 1.05-2.12; P = .03). Paper 6 further confirms the effectiveness of combination nicotine replacement therapies compared to single therapies. Given these results, the evidence provided contradicts the claim."
    },
    "overthinking_doc_ids": [
      "11614737",
      "34369306",
      "6191684",
      "1287809",
      "3690068"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion. Paper 1 directly addresses this claim by comparing varenicline monotherapy with combination therapy using varenicline and bupropion. The results show that combination therapy had higher abstinence rates at 12 weeks compared to varenicline monotherapy (53.0% vs. 43.2% for prolonged abstinence, and 56.2% vs. 48.6% for 7-day point-prevalence abstinence). Although the differences were not statistically significant for the 7-day point-prevalence, the prolonged abstinence rate was significant, suggesting the combination is more effective. Therefore, the evidence in Paper 1 contradicts the claim that varenicline monotherapy is more effective."
    },
    "posthoc_doc_ids": [
      "11614737",
      "34369306",
      "1759213",
      "1805641",
      "39532074"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "385",
    "claim": "Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The provided papers contain substantial evidence supporting the claim that epigenetic modulating agents (EMAs) modulate antitumor immune response. Paper 1 discusses the reversal of immunosuppression by epigenetic modulation, enhancing immune system elements like antigen presentation and effector T-cell function. Paper 3 details how DNMTi and HDACi reduce the immune suppressive environment in an ovarian cancer model through type I IFN signaling and improve responses to immune checkpoint therapy by increasing T and NK cell activation while reducing immunosuppressive cells. Similarly, Paper 7 outlines how combining DNMTis with HDACis in a lung cancer model leads to improved antigen presentation and modulation of T cell states, thereby reversing tumor immune evasion. These findings collectively align with the claim, showing that EMAs can indeed modulate antitumor immune responses."
    },
    "naive_doc_ids": [
      "1032372",
      "32742683",
      "9767444",
      "20127522",
      "3981033"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The papers provide multiple lines of evidence that support the claim that Epigenetic modulating agents (EMAs) modulate the antitumor immune response. Paper 1 discusses the potential reversal of immunosuppression by epigenetic modulation, leading to improved immune recognition and tumor lysis. Paper 2 presents findings where DNMTis and HDACis enhance cancer immune therapy by upregulating antigen presentation machinery and reversing tumor immune evasion in a lung cancer model. These findings align with the claim by showing that EMAs can modulate the immune system to enhance antitumor responses. The other papers, while related to cancer and immunity, do not specifically provide evidence on EMAs, resulting in the focus on evidence from Papers 1 and 2."
    },
    "overthinking_doc_ids": [
      "1032372",
      "9955779",
      "32742683",
      "3981033",
      "7975937"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The claim that epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system is supported by evidence from papers 1 and 3. Paper 1 discusses the impact of epigenetic modifying agents on the immune system, highlighting improvements in antigen presentation and effector T-cell function which align with the claim. Paper 3 provides specific experimental data from a mouse model of ovarian cancer, demonstrating that DNMTi and HDACi activate type I interferon signaling, reduce immune suppression, and enhance immune response, which supports the claim. While papers 2, 4, 5, 6, and 7 discuss related topics, they do not provide direct evidence related to EMAs modulating the antitumor immune response itself. Therefore, the evidence collectively supports the claim with moderate confidence since it is based on experimental data from relevant model systems."
    },
    "posthoc_doc_ids": [
      "1032372",
      "32742683",
      "9767444",
      "4468861",
      "1554348"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1239",
    "claim": "The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that myocardial cell lineage develops exclusively from endodermal origin. However, several papers provide evidence of a neural crest origin for some cardiac progenitors, particularly Paper 3, which discusses that cardiac neural crest-derived cells migrate into the heart and remain there as dormant multipotent stem cells, and Paper 8, which implicates neural crest cells in the development of the cardiac outflow tract and ventricular myocardium. These findings clearly indicate contributions from the neural crest, a derivative of the ectoderm, thereby contradicting the claim of exclusive endodermal origin."
    },
    "naive_doc_ids": [
      "20186814",
      "32797183",
      "106301",
      "1905095",
      "5085118"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim that myocardial cell lineage develops exclusively from cardiac progenitors of endodermal origin is contradicted by evidence presented in the papers. Paper 2 provides information on neural crest-derived stem cells, which, after migration and differentiation, become cardiomyocytes. This suggests a non-endodermal origin pathway for certain cardiac progenitors, specifically from neural crest cells, which are derived from the ectoderm. Paper 6 also describes the lineage contributions during germ layer formation, identifying that endoderm, mesoderm, and ectoderm progenitors all have distinct roles, indicating myocardial cells can originate from mesodermal progenitors. This evidence collectively suggests that myocardial cell lineage is not exclusively endodermal. Therefore, the papers provide substantial evidence contradicting the claim."
    },
    "overthinking_doc_ids": [
      "1905095",
      "5085118",
      "14060030",
      "26612216",
      "11344428"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The claim states that the myocardial cell lineage develops exclusively from endodermal origin. However, several papers provide evidence that this is not the case. Paper 4 shows that neural crest cells, which are derived from the ectoderm, are crucial for the development of the cardiac outflow tract and ventricular myocardium. Additionally, Paper 7 indicates that Islet1 derivatives in the heart are of both neural crest and second heart field origin, further confirming that cardiac progenitors are not exclusively of endodermal origin, as the second heart field primarily originates from mesodermal cells. These findings directly contradict the claim that myocardial cells are derived solely from endodermal progenitors. Therefore, the evidence contradicts the claim with high confidence."
    },
    "posthoc_doc_ids": [
      "5002665",
      "20186814",
      "32797183",
      "38727075",
      "301838"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "823",
    "claim": "N348I mutations cause resistance to zidovudine (AZT).",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence supporting the claim that N348I mutations cause resistance to zidovudine (AZT). The study identifies the N348I mutation in the HIV-1 reverse transcriptase connection domain as associated with increased prevalence in treatment-experienced patients and a significant increase in viral load. Moreover, the introduction of the N348I mutation into HIV-1 molecular clones decreased zidovudine susceptibility 2- to 4-fold. This evidence strongly aligns with the claim that N348I mutations confer resistance to zidovudine. Papers 2, 3, 4, 5, and 6 do not provide relevant information regarding this specific claim, as they discuss unrelated topics such as ALL resistance, PI3K pathway in cancer, obesity-related diabetes, and malaria resistance."
    },
    "naive_doc_ids": [
      "15319019",
      "6421792",
      "14819804",
      "120626",
      "2319305"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 1.0,
      "justification": "Paper 1 provides strong evidence supporting the claim that N348I mutations cause resistance to zidovudine (AZT). The study directly investigates the prevalence and impact of the N348I mutation in the reverse transcriptase of HIV-1, showing that it leads to a decrease in zidovudine susceptibility by 2- to 4-fold. The paper describes N348I as conferring resistance to zidovudine in both wild-type HIV-1 and when combined with other thymidine analogue mutations (TAMs). Additionally, the biochemical analysis of recombinant reverse transcriptase containing N348I supports its role in zidovudine resistance, aligning perfectly with the claim."
    },
    "overthinking_doc_ids": [
      "15319019",
      "9505402",
      "25014337",
      "2319305",
      "1605392"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence supporting the claim that N348I mutations cause resistance to zidovudine (AZT). The study showed that the N348I mutation, found in the connection domain of HIV-1 reverse transcriptase, decreased zidovudine susceptibility by 2- to 4-fold in various genetic contexts, including wildtype HIV-1 and when combined with thymidine analogue mutations (TAMs). This is experimental data aligning with the claim, with biochemical analyses of recombinant RT providing additional supportive evidence for this role in drug resistance."
    },
    "posthoc_doc_ids": [
      "15319019",
      "9505402",
      "25014337",
      "3210545",
      "4587978"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1028",
    "claim": "Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 3 and 4 provide direct evidence supporting the claim. Paper 3 describes how reduced IL-2 production correlates with reduced function of regulatory T cells (Tregs), essential for immune homeostasis, and links this to autoimmune dysregulation. Paper 4 further elaborates on this by showing that IL2RA polymorphisms associated with type 1 diabetes result in diminished IL-2 signaling in Tregs, reducing their suppressive function and contributing to autoimmune disease susceptibility. Although other papers mention factors related to autoimmunity, papers 3 and 4 specifically link IL-2 responsiveness to Treg dysfunction in autoimmune diseases, aligning with the claim."
    },
    "naive_doc_ids": [
      "1855679",
      "2388819",
      "13923140",
      "11899391",
      "16389141"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim states that reduced responsiveness to interleukin-2 (IL-2) in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes. Papers 3 and 4 provide direct evidence supporting this claim. Paper 3 discusses how variation in the interleukin-2 gene impairs regulatory T cell function, which is crucial for maintaining immune balance and is associated with autoimmunity. Paper 4 specifically links Type 1 diabetes to IL-2 signaling deficiencies, noting that certain IL2RA gene variations reduce IL-2 responsiveness in Tregs, impacting their function in suppressing autoimmunity. These findings directly align with and support the claim about the association between reduced IL-2 responsiveness in T cells and autoimmune diseases."
    },
    "overthinking_doc_ids": [
      "1855679",
      "2388819",
      "13923140",
      "11899391",
      "15578265"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that reduced responsiveness to interleukin-2 (IL-2) in regulatory T cells (Tregs) is associated with autoimmune diseases such as Type 1 Diabetes is supported by Paper 1. This paper identifies an IL2RA haplotype associated with Type 1 Diabetes in humans, demonstrating diminished IL-2 responsiveness in CD4+ T cells and reduced FOXP3 expression in Tregs, leading to compromised suppressive functions. Such impairments in Treg function are linked to increased susceptibility to autoimmune diseases, thus aligning with the claim. Although Paper 2 also discusses Tregs in the context of autoimmunity, it focuses on expanding antigen-specific Tregs for therapeutic purposes rather than IL-2 responsiveness specifically. Papers 3, 4, and 5 do not directly address IL-2 and Treg functionality in the context of T1D or similar autoimmune diseases, hence they are less relevant to the specific claim. Overall, Paper 1 provides direct supporting evidence, boosting confidence in the claim."
    },
    "posthoc_doc_ids": [
      "11899391",
      "2388819",
      "23342845",
      "1855679",
      "18348376"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1193",
    "claim": "The appearance of brown-like or beige cells primarily occurs in visceral fat, not subcutaneous fat.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided papers do not directly address the claim about the specific occurrence of brown-like or beige cells primarily in visceral fat as opposed to subcutaneous fat. Paper 1 discusses adipose tissue and differentiation but not specifically brown or beige adipocytes in visceral vs. subcutaneous fat. Paper 2 focuses on brown adipocyte function in obesity but does not make a distinction between subcutaneous and visceral fat. Paper 3 highlights general adipose depot remodeling without specific emphasis on the location of brown or beige cells. Paper 4 compares mitochondrial function in visceral and subcutaneous fat but does not focus on brown/beige adipocytes. Paper 5 investigates vascular function in adipose tissue but not the presence of brown or beige cells. Paper 6 discusses the origins and metabolic effects of brite/beige adipocytes without specifying their primary location. Paper 7 looks at beige fat thermogenesis independent of location specificity. Paper 8 is focused on UCP expression in relation to cancer cachexia rather than adipocyte type location. Therefore, none of the papers provide direct evidence regarding the specific claim about the primary location of brown-like or beige cells in visceral fat."
    },
    "naive_doc_ids": [
      "3621011",
      "38023457",
      "4854076",
      "39187170",
      "79447"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The claim states that the appearance of brown-like or beige cells primarily occurs in visceral fat, not subcutaneous fat. The provided papers mainly discuss mitochondrial respiration differences between visceral and subcutaneous fat (Paper 1), arteriolar function and adipose tissue phenotype (Paper 2), the role of tenomodulin in adipocyte differentiation and visceral adipose expansion (Paper 3), the development and metabolic role of brite/beige adipocytes (Paper 4), and the effects of ghrelin on lipid accumulation in visceral adipocytes (Paper 5). However, none of these papers provide direct evidence comparing the presence of brown-like or beige cells specifically in visceral versus subcutaneous fat depots. Paper 4 discusses brite/beige adipocytes but does not specify their preferential occurrence in either fat type. Thus, the claim is not explicitly supported or contradicted by the provided evidence."
    },
    "overthinking_doc_ids": [
      "39187170",
      "79447",
      "3621011",
      "17973161",
      "31564409"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain explicit evidence or results directly related to the claim that the appearance of brown-like or beige cells primarily occurs in visceral fat rather than subcutaneous fat. Most of the papers focus on different aspects of adipose tissue, such as mitochondrial respiration, the effects of maternal obesity, gene expression in subcutaneous stem cells, and the role of proteins like tenomodulin in adipose tissues, but do not specifically investigate or compare the presence of brown/beige adipocytes in visceral vs subcutaneous fat."
    },
    "posthoc_doc_ids": [
      "39187170",
      "14965508",
      "33634749",
      "13944805",
      "20457190"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "1371",
    "claim": "Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly investigates the relationship between vitamin D levels, calcium intake, and serum parathyroid hormone (PTH), showing that adequate vitamin D status is crucial for calcium homeostasis, as indicated by serum PTH. The results suggest that higher vitamin D levels correspond to lower serum PTH levels, confirming the role of vitamin D in the calcium-PTH relationship. Paper 5 further supports this by indicating that vitamin D insufficiency affects PTH response, emphasizing vitamin D's importance in regulating the calcium-PTH endocrine axis. Other papers focus more on PTH mechanisms in different contexts, which don't directly address the claim but do not contradict it either."
    },
    "naive_doc_ids": [
      "16256507",
      "21199527",
      "3758260",
      "21564598",
      "13312471"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly discusses the relationship between vitamin D, calcium, and parathyroid hormone (PTH). It provides clear evidence that vitamin D status is crucial for maintaining calcium metabolism, as indicated by serum PTH levels. The results show that serum PTH levels are affected by both vitamin D and calcium intake, with vitamin D specifically playing an essential role. Higher serum 25-hydroxyvitamin D levels are associated with lower PTH levels, and this interaction supports the claim that vitamin D is an important factor in the relationship between calcium and parathyroid hormone. The other papers do not address the specific interaction between calcium, vitamin D, and PTH, focusing instead on other unrelated biological processes."
    },
    "overthinking_doc_ids": [
      "16256507",
      "21564598",
      "9301606",
      "22914228",
      "24349992"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "The claim that Vitamin D is an important factor in the relationship between calcium and parathyroid hormone (PTH) is supported by Paper 1, which shows that serum 25-hydroxyvitamin D, an indicator of Vitamin D status, significantly affects serum PTH levels in relation to calcium intake. Specifically, PTH levels were lower with higher levels of Vitamin D, indicating that adequate Vitamin D sufficiency is necessary for optimal calcium metabolism and PTH regulation. This suggests a relationship where Vitamin D plays a critical role in modulating the effects of calcium on PTH, thus supporting the claim. The other papers do not contradict this and primarily focus on different aspects of bone metabolism, PTH signaling pathways, and other unrelated topics."
    },
    "posthoc_doc_ids": [
      "16256507",
      "9301606",
      "13312471",
      "21564598",
      "21199527"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "316",
    "claim": "Decreased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not discuss the conversion of PGE2 to PPARy ligand 15-ket-PGE2 or its impact on PGE accumulation. The claim is highly specific to certain biochemical pathways involving prostaglandins and their conversion, which are not addressed in any of the cited papers. The papers cover a range of unrelated topics, including glucagon-like peptide-1 receptor function, ligand discovery, T cell receptor interactions, Hippo pathway signaling, RAPID pathways in cancer, lipoprotein metabolism, and others, but do not mention or provide experimental data specific to the conversion of PGE2 or its accumulation."
    },
    "naive_doc_ids": [
      "3127341",
      "327319",
      "994800",
      "26019505",
      "86694016"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain relevant information regarding the specific claim of decreased conversion of PGE2 to PPARy ligand 15-ket-PGE2 causing accumulation of PGE. None of the papers discuss the biochemical pathway involving the transformation of PGE2 to 15-ket-PGE2, nor do they present findings related to prostaglandin E (PGE) accumulation as a direct consequence of this specific conversion change. The papers focus on different topics such as inflammation mechanisms in osteoarthritis, signaling pathways in epilepsy, cancer arginine metabolism, proteostasis in aging, macrophage lipid metabolism, neuroprotective effects of microRNAs, PPAR\u03b3 signaling in cystic fibrosis, inflammatory responses in chondrocytes, HER2/3 breast cancer therapy, and lifestyle impacts on mortality, which are not directly related to the claim at hand."
    },
    "overthinking_doc_ids": [
      "54482327",
      "116792",
      "293661",
      "10012166",
      "15879931"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 1.0,
      "justification": "The provided papers do not contain relevant information regarding the specific biochemical pathway involving the conversion of PGE2 to PPARy ligand 15-ket-PGE2 and its impact on PGE accumulation. The papers cover a range of topics such as PCSK9 inhibition, miRNA-22 neuroprotection, vasoconstriction effects, interleukin-10 roles, fetal growth regulation, FGF19 receptor specificity, cytokines in cachexia, CYP2D6 polymorphisms in tamoxifen metabolism, and prostaglandin E2 production by Candida albicans. None of these topics address the claim concerning the biochemical process of PGE2 to PPARy ligand conversion or accumulation of PGE."
    },
    "posthoc_doc_ids": [
      "6540064",
      "16605494",
      "26025370",
      "26068103",
      "2958458"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-4o",
    "claim_id": "623",
    "claim": "Individuals with low serum vitamin D concentrations have increased risk of multiple sclerosis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers do not contain specific and direct evidence addressing the claim that low serum vitamin D concentrations increase the risk of multiple sclerosis (MS). While some papers discuss vitamin D in relation to other conditions (e.g., diabetes, pregnancy outcomes, bone health) and environmental factors like sun exposure in MS, none explicitly link low serum vitamin D levels to an increased risk of developing MS. Paper 3 speaks of a potential relationship through environmental and genetic factors about vitamin D and latitude, but it does not provide direct evidence on serum vitamin D levels. Therefore, the information is not sufficiently relevant to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "25599283",
      "17000834",
      "22843838",
      "9555784",
      "10831818"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 suggests that higher sun exposure, which is linked to vitamin D production, is associated with a reduced risk of multiple sclerosis. Paper 2 discusses the potential link between vitamin D levels (affected by ultraviolet light exposure) and the prevalence of multiple sclerosis, implying that vitamin D could play a protective role. Although Paper 4 focuses on calcium metabolism and the importance of vitamin D for bone health, it indirectly supports the need for adequate vitamin D levels, which could extend to autoimmune conditions like MS. Collectively, these findings align with the claim that insufficient vitamin D concentrations may increase the risk of multiple sclerosis, providing supportive evidence for the claim."
    },
    "overthinking_doc_ids": [
      "17000834",
      "22843838",
      "43226130",
      "16256507",
      "34054472"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly address the claim that low serum vitamin D concentrations increase the risk of multiple sclerosis (MS). Although Paper 2 and Paper 3 discuss the role of sunlight exposure and latitude (factors related to vitamin D) in the risk of MS, they do not explicitly link low serum vitamin D levels to increased MS risk. Paper 1 focuses on the association between low vitamin D and diabetes, not MS. Papers 4, 5, and 6 address vitamin D status in postmenopausal women, immune cell roles in MS, and gender factors in MS risk respectively, with no direct connection to the specific claim regarding vitamin D and MS. Therefore, based on the provided evidence, there is insufficient information to classify the claim as supported or contradicted."
    },
    "posthoc_doc_ids": [
      "25599283",
      "17000834",
      "22843838",
      "9555784",
      "10831818"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "53",
    "claim": "ALDH1 expression is associated with poorer prognosis in breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers report on ALDH1 (aldehyde dehydrogenase 1) expression or its association with breast cancer prognosis. Several papers do address prognostic factors in breast cancer (e.g., tumor-associated macrophages in Paper 3, Orai1/STIM1 in Paper 5, TRPM7 in Paper 6), but none assess ALDH1 levels or present data linking ALDH1 to clinical outcomes. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "31591262",
      "24341590",
      "313403",
      "22401720",
      "1379127"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report data on ALDH1 expression or its association with breast cancer prognosis. Paper 4 addresses tumor-associated macrophages (CD68) and prognosis, Papers 2 and 3 analyze perinatal/intrauterine factors and breast cancer risk, Paper 6 examines CYP2D6 polymorphisms and tamoxifen outcomes, and Papers 1 and 5 concern lung cancer and pulmonologist care. No study here measures ALDH1 or links ALDH1 expression to clinical outcomes in breast cancer, so the evidence set does not support or refute the claim."
    },
    "overthinking_doc_ids": [
      "7639744",
      "17450673",
      "23557241",
      "313403",
      "24323695"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 4 directly addresses ALDH1 in breast cancer: in a series of 577 breast carcinomas, ALDH1 expression (detected by immunostaining) correlated with poor clinical outcome, and ALDH-high cells had tumorigenic/stem-like properties. None of the other provided papers present evidence contradicting this finding (they address other markers, angiogenesis, or different cancers), so the provided evidence supports the claim that ALDH1 expression is associated with poorer prognosis in breast cancer."
    },
    "posthoc_doc_ids": [
      "21439640",
      "22401720",
      "12358173",
      "45638119",
      "3899896"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "115",
    "claim": "Anthrax spores can be disposed of easily after they are dispersed.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided evidence is 'Error' and contains no papers, data, or discussion relevant to the claim. Because no supporting or contradicting information is available in the supplied materials, the claim cannot be verified from the evidence provided."
    },
    "naive_doc_ids": [],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses environmental behavior of Bacillus anthracis spores after contamination and shows that viable spores reaerosolize under both semiquiescent and simulated active office conditions, with a marked increase during normal activities and >80% of particles in a respirable size range. The authors state these findings have important implications for remediation and reoccupancy, implying that spores are difficult to remove and control once dispersed. The other provided papers do not address anthrax spore disposal. Therefore the evidence contradicts the claim that anthrax spores can be disposed of easily after dispersion."
    },
    "overthinking_doc_ids": [
      "33872649",
      "2904102",
      "12824568",
      "5151024",
      "6748318"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided evidence could not be read (listed as 'Error'), so there are no accessible papers to evaluate whether they support or contradict the claim. Because no usable data or findings were supplied, I cannot determine from the provided evidence whether anthrax spores can be disposed of easily after dispersion."
    },
    "posthoc_doc_ids": [],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "917",
    "claim": "PTEN is a regulator for the transcriptional activity of SRF",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 5 directly demonstrates that nuclear PTEN regulates SRF-dependent transcription: PTEN interacts with the N-terminal domain of SRF, promotes SRF binding to promoter elements of smooth muscle\u2013specific genes, and loss or nucleo-cytoplasmic translocation of PTEN reduces myogenic SRF activity while altering SRF target-gene selection. The other papers do not provide evidence relevant to PTEN\u2013SRF, so the provided evidence supports the claim."
    },
    "naive_doc_ids": [
      "15176526",
      "14367469",
      "2316374",
      "18264714",
      "34071621"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 7 directly demonstrates that nuclear PTEN is an essential regulator of SRF-dependent transcription: PTEN interacts with the N-terminal domain of SRF, promotes SRF binding to smooth muscle\u2013specific promoters, and loss or nucleo-cytoplasmic translocation of PTEN alters SRF activity and smooth muscle gene expression. No provided paper presents contradictory data. Therefore the evidence supports the claim that PTEN regulates SRF transcriptional activity."
    },
    "overthinking_doc_ids": [
      "2316374",
      "14367469",
      "15113221",
      "6493422",
      "15176526"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present data or discussion linking PTEN to regulation of Serum Response Factor (SRF) transcriptional activity. Paper 9 discusses PTEN and PI3K pathway activity in cancers but does not mention SRF or PTEN regulation of SRF. The other papers focus on unrelated transcription factors or pathways (p53, FOXO, KLF2, HDAC5, etc.) and do not address PTEN\u2013SRF interactions. Therefore the supplied evidence does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "14367469",
      "29429111",
      "2316374",
      "207972",
      "4483571"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "470",
    "claim": "Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 discusses PI3K pathway roles in tumor progression, explicitly linking misregulation to increased cell survival, motility/invasion, and multiple aspects of angiogenesis\u2014supporting the invasion and angiogenesis components of the claim. Paper 3 is a clinical trial in recurrent glioblastoma using bevacizumab (an anti-VEGF antiangiogenic agent), which implies angiogenesis is a relevant, targetable feature of GBM and also reports poor progression-free and overall survival consistent with an aggressive/rapidly growing tumor. Paper 2 is unrelated (Alzheimer\u2019s). While necrosis is not explicitly addressed in these papers, the provided evidence supports key elements of the claim (extensive invasion, angiogenesis, and rapid/ aggressive behavior); necrosis is not directly documented in the supplied evidence."
    },
    "naive_doc_ids": [
      "13329980",
      "46565020",
      "14482051"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 explicitly states that GBM \u201cis characterized by ... extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis.\u201d Paper 4 further supports the claim by linking AMPA receptor\u2013driven Ca2+/Akt signaling to proliferative and invasive growth of glioblastoma. Paper 3 notes tumor vascularization as a feature associated with outcome in GBM, supporting the angiogenesis component. Together the papers provide evidence consistent with the claim."
    },
    "overthinking_doc_ids": [
      "12685434",
      "1192458",
      "9486930",
      "12948892"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly states that GBM is characterized by extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis. Additional papers provide supporting evidence for these traits: Paper 6 reviews PI3K pathway roles in tumor invasion and angiogenesis; Paper 2 and Paper 8 describe highly tumorigenic/aggressive GBM cell populations (consistent with rapid growth/invasiveness); Paper 3 documents rapid intracranial xenograft growth that is targetable therapeutically. Together the provided studies confirm the claim rather than contradict it."
    },
    "posthoc_doc_ids": [
      "12685434",
      "7028976",
      "15570691",
      "6673421",
      "6580081"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1268",
    "claim": "The risk of cancer rises with level of alcohol consumption.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present direct evidence that cancer risk increases with level of alcohol consumption. Paper 9 reports associations between alcohol and major coronary events (cardiovascular outcomes), not cancer. Paper 8 includes alcohol consumption as one of several environmental factors when testing gene\u2013environment interactions for breast cancer, but it reports no significant interactions and does not provide results showing a dose\u2013response relationship between alcohol level and cancer risk. The remaining papers address intrauterine factors, metabolic/oxidative mechanisms, genetic\u2013nutrient interactions, or cardiovascular biomarkers and do not contain data linking alcohol consumption level to cancer incidence. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "6793674",
      "17450673",
      "23557241",
      "24349992",
      "1686997"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the five provided papers address alcohol consumption or present data on alcohol level and cancer risk. Paper 1 examines FEV1 and lung cancer risk; Paper 2 analyzes adiponectin/leptin and endometrial cancer risk; Paper 3 is a genetic polymorphism meta-analysis for gastric cancer; Paper 4 is an ASCO policy statement on prevention and risk assessment; Paper 5 studies chronic comorbidities and risk of chemotherapy-induced febrile neutropenia. None present evidence confirming or refuting a dose\u2013response relationship between alcohol consumption and cancer risk."
    },
    "overthinking_doc_ids": [
      "12145359",
      "12869200",
      "14729253",
      "2665675",
      "6334188"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the nine provided papers present results evaluating alcohol consumption as an exposure for cancer risk. The studies address lung function and lung cancer, adipokines and endometrial cancer, genetic polymorphisms and gastric cancer, bed-sharing/SIDS (which notes alcohol as a SIDS risk factor), familial lymphoma risk, fruit intake and diabetes, HDL and breast cancer, cancer prognosis predictors, and vitamin D and colorectal cancer. While some papers adjust for or mention alcohol as a potential confounder in analyses or as a risk factor for SIDS, none report data showing how cancer risk changes with levels of alcohol consumption, so the claim cannot be verified from this evidence."
    },
    "posthoc_doc_ids": [
      "12145359",
      "12869200",
      "14729253",
      "20240998",
      "1153655"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "659",
    "claim": "Ivermectin is used to treat lymphatic filariasis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the nine provided papers discuss ivermectin or lymphatic filariasis. The papers cover topics such as tuberculosis regimens (Papers 1 and 3), malaria elimination with artemisinin and primaquine (Paper 2), RNA editing and related genes (Papers 4 and 5), Helicobacter pylori urea channel structure (Paper 6), blood pressure management in dialysis (Paper 7), aliskiren safety (Paper 8), and vitamin D in pregnancy (Paper 9). Because no paper presents data or discussion about ivermectin or treatment of lymphatic filariasis, the provided evidence does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "341324",
      "3929361",
      "21479231",
      "22029384",
      "29107180"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the six provided papers discuss ivermectin or lymphatic filariasis. Paper 1 concerns malaria interventions (artemisinin-piperaquine and primaquine), Paper 2 addresses postmarket safety events of novel therapeutics, Paper 3 reports pharmacokinetics of ciclopiroxolamine, Paper 4 deals with androgen suppression in prostate cancer, Paper 5 evaluates a tuberculosis regimen, and Paper 6 examines case management in outpatient substance abuse. Therefore there is no evidence in these papers to support or contradict the claim that ivermectin is used to treat lymphatic filariasis."
    },
    "overthinking_doc_ids": [
      "3929361",
      "3578380",
      "26461066",
      "308862",
      "341324"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers mention ivermectin or lymphatic filariasis. The papers cover tuberculosis regimens, HIV ART guidelines, tumor response criteria, malaria strategies (primaquine/ACT), postmarket safety of novel therapeutics, ciclopirox pharmacokinetics, antimalarial prophylaxis side effects, metformin mechanism, and infant locomotor development\u2014none provide data or discussion about using ivermectin to treat lymphatic filariasis."
    },
    "posthoc_doc_ids": [
      "341324",
      "1986482",
      "15541119",
      "3929361",
      "3578380"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "324",
    "claim": "Deleting Raptor reduces G-CSF levels.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the four provided papers address deletion or manipulation of Raptor. While Papers 2 and 4 discuss regulation and requirement of G-CSF in granulopoiesis (Paper 2: adipocyte/NP-1-mediated inhibition of G-CSF; Paper 4: IL-17 requires G-CSF for granulopoiesis), and Paper 3 discusses colony-stimulating factors (GM-CSF), none report experiments deleting Raptor or link Raptor deletion to changes in G-CSF levels. Therefore the evidence does not support or contradict the claim."
    },
    "naive_doc_ids": [
      "25827024",
      "42465769",
      "188911",
      "24612804"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers report measurements of G-CSF (granulocyte-colony stimulating factor) or explicitly test the effect of raptor deletion on G-CSF levels. Paper 1 describes mTOR complexes and raptor as an mTOR binding partner, and Paper 7 reports T cell-specific raptor deletion affecting Th17 differentiation and related factors (Gfi1, ROR\u03b3, S6Ks), but neither paper \u2014 nor any of the others listed \u2014 measure or discuss G-CSF. Therefore the provided evidence does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "4658268",
      "10017612",
      "14188138",
      "3984231",
      "5409325"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the nine provided papers report experiments or results about deletion of Raptor (RPTOR) or its effects. While Papers 5 and 6 discuss granulocyte-colony-stimulating factor (G-CSF) and its role/regulation in granulopoiesis and bone marrow adipocyte effects, they do not examine Raptor deletion or link Raptor to changes in G-CSF levels. Therefore the provided evidence does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "982650",
      "5409325",
      "9846940",
      "188911",
      "24612804"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "205",
    "claim": "CDK6 shows improved binding to loss-of-function variants of p18 INK4C.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the eight provided papers discuss CDK6, p18 (INK4C), or interactions between CDK6 and INK4-family inhibitors. The articles cover topics including GLP-1 receptor polymorphisms, nucleolar protein B23 and ribosomal S9, Omi/HtrA2\u2013OPA1 interactions, CNBP and hnRNP K, two-component bacterial signaling specificity, H2A.Z nucleosome structure, MHC H2-M3 peptide binding, and plant urease structure. Therefore there is no relevant experimental evidence in the supplied papers to support or refute the claim that CDK6 shows improved binding to loss-of-function variants of p18 INK4C."
    },
    "naive_doc_ids": [
      "3127341",
      "26495128",
      "10698739",
      "10486817",
      "1225513"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss CDK6, p18 (INK4C), or the interaction/binding between CDK6 and p18 INK4C. The listed studies cover topics such as GLP-1R polymorphisms, mutant p53, T cell receptor binding strength, two-component bacterial signaling, dynein microtubule binding, H3K56 acetylation in adipocytes, YB-1 RNA binding, endometrial cancer genomics, neoantigen burden in myeloma, and MeCP2 effects on neurons \u2014 none provide experimental data relevant to CDK6 binding to p18 INK4C variants."
    },
    "overthinking_doc_ids": [
      "3127341",
      "35684881",
      "22874817",
      "1225513",
      "1546650"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present data on interactions between CDK6 and p18 (INK4C) variants. Paper 6 mentions CDK6 as a target of the inhibitor PD 0332991 (demonstrating CDK6 inhibition and antitumor activity) but does not report binding studies between CDK6 and p18/INK4C or effects of p18 loss-of-function variants on CDK6 binding. The other papers cover unrelated proteins and systems (GLP-1R, Cryptococcus ALL1, two-component signaling, PI3K/Ras, HP1, AMPK, START domains, MHC H2-M3) and do not address CDK6\u2013p18 interactions. Therefore the evidence set does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "3127341",
      "7717468",
      "1225513",
      "14819804",
      "8417211"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "68",
    "claim": "Activated Cdk5 regulates DNA damage-induced neuronal death.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 directly demonstrates that Cdk5 is activated by DNA damage in post-mitotic neurons, that activated Cdk5 phosphorylates and activates ATM, and that the Cdk5\u2013ATM pathway regulates downstream targets (p53, H2AX, PUMA, Bax) and neuronal cell-cycle re-entry and death. Interruption of this pathway protects neurons from DNA damage\u2013induced death. The other provided papers do not address Cdk5\u2019s role in DNA damage\u2013induced neuronal death."
    },
    "naive_doc_ids": [
      "1941721",
      "21295300",
      "10015292",
      "935034",
      "22937815"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct experimental evidence that activated Cdk5 (activated by DNA damage) phosphorylates ATM in post-mitotic neurons, is required for ATM activation, and that the Cdk5\u2013ATM pathway regulates downstream targets (p53, H2AX) and p53-dependent pro-apoptotic gene expression (PUMA, Bax). Interruption of this pathway attenuates DNA damage\u2013induced neuronal cell-cycle re-entry and protects neurons from death. The other papers do not provide evidence contradicting this mechanism or add relevant conflicting data. Therefore the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "21295300",
      "5572127",
      "10648422",
      "17231273",
      "10015292"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that Cdk5 is activated by DNA damage in post-mitotic neurons, phosphorylates ATM at Ser794 (required for ATM autophosphorylation and activation), and that disruption of the Cdk5\u2013ATM pathway attenuates DNA damage\u2013induced neuronal cell-cycle re-entry and expression of proapoptotic p53 targets (PUMA, Bax), protecting neurons from death. This is direct experimental evidence that activated Cdk5 regulates DNA damage\u2013induced neuronal death. The other provided papers are either unrelated to Cdk5 or do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "21295300",
      "1103795",
      "5572127",
      "1941721",
      "19522248"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "267",
    "claim": "Cognitive behavioral therapy is an ineffective treatment for insomnia",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 is a randomized, double-blind, placebo-controlled trial in older adults with chronic primary insomnia that found CBT produced improved short- and long-term outcomes versus zopiclone and placebo (improved sleep efficiency, more slow\u2011wave sleep, less wake time). This directly contradicts the claim that CBT is ineffective for insomnia. The other provided papers are on unrelated topics (TB regimens, antenatal steroids, umbilical cord blood for CP, tension\u2011type headache, benzodiazepines for parasomnias, CAR T cells) and do not support the claim. (Note: Paper 1 is a small trial in older adults, which limits generalizability, but its results nonetheless refute the blanket statement that CBT is ineffective.)"
    },
    "naive_doc_ids": [
      "5912283",
      "15997009",
      "20645335",
      "23073816",
      "6191684"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 is a randomized, double-blind, placebo-controlled trial in older adults with chronic primary insomnia that found CBT produced improved short- and long-term outcomes versus zopiclone and placebo (better sleep efficiency, more slow-wave sleep, less wake time). This directly contradicts the claim that CBT is ineffective for insomnia. Paper 5, while about tension headaches rather than insomnia, also shows CBT produced clinically significant improvements compared with medication, providing additional evidence that CBT can be an effective behavioral treatment. The other papers are not relevant to insomnia."
    },
    "overthinking_doc_ids": [
      "5912283",
      "5402581",
      "4515975",
      "28931537",
      "24865781"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 is a randomized, double-blind, placebo-controlled trial in older adults with chronic primary insomnia that found CBT produced superior short- and long-term outcomes versus zopiclone (improved sleep efficiency from 81.4% to 90.1% at 6 months, more slow-wave sleep, less nighttime wakefulness) and was superior on 3 of 4 outcome measures; zopiclone often did not differ from placebo. The other provided papers do not address insomnia. Thus the evidence directly contradicts the claim that CBT is ineffective for insomnia."
    },
    "posthoc_doc_ids": [
      "5912283",
      "24865781",
      "493346",
      "27150276",
      "4515975"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "114",
    "claim": "Anthrax spores are very difficult to dispose once they are dispersed.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided evidence string is \"Error\" and contains no accessible papers or data to evaluate the claim. Because no experimental results, analyses, or text from the referenced papers were supplied, I cannot determine whether they support or contradict the statement that anthrax spores are very difficult to dispose once dispersed."
    },
    "naive_doc_ids": [],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided evidence is unavailable (shows only 'Error') and contains no papers, data, or findings related to anthrax spore disposal. Therefore there is no information in the supplied evidence to confirm or refute the claim."
    },
    "overthinking_doc_ids": [],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that viable Bacillus anthracis (anthrax) spores reaerosolize from contaminated indoor surfaces under ordinary office conditions and increase markedly during simulated activity; most particles were in an alveolar respirable size range (0.95\u20133.5 \u00b5m). These findings imply environmental persistence and a high potential for re\u2011suspension, complicating remediation, reoccupancy, and disposal after dispersion. The other provided papers do not address anthrax spore environmental persistence or remediation."
    },
    "posthoc_doc_ids": [
      "33872649",
      "4325398",
      "15488881",
      "12824568",
      "2904102"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "585",
    "claim": "In the UK, drowning affects boys and girls equally.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Only Paper 1 is directly about drowning in UK children, but the provided excerpt does not give any sex-disaggregated data or state whether boys and girls are equally affected. The other papers address unrelated conditions (ALRI, cervical cancer, Salmonella, forearm fractures, CJD) and do not provide relevant UK drowning data. Therefore the provided evidence does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "42291761",
      "9167230",
      "12779444",
      "28562710",
      "7209559"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Only Paper 1 addresses drowning in UK children, but the provided excerpt does not report any sex-specific (boys vs girls) incidence or comparisons. Papers 2\u20134 are about drug poisoning, global cancer statistics, and neuroimaging in late-life depression and do not provide information on drowning or sex differences in drowning. Therefore the supplied evidence does not confirm or refute the claim that drowning affects boys and girls equally in the UK."
    },
    "overthinking_doc_ids": [
      "42291761",
      "12442311",
      "52188256",
      "1412089"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Only one paper (Paper 1) concerns drowning in children in the UK, but the provided excerpt does not report drowning rates by sex or compare boys and girls. The other papers do not address drowning or UK child drowning. Therefore the supplied evidence does not provide data to confirm or refute the claim that drowning affects boys and girls equally in the UK."
    },
    "posthoc_doc_ids": [
      "42291761",
      "2488880",
      "3150030",
      "2048139",
      "7209559"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1225",
    "claim": "The locus rs647161 is associated with colorectal carcinoma.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 reports a genome-wide association study identifying rs647161 (5q31.1) as a colorectal cancer susceptibility locus, with replication in European samples and a combined P value of 1.22 \u00d7 10^(-10). None of the other provided papers contradict this finding. Therefore the evidence supports the claim that rs647161 is associated with colorectal carcinoma."
    },
    "naive_doc_ids": [
      "9650982",
      "43334921",
      "31229233",
      "14315749",
      "2485101"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 is a genome-wide association study that explicitly reports rs647161 (5q31.1) as a colorectal cancer susceptibility locus, with replication in European-ancestry samples and a combined meta-analysis P value of 1.22\u00d710^-10. The other provided papers do not report data contradicting this finding. Therefore the evidence supports the claim that rs647161 is associated with colorectal carcinoma."
    },
    "overthinking_doc_ids": [
      "9650982",
      "520579",
      "2058909",
      "14315749",
      "21181273"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 reports a genome-wide association study identifying rs647161 (5q31.1) as a new colorectal cancer susceptibility locus. rs647161 showed highly significant association in combined analyses (combined P = 1.22 \u00d7 10^-10) and was replicated in a large European-ancestry sample. None of the other provided papers contradict this finding. Therefore the evidence supports the claim that rs647161 is associated with colorectal carcinoma (CRC)."
    },
    "posthoc_doc_ids": [
      "9650982",
      "14315749",
      "23665162",
      "2492146",
      "43334921"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1008",
    "claim": "RUNX is not expressed in skin tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper summaries report on RUNX gene expression or specifically on RUNX in skin tissue. The papers cover topics such as bacterial SSB binding, ADAMTS7 in peripheral artery disease, single-cell reprogramming and allelic expression, hematopoietic stem cells, UV effects on hSSB, and an enhancer atlas (FANTOM5) \u2014 the latter is a tissue-wide resource but the provided summary does not give any RUNX-specific or skin-specific expression data. Therefore the supplied evidence does not support or contradict the claim that RUNX is not expressed in skin."
    },
    "naive_doc_ids": [
      "8065561",
      "3093512",
      "8290760",
      "9154703",
      "13980338"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the five paper summaries mention RUNX genes or report data on RUNX expression in skin. Several papers study skin cells (keratinocytes, hair-follicle stem cells) and transcriptional regulators (Aire, PcG factors) but do not address RUNX expression. Therefore the provided evidence does not support or contradict the claim that RUNX is not expressed in skin."
    },
    "overthinking_doc_ids": [
      "12580014",
      "15907458",
      "31141365",
      "9185195",
      "11238951"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the eight provided papers report on RUNX expression in skin tissue. The papers cover MRSA epidemiology, vitamin D levels, KSHV-positive lymphomas, keratin 17/Aire regulation in tumor keratinocytes, p16INK4A aging marker in skin, melanoma growth in grafted human skin, monocyte transcriptomes, and palmitate effects in pancreatic islets. While Paper 4 and Paper 5 discuss gene expression in skin keratinocytes and skin respectively, they do not mention RUNX. Therefore the provided evidence does not support or contradict the claim that RUNX is not expressed in skin."
    },
    "posthoc_doc_ids": [
      "14408200",
      "3150030",
      "11238951",
      "12580014",
      "19343151"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "756",
    "claim": "Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers provide direct evidence that lysine residues on proteins in human cells are post-translationally modified by acetylation. Paper 1 reports genome-wide H3K56 acetylation in human adipocytes and names CBP/p300 (lysine acetyltransferases) and SIRT1 (deacetylase). Paper 4 documents E2F-dependent hyperacetylation of histones H3 and H4 in human cells and recruitment of the Tip60 acetyltransferase complex. Paper 5 describes experimentally induced histone acetylation in T cells. These results demonstrate lysine acetylation of histone proteins (and action of cellular acetyltransferases/deacetylases), supporting the claim that proteins in human cells can be post-translationally acetylated on lysine residues."
    },
    "naive_doc_ids": [
      "3052213",
      "984825",
      "1667063",
      "502591",
      "1243475"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly state that lysine acetylation is a conserved and widespread post-translational modification of proteins in eukaryotic (including human) cells. Paper 1 explicitly describes lysine acetylation as a conserved protein post-translational modification and discusses its broad role in regulating protein interactions, activity and localization. Paper 4 reviews histone lysine acetylation in gene regulation and notes effects on both histone and non-histone proteins. Paper 5 provides genome-wide data for H3K56 (a histone lysine) acetylation in human adipocytes and notes widespread occurrence. Together these findings confirm that many proteins in human cells can be post-translationally modified on lysine residues via acetylation."
    },
    "overthinking_doc_ids": [
      "27134527",
      "4462777",
      "11026600",
      "17919731",
      "3052213"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "The papers consistently describe lysine acetylation as a widespread, conserved and functionally important post-translational modification on proteins (especially histones) in human cells. Paper 1 states lysine acetylation is a conserved protein PTM and notes large-scale identification by mass spectrometry linking it to many biological processes. Paper 2 documents widespread H3K56 lysine acetylation in human adipocytes (\u2018\u2018almost half of the genome shows signs of H3K56 acetylation\u2019\u2019). Paper 3 describes acetyl-lysine as a docking mark recognized by bromodomains. Paper 4 and Paper 5 provide mechanistic and functional evidence for lysine acetylation/deacetylation on histones and other proteins, and Paper 6 reviews lysine acetylation as a reversible PTM regulated by acetyltransferases and deacetylases with broad metabolic relevance. Together these findings support the claim that many human proteins can be post-translationally acetylated on lysine residues."
    },
    "posthoc_doc_ids": [
      "27134527",
      "3052213",
      "12172346",
      "12588500",
      "22968257"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "650",
    "claim": "Integrating classroom-based collaborative learning with Web-based collaborative learning offers the best class performance.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the eight provided papers address educational methods, classroom-based collaborative learning, Web-based collaborative learning, or measures of class performance. The studies concern medical and biological topics (vitamin D in pregnancy, rifampin duration for TB, antihypertensives in dialysis, integrated clinical care for chronic disease and depression, genomic profiling of bladder tumors, BPA and IVF outcomes, lifestyle and mortality, and lifestyle effects on IVF). Although Paper 4 examines an integrated (collaborative) care intervention in healthcare, it evaluates clinical and quality-of-life outcomes, not classroom or web-based learning or student performance. Therefore the evidence does not inform the educational claim."
    },
    "naive_doc_ids": [
      "2425364",
      "15997009",
      "10072941",
      "15041758",
      "2402323"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the six provided papers evaluate or report on educational methods comparing classroom-based collaborative learning, Web-based collaborative learning, or their integration. The studies cover genetics and disease risk (Papers 1, 2, 3), a tai chi randomized trial in cancer survivors (Paper 4), integrated medical care for chronic disease and depression (Paper 5), and a school-based cognitive-behavioral intervention for trauma-exposed children (Paper 6). While Paper 6 concerns a school intervention, it examines a mental-health CBT program rather than classroom vs. Web-based collaborative learning or their combination. Therefore the evidence does not address the claim."
    },
    "overthinking_doc_ids": [
      "18199839",
      "21958900",
      "14729253",
      "24396137",
      "15041758"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present empirical evidence comparing integrated classroom-based collaborative learning plus web-based collaborative learning versus other approaches in terms of class performance. Most papers (1\u20133,6\u20138) are clinical or genetic studies unrelated to educational methods. Paper 4 discusses potential benefits and rationale for computer-assisted/online learning but is a commentary rather than experimental data demonstrating that integrating classroom and web-based collaborative learning produces the best class performance. Paper 5 validates an online dietary assessment tool against an interviewer-administered recall (agreement/reliability) but does not address collaborative learning or class performance outcomes. Therefore the set does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "8814634",
      "5691302",
      "12561083",
      "12789595",
      "2295434"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "250",
    "claim": "Chenodeoxycholic acid treatment decreases brown adipose tissue activity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly contradicts the claim: oral chenodeoxycholic acid (CDCA) increased human brown adipose tissue (BAT) activity and whole-body energy expenditure in a 2-day treatment of healthy subjects, and CDCA increased mitochondrial uncoupling and D2 expression in primary human brown adipocytes in vitro. The other papers do not provide evidence that CDCA decreases BAT activity (they either discuss BAT/UCP1 regulation in cachexia or other factors, or TGR5 effects in endothelial cells), so the available evidence refutes the claim that CDCA treatment decreases BAT activity."
    },
    "naive_doc_ids": [
      "1568684",
      "26902591",
      "1507222",
      "3621011",
      "13902570"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly contradicts the claim: oral chenodeoxycholic acid (CDCA) treatment in 12 healthy female subjects for 2 days increased human brown adipose tissue (BAT) activity and whole-body energy expenditure, and CDCA increased mitochondrial uncoupling and D2 expression in primary human brown adipocytes in vitro. None of the other provided papers present data showing that CDCA decreases BAT activity (Paper 3 even reports increased Ucp1 in brown fat in a different context). Therefore the provided evidence opposes the claim that CDCA treatment decreases BAT activity."
    },
    "overthinking_doc_ids": [
      "1568684",
      "40232172",
      "3621011",
      "13902570",
      "29381091"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly tests chenodeoxycholic acid (CDCA) in humans and reports that oral CDCA treatment (2 days, n=12 healthy female subjects) increased brown adipose tissue (BAT) activity and whole-body energy expenditure; in vitro CDCA or TGR5 agonists increased mitochondrial uncoupling and D2 expression in primary human brown adipocytes. The other papers do not provide evidence that CDCA decreases BAT activity (Paper 3 even reports increased UCP1 in brown fat with TNMD overexpression). Therefore the provided evidence contradicts the claim that CDCA treatment decreases BAT activity."
    },
    "posthoc_doc_ids": [
      "1568684",
      "40232172",
      "3621011",
      "14865329",
      "79447"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1183",
    "claim": "The TRaF1/C5 rs10818488 allele polymorphism regulates the neighboring C5 gene.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present direct evidence that the rs10818488 allele in the TRAF1/C5 region regulates the neighboring C5 gene. Paper 5 reports association of the TRAF1/C5 region with rheumatoid arthritis (and corrects allele-labeling), but does not show that rs10818488 alters C5 expression. Other papers describe general mechanisms of transcriptional regulation, RNA stability, chromatin interactions, and eQTL concepts (Papers 1, 3, 6, 7), which are relevant background for how a variant might affect gene regulation, but they do not provide experimental data linking rs10818488 specifically to regulation of C5. Therefore the available evidence is insufficient to support or contradict the claim."
    },
    "naive_doc_ids": [
      "28928964",
      "8496132",
      "33986507",
      "12580014",
      "1967017"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present experimental or association data showing that the TRAF1/C5 rs10818488 allele alters expression of the neighboring C5 gene. Paper 4 discusses the TRAF1/C5 region as an RA risk locus (and corrects an allele-labeling detail) but does not report that rs10818488 regulates C5 expression. Papers 1 and 2 describe eQTL methods and RNA\u2011seq eQTL mapping in general, and Paper 3 reports eQTL hotspots in mice, but none of these include results tying rs10818488 to C5 regulation. Papers 5\u20137 are on unrelated molecular pathways. Therefore the provided evidence does not support or contradict the specific regulatory claim."
    },
    "overthinking_doc_ids": [
      "15286783",
      "4378885",
      "28928964",
      "1967017",
      "164985"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present direct evidence that the TRAF1/C5 rs10818488 polymorphism regulates expression of the neighboring C5 gene. Paper 1 reports an association in the TRAF1/C5 region with rheumatoid arthritis and corrects allele-labeling, but does not provide functional data showing rs10818488 alters C5 expression. Paper 2 describes a general mechanism by which DNA repair can change methylation and gene expression, which is mechanistically relevant but does not demonstrate that rs10818488 affects C5. Papers 3\u20139 address other genes, loci, or general methodological topics and do not report data on rs10818488 or C5 regulation. Therefore the supplied evidence is insufficient to confirm or refute the specific regulatory effect of rs10818488 on C5."
    },
    "posthoc_doc_ids": [
      "1967017",
      "13906892",
      "21641088",
      "164985",
      "5612738"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1190",
    "claim": "The amount of publicly available DNA data doubles every 10 months.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper excerpts report measurements or statistics on the global growth rate or doubling time of publicly available DNA data. Paper 1 (GEO) only describes the repository and tools (no growth/doubling figures in the provided text). Papers 2, 3, 6, and 7 are methods or specific NGS/assembly studies and do not provide overall repository growth rates. Paper 4 discusses open-access citation effects, and Paper 5 is an epidemiology study unrelated to database growth. Therefore the supplied evidence does not confirm or refute the claim that publicly available DNA data doubles every 10 months."
    },
    "naive_doc_ids": [
      "15617300",
      "1544804",
      "7324039",
      "27768226",
      "3801693"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report quantitative measurements of the total amount of publicly available DNA data over time or a doubling time. The collection includes methods, software, resources and analyses (e.g., GeneTrack, MicroScope, GEO description, IGV, Trimmomatic, SRMA, studies of genome doubling and GC bias, hierarchical phylogenetic models), but none present data or estimates showing that public DNA data volume doubles every 10 months. Some papers mention public repositories (GEO) or growing data resources (MicroScope contains >1600 genomes and ongoing curation), but they do not provide time-series growth rates or the specific doubling-period claim, so the evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "7838799",
      "7211056",
      "18494847",
      "15617300",
      "7324039"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data or analyses about the growth rate or total volume of publicly available DNA sequence data. The papers cover topics such as socioeconomic health (Paper 1), methods for inferring nucleosome positions from ChIP-seq (Paper 2), network visualization software (Paper 3), haplotype-tagging SNP selection (Paper 4), blood pressure and cognition in children with CKD (Paper 5), a read-trimming tool for Illumina data (Paper 6), hierarchical phylogenetic models (Paper 7), and whole-genome doubling in cancer (Paper 8). Although some discuss sequencing methods or data processing (Papers 2, 6, 7), none report measurements of public DNA data volume or its doubling time. Therefore the set of papers does not provide evidence to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "1781626",
      "175735",
      "2883827",
      "15570962",
      "19804204"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "34",
    "claim": "A deficiency of folate increases blood levels of homocysteine.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple randomized trials, meta-analyses and genetic studies in the provided papers consistently show that increasing folate (folic acid) lowers plasma/serum homocysteine, implying that low folate (deficiency) increases homocysteine. Paper 1 (randomized dose trial) found a dose-dependent decrease in serum homocysteine with folic acid (maximum placebo-adjusted reduction 2.7 \u03bcmol/L at 0.8 mg/day). Paper 3 (elderly RCT) showed significant homocysteine reductions only at 400\u2013600 \u03bcg/day supplements. Paper 2 (meta-analysis) reports substantial percent reductions in homocysteine with supplementation, larger in populations without folate fortification. Paper 4 demonstrates that individuals with the MTHFR 677TT genotype have higher homocysteine and require higher folate thresholds to normalize it. Paper 5 shows the MTHFR effect on homocysteine is larger in low-folate regions (TT vs CC difference \u22483.12 \u03bcmol/L), and trials/meta-analysis findings vary by population folate status. Paper 6 is mechanistic (methionine\u2192homocysteine) and does not contradict the folate\u2013homocysteine relationship. Taken together, the evidence supports the claim that folate deficiency increases blood homocysteine levels."
    },
    "naive_doc_ids": [
      "11705328",
      "37424881",
      "21636085",
      "42441846",
      "8595678"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers show that folate status causally influences plasma homocysteine. Paper 5 (randomized trial) demonstrates dose-dependent reductions in serum homocysteine with folic acid supplementation (maximum ~23% reduction at 0.8\u20131.0 mg/day). Paper 2 (meta-analysis) reports larger homocysteine reductions from folic acid supplementation in populations without folate fortification (~27%) versus with fortification (~18%), implying low folate is associated with higher homocysteine. Paper 4 shows the MTHFR 677TT genotype raises homocysteine much more in low-folate regions (TT vs CC difference ~3.12 \u03bcmol/L in Asia) than in folate-fortified regions (~0.13 \u03bcmol/L), indicating effect modification by folate status. Paper 3 similarly finds higher homocysteine and a higher folate threshold to normalize it in TT individuals. (Paper 1 addresses methionine-induced homocysteine but not folate deficiency directly.) Together these data support the claim that folate deficiency increases blood homocysteine levels."
    },
    "overthinking_doc_ids": [
      "36654066",
      "37424881",
      "42441846",
      "8595678",
      "11705328"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers in the set report that low folate status or absence of folate fortification is associated with higher homocysteine and that folic acid supplementation lowers homocysteine. Paper 1: the MTHFR 677TT genotype raised homocysteine much more in low-folate regions (difference TT vs CC = 3.12 \u03bcmol/L) than in folate-fortified regions (0.13 \u03bcmol/L), indicating folate status modifies homocysteine levels. Paper 4: randomized-trial meta-analysis found larger homocysteine reductions in trials without folate fortification (\u224827%) versus with fortification (\u224818%), consistent with higher baseline homocysteine when folate is low. Paper 7: individuals with the MTHFR TT genotype had significantly elevated homocysteine and required higher folate thresholds to maintain normal homocysteine. Together these data support that folate deficiency is associated with, and causally linked by intervention studies to, increased blood homocysteine levels."
    },
    "posthoc_doc_ids": [
      "8595678",
      "2481032",
      "1538080",
      "37424881",
      "4550036"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "813",
    "claim": "Mutations in G-Beta protein GNB1 are present in many cancers, resulting in loss of interaction with G-alpha subunits and concomitant activation of AKT pathway.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the eight provided papers mention GNB1 or G-protein \u03b2 subunit mutations, loss of G\u03b1\u2013G\u03b2 interaction, or a direct link from GNB1 mutations to AKT activation. Several papers discuss PI3K/AKT pathway activation (e.g., via PTEN loss or PIK3CA mutations) and therapeutic targeting of that pathway, but they do not provide experimental evidence for the specific claim about GNB1 mutations being common in cancers and causing loss of G\u03b1 interaction with concomitant AKT activation. Therefore the supplied evidence does not support or contradict the claim."
    },
    "naive_doc_ids": [
      "11271123",
      "14241418",
      "22401720",
      "21164071",
      "6492658"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers report on GNB1 (G-protein beta subunit) mutations, their interaction with G-alpha subunits, or effects on AKT activation. Paper 1 discusses PI3K/AKT pathway activation due to p110-alpha mutations and inhibition by NVP-BEZ235, but it does not mention GNB1 or G-beta/G-alpha interactions. The other papers cover unrelated genes/proteins (EGFR mutation detection, PPM1D mosaic mutations, p62/VDR in liver, TDP43/SRSF3 in TNBC splicing, adenovirus E3 interactions, integrin beta3 mutation in Glanzmann thrombasthenia, and AMPK beta1 post\u2011translational modification) and do not provide evidence for or against the claim. Therefore there is no information in these papers to support or contradict the statement about GNB1 mutations and AKT activation."
    },
    "overthinking_doc_ids": [
      "14241418",
      "711256",
      "4414547",
      "3701541",
      "4889228"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the eight provided papers report on GNB1 (G-protein beta subunit) mutations, loss of interaction with G-alpha subunits, or AKT activation as a consequence of GNB1 alteration. Several papers (1,4,7) discuss PI3K/AKT/mTOR pathway activity and inhibitors in cancers, and paper 6 addresses the beta-1 subunit of AMPK (not G-protein beta), but none present data linking GNB1 mutations to disrupted G-alpha binding or to concomitant AKT pathway activation. Therefore the supplied evidence does not support or refute the claim."
    },
    "posthoc_doc_ids": [
      "14241418",
      "4414547",
      "16745747",
      "4961038",
      "7005276"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "789",
    "claim": "Microglia are an innate immune cell type of the central nervous system.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers explicitly state or present experimental evidence that microglia are an innate immune cell type of the central nervous system. The papers discuss immune components (macrophages, dendritic cells, T cells, Toll\u2011like receptors, NOX2, innate immunity) and immune processes in the CNS or other tissues, but they do not identify or characterize microglia as the CNS-resident innate immune cells. Therefore the supplied evidence does not directly confirm or refute the claim."
    },
    "naive_doc_ids": [
      "19238",
      "22647695",
      "3329824",
      "56486733",
      "24707550"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 6 explicitly describes microglia as \"resident tissue macrophages of the brain\" and shows they respond to innate stimuli (inflammasome activation and IL-1\u03b2 secretion), demonstrating microglial innate immune functions in the CNS. Related papers on macrophage innate responses (Papers 4 and 5) provide additional context for macrophage-like innate roles. Therefore the provided evidence supports the claim that microglia are an innate immune cell type of the central nervous system."
    },
    "overthinking_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "14474178",
      "9784254"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided paper excerpts explicitly identify or describe microglia. The papers discuss CNS inflammation, myelin gene expression, and various innate immune cell types (macrophages, neutrophils, ILCs, iNKT cells) or peripheral innate immunity, but none state that microglia are a CNS-resident innate immune cell type or present experimental data about microglial identity or function. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "3672261",
      "14474178"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "126",
    "claim": "Approximately 250,000 people are infected with human T-cell lymphotropic virus type 1 in the United Kingdom.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers gives an estimate or data supporting or refuting a figure of ~250,000 people infected with HTLV-1 in the United Kingdom. Paper 1 reports diagnosed cases of HTLV-I\u2013related disease in the UK (e.g., 100 HAM and 44 ATLL cases 1986\u20131992) and notes infection among immigrants, but does not provide a population prevalence or total infected count. The other papers address unrelated infections or conditions (self-harm in prisons, glaucoma, HCV transfusion risk, CJD lookback, HIV cell biology, clinical series from Barbados, and ATLL treatment outcomes) and do not supply UK HTLV-1 prevalence data. Therefore the evidence set neither confirms nor contradicts the claim."
    },
    "naive_doc_ids": [
      "24512064",
      "13900610",
      "8298120",
      "3698758",
      "11349166"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the five provided papers address human T\u2011cell lymphotropic virus type 1 (HTLV\u20111) or report data on HTLV\u20111 prevalence or infection counts in the United Kingdom. The papers concern bariatric surgery outcomes, overweight prevalence in US youth, cancer survivor prevalence in the US, drowning in UK children, and blood\u2011pressure diagnostic cost\u2011effectiveness\u2014topics unrelated to HTLV\u20111. Therefore the claim about ~250,000 people infected with HTLV\u20111 in the UK cannot be verified or refuted from the supplied evidence."
    },
    "overthinking_doc_ids": [
      "5824985",
      "6876224",
      "9547722",
      "42291761",
      "5151024"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers address human T\u2011cell lymphotropic virus type 1 (HTLV\u20111) or give prevalence/epidemiological data for HTLV\u20111 infections in the United Kingdom. The papers cover topics such as cancer survivorship, Creutzfeldt\u2011Jakob disease, bariatric surgery, HIV biology and cohorts, CTCF binding, SIV history, and antidepressant risks, but no study reports numbers or estimates of HTLV\u20111\u2013infected people in the UK. Therefore the supplied evidence does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "9547722",
      "27063470",
      "5824985",
      "46202852",
      "20996244"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "27",
    "claim": "A 100g dose of chloroquine chemoprophylactic regimen results in retinal toxicity after 5-6 years of weekly intake.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers report data on chloroquine dosing, cumulative 100 g exposure, or chloroquine-induced retinal toxicity. Paper 3 (malaria prevention in long-term travelers) discusses long-term chemoprophylaxis strategies and safety in general but the excerpt contains no specific findings about chloroquine cumulative dose or timing of retinal toxicity. The other papers address unrelated topics (tamoxifen, critical care outcomes, aspirin and AMD, mechanisms of choroidal neovascularisation, protein aggregation, and autophagy). Therefore the supplied evidence does not support or refute the claim."
    },
    "naive_doc_ids": [
      "12438901",
      "20606520",
      "32390525",
      "24735908",
      "17708753"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the seven provided papers address chloroquine, antimalarial chemoprophylaxis, retinal toxicity, or dosing/duration related to chloroquine. The studies cover topics such as chemotherapy-induced febrile neutropenia, HIV PrEP in macaques, tuberculosis treatment regimens, polyglutamine toxicity in C. elegans, physical activity and mortality, HPV testing, and mammographic screening; therefore they contain no evidence to support or refute the specific claim about a 100 g chloroquine regimen causing retinal toxicity after 5\u20136 years of weekly use."
    },
    "overthinking_doc_ids": [
      "6334188",
      "14260013",
      "341324",
      "7042304",
      "6647414"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on chloroquine-induced retinal toxicity, cumulative chloroquine dosing, or long-term weekly chloroquine chemoprophylaxis. Paper 1 reports self\u2011reported acute/short\u2011term side effects in travelers using chloroquine (and other antimalarials) but does not report ophthalmologic outcomes or cumulative doses; the other papers address unrelated topics (plant toxin in monkeys, TB regimens, comorbidity and febrile neutropenia, physical activity, PrEP in macaques, tamoxifen, ICU outcomes, post\u2011transplant immune reconstitution). Therefore the supplied evidence does not confirm or refute the specific claim about 100 g cumulative chloroquine causing retinal toxicity after 5\u20136 years of weekly intake."
    },
    "posthoc_doc_ids": [
      "38410121",
      "22334300",
      "341324",
      "6334188",
      "6647414"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "224",
    "claim": "Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers explicitly identify cancer-associated fibroblasts (CAFs) as components of the tumor microenvironment and report experimental findings consistent with that role. Paper 1 states CAFs are \"one of the most crucial components of the tumor microenvironment.\" Paper 2 shows carcinoma-associated fibroblasts in tumors produce chemokines that recruit granulocytes, affecting response to CSF1R inhibition. Paper 3 describes CAF\u2013tumor cell crosstalk in the tumor microenvironment driving EMT and metastasis. Paper 7 demonstrates IL6 derived from CAFs in the tumor microenvironment promotes chemoresistance in esophageal cancer. Paper 9 provides evidence that diverse tumor-associated processes (including endothelial-to-mesenchymal transition) generate carcinoma-associated fibroblasts that accumulate at tumor invasive fronts. Collectively, these findings confirm the claim that CAFs are constituents of tumor microenvironments."
    },
    "naive_doc_ids": [
      "952111",
      "3559136",
      "8702697",
      "4583180",
      "13329980"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple provided papers explicitly state that cancer-associated fibroblasts (CAFs) are components of the tumor microenvironment and play active roles there. Paper 1 directly states that CAFs \"is one of the most crucial components of the tumor microenvironment\" and discusses their role in promoting cancer growth and invasion. Paper 2 describes carcinoma-associated fibroblasts as major sources of chemokines that recruit granulocytes to tumors, implicating CAFs in tumor microenvironmental crosstalk. Paper 3 analyzes oxidative stress in cancer-associated fibroblasts driving tumor\u2013stroma co-evolution, again placing CAFs within the tumor stroma/microenvironment. Papers 4 and 5 do not address CAFs or the tumor microenvironment. Collectively, the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "952111",
      "3559136",
      "24349992",
      "207972",
      "1522336"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple provided papers explicitly state that cancer-associated fibroblasts (CAFs) are components of the tumor microenvironment. Paper 1 directly states CAFs are \"one of the most crucial components of the tumor microenvironment.\" Paper 3 lists fibroblasts among the cellular constituents of the tumor microenvironment (tumor cells, fibroblasts, endothelial cells, immune cells). Paper 2 describes carcinoma-associated fibroblasts within tumors as major sources of chemokines that recruit granulocytes, and Paper 6 discusses cancer-associated fibroblasts driving tumor\u2013stroma co-evolution. Together these findings confirm that CAFs are constituents of tumor microenvironments."
    },
    "posthoc_doc_ids": [
      "952111",
      "3559136",
      "313403",
      "2014909",
      "2734421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.98,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "350",
    "claim": "Discrimination between the initiator and elongation tRNAs depends on the translation initiation factor IF3.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly addresses bacterial translation initiation and states that the three initiation factors (IF1\u20133) enable selection of the initiator tRNA and start codon. It specifically reports that IF3 and tRNA undergo large conformational changes to facilitate accommodation of formylmethionyl-tRNA (fMet-tRNAfMet) into the P site for start codon recognition, implicating IF3 in discriminating the initiator versus elongator tRNAs. The other provided papers do not provide relevant evidence on bacterial IF3\u2019s role in initiator/elongator tRNA discrimination."
    },
    "naive_doc_ids": [
      "16927286",
      "2479538",
      "9505448",
      "6492658",
      "4465762"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address bacterial translation initiation factor IF3 or the molecular discrimination between initiator and elongator tRNAs. The papers cover neuronal migration (Paper 1), effects of hypnotics on sleep (Paper 2), green tea polyphenols and oxidative stress (Paper 3), an alphavirus opal termination codon and readthrough affecting infectivity (Paper 4), silver nanoparticles and AGEs (Paper 5), and tobacco-exposed fibroblasts promoting epithelial changes (Paper 6). While Paper 4 discusses translational readthrough at a stop codon in a viral genome, it does not investigate IF3 or experimental discrimination between initiator and elongator tRNAs. Therefore the evidence set contains no relevant information to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "469066",
      "5431268",
      "6650933",
      "152245",
      "719812"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 directly addresses bacterial initiation and states that the three initiation factors (IF1\u20133) enable selection of the initiator tRNA and start codon, and specifically describes large conformational changes of IF3 and tRNA that facilitate accommodation of formylmethionyl-tRNA(fMet) into the P site for start-codon recognition. This indicates that IF3 plays an active role in discriminating the initiator tRNA from elongator tRNAs during translation initiation. The other provided papers do not present contrary evidence relevant to this specific bacterial IF3-dependent discrimination (some discuss unrelated initiation factors in eukaryotes or other topics), so the set of papers supports the claim."
    },
    "posthoc_doc_ids": [
      "16927286",
      "2479538",
      "9505448",
      "22896970",
      "2851611"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "574",
    "claim": "In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the supplied paper excerpts report data on the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae. Paper 8 (Domestication and Divergence of Saccharomyces cerevisiae Beer Yeasts) is the only one directly about domesticated/industrial S. cerevisiae and mentions genome sequencing of 157 strains and genomic/phenotypic divergence, but the excerpt provided does not state whether segmental aneuploidy is common or rare. The other papers are about unrelated organisms or topics (human/mouse cancer, array CGH in bladder tumors, methods for RNA processing, baker\u2019s yeast metabolism) and do not provide evidence addressing the specific claim. Therefore there is insufficient information in the provided evidence to support or contradict the claim."
    },
    "naive_doc_ids": [
      "13934676",
      "365896",
      "14019636",
      "2402323",
      "4457160"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper excerpts report data on the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae populations. Paper 4 (domestication/divergence of industrial yeasts) is the most relevant source but the excerpt does not mention aneuploidy or segmental copy-number changes. The other papers deal with RNA processing, transcription regulation, lifespan, chromosome segregation mechanisms, meiotic DSB mapping, or rDNA copy number in cancer\u2014none provide population-level measurements of segmental aneuploidy in domesticated S. cerevisiae. Therefore the evidence set neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "10300888",
      "14019636"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided paper excerpts report data or results about the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae. While Paper 8 describes genomic and phenomic analysis of 157 industrial (domesticated) S. cerevisiae strains, the excerpt does not mention aneuploidy or segmental copy-number changes. The other papers address unrelated topics (RNA processing, transcription regulation database, calorie restriction, condensin in fission yeast, promoter histone dynamics, stress signaling, rDNA copy number in cancer) and do not provide evidence bearing on segmental aneuploidy in domesticated S. cerevisiae. Therefore the provided evidence is insufficient to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "335029",
      "406733"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "985",
    "claim": "Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 directly demonstrates that the PTEN pseudogene PTENP1 is biologically active and can regulate cellular PTEN levels via a coding-independent mechanism in which transcripts compete for microRNA binding (i.e., acting as a ceRNA/miRNA decoy). Papers 1 and 6 provide independent support for the general mechanism (linc-RoR and engineered miRNA sponges act as competing endogenous RNAs), and Paper 7 shows a similar decoy-like regulation of PTEN by a lncRNA (GAS5 inhibiting miR-103). Paper 2 raises a quantitative caveat that ceRNA effects may require very high target-site abundance in some contexts, but it does not refute the specific experimental demonstration in Paper 3. Taken together, the evidence supports the claim that PTENP1 regulates PTEN expression by functioning as an miRNA decoy."
    },
    "naive_doc_ids": [
      "42662816",
      "18421962",
      "6828370",
      "25827024",
      "2619579"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 1 (Poliseno et al.) provides direct experimental evidence that the PTEN pseudogene PTENP1 can regulate cellular PTEN levels and act in a growth-suppressive manner via a coding-independent mechanism consistent with functioning as a competing endogenous RNA / miRNA decoy. Paper 2 further supports the biology of miRNA-mediated regulation of PTEN (miR-21 targets PTEN), which is mechanistically compatible with a decoy model. Paper 6, however, presents quantitative data challenging the generality of the ceRNA hypothesis, showing that very large changes in target-site abundance are required to measurably affect miRNA activity, and thus cautions that ceRNA effects may be context- and abundance-dependent. Other provided papers are not relevant. Overall, the set includes direct supportive evidence for PTENP1 acting as an miRNA decoy for PTEN, but also a broader study that questions how generally and effectively ceRNA mechanisms operate under physiological conditions."
    },
    "overthinking_doc_ids": [
      "6828370",
      "654735",
      "1191830",
      "4886637",
      "14584755"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides direct experimental evidence that the PTEN pseudogene transcript PTENP1 regulates cellular PTEN levels via a coding-independent mechanism\u2014i.e., by competing for microRNA binding sites\u2014and that this influences growth suppression and is relevant in cancer. Paper 1 provides supporting mechanistic precedent by showing a 3'UTR fragment can act as an miRNA decoy and de-repress PTEN. Paper 4 further supports the general competing endogenous RNA (ceRNA)/miRNA sponge mechanism. Paper 5 raises quantitative constraints on how broadly ceRNA effects operate but does not disprove the specific PTENP1\u2013PTEN interaction. Taken together, the provided literature supports the claim that PTENP1 regulates PTEN by functioning as an miRNA decoy."
    },
    "posthoc_doc_ids": [
      "13964633",
      "6828370",
      "29429111",
      "42662816",
      "18421962"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1098",
    "claim": "Stacking is more stable when a purine is present in the +5 position (C1698).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper abstracts or summaries present experimental data or statements about base stacking at a +5 position (C1698) or about the effect of a purine at that position on stacking stability. Paper 1 (60S ribosome) reports a ribosomal structure but the summary does not mention the specific nucleotide C1698, a +5 position, or comparative stacking stabilitites. The other papers concern viral capsids, histones/nucleosomes in general, statin effects, wound healing, virus experimental evolution, radiation effects, glycosylation of a potassium channel, and a physical activity trial \u2014 none discuss nucleotide base stacking or the described positional purine effect. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "22896970",
      "4828984",
      "13790144",
      "6212802",
      "6308416"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers report experimental or computational results about base stacking stability as a function of the identity at a +5 position (or specifically at C1698). The papers cover topics such as pre-rRNA processing and binding factors (Paper 1 and 2), an enzymatic characterization (Paper 3), protein structure and interactions (Paper 4 and 6), chromatin remodeling and repair (Paper 5), DNA methylomes (Paper 8), signaling (Paper 9), and an unrelated behavioral study (Paper 7). No article presents data on nucleotide stacking energetics, comparisons of purine versus pyrimidine at a +5 position, or the specific residue C1698. Therefore there is no information in the supplied evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "18467982",
      "26112624",
      "393001",
      "8093935",
      "6536598"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the eight provided papers address nucleotide base stacking, the identity of bases at a +5 position (e.g., C1698), or experiments measuring stacking stability related to purine versus pyrimidine at that position. The papers cover DNA methylomes (Paper 1), replication fork stability and chemoresistance (Paper 2), atherosclerotic plaque pathology (Paper 3), microtubule regulation in Drosophila neurons (Paper 4), bile-acid activation of brown adipose tissue (Paper 5), neuronal Sirt1 and insulin sensitivity (Paper 6), an HDA\u2013EBV gene delivery system (Paper 7), and Pax7 pioneer-factor activity (Paper 8). None present data or discussion relevant to the claim, so the claim cannot be confirmed or refuted from this evidence set."
    },
    "posthoc_doc_ids": [
      "3174305",
      "4444861",
      "4890578",
      "36111909",
      "1568684"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "658",
    "claim": "It is not proven that moderate consumption of candy and chocolate reduces the risk of cardiovascular disease (CVD) specifically.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly examine moderate consumption of candy or chocolate and subsequent cardiovascular disease risk. Paper 1 reports an association between higher dietary flavonol intake (from fruits, vegetables, tea, red wine) and lower CHD mortality, but it does not study chocolate/candy specifically. Papers 2 and 3 report associations of biomarkers (TMAO, Lp(a)) with cardiovascular risk, and Papers 4\u20135 address blood-pressure lowering treatments in dialysis patients \u2014 none provide experimental or observational data about candy or chocolate consumption. Therefore these papers neither prove nor disprove the claim that moderate candy/chocolate consumption reduces CVD risk."
    },
    "naive_doc_ids": [
      "12102963",
      "6793674",
      "21571708",
      "202259",
      "10072941"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers examine the effects of candy or chocolate consumption on cardiovascular disease risk. The papers address unrelated CVD topics (circulating TMAO levels, migraine association with stroke, blood pressure lowering in dialysis patients, QRISK3 prediction model, CVD risk factor prevalence in China, and antidepressant risks in older adults). While they concern cardiovascular risk or risk factors, none present data on moderate candy or chocolate intake or its association with CVD, so they do not support or refute the claim."
    },
    "overthinking_doc_ids": [
      "6793674",
      "15984735",
      "202259",
      "27466734",
      "2138767"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the eight provided papers address moderate consumption of candy or chocolate or its effect on cardiovascular disease risk. The papers cover migraine and CVD risk (Paper 1), circulating TMAO and CVD (Paper 2), blood pressure lowering in dialysis patients (Paper 3), physical activity and cognition (Paper 4), fluid balance in critically ill patients (Paper 5), prevalence of CVD risk factors in China (Paper 6), osteoporosis treatments and fractures (Paper 7), and gastric lavage in pesticide poisoning (Paper 8). While some discuss CVD risk factors or markers (e.g., TMAO, hypertension), none present data on candy/chocolate intake, so they neither support nor contradict the claim that moderate candy/chocolate consumption reduces CVD risk."
    },
    "posthoc_doc_ids": [
      "15984735",
      "6793674",
      "202259",
      "1642727",
      "20473074"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "439",
    "claim": "Fz/PCP-dependent Pk localizes to the anterior membrane of neuroectoderm cells during zebrafish neuralation",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "None of the provided papers report experimental data showing that Prickle (Pk) localizes to the anterior membrane of neuroectoderm cells during zebrafish neurulation. Paper 1 (zebrafish) shows that PCP/Vangl2 polarizes neural progenitors and is required for neurulation but the abstract does not describe Prickle\u2019s subcellular/anterior localization. The other papers discuss PCP components or PCP in other tissues/species (mouse cochlea, Dvl in mouse, general PCP review) or unrelated zebrafish topics, but none provide direct evidence for Fz/PCP-dependent anterior membrane localization of Pk in zebrafish neuroectoderm. Therefore the provided evidence does not confirm or refute the specific claim."
    },
    "naive_doc_ids": [
      "4423559",
      "18575183",
      "5944514",
      "317204",
      "4932668"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided paper summaries report experimental data on Prickle (Pk) localization or Frizzled (Fz)-dependent anterior membrane localization in zebrafish neuroectoderm during neurulation. Paper 7 addresses PCP signalling and Vangl2 function in zebrafish neurulation (polarization of neural progenitors, effects of trilobite mutants), but the excerpt does not describe Pk localization or Fz-dependent anterior membrane recruitment. The other papers are unrelated to PCP/Prickle localization. Therefore the provided evidence does not confirm or contradict the specific claim."
    },
    "overthinking_doc_ids": [
      "4932668",
      "5395426",
      "313394",
      "8533245",
      "22025252"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report or show that Prickle (Pk) localizes to the anterior membrane of neuroectoderm cells in zebrafish during neurulation, nor do they describe Fz/PCP-dependent anterior membrane localization of Pk. Paper 2 addresses PCP function in zebrafish neurulation (Vangl2/trilobite effects on neural keel cell polarity and reintegration) but does not report Pk subcellular localization. Paper 7 and the review (Paper 8) discuss PCP components and localization in mouse and general PCP mechanisms, but not zebrafish Pk anterior membrane localization. The remaining papers are unrelated to PCP localization. Therefore the provided evidence does not confirm or refute the specific claim."
    },
    "posthoc_doc_ids": [
      "4388082",
      "4423559",
      "5395426",
      "3419802",
      "4037034"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1322",
    "claim": "Transplanted human glial progenitor cells can mature in their host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports transplantation (engraftment) of human glial progenitor cells into neonatal immunodeficient mice and shows that, upon maturation, the recipient brains contained large numbers/proportions of human glial progenitors and mature astrocytes. The engrafted human glia retained human-specific morphology and were functionally integrated (gap-junction coupling, altered Ca2+ signaling) \u2014 evidence that transplanted human GPCs can mature in the host. The other provided papers do not contradict this finding and are not directly relevant to glial graft maturation."
    },
    "naive_doc_ids": [
      "16284655",
      "1667063",
      "4427392",
      "3360421",
      "19510470"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates this: human glial progenitor cells engrafted into neonatal immunodeficient mice gave rise to large numbers of human glial progenitors and mature human astrocytes in the recipient brains; the engrafted cells were functionally integrated (gap-junction coupling, altered Ca2+ signalling) and produced physiological effects (enhanced LTP and learning). The other papers do not contradict this (Paper 2 further shows human progenitors can mature and function after transplantation in mice for a different lineage), so the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "16284655",
      "37699461",
      "1667063",
      "1905095"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that human glial progenitor cells (GPCs) engrafted into neonatal immunodeficient mice matured in the host: recipient brains contained large numbers and high proportions of human glial progenitors and astrocytes, the engrafted human glia retained characteristic human morphology, were functionally integrated (gap-junction coupling, faster Ca2+ signaling), and enhanced host synaptic plasticity and learning. Additional papers (Paper 2 and Paper 3) provide corroborative evidence that transplanted human progenitor cells (cardiac progenitors, fetal liver progenitors) can differentiate and functionally mature in mouse hosts, further supporting the general principle that human progenitor cells can mature after transplantation into animals. Other listed papers do not address transplanted human glial progenitors specifically."
    },
    "posthoc_doc_ids": [
      "16284655",
      "9122283",
      "37699461",
      "7492250",
      "803312"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1319",
    "claim": "Transplanted human glial cells can differentiate within the host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that human glial progenitor cells (GPCs) engrafted into neonatal immunodeficient mice matured in the host brain into large numbers of human glial progenitors and astrocytes, showing differentiation of transplanted human glia in vivo. Paper 3 further shows human embryonic stem\u2013derived cells can differentiate and give rise to neural lineages and teratomas after grafting in mice, supporting the general principle that human progenitor/embryonic cells can differentiate in a host. Paper 2 describes differentiation of human cardiovascular progenitors after transplantation (different lineage), which is supportive of the broader concept but not specific to glia. Together, the evidence confirms that transplanted human glial/progenitor cells can differentiate within a host animal."
    },
    "naive_doc_ids": [
      "16284655",
      "4427392",
      "3360421"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that human glial progenitor cells (GPCs) engrafted into neonatal immunodeficient mice matured in the host brain, yielding large numbers/proportions of human glial progenitors and astrocytes (i.e., differentiation into astrocytes). Papers 2 and 3 further corroborate that transplanted human progenitor cells can differentiate in vivo (into insulin-producing cells or cardiovascular lineages), while Papers 4 and 5 are unrelated to transplantation/differentiation. Taken together, the evidence supports the claim that transplanted human glial cells can differentiate within a host animal."
    },
    "overthinking_doc_ids": [
      "16284655",
      "37699461",
      "4427392",
      "23601616",
      "980008"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple papers provide direct experimental evidence that transplanted human glial or neural precursor cells differentiate in host animals. Paper 1: human glial progenitor cells engrafted into neonatal immunodeficient mice matured in situ, producing large numbers of human glial progenitors and astrocytes in the recipient brain. Paper 4: human ES cell\u2013derived neural precursors transplanted into neonatal mouse brain differentiated into neurons and astrocytes. Paper 9: iPS-derived neural precursors transplanted into fetal mouse brain gave rise to glia and neurons and functionally integrated. Additional studies (Paper 3, Paper 2) show human progenitor cells transplanted in vivo can produce multiple lineages, further supporting the claim. None of the provided papers contradict this finding."
    },
    "posthoc_doc_ids": [
      "16284655",
      "9122283",
      "36398420",
      "2437807",
      "3360421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1288",
    "claim": "There is a positive correlation between hip fractures and statin use.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Of the eight papers provided, only Paper 1 directly examines the association between statin use and hip fractures. That case\u2013control study (JAMA 2000) found statin use was associated with a significantly lower risk of hip fracture (adjusted ORs 0.50 for prior 180 days and 0.57 for prior 3 years; current use associated with OR 0.29 after adjustment), i.e., an inverse rather than positive correlation. None of the other papers report data linking statin use to hip fractures. Therefore the provided evidence contradicts the claim that statin use is positively correlated with hip fractures. (Note: Paper 1 is observational and authors call for randomized trials to exclude unmeasured confounding.)"
    },
    "naive_doc_ids": [
      "4687948",
      "4883040",
      "6793674",
      "1711571",
      "11246427"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the six provided papers examine statin use or its association with hip fractures. The studies cover gestational diabetes (Paper 1), circulating TMAO and cardiovascular risk (Paper 2), FEV1 and lung cancer (Paper 3), antidepressant use and various adverse outcomes including fractures (Paper 4) \u2014 which is about antidepressants, not statins \u2014 lifestyle factors and mortality in Chinese women (Paper 5), and BMI and cancer risk (Paper 6). Because the evidence set contains no data on statins and hip fractures, it cannot confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "439670",
      "6793674",
      "12145359",
      "5691302",
      "1456068"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers report data on an association between statin use and hip fractures. Several papers address bone health and fractures (papers 1, 2, 5) but they investigate diabetes, trabecular bone score, or bisphosphonate treatments, not statins. Paper 8 reviews statin trials but focuses on cardiovascular and mortality outcomes and does not provide evidence about hip fractures. Therefore the evidence set does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "1711571",
      "11246427",
      "20280410",
      "17077004",
      "19878070"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "680",
    "claim": "Lack of FGF21 in mice increases life expectancy.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that FGF21 deficiency in apolipoprotein E(-/-) mice causes marked exacerbation of atherosclerosis and premature death, i.e. reduced lifespan. None of the other provided papers present experimental data showing that absence of FGF21 increases life expectancy; several discuss other genes/pathways affecting aging but do not support the claim. Therefore the provided evidence contradicts the claim that lack of FGF21 increases life expectancy in mice."
    },
    "naive_doc_ids": [
      "9315213",
      "25827024",
      "40349336",
      "9513785",
      "43014661"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers report experiments testing whether lack (knockout) of Fgf21 alters mouse lifespan. Paper 4 describes that induction of Fgf21 (from autophagy deficiency/mitochondrial stress) protects mice from diet-induced obesity and insulin resistance, implying Fgf21 has beneficial metabolic effects, which would, if anything, argue against the claim \u2014 but it does not measure longevity or the effects of Fgf21 deficiency. Other papers address lifespan-related pathways (e.g., GH/IGF1 in Paper 5, maternal protein restriction in Paper 1) but not Fgf21 loss. Therefore there is no direct evidence here to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "9513785",
      "10017612",
      "14188138",
      "6227220",
      "6313547"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.7,
      "justification": "None of the provided papers report that loss of Fgf21 increases mouse lifespan. Paper 6 directly addresses Fgf21 biology: autophagy deficiency induces Fgf21, and this induction protects mice from diet-induced obesity and insulin resistance (improved metabolic health). Those results imply Fgf21 is beneficial for metabolic health (and by extension would be expected to support, not reduce, longevity), which contradicts the claim that lack of Fgf21 increases life expectancy. The other papers do not provide evidence that Fgf21 deficiency lengthens lifespan."
    },
    "posthoc_doc_ids": [
      "9513785",
      "10017612",
      "14188138",
      "18691097",
      "2481032"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "389",
    "claim": "Ethanol stress increases the expression of IBP in bacteria.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the seven provided papers report experimental data linking ethanol stress to increased expression of IBP in bacteria. Paper 5 mentions ethanol as one of multiple stresses experienced by an ethanologenic E. coli in lignocellulosic hydrolysate but does not measure or report IBP (ice\u2011binding/IBP) expression. Paper 1 addresses redox/oxidative stress (soxRS) in E. coli, Paper 4 examines protein acetylation and responses to acetate/acid stress, and the remaining papers concern unrelated eukaryotic processes (AP-1 activation, TGF-\u03b2 effects, EBV, mitochondrial RNA binding). Therefore the evidence set does not contain information that supports or contradicts the specific claim."
    },
    "naive_doc_ids": [
      "471735",
      "16546131",
      "20675284",
      "6669242",
      "21602220"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report on 'IBP' expression in bacteria in response to ethanol. Several papers (Paper 2 and Paper 3) discuss ethanol stress or ethanol tolerance in E. coli, but they do not present data on IBP (ice\u2011binding protein or any other protein abbreviated IBP). The other papers address unrelated stress pathways, transcription factors, or proteins. Therefore the supplied evidence does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "471735",
      "21602220",
      "1148122",
      "9784254",
      "13912224"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the eight provided papers report experiments or results on ethanol stress inducing IBP expression in bacteria. The closest relevant study (Paper 1) examines redox/oxidative stress regulation (soxR/soxS) in Escherichia coli but does not address ethanol exposure or IBP. The remaining papers concern eukaryotic stress responses, development, inflammation, or viral transformation and do not provide data on bacterial IBP expression under ethanol stress. Therefore the supplied evidence does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "471735",
      "16546131",
      "24185667",
      "9614443",
      "9646449"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "615",
    "claim": "Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly addresses LRRK2 Roc-COR mutations and microtubule acetylation: increasing microtubule acetylation (via deacetylase inhibitors, \u03b1TAT1 expression, or HDAC6/Sirt2 knockdown) prevents mutant LRRK2 association with microtubules and restores/rescues axonal transport and locomotor deficits in neurons and Drosophila. This is the opposite of the claim (which states increased acetylation worsens transport defects). The other papers (2\u20135) do not provide evidence about LRRK2 Roc-COR mutations or the effects of microtubule acetylation on those mutants, so they are not supportive of the claim. Therefore the provided evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "9638032",
      "7549811",
      "1889358",
      "28369117",
      "54562433"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses LRRK2 Roc-COR domain mutations (R1441C, Y1699C) and shows that these mutant LRRK2 proteins preferentially bind deacetylated microtubules and inhibit axonal transport. Importantly, increasing microtubule acetylation (via deacetylase inhibitors such as TSA, \u03b1TAT1 expression, or knockdown of HDAC6/Sirt2) prevents mutant LRRK2 binding to microtubules and rescues axonal transport and locomotor deficits in primary neurons and Drosophila. Thus the experimental evidence indicates increased microtubule acetylation ameliorates \u2014 not worsens \u2014 the transport defects caused by LRRK2 Roc-COR mutations. The other papers discuss motor proteins, microtubule polarity, and energy supply for transport but do not provide evidence that would support the claim."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "7549811",
      "18678095"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly addresses LRRK2 Roc-COR domain mutations and shows the opposite effect to the claim: pathogenic Roc-COR LRRK2 mutants preferentially bind deacetylated microtubules and inhibit axonal transport, whereas increasing microtubule acetylation (via \u03b1TAT1 expression, HDAC6/Sirt2 knockdown, or the deacetylase inhibitor TSA) prevents mutant LRRK2 association with microtubules and restores axonal transport and locomotor behavior. Other provided papers do not present evidence that increased acetylation worsens LRRK2-induced transport defects; Paper 5 further supports a stabilizing role for tubulin acetylation on microtubule structure. Thus the available evidence contradicts the claim that increased acetylation worsens LRRK2 Roc-COR\u2013mediated interference with axonal transport."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "7549811",
      "16056410"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "747",
    "claim": "MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers examine MafA or the specific effect of MafA ubiquitination on recruitment of the coactivator P/CAF. While several papers touch on related topics\u2014Paper 4 notes PCAF/GCN5 can be recruited by transcription factors (E2F1), Paper 8 summarizes general consequences of ubiquitination (often leading to proteasomal degradation), and Paper 9 shows ubiquitination can decrease protein stability and activity (Notch3)\u2014there is no experimental data or direct discussion about MafA ubiquitination or its impact on MafA\u2013P/CAF interactions. Therefore the corpus does not provide evidence to support or contradict the claim."
    },
    "naive_doc_ids": [
      "22495397",
      "4270992",
      "21557055",
      "502591",
      "27545868"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers address MafA or the effect of MafA ubiquitination on recruitment of the coactivator P/CAF. Several papers discuss ubiquitination mechanisms (Papers 1\u20134,7) and others describe PCAF function or recruitment by other transcription factors (Papers 5 and 6), but there is no experimental data or results linking MafA ubiquitination to decreased P/CAF recruitment. Therefore the corpus does not provide evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "12225214",
      "21307488",
      "23513818",
      "24725136",
      "502591"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses MafA phosphorylation, ubiquitination and interaction with the coactivator P/CAF. It reports that GSK-3\u2013dependent phosphorylation of MafA induces its ubiquitination and degradation, but paradoxically phosphorylation increases MafA transcriptional activity through recruitment of P/CAF. Importantly, the paper states that P/CAF protects MafA from ubiquitination and degradation and that MafA becomes polyubiquitinated and degraded upon release of the coactivator complex. This indicates that P/CAF recruitment reduces MafA ubiquitination (the opposite causal direction of the claim), and that ubiquitination follows coactivator release rather than causing decreased P/CAF recruitment. None of the other provided papers present evidence supporting the claim. Therefore the available evidence contradicts the claim that MafA ubiquitination decreases P/CAF recruitment."
    },
    "posthoc_doc_ids": [
      "11291348",
      "14198646",
      "33370",
      "16389141",
      "19756935"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "962",
    "claim": "Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly demonstrate that mitochondrial RNA granules (MRGs) are sites of post\u2011transcriptional handling of mitochondrial transcripts. Paper 1 explicitly shows MRGs contain a large complement of RNA\u2011metabolism proteins, that helicases (DDX28, DHX30) and FASTKD family members localize there and are required for mitoribosome biogenesis and maturation of precursor mRNAs (e.g., FASTKD5 required for COX I mRNA maturation). Papers 3 and 4 identify GRSF1 in discrete mitochondrial foci (MRGs) that contain nascent mtRNA and RNase P, and show loss of GRSF1 causes abnormal primary transcript cleavage, reduced mitochondrial protein expression, impaired ribosome assembly and posttranscriptional defects. Paper 5 shows the DEAD\u2011box protein DDX28 resides in RNA granules and is essential for assembly of the mitoribosomal large subunit. (Paper 2 is unrelated to mitochondrial RNA granules.) Collectively these experimental results confirm that post\u2011transcriptional processing and ribosome biogenesis of mitochondrial transcripts occur in mitochondrial RNA granules."
    },
    "naive_doc_ids": [
      "20018321",
      "13867350",
      "13931771",
      "935538",
      "4306711"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "All three papers provide direct experimental evidence that mitochondrial RNA granules are sites of post-transcriptional handling of mitochondrial transcripts. Paper 1 characterizes the granule proteome, shows they contain RNA-processing factors (helicases, FASTKD proteins), demonstrates binding of factors (DDX28, FASTKD2) to 16S rRNA, and shows FASTKD5 is required for maturation of precursor mRNAs and for COX I production\u2014supporting granules as centers for posttranscriptional processing and ribosome biogenesis. Paper 2 shows the RNA-binding protein GRSF1 localizes to mitochondrial granules that colocalize with newly synthesized mtRNA; GRSF1 knockdown alters RNA stability, ribosome loading, and ribosome assembly, indicating posttranscriptional regulation occurs at these granules. Paper 3 finds GRSF1 and RNase P in discrete mitochondrial matrix foci (termed mitochondrial RNA granules), demonstrates their interaction, and shows they are required for processing primary transcripts (including tRNA-less precursors), consistent with granules being sites of transcript processing."
    },
    "overthinking_doc_ids": [
      "20018321",
      "935538",
      "13931771"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly report that mitochondrial RNA granules are sites of post\u2011transcriptional handling of mitochondrial transcripts. Paper 1 (GRSF1 Regulates RNA Processing in Mitochondrial RNA Granules) shows an isoform of the RNA\u2011binding protein GRSF1 localizes to discrete mitochondrial matrix foci composed of nascent mtRNA and RNase P and is required for processing primary transcripts, leading the authors to define these foci as \"mitochondrial RNA granules.\" Paper 5 likewise shows GRSF1 localizes to RNA granules that colocalize with newly synthesized mtRNA and that GRSF1 is required for posttranscriptional mitochondrial gene expression (affecting RNA stability, ribosome loading and assembly). Paper 3 explicitly characterizes mitochondrial RNA granules as centers for posttranscriptional RNA processing and mitochondrial ribosome biogenesis, identifying multiple processing factors (helicases, FASTKD proteins) whose loss impairs rRNA binding, mRNA maturation, and translation. Papers 2 and 4 do not contradict this (paper 2 documents tRNA modifications but does not locate them to granules; paper 4 is unrelated). Collectively, the experimental data support the claim."
    },
    "posthoc_doc_ids": [
      "13931771",
      "16242975",
      "20018321",
      "13867350",
      "935538"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "306",
    "claim": "DUSP4 decreases apoptosis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 4 directly addresses DUSP4: it identifies DUSP4 as an ERK phosphatase and reports that DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion reduced the apoptotic response and correlated with treatment-refractory tumors and worse outcomes. Thus the provided evidence indicates DUSP4 promotes (increases) apoptosis, which contradicts the claim that DUSP4 decreases apoptosis. No papers in the set provide evidence that DUSP4 reduces apoptosis."
    },
    "naive_doc_ids": [
      "33667484",
      "25251625",
      "22890091",
      "7821634",
      "32852283"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence opposing the claim: in breast cancer models, DUSP4 overexpression increased chemotherapy-induced apoptosis, and DUSP4 depletion reduced the apoptotic response. This indicates DUSP4 promotes (increases) apoptosis rather than decreases it. The other papers either do not address DUSP4\u2019s effect on apoptosis (Paper 4 notes DUSP4 overexpression with KRAS but not apoptosis) or are unrelated to DUSP4. Therefore the provided evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "7821634",
      "238409",
      "935034",
      "24190159",
      "3765739"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly tests DUSP4 function: DUSP4 overexpression increased chemotherapy-induced apoptosis and DUSP4 depletion reduced the apoptotic response, indicating DUSP4 promotes (increases) apoptosis rather than decreases it. Paper 1 only reports DUSP4 upregulation in KRAS-mutant rectal cancers without apoptosis data; the other papers do not provide relevant data on DUSP4 and apoptosis. Therefore the provided evidence contradicts the claim that DUSP4 decreases apoptosis."
    },
    "posthoc_doc_ids": [
      "24190159",
      "7821634",
      "5254463",
      "3531388",
      "5137019"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1364",
    "claim": "Venules have less significant tunica adventitia than arterioles.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers present anatomical or histological data comparing the tunica adventitia of venules and arterioles. The papers cover topics such as electron microscopy staining methods (Papers 1\u20132), stent effects and inflammation (Paper 3), angiogenesis outcomes mentioning arterioles and venules without structural detail (Paper 4), extracellular matrix and cell biology (Papers 5\u20139), but do not report measurements or descriptions of adventitial thickness or prominence in venules versus arterioles. Therefore the supplied evidence does not support or contradict the claim."
    },
    "naive_doc_ids": [
      "32827351",
      "46193478",
      "34268160",
      "8290953",
      "4164929"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers address vessel wall histology comparing the tunica adventitia of venules and arterioles. The studies focus on topics such as atheroma burden, burn dressings, HCV PCR, cancer screening, endothelial function, and angiogenesis, but do not present experimental data or descriptions about relative adventitial thickness of venules versus arterioles. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "87758",
      "3690068",
      "3692112",
      "285794",
      "756887"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address the anatomical comparison of tunica adventitia between venules and arterioles. Paper 2 discusses functional and molecular properties of coronary arterioles (e.g., endothelium-dependent relaxation and eNOS mRNA) but does not report histological details of the tunica adventitia. The other papers cover unrelated topics (atheroma imaging, wound dressings, HCV PCR, cancer screening, COPD costs, T cell receptor biochemistry, nuclear receptor structure) and do not provide data on vessel wall layers. Therefore the supplied evidence does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "87758",
      "1122279",
      "3690068",
      "285794",
      "756887"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1227",
    "claim": "The mean suicide rate in women is higher after miscarriage than live birth.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report or compare suicide rates in women after miscarriage versus after live birth. Several papers touch on related topics (Paper 5 and Paper 8 provide data on deliberate self-harm/suicide by age and sex; Paper 4 reports suicide/self-harm in older people), but none present outcomes stratified by pregnancy result (miscarriage vs live birth) or provide mean suicide rates for these groups. Therefore the evidence set does not address the claim."
    },
    "naive_doc_ids": [
      "43329366",
      "11360768",
      "2425364",
      "5691302",
      "1102268"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers report or compare suicide rates in women after miscarriage versus after live birth. Only Paper 8 addresses outcomes after miscarriage, and it reports on depressive symptoms (an increased odds of probable depression at 1 month postpartum only), not suicide rates. The other papers do not address miscarriage or postpartum suicide. Therefore the supplied evidence is insufficient to support or refute the claim."
    },
    "overthinking_doc_ids": [
      "14700857",
      "21239672",
      "829646",
      "14682243",
      "5691302"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 (Suicides after pregnancy in Finland, 1987\u201394) directly reports suicide rates by pregnancy type: suicide rate associated with birth = 5.9 per 100,000, and suicide rate associated with miscarriage = 18.1 per 100,000. The miscarriage-associated rate is substantially and significantly higher than the birth-associated rate, which supports the claim. The other provided papers do not report suicide rates by pregnancy outcome or are not relevant to this specific comparison."
    },
    "posthoc_doc_ids": [
      "22815457",
      "25641414",
      "5145974",
      "5691302",
      "4828631"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1200",
    "claim": "The binding orientation of the ML-SA1 activator at hTRPML2 is different from the binding orientation of the ML-SA1 activator at hTRPML1.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the six provided papers discuss ML-SA1, TRPML channels (hTRPML1 or hTRPML2), or ligand binding orientations for these proteins. The papers cover unrelated structures and mechanisms (MHC peptide binding, activin:follistatin, GLP-1 receptor\u2013Gs, p53/chromatin, HNF3/nucleosome, and homeodomain\u2013DNA dynamics). Therefore there is no evidence in these documents to support or contradict the claim about ML-SA1 binding orientations; additional, directly relevant structural data (e.g., cryo-EM/crystal structures or biochemical mapping of ML-SA1 bound to hTRPML1 and hTRPML2) would be required to evaluate the claim."
    },
    "naive_doc_ids": [
      "16270577",
      "40383969",
      "3610282",
      "21557055",
      "8331432"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report structural or biochemical data comparing ML\u2011SA1 binding orientations at human TRPML2 versus TRPML1. Paper 8 describes agonist-bound structures of human TRPML1 (but does not explicitly identify ML\u2011SA1 or compare binding orientation with TRPML2), and Paper 7 addresses TRPML subunit localization/oligomerization but not ligand binding/orientation. The other papers are unrelated to TRPML ligand binding. Therefore the provided evidence does not support or contradict the specific claim."
    },
    "overthinking_doc_ids": [
      "3610282",
      "4828984",
      "6903077",
      "9889151",
      "14155726"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report structural or biochemical data comparing ML\u2011SA1 binding at human TRPML2 versus TRPML1. Paper 4 describes agonist-bound and apo structures of human TRPML1 and mentions a hydrophobic agonist-binding cavity, but the excerpt does not identify ML\u2011SA1 or provide any comparison to TRPML2. The other papers are on unrelated proteins or topics. Therefore there is no evidence here to support or contradict the claim about different ML\u2011SA1 binding orientations between hTRPML2 and hTRPML1."
    },
    "posthoc_doc_ids": [
      "19313533",
      "16546131",
      "21219071",
      "3441524",
      "3610282"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "643",
    "claim": "Insulin effects appetite via ventral tegmental neurons.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 provides direct experimental evidence that insulin acts on midbrain catecholaminergic neurons (including VTA/SN dopaminergic neurons) to regulate food intake and energy balance: acute insulin stimulation increased firing in ~50% of VTA/SN dopaminergic neurons, and selective loss of insulin receptor signaling in Tyrosine Hydroxylase\u2013expressing cells abolished this electrophysiological response and produced hyperphagia, increased body weight and fat mass. The other papers do not provide contradictory evidence relevant to insulin acting via VTA neurons. Therefore the set of papers supports the claim that insulin affects appetite via ventral tegmental neurons."
    },
    "naive_doc_ids": [
      "23869951",
      "15535511",
      "4611267",
      "25050364",
      "343052"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that insulin acts on midbrain dopaminergic (VTA/SN) neurons: insulin acutely increased firing in ~50% of VTA/SN dopamine neurons, and selective insulin receptor (IR) deletion in Th-expressing (catecholaminergic) cells abolished that response and produced hyperphagia and increased body weight/fat. This indicates insulin signaling in VTA dopaminergic neurons influences feeding. Paper 3 further supports the role of midbrain dopamine neurons in controlling binge-like eating (though via 5-HT2C receptors rather than insulin). The other papers do not provide contrary evidence relevant to insulin acting via VTA neurons."
    },
    "overthinking_doc_ids": [
      "15535511",
      "23869951",
      "1084062",
      "16389141",
      "2436602"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 3 provides direct experimental evidence that insulin signalling in catecholaminergic (tyrosine hydroxylase\u2013expressing) midbrain neurons controls food intake and energy homeostasis: insulin acutely increased firing in ~50% of dopaminergic VTA/SN neurons, and conditional insulin receptor loss in TH+ cells abolished that response and produced hyperphagia, increased body weight, and fat mass. This shows insulin acts on VTA/SN dopaminergic neurons to influence appetite. Paper 1 further supports the role of VTA dopamine neurons in regulating feeding (via 5-HT2C receptors), reinforcing that modulation of VTA DA neurons alters appetite. None of the other provided papers present contradictory evidence."
    },
    "posthoc_doc_ids": [
      "1084062",
      "13322804",
      "15535511",
      "23869951",
      "10790846"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "693",
    "claim": "Leuko-reduced blood reduces infectious complications in red blood cell transfusion.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Only Paper 4 addresses leukoreduction directly: a large before-and-after cohort (14,786 patients) found that after universal prestorage leukoreduction there was no significant decrease in serious nosocomial infections (adjusted OR 0.97, 95% CI 0.87\u20131.09). The study did report reductions in posttransfusion fever (adjusted OR 0.86, 95% CI 0.79\u20130.94), antibiotic use (adjusted OR 0.90, 95% CI 0.82\u20130.99), and a small reduction in adjusted mortality (OR 0.87, 95% CI 0.75\u20130.99), but these do not demonstrate a reduction in serious infectious complications. The other provided papers are unrelated to leukoreduction. Therefore the available evidence here does not support the claim that leukoreduced red blood cells reduce infectious complications; the direct study presented finds no significant reduction in serious infections."
    },
    "naive_doc_ids": [
      "202259",
      "4883040",
      "15948830",
      "24088502",
      "23203102"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Only one provided paper (Paper 2) directly addresses leukoreduction and transfusion outcomes. In a large before-and-after study of universal prestorage leukoreduction in Canada, adjusted odds of serious nosocomial infections after transfusion did not decrease (adjusted OR 0.97, 95% CI 0.87\u20131.09). Although the study reported reductions in posttransfusion fever (adjusted OR 0.86, 95% CI 0.79\u20130.94), antibiotic use (adjusted OR 0.90, 95% CI 0.82\u20130.99), and a small reduction in mortality (adjusted OR 0.87, 95% CI 0.75\u20130.99), the predefined measure of serious infectious complications was essentially unchanged. The other provided papers do not address leukoreduction. Thus the available evidence here does not support the claim that leukoreduced blood reduces infectious complications (serious nosocomial infections) and is instead neutral for that outcome."
    },
    "overthinking_doc_ids": [
      "5402581",
      "24088502",
      "202259",
      "10582939",
      "12409683"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Only Paper 2 addresses leukoreduction directly. In a large before-and-after cohort study of universal prestorage leukoreduction, adjusted odds of death were reduced after leukoreduction (OR 0.87), and rates of posttransfusion fever (adjusted OR 0.86) and antibiotic use (adjusted OR 0.90) decreased. However, serious nosocomial infections (pneumonia, bacteremia, septic shock, surgical site infections) did not decrease (adjusted OR 0.97; 95% CI 0.87\u20131.09), i.e. no statistically significant reduction in infectious complications. The other provided papers do not provide relevant data on leukoreduction or transfusion-related infections. Therefore the supplied evidence does not support the claim that leukoreduced blood reduces infectious complications of red blood cell transfusion (it may reduce febrile reactions and antibiotic use but not serious nosocomial infections)."
    },
    "posthoc_doc_ids": [
      "11344428",
      "24088502",
      "243694",
      "12009265",
      "19878070"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "689",
    "claim": "Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report data on the fraction of patients exposed to radiation who have activated markers of mesenchymal stem cells. Paper 2 describes radiation-induced FGF-2 expression in mouse intestine (and increased expression in mesenchyme) but is an animal study and does not measure MSC activation in irradiated patients or report patient percentages. Paper 3 identifies ALDH1 as a stem cell marker in breast tissue but is unrelated to radiation-exposed patient cohorts. The other papers concern MSC biology, migration, signaling, or in vitro/animal findings (circadian regulation, MMP1, CD200, mesenchymal inflammation, embryonic-like cells) and do not provide clinical epidemiologic data on the proportion of radiation-exposed patients with activated MSC markers. Therefore the evidence does not permit support or contradiction of the claim."
    },
    "naive_doc_ids": [
      "21645205",
      "25238950",
      "45638119",
      "16853734",
      "3531388"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report clinical data on the proportion of patients exposed to radiation who have activated mesenchymal stem cell (MSC) markers. Several papers mention MSC biology or responses to injury/irradiation in non\u2011human or ex vivo settings (e.g., Paper 7 reports FGF-2 induction after gamma-irradiation in mouse intestine; Paper 8 shows LepR+ MSCs proliferate after injury including irradiation in mice), but these are experimental/animal or mechanistic findings and do not provide patient-level percentages. Other papers discuss MSC markers in various diseases or MSC therapies (Papers 1\u20136, 9\u201310) without giving statistics on patients exposed to radiation having activated MSC markers. Therefore the evidence supplied neither confirms nor refutes the claim."
    },
    "overthinking_doc_ids": [
      "9997636",
      "21645205",
      "25050969",
      "39851630",
      "40164383"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers report the fraction of patients exposed to radiation who show activation of mesenchymal stem cell (MSC) markers. Several papers are related to stem cells or radiation but do not address the claim directly: Paper 2 reports radiation-induced FGF-2 expression in mouse intestinal mesenchyme and improved crypt stem cell survival with exogenous FGF-2 (mouse study, not patients, and not quantifying MSC activation in exposed individuals). Paper 6 shows long-term senescence marker expression after ionizing radiation in mice (again not MSC activation in patients). Papers 1, 3, 4, and 5 discuss stem cells or MSC properties in non-radiation contexts or in disease cohorts (ovary, bone marrow, dexamethasone effects, MDS), and papers 7 and 8 are unrelated clinical topics. Therefore the evidence set does not provide data to support or contradict the stated percentage (<10%) in patients exposed to radiation."
    },
    "posthoc_doc_ids": [
      "9997636",
      "25238950",
      "35811036",
      "21645205",
      "39851630"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "298",
    "claim": "Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly report or describe cytochrome c release from the mitochondrial intermembrane space into the cytosol during apoptosis. Paper 1 states that mitochondrial outer membrane permeabilization (MOMP) is responsible for release of cytochrome c and other intermembrane-space proteins. Paper 2 notes that cell death can result from release to the cytosol of proteins normally hidden in the mitochondrial intermembrane space. Papers 3 and 4 report cytochrome c release in H. pylori\u2013induced apoptosis (Paper 3 cites prior demonstrations of cytochrome c release; Paper 4 shows Bax-dependent cytochrome c release experimentally). Paper 5 describes downstream apoptosome/caspase-9 activation, a pathway that depends on cytochrome c release. Together these findings confirm the claim."
    },
    "naive_doc_ids": [
      "39381118",
      "23403754",
      "8654183",
      "7465900",
      "13583521"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly state or experimentally demonstrate that cytochrome c is released from mitochondria to the cytosol during apoptosis. Paper 3 explicitly reports that H. pylori-related p53-mediated apoptosis involves Bax induction and cytochrome c release from mitochondria, and their experiments show expression of a non-acetylatable APE-1 induced cytochrome c release and DNA fragmentation. Paper 5 states that mitochondrial outer membrane permeabilization (MOMP) is responsible for release of cytochrome c and other intermembrane-space proteins in the mitochondrial (intrinsic) apoptosis pathway. Paper 4 (review) and Paper 2 (Apaf-1 apoptosome/caspase-9 activation) describe the mechanistic context in which cytochrome c released to the cytosol triggers apoptosome formation and caspase activation. Paper 6 also references cytochrome c release in H. pylori\u2013induced cell death. None of the provided papers contradict this mechanism (Paper 1 discusses Mtb-induced necrosis but does not refute cytochrome c release in apoptosis). Therefore the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "11837657",
      "13583521",
      "7465900",
      "23403754",
      "39381118"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple provided papers report experimental evidence that cytochrome c is released from mitochondria into the cytosol during apoptotic processes. Paper 1 explicitly states ouabain treatment caused \u201ccytochrome c release, caspase-3 activation, and DNA laddering.\u201d Paper 3 reports mitochondria-dependent apoptosis with \u201crelease of cytochrome c from the mitochondria into the cytosol and subsequent activation of caspase-3.\u201d Paper 4 notes cytochrome c release in H. pylori\u2013induced apoptosis alongside mitochondrial depolarization and caspase-3 activity. Paper 2 (review) describes release to the cytosol of death proteins normally in the mitochondrial intermembrane space during mitoptosis/apoptosis. No papers present evidence contradicting this mechanism. Collectively, the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "17231273",
      "23403754",
      "9588931",
      "8654183",
      "26071782"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "182",
    "claim": "Bone Marrow (BM) transplantation is used to treat acute myeloid leukemia (AML)",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple provided papers describe allogeneic hematopoietic (bone marrow/stem cell) transplantation in cohorts that include patients with acute myeloid leukemia (AML). For example, Paper 6 reports 69 allogeneic transplant recipients, of whom 42 had acute myeloid leukemia, and analyzes transplant outcomes in that group. Paper 3 reports cases of donor-cell leukemia after allogeneic stem cell transplantation, identifying 7 cases with an acute myeloid leukemia phenotype\u2014further indicating that AML is encountered in the context of allogeneic SCT. Other transplant-focused papers (Paper 2, Paper 4) discuss hematopoietic stem cell transplantation for hematologic diseases and posttransplant hematopoiesis. Together these studies support the claim that bone marrow/hematopoietic stem cell transplantation is used to treat AML."
    },
    "naive_doc_ids": [
      "40164383",
      "10128893",
      "11344428",
      "3090454",
      "1759213"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 directly concerns allogeneic stem cell transplantation (SCT) across many centers and documents donor\u2011cell leukemias after allogeneic SCT, including seven cases with an acute myeloid leukemia (AML) phenotype \u2014 which implies that allogeneic bone marrow/stem cell transplantation is performed in the clinical setting of hematologic malignancies such as AML. Papers 2 and 3 describe bone marrow hematopoietic stem cell niche biology (background relevant to transplantation), and Paper 4 demonstrates clinical use of allogeneic versus autologous stem cells in another disease, supporting the clinical application of bone marrow\u2013derived cell therapies. None of the provided papers contradict that bone marrow/allogeneic stem cell transplantation is used to treat AML."
    },
    "overthinking_doc_ids": [
      "11344428",
      "12130067",
      "17271462",
      "40164383",
      "3391547"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple provided papers describe the use of allogeneic bone marrow / hematopoietic stem cell transplantation (SCT/HSCT) in patients with acute myeloid leukemia. Paper 2 reports a cohort of 69 allogeneic SCT recipients that included 42 patients with AML and analyzes transplant-related outcomes (CD4 recovery, overall survival, NRM). Paper 1 is an EBMT survey covering 10,489 allogeneic SCTs and describes donor-cell leukemias including seven cases with an acute myeloid phenotype, indicating AML appears in the context of allogeneic SCT. These documents show that bone marrow / allogeneic stem cell transplantation is used in the treatment of AML, supporting the claim."
    },
    "posthoc_doc_ids": [
      "11344428",
      "24795767",
      "6374918",
      "3391547",
      "188911"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "764",
    "claim": "Medications to treat obesity are highly effective.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided evidence does not support the blanket claim that obesity medications are \"highly effective.\" A large meta-analysis of long\u2011term pharmacotherapy (Paper 7) found orlistat, sibutramine, and rimonabant produced modest mean weight losses versus placebo (orlistat \u22122.9 kg; sibutramine \u22124.2 kg; rimonabant \u22124.7 kg) and concluded they \"modestly reduce weight.\" Paper 1 (oral/subcutaneous semaglutide in patients with type 2 diabetes) showed dose\u2011dependent weight reductions (approximately \u22122.1 to \u22126.9 kg for oral semaglutide and \u22126.4 kg for subcutaneous at 26 weeks versus \u22121.2 kg for placebo), indicating greater but still moderate losses in that population and with some adverse effects. In contrast, bariatric surgery (Papers 3 and 4) produced much larger, sustained weight loss and higher rates of diabetes remission (e.g., ~20.7% weight loss at 2 years and rapid monthly losses after surgery), highlighting that surgical treatment is far more effective than pharmacotherapy in these datasets. Several papers also note common adverse effects with drug therapy. Overall, the evidence here supports that available medications produce modest-to-moderate weight loss but do not substantiate the claim that obesity medications are \"highly effective.\""
    },
    "naive_doc_ids": [
      "3654468",
      "40790033",
      "5824985",
      "7098463",
      "22467585"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Only two of the provided papers directly evaluate pharmacologic treatments for weight loss. The 2007/2006 updated meta-analysis of long-term anti-obesity drugs (orlistat, sibutramine, rimonabant) found modest mean benefits versus placebo after \u22651 year: orlistat \u2248 \u22122.9 kg, sibutramine \u2248 \u22124.2 kg, rimonabant \u2248 \u22124.7 kg, with notable adverse effects. A randomized trial of semaglutide in patients with type 2 diabetes showed larger but still moderate weight reductions over 26 weeks (oral semaglutide dose-dependent \u22122.1 to \u22126.9 kg; subcutaneous semaglutide \u22126.4 kg vs placebo \u22121.2 kg), but this was in a diabetic population, short-term (26 weeks), and reported frequent GI adverse events. The remaining papers are not relevant to pharmacologic obesity treatment. Overall, the evidence here indicates modest-to-moderate efficacy for older approved drugs and promising but not universally \u201chighly effective\u201d results for newer GLP-1 agents in specific contexts; it does not support the broad claim that obesity medications are highly effective for general use."
    },
    "overthinking_doc_ids": [
      "3654468",
      "22467585",
      "22922353",
      "5824985",
      "11939159"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 (updated meta-analysis of long-term anti-obesity drugs) directly addresses pharmacotherapy for obesity and finds that approved drugs produce only modest weight loss versus placebo (orlistat \u22122.9 kg, sibutramine \u22124.2 kg, rimonabant \u22124.7 kg over 1+ year) and have specific adverse effects; attrition rates were high (30\u201340%). Paper 4 (review) further emphasizes the limited effectiveness of existing anti-obesity drugs, safety issues, and that current pharmacologic approaches do not approach the magnitude of weight loss seen with surgery. No provided paper presents evidence that obesity medications are \u201chighly effective\u201d; the available data indicate modest efficacy and notable limitations."
    },
    "posthoc_doc_ids": [
      "4515975",
      "5402581",
      "7552215",
      "5839365",
      "1522336"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "992",
    "claim": "Pyridostatin deregulates G2/M progression.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper summaries mention pyridostatin or report experiments using pyridostatin. While several papers (e.g., Paper 2 on replication stress, RPA phosphorylation and G2/M checkpoint defects; Paper 8 on telomeric replication stress and mitotic DNA synthesis) describe mechanisms by which replication stress can perturb G2/M progression, these are indirect mechanistic links and do not constitute direct evidence that pyridostatin specifically deregulates G2/M progression. Therefore, based on the supplied evidence, there is no direct information to support or contradict the claim about pyridostatin."
    },
    "naive_doc_ids": [
      "10165258",
      "12909503",
      "15473205",
      "4412772",
      "19522248"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the nine provided papers mention pyridostatin or report experiments using it. While several papers (e.g., 7, 8, 9) describe replication stress responses and checkpoint mechanisms (ATR/Chk1, MDC1/TopBP1, RPA phosphorylation, DNA-PKcs) and others discuss G2/M regulators (e.g., cyclin B1/Cdc2 in paper 5), these are mechanistic background studies and do not provide experimental evidence that pyridostatin deregulates G2/M progression. Therefore the provided evidence does not confirm or refute the specific claim about pyridostatin."
    },
    "overthinking_doc_ids": [
      "7506409",
      "9641846",
      "29851836",
      "23269537",
      "23918031"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention pyridostatin or report experiments using it. While some papers discuss related concepts (e.g., G-quadruplex-related DNA damage and replication stress in Paper 2, CDK1 inhibition and effects on G2/M/endoreduplication in Paper 1, and G2/antephase arrest after pericentrin loss in Paper 8), these are indirect and do not provide experimental evidence that pyridostatin deregulates G2/M progression. Therefore the supplied evidence neither confirms nor refutes the specific claim about pyridostatin."
    },
    "posthoc_doc_ids": [
      "1595617",
      "12922760",
      "13906892",
      "15473205",
      "10608822"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "667",
    "claim": "Klf2 is important for proper myeloid cell function.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple provided studies show that KLF2 modulates myeloid-lineage cell behavior and that loss or reduction of KLF2 impairs/aberrantly activates these cells. Paper 1: DC-specific KLF2 deficiency increases costimulatory molecule expression, promotes T cell activation/apoptosis, and exacerbates atherosclerosis, indicating KLF2 controls dendritic cell activation/function. Paper 3: myeloid-specific Klf2 knockout macrophages and neutrophils show increased adhesion to endothelium, altered neutrophil survival, and increased macrophage/neutrophil accumulation with worsened atherosclerosis, demonstrating KLF2 is required for normal macrophage/neutrophil function. Paper 5: KLF2 hemizygous mice have increased recruitment of inflammatory monocytes, elevated proinflammatory mediators, greater monocyte-to-osteoclast differentiation, and more severe arthritis, indicating KLF2 regulates monocyte differentiation and inflammatory function. Other papers (2,4,6) are about CD200R, T cells, or KLF4 and are not directly relevant. Together the experimental data support the claim that Klf2 is important for proper myeloid cell function."
    },
    "naive_doc_ids": [
      "5979056",
      "14386505",
      "14407673",
      "22997657",
      "7948486"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly show that KLF2 in myeloid-lineage cells (macrophages, neutrophils, and dendritic cells) controls key myeloid functions. Paper 4 (myeloid-specific Klf2 knockout) reports increased macrophage and neutrophil adhesion, reduced neutrophil survival, and worsened atherosclerosis when Klf2 is absent in myeloid cells. Paper 5 demonstrates that myeloid KLF2 is a tonic repressor of myeloid activation (inhibiting NF-\u03baB\u2013dependent HIF-1\u03b1) and is critical for outcome in polymicrobial infection and endotoxemia. Paper 7 shows that KLF2 deficiency in dendritic cells enhances costimulatory molecule expression, increases T cell activation, and promotes proatherogenic inflammation. Together these experimental results indicate Klf2 is important for proper myeloid cell function."
    },
    "overthinking_doc_ids": [
      "5511240",
      "2824347",
      "3118719",
      "14407673",
      "6493422"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple papers directly show that KLF2 in myeloid cells controls key myeloid functions. Paper 3 identifies KLF2 as a tonic repressor of myeloid cell activation (regulating NF-\u03baB\u2013dependent HIF-1\u03b1 and innate responses). Paper 7 shows KLF2 limits gram-positive endotoxin\u2013induced HIF-1\u03b1, motility and proinflammatory gene expression and that myeloid Klf2-deficient mice are more susceptible to sepsis. Paper 6 demonstrates that myeloid-specific Klf2 loss increases macrophage and neutrophil adhesion, alters neutrophil survival, and promotes atherosclerosis. These experimental results indicate KLF2 is important for proper myeloid cell function. Other listed papers do not contradict this conclusion."
    },
    "posthoc_doc_ids": [
      "5836",
      "2030623",
      "6493422",
      "3118719",
      "14386505"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1278",
    "claim": "The treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 4 (pembrolizumab in advanced melanoma) reports treatment-related adverse events in humans: 14% experienced grade 3\u20134 treatment-related AEs, 9% had treatment-related serious AEs, and 4% discontinued because of treatment-related AEs. These clinical safety data contradict the claim that checkpoint (co-IR) blockade causes no adverse autoimmune events. Mechanistic and immunology papers (Paper 7 and Papers 8\u20139) explain that checkpoint pathways maintain self-tolerance and that their blockade (especially combined blockade) enhances T-cell activation and can perturb tolerance, providing a plausible basis for immune-related (autoimmune) toxicity. Paper 6 (nivolumab in non-human primates) noted no immune-related events in that preclinical model, but this does not override human clinical findings showing significant immune-related adverse events. Other listed papers address unrelated drug safety contexts. Taken together, the evidence does not support the absolute claim that co-IR blockade causes no adverse autoimmune events."
    },
    "naive_doc_ids": [
      "7639744",
      "11254040",
      "1759213",
      "3471191",
      "42404093"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present data that directly address whether combined immune-checkpoint (co-IR) blockade in cancer patients causes autoimmune adverse events. Paper 4 is the only paper that discusses combination checkpoint blockade (anti-CTLA4 plus anti-PD-1/PD-L1) but it focuses on mechanisms and antitumor efficacy and does not report safety or immune-related adverse events. The other papers concern unrelated treatments (bevacizumab, oncolytic virus, tamoxifen, MDR-TB therapy, aliskiren combinations, MSC induction in transplant, ART timing) and either report different types of adverse events or address non-cancer contexts. Therefore the provided evidence is insufficient to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "11254040",
      "25589047",
      "1759213",
      "4468861",
      "27437459"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 explicitly states that immune checkpoint therapy is associated with \"numerous immunologic adverse-events,\" listing immunologic adverse events as a major issue of checkpoint blockade. Papers related to combined checkpoint blockade (Paper 1 and Paper 4) discuss enhanced immune activation with combined anti-CTLA-4 and anti-PD-(L)1 treatments and mechanisms that could increase immune-mediated effects; none of the provided papers report evidence that co-IR (combined immune\u2011checkpoint) blockade causes no autoimmune adverse events. On the contrary, the review in Paper 2 directly contradicts the claim by recognizing frequent immune-related adverse events with checkpoint therapies."
    },
    "posthoc_doc_ids": [
      "4468861",
      "49432306",
      "3329824",
      "15128866",
      "3654468"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1070",
    "claim": "Self-advocacy training is effective at decreasing homelessness.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers evaluate or report on \u201cself-advocacy training\u201d as an intervention for preventing or ending homelessness or on homelessness outcomes (e.g., housing status, exit from homelessness, housing stability). Several studies are unrelated clinical trials (diabetes education, ICU fluid balance, exercise in heart failure, insomnia, internet grief intervention, school trauma CBT). Two papers touch on related social-service topics: Paper 4 (case management in outpatient substance-abuse treatment) finds more active/on-site case management increases use of general health and mental-health services but has little effect on use of social services or aftercare plans, and Paper 5 (mental health outreach for homeless families) shows improved child mental-health scores but does not report reductions in homelessness or housing outcomes. Therefore the evidence does not address whether self-advocacy training decreases homelessness."
    },
    "naive_doc_ids": [
      "12584053",
      "20473074",
      "40817021",
      "485020",
      "6129301"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers evaluate or report on \"self-advocacy training\" as an intervention to reduce homelessness or present outcomes measuring change in housing status. Paper 5 describes a mental health outreach service for homeless families that improved child psychosocial scores and satisfaction but does not test self-advocacy training nor report reductions in homelessness. Paper 6 discusses citizen participation in disaster recovery (not homelessness) and the other papers address medical, behavioral, or methodological topics unrelated to self-advocacy or homelessness. Therefore there is no evidence in these papers to support or contradict the claim that self-advocacy training decreases homelessness."
    },
    "overthinking_doc_ids": [
      "40817021",
      "24396137",
      "5912283",
      "2242416",
      "6129301"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the nine provided papers address self-advocacy training or homelessness. The studies cover critical care fluid balance, diabetes self-management education, exercise in heart failure, antiretroviral therapy and tuberculosis, smoking cessation after lung cancer, lung function and cancer risk, maternal/child nutrition interventions, non-invasive ventilation for COPD, and HPV vaccination/screening. While Paper 2 evaluates a self-management education programme, its outcomes are biomedical and illness-belief measures for people with type 2 diabetes and do not include housing or homelessness-related endpoints. Therefore the evidence does not bear on whether self-advocacy training decreases homelessness."
    },
    "posthoc_doc_ids": [
      "20473074",
      "12584053",
      "40817021",
      "4883040",
      "7639744"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "730",
    "claim": "Lysine histone demethylase inhibitor JIB 04 is inactive against KDM5A.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers mention JIB 04 or report biochemical or cellular activity data for KDM5A. Paper 5 discusses KDM5B (a related demethylase) but does not provide information about JIB 04 or KDM5A inhibition. Therefore the corpus contains no relevant evidence to support or refute the claim that JIB 04 is inactive against KDM5A."
    },
    "naive_doc_ids": [
      "12622860",
      "22036571",
      "30543439",
      "39391953",
      "6455142"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers report experimental data testing JIB-04 against KDM5A specifically. Paper 7 describes JIB-04 as a novel inhibitor of the Jumonji family of histone demethylases in vitro and in vivo, which implies activity against members of that family, but it does not explicitly state results for KDM5A (JARID1A). Paper 8 discusses KDM5B, not KDM5A. The other papers are unrelated to JIB-04 or KDM5A. Therefore the corpus does not contain direct evidence to confirm or refute the claim that JIB-04 is inactive against KDM5A."
    },
    "overthinking_doc_ids": [
      "864491",
      "1275505",
      "1285713",
      "7821634",
      "11256632"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the nine provided papers report data on JIB-04 or on KDM5A. The papers discuss other histone demethylases (e.g., JMJD3/KDM6B and its inhibitor GSK-J4, and LSD1) or unrelated topics, but there is no experimental result or statement addressing whether JIB-04 inhibits or is inactive against KDM5A. Therefore the provided evidence does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "18841257",
      "15215393",
      "4387494",
      "99829811",
      "6182947"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "18",
    "claim": "61% of colorectal cancer patients are diagnosed with regional or distant metastases.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The provided papers do not report the specific combined proportion of colorectal cancer patients diagnosed with regional (e.g., stage III) plus distant (stage IV) disease as 61%. Paper 2 reports the proportion with synchronous metastases (stage IV) in the Netherlands as 19% rising to 23% (overall ~21% in that cohort), which is far below 61% but only covers distant metastases, not regional disease. Paper 4 reports the proportion diagnosed at early stage (stage I) increased from 22.5% to 26.3%, which implies the remainder are stages II\u2013IV but does not separate regional from distant. Other papers either do not give stage-distribution percentages or focus on nonmetastatic cases or different outcomes. Because none of the papers present the combined regional+distant (stage III+IV) percentage or equivalent data needed to confirm or refute the 61% figure, there is insufficient information to support or contradict the claim."
    },
    "naive_doc_ids": [
      "5641851",
      "10958594",
      "2058909",
      "22942787",
      "3899896"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the three provided papers reports the specific proportion of colorectal cancer patients diagnosed with regional (stage III) or distant (stage IV) disease as 61%. Paper 1 reports the proportion diagnosed at early stage (stage I) increased from 22.5% to ~26% (implying stages II\u2013IV account for the remainder) but does not break out regional vs distant. Paper 3 notes higher odds of stage 4 diagnosis in deprived groups but gives no overall percentage for regional + distant disease. Paper 2 discusses short-term survival differences by socioeconomic group but does not report the percentage diagnosed with regional or distant metastases. Therefore the evidence provided does not confirm or refute the specific 61% figure."
    },
    "overthinking_doc_ids": [
      "22942787",
      "2058909",
      "5641851"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers directly reports the combined proportion of colorectal cancer patients diagnosed with \"regional or distant metastases\" (i.e., stage III + stage IV) as 61%. Paper 1 gives the proportion with synchronous distant metastases (stage IV) as 19% rising to 23% (1996\u20132011), which is far below 61% but pertains only to distant metastases. Paper 7 reports the proportion diagnosed at early stage (stage I) as ~22.5\u201326.3%, implying the remainder are stages II\u2013IV, but it does not break out the specific share that are regional (stage III) versus distant (stage IV). Other papers do not provide relevant stage-at-diagnosis distributions. Because the exact combined regional+distant percentage is not given, the evidence set neither confirms nor directly refutes the 61% claim."
    },
    "posthoc_doc_ids": [
      "10958594",
      "24980622",
      "3329824",
      "15476777",
      "42731834"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "277",
    "claim": "Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that the Commelina yellow mottle virus (CoYMV/ComYMV) transcribed strand contains three open reading frames capable of encoding proteins of 23, 15 and 216 kD, and interprets the 216 kD product as the polyprotein typical of pararetroviruses/badnaviruses. Paper 2 additionally notes that badnaviruses typically encode three conserved ORFs, supporting that this genome organization is characteristic of the genus. The other provided papers are unrelated to ComYMV or badnavirus ORF content."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "152245",
      "21230110",
      "18188022"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that the Commelina (Co)YMV genome (7,489 bp) contains three open reading frames on the transcribed strand capable of encoding proteins of 23, 15 and 216 kD, matching the claim. Paper 2 additionally notes that badnaviruses typically have three conserved ORFs, supporting that this organization is characteristic of the genus. Paper 3 is not directly relevant. Therefore the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "83667891"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (Properties of Commelina yellow mottle virus's complete DNA sequence...) explicitly states that the transcribed strand of the CoYMV genome 'contains three open reading frames capable of encoding proteins of 23, 15 and 216 kd.' This directly confirms the claim. Paper 2 also notes that newly characterized badnaviruses typically encode three conserved ORFs on the plus strand, providing additional contextual support that badnaviruses commonly have a three-ORF organization. The remaining papers are unrelated to this specific claim."
    },
    "posthoc_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "20045514",
      "34604584"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "368",
    "claim": "Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses early PDA screening and reports that infants screened before day 3 had LOWER in-hospital mortality (14.2% vs 18.5%; OR 0.73, ARR 4.3%). Although the instrumental-variable analysis was somewhat ambiguous (adjusted OR 0.62, 95% CI 0.37\u20131.04), the primary analyses show reduced mortality with early screening. Papers 2 and 3 (treatment comparisons) do not provide evidence that screening increases mortality (paper 2 shows pharmacologic treatment can reduce adverse outcomes; paper 3 found no mortality difference between surgical and medical initial treatments). Papers 4 and 5 are unrelated cancer-screening trials.Taken together, the provided evidence does not support the claim that early PDA screening increases in-hospital mortality and instead points toward the opposite."
    },
    "naive_doc_ids": [
      "27099731",
      "34544514",
      "9967265",
      "32423829",
      "11880289"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses early PDA screening and reports that screening before day 3 was associated with LOWER in-hospital mortality (hospital death 14.2% vs 18.5%; OR 0.73, 95% CI 0.54\u20130.98; absolute risk reduction 4.3%). The instrumental-variable analysis was imprecise but did not show increased mortality. Papers 2 and 3 concern PDA treatments (surgery vs medical; ibuprofen vs indomethacin) and do not provide evidence that early screening increases in-hospital mortality. The remaining papers are unrelated. Overall, the provided evidence does not support the claim that early PDA screening increases in-hospital mortality; the primary relevant study actually shows an association with reduced mortality (though residual confounding and some analytic ambiguity were noted by the authors)."
    },
    "overthinking_doc_ids": [
      "27099731",
      "9967265",
      "34544514",
      "7662395",
      "5824985"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1\u2014directly relevant\u2014found that early screening echocardiography (before day 3) was associated with LOWER in-hospital mortality (14.2% vs 18.5%; OR 0.73, 95% CI 0.54\u20130.98) and a lower rate of pulmonary hemorrhage; instrumental-variable analysis was directionally consistent (adjusted OR 0.62, 95% CI 0.37\u20131.04) though somewhat imprecise. The other papers address treatment (surgical vs medical, or ibuprofen vs indomethacin) or review management and do not provide evidence that early screening increases mortality. Taken together, the provided evidence does not support the claim that early PDA screening increases in-hospital mortality and in fact contradicts it."
    },
    "posthoc_doc_ids": [
      "27099731",
      "9967265",
      "34544514",
      "25691541"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "278",
    "claim": "Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 reports the complete genome sequence of Commelina yellow mottle virus (CoYMV) and states explicitly that the genome is 7489 bp in size. None of the other provided papers report a genome size of ~2140 bp for Commelina yellow mottle virus or provide data supporting a 2140-bp genome. Therefore the claim that ComYMV's genome consists of 2140 base pairs is contradicted by the experimental sequencing result in Paper 1 (7489 bp)."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "152245",
      "20375264"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports the complete genome sequence of Commelina yellow mottle virus (CoYMV/ComYMV) and states the genome is 7489 bp in size, which contradicts the claim of 2140 bp. The other papers do not provide supporting evidence for a 2140-bp genome (Paper 2 reports ~7424 nt for a different badnavirus; Papers 3\u20135 are unrelated to ComYMV). Therefore the provided evidence refutes the 2140-bp genome claim."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "152245",
      "32770503",
      "14185503"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 reports the complete genome sequence of Commelina yellow mottle virus (CoYMV/ComYMV) and states the genome is 7489 base pairs long, which directly contradicts the claim of 2140 base pairs. The other provided papers do not support the 2140 bp figure (they discuss other badnaviruses or methods), so the evidence refutes the claim."
    },
    "posthoc_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "20375264"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "208",
    "claim": "CHEK2 is not associated with breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers address the CHEK2 gene or report data on CHEK2 variants and breast cancer risk. The articles cover perinatal/intrauterine factors, ADHD/obesity, clomifene use, alcohol and coronary risk, HPV and cervical disease, oncolytic viral therapy for breast cancer, ovarian cancer models, and leukemia effects on bone \u2014 but do not present evidence for or against an association between CHEK2 and breast cancer. Therefore the supplied evidence cannot confirm or refute the claim."
    },
    "naive_doc_ids": [
      "17450673",
      "23557241",
      "1831916",
      "43329366",
      "20526907"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.7,
      "justification": "Only Paper 3 directly examines CHEK2. It found no convincing association between common CHEK2 haplotypes and breast cancer risk, but it reported an elevated odds ratio for the rare 1100delC truncating mutation (OR 2.26, 95% CI 0.99\u20135.15; frequency 0.7% in cases vs 0.4% in controls), consistent with a possible increased risk. The other papers do not address CHEK2. Because Paper 3 indicates that at least one CHEK2 mutation (1100delC) may increase breast cancer risk, the blanket claim that \u201cCHEK2 is not associated with breast cancer\u201d is contradicted by the provided evidence."
    },
    "overthinking_doc_ids": [
      "17450673",
      "23557241",
      "13519661",
      "3285322",
      "14118484"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 8 directly addresses CHEK2 and breast cancer. It reports no convincing association between common CHEK2 haplotypes and breast cancer risk (supporting a lack of effect for common variants), but it also reports that the rare 1100delC truncating mutation was more frequent in cases than controls with an odds ratio of 2.26 (95% CI 0.99\u20135.15) and notes prior evidence implicating CHEK2 in breast cancer aetiology. The existence of a deleterious rare CHEK2 mutation associated with increased breast cancer risk contradicts the absolute claim that \u201cCHEK2 is not associated with breast cancer.\u201d The other provided papers do not provide relevant data on CHEK2."
    },
    "posthoc_doc_ids": [
      "17450673",
      "23557241",
      "12145359",
      "4828631",
      "14682243"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1174",
    "claim": "The PPR MDA5 has twenty N-terminal CARD domains.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers state the domain architecture or the number of N-terminal CARD domains of MDA5. Only Paper 5 mentions the cytoplasmic RNA sensor Mda5 in the context of 2\u2032-O-methylation and interferon induction, but it does not describe Mda5\u2019s domain structure or CARD count. The other papers address unrelated proteins or domains (glutamate receptor ATDs, G-quadruplex recognition, MBT repeats, PAAR-repeat proteins) and provide no information relevant to the claim."
    },
    "naive_doc_ids": [
      "612002",
      "26011884",
      "31387717",
      "6386930",
      "2566674"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss MDA5 (IFIH1), PPR, or N-terminal CARD domains. The six papers cover Polycomb complexes in ES cells, an adenovirus E3-interacting protein (FIP-2), array CGH in bladder tumors, glutamate receptor amino-terminal domains, and the Sec7 domain of Arno; none contain experimental data or statements about the domain architecture of MDA5. Therefore the supplied evidence cannot confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "1791637",
      "207972",
      "2402323",
      "31387717",
      "612002"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss MDA5 (melanoma differentiation-associated protein 5) or the number of its N-terminal CARD (caspase activation and recruitment) domains. The papers focus on topics such as ionotropic glutamate receptor ATDs, an adenovirus-interacting protein, lentiviral vectors, the Conserved Domain Database in general, corin in pregnancy hypertension, GLP-1 receptor structure, and PPAR\u03b3 effects on NLRP3\u2014none present experimental data or statements about MDA5 domain architecture. Paper 4 (CDD) is a general resource about conserved domains but does not provide specific evidence about MDA5 having twenty N-terminal CARD domains. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "26011884",
      "207972",
      "13368032",
      "10029970",
      "31387717"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "480",
    "claim": "Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 provides direct experimental evidence that endothelial Gpr124 is required to maintain BBB integrity in adult mice under pathological conditions: endothelial Gpr124 conditional knockout caused BBB disruption and microvascular hemorrhage in mouse models of ischemic stroke, and constitutive activation of Wnt\u2013\u03b2-catenin signaling rescued the BBB defects. This indicates that Gpr124 suppresses BBB breakdown in ischemic stroke models. The other papers do not address Gpr124 and are not directly relevant to this claim."
    },
    "naive_doc_ids": [
      "3761017",
      "6325527",
      "27602752",
      "25827024"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly tests Gpr124 in adult mice and reports that endothelial conditional knockout of Gpr124 caused blood\u2013brain barrier (BBB) disruption and microvascular hemorrhage in mouse models of ischemic stroke, while constitutive activation of Wnt\u2013\u03b2-catenin signaling corrected the BBB disruption. This indicates that Gpr124 is required to maintain/suppress BBB breakdown under ischemic stroke conditions. The other papers address BBB biology and stroke treatments but do not provide contradictory evidence about Gpr124."
    },
    "overthinking_doc_ids": [
      "6325527",
      "3761017",
      "14753395",
      "25789730",
      "33884866"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that endothelial Gpr124 is required to maintain BBB integrity in adult mice under pathological conditions: endothelial conditional knockout of Gpr124 caused BBB disruption and microvascular hemorrhage in mouse models of ischemic stroke, and constitutive activation of Wnt\u2013\u03b2-catenin signaling rescued these defects. This provides direct experimental evidence that Gpr124 prevents (suppresses) BBB breakdown in ischemic stroke models. The other provided papers do not provide contradictory evidence relevant to Gpr124 and stroke."
    },
    "posthoc_doc_ids": [
      "6325527",
      "3761017",
      "14753395",
      "2682997",
      "21564598"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1272",
    "claim": "The single flash-evoked ERG b-wave is generated by activity of ON-bipolar cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers directly address the origin of the single flash-evoked electroretinogram (ERG) b-wave or explicitly link it to ON-bipolar cell activity. Most papers are unrelated (cell cycle, immunology, metabolism, etc.). Paper 3 studies retinal ganglion cell synaptic currents and reports effects on light-evoked On-EPSCs and Off-IPSCs under BK(Ca) channel blockade, which relates to ON vs. OFF retinal pathways but does not demonstrate that the single flash-evoked ERG b-wave is generated by ON-bipolar cells. Therefore the evidence set does not confirm or refute the specific claim."
    },
    "naive_doc_ids": [
      "29851836",
      "7036529",
      "15685921",
      "25050364",
      "1605392"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the six provided papers address retinal physiology, electroretinogram (ERG) components, bipolar cells, or the cellular origin of the single flash\u2013evoked b-wave. The papers cover pancreatic beta-cell insulin receptor knockout, CHD4 and spindle assembly, regulatory T cells and colitis, cyclosporine-induced renal apoptosis, statins in head-and-neck cancer cell lines, and type I interferon signaling in chemotherapy\u2014topics unrelated to the ERG b-wave or ON-bipolar cell activity. Therefore the provided evidence does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "16389141",
      "1684489",
      "5800138",
      "238409",
      "1522336"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 10 describes a naturally occurring 'no b-wave' (nob) mouse in which the photoreceptor-mediated a-wave is normal but the ERG b-wave, the major postreceptoral response component, is absent. The authors conclude the defect interferes with transmission between photoreceptors and second-order retinal neurons and models congenital stationary night blindness. This finding is consistent with the widely accepted interpretation that the flash-evoked b-wave arises from depolarizing (ON) bipolar cell activity: loss of postreceptoral transmission that spares photoreceptors eliminates the b-wave. None of the other provided papers address ERG physiology or retinal bipolar cell function. Because the provided evidence is indirect (the paper documents loss of postreceptoral b-wave but does not explicitly name ON-bipolar cells in the excerpt), confidence is moderate rather than maximal."
    },
    "posthoc_doc_ids": [
      "2212067",
      "2888272",
      "9154703",
      "20220731",
      "37437064"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "398",
    "claim": "Exhaustion of B cells contributes to poor Ab response in HIV-infected individuals.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present direct evidence that B cell exhaustion contributes to poor antibody responses in HIV-infected individuals. The documents include: (a) papers on T cell trafficking and tissue-resident memory T cells (Papers 1 and 3) that do not address B cell exhaustion; (b) a paper showing germinal center T follicular helper (Tfh) cells are highly permissive to HIV-1 (Paper 6), which implicates Tfh infection as a possible mechanism for altered humoral responses but does not demonstrate B cell exhaustion; (c) a study on antigen relay and affinity maturation by subcapsular sinus macrophages and non-cognate B cells (Paper 4), which describes antigen transport necessary for affinity maturation but does not report B cell exhaustion in HIV; (d) a neutralizing antibody kinetics paper in acute HIV-1 infection (Paper 7) that documents limited breadth and timing of neutralizing responses but does not attribute these findings to B cell exhaustion; and (e) other papers that are unrelated. Because none of the papers explicitly document B cell exhaustion in HIV or link exhausted B cells to impaired antibody responses, the provided evidence does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "2248870",
      "23052989",
      "3155731",
      "9705208",
      "24879055"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers address B cell exhaustion in the context of HIV infection or present data linking B cell exhaustion to impaired antibody responses in HIV-infected individuals. The cited articles cover: immune responses to attenuated Salmonella and Japanese encephalitis vaccines (papers 1 and 6), B-cell migration during normal T-dependent responses (paper 2), T cell (CAR) exhaustion and costimulation (paper 3), expanded TG2-specific plasma cells in celiac disease (paper 4), and memory CD4+ T cell\u2013induced innate responses (paper 5). While some discuss B cell biology or immune exhaustion more broadly, none provide experimental findings about B cell exhaustion contributing to poor antibody responses in HIV, so the evidence set does not support or refute the claim."
    },
    "overthinking_doc_ids": [
      "18275697",
      "38587347",
      "18231807",
      "1471041",
      "19005293"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 6 directly addresses B-cell dysfunction in HIV infection and describes the emergence of exhausted, CD21\u2013 \"tissue-like\" memory B cells and separable activation (CD95 upregulation) and exhaustion (CD21 loss) phenotypes in patients. The study shows that B-cell exhaustion is a distinct, infection-associated state present in progressors and controllers and that activated memory B-cell frequencies differ with viral control. These findings provide mechanistic evidence that B-cell exhaustion is a feature of HIV infection and a likely contributor to impaired humoral (antibody) responses. The other provided papers do not present contrary evidence relevant to B-cell exhaustion in HIV. Note: Paper 6 characterizes exhaustion and its association with disease state but does not directly prove causal impairment of specific antibody titers in all contexts, so confidence is moderate-to-high rather than maximal."
    },
    "posthoc_doc_ids": [
      "18275697",
      "14934137",
      "38587347",
      "12966719",
      "3155731"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "617",
    "claim": "Increased mobility of retrotransposons is assosciated with mutation and higher tumorigenesis rates.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.65,
      "justification": "Paper 2 provides direct experimental evidence that increased transposon-mediated mutagenesis accelerates tumorigenesis: a Sleeping Beauty (SB) transposon mutagenesis screen in a MYC-driven mouse liver cancer model produced insertions that promoted tumor development and identified tumor suppressors (Ncoa2/Src-2, Zfx, Dtnb). This demonstrates that mobilizing a transposable element can generate mutations that increase cancer rates. Several other papers in the set document related phenomena (Paper 1: stromal oxidative stress drives genomic instability and mutagenesis in adjacent cancer cells; Paper 7: cancer genomes show recurrent rDNA copy-number loss and increased sequence variation and hypersensitivity to DNA damage), which are consistent with mechanisms that could promote transposon activity or amplify mutational burden. However, none of the provided papers directly measure increased mobility of endogenous retrotransposons (e.g., LINE-1) in human cancers; the SB system is a DNA transposon used as an experimental mutagenesis tool rather than an endogenous retrotransposon. Therefore the evidence supports the general concept that transposon mobility/mutagenesis is associated with increased mutation and tumorigenesis, but direct evidence specific to endogenous retrotransposon mobility in cancer is limited in the provided set."
    },
    "naive_doc_ids": [
      "24349992",
      "11255504",
      "11271123",
      "9394119",
      "22975806"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The provided papers contain evidence that transposon mobilization or markers of retrotransposon activation are associated with increased mutation burden and cancer. Paper 1 demonstrates that SB transposon-mediated mutagenesis (a forward genetic screen using an active transposon) produces insertions that accelerate tumorigenesis and reveal cancer driver/suppressor loci, directly linking transposition-driven mutation to increased cancer. Paper 5 shows that reduced methylation of LINE-1 repeats (LINE-1 are autonomous retrotransposons) in blood DNA is associated with a higher risk of hepatocellular carcinoma, consistent with retrotransposon hypomethylation/activation being associated with cancer risk. Other papers discuss mechanisms of genomic instability (Paper 6) but do not directly measure retrotransposition. Limitations: the SB system is a DNA transposon (not a retrotransposon) and Paper 5 reports an association using LINE-1 methylation as a surrogate for activity rather than direct measurements of increased retrotransposition. Nonetheless, the evidence collectively supports the claim that increased transposon/retrotransposon mobility is associated with mutation and higher tumorigenesis rates."
    },
    "overthinking_doc_ids": [
      "11255504",
      "22049489",
      "29366489",
      "6327940",
      "23665162"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report on retrotransposon activity or mobility (e.g., LINE-1, Alu, SVA) or directly link transposon mobilization to mutation burden or tumorigenesis. Several papers (e.g. Paper 7 and Paper 9) describe mechanisms that increase genomic instability and mutation rates (ROS, error-prone DSB repair, stromal-driven DNA damage) and others catalog or analyze somatic mutations in cancer (Paper 4), but these do not attribute mutations or increased tumorigenesis to increased retrotransposon mobility. Therefore the corpus does not provide evidence to support or contradict the specific claim about retrotransposon mobility."
    },
    "posthoc_doc_ids": [
      "3210545",
      "8698208",
      "8892905",
      "13916484",
      "711256"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "35",
    "claim": "A deficiency of vitamin B12 decreases blood levels of homocysteine.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "The supplied papers do not support the claim that vitamin B12 deficiency decreases blood homocysteine; instead they (directly or indirectly) indicate B\u2011vitamin insufficiency is associated with higher homocysteine and that supplementation or higher folate reduces tHcy. Paper 3 reviews evidence that B vitamins (folate, B6 and related B vitamins) influence plasma homocysteine and that folate supplementation lowers tHcy. Paper 4 shows raising folate intake decreases plasma homocysteine (while serum B12 was unchanged). Paper 5 explicitly evaluated plasma homocysteine together with folate and vitamin B12 and defined genotype-specific folate/B12 thresholds required to keep homocysteine in the normal range, reporting higher homocysteine in risk genotypes \u2014 consistent with low B\u2011vitamin status raising homocysteine. Other papers are unrelated methods or about vitamin D or cancer markers. Overall, the evidence in these papers contradicts the claim (a B12 deficiency would be expected to increase, not decrease, homocysteine)."
    },
    "naive_doc_ids": [
      "3150030",
      "9555784",
      "16252863",
      "18557974",
      "42441846"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on the effect of vitamin B12 deficiency on blood homocysteine. Papers 5 and 6 report that increasing folate (dietary folate or folic acid supplementation) lowers plasma homocysteine (and Paper 5 notes serum B12 remained unchanged during that intervention), but they do not examine B12 deficiency or show that B12 deficiency decreases homocysteine. The other papers deal with vitamin D, magnesium, or cancer risk and do not address the B12\u2013homocysteine relationship. Therefore the corpus does not provide evidence to support or refute the specific claim."
    },
    "overthinking_doc_ids": [
      "3150030",
      "9555784",
      "13312471",
      "520579",
      "18557974"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report data on vitamin B12 deficiency and its effect on blood homocysteine levels. Most papers concern vitamin D, NAD/NAMPT, blood-pressure drugs, dialysis, or glycemic biomarkers. Paper 8 mentions that methionine is converted to homocysteine (background on homocysteine biology) but does not present data linking vitamin B12 deficiency to decreased homocysteine. The well-known biochemistry (not provided in these papers) indicates B12 deficiency would raise, not lower, homocysteine; however, that evidence is not present among the supplied documents. Therefore the corpus provides no information to support or refute the specific claim."
    },
    "posthoc_doc_ids": [
      "7116734",
      "38551172",
      "520579",
      "1759213",
      "202259"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "994",
    "claim": "Pyridostatin encourages proliferation of homologous recombination - defective cells.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 3 (Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds) directly tests the G4-stabilizing compound pyridostatin (PDS) on HR-defective cells and reports that PDS reduces proliferation of HR-defective (BRCA2-deficient) cells by inducing DSB accumulation, checkpoint activation, deregulated G2/M progression and increased telomere fragility. PDS toxicity also extends to HR-defective cells that acquired PARP inhibitor resistance. The other provided papers discuss HR deficiency mechanisms and resistance but do not present data showing PDS promotes proliferation. Thus the available evidence contradicts the claim that pyridostatin encourages proliferation of HR-defective cells."
    },
    "naive_doc_ids": [
      "13791206",
      "15600979",
      "16472469",
      "52944377",
      "4444861"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly addresses pyridostatin (PDS) and reports that PDS reduces proliferation of HR-defective cells: PDS increases telomere fragility in BRCA2-deficient cells and \"reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.\" It also notes PDS toxicity extends to HR-defective cells with acquired olaparib resistance. The other papers discuss HR regulation and telomere/repair pathways but do not provide evidence that PDS promotes proliferation of HR-defective cells. Therefore the provided evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "13791206",
      "16472469",
      "52944377",
      "16644043"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 2 directly reports that the G-quadruplex\u2013stabilizing compound pyridostatin (PDS) \"reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.\" It further states that PDS toxicity extends to HR-defective cells, including those with acquired PARP inhibitor resistance. None of the other provided papers report that PDS promotes proliferation of HR-defective cells. Thus the evidence opposes the claim."
    },
    "posthoc_doc_ids": [
      "13791206",
      "16472469",
      "52944377",
      "4899981",
      "3173489"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "106",
    "claim": "Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The provided papers consistently treat ambulatory blood pressure monitoring (ABPM) as a more accurate or clinically valuable standard for diagnosing and risk-stratifying hypertension rather than an inaccurate test. Paper 1 (systematic review) uses ambulatory monitoring as the reference standard and concludes clinic and home measurements lack sufficient sensitivity/specificity compared with ambulatory monitoring, warning that clinic/home-based decisions may lead to overdiagnosis. Paper 2 states ABPM is more accurate than clinic and home measurements, is the most cost-effective diagnostic strategy, and recommends ABPM before starting antihypertensive drugs. Papers 3 and 4 show ABPM-derived measures (BP variability, 24-h/day/night ambulatory BP) predict cardiovascular events and correlate with renal dysfunction, supporting the clinical validity of ABPM. Paper 5 does not provide evidence that ABPM is inaccurate. Collectively, these studies contradict the claim that ambulatory monitoring is inaccurate for diagnosing hypertension."
    },
    "naive_doc_ids": [
      "25515907",
      "5151024",
      "54490092",
      "8318922",
      "19804204"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple provided papers treat 24\u2011hour ambulatory blood pressure monitoring (ABPM) as the reference standard and report that ABPM is more accurate and clinically useful than clinic or home measurements. Paper 1 (systematic review) used ABPM as the reference and concluded clinic and home measurements lacked sufficient sensitivity and specificity and that ABPM should be used before lifelong treatment. Paper 4 states ABPM better correlates with cardiovascular outcomes, is more accurate than clinic/home monitoring, and is the most cost\u2011effective diagnostic strategy. Paper 5 shows information obtained from 24\u2011h ABPM (blood pressure variability) independently predicts cardiovascular events, supporting its clinical validity. Papers 2 and 3 are irrelevant to the diagnostic accuracy of ABPM. Overall, the evidence provided opposes the claim that ABPM is inaccurate for diagnosing hypertension."
    },
    "overthinking_doc_ids": [
      "25515907",
      "202259",
      "34873974",
      "5151024",
      "54490092"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple provided papers treat 24\u2011hour ambulatory blood pressure monitoring (ABPM) as the reference standard and report that it is more accurate or more prognostically informative than clinic or home measurements. Paper 1 (systematic review) uses ambulatory monitoring as the reference and concludes clinic and home measurements lack sufficient sensitivity/specificity and that ambulatory monitoring should be used before lifelong treatment. Paper 2 (cost\u2011effectiveness modelling) states ambulatory monitoring is more accurate than clinic/home measurement, is the most cost\u2011effective diagnostic strategy, and would reduce misdiagnosis. Papers 4 and 5 show ABPM provides clinically useful information (blood pressure variability predicts cardiovascular events; 24\u2011h ABP detects treatment effects), supporting its validity. Paper 3 is unrelated (troponin assay). Overall, the evidence contradicts the claim that ambulatory blood pressure monitoring is inaccurate for diagnosing hypertension."
    },
    "posthoc_doc_ids": [
      "25515907",
      "5151024",
      "34873974",
      "54490092",
      "22730024"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.18,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "677",
    "claim": "LRBA promotes CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention LRBA or present experimental data connecting LRBA to CTLA-4 trafficking. Several papers touch CTLA-4 biology (Paper 2 describes CTLA-4 mutations affecting expression, ligand binding and transendocytosis; Paper 3 identifies CTLA-4 endocytic motifs), but none report on LRBA promoting CTLA-4 recycling. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "14893425",
      "857189",
      "36816310",
      "3127341",
      "1605392"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address LRBA or directly examine CTLA-4 recycling. Paper 2 discusses CTLA-4 expression on Th17 cells and responses to belatacept, but it does not study LRBA or the recycling pathway of CTLA-4. The other papers cover unrelated proteins/processes (synaptic vesicle recycling, torsinA, PML/APBs, Aurora kinase, NMDA receptor endocytosis, KLF2, ARNO/VEGFR-2, etc.) and do not provide experimental data on LRBA or CTLA-4 trafficking. Therefore the evidence set does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "11250124",
      "13398997",
      "14893425",
      "164985",
      "213017"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address LRBA or the recycling of CTLA-4. Paper 5 discusses CTLA-4 expression levels on Th17 versus Th1 cells and sensitivity to CTLA-4\u2013mediated coinhibition, but it does not present data on CTLA-4 intracellular trafficking or LRBA function. The other papers cover unrelated topics (splicing, telomeres/PML, cell clearance/RhoGAP, AP-1/sigma1B, KLF2, ARNO/VEGFR-2, GluN3A endocytosis) and do not mention LRBA or CTLA-4. Therefore the evidence provided is insufficient to support or contradict the claim that LRBA promotes CTLA-4 recycling."
    },
    "posthoc_doc_ids": [
      "20585600",
      "213017",
      "1127562",
      "11250124",
      "13398997"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "739",
    "claim": "MT binding domain drives amyloid structure formation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers present evidence that a microtubule (MT) binding domain drives amyloid structure formation. Papers 1 and 4 discuss MT-binding proteins/domains (dynein and LRRK2) and their interactions with microtubules but do not report amyloid formation driven by those domains. Paper 2 addresses amyloid/prion aggregates and small-molecule binding to amyloid structures, but it does not link amyloid formation to any MT-binding domain. The remaining papers (3, 5, 6, 7) cover histone docking domains, telomere-binding, pore-forming proteins, and viral genome structure, none of which provide relevant data connecting MT-binding domains to driving amyloid assembly. Therefore the set of papers does not support or contradict the claim."
    },
    "naive_doc_ids": [
      "1546650",
      "9272598",
      "17518195",
      "9638032",
      "15121114"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data linking a microtubule (MT) binding domain to amyloid formation. Paper 1 characterizes dynein's MT-binding site and residues controlling affinity/release but does not report aggregation or amyloidogenesis. Papers 2, 3, 4, and 5 address histone H2A docking domain effects on nucleosome structure, AMPA receptor ligand\u2011binding domain mobility/crosslinking, CD3\u03b5 membrane binding and lipid changes, and GluA2 LBD structural pharmacology, respectively \u2014 none describe amyloid structure formation driven by an MT-binding domain. Therefore the supplied evidence does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "1546650",
      "17518195",
      "18346333",
      "5914739",
      "7729656"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers directly support or refute the specific claim that a microtubule (MT) binding domain drives amyloid structure formation. Paper 1 describes residues required for dynein microtubule binding but does not discuss amyloid formation. Paper 2 and Paper 8 describe proteins (Orb2A and bacterial curli) whose glutamine\u2011rich or amyloidogenic regions drive aggregation/amyloid formation, but these involve prion\u2011like or amyloid domains, not MT\u2011binding domains. Paper 7 discusses uptake and propagation of tau fibrils (tau is a microtubule\u2011binding protein), but the study focuses on HSPG\u2011mediated cellular uptake and seeding rather than showing that the tau microtubule\u2011binding domain itself drives amyloid formation. Other papers address unrelated domains or processes (membrane binding, RNA packaging, cytokine diffusion, p53 oligomerization) and do not link MT binding domains to amyloidogenesis. Therefore the provided evidence does not answer the claim."
    },
    "posthoc_doc_ids": [
      "1546650",
      "15655418",
      "35684881",
      "5914739",
      "6903077"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1068",
    "claim": "ScPif1p has reduced binding ability to G-rich ssDNA compared to non-G-rich ssDNA.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the six provided papers study Saccharomyces cerevisiae Pif1 (ScPif1p) or directly measure Pif1 binding to G-rich versus non\u2011G\u2011rich single\u2011stranded DNA. The papers describe other ssDNA\u2011binding proteins (SsbB, PriB, PaSSB, hRad52, CNBP, BLM) and some discuss G\u2011rich sequences or G\u2011quadruplex biology (e.g., CNBP and BLM), but none present experimental data comparing ScPif1p binding affinities to G\u2011rich and non\u2011G\u2011rich ssDNA. Therefore the evidence does not support or contradict the specific claim about ScPif1p."
    },
    "naive_doc_ids": [
      "799586",
      "29098525",
      "1914588",
      "15659108",
      "10486817"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report data on Saccharomyces cerevisiae Pif1 (ScPif1p) or directly compare its binding to G\u2011rich versus non\u2011G\u2011rich single\u2011stranded DNA. Several papers discuss other ssDNA\u2011binding proteins (e.g., bacterial SSBs, SsbB) or other helicases (BLM) and mention G\u2011quadruplexes or ssDNA interactions, but these are different proteins and systems and do not provide evidence about ScPif1p\u2019s binding preferences. Therefore the supplied evidence does not support or contradict the specific claim about ScPif1p."
    },
    "overthinking_doc_ids": [
      "1256116",
      "10874408",
      "365896",
      "1914588",
      "16217855"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers present experimental data comparing ScPif1p binding to G-rich single-stranded DNA versus non-G-rich single-stranded DNA. Paper 7 describes Pif1p displacing telomerase from telomeric (G-rich) oligonucleotides and reducing telomerase processivity, but it does not report a direct comparison of Pif1p binding affinity for G-rich versus non-G-rich ssDNA. The other papers address unrelated proteins or topics (SSBs, BLM helicase, replication, mapping DSBs, etc.) and do not provide relevant evidence. Therefore the supplied evidence set does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "1256116",
      "10874408",
      "365896",
      "16217855",
      "29851836"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "653",
    "claim": "Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple papers provide direct experimental evidence that IL-18 is involved in atherogenesis. Paper 1 shows IL-18 is highly expressed in human atherosclerotic plaques (localized mainly to macrophages) and is significantly higher in symptomatic/unstable versus asymptomatic/stable plaques, implicating IL-18 in plaque destabilization. Paper 8 demonstrates in mouse models that IL-18 promotes atherosclerosis: interruption of IL-18 signaling reduces lesion development, and combined deficiency of IL-18 receptor and the Na\u2013Cl cotransporter protects Apoe\u2212/\u2212 mice from atherosclerosis while blunting macrophage IL-18 responses. Other included studies (e.g., on TNF-\u03b1 and IL-6 pathways) reinforce the broader role of inflammatory cytokines in atherosclerosis. No provided paper contradicts the role of IL-18."
    },
    "naive_doc_ids": [
      "17421851",
      "9814332",
      "4890578",
      "12102963",
      "12130200"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report data or discussion about interleukin-18 (IL-18) or its role in atherosclerosis. While Paper 4 addresses atherosclerosis (macrophage apoE and foam cell formation), it does not mention IL-18 or provide evidence linking IL-18 to atherogenesis. The other papers cover unrelated topics (stress/HPA axis, uterine artery ligation, serum metabolomics, and HIV antibody evolution) and do not address IL-18 or atherosclerosis. Therefore the supplied evidence does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "4951831",
      "18104691",
      "31070360",
      "1122198",
      "3566945"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence linking IL-18 to atherosclerosis: IL-18 is highly expressed in human atherosclerotic plaques (vs normal arteries), localized mainly to plaque macrophages, the IL-18 receptor is upregulated in plaques, and IL-18 mRNA levels are significantly higher in symptomatic (unstable) plaques than asymptomatic (stable) ones (P<0.01), suggesting a role in plaque destabilization. None of the other papers present data that contradict this finding; most are unrelated to IL-18. Therefore the provided evidence supports the claim that IL-18 plays an important role in the pathogenesis of atherosclerosis."
    },
    "posthoc_doc_ids": [
      "17421851",
      "22080671",
      "4890578",
      "22674621",
      "2533768"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "676",
    "claim": "LRBA prevents CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present evidence about LRBA\u2019s role in CTLA-4 trafficking. While Paper 3 mentions CTLA-4 in the context of Ctla4(-/-) mice and T cell trafficking, it does not study LRBA or CTLA-4 recycling. The other papers cover unrelated molecules and processes (NMDA receptor endocytosis, KLF2 in B cells, Orai1/CRAC channels, GLP-1R polymorphisms, Rac endocytic trafficking, and a differentiation-dependent gene) and do not address LRBA or CTLA-4 recycling. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "naive_doc_ids": [
      "14405193",
      "32101982",
      "2462673",
      "1605392",
      "3127341"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers test or report on LRBA's effect on CTLA-4 recycling. Paper 2 discusses CTLA-4 expression on Th17 cells and belatacept sensitivity but does not address LRBA or CTLA-4 intracellular trafficking. The other papers cover topics such as synaptic vesicle recycling (AP-1, torsinA), endosomal sorting (ESCRT-II/Vps22), DNA oxidation/TREX1, and long-term immune reconstitution after transplantation, but do not mention LRBA or experimental data on CTLA-4 recycling. Therefore the provided evidence does not confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "11250124",
      "13398997",
      "14893425",
      "9680193",
      "13106686"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the nine provided papers mention LRBA or CTLA-4 or present experiments measuring CTLA-4 trafficking or recycling. While several papers address general endocytosis/recycling mechanisms (e.g., Rab5/Rac, ARNO/VEGFR-2, endocytic motifs, synaptic vesicle recycling), they do not study LRBA or CTLA-4 directly and therefore do not provide supporting or contradicting evidence for the specific claim that LRBA prevents CTLA-4 recycling. Direct tests of this claim would require data such as CTLA-4 surface expression/recycling assays, LRBA loss- or gain-of-function experiments, co-localization/co-immunoprecipitation, or lysosomal-degradation measurements comparing LRBA-deficient and control cells\u2014none of which are present in the supplied papers."
    },
    "posthoc_doc_ids": [
      "854417",
      "2436602",
      "6776834",
      "17017465",
      "9304312"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "181",
    "claim": "Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 directly addresses the mechanism and shows that TDP-43 accumulates in neuronal mitochondria, preferentially binds mitochondrially encoded Complex I mRNAs (ND3 and ND6), impairs their expression and causes Complex I disassembly. Crucially, the study reports that suppression of TDP-43 mitochondrial localization (and thereby its interaction with mitochondrial transcripts/Complex I components) abolishes both TDP-43\u2013induced mitochondrial dysfunction and neuronal loss and improves phenotypes in transgenic mice. Thus the provided evidence supports the claim that preventing the TDP-43 interaction with ND3/ND6-related mitochondrial components prevents TDP-43\u2013induced neuronal loss. Note: the paper describes binding to mitochondrially encoded mRNAs (ND3/ND6) and inhibition of mitochondrial localization rather than an explicit blockade of a direct TDP-43\u2013protein interaction with ND3/ND6 proteins, but functionally the interventions that prevent TDP-43 mitochondrial association abrogate neuronal toxicity."
    },
    "naive_doc_ids": [
      "3127341",
      "2119889",
      "4320424",
      "13380011",
      "16966326"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 directly supports the claim. It shows that TDP-43 accumulates in mitochondria and preferentially binds mitochondrially encoded mRNAs for complex I subunits ND3 and ND6, impairing their expression and causing complex I disassembly. Crucially, suppression of TDP-43 mitochondrial localization (thereby preventing its interaction with those mitochondrial RNAs/complex I biogenesis) abolishes TDP-43\u2013induced mitochondrial dysfunction and neuronal loss and improves phenotypes in transgenic mice. None of the other provided papers address TDP-43/ND3/ND6 interactions or TDP-43\u2013induced neuronal loss. Note: the paper describes binding to ND3/ND6 mRNAs and inhibition of mitochondrial localization rather than a direct protein\u2013protein blockade of ND3/ND6 proteins, but the experimental result\u2014preventing the TDP-43\u2013mitochondrial interaction\u2014prevents neuronal loss, which aligns with the claim."
    },
    "overthinking_doc_ids": [
      "13380011",
      "16966326",
      "10698739",
      "11289247",
      "854417"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses the mechanism and outcome in the claim: TDP-43 localizes to mitochondria, preferentially binds mitochondrially encoded complex I mRNAs (ND3 and ND6), impairs their expression and causes complex I disassembly. Crucially, suppression of TDP-43 mitochondrial localization abolishes TDP-43\u2013induced mitochondrial dysfunction and neuronal loss. Although the paper describes binding to ND3/ND6 mRNAs and inhibition of mitochondrial localization rather than a targeted blockade of a protein\u2013protein interaction with ND3/ND6 proteins per se, the reported prevention of neuronal loss by preventing TDP-43 mitochondrial localization functionally supports the claim that blocking the TDP-43\u2013ND3/ND6 interaction prevents TDP-43\u2013induced neuronal loss. The other listed papers do not provide relevant contrary or additional evidence."
    },
    "posthoc_doc_ids": [
      "16966326",
      "6776834",
      "10698739",
      "2436602",
      "7915836"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "236",
    "claim": "Cell autonomous sex determination in somatic cells occurs in Passeriformes.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Paper 1 provides clear experimental evidence that somatic cells are cell-autonomously sexed in the chicken (Gallus gallus), demonstrating that avian somatic sex identity can be cell-autonomous. However, the claim is specific to Passeriformes (perching/songbirds). None of the other provided papers study Passeriformes or present data from passerine species. The remaining papers concern human/mammalian epigenetics, glioblastoma, ALS, or chick smooth muscle lineage (also Gallus). Because there is no direct evidence from Passeriformes in the supplied set, the materials do not confirm or refute the claim for that avian order."
    },
    "naive_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "11578459",
      "13969173"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Only Paper 1 provides direct experimental evidence that avian somatic cells (in chicken, a Galliformes species) have cell-autonomous sex identity. None of the other papers address avian sex determination or study Passeriformes. Because the provided evidence demonstrates the phenomenon in chicken but does not include data from Passeriformes (perching birds), it does not confirm or refute that cell-autonomous somatic sex determination occurs specifically in Passeriformes."
    },
    "overthinking_doc_ids": [
      "4388470",
      "5500086",
      "13651792",
      "15803282",
      "23959496"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Only one paper (Paper 1) addresses cell-autonomous somatic sex identity, and it reports this phenomenon in chicken (order Galliformes). None of the provided papers present data on Passeriformes (songbirds) specifically. The other papers (2\u20136) concern mammalian/human stem cell reprogramming or clinical transplantation and are not relevant to avian somatic sex determination. Therefore, the provided evidence does not directly confirm or refute that cell-autonomous sex determination in somatic cells occurs in Passeriformes."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "7426741",
      "3360421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "823",
    "claim": "N348I mutations cause resistance to zidovudine (AZT).",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple provided papers report that the N348I substitution in the connection domain of HIV-1 reverse transcriptase reduces susceptibility to zidovudine (AZT). Paper 1 explicitly states N348I \u201cconfers zidovudine and nevirapine resistance,\u201d reporting a 2\u2013 to 4\u2013fold decrease in zidovudine susceptibility in molecular clones and an association of N348I with treatment regimens including zidovudine. Paper 5 further supports that connection-domain mutations (like N348I) can mediate NRTI (including AZT) resistance via effects on RNase H/connection domain function. Paper 4, while focused on NNRTI effects, provides mechanistic evidence that N348I alters RNase H activity and RT\u2013nucleic acid interactions in ways consistent with drug resistance. Other supplied papers are unrelated. Together, the experimental and clinical data in the cited papers support the claim that N348I causes resistance to zidovudine."
    },
    "naive_doc_ids": [
      "15319019",
      "3929361",
      "7821634",
      "2319305",
      "6426919"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that N348I in the RT connection domain decreases zidovudine (AZT) susceptibility 2- to 4-fold in molecular clones and is epidemiologically associated with selection in patients treated with zidovudine (and with TAMs). Papers 2 and 3 provide mechanistic support (connection/RNase H domain mutations affecting RT function and contributing to dual NRTI/NNRTI resistance), consistent with Paper 1\u2019s finding. Together the evidence confirms that N348I causes reduced susceptibility/resistance to zidovudine."
    },
    "overthinking_doc_ids": [
      "15319019",
      "2319305",
      "6426919"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers directly support that N348I in the connection domain of HIV-1 reverse transcriptase confers resistance to zidovudine (AZT). Paper 1 reports that N348I prevalence rises in treatment-experienced patients, is associated with TAMs and AZT-containing regimens, and that introduction of N348I into molecular clones decreased AZT susceptibility ~2\u20134-fold; biochemical analyses there also support a role in AZT resistance. Papers 3 and 4 provide mechanistic support showing N348I and other connection/RNase H domain mutations alter RNase H/polymerase balance and can produce dual NRTI/NNRTI resistance, which is consistent with reduced AZT efficacy. The remaining papers are unrelated to this mutation. Therefore the evidence confirms the claim."
    },
    "posthoc_doc_ids": [
      "15319019",
      "25014337",
      "2319305",
      "6426919",
      "7227763"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "881",
    "claim": "Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 4 (Intestinal microbiota metabolism of L-carnitine...) directly addresses this question: it reports that omnivorous human subjects produced more TMAO than vegans or vegetarians after ingesting L\u2011carnitine via a microbiota\u2011dependent mechanism. The other provided papers do not provide relevant conflicting data. Therefore the evidence contradicts the claim that omnivores produce less TMAO from dietary L\u2011carnitine than vegans."
    },
    "naive_doc_ids": [
      "7751726",
      "6793674",
      "9764256",
      "14803797",
      "5687200"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 2 directly addresses L-carnitine metabolism in humans and reports that omnivorous subjects produced more TMAO than vegans or vegetarians following ingestion of L-carnitine via a microbiota-dependent mechanism. This finding is the opposite of the claim that omnivores produce less TMAO from dietary L-carnitine than vegans. The other provided papers do not provide evidence supporting the claim."
    },
    "overthinking_doc_ids": [
      "3716075",
      "14803797",
      "3205945",
      "7230315",
      "44384384"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 3 directly addresses L-carnitine metabolism and reports that omnivorous human subjects produced more TMAO than vegans or vegetarians after ingestion of L-carnitine via a microbiota-dependent mechanism. None of the other provided papers present data showing omnivores produce less TMAO than vegans. Therefore the provided evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "4939312",
      "10557471",
      "14803797",
      "6793674",
      "12709184"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.95,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "516",
    "claim": "High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 (large prospective cohort) directly contradicts the claim: elevated inflammatory biomarkers including CRP measured in stable COPD were associated with increased risk of exacerbations (e.g., first-year odds ratios for frequent exacerbations rose with number of high biomarkers and multi-year hazard ratios were 1.4, 1.6, and 2.5 for 1, 2, and 3 high biomarkers respectively). Paper 2 supports an inflammation\u2013worse outcomes link (the frequent-exacerbation phenotype was independently associated with elevated white-cell count). Paper 4 also links higher systemic inflammation (high-sensitivity CRP/fibrinogen) with adverse effects (reduced physical activity). Papers 3 and 5 do not address CRP\u2013exacerbation relationships. Overall, the provided evidence indicates higher CRP is associated with higher, not lower, exacerbation risk."
    },
    "naive_doc_ids": [
      "29564505",
      "18988265",
      "3580005",
      "26107000",
      "2425364"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "None of the provided papers support the claim that high CRP reduces COPD exacerbation risk. Paper 3 (directly about COPD exacerbations after ICS withdrawal) measured serum CRP but did not identify it as a protective predictor of exacerbations; sputum eosinophils (and other sputum markers) predicted exacerbations instead. Papers 1 and 2 show the opposite direction in other diseases: higher CRP predicted higher risk of peripheral arterial disease (Paper 1) and improved identification of pneumonia (higher CRP associated with greater probability of pneumonia) (Paper 2). Papers 4 and 5 do not address CRP and COPD exacerbations. Overall the evidence does not support a protective effect of high CRP on COPD exacerbations and in related contexts higher CRP is associated with increased disease risk."
    },
    "overthinking_doc_ids": [
      "72933407",
      "5558754",
      "25319221",
      "3580005",
      "4515975"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 (large prospective cohort) directly contradicts the claim: elevated baseline CRP (cutpoint 3 mg/L), together with other inflammatory markers, was associated with increased risk of COPD exacerbations (first-year multivariable-adjusted ORs for frequent exacerbations rose with number of high biomarkers; HRs over maximum follow-up were 1.4, 1.6, and 2.5 for 1, 2, and 3 high biomarkers vs none; higher 5-year absolute risks in those with high biomarkers). Paper 3 also supports the opposite association, reporting that elevated white-cell count (an inflammation marker) was associated with greater exacerbation susceptibility. The other papers do not provide evidence that high CRP reduces exacerbation risk. Overall, the provided evidence shows higher CRP/inflammation is linked to increased \u2014 not reduced \u2014 exacerbation risk."
    },
    "posthoc_doc_ids": [
      "29564505",
      "3580005",
      "18988265",
      "27466734",
      "13843341"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "744",
    "claim": "Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that Ras-transformed cells internalize extracellular protein via macropinocytosis, degrade the protein in lysosomes, and use the resulting amino acids (including glutamine) to fuel central carbon metabolism and support growth; pharmacologic inhibition of macropinocytosis reduces tumor growth. Paper 2 independently shows that endocytosed/extracellular proteins (taken up by macropinocytosis) can be lysosomally degraded to provide essential amino acids that sustain cell survival and activate mTORC1, and that modulation of mTORC1 alters the catabolism of these endocytosed proteins. Papers 3 and 5 do not address this topic, and Paper 4 describes increased systemic protein breakdown in early pancreatic cancer (raising circulating amino acids) but does not provide evidence about macropinocytosis. Together, the experimental findings in Papers 1 and 2 provide direct support for the claim that macropinocytosis contributes to a cell's supply of amino acids via intracellular uptake and degradation of protein, particularly in transformed/cancer contexts."
    },
    "naive_doc_ids": [
      "4138659",
      "8460275",
      "3845894",
      "4959368",
      "7228140"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that Ras-transformed cells use macropinocytosis to internalize extracellular protein, which is proteolytically degraded intracellularly to yield amino acids (including glutamine) that feed central carbon metabolism and can substitute for free extracellular glutamine; pharmacologic inhibition of macropinocytosis reduces growth of Ras-driven pancreatic tumor xenografts. Papers 2 and 4 do not address macropinocytosis or protein-derived amino acid supply, and Paper 3 describes systemic protein breakdown and elevated circulating BCAAs in early pancreatic cancer (not macropinocytic uptake), so they do not contradict the claim. Therefore the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "4138659",
      "3845894",
      "4959368",
      "4920376"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct experimental evidence that Ras-transformed cells use macropinocytosis to internalize extracellular protein, which is proteolytically degraded intracellularly to yield amino acids (including glutamine) that enter central carbon metabolism and can substitute for free extracellular glutamine. Paper 4 independently shows that lysosomal degradation of endocytosed/extracellular proteins (taken up by macropinocytosis) can serve as an essential amino acid source for cells. Together these papers directly support the claim that macropinocytosis contributes to a cell's supply of amino acids via intracellular uptake and degradation of protein. Other provided papers do not contradict this mechanism (some are tangentially related to amino acid metabolism) but do not negate the experimental findings."
    },
    "posthoc_doc_ids": [
      "4138659",
      "4959368",
      "12207167",
      "8460275",
      "23895668"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "841",
    "claim": "Natriuretic peptides protect against diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 6 provides direct, relevant evidence: higher circulating NT-pro-BNP levels were prospectively associated with a lower risk of incident type 2 diabetes (\u224821% lower risk per SD higher log NT-pro-BNP), and the BNP locus variant rs198389 (C allele) was associated with reduced T2D risk in case-control studies. A Mendelian randomization analysis showed the genetic association magnitude was consistent with the NT-pro-BNP\u2192T2D association, supporting a potential causal protective role of the BNP system against type 2 diabetes. The other included papers do not provide evidence for or against natriuretic peptides and therefore do not contradict this finding. (Limitations: the MR result indicates a likely causal relationship but does not prove mechanism; further mechanistic and interventional studies are needed.)"
    },
    "naive_doc_ids": [
      "27166444",
      "11201004",
      "1974176",
      "14116046",
      "18450716"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 directly addresses natriuretic peptides (BNP/NT-pro-BNP) and type 2 diabetes, reporting an inverse prospective association (\u224821% lower incident T2D per 1 SD higher log NT-pro-BNP) and Mendelian randomization results (rs198389 C allele OR 0.94 for T2D) consistent with a causal protective effect. The other provided papers do not assess natriuretic peptides or their relationship to diabetes, so they are not relevant to this claim. Therefore the available evidence supports the claim that natriuretic peptides protect against diabetes."
    },
    "overthinking_doc_ids": [
      "15663829",
      "1974176",
      "10071552",
      "14116046",
      "2481032"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct, population-level and Mendelian-randomization evidence that higher B-type natriuretic peptide (measured as NT-pro-BNP) is associated with a lower risk of incident type 2 diabetes (\u224821% lower risk per 1 SD higher log NT-pro-BNP) and that the BNP locus variant rs198389 (C allele), which raises BNP, is associated with reduced T2D risk consistent with a causal effect. None of the other provided papers present data that contradict this link (they address obesity, insulin resistance, inflammation, diet, or natriuretic peptides in pregnancy but not diabetes risk). Thus the provided evidence supports the claim that natriuretic peptides protect against diabetes, though the MR paper itself notes further work is needed to define mechanisms and translational implications."
    },
    "posthoc_doc_ids": [
      "120626",
      "195352",
      "5687200",
      "15663829",
      "18450716"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "840",
    "claim": "Natriuretic peptides increase susceptibility to diabetes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (Mendelian randomization study) directly addresses B-type natriuretic peptide (BNP) and type 2 diabetes risk and finds the opposite of the claim: higher NT-pro-BNP levels are associated with a lower risk of incident T2D (\u224821% lower risk per SD higher NT-pro-BNP), and a BNP-raising allele (rs198389 C) is associated with reduced odds of T2D consistent with a causal protective effect. The other provided papers do not present data on natriuretic peptides and diabetes risk (they concern diet, hypoglycaemia, insulin resistance measures, insulin-sensitizing drugs, or beta-cell insulin signaling) and therefore do not support the claim. Overall, the evidence here contradicts the statement that natriuretic peptides increase susceptibility to diabetes."
    },
    "naive_doc_ids": [
      "15663829",
      "1974176",
      "13282296",
      "24872571",
      "11201004"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses natriuretic peptides and type 2 diabetes and provides evidence opposite to the claim: higher circulating NT-pro-BNP was associated with a lower risk of incident T2D (\u224821% decreased risk per SD higher NT-pro-BNP) and Mendelian randomization using rs198389 supported a likely causal protective effect (observed OR \u22480.94 per C allele). None of the other papers present evidence that natriuretic peptides increase diabetes susceptibility (Paper 8 reports pregnancy-related ANP/corin changes linked to preeclampsia, not diabetes; Papers 2\u20137 address unrelated pathways/biomarkers). Overall, the available evidence in these papers contradicts the claim that natriuretic peptides increase susceptibility to diabetes."
    },
    "overthinking_doc_ids": [
      "15663829",
      "1974176",
      "6176498",
      "2481032",
      "6042706"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 2 directly addresses B-type natriuretic peptide (BNP) and type 2 diabetes: higher NT-pro-BNP was associated with a lower risk of incident T2D (\u224821% decreased risk per SD higher NT-pro-BNP), and the BNP-associated genotype rs198389 showed an association with reduced T2D risk consistent with Mendelian randomization\u2014supporting a protective (causal) effect of BNP on T2D risk. None of the other provided papers present evidence that natriuretic peptides increase diabetes susceptibility. Therefore the supplied evidence contradicts the claim that natriuretic peptides increase susceptibility to diabetes."
    },
    "posthoc_doc_ids": [
      "6372244",
      "15663829",
      "5567005",
      "13619127",
      "829646"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1237",
    "claim": "The most prevalent adverse events to Semaglutide are cardiovascular.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 (oral vs subcutaneous semaglutide randomized trial) directly reports adverse events for semaglutide and states that mild-to-moderate gastrointestinal events were the most common adverse events. None of the other provided papers report semaglutide adverse-event profiles. Therefore the evidence contradicts the claim that the most prevalent adverse events to semaglutide are cardiovascular."
    },
    "naive_doc_ids": [
      "6070278",
      "11254040",
      "10984005",
      "3654468",
      "11939159"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2, a randomized clinical trial of oral and subcutaneous semaglutide, reports that adverse events were common but that mild-to-moderate gastrointestinal events were the most common adverse events. This directly opposes the claim that the most prevalent adverse events to semaglutide are cardiovascular. The other provided papers do not report semaglutide safety data (Paper 1: fluorescein safety; Paper 3: MDR-TB drugs; Paper 4: atherosclerotic burden predicting MACE) and therefore do not support the claim. Based on the trial evidence, the claim is contradicted."
    },
    "overthinking_doc_ids": [
      "37628989",
      "3654468",
      "11254040",
      "6070278"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 (randomized trial of oral and subcutaneous semaglutide) directly reports adverse events for semaglutide: adverse events occurred in 63%\u201386% of oral semaglutide recipients and 81% of subcutaneous recipients, with mild-to-moderate gastrointestinal events being the most common. None of the other provided papers present evidence that cardiovascular events are the most prevalent adverse events of semaglutide. Therefore the provided evidence contradicts the claim that cardiovascular events are the most prevalent adverse events for semaglutide."
    },
    "posthoc_doc_ids": [
      "6070278",
      "11254040",
      "3654468",
      "5698494",
      "202259"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1207",
    "claim": "The composition of myosin-II isoform switches from the polarizable B isoform to the more homogenous A isoform during hematopoietic differentiation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the seven provided papers address myosin-II isoform composition or a switch from a \u2018polarizable B\u2019 isoform to a \u2018homogenous A\u2019 isoform during hematopoietic differentiation. The papers cover miRNA expression in CD34+ HSPCs (Paper 1), mitochondrial phosphatase PTPMT1 and metabolic control of HSC differentiation (Paper 2), miR-184/MBD1 in neural stem cells (Paper 3), polarity mechanisms in plants (Paper 4), Wnt5a and planar cell polarity in the mouse cochlea (Paper 5), osteoclasts and HSC niche formation (Paper 6), and embryonic-like stem cells differentiating into myotubes with myosin heavy chain expression (Paper 7). None report experimental data or results about myosin-II A/B isoforms or an isoform switch during hematopoietic differentiation, so the claim cannot be confirmed or refuted from this evidence."
    },
    "naive_doc_ids": [
      "23727313",
      "11289247",
      "2356950",
      "4350400",
      "18575183"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers present data on myosin-II isoform composition or on a switch from a \"B\" to an \"A\" myosin-II isoform during hematopoietic differentiation. Although several papers address hematopoiesis (PTPMT1 in HSC differentiation, HSC review, CD34+ miRNAs, asymmetric divisions) and one paper on smooth-muscle differentiation mentions myosin heavy chain II (a different protein class), none report measurements of nonmuscle myosin-II A vs B expression, localization, or switching during HSC differentiation. Therefore the supplied evidence neither supports nor contradicts the specific claim."
    },
    "overthinking_doc_ids": [
      "1507222",
      "23253955",
      "25827024",
      "11289247",
      "13116880"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 (Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells) directly addresses nonmuscle myosin-II isoforms in hematopoiesis: MIIB is a major, strongly polarized isoform in HSCs/HSPCs and is downregulated in differentiated cells via asymmetric division, whereas MIIA is constitutive and becomes activated during cytokine-triggered differentiation. This evidence supports the claim that myosin-II composition shifts from a polarized MIIB-dominated state toward a more MIIA-dominated/activated state during hematopoietic differentiation. Other listed papers do not provide contradictory data relevant to this specific isoform switch."
    },
    "posthoc_doc_ids": [
      "14581009",
      "27061085",
      "12315072",
      "30303335",
      "18909530"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "308",
    "claim": "DUSP4 downregulation deactivates the Ras-ERK pathway",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Multiple papers contradict the claim. Paper 5 explicitly identifies DUSP4 as an ERK phosphatase and reports that DUSP4 downregulation activates (not deactivates) the Ras-ERK pathway in basal-like breast cancer, linking low DUSP4 to Ras-ERK pathway activation and chemoresistance. Papers 6 and 9 provide corroborating mechanistic context using related dual-specificity phosphatases (MKP-2): increased expression of these phosphatases represses ERK activity, implying that loss/downregulation of such phosphatases would relieve repression and increase ERK signaling. Thus the provided evidence shows DUSP4 downregulation activates, rather than deactivates, the Ras-ERK pathway."
    },
    "naive_doc_ids": [
      "4662264",
      "7506409",
      "29689140",
      "32598644",
      "7821634"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the six provided papers address DUSP4 (MKP-2) or directly test effects of DUSP4 downregulation on the Ras\u2013ERK pathway. While Paper 2 mentions ERK in a different context (as a kinase tested for involvement in AMPK Ser485/491 phosphorylation), it does not involve DUSP4 or report Ras\u2013ERK activation/deactivation when DUSP4 is altered. The other papers do not discuss DUSP4 or the Ras\u2013ERK pathway. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "14198646",
      "23974474",
      "37164306",
      "16626264",
      "26658659"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses DUSP4 and Ras-ERK signaling: it identifies DUSP4 as an ERK phosphatase and reports that DUSP4 downregulation activates (not deactivates) the Ras-ERK pathway in basal-like breast cancer, with downstream effects on proliferation and chemotherapy resistance. None of the other provided papers present data supporting the claim that DUSP4 downregulation deactivates Ras-ERK. Mechanistically, loss of an ERK phosphatase would be expected to increase ERK pathway activity, consistent with Paper 1, and therefore contradicts the claim."
    },
    "posthoc_doc_ids": [
      "7821634",
      "6121555",
      "17648235",
      "7506409",
      "8446259"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "871",
    "claim": "Obesity decreases life quality.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Taken together the papers provide evidence that obesity and conditions strongly linked to obesity reduce health-related quality of life (HRQoL). Paper 1 reports substantial HRQoL impairments and increased healthcare use/costs in patients with binge eating disorder, a condition often associated with overweight/obesity (SF-36 physical and mental component scores well below population norms). Paper 2 shows higher prepregnancy BMI strongly increases risk of gestational diabetes, a morbidity that negatively affects health. Paper 5 reviews mechanistic and epidemiologic links between obesity and metabolic diseases (insulin resistance, type 2 diabetes, dyslipidemia, NAFLD) that are known to reduce quality of life. Paper 6 demonstrates obesity is associated with adipose inflammation and metabolic dysfunction in animal models, supporting a biological pathway to poorer health. Paper 4 shows chronic diseases lower EQ-5D scores (EQ VAS), and since obesity increases risk of multiple chronic conditions, this implies lower HRQoL. Paper 3 documents increased psychiatric/neurobehavioral comorbidity (ADHD associated with higher obesity prevalence), further linking obesity to mental-health burden. Although none of the included studies is a single large trial directly measuring HRQoL across BMI categories, the clinical, epidemiologic and mechanistic evidence in these papers supports the claim that obesity decreases life (health-related) quality."
    },
    "naive_doc_ids": [
      "40666943",
      "439670",
      "1831916",
      "463533",
      "5268462"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers directly test whether obesity per se decreases quality of life. Paper 1 documents reduced health-related quality of life (HRQoL) in people with binge eating disorder (BED), which is an eating disorder that can be associated with obesity but is not equivalent to obesity itself. Paper 5 shows that bariatric surgery produces large, sustained weight loss and reduces obesity-related comorbidities (T2DM, hypertension, angina, MI risk, obstructive sleep apnoea), which implies health benefits of weight reduction but does not directly report quality of life outcomes in obese vs non\u2011obese individuals. Papers 2, 3, 4, and 6 address other topics (ADHD\u2013obesity association, angiotensin blockade and mental QoL, visual field loss in glaucoma and QoL, and QoL evidence for cancer drugs) and do not provide direct evidence about the effect of obesity on overall quality of life. Therefore the set does not provide direct evidence to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "40666943",
      "1831916",
      "26199970",
      "31208367",
      "5824985"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers directly assess the effect of obesity on health-related quality of life. Paper 1 shows that binge eating disorder (BED) impairs HRQoL (and BED can co-occur with obesity) but does not directly evaluate obesity itself. Paper 6 examines HRQoL across chronic conditions but does not explicitly present obesity-specific HRQoL data in the provided summary. The other studies address different topics (ADHD\u2013obesity association, blood pressure lowering in dialysis, cancer survivorship, sexual health and aging, perioperative fluids, angiotensin blockade effects) and do not provide direct evidence that obesity decreases quality of life. Therefore the set of papers does not contain direct supporting or contradicting evidence for the specific claim."
    },
    "posthoc_doc_ids": [
      "40666943",
      "1831916",
      "202259",
      "24988745",
      "3981244"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "776",
    "claim": "Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers directly report experiments testing ionizing-radiation sensitivity in mice lacking DNA polymerase mu (pol \u03bc). Paper 4 shows that pol \u03bc protein levels rise after IR, that pol \u03bc forms IR-induced foci coincident with \u03b3H2AX, and that it biochemically interacts with Ku and XRCC4\u2013ligase IV and facilitates end joining, implying a role in double-strand-break repair. However, that paper does not present data on pol \u03bc-deficient mice or their survival/sensitivity to IR. The other papers do not address pol \u03bc or IR sensitivity in pol \u03bc-deficient animals. Therefore the provided evidence neither confirms nor refutes the specific claim that pol \u03bc-defective mice fail to reveal increased sensitivity to ionizing radiation."
    },
    "naive_doc_ids": [
      "43014661",
      "21878751",
      "31293581",
      "27635177",
      "12552297"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers report experiments or results on mice deficient for DNA polymerase mu (polm) and their sensitivity to ionizing radiation. The closest relevant study (Paper 7) examines DNA polymerase eta (pol eta) and UV sensitivity, which is a different polymerase and a different DNA-damaging agent. Other papers address unrelated genes or contexts (p53, ATM, TLR2, p75NTR, mast cells, CFTR) and do not test polm-deficient mice with ionizing radiation. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "31293581",
      "52805891",
      "5572127",
      "368506",
      "597790"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report experiments testing IR sensitivity of mice lacking DNA polymerase mu (pol \u03bc / polm). Paper 6 describes pol \u03bc induction after IR, its localization to DSB foci, and biochemical/ cell-extract evidence that pol \u03bc participates in nonhomologous end-joining, but it does not present data from pol \u03bc-deficient mice or measure whole-animal IR sensitivity. Other papers concern different polymerases (Pol \u03b2, Pol \u03b7, Pol \u03bb), IR-induced senescence, ATM-deficiency, or unrelated topics (microbiota), and thus do not provide direct evidence that polm-defective mice fail to show increased sensitivity to ionizing radiation."
    },
    "posthoc_doc_ids": [
      "11569583",
      "31293581",
      "52805891",
      "5572127",
      "43014661"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "798",
    "claim": "Mitochondria play a trivial role in calcium homeostasis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 2 directly contradicts the claim: it states that mitochondrial Ca2+ accumulation is of \u201cutmost physiological relevance,\u201d that mitochondrial Ca2+ uptake controls intracellular Ca2+ signalling by buffering cytosolic Ca2+ and regulating downstream effectors, and that the molecular identity of mitochondrial Ca2+ transporters has only recently been revealed\u2014supporting a significant, not trivial, role. None of the other papers support the idea that mitochondria play only a trivial role in calcium homeostasis; several (e.g., Paper 7 on mitochondrial bioenergetics and Paper 4 on ER\u2013mitochondria interactions) describe essential mitochondrial functions that are mechanistically connected to cellular homeostasis. Together, the evidence opposes the claim that mitochondria have a trivial role in calcium homeostasis."
    },
    "naive_doc_ids": [
      "3883485",
      "5094468",
      "19205437",
      "4701662",
      "2481032"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data directly testing or quantifying the contribution of mitochondria to cellular Ca2+ homeostasis. Several papers (Paper 4 and Paper 6) emphasize the importance of ER-based store-operated Ca2+ entry and the STIM1/Orai1 machinery in Ca2+ signaling, and Paper 2 describes chemokine-induced Ca2+ flux in neutrophils, but these findings do not assess mitochondrial Ca2+ uptake, buffering, or regulation. Paper 5 discusses mitochondrial biogenesis in adipose tissue but not mitochondrial roles in Ca2+ handling. Because the evidence does not directly support or refute the statement that mitochondria play a trivial role in calcium homeostasis, the appropriate classification is NOINFO."
    },
    "overthinking_doc_ids": [
      "7373453",
      "12058271",
      "16728949",
      "7736860",
      "11615242"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 5 directly states that mitochondrial Ca2+ uptake is of \u201cutmost physiological relevance,\u201d controlling intracellular Ca2+ signaling, buffering cytosolic Ca2+, and regulating metabolism and cell survival \u2014 which contradicts the idea that mitochondria play only a trivial role. Paper 6 further supports a regulatory role for mitochondria in signaling/homeostasis by showing that damaged, ROS-generating mitochondria activate the NLRP3 inflammasome and that mitochondrial dysfunction affects inflammasome activity. While Papers 2, 3, and 8 describe important Ca2+ roles for other organelles/systems (SERCA/ER Ca2+ cycling, endolysosomal channels, STIM1-mediated SOCE), none provide evidence that mitochondrial contributions are negligible. Together the evidence indicates mitochondria have significant, non\u2011trivial roles in cellular Ca2+ homeostasis."
    },
    "posthoc_doc_ids": [
      "12058271",
      "19205437",
      "28724565",
      "20008796",
      "5094468"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1216",
    "claim": "The extracellular domain of TMEM27 is cleaved in human beta cells.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Paper 1 reports that the extracellular domain of Tmem27 is glycosylated, cleaved and shed from the plasma membrane of pancreatic beta cells and that this cleavage is beta cell\u2013specific; however, that study uses mouse models (mentions Tcf1(-/-) mice and transgenic mice). None of the other provided papers report TMEM27/collectrin extracellular-domain cleavage in human beta cells. Papers 2, 3, 5, and 6 concern human islets or beta-cell biology but do not present data showing TMEM27 cleavage in human cells. Therefore the provided evidence does not directly demonstrate cleavage of the TMEM27 extracellular domain in human beta cells."
    },
    "naive_doc_ids": [
      "24142891",
      "16527698",
      "19756935",
      "22401720",
      "27588420"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "Only Paper 7 describes cleavage and shedding of the TMEM27 extracellular domain, but that work is presented in the context of rodent/mouse pancreatic beta cells (references to Tcf1(-/-) mice and mouse models). None of the other provided papers report experimental evidence for cleavage of TMEM27 in human beta cells specifically. Therefore the set does not provide direct evidence that the TMEM27 extracellular domain is cleaved in human beta cells."
    },
    "overthinking_doc_ids": [
      "19756935",
      "27588420",
      "43661837",
      "16527698",
      "16572581"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Paper 1 provides clear experimental evidence that Tmem27 is glycosylated, its extracellular domain is cleaved and shed from the plasma membrane, and this cleavage is beta-cell specific \u2014 but the study is in mice (references to Tcf1(-/-) and transgenic mouse models). None of the other provided papers report on TMEM27 cleavage in human beta cells. Therefore the provided corpus does not contain direct experimental evidence that the extracellular domain of TMEM27 is cleaved in human beta cells; it only documents cleavage in (mouse) beta cells."
    },
    "posthoc_doc_ids": [
      "24142891",
      "1905095",
      "19756935",
      "27588420",
      "16527698"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "645",
    "claim": "Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "All relevant trials and analyses in the provided papers report that folic acid (and folic acid combined with B vitamins including vitamin B6) lower or do not increase plasma homocysteine, rather than raise it. Examples: Paper 1 \u2014 randomized dosing trial: folic acid reduced median serum homocysteine up to 2.7 \u00b5mol/L (\u224823%) at 0.8 mg/day. Paper 2 \u2014 large RCT in advanced CKD/ESRD: daily 40 mg folic acid + 100 mg pyridoxine (B6) + 2 mg B12 lowered homocysteine by 6.3 \u00b5mol/L (25.8%) at 3 months. Paper 3 \u2014 elderly RCT: 400 \u00b5g and 600 \u00b5g folic acid produced significant homocysteine reductions versus placebo. Paper 4 \u2014 meta-analysis: folic acid supplementation produced mean homocysteine reductions (e.g., ~27% in non-fortified settings). Paper 7 showed improvement in endothelial function largely independent of homocysteine lowering and reported no acute increase in total homocysteine (slight reduction in non\u2013protein-bound homocysteine). None of the cited studies report that folic acid or B6 intake increases homocysteine. Therefore the evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "11705328",
      "33409100",
      "21636085",
      "37424881",
      "6793674"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers show that folic acid intake lowers \u2014 not raises \u2014 serum homocysteine. Paper 3 (randomized trial) found folic acid reduced median homocysteine (placebo-adjusted reduction up to 2.7 \u00b5mol/L, ~23% at 0.8 mg/day). Paper 1 (meta-analysis of RCTs) reports homocysteine reductions of ~27% (no folate fortification subgroup), ~18% (with fortification), etc., with folic acid supplementation. Paper 5 shows that higher folate status is associated with lower homocysteine (MTHFR effects larger in low-folate regions) and that trials of homocysteine-lowering (via folate) did not increase homocysteine. Papers 2 and 4 are not relevant to folic acid or vitamin B6 effects on homocysteine. None of the supplied papers provide evidence that folic acid or vitamin B6 intake increases homocysteine; on the contrary, the evidence for folic acid is that it decreases homocysteine. (Note: the supplied set contains no direct data on vitamin B6 alone.)"
    },
    "overthinking_doc_ids": [
      "37424881",
      "4515975",
      "11705328",
      "5402581",
      "8595678"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "All four provided papers report that folic acid (and in Paper 4, folic acid combined with vitamin B6 and B12) reduces plasma/serum homocysteine, not increases it. Paper 1 (randomized trial) found dose-dependent decreases in serum homocysteine with folic acid, with a maximum placebo-adjusted reduction of 2.7 \u00b5mol/L (23%) at 0.8 mg/day. Paper 2 (elderly RCT) reported significant homocysteine reductions for 400 \u00b5g and 600 \u00b5g folic acid groups versus placebo. Paper 3 (meta-analysis) shows mean homocysteine reductions of ~27%, ~18%, and ~21% across subgroups (no fortification, full, partial fortification) with folic-acid\u2013based interventions. Paper 4 (large RCT in advanced CKD/ESRD) showed that daily treatment with high-dose folic acid plus pyridoxine (vitamin B6) and B12 lowered homocysteine by 6.3 \u00b5mol/L (25.8%) at 3 months versus placebo. None of the papers report an increase in homocysteine following folic acid or vitamin B6 intake, so the evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "11705328",
      "21636085",
      "37424881",
      "33409100"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1141",
    "claim": "Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (Physicians' Health Study II), a large randomized, double-blind, placebo-controlled trial in 14,641 men, tested vitamin E (400 IU every other day) and vitamin C (500 mg daily) (factorial design). During a mean 8.0 years of follow-up neither vitamin E nor vitamin C reduced prostate cancer incidence. Reported hazard ratios were null (vitamin E HR 0.97, 95% CI 0.85\u20131.09, P = .58; vitamin C HR 1.02, 95% CI 0.90\u20131.15, P = .80). None of the other provided papers address vitamin E + vitamin C and prostate cancer. Therefore the available randomized trial evidence in these papers does not support the claim that taking vitamin E (\u03b1\u2011tocopheryl acetate) with vitamin C reduces prostate cancer risk."
    },
    "naive_doc_ids": [
      "12009265",
      "27437459",
      "24634621",
      "21502234",
      "7639744"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 is a large randomized, double-blind, placebo-controlled trial (Physicians' Health Study II; n = 14,641 men, mean follow-up 8.0 years) that directly tested vitamin E (400 IU every other day, \u03b1-tocopheryl form) and vitamin C (500 mg daily). It found no reduction in prostate cancer incidence with vitamin E (HR 0.97; 95% CI 0.85\u20131.09; P = .58) or vitamin C (HR 1.02; 95% CI 0.90\u20131.15; P = .80). Adjustment for adherence and other sensitivity analyses did not change the results. The other provided papers do not provide relevant evidence on vitamin E/C and prostate cancer. Therefore the available randomized trial evidence in these papers does not support the claim and in fact contradicts it."
    },
    "overthinking_doc_ids": [
      "12009265",
      "308862",
      "5649538",
      "5402581",
      "31229233"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 is a large randomized, double-blind, placebo-controlled trial (Physicians' Health Study II; n=14,641, mean follow-up 8.0 years) that directly tested vitamin E (400 IU every other day) and vitamin C (500 mg daily) supplementation. It found no reduction in prostate cancer incidence for vitamin E (HR 0.97; 95% CI 0.85\u20131.09; P = .58) or vitamin C (HR 1.02; 95% CI 0.90\u20131.15; P = .80). None of the other provided papers present evidence that vitamin E plus vitamin C reduces prostate cancer risk. Therefore the provided evidence does not support the claim and directly contradicts it. (Note: the trial used 400 IU vitamin E rather than 400 mg \u03b1-tocopheryl acetate, but it is the directly relevant randomized evidence among the supplied papers.)"
    },
    "posthoc_doc_ids": [
      "12009265",
      "24396137",
      "15648443",
      "38551172",
      "520579"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "914",
    "claim": "PPAR-RXRs can be activated by PPAR ligands.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Taken together the papers provide indirect but consistent evidence that PPAR-containing nuclear receptor complexes can be activated by PPAR ligands. Paper 2 shows that the PPAR\u03b3 agonist rosiglitazone produces PPAR\u03b3-dependent biological effects in vivo (increased PPAR\u03b3 expression and downstream anti\u2011inflammatory effects), demonstrating that a PPAR ligand can activate PPAR signaling. Paper 1 describes the general ligand-dependency of nuclear receptor activation and mechanisms that govern ligand-dependent coactivator exchange, supporting the notion that nuclear receptors (including PPARs) require ligand binding for activation. Paper 7, while focused on RAR/RXR heterodimers, shows that ligand binding of one heterodimer partner can drive coactivator recruitment and that combinatorial ligand occupancy modulates activation strength; this is mechanistically consistent with PPAR\u2013RXR heterodimers being activated by ligands that bind the PPAR protomer. None of the provided papers explicitly demonstrate PPAR\u2013RXR heterodimer activation by a PPAR ligand in a structural or biochemical assay, so the support is inferential rather than a direct experimental demonstration in these specific articles."
    },
    "naive_doc_ids": [
      "13639330",
      "56486733",
      "20960682",
      "7729656",
      "18346333"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided papers document effects of PPAR agonists (e.g., fenofibrate, rosiglitazone) on cellular outcomes and report PPAR-dependent transcriptional activity, but none explicitly discuss PPAR\u2013RXR heterodimers or state that PPAR\u2013RXRs are activated by PPAR ligands. The summaries do not provide direct experimental evidence about activation of PPAR\u2013RXR complexes by PPAR ligands, so the claim cannot be confirmed or refuted from these sources."
    },
    "overthinking_doc_ids": [
      "15972906",
      "33499189",
      "5403286",
      "25328476",
      "56486733"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "The provided papers do not directly test PPAR\u2013RXR heterodimers, but they present relevant and supportive evidence. Paper 9 (RAR/RXR structural/biochemical study) shows that nuclear receptor heterodimers recruit coactivators in a ligand-dependent manner and that the combinatorial presence of both partner ligands gives the highest coactivator binding, while also noting that a protomer can recruit an NR box peptide regardless of the ligand status of its partner. This indicates that ligand binding to one receptor in an RXR heterodimer can drive activation/coactivator recruitment. Paper 5 describes general mechanisms of ligand-dependent activation of nuclear receptors (including requirements for corepressor/coactivator exchange and epigenetic gating), supporting the concept that single-receptor ligands can activate their receptor-containing heterodimers. Paper 6 confirms PPAR-\u03b3 is expressed and ligand-regulated in human liver, showing the biological relevance of PPAR ligands. Taken together, these papers provide indirect but consistent evidence that PPAR\u2013RXR heterodimers can be activated by PPAR ligands. No paper explicitly tests PPAR\u2013RXR activation by PPAR ligands, so the support is inferential rather than direct."
    },
    "posthoc_doc_ids": [
      "5828251",
      "15972906",
      "20690388",
      "8453819",
      "13639330"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "478",
    "claim": "Golli-deficient T-cells prefer to differentiate into an anergic phenotype in the adaptive immune response when there are increased levels of Ca2+ in the cytosol.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 6 directly addresses golli in T cells and reports that golli-deficient T cells show enhanced Ca2+ entry upon TCR stimulation and are hyperproliferative, indicating increased activation rather than anergy. The study identifies golli as a negative regulator of store-operated Ca2+ influx; loss of golli increases Ca2+ signaling and proliferation. None of the other provided papers report that golli-deficient T cells adopt an anergic phenotype with elevated cytosolic Ca2+. Thus the available evidence contradicts the claim: increased cytosolic Ca2+ in golli-deficient T cells is associated with heightened activation/proliferation, not preferential differentiation to anergy."
    },
    "naive_doc_ids": [
      "1976183",
      "2099400",
      "2825380",
      "2727303",
      "13760557"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses golli in T cells and reports that golli-deficient T cells show enhanced Ca2+ entry upon TCR stimulation and are hyperproliferative \u2014 i.e., more activated rather than anergized. None of the other papers provide evidence that golli deficiency drives T cells toward an anergic phenotype in the context of increased cytosolic Ca2+. Paper 3 describes a distinct, PD-L1\u2013mediated mechanism for parasite-induced T cell anergy but does not implicate golli or Ca2+ increases. Papers 4\u20136 discuss components of SOCE (STIM1, Orai/CRACM) and their roles in proliferation or effector functions, but they do not support the specific claim that golli deficiency combined with elevated cytosolic Ca2+ promotes T cell anergy. Overall, the available data contradict the claim."
    },
    "overthinking_doc_ids": [
      "14767844",
      "4444861",
      "7386360",
      "2727303",
      "13283919"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 2 directly addresses golli in T cells and shows that golli-deficient T cells display enhanced Ca2+ entry upon TCR stimulation and are hyperproliferative; golli normally inhibits store-operated Ca2+ influx. This evidence indicates increased cytosolic Ca2+ in golli-deficient T cells is associated with increased activation/proliferation, not anergy. None of the other provided papers present data supporting golli-driven anergic differentiation under high cytosolic Ca2+. Therefore the supplied evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "5572127",
      "14767844",
      "39225849",
      "14474178",
      "2506153"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "5",
    "claim": "1/2000 in UK have abnormal PrP positivity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly addresses abnormal PrP prevalence in the UK: 16 positives among 32,441 appendix samples \u2192 an estimated prevalence of 493 per million (95% CI 282\u2013801 per million), which is essentially 1/2,028 and consistent with the claim of ~1/2,000. Paper 2 provides additional (qualitative) evidence that subclinical/prion positivity exists in the population. Papers 3\u20138 are unrelated to prion prevalence. Therefore the provided evidence supports the claim."
    },
    "naive_doc_ids": [
      "13734012",
      "18617259",
      "75636923",
      "42291761",
      "2138767"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (large-scale UK survey of 32,441 archived appendix samples) found 16 positives for abnormal PrP, giving an overall prevalence of 493 per million (95% CI 282\u2013801 per million), which is approximately 1/2000 (\u22481/2028). The other papers do not provide contradictory population prevalence data for abnormal PrP in the UK. Therefore the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "13734012",
      "5824985",
      "42291761",
      "75636923",
      "756887"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly estimates abnormal prion protein (PrP) prevalence in UK appendix samples: 16 positives among 32,441 samples, giving a prevalence of 493 per million (95% CI 282\u2013801 per million). 493 per million is \u22481/2028, which matches the claim of ~1/2000. The other provided papers do not address PrP prevalence."
    },
    "posthoc_doc_ids": [
      "13734012",
      "5824985",
      "6876224",
      "25355575",
      "75636923"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "772",
    "claim": "Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly contradicts the claim: it reports that a single dose of an EILV/CHIKV chimera produced in mosquito cells elicited rapid (within 4 days) and long-lasting (>290 days) neutralizing antibodies in mice and provided complete protection in two different mouse models. None of the other provided papers present data showing that mice are incapable of mounting neutralizing antibody responses to mosquito-produced CHIKV."
    },
    "naive_doc_ids": [
      "24922825",
      "21141798",
      "2559303",
      "13469921",
      "343052"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly contradicts the claim: a single dose of the EILV/CHIKV chimera produced in mosquito cells elicited rapid (within 4 days) and long-lasting (>290 days) neutralizing antibodies in mice and provided complete protection in two mouse models. The other provided papers (2\u20136) do not address Chikungunya virus, mosquito-derived CHIKV, or mouse neutralizing antibody responses and are therefore not relevant. Taken together, the evidence disproves the claim that mice are incapable of producing neutralizing antibodies to mosquito-produced CHIKV."
    },
    "overthinking_doc_ids": [
      "24922825",
      "23915841",
      "643765",
      "9122283",
      "25726838"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly contradicts the claim: a chikungunya vaccine candidate (EILV/CHIKV) produced in mosquito cells elicited rapid (within 4 days) and long-lasting (>290 days) neutralizing antibodies in mice and provided complete protection in two different mouse models. The other papers do not provide relevant data about mouse antibody responses to mosquito-derived CHIKV. Therefore the provided evidence refutes the claim that mice are incapable of producing neutralizing antibodies to CHIKV produced in mosquitoes."
    },
    "posthoc_doc_ids": [
      "24922825",
      "9122283",
      "10559501",
      "13469921",
      "35062452"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1230",
    "claim": "The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that the minor G allele of FOXO3A (rs12212067 T>G) limits inflammatory responses in monocytes via a FOXO3-driven pathway: through TGF\u03b21 it reduces production of proinflammatory cytokines (including TNF\u03b1) and increases anti-inflammatory IL-10. The other provided papers do not report evidence contradicting this SNP effect (they are about other factors or general inflammation), so the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "13905670",
      "343052",
      "25148216",
      "9334631",
      "2844490"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that the FOXO3A SNP rs12212067 (T>G) minor G allele limits inflammatory responses in monocytes via a FOXO3-driven pathway: through TGF\u03b21 it reduces production of proinflammatory cytokines (including TNF\u03b1) and increases IL-10. This experimental finding directly supports the claim that the minor G allele of FOXO3 downregulates pro-inflammatory cytokines. The other provided papers do not address the FOXO3 rs12212067 allele and are not directly relevant."
    },
    "overthinking_doc_ids": [
      "13905670",
      "14092737",
      "15381976",
      "36242796",
      "14938990"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that the FOXO3A SNP rs12212067 (T>G) minor G allele \u2018limits inflammatory responses in monocytes via a FOXO3-driven pathway\u2019 and that this pathway, via TGF\u03b21, reduces production of proinflammatory cytokines including TNF\u03b1 while increasing anti-inflammatory IL-10. Papers 4 and 5 provide supporting mechanistic context by showing IL-10\u2019s role in downregulating proinflammatory T cell and monocyte responses. Together the evidence supports the claim that the minor G allele of FOXO3 downregulates pro-inflammatory cytokines."
    },
    "posthoc_doc_ids": [
      "13905670",
      "11233339",
      "25315295",
      "8639034",
      "10648422"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1118",
    "claim": "Sweet taste receptors on the tongue are deactivated by between 1 and 10 mM glucose.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report that sweet taste receptors on the tongue are deactivated by 1\u201310 mM glucose. Paper 1 identifies T1r2+T1r3 as sweet receptors but does not report glucose-induced deactivation or concentration ranges. Papers 2 and 3 describe glucose sensing by gut L cells (which express taste receptors) and show activation of GLP-1 secretion by sugars, not deactivation of tongue receptors. Paper 6 describes intracellular transduction components required for sweet taste but does not provide evidence that 1\u201310 mM glucose deactivates tongue sweet receptors. The other papers are unrelated. Therefore the provided evidence does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "23351136",
      "6061927",
      "20829129",
      "40710501",
      "3127341"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report data showing that sweet taste receptors on the tongue are deactivated by 1\u201310 mM glucose. Paper 1 discusses T1r2/T1r3 involvement in sweet sensing and that T1r3 knockout reduces but does not abolish responses to sugars, but it does not report glucose concentrations that deactivate receptors or describe deactivation in the 1\u201310 mM range. Papers 2\u20135 address unrelated pathways (FGF19/FGFR, PPAR\u03b1/ Akt, IL-4R/helminth effects, cystine/glutamate exchange) and do not provide evidence for or against the claim. Therefore there is no information in these papers to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "23351136",
      "6588614",
      "25328476",
      "7433668",
      "13172737"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present experimental data showing that sweet taste receptors on the tongue are deactivated by 1\u201310 mM glucose. Paper 1 addresses the role of T1r receptors (and T1r3 knockout effects) in sweet/umami detection but does not report glucose concentrations that deactivate taste receptors. Paper 2 shows that gut enteroendocrine L cells express sweet taste receptors and respond to glucose (and that responses can be blocked by a sweet-receptor antagonist), but it concerns intestinal cells and GLP\u20111 secretion rather than deactivation of lingual sweet receptors at 1\u201310 mM. Papers 3\u20138 are unrelated to lingual sweet-receptor deactivation. Therefore the evidence set does not support or contradict the specific claim."
    },
    "posthoc_doc_ids": [
      "23351136",
      "20829129",
      "7875158",
      "3531388",
      "10883736"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1280",
    "claim": "The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "All three papers provide direct experimental evidence that the ure accessory genes ureD (also known as UreH in some contexts), ureE, ureF, and ureG encode proteins required for urease maturation. Paper 1 maps and sequences ureD adjacent to the structural genes and shows deletions in ureD, ureE, ureF, or ureG produce inactive or partially active urease and that UreE and UreG were identified by amino-terminal sequencing, implicating these ORFs as accessory proteins required for nickel metallocenter assembly. Papers 2 and 3 demonstrate that UreD, UreF, and UreG form activation-competent urease apoprotein complexes (with UreE facilitating activation), and that these accessory proteins govern metallocenter assembly and activation properties. Together these results confirm that the ureABIEFGH gene region encodes urease maturation proteins UreD/UreH, UreE, UreF, and UreG."
    },
    "naive_doc_ids": [
      "29214508",
      "37768883",
      "36233757"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "All three papers provide experimental evidence that the ure accessory genes ureD, ureE, ureF, and ureG encode proteins required for urease maturation/metal center assembly. Paper 1 shows deletions in ureD, ureF, or ureG produce inactive urease (and ureE deletions produce partially active enzyme) with activity correlating to nickel content, and identifies the UreD, UreE, UreF, and UreG peptides. Papers 2 and 3 demonstrate that UreD, UreF, and UreG form apoprotein complexes with urease that are required for in vivo activation and modulate activation properties, with UreE facilitating activation. Together these findings confirm that the gene cluster encodes urease maturation (accessory) proteins (UreD (sometimes called UreH in other systems), UreE, UreF, and UreG)."
    },
    "overthinking_doc_ids": [
      "29214508",
      "37768883",
      "36233757"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Papers 1\u20133 provide direct experimental evidence that the urease gene region includes accessory/maturation genes ureD, ureE, ureF, and ureG and that these gene products are required for assembly of the nickel metallocenter and in vivo activation of urease. Paper 1 shows deletions in ureD/ureE/ureF/ureG produce inactive or low-activity urease and identifies the corresponding peptides. Papers 2 and 3 demonstrate formation of urease apoprotein complexes containing UreD, UreF and UreG (with UreE facilitating activation) and describe their roles in maturation/activation. Paper 4 is irrelevant. Together the evidence confirms that the cluster encodes urease maturation proteins UreD (UreH), UreE, UreF, and UreG."
    },
    "posthoc_doc_ids": [
      "29214508",
      "37768883",
      "36233757",
      "152245"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "249",
    "claim": "Chenodeosycholic acid treatment reduces whole-body energy expenditure.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly tests chenodeoxycholic acid (CDCA) in humans and reports that 2 days of oral CDCA increased brown adipose tissue activity and whole-body energy expenditure. The mechanistic data in that paper (CDCA/TGR5 \u2192 D2 induction, mitochondrial uncoupling, increased O2 consumption) explain the increase in energy expenditure. None of the other provided papers report that CDCA reduces whole-body energy expenditure; several report increased or preserved energy expenditure under different interventions or discuss related pathways. Therefore the provided evidence contradicts the claim that CDCA treatment reduces whole-body energy expenditure."
    },
    "naive_doc_ids": [
      "1568684",
      "25050364",
      "23017040",
      "3619931",
      "13902570"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses chenodeoxycholic acid (CDCA) treatment in humans and reports that 2 days of oral CDCA increased brown adipose tissue activity and increased whole-body energy expenditure. None of the other papers provide evidence that CDCA reduces whole-body energy expenditure (papers 2, 4, and 5 discuss other causes of altered energy expenditure, and paper 3 is unrelated). Therefore the provided evidence contradicts the claim that CDCA treatment reduces whole-body energy expenditure."
    },
    "overthinking_doc_ids": [
      "1568684",
      "24917562",
      "9197092",
      "26902591",
      "25050364"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly tests chenodeoxycholic acid (CDCA) in humans and reports that 2 days of oral CDCA increased brown adipose tissue activity and increased whole-body energy expenditure. In vitro data in the same paper show CDCA increases mitochondrial uncoupling in human brown adipocytes, consistent with increased energy expenditure. None of the other provided papers report CDCA causing a reduction in whole-body energy expenditure; several describe other interventions or conditions that alter energy expenditure but are not relevant to CDCA. Therefore the provided evidence contradicts the claim that CDCA treatment reduces whole-body energy expenditure."
    },
    "posthoc_doc_ids": [
      "1568684",
      "25050364",
      "26902591",
      "24917562",
      "23369842"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1307",
    "claim": "Tonic signaling from the scFv induces constitutive stimulation.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly documents that antigen-independent clustering of CAR single-chain variable fragments (scFv) produces tonic CAR CD3-\u03b6 phosphorylation and persistent (constitutive) activation that drives early T cell exhaustion. That finding is a direct description of scFv-mediated tonic signaling causing constitutive stimulation. The other provided papers do not present data contradicting this mechanism (most address unrelated signaling contexts), so the corpus supports the claim."
    },
    "naive_doc_ids": [
      "18231807",
      "22210434",
      "25353658",
      "19482914",
      "20261352"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that antigen-independent clustering of CAR single-chain variable fragments (scFv) produces tonic CAR CD3-\u03b6 phosphorylation and persistent signaling that induces early T cell exhaustion \u2014 i.e., scFv-driven tonic signaling causes constitutive (antigen-independent) stimulation. The other papers do not address scFv/tonic CAR signaling and are not relevant to this specific claim."
    },
    "overthinking_doc_ids": [
      "18231807",
      "34016944",
      "19205437",
      "2825380",
      "301838"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly reports that antigen-independent clustering of CAR single-chain variable fragments (scFv) produces tonic CAR CD3-\u03b6 phosphorylation and persistent (constitutive) signaling that drives early T cell exhaustion. This is an explicit demonstration that tonic signaling from the scFv induces constitutive stimulation. The other provided papers do not contradict this finding (they address different signaling contexts), so the set of papers overall supports the claim."
    },
    "posthoc_doc_ids": [
      "18231807",
      "34016944",
      "19205437",
      "35660758",
      "18450716"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1386",
    "claim": "cSMAC formation represses weak ligand signalling.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that enhancing cSMAC formation reduced the stimulatory capacity of a weak peptide agonist, and an in silico model implicated inability to form the cSMAC in the increased proliferation driven by that weak ligand. Paper 4 provides mechanistic support by showing that TCR signaling is sustained in peripheral microclusters and terminated in the cSMAC (a site for TCR sorting/degradation), consistent with cSMAC-mediated repression of ongoing signaling. Papers 2 and 3 do not directly address cSMAC-mediated repression of weak ligands (Paper 2 concerns Nck-dependent synapse maturation and activation; Paper 3 concerns ligand potency/density effects on Foxp3 induction), so the combined evidence supports the claim that cSMAC formation represses weak ligand signaling."
    },
    "naive_doc_ids": [
      "306006",
      "2714623",
      "994800",
      "9283422"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides mechanistic evidence that signaling is terminated in the cSMAC: TCR-proximal signals are sustained in peripheral microclusters and are terminated in the cSMAC, which is associated with sorting/degradation of TCRs. Paper 2 directly links cSMAC formation to reduced responses to a weak ligand: a weak agonist that failed to form the cSMAC elicited greater proliferation, and experimentally enhancing cSMAC formation reduced the stimulatory capacity of that weak peptide. Together these studies support the claim that cSMAC formation represses weak ligand signalling. The remaining papers (3\u20137) do not provide relevant information for this specific claim."
    },
    "overthinking_doc_ids": [
      "9283422",
      "306006",
      "5828251",
      "23260700",
      "38143689"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple provided papers directly support the claim. Paper 2 reports that a peptide with characteristics of a weak agonist stimulated T cells more than the strong agonist, and that an inability to form the cSMAC correlated with that increased stimulation; importantly, experiments showed that enhancing cSMAC formation reduced the stimulatory capacity of the weak peptide. Paper 4 shows that TCR signaling is sustained in peripheral microclusters but terminated in the cSMAC, which is enriched for components involved in receptor sorting/degradation, consistent with cSMAC formation repressing ongoing TCR signaling. Other papers (e.g. Paper 3) describe roles of synapse maturation in signaling but do not contradict the above findings. Together, the evidence supports that cSMAC formation can repress/terminate weak ligand\u2013induced signaling."
    },
    "posthoc_doc_ids": [
      "8458567",
      "306006",
      "2714623",
      "9283422",
      "21754541"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.34,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "938",
    "claim": "Persister cells provide relapse resistance in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Several papers describe small tumor cell subpopulations or minimal residual disease that survive therapy and drive recurrence, which is the functional concept of 'persister' cells. Paper 4 describes cancer stem\u2013like cells (rare, quiescent, high ABC transporter expression, enhanced DNA repair and apoptosis resistance) that survive chemo/radiation and can repopulate tumors. Paper 1 shows that minimal residual disease gives rise to recurrent tumors with an escape phenotype (innate-immune and therapy insensitivity) and that targeting the cells responsible for early recurrence prevents relapse in mice. Paper 5 documents that acquired resistance in NSCLC can be mediated by resistant tumor cell populations and that alternating chemotherapy can eliminate those cells and restore TKI sensitivity. Papers 2, 3 and 6 provide additional, indirect support (CTCs/exosomes as markers of residual/resistant disease and molecular mechanisms of therapy resistance). None of the provided papers use the exact term 'persister cells,' but together they provide experimental and clinical evidence consistent with the claim that therapy\u2011tolerant/persistent tumor cell populations underlie relapse resistance in cancer patients."
    },
    "naive_doc_ids": [
      "1921218",
      "20127522",
      "9095943",
      "8891333",
      "9929089"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the nine provided papers address cancer \"persister\" cells (drug\u2011tolerant/quiescent tumor cells) or present experimental/clinical data linking such persister cells to relapse resistance in patients. The papers cover circulating DNA origins (Paper 1), lung nodule management (Paper 2), regulatory outcomes and limited survival benefit of approved drugs (Paper 3), genomic predictors for dasatinib (Paper 4), iPSC models for Alzheimer\u2019s (Paper 5), metabolic targeting of myeloid\u2011derived suppressor cells (Paper 6), mismatch repair and endometrial cancer prognosis (Paper 7), lung cancer pathology/classification (Paper 8), and extracellular vesicles biology (Paper 9). While Paper 3 (limited survival benefits) and Paper 9 (vesicles can help tumors evade immune surveillance) are tangentially related to therapy failure or tumor escape mechanisms, none provide direct evidence that persister cells cause relapse resistance in cancer patients. Therefore the set of papers does not contain information to confirm or refute the specific claim."
    },
    "overthinking_doc_ids": [
      "2841164",
      "6137330",
      "32421068",
      "5649538",
      "13814480"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "While none of the papers explicitly use the term \u201cpersister cells,\u201d several provide experimental and clinical evidence that small subpopulations or tolerant/resistant tumor cells and microenvironmental mechanisms allow survival after therapy and drive relapse. Paper 5 shows that tolerance of whole-genome doubling produces genomically evolving tetraploid cells and that a genome-doubling event predicts worse relapse-free survival, consistent with a surviving tolerant population fueling relapse. Paper 7 documents emergence of acquired EGFR C797S and other molecular subtypes in patients who relapsed on AZD9291, demonstrating that resistant tumor cell clones that survive therapy produce clinical relapse. Paper 9 characterizes signalling changes in cells that acquired TKI resistance and links acquired resistance to patient relapse. Papers 1, 3, and 8 describe mechanisms (ER\u2013HER crosstalk, PD-L1\u2013mediated immune escape, and CAF-mediated chemoresistance) by which subsets of tumor cells or their microenvironment survive therapy and enable progression. Collectively these findings support the claim that therapy-surviving cell populations (i.e., persister/tolerant/resistant cells) contribute to relapse in cancer patients. Note: the evidence supports the general concept but does not always use the specific \u201cpersister cell\u201d nomenclature."
    },
    "posthoc_doc_ids": [
      "34066665",
      "13814480",
      "4468861",
      "18062308",
      "7211056"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1239",
    "claim": "The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers do not support an exclusively endodermal origin of the myocardial lineage and in fact provide evidence to the contrary. Paper 7 shows that loss of BAF250a causes absence of mesoderm and failure to generate mesoderm-derived cardiomyocytes, indicating a mesodermal origin for cardiomyocytes. Papers 3 and 4 demonstrate that cardiac neural crest (an ectodermal lineage) can migrate into the heart and differentiate into cardiomyocytes (mammalian side\u2011population/cardiosphere data in Paper 3; direct fate\u2011mapping in zebrafish in Paper 4). Paper 6 further shows Isl1+ cardiac progenitors include neural crest derivatives, complicating the idea of a single germ\u2011layer source. Papers 1 and 2 concern therapeutic cardiac progenitor cells and do not support an endodermal\u2011only origin; Paper 5 is unrelated. Taken together, these data contradict the claim that myocardial cells originate exclusively from endodermal progenitors."
    },
    "naive_doc_ids": [
      "1905095",
      "9622258",
      "106301",
      "4932668",
      "123859"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly indicates that the murine homeobox gene Nkx2-5 is expressed in precardiac mesoderm and discusses cardiac progenitors as precardiac mesoderm, which supports a mesodermal (not endodermal) origin of myocardium. The other papers do not provide evidence that myocardial lineage is of endodermal origin (most are unrelated or concern other topics). Therefore the provided evidence contradicts the claim that myocardial lineage originally develops from cardiac progenitors of exclusively endodermal origin."
    },
    "overthinking_doc_ids": [
      "5002665",
      "25858295",
      "27588420",
      "2559303",
      "2841164"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers do not support an exclusively endodermal origin for myocardial cells and instead indicate mesodermal and neural-crest (ectodermal) contributions. Paper 3 shows cardiac neural crest\u2013derived cells can differentiate into cardiomyocytes in mammals. Paper 6 demonstrates cardiac neural crest contributes to cardiomyogenesis in zebrafish. Paper 4 implicates neural crest derivatives (via BMP signaling) in ventricular myocardium development/proliferation. Paper 2 documents vascular smooth muscle populations arising from neural crest (ectoderm) and from mesoderm, illustrating multiple embryonic origins for cardiovascular lineages. Paper 8\u2019s fate-mapping of the epiblast is consistent with mesodermal derivation of embryonic mesodermal derivatives. No paper provides evidence that myocardium derives exclusively from endoderm. Together, the evidence contradicts the claim of an exclusively endodermal origin."
    },
    "posthoc_doc_ids": [
      "20186814",
      "32797183",
      "106301",
      "38727075",
      "27550580"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "141",
    "claim": "Auditory entrainment is strengthened when people see congruent visual and auditory information.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "All four papers provide converging evidence that visual information that is temporally/contextually congruent with auditory speech strengthens neural entrainment to the auditory signal. Paper 1 directly shows that the cortical representation (entrainment) of the speech envelope is enhanced when audiovisual speech is congruent and is inhibited when streams are incongruent. Paper 2 demonstrates low-frequency (2\u20137 Hz) phase in auditory cortex carries information about both auditory and visual stimulus dynamics, supporting cross-modal phase modulation that can strengthen auditory tracking when visual timing matches auditory timing. Paper 3 shows lip movements entrain observers\u2019 low-frequency brain oscillations (including motor and visual areas) and that visually driven entrainment predicts speech comprehension, especially with attention to visual speech. Paper 4 documents the natural temporal correlations between mouth movements and the acoustic envelope (2\u20137 Hz, 100\u2013300 ms lead of mouth movements), providing a mechanistic basis for why congruent visual signals can enhance auditory entrainment. Together, these results align with and support the claim."
    },
    "naive_doc_ids": [
      "14437255",
      "6955746",
      "10624000",
      "18379855"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple papers provide converging evidence that visual information that is temporally and contextually congruent with auditory speech strengthens neural entrainment to the auditory signal. Paper 1 directly shows that cortical representation (entrainment) of the speech envelope is enhanced by congruent audiovisual speech and inhibited by incongruence. Paper 2 demonstrates that lip movements entrain low-frequency brain activity (in visual and motor cortex), that this visually driven entrainment is attention-modulated, and that it predicts comprehension\u2014supporting a role for congruent visual input in strengthening relevant neural rhythms. Paper 6 documents the natural temporal correlations between mouth movements and the acoustic envelope (2\u20137 Hz, with consistent timing offsets), providing a plausible mechanism for how visual cues can enhance auditory entrainment. Papers 3\u20135 further establish that delta\u2013theta oscillations track acoustic features and that entrainment to temporal dynamics benefits perception, which is consistent with the idea that congruent visual timing can augment auditory-driven entrainment. No papers here provide evidence contradicting the claim."
    },
    "overthinking_doc_ids": [
      "14437255",
      "10624000",
      "6985854",
      "23331269",
      "38794814"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that the cortical representation/entrainment to the speech envelope is enhanced when visual speech is temporally and contextually congruent with auditory speech, and that incongruent audiovisual streams inhibit entrainment. Paper 2 provides complementary evidence that low-frequency (2\u20137 Hz) phase in auditory cortex tracks both auditory and visual stimulus dynamics and reflects cross-sensory interaction, implying visual information can modulate/strengthen auditory phase entrainment. Paper 4 shows that auditory-driven entrainment of slow oscillations improves perception (supporting the functional relevance of entrainment), while Paper 3 addresses spatial coding in auditory cortex and does not bear on audiovisual congruence. Taken together, the evidence supports the claim that auditory entrainment is strengthened when congruent visual and auditory information are seen together."
    },
    "posthoc_doc_ids": [
      "14437255",
      "6955746",
      "6431384",
      "38794814"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "964",
    "claim": "Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers directly measure or report the stability (decay rates or half-lives) of pre-mRNAs as a function of their physical association with spliceosomal components versus being unassociated. The papers describe (1) proteins (SRm160/300) that associate with splicing complexes and promote splicing (Paper 1), (2) the timing of U2 snRNP association in A complex formation (Paper 2), (3) recruitment during splicing of an EJC component (eIF4AIII) that functions in nonsense-mediated decay (Paper 3), (4) RNAP II-mediated coupling that channels nascent transcripts into spliceosome assembly increasing splicing efficiency (Paper 4), and (5) in vitro assay methods for studying spliceosomal complexes and kinetics (Paper 5). While these studies show that association with splicing machinery affects splicing efficiency, complex assembly, and downstream mRNA surveillance (Paper 3 implicates splicing-associated EJC factors in promoting decay of PTC-containing mRNAs), none provide direct experimental data comparing the intrinsic stability of associated versus unassociated pre-mRNA substrates. Therefore the claim is not confirmed or refuted by the provided evidence."
    },
    "naive_doc_ids": [
      "10423989",
      "4067274",
      "30261663",
      "7860396",
      "29828242"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers directly measure or report that pre-mRNAs bound by spliceosomal components are more stable than unassociated splicing substrates. Paper 1 describes the timing of U2 snRNP association (A complex) but does not report effects on pre-mRNA stability. Paper 7 shows that the splicing-linked factor eIF4AIII is deposited on mRNA as part of the exon\u2013junction complex and is required for nonsense-mediated decay (NMD), which is a pathway that can promote mRNA degradation when a premature termination codon is present; this does not provide evidence that spliceosome-associated pre-mRNAs are generally more stable (and in some contexts is linked to decay). The remaining papers address unrelated topics. Therefore there is no direct supporting or contradicting evidence in the supplied set."
    },
    "overthinking_doc_ids": [
      "4067274",
      "13763195",
      "3093512",
      "708425",
      "11844791"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 6 provides direct experimental evidence that RNAs synthesized by RNA polymerase II that contain functional splice sites and are associated with the splicing machinery are protected from nuclear degradation and have an extended half-life, i.e. pre-mRNAs associated with spliceosomal components are more stable than unprotected substrates. Paper 1 complements this by showing stable U2 snRNP association in the A complex (commitment to splice site pairing), which implies formation of spliceosomal complexes on pre-mRNAs; Papers 8 and 9 describe cotranscriptional/spliceosomal assembly and kinetic analyses that are consistent with association-dependent protection, although they do not directly measure stability. Other listed papers do not address pre-mRNA stability in relation to spliceosomal association. Taken together, the provided literature supports the claim."
    },
    "posthoc_doc_ids": [
      "4067274",
      "13763195",
      "3093512",
      "7029990",
      "2194320"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "565",
    "claim": "In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that loss of RNA surveillance factors in S. cerevisiae (e.g., the RNase III ortholog Rnt1p, nuclear exosome component Rrp6p, and 5'\u21923' exonucleases Xrn1p and Rat1p) causes aberrant expression/accumulation of iron uptake mRNAs in iron-replete conditions and reports that RNase III\u2013deficient cells are hypersensitive to high iron concentrations. This provides experimental evidence that absence of RNA surveillance pathways leads to sensitivity to high iron in S. cerevisiae. The other papers do not provide contradictory evidence relevant to this specific claim."
    },
    "naive_doc_ids": [
      "16120395",
      "30261663",
      "365896",
      "26596106",
      "7506409"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that loss of RNA surveillance factors in S. cerevisiae leads to misexpression of iron-uptake mRNAs in iron-replete conditions and that RNase III (Rnt1p)-deficient cells are hypersensitive to high iron. The study further shows extended mRNA forms accumulate when Rnt1p or 5'\u21923' exonucleases (Xrn1p, Rat1p) or the nuclear exosome component Rrp6p are absent, indicating multiple RNA degradative/surveillance pathways prevent iron toxicity. The other provided papers do not provide contradictory evidence relevant to iron sensitivity. Therefore the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "16120395",
      "26596106",
      "42267740",
      "30261663",
      "335029"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly demonstrates that loss of RNA surveillance components in S. cerevisiae leads to misexpression of iron-uptake mRNAs and that RNase III (Rnt1p)-deficient cells are hypersensitive to high iron. The paper further implicates other RNA degradative pathways (Rrp6, Xrn1, Rat1) in preventing iron toxicity, providing direct experimental evidence that absence/impairment of RNA surveillance causes sensitivity to high iron. The other provided papers do not contradict this finding (they are methodological or address different processes/species) and thus do not alter the conclusion."
    },
    "posthoc_doc_ids": [
      "16120395",
      "365896",
      "26596106",
      "30261663",
      "23664875"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1387",
    "claim": "eRNAs influence is linked to senescence, aging, and carcinogenesis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss enhancer RNAs (eRNAs) or present data on eRNA function. The studies do report links between noncoding RNAs (microRNAs, a lncRNA), signaling pathways (p53, Wnt, ERK/MYC), senescence/aging, and carcinogenesis (e.g., Papers 1, 8, 9 for aging/senescence; Papers 4, 5, 6, 7 for cancer). However, these involve miRNAs, lncRNAs, protein factors, and autophagy rather than eRNAs. Because the evidence does not address eRNAs specifically, the claim that \u201ceRNAs influence is linked to senescence, aging, and carcinogenesis\u201d cannot be confirmed or refuted from the supplied papers."
    },
    "naive_doc_ids": [
      "4653837",
      "21557055",
      "43880096",
      "10024681",
      "22049489"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention enhancer RNAs (eRNAs) or present data on eRNA function. The corpus contains studies on microRNAs, a lncRNA (H19/miR-675), p53, SASP, Wnt signaling, tumor microenvironment and senescence/aging-related pathways, which show that noncoding RNAs and signaling pathways can influence senescence, aging and carcinogenesis. However, these findings do not provide direct evidence about eRNAs specifically, so the claim that eRNAs influence senescence, aging, and carcinogenesis is not supported or refuted by the provided papers."
    },
    "overthinking_doc_ids": [
      "4653837",
      "6896063",
      "3230557",
      "22049489",
      "57783564"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present direct experimental evidence that enhancer RNAs (eRNAs) influence senescence, aging, or carcinogenesis. Several papers (1, 6, 7) describe roles for microRNAs in senescence and the SASP; papers 2 and 3 discuss p16INK4a and p53 in senescence and tumor biology; paper 9 describes enhancer\u2013promoter chromatin interactions and disease-associated noncoding elements; and paper 5 (a lncRNA review) briefly notes enhancer RNAs as an emerging area. However, these sources do not report data showing eRNAs specifically modulate senescence, aging, or cancer. At best there is indirect or conceptual mention (paper 5) and related evidence that enhancers/noncoding elements can affect gene regulation (paper 9), but no direct support or contradiction of the claim."
    },
    "posthoc_doc_ids": [
      "4653837",
      "17717391",
      "6896063",
      "797114",
      "5519177"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "165",
    "claim": "Bariatric surgery increases rates of postmenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.7,
      "justification": "Paper 2 (UK cohort of 3,882 bariatric surgery patients matched to controls) explicitly reports no association between bariatric surgery and cancer overall. None of the other provided papers present data showing bariatric surgery increases postmenopausal breast cancer; several discuss mechanisms of estrogen signaling or risk factors (papers 1,3,4,6,8) but do not provide evidence that bariatric surgery raises postmenopausal breast cancer rates. Note: the cohort study\u2019s follow-up (weight outcomes reported up to 4 years) and reporting of a null overall cancer association limit certainty about long-term postmenopausal breast cancer specifically, but on the evidence provided the claim is not supported and is contradicted by the available data."
    },
    "naive_doc_ids": [
      "17450673",
      "5824985",
      "23557241",
      "4999633",
      "15721252"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "None of the provided papers report that bariatric surgery increases postmenopausal breast cancer. The UK cohort study of 3,882 bariatric patients matched to controls (Paper 1) found no association between bariatric surgery and cancer incidence. In addition, that study observed reductions in obesity-related conditions (including incident type 2 diabetes), and Paper 9 shows type 2 diabetes is modestly associated with increased breast cancer risk \u2014 implying that bariatric surgery\u2019s reduction of diabetes would not be expected to increase breast cancer rates. The other papers address breast cancer risk factors (mammographic density, perinatal factors, lipids, biomarkers, tamoxifen metabolism, platelet indices) but do not provide evidence that bariatric surgery raises postmenopausal breast cancer risk. Given the direct null finding for cancer in the bariatric cohort and absence of supporting evidence for an increased risk, the available evidence contradicts the claim. Note: Paper 1 reports overall cancer incidence and does not provide a detailed subgroup analysis specifically limited to postmenopausal breast cancer, which slightly reduces certainty."
    },
    "overthinking_doc_ids": [
      "5824985",
      "38551172",
      "9171913",
      "17450673",
      "18872233"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "None of the provided studies support the claim that bariatric surgery increases postmenopausal breast cancer rates. Paper 4 (UK cohort of 3,882 surgery patients matched to controls) explicitly found no association between bariatric surgery and cancer incidence. Papers 5 and 6 show that higher BMI is positively associated with postmenopausal breast cancer risk (Paper 5: HR per 5 kg/m2 increase ~1.05 for postmenopausal breast cancer; Paper 6: BMI positively associated in postmenopausal women), implying that substantial weight loss after bariatric surgery would not be expected to increase \u2014 and would more plausibly reduce \u2014 postmenopausal breast cancer risk. None of the other papers report an increased postmenopausal breast cancer risk after bariatric surgery. Limitations: the surgery cohort study reported cancer outcomes in aggregate (not necessarily breast-specific in the summary), and most evidence is indirect (associations of BMI with breast cancer), but overall the provided evidence does not support the claim and instead contradicts it or shows no increase."
    },
    "posthoc_doc_ids": [
      "38551172",
      "2140497",
      "9171913",
      "5824985",
      "4828631"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "169",
    "claim": "Bariatric surgery reduces postmenopausal breast cancer.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.75,
      "justification": "None of the provided papers directly show that bariatric surgery reduces risk of postmenopausal breast cancer. Paper 1 (a UK cohort of bariatric patients) reports no association between bariatric surgery and cancer overall, but does not report a specific effect on postmenopausal breast cancer. Papers 2 and 8 show that higher BMI is positively associated with postmenopausal breast cancer (supporting the plausibility that weight loss could lower risk), and Papers 4 and 5 give mechanistic links between obesity and adverse adipose biology. However, these are indirect lines of evidence (BMI\u2013cancer associations and mechanistic data), not direct evidence that bariatric surgery itself reduces postmenopausal breast cancer incidence. Therefore the set of papers does not provide direct confirmation or refutation of the specific claim."
    },
    "naive_doc_ids": [
      "5824985",
      "4828631",
      "16422880",
      "10463997",
      "1907601"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1, a large UK propensity\u2011matched cohort of 3,882 bariatric surgery patients vs matched obese controls, explicitly tested incident cancer and reported no association between bariatric surgery and cancer incidence. That study therefore does not support a reduction in cancer following surgery. The other papers do not provide direct evidence that bariatric surgery lowers postmenopausal breast cancer: Paper 2 shows higher BMI is associated with increased postmenopausal breast cancer risk (providing biologic plausibility that weight loss could lower risk), and Paper 3 shows type 2 diabetes modestly raises breast cancer risk while Paper 1 shows surgery reduces diabetes \u2014these are indirect links but not direct evidence that surgery reduces postmenopausal breast cancer. Papers 4\u20137 address other risk factors or cellular mechanisms and do not provide direct supporting clinical evidence. Taken together, the provided studies do not demonstrate that bariatric surgery reduces postmenopausal breast cancer incidence; the largest direct study found no association."
    },
    "overthinking_doc_ids": [
      "5824985",
      "13831842",
      "32534305",
      "17450673",
      "23557241"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "Among the provided papers, none present evidence that bariatric surgery lowers postmenopausal breast cancer incidence. Paper 4 (large UK cohort) directly examined incident diagnoses including cancer and reported \"No association was detected between bariatric surgery and ... cancer,\" i.e., no reduction in cancer incidence after surgery. Other papers (Paper 5 and Paper 6) document that higher BMI and type 2 diabetes are associated with increased postmenopausal breast cancer risk, which provides indirect biological plausibility that weight loss might reduce risk, but they do not provide direct evidence that bariatric surgery causes a reduction in postmenopausal breast cancer. Because a large observational study found no association and no paper here shows a postoperative reduction in postmenopausal breast cancer, the provided evidence does not support the claim and instead contradicts it."
    },
    "posthoc_doc_ids": [
      "38551172",
      "5864770",
      "9171913",
      "5824985",
      "13831842"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "13",
    "claim": "5% of perinatal mortality is due to low birth weight.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers gives an estimate that 5% of perinatal mortality is attributable to low birth weight. Several papers show that low birth weight or small size at birth is a risk factor for neonatal/perinatal outcomes (Paper 7 reports increased odds of neonatal death for smaller-than-average infants; Papers 1 and 4 report associations between antenatal depression or low vitamin D and low birthweight/SGA), but none reports an attributable fraction or percentage of perinatal mortality caused by low birth weight (e.g. a 5% figure). Therefore the set of papers does not provide the specific evidence needed to confirm or refute the numeric claim."
    },
    "naive_doc_ids": [
      "26611834",
      "4810810",
      "5487448",
      "2425364",
      "7639744"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers reports or estimates the proportion (percent) of perinatal mortality that is attributable to low birth weight. Paper 1 gives perinatal mortality rates but does not attribute causes or report fractions due to low birth weight. Paper 3 identifies \u2018smaller than average\u2013sized\u2019 (proxy for low birth weight) infants as having higher odds of neonatal death (OR=2.80) and notes low birth weight as an important determinant, but it does not quantify the percentage of perinatal mortality attributable to low birth weight. Paper 2 concerns treatment of PDA in preterm/low birth weight infants and reports outcomes of drug trials, not population-attributable fractions. The remaining papers are unrelated to perinatal mortality. Therefore the evidence set neither confirms nor refutes the specific numeric claim that 5% of perinatal mortality is due to low birth weight."
    },
    "overthinking_doc_ids": [
      "7662395",
      "34544514",
      "1263446",
      "202259",
      "17450673"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report or estimate that 5% of perinatal mortality is attributable to low birth weight. Paper 1 gives perinatal mortality rates but no cause-attribution to low birth weight. Paper 3 identifies smaller-than-average or low birth weight infants as having higher odds of neonatal death (OR\u22482.8) but does not provide a population-attributable fraction or percent of perinatal mortality due to low birth weight. Papers 2 and 5\u20137 do not provide a direct estimate linking low birth weight to a specific percentage of perinatal mortality (GBD papers discuss childhood undernutrition and risk burdens broadly but do not state \u201c5% of perinatal mortality is due to low birth weight\u201d). Therefore the evidence set does not confirm or refute the specific 5% figure."
    },
    "posthoc_doc_ids": [
      "7662395",
      "34544514",
      "1263446",
      "5824985",
      "5487448"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "375",
    "claim": "Elevated cell-free mitochondrial DNA levels are associated with mortality.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly tests the claim and provides strong evidence that elevated circulating cell-free mitochondrial DNA (mtDNA) is associated with mortality: in two independent ICU cohorts, medical ICU patients with plasma mtDNA \u22653,200 copies/\u00b5l had markedly increased odds of 28-day death (BWH RoCI OR 7.5, 95% CI 3.6\u201315.8, p=1\u00d710^-7; ME ARDS OR 8.4, 95% CI 2.9\u201324.2, p=9\u00d710^-5), and adding mtDNA improved risk prediction (significant NRI). The other papers do not contradict this finding (Paper 2 shows elevated circulating mtDNA in active vasculitis but not mortality data; Papers 3\u20136 do not provide relevant data on circulating mtDNA and mortality). Taken together, the provided evidence supports the claim, with caveats noted in Paper 1 about mechanistic understanding and biomarker measurement limitations."
    },
    "naive_doc_ids": [
      "1522647",
      "20459964",
      "2543135",
      "9486930",
      "56486733"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly tests circulating cell-free mitochondrial DNA (mtDNA) and reports a strong, replicated association with mortality in ICU patients: in two independent cohorts (BWH RoCI, n=200; ME ARDS, n=243) an elevated plasma mtDNA level (\u22653,200 copies/\u00b5l) was associated with markedly higher odds of 28-day death (OR 7.5, 95% CI 3.6\u201315.8, p=1\u00d710\u207b\u2077 and OR 8.4, 95% CI 2.9\u201324.2, p=9\u00d710\u207b\u2075) and improved risk prediction for medical ICU patients. The other provided papers do not address cell-free mtDNA. Note: the evidence is associative (ICU medical patients) and may not generalize beyond those settings, but it supports the claim that elevated cell-free mtDNA levels are associated with mortality."
    },
    "overthinking_doc_ids": [
      "1522647",
      "11289247",
      "14021596",
      "1456068",
      "3878434"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly supports the claim: in two independent ICU cohorts, elevated circulating cell-free mtDNA (\u22653,200 copies/\u00b5l plasma) was strongly associated with increased 28-day mortality (BWH RoCI OR 7.5, 95% CI 3.6\u201315.8, p=1\u00d710^-7; ME ARDS OR 8.4, 95% CI 2.9\u201324.2, p=9\u00d710^-5) and improved risk prediction (NRI improvements). Paper 4 also shows markedly elevated circulating mtDNA in active granulomatosis with polyangiitis (supporting that high cell-free mtDNA marks disease severity/activity), although it does not directly report mortality associations. The remaining papers (2,3,5\u20139) do not provide relevant data on cell-free mitochondrial DNA and mortality. Taken together, the provided evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "1522647",
      "3899896",
      "9285396",
      "20459964",
      "45199834"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "648",
    "claim": "Integrated care is successful at tackling multiple comorbidities.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 4 is a randomized controlled trial of multi-condition collaborative (integrated) care for depression plus poorly controlled diabetes and/or coronary heart disease risk factors and found significant improvements in social role disability and global quality of life versus usual care, directly supporting the claim that integrated care can successfully address multiple comorbidities. Paper 3 (narrative review) describes expanded pharmacist roles within multidisciplinary teams, which is supportive of integrated approaches. Paper 1 documents that multiple chronic conditions worsen HRQoL (underscoring the need for integrated care). Papers 5 and 6 report on single-condition interventions (exercise for heart failure; a diabetes education program) with modest or limited long-term biomedical effects and do not directly evaluate multi-condition integrated care. Paper 2 (teaching vs nonteaching) is not relevant. Overall, the direct experimental evidence for multi-condition integrated care in this set is limited but positive (RCT), and no included paper provides strong contradictory evidence, so the net evidence supports the claim with moderate confidence."
    },
    "naive_doc_ids": [
      "463533",
      "13906581",
      "29845974",
      "15041758",
      "40817021"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the nine papers present evidence on integrated care interventions designed to manage multiple comorbid conditions simultaneously. The studies address single-disease interventions (blood\u2011pressure treatment in dialysis patients; smoking cessation after lung cancer; troponin testing for MI; exercise in heart failure; treatments for tension\u2011type headache; glucosamine for low back pain; blood pressure measurement methods; vision screening; a diabetes self\u2011management programme). One trial (paper 5) tests combined behavioral and pharmacologic therapy, but that addresses a single condition (chronic tension\u2011type headache), not multimorbidity or an integrated care model targeting several coexisting diseases. Therefore the provided evidence does not confirm or refute the claim about integrated care for multiple comorbidities."
    },
    "overthinking_doc_ids": [
      "202259",
      "7639744",
      "34873974",
      "40817021",
      "6191684"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 3 (a randomized controlled trial) provides direct experimental evidence that an integrated, multi-condition collaborative care intervention (targeting depression plus poorly controlled diabetes and/or coronary heart disease risk factors) produced clinically meaningful improvements in disability (Sheehan disability scale) and global quality of life versus usual care. No included papers present randomized evidence that integrated care fails to address multiple comorbidities. However, the supporting evidence is limited: it is a single RCT with a specific combination of conditions (depression plus cardiometabolic disease/risk factors) and modest sample size, so generalization to all forms of multimorbidity or other condition combinations is uncertain. Other papers in the set address related topics (patient experience, costs, single-condition interventions) but do not directly test integrated-care models for multiple comorbidities."
    },
    "posthoc_doc_ids": [
      "19945096",
      "13906581",
      "15041758",
      "13914633",
      "40666943"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1404",
    "claim": "siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report an experiment in which A20 (TNFAIP3) was knocked down by siRNA in an in vivo murine xenograft model. Several papers describe related themes\u2014e.g. Paper 7 shows that siRNA knockdown of c-Src reduces tumor progression in an orthotopic mouse model, and Paper 1 shows that inhibiting NF-\u03baB in tumor cells reduces tumor burden\u2014but none present data on siRNA-mediated A20 knockdown or its effects on tumor growth in mice. Therefore the provided evidence does not support or contradict the specific claim."
    },
    "naive_doc_ids": [
      "14615911",
      "9767444",
      "33638477",
      "5774746",
      "10218447"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 4 reports that targeting A20 (TNFAIP3) in glioma stem cells using RNAi (lentiviral-delivered shRNA) decreased GSC growth and survival, reduced self-renewal, diminished tumorigenic potential, and resulted in increased survival of mice bearing human glioma xenografts. This provides direct in vivo xenograft evidence that RNAi-mediated knockdown of A20 slows tumor progression. Note: the reported experiments used shRNA (lentiviral) rather than transient siRNA, and findings are shown in a glioma xenograft model (A20 effects may differ by tumor type), but the data support the claim that RNAi knockdown of A20 can slow tumor progression in a murine xenograft model."
    },
    "overthinking_doc_ids": [
      "13108582",
      "38243984",
      "368506",
      "33370",
      "7583725"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that RNAi-mediated targeting of A20 (TNFAIP3) in glioma stem cells using lentiviral-delivered shRNA reduces GSC growth, survival and self-renewal and decreases tumorigenic potential, resulting in increased survival of mice bearing human glioma xenografts. Although the paper used shRNA rather than siRNA, both are RNAi approaches that knock down A20 in vivo and the reported effect is slowed tumor progression in a murine xenograft model. The other provided papers do not report A20 knockdown in vivo and are not directly relevant."
    },
    "posthoc_doc_ids": [
      "33370",
      "14615911",
      "33638477",
      "45764440",
      "8671456"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "903",
    "claim": "PD-1 triggering on monocytes reduces IL-10 production by monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly addresses PD-1 on monocytes and reports that triggering PD-1 (by PD-L1) induces IL-10 production by monocytes, leading to impaired CD4+ T cell activation in HIV infection. This finding is the opposite of the claim that PD-1 triggering reduces IL-10 production. The other provided papers do not present evidence that PD-1 triggering on monocytes decreases IL-10 (Paper 1 describes CRP-mediated IL-10 reduction by a different mechanism; Paper 8 characterizes anti\u2011PD\u20111 antibody effects on T cells but does not show PD\u20111 triggering reducing monocyte IL\u201110). Therefore the available evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "9334631",
      "10648422",
      "3118719",
      "3616843",
      "23273454"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "I found no experimental data in the ten provided papers that directly address PD-1 triggering on monocytes or its effect on monocyte IL-10 production. Several papers discuss monocyte isolation (Paper 1), monocyte/macrophage biology and cytokine regulation (Papers 3, 4, 5, 7, 10), or HIV interactions with immune cells (Papers 2, 8), but none report experiments in which PD-1 was engaged on monocytes and IL-10 output was measured. Therefore the supplied evidence neither supports nor contradicts the claim."
    },
    "overthinking_doc_ids": [
      "623486",
      "6936141",
      "7489663",
      "5798227",
      "8477699"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 2 directly addresses PD-1 on monocytes and reports that triggering PD-1 (via PD-L1) induces IL-10 production by monocytes, causing reversible CD4+ T cell dysfunction. This finding indicates PD-1 engagement increases IL-10 production, which is the opposite of the claim. The other provided papers do not provide relevant data on PD-1 and monocyte IL-10."
    },
    "posthoc_doc_ids": [
      "13902570",
      "10648422",
      "5260382",
      "6327940",
      "6625693"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "684",
    "claim": "Lack of clpC does not affect sporulation efficiency in Bacillus subtilis cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present experimental data directly testing the effect of clpC loss on sporulation efficiency. Paper 1 describes a Tn-seq screen and characterization of many sporulation genes but the excerpt does not mention clpC or report sporulation phenotypes for a clpC mutant. Papers 2 and 3 discuss regulation and proteolytic roles of clpC (expression control by CtsR, ClpC interactions with ClpP and effects under heat stress) but do not report sporulation efficiency of clpC deletion strains. Paper 4 is unrelated (mouse CuZnSOD). Because no direct measurements or results about sporulation efficiency in clpC mutants are provided in these excerpts, the evidence is insufficient to support or contradict the claim."
    },
    "naive_doc_ids": [
      "4942718",
      "34386619",
      "12881593",
      "25827024"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the three papers provide direct experimental data on the sporulation efficiency of a clpC deletion strain. Paper 1 is a Tn-seq and knockout-collection screen for sporulation genes and reports many known and new sporulation factors, but the provided summary does not mention clpC or present results specifically testing a clpC null for sporulation defects. Paper 2 characterizes regulation of the clpC operon by CtsR (transcriptional regulation) and does not report sporulation phenotypes. Paper 3 examines Clp protein levels, interactions, and their roles in stress/heat-shock responses and proteolysis, but likewise does not assess sporulation efficiency of clpC mutants. Because the provided evidence does not report experiments measuring sporulation in clpC-deficient cells, the claim cannot be confirmed or refuted from these papers."
    },
    "overthinking_doc_ids": [
      "4942718",
      "34386619",
      "12881593"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report experimental measurements of sporulation efficiency for a clpC deletion or otherwise directly address the effect of loss of clpC on sporulation. Paper 1 and Paper 3 discuss regulation and proteolytic roles of the clpC operon/ClpC protein under stress, but do not present sporulation phenotypes. Paper 2 is a Tn-seq screen for sporulation genes but the summary does not mention clpC as having a sporulation defect and no specific clpC data are given. Papers 4 and 5 are unrelated to clpC/sporulation. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "34386619",
      "4942718",
      "12881593",
      "2851611",
      "2904102"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "109",
    "claim": "An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that cold exposure \"rapidly promoted alternative activation of adipose tissue macrophages,\" and describes these alternatively activated macrophages as producing catecholamines that drive thermogenic gene expression in brown adipose tissue. \u2018\u2018Alternatively activated\u2019\u2019 corresponds to an M2-like phenotype. The other papers do not provide evidence that contradicts this finding (Paper 3 describes M2-like ATMs in lean animals but not cold-specific induction; Papers 2, 4, and 5 do not refute the rapid cold-induced M2 activation in BAT), so the corpus supports the claim."
    },
    "naive_doc_ids": [
      "4319174",
      "29381091",
      "43192375",
      "40232172",
      "970012"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly reports that cold exposure \"rapidly promoted alternative activation of adipose tissue macrophages,\" and defines these as IL-4\u2013stimulated/\u2018alternatively activated\u2019 (M2-like) macrophages that act in brown adipose tissue to induce thermogenic genes. This directly confirms the claim that an M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold. The other papers either address BAT activation by other mechanisms or macrophage phenotypes in other tissues and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "4319174",
      "29381091",
      "1568684",
      "22621251",
      "24721866"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 directly reports that cold exposure \"rapidly promoted alternative activation of adipose tissue macrophages,\" and that these alternatively activated (M2-like) macrophages secrete catecholamines to drive thermogenic gene expression and lipolysis. Alternative activation is synonymous with an M2-like phenotype, so this provides direct experimental support that cold quickly induces an M2-like state in adipose (including brown) tissue macrophages. The other provided papers do not present evidence that contradicts this finding (Paper 2 reports increased inflammatory cells in atherosclerotic plaques with cold but addresses lesion inflammation/systemic effects rather than BAT macrophage polarization). Therefore the set of papers supports the claim."
    },
    "posthoc_doc_ids": [
      "29381091",
      "970012",
      "1568684",
      "4319174",
      "21626639"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "713",
    "claim": "Low expression of miR7a does not repress target genes or exert a biological function in ovaries.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report experiments on miR-7a in ovaries or directly measure whether low miR-7a expression fails to repress its targets or to exert biological effects in ovarian tissue. Papers 1 and 4 describe general principles of miRNA action (threshold-like behavior, dependence of repression on relative miRNA/target-site abundance), which conceptually imply that miRNA function can depend on expression level, but they do not provide direct data about miR-7a or ovarian biology. The other papers do not address miR-7a or ovarian miRNA function. Therefore the evidence set does not directly support or contradict the specific claim."
    },
    "naive_doc_ids": [
      "2000038",
      "9784254",
      "25827024",
      "18421962",
      "950306"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on miR-7a expression or its activity in ovaries. The reproductive papers (1, 7, 9) discuss ovarian genes/proteins or fertility but not miR-7a. The mechanistic miRNA papers (4, 5, 6) describe general principles of RISC/miRNA function and threshold effects, but do not test miR-7a or its ovarian function or repression at low expression levels. Therefore the evidence set does not support or contradict the specific claim about low miR-7a expression in ovaries."
    },
    "overthinking_doc_ids": [
      "643765",
      "3788528",
      "6042706",
      "950306",
      "2000038"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on miR-7a expression or its activity in ovaries. Papers 1 and 2 address general principles of miRNA-mediated repression and threshold/titration effects (miR-122 in hepatocytes in Paper 1; single-cell threshold behavior of miRNAs in Paper 2), which are conceptually relevant to how miRNAs can act at different abundances, but they do not test miR-7a or ovarian tissue. The remaining papers focus on unrelated factors (Blimp-1 in T cells, FOXO in neurons, various other miRNAs in cancer, Myc targets, CuZnSOD, GLP-1R polymorphisms) and do not provide evidence for or against the specific claim. Therefore the set of papers does not contain direct experimental evidence to confirm or refute the claim about low miR-7a in ovaries."
    },
    "posthoc_doc_ids": [
      "18421962",
      "2000038",
      "21363424",
      "29429111",
      "19358586"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.08,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1041",
    "claim": "Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers directly test or report that replacement of H2A with H2A.Z slows gene activation in yeast by stabilizing +1 nucleosomes. Paper 4 describes the SWR1-catalyzed, stepwise replacement of H2A by H2A.Z and shows promoter-proximal nucleosomes are heterogeneous for H2A.Z, but it does not present data linking H2A.Z incorporation to slowed activation or to increased stability of the +1 nucleosome. Paper 2 reports how SWI/SNF-mediated nucleosome removal affects GAL gene activation and shows delayed activation when SWI/SNF is absent, but it does not discuss H2A.Z. The other papers either address unrelated topics (IME1 regulation, transcription factor databases, splicing kinetics, galactokinase induction) or methodological issues. Therefore the supplied evidence does not confirm or refute the specific claim."
    },
    "naive_doc_ids": [
      "23604601",
      "18895793",
      "1256116",
      "9451052",
      "365896"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Multiple yeast studies in the provided set indicate that H2A.Z (Htz1) at promoters poises genes for activation and is associated with greater nucleosome lability rather than stabilization that would slow activation. Genome-wide mapping (Paper 2) shows H2A.Z is enriched at promoter nucleosomes of inactive genes and can modulate nucleosome positioning at the GAL1 promoter, consistent with a role in preparing promoters for induction. Paper 3 shows Htz1 localizes to many repressed/basal Pol II promoters, promotes full gene activation, and that Htz1-containing nucleosomes are selectively released (Htz1 leaves chromatin in conditions where H2A and H3 remain), suggesting H2A.Z-bearing nucleosomes are more susceptible to loss to expose promoter DNA and facilitate activation. Paper 4 describes SWR1-mediated replacement dynamics but does not support a model where H2A.Z-stabilized +1 nucleosomes slow activation. Paper 5 shows that activator-recruited remodelers (SWI/SNF) remove promoter nucleosomes to permit rapid activation; absence of remodeling delays activation, but this is not attributed to H2A.Z-mediated stabilization. Collectively, these data contradict the claim that H2A\u2192H2A.Z replacement slows activation by stabilizing +1 nucleosomes; instead, they support H2A.Z contributing to a poised state that can be more readily disrupted during activation."
    },
    "overthinking_doc_ids": [
      "23305884",
      "15778034",
      "16626264",
      "9451052",
      "18895793"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Several of the provided papers directly address the role of H2A.Z (Htz1) at promoters and contradict the claim that H2A\u2192H2A.Z replacement slows gene activation by stabilizing +1 nucleosomes. Paper 7 (Genome-Wide Dynamics of Htz1) shows Htz1 localizes to many repressed/basal promoters, promotes full gene activation, and that Htz1-bearing nucleosomes are unusually susceptible to loss (Htz1 is released under activating conditions), implying H2A.Z facilitates activation rather than stabilizing nucleosomes to slow it. Paper 8 (Variant Histone H2A.Z ...) likewise reports H2A.Z is localized at promoters of inactive genes and configures chromatin to poise genes for activation and can affect nucleosome positioning at GAL1, consistent with a role in poising/activation. Paper 1 describes SWR1-mediated stepwise deposition of H2A.Z but does not provide evidence that H2A.Z stabilizes +1 nucleosomes to retard activation. Paper 2 shows that nucleosome removal by remodelers (SWI/SNF) accelerates activation and that absence of remodeler delays activation, again not supporting a model where H2A.Z substitution per se stabilizes +1 nucleosomes to slow activation. Taken together, the evidence supports that H2A.Z/Htz1 is associated with poising and facilitation of activation (via nucleosome loss or altered positioning), which contradicts the claim."
    },
    "posthoc_doc_ids": [
      "9451052",
      "18895793",
      "43156471",
      "23604601",
      "1256116"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1289",
    "claim": "There is a relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (a large nationwide cohort study) directly examined macrolide use and infantile hypertrophic pyloric stenosis (IHPS). Macrolides include erythromycin. The study found a very strong association for direct infant exposure to macrolides in the first 13 days after birth (adjusted rate ratio 29.8, 95% CI 16.4\u201354.1; absolute risk difference ~24.4 cases per 1000 exposed infants). Maternal macrolide use in the first 13 days after birth was also associated with increased risk (rate ratio 3.49, 95% CI 1.92\u20136.34), and a possible association was seen with use in late pregnancy. The other provided papers do not address erythromycin or hypertrophic pyloric stenosis. Therefore the evidence supports a relation between erythromycin (a macrolide) use and increased risk of hypertrophic pyloric stenosis, especially with neonatal exposure and maternal use shortly after birth."
    },
    "naive_doc_ids": [
      "21239672",
      "20240998",
      "2425364",
      "21297708",
      "24338780"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (nationwide Danish cohort) directly examines macrolide use and infantile hypertrophic pyloric stenosis (IHPS). It reports a very large increased rate ratio for IHPS after infant macrolide exposure in days 0\u201313 (adjusted RR 29.8, 95% CI 16.4\u201354.1) and an elevated RR for days 14\u2013120 (3.24, 1.20\u20138.74). Maternal macrolide use in the first 2 weeks after birth was also associated with increased risk (RR 3.49, 1.92\u20136.34). Erythromycin is a macrolide antibiotic, so these findings support a relation between erythromycin use and hypertrophic pyloric stenosis. The other provided papers do not address this topic. (Note: the evidence is observational and shows association rather than definitive causation.)"
    },
    "overthinking_doc_ids": [
      "21239672",
      "2425364",
      "439670",
      "1456068",
      "5824985"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 is a large nationwide cohort study directly addressing macrolide use and infantile hypertrophic pyloric stenosis (IHPS). Erythromycin is a macrolide antibiotic, and the study found a very strong association between macrolide use in young infants and IHPS (adjusted rate ratio 29.8, 95% CI 16.4\u201354.1 for use days 0\u201313 after birth; RR 3.24, 1.20\u20138.74 for days 14\u2013120). Maternal macrolide use in the first two weeks after birth was also associated with increased risk (RR 3.49, 1.92\u20136.34), and a possible association was seen with late pregnancy use. The other provided papers do not address erythromycin or IHPS. Therefore the evidence supports a relation between erythromycin (a macrolide) use and hypertrophic pyloric stenosis."
    },
    "posthoc_doc_ids": [
      "21239672",
      "7647224",
      "24269361",
      "791050",
      "2425364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "594",
    "claim": "Incidence of heart failure increased by 10% in women since 1979.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses heart failure incidence in a community cohort (Olmsted County) from 1979\u20132000 and reports that the incidence did not change over time among women (and men). None of the other provided papers present data showing a 10% increase in heart\u2011failure incidence in women since 1979. Therefore the provided evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "19675911",
      "33533307",
      "195680777",
      "12206390",
      "7209559"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1 directly addresses heart failure incidence by sex from 1979\u20132000 in a community cohort (n=4,537). It reports that incidence was higher in men (378/100,000) than women (289/100,000) and that incidence \u201cdid not change over time among men or women.\u201d None of the other provided papers present evidence showing a 10% increase in heart\u2011failure incidence in women since 1979. Therefore the provided evidence contradicts the claim. (Note: the primary contrary evidence covers 1979\u20132000; no provided paper documents trends in women beyond 2000.)"
    },
    "overthinking_doc_ids": [
      "19675911",
      "4824840",
      "12206390",
      "20945963",
      "24408040"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses sex-specific temporal trends in heart failure incidence from 1979\u20132000 and reports that the incidence did not change over time among men or women. None of the other provided papers present data showing a 10% increase in heart-failure incidence in women since 1979. Therefore the provided evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "19675911",
      "31889025",
      "24408040",
      "4445629",
      "13481731"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "661",
    "claim": "JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that JMJD6 is an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that hydroxylates p53 in vivo, mainly at lysine 382 (a C\u2011terminal p53 residue), and that JMJD6 antagonizes p53 acetylation and represses p53 transcriptional activity. Papers 2\u20134 do not address JMJD6 and are not relevant. Therefore the provided literature supports the claim."
    },
    "naive_doc_ids": [
      "37204802",
      "2316374",
      "14367469",
      "23604601"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly supports the claim: it shows JMJD6 is an \u03b1\u2011ketoglutarate/Fe(II)\u2011dependent lysyl hydroxylase that hydroxylates p53 at lysine 382 (a C\u2011terminal lysine) in vivo, and that JMJD6 antagonizes p53 acetylation and represses p53 transcriptional activity (JMJD6 depletion enhances p53 transcriptional activity). The other provided papers do not provide additional relevant evidence for JMJD6 and transcriptional repression."
    },
    "overthinking_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "3270834",
      "4462777"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct experimental evidence that JMJD6 is an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that hydroxylates p53 in vivo, primarily at lysine 382 (a C-terminal p53 lysine). The same study shows JMJD6 antagonizes p53 acetylation, promotes p53 association with its negative regulator MDMX, and represses p53 transcriptional activity (with JMJD6 depletion enhancing p53 activity). No other provided papers contradict this. Therefore the provided evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "37204802",
      "2316374",
      "14367469",
      "38009906",
      "29125354"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "411",
    "claim": "Febrile seizures reduce the threshold for development of epilepsy.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the four provided papers address febrile seizures or their long-term effect on seizure threshold/epilepsy risk. Paper 1 studies mTOR signaling in a kainate/status epilepticus model of temporal lobe epileptogenesis and rapamycin effects; Paper 2 reports an association between a prodynorphin promoter polymorphism and temporal lobe epilepsy; Paper 3 describes interneuron loss and GABAA-receptor changes in a kainic-acid model of mesial temporal lobe epilepsy; Paper 4 reports long-term senescence markers after ionizing radiation. While several papers discuss mechanisms of epileptogenesis in animal models and genetic risk factors, none provide experimental or clinical data about febrile seizures lowering the threshold for later development of epilepsy, so the evidence set does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "116792",
      "29723642",
      "35520219",
      "31293581"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address febrile seizures or present data linking febrile seizures to later development of epilepsy. Papers 1\u20133 are unrelated (gastroenteritis/IBD, TMAO and cardiovascular risk, obesity pharmacotherapy). Papers 4 and 5 report mechanisms of epileptogenesis in kainate/status\u2011epilepticus animal models (mTOR activation, interneuron loss) which show that certain severe seizures can promote epileptogenesis, but they do not study febrile seizures specifically. Paper 6 describes clinical features of medial temporal lobe epilepsy but does not evaluate febrile seizure history as a causal factor lowering seizure threshold. Therefore the evidence provided does not confirm or refute the specific claim about febrile seizures."
    },
    "overthinking_doc_ids": [
      "44672703",
      "6793674",
      "7552215",
      "116792",
      "35520219"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.7,
      "justification": "Only one paper (Paper 2) directly addresses febrile seizures. In a rat model it reports that hyperthermia\u2011induced (febrile) seizures produce a long\u2011lasting presynaptic increase in inhibitory synaptic transmission in the hippocampus that persists into adulthood. That result indicates persistent changes in excitability but in the direction of enhanced inhibition, which would not be expected to lower the threshold for developing epilepsy. The other provided papers do not address febrile seizures or later epileptogenesis. Therefore the supplied evidence does not support the claim and, based on Paper 2\u2019s findings, tends to contradict it."
    },
    "posthoc_doc_ids": [
      "1410197",
      "14924526",
      "24269361",
      "1974176",
      "1538080"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "78",
    "claim": "Active caspase-11 participate in regulating phagosome-lysosome fusion.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 directly demonstrates that active caspase-11 promotes fusion of pathogen-containing phagosomes (Legionella-containing vacuoles) with lysosomes by modulating actin polymerization through cofilin; human homologs (caspase-4/5) show similar activity. The other papers discuss phagosome maturation and trafficking (including pathogen-mediated arrest) but do not contradict this specific role. Note: the caspase-11 effect was reported as cargo-dependent (required for pathogenic but not nonpathogenic bacteria)."
    },
    "naive_doc_ids": [
      "38043606",
      "5099266",
      "35079452",
      "15414628"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that active caspase-11 promotes fusion of pathogen-containing phagosomes (specifically L. pneumophila vacuoles) with lysosomes by modulating actin polymerization through cofilin, and that active caspase-11 is required to restrict infection. None of the other papers provide evidence that contradicts this role (they mostly cover phagosome maturation mechanisms or caspase-1/NLRP3 pathways), so the provided evidence supports the claim that active caspase-11 participates in regulating phagosome\u2013lysosome fusion."
    },
    "overthinking_doc_ids": [
      "5099266",
      "38043606",
      "4345315",
      "35079452",
      "43390777"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct experimental evidence that active caspase-11 promotes fusion of pathogen-containing phagosomes (Legionella-containing vacuoles) with lysosomes by modulating actin polymerization via cofilin. The study shows active mouse caspase-11 (and human homologs caspase-4/5) is required to restrict L. pneumophila infection through promoting phagosome\u2013lysosome fusion. Other provided papers do not address caspase-11 or phagosome\u2013lysosome fusion. Therefore the available evidence supports the claim (with the caveat that the effect was shown for pathogenic bacteria in that study and was dispensable for phagosomes containing nonpathogenic bacteria)."
    },
    "posthoc_doc_ids": [
      "5099266",
      "6565037",
      "24783597",
      "46594244",
      "1964163"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "623",
    "claim": "Individuals with low serum vitamin D concentrations have increased risk of multiple sclerosis.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Two of the provided papers (Paper 1 and Paper 4) present evidence consistent with the claim. Paper 1 (population-based case-control in Tasmania) found that higher childhood/adolescent sun exposure was strongly associated with a reduced risk of MS (adjusted OR 0.31, 95% CI 0.16\u20130.59) and that greater actinic (UV) skin damage was independently associated with lower MS risk (OR 0.32, 0.11\u20130.88), implying that insufficient ultraviolet radiation \u2014 the main source of vitamin D \u2014 may influence MS development. Paper 4 reviews the latitudinal gradient in MS prevalence, links reduced ambient UV (and thus lower vitamin D synthesis) to higher MS prevalence, notes vitamin D\u2019s immunomodulatory effects (including suppression of an animal model of MS), and discusses vitamin D\u2013related genetic susceptibility. Together these findings support the claim that lower vitamin D status is associated with increased MS risk. However, the evidence in these papers is indirect (based on UV/sunlight, latitude, and mechanistic/genetic arguments) rather than direct measurements of serum 25-hydroxyvitamin D; no provided paper measured serum vitamin D levels and incident MS directly. This is why confidence is high but not maximal."
    },
    "naive_doc_ids": [
      "17000834",
      "1974176",
      "1538080",
      "22843838",
      "3222187"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.6,
      "justification": "Among the provided papers, Paper 4 (case\u2013control study) reports that higher past sun exposure in childhood/adolescence and greater actinic damage were associated with a substantially reduced risk of multiple sclerosis (adjusted ORs \u22480.31 and 0.32). This finding is relevant because sun/UV exposure is a major determinant of serum vitamin D levels, so the result provides indirect support for the claim that lower vitamin D status is associated with higher MS risk. None of the other papers present direct data linking measured serum 25-hydroxyvitamin D concentrations to MS risk (Paper 5 discusses reproductive factors and MS risk but not vitamin D; Paper 2 examines vitamin D in pregnancy outcomes; Papers 1, 3, 6 are on other topics). Therefore the evidence supplied is supportive but indirect and limited (no direct measurements of serum vitamin D and MS risk in the provided set), so confidence is moderate."
    },
    "overthinking_doc_ids": [
      "6793674",
      "2425364",
      "12102963",
      "17000834",
      "43226130"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Two of the provided papers present evidence consistent with the claim. The Tasmanian case-control study (Paper 2) found higher childhood/early-adolescent sun exposure (a major source of vitamin D) was associated with a substantially lower risk of multiple sclerosis (adjusted OR 0.31, 95% CI 0.16\u20130.59). A review on latitude and vitamin D (Paper 4) notes the marked increase in MS prevalence with distance from the equator, links reduced UV-driven vitamin D production to that gradient, and cites immunomodulatory effects of vitamin D including suppression of an animal MS model. Other included papers do not address MS directly. Taken together, the provided evidence supports an association between lower vitamin D (or lower UV exposure as a proxy) and increased MS risk, although the evidence here is observational/indirect and does not by itself prove causation."
    },
    "posthoc_doc_ids": [
      "4462079",
      "17000834",
      "43226130",
      "22843838",
      "1456068"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "19",
    "claim": "7-day-old adult Caenorhabditis elegans exhibit approximately 5% of the learning capacity seen in 1-day old adults.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report the specific quantitative comparison asserted in the claim (that 7-day-old adult C. elegans retain ~5% of the learning capacity of 1-day adults). Paper 1 (Insulin Signaling and Dietary Restriction...) discusses age-related declines in learning and memory and that certain genotypes alter the rate of decline, but the supplied summary does not give the numeric value of ~5% at day 7. Paper 2 provides genome-wide transcriptional profiles across lifespan (biomarkers of aging) without reporting a 1-day vs 7-day learning percentage. Paper 3 documents morphological and synaptic deterioration with age but does not quantify behavioral learning capacity as a percentage relative to day 1. Papers 4 and 5 address synaptic plasticity in mammalian systems, Paper 6 describes odorant-specific adaptation mechanisms (not age-dependent quantitative decline to 5%), and Paper 7 concerns steroid signaling and lifespan under dietary restriction. Taken together, these papers discuss age-related neural and cognitive changes in C. elegans but do not provide the specific experimental data needed to confirm or refute the exact numeric claim, so the evidence is insufficient to support or contradict it."
    },
    "naive_doc_ids": [
      "3202143",
      "7834603",
      "13072113",
      "10790846",
      "10795063"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided paper summaries discuss age-related declines in learning and memory (Paper 1) and age-associated neuronal and synaptic deterioration (Paper 4), but none of the supplied abstracts or excerpts give the specific quantitative comparison that 7-day-old adults retain ~5% of the learning capacity of 1-day-old adults. Other papers concern unrelated molecular or developmental topics. Because the exact numeric claim (\u2018\u2018~5%\u2019\u2019 at day 7 vs day 1) is not reported in the provided evidence, the collection does not confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "3202143",
      "6333347",
      "7042304",
      "13072113",
      "1127562"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report the specific quantitative comparison in the claim (that 7\u2011day\u2011old adult C. elegans retain ~5% of the learning capacity of 1\u2011day adults). Paper 3 directly addresses age\u2011related decline in learning and memory in C. elegans and shows that learning and memory decrease with age and that longevity mutants alter that decline, but the excerpted text does not give the numerical figure in the claim. The other C. elegans papers discuss related topics (olfactory adaptation, transcriptional profiles with age) but do not provide the stated ~5% measurement. Therefore the provided evidence does not confirm or refute the specific numeric claim."
    },
    "posthoc_doc_ids": [
      "6333347",
      "7834603",
      "3202143",
      "602760",
      "17050065"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "422",
    "claim": "Flexible molecules experience less steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report data or analyses comparing flexible versus rigid small molecules with respect to steric hindrance within the tumor microenvironment. Paper 1 discusses how extracellular matrix stiffness alters cellular responses to a drug via mechanotransduction (YAP/TAZ) but does not address molecular flexibility or steric hindrance of drugs. Papers 2\u20138 cover topics such as CAF biology, stromal metabolism, MMP genotypes, receptor signaling, tumor dormancy, and drug effects (e.g., zoledronic acid, ApoE4 structure correction), but none present experimental or theoretical evidence that flexible molecules experience less steric hindrance in the tumor microenvironment than rigid molecules. Therefore the claim cannot be confirmed or refuted from these sources."
    },
    "naive_doc_ids": [
      "1065627",
      "952111",
      "2734421",
      "27647593",
      "13007205"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers test or report data comparing how flexible versus rigid molecules traverse or experience steric hindrance in the tumor microenvironment. Several papers (1, 3, 4, 5) describe ECM composition, remodeling, stiffening, and protease activity that affect physical barriers in tissues, and paper 1 discusses integrin conformational changes, but none present experimental or observational evidence that flexible molecules experience less steric hindrance than rigid ones. Therefore the claim is not supported or contradicted by the supplied evidence."
    },
    "overthinking_doc_ids": [
      "44640124",
      "51706771",
      "4164929",
      "1727042",
      "13007205"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present experimental data or analyses comparing the transport, penetration, or steric interactions of flexible versus rigid molecules within the tumor microenvironment. The papers do describe relevant aspects of the TME that create physical barriers (e.g., desmoplastic stroma and hyaluronan-driven high interstitial pressure in Paper 9; matrix stiffness affecting cellular responses in Paper 8; ECM composition and remodeling in Papers 4 and 5), but they do not test or report whether conformational flexibility of molecules reduces steric hindrance relative to rigid molecules. Therefore the claim is not supported or contradicted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "21033230",
      "44640124",
      "4164929"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1324",
    "claim": "Treatment with a protein named FN restores regenerative abilities of aged muscles.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly shows that fibronectin (FN) is depleted in the aged muscle stem cell niche, that deleting FN in young muscle reproduces the aging phenotype, and that reconstitution of FN levels in the aged niche 'remobilizes stem cells and restores youth-like muscle regeneration.' This is direct experimental evidence that treatment restoring FN can recover regenerative ability in aged muscle. The other papers discuss related aspects of muscle stem cell biology (satellite cell identity, Sprouty1 in quiescence, FAK signaling, pericytes, effects of satellite cell depletion) but do not contradict the FN finding."
    },
    "naive_doc_ids": [
      "19912367",
      "20186814",
      "16660256",
      "5172048",
      "19204979"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that fibronectin (FN) levels are reduced in the aged muscle stem cell niche, that deleting the FN gene in young regenerating muscle mimics the aging phenotype, and \u2014 critically \u2014 that reconstitution of FN levels in the aged niche remobilizes muscle stem cells and restores youth-like muscle regeneration in mice. None of the other provided papers present data that contradicts this finding; they largely address related topics (satellite cell biology, progenitor origins, or paracrine effects) but do not refute FN-mediated rescue. Therefore the evidence supports the claim that treatment with FN restores regenerative abilities of aged muscles (in the mouse models studied)."
    },
    "overthinking_doc_ids": [
      "19912367",
      "9122283",
      "20418809",
      "20186814",
      "8771704"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that fibronectin (FN) levels are reduced in the aged muscle stem cell niche, that FN deletion in young muscle reproduces the aging phenotype, and that reconstitution of FN in the aged niche remobilizes stem cells and restores youth-like muscle regeneration. The other papers discuss related aspects of satellite cell function, niche/ECM roles, and systemic rejuvenation but do not contradict the FN finding. Thus the provided evidence supports the claim that treatment with FN restores regenerative abilities of aged muscles."
    },
    "posthoc_doc_ids": [
      "19912367",
      "20418809",
      "8771704",
      "20186814",
      "4326318"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "724",
    "claim": "Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that the inhibitory MHC I receptor Ly49Q is crucial for neutrophil polarization and tissue infiltration and states that Ly49Q-dependent polarization and migration are mediated by Ly49Q regulation of membrane raft functions (including raft trafficking and spatiotemporal regulation of raft-associated signaling molecules). The other papers do not provide evidence contradicting this finding (they address different molecules/cell types or related signaling but not Ly49Q\u2019s role in raft-mediated neutrophil polarization). Therefore the provided evidence supports the claim."
    },
    "naive_doc_ids": [
      "5531479",
      "52925737",
      "1241113",
      "36345185",
      "8596357"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that Ly49Q is crucial for neutrophil polarization and tissue infiltration and states that Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions (Ly49Q regulates raft trafficking). The paper further describes ITIM-dependent signaling and involvement of SHP-1/SHP-2 in switching neutrophil behavior, providing mechanistic support. The other cited papers do not contradict this and some provide related context on membrane lipid/raft roles in immune cells, but Paper 1 alone provides direct experimental evidence that supports the claim."
    },
    "overthinking_doc_ids": [
      "5531479",
      "1049501",
      "1800734",
      "797114",
      "5914739"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly reports that the inhibitory MHC I receptor Ly49Q is crucial for neutrophil polarization and migration and states that Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions. The paper describes mechanistic details (ITIM-domain dependence, involvement of SHP-1/SHP-2, effects on adhesion and focal-complex formation) and directly links Ly49Q activity to spatiotemporal regulation of membrane rafts and raft-associated signaling during neutrophil polarization. The other provided papers discuss lipid rafts or membrane lipid biology more generally but do not address Ly49Q or neutrophil polarization directly; they do not contradict Paper 1. Therefore the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "5531479",
      "8396189",
      "797114",
      "600437",
      "6788835"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "14",
    "claim": "5'-nucleotidase metabolizes 6MP.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 2 directly link the cytosolic 5'-nucleotidase NT5C2 to inactivation of nucleoside-analog chemotherapy and show that activating NT5C2 mutations increase nucleotidase activity and confer resistance to 6-mercaptopurine (6MP) and 6-thioguanine. This supports the claim that a 5'-nucleotidase (NT5C2) metabolizes (i.e., dephosphorylates/inactivates) 6MP-derived nucleotide metabolites. The other papers are unrelated."
    },
    "naive_doc_ids": [
      "6421792",
      "641786",
      "1373287",
      "27373088",
      "30379039"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 2 identify NT5C2, which encodes a cytosolic 5'-nucleotidase, as mediating inactivation of nucleoside-analog chemotherapy and show that activating NT5C2 mutations increase nucleotidase activity and confer resistance to 6-mercaptopurine (6MP) and 6-thioguanine. These results indicate that 5'-nucleotidase (NT5C2) metabolizes the active/monophosphorylated thiopurine metabolites arising from 6MP, reducing their cytotoxicity and causing drug resistance. Paper 3 does not address NT5C2 directly. Note: the papers imply NT5C2 acts on phosphorylated nucleotide forms (thiopurine nucleotides) rather than necessarily on the unmodified parent 6MP, but functionally this results in metabolic inactivation of 6MP-derived active metabolites."
    },
    "overthinking_doc_ids": [
      "6421792",
      "641786",
      "1373287"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1 and 3 directly report that NT5C2, a cytosolic 5'-nucleotidase, inactivates nucleoside-analog chemotherapy drugs and that activating (relapse-specific) NT5C2 mutations increase nucleotidase activity and confer resistance to 6-mercaptopurine (6MP) and 6-thioguanine. These experimental findings support the claim that a 5'-nucleotidase metabolizes (inactivates) 6MP. Other cited papers do not address this question."
    },
    "posthoc_doc_ids": [
      "6421792",
      "6588614",
      "641786",
      "1373287",
      "14663842"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "124",
    "claim": "Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 is a systematic review and meta-analysis explicitly addressing this claim: ART was strongly associated with reduced tuberculosis incidence in all baseline CD4 categories (<200: HR 0.16; 200\u2013350: HR 0.34; >350: HR 0.43; any CD4: HR 0.35) and there was no evidence of effect modification by CD4 category (p=0.20). Paper 4 also reports trends toward worse TB outcomes when ART is not used, consistent with benefit from ART. Papers 1 and 5 do not bear on this claim, and Paper 3 focuses on timing of ART during TB treatment (showing survival benefit in very low CD4 counts) rather than primary prevention of TB incidence. Overall the presented evidence supports the claim that antiretroviral therapy reduces TB rates across a broad range of CD4 strata."
    },
    "naive_doc_ids": [
      "17077004",
      "4883040",
      "7111021",
      "31363207",
      "11254040"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 is a systematic review and meta-analysis directly addressing the claim and finds that antiretroviral therapy (ART) is strongly associated with reduced tuberculosis incidence in all baseline CD4 categories: HR 0.16 (<200 cells/\u00b5L), HR 0.34 (200\u2013350), HR 0.43 (>350), and HR 0.35 (any CD4), with no evidence of effect modification by baseline CD4 (p=0.20). Paper 3 also reports that concurrent ART trends toward better TB treatment outcomes in HIV-coinfected patients (supportive though focused on treatment outcomes rather than incidence). Papers 2, 4, and 5 do not provide relevant data on ART\u2019s effect on TB incidence across CD4 strata. Overall the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "4883040",
      "13899137",
      "31363207",
      "4506414",
      "2931832"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 is a systematic review and meta-analysis directly addressing the claim: it found antiretroviral therapy (ART) was strongly associated with reduced tuberculosis incidence across all baseline CD4 categories (<200: HR 0.16; 200\u2013350: HR 0.34; >350: HR 0.43; any CD4: HR 0.35) and reported no evidence of effect modification by baseline CD4 (p=0.20). Other provided papers do not contradict this finding (Paper 2 addresses timing of ART during TB treatment and clinical outcomes rather than TB incidence by CD4 strata; the rest are unrelated to the claim). Therefore the evidence supports the statement that ART reduces TB rates across a broad range of CD4 strata."
    },
    "posthoc_doc_ids": [
      "4883040",
      "7111021",
      "13899137",
      "22467585",
      "2931832"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1295",
    "claim": "There is no relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 3 is a large nationwide cohort study of macrolide use and infantile hypertrophic pyloric stenosis (IHPS). It found strong associations: adjusted rate ratio (RR) for IHPS in infants given macrolides in days 0\u201313 after birth = 29.8 (95% CI 16.4\u201354.1); RR for days 14\u2013120 = 3.24 (1.20\u20138.74). Maternal macrolide use in days 0\u201313 after birth was also associated with increased risk (RR 3.49, 95% CI 1.92\u20136.34). Erythromycin is a macrolide antibiotic, so these findings directly contradict the claim that there is no relation between erythromycin use and hypertrophic pyloric stenosis. The other provided papers do not address erythromycin/IHPS."
    },
    "naive_doc_ids": [
      "6793674",
      "15984735",
      "21239672",
      "2138767",
      "3329824"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 4 (nationwide Danish cohort) directly addresses macrolide use and infantile hypertrophic pyloric stenosis (IHPS) and reports strong associations: infants given macrolides in days 0\u201313 had an adjusted rate ratio of 29.8 (95% CI 16.4\u201354.1) and days 14\u2013120 had RR 3.24 (1.20\u20138.74). Maternal macrolide use in days 0\u201313 after birth was also associated with increased risk (RR 3.49, 95% CI 1.92\u20136.34), with a possible association for late pregnancy use. The other provided papers do not address erythromycin/macrolides and IHPS. Therefore the evidence contradicts the claim that there is no relation between erythromycin (macrolide) use and hypertrophic pyloric stenosis."
    },
    "overthinking_doc_ids": [
      "202259",
      "439670",
      "1759213",
      "21239672",
      "1263446"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly addresses macrolide antibiotics (the class that includes erythromycin) and infantile hypertrophic pyloric stenosis (IHPS). It reports a very large increased risk of IHPS after macrolide use in young infants (adjusted rate ratio 29.8, 95% CI 16.4\u201354.1 for days 0\u201313 after birth) and an increased risk with maternal macrolide use in the first two weeks after birth (rate ratio 3.49, 95% CI 1.92\u20136.34). A possible association was also observed with use in late pregnancy. The other provided papers do not address erythromycin or IHPS. Therefore the evidence contradicts the claim that there is no relation between erythromycin use and hypertrophic pyloric stenosis."
    },
    "posthoc_doc_ids": [
      "21239672",
      "6157837",
      "471921",
      "6793674",
      "439670"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1379",
    "claim": "Women with a higher birth weight are more likely to develop breast cancer later in life.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple high-quality syntheses and pooled analyses in the provided evidence report a positive association between higher birth weight and later breast cancer risk. Paper 1 (meta-analysis) found increased odds for heavier birth weights (e.g. OR 1.24 for \u22654000 g vs 2,500\u20132,599 g). Paper 2 reported a pooled RR of 1.15 (95% CI 1.09\u20131.21) for increased birthweight. Paper 5 (review) pooled studies to give RR \u22481.23 (95% CI 1.13\u20131.34) for high versus low birthweight. Paper 6 (individual participant data from 32 studies) found a positive association in birth-record\u2013based data (pooled RR per 0.5 kg = 1.06; RR 1.12 for \u22654.0 kg vs 3.0\u20133.499 kg) and also linked birth length/head circumference to risk. Paper 4 provides supportive mechanistic evidence by showing higher birth weight was associated with greater adult mammographic density, a strong predictor of breast cancer (OR 2.9 for >4000 g vs 3001\u20133500 g for high density). Some heterogeneity exists (weaker/null findings in studies using adult recall of birth weight), and effect sizes are modest, but the overall evidence set consistently points toward a small increased risk of breast cancer with higher birth weight."
    },
    "naive_doc_ids": [
      "17450673",
      "23557241",
      "13831842",
      "5487448",
      "27123743"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers directly address birth weight and later breast cancer risk and report a positive association. Paper 1 (meta-analysis) found heavier birth weights associated with increased breast cancer risk (e.g., OR 1.24 [95% CI 1.04\u20131.48] for \u22654000 g vs 2,500\u20132,599 g). Paper 2 (systematic review/meta-analysis) reported an increased risk with higher birthweight (RR 1.15 [95% CI 1.09\u20131.21]). Paper 6 (pooled individual participant data from 32 studies) also found a positive association in birth-record\u2013based data (pooled RR per 0.5 kg increment = 1.06 [95% CI 1.02\u20131.09]; RR 1.12 [95% CI 1.00\u20131.25] for \u22654.0 kg vs 3.0\u20133.499 kg). Paper 4 shows related pregnancy markers (placental weight) are associated with maternal breast cancer risk and that the birth-weight association can be attenuated after adjustment for placental weight, indicating some complexity in underlying mechanisms. Papers 3 and 5 are not relevant to birth weight. Overall, the evidence consistently points to a modest increased breast cancer risk in women with higher birth weight, though effects are small, there is heterogeneity across studies, and measurement/source differences (birth record vs adult recall) influence estimates."
    },
    "overthinking_doc_ids": [
      "17450673",
      "23557241",
      "12145359",
      "37480103",
      "13831842"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Three of the provided papers (Papers 2, 3, and 4) report consistent positive associations between higher birth weight and later breast cancer risk. Paper 2 (pooled individual participant data from 32 studies, 22,058 cases) found a positive association using birth records (pooled RR per 1 SD = 1.06, 95% CI 1.02\u20131.09) and higher categorical risk for \u22654.0 kg (RR ~1.12). Paper 3 (meta-analysis) reported elevated ORs for higher birthweight categories (e.g., OR 1.24 for \u22654,000 g versus 2,500\u20132,599 g). Paper 4 (systematic review/meta-analysis) likewise found increased risk with greater birthweight (RR 1.15, 95% CI 1.09\u20131.21). Paper 1 does not address birth weight. The effect sizes are modest and some heterogeneity/measurement issues (e.g., adult self-report vs. birth records) were noted, but the overall evidence supports the claim that higher birth weight is associated with a small increased risk of breast cancer later in life."
    },
    "posthoc_doc_ids": [
      "13831842",
      "16322674",
      "17450673",
      "23557241"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1058",
    "claim": "Roughly 55% of women with chronic pelvic pain have no underlying pathology.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers report or estimate the proportion of women with chronic pelvic pain (CPP) who have no underlying pathology. Paper 2 (the LUNA randomized trial) enrolled women with CPP \u201cwithout or with minimal endometriosis, adhesions, or pelvic inflammatory disease,\u201d which indicates the study population included women without major identifiable pathology, but it does not provide a numeric prevalence (\u224855%) of women with CPP who have no underlying pathology. The other papers address unrelated conditions (mortality and lifestyle, dependence in older people, chronic abdominal pain, low back pain treatment, multiple sclerosis) and do not provide data on the fraction of women with CPP who lack detectable pathology. Therefore the evidence set does not support or contradict the specific claim."
    },
    "naive_doc_ids": [
      "1456068",
      "13027590",
      "13934676",
      "3190689",
      "14724693"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "Only one paper (Paper 1) concerns chronic pelvic pain, and it describes a trial that enrolled women \u201cwithout or with minimal endometriosis, adhesions, or pelvic inflammatory disease\u201d but does not report a population prevalence (e.g., ~55%) of absent pathology. The other papers address chronic abdominal/back pain, shoulder diagnosis, or in vitro nephrotoxicity mechanisms and do not provide relevant prevalence data. Therefore the provided evidence does not confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "13027590",
      "3190689",
      "14724693",
      "44586415",
      "238409"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly report the prevalence that \u201croughly 55% of women with chronic pelvic pain have no underlying pathology.\u201d Paper 1 (the LUNA trial) enrolled women with chronic pelvic pain who had no or only minimal endometriosis, adhesions, or PID, but the abstract does not state a population-level estimate (such as 55%) of women with chronic pelvic pain who have no identifiable pathology. Paper 2 addresses chronic abdominal pain and the role of adhesions but does not provide a statistic about the proportion of women with chronic pelvic pain who have no underlying pathology. Papers 3\u20138 concern other conditions (low back pain, dependence in older people, chronic daily headache, lifestyle and mortality, glaucoma, gestational diabetes) and are not relevant. Because the evidence supplied neither presents nor substantiates the claimed 55% figure, the claim cannot be verified from these papers."
    },
    "posthoc_doc_ids": [
      "13027590",
      "3190689",
      "14724693",
      "13934676",
      "8570317"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "614",
    "claim": "Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that pathogenic LRRK2 Roc-COR domain mutations (R1441C, Y1699C) preferentially bind deacetylated microtubules and impair axonal transport in primary neurons and Drosophila, and that increasing microtubule acetylation (via deacetylase inhibitors like TSA, overexpression of the tubulin acetylase \u03b1TAT1, or knockdown of HDAC6/Sirt2) prevents mutant LRRK2 association with microtubules and restores axonal transport and locomotor behavior in vivo. Papers 3 and 4 provide mechanistic/supporting context: paper 3 shows \u03b1-tubulin acetylation stabilizes microtubule structure, and paper 4 shows HDAC6-mediated tubulin deacetylation affects microtubule-dependent trafficking. Paper 2 is not directly relevant. Taken together, the evidence supports the claim that increasing microtubule acetylation repairs axonal transport interference caused by LRRK2 Roc-COR mutations."
    },
    "naive_doc_ids": [
      "9638032",
      "7549811",
      "16056410",
      "2727303"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly tests this hypothesis and provides multiple lines of experimental evidence that increasing microtubule acetylation prevents mutant LRRK2 (Roc\u2011COR domain mutants R1441C, Y1699C) from associating with microtubules and restores axonal transport and locomotor behavior. Interventions that increase acetylation (\u03b1TAT1 expression, HDAC6/Sirt2 knockdown, or treatment with the deacetylase inhibitor TSA) blocked mutant LRRK2\u2013microtubule interaction and rescued transport defects in primary neurons and in Drosophila in vivo. The other listed papers provide background on motors, microtubule polarity, and axonal transport mechanisms but do not contradict these findings. Therefore the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "18678095",
      "20743803"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that pathogenic LRRK2 Roc-COR domain mutants (R1441C, Y1699C) preferentially bind deacetylated microtubules and impair axonal transport in neurons and Drosophila, and that increasing microtubule acetylation (via deacetylase inhibitors such as TSA or expression of the tubulin acetylase \u03b1TAT1) prevents mutant LRRK2 association with microtubules and restores axonal transport and locomotor behaviour. Additional papers (e.g., Paper 5) provide mechanistic support that \u03b1-tubulin acetylation stabilizes microtubule structure, consistent with a protective effect on transport. None of the other provided papers present data that contradict this result. Therefore the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "7549811",
      "16056410"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "657",
    "claim": "Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 provides direct experimental evidence that an ER-resident intramembrane protease (RHBDL4, a rhomboid) cleaves single-pass and polytopic membrane proteins with unstable transmembrane helices and thereby promotes their degradation via the canonical ERAD machinery, linking intramembrane proteolysis to removal of complex membrane proteins. Paper 3 shows regulated intramembrane proteolysis (RIP) of a type I membrane protein (EpCAM), confirming that intramembrane cleavage occurs for proteins with complex orientations and can affect their fate. Papers 4 and 5 discuss dislocation and ubiquitination of membrane proteins and do not contradict a role for intramembrane cleavage in facilitating degradation. None of the provided papers, however, specifically examine signal peptide peptidase (SPP) itself \u2014 the supporting data are for other intramembrane proteases (rhomboid/RIP systems). Therefore the collection supports the general claim that intramembrane cleavage aids degradation of membrane proteins with complex orientations, but does not provide direct evidence for SPP specifically."
    },
    "naive_doc_ids": [
      "8533245",
      "1744752",
      "3756384",
      "38477436",
      "6788835"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 provides direct experimental evidence that an ER-resident intramembrane protease (RHBDL4, a rhomboid family protease) cleaves single-spanning and polytopic membrane proteins with unstable transmembrane helices and that this proteolysis promotes their degradation via the canonical ERAD machinery. This demonstrates that intramembrane cleavage can facilitate removal/degradation of proteins with complex membrane topology. Paper 4 also shows regulated intramembrane proteolysis (RIP) of EpCAM alters protein fate and downstream cellular programs, consistent with functional consequences of intramembrane cleavage. None of the provided papers specifically test signal peptide peptidase (SPP) itself, so while the evidence supports the general principle that intramembrane proteolysis aids degradation of complex membrane proteins, it does not directly demonstrate this function for SPP specifically."
    },
    "overthinking_doc_ids": [
      "8533245",
      "8677721",
      "1044552",
      "3756384",
      "25001628"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 1 provides direct experimental evidence that an ER-resident intramembrane protease (RHBDL4, a rhomboid family member) cleaves single-spanning and polytopic membrane proteins with unstable transmembrane helices and thereby promotes their degradation via the canonical ERAD machinery; RHBDL4 also associates with the AAA+ ATPase p97, linking proteolysis to dislocation. This supports the general claim that intramembrane cleavage aids degradation of proteins with complex membrane orientation. None of the other provided papers study signal peptide peptidase (SPP) specifically, so while the evidence supports the broader mechanism (intramembrane proteolysis facilitating ERAD of complex membrane proteins), it does not directly demonstrate the role of SPP itself."
    },
    "posthoc_doc_ids": [
      "8533245",
      "7643848",
      "37643601",
      "76776022",
      "23195302"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "428",
    "claim": "Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple provided papers directly implicate members of the Forkhead O (FoxO) family in differentiation- and lineage-control processes. Paper 2 (review) states FoxO factors participate in differentiation and are required for long-term regenerative potential of hematopoietic stem cells, linking FoxO signaling to stem cell maintenance and fate. Paper 4 shows Foxo1 controls early Treg-lineage commitment and a Foxo1-dependent transcriptional program critical for regulatory T cell function, i.e., a role in lineage differentiation and cell identity. Paper 3 further shows FOXO3 activity is regulated in stress responses that shift cell-fate outcomes (cell-cycle arrest vs. apoptosis). Together these results support the claim that FoxO (\"forkhead O\") transcription factors are involved in cellular differentiation."
    },
    "naive_doc_ids": [
      "4896726",
      "16728949",
      "28937856",
      "4418070",
      "23727313"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple provided papers report that forkhead (Fox) family transcription factors regulate differentiation. Paper 1 (Cell Stem Cell Review) explicitly lists FoxO family roles including differentiation and shows FoxO signaling is required for hematopoietic stem cell maintenance and function. Paper 4 demonstrates that FOXO4 is necessary for neural differentiation of human embryonic stem cells (loss of FOXO4 reduces neural differentiation potential). Paper 8 shows that a forkhead-domain gene, FOXP2, is involved in developmental processes affecting speech/language, consistent with a role in development/differentiation. Paper 2 further documents FoxO3 regulation of cell-fate-related responses (cell-cycle arrest, survival vs apoptosis). Together these data support the claim that forkhead (Fox/FoxO) transcription factors are involved in cellular differentiation."
    },
    "overthinking_doc_ids": [
      "16728949",
      "28937856",
      "1065627",
      "1447990",
      "19489351"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple provided papers show that members of the FoxO (forkhead O) transcription factor family participate in and regulate cellular differentiation and lineage decisions. Paper 3 (Cell Stem Cell review) explicitly states FoxOs participate in differentiation and are required for long-term regenerative potential of hematopoietic stem cells, linking FoxO signaling to stem cell maintenance and differentiation. Paper 8 shows Foxo1 is pivotal for Treg-cell lineage commitment and for a Foxo1-dependent transcriptional program controlling Treg function, indicating a role beyond commitment in T cell differentiation. Paper 1 documents FKHR/FoxO activity changes in neurons with effects on transcriptional targets and downstream outcomes in neural tissue, consistent with FoxO involvement in neuronal gene regulation and cell-fate\u2013related processes. Paper 4 describes FOXO3 regulation of cell-cycle arrest versus apoptosis and stress-resistance programs, which influence cell fate decisions. Together these data provide direct experimental and mechanistic evidence that FoxO-family transcription factors are involved in cellular differentiation."
    },
    "posthoc_doc_ids": [
      "29429111",
      "1065627",
      "16728949",
      "28937856",
      "9641846"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1340",
    "claim": "Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 is a systematic review and meta-analysis of 14 randomized trials (1334 patients) comparing ultrasound imaging versus standard palpation for lumbar punctures and epidural catheterisations. It reports that ultrasound imaging significantly reduced the number of insertion attempts (mean difference \u22120.44, 95% CI \u22120.64 to \u22120.24, P<0.001). The other provided papers address unrelated topics (blood pressure, anticoagulation, TB, meningitis) and do not affect this conclusion. Therefore the evidence supports the claim that ultrasound guidance significantly reduces needle insertion attempts for the procedures studied."
    },
    "naive_doc_ids": [
      "15482274",
      "202259",
      "10072941",
      "34338075",
      "15997009"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 3 (systematic review and meta-analysis of 14 randomized trials, n=1334) directly addresses ultrasound guidance for lumbar punctures and epidural catheterisations and reports a statistically significant reduction in the number of insertion attempts with ultrasound (mean difference -0.44, 95% CI -0.64 to -0.24, P<0.001). The other papers (1, 2, 4) are unrelated to ultrasound or needle insertion attempts. Therefore the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "4515975",
      "5402581",
      "15482274",
      "34338075"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (systematic review and meta-analysis of 14 randomized trials, n=1334) directly addresses ultrasound guidance for lumbar puncture/epidural catheterisation and reports a statistically significant reduction in the number of insertion attempts (mean difference -0.44, 95% CI -0.64 to -0.24, P<0.001). None of the other provided papers address ultrasound guidance or needle insertion attempts. Therefore the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "15482274",
      "3770750",
      "7639744",
      "37037012",
      "3329824"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "437",
    "claim": "Functional consequences of genomic alterations due to Myelodysplastic syndrome (MDS) are poorly understood due to the lack of an animal model.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The provided papers show that functional consequences of MDS-associated genomic alterations are being characterized rather than being poorly understood due to lack of models. Paper 2 maps mutations in 944 MDS patients and links many genes to clinical risk and survival, providing functional/prognostic associations. Paper 3 demonstrates a mechanistic, genotype-independent pathogenic circuit (S100A9 \u2192 NLRP3 inflammasome \u2192 caspase-1, pyroptosis, ROS, \u03b2-catenin) in MDS HSPCs and shows that genetic or pharmacologic perturbation restores hematopoiesis, i.e. clear functional insight and therapeutic proof-of-concept. Paper 4 shows an in vivo murine model for myeloid neoplasia affecting stromal/osteoblastic function, indicating related myeloid disease processes can be modeled in animals. Together these findings contradict the claim that functional consequences are poorly understood due to lack of an animal model."
    },
    "naive_doc_ids": [
      "13293033",
      "2359152",
      "6000423",
      "10795340",
      "18104691"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers address the presence or absence of animal models for myelodysplastic syndromes (MDS) or directly link lack of an MDS animal model to poor understanding of functional consequences of MDS genomic alterations. Paper 4 characterizes the genetic landscape of 944 MDS patients but does not claim that functional consequences are poorly understood due to lack of an animal model. Papers 1, 2, 3, and 6 describe the utility of animal models to study other diseases (Down syndrome, stress/HPA buffering, uterine artery ligation/intrauterine growth restriction, SCA1), and Paper 5 demonstrates a mouse model for Diamond\u2011Blackfan anemia, a different hematologic disorder. While these papers illustrate that animal models can clarify functional consequences in other conditions, they do not provide evidence about the existence or absence of MDS animal models or directly support or refute the claim about MDS. Therefore the materials supplied do not contain relevant information to verify the claim."
    },
    "overthinking_doc_ids": [
      "7239105",
      "4951831",
      "18104691",
      "2359152",
      "12240507"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly reports a two-step transgenic mouse model (NRAS/BCL2) used to study progression from MDS-like ineffective hematopoiesis to myeloid leukemia, demonstrating increased ROS, DNA damage, and error-prone DSB repair and showing that these functional consequences can be modulated (e.g., by N\u2011acetyl cysteine). This provides experimental animal-model evidence linking genomic alterations to functional/pathophysiological outcomes in MDS. Additional papers (e.g., Paper 7) illustrate that mouse models are useful for studying functional consequences of chromosomal/genetic disorders. None of the provided papers support the claim that functional consequences are poorly understood due to a lack of any animal model; rather they show at least some animal models exist and yield mechanistic insight. (Caveat: MDS is heterogeneous, so one model may not capture all aspects of the human disease.)"
    },
    "posthoc_doc_ids": [
      "5765455",
      "13293033",
      "26025820",
      "4951831",
      "18104691"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "173",
    "claim": "Bcp1 is a chaperone for Rpl23.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers mention Bcp1 or Rpl23 (ribosomal protein L23) nor present experimental data linking Bcp1 to Rpl23. The papers focus on other ribosomal proteins and assembly factors (e.g., Rps3/Yar1/Ltv1, Rps9/B23, Ria1p, Exportin 5) or unrelated topics, so there is no evidence here to support or contradict the claim that Bcp1 is a chaperone for Rpl23."
    },
    "naive_doc_ids": [
      "15893330",
      "26495128",
      "7155555",
      "946756",
      "169264"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers mention Bcp1 or Rpl23 or present experimental data about an interaction or chaperone relationship between them. A few papers discuss ribosome biogenesis or ribosomal proteins (e.g., Ria1p involvement in 60S biogenesis, RPL32 characterization), but none address Bcp1 or identify a chaperone role for Bcp1 toward Rpl23. Therefore the supplied evidence does not support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "1084345",
      "12156187",
      "12428814",
      "23664875",
      "41087952"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention Bcp1 or provide evidence that Bcp1 acts as a chaperone for Rpl23. Paper 4 discusses Ria1p in 60S subunit biogenesis but does not mention Bcp1 or Rpl23; Paper 5 concerns Yar1/Ltv1 and Rps3 (40S) rather than Rpl23 (a 60S protein). Papers 1\u20133 address unrelated chaperone/autophagy or secretion topics. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "1084345",
      "12156187",
      "12428814",
      "41087952",
      "26596106"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1382",
    "claim": "aPKCz causes tumour enhancement by affecting glutamine metabolism.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 directly addresses atypical PKC zeta (PKC\u03b6) and glutamine metabolism: PKC\u03b6 represses key enzymes (PHGDH, PSAT1) of a pathway that allows cancer cells to utilize glutamine when glucose is scarce, and phosphorylates PHGDH to inhibit its activity. Loss or deficiency of PKC\u03b6 promotes metabolic reprogramming toward glutamine-dependent serine biosynthesis and results in enhanced tumorigenesis in mice; low PKC\u03b6 levels in patients correlate with poor prognosis. Thus the data indicate that loss of PKC\u03b6 (not PKC\u03b6 itself) causes tumor enhancement by enabling glutamine metabolism. Other papers (1, 2, 3) support the importance of glutamine metabolism for tumor growth but do not show that PKC\u03b6 promotes tumorigenesis. Therefore the provided evidence contradicts the claim as written (it shows the opposite causal direction)."
    },
    "naive_doc_ids": [
      "5256564",
      "27647593",
      "10169908",
      "17755060",
      "26735905"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 directly addresses PKC\u03b6 (aPKC\u03b6) and glutamine-linked metabolic reprogramming in tumorigenesis and shows that PKC\u03b6 acts as a metabolic tumor suppressor. Loss/deficiency of PKC\u03b6 promotes metabolic plasticity that enables tumor cells to use glutamine (via the serine biosynthetic pathway), increases expression and activity of PHGDH and PSAT1, and results in enhanced intestinal tumorigenesis; low PKC\u03b6 in patients correlates with poorer prognosis. Other papers (e.g. Papers 1,2,3,4,5,9,10) confirm that altered glutamine metabolism supports tumor growth more generally, but none provide evidence that PKC\u03b6 (aPKC\u03b6) promotes tumor enhancement via glutamine metabolism. Thus the provided evidence contradicts the claim: PKC\u03b6 restrains glutamine-driven metabolic reprogramming and tumorigenesis, and its loss \u2014 not its presence/activity \u2014 causes tumor enhancement."
    },
    "overthinking_doc_ids": [
      "22914228",
      "3831884",
      "10169908",
      "28334217",
      "5256564"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the supplied papers report on aPKCz (atypical PKC zeta) or link its activity to glutamine metabolism. Several papers (Paper 1, Paper 2, Paper 6) describe glutamine-dependent pathways, transporters (SLC1A5/ASCT2) and how glutamine supports tumour growth, but they do not mention aPKCz or demonstrate that aPKCz causes tumour enhancement via modulation of glutamine metabolism. The remaining papers are unrelated to aPKCz or glutamine metabolism. Therefore the provided evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "3831884",
      "10169908",
      "493346",
      "4899981",
      "4303939"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "264",
    "claim": "Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers provide converging evidence that citrullinated proteins exposed on NETs are antigenic and participate in a feed\u2011forward inflammatory loop. Paper 1 identifies citrullinated histone H4 from activated neutrophils/NETs as a target of ACPA in RA patients. Paper 2 shows NETs externalize citrullinated autoantigens, that NETosis correlates with ACPA levels, that RA sera/ACPA can induce NETosis, and that NETs stimulate inflammatory responses in synovial fibroblasts \u2014 together supporting a cycle where NETs present citrullinated antigens, autoantibodies form/are present, and inflammation is amplified. Paper 3 frames NETs as a source of nuclear autoantigens, and Paper 6 shows PAD4\u2011dependent citrullination is required for NET formation, tying citrullination to NET biology. While direct proof that NETs initiate the first break in tolerance (de novo induction of autoantibodies in vivo) is inferential rather than definitively proven in these papers, the experimental data strongly support the claim that citrullinated NET proteins promote autoantibody responses and thereby help perpetuate inflammation."
    },
    "naive_doc_ids": [
      "30041340",
      "11328820",
      "14853989",
      "10359591",
      "16550075"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1\u20133 provide direct evidence that NETs externalize citrullinated proteins that are antigenic and targeted by anti-citrullinated protein antibodies (ACPAs). Paper 1 identifies citrullinated histone H4 in NETs as a target of RA patient antibodies and suggests NETosis generates antigens for ACPA. Paper 2 shows NETs from RA patients externalize citrullinated autoantigens, that ACPA-positive RA sera/autoantibodies enhance NETosis, and that NETs drive inflammatory responses in synovial fibroblasts \u2014 together supporting a feed\u2011forward cycle in which NET-exposed citrullinated proteins lead to autoantibody responses that promote further NETosis and inflammation. Paper 3 reviews NETs as a source of nuclear autoantigens linking innate to adaptive autoimmunity. Paper 5 (immune-complex/Fc\u03b3R effects on neutrophils) is consistent with autoantibody effects on neutrophils; Paper 4 is unrelated. Overall, the evidence supports the claim that citrullinated proteins in NETs can indirectly perpetuate inflammation by inducing autoantibodies."
    },
    "overthinking_doc_ids": [
      "30041340",
      "11328820",
      "14853989",
      "5774746",
      "9225850"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers provide direct experimental evidence that NETs externalize citrullinated proteins which are targeted by autoantibodies and contribute to a self-amplifying inflammatory loop. Paper 2 identifies citrullinated histone H4 in NETs and shows rheumatoid arthritis (RA) sera/ACPA bind these NET-derived citrullinated epitopes. Paper 5 demonstrates (1) enhanced NETosis in RA, (2) externalization of citrullinated autoantigens during NETosis, (3) correlation between NETosis and ACPA levels, (4) that RA autoantibodies can themselves induce NET formation, and (5) that NETs amplify inflammatory responses in synovial fibroblasts\u2014together supporting an indirect perpetuation of inflammation via induction/maintenance of autoantibodies. Paper 3 further supports NET-derived material (oxidized mtDNA) driving autoimmunity/inflammation in lupus models. No provided paper contradicts this mechanism."
    },
    "posthoc_doc_ids": [
      "1800734",
      "30041340",
      "1049501",
      "3973445",
      "11328820"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1375",
    "claim": "Weighed food records (WFR) result in poor completion since they're costly to run and impose high participant burden.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.65,
      "justification": "Two of the provided papers address weighed food records (WFR) and report problems consistent with the claim. Paper 1 (Southern French study) shows only 98 of 150 volunteers completed the protocol that included a 4\u2011day weighed record (\u224865% completion), indicating nontrivial dropout/completion issues. Paper 2 finds systematic underreporting of energy intake measured by 7\u2011day weighed records compared with doubly labelled water (recorded intake substantially lower than measured expenditure), which indicates problems with data completeness/accuracy that are plausibly related to participant burden. None of the supplied studies, however, provide direct data on the monetary cost of running WFR or explicitly measure participant burden; the cost/burden aspect is implied rather than documented. Other supplied papers are not relevant to WFR. Therefore the evidence supports the claim that WFRs have completion/quality problems (and likely high burden), but does not directly document costs."
    },
    "naive_doc_ids": [
      "21623140",
      "21993510",
      "16322674",
      "5151024",
      "13625993"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.6,
      "justification": "Only one of the provided papers (Paper 3) directly addresses weighed dietary records. In that validation study 150 volunteers were enrolled but only 98 completed the full protocol that included a 4\u2011day weighed dietary record (PETRA), a 7\u2011day estimated record and an FFQ, indicating a substantial dropout/noncompletion (\u224835%). The paper also emphasizes the effort of multiple recording methods and validates photographic portion estimation as a less onerous alternative, implicitly supporting that weighed records are burdensome. The other papers do not provide relevant data about WFR completion, participant burden, or costs. Limitation: Paper 3 does not explicitly attribute noncompletion solely to the weighed record nor quantify the costs, so the evidence is indirect but consistent with the claim."
    },
    "overthinking_doc_ids": [
      "40666943",
      "8298120",
      "21623140",
      "2048139",
      "11748341"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.68,
      "justification": "Several included papers provide evidence consistent with the claim. Paper 1 reports that only 98 of 150 volunteers completed a protocol involving repeated 4-day weighed records (\u224865% completion), indicating non\u2011trivial dropout associated with an intensive weighed\u2011record protocol. Paper 3 evaluates seven\u2011day weighed dietary records and highlights practical problems (systematic underreporting of energy intake in many participants), which\u2014together with the intensive measurement/validation procedures used\u2014implies high respondent and study burden. Papers 6 and 7 show that self\u2011administered computerized 24\u2011h recalls produce comparable data while reducing resource needs, implying that weighed records are relatively more costly and burdensome. None of the papers directly measure cost or explicitly quantify participant burden as the causal reason for noncompletion, so the evidence is indirect but supportive."
    },
    "posthoc_doc_ids": [
      "21623140",
      "2048139",
      "21993510",
      "2659805",
      "16322674"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "421",
    "claim": "Flexible molecules experience greater steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present experimental data or analyses comparing steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The papers cover related topics \u2014 ECM stiffness and mechanotransduction (Paper 1), redox-regulation and integrin conformational states (Paper 2), protein conformational changes in pore formation (Paper 4), ECM remodelling (Paper 5), and several small\u2011molecule therapeutic developments (Papers 6\u20138) \u2014 but they do not measure or report that flexible molecules experience greater steric hindrance than rigid ones in tumors. Therefore the corpus does not provide evidence to support or contradict the specific claim."
    },
    "naive_doc_ids": [
      "1065627",
      "44640124",
      "2734421",
      "2617858",
      "4164929"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present experimental data or analyses that directly compare steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The papers cover related topics (ECM composition and redox regulation, fibrosis/desmoplasia, CAF- and MMP-mediated ECM remodelling, immune cell infiltration, and other unrelated biological processes), which describe changes to extracellular matrix density, protease activity, and tissue remodeling that could influence steric constraints in tumors. However, none report measurements, modelling, or direct observations of how molecular flexibility vs. rigidity affects steric hindrance in the tumor microenvironment, so the claim cannot be confirmed or refuted from this evidence."
    },
    "overthinking_doc_ids": [
      "44640124",
      "4164929",
      "3559136",
      "13007205",
      "219475"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present experimental data or analyses comparing how molecular flexibility versus rigidity affects steric hindrance or diffusion specifically within the tumor microenvironment. The papers cover topics such as cancer-associated fibroblasts and stromal/ECM remodeling (Papers 1, 3, 4, 5), signaling and immune context (Papers 2, 7, 6), and anti\u2011inflammatory effects of curcumin (Paper 8). Although several papers discuss extracellular matrix composition, desmoplasia, and increased collagen or ECM remodeling that can influence molecular transport in tumors, none investigate or report results on the relationship between molecular conformational flexibility and steric hindrance in the tumor microenvironment. Therefore the supplied evidence does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "44640124",
      "4164929"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "672",
    "claim": "L3MBTL2 binds to H2AK119Ub marked chromatin to form a PRC1 complex.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "Paper 1 directly shows that L3mbtl2 assembles an atypical PRC1-family complex (including Ring1b) in ES cells and that the presence of L3mbtl2 at target genes is associated with H2AK119 ubiquitination. This supports the claim that L3MBTL2 is part of a PRC1-like complex that occupies chromatin regions marked by H2AK119Ub. None of the other provided papers address L3MBTL2. Caveat: Paper 1 reports co\u2011occurrence/association of L3mbtl2 with H2AK119Ub but does not demonstrate a direct biochemical interaction between L3MBTL2 and the H2AK119Ub mark, nor that H2AK119Ub is dependent on L3MBTL2; therefore the evidence supports the assembly/colocalization aspect of the claim but not a demonstrated direct binding to the ubiquitin mark."
    },
    "naive_doc_ids": [
      "15635366",
      "23244529",
      "14581009",
      "140874",
      "4462777"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 1 directly shows that L3mbtl2 assembles an atypical PRC1-family complex (including Ring1b) in ES cells and that the presence of L3mbtl2 at target genes is associated with H2AK119 ubiquitination. Thus the papers support that L3MBTL2 localizes to chromatin regions marked by H2AK119Ub and recruits a PRC1-like complex. However, the evidence does not demonstrate that L3MBTL2 directly recognizes or binds the H2AK119Ub (ubiquitin) mark: Paper 1 states H2AK119Ub is neither dependent on L3mbtl2 nor sufficient for repression, and Paper 2 (structural work on MBT-repeat proteins related to L3MBTL2) shows MBT domains bind mono-/di-methylated lysines rather than ubiquitin. So the literature supports association/localization to H2AK119Ub-marked sites and formation of a PRC1-related complex, but does not provide direct biochemical evidence that L3MBTL2 specifically binds the ubiquitin modification itself."
    },
    "overthinking_doc_ids": [
      "15635366",
      "3829232",
      "3270834",
      "4462777",
      "8331432"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 directly shows that L3mbtl2 assembles an atypical PRC1-family complex (including Ring1b) in ES cells and that L3mbtl2 occupancy at target genes is associated with H2AK119 ubiquitination. This supports the claim that L3MBTL2 is part of a PRC1-related complex at chromatin marked by H2AK119Ub. The other provided papers do not address L3MBTL2 or H2AK119Ub. Caveat: Paper 1 reports that H2AK119Ub is neither dependent on L3mbtl2 nor alone sufficient for repression, and it does not demonstrate a direct biochemical interaction of L3MBTL2 with the ubiquitin on H2AK119 (i.e., direct binding to the mark is not proven). Therefore the evidence supports the formation of a PRC1-like complex at H2AK119Ub-marked sites but does not definitively prove L3MBTL2 directly binds the ubiquitin mark."
    },
    "posthoc_doc_ids": [
      "15635366",
      "140874",
      "17240457",
      "21557055",
      "502591"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "361",
    "claim": "During the primary early antibody response activated B cells migrate toward the inner-and outer follicular areas where oxysterol accumulation is generated by stromal cells.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 1\u20133 provide direct, relevant evidence. Paper 1 describes that activated B cells are guided to inter- and outer-follicular niches and notes that distinct stromal cell compartments define these niches. Paper 2 identifies the oxysterol 7\u03b1,25-dihydroxycholesterol (7\u03b1,25-OHC) as the physiological ligand of EBI2 and explains that gradients of this oxysterol regulate migration of B cells (and other immune cells). Paper 3 shows that EBI2 expression on activated B cells is required for their movement to extrafollicular (inter/outer-follicle) sites and early plasmablast responses, with downregulation permitting germinal center entry. Together these findings support the claim that activated B cells migrate to inner/outer follicular areas under the influence of an oxysterol (7\u03b1,25-OHC) gradient associated with stromal-cell defined niches."
    },
    "naive_doc_ids": [
      "38587347",
      "15058155",
      "15488881",
      "1071991",
      "42065070"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 (review) states that activated B cells are guided by the receptor EBI2 to inter- and outer-follicular niches during early T-dependent antibody responses and highlights the role of distinct stromal-cell niches in these follicular subcompartments. Paper 2 identifies the oxysterol 7\u03b1,25-dihydroxycholesterol as the physiological ligand of EBI2 and describes how an in vivo gradient of this oxysterol regulates B\u2011cell migration. Taken together these papers support the claim that activated B cells migrate to inner/outer follicular areas in an EBI2-dependent manner and that oxysterol accumulation (7\u03b1,25\u2011OHC) generates the positional cue controlling that migration \u2014 with stromal niches implicated as the relevant microenvironments. (Other provided papers are unrelated.) Note: the provided excerpts do not include a direct quotation explicitly saying which stromal cell types produce the oxysterol, so confidence is not maximal but the cited studies together substantiate the claim.)"
    },
    "overthinking_doc_ids": [
      "38587347",
      "15058155",
      "7736860",
      "11721286",
      "13469921"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 (review) states that the orphan receptor EBI2 (GPR183) guides activated B cells to inter- and outer-follicular niches and that these migration events occur in association with distinct stromal-cell-defined subcompartments. Paper 2 identifies the oxysterol 7\u03b1,25-dihydroxycholesterol (7\u03b1,25-OHC) as the physiological ligand for EBI2 and describes how an in vivo gradient of this oxysterol can be generated to regulate B cell migration. Together these papers provide direct mechanistic support for the claim that, during the early primary antibody response, activated B cells migrate to inner/outer follicular areas under the guidance of EBI2 and a stromally organized oxysterol gradient (7\u03b1,25-OHC). No provided paper contradicts this view."
    },
    "posthoc_doc_ids": [
      "38587347",
      "15058155",
      "40365566",
      "25353658",
      "13777138"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "662",
    "claim": "JMJD6 slows the hydroxylation of C-terminal lysine",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly contradicts the claim: it shows JMJD6 is an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that catalyzes hydroxylation of p53, with hydroxylation occurring mainly on lysine 382 (a C\u2011terminal region of p53). That indicates JMJD6 promotes/mediates hydroxylation of a (C\u2011terminal) lysine rather than slowing it. None of the other provided papers report JMJD6 slowing C\u2011terminal lysine hydroxylation or provide supporting evidence for the claim."
    },
    "naive_doc_ids": [
      "37204802",
      "31107919",
      "56486733",
      "2613813",
      "12582729"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses JMJD6 and shows that JMJD6 functions as an Fe(II)- and \u03b1-ketoglutarate-dependent lysyl hydroxylase that catalyzes hydroxylation of p53 (mainly at lysine 382). That report indicates JMJD6 promotes/mediates lysine hydroxylation rather than slowing it. None of the other provided papers present evidence that JMJD6 reduces or slows C-terminal lysine hydroxylation. Therefore the evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "982650",
      "11968641"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that JMJD6 functions as an Fe(II)- and \u03b1-ketoglutarate-dependent lysyl hydroxylase that catalyzes hydroxylation of p53 (chiefly at lysine 382). This indicates JMJD6 promotes/carries out hydroxylation of a C-terminal lysine on p53 rather than slowing it. None of the other provided papers report that JMJD6 inhibits or slows hydroxylation of C-terminal lysines. Therefore the supplied evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "3531388",
      "9814332"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "378",
    "claim": "Energy balance requires hypothalamic glutamate neurotransmission.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers provide experimental evidence that hypothalamic glutamatergic neurotransmission is necessary for normal energy balance. Paper 1 directly demonstrates necessity: selective disruption of glutamate release from Sim1-expressing PVH neurons (or adult PVH neurons) caused rapid obesity driven by reduced energy expenditure and hyperphagia, and abolished the anti-obesity effect of restored MC4R signaling. Paper 2 shows that loss or pathway-specific inhibition of lateral hypothalamic (LHA) glutamatergic neurons increases palatable food intake and body weight and that optogenetic manipulation of LHA\u2192lateral habenula glutamatergic projections bidirectionally controls feeding. Paper 5 provides convergent support that NMDA (glutamatergic) signaling in the LHA is critical for feeding responses. Paper 3 (brainstem glutamatergic neurons) further supports a role for glutamatergic circuits in feeding control more broadly. Paper 4 does not address glutamate. Taken together, the evidence supports the claim that hypothalamic glutamate neurotransmission is required for normal energy balance."
    },
    "naive_doc_ids": [
      "45154987",
      "23869951",
      "2225918",
      "25050364",
      "4611267"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Multiple papers directly show that glutamatergic neurotransmission in hypothalamic circuits is necessary for normal energy-balance regulation. Paper 6: selective disruption of glutamate release from Sim1/PVH neurons reverses the anti-obesity effect of restored MC4R and causes hyperphagia and reduced energy expenditure, and acute disruption of glutamate release from adult PVH neurons produces rapid obesity\u2014indicating glutamate release from hypothalamic neurons is required for MC4R-mediated control of body weight. Paper 8: fasting-induced activation of AgRP neurons requires NMDAR-dependent glutamatergic input; deleting NMDARs on AgRP neurons markedly alters feeding and body weight, showing excitatory glutamatergic synaptic transmission is critical for the neuronal responses that drive feeding. Paper 4: LHA glutamatergic neurons bidirectionally regulate feeding and their ablation increases caloric intake and weight gain. Together these experimental results support the claim that hypothalamic glutamate neurotransmission is required for normal energy balance."
    },
    "overthinking_doc_ids": [
      "10017612",
      "2028532",
      "11742219",
      "23869951",
      "4469125"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers provide direct experimental evidence that hypothalamic glutamate release is necessary for components of energy homeostasis. Paper 3 shows that conditional loss of VGLUT2 in VMH (SF1) neurons impairs counterregulatory responses and causes fasting hypoglycemia, demonstrating glutamatergic VMH output is required to prevent hypoglycemia. Paper 7 demonstrates that glutamate release from Sim1/PVH neurons mediates MC4R-driven reductions in body weight: selective disruption of glutamate release reverses the anti-obesity effects (causing hyperphagia and reduced energy expenditure). Paper 6 shows that LHA glutamatergic neurons (and their LHA\u2192LHb projections) negatively regulate palatable food intake and that genetic ablation of these glutamatergic neurons increases caloric intake and weight gain. Paper 1 further implicates hypothalamic glutamate handling (via astrocytic glutamate transporters) as modulated by metabolic signals and leptin, affecting POMC neuron activity. Together these experimental manipulations (loss of glutamate release or glutamatergic neuron ablation) produce dysregulation of feeding, body weight, or glucose homeostasis, supporting the claim that hypothalamic glutamate neurotransmission is required for normal energy balance."
    },
    "posthoc_doc_ids": [
      "17150648",
      "11742219",
      "11886686",
      "15535511",
      "22545779"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "399",
    "claim": "Exposure to fine particulate air pollution is relate to anxiety prevalence.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines the association between past exposure to fine particulate matter (PM2.5) and prevalent high symptoms of anxiety in a large cohort (71,271 women) and reports significant positive associations (e.g., OR per 10 \u00b5g/m3 increase in 1-month average PM2.5 = 1.12, 95% CI 1.06\u20131.19; 12-month average OR = 1.15, 95% CI 1.06\u20131.26). That study concludes PM2.5 exposure was associated with high anxiety symptoms, with more recent exposures potentially more relevant. The other provided papers do not provide direct evidence about fine particulate air pollution and anxiety (they address dengue, TMAO/cardiovascular risk, cryotherapy, stress models, hormonal or leptin effects on anxiety), so the available evidence overall supports the claim."
    },
    "naive_doc_ids": [
      "791050",
      "2097256",
      "6793674",
      "7198295",
      "2436602"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 4 directly examines the relation between past exposure to fine particulate matter (PM2.5) and anxiety symptoms in a large cohort (71,271 women). It reports significantly increased odds of high anxiety symptoms with higher PM2.5 exposure for multiple averaging periods (e.g., OR per 10 \u00b5g/m3 increase: 1.12 [1.06\u20131.19] for the prior 1-month average and 1.15 [1.06\u20131.26] for the prior 12-month average). Coarse particulates (PM2.5\u201310) and residential proximity to major roads were not associated. The other provided papers do not assess air pollution and anxiety (one reports global anxiety prevalence but not pollution). Thus the available evidence supports an association between fine particulate air pollution (PM2.5) and greater prevalence of anxiety symptoms, though the finding is observational (Nurses\u2019 Health Study; older women) and does not by itself prove causality or generalize to all populations."
    },
    "overthinking_doc_ids": [
      "8298120",
      "32357890",
      "439670",
      "791050",
      "829646"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly tests this relationship in 71,271 women (Nurses' Health Study) and reports that higher past exposure to fine particulate matter (PM2.5) was significantly associated with greater prevalence of high anxiety symptoms (e.g., OR per 10 \u00b5g/m3 increase in prior 1\u2011month PM2.5 = 1.12, 95% CI 1.06\u20131.19; prior 12\u2011month PM2.5 OR = 1.15, 95% CI 1.06\u20131.26). Shorter-term PM2.5 averaging windows were more relevant; coarse particles (PM2.5\u201310) and proximity to major roads showed no dose-dependent association. The other provided papers do not address PM2.5 exposure and anxiety. Therefore the provided evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "791050",
      "32357890",
      "2138767",
      "17124832",
      "2052720"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1043",
    "claim": "Retinoic acid receptor-related orphan receptor gamma (ROR\u03b3) is a therapeutic target for castration-resistant prostate cancer (CRPC)",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 provides direct experimental evidence that ROR\u03b3 is overexpressed and amplified in metastatic CRPC, drives AR gene transcription by recruiting NCOA1/3 to an AR\u2011RORE, and that ROR\u03b3 antagonists suppress AR and AR\u2011V7 expression, reduce genome\u2011wide AR binding and AR target gene activity, inhibit tumor growth in multiple AR\u2011expressing CRPC xenografts, and sensitize tumors to enzalutamide. These results establish ROR\u03b3 as a therapeutic target in AR\u2011positive CRPC. Other papers are either unrelated (Papers 2\u20135) or describe AR\u2011indifferent/neuroendocrine CRPC evolution (Paper 6), which highlights that ROR\u03b3\u2011targeting would be relevant primarily for AR\u2011expressing CRPC and likely not effective for AR\u2011negative/NEPC\u2014consistent with Paper 1\u2019s finding that antagonists did not affect AR\u2011negative models."
    },
    "naive_doc_ids": [
      "17671145",
      "22180793",
      "32852283",
      "8512633",
      "15721252"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 3 directly demonstrates that ROR-\u03b3 (ROR\u03b3) is overexpressed and amplified in metastatic CRPC, drives AR transcription by recruiting coactivators (NCOA1/3) to an AR\u2013ROR response element, and that small-molecule ROR-\u03b3 antagonists suppress AR and AR-V7 expression, reduce AR genomic binding/H3K27ac and AR target-gene expression, inhibit growth of AR-expressing xenograft tumors, and sensitize CRPC tumors to enzalutamide. These experimental results identify ROR-\u03b3 as a mechanistic upstream regulator of AR in CRPC and show therapeutic efficacy of ROR-\u03b3 antagonists, which supports the claim. The other provided papers do not present evidence that contradicts this finding (they are either on unrelated lncRNAs, clonal evolution/epigenetics, androgen suppression duration, or general gene-expression profiling)."
    },
    "overthinking_doc_ids": [
      "8512633",
      "14131683",
      "17671145",
      "308862",
      "6790197"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 provides direct experimental evidence that ROR\u03b3 is overexpressed/amplified in metastatic CRPC, drives AR (and AR-V7) gene expression via recruitment of coactivators to an AR-ROR response element, and that pharmacologic ROR\u03b3 antagonists suppress AR signaling, reduce genome-wide AR binding and H3K27ac, inhibit growth of AR-expressing CRPC xenografts, and sensitize tumors to enzalutamide. The other papers either address a different ROR isoform (ROR\u03b1) or unrelated CRPC mechanisms/targets (N-cadherin, lncRNAs, neuroendocrine evolution) and do not contradict the ROR\u03b3 findings. Therefore the provided evidence supports the claim that ROR\u03b3 is a therapeutic target for CRPC."
    },
    "posthoc_doc_ids": [
      "17671145",
      "37256966",
      "14131683",
      "22180793",
      "8512633"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1028",
    "claim": "Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers provide direct evidence that reduced IL-2 responsiveness or reduced IL-2 availability impairs regulatory T cell (Treg) function and is linked to autoimmunity, including type 1 diabetes (T1D). Paper 1 shows a T1D-associated IL2RA haplotype correlates with diminished IL-2 signaling (reduced STAT5a phosphorylation), lower FOXP3 in Tregs and reduced suppressive capacity. Paper 5 demonstrates that reduced IL-2 expression (genetic haplodeficiency) decreases Treg function and causes autoimmune disease in mice. Paper 6 genetically implicates IL2RA polymorphisms in T1D and associates risk genotypes with lower soluble IL-2RA, consistent with decreased IL-2 pathway responsiveness predisposing to T1D. Papers 3\u20134 provide mechanistic context (IL-2/STAT5 synergy enhances Treg expansion/function; alternative pathways can induce FOXP3), while Paper 2 is about Treg-mediated endothelial protection and does not counter the IL-2 evidence. Together these data support the claim."
    },
    "naive_doc_ids": [
      "11899391",
      "30908508",
      "38830961",
      "18546584",
      "13923140"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that a Type 1 diabetes\u2013associated IL2RA haplotype correlates with diminished IL-2 responsiveness (reduced STAT5 phosphorylation) in antigen-experienced CD4+ T cells, lower FOXP3 expression in Tregs, and reduced Treg suppressive function \u2014 directly supporting the claim. Paper 3 further supports the biological role of IL-2 signaling in maintaining/expanding functional Tregs (IL-2 synergizes with TNF to increase CD25/FOXP3 and STAT5 phosphorylation), consistent with the idea that reduced IL-2 responsiveness would impair Treg function. Paper 2 is relevant to Treg roles in autoimmunity/GVHD but does not address IL-2 responsiveness specifically. Together, the evidence supports the claim that reduced IL-2 responsiveness in Tregs is associated with autoimmune disease risk (e.g., Type 1 Diabetes)."
    },
    "overthinking_doc_ids": [
      "11899391",
      "33535222",
      "38830961"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that a Type 1 diabetes\u2013associated IL2RA haplotype correlates with diminished IL-2 responsiveness (reduced STAT5a phosphorylation) in antigen-experienced CD4+ T cells and is associated with lower FOXP3 expression and reduced suppressive function of CD4+CD25+ regulatory T cells. Paper 2 provides supporting mechanistic context by showing IL-2 (synergizing with TNF) enhances STAT5 phosphorylation, FoxP3 and Treg suppressive activity. Together these findings support the claim that reduced IL-2 responsiveness in Tregs is associated with autoimmune disease risk such as T1D."
    },
    "posthoc_doc_ids": [
      "11899391",
      "38830961",
      "30908508",
      "16712164",
      "712078"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "149",
    "claim": "Autophagy deficiency in the liver increases vulnerability to insulin resistance.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly contradicts the claim: mice with autophagy deficiency in the liver showed induction of Fgf21 and were resistant to diet-induced obesity with ameliorated (not worsened) insulin resistance. The other provided papers do not present evidence that hepatic autophagy deficiency increases susceptibility to insulin resistance (Paper 6 addresses restoration of chaperone-mediated autophagy and improved hepatic function but does not report increased insulin resistance when autophagy is deficient; Papers 2\u20135 discuss other regulators of insulin sensitivity or diet effects unrelated to hepatic autophagy). Thus the supplied evidence opposes the claim."
    },
    "naive_doc_ids": [
      "6227220",
      "2481032",
      "11201004",
      "14198646",
      "31001322"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 directly addresses autophagy deficiency in liver and reports that liver-specific autophagy (Atg7) deficiency induced Fgf21, produced resistance to diet-induced obesity and ameliorated insulin resistance. This indicates hepatic autophagy deficiency protected against \u2014 rather than increased vulnerability to \u2014 insulin resistance. The other papers do not provide evidence supporting increased insulin resistance from hepatic autophagy loss (they discuss beta-cell insulin receptor, adipokines/obesity, neuronal Sirt1, and cryptochrome effects). Therefore the provided evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "16389141",
      "5268462",
      "6227220",
      "2481032",
      "22500262"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 directly tests autophagy deficiency in liver and reports that hepatic autophagy deficiency induced Fgf21 (via mitochondrial dysfunction and Atf4) and produced resistance to diet-induced obesity and amelioration of insulin resistance, i.e., a protective effect rather than increased vulnerability. The other papers discuss alternate mechanisms of insulin resistance (hepatic NF-\u03baB/inflammation, gut microbiota, neuronal Sirt1, diet, adipokines) but do not provide evidence that hepatic autophagy deficiency increases susceptibility to insulin resistance. Therefore the provided evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "6227220",
      "31001322",
      "2481032",
      "52805891",
      "120626"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "946",
    "claim": "Physical activity level is associated with the difference in maximal oxygen consumption between black and white youth.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "The papers provide mixed but ultimately contradictory evidence about whether physical activity explains racial differences in VO2max. Paper 1 reports lower VO2max in black children and suggests this could be due in part to a more sedentary lifestyle (based on questionnaire data), which would support the claim. However, Paper 2 \u2014 a more objective study that measured total energy expenditure and activity energy expenditure with doubly labeled water \u2014 found African-American children had ~15% lower VO2max and that this difference persisted after adjustment for TEE and AEE, indicating the VO2max gap is independent of measured physical activity. Papers 3 and 4 document that non-Hispanic black youth are, on average, less physically active and less fit than whites (contextual support), but they do not demonstrate that activity differences account for the VO2max disparity. Taken together, the strongest direct evidence (Paper 2, with objective activity measures) does not support the claim that physical activity level is the driver of the VO2max difference, so the overall evidence contradicts the claim, though some studies and survey data suggest activity differences that could contribute."
    },
    "naive_doc_ids": [
      "18537148",
      "26112696",
      "13230773",
      "8428935"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "The papers provide mixed but ultimately contradictory evidence for the claim. Paper 1 (questionnaire-based activity data) reports lower VO2max in black children and suggests the difference could be due in part to a more sedentary lifestyle. Paper 3 documents lower vigorous-activity rates and higher TV time in non-Hispanic black children (supporting that activity levels differ by race). However, Paper 4 used objective measures (doubly labeled water for total and activity energy expenditure) and found African-American prepubertal children had ~15% lower VO2max than Caucasian children even after adjustment for activity energy expenditure (and other body-composition measures), indicating the VO2max difference is independent of measured physical activity. Papers 2 (hemoglobin differences) and others point to alternative explanations (hematologic or other factors). Taken together, although activity levels differ by race, the high-quality data showing the racial VO2max gap persists after controlling for activity argue against the claim that physical activity level explains/associates with that VO2max difference."
    },
    "overthinking_doc_ids": [
      "18537148",
      "4449524",
      "8428935",
      "26112696",
      "13230773"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "The papers provide mixed findings but overall do not support the claim that physical activity level explains the VO2max difference. Paper 2 (objective measures: doubly labeled water for TEE and AEE) found African-American children had ~15% lower VO2max and that the difference persisted after adjustment for total and activity energy expenditure, indicating the VO2max gap was independent of measured physical activity. Paper 1 reported lower VO2max in black children and suggested a more sedentary lifestyle (questionnaire-based) could contribute, but this is less robust and was presented as a partial/possible explanation. Papers 3 and 4 document that non-Hispanic black youth have lower fitness and lower reported vigorous activity (and more TV time), which is consistent with an association between activity and fitness but do not demonstrate that activity level accounts for the racial VO2max difference. Paper 5 is not relevant. Given the direct, objective negative finding in Paper 2, the overall evidence contradicts the claim that physical activity level explains the VO2max difference."
    },
    "posthoc_doc_ids": [
      "18537148",
      "26112696",
      "13230773",
      "8428935",
      "11201004"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "705",
    "claim": "Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "The provided papers discuss long-chain n-3 PUFA (fish oil) effects on atopy and early-life allergic outcomes, but none report direct, specific results for wheezing or asthma measured at ages 3 and 6 years. Paper 2 is a randomized trial with outcomes at 1 year (no reduction in overall IgE-associated allergy; reduced atopic eczema and egg sensitisation), and Paper 1 (a review) notes possible persistence of some protective effects into adolescence (including reduced asthma) but states the evidence is inconclusive. The other papers are unrelated. Therefore there is insufficient direct evidence in these papers to confirm or refute the claim about effects at 3 and 6 years."
    },
    "naive_doc_ids": [
      "24269361",
      "22442133",
      "20672596",
      "12438901",
      "1831916"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Most provided papers are unrelated to the claim. The only relevant items (Paper 4 and Paper 5) address n-3 long-chain PUFA supplementation and allergic outcomes in infancy/childhood but do not provide clear, direct randomized data on wheeze or asthma measured specifically at ages 3 and 6. Paper 4 reports outcomes at 1 year (no reduction in overall IgE-associated allergy; reduced atopic eczema and egg sensitisation) and calls for longer follow-up to assess respiratory allergic disease. Paper 5 (a review) notes inconsistent evidence and some suggestion of persistent reductions in eczema, hay fever, and asthma in some studies but does not clearly report consistent, significant effects at ages 3 and 6. Therefore the supplied evidence does not directly confirm or refute the specific claim about effects at 3 and 6 years."
    },
    "overthinking_doc_ids": [
      "46485368",
      "11705328",
      "34208005",
      "22442133",
      "24269361"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided papers do not contain direct data testing the claim about effects on wheeze or asthma at ages 3 and 6. Paper 1 (DOMInO) reports outcomes at 1 year and states longer follow-up is needed to determine effects on respiratory allergic disease. Paper 2 (systematic review) discusses possible protective effects of prenatal/early-life n\u20113 LCPUFA on sensitization and some atopic outcomes and notes uncertain/persistent effects into adolescence, but it does not provide definitive trial results specifically reporting wheeze/asthma outcomes at ages 3 and 6. The other papers are unrelated to LCPUFA and asthma. Therefore the evidence set does not confirm or refute the claim about no significant effects at 3 and 6 years."
    },
    "posthoc_doc_ids": [
      "22442133",
      "24269361",
      "10692948",
      "11880289",
      "20645335"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "233",
    "claim": "Cell autonomous sex determination in somatic cells does not occur in Galliformes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly contradicts the claim: studies of gynandromorph chickens and reciprocal presumptive-mesoderm transplants showed that avian somatic cells have an inherent sex identity and that donor cells in mixed-sex chimeras retain their original sex identity (e.g., female donor cells in a male host expressed female markers and were excluded from functional male gonadal structures). This demonstrates cell-autonomous sexual identity in chicken somatic cells (a Galliform). The other provided papers are either unrelated (papers 3,4,6) or neutral/consistent (paper 5 on gene-by-gene Z dosage regulation, paper 2 on quail\u2013chicken synteny) but do not support the claim that cell-autonomous somatic sex determination does not occur. Therefore the evidence refutes the claim."
    },
    "naive_doc_ids": [
      "4388470",
      "3823862",
      "3360421",
      "25827024",
      "12232678"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that avian (chicken, a Galliform) somatic cells have an inherent sex identity and that sexual differentiation is cell-autonomous: male/female donor cells in mixed-sex chimaeras retained their original sex identity and female donor cells in male hosts expressed female markers rather than adopting host male fate. Paper 2 provides supporting molecular evidence of intrinsic, sex-specific chromatin/transcriptional states in chicken somatic cells (female-specific, hypomethylated MHM transcripts adjacent to DMRT1). Papers 3\u20135 are unrelated to avian somatic sex determination. Together, the relevant papers contradict the claim that cell-autonomous somatic sex determination does not occur in Galliformes."
    },
    "overthinking_doc_ids": [
      "4388470",
      "4085204",
      "15803282",
      "238409",
      "1522336"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly contradicts the claim: title and experiments show that somatic sex identity is cell-autonomous in the chicken (a Galliform). The study of gynandromorph chickens and reciprocal presumptive mesoderm transplants produced mixed-sex chimaeras in which donor somatic cells retained their inherent sex identity and were excluded from functional structures of the host gonad; female donor cells in a male host continued to express a female marker. This is direct experimental evidence that somatic cell-autonomous sex determination occurs in at least one Galliform species (chicken). The other provided papers do not address avian somatic sex determination (they concern human/mouse reprogramming, ES cells, quail-genome synteny, or transplant complications) and therefore do not support the claim."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "3360421",
      "3823862"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1266",
    "claim": "The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 (a large population-based cohort of 314,019 parous women with linkage to cancer registries) directly reports a positive association between maternal placental weight and subsequent maternal breast cancer risk. Women with placentas \u2265700 g in both of two consecutive pregnancies had an adjusted hazard ratio of 2.05 (95% CI 1.15\u20133.64), and women with one pregnancy 500\u2013699 g and the other \u2265700 g had HR 1.82 (95% CI 1.07\u20133.08), relative to women with placentas <500 g in both pregnancies. Most incident cases in that cohort (95%) were diagnosed before age 50, i.e. premenopausal, and the authors conclude placental weight is positively associated with maternal breast cancer risk, supporting the idea that pregnancy hormone exposure (a placental function proxy) modifies subsequent maternal breast cancer risk. The other provided papers do not provide conflicting evidence on this specific association. Therefore the evidence in the set supports the claim, with the caveat that the strongest direct evidence comes from the single cohort study cited and that menopausal-specific comparisons are limited because most cases were premenopausal in that cohort."
    },
    "naive_doc_ids": [
      "13831842",
      "9171913",
      "16322674",
      "22401720",
      "37480103"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 directly examines placental weight and maternal breast cancer risk in a large population-based cohort (314,019 women). It reports a positive association between higher placental weight in successive pregnancies and increased maternal breast cancer risk (adjusted HR = 1.82, 95% CI 1.07\u20133.08 for mixed 500\u2013699 g/\u2265700 g; HR = 2.05, 95% CI 1.15\u20133.64 for \u2265700 g in both pregnancies). Most breast cancer cases in that cohort (95%) were diagnosed before age 50, indicating the observed association pertains mainly to premenopausal breast cancer. The other provided papers do not present evidence that contradicts this finding (they address unrelated risk factors such as adult anthropometry, birth size, mammographic density, lipids, or HPV). Therefore the supplied evidence supports the claim that breast cancer risk among parous women increases with placental weight and that this association is strongest for premenopausal breast cancer."
    },
    "overthinking_doc_ids": [
      "13831842",
      "37480103",
      "2140497",
      "9171913",
      "23136735"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 (Pregnancy characteristics and maternal risk of breast cancer) provides direct, prospective evidence that higher placental weight is associated with increased maternal breast cancer risk. In a cohort of 314,019 women, adjusted hazard ratios were increased for women with high placental weights across two pregnancies (e.g., HR = 1.82; 95% CI 1.07\u20133.08 for 500\u2013699 g then \u2265700 g; HR = 2.05; 95% CI 1.15\u20133.64 for \u2265700 g in both pregnancies). Most breast cancers in the cohort (95%) were diagnosed before age 50, indicating the observed association largely concerns premenopausal disease. The other provided papers do not present contrary evidence about placental weight and breast cancer risk. Therefore the supplied evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "13831842",
      "18340282",
      "2015126",
      "16701509",
      "37480103"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "316",
    "claim": "Decreased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly supports the claim: it shows 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the enzyme that converts PGE2 to its inactive/oxidized metabolite (15-keto/15-keto-PGE2), is down-regulated in colorectal cancer, that loss of 15-Pgdh activity blocks production of the urinary PGE2 metabolite, and implies impaired degradation of PGE2 (consistent with tissue PGE2 accumulation). Paper 4 is also relevant: it reports reduced levels of the endogenous PPAR\u03b3 ligand 15\u2011keto\u2011PGE2 in Cftr\u2011deficient mice, consistent with decreased conversion to that ligand; while Paper 4 does not explicitly report PGE2 accumulation, its finding is consistent with the same mechanism. The remaining papers do not address PGE2/15\u2011PGDH/15\u2011keto\u2011PGE2 metabolism. Thus the provided evidence supports the claim, particularly in the cancer context; generalization beyond the studied systems should be made cautiously."
    },
    "naive_doc_ids": [
      "21181273",
      "3285059",
      "5775033",
      "712078",
      "56486733"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly shows that the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) \u2014 the enzyme that converts PGE2 into its inactive/oxidized metabolites (including 15\u2011keto\u2011PGE2) \u2014 is down-regulated in colorectal cancer, and that genetic disruption of 15\u2011Pgdh abolishes production of PGE2 metabolites, implicating impaired conversion and reduced catabolism of PGE2. Paper 7 reports reduced amounts of the endogenous PPAR\u03b3 ligand 15\u2011keto\u2011PGE2 in Cftr\u2011deficient mice, linking decreased formation of 15\u2011keto\u2011PGE2 to impaired PPAR\u03b3 signaling. Together these findings support the causal chain in the claim: decreased conversion of PGE2 to 15\u2011keto\u2011PGE2 (a PPAR\u03b3 ligand) occurs when 15\u2011PGDH is reduced, which is consistent with\u2014and expected to cause\u2014accumulation of PGE2 and reduced levels of the 15\u2011keto ligand. Other provided papers do not contradict this mechanism."
    },
    "overthinking_doc_ids": [
      "21181273",
      "1686997",
      "654735",
      "2192419",
      "3113630"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly shows that 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the enzyme responsible for enzymatic degradation of PGE2 to downstream metabolites, is down-regulated in colorectal cancer, that genetic disruption of 15-Pgdh blocks production of a urinary PGE2 metabolite, and implies loss of 15-PGDH leads to impaired PGE2 catabolism (consistent with PGE2 accumulation). Paper 2 identifies 15-keto-PGE2 (15-ket-PGE2) as an endogenous PPAR\u03b3 ligand and reports reduced amounts of this ligand in a disease model, supporting the link between decreased conversion to 15-ket-PGE2 and lower ligand levels. Together these findings support the claim that decreased conversion of PGE2 to the PPAR\u03b3 ligand 15-ket-PGE2 (e.g., via reduced 15-PGDH) leads to reduced formation of the ligand and impaired PGE2 breakdown, which would cause PGE2 accumulation. (Note: not every paper directly measured tissue PGE2 accumulation, but Paper 1 provides direct metabolic and functional evidence consistent with accumulation.)"
    },
    "posthoc_doc_ids": [
      "21181273",
      "712078",
      "5775033",
      "2714623",
      "8458567"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "524",
    "claim": "Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 4 (Intestinal microbiota metabolism of L-carnitine) reports human data (n = 2,595) showing that plasma L\u2011carnitine predicted increased risk of prevalent CVD and incident major adverse cardiac events only among subjects with concurrently high TMAO levels, i.e., the adverse association of carnitine was present when coupled with elevated TMAO. Paper 2 (meta-analysis) further shows higher circulating TMAO is associated with increased risk of cardiovascular events. The other provided papers do not address carnitine/TMAO and cardiovascular events. Together these findings support the claim that higher plasma carnitine levels, when associated with TMAO, are positively correlated with cardiovascular events in humans."
    },
    "naive_doc_ids": [
      "4445629",
      "6793674",
      "6070278",
      "14803797",
      "2533768"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 directly supports the claim: in a human cohort (n = 2,595) plasma L-carnitine levels predicted both prevalent CVD and incident major adverse cardiac events, but this association was observed only among subjects with concurrently high TMAO levels. Paper 1 (a meta-analysis of 11 prospective cohorts) independently shows higher circulating TMAO is associated with increased risk of cardiovascular events (HR = 1.23, 95% CI 1.07\u20131.42) and mortality (HR = 1.55, 95% CI 1.19\u20132.02). Together these human-data studies indicate that higher plasma carnitine in the presence of elevated TMAO is positively correlated with cardiovascular events. The other provided papers (2, 4, 5) do not address carnitine/TMAO and are not directly relevant."
    },
    "overthinking_doc_ids": [
      "6793674",
      "12130200",
      "14803797",
      "27466734",
      "4647303"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Of the provided papers only Paper 1 directly addresses trimethylamine N-oxide (TMAO) and reports that higher circulating TMAO is associated with increased risk of cardiovascular events (HR 1.23, 95% CI 1.07\u20131.42). However, none of the supplied studies report data on plasma I\u2011carnitine (L\u2011carnitine) levels or the joint/combined association of carnitine together with TMAO and cardiovascular events. Therefore the materials support a link between TMAO and cardiovascular risk but do not provide evidence to verify the specific claim about higher plasma I\u2011carnitine in association with TMAO being positively correlated with cardiovascular events."
    },
    "posthoc_doc_ids": [
      "6793674",
      "4445629",
      "9813098",
      "27466734",
      "12130200"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "899",
    "claim": "Oxidative DNA damage inhibits STING signalling.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly addresses oxidatively damaged DNA (8\u2011OHG) and reports that oxidized DNA potentiates cytosolic immune recognition by resisting TREX1 degradation and enhancing STING-dependent sensing and type I IFN responses. Papers 2 and 3 describe the cGAS\u2013cGAMP\u2013STING pathway and cooperating sensors (background), while the remaining papers discuss ROS/oxidative DNA damage or unrelated signaling pathways but do not provide evidence that oxidative DNA damage inhibits STING. Thus the provided evidence contradicts the claim: oxidized DNA appears to enhance, not inhibit, STING signalling."
    },
    "naive_doc_ids": [
      "13106686",
      "40044800",
      "19688024",
      "24721866",
      "41913714"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Two papers directly address oxidized DNA and STING signalling and report that oxidative DNA damage enhances, rather than inhibits, STING-dependent responses. Paper 3 shows that the oxidized base 8\u2011OHG makes cytosolic DNA resistant to TREX1 degradation and potentiates STING-dependent immune sensing. Paper 2 reports that oxidized mitochondrial DNA released in NETs is proinflammatory and stimulates type I IFN signaling via a STING-dependent pathway. Paper 1 and Paper 6 describe components of the cGAS\u2013STING DNA sensing pathway but do not provide evidence that oxidative DNA damage inhibits STING. Papers 4 and 5 are unrelated to STING signalling. Taken together, the provided evidence contradicts the claim that oxidative DNA damage inhibits STING signalling."
    },
    "overthinking_doc_ids": [
      "19688024",
      "1049501",
      "13106686",
      "18358026",
      "22059387"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly addresses oxidatively damaged DNA (8\u2011hydroxyguanosine) and reports that oxidized DNA potentiates cytosolic immune recognition by resisting TREX1 degradation and promoting STING-dependent immune sensing and type I IFN responses. This indicates oxidative DNA damage enhances \u2014 rather than inhibits \u2014 STING signalling. The other papers either discuss oxidative stress or DNA damage in different contexts (epigenetic silencing, repair, ROS in cancer/leukemia, signaling pathways, or cytokine regulation) but do not provide evidence that oxidative DNA damage inhibits STING. Therefore the provided evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "13106686",
      "18358026",
      "19688024",
      "14496749",
      "5765455"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "448",
    "claim": "Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct human prospective evidence linking prior H. pylori infection to increased gastric cancer risk (cases had higher seropositivity; estimated OR 2.77, 95% CI 1.04\u20137.97). Paper 4 further supports a human association by showing vacA i1 (a more virulent H. pylori allele) is strongly associated with precancerous intestinal metaplasia in gastric biopsy specimens. Additional papers (5 and 6) provide mechanistic/animal-model support (H. pylori\u2013driven preneoplasia, immunologic tolerance effects, and infection-induced gastric mutations), reinforcing biological plausibility. Together the evidence in these papers supports the claim that H. pylori gastric infection increases risk of gastric cancer in humans."
    },
    "naive_doc_ids": [
      "2052720",
      "6793674",
      "17450673",
      "17464771",
      "39550665"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 provides direct prospective human data showing prior H. pylori infection was associated with an increased risk of subsequent gastric cancer (OR 2.77, 95% CI 1.04\u20137.97, p=0.039). Paper 4 (structural study) explicitly states that H. pylori infection causes gastritis, gastric ulcers and an increased incidence of gastric adenocarcinoma, supporting the link. Paper 1 also considered H. pylori status in subgroup analyses of genetic susceptibility to gastric cancer. Papers 3 and 5 are unrelated to this claim. Taken together the provided evidence supports the claim that gastric infection with H. pylori increases human gastric cancer risk."
    },
    "overthinking_doc_ids": [
      "14729253",
      "2052720",
      "12145359",
      "4387784",
      "12009265"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct prospective human epidemiologic evidence that prior H. pylori infection is associated with increased gastric cancer risk (OR = 2.77, 95% CI 1.04\u20137.97, p=0.039). Paper 7 provides biological/mechanistic support showing that cagPAI-positive H. pylori induces aberrant AID expression in gastric epithelium and promotes accumulation of TP53 mutations, a plausible mechanism for H. pylori\u2013driven gastric carcinogenesis. Other provided papers are not directly relevant. Together the epidemiologic association and mechanistic data support the claim that H. pylori infection increases risk of gastric cancer in humans."
    },
    "posthoc_doc_ids": [
      "2052720",
      "14729253",
      "31229233",
      "2425364",
      "1831916"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1345",
    "claim": "Up-regulation of the p53 pathway and related molecular events speeds cancer progression.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the nine provided papers present data or discussion showing that up-regulation of the p53 pathway (or p53 activation) speeds cancer progression. The studies focus on other pathways and factors (PI3K/PTEN, Wnt/BCL9, Src/integrin \u03b1v\u03b23, STAT3, microenvironmental IL\u20116, circadian clock effects, etc.) and report that up\u2011regulation/activation of those pathways promotes tumor growth, invasion, metastasis, or angiogenesis. Because the evidence set does not address p53 pathway up\u2011regulation specifically, it neither supports nor directly contradicts the claim."
    },
    "naive_doc_ids": [
      "2130391",
      "13329980",
      "15113221",
      "33638477",
      "1782201"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.6,
      "justification": "Paper 6 provides direct experimental evidence that tumor-derived (mutant) p53 can acquire a gain-of-function transcriptional activity that promotes tumorigenicity: mutant p53-281G transactivates proliferation-related promoters (EGFR, MDR-1, PCNA) and cells expressing intact mutant p53 are highly tumorigenic in nude mice, whereas deletion of C-terminal domains required for this activity abolishes tumor formation. This shows that up-regulated/active mutant p53 signaling can accelerate cancer progression. The other papers (1\u20135) do not address p53. Caveat: the evidence supports pro\u2011tumor effects of mutant (gain\u2011of\u2011function) p53 activity, not up\u2011regulation of wild\u2011type p53 (which is classically tumor\u2011suppressive), so the support is specific to mutant p53 contexts."
    },
    "overthinking_doc_ids": [
      "1782201",
      "20568364",
      "33638477",
      "7795952",
      "6923961"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.65,
      "justification": "Paper 7 provides direct experimental evidence that tumor-derived (mutant) p53 can acquire a gain-of-function that transcriptionally activates proliferation-related genes (EGFR, MDR1, PCNA) and increases tumorigenicity in vivo; deletion of C\u2011terminal domains abrogates this oncogenic activity. This shows that increased/altered p53 activity (specifically mutant p53 gain-of-function) can accelerate cancer progression. The other papers do not provide direct evidence that up\u2011regulation of wild\u2011type p53 speeds progression; Paper 4 even describes senescence-associated programs (p21/p15) that are tumor\u2011suppressive. Therefore, the provided evidence supports the claim only in the specific context of mutant/gain\u2011of\u2011function p53 rather than general up\u2011regulation of the wild\u2011type p53 pathway."
    },
    "posthoc_doc_ids": [
      "1976183",
      "12650610",
      "33638477",
      "17412260",
      "1782201"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1351",
    "claim": "Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.7,
      "justification": "Paper 1 directly addresses dynein\u2019s role in Drosophila neurons: loss of dynein disrupts uniform axonal microtubule polarity so that axons contain both plus- and minus-end distal microtubules. In wild-type neurons dynein is required to maintain the normal plus-end\u2013distal orientation of axonal microtubules (i.e., plus ends point away from the cell body). This evidence argues against the claim that increasing dynein would increase the number of microtubule plus-ends growing toward the cell body. None of the other papers provide data showing dynein upregulation increases soma-directed plus-end growth (other papers address microtubule anchoring, severing, or MAP identification but not dynein overexpression or soma-directed plus-end counts). Therefore the provided literature does not support the claim and, based on Paper 1, suggests the opposite relationship."
    },
    "naive_doc_ids": [
      "28369117",
      "18126445",
      "36111909",
      "1241113",
      "8087082"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers directly show that upregulation (overexpression) of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body. Paper 2 (Dynein is required for polarized dendritic transport and uniform microtubule orientation in axons) demonstrates that loss of dynein disrupts microtubule polarity (axon microtubules become mixed in polarity) and that dynein is required for proper polarized transport and microtubule organization. This indicates dynein is important for establishing/maintaining microtubule orientation, but it is loss-of-function evidence and does not report that increasing dynein levels drives more plus-end growth toward the soma. Papers 3 and 4 describe dynein\u2019s microtubule-binding and mechanistic properties (biochemistry/structural), paper 1 addresses EB1-labeled plus ends in the context of katanin, and papers 5 and 6 are unrelated. Therefore the set lacks experimental data on dynein upregulation and its effect on the number or directionality of growing plus ends toward the cell body."
    },
    "overthinking_doc_ids": [
      "36111909",
      "28369117",
      "1546650",
      "7925817",
      "7165938"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.6,
      "justification": "None of the provided papers directly test or report effects of dynein upregulation on the directionality of polymerizing microtubule plus-ends in Drosophila neurons. Paper 4 shows that dynein is required to establish/maintain proper microtubule polarity (loss of dynein produces mixed plus- and minus-end orientations in axons), which indicates dynein influences microtubule orientation, but it is a loss-of-function result and does not demonstrate that increasing dynein levels increases the number of plus-ends growing toward the cell body. Paper 1 uses EB1-GFP to report polymerizing microtubules in dendrites but addresses katanin, not dynein. The other papers are unrelated to dynein regulation in Drosophila neurons. Therefore there is not sufficient direct experimental evidence in the provided set to confirm or refute the specific claim about dynein upregulation increasing plus-ends growing toward the soma."
    },
    "posthoc_doc_ids": [
      "36111909",
      "12800122",
      "18126445",
      "28369117",
      "1889358"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.08,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "386",
    "claim": "Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (ethnographic study of IV drug errors) directly reports that \"most errors occurred when giving bolus doses or making up drugs that required multiple step preparation,\" which matches the claim. The other provided papers do not present contradictory evidence relevant to peripheral IV administration stages (Paper 3 addresses observation methodology but not error distribution by stage), so the available evidence supports the claim."
    },
    "naive_doc_ids": [
      "16495649",
      "8570317",
      "21260231",
      "43226130",
      "118568"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 (a prospective ethnographic study of IV drug errors) directly reports that most errors occurred when giving bolus doses or when making up drugs that required multiple-step preparation (249 errors identified; at least one error in 212/430 IV doses). Papers 2\u20134 do not provide relevant information on stages of IV drug administration (Paper 2 addresses observational methods reliability; Papers 3 and 4 are unrelated topics). Therefore the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "16495649",
      "21260231",
      "79231308",
      "18111172"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 (ethnographic study of intravenous drug errors) directly reports that most errors occurred when giving bolus doses or when making up drugs that required multiple-step preparation, which matches the claim. Paper 1 (on observational methods for medication administration errors) does not contradict this and supports the reliability of observational detection of MAEs. The other included papers do not address IV administration errors. Therefore the provided evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "21260231",
      "16495649",
      "79231308",
      "12471115",
      "118568"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1193",
    "claim": "The appearance of brown-like or beige cells primarily occurs in visceral fat, not subcutaneous fat.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers directly support or refute the specific claim that brown-like (beige/brite) cells appear primarily in visceral fat rather than subcutaneous fat. Paper 1 reviews browning of white adipose in general but does not specify depot predominance. Paper 3 examines depot-specific plasticity and defines a 'brite' signature after cold exposure, but the excerpt does not state which white depot (visceral vs subcutaneous) shows greater browning. Paper 4 shows visceral adipose has higher mitochondrial content and respiration than subcutaneous fat, which is suggestive of greater bioenergetic activity but does not measure canonical browning markers (e.g., UCP1, beige-specific genes) to demonstrate beige cell appearance. Papers 2, 5, and 6 do not provide direct evidence about depot-specific appearance of beige cells. Therefore the evidence is insufficient to confirm or contradict the claim."
    },
    "naive_doc_ids": [
      "14865329",
      "3621011",
      "29381091",
      "39187170",
      "79447"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.75,
      "justification": "None of the provided papers directly test or report that brown-like (beige) adipocytes appear primarily in visceral fat rather than subcutaneous fat. Paper 1 focuses on epigenetic programming of progenitors in epididymal (visceral) fat and their adipogenic capacity but does not assess browning/beige markers. Paper 2 reports improved visceral (eWAT) expansion with Tnmd and notes increased Ucp1 in classical brown fat in transgenic mice, but does not demonstrate depot-specific induction of beige cells in visceral versus subcutaneous WAT. Paper 3 shows higher mitochondrial content and respiration in human visceral versus subcutaneous adipose tissue, which is compatible with a more oxidative phenotype but does not measure brown/beige-specific markers (e.g., UCP1, Prdm16) or identify beige adipocytes. Paper 4 is a review of adipocyte progenitors and recruitment of white, brown, and beige adipocytes but the provided summary does not state that beigeing occurs primarily in visceral depots. Paper 5 addresses circadian gene expression in subcutaneous ASCs and does not bear on depot differences in browning. Therefore the evidence set does not confirm or refute the specific claim about primary occurrence of beige/brown cells in visceral versus subcutaneous fat."
    },
    "overthinking_doc_ids": [
      "13944805",
      "3621011",
      "39187170",
      "4854076",
      "33634749"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.75,
      "justification": "None of the provided papers directly demonstrates that brown-like (brite/beige) adipocytes appear primarily in visceral rather than subcutaneous fat. Paper 1 documents human brite/beige adipocytes and their metabolic effects but does not report a depot-specific predominance. Paper 2 shows higher mitochondrial content and greater coupled and uncoupled respiration per mg tissue in visceral versus subcutaneous fat, which is an indirect measure that could be consistent with greater bioenergetic activity in visceral fat, but it does not measure UCP1 or other definitive beige/brown markers or identify brown-like cells at the cellular level. Paper 7 examines white-to-brown transitions with cold exposure (in mice) and defines a brite transcriptional signature, but the summary does not state that browning occurs primarily in visceral depots (and much literature indicates subcutaneous depots are more prone to browning in rodents). The other papers characterize depot-specific inflammation, signaling, and adipogenesis (mostly in visceral fat) but do not address depot distributions of beige adipocytes. Therefore the evidence here is insufficient to support or to refute the specific claim about primary occurrence of beige cells in visceral versus subcutaneous fat."
    },
    "posthoc_doc_ids": [
      "17973161",
      "39187170",
      "79447",
      "31564409",
      "3621011"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "71",
    "claim": "Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 directly links SRGP-1 to regulation of the Rac1 homolog CED-10: SRGP-1 functions as a GAP for CED-10, and loss of srgp-1 (which would increase CED-10 activity) enhances engulfment. The paper shows that loss of srgp-1 promotes not only clearance of dead cells but also removal of cells that have been pushed to the verge of death by sublethal apoptotic, necrotic or cytotoxic insults; conversely, impaired engulfment allows such damaged cells to survive long-term. Thus the data support that increased CED-10 activity in srgp-1 mutants can lead to killing/removal of cells that would otherwise have survived. The other provided papers do not bear on this mechanism. Note: the primary paper describes removal of injured/near-death cells rather than killing of fully healthy, uncompromised cells, so the support applies mainly to removal of compromised/near-death cells in the srgp-1 mutant context."
    },
    "naive_doc_ids": [
      "1127562",
      "5002665",
      "1196631",
      "7036529",
      "35684881"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses SRGP-1 and CED-10 (the C. elegans Rac1 homolog). SRGP-1 is reported to act as a GAP for CED-10, and loss of srgp-1 (which would increase CED-10 activity) promotes engulfment-mediated removal not only of already dead cells but also of cells \"brought to the verge of death\" by sublethal insults. The authors further note that impaired engulfment allows damaged cells to survive long-term, consistent with the idea that enhanced CED-10\u2013dependent engulfment in srgp-1 mutants can eliminate cells that might otherwise have remained viable. The other listed papers do not provide relevant data on SRGP-1, CED-10, or this engulfment-driven killing. Therefore the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "1127562",
      "2686003",
      "7036529",
      "9550981",
      "43419566"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Only Paper 1 is directly relevant: it shows SRGP-1 is a GAP for CED-10 (Rac1) and that loss of srgp-1 (which would increase CED-10 activity) promotes engulfment and removal of dead or sublethally injured cells. The abstract states loss of srgp-1 causes clearance of cells brought to the verge of death by insults, but does not provide evidence that activation of CED-10 kills otherwise viable, healthy cells. The other provided papers are unrelated. Thus the supplied evidence does not confirm the specific claim that CED-10 activation kills viable cells in srgp-1 mutants."
    },
    "posthoc_doc_ids": [
      "1127562",
      "7036529",
      "7042304",
      "10648422",
      "34436231"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "940",
    "claim": "Pharmacist attendance at ward rounds increases adverse events in wards.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses pharmacist participation on rounds and reports a 66% reduction in preventable ordering-related adverse drug events (from 10.4 to 3.5 per 1000 patient-days; P<.001) in the ICU study unit versus no change in the control unit; pharmacists made many recommendations and 99% were accepted. The other papers are unrelated to pharmacist ward-round attendance. Thus the available evidence contradicts the claim that pharmacist attendance increases adverse events. (Note: Paper 1 is a before\u2013after study in a single ICU setting, which limits generalizability.)"
    },
    "naive_doc_ids": [
      "12258338",
      "14724693",
      "32423829",
      "39059143",
      "26611094"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 directly addresses pharmacist participation on rounds and reports a substantial REDUCTION in preventable adverse drug events (ADEs): preventable ordering ADEs fell from 10.4 to 3.5 per 1000 patient\u2011days (a 66% decrease; P<.001) after a senior pharmacist joined ICU rounds, while a control unit showed no change. Pharmacist interventions were almost always accepted (362/366, 99%). The other provided papers do not evaluate pharmacist ward\u2011round attendance and are not relevant to the claim. Therefore the available evidence contradicts the claim that pharmacist attendance at rounds increases adverse events; instead it shows decreased ADEs."
    },
    "overthinking_doc_ids": [
      "11254040",
      "5402581",
      "202259",
      "12258338",
      "39059143"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses pharmacist participation on rounds and reports a large reduction in preventable adverse drug events (ADEs): preventable ordering ADEs fell 66% (from 10.4 to 3.5 per 1000 patient\u2011days, P<.001) after a senior pharmacist joined ICU rounds, while a concurrent control unit showed no change; 99% of pharmacist recommendations were accepted. The other papers do not address pharmacist attendance on ward rounds. Therefore the provided evidence contradicts the claim that pharmacist attendance increases adverse events. (Limitation: the direct evidence is from a single ICU study of prescribing\u2011related ADEs, so generalizability to all ward settings may be limited.)"
    },
    "posthoc_doc_ids": [
      "12258338",
      "5402581",
      "1711571",
      "3578380",
      "32353339"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1027",
    "claim": "Reduced phosphorylation of PP2A suppresses HDAC4 dephosphorylation.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses the relationship: it reports that ATM-mediated phosphorylation downregulates PP2A activity, and that in ATM deficiency (i.e. reduced PP2A phosphorylation) PP2A activity is enhanced, leading to increased HDAC4 dephosphorylation and nuclear accumulation. Thus reduced phosphorylation of PP2A is associated with increased \u2014 not suppressed \u2014 HDAC4 dephosphorylation. Other provided papers do not support the opposite view."
    },
    "naive_doc_ids": [
      "3113630",
      "22185730",
      "6157371",
      "30379039",
      "25515662"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly addresses the regulatory relationship: ATM-mediated phosphorylation downregulates PP2A activity, whereas ATM deficiency (i.e., reduced PP2A phosphorylation) enhances PP2A activity, which leads to HDAC4 dephosphorylation and nuclear accumulation. Thus reduced phosphorylation of PP2A promotes HDAC4 dephosphorylation, the opposite of the claim. Other papers do not provide contrary evidence relevant to PP2A phosphorylation and HDAC4."
    },
    "overthinking_doc_ids": [
      "22185730",
      "3113630",
      "8417211",
      "207972",
      "4270992"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly addresses the relationship between PP2A phosphorylation and HDAC4 dephosphorylation. It reports that ATM-mediated phosphorylation downregulates PP2A activity; conversely, in ATM deficiency (reduced PP2A phosphorylation) PP2A activity is enhanced, leading to increased HDAC4 dephosphorylation and nuclear accumulation of HDAC4. This evidence indicates that reduced phosphorylation of PP2A promotes \u2014 not suppresses \u2014 HDAC4 dephosphorylation, which contradicts the claim. None of the other provided papers support the claim."
    },
    "posthoc_doc_ids": [
      "22185730",
      "3113630",
      "8417211",
      "164189",
      "19966976"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "887",
    "claim": "Only a minority of cells survive development after differentiation into stress-resistant spores.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "The provided papers do not present direct evidence for the quantitative claim that \u201conly a minority of cells survive development after differentiation into stress-resistant spores.\u201d Paper 7 and Paper 8 concern Bacillus subtilis sporulation and stress responses: Paper 7 identifies many genes required for sporulation and characterizes mutants with delays or defects in spore formation, but its summary does not report population-level survival fractions or state that only a minority survive. Paper 9 discusses differentiation and division of labor in B. subtilis during sliding motility (not spore formation). The other papers address oxidative stress, apoptosis, autophagy, Notch signaling, or stem cell biology in eukaryotes and do not provide data on spore differentiation survival rates. Thus there is no direct supporting or contradicting quantitative evidence in the set to evaluate the claim."
    },
    "naive_doc_ids": [
      "7875158",
      "14863011",
      "14972169",
      "33667484",
      "15728433"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.6,
      "justification": "Two papers in the set describe developmental programs in which only a subset of cells become stress-resistant spores while other cells die or sacrifice themselves. Paper 1 (Dictyostelium discoideum) explicitly describes altruistic cell death to form a stalk while the remaining cells become reproductive spores, and discusses pleiotropic links that limit cheating by cells that would avoid the dying prestalk fate. Paper 6 (Bacillus subtilis) treats sporulation as a differentiation pathway to a dormant spore and analyzes genes required for different stages of spore development; in Bacillus sporulation the mother cell ultimately lyses to release the mature, stress-resistant forespore. These findings support the claim that only a subset of cells survive development as stress-resistant spores. However, none of the provided papers give precise quantitative fractions across systems, so the evidence supports the qualitative statement but does not supply exact numbers to confirm the word \u201conly\u201d or the magnitude implied by \u201cminority.\u201d Papers 2\u20135,7\u20138 do not provide relevant data for this claim."
    },
    "overthinking_doc_ids": [
      "2140513",
      "18374364",
      "18924534",
      "25985964",
      "106301"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers present quantitative or qualitative evidence addressing the claim that only a minority of cells survive development after differentiation into stress-resistant spores. Papers 7 and 8 discuss Bacillus subtilis sporulation and differentiation (Paper 7: identification of new sporulation genes and roles in spore maturation; Paper 8: division of labor during colony migration), but they do not report the fraction of cells that survive development or whether only a minority become viable stress-resistant spores. The other papers concern unrelated differentiation or survival topics (neural crest stem cells, T cell activation, oxidative stress in cancer cells, microglial development, \u03b21 integrin in drug resistance, trophoblast giant cell differentiation) and do not provide information about spore formation or survival fractions. Therefore the evidence set does not support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "5085118",
      "6936141",
      "7875158",
      "17991818",
      "4820792"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "2",
    "claim": "1 in 5 million in UK have abnormal PrP positivity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 reports 16 positive appendix samples out of 32,441 tested, giving a prevalence of 493 per million (95% CI 282\u2013801 per million), i.e. about 1 in 2,000. The claim '1 in 5 million' equals 0.2 per million, which is orders of magnitude lower than the observed ~493 per million. None of the other provided papers give supporting prevalence data for abnormal PrP in the UK. Therefore the evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "13734012",
      "27063470",
      "1583041",
      "756887",
      "13934676"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly measured abnormal PrP in 32,441 archived UK appendix samples and found 16 positives, an overall prevalence of 493 per million (95% CI 282\u2013801 per million). That corresponds to roughly 1 in 2,030 people, which is orders of magnitude higher than the claim of 1 in 5,000,000 (0.2 per million). The other provided papers do not supply UK population prevalence data for abnormal PrP (Paper 6 is an experimental mouse study; Papers 2\u20135 are unrelated epidemiologic/public\u2011health topics). Therefore the evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "13734012",
      "13934676",
      "75636923",
      "13900610",
      "7373120"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 2 directly measured abnormal prion protein (PrP) in archived appendix samples from the UK (n = 32,441) and found 16 positives, giving an estimated prevalence of 493 per million (95% CI 282\u2013801 per million). That corresponds roughly to 1 in 2,000 people, not 1 in 5,000,000 (0.2 per million). None of the other provided papers report UK PrP prevalence. Therefore the evidence contradicts the claim that only 1 in 5 million in the UK have abnormal PrP positivity."
    },
    "posthoc_doc_ids": [
      "32481310",
      "13734012",
      "1606628",
      "2138767",
      "5824985"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "223",
    "claim": "Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 directly demonstrates that oncogenic mTOR signaling in cancer cells drives intratumoural accumulation of MDSCs by upregulating G-CSF production: inhibiting mTOR (or its activators) reduces MDSCs and tumour progression, which can be partially rescued by restoring MDSCs or G-CSF, and tumour-initiating cells show elevated G-CSF. Other provided papers discuss MDSC accumulation or modulation (e.g., Paper 1 shows NLRP3 is required for tumour MDSC accumulation, Paper 5 shows therapies can reduce MDSCs) but do not refute the mechanism involving cancer-cell\u2013derived G-CSF. Therefore the evidence supports the claim."
    },
    "naive_doc_ids": [
      "15435343",
      "2014909",
      "2030623",
      "22049489",
      "9767444"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 provides direct experimental evidence that cancer cells (via oncogenic mTOR signaling) drive intra-tumoural accumulation of MDSCs by upregulating G-CSF: mTOR activity in tumour cells regulates G-CSF, inhibition of this pathway reduces MDSCs and tumour progression, and restoration of G-CSF or MDSCs rescues the phenotype. Papers 1 and 2 further support the general concept that tumour-derived signals regulate tumour-associated MDSC accumulation (NLRP3 and IL-17 effects respectively), while Paper 3 discusses GM-CSF in dendritic cell culture (not G-CSF) and is not directly relevant. Together the evidence supports the claim that cancer cells can stimulate intra-tumoural MDSC accumulation by promoting G-CSF production."
    },
    "overthinking_doc_ids": [
      "15435343",
      "25726838",
      "188911",
      "2014909"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that signalling in cancer cells (oncogenic mTOR) controls a tumour's ability to recruit intratumoural MDSCs by regulating G-CSF production: inhibiting the pathway reduces MDSC accumulation and tumour progression, which can be partially rescued by restoring MDSCs or G-CSF; tumour\u2011initiating cells show elevated G-CSF. This provides direct experimental evidence that cancer cells can promote G-CSF production to drive intratumoural MDSC accumulation. Papers 3 and 5 provide additional, supportive context linking cytokine-driven G-CSF to increased myeloid/granulocytic responses and MDSC accumulation (IL-17 promotes MDSCs; IL-17\u2013mediated granulopoiesis requires G-CSF), reinforcing the biological plausibility of the pathway. Other listed papers do not contradict this mechanism."
    },
    "posthoc_doc_ids": [
      "2014909",
      "15435343",
      "25726838",
      "188911",
      "24612804"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "935",
    "claim": "Peroxynitrite is required for induction of T cell tolerance.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 4 provides direct experimental evidence that peroxynitrite produced by myeloid-derived suppressor cells (MDSCs) nitrates tyrosines in the TCR\u2013CD8 complex, preventing pMHC binding and rendering antigen-specific CD8+ T cells tolerant. This identifies peroxynitrite-mediated nitration as a mechanistic requirement for this form of T cell tolerance in the tumor/MDSC context. Supporting, indirect evidence comes from Paper 8 (iNOS/NO-dependent downregulation of T cell responses) and Paper 7 (NOS2 expression in human macrophages), which together indicate that reactive nitrogen species pathways can mediate T-cell suppression. Most other listed papers do not address peroxynitrite or related chemistry. Note: the evidence is context-specific (MDSC/tumor-induced CD8+ tolerance) rather than a universal statement for all forms of T cell tolerance."
    },
    "naive_doc_ids": [
      "3730196",
      "10169908",
      "24069089",
      "5483793",
      "1196631"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 provides direct experimental evidence linking peroxynitrite to induction of CD8+ T cell tolerance: myeloid-derived suppressor cells (MDSCs) hyperproduce reactive oxygen species and peroxynitrite during cell\u2013cell contact, causing nitration of tyrosines in the TCR\u2013CD8 complex, which prevents pMHC binding and renders antigen-specific CD8+ T cells tolerant. The other papers do not present relevant evidence that refutes or further addresses peroxynitrite\u2019s role in T cell tolerance (they focus on B cell tolerance, NADPH oxidase/ROS in other contexts, transcriptional regulators of T cell homeostasis, etc.), so the available evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "5483793",
      "37182501",
      "1744097",
      "1800734",
      "5484763"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 provides direct experimental evidence that myeloid-derived suppressor cells (MDSCs) hyperproduce reactive oxygen species and peroxynitrite during cell-cell contact, leading to nitration of tyrosine residues in the TCR\u2013CD8 complex. This nitration disrupts pMHC binding and renders antigen-specific CD8+ T cells unable to respond to their cognate peptide, i.e., induces antigen-specific T cell tolerance. None of the other provided papers present evidence that contradicts this mechanism (most are on unrelated topics or other MDSC functions). Note: the supporting evidence is specific to MDSC-mediated, antigen-specific CD8+ T-cell tolerance in cancer; the papers do not establish that peroxynitrite is universally required for all forms of T cell tolerance."
    },
    "posthoc_doc_ids": [
      "5483793",
      "37182501",
      "1744097",
      "3848469",
      "7399084"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "57",
    "claim": "APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 directly tests APOE4 in human iPSC-derived neurons and shows that APOE4 increases amyloid-\u03b2 (A\u03b2) production (in human neurons) and increases tau phosphorylation. However, these APOE4-expressing neurons displayed GABAergic neuron degeneration rather than a delay of degeneration. Converting APOE4 to APOE3 rescued the phenotypes, and a small-molecule structure corrector ameliorated the toxic effects, supporting that APOE4 exerts a gain-of-toxic-function. The other papers provided are background on iPSC properties or differentiation and do not support the claim that APOE4 delays GABA neuron degeneration. Therefore the evidence contradicts the claim\u2019s assertion about delayed GABA neuron degeneration, while supporting the increased A\u03b2 and tau phosphorylation components."
    },
    "naive_doc_ids": [
      "27588420",
      "10641715",
      "2853685",
      "36637129",
      "28386343"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (iPSC-derived human neurons) directly tests APOE4 effects: it reports that ApoE4-expressing neurons have increased A\u03b2 production (in human neurons) and higher levels of tau phosphorylation, but these ApoE4 neurons displayed GABAergic neuron degeneration rather than delayed degeneration. Paper 2 further supports APOE4's relationship to A\u03b2 pathology. No provided evidence supports the claim that APOE4 expression delays GABA neuron degeneration; on the contrary, Paper 1 shows it promotes GABAergic neuron degeneration. Therefore the claim is partly supported for A\u03b2 and tau effects but contradicted for the asserted delay in GABA neuron degeneration, so the overall claim is contradicted by the supplied evidence."
    },
    "overthinking_doc_ids": [
      "4709641",
      "20937018",
      "27588420",
      "11659421",
      "9197786"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (Gain of toxic Apolipoprotein E4 effects in Human iPSC-Derived Neurons ...) directly addresses APOE4 in human iPSC-derived neurons: it reports that ApoE4 increases amyloid-\u03b2 (A\u03b2) production (in human neurons) and that ApoE4-expressing neurons have higher levels of tau phosphorylation. However, the paper also reports GABAergic neuron degeneration in ApoE4-expressing cultures \u2014 i.e., APOE4 promotes, not delays, GABA neuron degeneration. The other listed papers do not provide contradictory data relevant to APOE4 effects in human iPSC neurons. Therefore the evidence supports the A\u03b2 and tau phosphorylation parts of the claim but directly contradicts the assertion that APOE4 delays GABA neuron degeneration, so the overall claim is contradicted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "4709641",
      "45336190",
      "3085264",
      "22401720",
      "11659421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "54",
    "claim": "AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers overall indicate that AMPK activation reduces inflammatory signaling and fibrosis rather than increasing it. Paper 4 directly shows that pharmacological activation of AMPK (metformin) accelerates resolution and reverses established bleomycin-induced lung fibrosis in an AMPK-dependent manner and that AMPK activity is low in fibrotic lung regions. Paper 1 reports that AMPK activation phosphorylates JAK1 and suppresses JAK\u2013STAT inflammatory signaling (including reduced STAT3 phosphorylation), indicating anti-inflammatory effects. Paper 3 shows AMPK activation (AICAR) suppresses oxidized LDL\u2013induced macrophage proliferation via cell-cycle arrest, which would be expected to reduce profibrotic macrophage expansion. Papers 2, 5, and 6 describe mechanisms of lung fibrosis and macrophage/fibroblast roles but do not support AMPK promoting inflammation\u2011related lung fibrosis. Taken together, the evidence contradicts the claim that AMPK activation increases inflammation-related lung fibrosis."
    },
    "naive_doc_ids": [
      "3973445",
      "22621251",
      "24721866",
      "49556906",
      "11200685"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple papers show that AMPK activation reduces inflammation and fibrotic responses rather than increasing inflammation-related lung fibrosis. Paper 4 (Metformin reverses established lung fibrosis) directly demonstrates that AMPK activity is reduced in fibrotic regions of human IPF and that pharmacologic AMPK activation (metformin) decreases myofibroblast fibrotic activity and accelerates resolution of established lung fibrosis in a bleomycin mouse model in an AMPK-dependent manner. Paper 1 shows AMPK suppresses inflammatory JAK\u2013STAT signaling, and Paper 2 shows AMPK activation suppresses macrophage proliferation\u2014both indicate anti-inflammatory effects. Review evidence in Paper 7 similarly describes anti-inflammatory actions of AMPK. Other papers (5,6,3,8) do not provide evidence supporting the claim. Overall, the provided evidence contradicts the claim that AMPK activation increases inflammation-related lung fibrosis."
    },
    "overthinking_doc_ids": [
      "3973445",
      "24721866",
      "4662264",
      "49556906",
      "25175997"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "The provided papers do not support the claim that AMPK activation increases inflammation-related lung fibrosis; they indicate the opposite. Paper 7 directly shows that AMPK activity is reduced in fibrotic lung regions in human IPF and in a bleomycin mouse model, and that pharmacologic AMPK activation (metformin) reverses established lung fibrosis by deactivating myofibroblasts, enhancing mitochondrial biogenesis, and restoring apoptosis sensitivity. Paper 4 shows AMPK suppresses inflammatory JAK\u2013STAT signaling via phosphorylation of JAK1, consistent with anti\u2011inflammatory effects. No paper here presents data that AMPK activation promotes pulmonary inflammation-driven fibrosis. Therefore the evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "1800734",
      "3984231",
      "10703001",
      "3973445",
      "5172048"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1347",
    "claim": "Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present experimental data or results showing that influenza-specific memory CD4+ T cells reduce early inflammatory chemokine production in the lung upon viral challenge. Paper 1 addresses CD4+ T cell help in generating CD103+ lung-resident CD8+ T cells and IFN-\u03b3-dependent effects on Trm development, but does not report suppression of early chemokine production. Paper 2 focuses on lung dendritic cell imprinting of T cell lung homing via CCR4. Paper 3 examines CCR7-dependent egress of CD8 effector T cells from infected lungs. Paper 4 describes a macrophage-derived chemokine network that sustains CD4 TRM in mucosa (i.e., chemokines maintaining CD4 TRM rather than CD4 TRM suppressing chemokine production). Paper 5 characterizes distinct memory CD4+ subsets (Tfh vs Th1) and their lineage commitment. None of these directly test or report that influenza-specific memory CD4+ T cells greatly diminish early inflammatory chemokine production in the lung, so the claim cannot be confirmed or refuted from the provided evidence."
    },
    "naive_doc_ids": [
      "3835423",
      "2248870",
      "12100963",
      "12966719",
      "24879055"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 4 directly contradicts the claim: it reports that influenza-specific memory CD4+ T cells enhance (not diminish) the early production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung during influenza infection, and that this memory CD4+ T cell\u2013induced IIC response contributes to early viral control. Papers 1\u20133 discuss T cell egress, CD4 help for CD8 Trm formation, and lung-homing imprinting, but do not provide evidence that memory CD4+ T cells reduce early inflammatory chemokine production. Therefore the provided evidence opposes the claim."
    },
    "overthinking_doc_ids": [
      "12100963",
      "3835423",
      "2248870",
      "19005293"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 4 directly contradicts the claim: it reports that memory (influenza-specific) CD4+ T cells enhance, not diminish, early production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung during influenza infection and that this IIC induction contributes to early viral control. The other papers do not provide evidence that influenza-specific memory CD4+ T cells reduce early lung chemokine production \u2014 papers 1\u20133 address T cell help, tissue residency, trafficking, and paper 5\u20136 concern regulatory T cells in non-influenza contexts. While regulatory CD4+ T cells can suppress inflammation in other settings, the provided experimental evidence regarding influenza-specific memory CD4+ T cells supports increased early inflammatory chemokine/cytokine production, so the claim is refuted by the cited literature."
    },
    "posthoc_doc_ids": [
      "3835423",
      "12100963",
      "2248870",
      "19005293",
      "30908508"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "606",
    "claim": "Increased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers indicate the opposite relationship. Paper 4 shows that 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzymatically converts PGE2 to 15-keto-PGE2 (the 15-keto metabolite) and that loss or down-regulation of 15-PGDH is associated with increased tissue PGE2 levels in cancers \u2014 i.e., decreased conversion leads to PGE2 accumulation. Paper 2 identifies 15-keto-PGE2 as an endogenous PPAR\u03b3 ligand and reports reduced levels of 15-keto-PGE2 in Cftr-deficient mice, consistent with the metabolite being produced from PGE2. Together these sources support that conversion of PGE2 to 15-keto-PGE2 is a degradative pathway for PGE2, so increased conversion would be expected to lower, not cause accumulation of, PGE2. None of the other papers provide evidence that increased conversion to 15-keto-PGE2 causes PGE2 accumulation."
    },
    "naive_doc_ids": [
      "56486733",
      "712078",
      "13639330",
      "21181273",
      "23863551"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the eight provided papers discuss prostaglandins, PGE2, 15-ket-PGE2, or PPAR\u03b3 ligand conversion. The summaries address Sirt1, Bmal1, IL-18, HER3/PI3K feedback, KRAS, LSD1/MYC, HuR/Bcl-2, and maternal protein restriction, but contain no data or discussion relevant to PGE2 metabolism or accumulation. Therefore the provided evidence cannot be used to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "2481032",
      "7165938",
      "25050364",
      "23863551",
      "3210545"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers do not support the claim; they indicate the opposite relationship. Paper 7 states that 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzymatically degrades PGE2 to 15-keto-PGE2 and that loss/down-regulation of 15-PGDH is associated with increased tissue PGE2 and tumor progression. This implies that increased conversion of PGE2 into 15-keto-PGE2 (i.e., increased 15-PGDH activity) should reduce, not cause accumulation of, PGE2. Paper 3 further supports the biochemical identity of 15-keto-PGE2 as the endogenous PPAR\u03b3 ligand and reports reduced 15-keto-PGE2 in Cftr-deficient mice (consistent with reduced conversion leading to altered PPAR\u03b3 signaling). None of the other papers provide evidence that increased conversion to 15-ket-PGE2 causes PGE2 accumulation. Therefore the evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "56486733",
      "8453819",
      "712078",
      "9159495",
      "8610932"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "209",
    "claim": "CHOP is a general endoplasmic reticulum stress marker.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple provided papers show CHOP (DDIT3) induction in contexts of ER stress/UPR across different models and cell types. Paper 1 reports time-dependent increases in Ddit3/Chop mRNA and increased islet CHOP protein in lipid-induced ER stress and in islets from diabetic mice and humans. Paper 3 shows UPR activation with up-regulation of ATF4 and CHOP in ARV1-deficient yeast and in murine macrophages with disturbed lipid/ER homeostasis. Paper 4 lists increased CHOP expression together with other ER stress markers (HERP, GRP78) in cyclosporine A\u2013treated renal cells. Together these findings support CHOP as a general marker of endoplasmic reticulum stress/UPR activation."
    },
    "naive_doc_ids": [
      "25510546",
      "471735",
      "35760786",
      "238409",
      "36398420"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly identifies DDIT3 (previously CHOP) as one of the ER stress marker genes whose mRNA and protein are increased in palmitate-treated MIN6 cells, db/db mouse islets, and human type 2 diabetes pancreas sections, and refers to it among \u2018\u2018marker genes of ER stress.\u2019\u2019 Paper 2 reports upregulation of CHOP alongside established ER stress markers (HERP, GRP78) in cyclosporine A\u2013treated renal cells. Papers 3\u20135 do not provide relevant data on CHOP or ER stress. Together, the cited experimental findings show CHOP/DDIT3 induction in canonical ER stress contexts in multiple cell/tissue types, supporting the claim that CHOP is an ER stress marker."
    },
    "overthinking_doc_ids": [
      "25510546",
      "238409",
      "2787558",
      "4680262",
      "7875158"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports time-dependent increases in Ddit3 (DDIT3/CHOP) mRNA in MIN6 beta cells exposed to the ER stress\u2013inducing fatty acid palmitate and increased CHOP protein in islets from db/db mice and human type 2 diabetic pancreas, linking CHOP induction to ER stress. Paper 6 (systematic review) also lists increased CHOP expression alongside other ER stress markers (e.g., GRP78/HERP) in Cyclosporine A\u2013treated renal cells. These findings provide experimental evidence that CHOP is induced during ER stress, supporting the claim."
    },
    "posthoc_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "4465608",
      "16201748"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1072",
    "claim": "Sepsis related mortality has remained stable between 2009-2014.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The provided papers do not support the claim that sepsis-related mortality remained stable from 2009\u20132014. Paper 1 (EHR-based, 409 US hospitals, 2009\u20132014) reports a significant decline in in-hospital sepsis mortality (\u22123.3%/year, P = .004), although the combined outcome of death or discharge to hospice did not change significantly (\u22121.3%/year, P = .19). Paper 2 (national ICU database, 2011\u20132015) reports risk-adjusted improvements in mortality over time for sepsis populations (Sepsis\u20112 severe sepsis and Sepsis\u20113 sepsis). Papers 3 and 4 (guidelines and Sepsis\u20113 definitions) discuss changes in definitions and management that affect measured outcomes and epidemiology but do not support a conclusion of stable mortality. Overall, the data show at least some measurable declines in sepsis mortality (and/or improvements when risk-adjusted), so the claim of stability is not supported; the findings are mixed for different mortality endpoints but predominantly indicate improvement rather than strict stability."
    },
    "naive_doc_ids": [
      "4824840",
      "3776162",
      "52827184",
      "5596332"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 directly examines sepsis trends from 2009\u20132014 using EHR clinical criteria and reports that the combined outcome of in-hospital death or discharge to hospice did not change significantly over that period (\u22121.3%/year; 95% CI \u22123.2% to 0.6%; P = .19). The paper does note a significant decline in in-hospital mortality alone (\u22123.3%/year; 95% CI \u22125.6% to \u22121.0%; P = .004), but when accounting for deaths plus hospice discharges (a broader measure of sepsis-related fatal outcome), there was no significant trend. The other provided papers do not address sepsis. Therefore, the evidence (primarily Paper 1) supports the claim that sepsis-related mortality remained stable between 2009 and 2014 when using the combined death-or-hospice outcome, though results differ if one considers in-hospital death alone."
    },
    "overthinking_doc_ids": [
      "4824840",
      "27240667",
      "12224536",
      "1456068",
      "12794099"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (EHR-based, 409 U.S. hospitals, 2009\u20132014) directly analyzes sepsis trends and reports a significant decline in in-hospital mortality for sepsis (\u22123.3% per year; 95% CI \u22125.6% to \u22121.0%; P = .004). Although Paper 1 found no significant change in the combined outcome of death or discharge to hospice (\u22121.3%/y; 95% CI \u22123.2% to 0.6%; P = .19), its primary mortality measure declined. Paper 2 (national ICU database, 2011\u20132015) also reports risk-adjusted improvements in mortality over time for sepsis cases (Sepsis-2 and Sepsis-3 sepsis). Other provided papers do not provide trend data for sepsis mortality. Overall, the available evidence contradicts the claim that sepsis-related mortality remained stable from 2009\u20132014, showing at least a decline in in-hospital sepsis mortality over that period (with a caveat that some composite outcomes including hospice discharge did not change significantly)."
    },
    "posthoc_doc_ids": [
      "4824840",
      "3776162",
      "6647414",
      "463533",
      "27240667"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1371",
    "claim": "Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple provided papers directly support that vitamin D status modulates the calcium\u2013PTH relationship. Paper 1 (Icelandic cohort) shows serum PTH is lowest at higher 25\u2011hydroxyvitamin D levels and that the effect of calcium intake on PTH depends on vitamin D status (e.g., low vitamin D plus low calcium \u2192 higher PTH; vitamin D modifies the impact of calcium intake). Paper 4 reports an inverse correlation between 25OHD and PTH and that vitamin D deficiency is associated with secondary hyperparathyroidism. Paper 5 demonstrates that calcium absorption rises substantially with higher serum 25OHD (65% higher absorption at ~86.5 nmol/L vs ~50 nmol/L), providing a mechanism by which vitamin D alters calcium availability and thus PTH regulation. Papers 2 and 3 address PTH signaling/effects but not vitamin D\u2019s modifying role; Papers 6 and 7 are unrelated. Collectively, the evidence supports the claim that vitamin D is an important factor in the relationship between calcium and parathyroid hormone."
    },
    "naive_doc_ids": [
      "16256507",
      "21199527",
      "3758260",
      "9555784",
      "3034412"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that serum 25-hydroxyvitamin D level strongly influences serum intact PTH: PTH was lowest when 25-OHD >18 ng/mL and highest when <10 ng/mL, and vitamin D status modified the effect of calcium intake on PTH (e.g. at low vitamin D, low calcium intake was associated with higher PTH). Paper 3 also supports an important role for vitamin D in the calcium\u2013PTH axis by documenting altered/blunted PTH responses in patients with vitamin D insufficiency (with interactions involving magnesium). Other provided papers are not directly relevant. Together, the relevant studies indicate vitamin D is an important factor in the relationship between calcium and parathyroid hormone."
    },
    "overthinking_doc_ids": [
      "16256507",
      "21564598",
      "13312471",
      "1759213",
      "202259"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that serum 25-hydroxyvitamin D status strongly influences serum intact PTH: PTH was lowest when 25-OHD >18 ng/mL and highest when 25-OHD <10 ng/mL, and the effect of calcium intake on PTH depended on vitamin D status (at low 25-OHD, low calcium intake was associated with higher PTH; even at high calcium intake, differences in vitamin D status produced significant PTH differences). Paper 5 provides mechanistic support showing that the active vitamin D hormone (1,25D) via VDR-RXR regulates genes that control intestinal calcium absorption and renal calcium handling, linking vitamin D to systemic calcium homeostasis and thereby to PTH regulation. Other papers in the set do not contradict this relationship. Taken together, the evidence supports the claim that vitamin D is an important factor in the relationship between calcium and parathyroid hormone."
    },
    "posthoc_doc_ids": [
      "16256507",
      "21564598",
      "9301606",
      "19205437",
      "8856690"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "310",
    "claim": "De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The supplied papers discuss de novo assembly methods (Paper 1, Paper 4) and factors affecting assembly quality/fragmentation (Paper 2), but none present a direct comparison of the number of \u2018specific contigs\u2019 in de novo-assembled data versus unassembled (raw read) data. Paper 1 describes Trinity reconstructing full-length transcripts; Paper 2 analyzes how GC bias affects assembly fragmentation; Paper 4 reports a de novo assembly to recover a draft genome. However, none report experimental results or metrics that directly support or refute the specific claim that de novo assembly yields fewer specific contigs than unassembled sequence data. Therefore the provided evidence is insufficient to confirm or contradict the claim."
    },
    "naive_doc_ids": [
      "32770503",
      "14464451",
      "22467585",
      "6173523",
      "7059897"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.7,
      "justification": "The provided papers do not directly address the claim as stated. Paper 1 reports a de novo assembly (10,687 contigs) but does not compare contig counts to the unassembled read set. Paper 4 describes transcriptome reconstruction by de novo assembly (Trinity) and its ability to recover full-length transcripts, but it does not present a direct comparison of numbers of \"specific contigs\" versus unassembled sequences. Paper 2 discusses how GC bias can increase assembly fragmentation (i.e., produce more contigs) under strong bias, which indicates assembly can sometimes produce many contigs, but this is a conditional technical effect rather than a direct test of the general claim. The other papers are unrelated to genome/transcriptome assembly. Because none of the articles directly compare assembled contig counts to unassembled read counts or explicitly state that de novo assembly yields fewer specific contigs than unassembled data, there is insufficient evidence here to either support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "14185503",
      "14464451",
      "143251",
      "32770503",
      "2991954"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers directly test or report a comparison of the number of (specific) contigs in de novo assembled data versus unassembled (raw) sequence data. Papers 1 and 8 describe successful de novo assemblies (Paper 1: assembled a draft outbreak genome; Paper 8: assembly yielded 10,687 contigs) but do not compare contig counts to the unassembled read set. Paper 2 analyzes how GC bias affects assembly completeness and fragmentation (which can change contig counts) but does not present a direct assembled-vs-unassembled contig-number comparison. The remaining papers are unrelated to assembly/contig counts. Therefore the corpus does not provide direct evidence to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "6173523",
      "14464451",
      "14915566",
      "143251",
      "4311206"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "345",
    "claim": "Differentiated E2f-1, -2, -3 TKO cells in the intestine do not exhibit apoptosis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the six provided papers study E2f-1/-2/-3 triple-knockout (TKO) intestinal cells or report experimental results on apoptosis status of differentiated E2F TKO enterocytes. The papers address related intestinal topics (effects of celiac IgA on T84 cell differentiation, NEMO-dependent epithelial cell death, inflammasome-driven enterocyte expulsion, FGF-2 effects on stem cell survival, microbiota regulation of SAA3, and Wip1/p53 regulation of stem cell apoptosis), but none contain data or discussion about E2f1/2/3 TKO differentiated intestinal cells. Therefore the evidence set does not support or contradict the specific claim."
    },
    "naive_doc_ids": [
      "27772649",
      "18956141",
      "11921405",
      "25238950",
      "12658073"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 2 (E2F1-3 Switch...) directly examines E2f1/2/3 triple deficiency in the mouse small intestine. The authors report that E2f1-3 are required for survival in dividing progenitor cells but, in differentiating intestinal cells, E2f1-3 act as Rb-associated repressors that facilitate cell-cycle exit. Loss of E2f1-3 suppressed the Rb-deficiency phenotypes in differentiating cells, consistent with absence of a pro-apoptotic effect in the differentiated compartment. Additionally, Paper 1 shows that E2F3 is required for DNA damage\u2013induced apoptosis, so loss of E2f factors would be expected to reduce apoptosis. The other provided papers do not address E2f1-3 TKO in differentiated intestinal cells. Taken together, the cited evidence supports the claim that differentiated intestinal cells lacking E2f1/2/3 do not exhibit apoptosis."
    },
    "overthinking_doc_ids": [
      "28697248",
      "4394817",
      "5254463",
      "11921405",
      "12658073"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 directly examines E2f1-3 triple deficiency in the small intestine and reports that E2f1-3 are \"necessary for cell survival\" in dividing progenitor cells but act as Rb-associated repressors in differentiating cells. This implies that the survival (apoptosis) phenotype is specific to proliferating progenitors, whereas differentiated intestinal cells do not require E2f1-3 for survival and do not show the apoptosis seen in progenitors. None of the other provided papers present data that directly contradicts this intestine/differentiation-specific finding (Paper 2 describes E2F3's role in DNA damage\u2013induced apoptosis in other contexts, but does not show differentiated intestinal TKO cells undergo apoptosis). Therefore the evidence supports the claim that differentiated E2f-1,-2,-3 TKO intestinal cells do not exhibit apoptosis."
    },
    "posthoc_doc_ids": [
      "4394817",
      "28697248",
      "5254463",
      "13481880",
      "30580263"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "728",
    "claim": "Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "Paper 1 directly examines mouse monocyte subsets defined by Ly-6C and reports that Ly-6C(high) (Ly6Chi) cells increase during acute and chronic inflammatory infections and are preferentially recruited to inflammatory sites (acute peritoneal inflammation recruited Ly-6C(med-high) monocytes). These findings indicate Ly6Chi monocytes are associated with inflammatory responses (i.e., higher inflammatory capacity) rather than lower. The other provided papers do not provide direct evidence about Ly6Chi vs Ly6Clo monocyte inflammatory capacities. Therefore the evidence in the set contradicts the claim."
    },
    "naive_doc_ids": [
      "36444198",
      "13902570",
      "343052",
      "13778710",
      "56486733"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 5 directly implicates Ly6C^hi monocytes in promoting pathology: depletion of Ly6C^hi monocytes reduced pulmonary fibrosis and markers of alternatively activated (profibrotic) macrophages, while adoptive transfer of Ly6C^hi cells exacerbated fibrosis (statistically significant effects reported). Paper 2 describes splenic monocytes (the reservoir population mobilized to injured/inflammatory sites) that accumulate in injured tissue and participate in wound healing, consistent with a pro-inflammatory/reparative role for recruited Ly6C^hi monocytes. The provided evidence therefore indicates Ly6C^hi monocytes have greater inflammatory/pro-fibrotic capacity than Ly6C^lo monocytes, which contradicts the claim that Ly6C^hi monocytes have a lower inflammatory capacity."
    },
    "overthinking_doc_ids": [
      "2391552",
      "7489663",
      "25878014",
      "11233339",
      "22621251"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that Ly-6C(high) monocytes increase during acute and chronic infection and are preferentially recruited to inflammatory sites, describing them as immature/inflammatory (a \u2018left shift\u2019) and differing in capacity to be recruited to inflammation. Paper 3 describes splenic monocytes that are rapidly deployed to injured/inflamed tissue and contribute to wound healing (the well-known splenic reservoir comprises Ly6C^hi inflammatory monocytes in the original study). These papers therefore support that Ly6C^hi monocytes are associated with inflammatory responses and recruitment to sites of inflammation, which is the opposite of the claim that Ly6C^hi monocytes have lower inflammatory capacity than Ly6C^lo monocytes. None of the provided papers present data showing Ly6C^hi monocytes are less inflammatory than Ly6C^lo monocytes."
    },
    "posthoc_doc_ids": [
      "36444198",
      "343052",
      "7489663",
      "21382907",
      "12370881"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1105",
    "claim": "Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 directly addresses the claim: in a multicentre matched case\u2013control study (59 doctors with proven serious professional misconduct and 236 controls), failure of early or preclinical examinations was independently associated with being a misconduct case (multivariable OR 5.47, 95% CI 2.17\u201313.79, P<0.001). The authors conclude early academic difficulties could be risk factors for later professional misconduct, while cautioning the study is small and findings are preliminary. The other provided papers (2\u20136) do not provide evidence about later professional misconduct following early poor performance in medical school, so they are not relevant to this claim. Given the direct positive finding but the study's limitations (small sample, preliminary nature), the evidence supports the claim but is not definitive."
    },
    "naive_doc_ids": [
      "6710713",
      "17374970",
      "3801693",
      "14700857",
      "10699587"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 2 (a matched case-control study) directly examined medical-school risk factors for later professional misconduct and found that failure of early/preclinical examinations was independently associated with subsequent proved serious professional misconduct (adjusted odds ratio 5.47, 95% CI 2.17\u201313.79, P<0.001). The authors note male sex and lower socioeconomic background were also independent risk factors and caution the study is small and preliminary. The other provided papers do not address later professional misconduct (they concern board certification, academic attrition, behavior-change coaction, and smoking cessation prognosis) and therefore neither strengthen nor contradict the association. Given the direct positive finding but the study's limitations, the evidence collectively supports the claim with moderate confidence."
    },
    "overthinking_doc_ids": [
      "11624482",
      "6710713",
      "33417012",
      "17374970",
      "7639744"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly addresses the claim: in a multicentre retrospective case-control study, doctors with proved serious professional misconduct were significantly more likely to have had early academic difficulties at medical school. Multivariable analysis found failure of early/preclinical exams was independently associated with being a misconduct case (odds ratio 5.47, 95% CI 2.17\u201313.79, P<0.001). The other provided papers do not address medical-student early performance and later professional misconduct (they are on unrelated topics or on academic attrition without misconduct outcomes). Note the Paper 1 authors caution the study is small and preliminary (59 cases), so while the evidence supports the claim, it is based on limited retrospective data and should be interpreted cautiously."
    },
    "posthoc_doc_ids": [
      "6710713",
      "17374970",
      "2424794",
      "12438901",
      "1538080"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.18,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "939",
    "claim": "Persistor cells are one reason for incomplete responses to Tyrosine kinase inhibitor (TKI) therapy in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers directly address or provide experimental evidence that 'persistor' (drug-tolerant persister) cells are a cause of incomplete responses to TKI therapy. The papers describe several mechanisms of incomplete/ acquired resistance to TKIs \u2014 e.g. emergence of resistant EGFR mutations (C797S) (Paper 5), pathway reactivation or PTEN loss causing PI3K/Akt-driven resistance (Papers 3 and 4), and broader phosphoproteomic changes in cells with acquired TKI resistance (Paper 2) \u2014 all of which are relevant to TKI failure but do not identify or characterize persister cell populations. Paper 7 shows that quiescent leukemia stem cells can survive chemotherapy and be targeted by forcing cell-cycle entry, which is conceptually analogous to drug-tolerant/quiescent persister cells, but this study concerns chemotherapy in AML rather than TKI therapy. Therefore the set of papers does not provide direct support or direct contradiction for the specific claim about persistor cells causing incomplete responses to TKIs."
    },
    "naive_doc_ids": [
      "9929089",
      "25895285",
      "34016944",
      "85665741",
      "9505402"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Multiple papers provide evidence that subpopulations of cancer cells that survive targeted therapy (tumor-initiating/sphere-forming cells or other resistant subclones) contribute to incomplete responses to TKIs. Paper 4 shows glioma tumor-initiating cells (TICs) can be insensitive to EGFR kinase inhibitors (with Akt/PTEN status explaining resistance in some cultures). Paper 6 reports sphere-forming (TIC-enriched) head and neck cancer cells are largely unsusceptible to anti-EGFR targeting, indicating a subpopulation survival mechanism independent of EGFR. Paper 1 demonstrates matrix-stiffness\u2013dependent resistance to the HER2 TKI lapatinib via YAP/TAZ, supporting non-genetic mechanisms that allow residual survival under TKI treatment. Paper 2 (clinical cases) shows that chemotherapy can reverse acquired TKI resistance and restore responsiveness on re-challenge, consistent with the presence of reversible/residual drug-tolerant cells. Paper 3 describes a tyrosine kinase (Etk/Bmx) that protects lung cancer cells from apoptosis, a possible mechanism for cell survival under therapy. While none of the papers use the exact term \u201cpersistor,\u201d their data on drug-tolerant/tumor-initiating subpopulations and microenvironment- or kinase-mediated survival mechanisms support the claim that persister cells are one reason for incomplete responses to TKI therapy."
    },
    "overthinking_doc_ids": [
      "1065627",
      "9929089",
      "20738970",
      "40710501",
      "1554348"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers explicitly describe or provide experimental evidence for drug-tolerant \u201cpersistor\u201d (persister) cells as a cause of incomplete responses to TKI therapy. The studies address other mechanisms of incomplete response or resistance: acquired/clinical TKI resistance reversible by alternating chemotherapy (Paper 1), use of circulating tumor cells as a predictor of progression (Paper 2), Etk-mediated protection from apoptosis (Paper 3), PTEN loss and constitutive PI3K/Akt signaling causing gefitinib resistance (Paper 4), ER\u2013HER crosstalk driving endocrine resistance (Paper 5), anti-angiogenic effects of RTK inhibitors in combination therapy (Paper 6), and tumor heterogeneity with selection of T790-wild-type or other resistant clones after third\u2011generation EGFR inhibitor therapy (Paper 7). While Paper 7 and several others document tumor heterogeneity and selection of resistant populations \u2014 concepts related to incomplete responses \u2014 none specifically identify or characterize persister cells or show that persister cells contribute to incomplete TKI responses. Therefore the provided evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "9929089",
      "20127522",
      "20738970",
      "34016944",
      "34066665"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1342",
    "claim": "Understanding epigenetic regulation of replication is essential for the reational design of episomally replicating vectors.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "The provided papers collectively show that epigenetic features (histone modifications and variants, chromatin remodelers, Polycomb, CTCF, noncoding RNA-directed silencing, etc.) control chromatin state, regulate DNA replication-related processes, and are maintained or re-established through replication. Examples: loss of H3K9 methylation and RNAi components disrupts heterochromatin and centromere function (Paper 1); histone modifications and variants influence DNA replication and nucleosome stability (Papers 3 and 5); Polycomb complexes can remain bound through DNA replication (Paper 8), and chromatin architecture factors like CTCF coordinate regional epigenetic marks and higher-order structure that affect gene regulation (Paper 4). These findings imply that epigenetic regulation determines whether sequences are replicated, expressed, silenced or stably maintained\u2014factors directly relevant to designing episomally replicating vectors that must replicate and be stably maintained and expressed in host chromatin. None of the papers directly test episomal vector design, so the support is indirect but consistent with the claim that understanding epigenetic regulation of replication is essential for rational design of episomal vectors."
    },
    "naive_doc_ids": [
      "2613813",
      "42009630",
      "8267678",
      "140874",
      "13790144"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "The provided papers collectively show that epigenetic mechanisms (histone modifications and variants, DNA methylation, chromatin remodelers, RNAi/heterochromatin, and retention of chromatin factors through S phase) strongly influence DNA replication, the restoration and inheritance of chromatin after replication, and transcriptional activity of viral/genomic elements. Examples: Paper 7 shows Polycomb complexes remain bound through DNA replication (implicating epigenetic inheritance during replication); Papers 8 and 9 show INO80 chromatin remodeling affects DNA replication and restoration of nucleosome structure; Paper 1 demonstrates histone acetylation changes control HIV-1 transactivation and viral replication; Paper 5 links RNAi to heterochromatin formation and H3K9 methylation that affect centromeric stability; Papers 3, 4, and 6 document how histone variants, acetylation, and DNA methylation control promoter activity and silencing. Although none of the papers study episomal vectors directly, they provide mechanistic evidence that epigenetic regulation modulates replication and expression of DNA elements in host cells, supporting the conclusion that understanding epigenetic regulation of replication is important (indeed essential for rational design) for episomally replicating vectors to ensure stable replication, proper chromatinization, and avoidance of silencing."
    },
    "overthinking_doc_ids": [
      "25606339",
      "2356950",
      "2817000",
      "1780819",
      "2613813"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers directly address whether epigenetic regulation of DNA replication controls or must be understood for the rational design of episomally replicating vectors. Paper 1 describes checkpoint (ATR/Chk1) control of replication-factory activation and dormant origin firing (cell-cycle/checkpoint regulation, not epigenetic marks). Papers 2, 3, 4, 5, 6 and 7 describe epigenetic regulation of transcription (vector promoter silencing, enhancer DNA methylation, histone acetylation/methylation, and epigenetic cancer therapies) and their effects on gene expression or viral transactivation, but do not provide data on epigenetic control of replication origin activity or episomal vector replication/maintenance. Therefore the set does not supply evidence to support or contradict the claim."
    },
    "posthoc_doc_ids": [
      "164189",
      "24512417",
      "2151983",
      "25606339",
      "13639330"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "434",
    "claim": "Foxp3 enables the expression of transcriptional regulators implicated in memory T cell development.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The provided papers do not supply direct evidence that Foxp3 (or Foxp3 expression in Treg cells) enables expression of transcriptional regulators that drive memory T cell development. Relevant points from the evidence: (1) Paper 1 shows CD4+CD25+Foxp3+ Tregs can induce KLF2 expression in endothelial cells impaired by ox-LDL, but this is an effect on endothelial cells (non\u2011T cells), not demonstration that Foxp3 enables KLF2 (or other memory\u2011related regulators) expression within T cells themselves. (2) Papers 4 and 5 review transcriptional regulators involved in memory T cell differentiation but do not link those regulators\u2019 expression to Foxp3. (3) Paper 7 describes Foxo1-dependent programs in Treg function and notes many Foxo1 targets are not directly regulated by Foxp3, arguing against a simple Foxp3\u2192memory\u2011regulator axis. (4) Other papers discuss factors (Blimp\u20111, STAT3, KLF2, PU.1) relevant to lymphocyte differentiation but do not show Foxp3 enabling their expression in the context of memory T cell development. Overall, the set lacks experimental data showing Foxp3 causes expression of memory\u2011associated transcription factors in T cells, so the claim is not supported by these papers."
    },
    "naive_doc_ids": [
      "30908508",
      "20179918",
      "32101982",
      "37311371",
      "5508750"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.65,
      "justification": "Among the provided papers only Paper 7 directly addresses Foxp3 biology in Treg cells. That study shows Foxo1-dependent transcriptional programs control Treg function and reports ~300 Foxo1-bound target genes \u201cthat do not seem to be directly regulated by Foxp3.\u201d This indicates that at least this important transcriptional regulator (Foxo1) and its targets are not enabled by Foxp3. None of the other papers provide data showing Foxp3 enables expression of transcriptional regulators implicated in memory T cell development (no positive evidence linking Foxp3 to induction of memory\u2011associated transcription factors such as those discussed for memory CD8 T cells in Paper 3). Therefore the available evidence does not support the claim and, insofar as Foxo1 is a relevant regulator, actually argues against Foxp3 being the enabler of such transcriptional programs."
    },
    "overthinking_doc_ids": [
      "5979056",
      "32101982",
      "40473317",
      "19293654",
      "140874"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers present evidence that Foxp3 directly enables expression of transcriptional regulators involved in memory T cell development. Paper 1 describes Foxp3 as a late Treg differentiation factor but shows Foxo1 controls a separate transcriptional program and notes many Foxo1 targets are not directly regulated by Foxp3. Paper 2 reviews transcriptional regulators of effector and memory T cells but does not link their expression to Foxp3. Other papers discuss transcription factors (Blimp-1, T-bet, KLF2) or Treg functions (papers 4, 5, 8) but do not report that Foxp3 enables expression of memory-associated transcriptional regulators. Therefore the supplied evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "4418070",
      "5508750",
      "10526279",
      "30908508",
      "3835423"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1030",
    "claim": "Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 directly demonstrates that inhibition of the H3K4 methyltransferase MLL1 (using the small molecule MM-401) reprograms mouse epiblast stem cells (EpiSCs) to a naive ESC-like state efficiently and synchronously (more than 50% of treated EpiSCs show naive features within 3 days). Reverted cells reactivate the inactive X and contribute to chimeras, indicating functional naive pluripotency. MLL1 is an H3K4 methyltransferase, so its inhibition reduces/redistributes H3K4 methylation and thereby drives the reversion. Other papers (1,3,4,5) provide supporting context about naive versus primed states and the role of H3K4 methylation machinery in pluripotency regulation (e.g., MOF/Wdr5 involvement in H3K4 methylation), reinforcing the mechanistic plausibility. Note: Paper 2 emphasizes redistribution of H3K4me1 at enhancers alongside repression of lineage factors, but the overall experimental result aligns with the claim that reducing H3K4 methylation activity induces efficient reprogramming of mouse EpiSCs to naive pluripotency."
    },
    "naive_doc_ids": [
      "4462419",
      "6441369",
      "4784069",
      "3882374",
      "12040627"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that blocking the H3K4 methyltransferase MLL1 with the small-molecule inhibitor MM-401 reprograms mouse epiblast stem cells (EpiSCs) to naive pluripotency in a highly efficient and synchronized manner (>50% of treated EpiSCs show naive ESC features within 3 days), with functional validation (X reactivation and chimera contribution). Paper 5 further supports the functional importance of H3K4me3 levels in pluripotency: depletion of the H3K4me3 demethylase KDM5B increases H3K4me3 and impairs ESC self-renewal, consistent with the idea that reducing H3K4me3 promotes or is compatible with the naive pluripotent state. None of the other provided papers contradict this finding."
    },
    "overthinking_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "3882374",
      "6455142"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 provides direct experimental evidence that inhibiting the H3K4 methyltransferase MLL1 (with the small molecule MM-401) reprograms mouse epiblast stem cells (EpiSCs) to a naive ESC-like state efficiently and synchronously (>50% of cells within 3 days). Reverted cells reactivate the inactive X and contribute to chimeras, and the mechanism involves perturbation of H3K4 methylation and redistribution of H3K4 marks at enhancers with repression of lineage determinants. The other papers provide background on naive vs primed states and related chromatin regulators but do not contradict this finding. Caveat: Paper 1 emphasizes redistribution of H3K4me1 at enhancers following MLL1 blockade; while MLL1 is an H3K4 methyltransferase and its inhibition alters H3K4 methylation broadly, the provided summary emphasizes H3K4me1 changes rather than explicitly quantifying H3K4me3 loss. Nonetheless, the data support the claim that reducing MLL-associated H3K4 methylation drives efficient reversion of mouse EpiSCs to naive pluripotency."
    },
    "posthoc_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "4784069",
      "23959496"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1385",
    "claim": "cSMAC formation enhances weak ligand signalling.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 reports that a weak agonist stimulated T cells more than the strong agonist and provides experimental evidence that enhanced cSMAC formation reduced the stimulatory capacity of that weak peptide \u2014 i.e. cSMAC formation decreased, not enhanced, weak-ligand signalling. Paper 1 further shows that TCR signaling is sustained in peripheral microclusters and terminated in the cSMAC, with cSMACs enriched for components linked to receptor sorting/degradation, arguing that cSMAC formation does not sustain signalling. The other papers do not provide direct evidence supporting the claim. Taken together, the provided literature contradicts the claim that cSMAC formation enhances weak ligand signalling."
    },
    "naive_doc_ids": [
      "9283422",
      "306006",
      "994800",
      "2714623",
      "15972906"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Papers 1 and 2 directly address cSMAC function and both provide evidence contrary to the claim. Paper 1 reports that TCR signaling is initiated and sustained in peripheral microclusters and is terminated in the cSMAC, which is associated with sorting TCRs for degradation, concluding that cSMAC formation is not sufficient to sustain signaling. Paper 2 shows that a weak agonist that fails to form the cSMAC stimulates T cells more strongly than the wild-type agonist, and experimentally enhancing cSMAC formation reduced the stimulatory capacity of the weak peptide. The other provided papers do not provide relevant evidence about cSMAC effects on weak ligand signaling. Together, the evidence indicates cSMAC formation diminishes or terminates signaling rather than enhancing weak ligand signaling."
    },
    "overthinking_doc_ids": [
      "9283422",
      "306006",
      "5828251",
      "6936141",
      "21746539"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly tests the relationship between cSMAC formation and a weak agonist: an inability to form a cSMAC correlated with increased proliferation to a weak peptide, and experimentally enhancing cSMAC formation reduced the stimulatory capacity of that weak peptide. Paper 4 provides mechanistic support by showing that TCR signaling is initiated and sustained in peripheral microclusters and is terminated in the cSMAC (a site for TCR sorting/degradation), indicating cSMAC formation does not sustain or enhance signaling. Other papers (3 and 5) discuss synapse formation and its requirements for activation but do not provide evidence that cSMAC formation enhances weak-ligand signaling; papers 1 and 6 are unrelated, and paper 7 discusses TCR\u03b6 membrane association without supporting the claim. Taken together, the provided evidence opposes the claim that cSMAC formation enhances weak ligand signaling."
    },
    "posthoc_doc_ids": [
      "8458567",
      "306006",
      "2714623",
      "9283422",
      "15972906"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "226",
    "claim": "Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Multiple papers document bidirectional crosstalk between tumor cells and stromal fibroblasts and show that tumor cells can induce the CAF phenotype. Paper 5 provides direct experimental evidence that cancer cells induce oxidative stress in adjacent fibroblasts (loss of stromal Cav\u20111, mitochondrial dysfunction, autophagy/mitophagy), driving the formation/activation of CAFs and metabolic reprogramming (\u201cReverse Warburg Effect\u201d). The review in Paper 4 explicitly states that crosstalk between cancer cells and CAFs plays a key role in CAF activation and tumor progression. Other papers (1, 2, 6) demonstrate strong paracrine interactions between CAFs and cancer cells (CAF \u2192 cancer), supporting the existence of reciprocal signaling in the tumor microenvironment. Taken together, the evidence supports the claim that interactions between cancer cells and fibroblasts mediate formation and activation of CAFs."
    },
    "naive_doc_ids": [
      "9648896",
      "3376731",
      "20568364",
      "952111",
      "24349992"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers show bidirectional cross-talk between cancer cells and fibroblasts that leads to activation/formation of a CAF phenotype. Paper 1 provides direct experimental evidence that cancer cells induce oxidative stress and Cav-1 loss in adjacent stromal fibroblasts, driving mitochondrial dysfunction, autophagy/mitophagy and a metabolic/gene-expression switch consistent with CAF activation (the 'Reverse Warburg Effect') and propagation of this phenotype to neighboring fibroblasts. Paper 5 shows tumor-driven activation of surrounding fibroblasts (and that blocking tumor signals via miR-205 prevents/reverts CAF-mediated effects), supporting that cancer cell\u2013fibroblast interactions mediate CAF formation/activation. Other papers (e.g., on tumor-derived exosomes and immune/stromal crosstalk) further illustrate tumor\u2013stroma communication. Taken together, the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "24349992",
      "52925737",
      "21439640",
      "20568364",
      "8702697"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Multiple papers provide direct experimental evidence that tumor cells communicate with stromal cells to induce fibroblast/mesenchymal stromal cell activation consistent with CAF/myofibroblast phenotypes. Paper 1 shows cancer-cell-derived exosomes bearing TGF-\u03b2/betaglycan trigger fibroblast \u2192 myofibroblast differentiation (\u2191\u03b1-SMA, SMAD signaling). Paper 4 shows extracellular vesicles from renal cancer stem cells reprogram mesenchymal stromal cells to a pro-tumorigenic phenotype (upregulation of migration, matrix-remodeling and pro-angiogenic genes) and promote tumor growth in vivo. Paper 3 provides complementary evidence that tumor-derived exosomes can polarize immune stromal cells (neutrophils) to pro-tumor states, supporting a general mechanism of tumor\u2192stroma reprogramming by EVs. Paper 7 demonstrates reciprocal CAF\u2192cancer cell signaling (IL-6 promoting chemoresistance), indicating bidirectional cancer\u2013CAF interactions in the tumor microenvironment. Together these data support the claim that interactions between cancer cells and stromal cells mediate formation/activation of CAF-like cells."
    },
    "posthoc_doc_ids": [
      "13889430",
      "25915873",
      "52925737",
      "14768471",
      "44640124"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "474",
    "claim": "Glycan adaptation is rarely observed in the B-cell repertoire.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.65,
      "justification": "Only one paper (Paper 8) among the provided set directly addresses glycan-dependent antibody responses. It reports that broadly neutralizing antibodies targeting an HIV gp120 glycan (Asn332) arose in a minority of infected individuals and only after months to years of infection\u2014i.e., such glycan-dependent BCN antibodies are uncommon. This is consistent with the claim that glycan adaptation in the B\u2011cell repertoire is rare. The other papers do not provide relevant data about B\u2011cell adaptation to glycans (Paper 6 discusses limited somatic hypermutation in anti\u2011TG2 autoantibodies but not glycan targets). Because the support is indirect and comes from a single relevant study, confidence is moderate rather than high."
    },
    "naive_doc_ids": [
      "34254203",
      "21392223",
      "27910499",
      "1544804",
      "14464451"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "None of the provided papers directly measure or report the frequency of glycan adaptation within the B\u2011cell (immunoglobulin) repertoire (for example, acquisition of N\u2011linked glycosylation motifs in antibody variable regions). Paper 2 reports limited somatic hypermutation in TG2\u2011specific intestinal plasma cells (suggesting limited affinity maturation in that autoimmune response), but it does not address glycan acquisition by BCRs. Papers 3, 7 and 8 describe viral envelope glycosylation changes and the development of glycan\u2011dependent broadly neutralizing antibodies (i.e., antibodies that recognize viral glycans), which concern viral glycan evolution and antibody specificities, not the prevalence of glycan adaptation in the B\u2011cell repertoire itself. The other papers are unrelated. Therefore the set does not provide direct evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "34254203",
      "1471041",
      "2601135",
      "8325952",
      "8354687"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Papers 8 and 9 provide relevant evidence indicating that glycan-directed broadly neutralizing antibody (bnAb) responses emerge only in a minority of individuals and require prolonged, iterative virus\u2013antibody co-evolution. Paper 8 explicitly states that only a minority of HIV-1\u2013infected individuals naturally develop broadly cross-neutralizing antibodies targeting a glycan (Asn332), and that this epitope evolved over months through immune escape, implying such glycan-specific B cell adaptations are uncommon. Paper 9 describes slow, iterative maturation of a V2-directed bnAb lineage with phenotypic viral changes and partial/limited escape, consistent with glycan- or epitope-directed B cell adaptation being an infrequent, prolonged process. The other papers largely address T cell biology, transcriptional regulation, or cancer genetics and do not bear on glycan adaptation in the B-cell repertoire. Taken together, the provided literature supports the claim (indirectly) that glycan adaptation in the B-cell repertoire is rarely observed."
    },
    "posthoc_doc_ids": [
      "8354687",
      "27910499",
      "4896726",
      "21392223",
      "36399107"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1359",
    "claim": "Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided evidence contradicts the claim. Paper 2 (network meta-analysis) reports that varenicline was not more effective than combination NRT (OR 1.06, 95% CredI 0.75\u20131.48), i.e. combination NRT and varenicline were similarly effective. Paper 3 (randomized trial) directly comparing varenicline+bupropion versus varenicline alone found the combination produced higher prolonged abstinence at 12 weeks (53.0% vs 43.2%; OR 1.49, 95% CI 1.05\u20132.12, P = .03), indicating combination therapy was superior at 12 weeks. The other papers do not provide relevant data. Together these results refute the claim that varenicline monotherapy is more effective after 12 weeks than combination therapies with varenicline or bupropion."
    },
    "naive_doc_ids": [
      "34369306",
      "5114940",
      "11614737",
      "7639744",
      "1759213"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Relevant trials and meta-analyses in the provided papers contradict the claim. Paper 1 (randomized trial) found that combination varenicline + bupropion produced higher 12-week prolonged abstinence than varenicline alone (53.0% vs 43.2%; OR 1.49, 95% CI 1.05\u20132.12, P = .03), i.e. combination was superior at 12 weeks. Paper 4 (network meta-analysis) reports that varenicline was not more effective than combination NRT (OR 1.06; 95% credible interval 0.75\u20131.48), indicating no superiority of varenicline monotherapy over combination NRT. Although varenicline is superior to single-form NRT and to bupropion alone, the provided evidence does not support the claim that varenicline monotherapy is more effective after 12 weeks than combination therapies (varenicline+bupropion or combination NRT); in fact, it opposes it."
    },
    "overthinking_doc_ids": [
      "11614737",
      "34369306",
      "35301079",
      "5114940",
      "4883040"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (randomized trial) directly compares varenicline monotherapy with combination varenicline + bupropion SR at 12 weeks and finds the combination superior: prolonged abstinence 53.0% vs 43.2% (OR 1.49, 95% CI 1.05\u20132.12, P = .03); 7-day point prevalence was numerically higher for combination as well. Paper 4 (network meta-analysis) reports that varenicline is not more effective than combination NRT (OR 1.06, 95% CredI 0.75\u20131.48) and states combination NRT and varenicline are equally effective. Other provided papers do not support the claim. Overall, the supplied evidence does not support \u2014 and in the case of the direct trial contradicts \u2014 the assertion that varenicline monotherapy is more effective after 12 weeks than combination therapies involving varenicline or bupropion."
    },
    "posthoc_doc_ids": [
      "11614737",
      "34369306",
      "8570690",
      "5114940",
      "6191684"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1212",
    "claim": "The deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers provide evidence that prolonged or dysregulated innate/monocyte-associated activation is harmful in chronic infection/inflammatory settings. Paper 5 directly links upregulation of TLR4 on a circulating monocyte subset (CD14++CD16+) to increased coronary plaque vulnerability, indicating a deleterious role for activated monocytes in chronic vascular disease. Paper 9 shows that chronic type I interferon signaling drives immune activation, lymphoid disorganization and viral persistence in a model of chronic viral infection, and that blocking this signaling (thereby reducing chronic innate/immune activation) enhances virus clearance. Paper 3 describes how chronic immune activation promotes HIV persistence, implying that sustained immune (including innate) activation is pathogenic in chronic infection. Paper 1 demonstrates that persistent immune activation during chronic colitis causes systemic damage and worse outcomes. Paper 4 shows that inhibiting innate inflammatory pathways (TLR2/NLRP3) ameliorates airway inflammation, consistent with a harmful effect of ongoing innate activation. Paper 2 highlights that monocyte recruitment can drive strong type-1 inflammatory responses (which can be tissue-damaging) before repair ensues. Collectively, these findings support the claim that deregulated and prolonged activation of monocytes/innate immune pathways has deleterious effects in chronic infectious or inflammatory conditions."
    },
    "naive_doc_ids": [
      "5572127",
      "5511240",
      "44562058",
      "56486733",
      "3616843"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Several papers provide evidence that chronic, dysregulated innate immune activation (which includes monocyte/macrophage pathways) is associated with harmful outcomes in persistent infections. Paper 6 shows that persistent type I interferon signaling drives chronic immune activation, negative regulator expression and lymphoid disorganization during persistent LCMV infection, and that blocking IFN-I (which reduces innate activation) lowers immune activation and improves viral clearance \u2014 supporting a causal link between prolonged innate activation and disease progression. Paper 5 shows that persistent immune activation in chronic intestinal inflammation produces systemic damage and worsened disease. Paper 4 demonstrates that recruited monocyte-derived macrophages drive a strong type-1 microbicidal inflammatory response (followed by type-2 repair), indicating monocyte activation can mediate potent inflammatory responses that must be regulated to restore homeostasis. Papers 1, 2 and 3 do not directly address prolonged monocyte activation causing harm (Paper 2 instead shows lack of macrophage activation is detrimental), but collectively the data are consistent with the claim that deregulated/prolonged activation of monocytes/innate immunity has deleterious effects in chronic infectious conditions."
    },
    "overthinking_doc_ids": [
      "21700295",
      "1386103",
      "4883040",
      "5511240",
      "5572127"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple papers provide direct and indirect evidence that prolonged or deregulated innate/monocyte-associated immune activation has harmful effects in chronic infectious or inflammatory settings. Paper 6 shows that PD-1\u2013triggered IL-10 production by monocytes during HIV causes reversible CD4+ T cell dysfunction, directly implicating monocyte dysregulation in impaired adaptive responses. Paper 5 reviews how chronic immune activation/inflammation in treated HIV promotes viral persistence, supporting a deleterious role for sustained immune activation. Paper 10 demonstrates that persistent type I IFN signaling drives chronic immune activation and tissue/lymphoid damage during persistent LCMV infection, and that blocking IFN-I reduces activation and improves viral clearance. Papers 2, 4 and 7 provide additional supporting evidence that chronic immune activation/inflammation (systemic or tissue-specific) leads to worse disease outcomes (exacerbated colitis and genomic damage, insulin resistance, and increased disease risk after stress-induced dysregulation). No papers presented contradict the claim. Overall, the evidence supports the claim that deregulated, prolonged activation of monocyte/innate immune pathways is deleterious in chronic infectious/inflammatory conditions."
    },
    "posthoc_doc_ids": [
      "14474178",
      "5572127",
      "5511240",
      "31001322",
      "44562058"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "153",
    "claim": "B3-Galectin decreases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The provided literature does not support the claim that \u201cB3\u2011Galectin decreases cell resistance to TKIs by engaging the alternate KRAS\u2011RalB signaling complex downstream of EGFR.\u201d None of the papers discuss a molecule called B3\u2011Galectin. Paper 3 directly addresses a related pathway: integrin \u03b1v\u03b23 (integrin \u03b23) recruits KRAS and RalB to activate TBK1/NF\u2011\u03baB and this KRAS\u2013RalB pathway is necessary and sufficient to drive tumour stemness and resistance to EGFR TKIs (erlotinib). Thus engagement of the KRAS\u2013RalB complex promotes resistance, not decreases it. The other papers (1,2,4,5) discuss TKI resistance mechanisms or stem\u2011like cells but do not provide evidence that a \u2018B3\u2011Galectin\u2019 reduces resistance via KRAS\u2013RalB. Therefore the evidence contradicts the claim (and additionally the key molecule named in the claim is not supported by the cited literature)."
    },
    "naive_doc_ids": [
      "40710501",
      "9929089",
      "4702639",
      "34066665",
      "9486930"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "None of the provided papers report that a 'B3-Galectin' decreases TKI resistance by engaging a KRAS\u2013RalB signaling complex downstream of EGFR. Instead, Paper 4 directly implicates a membrane protein (integrin \u03b1v\u03b23) in recruiting KRAS and RalB to drive TBK1/NF-\u03baB signaling that promotes tumour stemness and resistance to EGFR inhibitors (erlotinib). That finding indicates KRAS\u2013RalB complex engagement is associated with increased, not decreased, resistance to TKIs. None of the other papers describe B3-Galectin or present data showing a decrease in TKI resistance via KRAS\u2013RalB downstream of EGFR. Therefore the provided evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "2682997",
      "3943235",
      "5137019",
      "4702639",
      "9929089"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided literature does not support the claim that \u201cB3\u2011Galectin decreases cell resistance to TKIs by engaging the alternate KRAS\u2011RalB signaling complex downstream of EGFR.\u201d None of the papers mention a \u201cB3\u2011Galectin\u201d (or galectin\u20113) mediating such an effect. Instead, Paper 4 directly implicates a \u03b23\u2011containing integrin (\u03b1v\u03b23) as recruiting KRAS and RalB to form a signaling complex that promotes tumour stemness and resistance to EGFR tyrosine kinase inhibitors (erlotinib). Paper 7 similarly links integrin \u03b1v\u03b23 to oncogenic signaling and tumour aggressiveness. These findings indicate that engagement of a \u03b23\u2011related complex with KRAS\u2013RalB increases, not decreases, resistance to RTK inhibitors. Other papers address different resistance mechanisms (PTEN/PI3K\u2011Akt in Paper 6; NF1/RAS\u2011ERK in Paper 9; microenvironment/YAP\u2011TAZ in Paper 3) but do not provide evidence that a B3\u2011Galectin reduces TKI resistance via KRAS\u2011RalB. Therefore the available evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "40710501",
      "9929089",
      "1065627",
      "4702639",
      "33387953"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "619",
    "claim": "Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Papers 1 and 2 provide direct experimental evidence opposite to the claim: enzymatic depletion of hyaluronan (Paper 1) or stromal depletion via Hedgehog inhibition (Paper 2) reduced desmoplasia/fibrosis, increased intratumoral vascular density and perfusion, raised intratumoral concentrations of chemotherapeutics (doxorubicin, gemcitabine) and improved treatment responses (Paper 1: increased drug delivery and prolonged survival; Paper 2: increased drug concentration and transient disease stabilization). Other papers describe alternative mechanisms of chemoresistance (IL6/CXCR7, DUSP4, MMP genotypes, CTCs) but do not support the specific claim that increased vessel density plus reduced fibrosis decreases chemotherapy efficacy. Overall the provided evidence indicates the opposite: reduced fibrosis and increased vessel density enhance, not diminish, chemotherapy delivery and efficacy."
    },
    "naive_doc_ids": [
      "2565138",
      "20888849",
      "3376731",
      "7821634",
      "3984231"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Multiple provided papers show the opposite of the claim. In pancreatic cancer models, depletion of stromal/fibrotic components (Hedgehog inhibition in Paper 2; hyaluronan depletion with PEGPH20 in Paper 7) increased intratumoral vascular density or perfusion, raised intratumoral drug concentrations, and improved chemotherapy delivery and anti-tumor effect. Paper 1 reports that tumors enriched in stroma-related pathways are associated with gemcitabine resistance. Paper 4 found higher microvessel density (MVD) was independently associated with longer disease\u2011free survival after adjuvant anthracycline chemotherapy. Paper 3 also shows stromal-derived signals (exosomal miR21) can confer chemoresistance. Together these data indicate that increased vessel density and reduced fibrosis enhance \u2014 not decrease \u2014 chemotherapy efficacy, contradicting the claim. (Note: some effects can be transient or context/tumor-type dependent, but the cited evidence overall opposes the claim.)"
    },
    "overthinking_doc_ids": [
      "38243984",
      "20888849",
      "1727493",
      "1171121",
      "9929089"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "The provided papers do not support the claim; they show the opposite effect. Paper 3 reports that higher microvessel density (MVD) was independently associated with longer disease-free survival after adjuvant anthracycline chemotherapy, i.e. higher vascular density correlated with better chemo outcome. Papers 5 and 6 experimentally demonstrate that reducing desmoplastic stroma/fibrosis (Hedgehog inhibition in Paper 5; enzymatic hyaluronan depletion in Paper 6) transiently increases intratumoral vascular density and markedly increases intratumoral concentrations of gemcitabine (and doxorubicin in Paper 6), leading to improved drug delivery, tumor control, and prolonged survival versus chemotherapy alone. Paper 2 similarly shows that increasing tumor perfusion/oxygenation enhanced the efficacy of radiation (and reduced metastasis). Papers 1 and 4 discuss TAMs and DUSP4-related resistance mechanisms, which are not evidence that increased vessel density/reduced fibrosis decrease chemotherapy efficacy. Overall, the experimental data contradict the claim: increased vessel density and reduced fibrosis improve \u2014 not decrease \u2014 chemotherapy delivery/effectiveness."
    },
    "posthoc_doc_ids": [
      "25452937",
      "7986878",
      "1171121",
      "7821634",
      "20888849"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "759",
    "claim": "Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Three modeling studies (Papers 1, 3 and 4) predict that switching to or using ACTs can substantially reduce P. falciparum transmission, particularly with high coverage and in low-to-moderate transmission settings: Paper 1 reports modeled reductions up to ~53% prevalence reduction in low-transmission areas and concludes ACTs can approach the impact of ITNs in such settings (though impact is smaller in high-transmission areas and partner drug prophylaxis matters). Paper 3\u2019s individual-based simulations show that roll-out of ACTs together with other tools can produce major reductions and, in some low/moderate settings, drive prevalence to very low levels. Paper 4\u2019s model of Cambodian interventions attributes most initial prevalence declines to MDA with an ACT and sustained declines to high ACT treatment coverage (enhanced by primaquine). One empirical study (Paper 2) found only a moderate effect on transmission (submicroscopic gametocytemia persists and ACT did not significantly reduce the proportion of infectious children), indicating limits to the effect in some contexts. Overall the modeling evidence supports the claim but with important caveats: the magnitude of impact depends on baseline transmission intensity, coverage, partner drug properties (prophylactic duration), and presence of submicroscopic gametocytaemia and resistance."
    },
    "naive_doc_ids": [
      "1805641",
      "10617916",
      "18074797",
      "3929361"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 2 is a malaria transmission model that explicitly predicts substantial reductions in infection prevalence and clinical incidence when ACT is introduced as first-line therapy, with reductions up to ~53% in low-transmission settings and impacts comparable to insecticide-treated nets under some conditions. The model also notes the effect is context dependent (smaller percentage reductions in high-transmission areas and sensitive to coverage and drug prophylactic duration). Paper 1 (empirical) reports only a moderate effect of ACT on transmission and highlights limits due to submicroscopic gametocytemia, which qualifies the magnitude of impact predicted by models. Papers 3 and 4 address HIV and are not directly relevant to malaria. Overall, the modelling evidence supports the claim that ACTs can dramatically reduce malaria transmission in some settings, but with important caveats about transmission intensity, coverage, and submicroscopic gametocytemia."
    },
    "overthinking_doc_ids": [
      "10617916",
      "1805641",
      "374902",
      "13899137"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Multiple papers support the claim. Paper 1 (a mathematical model) predicts that switching to ACT as first-line treatment can produce large reductions in infection prevalence and clinical incidence\u2014e.g. up to a 53% reduction in prevalence in a low-transmission setting (and smaller reductions in high-transmission settings), and concludes ACTs can approach the transmission reductions achieved by ITNs in lower-transmission areas. Paper 3 (an individual-based transmission model) also incorporates the switch to ACT and shows that current tools including ACT can produce major reductions in transmission in low-to-moderate settings (though high-transmission settings may need additional tools). Empirical/pooled analyses (Paper 6) corroborate that ACTs substantially reduce patient infectiousness and gametocyte carriage versus non-artemisinin drugs. Some evidence qualifies the magnitude: Paper 2 finds only a moderate effect on transmission in a field trial (submicroscopic gametocytemia limits impact), and both modeling papers stress that impact depends on baseline transmission intensity, coverage, timing of treatment, and partner-drug properties. Overall, the body of evidence indicates mathematical models predict substantial (and in some contexts dramatic) reductions in transmission from using ACTs versus nongametocytocidal drugs, but the effect is context-dependent rather than universally dramatic."
    },
    "posthoc_doc_ids": [
      "1805641",
      "10617916",
      "18074797",
      "8133050",
      "3001685"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "611",
    "claim": "Increased lipolysis leads to higher P38 phosphorylation in adipose tissue.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 5 provides direct mechanistic data linking p38 MAPK activation to increased lipolysis in adipocytes: nicotine activates AMPK\u03b12 \u2192 MKP1 degradation \u2192 aberrant activation of p38 (and JNK), which leads to loss of insulin-mediated inhibition of lipolysis and thus increased lipolysis. This evidence indicates p38 phosphorylation is upstream of (causes) increased lipolysis, not downstream. None of the other papers present data showing that increased lipolysis drives higher p38 phosphorylation in adipose tissue. Therefore the provided evidence contradicts the claim's direction of causality."
    },
    "naive_doc_ids": [
      "1568684",
      "3621011",
      "29381091",
      "29362104",
      "32408470"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1 directly addresses the relationship between p38 phosphorylation and lipolysis in adipocytes. It shows that nicotine activates AMPK\u03b12, which causes degradation of MKP1 and consequent aberrant activation (phosphorylation) of p38 and JNK; this p38 activation leads to IRS1 phosphorylation, insulin signaling impairment and a loss of insulin-mediated inhibition of lipolysis, so that increased lipolysis is a downstream consequence of p38 activation. None of the other papers provide evidence that increased lipolysis drives higher p38 phosphorylation in adipose tissue. Thus the provided evidence indicates p38 activation precedes and causes increased lipolysis, contradicting the claim that increased lipolysis leads to higher p38 phosphorylation."
    },
    "overthinking_doc_ids": [
      "32408470",
      "17933691",
      "33063763",
      "29362104",
      "1568684"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 4 provides direct mechanistic data linking p38 activation to increased lipolysis, not the reverse. In that study nicotine activates AMPK\u03b12 \u2192 phosphorylation/degradation of MKP1 \u2192 aberrant activation of p38 (and JNK) \u2192 phosphorylation of IRS1 and loss of insulin-mediated inhibition of lipolysis, resulting in increased lipolysis. None of the other papers report experimental evidence that increased lipolysis causes higher p38 phosphorylation in adipose tissue. Thus the supplied evidence supports the opposite causal direction (p38 activation \u2192 increased lipolysis) rather than increased lipolysis \u2192 increased p38 phosphorylation."
    },
    "posthoc_doc_ids": [
      "3621011",
      "79447",
      "1568684",
      "32408470",
      "3943235"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "154",
    "claim": "B3-Galectin increases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "The provided papers contain relevant concepts about alternative KRAS\u2013RalB signaling causing resistance to EGFR tyrosine kinase inhibitors (paper 3 shows an integrin \u03b1v\u03b23\u2013KRAS\u2013RalB\u2013TBK1\u2013NF-\u03baB pathway that drives stemness and erlotinib resistance). However, none of the summaries mention B3-Galectin (or a galectin \u2018B3\u2019) or present data that B3-Galectin engages the KRAS\u2013RalB complex. In addition, paper 3 implicates an integrin-mediated bypass pathway rather than signaling strictly downstream of EGFR. Therefore the collection does not provide direct evidence that B3-Galectin increases TKI resistance via engagement of the KRAS\u2013RalB complex downstream of EGFR."
    },
    "naive_doc_ids": [
      "9929089",
      "40710501",
      "4702639",
      "17648235",
      "5406411"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "The papers include direct experimental evidence that an unliganded integrin \u03b1v\u03b23 (i.e., integrin \u03b23) recruits KRAS and RalB to activate a KRAS\u2013RalB\u2013TBK1\u2013NF-\u03baB pathway and thereby confers resistance to EGFR TKIs such as erlotinib (Paper 1). That finding supports the general mechanism that engagement of a \u03b23-containing integrin can drive TKI resistance via a KRAS\u2013RalB signaling axis. However, none of the provided papers mention \u201cB3\u2011Galectin\u201d (or galectin-3) or present data showing that a galectin family member engages the KRAS\u2013RalB complex to cause TKI resistance. The other papers describe alternative resistance mechanisms (reduced NF1, secondary EGFR mutations such as C797S/T790M, PTEN loss/PI3K\u2013AKT signaling, microenvironment/YAP\u2013TAZ effects, or clinical strategies to overcome resistance) but do not link galectins to KRAS\u2013RalB signaling. Therefore the specific claim as written (that B3\u2011Galectin increases TKI resistance via engaging the KRAS\u2013RalB complex downstream of EGFR) cannot be verified from the supplied evidence. If the intended molecule was integrin \u03b23 rather than a galectin, Paper 1 would SUPPORT that revised claim."
    },
    "overthinking_doc_ids": [
      "4702639",
      "2272614",
      "9505402",
      "34016944",
      "9929089"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.75,
      "justification": "The provided papers do not mention \u201cB3-Galectin\u201d (or galectin-3) specifically. Paper 2 directly demonstrates that integrin \u03b1v\u03b23 (i.e. \u03b23 integrin) recruits KRAS and RalB to activate a KRAS\u2013RalB\u2013TBK1\u2013NF-\u03baB pathway that drives tumor stemness and resistance to EGFR tyrosine kinase inhibition, which supports the mechanism portion of the claim (alternate KRAS\u2013RalB signaling conferring TKI resistance). However, none of the other papers provide evidence that a \u2018B3-Galectin\u2019 molecule increases TKI resistance or that galectin engages this KRAS\u2013RalB complex. Other papers describe different resistance mechanisms (PTEN loss \u2192 constitutive PI3K/Akt signaling, YAP/TAZ-mediated mechanotransduction, etc.). Therefore the evidence supports the KRAS\u2013RalB mechanism via \u03b23 integrin but does not provide information that B3-Galectin specifically performs this role."
    },
    "posthoc_doc_ids": [
      "40710501",
      "4702639",
      "9486930",
      "9929089",
      "1065627"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "978",
    "claim": "Pro-inflammatory cytokines are up repressed during tumor development.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple papers show pro-inflammatory cytokines are increased and promote tumor development rather than being repressed. Paper 6 shows loss of stromal p62 drives increased stromal IL-6 production required for tumor promotion. Paper 7 demonstrates IL-17 promotes tumor growth, increases MDSCs and creates a tumor-promoting microenvironment. Paper 8 reports oncogenic mTOR signaling in tumor cells drives G-CSF production and MDSC recruitment, promoting tumor initiation. Paper 3 implicates the inflammasome (NLRP3), which generates proinflammatory IL-1\u03b2/IL-18, in promoting tumor-associated MDSC accumulation and impairing antitumor immunity. While Paper 1 shows Treg-derived exosomes can suppress Th1 cytokine secretion (a context in which some pro-inflammatory cytokines are downregulated), the bulk of the tumor-focused evidence indicates pro-inflammatory cytokines are upregulated/active and contribute to tumor development, contradicting the claim that they are repressed during tumor development."
    },
    "naive_doc_ids": [
      "6913227",
      "10024681",
      "15435343",
      "3684342",
      "24396137"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.85,
      "justification": "The provided papers do not support the claim that pro-inflammatory cytokines are repressed during tumor development; instead they indicate these cytokines are active and often elevated in disease and cancer contexts. Paper 5 reports elevated IL\u20116 (a pro\u2011inflammatory cytokine) and VEGF as prognostic markers in squamous cell cervical cancer, consistent with increased cytokine activity in tumors. Paper 6 discusses IFN\u2011gamma as an active effector in the tumor microenvironment with both anti\u2011 and pro\u2011tumor effects, not a generalized repression. Other papers (1\u20134) show that reducing pro\u2011inflammatory cytokines (e.g., TNF\u2011alpha, IL\u20111beta, IL\u201113) modifies disease processes, implying these cytokines are functionally important and not broadly downregulated during pathology. None of the studies report a general repression of pro\u2011inflammatory cytokines during tumor development, so the evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "343052",
      "2391552",
      "22889972",
      "21258863",
      "14664424"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Several papers indicate that tumors suppress pro\u2011inflammatory/immune signaling during tumorigenesis and that reversing this repression can restore antitumor immunity. Paper 9 explicitly states that epigenetic silencing of immune\u2011related genes occurs during tumorigenesis and that altered (immunosuppressive) cytokine expression in the tumor microenvironment impairs antigen presentation and cytolytic T\u2011cell function, consistent with repression of pro\u2011inflammatory signals. Paper 7 shows that epigenetic therapy (DNMTi + HDACi) reactivates an interferon \u03b1/\u03b2 transcriptional program and antigen\u2011presentation machinery in NSCLC cells (i.e., restores pathways that had been suppressed during tumor development), further supporting tumor-associated downregulation of pro\u2011inflammatory/antiviral pathways. Paper 8 also discusses tumor-mediated impairment of IFN\u2011\u03b3 signaling and downstream antigen\u2011presentation, consistent with suppression of pro\u2011inflammatory responses in some tumor contexts. The remaining papers do not provide direct evidence relevant to pro\u2011inflammatory cytokine levels during tumor development. Overall, the provided evidence supports the claim that pro\u2011inflammatory cytokine/immune programs are repressed during tumor development."
    },
    "posthoc_doc_ids": [
      "21258863",
      "25315295",
      "2734421",
      "24396137",
      "4889228"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "975",
    "claim": "Primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers in the set provide experimental evidence that primary pro-inflammatory cytokines trigger downstream mediators that have either pro- or anti-inflammatory effects. Examples: Paper 7 shows the pro-inflammatory cytokine IFN-\u03b3 induces inducible nitric oxide synthase (iNOS) and nitric oxide production that then downregulates T-cell responses (an anti-inflammatory/regulatory consequence). Paper 6 shows stimuli that activate NF-\u03baB (including proinflammatory signals) induce SOCS3, which inhibits IFN-\u03b2 signaling and thereby suppresses antiviral responses (a negative regulatory mediator). Paper 8 demonstrates that pro-inflammatory cytokines IL-17A and TNF-\u03b1 induce NETosis, and NETs stimulate synovial cells to produce inflammatory mediators such as IL-6 and IL-8 (secondary pro-inflammatory mediators). Additional papers (e.g., Paper 5) document NF-\u03baB\u2013driven production of cytokines that propagate systemic inflammatory signaling. Together these findings support the claim that primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators."
    },
    "naive_doc_ids": [
      "22401720",
      "16066726",
      "7795952",
      "18546584",
      "31001322"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.75,
      "justification": "The provided papers do not directly demonstrate the specific claim that primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators. Most studies address related topics but not the exact causal cascade: Paper 4 reports changes in cytokine levels (IL-6, IL-8, TNF-\u03b1, hsCRP) after cardiopulmonary bypass and their attenuation by statins, but does not show primary cytokines inducing secondary mediators. Paper 5 reviews TNF-\u03b1 as central in autoimmune inflammation and therapeutic targeting, implying cytokine network effects but without direct experimental evidence of primary-to-secondary mediator induction in the excerpts. Paper 6 describes broad downstream effects of inflammatory cytokines on neurotransmitter systems and growth factors, indicating cytokines can drive secondary changes, but it does not explicitly document induction of secondary pro- and anti-inflammatory cytokine mediators. Papers 1, 2 and 3 are unrelated to this specific cytokine induction claim. Therefore the corpus does not provide explicit experimental support or contradiction for the claim."
    },
    "overthinking_doc_ids": [
      "7370282",
      "11557602",
      "14584755",
      "2391552",
      "12705056"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple papers among the provided evidence show that primary pro-inflammatory cytokines induce downstream (secondary) mediators, including both pro- and anti-inflammatory factors. Examples: Paper 7 reports that TNF-\u03b1 treatment induces expression of the cellular protein FIP-2 (a TNF-inducible protein). Paper 4 shows IL-1\u03b2/TNF-\u03b1\u2013driven inflammatory responses include induction of COX-2, PGE2 and MMPs in synovial fibroblasts (mediators downstream of primary cytokines). Paper 3 demonstrates activated T cells secrete cytokines that up-regulate RANK, osteoprotegerin and TNF-related apoptosis-inducing ligand in stromal/osteoblastic cells (a mixture of osteoclastogenic and regulatory factors\u2014i.e., pro- and anti-inflammatory/ regulatory mediators). Paper 8 states that acute-phase protein SAA synthesis is regulated by inflammation-associated cytokines (primary cytokines driving a secondary acute-phase mediator). Paper 5 provides mechanistic support showing stress and cytokine-related activation of NF-\u03baB, a transcriptional pathway that drives secondary mediator production. None of the supplied papers contradict this mechanism. Together these studies support the claim that primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators."
    },
    "posthoc_doc_ids": [
      "25315295",
      "2391552",
      "43619625",
      "343052",
      "1887056"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "482",
    "claim": "Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that two Rho GEFs (LARG and GEF\u2011H1) are activated by tensional force on integrins, are recruited to adhesion complexes, and regulate the cellular mechanical response\u2014i.e., they mediate the pathway linking force on integrins to Rho activity. Paper 4 corroborates that mechanical force on integrin-containing adhesions induces Rho-dependent focal contact formation, supporting the link between integrin-applied tension and Rho activation. Paper 6 establishes integrin\u2013fibronectin interactions (relevant receptor context). Together these results align with the claim that GEFs mediate RhoA activation in response to tensional forces on fibronectin-binding integrins."
    },
    "naive_doc_ids": [
      "10991183",
      "8093935",
      "4662264",
      "9507605",
      "10530014"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that application of tensional force on integrins triggers activation and recruitment of two Rho-specific GEFs (LARG and GEF-H1) to adhesion complexes, and links their activation to signalling pathways downstream of integrin force. This provides direct experimental evidence that GEFs mediate RhoA-related signalling in response to tension on integrins. Paper 2 further supports the physiological relevance by showing that Rho activity is required for force-induced focal contact growth at integrin-based adhesions (though it does not identify the upstream GEFs). Papers 3\u20135 describe other aspects of integrin regulation and fibronectin interactions but do not contradict the GEF-mediated RhoA activation mechanism. Taken together, the provided literature supports the claim."
    },
    "overthinking_doc_ids": [
      "10991183",
      "9507605",
      "8453819",
      "20943272",
      "10669582"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly demonstrates that application of tensional force on integrins triggers activation and recruitment of the RhoA-specific GEFs LARG and GEF-H1 to adhesion complexes and that these GEFs regulate the cellular mechanical (reinforcement) response mediated by RhoA. Paper 6 further supports the role of GEF-H1 as a RhoA-specific exchange factor. Other provided papers describe fibronectin\u2013integrin interactions ( Papers 2 and 3 ), giving context that integrin-mediated adhesion can involve fibronectin-binding integrins. Taken together, the evidence shows GEFs (LARG and GEF-H1) mediate RhoA activation downstream of tensional forces applied to integrins, consistent with the claim."
    },
    "posthoc_doc_ids": [
      "10991183",
      "20943272",
      "10669582",
      "8453819",
      "10530014"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "184",
    "claim": "Bone marrow cells don't contribute to adult macrophage compartments.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Papers 1 and 4 provide direct experimental evidence that adult tissue-resident macrophage compartments are established before birth and are maintained by local self\u2011renewal with minimal contribution from circulating monocytes/bone marrow in the steady state (parabiosis, fate\u2011mapping, and transplant experiments). Paper 1 further shows host macrophages can expand in situ after depletion and after bone marrow transplant when donor macrophage development is impaired, supporting independent maintenance. Paper 5 qualifies this picture by showing that when fetal\u2011origin Kupffer cells are killed during infection, recruited monocytes (bone marrow\u2013derived) can replace them \u2014 i.e., contribution can occur in injury/inflammation contexts. Papers 2 and 3 do not bear directly on adult macrophage origin. Thus, the provided evidence largely supports the claim for the steady state but indicates exceptions during damage/infection."
    },
    "naive_doc_ids": [
      "12827098",
      "13002003",
      "35811036",
      "7521113",
      "5511240"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Papers 1 and 3 directly support the claim: fate-mapping and parabiosis studies show major tissue-resident macrophage populations are established before birth and self-maintain in adulthood with minimal or no steady-state replenishment from circulating monocytes (bone marrow\u2013derived). Paper 1 explicitly states monocytes do not show significant contribution in the steady state and that repopulation after depletion occurs largely by local proliferation. Paper 3 likewise finds tissue macrophages are maintained independent of blood-monocyte replenishment. The other papers (2 and 5) are unrelated to monocyte/macrophage ontogeny, and Paper 4 describes how systemic signals alter bone-marrow\u2013derived macrophage activation in experimental settings but does not demonstrate steady-state contribution of bone marrow cells to resident tissue macrophage compartments. Note: the evidence supports minimal/absent contribution in steady state; under inflammation or certain experimental perturbations some bone-marrow-derived input can occur, which the provided papers do not dispute but do not emphasize."
    },
    "overthinking_doc_ids": [
      "12827098",
      "3758260",
      "7521113",
      "24707550",
      "35811036"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple fate-mapping and parabiosis studies (Papers 1 and 2), and a recent review (Paper 4), provide direct in vivo evidence that major tissue-resident macrophage populations (e.g., Kupffer cells, alveolar, splenic, peritoneal macrophages) are established before birth and self-maintain throughout adult life with minimal replenishment from circulating monocytes/bone-marrow progenitors in the steady state. Paper 1 specifically shows little monocyte contribution in parabiosis and that post-depletion repopulation occurs largely by local proliferation. Papers 3\u20136 do not provide strong in vivo evidence contradicting this: Paper 6 describes that bone marrow precursors can be induced in vitro to yield myeloid cells (including dendritic cells/macrophages) under cytokine culture, and Papers 3 and 5 describe other marrow progenitor capacities, but these findings do not refute the in vivo fate-mapping/parabiosis evidence that bone-marrow-derived cells do not substantially contribute to adult tissue-resident macrophage compartments during homeostasis. Note: this conclusion applies to steady-state conditions; marrow/monocyte contribution can increase during inflammation, injury, or certain experimental manipulations."
    },
    "posthoc_doc_ids": [
      "12827098",
      "7521113",
      "10078024",
      "22406695",
      "36398420"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1352",
    "claim": "Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly states and provides experimental evidence that the Aedes aegypti C-type lectin mosGCTL-1 is induced by West Nile virus (WNV), interacts with WNV, and facilitates infection; it also reports a similar phenomenon in Culex quinquefasciatus. The other provided papers do not address mosGCTL-1 or its regulation by WNV."
    },
    "naive_doc_ids": [
      "12885341",
      "6144969",
      "1507222",
      "10559501",
      "38376189"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly states that the Aedes aegypti C-type lectin mosGCTL-1 \"is induced by WNV,\" and presents functional data showing mosGCTL-1 interacts with WNV and facilitates infection. The other papers do not provide contradictory evidence relevant to mosGCTL-1 regulation. Therefore the provided evidence supports the claim that mosGCTL-1 is upregulated upon West Nile virus infection."
    },
    "overthinking_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "13702924",
      "1686881"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that the Aedes aegypti C-type lectin mosGCTL-1 \"is induced by WNV,\" interacts with WNV, and facilitates infection in vivo and in vitro; a similar phenomenon was observed in Culex quinquefasciatus. The other provided papers do not contradict this finding and do not provide additional relevant data on mosGCTL-1 expression."
    },
    "posthoc_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "22703082",
      "6144969"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "385",
    "claim": "Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 provides direct experimental evidence in a murine epithelial ovarian cancer model that epigenetic modulators (a DNMT inhibitor, 5\u2011azacytidine, and an HDAC inhibitor) alter the tumor immune microenvironment: activation of type I interferon signaling, increased CD45+ immune infiltration and activated CD8+ T and NK cells, decreased macrophages and myeloid\u2011derived suppressor cells, improved response to PD\u20111 blockade, reduced tumor burden and prolonged survival. Paper 2 describes a syngeneic mouse ovarian cancer model used for such immune studies. The other papers discuss immune components (MDSCs, inflammasome, IL\u201117, NF\u2011\u03baB, MHC I) relevant to tumor immunity but do not contradict the direct findings. Therefore the provided evidence supports the claim that EMAs modulate antitumor immune responses in a cancer model system."
    },
    "naive_doc_ids": [
      "9767444",
      "21891856",
      "14615911",
      "9278263",
      "2014909"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers provide direct experimental and mechanistic evidence that epigenetic-modifying agents (EMAs) alter antitumor immune responses in cancer model systems. Paper 4 reports in a murine ovarian cancer model that DNMT inhibitor (5-azacytidine) and HDAC inhibitors activate type I interferon signaling, increase CD45+ immune infiltrates and active CD8+ T and NK cells, reduce macrophages and MDSCs, decrease tumor burden and extend survival, and improve response to PD-1 blockade \u2014 direct in vivo evidence that EMAs modulate antitumor immunity. Paper 1 (review) summarizes preclinical studies showing EMAs improve antigen presentation, effector T-cell function and reverse immunosuppression. Paper 5 provides supportive mechanistic context (epigenetic control of endogenous retroviruses and associated viral-defense/IFN responses) that helps explain how epigenetic perturbation can activate immune pathways. Paper 2 describes a relevant syngeneic mouse ovarian cancer model used for such immune studies. Other listed papers (3 and 6) address different therapeutic modalities and do not contradict the EMA\u2013immune modulation findings."
    },
    "overthinking_doc_ids": [
      "1032372",
      "21891856",
      "2565138",
      "9767444",
      "4323449"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple provided papers report experimental data showing that epigenetic-modifying agents alter antitumor immune responses in cancer model systems. Paper 1 (murine ovarian cancer) shows the DNMT inhibitor 5-azacytidine (AZA) activates type I IFN signaling, increases CD45+ immune infiltrates and activated CD8+ T and NK cells, reduces macrophages and MDSCs, lowers tumor burden and extends survival; addition of an HDAC inhibitor further enhances these immune changes and survival, and triple therapy with \u03b1-PD-1 gives the best antitumor effect. Paper 3 (NSCLC models) demonstrates that DNMTi+HDACi induces an IFN\u03b1/\u03b2 transcriptional program, upregulates antigen-presentation machinery, increases chemoattractant CCL5, suppresses MYC, and in mouse models reverses immune evasion and shifts T-cell exhaustion toward memory/effector phenotypes. Paper 2 (review) summarizes preclinical evidence that epigenetic therapies restore immune-related gene expression, improve antigen presentation and effector T-cell function, and reverse immunosuppression. The other papers do not contradict these findings. Together, the evidence supports the claim that EMAs modulate antitumor immune responses in cancer model systems."
    },
    "posthoc_doc_ids": [
      "9767444",
      "1032372",
      "9955779",
      "45764440",
      "1196631"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5-mini",
    "claim_id": "1390",
    "claim": "mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple provided papers directly support the claim. Paper 3 explicitly states that the wobble modification 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) is required for proper decoding of NNR codons in eukaryotes and explains the mechanistic basis (the 2-thio group fixes ribose conformation to ensure stable and accurate codon\u2013anticodon pairing). Paper 1 provides supporting experimental evidence in yeast: loss of the thiolation (TUC1) together with loss of the mcm5 side chain (ELP3) abolishes wobble U34 modifications in tRNAs for Gln/Lys/Glu and is lethal, and the primary role appears to be improving decoding efficiency of cognate codons. Together these findings confirm that mcm5s2U is required for accurate decoding of NNR codons in eukaryotes."
    },
    "naive_doc_ids": [
      "34498325",
      "984825",
      "2890952",
      "13552682",
      "8426046"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly supports the claim. It shows that eukaryotic cytoplasmic tRNAs (Gln, Lys, Glu) carry the mcm5s2U wobble modification at U34, and that these tRNAs read A- and G-ending codons (i.e., NNR codons). Genetic removal of the mcm5 side chain (elp3) together with loss of thiolation (tuc1) eliminates the wobble U modifications and is lethal, and the authors conclude the primary role of mcm5s2U34 is to improve efficiency of reading the cognate codons. These data in yeast (a eukaryote) therefore support that mcm5s2U is required for proper decoding of NNR codons. The other provided papers do not provide relevant contradictory information."
    },
    "overthinking_doc_ids": [
      "34498325",
      "9724974",
      "13552682",
      "8426046",
      "984825"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 explicitly states that the wobble modification mcm(5)s(2)U is required for proper decoding of NNR codons in eukaryotes and provides a mechanistic explanation (the 2-thio group stabilizes ribose conformation to ensure accurate codon\u2013anticodon pairing) and identifies the biosynthetic machinery. Paper 1 corroborates this functional role: mcm(5)s(2)U is present in cytoplasmic tRNAs that read A- and G-ending codons (i.e., NNR codons), and loss of the mcm(5) and 2-thio modifications impairs function and is lethal unless unmodified tRNAs are overexpressed, indicating the modification\u2019s primary role is to improve decoding efficiency. The other provided papers do not address this modification. Together the data support the claim."
    },
    "posthoc_doc_ids": [
      "34498325",
      "2890952",
      "236204",
      "984825",
      "1748921"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "585",
    "claim": "In the UK, drowning affects boys and girls equally.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.46,
      "justification": "Only Paper 1 pertains to drowning in UK children, but the provided excerpt contains no data on sex differences. The other papers address unrelated topics (self-harm in prisons, breast density, bariatric surgery, ICU organization, fractures in Minnesota, and global ALRI). Therefore, based on the supplied text, there is no evidence to confirm or refute whether drowning affects boys and girls equally in the UK."
    },
    "naive_doc_ids": [
      "42291761",
      "13900610",
      "38784540",
      "5824985",
      "21323587"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided excerpts, only Paper 1 addresses child drowning in the UK, but it does not report any sex-specific data or comparisons between boys and girls. The other papers concern perinatal mortality in rural China, undernutrition, and mortality surveillance in India, which are not relevant to UK drowning by sex. Therefore, the evidence provided does not allow verification of whether drowning affects boys and girls equally in the UK."
    },
    "overthinking_doc_ids": [
      "42291761",
      "7662395",
      "8529693",
      "11748341",
      "17415081"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "Among the provided papers, only Paper 4 addresses drowning in UK children, but the excerpt contains no data on sex distribution or comparisons between boys and girls. The remaining papers are unrelated to drowning or to UK child injury epidemiology. Therefore, the evidence provided does not allow assessment of whether drowning affects boys and girls equally in the UK."
    },
    "posthoc_doc_ids": [
      "41380943",
      "4085204",
      "13944805",
      "42291761",
      "7662395"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1268",
    "claim": "The risk of cancer rises with level of alcohol consumption.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.97,
      "justification": "None of the provided papers examine alcohol consumption levels in humans and subsequent cancer risk. The studies focus on lung function and lung cancer (FEV1), intrauterine/perinatal factors and breast cancer, statins\u2019 in vitro effects on head and neck cancer cells, tumor microenvironment\u2013mediated chemoresistance in ESCC, p16 inactivation in head and neck cancer, arginine metabolism targeting, yeast aging, and ethanol tolerance in E. coli. Paper 9 mentions ethanol but pertains to bacterial ethanol tolerance, not human alcohol intake or cancer incidence. Therefore, the evidence does not address the claim."
    },
    "naive_doc_ids": [
      "12145359",
      "17450673",
      "23557241",
      "1522336",
      "3376731"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.97,
      "justification": "None of the provided papers examine alcohol consumption or its dose-response relationship with cancer risk. The studies focus on perinatal factors and breast cancer risk, HER2-positive breast cancer and CNS metastases, physical activity and mortality, chemotherapy predictors, and a Japanese encephalitis vaccine. Therefore, they do not provide relevant data to confirm or refute the claim about alcohol and cancer risk."
    },
    "overthinking_doc_ids": [
      "17450673",
      "23557241",
      "3329824",
      "6647414",
      "24834968"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers evaluate alcohol consumption in relation to cancer risk. Paper 2 discusses alcohol and coronary events (cardiovascular outcomes), not cancer. The other papers address different risk factors (e.g., lung function, H. pylori, thiazolidinediones, BMI, ionising radiation, HPV) and their associations with various cancers but do not involve alcohol. Therefore, the evidence set does not contain information to assess whether cancer risk rises with level of alcohol consumption."
    },
    "posthoc_doc_ids": [
      "12145359",
      "20526907",
      "2052720",
      "31229233",
      "439670"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1183",
    "claim": "The TRaF1/C5 rs10818488 allele polymorphism regulates the neighboring C5 gene.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 7 pertains to the TRAF1/C5 locus and discusses its association with rheumatoid arthritis risk; it does not present data on how rs10818488 affects expression of the neighboring C5 gene. The other papers focus on unrelated topics (oxidative stress regulation in E. coli, general eQTL/GWAS integration methodology without specific findings for C5, growth factor signaling, chromatin regulation, lncRNAs, RA classification, and NETosis). No provided study offers experimental or eQTL evidence that the rs10818488 polymorphism regulates C5 expression."
    },
    "naive_doc_ids": [
      "471735",
      "2485101",
      "20675284",
      "17919731",
      "9881829"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers present data on the TRAF1/C5 locus or the specific SNP rs10818488 affecting C5 expression. Several papers discuss eQTLs in general (e.g., RNA-seq eQTL mapping, Matrix eQTL) or gene regulation mechanisms broadly, but there is no direct evidence about rs10818488 regulating the neighboring C5 gene."
    },
    "overthinking_doc_ids": [
      "4378885",
      "15286783",
      "28928964",
      "39326723",
      "313394"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 4 mentions the TRAF1/C5 region and associates it with rheumatoid arthritis risk, but it does not present functional data showing that the rs10818488 polymorphism regulates expression of the neighboring C5 gene. The other papers address unrelated genes, pathways, or mechanisms. Therefore, there is no direct evidence here confirming or refuting that rs10818488 regulates C5."
    },
    "posthoc_doc_ids": [
      "164985",
      "5979056",
      "6828370",
      "1967017",
      "19238"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "115",
    "claim": "Anthrax spores can be disposed of easily after they are dispersed.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided evidence is 'Error' and contains no relevant paper content, so there is no information to assess whether anthrax spores can be easily disposed of after dispersion."
    },
    "naive_doc_ids": [],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "The provided evidence contains an error and does not include any data or findings relevant to evaluating the claim."
    },
    "overthinking_doc_ids": [],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "No usable evidence was provided (input shows 'Error'), so there is no information to assess whether the claim is supported or contradicted by the papers."
    },
    "posthoc_doc_ids": [],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "114",
    "claim": "Anthrax spores are very difficult to dispose once they are dispersed.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.96,
      "justification": "No evaluable evidence was provided (the evidence field contains 'Error'), so the papers cannot be assessed for support or contradiction of the claim."
    },
    "naive_doc_ids": [],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.99,
      "justification": "No usable evidence from papers was provided (input shows 'Error'), so the claim cannot be assessed against the referenced literature."
    },
    "overthinking_doc_ids": [],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "No usable evidence was provided (input shows 'Error'), so the claim cannot be verified or refuted based on the supplied papers."
    },
    "posthoc_doc_ids": [],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "677",
    "claim": "LRBA promotes CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers examine LRBA or its role in CTLA-4 trafficking/recycling. While some studies discuss CTLA-4 biology (e.g., Th17 sensitivity, CTLA4 mutations) and others address endocytosis/recycling of unrelated proteins (Met, VEGFR-2, EGFR, synaptic vesicles), there is no evidence here linking LRBA to CTLA-4 recycling."
    },
    "naive_doc_ids": [
      "11250124",
      "22317868",
      "2462673",
      "935538",
      "9185195"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss LRBA or CTLA-4, nor do they present data on CTLA-4 recycling. The studies focus on VEGFR-2 internalization (Paper 1), synaptic vesicle recycling via AP-1/sigma1B (Paper 2), tick-host immunity (Paper 3), ESCRT-II in EGFR/CXCR4 sorting (Paper 4), oxidized DNA sensing and TREX1 (Paper 5), and immune reconstitution after stem cell transplantation (Paper 6). Therefore, the evidence does not address whether LRBA promotes CTLA-4 recycling."
    },
    "overthinking_doc_ids": [
      "2593298",
      "11250124",
      "33934971",
      "9680193",
      "13106686"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss LRBA or its role in CTLA-4 trafficking/recycling. While some papers mention CTLA-4 in the context of T cell regulation or checkpoint blockade, they do not address LRBA or CTLA-4 recycling mechanisms. Therefore, the evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "164985",
      "213017",
      "493346",
      "11250124",
      "2462673"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "659",
    "claim": "Ivermectin is used to treat lymphatic filariasis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.97,
      "justification": "None of the provided papers address ivermectin or lymphatic filariasis. The studies cover topics such as antipsychotics in dementia, sildenafil for antidepressant-associated sexual dysfunction, brain metastasis treatments, RNA editing, astrocyte hemichannels, smoking reduction and lung cancer risk, antiplatelet therapy in diabetes, gemcitabine for pancreatic cancer, and off-label targeted therapy in advanced cancer."
    },
    "naive_doc_ids": [
      "5402581",
      "39281140",
      "3944632",
      "22029384",
      "15657779"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.96,
      "justification": "None of the provided papers discuss ivermectin or lymphatic filariasis. The studies cover malaria interventions, FDA postmarket safety events, ciclopirox pharmacokinetics, prostate cancer treatment, tuberculosis regimens, and case management in substance abuse treatment, which are not relevant to the claim."
    },
    "overthinking_doc_ids": [
      "3929361",
      "3578380",
      "26461066",
      "308862",
      "341324"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.97,
      "justification": "None of the provided papers discuss ivermectin or lymphatic filariasis. The studies cover topics including prostate cancer androgen suppression, tuberculosis regimens, case management in substance abuse treatment, malaria elimination strategies (artemisinin/piperaquine and primaquine), FDA postmarket safety events, ciclopirox pharmacokinetics, CCR2 antagonism in autoimmune encephalomyelitis, HIV PrEP with emtricitabine/tenofovir, and glial regulation of synaptic transmission. Therefore, they provide no relevant evidence to confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "308862",
      "341324",
      "485020",
      "3929361",
      "3578380"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "53",
    "claim": "ALDH1 expression is associated with poorer prognosis in breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 7 directly reports that ALDH1 expression (by immunostaining) in a cohort of 577 breast carcinomas correlates with poor prognosis and is a predictor of poor clinical outcome. The other papers do not address ALDH1 in breast cancer prognosis, but the direct evidence from Paper 7 supports the claim."
    },
    "naive_doc_ids": [
      "2931832",
      "14664424",
      "1171121",
      "7639744",
      "17450673"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 directly reports that in a cohort of 577 breast carcinomas, ALDH1 expression by immunostaining correlated with poor prognosis, identifying it as a predictor of poor clinical outcome. The other provided papers do not address ALDH1 in breast cancer prognosis."
    },
    "overthinking_doc_ids": [
      "21502234",
      "52180874",
      "7639744",
      "45638119",
      "313403"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 5 reports that in a cohort of 577 breast carcinomas, ALDH1 expression by immunostaining correlated with poor prognosis and was a predictor of poor clinical outcome. This directly supports the claim. The other papers do not address ALDH1 in breast cancer prognosis."
    },
    "posthoc_doc_ids": [
      "21439640",
      "22401720",
      "12358173",
      "15113221",
      "45638119"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "224",
    "claim": "Cancer-associated fibroblasts (CAFs) are constituents of tumor microenvironments",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Multiple papers explicitly state or demonstrate that cancer-associated fibroblasts (CAFs) are components of the tumor microenvironment. Paper 1 directly calls CAFs one of the most crucial components of the tumor microenvironment. Papers 2 and 4 discuss CAFs within the tumor stroma/micro-environment and their roles in tumor progression and immune cell recruitment. Paper 3 notes fibroblasts as constituents of the tumor microenvironment, and Paper 5 shows functional interactions between CAFs and cancer cells within this context. Together, these findings confirm the claim."
    },
    "naive_doc_ids": [
      "952111",
      "24349992",
      "313403",
      "3559136",
      "8702697"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Multiple papers explicitly state that cancer-associated fibroblasts (CAFs) are components of the tumor microenvironment. Paper 1 directly states CAFs are \"one of the most crucial components of the tumor microenvironment.\" Paper 4 notes cancer cells are surrounded by stromal cells, especially CAFs, within the tumor microenvironment. Paper 2 functionally places CAFs within tumors as sources of chemokines affecting immune cell infiltration. Papers 3 and 5 further discuss stromal fibroblasts in tumors. Together, these confirm that CAFs are constituents of tumor microenvironments."
    },
    "overthinking_doc_ids": [
      "952111",
      "3559136",
      "24349992",
      "27647593",
      "313403"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Multiple papers explicitly place cancer-associated fibroblasts within the tumor microenvironment. Paper 1 states CAFs are crucial components of the tumor microenvironment. Paper 2 shows IL-6 derived from CAFs in esophageal tumors drives chemoresistance, implying CAF presence within the tumor milieu. Paper 3 demonstrates CAFs in tumors produce chemokines that recruit granulocytes, directly situating CAFs in the tumor microenvironment. Additionally, Paper 7 describes fibroblasts as part of the tumor microenvironment, consistent with CAFs being constituent fibroblasts associated with tumors. Together, these data support the claim."
    },
    "posthoc_doc_ids": [
      "952111",
      "3376731",
      "3559136",
      "19130782",
      "2014909"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.95,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1070",
    "claim": "Self-advocacy training is effective at decreasing homelessness.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers evaluate self-advocacy training or measure homelessness reduction as an outcome. The only study involving homeless populations (Paper 8) assesses a mental health outreach service for homeless families and reports improvements in child psychosocial functioning, not changes in homelessness status. The remaining papers address unrelated medical interventions (exercise, coping intervention in miscarriage, fluid balance, TB treatment regimens, blood pressure control in dialysis, pharmacy education, and acetylcysteine for contrast nephropathy). Therefore, the evidence does not inform whether self-advocacy training decreases homelessness."
    },
    "naive_doc_ids": [
      "2028532",
      "7751726",
      "20473074",
      "15997009",
      "202259"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers evaluate self-advocacy training or its impact on homelessness rates. The only study involving homeless populations (Paper 4) assesses a mental health outreach service for homeless families with outcomes on child psychosocial functioning, not homelessness reduction, and it is not a self-advocacy training intervention. All other papers are unrelated to homelessness or self-advocacy."
    },
    "overthinking_doc_ids": [
      "40817021",
      "22467585",
      "3944632",
      "6129301",
      "18074797"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.99,
      "justification": "None of the provided papers evaluate self-advocacy training or measure homelessness outcomes. The studies cover topics such as vision screening in older adults, caregiver interventions in cancer/palliative care, blood pressure monitoring accuracy, internet-based therapy for grief/PTSD, acetylcysteine for contrast nephropathy, school-based PTSD treatment, dietary recall methods, exercise programs for older adults, and malaria elimination terminology. Therefore, they provide no relevant evidence to confirm or refute the claim about self-advocacy training decreasing homelessness."
    },
    "posthoc_doc_ids": [
      "26016929",
      "22446093",
      "25515907",
      "22467585",
      "4678846"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1237",
    "claim": "The most prevalent adverse events to Semaglutide are cardiovascular.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers address semaglutide or its adverse event profile. The studies focus on MDR-TB treatment adverse events, blood pressure lowering and cardiovascular outcomes in dialysis patients, beta-adrenergic receptor polymorphisms in heart failure, imaging biomarkers for cardiovascular risk, plasma corin in chronic heart failure, and ADHD medications\u2019 cardiovascular risks. Therefore, they neither support nor contradict the claim about the prevalence of cardiovascular adverse events with semaglutide."
    },
    "naive_doc_ids": [
      "11254040",
      "202259",
      "10072941",
      "24586989",
      "6070278"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that in a randomized trial of oral and subcutaneous semaglutide, the most common adverse events were mild to moderate gastrointestinal events, not cardiovascular events. The other papers do not address semaglutide adverse event profiles. Therefore, the claim that the most prevalent adverse events to semaglutide are cardiovascular is contradicted by the provided evidence."
    },
    "overthinking_doc_ids": [
      "3654468",
      "23349986",
      "29387024",
      "202259",
      "11254040"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3, a randomized clinical trial of oral and subcutaneous semaglutide, explicitly reports that mild to moderate gastrointestinal events were the most common adverse events. This directly opposes the claim that cardiovascular adverse events are the most prevalent with semaglutide. The other papers do not provide data on semaglutide adverse event profiles."
    },
    "posthoc_doc_ids": [
      "6070278",
      "11254040",
      "3654468",
      "202259",
      "5402581"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1227",
    "claim": "The mean suicide rate in women is higher after miscarriage than live birth.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 5 (Suicides after pregnancy in Finland, 1987\u201394) directly reports that the suicide rate associated with miscarriage (18.1 per 100,000) was higher than the rate associated with live birth (5.9 per 100,000), and notes these differences were significant. Other provided papers do not address suicide rates after miscarriage versus live birth."
    },
    "naive_doc_ids": [
      "14682243",
      "20321154",
      "5691302",
      "1102268",
      "25641414"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly reports suicide rates by pregnancy outcome in Finland (1987\u201394): after live birth 5.9 per 100,000 vs after miscarriage 18.1 per 100,000, with miscarriage being significantly higher. This aligns with the claim. The other papers do not provide suicide-rate comparisons by miscarriage versus live birth."
    },
    "overthinking_doc_ids": [
      "25641414",
      "25806385",
      "881332",
      "13900610",
      "17626822"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly reports that the suicide rate associated with miscarriage (18.1 per 100,000) is significantly higher than the rate associated with live birth (5.9 per 100,000) among Finnish women, 1987-94. The other papers do not provide relevant data on suicide rates after miscarriage vs live birth."
    },
    "posthoc_doc_ids": [
      "25641414",
      "5145974",
      "7662395",
      "37480103",
      "26611834"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "744",
    "claim": "Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 1 shows that Ras-transformed cells use macropinocytosis to internalize extracellular protein, which is proteolytically degraded to amino acids (including glutamine) that feed central carbon metabolism and support growth; blocking macropinocytosis impairs tumor growth. Paper 3 further demonstrates that macropinocytosed proteins are degraded in lysosomes to provide essential amino acids, sustaining survival and modulating mTORC1 signaling. These findings directly confirm that macropinocytosis supplies amino acids via intracellular uptake of protein. Papers 2, 4, and 5 are not directly relevant and do not contradict this."
    },
    "naive_doc_ids": [
      "4138659",
      "3845894",
      "8460275",
      "36310858",
      "4959368"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that cells (specifically Ras-transformed cells) use macropinocytosis to internalize extracellular protein, which is then proteolytically degraded to amino acids (including glutamine) that feed central carbon metabolism. It also shows that macropinocytic protein uptake can reduce dependence on free extracellular glutamine and that inhibiting macropinocytosis impairs tumor growth, reinforcing its role as an amino acid supply route. The other papers do not materially affect this conclusion."
    },
    "overthinking_doc_ids": [
      "4138659",
      "3845894",
      "10486817",
      "4959368",
      "4920376"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 provides direct experimental evidence that cells (Ras-transformed) use macropinocytosis to internalize extracellular protein, which is subsequently degraded to amino acids (including glutamine) that feed central carbon metabolism. This macropinocytic protein uptake reduces dependence on free extracellular glutamine and its inhibition impairs tumor growth, confirming that macropinocytosis contributes to cellular amino acid supply via intracellular protein uptake. The other papers do not address this mechanism."
    },
    "posthoc_doc_ids": [
      "4138659",
      "3845894",
      "4231060",
      "14768471",
      "1554348"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "917",
    "claim": "PTEN is a regulator for the transcriptional activity of SRF",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 3 directly shows that nuclear PTEN interacts with SRF, promotes SRF binding to promoter elements of smooth muscle-specific genes, and functions as an essential regulator of SRF-dependent transcription. This establishes PTEN as a regulator of SRF transcriptional activity. The other papers do not address PTEN-SRF and do not contradict this finding."
    },
    "naive_doc_ids": [
      "25263810",
      "24624992",
      "34071621",
      "9724974",
      "15176526"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 5 directly shows that nuclear PTEN regulates SRF-dependent transcription. PTEN physically interacts with the N-terminal domain of SRF, promotes SRF binding to promoter elements of smooth muscle\u2013specific genes, and its nuclear-cytoplasmic translocation modulates SRF\u2019s gene-selective activity. This provides explicit experimental evidence that PTEN is a regulator of SRF transcriptional activity. The other provided papers do not address PTEN\u2013SRF regulation and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "1964163",
      "2316374",
      "7039855",
      "15176526",
      "34071621"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 7 directly shows that nuclear PTEN interacts with the N-terminal domain of SRF and regulates SRF-dependent transcription by promoting SRF binding to smooth muscle gene promoters, thereby controlling smooth muscle differentiation. This demonstrates that PTEN regulates the transcriptional activity of SRF. Other provided papers do not contradict this."
    },
    "posthoc_doc_ids": [
      "1964163",
      "2316374",
      "7039855",
      "6493422",
      "15176526"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1340",
    "claim": "Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (systematic review and meta-analysis of RCTs on lumbar punctures and epidural catheterisations) found that ultrasound guidance significantly reduced the number of insertion attempts compared with standard palpation (mean difference -0.44 attempts, 95% CI -0.64 to -0.24, P<0.001). Other provided papers are unrelated to ultrasound guidance and needle insertion attempts."
    },
    "naive_doc_ids": [
      "15482274",
      "15948830",
      "15997009",
      "7751726",
      "11718220"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 (systematic review and meta-analysis of RCTs on lumbar punctures and epidural catheterisations) reports that ultrasound guidance significantly reduced the number of needle insertion attempts compared with palpation alone (mean difference -0.44, 95% CI -0.64 to -0.24; P<0.001). This directly confirms the claim. The other papers are not relevant to ultrasound-guided needle insertion and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "15482274",
      "7639744",
      "14606752",
      "34873974",
      "6319826"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 4 (a systematic review and meta-analysis of 14 randomized trials, n=1334) directly shows that ultrasound imaging for lumbar punctures and epidural catheterizations significantly reduces the number of needle insertion attempts compared with palpation (mean difference -0.44, 95% CI -0.64 to -0.24; P<0.001). It also reduced needle redirections and failed/traumatic procedures. The other papers do not address this outcome. Therefore, the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "22467585",
      "34369306",
      "3944632",
      "15482274",
      "6319826"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "881",
    "claim": "Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.98,
      "justification": "Paper 1 reports that omnivorous human subjects produced more TMAO than vegans or vegetarians after ingestion of L-carnitine via a microbiota-dependent mechanism. This directly opposes the claim that omnivores produce less TMAO than vegans."
    },
    "naive_doc_ids": [
      "14803797",
      "29947146",
      "275294",
      "3493623",
      "154050141"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.96,
      "justification": "Paper 1 directly reports that omnivorous human subjects produced more TMAO than vegans or vegetarians after ingestion of L-carnitine via a microbiota-dependent mechanism. This is the opposite of the claim that omnivores produce less TMAO than vegans. The other papers are unrelated to TMAO or L-carnitine metabolism."
    },
    "overthinking_doc_ids": [
      "14803797",
      "253672",
      "3716075",
      "5885376",
      "7224632"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.94,
      "justification": "Paper 5 reports that, after ingestion of L-carnitine, omnivorous human subjects produced more TMAO than vegans or vegetarians via a microbiota-dependent mechanism. This directly opposes the claim that omnivores produce less TMAO than vegans from dietary L-carnitine. Other provided papers do not address this specific comparison."
    },
    "posthoc_doc_ids": [
      "6793674",
      "7230315",
      "26658659",
      "3716075",
      "14803797"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "841",
    "claim": "Natriuretic peptides protect against diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 directly examines natriuretic peptides (BNP/NT-pro-BNP) and type 2 diabetes. It reports that higher baseline NT-pro-BNP is associated with a 21% lower risk of incident T2D per SD increase after multivariable adjustment, and Mendelian randomization using a BNP-raising variant (rs198389) shows a concordant, inverse association with T2D risk, supporting a potential causal protective effect of the BNP system. The other papers do not address natriuretic peptides and provide no relevant information for this claim."
    },
    "naive_doc_ids": [
      "1907601",
      "3621011",
      "120626",
      "15663829",
      "1974176"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 directly tests the relationship between natriuretic peptides and type 2 diabetes. In a prospective analysis, higher NT\u2011pro\u2011BNP levels were associated with lower incident T2D risk (HR \u2248 0.82 per SD increase), and Mendelian randomization using rs198389 (which raises BNP) showed reduced T2D odds (OR \u2248 0.94 per allele), consistent with a causal protective effect. The other papers do not address natriuretic peptides in relation to diabetes risk. Thus, the provided evidence supports that natriuretic peptides protect against diabetes."
    },
    "overthinking_doc_ids": [
      "15663829",
      "1974176",
      "13619127",
      "68317730",
      "3067015"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 3 provides direct evidence that higher circulating B-type natriuretic peptide (NT-pro-BNP) levels are associated with a lower risk of incident type 2 diabetes and uses Mendelian randomization (rs198389 in the BNP locus) to support a likely causal protective role of the BNP system. The remaining papers do not address natriuretic peptides in relation to diabetes risk and do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "43483151",
      "13619127",
      "15663829",
      "6176498",
      "1974176"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "650",
    "claim": "Integrating classroom-based collaborative learning with Web-based collaborative learning offers the best class performance.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the provided papers address educational interventions or compare classroom-based and Web-based collaborative learning or their integration on class performance. The studies focus on medical treatments, diagnostics, and online medication information, which are unrelated to the claim."
    },
    "naive_doc_ids": [
      "13256155",
      "15997009",
      "10072941",
      "3654468",
      "4506702"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers present data on integrating classroom-based collaborative learning with Web-based collaborative learning or compare class performance across such modalities. The only education-related paper (Paper 7) discusses computer assisted learning conceptually in medical education without empirical results on collaborative learning integration. The remaining papers concern biomedical topics or healthcare delivery, not instructional modality comparisons."
    },
    "overthinking_doc_ids": [
      "18199839",
      "21958900",
      "27866735",
      "96222213",
      "313394"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.96,
      "justification": "None of the provided papers present empirical data on integrating classroom-based collaborative learning with Web-based collaborative learning or its impact on class performance. Paper 8 discusses computer-assisted learning conceptually without comparative outcomes on this specific integration, and the remaining papers focus on medical/clinical topics unrelated to educational pedagogy or performance."
    },
    "posthoc_doc_ids": [
      "841371",
      "1191830",
      "1412089",
      "18199839",
      "21958900"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1352",
    "claim": "Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Paper 1 explicitly reports that the Aedes aegypti C-type lectin mosGCTL-1 is induced by West Nile virus infection and facilitates infection, directly supporting the claim. The other papers do not address mosGCTL-1 regulation during WNV infection."
    },
    "naive_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "23915841",
      "13702924"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Paper 1 explicitly reports that the Aedes aegypti C-type lectin mosGCTL-1 is induced by West Nile virus (WNV), interacts with WNV, and facilitates infection. This directly confirms the claim of upregulation upon WNV infection. Papers 2\u20134 do not address mosGCTL-1 expression and are not relevant to this specific claim."
    },
    "overthinking_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "38376189"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Paper 1 directly reports that the Aedes aegypti C-type lectin mosGCTL-1 is induced by West Nile virus infection and facilitates infection, indicating upregulation upon WNV exposure. The other papers do not address mosGCTL-1. Thus, the claim is supported by experimental evidence in Paper 1."
    },
    "posthoc_doc_ids": [
      "12885341",
      "10559501",
      "34287602",
      "2947124",
      "8563659"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1347",
    "claim": "Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 2 reports that memory (but not naive) CD4+ T cells enhance production of multiple innate inflammatory cytokines and chemokines in the lung during influenza infection, leading to early viral control. This directly opposes the claim that influenza-specific memory CD4+ T cells greatly diminish early inflammatory chemokine production. The other papers do not address early chemokine production by memory CD4+ T cells."
    },
    "naive_doc_ids": [
      "3835423",
      "19005293",
      "2248870",
      "12100963",
      "26068103"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 4 directly reports that memory (but not naive) CD4+ T cells enhance production of multiple innate inflammatory cytokines and chemokines in the lung during influenza infection, leading to early viral control. This is the opposite of the claim that they diminish early inflammatory chemokine production. The other papers do not address this specific outcome."
    },
    "overthinking_doc_ids": [
      "3835423",
      "2248870",
      "12100963",
      "19005293",
      "696006"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.91,
      "justification": "Paper 3 directly reports that influenza-specific memory CD4+ T cells enhance, rather than diminish, early production of multiple innate inflammatory cytokines and chemokines in the lung, leading to early viral control. Papers 1 and 2 do not address early chemokine production, and Paper 4 is unrelated to influenza or T cell\u2013mediated chemokine responses. Therefore, the provided evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "3835423",
      "12100963",
      "19005293",
      "11721286"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1364",
    "claim": "Venules have less significant tunica adventitia than arterioles.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address or present data on the comparative structure of venules versus arterioles, specifically the thickness or significance of the tunica adventitia. The studies focus on burn treatments, imaging of atherosclerosis, staining methods, EMT in cancer cells, bacterial chemotaxis, and functional vasoreactivity of arterioles, but not vessel wall histology comparing venules and arterioles."
    },
    "naive_doc_ids": [
      "3690068",
      "27944135",
      "87758",
      "32827351",
      "3848469"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers address vascular wall histology or compare the tunica adventitia of venules versus arterioles. Paper 1 concerns atherosclerotic burden and imaging; Paper 2 studies endothelium-mediated relaxation in coronary arterioles without discussing adventitia; Paper 3 analyzes cost-effectiveness of burn dressings; Paper 4 compares asthma treatments; Paper 5 evaluates semaglutide for type 2 diabetes. Therefore, the evidence does not inform the specific anatomical claim."
    },
    "overthinking_doc_ids": [
      "87758",
      "1122279",
      "3690068",
      "602760",
      "3654468"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers address comparative vessel wall histology of venules versus arterioles or the relative prominence of the tunica adventitia. The studies focus on atherosclerosis imaging, microvascular function in arterioles, burn dressings, surgical mesh biocompatibility, proteasome structures, GPCR signaling, gallstone pain patterns, plant DNA cytometry, and nephroprotection\u2014none provide data on venule vs arteriole adventitia."
    },
    "posthoc_doc_ids": [
      "87758",
      "1122279",
      "3690068",
      "1156322",
      "1744752"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "776",
    "claim": "Mice defective for deoxyribonucleic acid (DNA) polymerase m (polm) fail to reveal increased sensitivity to ionizing radiation (IR).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the provided papers report experimental data on ionizing radiation sensitivity in DNA polymerase mu (pol \u03bc)-defective mice. Paper 5 implicates pol \u03bc in NHEJ and shows its recruitment after IR in cells, but does not assess IR sensitivity in pol \u03bc knockout mice. Other papers focus on different polymerases (pol \u03b7, pol \u03bb, pol \u03b2) or unrelated systems. Thus, there is no direct evidence here to confirm or refute the claim."
    },
    "naive_doc_ids": [
      "43014661",
      "21878751",
      "31293581",
      "12552297",
      "27635177"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers examine DNA polymerase mu (Pol \u03bc) or the ionizing radiation sensitivity of Pol \u03bc\u2013deficient mice. The studies address other DNA polymerases (Pol \u03b2 in CHO cells), IR-induced senescence irrespective of p53/immune status, or unrelated pathways and models (TLR2, CD4, IFN-\u03b3 receptor, ATM, CFTR/PPAR\u03b3, TRP2, pancreatic cancer xenografts). Therefore, the evidence set does not support or refute the specific claim about Pol \u03bc\u2013defective mice and IR sensitivity."
    },
    "overthinking_doc_ids": [
      "11569583",
      "31293581",
      "52805891",
      "21878751",
      "24338780"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers evaluate ionizing radiation sensitivity in DNA polymerase mu (pol\u03bc/polm)-defective mice. The papers address other polymerases (Pol \u03b2, Pol \u03bb, Pol \u03b7), general IR-induced senescence, or unrelated genetic models. Paper 3 mentions pol\u03bc only in the context of NHEJ repair assays in cells, not IR sensitivity in mice."
    },
    "posthoc_doc_ids": [
      "11569583",
      "31293581",
      "12552297",
      "37205759",
      "52805891"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "250",
    "claim": "Chenodeoxycholic acid treatment decreases brown adipose tissue activity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 directly reports that oral chenodeoxycholic acid (CDCA) treatment in humans increases brown adipose tissue (BAT) activity and whole-body energy expenditure, and in vitro CDCA increases mitochondrial uncoupling and D2 expression in human brown adipocytes. This directly opposes the claim that CDCA decreases BAT activity. The other papers discuss BAT/beige fat thermogenesis and related mechanisms but do not address CDCA; thus they neither support nor alter the contradiction established by Paper 1."
    },
    "naive_doc_ids": [
      "1568684",
      "26902591",
      "4319174",
      "40232172",
      "17973161"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 reports that oral chenodeoxycholic acid (CDCA) treatment in humans increased brown adipose tissue (BAT) activity and whole-body energy expenditure, and in vitro CDCA increased mitochondrial uncoupling and D2 expression in human brown adipocytes. This directly opposes the claim that CDCA decreases BAT activity. Papers 2\u20134 do not address CDCA\u2019s effect on BAT activity."
    },
    "overthinking_doc_ids": [
      "1568684",
      "40232172",
      "41790911",
      "3621011"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.96,
      "justification": "Paper 1 directly reports that oral chenodeoxycholic acid (CDCA) increased human brown adipose tissue (BAT) activity and whole-body energy expenditure, and enhanced mitochondrial uncoupling and D2 expression in primary human brown adipocytes. This opposes the claim that CDCA decreases BAT activity. The other papers do not provide relevant data on CDCA\u2019s effect on BAT."
    },
    "posthoc_doc_ids": [
      "1568684",
      "40232172",
      "3621011",
      "9846940",
      "14865329"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "126",
    "claim": "Approximately 250,000 people are infected with human T-cell lymphotropic virus type 1 in the United Kingdom.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "None of the provided papers report a population-level estimate of HTLV-1 prevalence in the UK. Paper 1 discusses HTLV-I/II-associated diseases and notes small numbers of diagnosed ATLL and HAM/TSP cases in the UK during specific years, but does not provide an estimate of total infections. The other papers concern unrelated topics (HIV, other STIs, transplantation complications, KSHV-related lymphomas, prison self-harm) or clinical management of ATLL, without UK prevalence figures for HTLV-1. Therefore, the evidence does not confirm or refute the claim that ~250,000 people in the UK are infected with HTLV-1."
    },
    "naive_doc_ids": [
      "24512064",
      "13900610",
      "5850219",
      "11344428",
      "20996244"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.97,
      "justification": "None of the provided papers address human T-cell lymphotropic virus type 1 (HTLV-1) or its prevalence in the United Kingdom. The papers cover unrelated topics such as childhood underweight, mental disorders, glaucoma, Creutzfeldt-Jakob disease, cancer survivorship in the US, bariatric surgery outcomes in the UK, and ICU organizational changes. Therefore, they provide no information to verify the claim about 250,000 HTLV-1 infections in the UK."
    },
    "overthinking_doc_ids": [
      "1606628",
      "6490571",
      "8298120",
      "27063470",
      "9547722"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the provided papers address human T-cell lymphotropic virus type 1 (HTLV-1) or its prevalence in the United Kingdom. The papers cover topics such as Creutzfeldt-Jakob disease, cancer survivorship in the US, bariatric surgery outcomes, HIV-related biomarkers and virology, mesenchymal stem cells, statin effects, and mechanisms of beta-cell death in diabetes. Therefore, they contain no relevant information to verify or refute the claim about ~250,000 HTLV-1 infections in the UK."
    },
    "posthoc_doc_ids": [
      "27063470",
      "9547722",
      "5824985",
      "20471181",
      "2853291"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1288",
    "claim": "There is a positive correlation between hip fractures and statin use.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 5 directly examines statin use and hip fracture risk in elderly patients and finds a significant reduction in hip fractures among statin users (adjusted ORs 0.50 for prior 180 days, 0.57 for prior 3 years; current use OR 0.29), indicating a negative association, not a positive one. Other papers do not address statin use and hip fractures. Therefore, the claim of a positive correlation is contradicted by the provided evidence."
    },
    "naive_doc_ids": [
      "6793674",
      "439670",
      "1831916",
      "46182525",
      "4687948"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers analyze the association between statin use and hip fractures. Paper 1 discusses statins but only in relation to cardiovascular outcomes and mortality, not fractures. Other papers address unrelated topics (osteoporosis treatments unrelated to statins, antidepressants and fractures, pollution and anxiety, vitamin D and pregnancy outcomes, etc.). Therefore, there is no relevant evidence to assess a correlation between statin use and hip fractures."
    },
    "overthinking_doc_ids": [
      "5698494",
      "26000593",
      "439670",
      "27150276",
      "15997009"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers analyze hip fractures in relation to statin use. Papers mentioning statins address cost-effectiveness (Paper 1) or gallstone disease risk (Paper 3). Fracture outcomes appear only in the context of antidepressant use (Paper 4) or osteoporosis treatments (Paper 7), not statins. Therefore, there is no relevant evidence here to assess a correlation between statin use and hip fractures."
    },
    "posthoc_doc_ids": [
      "1287809",
      "2052720",
      "22420524",
      "5691302",
      "791050"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1200",
    "claim": "The binding orientation of the ML-SA1 activator at hTRPML2 is different from the binding orientation of the ML-SA1 activator at hTRPML1.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Only Paper 1 discusses TRPML1 and its agonist-binding site (likely with ML-SA1), but none of the papers provide structural or binding-orientation data for ML-SA1 at hTRPML2 or a direct comparison between hTRPML1 and hTRPML2. The remaining papers are unrelated to TRPML channels. Therefore, the provided evidence does not address whether ML-SA1 binds in a different orientation at hTRPML2 versus hTRPML1."
    },
    "naive_doc_ids": [
      "3441524",
      "4828984",
      "6903077",
      "32827351",
      "3052213"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss TRPML1, TRPML2, or the ML-SA1 activator, nor do they address ligand binding orientations for these channels. Therefore, they do not contain information relevant to verifying whether ML-SA1 binds in different orientations to hTRPML1 versus hTRPML2."
    },
    "overthinking_doc_ids": [
      "3610282",
      "4828984",
      "6903077",
      "169264",
      "799586"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "Among the provided papers, only Paper 4 addresses TRPML channels and presents hTRPML1 structures with an agonist (likely ML-SA1) and its binding site. None of the papers provide structural or biochemical data on ML-SA1 binding to hTRPML2, nor do they compare binding orientations between hTRPML2 and hTRPML1. Therefore, the evidence set does not contain information to confirm or refute the claim about differing binding orientations between hTRPML2 and hTRPML1."
    },
    "posthoc_doc_ids": [
      "15472716",
      "25682129",
      "140874",
      "3441524",
      "10247314"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "789",
    "claim": "Microglia are an innate immune cell type of the central nervous system.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.69,
      "justification": "Paper 9 identifies microglia as phagocytic cells within the CNS that, upon activation, directly interact with injured axons\u2014behavior characteristic of innate immune phagocytes. Paper 7 states that mononuclear phagocytes (e.g., macrophages) contribute to innate immunity; together with Paper 9 showing microglia as CNS-resident phagocytes functionally akin to macrophages, this supports that microglia are an innate immune cell type of the CNS."
    },
    "naive_doc_ids": [
      "19238",
      "3118719",
      "12742164",
      "4402497",
      "1196631"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data or discussion specifically about microglia or their classification as innate immune cells of the central nervous system. The papers address CNS stem cells, myelin basic protein gene expression, T cell\u2013mediated CNS autoimmunity, innate lymphoid cells in influenza, MDA5 in chicken macrophages, and NADPH oxidase in phagocytes, but do not mention microglia."
    },
    "overthinking_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "696006",
      "14474178"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data or statements specifically about microglia or explicitly classify microglia as innate immune cells of the CNS. The papers cover CNS stem cells, myelin gene expression, T cell-mediated CNS autoimmunity, costimulation in systemic infection, neuroinflammation after spinal cord injury, IFN-\u03b3 in tuberculosis, and tissue macrophage origins/maintenance (largely non-CNS examples). While some discuss macrophages and innate immunity broadly, they do not connect this to microglia within the CNS in the provided evidence."
    },
    "posthoc_doc_ids": [
      "12742164",
      "19238",
      "22647695",
      "35651106",
      "41822527"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "398",
    "claim": "Exhaustion of B cells contributes to poor Ab response in HIV-infected individuals.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers address B cell exhaustion in HIV-infected individuals or link it to poor antibody responses. The studies cover vaccine immunogenicity in healthy adults, T cell costimulation in influenza, B cell migration mechanisms (EBI2/CXCL13/S1P), macrophage-mediated antigen relay, T cell anergy in schistosomiasis, IL28B genetics in HCV therapy response, and exosomes in ovarian cancer. No experimental data or results pertain to B cell exhaustion in HIV or its impact on antibody responses."
    },
    "naive_doc_ids": [
      "32353339",
      "40473317",
      "38587347",
      "15488881",
      "7386360"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers address B cell exhaustion or antibody responses in HIV-infected individuals. The studies focus on T cell costimulation in influenza, B cell migration and niche signaling, memory T cell lineages, NLRP3 in antitumor immunity, antigen relay by SCS macrophages, and DNA damage responses in hematopoietic stem cells. Therefore, they do not provide evidence to confirm or refute the claim about B cell exhaustion contributing to poor antibody responses in HIV."
    },
    "overthinking_doc_ids": [
      "40473317",
      "38587347",
      "991137",
      "15435343",
      "9705208"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on B cell exhaustion in HIV or link B cell exhaustion to poor antibody responses in HIV-infected individuals. Most papers address B cell migration (EBI2/CXCL13), T cell help and tissue-resident memory, cancer prognosis, or inflammasome effects in tumors. The single HIV-related paper (Paper 9) describes the kinetics and specificity of neutralizing antibodies in acute subtype C infection but does not evaluate B cell exhaustion or its impact on antibody quality or magnitude."
    },
    "posthoc_doc_ids": [
      "38587347",
      "39443128",
      "3899896",
      "24879055",
      "3835423"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1324",
    "claim": "Treatment with a protein named FN restores regenerative abilities of aged muscles.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that aged skeletal muscle niches have reduced fibronectin (FN) and that reconstituting FN levels in aged mice remobilizes muscle stem cells and restores youth-like muscle regeneration. The other papers do not address FN treatment and neither contradict this finding. Therefore, the evidence supports the claim (in mice)."
    },
    "naive_doc_ids": [
      "19912367",
      "20418809",
      "20186814",
      "16660256",
      "8771704"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that aged skeletal muscle niches have reduced fibronectin (FN) and that reconstituting FN levels in the aged niche remobilizes muscle stem cells and restores youth-like muscle regeneration in mice. The other papers do not address FN in muscle regeneration and neither contradict nor add to this specific claim. Thus, the evidence supports that FN treatment can restore regenerative abilities of aged muscles (at least in a mouse model)."
    },
    "overthinking_doc_ids": [
      "19912367",
      "16660256",
      "19770974",
      "20418809",
      "3464191"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that aged skeletal muscle has reduced fibronectin (FN) in the stem cell niche, impairing muscle stem cell function, and that reconstitution of FN levels in the aged niche remobilizes stem cells and restores youth-like muscle regeneration. This matches the claim that FN treatment restores regenerative abilities of aged muscles. The other papers are not directly relevant to FN and do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "19912367",
      "20418809",
      "4326318",
      "2559303",
      "20186814"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1008",
    "claim": "RUNX is not expressed in skin tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers discuss RUNX (RUNX1/2/3 or CBF-related factors) expression in skin tissue. The evidence focuses on other genes (e.g., K17, AIRE, p16INK4A, MBP/Golli, HOX) or on general single-cell transcription dynamics, placental transcription factors, and glioblastoma profiles. Therefore, the papers do not provide relevant data to confirm or refute the claim about RUNX expression in skin."
    },
    "naive_doc_ids": [
      "12580014",
      "19343151",
      "19238",
      "8290760",
      "9154703"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention RUNX (RUNX1/2/3) expression or analyze its presence in skin tissue. The studies focus on MBP/Golli expression (immune/CNS), Aire and keratin 17 in skin tumor keratinocytes, microRNA in blood, epidermal keratinocyte protocols, and iPSC gene regulation/reprogramming. Therefore, they do not provide evidence to support or refute the claim about RUNX expression in skin."
    },
    "overthinking_doc_ids": [
      "19238",
      "12580014",
      "663464",
      "15907458",
      "4632921"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data on RUNX (RUNX1/2/3) expression in skin tissue. Paper 1 discusses RUNX1 in hematopoiesis; Paper 2 examines keratin/Aire in skin tumor keratinocytes without mentioning RUNX; Paper 3 addresses p16INK4A in skin; the remaining papers concern other tissues or pathways. There is no evidence here confirming absence or presence of RUNX in skin."
    },
    "posthoc_doc_ids": [
      "12315072",
      "12580014",
      "19343151",
      "19238",
      "663464"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.08,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "306",
    "claim": "DUSP4 decreases apoptosis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 reports that DUSP4 overexpression increases chemotherapy-induced apoptosis, while DUSP4 depletion reduces the apoptotic response to chemotherapy. This indicates DUSP4 promotes, rather than decreases, apoptosis under these conditions. The other papers do not provide evidence about DUSP4 and apoptosis."
    },
    "naive_doc_ids": [
      "33667484",
      "935034",
      "2543135",
      "10450725",
      "32852283"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 reports that DUSP4 overexpression increases chemotherapy-induced apoptosis, while DUSP4 depletion reduces the apoptotic response to chemotherapy in breast cancer. This indicates DUSP4 promotes, not decreases, apoptosis (at least in the context of chemotherapy). The other papers do not provide relevant data on DUSP4's effect on apoptosis."
    },
    "overthinking_doc_ids": [
      "7821634",
      "238409",
      "935034",
      "24190159",
      "7165938"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 2 directly examines DUSP4 and reports that DUSP4 overexpression increases chemotherapy-induced apoptosis, while DUSP4 depletion reduces the apoptotic response to chemotherapy in breast cancer models. This indicates DUSP4 promotes, rather than decreases, apoptosis in this context. The other papers do not address DUSP4."
    },
    "posthoc_doc_ids": [
      "33370",
      "7821634",
      "10852047",
      "17231273",
      "3765739"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "124",
    "claim": "Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 (systematic review and meta-analysis) directly shows that ART reduces tuberculosis incidence across CD4 strata, reporting hazard ratios well below 1 for <200 (HR 0.16), 200\u2013350 (HR 0.34), and >350 cells/\u00b5l (HR 0.43), with no evidence of effect modification by baseline CD4 (p=0.20). This aligns precisely with the claim. The other papers do not address TB incidence across CD4 strata and do not contradict this finding."
    },
    "naive_doc_ids": [
      "4883040",
      "7111021",
      "13899137",
      "11254040",
      "31363207"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 (systematic review and meta-analysis) directly shows that ART reduces tuberculosis incidence across baseline CD4 categories: HR 0.16 (<200 cells/\u00b5l), 0.34 (200\u2013350), and 0.43 (>350), with no evidence of effect modification by CD4 (p=0.20). This aligns precisely with the claim. The other papers do not address TB incidence across CD4 strata and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "4883040",
      "7111021",
      "31363207",
      "13899137",
      "13901073"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Paper 1 (systematic review and meta-analysis) directly shows that ART reduces tuberculosis incidence across all baseline CD4 strata, reporting significant hazard ratio reductions for <200, 200\u2013350, and >350 cells/\u00b5l, with no evidence of effect modification by CD4 category. Other papers are not directly relevant and do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "4883040",
      "7111021",
      "13899137",
      "2931832",
      "22123421"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "574",
    "claim": "In domesticated populations of Saccharomyces cerevisiae, segmental aneuploidy occurs infrequently.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 1 addresses domesticated/industrial Saccharomyces cerevisiae populations, but the excerpt does not report on the frequency of segmental aneuploidy. The other papers focus on RNA processing (Paper 2), human health-related quality of life (Paper 3), rDNA copy number in cancer (Paper 4), meiotic DSB mapping in yeast (Paper 5), and SIR2 and lifespan in yeast (Paper 6), none of which provide data about segmental aneuploidy in domesticated S. cerevisiae. Therefore, the claim cannot be verified with the provided evidence."
    },
    "naive_doc_ids": [
      "10300888",
      "365896",
      "463533",
      "14019636",
      "10874408"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper excerpts present data on the frequency of segmental aneuploidy in domesticated/industrial Saccharomyces cerevisiae. Paper 1 discusses domestication, lineage structure, and selection on traits in industrial yeasts but does not mention aneuploidy. Papers 2\u20134 address galactokinase induction, RNA processing kinetics, and meiotic DSB mapping, respectively, which are unrelated to segmental aneuploidy frequency."
    },
    "overthinking_doc_ids": [
      "10300888",
      "42421723",
      "365896",
      "10874408"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided paper summaries report data or explicit statements about the frequency of segmental aneuploidy in domesticated Saccharomyces cerevisiae. Papers 1\u20133 and 4 are unrelated to aneuploidy. Paper 5 discusses domestication, genomic/phenotypic divergence, and selection in industrial yeasts but, in the provided text, does not mention segmental aneuploidy or its frequency. Therefore, the claim cannot be verified or refuted from the given evidence."
    },
    "posthoc_doc_ids": [
      "365896",
      "1256116",
      "4414481",
      "463533",
      "10300888"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "684",
    "claim": "Lack of clpC does not affect sporulation efficiency in Bacillus subtilis cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "None of the provided excerpts report experimental data on sporulation efficiency of a clpC knockout in Bacillus subtilis. Paper 1 discusses identification of sporulation genes but does not mention clpC in the excerpt. Papers 2 and 4 address regulation and roles of clpC/CtsR and Clp proteolysis under stress, and Paper 3 concerns motility; none evaluate sporulation efficiency in clpC-deficient cells."
    },
    "naive_doc_ids": [
      "4942718",
      "34386619",
      "12824568",
      "12881593"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.74,
      "justification": "None of the provided paper summaries present data on the effect of clpC deletion on sporulation efficiency in Bacillus subtilis. Paper 1 discusses identification of sporulation genes via Tn-seq but does not mention clpC specifically or its phenotype. Papers 2 and 3 focus on regulation and proteolysis of Clp proteins under stress, not sporulation outcomes. Paper 4 concerns regulation of an ABC transporter and is unrelated to sporulation. Therefore, the evidence provided does not address the claim."
    },
    "overthinking_doc_ids": [
      "4942718",
      "34386619",
      "12881593",
      "2851611"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on how deletion or absence of clpC affects sporulation efficiency in Bacillus subtilis. Paper 1 focuses on regulation of the clpC operon by CtsR and heat shock response, not sporulation. Paper 2 describes a Tn-seq screen for sporulation genes but the excerpt does not indicate whether clpC was implicated. Paper 3 discusses Clp protein regulation and interactions under stress, without addressing sporulation outcomes. Therefore, the evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "34386619",
      "4942718",
      "12881593"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "992",
    "claim": "Pyridostatin deregulates G2/M progression.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers mention pyridostatin or present data on its effects on G2/M progression. While some papers discuss cell cycle regulation, DNA replication stress, G-quadruplex biology, and mitotic DNA synthesis, they do not evaluate pyridostatin specifically or its impact on G2/M. Therefore, the evidence set does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "16839245",
      "2212067",
      "2613411",
      "12922760",
      "15600979"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers mention pyridostatin or present experimental data on its effects on the cell cycle. While some papers discuss general cell cycle regulation (e.g., APC/C, E2F, checkpoints) or use flow cytometry, they do not address pyridostatin or G2/M deregulation specifically."
    },
    "overthinking_doc_ids": [
      "8025177",
      "371289",
      "5700349",
      "16839245",
      "39225849"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 7 reports that the G-quadruplex-stabilizing compound pyridostatin (PDS) reduces proliferation of homologous recombination\u2013defective cells by inducing DNA double-strand breaks, checkpoint activation, and deregulated G2/M progression. This directly supports the claim that pyridostatin deregulates G2/M progression. Other provided papers do not address pyridostatin."
    },
    "posthoc_doc_ids": [
      "2212067",
      "2613411",
      "4412772",
      "263364",
      "601033"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "680",
    "claim": "Lack of FGF21 in mice increases life expectancy.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 5 shows that FGF21 deficiency in mice (ApoE\u2212/\u2212 background) markedly worsens atherosclerosis and leads to premature death, while FGF21 replenishment is protective. This indicates reduced, not increased, lifespan with lack of FGF21. The other papers do not provide lifespan data related to FGF21."
    },
    "naive_doc_ids": [
      "6313547",
      "4434951",
      "597790",
      "9513785",
      "9315213"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 directly examines FGF21 deficiency in mice (on an apolipoprotein E\u2212/\u2212 background) and reports that lack of FGF21 causes marked exacerbation of atherosclerosis and premature death, indicating shortened lifespan, not increased life expectancy. Other provided papers do not address FGF21 and lifespan. Therefore, the claim that lack of FGF21 increases life expectancy in mice is contradicted by the evidence."
    },
    "overthinking_doc_ids": [
      "9513785",
      "10017612",
      "14188138",
      "980008",
      "4414481"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers evaluate lifespan or life expectancy in FGF21-deficient (knockout) mice. The only FGF21-related study (Paper 6) shows that increased FGF21 expression (induced by autophagy deficiency) protects against obesity and insulin resistance, but it does not address longevity and does not test FGF21 loss. Therefore, the set does not contain direct evidence to confirm or refute that lack of FGF21 increases life expectancy."
    },
    "posthoc_doc_ids": [
      "9513785",
      "6313547",
      "10017612",
      "18691097",
      "2481032"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1058",
    "claim": "Roughly 55% of women with chronic pelvic pain have no underlying pathology.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report the proportion of women with chronic pelvic pain who lack an identifiable underlying pathology. The relevant gynecologic study (Paper 3) is an RCT evaluating the efficacy of laparoscopic uterosacral nerve ablation and does not provide prevalence data on pathology absence. The other papers address unrelated topics (anxiety prevalence, rotator cuff test accuracy, adhesiolysis for abdominal\u2014not specifically pelvic\u2014pain, CKD, COPD, and fructosamine). Therefore, the evidence set does not confirm or refute the claim that ~55% of women with chronic pelvic pain have no underlying pathology."
    },
    "naive_doc_ids": [
      "32357890",
      "44586415",
      "13027590",
      "3190689",
      "8318922"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper excerpts report the proportion of women with chronic pelvic pain who have no identifiable underlying pathology. Paper 1 evaluates LUNA effectiveness and mentions inclusion criteria (without or minimal pathology) but does not quantify how many had no pathology. Papers 2\u20134 address different conditions (adhesions in chronic abdominal pain, low back pain with osteoarthritis, and CKD/hypertension) and do not provide relevant prevalence data. Therefore, the claim cannot be verified from these excerpts."
    },
    "overthinking_doc_ids": [
      "13027590",
      "3190689",
      "14724693",
      "8318922"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the provided papers report the proportion of women with chronic pelvic pain who have no identifiable underlying pathology. Paper 1 is an RCT of LUNA in women with chronic pelvic pain (with or without minimal pathology) and reports treatment outcomes, not prevalence of absent pathology. The remaining papers address unrelated topics (lifestyle and mortality, gallstone pain, adhesiolysis for abdominal pain, glucosamine for low back pain, CKD hemodynamics, troponin assay accuracy, and glaucoma prevalence). Therefore, the claim is not verifiable from the provided evidence."
    },
    "posthoc_doc_ids": [
      "13027590",
      "1456068",
      "13223957",
      "3190689",
      "14724693"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "267",
    "claim": "Cognitive behavioral therapy is an ineffective treatment for insomnia",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 4 reports a randomized, double-blind, placebo-controlled trial in older adults with chronic primary insomnia showing that cognitive behavioral therapy (CBT) produced superior short- and long-term outcomes compared with zopiclone and placebo. CBT significantly improved sleep efficiency (from 81.4% to 90.1% at 6 months), increased slow-wave sleep, and reduced wake time. These results indicate CBT is effective for insomnia, contradicting the claim. The other papers are not about insomnia and do not affect this conclusion."
    },
    "naive_doc_ids": [
      "4883040",
      "14606752",
      "15997009",
      "5912283",
      "6191684"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 4 reports a randomized, double-blind, placebo-controlled trial in older adults with chronic primary insomnia showing that cognitive behavioral therapy (CBT) produced significant short- and long-term improvements (e.g., increased sleep efficiency from 81.4% to 90.1%, more slow-wave sleep, less wake time) and was superior to zopiclone, which often did not differ from placebo. This demonstrates CBT is effective for insomnia, contradicting the claim. The other papers are unrelated to insomnia or CBT."
    },
    "overthinking_doc_ids": [
      "6137330",
      "1191830",
      "24323369",
      "5912283",
      "7074001"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly tests CBT for chronic primary insomnia in older adults in a randomized, double-blind, placebo-controlled trial and finds CBT improves sleep efficiency, increases slow-wave sleep, and reduces wake time, with benefits persisting at 6 months and outperforming zopiclone (which often did not differ from placebo). These results indicate CBT is effective for insomnia, contradicting the claim. The other papers are not about insomnia and are not relevant to this claim."
    },
    "posthoc_doc_ids": [
      "5912283",
      "24865781",
      "6191684",
      "4515975",
      "5402581"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "324",
    "claim": "Deleting Raptor reduces G-CSF levels.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers examine Raptor deletion or report its effect on G-CSF levels. While some papers discuss G-CSF regulation (e.g., by IL-17 or adipocytes via neuropilin-1) and others address mTOR pathway components (rictor/rictor-mTOR, mTOR inhibition), there is no direct evidence linking Raptor deletion to reduced G-CSF."
    },
    "naive_doc_ids": [
      "188911",
      "42465769",
      "24612804",
      "4658268",
      "26735905"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers examine the effects of Raptor deletion on G-CSF (granulocyte colony-stimulating factor) levels. While several papers discuss mTOR pathway components (raptor, rictor, mTORC1) and related signaling or outcomes (e.g., cytoskeleton regulation, inflammation, ICAM-1 expression, tumorigenesis), there is no experimental data or results linking Raptor deletion specifically to changes in G-CSF."
    },
    "overthinking_doc_ids": [
      "3984231",
      "4658268",
      "5409325",
      "1344498",
      "26735905"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention Raptor (Rptor) or investigate the effect of Raptor deletion on granulocyte colony-stimulating factor (G-CSF) levels. While some papers discuss G-CSF in contexts such as IL-17-mediated granulopoiesis or adipocyte-mediated inhibition via neuropilin-1, there is no evidence relating Raptor deletion to changes in G-CSF. Therefore, the claim is not addressed by the supplied evidence."
    },
    "posthoc_doc_ids": [
      "5409325",
      "11428884",
      "654735",
      "188911",
      "24612804"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1174",
    "claim": "The PPR MDA5 has twenty N-terminal CARD domains.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss MDA5 (IFIH1) or quantify its N-terminal CARD domains. The articles cover topics such as PPAR\u03b3/NLRP3 signaling, HIV-1 Nef, c-Myb with CBP/p300, glutamate receptor ATDs, AgDscam PRRs, Sec7 domains, START domains, and RAR/RXR-coactivator interactions. While Paper 1 mentions a CARD-containing protein (ASC), it does not address MDA5 or the number of its CARD domains."
    },
    "naive_doc_ids": [
      "56486733",
      "6936141",
      "16745747",
      "26011884",
      "6144337"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers discuss MDA5 (IFIH1), pattern recognition receptors, or the number of CARD domains in MDA5. The papers focus on glutamate receptor amino-terminal domains, NusG domain architecture, the Conserved Domain Database generally, Polycomb bivalent domains, and the H2A.Z nucleosome structure. Therefore, they contain no relevant information to verify the specific claim about MDA5 having twenty N-terminal CARD domains."
    },
    "overthinking_doc_ids": [
      "26011884",
      "612002",
      "24550453",
      "10029970",
      "1791637"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss MDA5 (IFIH1) or its domain architecture. While Paper 8 mentions CARD domains in the context of ASC, no paper addresses the number of N-terminal CARD domains in MDA5. Therefore, the claim cannot be verified or refuted from the supplied evidence."
    },
    "posthoc_doc_ids": [
      "26011884",
      "612002",
      "1791637",
      "12149169",
      "24042363"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1190",
    "claim": "The amount of publicly available DNA data doubles every 10 months.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report quantitative growth rates or doubling times for publicly available DNA data. While Paper 1 (NCBI GEO update) and Paper 4 (EMBL nucleotide sequence database) describe public repositories, their excerpts do not provide metrics on data volume growth or a 10-month doubling time. The other papers focus on sequencing tools, alignment formats, bibliometrics, or unrelated clinical studies, and do not address repository growth. Therefore, the claim is not supported or refuted by the provided evidence."
    },
    "naive_doc_ids": [
      "15617300",
      "7324039",
      "1544804",
      "30655442",
      "28633594"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers present quantitative data or time-series analyses on the growth rate of publicly available DNA data. While Paper 1 (GEO update) describes a public genomics repository, it does not report doubling times or growth metrics. The remaining papers focus on molecular interactions, yeast mRNA processing, data visualization tools (IGV, Cytoscape), and public health topics, which are unrelated to the specific claim about data doubling every 10 months."
    },
    "overthinking_doc_ids": [
      "15617300",
      "10247314",
      "17539488",
      "3444507",
      "1606628"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.97,
      "justification": "None of the provided papers present data or analysis on the growth rate or doubling time of publicly available DNA data. They cover topics like health surveys, cost-effectiveness of drugs, SNP selection, genomic software/tools, sequencing biases, and nucleosome inference, but do not quantify repository growth or doubling intervals. Therefore, they do not confirm or refute the claim that DNA data doubles every 10 months."
    },
    "posthoc_doc_ids": [
      "1781626",
      "15048300",
      "15570962",
      "7838799",
      "18494847"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "34",
    "claim": "A deficiency of folate increases blood levels of homocysteine.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple randomized trials and dietary interventions show that increasing folate intake lowers blood homocysteine, implying that low/deficient folate status is associated with higher homocysteine. Paper 1: elderly RCT\u2014400\u2013600 \u00b5g/day folic acid significantly reduced plasma homocysteine vs placebo. Paper 3: dose\u2013response RCT\u2014up to ~23% homocysteine reduction with 0.8 mg/day. Paper 4: crossover diet\u2014high-folate diet raised folate status and lowered tHcy by 13% vs low-folate diet. Paper 6: increased folate from wholegrain bread inversely associated with plasma homocysteine. Population/meta-analytic data align: Paper 5 shows larger homocysteine reductions in regions without folate fortification (i.e., lower baseline folate), and Paper 7 shows the MTHFR variant elevates homocysteine more in low-folate regions. Together, these findings support that folate deficiency increases homocysteine levels. (Paper 8 is unrelated; Paper 2 does not contradict the relationship.)"
    },
    "naive_doc_ids": [
      "21636085",
      "5152028",
      "11705328",
      "18557974",
      "37424881"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple studies show that increasing folate reduces homocysteine, implying that low/deficient folate elevates homocysteine. RCTs in elderly and cardiac patients (Papers 4 and 5) demonstrate significant decreases in plasma/serum homocysteine with folic acid supplementation versus placebo. A genetic meta-analysis (Paper 1) shows the MTHFR 677C\u2192T variant raises homocysteine more in low-folate regions, indicating folate status modifies (and low folate amplifies) homocysteine levels. A meta-analysis of trials (Paper 2) finds larger homocysteine reductions with folic acid in regions without folate fortification, consistent with higher baseline homocysteine due to lower folate. Paper 3 is unrelated. Collectively, the evidence supports that folate deficiency increases blood homocysteine."
    },
    "overthinking_doc_ids": [
      "8595678",
      "37424881",
      "4515975",
      "21636085",
      "11705328"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple papers show that lower folate status is associated with higher homocysteine and that increasing folate lowers homocysteine. A randomized trial (Paper 3) demonstrated dose-dependent reductions in serum homocysteine with folic acid supplementation, implying that inadequate folate is linked to elevated homocysteine. A dietary intervention (Paper 8) increased folate intake and observed corresponding decreases in plasma total homocysteine. Large genetic analyses (Paper 2) found that the MTHFR 677C\u2192T variant raised homocysteine much more in low-folate regions than in high-folate regions, indicating folate deficiency amplifies homocysteine levels. Additional observational/genetic evidence (Paper 7) supports higher homocysteine with lower folate status, particularly in individuals with the TT genotype. Reviews/guidance (Paper 6) also identify low folate as a cause of hyperhomocysteinemia and recommend folic acid to lower homocysteine."
    },
    "posthoc_doc_ids": [
      "2481032",
      "8595678",
      "11705328",
      "12810152",
      "3113630"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "35",
    "claim": "A deficiency of vitamin B12 decreases blood levels of homocysteine.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.75,
      "justification": "The claim states that vitamin B12 deficiency decreases homocysteine, but the provided evidence shows the opposite direction of effect when B vitamins (including B12) are supplied. In a randomized trial in patients with advanced CKD (Paper 8), daily supplementation with folic acid, vitamin B6, and vitamin B12 lowered plasma homocysteine by 25.8% versus placebo. If B12 deficiency decreased homocysteine, adding B12 would be expected to raise, not lower, homocysteine. Additional studies show homocysteine is reduced by folate intake/supplementation (Papers 1 and 7), with no indication that lowering B12 reduces homocysteine. No paper supports the claim that B12 deficiency decreases homocysteine."
    },
    "naive_doc_ids": [
      "18557974",
      "4442799",
      "9555784",
      "36654066",
      "7821634"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.67,
      "justification": "Paper 4 shows that supplementation with folic acid, vitamin B6, and vitamin B12 lowers plasma homocysteine by 25.8%, indicating that adequate B-vitamin status reduces homocysteine rather than deficiency doing so. Paper 5 also shows folic acid supplementation lowers homocysteine. These findings oppose the claim that vitamin B12 deficiency decreases homocysteine. The other papers do not address B12 deficiency or homocysteine."
    },
    "overthinking_doc_ids": [
      "2481032",
      "9555784",
      "13312471",
      "33409100",
      "11705328"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers examine vitamin B12 deficiency or its effect on homocysteine levels. One study (Paper 4) measures homocysteine but only in the context of soy protein/isoflavones and reports no change; the rest focus on vitamin D, orthopedic surgery, lipid metabolism, or magnesium. Therefore, there is no direct evidence here to assess the claim about vitamin B12 deficiency decreasing homocysteine."
    },
    "posthoc_doc_ids": [
      "3150030",
      "9555784",
      "3222187",
      "20083834",
      "11933721"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1345",
    "claim": "Up-regulation of the p53 pathway and related molecular events speeds cancer progression.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "The provided papers discuss pathways and factors such as VEGFR2\u2013GEP100\u2013Arf6\u2013AMAP1, PI3K/AKT/mTOR, Hedgehog and TGF-\u03b2 signaling, MMP polymorphisms, cancer-associated fibroblasts and adipocytes, macrophages, and SREBP2 activation under acidic pH. None address regulation of the p53 pathway or its effects on cancer progression. Thus, they neither support nor contradict the claim about p53 up-regulation accelerating cancer."
    },
    "naive_doc_ids": [
      "9600826",
      "35993767",
      "13329980",
      "13007205",
      "952111"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers assess or report on p53 pathway up-regulation or its effects on cancer progression. The studies focus on hyaluronan and drug delivery (Paper 1), NF-\u03baB inhibition in malignant pleural effusion (Paper 2), lithium in a neurodegenerative model (Paper 3), exercise reducing tumor growth (Paper 4), statins\u2019 in vitro effects on HNSCC (Paper 5), and glutamine transport inhibition (Paper 6). These do not present data about p53 pathway up-regulation accelerating cancer."
    },
    "overthinking_doc_ids": [
      "2565138",
      "14615911",
      "31884697",
      "2242416",
      "1522336"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.96,
      "justification": "None of the provided papers assess up-regulation of the p53 pathway or its related molecular events in relation to cancer progression. The studies focus on integrin signaling, Wnt/BCL9, Notch/MAPK crosstalk, myeloid cells and MMP9, surfactant protein B, statins, and tumor dormancy. Thus, they do not provide data that confirm or refute the claim about p53 pathway up-regulation accelerating cancer progression."
    },
    "posthoc_doc_ids": [
      "4820792",
      "23599024",
      "33638477",
      "1782201",
      "20568364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "615",
    "claim": "Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 shows that LRRK2 Roc-COR mutants (R1441C, Y1699C) preferentially bind deacetylated microtubules and inhibit axonal transport. Increasing microtubule acetylation (via TSA, \u03b1TAT1, or HDAC6/Sirt2 knockdown) prevents mutant LRRK2\u2013microtubule association and restores axonal transport and locomotor behavior. Thus, increased acetylation alleviates rather than worsens the transport interference caused by these mutations. The other papers do not address this specific relationship."
    },
    "naive_doc_ids": [
      "9638032",
      "7549811",
      "16056410",
      "18678095",
      "20743803"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly reports that increasing microtubule acetylation (via deacetylase inhibitors or \u03b1TAT1) prevents mutant LRRK2 (Roc-COR domain) association with microtubules and rescues axonal transport and locomotor deficits. It also shows that mutants preferentially bind deacetylated microtubules. Thus, increased acetylation improves, rather than worsens, the transport defects. Papers 2\u20137 do not address LRRK2\u2013acetylation effects on axonal transport."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "7549811",
      "7925817"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that increasing microtubule acetylation rescues\u2014rather than worsens\u2014axonal transport and locomotor deficits caused by LRRK2 Roc-COR mutations (R1441C, Y1699C). Mutant LRRK2 preferentially associates with deacetylated microtubules; elevating acetylation via deacetylase inhibitors (e.g., TSA) or \u03b1TAT1 prevents this association and restores axonal transport in vitro and in vivo. Papers 2\u20136 do not address the LRRK2\u2013acetylation relationship. Therefore, the claim is contradicted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1546650",
      "1889358",
      "7549811"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "713",
    "claim": "Low expression of miR7a does not repress target genes or exert a biological function in ovaries.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers examine miR-7a expression or function in ovaries. Papers 4 and 6 discuss general microRNA-mediated repression and threshold effects (miRNA targeting and ceRNA dynamics) but do not address miR-7a or ovarian biology. The remaining papers focus on unrelated topics (neuronal SOD1, BPA and IVF outcomes, fungal virulence, avian dosage compensation, and neurotrophin-induced miRNA regulation). Therefore, the evidence does not confirm or refute the specific claim about low miR-7a expression in ovaries."
    },
    "naive_doc_ids": [
      "25827024",
      "5145974",
      "7717468",
      "2000038",
      "12232678"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address miR-7a expression or function in ovaries. The only ovarian-related study (Paper 5) focuses on miR-551b-3p in ovarian cancer, not miR-7a. Other papers discuss unrelated microRNAs (e.g., miR-29a), immune markers, adhesion molecules, or stem cells without mentioning miR-7a or its role in ovarian biology. Therefore, the evidence does not inform whether low miR-7a fails to repress targets or exert function in ovaries."
    },
    "overthinking_doc_ids": [
      "266641",
      "27279525",
      "3118719",
      "16882895",
      "19047331"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers address miR-7a (miR7a) expression, its target repression, or biological function in ovaries. The studies discuss other transcription factors (FOXO, BCL-6, Blimp-1, SATB1), other miRNAs (miR-192, miR-205, miR-71, miR-122), or general miRNA regulatory principles, and in different tissues (brain, lymphocytes, kidney, liver, prostate, T cells). Therefore, they do not provide evidence to confirm or refute the specific claim about low miR-7a in ovaries."
    },
    "posthoc_doc_ids": [
      "29429111",
      "16550075",
      "19828689",
      "18421962",
      "9159495"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "141",
    "claim": "Auditory entrainment is strengthened when people see congruent visual and auditory information.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that congruent audiovisual speech enhances cortical entrainment to the auditory speech envelope (particularly at 2\u20136 Hz) and that incongruence inhibits it, matching the claim. Paper 2 demonstrates low-frequency phase mechanisms that concurrently track audiovisual dynamics, consistent with cross-modal strengthening of entrainment. Paper 4 shows lip-driven visual rhythms entrain brain activity and facilitate intelligibility, supporting the role of visual timing cues in enhancing speech processing. Papers 3 and 5 address auditory entrainment mechanisms but do not bear on audiovisual congruency. No evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "14437255",
      "6955746",
      "23331269",
      "10624000",
      "6985854"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that congruent audiovisual speech enhances cortical entrainment to the auditory speech envelope (most prominently at 2\u20136 Hz) and that incongruent AV information inhibits entrainment, matching the claim. Paper 2 further supports the mechanism by showing that visual speech (lip movements) entrains low-frequency brain oscillations and facilitates speech processing, consistent with enhanced AV integration. Papers 3, 4, and 5 do not directly test congruency effects on auditory entrainment; 4 shows cross-modal phase tracking but not the congruency manipulation. Overall, the evidence confirms that auditory entrainment is strengthened by congruent visual-auditory information."
    },
    "overthinking_doc_ids": [
      "14437255",
      "10624000",
      "6985854",
      "6955746",
      "313394"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that congruent audiovisual speech enhances cortical entrainment to the auditory speech envelope (especially at 2\u20136 Hz) and that entrainment is inhibited when streams are temporally and contextually incongruent. Paper 2 demonstrates low-frequency phase mechanisms in auditory cortex that track both auditory and visual dynamics, supporting a cross-modal basis for such entrainment effects. Paper 4 shows that visual speech (lip movements) entrains low-frequency brain oscillations and facilitates intelligibility, consistent with visual timing cues enhancing auditory processing. Other papers are not relevant. Together, the evidence supports the claim that auditory entrainment is strengthened by congruent audiovisual information."
    },
    "posthoc_doc_ids": [
      "14437255",
      "6955746",
      "3099497",
      "10624000",
      "313394"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.75,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "914",
    "claim": "PPAR-RXRs can be activated by PPAR ligands.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 8 shows that PPAR and RXR\u03b1 form a heterodimer that activates target gene expression (e.g., acyl-CoA oxidase) in response to a PPAR ligand (clofibric acid) as well as to an RXR ligand (9-cis retinoic acid), with synergistic activation when both are present. This directly demonstrates that PPAR\u2013RXR complexes can be activated by PPAR ligands. The other papers do not directly address PPAR\u2013RXR activation, but do not contradict it."
    },
    "naive_doc_ids": [
      "13639330",
      "25606339",
      "56486733",
      "25328476",
      "30805636"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 3 shows that the peroxisome proliferator-activated receptor (PPAR) and retinoid X receptor-\u03b1 (RXR\u03b1) form a heterodimer that activates target gene (acyl-CoA oxidase) expression in response to clofibric acid, a peroxisome proliferator and PPAR ligand. This demonstrates that PPAR\u2013RXR heterodimers can be activated by PPAR ligands. Other papers provided do not address this mechanistic point."
    },
    "overthinking_doc_ids": [
      "24150328",
      "4319174",
      "8458567",
      "13368032",
      "13916951"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "Among the provided papers, only Paper 5 and Paper 6 touch on PPARs. Paper 5 measures PPAR-gamma mRNA expression in obese patients\u2019 livers; it does not address activation of PPAR-RXR heterodimers or ligand-driven activation. Paper 6 uses a PPAR-gamma agonist (rosiglitazone) in a clinical trial and reports clinical/biochemical outcomes but provides no molecular evidence about activation of PPAR-RXR complexes by PPAR ligands. The remaining papers are unrelated to PPAR/RXR biology. Therefore, the set does not contain direct evidence confirming or refuting that PPAR-RXRs can be activated by PPAR ligands."
    },
    "posthoc_doc_ids": [
      "5828251",
      "15972906",
      "20690388",
      "8453819",
      "22478394"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1322",
    "claim": "Transplanted human glial progenitor cells can mature in their host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 reports that human glial progenitor cells engrafted into neonatal immunodeficient mice matured in the host brain, yielding large numbers of human glial progenitors and astrocytes. The human glia integrated functionally (gap-junction coupling) and exhibited species-typical properties, indicating maturation in the animal host. Papers 2\u20134 do not address glial progenitors and are not relevant to this claim."
    },
    "naive_doc_ids": [
      "16284655",
      "4427392",
      "5633876",
      "1905095"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that human glial progenitor cells engrafted into neonatal immunodeficient mice differentiate and persist in the host brain, yielding large numbers of human astrocytes and glial progenitors. This indicates that transplanted human GPCs can mature within the host animal. The other papers concern non-glial cell types or cancer models and are not relevant to this claim."
    },
    "overthinking_doc_ids": [
      "16284655",
      "37699461",
      "9122283",
      "12489130"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly demonstrates that human glial progenitor cells (GPCs) engrafted into neonatal immunodeficient mice matured in vivo: the recipient brains later contained large numbers of human astrocytes, and the engrafted human glia integrated functionally (gap-junction coupling, human-specific astrocyte morphology, faster Ca2+ signaling). This shows maturation and functional integration of transplanted human GPCs in the host animal. The other papers do not address glial progenitors and are not needed to support the claim."
    },
    "posthoc_doc_ids": [
      "16284655",
      "37699461",
      "4427392",
      "5633876",
      "9122283"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "223",
    "claim": "Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 3 provides direct mechanistic evidence that cancer cell mTOR signaling regulates G-CSF production, which in turn dictates the tumor\u2019s ability to stimulate accumulation of myeloid-derived suppressor cells (MDSCs). Inhibition of this pathway reduces MDSC accumulation and tumor progression, and these effects are partially rescued by restoring G-CSF or MDSCs. This aligns precisely with the claim that cancer cells can drive intra-tumoral MDSC accumulation by promoting G-CSF production. Other papers discuss MDSC accumulation (e.g., via NLRP3 or IL-17) but do not contradict this mechanism."
    },
    "naive_doc_ids": [
      "15435343",
      "24612804",
      "2014909",
      "25726838",
      "5836"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 3 shows that oncogenic mTOR signaling in cancer cells regulates production of G-CSF, which in turn drives accumulation of myeloid-derived suppressor cells (MDSCs) in tumors. Inhibition of this pathway reduces MDSCs and tumor progression, and restoration of G-CSF rescues these effects, directly supporting the claim. Papers 1, 2, 4, and 5 discuss MDSC or myeloid cell dynamics via other mechanisms but do not contradict this mechanism."
    },
    "overthinking_doc_ids": [
      "15435343",
      "25726838",
      "2014909",
      "3559136",
      "313403"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 5 directly shows that oncogenic mTOR signaling in cancer cells regulates granulocyte colony-stimulating factor (G-CSF) production, which in turn drives the accumulation of myeloid-derived suppressor cells (MDSCs) within tumors. Inhibition of this pathway reduces MDSC accumulation and tumor progression, and rescue with G-CSF or MDSCs restores effects, confirming causality. Other papers discuss MDSC accumulation via different pathways (e.g., NLRP3, IL-17) but do not contradict this mechanism."
    },
    "posthoc_doc_ids": [
      "24349992",
      "2030623",
      "12871281",
      "188911",
      "2014909"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "278",
    "claim": "Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 reports that the complete genome of Commelina yellow mottle virus (CoYMV) is 7489 bp, not 2140 bp. The other papers concern different viruses and do not address CoYMV genome size. Therefore, the claim is contradicted by the provided evidence."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "152245",
      "83667891"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 directly reports the complete genome size of Commelina yellow mottle virus (CoYMV) as 7489 base pairs, not 2140. The other papers discuss different viruses or methods and do not pertain to ComYMV genome size. Therefore, the claim is contradicted by the provided evidence."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "32770503"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.96,
      "justification": "Paper 1 directly reports the complete genome size of Commelina yellow mottle virus (CoYMV/ComYMV) as 7,489 base pairs, not 2,140 bp. This contradicts the claim. Additionally, badnavirus genomes (e.g., Paper 2) are typically around 7\u20138 kb, reinforcing that 2,140 bp is not plausible for this virus."
    },
    "posthoc_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "1067605",
      "4421746"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "724",
    "claim": "Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly shows that Ly49Q is crucial for neutrophil polarization and migration and that this effect is mediated by Ly49Q's regulation of membrane raft functions/trafficking. The authors propose Ly49Q switches neutrophils to a polarized morphology via spatiotemporal regulation of membrane rafts and associated signaling. The other papers do not address Ly49Q or neutrophils and neither contradict nor support the claim. Thus, the evidence aligns with the claim."
    },
    "naive_doc_ids": [
      "5531479",
      "797114",
      "5914739",
      "18042803",
      "1241113"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 provides direct experimental evidence that Ly49Q is crucial for rapid neutrophil polarization and migration and that these processes are mediated by Ly49Q regulation of membrane raft functions/trafficking. This aligns precisely with the claim. Papers 2, 3, 4, and 5 discuss membrane organization or lipid signaling in other contexts and do not address Ly49Q or neutrophils, but they do not contradict the claim."
    },
    "overthinking_doc_ids": [
      "5531479",
      "20758340",
      "3155374",
      "797114",
      "5914739"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that Ly49Q is crucial for rapid neutrophil polarization and migration, and that these processes are mediated by Ly49Q\u2019s regulation of membrane raft functions and raft trafficking. It further links Ly49Q\u2019s ITIM-dependent signaling and use of SHP-1/2 to raft-associated signaling, supporting the claim that Ly49Q directs the organization of neutrophil polarization via membrane rafts. The other papers are background or unrelated and do not contradict this."
    },
    "posthoc_doc_ids": [
      "5531479",
      "20758340",
      "3155374",
      "4389252",
      "5484763"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.78,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "422",
    "claim": "Flexible molecules experience less steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers examine or compare how molecular flexibility versus rigidity affects steric hindrance in the tumor microenvironment. The papers address ECM stiffness and drug resistance (YAP/TAZ), redox regulation of integrins, acidic pH and SREBP2, hyaluronan\u2019s effect on vascular permeability and drug delivery, fibroblast MMP genotypes and invasion, CSC-derived extracellular vesicles, oxidative stress in cancer-associated fibroblasts, neuronal regulation of glial transporters, and glutamine transport inhibition. No experimental data or results relate to steric hindrance differences between flexible and rigid molecules in tumors."
    },
    "naive_doc_ids": [
      "1065627",
      "44640124",
      "4583180",
      "2565138",
      "13007205"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers investigate or compare steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The citations focus on MMP genotypes and fibroblast-driven invasion (Paper 1), matrix stiffness effects on drug response via YAP/TAZ (Paper 2), ECM remodeling in obesity and exercise (Paper 3), redox regulation of integrins (Paper 4), ECM stiffening in pulmonary hypertension (Paper 5), fluid therapy (Paper 6), burn dressings (Paper 7), and postpartum depression after miscarriage (Paper 8). They do not present data on molecular flexibility or steric hindrance of molecules in tumors."
    },
    "overthinking_doc_ids": [
      "13007205",
      "1065627",
      "4164929",
      "44640124",
      "1727042"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers investigate or report data on how molecular flexibility versus rigidity affects steric hindrance within the tumor microenvironment. The articles focus on cancer-associated fibroblasts, metabolic coupling, extracellular matrix remodeling (in obesity), acidic pH effects on transcriptional regulation, fibroblast MMP genotypes, immune checkpoint blockade, a hedgehog inhibitor trial, and RECIST guidelines. They do not compare flexible and rigid molecules or assess steric hindrance, so they neither support nor contradict the claim."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "27647593",
      "4164929",
      "4583180"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "623",
    "claim": "Individuals with low serum vitamin D concentrations have increased risk of multiple sclerosis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers present direct data relating measured serum 25-hydroxyvitamin D concentrations to multiple sclerosis risk. Paper 1 links higher sun exposure (a proxy for vitamin D) with reduced MS risk but does not measure serum vitamin D. Paper 6 discusses vitamin D and latitude conceptually without providing serum-level risk data. The remaining papers address other diseases, biomarkers, diagnostic criteria, or reproductive factors, and do not test the stated claim."
    },
    "naive_doc_ids": [
      "17000834",
      "1974176",
      "23577867",
      "15663829",
      "3222187"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers present data on serum 25-hydroxyvitamin D concentrations in relation to multiple sclerosis risk. Paper 1 shows an association between higher sun exposure in youth and reduced MS risk, which is indirect and does not measure serum vitamin D. Papers 2, 3, and 4 do not address MS risk in relation to vitamin D levels. Therefore, the specific claim about low serum vitamin D increasing MS risk is not directly evaluated by these studies."
    },
    "overthinking_doc_ids": [
      "17000834",
      "43226130",
      "4462079",
      "3067015"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present human data directly linking low serum vitamin D concentrations to increased risk of multiple sclerosis. Most papers address unrelated outcomes (diabetes: Papers 1 and 4; cardiovascular disease: Paper 5; breast cancer: Paper 6; PTH/calcium homeostasis: Paper 3; global vitamin D status without MS outcomes: Paper 7). Paper 2 focuses on sex/reproductive factors in MS, not vitamin D. Paper 9 is about CSF diagnostics in MS. Paper 8 discusses vitamin D and latitude as potential environmental factors and cites animal model and genetic considerations but does not provide empirical evidence that individuals with low serum vitamin D have higher MS risk. Therefore, the supplied evidence does not confirm or refute the specific claim."
    },
    "posthoc_doc_ids": [
      "25599283",
      "43226130",
      "16256507",
      "1974176",
      "6793674"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1068",
    "claim": "ScPif1p has reduced binding ability to G-rich ssDNA compared to non-G-rich ssDNA.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers examine Saccharomyces cerevisiae Pif1 (ScPif1p) binding to G-rich versus non-G-rich single-stranded DNA. The papers focus on unrelated systems (two-component signaling, kinesin-microtubule interactions, ADAM13\u2013fibronectin binding, Pseudomonas SSB, BLM helicase, yeast replication proteins Tof1/Csm3/Rrm3, NF-\u03baB in asthma, and CNBP/G-quadruplex), with no experimental comparison of ScPif1p binding affinities to different ssDNA sequences."
    },
    "naive_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "1914588",
      "16217855"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Among the provided papers, only Paper 8 concerns Saccharomyces cerevisiae Pif1 (ScPif1p), showing that G-quadruplex (G4) structures stimulate Pif1-catalyzed duplex unwinding via G4-enhanced dimerization. However, it does not measure or compare ScPif1p binding affinity to G-rich single-stranded DNA versus non-G-rich single-stranded DNA. The other papers are unrelated to Pif1 ssDNA-binding preferences. Therefore, there is no direct evidence here to confirm or refute the claim about reduced binding to G-rich ssDNA."
    },
    "overthinking_doc_ids": [
      "1225513",
      "1256116",
      "10247314",
      "7549811",
      "20943272"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.97,
      "justification": "None of the provided papers address ScPif1p (the S. cerevisiae Pif1 helicase) or compare its binding to G-rich versus non-G-rich ssDNA. The studies focus on unrelated systems: bacterial two-component signaling, kinesin\u2013microtubule interactions, ADAM13\u2013fibronectin binding, bacterial SSB proteins, immune factors in listeriosis, and HIF-1alpha\u2013p53 interactions. No relevant experimental data are presented for the claim."
    },
    "posthoc_doc_ids": [
      "1225513",
      "7549811",
      "20943272",
      "799586",
      "1914588"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.02,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "676",
    "claim": "LRBA prevents CTLA - 4 recycling.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "Among the provided papers, none mention LRBA or examine CTLA-4 recycling. Paper 1 discusses CTLA4 mutations and Treg dysfunction without addressing recycling or LRBA. Paper 8 concerns CTLA-4 expression on Th17 cells and belatacept resistance but does not involve LRBA or trafficking. The remaining papers are on unrelated pathways or receptors. Therefore, the evidence set does not contain information to evaluate the claim about LRBA preventing CTLA-4 recycling."
    },
    "naive_doc_ids": [
      "857189",
      "2436602",
      "3756384",
      "9680193",
      "4920376"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address LRBA or its role in CTLA-4 trafficking or recycling. Paper 2 discusses CTLA-4 expression and functional sensitivity in Th17 cells but does not mention LRBA or recycling mechanisms. The other papers focus on synaptic vesicle recycling, ESCRT-mediated endosomal sorting, autophagy of nuclear lamina, and DNA sensing, which are unrelated to LRBA-CTLA-4 interactions."
    },
    "overthinking_doc_ids": [
      "11250124",
      "13398997",
      "14893425",
      "9680193",
      "4452659"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers examine LRBA or CTLA-4 recycling. The only mention of CTLA-4 (Paper 7) concerns its role in autoimmunity and T cell trafficking, not its intracellular trafficking or LRBA interactions. The other papers address unrelated topics (IL-10 in EAE, stress and microglia, OPA1 gene therapy, synaptic vesicle recycling mechanisms, yeast aging, Rac trafficking). Thus, the evidence does not inform whether LRBA prevents CTLA-4 recycling."
    },
    "posthoc_doc_ids": [
      "854417",
      "2436602",
      "6776834",
      "11250124",
      "14893425"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "68",
    "claim": "Activated Cdk5 regulates DNA damage-induced neuronal death.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 provides direct experimental evidence that DNA damage activates Cdk5 in post-mitotic neurons, which then phosphorylates ATM (Ser794) to activate ATM signaling (including p53 and H2AX). Disrupting the Cdk5\u2013ATM pathway reduces DNA-damage-induced neuronal cell cycle re-entry, lowers p53 target (PUMA, Bax) expression, and protects neurons from death, demonstrating that activated Cdk5 regulates DNA damage-induced neuronal death. The other papers are not directly relevant or do not contradict this finding."
    },
    "naive_doc_ids": [
      "21295300",
      "935034",
      "19079491",
      "18956141",
      "19522248"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 1 provides direct experimental evidence that DNA damage activates Cdk5, which phosphorylates ATM (Ser794), enabling ATM autophosphorylation (Ser1981) and kinase activation. This Cdk5-ATM signaling regulates downstream targets (p53, H2AX), and disrupting the pathway reduces DNA-damage-induced neuronal cell cycle re-entry, PUMA/Bax expression, and neuronal death. Thus, activated Cdk5 regulates DNA damage-induced neuronal death. Paper 4 is consistent with Cdk5\u2019s role in neuronal death broadly, while Papers 2, 3, and 5 are not relevant to the claim."
    },
    "overthinking_doc_ids": [
      "21295300",
      "25827024",
      "1410197",
      "29422484",
      "19957813"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that DNA damage activates Cdk5, which phosphorylates and activates ATM in post-mitotic neurons, leading to downstream p53/H2AX signaling. Disrupting the Cdk5\u2013ATM pathway reduces DNA-damage-induced neuronal cell cycle re-entry, lowers PUMA/Bax expression, and protects neurons from death. This demonstrates that activated Cdk5 regulates DNA damage-induced neuronal death. The other papers do not address Cdk5 in this context."
    },
    "posthoc_doc_ids": [
      "21295300",
      "1103795",
      "5572127",
      "17231273",
      "23887844"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "823",
    "claim": "N348I mutations cause resistance to zidovudine (AZT).",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 provides direct evidence that the HIV-1 RT connection-domain mutation N348I reduces susceptibility to zidovudine (AZT) by 2\u20134-fold in vitro and is associated with selection under zidovudine-containing regimens in patients. It also shows clinical correlations (increased prevalence in treated patients and association with thymidine analogue mutations). Paper 3 offers mechanistic support that connection/RNase H domain mutations can confer NRTI resistance, consistent with AZT resistance from N348I. The other papers are not relevant to this claim."
    },
    "naive_doc_ids": [
      "15319019",
      "2319305",
      "6426919",
      "641786",
      "1538080"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 1 directly demonstrates that introducing the N348I mutation into HIV-1 RT reduces susceptibility to zidovudine (AZT) by 2- to 4-fold in both wild-type and TAM-containing backbones, and shows clinical association with AZT use. Papers 2 and 3 focus on NNRTI mechanisms but are consistent with connection/RNase H domain mutations conferring drug resistance, supporting the broader context. Therefore, the evidence confirms that N348I causes AZT resistance."
    },
    "overthinking_doc_ids": [
      "15319019",
      "2319305",
      "6426919"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Paper 1 directly shows that the HIV-1 RT connection-domain mutation N348I reduces susceptibility to zidovudine (AZT) by 2\u20134 fold in molecular clones, is enriched in treatment-experienced patients, and is associated with TAMs and AZT-containing regimens, indicating AZT resistance. Paper 4 further supports that connection/RNase H domain mutations can confer NRTI resistance, consistent with AZT resistance. Other papers are not relevant to AZT. Overall, the evidence confirms the claim."
    },
    "posthoc_doc_ids": [
      "15319019",
      "9505402",
      "25014337",
      "6426919",
      "2319305"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "389",
    "claim": "Ethanol stress increases the expression of IBP in bacteria.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.87,
      "justification": "None of the provided papers directly examine or report on IBP (e.g., inclusion body-binding proteins IbpA/IbpB or ice-binding proteins) expression in bacteria under ethanol stress. Paper 3 mentions ethanol stress in E. coli during fermentation but provides no specific data on IBP expression. The other papers address oxidative stress (soxRS), mammalian or insect heat shock responses, or unrelated cellular pathways, and do not test ethanol-induced IBP expression in bacteria."
    },
    "naive_doc_ids": [
      "471735",
      "20524091",
      "21602220",
      "26886351",
      "45364685"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided paper summaries report data on IBP (e.g., IbpA/IbpB small heat shock proteins) expression under ethanol stress in bacteria. Paper 2 mentions ethanol stress in E. coli during hydrolysate fermentation and gene expression profiling in general, but the excerpt does not specify IBP induction. The other papers address oxidative stress (SoxR/SoxS), acetylation, mammalian hsp90/chaperones, leukemia cell apoptosis, or yeast salt stress, none of which provide evidence about ethanol-induced IBP expression in bacteria."
    },
    "overthinking_doc_ids": [
      "471735",
      "21602220",
      "6669242",
      "26886351",
      "30184745"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data on IBP (e.g., E. coli inclusion body\u2013binding proteins IbpA/IbpB or any 'IBP') expression under ethanol stress in bacteria. Paper 2 discusses ethanol stress during fermentation and global stress responses but does not report IBP-specific expression changes. The other papers address unrelated stress pathways (e.g., SoxRS oxidative stress, heat shock in eukaryotes, protein acetylation, steroid receptor chaperones, CO2-induced heat shock in insects, cachexia UCPs, and enterovirus responses). Therefore, the provided evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "471735",
      "21602220",
      "6669242",
      "20524091",
      "30184745"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "728",
    "claim": "Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 reports that Ly-6C(high) monocytes increase during acute and chronic infections and are preferentially recruited to sites of acute peritoneal inflammation, indicating a stronger involvement in inflammatory responses than Ly-6C(low) cells. Paper 8 identifies a CX3CR1(lo)CCR2(+)Gr1(+) (corresponding to Ly6C(high)) subset that is actively recruited to inflamed tissues, whereas the CX3CR1(hi)Gr1(-) (Ly6C(low)) subset homes to noninflamed tissues. Together, these findings indicate Ly6C(high) monocytes have higher, not lower, inflammatory capacity than Ly6C(low) monocytes. Other papers provided are not relevant to Ly6C-defined monocyte inflammatory capacity."
    },
    "naive_doc_ids": [
      "343052",
      "36444198",
      "22505710",
      "9614443",
      "6042706"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that Ly-6C(high) monocytes increase during inflammatory conditions and are preferentially recruited to sites of acute peritoneal inflammation, indicating greater (not lower) inflammatory involvement compared with Ly-6C(low) cells. This opposes the claim. Papers 2, 3, and 5 address inflammation broadly but not Ly6C-defined monocyte subsets, and Paper 4 discusses splenic reservoir monocytes without comparing Ly6C(high) vs Ly6C(low) inflammatory capacity."
    },
    "overthinking_doc_ids": [
      "36444198",
      "2391552",
      "343052",
      "7489663",
      "29564505"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 1 directly compares mouse monocyte subsets and shows Ly-6C(high) monocytes increase during infection and are preferentially recruited to inflammatory sites, indicating greater (not lower) inflammatory capacity than Ly-6C(low) monocytes. Papers 2\u20136 do not provide comparative data on Ly6C(high) vs Ly6C(low) inflammatory capacity. Therefore, the claim is contradicted by the relevant evidence."
    },
    "posthoc_doc_ids": [
      "36444198",
      "7489663",
      "7521113",
      "5172048",
      "10648422"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "233",
    "claim": "Cell autonomous sex determination in somatic cells does not occur in Galliformes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 directly shows that in chickens (a Galliform), somatic cells possess inherent sex identity and sexual differentiation is substantively cell-autonomous, including in mixed-sex chimeras where donor cells retain their original sex identity. This contradicts the claim that cell-autonomous sex determination in somatic cells does not occur in Galliformes. Paper 2 further supports sex-specific, cell-intrinsic regulation (female-specific transcription at the MHM region adjacent to DMRT1) in chicken. The other papers are not relevant."
    },
    "naive_doc_ids": [
      "4388470",
      "4085204",
      "15803282",
      "5500086",
      "3823862"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly demonstrates that somatic sex identity in chickens (a Galliform) is cell-autonomous. Studies of natural gynandromorph chickens and reciprocal mesoderm transplants showed that male and female avian somatic cells retain an inherent sex identity and are excluded from opposite-sex gonadal structures, indicating cell-autonomous sexual differentiation. Paper 5 further supports intrinsic sex-specific regulation in chicken somatic cells via sex chromosome-linked transcription (MHM region), consistent with cell-intrinsic sex identity. Other papers are unrelated. Thus, the claim that cell-autonomous sex determination in somatic cells does not occur in Galliformes is refuted."
    },
    "overthinking_doc_ids": [
      "4388470",
      "25085979",
      "33370",
      "37822406",
      "4085204"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly shows that in chickens (a Galliforme), somatic cells possess an inherent sex identity and sexual differentiation is substantively cell autonomous, evidenced by gynandromorph analyses and mixed-sex chimera experiments. This directly opposes the claim that cell-autonomous sex determination in somatic cells does not occur in Galliformes. The other papers are unrelated to avian sex determination."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "5500086",
      "10546779"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "524",
    "claim": "Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 3 reports that in humans (n=2,595), higher plasma L-carnitine predicted increased risk of incident major adverse cardiac events, but only among individuals with concurrently high TMAO levels\u2014directly matching the claim\u2019s conditional association. Paper 1 further shows that higher circulating TMAO is associated with increased cardiovascular event risk in prospective cohorts, supporting the mechanistic and epidemiologic link. Other papers are not relevant to this claim."
    },
    "naive_doc_ids": [
      "6793674",
      "4445629",
      "14803797",
      "5698494",
      "15274349"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 4 addresses trimethylamine N-oxide (TMAO), showing that higher circulating TMAO is associated with increased cardiovascular events and mortality. However, none of the papers assess plasma L-carnitine levels or the conditional/interactive relationship between L-carnitine and TMAO in relation to cardiovascular events. Papers 1\u20133 are unrelated (blood pressure lowering in dialysis, plasma corin in CHF, and whole-body MRA atherosclerotic burden). Therefore, the specific claim about higher plasma L-carnitine, when associated with TMAO, being positively correlated with cardiovascular events is not supported or refuted by the provided evidence."
    },
    "overthinking_doc_ids": [
      "202259",
      "4445629",
      "6070278",
      "6793674"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 7 reports that in humans, plasma L-carnitine levels predicted increased risk of both prevalent cardiovascular disease and incident major adverse cardiac events, but only among individuals with concurrently high TMAO levels\u2014directly matching the claim. Paper 1 further supports the link by showing higher circulating TMAO is associated with increased risk of cardiovascular events. Other papers are not relevant to this specific L-carnitine\u2013TMAO interaction."
    },
    "posthoc_doc_ids": [
      "6793674",
      "4445629",
      "25822299",
      "2138767",
      "4647303"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "428",
    "claim": "Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Direct experimental evidence shows FoxO factors participate in differentiation. Paper 4 demonstrates that FOXO4 is necessary for neural differentiation of human embryonic stem cells, with FOXO4 loss reducing neural lineage differentiation potential. Paper 8 shows Foxo1-dependent transcriptional programs essential for Treg cell function and notes FoxO involvement in early Treg lineage commitment, indicating a role in immune cell differentiation. Paper 3 (review) further supports that FoxO factors participate in processes including differentiation. Other papers provided are not about FoxO and do not affect this conclusion."
    },
    "naive_doc_ids": [
      "18489989",
      "4896726",
      "16728949",
      "1447990",
      "6285534"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 1 explicitly states that the FoxO family of transcription factors participates in diverse physiological processes, including differentiation, supporting the claim. The other papers focus on different pathways (SIRT1-FOXO effects on stress/cell cycle, YAP/TAZ, HSPs, T cell-induced osteoblast differentiation, NF-kappaB in neural stem cells) and do not contradict the claim. Thus, the provided evidence supports that FoxO factors are involved in cellular differentiation."
    },
    "overthinking_doc_ids": [
      "16728949",
      "28937856",
      "1065627",
      "20524091",
      "43619625"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 5 provides direct experimental evidence that FoxO transcription factors (Foxo3a/Foxo1) regulate immunoglobulin light chain recombination in pre-B cells, a key step required for pre-B cell differentiation, indicating FoxO involvement in cellular differentiation. Paper 1, a review, also states that FoxO factors participate in differentiation among other processes. Other provided papers focus on stress responses or unrelated pathways and do not contradict this."
    },
    "posthoc_doc_ids": [
      "16728949",
      "28937856",
      "1065627",
      "20524091",
      "3748310"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.78,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "747",
    "claim": "MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address MafA or examine how MafA ubiquitination affects recruitment of the coactivator P/CAF. While several papers discuss ubiquitination mechanisms, histone acetyltransferases (e.g., p300/CBP, Tip60, PCAF) and transcription factor regulation (e.g., p53, E2F), there is no experimental data or findings about MafA-P/CAF interactions or the impact of MafA ubiquitination on coactivator recruitment."
    },
    "naive_doc_ids": [
      "12225214",
      "14198646",
      "3052213",
      "23269537",
      "12040627"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers investigate MafA, its ubiquitination, or its interaction with the coactivator P/CAF. While some papers discuss ubiquitination (e.g., Mcl-1, p53, KLF2) and others address coactivator recruitment in different transcription factor systems (e.g., RAR/RXR, E2F recruiting PCAF/GCN5), there is no direct evidence about MafA or P/CAF recruitment by MafA. Therefore, the claim cannot be evaluated with the given evidence."
    },
    "overthinking_doc_ids": [
      "23513818",
      "21307488",
      "23938319",
      "502591",
      "2714623"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 2 directly addresses MafA, its ubiquitination, and P/CAF recruitment. It shows that GSK-3\u2013mediated phosphorylation enhances MafA transcriptional activity via recruitment of the coactivator P/CAF, and that P/CAF protects MafA from ubiquitination and degradation. It further suggests that upon release of P/CAF, MafA becomes polyubiquitinated and degraded. Thus, the evidence indicates that P/CAF recruitment reduces ubiquitination, not that ubiquitination decreases P/CAF recruitment. The other papers are not about MafA/P/CAF and provide no relevant counterevidence."
    },
    "posthoc_doc_ids": [
      "502591",
      "11291348",
      "14198646",
      "10423989",
      "33068577"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "840",
    "claim": "Natriuretic peptides increase susceptibility to diabetes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct and relevant evidence: higher NT-pro-BNP levels are associated with a lower incidence of type 2 diabetes, and a BNP gene variant that increases NT-pro-BNP is associated with reduced diabetes risk. This suggests a protective (inverse) relationship, not increased susceptibility. The other papers do not address natriuretic peptides in relation to diabetes risk."
    },
    "naive_doc_ids": [
      "15663829",
      "1974176",
      "31229233",
      "24872571",
      "52805891"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 shows an inverse association between natriuretic peptides (NT-pro-BNP) and type 2 diabetes risk: a 21% lower risk per SD higher NT-pro-BNP in a prospective analysis, and Mendelian randomization evidence (rs198389 C allele) consistent with a causal protective effect (OR ~0.94 per allele). This directly opposes the claim that natriuretic peptides increase susceptibility to diabetes. Papers 2\u20135 do not address natriuretic peptides and are not relevant to this claim."
    },
    "overthinking_doc_ids": [
      "15663829",
      "1974176",
      "9822397",
      "25571386",
      "27166444"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that higher circulating NT-proBNP is associated with a lower risk of incident type 2 diabetes (\u224821% decrease per SD increase) and that a BNP-locus variant linked to higher NT-proBNP is associated with reduced T2D odds (OR 0.94 per allele). Mendelian randomization supports a causal protective effect of the BNP system. The other papers do not provide data linking natriuretic peptides to diabetes susceptibility. Therefore, the claim that natriuretic peptides increase susceptibility to diabetes is contradicted by the evidence."
    },
    "posthoc_doc_ids": [
      "15663829",
      "439670",
      "1974176",
      "120626",
      "195352"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "106",
    "claim": "Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 treats ambulatory blood pressure monitoring (ABPM) as the reference standard for diagnosing hypertension and shows that clinic and home measurements have inferior sensitivity and specificity compared with ABPM, implying ABPM is the more accurate method. Paper 6 explicitly states that ABPM is more accurate than clinic and home monitoring for diagnosing hypertension and that using ABPM reduces misdiagnosis and is recommended before starting treatment. Other papers are not directly about diagnostic accuracy. Together, the evidence refutes the claim that ABPM is inaccurate at diagnosing hypertension."
    },
    "naive_doc_ids": [
      "25515907",
      "34873974",
      "202259",
      "54490092",
      "45447613"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1 treats ambulatory blood pressure monitoring (ABPM) as the reference standard for diagnosing hypertension and shows that clinic and home measurements have limited sensitivity and specificity when compared with ABPM. It concludes that ABPM before initiating lifelong treatment may lead to more appropriate targeting, implying ABPM is the more accurate method. The other papers do not address ABPM accuracy. Therefore, the evidence contradicts the claim that ABPM is inaccurate for diagnosing hypertension."
    },
    "overthinking_doc_ids": [
      "25515907",
      "202259",
      "34873974",
      "6137330",
      "23983289"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 treats ambulatory blood pressure monitoring (ABPM) as the reference standard for diagnosing hypertension and shows that clinic and home measurements have insufficient sensitivity/specificity compared with ABPM, concluding ABPM before treatment may better target therapy. Paper 2 explicitly states ABPM is more accurate than clinic and home monitoring for diagnosing hypertension and reduces misdiagnosis, being the most cost-effective strategy. Other papers use ABPM to capture clinically meaningful measures (e.g., variability, renal associations), further supporting its utility. Together, these findings refute the claim that ABPM is inaccurate at diagnosing hypertension."
    },
    "posthoc_doc_ids": [
      "25515907",
      "5151024",
      "54490092",
      "3067015",
      "202259"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "205",
    "claim": "CDK6 shows improved binding to loss-of-function variants of p18 INK4C.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the provided papers address CDK6, p18 INK4C, or their binding interactions. The studies focus on GLP-1 receptor polymorphisms and allosteric modulation, integrin \u03b23 mutations in Glanzmann thrombasthenia, MHC class II\u2013CD4 interaction, mutant p53 gain-of-function, MeCP2 effects on neuronal morphology, and CNBP regulation of hnRNP K. Therefore, they provide no relevant evidence to verify the claim about CDK6 binding to loss-of-function variants of p18 INK4C."
    },
    "naive_doc_ids": [
      "3127341",
      "21164071",
      "4270992",
      "35684881",
      "41644178"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the provided papers address CDK6, p18 INK4C (CDKN2C), or their binding interactions. The articles cover unrelated topics (e.g., transcription factor HNF3, AMPA receptors, CLIP-170 interactions, GLP-1 receptor polymorphisms, inositol phosphatase mutations, bacterial two-component systems, telomere maintenance in ALT cells, PI3K/mTOR inhibition in HER2+ brain metastases, MDSC metabolism, and START domains). Therefore, there is no relevant evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "8331432",
      "18346333",
      "35231675",
      "3127341",
      "6492658"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address CDK6, p18 INK4C (CDKN2C), or their binding interactions. The studies cover topics such as GLP-1 receptor polymorphisms and allosteric modulation, fungal virulence factors, T cell receptor binding strength, Bardet-Biedl syndrome in C. elegans, oxidative DNA damage and SOD mutants, estrogen receptor phosphorylation by MAPK, urease chaperone UreG, and the H2A.Z nucleosome structure. Therefore, they offer no relevant evidence to confirm or refute improved binding of CDK6 to loss-of-function p18 INK4C variants."
    },
    "posthoc_doc_ids": [
      "3127341",
      "7717468",
      "22874817",
      "1281769",
      "1941721"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1028",
    "claim": "Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly links a Type 1 diabetes\u2013associated IL2RA haplotype to reduced IL-2 signaling (lower STAT5 phosphorylation), lower FOXP3 in Tregs, and impaired Treg suppression, indicating diminished IL-2 responsiveness in Tregs associated with T1D risk. Paper 4 shows IL2RA susceptibility genotypes are associated with lower soluble IL-2RA levels, consistent with reduced IL-2 responsiveness predisposing to T1D. Papers 2 and 3 reinforce the mechanistic role of IL-2 in promoting Treg function and expansion. Paper 5 is not directly relevant. Together, the evidence supports the claim."
    },
    "naive_doc_ids": [
      "11899391",
      "38830961",
      "2388819",
      "13940200",
      "30908508"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly shows that a Type 1 Diabetes\u2013associated IL2RA haplotype correlates with diminished IL-2 signaling (reduced STAT5 phosphorylation) in antigen-experienced CD4+ T cells, including Tregs, along with lower FOXP3 expression and reduced suppressive function. This links reduced IL-2 responsiveness in Tregs to T1D risk, supporting the claim. Papers 2\u20134 do not provide information directly addressing IL-2 responsiveness in Tregs relative to autoimmunity."
    },
    "overthinking_doc_ids": [
      "11899391",
      "2388819",
      "8790729",
      "33535222"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly shows that a Type 1 diabetes\u2013associated IL2RA haplotype correlates with diminished IL-2 signaling (reduced STAT5 phosphorylation) and reduced FOXP3 expression/suppressive function in Tregs. This provides a mechanistic link between reduced IL-2 responsiveness in Tregs and susceptibility to autoimmune disease such as T1D. The other papers do not materially address IL-2 responsiveness in Tregs in the context of autoimmunity."
    },
    "posthoc_doc_ids": [
      "11899391",
      "2388819",
      "8790729",
      "24338780",
      "18546584"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1230",
    "claim": "The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 2 directly reports that the minor (G) allele of FOXO3A (rs12212067) limits inflammatory responses in monocytes via a FOXO3-driven, TGF\u03b21-mediated pathway, reducing pro-inflammatory cytokines (including TNF\u03b1) and increasing anti-inflammatory IL-10. This aligns with the claim that the minor G allele downregulates pro-inflammatory cytokines. The other papers do not address FOXO3 genotype effects and are not relevant to this specific claim."
    },
    "naive_doc_ids": [
      "343052",
      "13905670",
      "6397191",
      "9334631",
      "37269418"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 directly reports that the minor (G) allele of FOXO3A (rs12212067 T>G) limits inflammatory responses in monocytes via a FOXO3-driven, TGF\u03b21-dependent pathway, reducing pro-inflammatory cytokines (including TNF\u03b1) and increasing anti-inflammatory IL-10. This aligns with the claim that the minor G allele downregulates pro-inflammatory cytokines. The other papers do not address FOXO3 alleles and provide no contradictory evidence."
    },
    "overthinking_doc_ids": [
      "13905670",
      "7735859",
      "12705056",
      "2844490",
      "883747"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Paper 1 directly reports that the minor G allele of the FOXO3A (FOXO3) SNP rs12212067 limits inflammatory responses in monocytes via a FOXO3-driven, TGF\u03b21-mediated pathway, reducing pro-inflammatory cytokines (e.g., TNF\u03b1) and increasing anti-inflammatory IL-10. The other papers provide general cytokine context but neither contradict nor add specificity to the FOXO3 SNP effect. Therefore, the claim is supported by experimental findings in Paper 1."
    },
    "posthoc_doc_ids": [
      "13905670",
      "11233339",
      "25315295",
      "2844490",
      "4427060"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.82,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "516",
    "claim": "High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 directly examines inflammatory biomarkers in COPD and finds that elevated CRP (along with fibrinogen and leukocyte count) is associated with an increased, not reduced, risk of exacerbations. Individuals with more high biomarkers had higher odds/hazards of frequent exacerbations (e.g., HR up to 2.5 for three high biomarkers; significant trend). Paper 2 also links elevated white-cell count with a frequent-exacerbation phenotype, consistent with higher systemic inflammation increasing risk. The other papers do not address CRP or its relation to exacerbation risk. Therefore, the claim that high CRP reduces exacerbation risk is contradicted by the evidence."
    },
    "naive_doc_ids": [
      "19464037",
      "18988265",
      "29564505",
      "3580005",
      "13843341"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 directly examines CRP and COPD exacerbations and finds that elevated inflammatory biomarkers (including CRP \u22653 mg/L) are associated with an increased\u2014not reduced\u2014risk of frequent exacerbations. Multivariable-adjusted hazard ratios rose with the number of elevated biomarkers (e.g., HR 2.5 for three high biomarkers vs none), contradicting the claim. The other papers do not address COPD exacerbation risk; Paper 2 shows higher CRP predicts higher vascular disease risk, which is directionally inconsistent with a protective effect but is not about COPD. Therefore, the provided evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "29564505",
      "72933407",
      "5558754",
      "8595678",
      "17450673"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers evaluate C-reactive protein (CRP) levels in relation to risk of exacerbations in chronic obstructive pulmonary disease (COPD). The studies focus on cardiovascular disease risk factors (e.g., CRP predicting peripheral arterial disease; IL6R variants affecting CRP and coronary heart disease risk), lipid genetics, hypertension, type 2 diabetes, sexual health, MDR-TB adverse events, and headache treatment. Since there is no evidence about COPD exacerbations and CRP, the claim cannot be verified with these papers."
    },
    "posthoc_doc_ids": [
      "72933407",
      "3868322",
      "27466734",
      "3981244",
      "25562234"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "5",
    "claim": "1/2000 in UK have abnormal PrP positivity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 (UK appendix survey) found 16/32,441 positives for abnormal PrP, giving a prevalence of 493 per million (95% CI 282\u2013801 per million). This corresponds to ~1 in 2,028 people, effectively ~1/2000, and the confidence interval includes 500 per million (1/2000). Other papers provided are not relevant to abnormal PrP prevalence in the UK."
    },
    "naive_doc_ids": [
      "13734012",
      "26107000",
      "87758",
      "13934676",
      "29460384"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 reports 16 positives among 32,441 UK appendix samples, an overall prevalence of 493 per million (95% CI 282\u2013801 per million). This corresponds to approximately 1 in 2,028 individuals, effectively ~1/2000, aligning with the claim. Papers 2\u20135 do not address UK prevalence of abnormal PrP positivity."
    },
    "overthinking_doc_ids": [
      "13734012",
      "42240424",
      "23124332",
      "75636923",
      "29460384"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 (UK appendix survey) found 16 positives among 32,441 samples, yielding an estimated prevalence of 493 per million (95% CI 282\u2013801 per million). This is approximately 1 in 2,028 people, which aligns closely with the claim of ~1/2,000. The other papers do not address abnormal PrP prevalence in the UK."
    },
    "posthoc_doc_ids": [
      "13734012",
      "42240424",
      "5558754",
      "5824985",
      "6876224"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "209",
    "claim": "CHOP is a general endoplasmic reticulum stress marker.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 shows that palmitate-induced ER stress in beta cells increases Ddit3 (CHOP) mRNA and that CHOP protein is elevated in islets from db/db mice and humans with type 2 diabetes, alongside other ER stress markers (BiP/HSPA5, XBP1 splicing). Paper 3 demonstrates UPR activation due to ARV1 deficiency with up-regulation of ATF4 and CHOP in murine macrophages, further enhanced by cholesterol loading. These independent contexts (lipotoxic stress in beta cells and lipid/membrane perturbation in macrophages) both show CHOP induction as part of the ER stress/UPR, supporting CHOP as a general ER stress marker. Other papers are not relevant to CHOP/ER stress."
    },
    "naive_doc_ids": [
      "25510546",
      "9752604",
      "35760786",
      "9614443",
      "15590539"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 directly shows that DDIT3 (CHOP) is upregulated as part of the ER stress response in multiple contexts: palmitate-treated beta cells (with concurrent ER stress markers such as ATF4, DNAJC3 and XBP1 splicing), islets from db/db mice, and human type 2 diabetes pancreas sections. This aligns with CHOP functioning as an ER stress marker. The other papers do not address CHOP or ER stress and thus neither support nor contradict the claim."
    },
    "overthinking_doc_ids": [
      "25510546",
      "1554348",
      "3173489",
      "6669242",
      "20864487"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers show CHOP (DDIT3) is induced during ER stress/UPR across diverse contexts, supporting its use as a general ER stress marker. Paper 1: Palmitate-induced ER stress in beta cells increases Atf4 and Ddit3 (CHOP) mRNA, with elevated CHOP protein in human T2D islets. Paper 5: ARV1 deficiency activates the UPR in yeast and murine cells, notably upregulating ATF4 and CHOP, with further CHOP elevation upon cholesterol perturbation. Paper 7: Systematic review reports cyclosporine A increases GRP78 and CHOP expression in renal cells, consistent with ER stress/UPR activation. Other papers are not directly relevant and none contradict the claim."
    },
    "posthoc_doc_ids": [
      "25510546",
      "8453819",
      "19561411",
      "9752604",
      "35760786"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1225",
    "claim": "The locus rs647161 is associated with colorectal carcinoma.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 reports a genome-wide association study identifying rs647161 (5q31.1) as a colorectal cancer susceptibility locus with a combined P value of 1.22\u00d710^-10 across East Asian and European-ancestry populations, indicating a robust association. The other papers do not address rs647161 or colorectal carcinoma and do not contradict this finding."
    },
    "naive_doc_ids": [
      "9650982",
      "43334921",
      "520579",
      "35329820",
      "1428840"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 reports a genome-wide association study identifying rs647161 at 5q31.1 as a colorectal cancer susceptibility locus, with strong statistical significance in East Asians and replication/meta-analysis including Europeans (combined P = 1.22\u00d710^-10). The other papers do not address rs647161. Thus, the evidence supports an association between rs647161 and colorectal carcinoma."
    },
    "overthinking_doc_ids": [
      "9650982",
      "520579",
      "2058909",
      "14315749",
      "21181273"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 reports a genome-wide association study identifying rs647161 (5q31.1) as significantly associated with colorectal cancer, with a combined P value of 1.22\u00d710^-10 across East Asian and European cohorts. This directly supports the claim. The other papers do not address rs647161."
    },
    "posthoc_doc_ids": [
      "14315749",
      "9650982",
      "21181273",
      "520579",
      "2058909"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1382",
    "claim": "aPKCz causes tumour enhancement by affecting glutamine metabolism.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The provided papers discuss the importance of glutamine transport and metabolism (e.g., SLC1A5, GLS) and broader metabolic reprogramming in cancer (e.g., SRC-2, stromal mTORC1/c-Myc), but none mention atypical PKC zeta (aPKC\u03b6) or directly link aPKC\u03b6 to tumor enhancement via glutamine metabolism. Therefore, they neither support nor contradict the specific claim about aPKC\u03b6."
    },
    "naive_doc_ids": [
      "10169908",
      "28334217",
      "27647593",
      "25513319",
      "26735905"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly addresses PKC\u03b6 (aPKC\u03b6) and shows it functions as a metabolic tumor suppressor. PKC\u03b6 represses glutamine-fueled metabolic reprogramming by inhibiting PHGDH/PSAT1 and phosphorylating PHGDH to reduce its activity. Loss of PKC\u03b6 promotes utilization of glutamine via the serine biosynthetic pathway under glucose stress and enhances tumorigenesis; low PKC\u03b6 correlates with poor prognosis. Thus, tumor enhancement is linked to PKC\u03b6 deficiency, not PKC\u03b6 activity. The other papers do not discuss aPKC\u03b6. Therefore, the claim that aPKC\u03b6 causes tumor enhancement by affecting glutamine metabolism is contradicted by the evidence."
    },
    "overthinking_doc_ids": [
      "5256564",
      "17755060",
      "27647593",
      "4889228",
      "14019636"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention atypical PKC zeta (aPKC\u03b6) or link it to regulation of glutamine metabolism or tumor enhancement. Papers discussing glutamine metabolism in cancer attribute effects to KRAS-driven pathways (PDAC) or mTORC2/xCT regulation, not aPKC\u03b6. Other papers focus on unrelated pathways (STIM1/SOCE, TGF-\u03b2/exosomal lncRNAs, EMT, inflammasomes). Therefore, the evidence does not address the specific claim."
    },
    "posthoc_doc_ids": [
      "20672596",
      "22914228",
      "3831884",
      "7736860",
      "23895668"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1379",
    "claim": "Women with a higher birth weight are more likely to develop breast cancer later in life.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Multiple high-quality syntheses show higher birth weight is associated with increased breast cancer risk. Paper 1 (meta-analysis) reports elevated odds for \u22654,000 g (OR 1.24, 95% CI 1.04\u20131.48) and 3,500\u20133,999 g (OR 1.15, 95% CI 1.04\u20131.26) vs lower birth weights. Paper 2 (systematic review/meta-analysis) finds increased risk with higher birthweight (RR 1.15, 95% CI 1.09\u20131.21). Paper 9 (pooled re-analysis of 32 studies) shows a positive association from birth records (RR per 0.5 kg 1.06, 95% CI 1.02\u20131.09) and higher risk for \u22654.0 kg vs 3.0\u20133.499 kg (RR 1.12, 95% CI 1.00\u20131.25), with a significant linear trend. While associations are weaker with self-reported birth weight, the overall evidence supports the claim."
    },
    "naive_doc_ids": [
      "17450673",
      "23557241",
      "13831842",
      "22401720",
      "34066665"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Multiple high-quality syntheses report that higher birth weight is associated with a modestly increased risk of breast cancer in adulthood. Paper 1 (meta-analysis) shows elevated odds for 3,500\u20133,999 g (OR 1.15, 95% CI 1.04\u20131.26) and \u22654,000 g (OR 1.24, 95% CI 1.04\u20131.48). Paper 2 (pooled re-analysis of 32 studies) finds a positive trend in birth-record data (RR per 0.5 kg = 1.06, 95% CI 1.02\u20131.09; \u22654,000 g vs 3.0\u20133.499 kg RR 1.12, 95% CI 1.00\u20131.25). Paper 3 (systematic review/meta-analysis) reports increased risk with higher birthweight (RR 1.15, 95% CI 1.09\u20131.21). Papers 4 and 5 address other risk factors and are not directly relevant. Overall, the evidence supports the claim that women with higher birth weight are more likely to develop breast cancer later in life."
    },
    "overthinking_doc_ids": [
      "17450673",
      "16322674",
      "23557241",
      "13831842",
      "13765757"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple high-quality syntheses report a positive association between higher birth weight and subsequent breast cancer risk. Paper 1 (pooled re-analysis of 32 studies; 22,058 cases) found a significant increase in risk per 0.5 kg higher birth weight when based on birth records (RR 1.06; 95% CI 1.02\u20131.09) and elevated risk for \u22654.0 kg vs 3.0\u20133.49 kg (RR 1.12; 95% CI 1.00\u20131.25). Paper 7 (meta-analysis) reported higher odds for \u22654,000 g (OR 1.24; 95% CI 1.04\u20131.48) and 3,500\u20133,999 g (OR 1.15; 95% CI 1.04\u20131.26) vs lower birth weights. Paper 8 (systematic review/meta-analysis of 57 studies) found increased risk with higher birthweight (RR 1.15; 95% CI 1.09\u20131.21). While Paper 4 found no association between birth weight and adult breast density, density is a surrogate marker, not the outcome. Overall, the evidence supports that higher birth weight is associated with a modestly increased risk of breast cancer later in life."
    },
    "posthoc_doc_ids": [
      "16322674",
      "13765757",
      "13831842",
      "38784540",
      "313403"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "693",
    "claim": "Leuko-reduced blood reduces infectious complications in red blood cell transfusion.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Only Paper 3 is directly relevant. In a large before-and-after cohort across 23 Canadian hospitals, universal prestorage leukoreduction of red blood cells did not reduce serious nosocomial infections (adjusted OR 0.97, 95% CI 0.87\u20131.09) despite reductions in mortality, posttransfusion fevers, and antibiotic use. The other papers do not address leukoreduction or infectious complications from red blood cell transfusion."
    },
    "naive_doc_ids": [
      "23073816",
      "24396137",
      "24088502",
      "18670",
      "9110810"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Among the provided papers, only Paper 1 directly addresses leukoreduction and infectious outcomes after red blood cell transfusion. In a large before\u2013after cohort across 23 hospitals, universal prestorage leukoreduction did not reduce serious nosocomial infections (adjusted OR 0.97; 95% CI 0.87\u20131.09), despite reductions in mortality, posttransfusion fevers, and antibiotic use. The remaining papers are unrelated to leukoreduced transfusions. Therefore, the evidence provided does not support the claim and instead suggests no reduction in infectious complications."
    },
    "overthinking_doc_ids": [
      "24088502",
      "202259",
      "13857083",
      "23349986",
      "10582939"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 4 directly evaluates infection outcomes after instituting universal prestorage leukoreduction of red blood cells in 14,786 transfused patients. It found no reduction in serious nosocomial infections post-leukoreduction (adjusted OR 0.97; 95% CI 0.87\u20131.09), despite reductions in mortality, posttransfusion fever, and antibiotic use. The other papers do not address leukoreduction or transfusion-related infections. Therefore, the provided evidence does not support the claim that leukoreduced blood reduces infectious complications; it suggests no significant effect on serious infections."
    },
    "posthoc_doc_ids": [
      "23073816",
      "24396137",
      "7098463",
      "24088502",
      "13514898"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "421",
    "claim": "Flexible molecules experience greater steric hindrance in the tumor microenviroment than rigid molecules.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers examine or compare steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The studies address matrix stiffness and drug response (Paper 1), redox regulation of integrins (Paper 2), ECM remodeling in obesity and exercise (Paper 3), nanoparticle size-dependent lymphatic transport (Paper 4), glutamine transport inhibition (Paper 5), fibroblast MMP genotypes and invasion (Paper 6), and extracellular vesicle effects on stromal cells (Paper 7). These do not provide data on molecular flexibility-related steric hindrance."
    },
    "naive_doc_ids": [
      "1065627",
      "44640124",
      "4164929",
      "17327939",
      "5256564"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers evaluate or compare steric hindrance experienced by flexible versus rigid molecules in the tumor microenvironment. The studies address ECM remodeling, redox regulation of integrins, tumor fibroblast-mediated immune cell recruitment, imaging of extracellular volume or brain tissue, cytokine diffusion-consumption dynamics, receptor stalk effects on ligand responsiveness, microenvironment stiffness effects on drug response, and anti-inflammatory effects of curcumin. No paper presents data or analysis on molecular flexibility and steric hindrance in tumors."
    },
    "overthinking_doc_ids": [
      "4164929",
      "44640124",
      "3559136",
      "27550580",
      "40963697"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.96,
      "justification": "None of the provided papers evaluate or compare steric hindrance of flexible versus rigid molecules in the tumor microenvironment. The studies address cancer-associated fibroblasts, immune signaling (RANK/CD40), circulating tumor cells, extracellular matrix remodeling, acidic pH effects on SREBP2, MMP genotypes in fibroblasts, CSF1R/CXCR2 in myeloid recruitment, glutamine transport inhibition, and stromal oxidative stress. They do not present data on molecular flexibility, rigidity, or steric hindrance in the TME."
    },
    "posthoc_doc_ids": [
      "952111",
      "2734421",
      "21033230",
      "4164929",
      "4583180"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "887",
    "claim": "Only a minority of cells survive development after differentiation into stress-resistant spores.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "Among the provided papers, only Papers 4\u20136 touch on Bacillus subtilis sporulation or stress-response regulation, focusing on identifying sporulation genes (Paper 4) and regulation of heat-shock/Clp proteolysis (Papers 5\u20136). None report data on the fraction of cells that survive or the proportion that become stress\u2011resistant spores, nor do they state that only a minority survive post-differentiation. The other papers concern mammalian cell death, HIV infection of progenitors, neural stem cell regulation, or breast cancer resistance, which are unrelated to spore survival fractions. Therefore, the evidence does not address the specific claim about survival after differentiation into spores."
    },
    "naive_doc_ids": [
      "7875158",
      "7224723",
      "10486817",
      "4942718",
      "34386619"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address differentiation into stress\u2011resistant spores or quantify what fraction of cells survive development via sporulation. The studies cover Myxococcus xanthus swarming (not sporulation), iPSC mutations and immunogenicity, programmed cell death mechanisms, HIV-related immune modulation, metabolic stress, integrin-mediated survival pathways, and glioblastoma chemoresistance. Therefore, they do not provide evidence to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "4321295",
      "2608447",
      "4416964",
      "33667484",
      "2543135"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers investigate sporulation or survival fractions after differentiation into stress-resistant spores. The studies focus on mammalian cell differentiation (trophoblasts, neural crest cells, microglia, mesenchymal stem cells), stress responses and cytotoxicity, leukocyte trafficking under social stress, replication stress, and bacterial cooperative swarming in Myxococcus xanthus without addressing spore formation. Therefore, the evidence does not speak to the claim."
    },
    "posthoc_doc_ids": [
      "1595617",
      "5085118",
      "17991818",
      "7875158",
      "4321295"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "386",
    "claim": "Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly reports that most intravenous drug administration errors occurred during bolus dosing and during preparation of drugs requiring multiple steps, aligning with the claim. Papers 2\u20135 do not provide relevant data on error stages in IV administration. Minor caveat: Paper 1 refers to intravenous drugs generally without specifying peripheral lines, but ward-based IVs are typically peripheral, so the evidence is strongly supportive."
    },
    "naive_doc_ids": [
      "16495649",
      "21260231",
      "79231308",
      "9310407",
      "27550580"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 (prospective ethnographic study of IV drug administration) directly reports that most intravenous drug errors occurred when giving bolus doses or when preparing drugs requiring multiple-step preparation. This aligns with the claim. The other papers do not address the specific stages of IV administration errors and are not pertinent to this claim."
    },
    "overthinking_doc_ids": [
      "21260231",
      "16495649",
      "46112052",
      "79231308",
      "19052713"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 2 (Ethnographic study of incidence and severity of intravenous drug errors) directly reports that most errors occurred when giving bolus doses or when making up drugs requiring multiple-step preparation. Although it does not explicitly limit to peripheral IVs, the ward-based IV administrations observed are predominantly peripheral in typical practice. Other papers do not provide relevant data. Thus, the evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "21260231",
      "16495649",
      "79231308",
      "3578380",
      "27550580"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "940",
    "claim": "Pharmacist attendance at ward rounds increases adverse events in wards.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly examines pharmacist participation on ICU rounds and found a 66% reduction in preventable adverse drug events due to prescribing errors when a pharmacist attended rounds (from 10.4 to 3.5 per 1000 patient-days), with no change in the control unit. This refutes the claim that pharmacist attendance increases adverse events. Paper 2 further supports the plausibility of reduction by noting most preventable ADEs occur at the ordering stage where early interception (such as by pharmacists) is effective. Other papers are not relevant to pharmacist attendance on rounds."
    },
    "naive_doc_ids": [
      "12258338",
      "42404093",
      "583260",
      "22467585",
      "32423829"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines pharmacist participation on rounds and shows a 66% reduction in preventable prescribing-related adverse drug events in the ICU (from 10.4 to 3.5 per 1000 patient-days), with no change in a control unit. This contradicts the claim that pharmacist attendance increases adverse events. The other papers do not address pharmacist attendance on rounds or its effect on adverse events and are not relevant to the claim."
    },
    "overthinking_doc_ids": [
      "12258338",
      "5402581",
      "20454006",
      "11254040",
      "42404093"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines pharmacist participation on ICU rounds and shows a 66% reduction in preventable adverse drug events due to prescribing errors (from 10.4 to 3.5 per 1000 patient-days), while a control unit without pharmacist participation showed no improvement. This opposes the claim that pharmacist attendance increases adverse events. The other papers do not evaluate the impact of pharmacist attendance on ward rounds and are not directly relevant to the claim."
    },
    "posthoc_doc_ids": [
      "12258338",
      "42404093",
      "583260",
      "11254040",
      "13959707"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "798",
    "claim": "Mitochondria play a trivial role in calcium homeostasis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 explicitly states that mitochondrial Ca2+ uptake is of utmost physiological relevance, controlling intracellular Ca2+ signaling, metabolism, and cell survival by buffering cytosolic Ca2+ and regulating mitochondrial effectors. This indicates a major, not trivial, role for mitochondria in calcium homeostasis. The other papers focus on non-mitochondrial Ca2+ pathways or unrelated topics and do not provide evidence that mitochondria\u2019s role is trivial."
    },
    "naive_doc_ids": [
      "5094468",
      "13573143",
      "19205437",
      "1905095",
      "19079491"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly assess or report on mitochondria's role in calcium homeostasis. Paper 2 discusses SERCA2b- and RyR2-mediated Ca2+ cycling in beige fat (ER/SR pathways) without evaluating mitochondrial Ca2+ handling. Papers 1, 3, 4, and 5 focus on FoxO signaling in HSCs, psychiatric manifestations of mitochondrial disorders, gut microbiota and insulin resistance, and PPAR\u03b3 signaling in CF, respectively\u2014none provide data on mitochondrial Ca2+ buffering, MCU/NCLX function, or ER\u2013mitochondria Ca2+ exchange. Therefore, the evidence does not confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "16728949",
      "19205437",
      "21246752",
      "52805891",
      "712078"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 7 explicitly states that mitochondria act as sensors and regulators of calcium signaling, buffering cytosolic Ca2+ and controlling intracellular Ca2+ signaling, metabolism, and cell survival. This indicates a significant, not trivial, role in calcium homeostasis. The other papers focus on ER/SOCE mechanisms or mitochondrial functions unrelated to Ca2+, and do not diminish mitochondria\u2019s importance in Ca2+ regulation."
    },
    "posthoc_doc_ids": [
      "12058271",
      "16728949",
      "19205437",
      "797114",
      "3619931"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "903",
    "claim": "PD-1 triggering on monocytes reduces IL-10 production by monocytes.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly shows that triggering PD-1 on monocytes by PD-L1 induces (increases) IL-10 production by monocytes, leading to reversible CD4+ T cell dysfunction. This is the opposite of the claim. The other papers are either unrelated to PD-1/IL-10 in monocytes (Papers 3, 4, 6\u20138) or do not provide evidence that PD-1 triggering reduces IL-10 (Paper 2 focuses on PD-L1-mediated T cell anergy independent of IL-10; Paper 5 discusses CRP decreasing IL-10 via a different pathway). Therefore, the claim is contradicted by the provided evidence."
    },
    "naive_doc_ids": [
      "10648422",
      "7386360",
      "2824347",
      "5372773",
      "9334631"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers examine PD-1 (programmed death-1) signaling on monocytes or its effect on IL-10 production. The studies address CRP effects on IL-10 via cAMP (Paper 1), endothelial TGR5 signaling (Paper 2), dendritic cell subsets (Papers 3 and 8), angiopoietin-1 in sepsis (Paper 4), monocyte isolation (Paper 5), TOLLIP variants and cytokines TNF-\u03b1/IL-6 (Paper 6), PI3K\u03b3 in obesity-related inflammation (Paper 7), and macrophage proliferation in atherosclerosis (Paper 9). None provide data on PD-1 triggering in monocytes or IL-10 outcomes."
    },
    "overthinking_doc_ids": [
      "9334631",
      "13902570",
      "40365566",
      "118568",
      "623486"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 4 directly reports that triggering PD-1 on monocytes by PD-L1 induces (increases) IL-10 production, which impairs CD4+ T cell activation. This is the opposite of the claim that PD-1 triggering reduces IL-10. The other papers do not provide relevant data on PD-1-triggered IL-10 production by monocytes."
    },
    "posthoc_doc_ids": [
      "623486",
      "6936141",
      "7489663",
      "10648422",
      "5752492"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "689",
    "claim": "Less than 10% of patients exposed to radiation have activated markers of mesenchymal stem cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers report data on the proportion of patients exposed to radiation who show activated markers of mesenchymal stem cells. The only radiation-related study (Paper 7) is in mice and examines FGF-2 expression and intestinal crypt stem cell survival, not MSC marker activation or patient prevalence. The other papers address MSC biology, immune modulation, cancer stem cells, or methodological advances unrelated to the claim\u2019s specific metric."
    },
    "naive_doc_ids": [
      "21645205",
      "3531388",
      "16532419",
      "14768471",
      "24101431"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.91,
      "justification": "None of the provided papers report data on patients exposed to radiation or quantify the proportion with activated mesenchymal stem cell (MSC) markers. The studies cover topics such as stem cell populations in cord blood and ovarian tissue, EMT and stemness in cancer cell lines, PTH effects on mesenchymal fate, inflammatory markers in atherosclerosis, diagnostic markers for pneumonia, MSC effects in T1DM models, MSC properties in myelodysplastic syndromes, MSC therapy in ischemic cardiomyopathy, and outcomes after bariatric surgery. While some papers mention MSC markers, they do not involve radiation exposure or provide percentages relevant to the claim."
    },
    "overthinking_doc_ids": [
      "25985964",
      "3758260",
      "9997636",
      "3848469",
      "2587396"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers report data on patients exposed to radiation or quantify the proportion with activated markers of mesenchymal stem cells. The studies focus on MSC therapies in cardiomyopathy, stem cell biology in various tissues, cancer signaling, ICU biomarkers, antiplatelet therapy, and diabetes models, without addressing radiation exposure or prevalence of MSC activation markers in such patients."
    },
    "posthoc_doc_ids": [
      "40164383",
      "25050969",
      "35811036",
      "9997636",
      "1522647"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.03,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "962",
    "claim": "Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 1 identifies mitochondrial RNA granules (containing GRSF1 and RNase P) as foci where nascent mitochondrial transcripts are processed, indicating post-transcriptional handling within these structures. Paper 2 directly concludes that mitochondrial RNA granules are centers for posttranscriptional RNA processing and ribosome biogenesis, with functional data (e.g., roles for DDX28, DHX30, FASTKD2, FASTKD5 in rRNA binding, mRNA maturation, and ribosome assembly). Paper 4 shows GRSF1 localizes to mitochondrial RNA granules and is required for posttranscriptional mitochondrial gene expression, affecting RNA stability and ribosome loading. Papers 3 and 5 are not relevant to the location of post-transcriptional handling in mitochondria, and do not contradict. Together, the evidence supports the claim."
    },
    "naive_doc_ids": [
      "13931771",
      "20018321",
      "13867350",
      "935538",
      "16242975"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.97,
      "justification": "Multiple papers directly show that mitochondrial RNA granules are sites of post-transcriptional events. Paper 1 explicitly concludes that mitochondrial RNA granules are centers for posttranscriptional RNA processing and mitoribosome biogenesis, with functional data on FASTKD5, DDX28, and others. Paper 4 demonstrates that GRSF1- and RNase P-containing mitochondrial RNA granules are where primary mitochondrial transcripts are processed, including tRNA-less precursors. Paper 3 shows GRSF1 localizes to RNA granules and is required for posttranscriptional mitochondrial gene expression, affecting RNA stability and ribosome loading. Paper 2 identifies DDX28 in RNA granules as essential for mitoribosome large subunit assembly, a post-transcriptional process occurring in this compartment. Paper 5 is unrelated to granule localization but does not contradict. Overall, the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "20018321",
      "4306711",
      "935538",
      "13931771",
      "16242975"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Multiple papers directly show that mitochondrial RNA granules are sites of post-transcriptional handling of mitochondrial transcripts. Paper 4 identifies GRSF1-containing foci in the mitochondrial matrix that include RNase P and nascent mtRNA, demonstrates their role in processing primary mitochondrial RNA transcripts, and names them mitochondrial RNA granules. Paper 5 further shows these granules house numerous RNA metabolism proteins and are centers for posttranscriptional RNA processing and mitochondrial ribosome biogenesis, including maturation of specific mRNAs (e.g., COX I) and handling of 16S rRNA. Paper 2 shows GRSF1 localizes to these granules and is required for posttranscriptional mitochondrial gene expression, affecting RNA stability and ribosome assembly. Papers 1 and 3 are not directly relevant. Overall, the evidence confirms the claim."
    },
    "posthoc_doc_ids": [
      "16242975",
      "935538",
      "9091863",
      "13931771",
      "20018321"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1319",
    "claim": "Transplanted human glial cells can differentiate within the host animal.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that human glial progenitor cells engrafted into neonatal mouse brains matured in vivo, yielding large numbers of human astrocytes alongside remaining progenitors, indicating differentiation within the host. Paper 2 reports that transplanted human ES cell\u2013derived neural precursors integrated into neonatal mouse brains and differentiated into neurons and astrocytes. These findings demonstrate that transplanted human glial-lineage cells can differentiate within animal hosts."
    },
    "naive_doc_ids": [
      "16284655",
      "2437807",
      "4427392",
      "9122283",
      "3360421"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 directly shows that transplanted human glial progenitor cells, when engrafted into neonatal immunodeficient mice, matured in vivo into human astrocytes within the host brain, indicating differentiation after transplantation. The other papers are unrelated to glial differentiation in host animals and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "4427392",
      "19510470",
      "3360421",
      "16284655",
      "11335860"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 3 directly shows that transplanted human glial progenitor cells engrafted into neonatal immunodeficient mice matured in vivo into human astrocytes within the host brain, indicating differentiation after transplantation. Other provided papers are not directly about transplanted human glial cells differentiating in animals."
    },
    "posthoc_doc_ids": [
      "3360421",
      "4427392",
      "16284655",
      "38296571",
      "4430962"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "653",
    "claim": "Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 3 shows IL-18 is highly expressed in human atherosclerotic plaques (vs. normal arteries), with upregulated IL-18 receptor in plaque macrophages/endothelium, and higher IL-18 mRNA in symptomatic (unstable) vs. stable plaques\u2014linking IL-18 to plaque destabilization. Paper 6 demonstrates mechanistically in Apoe\u2212/\u2212 mice that IL-18 signaling (via cooperation of IL-18 receptor and the Na-Cl co-transporter NCC) drives inflammatory responses in macrophages and that combined disruption of IL-18R and NCC reduces atherosclerosis, identifying IL-18 as a functional contributor to atherogenesis. Together, these data support an important role for IL-18 in atherosclerosis pathogenesis."
    },
    "naive_doc_ids": [
      "22080671",
      "4890578",
      "17421851",
      "7155555",
      "9315213"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 2 provides direct experimental evidence that IL-18 contributes to atherogenesis. It shows IL-18 signals via both IL-18 receptor (IL18r) and the Na-Cl co-transporter (NCC) in macrophages and lesions; combined deficiency of IL18r and NCC (disrupting IL-18 signaling) protects Apoe\u2212/\u2212 mice from atherosclerosis and blunts IL-18\u2013induced inflammatory responses. This supports an important role for IL-18 in the pathogenesis of atherosclerosis. The other papers do not address IL-18\u2019s role."
    },
    "overthinking_doc_ids": [
      "22889972",
      "24384587",
      "1122198",
      "4445629",
      "4647303"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 2 provides mechanistic and experimental evidence that IL-18 contributes to atherogenesis: IL-18 interacts with the IL-18 receptor and the Na-Cl co-transporter (NCC) to drive inflammatory signaling in macrophages, and combined deficiency of IL-18R and NCC protects Apoe\u2212/\u2212 mice from atherosclerosis. Paper 5 shows IL-18 and its receptor are highly expressed in human atherosclerotic plaques, particularly in macrophages and endothelial cells, with higher IL-18 levels in unstable versus stable plaques, supporting a role in plaque destabilization. Other papers are not directly relevant to IL-18. Together, these findings support the claim that IL-18 plays an important role in the pathogenesis of atherosclerosis."
    },
    "posthoc_doc_ids": [
      "6853699",
      "24384587",
      "854417",
      "4890578",
      "17421851"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.58,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "448",
    "claim": "Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 provides prospective human evidence that prior H. pylori infection increases gastric cancer risk (seropositivity 69% in cases vs 47% in controls; OR 2.77, 95% CI 1.04\u20137.97). Paper 4 links more virulent H. pylori VacA genotypes to precancerous intestinal metaplasia in humans, supporting a carcinogenic pathway. Papers 5 and 6 offer mechanistic and preneoplastic evidence consistent with increased risk. Other papers are not relevant. Overall, the evidence supports the claim that H. pylori infection increases gastric cancer risk in humans."
    },
    "naive_doc_ids": [
      "2052720",
      "6793674",
      "14729253",
      "17464771",
      "29367554"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 provides direct human prospective evidence: prediagnostic H. pylori IgG positivity was more common in future gastric cancer cases than controls, with an odds ratio of 2.77 (95% CI 1.04\u20137.97), indicating increased risk. Papers 3 and 5 add mechanistic support, showing H. pylori induces mutagenic processes in gastric epithelium (AID upregulation leading to TP53 mutations in vitro; oxidative DNA damage and mutations in mice). Papers 2 and 4 are not directly about human cancer risk but do not contradict the claim. Overall, the evidence supports that H. pylori infection increases gastric cancer risk in humans."
    },
    "overthinking_doc_ids": [
      "2052720",
      "26488879",
      "22703082",
      "14729253",
      "24705390"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 provides direct human prospective evidence: individuals seropositive for H. pylori before diagnosis had a higher subsequent risk of gastric cancer (OR 2.77, 95% CI 1.04\u20137.97), indicating increased risk associated with infection. Paper 2 adds mechanistic support by showing that H. pylori infection induces aberrant AID expression and accumulation of TP53 mutations in gastric epithelial cells, offering a plausible carcinogenic pathway. Other listed papers are not directly relevant to the claim. Together, the evidence supports that H. pylori infection increases gastric cancer risk in humans."
    },
    "posthoc_doc_ids": [
      "2052720",
      "22703082",
      "14729253",
      "439670",
      "26488879"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "27",
    "claim": "A 100g dose of chloroquine chemoprophylactic regimen results in retinal toxicity after 5-6 years of weekly intake.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address long-term chloroquine retinal toxicity or cumulative dose thresholds. Paper 4 mentions self-reported symptoms with chloroquine-based prophylaxis among travelers but does not evaluate retinal toxicity or long-term cumulative dosing (e.g., 100 g over 5\u20136 years). The other papers focus on unrelated topics (chemotherapy-induced neutropenia, HIV PrEP, TB treatment, malaria prophylaxis with other agents like mefloquine or tafenoquine, and traveler behaviors). Therefore, the evidence set does not confirm or refute the specific claim."
    },
    "naive_doc_ids": [
      "6334188",
      "14260013",
      "341324",
      "38410121",
      "8593263"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided paper excerpts present data or statements about chloroquine retinal toxicity thresholds, cumulative 100 g dosing, or a 5\u20136 year timeline for toxicity during weekly chemoprophylaxis. Paper 1 discusses long-term malaria prevention generally without specifying retinal toxicity or cumulative-dose thresholds; Paper 5 reports short-term self-reported side effects of chloroquine/mefloquine but not long-term ocular toxicity; the other papers are unrelated to chloroquine toxicity. Therefore, the claim is neither supported nor contradicted by the supplied evidence."
    },
    "overthinking_doc_ids": [
      "32390525",
      "301866",
      "323335",
      "8593263",
      "38410121"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 1 addresses chloroquine as malaria chemoprophylaxis, reporting short-term self-reported side effects in travelers. It does not assess retinal toxicity, cumulative dosing, or long-term (5\u20136 years) weekly intake. The other papers are unrelated (e.g., tuberculosis therapy, leukemia treatment dosing, tafenoquine vs mefloquine prophylaxis, screening recommendations, exercise and mortality). None provide data on chloroquine retinal toxicity at a cumulative 100 g dose over 5\u20136 years, so the claim is neither supported nor refuted by this evidence set."
    },
    "posthoc_doc_ids": [
      "38410121",
      "341324",
      "1373287",
      "8593263",
      "8756719"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "470",
    "claim": "Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly states that GBM is characterized by extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis. While other papers discuss invasion and angiogenesis in cancer more broadly, Paper 1 directly affirms the full set of features in the claim for GBM."
    },
    "naive_doc_ids": [
      "12685434",
      "13329980",
      "195689757",
      "24974080",
      "42080024"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 1 explicitly states that GBM is characterized by extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis, and provides experimental data supporting GBM\u2019s invasive behavior. The other papers do not contradict this and are either tangential or unrelated to these specific hallmarks."
    },
    "overthinking_doc_ids": [
      "12685434",
      "51706771",
      "23934390",
      "9486930",
      "9600826"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly states that glioblastoma multiforme (GBM) is characterized by extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis. This directly matches the claim."
    },
    "posthoc_doc_ids": [
      "12685434",
      "7028976",
      "15570691",
      "42298280",
      "23848916"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "277",
    "claim": "Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 explicitly reports that the Commelina yellow mottle virus (CoYMV/ComYMV) genome has three open reading frames encoding proteins of approximately 23, 15, and 216 kDa. This matches the claim precisely. Paper 2 further supports the notion that badnaviruses typically have three conserved ORFs, aligning with the description of these as 'typical badnavirus ORFs.' Papers 3 and 4 are not relevant to this specific claim."
    },
    "naive_doc_ids": [
      "14376683",
      "37677954",
      "83667891",
      "2319305"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 explicitly reports that the Commelina yellow mottle virus (CoYMV) genome (7489 bp) has three open reading frames on the transcribed strand capable of encoding proteins of 23, 15, and 216 kD, and discusses the 216 kD product as a typical badnavirus-like polyprotein (coat protein, protease, reverse transcriptase/RNase H). Paper 2 provides context that badnaviruses classically have three conserved ORFs, aligning with the claim that these are the typical badnavirus ORFs. Paper 3 is not directly relevant. Together, the evidence confirms the claim."
    },
    "overthinking_doc_ids": [
      "14376683",
      "37677954",
      "83667891"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 1 directly reports that the Commelina yellow mottle virus (CoYMV/ComYMV) genome has three open reading frames on the transcribed strand encoding proteins of approximately 23, 15, and 216 kD. It further notes that the 216 kD product is a polyprotein consistent with badnavirus ORF3 functions, matching the typical badnavirus ORF architecture. Other papers are not directly about ComYMV. Therefore, the claim is supported by Paper 1."
    },
    "posthoc_doc_ids": [
      "14376683",
      "83667891",
      "37677954",
      "21230110",
      "1974176"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1289",
    "claim": "There is a relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports a strong association between macrolide antibiotic exposure and infantile hypertrophic pyloric stenosis (IHPS), particularly when infants receive macrolides in the first 14 days of life (adjusted rate ratio ~29.8) and, to a lesser extent, from days 14\u2013120 (RR ~3.24). Maternal macrolide use in the first two weeks postpartum was also associated with increased IHPS risk (RR ~3.49). Erythromycin is a macrolide; thus these findings support a relationship between erythromycin use and IHPS. The other provided papers do not address this topic."
    },
    "naive_doc_ids": [
      "21239672",
      "20240998",
      "6710713",
      "8563659",
      "20960682"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 1 shows a strong association between macrolide antibiotic exposure and infantile hypertrophic pyloric stenosis (IHPS): infant exposure days 0\u201313 after birth had an adjusted rate ratio of 29.8, and days 14\u2013120 had a rate ratio of 3.24; maternal macrolide use in the first two weeks postpartum also increased risk (RR 3.49). Erythromycin is a macrolide, so these findings support a relationship between erythromycin use and IHPS. The other papers are unrelated to this claim."
    },
    "overthinking_doc_ids": [
      "21239672",
      "202259",
      "439670",
      "13619127",
      "791050"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 shows a strong association between macrolide antibiotic exposure and infantile hypertrophic pyloric stenosis (IHPS), especially when given directly to infants in the first 13 days of life (adjusted rate ratio ~29.8) and to a lesser extent through maternal use in the first two weeks postpartum. Erythromycin is a macrolide, so these findings support a relation between erythromycin use and IHPS. The other papers are not relevant to this claim."
    },
    "posthoc_doc_ids": [
      "21239672",
      "2774906",
      "6957332",
      "829646",
      "2097256"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "375",
    "claim": "Elevated cell-free mitochondrial DNA levels are associated with mortality.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly shows that elevated circulating cell-free mitochondrial DNA (mtDNA) levels are associated with higher mortality in medical ICU patients. In two prospective cohorts, patients with mtDNA \u22653,200 copies/\u00b5l had markedly increased odds of 28-day death (OR 7.5, 95% CI 3.6\u201315.8; and OR 8.4, 95% CI 2.9\u201324.2), and adding mtDNA improved mortality risk prediction. While the association was not seen in non-medical ICU patients, this evidence supports the claim that elevated cell-free mtDNA is associated with mortality. The other papers provided do not address mtDNA and mortality."
    },
    "naive_doc_ids": [
      "1522647",
      "1456068",
      "6793674",
      "3776162",
      "5596332"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 4 directly investigates circulating cell-free mitochondrial DNA (mtDNA) levels in ICU patients and shows that elevated mtDNA is strongly associated with higher 28-day mortality in two independent cohorts (ORs ~7.5 and 8.4). It also demonstrates improved risk prediction when mtDNA is added to clinical models. The other papers do not address mtDNA and are not relevant to this claim. Therefore, the provided evidence supports the claim that elevated cell-free mitochondrial DNA levels are associated with mortality."
    },
    "overthinking_doc_ids": [
      "12102963",
      "202259",
      "25589047",
      "1522647",
      "1456068"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly shows that elevated circulating cell-free mitochondrial DNA (mtDNA) is associated with higher 28-day mortality among medical ICU patients, with large effect sizes (OR 7.5 and 8.4 in two cohorts) and improved risk reclassification. Although this association was not observed in non-medical ICU subgroups, the claim does not specify setting, and thus the evidence supports the association. Paper 8 shows elevated mtDNA in active disease but does not address mortality; other papers are unrelated to mtDNA. Therefore, the provided evidence supports the claim."
    },
    "posthoc_doc_ids": [
      "1522647",
      "14021596",
      "30398773",
      "3222187",
      "3801693"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1043",
    "claim": "Retinoic acid receptor-related orphan receptor gamma (ROR\u03b3) is a therapeutic target for castration-resistant prostate cancer (CRPC)",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 provides direct experimental evidence that ROR\u03b3 is overexpressed/amplified in metastatic CRPC, drives AR transcription, and that ROR\u03b3 antagonists suppress AR and AR-V7 expression, reduce AR genomic activity, inhibit growth of AR-positive CRPC xenografts, and sensitize tumors to enzalutamide without overt toxicity in mice. This aligns with the claim that ROR\u03b3 is a therapeutic target for CRPC. The other papers do not address ROR\u03b3 and are not relevant to the claim."
    },
    "naive_doc_ids": [
      "17671145",
      "22180793",
      "8512633",
      "14131683",
      "27167110"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that ROR\u03b3 is overexpressed/amplified in metastatic CRPC, drives AR transcription via an AR-ROR response element with NCOA1/3, and that ROR\u03b3 antagonists suppress AR and AR-V7 expression, diminish AR cistrome activity, inhibit growth of AR-positive prostate cancer xenografts, and sensitize CRPC to enzalutamide without overt toxicity. This demonstrates therapeutic target potential for ROR\u03b3 in CRPC. The other papers are unrelated to ROR\u03b3 or do not address this claim and do not contradict it."
    },
    "overthinking_doc_ids": [
      "17671145",
      "8512633",
      "14131683",
      "27167110",
      "308862"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 1 provides direct experimental evidence that ROR\u03b3 is overexpressed/amplified in metastatic CRPC, drives AR transcription by recruiting NCOA1/3 to an AR RORE, and that ROR\u03b3 antagonists suppress AR and AR-V7 expression, reduce AR genomic binding and H3K27ac, inhibit growth of AR-positive prostate cancer xenografts, and sensitize CRPC to enzalutamide. This establishes ROR\u03b3 as an upstream regulator of AR and a therapeutic target in CRPC. Other papers are unrelated to ROR\u03b3 in CRPC (Papers 2, 4\u20138) or provide context on AR-indifferent disease (Paper 3) without contradicting the claim; indeed, Paper 1 already notes ROR\u03b3 antagonists are effective in AR-expressing but not AR-negative models."
    },
    "posthoc_doc_ids": [
      "17671145",
      "8512633",
      "14131683",
      "23260700",
      "56486733"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "310",
    "claim": "De novo assembly of sequence data has fewer specific contigs than unassembled sequence data.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data comparing the number of 'specific contigs' produced by de novo assembly to those in unassembled sequence data (raw reads). Paper 1 discusses metagenomic sequencing and de novo assembly to obtain a draft genome and detect pathogen sequences, but does not compare specificity or counts of contigs vs raw reads. Paper 2 analyzes how GC bias affects assembly completeness and fragmentation, not contig specificity relative to unassembled data. The remaining papers are unrelated to genome assembly metrics. Therefore, there is no direct evidence to support or refute the claim."
    },
    "naive_doc_ids": [
      "6173523",
      "14464451",
      "19140422",
      "143251",
      "4993011"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly compare the specificity or number of target-specific sequences between de novo assembled contigs and unassembled (raw) sequence reads. Relevant genomics papers (e.g., de novo metagenomic assembly in Paper 4, Trinity transcriptome assembly in Paper 5, and plant genome assembly in Paper 10) discuss assembly outcomes and coverage but do not assess whether assembly yields fewer specific contigs than unassembled data. Other papers are unrelated to sequence assembly. Therefore, there is no evidence here to support or refute the specific claim."
    },
    "overthinking_doc_ids": [
      "19140422",
      "11419230",
      "15153602",
      "6173523",
      "32770503"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers compare the number of 'specific contigs' produced by de novo assembly to 'unassembled sequence data' (which by definition has no contigs). Papers 2, 5, and 7 discuss de novo assembly performance, effects of GC bias, and metagenomic assembly utility, but they do not present data showing that assembly yields fewer specific contigs than unassembled reads. The other papers are unrelated to sequence assembly. Therefore, the claim is not addressed by the provided evidence."
    },
    "posthoc_doc_ids": [
      "4407385",
      "14464451",
      "143251",
      "44737533",
      "32770503"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "648",
    "claim": "Integrated care is successful at tackling multiple comorbidities.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "Paper 4 directly tests integrated (multi-condition collaborative) care for patients with comorbid chronic physical disease (diabetes and/or coronary heart disease risk factors) and depression. In this randomized controlled trial, the integrated intervention significantly improved social role disability (Sheehan disability scale: \u22120.9, 95% CI \u22121.5 to \u22120.2; P=0.006) and global quality of life (0.7, 0.2 to 1.2; P=0.005) at 6 and 12 months, with a trend toward improved activities of daily living. This supports that integrated care can successfully address multiple comorbidities by improving patient-centered outcomes. The other papers are largely unrelated to integrated care or multimorbidity management."
    },
    "naive_doc_ids": [
      "202259",
      "26199970",
      "10072941",
      "15041758",
      "3654468"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.73,
      "justification": "Paper 2 reports a randomized controlled trial of multi-condition collaborative (integrated) care for patients with comorbid depression and chronic physical diseases (diabetes and/or coronary heart disease risk factors). The intervention led to significant improvements in social role disability and global quality of life over 6\u201312 months compared with usual care, indicating successful management in the context of multiple comorbidities. The other papers do not provide relevant data on integrated care for comorbidities and neither support nor contradict the claim."
    },
    "overthinking_doc_ids": [
      "40666943",
      "15041758",
      "22446093",
      "13732033",
      "1522336"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers evaluate integrated care models or coordinated multidisciplinary approaches aimed at managing multiple comorbidities. The studies focus on single-condition or single-intervention outcomes (e.g., vitamin D in pregnancy, lifestyle interventions in pregnancy, influenza vaccination and cardiovascular events, obesity counseling in primary care, ICU outcomes in COPD exacerbations, caregiver interventions in palliative care, zinc supplementation in children, antipsychotic risks in dementia, acupuncture for depression). They do not test or report on integrated care effectiveness across multiple comorbid conditions."
    },
    "posthoc_doc_ids": [
      "2425364",
      "11360768",
      "11939159",
      "12672066",
      "19464037"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "994",
    "claim": "Pyridostatin encourages proliferation of homologous recombination - defective cells.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 2 directly examines pyridostatin (PDS) and shows that it reduces proliferation of homologous recombination (HR)-defective cells by inducing DNA double-strand break accumulation, checkpoint activation, and exacerbating replication defects. It also selectively eliminates HR-compromised cells, including PARP inhibitor\u2013resistant ones. This is the opposite of the claim that PDS encourages proliferation of HR-defective cells. The other papers do not provide evidence supporting increased proliferation by PDS."
    },
    "naive_doc_ids": [
      "13791206",
      "16472469",
      "15721252",
      "10526279",
      "22901758"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 2 directly reports that the G-quadruplex-stabilizing compound pyridostatin (PDS) reduces proliferation of homologous recombination (HR)-defective cells by inducing DSB accumulation, checkpoint activation, and worsening replication defects. It further notes PDS selectively eliminates HR-compromised cells, including those with PARP inhibitor resistance. This is the opposite of encouraging proliferation. Papers 1, 3, and 4 discuss HR and related pathways but do not support increased proliferation with PDS."
    },
    "overthinking_doc_ids": [
      "13791206",
      "16472469",
      "52944377",
      "4444861"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.97,
      "justification": "Paper 4 directly reports that the G-quadruplex stabilizer pyridostatin (PDS) reduces proliferation of homologous recombination (HR)-defective cells by inducing double-strand break accumulation, checkpoint activation, and exacerbating replication defects. It further highlights PDS's selective toxicity toward HR-compromised cells, including those with PARP inhibitor resistance. This opposes the claim that pyridostatin encourages proliferation of HR-defective cells. The other papers do not provide evidence about pyridostatin's effect on proliferation."
    },
    "posthoc_doc_ids": [
      "13791206",
      "4444861",
      "39225849",
      "16472469",
      "10169908"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "871",
    "claim": "Obesity decreases life quality.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers directly assess health-related quality of life (QoL) as a function of obesity status. Paper 1 shows impaired QoL in binge eating disorder (not obesity per se). Paper 2 links higher BMI to gestational diabetes risk but does not measure QoL. Paper 3 examines ADHD\u2013obesity association without QoL outcomes. Papers 4, 5, 7, and 9 are unrelated to obesity\u2019s QoL effects. Paper 6 evaluates QoL across chronic diseases but does not analyze obesity specifically. Paper 8 reports mental health conditions in bariatric (severely obese) patients and improvement in depression after surgery, but it does not directly quantify QoL change due to obesity. Therefore, the set lacks direct evidence that obesity decreases life quality."
    },
    "naive_doc_ids": [
      "40666943",
      "439670",
      "1831916",
      "38023457",
      "207972"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers directly evaluate health-related quality of life in people with obesity. Paper 1 links ADHD with higher odds of obesity but does not assess quality of life. Paper 2 shows binge eating disorder (not obesity per se) impairs HRQoL. Paper 3 concerns antihypertensive effects on QoL. Paper 4 assesses QoL across chronic conditions but does not specifically report on obesity. Paper 5 examines QoL in pediatric leukemia. Therefore, there is no direct evidence here that obesity decreases life quality."
    },
    "overthinking_doc_ids": [
      "1831916",
      "40666943",
      "26199970",
      "463533",
      "42913391"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers directly assess quality of life in relation to obesity. The studies focus on glaucoma-related visual field loss and QoL (Paper 1), health literacy and HRQoL in ischaemic heart disease (Paper 2), effects of angiotensin system blockers on mental health QoL (Paper 3), general HRQoL across chronic diseases without specifying obesity (Paper 4), HRQoL in binge eating disorder (which is distinct from obesity) (Paper 5), HRQoL in pediatric leukemia (Paper 6), association between ADHD and obesity (Paper 7), and associations of BMI with gestational diabetes/pregnancy outcomes (Papers 8\u20139). None provide direct evidence that obesity decreases quality of life."
    },
    "posthoc_doc_ids": [
      "31208367",
      "17693849",
      "26199970",
      "463533",
      "40666943"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "169",
    "claim": "Bariatric surgery reduces postmenopausal breast cancer.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers evaluate bariatric surgery or its effect on postmenopausal breast cancer incidence. The closest relevant evidence (Papers 1, 2, and 7) links higher BMI and metabolic syndrome to increased postmenopausal breast cancer risk, suggesting weight control may help, but they do not study bariatric surgery specifically. The other papers focus on unrelated topics (gastric cancer genetics, trastuzumab CNS relapse risk, CDK4/6 inhibition, tamoxifen duration, angiogenic factors, and FGF21 in atherosclerosis). Therefore, the claim is not addressed by the given evidence."
    },
    "naive_doc_ids": [
      "13831842",
      "16701509",
      "14729253",
      "3329824",
      "15721252"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "None of the provided papers directly evaluate whether bariatric surgery reduces postmenopausal breast cancer. Paper 1 assesses bariatric surgery and incident cancer overall and finds no association, but it does not report breast cancer-specific or postmenopausal-specific outcomes. The other papers address vitamin D, lipids, diabetes, intrauterine factors, HER2 therapy, and BMI associations with breast cancer risk, which are related concepts but do not test the effect of bariatric surgery on postmenopausal breast cancer. Therefore, the evidence provided does not confirm or refute the specific claim."
    },
    "overthinking_doc_ids": [
      "5824985",
      "38551172",
      "9171913",
      "32534305",
      "3329824"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers evaluate bariatric surgery or report breast cancer incidence after bariatric procedures. Paper 1 shows higher BMI is associated with increased postmenopausal breast cancer risk (suggesting weight control may reduce risk), and Paper 8 links type 2 diabetes to slightly increased breast cancer risk, but neither examines surgical weight loss. The remaining papers address unrelated factors (vitamin D, trastuzumab and CNS metastases, intrauterine factors, platelet markers, CYP2D6). Therefore, there is no direct evidence here to confirm or refute that bariatric surgery reduces postmenopausal breast cancer."
    },
    "posthoc_doc_ids": [
      "13831842",
      "38551172",
      "3329824",
      "17450673",
      "23557241"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "385",
    "claim": "Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Direct experimental evidence shows epigenetic modulating agents alter antitumor immunity in cancer models. Paper 1 demonstrates that DNMT inhibitors (5-azacytidine) and HDAC inhibitors in a murine ovarian cancer model activate type I interferon signaling, increase CD8+ T and NK cell activity, reduce immunosuppressive myeloid cells, decrease tumor burden, and enhance response to anti\u2013PD-1. Paper 3 shows DNMTi+HDACi induce an IFN\u03b1/\u03b2 program, upregulate antigen presentation, increase T-cell chemoattractants, and in mouse NSCLC models reverse immune evasion and shift T cells toward effector/memory phenotypes. Paper 2 reviews multiple preclinical findings that EMAs restore immune recognition and function. Together, these support that EMAs modulate antitumor immune responses in cancer model systems."
    },
    "naive_doc_ids": [
      "9767444",
      "1032372",
      "9955779",
      "9278263",
      "5500086"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 3 shows that epigenetic modulating agents\u2014specifically a DNA methyltransferase inhibitor (5-azacytidine) and histone deacetylase inhibitors\u2014activate type I interferon signaling in a murine ovarian cancer model, increase CD45+ infiltration, enhance CD8+ T and NK cell activation, reduce immunosuppressive macrophages and MDSCs, decrease tumor burden, extend survival, and improve response to PD-1 blockade. This directly demonstrates that EMAs modulate the antitumor immune response in a cancer model. Paper 6 provides the relevant syngeneic, immune-competent ovarian cancer model context. Other papers are not directly relevant."
    },
    "overthinking_doc_ids": [
      "3493623",
      "31324978",
      "9767444",
      "32742683",
      "9929089"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Direct experimental data show that epigenetic agents modulate antitumor immunity in cancer models. In a murine ovarian cancer model, DNMTi (5-azacytidine) and HDACi activated type I interferon signaling, increased CD45+ immune infiltration, enhanced CD8+ T and NK cell activation, reduced immunosuppressive macrophages/MDSCs, decreased tumor burden, extended survival, and improved response to anti\u2013PD-1 (Paper 3). In NSCLC models, a DNMTi+HDACi regimen induced an IFN\u03b1/\u03b2 program, upregulated antigen presentation machinery, increased T cell chemoattractants, and reversed immune evasion while shifting T cells toward effector/memory phenotypes (Paper 4). A review (Paper 1) further supports the concept. Other papers are not about epigenetic agents but do not contradict the claim."
    },
    "posthoc_doc_ids": [
      "1032372",
      "32742683",
      "9767444",
      "9955779",
      "3981033"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "2",
    "claim": "1 in 5 million in UK have abnormal PrP positivity.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 1 directly estimates abnormal PrP prevalence in UK appendix samples at 493 per million (95% CI 282\u2013801), approximately 1 in 2,000. This strongly contradicts the claim of 1 in 5,000,000 (~0.2 per million). The other papers provided are not about UK population prevalence of abnormal PrP and do not support the claim."
    },
    "naive_doc_ids": [
      "13734012",
      "6876224",
      "29460384",
      "3078080",
      "11349166"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.98,
      "justification": "Paper 1 directly measures abnormal PrP positivity in UK appendix samples and estimates prevalence at 493 per million (\u22481 in 2,000), with a 95% CI of 282\u2013801 per million. This is vastly higher than the claim of 1 in 5 million (0.2 per million). Papers 2\u20135 are unrelated to prion prevalence and do not affect this conclusion."
    },
    "overthinking_doc_ids": [
      "13734012",
      "5824985",
      "42291761",
      "6876224",
      "9547722"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.96,
      "justification": "Paper 2 directly measures abnormal prion protein (PrP) positivity in UK appendix samples and finds a prevalence of 493 per million (95% CI 282\u2013801 per million), i.e., about 1 in 2,000. This is orders of magnitude higher than the claim of 1 in 5 million (0.2 per million). The other papers are not relevant to PrP prevalence in the UK."
    },
    "posthoc_doc_ids": [
      "32481310",
      "13734012",
      "3823862",
      "9547722",
      "5824985"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.85,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1272",
    "claim": "The single flash-evoked ERG b-wave is generated by activity of ON-bipolar cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "Among the provided papers, only Papers 5 and 7 are relevant to electroretinography. Paper 7 shows that a mutation disrupts transmission from photoreceptors to second-order neurons and abolishes the ERG b-wave while sparing the a-wave, implying a postreceptoral origin for the b-wave. However, it does not specify that ON-bipolar cells generate the b-wave. Paper 5 is a general ERG methods/overview abstract and does not state that the b-wave arises from ON-bipolar cell activity. The remaining papers are unrelated to retinal electrophysiology. Therefore, the provided evidence does not explicitly confirm that the single flash-evoked ERG b-wave is generated by ON-bipolar cells."
    },
    "naive_doc_ids": [
      "4138659",
      "23895668",
      "2030623",
      "19185192",
      "19521501"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the provided papers address electroretinography (ERG), retinal physiology, or ON-bipolar cell activity. The papers focus on circulating DNA in cancer, endothelin-1 in vascular smooth muscle, gibberellin/elicitor signaling in rice, intrauterine factors and breast cancer risk, and intestinal cancer stem cells. Therefore, they provide no relevant evidence for or against the claim about the ERG b-wave origin."
    },
    "overthinking_doc_ids": [
      "2841164",
      "6397191",
      "32598644",
      "23557241",
      "4422868"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.74,
      "justification": "Only Paper 9 discusses the ERG b-wave, showing it reflects postreceptoral retinal activity and is absent in a mouse model with defective transmission between photoreceptors and second-order neurons. However, it does not identify ON-bipolar cells specifically as the generator of the b-wave. The other papers are unrelated to ERG components or retinal bipolar cell pathways. Therefore, the provided evidence does not directly confirm that the single flash-evoked ERG b-wave is generated by ON-bipolar cell activity."
    },
    "posthoc_doc_ids": [
      "2212067",
      "2888272",
      "9154703",
      "2841164",
      "4422868"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "399",
    "claim": "Exposure to fine particulate air pollution is relate to anxiety prevalence.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.94,
      "justification": "Paper 1 directly examines fine particulate matter (PM2.5) exposure and prevalent anxiety symptoms in a large cohort (N=71,271) and finds significantly increased odds of high anxiety symptoms with higher recent PM2.5 exposure (e.g., OR per 10 \u00b5g/m3 increase: 1.12 for prior 1-month average; 1.15 for prior 12-month average). This provides observational evidence that PM2.5 exposure is related to anxiety prevalence. The other papers do not address this relationship."
    },
    "naive_doc_ids": [
      "791050",
      "25157790",
      "20526907",
      "32357890",
      "6793674"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 4 directly tests the relationship between fine particulate matter (PM2.5) exposure and prevalent anxiety symptoms in a large cohort (N=71,271) and finds significant positive associations across multiple exposure windows (e.g., OR per 10 \u00b5g/m3 increase in prior 1-month PM2.5: 1.12 [1.06\u20131.19]; prior 12-month PM2.5: 1.15 [1.06\u20131.26]). This indicates that higher PM2.5 exposure is associated with higher prevalence of clinically meaningful anxiety symptoms. Other papers provided do not address PM2.5-anxiety links and neither contradict this finding."
    },
    "overthinking_doc_ids": [
      "8298120",
      "32357890",
      "439670",
      "791050",
      "1472815"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly reports that higher exposure to fine particulate matter (PM2.5) is associated with increased odds of prevalent high anxiety symptoms in the Nurses' Health Study cohort (e.g., OR per 10 \u00b5g/m3 increase in prior 1-month PM2.5: 1.12 [95% CI 1.06\u20131.19]; prior 12-month PM2.5: 1.15 [1.06\u20131.26]). Other provided papers do not address this relationship and do not contradict it."
    },
    "posthoc_doc_ids": [
      "791050",
      "471921",
      "32357890",
      "13900610",
      "3580005"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1307",
    "claim": "Tonic signaling from the scFv induces constitutive stimulation.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 shows that antigen-independent clustering of CAR single-chain variable fragments (scFvs) triggers tonic CAR CD3\u03b6 phosphorylation and persistent (constitutive) signaling, leading to early T cell exhaustion. This directly supports the claim that tonic signaling from the scFv induces constitutive stimulation. The other papers do not provide relevant information on scFv-driven tonic signaling."
    },
    "naive_doc_ids": [
      "18231807",
      "5132358",
      "20311968",
      "213017",
      "2825380"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that antigen-independent clustering of CAR single-chain variable fragments (scFv) leads to tonic CAR CD3-\u03b6 phosphorylation and persistent CAR signaling, which induces early T-cell exhaustion. This constitutes constitutive stimulation arising from scFv-driven tonic signaling. The other papers do not address scFv/CAR tonic signaling."
    },
    "overthinking_doc_ids": [
      "18231807",
      "34016944",
      "20568364",
      "35987381",
      "2099400"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.83,
      "justification": "Paper 4 shows that antigen-independent clustering of CAR single-chain variable fragments (scFv) triggers tonic CAR CD3-\u03b6 phosphorylation, leading to persistent/constitutive signaling and early T cell exhaustion. This directly supports the claim that tonic signaling from the scFv induces constitutive stimulation. The other papers do not address scFv-driven tonic signaling."
    },
    "posthoc_doc_ids": [
      "2593298",
      "2825380",
      "4611267",
      "18231807",
      "34016944"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "308",
    "claim": "DUSP4 downregulation deactivates the Ras-ERK pathway",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Paper 3 explicitly reports that DUSP4 (an ERK phosphatase) downregulation activates the Ras-ERK pathway in basal-like breast cancer. This directly opposes the claim. Supporting mechanistic evidence: Paper 6 shows that upregulation of MKP-2/DUSP4 suppresses ERK activity, implying that its downregulation would relieve this suppression and thus activate ERK. Paper 5 further indicates that functional MKP-2/DUSP4 is required to reverse ERK activation, reinforcing that loss or reduction of DUSP4 would not deactivate, but rather permit activation of the Ras-ERK pathway."
    },
    "naive_doc_ids": [
      "213017",
      "4729644",
      "7821634",
      "15590539",
      "10279084"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers examine DUSP4 (dual-specificity phosphatase 4) or its modulation and effects on the Ras-ERK/MAPK pathway. While some papers mention ERK activity in other contexts (e.g., WNT-EGFR transactivation, PKD1 effects on AMPK), there is no data linking DUSP4 downregulation to activation or deactivation of the Ras-ERK pathway in the supplied evidence."
    },
    "overthinking_doc_ids": [
      "23974474",
      "735130",
      "2481032",
      "778436",
      "5798227"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.97,
      "justification": "Paper 1 directly addresses DUSP4 and reports that DUSP4 is an ERK phosphatase; its downregulation (deficiency) correlates with gene expression patterns of Ras-ERK pathway activation in basal-like breast cancer. The authors explicitly conclude that DUSP4 downregulation activates the Ras-ERK pathway, not deactivates it. The other papers do not provide information about DUSP4\u2019s effect on the Ras-ERK pathway."
    },
    "posthoc_doc_ids": [
      "7821634",
      "6121555",
      "17648235",
      "15381976",
      "23974474"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1216",
    "claim": "The extracellular domain of TMEM27 is cleaved in human beta cells.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "Paper 1 shows that Tmem27\u2019s extracellular domain is cleaved and shed from beta cells, but the evidence presented is in mouse models (Tmem27, Tcf1\u2212/\u2212 mice, transgenic mice) and does not explicitly demonstrate this in human beta cells. Papers 2\u20135 do not address TMEM27/Tmem27 cleavage in beta cells. Therefore, based on the provided papers, there is no direct evidence confirming cleavage of the extracellular domain of TMEM27 in human beta cells."
    },
    "naive_doc_ids": [
      "24142891",
      "27588420",
      "6144969",
      "10207180",
      "22401720"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "Among the provided papers, only Paper 3 discusses TMEM27 cleavage, showing that its extracellular domain is glycosylated, cleaved, and shed from beta cells. However, the evidence in Paper 3 is derived from mouse models (e.g., Tcf1\u2212/\u2212 mice, transgenic mice) and does not explicitly demonstrate this cleavage in human beta cells. The other papers do not address TMEM27. Therefore, there is insufficient evidence here to confirm the human-specific claim."
    },
    "overthinking_doc_ids": [
      "1905095",
      "19756935",
      "24142891",
      "16527698",
      "16572581"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "Paper 1 shows that TMEM27\u2019s extracellular domain is cleaved and shed from beta cells, but the experiments are in mouse models and do not provide human-specific data. Papers 2\u20135 are unrelated to TMEM27 cleavage in beta cells. Therefore, the provided evidence does not confirm cleavage in human beta cells."
    },
    "posthoc_doc_ids": [
      "24142891",
      "1905095",
      "19756935",
      "27588420",
      "43661837"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "611",
    "claim": "Increased lipolysis leads to higher P38 phosphorylation in adipose tissue.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data linking increased lipolysis to p38 MAPK phosphorylation in adipose tissue. Paper 1 focuses on tenomodulin, adipogenesis, and insulin signaling (Akt) without discussing p38 or lipolysis. Paper 2 addresses estrogen receptor phosphorylation by MAPK (primarily ERK) in response to EGF/IGF, not p38 or adipose lipolysis. Paper 3 is a review on adipocyte progenitors and tissue expansion, not signaling. Paper 4 examines beta-adrenergic effects on immune cells during stress, not adipose signaling. Paper 5 describes a BAT mitochondrial respiration protocol, and Paper 6 concerns neuronal CuZnSOD and muscle function. No direct evidence for the claim is provided."
    },
    "naive_doc_ids": [
      "3621011",
      "4662264",
      "4854076",
      "3943235",
      "40232172"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Among the provided papers, only Paper 10 links p38 MAPK and adipocyte lipolysis, showing that nicotine activates AMPK\u03b12, which reduces MKP1 and thereby activates p38/JNK, leading to loss of insulin-mediated suppression of lipolysis and thus increased lipolysis. This indicates p38 activation upstream of increased lipolysis, not that increased lipolysis increases p38 phosphorylation. None of the papers present data showing that increased lipolysis leads to higher p38 phosphorylation in adipose tissue."
    },
    "overthinking_doc_ids": [
      "40232172",
      "1568684",
      "3621011",
      "14362678",
      "3943235"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers report measurements of p38 MAPK phosphorylation in adipose tissue or directly test whether increased lipolysis elevates p38 phosphorylation. The cited studies address adipogenesis (TNMD), adipose mitochondrial respiration and methods, cold-induced lipolysis and atherosclerosis, adrenergic signaling in heart or immune cells, and adipose cell lineage/browning, but do not present data linking lipolysis to p38 phosphorylation in adipose tissue."
    },
    "posthoc_doc_ids": [
      "3621011",
      "39187170",
      "40232172",
      "14362678",
      "3943235"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1295",
    "claim": "There is no relation between Erythromycin use and hypertrophic pyloric stenosis.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 1 (a nationwide cohort study) found a strong association between macrolide antibiotic use in early infancy and infantile hypertrophic pyloric stenosis (IHPS), with adjusted rate ratios of 29.8 (days 0\u201313) and 3.24 (days 14\u2013120) after birth, and increased risk with maternal macrolide use in the first two weeks postpartum. Erythromycin is a macrolide; thus evidence of a class effect contradicts the claim that there is no relation between erythromycin use and hypertrophic pyloric stenosis. The other papers are not relevant to this claim."
    },
    "naive_doc_ids": [
      "21239672",
      "5691302",
      "25157790",
      "202259",
      "439670"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (a nationwide cohort study) shows a strong association between macrolide use and infantile hypertrophic pyloric stenosis (IHPS), with adjusted rate ratios of 29.8 (95% CI 16.4\u201354.1) for infant exposure in days 0\u201313, and 3.24 (1.20\u20138.74) for days 14\u2013120. Maternal macrolide use in the first two weeks postpartum was also associated with increased IHPS risk (RR 3.49, 95% CI 1.92\u20136.34), with a possible association in late pregnancy. Erythromycin is a macrolide; thus, these findings contradict the claim of no relation. Papers 2\u20135 are unrelated to IHPS or erythromycin."
    },
    "overthinking_doc_ids": [
      "21239672",
      "3801693",
      "4647303",
      "439670",
      "6793674"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (a nationwide cohort study) found a strong association between macrolide antibiotic use and infantile hypertrophic pyloric stenosis (IHPS), especially when administered to infants in the first 2 weeks after birth (adjusted rate ratio ~29.8) and still elevated up to 120 days (RR ~3.24). Maternal macrolide use in the first 2 weeks postpartum was also associated with increased IHPS risk (RR ~3.49), with a possible association in late pregnancy. Since erythromycin is a macrolide, these findings directly contradict the claim that there is no relation between erythromycin use and hypertrophic pyloric stenosis. The other papers provided do not address this specific association."
    },
    "posthoc_doc_ids": [
      "21239672",
      "2425364",
      "2052720",
      "2095573",
      "2587396"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "899",
    "claim": "Oxidative DNA damage inhibits STING signalling.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that oxidative DNA damage (8-hydroxyguanosine in DNA) potentiates STING-dependent immune sensing by making DNA more resistant to TREX1-mediated degradation, leading to increased type I interferon responses. Papers 2 and 3 outline cGAS/IFI16-STING activation by cytosolic DNA but do not suggest inhibition by oxidative damage. No provided paper shows oxidative DNA damage inhibiting STING signaling. Therefore, the claim is contradicted by the evidence."
    },
    "naive_doc_ids": [
      "13106686",
      "40044800",
      "19688024",
      "10279084",
      "28195565"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Papers 2 and 3 show that oxidized DNA activates, rather than inhibits, STING signaling. Paper 2 reports that oxidized mitochondrial DNA released in NETs stimulates type I interferon via a STING-dependent pathway. Paper 3 demonstrates that oxidative DNA damage (e.g., 8-hydroxyguanosine) resists TREX1 degradation and potentiates STING-dependent immune sensing. Other papers do not provide relevant information on oxidative DNA damage and STING."
    },
    "overthinking_doc_ids": [
      "19688024",
      "1049501",
      "13106686",
      "2582169",
      "6690087"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly addresses oxidative DNA damage and STING signaling, showing that the oxidized DNA base 8-hydroxyguanosine (8-OHG) decreases TREX1-mediated degradation of cytosolic DNA and thereby potentiates (enhances) STING-dependent immune sensing. This is the opposite of the claim that oxidative DNA damage inhibits STING signaling. The remaining papers do not provide information on STING signaling."
    },
    "posthoc_doc_ids": [
      "13106686",
      "22059387",
      "213017",
      "14496749",
      "2686003"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "149",
    "claim": "Autophagy deficiency in the liver increases vulnerability to insulin resistance.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines autophagy deficiency and reports that liver-specific autophagy deficiency induces Fgf21 and leads to resistance to diet-induced obesity and amelioration of insulin resistance, indicating improved (not worsened) insulin sensitivity. The other papers do not provide relevant data on hepatic autophagy and insulin resistance. Therefore, the claim that autophagy deficiency in the liver increases vulnerability to insulin resistance is contradicted by the provided evidence."
    },
    "naive_doc_ids": [
      "6227220",
      "2481032",
      "16389141",
      "11201004",
      "2605032"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly reports that liver-specific autophagy deficiency induces Fgf21 and is associated with resistance to diet-induced obesity and amelioration of insulin resistance, indicating protection rather than increased vulnerability. The other papers do not address liver autophagy, so the only relevant evidence opposes the claim."
    },
    "overthinking_doc_ids": [
      "6227220",
      "16389141",
      "52805891",
      "31001322",
      "2481032"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly examines autophagy deficiency and reports that liver autophagy deficiency induces Fgf21 and confers resistance to diet-induced obesity with amelioration of insulin resistance. This indicates protection, not increased vulnerability, to insulin resistance. The other papers do not address hepatic autophagy status and insulin resistance directly. Therefore, the provided evidence contradicts the claim."
    },
    "posthoc_doc_ids": [
      "6227220",
      "31001322",
      "2481032",
      "16389141",
      "52805891"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "480",
    "claim": "Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 shows that endothelial-specific Gpr124 conditional knockout in adult mice leads to BBB disruption and microvascular hemorrhage in mouse models of ischemic stroke, and that restoring downstream Wnt\u2013\u03b2-catenin signaling rescues these defects. This indicates that Gpr124 is required to maintain BBB integrity under ischemic conditions, i.e., it suppresses BBB breakdown. The other papers do not directly address Gpr124 in stroke."
    },
    "naive_doc_ids": [
      "3761017",
      "6325527",
      "27602752",
      "2682997",
      "14753395"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 directly shows that endothelial-specific knockout of Gpr124 in adult mice leads to BBB disruption and microvascular hemorrhage in mouse models of ischemic stroke, indicating that Gpr124 is required to maintain BBB integrity under ischemic conditions. This implies that normal Gpr124 function suppresses BBB breakdown. Rescue by constitutive Wnt\u2013\u03b2-catenin signaling further supports the mechanism. The other papers do not address Gpr124 and are not relevant to this specific claim."
    },
    "overthinking_doc_ids": [
      "6325527",
      "3761017",
      "14753395",
      "6580081",
      "21789744"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that endothelial-specific deletion of Gpr124 in adult mice does not affect baseline BBB integrity but causes BBB disruption and microvascular hemorrhage specifically in mouse models of ischemic stroke (and glioblastoma). This indicates Gpr124 is required to maintain BBB integrity under ischemic conditions\u2014i.e., it suppresses BBB breakdown. Rescue by constitutive Wnt\u2013\u03b2-catenin signaling further links Gpr124 function to preserving the BBB during pathology. The other papers do not address Gpr124 in stroke and are not relevant to this claim."
    },
    "posthoc_doc_ids": [
      "6325527",
      "3761017",
      "14753395",
      "22281684",
      "33884866"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "985",
    "claim": "Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers directly investigate the PTEN pseudogene (PTENP1) or demonstrate that it regulates PTEN by acting as an miRNA decoy. Most studies address unrelated topics (viral ncRNAs modulating miRNAs, miRNA biogenesis/decay, catecholamines, ERV repression, endothelin). Paper 7 evaluates the ceRNA/sponge concept in general and finds limited impact under physiological conditions, which could cast doubt on ceRNA effects broadly, but it does not test PTENP1 or PTEN specifically. Therefore, the evidence set does not confirm or directly refute the specific claim about PTENP1."
    },
    "naive_doc_ids": [
      "153744",
      "2619579",
      "8006440",
      "9257019",
      "4323449"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 2 provides direct experimental evidence that the PTEN pseudogene (PTENP1) regulates PTEN levels via a coding-independent mechanism consistent with miRNA decoy/ceRNA activity, showing that PTENP1 expression modulates PTEN and has growth-suppressive effects. Paper 1 challenges the generality of ceRNA effects by arguing they require very high target-site abundance and may be uncommon, but it does not test PTENP1 specifically. Paper 3 supports that miRNAs (e.g., miR-21) regulate PTEN, which is compatible with a decoy mechanism but does not address PTENP1. Papers 4 and 5 are not directly relevant. Overall, the set contains specific support for the claim with some general skepticism about ceRNA prevalence, leading to a supportive classification."
    },
    "overthinking_doc_ids": [
      "18421962",
      "6828370",
      "654735",
      "12652963",
      "14050257"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 1 directly shows that the PTEN pseudogene PTENP1 regulates PTEN levels by competing for shared microRNAs (acting as a decoy/ceRNA), leading to growth suppression and noting selective loss of PTENP1 in cancers. This matches the claim precisely. Other papers discuss miRNA sponges/decoys in general (e.g., versican 3'UTR, lincRNA-RoR, GAS5) but are not necessary for the specific claim; none contradict it."
    },
    "posthoc_doc_ids": [
      "6828370",
      "11771811",
      "7281161",
      "13964633",
      "42662816"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "208",
    "claim": "CHEK2 is not associated with breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 5 directly examines CHEK2 and breast cancer risk. While it finds no association for common CHEK2 haplotypes, it reports an elevated odds ratio for the CHEK2 1100delC mutation (OR ~2.26; 95% CI 0.99\u20135.15) and notes that prior studies have established a role for CHEK2 in breast cancer etiology. This indicates an association for at least some CHEK2 variants, contradicting the claim that CHEK2 is not associated with breast cancer. Other provided papers do not address CHEK2."
    },
    "naive_doc_ids": [
      "17450673",
      "23557241",
      "6793674",
      "439670",
      "13519661"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.71,
      "justification": "Paper 1 directly examines CHEK2 and reports that while common CHEK2 variants showed no convincing association with breast cancer risk, the rare CHEK2 1100delC mutation was associated with an elevated odds ratio for breast cancer (OR 2.26; 95% CI 0.99\u20135.15), and notes prior evidence implicating CHEK2 in breast cancer. This contradicts the blanket claim that CHEK2 is not associated with breast cancer. Papers 2\u20135 do not provide information about CHEK2."
    },
    "overthinking_doc_ids": [
      "13519661",
      "18340282",
      "16734530",
      "17450673",
      "23557241"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.76,
      "justification": "Paper 6 directly examines CHEK2 and breast cancer. While it reports no convincing association for common CHEK2 haplotypes, it observes an elevated risk for carriers of the rare CHEK2 1100delC mutation (0.7% in cases vs 0.4% in controls; OR 2.26, 95% CI 0.99\u20135.15) and references prior evidence establishing CHEK2\u2019s role in breast cancer etiology. This contradicts the blanket claim that CHEK2 is not associated with breast cancer. Other provided papers do not pertain to CHEK2."
    },
    "posthoc_doc_ids": [
      "4414547",
      "20280410",
      "313403",
      "17450673",
      "23557241"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "298",
    "claim": "Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 reports experimental evidence that during H. pylori\u2013induced apoptosis in gastric epithelial cells, cytochrome c is released from mitochondria, a process that implies movement from the mitochondrial intermembrane space into the cytosol. Paper 1 (review) explicitly states that cell-death proteins located in the mitochondrial intermembrane space are released into the cytosol during cell death, aligning with the claim. Paper 6 cites prior demonstrations of cytochrome c release in H. pylori\u2013induced apoptosis and shows upstream mitochondrial events (Bax translocation, depolarization) consistent with cytochrome c release. Papers 3 and 7 discuss cytochrome c\u2019s role in apoptosome activation and its regulation, consistent with cytosolic cytochrome c in apoptosis, though they do not directly measure release. Overall, the provided evidence supports the claim."
    },
    "naive_doc_ids": [
      "23403754",
      "7465900",
      "23887844",
      "797114",
      "6836086"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers report cytochrome c release from mitochondria during apoptosis. Paper 3 explicitly states cytochrome c release from mitochondria to the cytosol in trophoblast apoptosis. Paper 4 shows cytochrome c release alongside apoptotic markers (caspase-3 activation, DNA laddering) in neurons, consistent with cytosolic translocation. Paper 1 reports Bax-associated cytochrome c release during p53-mediated apoptosis in gastric epithelial cells. Paper 2 discusses cytochrome c\u2019s apoptotic function and its redox regulation, supporting its role in apoptosis. Together, these align with the claim that cytochrome c is released from the mitochondrial intermembrane space to the cytosol during apoptosis."
    },
    "overthinking_doc_ids": [
      "7465900",
      "23887844",
      "25439264",
      "17231273"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple papers provide evidence that cytochrome c is released from mitochondria into the cytosol during apoptosis. Paper 2 explicitly reports mitochondria-dependent apoptotic events including release of cytochrome c into the cytosol with subsequent caspase-3 activation in vascular smooth muscle cells. Paper 3 shows that stabilizing mitochondrial cristae via OPA1 blunts cytochrome c release during apoptotic and ischemic damage, implying its release is part of apoptosis. Paper 4 observes cytochrome c release together with caspase activation and DNA laddering in ouabain-induced neuronal apoptosis. Paper 1 notes the release to cytosol of proteins normally in the mitochondrial intermembrane space during cell death, consistent with cytochrome c behavior. Together, these align with the claim."
    },
    "posthoc_doc_ids": [
      "23403754",
      "9588931",
      "15836115",
      "17231273",
      "15414628"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1239",
    "claim": "The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 explicitly states that the heart is comprised of distinct mesoderm-derived lineages including cardiomyocytes and identifies a KDR+ mesodermal cardiovascular progenitor that gives rise to cardiomyocytes, endothelial cells, and vascular smooth muscle. This directly contradicts the claim of an exclusively endodermal origin for myocardial cells. Paper 1 further situates key cardiac patterning within the lateral plate mesoderm, and Paper 5 highlights neural crest (ectoderm-derived) contributions to cardiac development, collectively reinforcing that myocardial and related cardiac lineages are not of endodermal origin."
    },
    "naive_doc_ids": [
      "11831598",
      "13777138",
      "17685207",
      "6270720",
      "38727075"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 explicitly identifies cardiomyocytes as mesoderm-derived and shows mesodermal defects abolish cardiomyocyte formation, refuting an endodermal origin. Papers 5 and 6 further show contributions of neural crest (ectodermal lineage) to cardiac lineages, including cardiomyocytes, demonstrating that myocardial progenitors are not exclusively endodermal. Paper 1 maps early germ layers but does not support an endodermal origin for myocardium. Overall, the evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "17685207",
      "26612216",
      "5266423",
      "4421787",
      "6148876"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "The claim states that myocardial lineage derives exclusively from endodermal progenitors. Paper 7 explicitly identifies cardiomyocytes as mesoderm-derived, directly contradicting an endodermal origin. Paper 6 shows that cardiac progenitors marked by Isl1 include both second heart field (mesoderm) and neural crest (ectoderm) derivatives in the outflow tract, further contradicting exclusivity to endoderm. Paper 5 demonstrates a role for neural crest (ectoderm-derived) signaling in ventricular myocardium proliferation via epicardial derivatives, indicating non-endodermal contributions to myocardial development. Collectively, the evidence supports mesodermal (and some neural crest-related) involvement, not exclusive endodermal origin."
    },
    "posthoc_doc_ids": [
      "5002665",
      "20186814",
      "32797183",
      "13002003",
      "38727075"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "368",
    "claim": "Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly evaluates early PDA screening (echocardiography before day 3) and finds it is associated with lower in-hospital mortality (14.2% vs 18.5%; OR 0.73, 95% CI 0.54\u20130.98). An instrumental variable analysis also trends toward reduced mortality (adjusted OR 0.62, 95% CI 0.37\u20131.04), not increased. Papers 2\u20134 address treatment modalities rather than the effect of screening on mortality and do not provide evidence that screening increases mortality. Overall, the available evidence refutes the claim."
    },
    "naive_doc_ids": [
      "27099731",
      "34544514",
      "9967265",
      "25612629"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly examines early PDA screening (echocardiography before day 3) and reports lower in-hospital mortality in screened vs unscreened extremely preterm infants (14.2% vs 18.5%; OR 0.73, 95% CI 0.54\u20130.98). Instrumental variable analysis also suggested reduced mortality (adjusted OR 0.62, 95% CI 0.37\u20131.04), not an increase. Papers 2\u20136 do not address the effect of early PDA screening on in-hospital mortality. Therefore, the claim that early PDA screening increases in-hospital mortality is contradicted by the relevant evidence."
    },
    "overthinking_doc_ids": [
      "27099731",
      "9967265",
      "25691541",
      "12779444",
      "11880289"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 directly evaluates early PDA screening (echocardiography before day 3) and reports lower in-hospital mortality in the screened group vs. not screened (14.2% vs 18.5%; OR 0.73, 95% CI 0.54\u20130.98). Instrumental variable analysis likewise favored screening (adjusted OR 0.62, 95% CI 0.37\u20131.04), though not statistically significant, but it does not indicate increased mortality. Papers 2 and 3 address PDA treatment, not screening, and do not show that early screening increases mortality. The remaining papers are unrelated. Overall, available evidence contradicts the claim that early PDA screening increases in-hospital mortality."
    },
    "posthoc_doc_ids": [
      "27099731",
      "9967265",
      "34544514",
      "32423829",
      "3878434"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1375",
    "claim": "Weighed food records (WFR) result in poor completion since they're costly to run and impose high participant burden.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "Only Paper 1 involves weighed food records (WFR), reporting 98/150 participants completed a demanding, year-round protocol that included repeated WFRs and 7-day estimated records. However, it does not attribute non-completion to cost or participant burden, nor does it quantify these factors. Paper 3 evaluates WFR accuracy (underreporting) but not completion, cost, or burden. The other papers are unrelated. Thus, the provided evidence does not substantiate that WFRs have poor completion because they are costly and burdensome."
    },
    "naive_doc_ids": [
      "21623140",
      "2048139",
      "21993510",
      "5151024",
      "13625993"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "Most provided papers do not address weighed food records (WFR) completion, cost, or participant burden. Paper 1 includes WFR as part of a multi-method protocol and reports 98/150 participants completed the overall protocol, but it does not attribute non-completion specifically to WFR nor discuss cost or burden of WFR. Papers 6 and 7 concern online 24-h recalls and feasibility, not WFR burden/cost. The remaining papers are unrelated. Thus, there is insufficient evidence here to confirm or refute the claim that WFR have poor completion due to cost and participant burden."
    },
    "overthinking_doc_ids": [
      "21623140",
      "11748341",
      "16322674",
      "12672066",
      "14606752"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data directly linking weighed food records to poor completion due to high cost and participant burden. Paper 2 reports correlations and some overall protocol completion (98/150) but does not attribute non-completion to WFR burden or compare completion across methods. Paper 8 discusses feasibility of a computerized 24-h recall without directly comparing cost/burden or completion to WFR. Paper 9 evaluates accuracy of weighed records, not completion or cost. The other papers are unrelated to dietary assessment methods."
    },
    "posthoc_doc_ids": [
      "2048139",
      "21623140",
      "11748341",
      "3572885",
      "11837657"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "658",
    "claim": "It is not proven that moderate consumption of candy and chocolate reduces the risk of cardiovascular disease (CVD) specifically.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers investigate the effect of moderate candy or chocolate consumption on cardiovascular disease risk. The studies focus on blood pressure reduction in dialysis patients, migraine associations, lipoprotein(a), dietary flavonols (from fruits/vegetables, tea, red wine\u2014not chocolate), QRISK3 predictors, and TMAO. Therefore, they neither prove nor refute the specific claim about candy/chocolate and CVD risk."
    },
    "naive_doc_ids": [
      "202259",
      "10072941",
      "15984735",
      "12102963",
      "21571708"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.95,
      "justification": "None of the provided papers examine candy or chocolate consumption in relation to cardiovascular disease risk. The studies focus on antihypertensive therapies, air pollution, statin therapy and cost-effectiveness, influenza vaccination, migraine associations, and physician adherence to guidelines. Therefore, they provide no evidence to verify or refute whether moderate candy/chocolate intake reduces CVD risk."
    },
    "overthinking_doc_ids": [
      "40790033",
      "471921",
      "1287809",
      "5698494",
      "11939159"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.94,
      "justification": "None of the provided papers directly examine candy or chocolate consumption in relation to cardiovascular disease risk. Most papers address other exposures or interventions (e.g., migraine, TMAO, blood pressure lowering, risk prediction, tai chi, glucosamine, physical activity, homocysteine). Paper 8 assesses dietary flavonols and CHD mortality, with main sources listed as certain fruits/vegetables, tea, and red wine\u2014not candy or chocolate\u2014and it does not evaluate chocolate intake or \u2018moderate consumption\u2019 specifically. Therefore, the evidence set does not confirm or refute the claim about candy/chocolate and CVD risk."
    },
    "posthoc_doc_ids": [
      "15984735",
      "6793674",
      "202259",
      "27466734",
      "40790033"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1098",
    "claim": "Stacking is more stable when a purine is present in the +5 position (C1698).",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data or discussion about nucleotide stacking at the +5 mRNA position or interactions involving rRNA residue C1698. Paper 1 discusses ribosome\u2013GTPase complexes without detailing +5 stacking or C1698. Papers 2\u20136 address unrelated topics (translational specificity via RPL38, pre-rRNA processing by Rat1, ion channels, and YB-1\u2013RNA interactions). Therefore, the evidence does not inform the specific claim about increased stacking stability with a purine at +5 (C1698)."
    },
    "naive_doc_ids": [
      "13552682",
      "12486491",
      "18467982",
      "13760557",
      "40721190"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers address base-stacking stability as a function of nucleotide identity at a +5 position relative to a specific rRNA residue (C1698), nor do they discuss this residue or a related stacking interaction. The papers focus on rRNA processing factors (Papers 1\u20132), enzyme kinetics of 5'-nucleotidase (Paper 3), ribosomal protein-mediated translational specificity (Paper 4), structures of ribosome\u2013GTPase complexes without residue-specific stacking analysis (Paper 5), mRNA pseudouridylation (Paper 6), DNA methylation functions (Paper 7), an alphavirus stop codon effect (Paper 8), and SMC complex chromosome compaction (Paper 9). Therefore, they provide no relevant evidence to support or contradict the claim."
    },
    "overthinking_doc_ids": [
      "18467982",
      "26112624",
      "393001",
      "12486491",
      "13552682"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the provided papers address nucleic acid base stacking, sequence-dependent stacking stability, or the specific context of a +5 position relative to C1698 (likely an rRNA nucleotide). The articles focus on topics such as DNA repair and replication fork protection, atherosclerosis, SIRT1 and aging, dietary effects on insulin resistance, antiplatelet therapy in diabetes, respiratory muscle function in pulmonary hypertension, adenoviral protein interactions, MHC\u2013CD4 interactions, and KRAS\u2013PDE\u03b4 inhibition. They provide no data relevant to the claim about stacking stability with a purine at the +5 position."
    },
    "posthoc_doc_ids": [
      "4444861",
      "4890578",
      "5824955",
      "5687200",
      "6158879"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "643",
    "claim": "Insulin effects appetite via ventral tegmental neurons.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 3 provides direct evidence that insulin signaling in catecholaminergic neurons, including dopaminergic neurons in the ventral tegmental area (VTA), regulates feeding and energy homeostasis. Mice lacking insulin receptors in tyrosine hydroxylase\u2013expressing neurons (which include VTA dopaminergic neurons) exhibited hyperphagia and increased body weight, and insulin acutely modulated firing in VTA/SN neurons. This supports the claim that insulin affects appetite/feeding via VTA neurons. The other papers are not about insulin action in VTA or appetite and do not contradict this finding."
    },
    "naive_doc_ids": [
      "23869951",
      "4611267",
      "15535511",
      "4700428",
      "16389141"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers examine insulin\u2019s role or its actions on ventral tegmental area (VTA) neurons. The studies focus on LHA\u2192LHb circuits (Paper 1), serotonin 2C receptors on midbrain dopamine neurons affecting binge eating (Paper 2), JC virus neuropathology (Paper 3), IL-18\u2019s effects on feeding and metabolism (Paper 4), Src kinase signaling in LHA-related feeding (Paper 5), and dorsal raphe circuits controlling feeding (Paper 6). While Paper 2 involves midbrain dopamine neurons, it addresses serotonin signaling, not insulin. Therefore, these papers do not provide evidence relevant to the claim that insulin affects appetite via VTA neurons."
    },
    "overthinking_doc_ids": [
      "23869951",
      "1084062",
      "13322804",
      "25050364",
      "4611267"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.79,
      "justification": "Paper 5 provides direct evidence that insulin signaling in catecholaminergic neurons, including dopaminergic neurons in the ventral tegmental area (VTA), regulates food intake: insulin acutely increases firing in dopaminergic VTA/SN neurons, and deleting insulin receptors in tyrosine hydroxylase\u2013expressing neurons leads to hyperphagia and increased adiposity. This supports the claim that insulin affects appetite via VTA neurons. Paper 4 further supports the role of midbrain dopamine neurons in controlling feeding (though via 5-HT2C receptors, not insulin). The other papers do not address insulin action in VTA neurons or appetite."
    },
    "posthoc_doc_ids": [
      "23869951",
      "4709641",
      "6313547",
      "1084062",
      "15535511"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "249",
    "claim": "Chenodeosycholic acid treatment reduces whole-body energy expenditure.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that oral chenodeoxycholic acid (CDCA) treatment in humans increased brown adipose tissue activity and whole-body energy expenditure after 2 days, which is the opposite of the claim. The other papers do not assess CDCA\u2019s effect on whole-body energy expenditure; some discuss energy expenditure in other contexts (inflammation, browning, thermogenesis) but do not support a reduction with CDCA. Therefore, the claim that CDCA reduces whole-body energy expenditure is contradicted by the provided evidence."
    },
    "naive_doc_ids": [
      "1568684",
      "24917562",
      "25050364",
      "26902591",
      "4319174"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that oral chenodeoxycholic acid (CDCA) treatment in humans increased brown adipose tissue activity and increased whole-body energy expenditure, directly opposing the claim that it reduces energy expenditure. The other papers do not address CDCA and are not relevant to this specific claim."
    },
    "overthinking_doc_ids": [
      "1568684",
      "25050364",
      "24917562",
      "26902591",
      "4319174"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 directly tests chenodeoxycholic acid (CDCA) in humans and reports that CDCA treatment increased brown adipose tissue activity and increased whole-body energy expenditure. This is the opposite of the claim. The other papers do not provide direct evidence about CDCA's effect on whole-body energy expenditure."
    },
    "posthoc_doc_ids": [
      "1568684",
      "25050364",
      "13902570",
      "24917562",
      "9310407"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "13",
    "claim": "5% of perinatal mortality is due to low birth weight.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers quantify perinatal mortality or the proportion attributable to low birth weight. Several papers discuss related topics (e.g., antenatal depression and risk of low birth weight, vitamin D insufficiency and birth outcomes), but they do not report the share of perinatal deaths caused by low birth weight. Other papers focus on unrelated outcomes (temperature-related mortality, cancer risks, global DALYs, alcohol). Therefore, the evidence does not address the specific claim that 5% of perinatal mortality is due to low birth weight."
    },
    "naive_doc_ids": [
      "4810810",
      "26611834",
      "4828631",
      "2425364",
      "17450673"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers quantify the proportion of perinatal mortality attributable to low birth weight. Papers 1 and 7 discuss mortality patterns and perinatal mortality rates without cause attribution to low birth weight. Papers 2, 5, and 6 involve preterm birth/low birth weight risk or treatment but do not report the fraction of perinatal deaths due to low birth weight. Paper 3 examines determinants of neonatal mortality (not perinatal) and reports associations, not attributable fractions. Paper 4 is unrelated. Therefore, the evidence does not confirm or refute the specific claim that 5% of perinatal mortality is due to low birth weight."
    },
    "overthinking_doc_ids": [
      "14823313",
      "22815457",
      "1263446",
      "5487448",
      "26611834"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers quantify the proportion of perinatal mortality attributable specifically to low birth weight. Paper 1 reports perinatal mortality rates but not causes. Paper 3 identifies determinants of neonatal mortality (including smaller-than-average size) with odds ratios, not an attributable fraction for perinatal mortality. Papers 4 and 5 discuss risk factors for low birth weight, not perinatal deaths caused by it. Paper 2 addresses treatment of PDA in preterm/LBW infants, and Papers 6\u20137 concern global DALYs and risk factors broadly. No study provides the claimed 5% figure or an equivalent causal attribution for perinatal mortality due to low birth weight."
    },
    "posthoc_doc_ids": [
      "7662395",
      "34544514",
      "1263446",
      "2425364",
      "26611834"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1193",
    "claim": "The appearance of brown-like or beige cells primarily occurs in visceral fat, not subcutaneous fat.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "Paper 3 explicitly reports that during cold-induced browning, beige adipocytes arise in subcutaneous fat, indicating subcutaneous depots are the primary site of beige cell appearance under this stimulus. None of the provided papers present evidence that beige/brown-like cells primarily occur in visceral fat. Papers 1, 2, 4, 5, 6, and 7 do not provide depot-specific evidence supporting visceral predominance of beige cells. Therefore, the claim is contradicted by the evidence."
    },
    "naive_doc_ids": [
      "29381091",
      "17973161",
      "20532591",
      "79447",
      "3621011"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers directly compare where beige (brite) adipocytes primarily appear between visceral and subcutaneous depots. Paper 1 and Paper 2 address beige adipocyte biology and thermogenic mechanisms without specifying depot predominance. Paper 3 is a general review excerpt without depot-specific distribution data. Paper 4 examines vascular dysfunction in visceral fat, not beige cell presence. Paper 5 discusses visceral adipose expansion and Ucp1 changes in brown fat, not beige cells in visceral fat. Paper 6 compares mitochondrial respiration between depots but does not assess beige markers (e.g., UCP1) or beige cell abundance. Therefore, the evidence provided does not confirm or refute the claim about depot-specific beige cell appearance."
    },
    "overthinking_doc_ids": [
      "17973161",
      "19205437",
      "14865329",
      "79447",
      "3621011"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.76,
      "justification": "None of the provided papers directly compare or localize the appearance/prevalence of brown-like (brite/beige) adipocytes between visceral and subcutaneous fat depots. Papers 1, 2, 3, and 5 focus on bioenergetics, vascular function, inflammation, and angiogenesis differences between depots, not beiging. Paper 6 discusses human brite/beige progenitors and function without specifying depot of origin. Paper 7 examines browning plasticity in mice without explicitly stating visceral vs subcutaneous distribution in the excerpt. Paper 8 addresses BAT/UCP1 and atherosclerosis, not depot-specific beiging. Therefore, the evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "39187170",
      "79447",
      "3621011",
      "143251",
      "41790911"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "173",
    "claim": "Bcp1 is a chaperone for Rpl23.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.91,
      "justification": "None of the provided papers address Bcp1 or its interaction with Rpl23. Several discuss ribosome biogenesis factors (e.g., Yar1/Ltv1 with Rps3 for 40S, Ria1 and Tif6 for 60S, Exportin 5 for 60S export), but there is no experimental evidence here about Bcp1 functioning as a chaperone for Rpl23."
    },
    "naive_doc_ids": [
      "26596106",
      "41087952",
      "8327914",
      "37164306",
      "213017"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address Bcp1 or evaluate its interaction with Rpl23. The evidence discusses topics such as chromatin remodeling (Asf1, SWR1, condensin), PHO5 promoter reassembly, general ribosome biogenesis factors in human cells, mitochondrial RNA granules, the chaperone Yar1 for Rps3, and RPL23\u2019s role in p53 regulation\u2014none test or report that Bcp1 functions as a chaperone for Rpl23."
    },
    "overthinking_doc_ids": [
      "12086599",
      "335029",
      "406733",
      "24311787",
      "8327914"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers mention Bcp1 or Rpl23, nor do they address dedicated chaperones for Rpl23. The studies cover topics such as chaperone-mediated autophagy, histone chaperones (ASF1), Hcp as a chaperone for type VI secretion substrates, DNA replication control, ribosome biogenesis factors (Ria1p, Nol11) and other unrelated proteins (Rpl32, KDM4E, NF-\u03baB). Therefore, there is no relevant information to confirm or refute that Bcp1 is a chaperone for Rpl23."
    },
    "posthoc_doc_ids": [
      "1084345",
      "12156187",
      "12428814",
      "23664875",
      "41087952"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "78",
    "claim": "Active caspase-11 participate in regulating phagosome-lysosome fusion.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 provides direct experimental evidence that active caspase-11 promotes fusion of pathogen-containing phagosomes (L. pneumophila vacuoles) with lysosomes by modulating actin polymerization via cofilin, indicating it regulates phagosome\u2013lysosome fusion. It notes caspase-11 is dispensable for nonpathogenic cargo, showing context-specific regulation but still confirming the regulatory role. Papers 1, 3, and 4 discuss phagosome maturation and Legionella vacuole integrity/inflammasome activation without addressing caspase-11\u2019s role, and do not contradict the claim."
    },
    "naive_doc_ids": [
      "38043606",
      "5099266",
      "35079452",
      "15414628"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that active caspase-11 promotes fusion of Legionella pneumophila\u2013containing phagosomes with lysosomes by modulating actin polymerization via cofilin. It further notes that caspase-11 is dispensable for fusion with nonpathogenic cargo, indicating a regulatory role dependent on phagosomal content. This demonstrates that active caspase-11 participates in regulating phagosome\u2013lysosome fusion. The other papers do not address caspase-11\u2019s role in this process."
    },
    "overthinking_doc_ids": [
      "5099266",
      "38043606",
      "4345315",
      "9705208",
      "11837657"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct experimental evidence that active caspase-11 promotes fusion of pathogen-containing phagosomes with lysosomes by modulating actin polymerization (via cofilin), demonstrating its regulatory role in phagosome\u2013lysosome fusion. The other papers do not address caspase-11\u2019s role in this process and do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "5099266",
      "38043606",
      "4345315",
      "393001",
      "3118719"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "617",
    "claim": "Increased mobility of retrotransposons is assosciated with mutation and higher tumorigenesis rates.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on endogenous retrotransposon (e.g., LINE-1, ERV) mobility/activity or directly associate increased retrotransposition with mutation rates or heightened tumorigenesis. The studies instead address chromosomal instability after genome doubling, oxidative stress in cancer-associated fibroblasts, CRISPR genome engineering, senescence/SASP, EMT and stemness, ribosome biogenesis, miR-205/MED1 regulation, epigenetic therapy-induced IFN signaling, and a Sleeping Beauty transposon mutagenesis screen (as an experimental tool, not endogenous retrotransposon activity). Therefore, the evidence does not speak to the specific claim."
    },
    "naive_doc_ids": [
      "7211056",
      "24349992",
      "1286352",
      "15521377",
      "3848469"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Across the provided papers, none present data on retrotransposon mobility or its association with mutation burden or tumorigenesis rates. The studies cover somatic mutation cataloging (COSMIC), EGFR mutation detection methods, chromatin remodeling mutations in pediatric GBM, BRCA1/2 mutation-specific risks, whole-genome features of pancreatic cancer, ROS-driven DNA damage in myeloid disease, epidemiology of diabetes and breast cancer, regulatory roles of transposable elements in embryonic stem cells (without tumorigenesis context), and the impact of smoking cessation on lung cancer prognosis. Only the stem cell paper discusses transposable elements, but it addresses regulatory rewiring rather than increased mobility leading to cancer or mutations. Therefore, the provided evidence does not confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "13916484",
      "711256",
      "4312169",
      "9394119",
      "4457160"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "None of the provided papers present data on endogenous retrotransposon mobility or its association with mutation burden and tumorigenesis. Paper 4 uses the engineered Sleeping Beauty DNA transposon system (not a retrotransposon) to induce insertional mutagenesis and accelerate tumorigenesis in a mouse model, which does not address natural retrotransposon activity. The other papers discuss KRAS/PI3K alterations, EMT, oxidative stress, amyloid processing, and mutation cataloging, without evidence linking increased retrotransposon mobility to cancer risk."
    },
    "posthoc_doc_ids": [
      "3127341",
      "3210545",
      "8892905",
      "11255504",
      "3848469"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.12,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "813",
    "claim": "Mutations in G-Beta protein GNB1 are present in many cancers, resulting in loss of interaction with G-alpha subunits and concomitant activation of AKT pathway.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers discuss GNB1 (G-beta) mutations, their frequency across cancers, loss of interaction with G-alpha subunits, or a direct link from GNB1 alterations to AKT pathway activation. The cited studies focus on PI3K/AKT pathway components (e.g., PIK3CA, PTEN), p53 phosphorylation, endometrial cancer genetics, glioblastoma pathways, pancreatic cancer genomics, and tumor microenvironment effects, but do not address GNB1 specifically."
    },
    "naive_doc_ids": [
      "14241418",
      "36464673",
      "11271123",
      "5403286",
      "601033"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 6 reports recurrent mutations in the G\u03b2 proteins GNB1 and GNB2 across multiple human tumor types (myeloid and B-cell malignancies, among others), demonstrating they confer transformed phenotypes. It shows that many GNB1 mutations affect the interface that binds G\u03b1 and disrupt G\u03b1\u2013G\u03b2\u03b3 interactions, matching the claim\u2019s loss of G\u03b1 interaction. The study also shows that GNB1-induced signaling is suppressed in vivo by the dual PI3K\u2013mTOR inhibitor BEZ235, implying activation of the PI3K/AKT/mTOR axis. Other papers do not address GNB1 and do not contradict this. Thus, the provided evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "14241418",
      "3590806",
      "4325398",
      "1387104",
      "5492542"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.92,
      "justification": "None of the provided papers discuss GNB1 (G-beta) mutations, their impact on interaction with G-alpha subunits, or a causal link to AKT pathway activation. The papers focus on PI3K/mTOR inhibitors, WNT signaling, AMPK regulation, adenoviral protein interactions, and G-alpha localization in neurons, but do not provide data on GNB1 mutations in cancer."
    },
    "posthoc_doc_ids": [
      "14241418",
      "17648235",
      "3590806",
      "207972",
      "22036571"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.0,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "614",
    "claim": "Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.98,
      "justification": "Paper 1 directly demonstrates that increasing microtubule acetylation (via deacetylase inhibitors like TSA or overexpression of the tubulin acetyltransferase \u03b1TAT1, and by knockdown of HDAC6/Sirt2) prevents mutant LRRK2 (Roc-COR domain mutations R1441C, Y1699C) association with microtubules and rescues axonal transport defects in neurons and Drosophila, also restoring locomotor behavior. The other papers discuss motor preferences and transport mechanisms but do not address LRRK2 or acetylation and thus do not contradict this. Therefore, the evidence supports the claim."
    },
    "naive_doc_ids": [
      "9638032",
      "7549811",
      "1546650",
      "28369117",
      "18678095"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly shows that LRRK2 Roc-COR mutations (R1441C, Y1699C) impair axonal transport by associating with deacetylated microtubules, and that increasing microtubule acetylation (via deacetylase inhibitors like TSA or by \u03b1TAT1) prevents mutant LRRK2-microtubule association and restores axonal transport in neurons and Drosophila, also rescuing locomotor deficits in vivo. Papers 2\u20135 discuss other aspects of axonal transport and cytoskeletal organization but do not address LRRK2 or microtubule acetylation regarding this claim. Therefore, the evidence supports the claim."
    },
    "overthinking_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "18678095",
      "20743803"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Paper 1 directly shows that LRRK2 Roc-COR mutations (R1441C, Y1699C) impair axonal transport and that increasing microtubule acetylation\u2014via deacetylase inhibitors (e.g., TSA), \u03b1TAT1 overexpression, or knockdown of HDAC6/Sirt2\u2014prevents mutant LRRK2\u2013microtubule association and restores axonal transport and locomotor behavior. The other papers are not directly relevant to this claim."
    },
    "posthoc_doc_ids": [
      "9638032",
      "28369117",
      "1889358",
      "1546650",
      "7549811"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1387",
    "claim": "eRNAs influence is linked to senescence, aging, and carcinogenesis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers discuss enhancer RNAs (eRNAs) or extracellular RNAs in relation to senescence, aging, or carcinogenesis. The studies focus on senescence mechanisms (SASP, metabolic changes, inflammasome/IL-1 signaling), chromatin architecture via CTCF/cohesin and enhancer insulation, transcriptional coactivators (p300/Mediator/PGC-1\u03b1), and unrelated interventions (tai chi, NSAIDs). While some papers mention enhancers or microRNAs, there is no evidence linking eRNAs specifically to senescence, aging, or cancer in the provided set."
    },
    "naive_doc_ids": [
      "15521377",
      "35543846",
      "17412260",
      "24995939",
      "43711341"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "Only Paper 1 directly involves eRNAs, showing they are required for p53-dependent enhancer activity and for inducing a p53-dependent cell-cycle arrest, which relates to tumor suppression and thus carcinogenesis. However, none of the papers link eRNAs specifically to senescence or aging. Paper 2 addresses senescence (SASP, inflammasome) but does not involve eRNAs. The remaining papers do not discuss eRNAs in the context of senescence, aging, or carcinogenesis. Therefore, the provided evidence does not substantiate that eRNAs are linked to senescence and aging, and only indirectly touches carcinogenesis via p53."
    },
    "overthinking_doc_ids": [
      "9669099",
      "17412260",
      "140874",
      "3446400",
      "11254040"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 shows that p53-bound enhancers produce eRNAs that are required for efficient transcriptional enhancement and induction of a p53-dependent cell-cycle arrest, directly linking eRNAs to senescence-related mechanisms and tumor suppressor function. Paper 3 establishes that p53 regulates cellular senescence and organismal aging and contributes to tumor suppression, connecting p53 activity to both aging and carcinogenesis. Together, these findings imply that eRNAs, by enabling p53 enhancer activity, are linked to senescence, aging, and cancer-related processes. The other papers do not address eRNAs and do not contradict this link."
    },
    "posthoc_doc_ids": [
      "9669099",
      "4653837",
      "6896063",
      "14225271",
      "17876040"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "730",
    "claim": "Lysine histone demethylase inhibitor JIB 04 is inactive against KDM5A.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Among the provided papers, only Paper 5 discusses JIB-04, stating it inhibits Jumonji family histone demethylases in general, but it does not specify activity against KDM5A in particular. None of the papers present data directly assessing JIB-04\u2019s activity against KDM5A. Therefore, there is insufficient information here to confirm or refute the specific claim that JIB-04 is inactive against KDM5A."
    },
    "naive_doc_ids": [
      "39391953",
      "26491450",
      "26607366",
      "4387494",
      "13400643"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "Among the provided papers, only Paper 6 mentions JIB-04, describing it as an inhibitor of Jumonji histone demethylases, but it does not specify activity or inactivity against KDM5A. None of the other papers address JIB-04 or KDM5A. Therefore, there is no direct evidence in these papers to confirm or refute the claim that JIB-04 is inactive against KDM5A."
    },
    "overthinking_doc_ids": [
      "25970224",
      "26118532",
      "26491450",
      "2817000",
      "4387494"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.98,
      "justification": "None of the provided papers mention JIB-04, KDM5A, or lysine histone demethylase inhibition assays. The studies focus on extracellular vesicles, cardiac fibroblasts, small RNAs, histone variant H2A.Z, EGCG in myeloma, HDL and breast cancer risk, and CTCF\u2013cohesin interactions, which are unrelated to the claim."
    },
    "posthoc_doc_ids": [
      "1905095",
      "2828460",
      "4411760",
      "2817000",
      "15778034"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "705",
    "claim": "Long chain polyunsaturated fatty acids supplementation has no significant effects on wheezing or asthma at 3 and 6 years.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers report wheezing or asthma outcomes at 3 or 6 years following long-chain polyunsaturated fatty acid supplementation. Paper 1 reports only 1-year allergic outcomes and explicitly calls for longer-term follow-up for respiratory diseases. Paper 2 is a review suggesting possible protective effects on atopic outcomes (including asthma) but does not present specific, definitive results at 3 or 6 years. Papers 3\u20137 are unrelated to LCPUFA supplementation effects on childhood wheeze/asthma. Therefore, the evidence set does not confirm or refute the specific claim."
    },
    "naive_doc_ids": [
      "22442133",
      "24269361",
      "20672596",
      "22467585",
      "10692948"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers report outcomes on wheezing or asthma at ages 3 or 6 years after long-chain polyunsaturated fatty acid (LCPUFA) supplementation. Paper 1 is a pregnancy fish oil RCT with outcomes at 1 year (eczema/food allergy), explicitly noting longer-term respiratory outcomes were not assessed. Paper 2 is a broad systematic review discussing potential protective effects of fish/n-3 PUFAs but does not provide specific evidence for wheeze/asthma at 3 or 6 years. The remaining papers are unrelated to LCPUFA and asthma/wheezing outcomes."
    },
    "overthinking_doc_ids": [
      "22442133",
      "24269361",
      "20672596",
      "34208005",
      "602760"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 1 and Paper 2 address n-3 long-chain polyunsaturated fatty acids in relation to allergic outcomes. Paper 1 reports first-year outcomes (eczema and egg sensitization) and explicitly notes that longer-term respiratory outcomes were not assessed. Paper 2 is a general systematic review suggesting possible benefits but does not provide specific data on wheezing or asthma at 3 or 6 years. The remaining papers are unrelated. Therefore, there is no direct evidence here about wheezing/asthma outcomes at 3 and 6 years."
    },
    "posthoc_doc_ids": [
      "22442133",
      "24269361",
      "11705328",
      "11939159",
      "2425364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1041",
    "claim": "Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "Among the provided papers, only Papers 4 and 6 address H2A.Z and its deposition. Paper 4 demonstrates SWR1-mediated, stepwise replacement of H2A by H2A.Z at promoters but does not assess effects on gene activation kinetics or +1 nucleosome stability. Paper 6 shows that H2A.Z deposition is dispensable for nucleosome positioning and that NFR establishment precedes H2A.Z deposition, but it does not evaluate whether H2A.Z stabilizes +1 nucleosomes or alters activation speed. The other papers concern unrelated topics (induction of galactokinase, RNA processing kinetics, DSB repair, and IME1 regulation). Therefore, the provided evidence neither supports nor contradicts the specific claim that H2A.Z replacement slows gene activation by stabilizing +1 nucleosomes."
    },
    "naive_doc_ids": [
      "42421723",
      "365896",
      "25462689",
      "9451052",
      "23604601"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "Among the provided papers, only Paper 3 directly concerns H2A.Z, showing it is enriched at promoters of inactive genes and can regulate nucleosome positioning (e.g., at GAL1), suggesting a role in poising genes for activation. However, none of the papers measure activation kinetics as a function of H2A\u2192H2A.Z replacement or demonstrate that H2A.Z stabilizes the +1 nucleosome to slow activation. Papers 1 and 4 discuss GAL gene induction kinetics and nucleosome remodeling but do not involve H2A.Z. The remaining papers address HDACs, RNA processing, meiosis regulation, histone reassembly, or sporulation programs, not H2A.Z\u2019s effect on activation speed or +1 nucleosome stability. Therefore, the specific claim is not supported or refuted by the provided evidence."
    },
    "overthinking_doc_ids": [
      "18895793",
      "43156471",
      "15778034",
      "42421723",
      "365896"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 4 reports that the yeast H2A.Z variant (Htz1) is enriched at repressed/basal promoters and facilitates full gene activation by making promoter nucleosomes more susceptible to loss. It explicitly shows H2A.Z-bearing nucleosomes release under conditions where canonical H2A nucleosomes remain, indicating decreased stability, not stabilization, and a role in promoting (not slowing) activation. Paper 1 describes the SWR1-mediated replacement mechanism but provides no evidence that H2A.Z stabilizes +1 nucleosomes or slows activation. The other papers are not relevant to this specific claim. Therefore, the provided evidence contradicts the claim that H2A.Z replacement slows activation by stabilizing +1 nucleosomes."
    },
    "posthoc_doc_ids": [
      "9451052",
      "23269537",
      "13639330",
      "16626264",
      "18895793"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1118",
    "claim": "Sweet taste receptors on the tongue are deactivated by between 1 and 10 mM glucose.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.83,
      "justification": "None of the provided papers test or report that tongue sweet taste receptors are deactivated by 1\u201310 mM glucose. Papers 1 and 2 address the genetic and signaling components of sweet taste but do not examine glucose concentration-dependent deactivation. Papers 4 and 5 discuss glucose responses in gut L cells (often activation at low-millimolar glucose), not deactivation on the tongue. Papers 3 and 6 are unrelated to taste. Therefore, the specific claim about deactivation by 1\u201310 mM glucose is not supported or refuted by the provided evidence."
    },
    "naive_doc_ids": [
      "23351136",
      "718601",
      "20960682",
      "6061927",
      "20829129"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers test or report that sweet taste receptors on the tongue are deactivated by 1\u201310 mM glucose. Papers 1 and 2 discuss receptor identity and signaling for sweet/umami/bitter taste but do not examine glucose concentration-dependent effects or deactivation. Paper 7 shows sugars (including glucose) activate sweet-taste-like pathways in gut L cells, not deactivation, and does not provide tongue receptor concentration data. The remaining papers are unrelated to taste receptor pharmacology. Therefore, the specific claim about deactivation by 1\u201310 mM glucose is not addressed by the provided evidence."
    },
    "overthinking_doc_ids": [
      "23351136",
      "718601",
      "3701541",
      "13277039",
      "23260700"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers measure or report deactivation of tongue sweet taste receptors by 1\u201310 mM glucose. Paper 1 shows activation of gut L-cell sweet taste receptors by sugars/sucralose (not deactivation and not tongue). Papers 2 and 4 discuss genetic components of sweet taste signaling but do not address glucose concentration-dependent deactivation. The remaining papers are unrelated to sweet receptor modulation by glucose. Therefore, the specific claim is not supported or refuted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "20829129",
      "23351136",
      "12943966",
      "718601",
      "3701541"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "739",
    "claim": "MT binding domain drives amyloid structure formation.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 4 shows that the cores of Alzheimer\u2019s disease tau filaments are composed of tau residues 306\u2013378, which lie within tau\u2019s microtubule-binding domain, and that this region forms the cross-\u03b2/\u03b2-helix structure that seeds tau aggregation. This directly supports the idea that the microtubule-binding domain drives amyloid structure formation. The other cited papers do not address microtubule-binding domains and amyloid formation directly."
    },
    "naive_doc_ids": [
      "1546650",
      "15655418",
      "35684881",
      "4446814",
      "20937018"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Paper 4 shows that the amyloid cores of Alzheimer\u2019s disease tau filaments comprise residues 306\u2013378, which form the seed for tau aggregation. This segment lies within tau\u2019s microtubule-binding repeat region (the MT-binding domain), indicating that the MT-binding domain drives amyloid core formation. The other papers discuss microtubule-binding interactions (e.g., dynein, LRRK2) or unrelated topics, and do not contradict this. Thus, the provided evidence supports the claim, albeit based primarily on the tau case."
    },
    "overthinking_doc_ids": [
      "1546650",
      "9638032",
      "15121114",
      "4446814",
      "35684881"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 9 shows that the amyloid cores of Alzheimer\u2019s disease tau filaments are formed by tau residues 306\u2013378, which lie within the microtubule-binding repeat region (R3\u2013R4). These residues define the seed for tau aggregation, indicating that the microtubule-binding domain drives amyloid structure formation. The other papers do not address amyloid formation in microtubule-binding domains and do not contradict this finding."
    },
    "posthoc_doc_ids": [
      "1546650",
      "40383969",
      "5914739",
      "15655418",
      "35684881"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1105",
    "claim": "Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly examines medical school factors and later professional misconduct and finds that failure of early or preclinical examinations is independently associated with higher odds of subsequent serious professional misconduct (OR 5.47, 95% CI 2.17\u201313.79). This aligns with the claim that poor early performance increases misconduct risk. The other papers do not address professional misconduct and are not relevant to this claim."
    },
    "naive_doc_ids": [
      "6710713",
      "11624482",
      "13619127",
      "3878434",
      "7419612"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 directly shows that early academic difficulties (failure of early/preclinical exams) were independently associated with a higher risk of later professional misconduct (OR 5.47, 95% CI 2.17\u201313.79, P<0.001). This aligns with the claim that poor early performance increases misconduct risk. Papers 2\u20134 do not address professional misconduct and are not relevant to the claim."
    },
    "overthinking_doc_ids": [
      "6710713",
      "313394",
      "11624482",
      "17374970"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines medical school factors linked to later professional misconduct and finds an independent association between early academic difficulties (failure of early/preclinical exams) and subsequent serious professional misconduct (OR 5.47, 95% CI 2.17\u201313.79). This aligns with the claim that poor early performance increases risk of later misconduct. Other papers provided are not about professional misconduct and do not affect this conclusion."
    },
    "posthoc_doc_ids": [
      "6710713",
      "13933299",
      "17374970",
      "313394",
      "11624482"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1371",
    "claim": "Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Paper 1 directly examines calcium homeostasis via PTH and shows that serum PTH is lowest at higher vitamin D status (>18 ng/mL 25(OH)D) and highest at low vitamin D (<10 ng/mL). It also reports significant interactions between vitamin D status and calcium intake on PTH (e.g., at low vitamin D, <800 vs >1200 mg/d calcium associated with higher PTH, P=0.04; at high calcium intake, PTH differs significantly between low and high vitamin D groups, P=0.04). This demonstrates vitamin D is an important factor in the calcium\u2013PTH relationship. The other papers do not address this relationship."
    },
    "naive_doc_ids": [
      "16256507",
      "21564598",
      "13621186",
      "2425364",
      "1538080"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 directly examines calcium intake, serum 25-hydroxyvitamin D (vitamin D status), and intact PTH in adults. It finds PTH is lowest at higher vitamin D levels and highest at deficient levels, and shows that vitamin D status modifies the effect of calcium intake on PTH (e.g., even with high calcium intake, PTH differs significantly between low and high vitamin D groups). The authors conclude that ensuring adequate vitamin D status is key for calcium metabolism, indicating vitamin D is an important factor in the calcium\u2013PTH relationship. Papers 2\u20136 do not provide relevant data on vitamin D in this context."
    },
    "overthinking_doc_ids": [
      "16256507",
      "21199527",
      "3758260",
      "4515975",
      "5402581"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers show that vitamin D status modulates parathyroid hormone (PTH) in relation to calcium. Paper 1 directly demonstrates that serum PTH varies with 25-hydroxyvitamin D levels and interacts with calcium intake: low vitamin D is associated with higher PTH, and differences in PTH persist across calcium intake strata. Paper 5 shows an inverse correlation between 25OHD and PTH and reports secondary hyperparathyroidism in vitamin D deficiency, linking vitamin D to the calcium\u2013PTH axis. Paper 4, while highlighting magnesium as a modifier, still indicates that vitamin D insufficiency commonly affects PTH responses within the calcium\u2013PTH endocrine axis. Together, these findings support that vitamin D is an important factor in the calcium\u2013PTH relationship."
    },
    "posthoc_doc_ids": [
      "16256507",
      "21199527",
      "3758260",
      "13312471",
      "9555784"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "18",
    "claim": "61% of colorectal cancer patients are diagnosed with regional or distant metastases.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers report the overall proportion of colorectal cancer patients diagnosed with regional or distant metastases. Paper 1 groups stage at diagnosis as stage I versus stages II\u2013IV combined, which does not allow isolating the percentage with regional/distant disease (stages III\u2013IV). Papers 3 and 4 discuss socioeconomic effects and survival but do not provide the aggregate stage distribution needed. The remaining papers are unrelated to colorectal cancer staging. Therefore, the evidence provided does not confirm or refute the specific 61% figure."
    },
    "naive_doc_ids": [
      "22942787",
      "35314705",
      "5641851",
      "2058909",
      "7639744"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers report the overall proportion of colorectal cancer patients diagnosed with regional or distant metastases. Paper 1 dichotomizes stage as stage I vs stages II\u2013IV, which does not correspond to localized vs regional/distant (since stage II is localized). Papers 2 and 3 discuss survival differences and deprivation-related stage/treatment patterns but do not provide population-level percentages of regional or distant diagnosis. Therefore, the specific claim that 61% present with regional or distant disease is not verifiable from these sources."
    },
    "overthinking_doc_ids": [
      "22942787",
      "2058909",
      "5641851"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.81,
      "justification": "None of the provided papers report the combined proportion of colorectal cancer patients diagnosed with regional or distant disease. Paper 1 gives only the proportion with distant (Stage IV) at diagnosis (19%-23% in the Netherlands, 1996\u20132011) and does not report regional-stage proportions. Other papers address treatment access, survival disparities, hypoxia in metastases, or cancers other than colorectal, without providing overall stage-at-diagnosis distributions. Therefore, the evidence set does not confirm or refute the claim that 61% present with regional or distant metastases."
    },
    "posthoc_doc_ids": [
      "10958594",
      "24980622",
      "3329824",
      "5641851",
      "18062308"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "667",
    "claim": "Klf2 is important for proper myeloid cell function.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Multiple studies show that KLF2 regulates key functional aspects of myeloid cells. Myeloid-specific Klf2 knockout increases macrophage and neutrophil adhesion to endothelium and reduces neutrophil survival, leading to greater inflammatory cell accumulation and atherosclerosis (Paper 1). Partial Klf2 deficiency alters in vivo responses to acute and subacute inflammatory challenges via NF-\u03baB inhibition, indicating control of myeloid proinflammatory activation (Paper 4). KLF2 hemizygosity enhances recruitment of inflammatory monocytes, upregulates inflammatory mediators, promotes osteoclast differentiation, and worsens arthritis, demonstrating regulation of monocyte differentiation and function (Paper 5). Dendritic cell\u2013specific KLF2 loss heightens DC activation (CD40/CD86), boosts T cell responses, and aggravates atherosclerosis (Paper 3). Together, these data confirm KLF2 is important for proper myeloid cell function."
    },
    "naive_doc_ids": [
      "14407673",
      "32101982",
      "5979056",
      "44724517",
      "7948486"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Multiple studies demonstrate that KLF2 is required to maintain normal myeloid cell behavior. Myeloid-specific Klf2 knockout increased macrophage and neutrophil adhesion and reduced neutrophil survival, promoting atherosclerosis (Paper 1). KLF2 hemizygosity led to increased inflammatory monocyte recruitment, elevated inflammatory mediators, and enhanced osteoclast differentiation, worsening arthritis (Paper 6). Dendritic cell\u2013specific KLF2 deficiency heightened DC activation (increased CD40/CD86), boosted T cell proliferation/apoptosis, and aggravated atherosclerosis (Paper 8). Together, these findings show KLF2 is important for proper myeloid cell function."
    },
    "overthinking_doc_ids": [
      "14407673",
      "25827024",
      "14386505",
      "3118719",
      "5511240"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.96,
      "justification": "Multiple studies show that KLF2 is a key regulator of myeloid cell function. Myeloid-specific or partial loss of KLF2 leads to dysregulated monocyte/macrophage and neutrophil behavior, including increased inflammatory activation and cytokine production, altered differentiation (e.g., enhanced osteoclastogenesis), increased adhesion and reduced neutrophil survival, and worsened outcomes in disease models such as arthritis, atherosclerosis, polymicrobial infection, and endotoxemia (Papers 3, 4, 5, 8). Dendritic cell\u2013specific KLF2 loss also heightens DC activation and proatherogenic T cell responses (Paper 7). These experimental findings demonstrate KLF2 is important for proper regulation of myeloid cell function."
    },
    "posthoc_doc_ids": [
      "3118719",
      "14386505",
      "7948486",
      "14407673",
      "44724517"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "645",
    "claim": "Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.98,
      "justification": "Multiple randomized trials and a meta-analysis show folic acid (and B-vitamin) intake lowers, not increases, homocysteine. Paper 1: folic acid supplementation reduced serum homocysteine up to ~23%. Paper 2: meta-analysis found homocysteine reductions of ~18\u201327% with folic acid supplementation. Paper 3: 400\u2013600 \u03bcg/day folic acid significantly lowered plasma homocysteine in the elderly. Paper 6: high-dose folic acid + vitamin B6 + B12 lowered homocysteine by 25.8% in CKD/ESRD patients. Paper 5 also notes consistent evidence that folic acid reduces homocysteine and suggests vitamin B6 is protective. Paper 4 is unrelated. Therefore, the claim that folic acid and vitamin B6 increase homocysteine is refuted by the evidence."
    },
    "naive_doc_ids": [
      "11705328",
      "37424881",
      "21636085",
      "13312471",
      "16252863"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.95,
      "justification": "Multiple randomized trials and a meta-analysis show that folic acid supplementation lowers\u2014not increases\u2014homocysteine levels. Paper 1 reports significant homocysteine reductions with folic acid supplementation across fortification strata. Paper 4 (elderly RCT) found significant decreases in homocysteine at 400\u2013600 \u00b5g/day. Paper 5 (dose-ranging RCT) showed dose-dependent reductions up to ~23% at 0.8 mg/day. Papers 2 and 3 are not relevant to homocysteine or folic acid/VB6. Although vitamin B6 is not directly assessed here, the claim that intake of folic acid (and VB6) increases homocysteine is contradicted by these data on folic acid."
    },
    "overthinking_doc_ids": [
      "37424881",
      "4515975",
      "5402581",
      "21636085",
      "11705328"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.97,
      "justification": "Multiple randomized trials and meta-analyses show that folic acid lowers, not increases, homocysteine. Paper 1: FA dose-dependently reduced serum homocysteine (~23% at 0.8 mg/d). Paper 2: 400\u2013600 \u00b5g/d FA significantly lowered plasma homocysteine in elderly participants. Paper 3: Meta-analysis shows FA supplementation reduces homocysteine by ~18\u201327% depending on folate fortification context. Paper 5: Genetic evidence indicates higher homocysteine with low folate status; increased folate mitigates this, not the reverse. Paper 6: High-dose FA + vitamin B6 + B12 reduced homocysteine by ~26% in CKD/ESRD patients. No paper reports an increase in homocysteine from FA or VB6 intake; the evidence consistently shows reduction."
    },
    "posthoc_doc_ids": [
      "11705328",
      "21636085",
      "37424881",
      "42441846",
      "8595678"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.9,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "439",
    "claim": "Fz/PCP-dependent Pk localizes to the anterior membrane of neuroectoderm cells during zebrafish neuralation",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "Among the provided papers, only Paper 1 addresses zebrafish neurulation and PCP signaling, showing that PCP polarizes neural progenitors along the anteroposterior axis and that this polarity depends on Vangl2. However, none of the provided excerpts report Prickle (Pk) localization, its anterior membrane enrichment, or its dependence on Frizzled/PCP during zebrafish neurulation. The other papers are reviews or concern different systems (mouse PCP, cardiac development, immune cells, adult neurogenesis), and do not provide experimental evidence about Pk localization in zebrafish neuroectoderm. Therefore, the specific claim about Fz/PCP-dependent anterior membrane localization of Pk is not supported or refuted by the provided evidence."
    },
    "naive_doc_ids": [
      "4423559",
      "5944514",
      "6729465",
      "317204",
      "4932668"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers present data on Prickle (Pk) localization in zebrafish neuroectoderm during neurulation or its dependence on Frizzled/PCP. Paper 1 addresses PCP roles in zebrafish neurulation but does not mention Pk membrane localization. The other papers are on unrelated topics (injury-induced neurogenesis, antimicrobial peptides, mouse cochlear PCP, general PCP review, Notch signaling, human sound localization). Therefore, the specific claim is not supported or refuted by the given evidence."
    },
    "overthinking_doc_ids": [
      "4423559",
      "5395426",
      "350542",
      "18575183",
      "5944514"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "Among the provided papers, only Paper 4 addresses planar cell polarity during zebrafish neurulation, focusing on Vangl2-dependent polarization and coupling of cell division to morphogenesis. None of the papers present data on Prickle (Pk) localization, its anterior membrane enrichment in neuroectoderm cells, or its dependency on Frizzled/PCP signaling in zebrafish. Therefore, there is no direct evidence in the supplied sources to confirm or refute the specific claim about Fz/PCP-dependent Pk localization."
    },
    "posthoc_doc_ids": [
      "3835423",
      "4999633",
      "26625002",
      "4423559",
      "18575183"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "478",
    "claim": "Golli-deficient T-cells prefer to differentiate into an anergic phenotype in the adaptive immune response when there are increased levels of Ca2+ in the cytosol.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 1 directly reports that golli-deficient T cells show enhanced Ca2+ entry and are hyperproliferative upon TCR stimulation, indicating heightened activation rather than anergy. None of the other papers provide evidence that golli-deficient T cells preferentially become anergic under increased cytosolic Ca2+. Thus, the available evidence contradicts the claim."
    },
    "naive_doc_ids": [
      "14767844",
      "3788528",
      "7736860",
      "24872571",
      "25827024"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.8,
      "justification": "Paper 1 directly examines golli-deficient T cells and shows they have enhanced store-depletion\u2013induced Ca2+ influx and are hyperproliferative upon TCR stimulation. This phenotype is consistent with heightened activation, not anergy (which is characterized by hyporesponsiveness and poor proliferation). The other papers either discuss T cell anergy in unrelated contexts (Paper 2, via PD-L1 on macrophages) or address calcium signaling in non\u2013T cell systems (Papers 3\u20135) or different immune cell types (Paper 6) and are not relevant to golli-deficient T cell anergy. Thus, the available evidence opposes the claim that increased cytosolic Ca2+ in golli-deficient T cells promotes an anergic phenotype."
    },
    "overthinking_doc_ids": [
      "14767844",
      "7386360",
      "23509593",
      "24349430",
      "7736860"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 5 shows that golli-deficient T cells exhibit enhanced store-operated Ca2+ influx upon TCR stimulation and are hyperproliferative, indicating increased activation rather than anergy. No provided paper reports that golli deficiency biases T cells toward an anergic phenotype under high cytosolic Ca2+. Other golli-related papers (7, 8) address expression, not functional anergy. Thus, the claim conflicts with the experimental evidence."
    },
    "posthoc_doc_ids": [
      "2506153",
      "5386514",
      "5572127",
      "13959707",
      "14767844"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.8,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "437",
    "claim": "Functional consequences of genomic alterations due to Myelodysplastic syndrome (MDS) are poorly understood due to the lack of an animal model.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple papers document the use of animal (mouse) models that elucidate functional consequences of genomic alterations in MDS. Paper 1 explicitly states that animal models have advanced insights into the hematopoietic niche in MDS. Paper 2 uses a two-step mouse model (mutant NRAS/BCL2) to mechanistically link gene abnormalities to ROS, DNA damage, and error-prone repair during MDS progression. Paper 4 generates transgenic mice overexpressing miR-22 that develop MDS, identifying TET2 as a functional target and demonstrating rescue by TET2, directly addressing functional consequences. These studies show that animal models exist and are actively used to study MDS mechanisms, contradicting the claim that understanding is poor due to lack of an animal model."
    },
    "naive_doc_ids": [
      "3391547",
      "5765455",
      "8063697",
      "33677323",
      "2359152"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.73,
      "justification": "Paper 3 explicitly states that animal models have been used to interrogate the bone marrow microenvironment in myelodysplastic syndromes and have furthered insights in recent years, contradicting the claim that a lack of animal models hinders understanding. Paper 2 shows substantial progress in defining genetic lesions and their prognostic impact in MDS, undermining the notion that functional consequences are broadly poorly understood. Additionally, Paper 4 demonstrates effective use of mouse models to study functional niche consequences in related myeloid malignancies, further contradicting the assertion of a lacking animal model."
    },
    "overthinking_doc_ids": [
      "39776978",
      "2359152",
      "3391547",
      "10795340",
      "14610165"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.84,
      "justification": "Paper 3 describes a two-step mouse model of myeloid leukemic disease progression relevant to MDS progression, demonstrating functional consequences of genomic alterations (elevated ROS, increased DNA damage, error-prone double-strand break repair) and suggesting therapeutic targets. This directly counters the claim that such consequences are poorly understood due to a lack of an animal model. Additionally, Paper 2 shows that the biological and prognostic significance of many genomic lesions in MDS is well characterized in humans, further undermining the claim."
    },
    "posthoc_doc_ids": [
      "39851630",
      "2359152",
      "5765455",
      "123859",
      "10795340"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "474",
    "claim": "Glycan adaptation is rarely observed in the B-cell repertoire.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the provided papers evaluate or report on glycan adaptation within the B-cell repertoire. Paper 4 discusses glycan evolution on the HIV-1 viral envelope (a viral epitope change), not antibody/BCR glycan adaptation. Other papers focus on celiac autoantibodies without glycan analysis (Paper 1), antigen transport and affinity maturation mechanisms (Paper 2), B-cell migration (Paper 3), and T-cell or transcriptional topics (Papers 5\u20139). Therefore, the evidence does not address the claim."
    },
    "naive_doc_ids": [
      "1471041",
      "9705208",
      "38587347",
      "7177329",
      "21392223"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data on how often glycan adaptation occurs within the B-cell repertoire. Relevant papers (1 and 7) discuss viral envelope glycosylation changes and the evolution of glycan-dependent antibody epitopes in HIV, which pertain to viral glycan shifts rather than adaptation within B-cell receptors. Other papers address immunoglobulin analysis tools (IgBLAST), pre-BCR selection, T-cell cytokines, CTCF binding, and unrelated immunology topics, none of which quantify or assess glycan adaptation frequency in B cells."
    },
    "overthinking_doc_ids": [
      "2601135",
      "7059897",
      "34254203",
      "8639034",
      "14530534"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data on how frequently glycan adaptation occurs within the B-cell repertoire. The only glycan-related study (Paper 4) examines HIV viral glycan evolution (shift to Asn332) and notes that glycan-dependent broadly neutralizing antibodies arise in a minority of infected individuals, but it does not quantify or analyze glycan adaptation within the B-cell repertoire itself. The remaining papers focus on T-cell selection, transcription factors, smoking cessation, influenza vaccination, and other topics unrelated to B-cell glycan adaptation. Therefore, the claim cannot be verified or refuted from the provided evidence."
    },
    "posthoc_doc_ids": [
      "4896726",
      "8354687",
      "21392223",
      "7177329",
      "8325952"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "109",
    "claim": "An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 reports that exposure to cold temperature rapidly promotes alternative (M2-like) activation of adipose tissue macrophages, which then secrete catecholamines to induce thermogenic gene expression in brown adipose tissue. This directly aligns with the claim that an M2-like phenotype in BAT macrophages is quickly induced by cold exposure. The other papers do not provide direct evidence on this specific point."
    },
    "naive_doc_ids": [
      "4319174",
      "29381091",
      "43192375",
      "970012",
      "1507222"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 4 reports that cold exposure rapidly promotes alternative (M2) activation of adipose tissue macrophages, which then support thermogenic responses in brown adipose tissue. This directly aligns with the claim that an M2-like phenotype in BAT macrophages is quickly induced by cold exposure. The other papers do not provide relevant information on macrophage polarization in BAT."
    },
    "overthinking_doc_ids": [
      "29381091",
      "40232172",
      "970012",
      "4319174",
      "21626639"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 reports that exposure to cold rapidly promotes alternative (M2-like) activation of adipose tissue macrophages, which then secrete catecholamines to induce thermogenic gene expression in brown adipose tissue. This directly supports that an M2-like phenotype in BAT macrophages is quickly induced by cold. The other provided papers do not address this specific macrophage polarization in response to cold."
    },
    "posthoc_doc_ids": [
      "29381091",
      "970012",
      "1568684",
      "4319174",
      "8477699"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "57",
    "claim": "APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly examines APOE4 in human iPSC-derived neurons and shows that APOE4 increases amyloid-\u03b2 production and tau phosphorylation, but it also causes GABAergic neuron degeneration (a toxic gain of function). This contradicts the claim that APOE4 delays GABA neuron degeneration. The other papers do not provide relevant data on APOE4 effects in iPSC-derived neurons."
    },
    "naive_doc_ids": [
      "27588420",
      "4709641",
      "11674288",
      "11659421",
      "4459491"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that APOE4 expression in human iPSC-derived neurons increases amyloid-\u03b2 production and tau phosphorylation, but it also induces (not delays) GABAergic neuron degeneration. The other papers do not address APOE4 effects in iPSC-derived neurons. Therefore, while the first two parts of the claim are supported, the statement that APOE4 delays GABA neuron degeneration is contradicted by the evidence."
    },
    "overthinking_doc_ids": [
      "4709641",
      "27588420",
      "9334631",
      "35520219",
      "6776834"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly examines APOE4 in human iPSC-derived neurons and reports that APOE4 increases amyloid-\u03b2 production and elevates tau phosphorylation, but it also causes GABAergic neuron degeneration rather than delaying it. The other papers do not provide relevant evidence about APOE4 effects in iPSC-derived neurons on A\u03b2, tau, or GABA neuron degeneration. Therefore, while the first two parts of the claim are supported, the statement that APOE4 delays GABA neuron degeneration is contradicted by the evidence."
    },
    "posthoc_doc_ids": [
      "4709641",
      "45336190",
      "3085264",
      "11659421",
      "12086818"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "938",
    "claim": "Persister cells provide relapse resistance in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.79,
      "justification": "None of the provided papers directly investigate or identify drug-tolerant persister cells as the cause of relapse resistance in cancer patients. The evidence focuses on other relapse/resistance mechanisms: sanctuary-site relapse in the CNS with trastuzumab (Paper 1), correlations of residual cell gene expression with recurrence after chemoradiotherapy (Paper 2), minimal residual disease kinetics in ALL (Paper 3), acquired genetic resistance mutations and lineage transformation in EGFR-mutant lung cancer (Papers 4, 6, 9), case reports of overcoming TKI resistance (Paper 5), and phosphoproteomic changes in cell-line models of acquired resistance (Paper 8). Paper 7 describes a slow-cycling melanoma subpopulation in experimental models, but does not link this to clinical relapse resistance in patients. Therefore, the set does not provide direct supporting evidence for the specific claim about persister cells in patients."
    },
    "naive_doc_ids": [
      "3329824",
      "31591262",
      "80522346",
      "9505402",
      "9929089"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers directly investigate or demonstrate that drug-tolerant persister cells cause relapse resistance in cancer patients. The studies address circulating tumor DNA (Paper 1), acquired TKI resistance mechanisms and signaling changes (Papers 2, 7, 8), xenograft engraftment and stromal signatures linked to chemoresistance (Paper 3), minimal residual disease kinetics (Paper 4), prognostic impact of AIM2 loss (Paper 5), and tumor stemness-associated resistance (Paper 9). While several papers show resistance and relapse/progression, they do not specifically implicate persister cells as the mechanism in patients."
    },
    "overthinking_doc_ids": [
      "2841164",
      "25895285",
      "38243984",
      "80522346",
      "42731834"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data on drug-tolerant persister cells or directly link persister cells to relapse resistance in cancer patients. The evidence covers acquired TKI resistance (cell lines), stromal-mediated chemoresistance (exosomal miR-21), xenograft engraftment and gemcitabine resistance, tumor dormancy/MRD and innate immune evasion at recurrence, and other unrelated topics. While some papers discuss resistance, dormancy, and relapse broadly, they do not specifically investigate or demonstrate a role for persister cells in patient relapse resistance."
    },
    "posthoc_doc_ids": [
      "25895285",
      "38243984",
      "1727493",
      "1921218",
      "30919024"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "772",
    "claim": "Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 reports that a single dose of an Eilat/CHIKV chimeric virus produced in mosquito cells elicited rapid and long-lasting neutralizing antibodies in mice and provided complete protection in two mouse models. This directly contradicts the claim that mice are incapable of producing neutralizing antibodies in response to CHIKV produced in mosquitos. The other papers do not provide relevant data regarding CHIKV or mouse neutralizing antibody responses to mosquito-produced virus."
    },
    "naive_doc_ids": [
      "24922825",
      "13702924",
      "13965483",
      "2559303",
      "3930020"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that a chimeric EILV/CHIKV virus produced in mosquito cells elicited rapid and long-lasting neutralizing antibodies in mice that conferred complete protection. This demonstrates mice can generate neutralizing antibodies to CHIKV structural proteins presented on mosquito-produced particles. The other papers are not relevant to CHIKV neutralizing responses in mice."
    },
    "overthinking_doc_ids": [
      "24922825",
      "10559501",
      "42065070",
      "343052",
      "13469921"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly reports that a single dose of an EILV/CHIKV chimeric virus produced in mosquito cells elicited rapid and long-lasting neutralizing antibodies in mice, conferring complete protection in two mouse models. This demonstrates that mice are capable of generating neutralizing antibodies to CHIKV structural proteins presented on particles produced in mosquito cells, contradicting the claim. The other papers do not address CHIKV neutralizing responses in mice."
    },
    "posthoc_doc_ids": [
      "24922825",
      "10559501",
      "23915841",
      "44562221",
      "5572127"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "165",
    "claim": "Bariatric surgery increases rates of postmenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers evaluate breast cancer incidence after bariatric surgery. Paper 8 discusses preoperative predictors of weight loss following bariatric surgery, not cancer outcomes. Other papers address breast cancer risk factors (e.g., BMI, diabetes, hormones, vitamin D, perinatal factors) but do not link bariatric surgery to postmenopausal breast cancer rates. Therefore, the claim cannot be verified with the given evidence. Indirectly, Paper 2 notes higher BMI increases postmenopausal breast cancer risk, which would suggest weight loss (as from bariatric surgery) might reduce\u2014not increase\u2014risk, but this is not direct evidence about surgery."
    },
    "naive_doc_ids": [
      "3329824",
      "13831842",
      "32534305",
      "12869200",
      "38551172"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.76,
      "justification": "None of the provided papers evaluate postmenopausal breast cancer incidence specifically after bariatric surgery. Paper 1 examines bariatric surgery and reports no association with overall cancer incidence but does not analyze breast cancer or menopausal status separately. Papers 2, 3, 4, and 6 address other cancer risk factors (radiation, blood lipids, intrauterine factors), and Paper 5 focuses on mental health in bariatric patients. Therefore, the evidence does not confirm or refute that bariatric surgery increases rates of postmenopausal breast cancer."
    },
    "overthinking_doc_ids": [
      "5824985",
      "14700857",
      "9171913",
      "17450673",
      "18872233"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "None of the provided papers report postmenopausal breast cancer incidence after bariatric surgery. Paper 4 assessed overall cancer after bariatric surgery and found no association, but did not analyze breast cancer specifically or by menopausal status. Papers 2, 3, and 7 show that higher BMI increases postmenopausal breast cancer risk (and Paper 4 shows bariatric surgery causes substantial weight loss), which indirectly suggests surgery would not increase risk, but this is not direct evidence about postmenopausal breast cancer rates post-surgery. Therefore, the specific claim is not directly addressed by the provided evidence."
    },
    "posthoc_doc_ids": [
      "38551172",
      "13831842",
      "5864770",
      "5824985",
      "32534305"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "619",
    "claim": "Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple papers indicate that increasing vascular density and reducing stromal fibrosis improve, not diminish, chemotherapy efficacy. Paper 1 shows Hedgehog pathway inhibition transiently increases intratumoral vascular density and gemcitabine delivery, stabilizing disease. Paper 4 demonstrates enzymatic stromal depletion normalizes pressure, re-expands microvasculature, and, with gemcitabine, doubles survival. Paper 2 finds higher microvessel density predicts longer disease-free survival in anthracycline-treated breast cancer. Paper 3 links gemcitabine resistance to enrichment in stromal pathways, implying that reducing fibrosis would counter resistance. Papers 5 and 6 are not directly about chemo efficacy relative to fibrosis/vascular density. Overall, the evidence opposes the claim."
    },
    "naive_doc_ids": [
      "20888849",
      "1171121",
      "38243984",
      "12866641",
      "3559136"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that reducing stromal tissue (fibrosis) via Hedgehog inhibition transiently increases intratumoral vascular density and gemcitabine concentration, improving disease control\u2014indicating enhanced, not decreased, chemotherapy efficacy. Paper 2 demonstrates that depleting hyaluronan reduces desmoplasia, restores vessel function, increases drug delivery, and improves survival when combined with gemcitabine. Papers 3 and 4 are not relevant to vessel density/fibrosis effects on chemotherapy efficacy. Overall, the evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "20888849",
      "2565138",
      "16630996",
      "9767444"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 reports that higher microvessel density (MVD) in early breast cancer patients treated with anthracycline chemotherapy is independently associated with longer disease-free survival, indicating better chemotherapy outcomes with increased vessel density. Paper 5 shows that Hedgehog pathway inhibition depletes stromal tissue (reduces fibrosis), transiently increases intratumoral vascular density and gemcitabine concentration, leading to improved disease stabilization. Paper 6 demonstrates that enzymatic depletion of hyaluronan (reducing desmoplasia/fibrosis) re-expands tumor vessels, enhances drug delivery, and improves survival when combined with gemcitabine. Together, these findings indicate that increased vessel density and reduced fibrosis improve, not decrease, chemotherapy efficacy. Other papers are not directly relevant to the claim."
    },
    "posthoc_doc_ids": [
      "1171121",
      "7986878",
      "1711571",
      "7821634",
      "20888849"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "978",
    "claim": "Pro-inflammatory cytokines are up repressed during tumor development.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Tumor-related papers indicate pro-inflammatory cytokines are elevated or functional in promoting tumor progression, not repressed. Paper 5 shows oncogenic mTOR signaling increases G-CSF production in tumor cells, recruiting MDSCs and promoting tumor initiation/progression. Paper 6 shows NLRP3-driven IL-1\u03b2/IL-18 activity is important for tumor-associated MDSC accumulation; loss of NLRP3 reduces these cells at tumors, implying these cytokines are active rather than repressed during tumor development. Paper 8 reports elevated IL-6 (and VEGF) levels in cervical cancer patients with prognostic significance. Together, these findings oppose the claim that pro-inflammatory cytokines are repressed during tumor development."
    },
    "naive_doc_ids": [
      "22889972",
      "24998637",
      "343052",
      "41877386",
      "2014909"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "The provided papers do not support the idea that pro-inflammatory cytokines are repressed during tumor development. Paper 2 shows that the pro-inflammatory cytokine IL-6 (and soluble TNF receptors) has prognostic value in cervical cancer, indicating active involvement rather than repression. Paper 1 describes cancer-associated fibroblasts promoting tumor progression via crosstalk that typically involves cytokine signaling, not suppression. Paper 6 discusses interferon-gamma as actively shaping tumor immunity with both anti- and pro-tumor roles, again not indicating repression. Other papers are not about tumor development or do not address cytokine levels in tumors. Overall, the evidence points away from a general repression of pro-inflammatory cytokines in tumors."
    },
    "overthinking_doc_ids": [
      "952111",
      "14664424",
      "22889972",
      "35766603",
      "2391552"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.73,
      "justification": "Paper 5 directly links colorectal tumorigenesis with increased (not repressed) production of inflammatory cytokines in Nlrp12-deficient mice, indicating that pro-inflammatory cytokines are elevated during tumor development in this model. The other papers do not provide relevant data on cytokine levels specifically during tumor development. Therefore, the provided evidence contradicts the claim that pro-inflammatory cytokines are repressed during tumor development."
    },
    "posthoc_doc_ids": [
      "21258863",
      "22889972",
      "11233339",
      "25315295",
      "17223891"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1266",
    "claim": "The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "Paper 1 directly shows that higher placental weight across successive pregnancies is associated with increased maternal breast cancer risk (adjusted HR 1.82 for mixed 500\u2013699 g/\u2265700 g vs <500 g; HR 2.05 for \u2265700 g in both pregnancies vs <500 g in both), indicating a dose-response. In this cohort, 95% of breast cancers were diagnosed before age 50, implying the observed association pertains largely to premenopausal cases, consistent with the claim that the association is strongest premenopausally. The other provided papers do not address placental weight\u2013breast cancer risk and neither refute nor add to this specific claim. Note that explicit pre- vs postmenopausal stratified estimates are not provided, so the \"strongest for premenopausal\" part is suggested rather than conclusively demonstrated within these excerpts."
    },
    "naive_doc_ids": [
      "37480103",
      "13831842",
      "3329824",
      "11360768",
      "22401720"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Paper 1 supports that higher placental weight is associated with increased maternal breast cancer risk (e.g., HR ~2.05 for high placental weight in two consecutive pregnancies), but it does not compare effects by menopausal status. Although most cases occurred before age 50, no explicit analysis shows the association is strongest for premenopausal breast cancer. Papers 2\u20135 do not address placental weight and maternal breast cancer risk by menopausal status. Therefore, the claim\u2019s second component (strongest for premenopausal) is not substantiated by the provided evidence."
    },
    "overthinking_doc_ids": [
      "37480103",
      "13831842",
      "16322674",
      "4828631",
      "23136735"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "Paper 1 directly supports that higher placental weight across pregnancies is associated with increased maternal (parous) breast cancer risk (e.g., HR\u22482.05 for \u2265700 g in two pregnancies vs <500 g). However, it does not provide a clear comparison by menopausal status to show the association is strongest for premenopausal breast cancer; although most cases occurred before age 50, no stratified effect estimates are reported. Papers 2\u20136 do not address placental weight or its relation to breast cancer risk. Therefore, the first part of the claim is supported, but the assertion that the association is strongest premenopausally is not established by the provided evidence."
    },
    "posthoc_doc_ids": [
      "37480103",
      "13831842",
      "9171913",
      "2140497",
      "9394119"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1342",
    "claim": "Understanding epigenetic regulation of replication is essential for the reational design of episomally replicating vectors.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The papers discuss chromatin regulation (histone modifications, RNAi-directed heterochromatin, CTCF-mediated looping, SIRT1 relocalization) and replication programs/timing, as well as EBV episomal maintenance via EBNA1 and oriP. However, none present data or arguments that directly link epigenetic regulation of replication to the rational design requirements of episomally replicating vectors or show that such understanding is essential for vector design. The one paper on episomal vector development (Paper 5) focuses on EBNA1 and ori sequences without addressing epigenetic regulation. Therefore, the provided evidence does not confirm the claim."
    },
    "naive_doc_ids": [
      "8267678",
      "2613813",
      "8759633",
      "3765739",
      "4037034"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The cited papers discuss epigenetic regulation of chromatin architecture, replication timing, CTCF/cohesin roles, Polycomb retention during replication, and DNA methylation in cancer. None of them examine episomally replicating vectors or provide data linking epigenetic regulation of replication to the rational design of episomal vectors. Therefore, they do not provide direct evidence to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "8006440",
      "8759633",
      "18924534",
      "8494570",
      "37249641"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "The papers provide evidence that chromatin state, histone modifications, RNAi, and nuclear organization influence DNA replication timing and origin activity (e.g., Papers 6, 7, 8, 9) and detail epigenetic regulation more broadly (Papers 1\u20133). However, none of the papers address episomally replicating vectors or demonstrate that understanding epigenetic regulation is essential for their rational design. Without data linking epigenetic replication control to episomal vector design or performance, the claim is not substantiated by the provided evidence."
    },
    "posthoc_doc_ids": [
      "8267678",
      "2613813",
      "2888272",
      "26607366",
      "9272598"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1385",
    "claim": "cSMAC formation enhances weak ligand signalling.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Multiple papers indicate that the cSMAC does not enhance, and can actually dampen or terminate, TCR signaling, including for weak ligands. Paper 1 shows that a weak agonist\u2019s increased stimulatory potency correlates with an inability to form the cSMAC; experimentally enhancing cSMAC formation reduced the weak peptide\u2019s stimulatory capacity. Paper 4 demonstrates that TCR-proximal signals are sustained in peripheral microclusters and are terminated in the cSMAC. Paper 2 finds prolonged signaling when TCR microclusters are trapped peripherally, implying that translocation toward the center (cSMAC) downregulates signaling. Paper 5 shows signaling can initiate without a central TCR-rich cluster, indicating the cSMAC is not required to enhance signaling. Papers 6\u20139 are unrelated to this claim. Therefore, the claim that cSMAC formation enhances weak ligand signalling is contradicted by the provided evidence."
    },
    "naive_doc_ids": [
      "306006",
      "41982985",
      "2714623",
      "9283422",
      "2825380"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 directly shows that when a weak agonist fails to form a cSMAC, T cell proliferation is increased, and experimentally enhancing cSMAC formation reduces the weak peptide\u2019s stimulatory capacity. Paper 4 further supports this by demonstrating that TCR signaling is sustained in peripheral microclusters and is terminated in the cSMAC. Together, these findings indicate that cSMAC formation dampens rather than enhances weak ligand signaling."
    },
    "overthinking_doc_ids": [
      "20344442",
      "301838",
      "306006",
      "9283422",
      "13639330"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 reports that enhancing cSMAC formation reduces the stimulatory capacity of a weak agonist peptide and that failure to form the cSMAC is associated with increased T cell proliferation, indicating cSMAC formation dampens weak ligand signaling. Paper 4 shows that TCR signaling is sustained in peripheral microclusters and terminated in the cSMAC, further indicating that cSMAC formation does not enhance signaling. The other papers are not directly relevant to cSMAC effects on weak ligand signaling."
    },
    "posthoc_doc_ids": [
      "8458567",
      "306006",
      "2714623",
      "9283422",
      "23260700"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1404",
    "claim": "siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided papers investigate A20 (TNFAIP3) or report siRNA-mediated knockdown of A20 in a murine xenograft model. While Paper 3 shows that siRNA knockdown of c-Src slows tumor progression in an orthotopic mouse model, and other papers address NF-\u03baB, BCL9, TGF-\u03b2, circadian clock genes, and integrin/Src signaling, there is no experimental evidence here specifically about A20 knockdown affecting tumor progression in vivo."
    },
    "naive_doc_ids": [
      "14615911",
      "33638477",
      "45764440",
      "11968641",
      "31682248"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "Paper 2 shows that knocking down A20 (TNFAIP3) with lentiviral shRNA in glioblastoma stem cells decreases tumor growth/tumorigenic potential and increases survival in mice bearing human glioma xenografts, which is consistent with slowed tumor progression in an in vivo murine xenograft model. While the method used is shRNA (not siRNA), both achieve RNAi-mediated A20 knockdown, supporting the claim\u2019s core assertion that reducing A20 expression slows in vivo tumor progression. Other papers are not about A20 (Paper 1 uses siRNA but targets Src) or are unrelated."
    },
    "overthinking_doc_ids": [
      "45764440",
      "33370",
      "7975937",
      "831167",
      "35314705"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "Paper 5 shows that RNAi-mediated knockdown of A20 (via lentiviral shRNA) in glioblastoma stem cells reduces tumorigenic potential and increases survival in mice bearing human glioma xenografts, indicating slowed tumor progression in an in vivo murine xenograft model. While the paper uses shRNA rather than siRNA, it directly supports the core claim that A20 knockdown slows tumor progression in vivo. No other provided papers assess A20 with siRNA specifically."
    },
    "posthoc_doc_ids": [
      "45764440",
      "14615911",
      "33638477",
      "32852283",
      "33370"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "964",
    "claim": "Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "None of the provided paper summaries present data comparing the stability (e.g., half-life or degradation rate) of pre-mRNAs associated with spliceosomal components versus unassociated splicing substrates. The papers address NMD and EJC deposition (Paper 1), evolution of polyadenylation sites (Paper 2), kinetic monitoring of splicing and 3'-end processing without stability comparisons by spliceosome association (Paper 3), TOR/Ras signaling and transcription factor localization (Papers 4\u20135), spliceosome assembly and commitment (Paper 6), and splicing coactivators SRm160/300 (Paper 7). No direct evidence on stability differences related to spliceosomal association is provided."
    },
    "naive_doc_ids": [
      "30261663",
      "16167746",
      "365896",
      "4324278",
      "8210189"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data comparing the stability/half-life of pre-mRNAs when associated with spliceosomal components versus unassociated substrates. The relevant splicing papers address timing of splice site pairing (A complex), coupling of RNAP II transcription to spliceosome assembly, in vitro assay methodologies, and factors involved in NMD/EJC deposition, but do not measure or conclude on pre-mRNA stability as a function of spliceosomal association."
    },
    "overthinking_doc_ids": [
      "708425",
      "11844791",
      "22281684",
      "4067274",
      "30261663"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.67,
      "justification": "The provided papers discuss spliceosome assembly steps (A complex commitment, U2 association), in vitro splicing assay methodologies, coactivators (SRm160/300), and coupling of RNAP II transcription to spliceosome assembly. While Paper 9 shows that RNAP II-driven transcripts are directed into spliceosome assembly with increased splicing kinetics and yield compared to T7 transcripts, none of the papers present data comparing the stability (e.g., half-life or degradation resistance) of pre-mRNAs when associated with spliceosomal components versus unassociated substrates. Therefore, the claim about increased stability is not directly supported or refuted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "4067274",
      "29828242",
      "10423989",
      "5687200",
      "7729656"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "594",
    "claim": "Incidence of heart failure increased by 10% in women since 1979.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (Olmsted County, 1979\u20132000) explicitly reports that heart failure incidence did not change over time among women (incidence 289 per 100,000; 95% CI 277\u2013300), directly contradicting a claimed 10% increase since 1979. The other papers do not provide relevant data on temporal trends in heart failure incidence by sex."
    },
    "naive_doc_ids": [
      "19675911",
      "20321154",
      "14682243",
      "31889025",
      "4445629"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly reports that heart failure incidence did not change over time among women (1979\u20132000) in a community-based cohort, contradicting the claim of a 10% increase since 1979. Papers 2\u20134 do not provide incidence trend data for heart failure in women and are not relevant to this specific trend claim."
    },
    "overthinking_doc_ids": [
      "19675911",
      "12206390",
      "31889025",
      "4445629"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 (community-based cohort, Olmsted County, 1979\u20132000) directly examines sex-specific trends in heart failure incidence and reports that incidence did not change over time among women. This contradicts the claim of a 10% increase since 1979. The other papers focus on hypertension risk, progression to heart failure, biomarkers, or other cardiovascular/breast cancer outcomes and do not provide incidence trend data for heart failure in women."
    },
    "posthoc_doc_ids": [
      "19675911",
      "12206390",
      "31889025",
      "4445629",
      "4506414"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1386",
    "claim": "cSMAC formation represses weak ligand signalling.",
    "gold": "CONTRADICT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 2 provides direct experimental evidence that enhancing cSMAC formation reduces the stimulatory capacity of a weak agonist peptide, implying that cSMAC formation represses weak ligand signaling. Paper 1 supports the mechanistic basis by showing that signaling is sustained in peripheral microclusters and terminated in the cSMAC, indicating cSMAC is a site of signal termination rather than propagation. Paper 6 is consistent with this by showing signaling can occur without a central TCR-rich cluster. Papers 3, 4, and 5 are not directly relevant to the specific claim."
    },
    "naive_doc_ids": [
      "9283422",
      "306006",
      "25328476",
      "994800",
      "2714623"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.92,
      "justification": "Paper 3 provides direct experimental evidence: enhancing cSMAC formation reduced the stimulatory capacity of a weak agonist peptide, indicating that cSMAC formation represses weak ligand signaling. Paper 4 supports the mechanism by showing that TCR signaling is terminated in the cSMAC and receptors are sorted for degradation there, consistent with a repressive role of cSMAC on signaling. The other papers are not directly relevant to this claim."
    },
    "overthinking_doc_ids": [
      "20344442",
      "301838",
      "306006",
      "9283422",
      "13639330"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 directly shows that increasing cSMAC formation reduces the stimulatory capacity of a weak agonist peptide, implying that cSMAC formation represses weak ligand signaling. Paper 4 provides a mechanistic basis by demonstrating that TCR signaling is sustained in peripheral microclusters and is terminated in the cSMAC. The other papers are unrelated and do not contradict this conclusion."
    },
    "posthoc_doc_ids": [
      "8458567",
      "306006",
      "2714623",
      "9283422",
      "20568364"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "411",
    "claim": "Febrile seizures reduce the threshold for development of epilepsy.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Only Paper 7 pertains to febrile seizures. It reports long-lasting alterations in neuronal excitability after early-life febrile seizures in a rat model, arguing against their benign nature, but it does not provide data on epilepsy incidence, epileptogenesis, or a lowered threshold for developing epilepsy. The other papers are unrelated to febrile seizures. Therefore, the provided evidence does not directly confirm or refute that febrile seizures reduce the threshold for development of epilepsy."
    },
    "naive_doc_ids": [
      "5691302",
      "6793674",
      "23136735",
      "116792",
      "35520219"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address febrile seizures or their effect on epilepsy risk or threshold. The studies cover cardiovascular risk (TMAO), dietary flavonols and CHD, sequelae of bacterial meningitis, kainate-induced epileptogenesis mechanisms (GABAergic changes, mTOR signaling), and characteristics of medial temporal lobe epilepsy. While some discuss epileptogenesis in general, they do not evaluate whether febrile seizures reduce the threshold for developing epilepsy."
    },
    "overthinking_doc_ids": [
      "6793674",
      "12102963",
      "27866735",
      "35520219",
      "116792"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.58,
      "justification": "Only Paper 1 is directly relevant to febrile seizures. It shows that hyperthermia-induced (febrile) seizures in immature rats cause long-lasting modifications of neuronal excitability in hippocampal limbic circuits into adulthood and explicitly challenges the notion that early-life febrile convulsions are benign. These persistent circuit changes are consistent with increased susceptibility to later epilepsy (i.e., a lowered threshold for epileptogenesis), although the study does not directly measure epilepsy incidence or seizure threshold. The other papers address different mechanisms or diseases and do not inform this claim."
    },
    "posthoc_doc_ids": [
      "14924526",
      "1410197",
      "116792",
      "6793674",
      "17450673"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "54",
    "claim": "AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.73,
      "justification": "Paper 1 shows AMPK activation directly phosphorylates JAK1 to suppress JAK\u2013STAT inflammatory signaling in endothelial cells and fibroblasts, indicating an anti-inflammatory role, not pro-inflammatory/fibrotic. Paper 4 shows AMPK activation suppresses macrophage proliferation, a process typically associated with inflammatory responses. Paper 5 links AMPK activation (e.g., by metformin) to beneficial, anti-inflammatory/metabolic effects. Papers 2 and 3 do not assess AMPK. Overall, the available evidence opposes the claim that AMPK activation increases inflammation-related lung fibrosis."
    },
    "naive_doc_ids": [
      "3973445",
      "56486733",
      "22621251",
      "24721866",
      "9899292"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly tests AMPK in lung fibrosis and shows the opposite of the claim: AMPK activity is reduced in fibrotic regions, and pharmacologic AMPK activation (e.g., by metformin) lowers myofibroblast fibrotic activity and accelerates resolution of established bleomycin-induced lung fibrosis in an AMPK-dependent manner. Papers 2\u20134 describe fibrosis mechanisms and models (bleomycin injury, YAP/TAZ signaling, vascular lesions) but do not address AMPK. Therefore, the provided evidence contradicts the claim that AMPK activation increases inflammation-related lung fibrosis."
    },
    "overthinking_doc_ids": [
      "49556906",
      "10703001",
      "11535539",
      "25175997"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 6 directly shows that AMPK activity is reduced in fibrotic lung regions and that pharmacologic AMPK activation (e.g., metformin) reverses established lung fibrosis in mice in an AMPK-dependent manner and reduces fibrotic activity in human IPF myofibroblasts. This indicates AMPK activation is anti-fibrotic, not pro-fibrotic. Additionally, Paper 3 shows AMPK activation suppresses macrophage proliferation, suggesting anti-inflammatory effects rather than promoting inflammation-driven fibrosis. The other papers do not link AMPK activation to increased lung fibrosis. Therefore, the claim that AMPK activation increases inflammation-related lung fibrosis is contradicted by the evidence."
    },
    "posthoc_doc_ids": [
      "4662264",
      "7875158",
      "24721866",
      "22621251",
      "25175997"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.78,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "345",
    "claim": "Differentiated E2f-1, -2, -3 TKO cells in the intestine do not exhibit apoptosis.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "Only Paper 1 is directly relevant to E2f1-3 function in the intestine. Its abstract reports that E2f1-3 are required for survival of dividing progenitor cells (implying apoptosis upon loss) and function as repressors with Rb in differentiating cells, but it does not state whether differentiated E2f1-3 triple-knockout intestinal cells do or do not undergo apoptosis. The remaining papers discuss unrelated pathways or tissues. Therefore, the provided excerpts do not explicitly confirm or refute the claim about apoptosis in differentiated E2f1-3 TKO intestinal cells."
    },
    "naive_doc_ids": [
      "4394817",
      "5254463",
      "6182947",
      "12658073",
      "28697248"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.47,
      "justification": "Among the provided papers, only Paper 2 examines E2f1-3 triple deficiency in the mouse small intestine, showing that E2f1-3 are required for survival of dividing progenitor cells and function as repressors in differentiating cells. However, the abstract does not report whether differentiated intestinal E2f1-3 TKO cells undergo apoptosis. Paper 1 shows E2F3 is required for DNA damage\u2013induced apoptosis, but this is not specific to differentiated intestinal cells under baseline conditions. The other papers are unrelated to E2f1-3 TKO apoptosis in differentiated intestinal cells. Therefore, the specific claim that differentiated E2f1/2/3 TKO intestinal cells do not exhibit apoptosis is not directly supported or refuted by the provided text."
    },
    "overthinking_doc_ids": [
      "28697248",
      "4394817",
      "5254463",
      "30580263",
      "27772649"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers address E2f-1/-2/-3 triple knockout (TKO) in intestinal cells or measure apoptosis specifically in differentiated E2f TKO intestinal cells. The studies focus on unrelated pathways (e.g., Wip1/p53 in stem cells, inflammasome-mediated enterocyte expulsion, bcl-2 patterns in crypts, SAA3 regulation by microbiota, FOXO/SIRT1 signaling, and cardiomyocyte apoptosis). Therefore, the evidence does not confirm or refute the claim."
    },
    "posthoc_doc_ids": [
      "5254463",
      "1905095",
      "3435889",
      "11921405",
      "12658073"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.05,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1027",
    "claim": "Reduced phosphorylation of PP2A suppresses HDAC4 dephosphorylation.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 3 directly shows that ATM-mediated phosphorylation downregulates PP2A activity. In ATM deficiency (i.e., reduced phosphorylation of PP2A), PP2A activity is enhanced, which increases HDAC4 dephosphorylation and drives its nuclear accumulation. Thus, reduced phosphorylation of PP2A promotes, rather than suppresses, HDAC4 dephosphorylation. Other papers do not address HDAC4/PP2A phosphorylation directly."
    },
    "naive_doc_ids": [
      "8417211",
      "22185730",
      "3113630",
      "4324278"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 2 directly links PP2A phosphorylation status to its activity toward HDAC4. It states that PP2A is downregulated by ATM-mediated phosphorylation, and that in ATM deficiency (i.e., reduced PP2A phosphorylation) PP2A activity is enhanced, leading to HDAC4 dephosphorylation and nuclear accumulation. Thus, reduced phosphorylation of PP2A promotes, rather than suppresses, HDAC4 dephosphorylation. The other papers do not provide relevant information about PP2A-HDAC4 regulation."
    },
    "overthinking_doc_ids": [
      "22185730",
      "3113630",
      "735130",
      "11291348",
      "22036571"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.93,
      "justification": "Paper 2 explicitly states that ATM-mediated phosphorylation downregulates PP2A activity. In ATM deficiency (i.e., reduced phosphorylation of PP2A), PP2A activity is enhanced, which leads to increased HDAC4 dephosphorylation and nuclear accumulation. Thus, reduced phosphorylation of PP2A enhances, rather than suppresses, HDAC4 dephosphorylation. Other papers provided do not address PP2A-HDAC4 directly."
    },
    "posthoc_doc_ids": [
      "22185730",
      "3113630",
      "3973445",
      "10279084",
      "11289247"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "350",
    "claim": "Discrimination between the initiator and elongation tRNAs depends on the translation initiation factor IF3.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.64,
      "justification": "Paper 4 directly addresses bacterial translation initiation and shows that the three initiation factors (IF1\u2013IF3) enable selection of the initiator tRNA in the P site. It further reports large conformational changes of IF3 and tRNA that facilitate accommodation of fMet-tRNAfMet for start codon recognition, implying IF3\u2019s active role in discriminating initiator tRNA from elongator tRNAs. The other papers do not provide relevant information on this claim."
    },
    "naive_doc_ids": [
      "6836086",
      "21602220",
      "22896970",
      "16927286",
      "47240151"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.63,
      "justification": "Only Paper 4 is relevant. It presents cryo-EM evidence that the bacterial initiation factors IF1\u2013IF3 enable selection of initiator tRNA in the 30S P site, and specifically shows IF3 undergoing conformational changes with tRNA to facilitate accommodation of fMet-tRNAfMet for start codon recognition. This supports the idea that discrimination of initiator versus elongator tRNAs involves and depends on IF3 activity. The other papers discuss unrelated topics (eukaryotic NMD, HIV RT, immunology, splicing, rRNA modifications)."
    },
    "overthinking_doc_ids": [
      "30261663",
      "2319305",
      "7155555",
      "16927286",
      "20585600"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "Paper 4 shows that in bacterial translation initiation, IFs 1\u20133 enable selection of the initiator tRNA, and specifically that IF3 undergoes conformational changes with tRNA to facilitate accommodation of fMet-tRNAfMet into the P site for start codon recognition. This indicates IF3 contributes to discriminating the initiator tRNA from elongator tRNAs. The other papers provided are not relevant to this claim."
    },
    "posthoc_doc_ids": [
      "8698857",
      "9505448",
      "24521894",
      "16927286",
      "2890952"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1359",
    "claim": "Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.92,
      "justification": "Paper 1 (RCT) shows combination varenicline+bupropion achieved higher week-12 abstinence than varenicline monotherapy (prolonged abstinence 53.0% vs 43.2%; OR 1.49, 95% CI 1.05\u20132.12; p=0.03), directly contradicting the claim. Paper 3 (network meta-analysis) finds varenicline monotherapy is not more effective than combination NRT (OR 1.06, 95% CredI 0.75\u20131.48), indicating no superiority of monotherapy over combination therapies. Papers 2, 4, and 5 are not relevant to this comparison."
    },
    "naive_doc_ids": [
      "11614737",
      "34369306",
      "5114940",
      "8570690",
      "39892135"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 directly compares varenicline monotherapy with combination varenicline+bupropion over a 12-week treatment period and shows higher prolonged abstinence with the combination (53.0% vs 43.2%; OR 1.49, 95% CI 1.05\u20132.12; P=0.03), contradicting the claim that monotherapy is more effective at 12 weeks. Paper 4 (network meta-analysis) further indicates varenicline is not more effective than combination NRT (OR 1.06; 95% CredI 0.75\u20131.48), reinforcing that monotherapy is not superior to combination therapies. Other papers are unrelated to smoking cessation pharmacotherapy."
    },
    "overthinking_doc_ids": [
      "11614737",
      "3944632",
      "5912283",
      "5114940",
      "7639744"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (randomized trial) found combination varenicline+bupropion achieved higher 12-week prolonged abstinence than varenicline monotherapy (53.0% vs 43.2%; OR 1.49; 95% CI 1.05\u20132.12; p=0.03), contradicting the claim that monotherapy is more effective at 12 weeks. Paper 4 (network meta-analysis) reported varenicline was not more effective than combination NRT (OR 1.06; 95% CredI 0.75\u20131.48), indicating equal efficacy, not superiority of monotherapy. Other papers are not directly relevant. Overall, evidence opposes the claim."
    },
    "posthoc_doc_ids": [
      "11614737",
      "8570690",
      "34369306",
      "5114940",
      "14361849"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "662",
    "claim": "JMJD6 slows the hydroxylation of C-terminal lysine",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that JMJD6 is an alpha-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that catalyzes hydroxylation of p53, primarily at Lys382, a C-terminal lysine. This indicates JMJD6 promotes (accelerates) hydroxylation rather than slowing it. The other papers do not address JMJD6\u2019s effect on C-terminal lysine hydroxylation."
    },
    "naive_doc_ids": [
      "37204802",
      "25388309",
      "40901687",
      "16086778",
      "19004126"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.83,
      "justification": "Paper 1 reports that JMJD6 functions as an alpha-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that catalyzes hydroxylation of p53 at lysine 382 (a C-terminal lysine region), thereby promoting this modification. This opposes the claim that JMJD6 slows hydroxylation. The other papers do not provide relevant information about JMJD6\u2019s effect on lysine hydroxylation."
    },
    "overthinking_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "2831620",
      "39729277"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 shows that JMJD6 acts as an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that catalyzes (promotes) hydroxylation of p53 at lysine 382, which is in the C-terminal region of p53. This indicates JMJD6 facilitates, not slows, lysine hydroxylation. The other papers do not provide relevant evidence about JMJD6\u2019s effect on hydroxylation rates."
    },
    "posthoc_doc_ids": [
      "37204802",
      "12172346",
      "12588500",
      "18841257",
      "4429932"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.1,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "606",
    "claim": "Increased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.74,
      "justification": "Paper 4 shows that 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the enzyme that converts PGE2 to 15-keto-PGE2, is down-regulated in colorectal cancer, and this down-regulation is associated with increased PGE2 levels. This indicates that reduced conversion (not increased conversion) leads to PGE2 accumulation. Paper 2 further notes reduced levels of the PPAR\u03b3 ligand 15-keto-PGE2 in Cftr-deficient mice, consistent with decreased conversion from PGE2, not increased. No provided paper shows that increased conversion of PGE2 to 15-keto-PGE2 causes PGE2 accumulation; the available evidence supports the opposite relationship."
    },
    "naive_doc_ids": [
      "56486733",
      "712078",
      "9956893",
      "21181273",
      "5775033"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 shows that enzymatic degradation of PGE2 to 15-keto-PGE2 is mediated by 15-PGDH. When 15-PGDH is downregulated (i.e., conversion to 15-keto-PGE2 is reduced), PGE2 levels are elevated, indicating that reduced conversion leads to PGE2 accumulation. Therefore, increasing the conversion of PGE2 to 15-keto-PGE2 would be expected to decrease, not increase, PGE2 levels. Paper 4 mentions reduced 15-keto-PGE2 in a disease model but does not report PGE2 accumulation with increased conversion. The other papers are not relevant to PGE2 metabolism. Thus, the claim is contradicted by the evidence."
    },
    "overthinking_doc_ids": [
      "21181273",
      "778436",
      "1686997",
      "712078",
      "44693226"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 4 shows that PGE2 is degraded via 15-hydroxyprostaglandin dehydrogenase (15-PGDH) to 15-keto-PGE2. Down-regulation or genetic disruption of 15-PGDH decreases this conversion, leading to higher PGE2 levels (accumulation) and loss of PGE2 metabolites, indicating that increased conversion would reduce, not increase, PGE2. Paper 1 identifies 15-keto-PGE2 as an endogenous PPAR\u03b3 ligand and reports reduced 15-keto-PGE2 in certain conditions but does not support that increasing conversion causes PGE2 accumulation. Thus, the claim is opposite to the evidence."
    },
    "posthoc_doc_ids": [
      "712078",
      "3127341",
      "31564409",
      "21181273",
      "5775033"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "939",
    "claim": "Persistor cells are one reason for incomplete responses to Tyrosine kinase inhibitor (TKI) therapy in cancer patients.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "The provided papers document mechanisms of incomplete TKI responses such as acquired resistance mutations (e.g., EGFR C797S; Paper 4), histologic transformation to SCLC with RB loss (Paper 5), microenvironment-driven resistance via YAP/TAZ (Paper 2), and variable sensitivity in tumor-initiating cells linked to PTEN/Akt status (Paper 3). However, none present data on drug-tolerant persister (persistor) cells as a cause of incomplete responses. Therefore, the evidence does not address the specific claim about persister cells."
    },
    "naive_doc_ids": [
      "9929089",
      "1065627",
      "40710501",
      "9505402",
      "18682109"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data on drug-tolerant persister (persistor) cells as a cause of incomplete responses to TKIs. Paper 1 discusses alternating chemotherapy reversing acquired resistance to EGFR TKIs but does not mention persister cells. Paper 3 shows microenvironment stiffness mediates lapatinib resistance via YAP/TAZ, a different mechanism. Paper 4 evaluates KRAS/EGFR biomarkers predicting erlotinib response. Paper 2 addresses Etk and doxorubicin-induced apoptosis (not TKI response). Papers 5 and 6 concern IBD and celiac disease, unrelated to TKI therapy. Therefore, the claim is not supported or refuted by these papers."
    },
    "overthinking_doc_ids": [
      "9929089",
      "20738970",
      "1065627",
      "41650417",
      "1022115"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "Multiple papers show that specific subpopulations of tumor cells survive or are intrinsically resistant to TKIs, leading to incomplete responses. Paper 9 identifies an integrin \u03b1v\u03b23-positive, stem-like subpopulation that is necessary and sufficient for tumor initiation and erlotinib resistance, observed in vitro, in patient-derived xenografts, and in clinical specimens from patients who progressed on erlotinib; targeting this pathway reverses resistance. Paper 2 shows glioma tumor-initiating cells with variable sensitivity to EGFR TKIs, with some lines completely insensitive due to PTEN loss and persistent AKT activation, indicating a resistant subpopulation. Paper 8 demonstrates sphere-forming (tumor-initiating) HNSCC cells are unsusceptible to EGFR/\u03b21-integrin targeting and display distinct survival strategies. Paper 3 illustrates clinical re-sensitization after chemotherapy, consistent with survival of a resistant cell fraction after initial TKI therapy. Although the term 'persister cells' is not explicitly used, the data collectively support the concept that drug-tolerant/resistant subpopulations contribute to incomplete TKI responses."
    },
    "posthoc_doc_ids": [
      "20738970",
      "40710501",
      "9929089",
      "26952804",
      "10015292"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "236",
    "claim": "Cell autonomous sex determination in somatic cells occurs in Passeriformes.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "The only relevant evidence (Paper 1) demonstrates cell-autonomous somatic sex identity in chickens (order Galliformes), not Passeriformes. The other papers address unrelated topics (cancer immunology, neurogenesis, and somatic cell reprogramming). There is no direct evidence presented about Passeriformes."
    },
    "naive_doc_ids": [
      "4388470",
      "5500086",
      "7492250",
      "7426741",
      "4457834"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The only relevant evidence provided (Paper 1) demonstrates cell-autonomous somatic sex identity in chickens (Gallus gallus, order Galliformes), not in Passeriformes. Paper 4 discusses Z-chromosome dosage compensation in chicken, which does not establish cell-autonomous sex determination and is not in Passeriformes. The other papers are unrelated to sex determination in birds. Therefore, there is no direct evidence here about Passeriformes."
    },
    "overthinking_doc_ids": [
      "4388470",
      "4928282",
      "5500086",
      "12232678",
      "22509015"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.9,
      "justification": "The only avian data presented are from chickens (Galliformes), showing cell-autonomous somatic sex identity, and from chicken Z-chromosome dosage compensation. No paper provides data on Passeriformes. The remaining papers concern mammals or unrelated topics. Therefore, the provided evidence does not address whether cell-autonomous sex determination occurs in passerine somatic cells."
    },
    "posthoc_doc_ids": [
      "4388470",
      "15803282",
      "23959496",
      "7492250",
      "12232678"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "657",
    "claim": "Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data on signal peptide peptidase (SPP/HM13) or its role in degrading proteins with complex membrane orientations. Paper 1 shows that another intramembrane protease (RHBDL4, a rhomboid) promotes ERAD of membrane proteins, but this does not address SPP specifically. Papers 2\u20136 discuss unrelated pathways (EpCAM RIP/Wnt, viral protein maturation, PAR-2 signaling, autophagy of nuclear lamina, and general ubiquitin-dependent degradation) without mentioning SPP. Therefore, the claim about SPP cannot be verified with the given evidence."
    },
    "naive_doc_ids": [
      "8533245",
      "3756384",
      "37643601",
      "1044552",
      "4452659"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.82,
      "justification": "None of the provided papers present data on signal peptide peptidase (SPP) or its role in degrading proteins with complex membrane topology. Paper 1 shows that an ER-resident intramembrane rhomboid protease (RHBDL4), not SPP, promotes ERAD of certain membrane proteins. Papers 2 and 4 address ER dislocation mediated by viral proteins (US11/US2) without implicating intramembrane cleavage by SPP. Papers 3, 5, and 6 are unrelated to SPP or intramembrane proteolysis in ERAD. Therefore, the evidence set does not confirm or refute the specific claim about SPP."
    },
    "overthinking_doc_ids": [
      "8533245",
      "6788835",
      "21931005",
      "38477436",
      "2194320"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "Among the provided papers, only Paper 3 addresses intramembrane proteolysis facilitating ER-associated degradation (ERAD), but it involves the ER-resident rhomboid protease RHBDL4\u2014not signal peptide peptidase (SPP). None of the papers present data on SPP-mediated intramembrane cleavage promoting degradation of proteins with complex (e.g., polytopic) membrane orientation. Other papers discuss unrelated topics (viral maturation by furin-like cleavage, membrane protein topology, signaling, biofilms, etc.). Therefore, the specific claim about SPP is not supported or refuted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "37643601",
      "7643848",
      "8533245",
      "3756384",
      "6836086"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "184",
    "claim": "Bone marrow cells don't contribute to adult macrophage compartments.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 (CX3CR1 fate mapping) shows that major tissue-resident macrophage populations (e.g., Kupffer cells, alveolar, splenic, peritoneal) are established prenatally and maintained during adulthood without replenishment by blood monocytes, which are bone marrow derived. Paper 2 (parabiosis and fate mapping) similarly finds that circulating monocytes do not significantly contribute to tissue macrophages in the steady state and that repopulation after depletion occurs largely via local proliferation. Together, these data support that, under adult homeostasis, bone marrow-derived cells (via circulating monocytes) contribute minimally or not at all to resident macrophage compartments. The other papers do not provide relevant in vivo evidence on macrophage origin or maintenance."
    },
    "naive_doc_ids": [
      "7521113",
      "12827098",
      "3118719",
      "22791348",
      "188911"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.71,
      "justification": "Paper 1 shows tissue-resident macrophages self-maintain with minimal monocyte contribution at steady state and repopulate largely by local proliferation after depletion, but it does not exclude contribution entirely and suggests donor bone marrow\u2013derived macrophages can develop post-transplant when competent. Paper 2 (review) states most adult tissue macrophages are embryonically derived, yet emphasizes that tissues contain mixtures of embryonically and adult-derived macrophages and that monocytes (bone marrow\u2013derived) can differentiate into macrophages during inflammation. Together, these indicate that while steady-state contribution from bone marrow is limited, bone marrow cells do contribute to adult macrophage compartments in certain contexts, contradicting the absolute claim. Other papers provided do not address macrophage ontogeny (NOINFO)."
    },
    "overthinking_doc_ids": [
      "12827098",
      "22406695",
      "35811036",
      "9334631",
      "25942757"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.74,
      "justification": "Papers 4 and 5 provide direct, in vivo evidence that adult tissue-resident macrophage populations are largely self-maintained and receive minimal to no replenishment from bone marrow\u2013derived circulating monocytes under steady-state conditions. Paper 5 (fate mapping) shows major adult macrophage compartments (e.g., Kupffer cells, alveolar, splenic, peritoneal) are established before birth and maintained independently of blood monocytes. Paper 4 (parabiosis and fate mapping) confirms monocytes do not significantly contribute to tissue macrophages in steady state and that repopulation after depletion occurs mainly via local proliferation. The other papers are not directly relevant to adult macrophage maintenance in vivo. Thus, the provided evidence supports the claim in the context of steady-state adult macrophage compartments."
    },
    "posthoc_doc_ids": [
      "188911",
      "10078024",
      "25985964",
      "12827098",
      "7521113"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.78,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "182",
    "claim": "Bone Marrow (BM) transplantation is used to treat acute myeloid leukemia (AML)",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 6 analyzes outcomes after allogeneic stem cell transplantation in a cohort that includes 42 patients with acute myeloid leukemia, demonstrating that transplantation is used in AML treatment. Paper 2, from the European Group for Blood and Marrow Transplantation, further situates AML within the context of allogeneic stem cell (blood/bone marrow) transplantation. Together, these provide direct evidence that bone marrow/hematopoietic stem cell transplantation is used to treat AML."
    },
    "naive_doc_ids": [
      "10128893",
      "11344428",
      "19510470",
      "6374918",
      "13205096"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.93,
      "justification": "Paper 2 explicitly includes 42 patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation and analyzes outcomes, demonstrating that hematopoietic/bone marrow transplantation is used in AML. Paper 1 surveys thousands of allogeneic blood and marrow transplants and discusses post-transplant complications, further indicating clinical use of BMT/HSCT in hematologic malignancies including AML."
    },
    "overthinking_doc_ids": [
      "11344428",
      "24795767",
      "30398773",
      "301866",
      "3090454"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 4 explicitly reports outcomes after allogeneic stem cell transplantation in a cohort that includes 42 patients with acute myeloid leukemia, demonstrating that transplantation is used as a treatment for AML. Papers 2, 5, and 8 discuss complications and immune reconstitution after allogeneic (blood and marrow) transplantation in cohorts that include AML, further supporting that bone marrow/hematopoietic stem cell transplantation is employed in AML therapy."
    },
    "posthoc_doc_ids": [
      "6374918",
      "11344428",
      "13205096",
      "24795767",
      "301866"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "316",
    "claim": "Decreased conversion of PGE 2 to PPARy ligand 15-ket-PGE 2 causes accumulation of PGE.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Paper 1 shows that 15-hydroxyprostaglandin dehydrogenase (15-PGDH)\u2014the enzyme that initiates PGE2 catabolism by converting it to 15-keto metabolites\u2014is down-regulated, and its genetic disruption abolishes production of PGE2 metabolites, indicating impaired conversion/degradation of PGE2. Paper 3 reports reduced levels of the endogenous PPAR\u03b3 ligand 15-keto-PGE2, consistent with decreased conversion from PGE2. Together, these findings support the mechanistic conclusion that reduced conversion to 15-keto-PGE2 would shift steady-state toward accumulation of PGE2, even though direct increases in PGE2 levels are not explicitly reported in these abstracts."
    },
    "naive_doc_ids": [
      "21181273",
      "5775033",
      "712078",
      "19185192",
      "22478394"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "Paper 1 shows that the enzyme responsible for the first step of PGE2 catabolism (15-PGDH) is down-regulated in colorectal cancer, and that genetic disruption of 15-Pgdh completely blocks production of the PGE2 metabolite. This demonstrates decreased conversion of PGE2 via the 15-PGDH pathway, which would be expected to increase PGE2 levels given that steady-state PGE2 depends on the balance of synthesis and breakdown. Paper 6 identifies 15-keto-PGE2 as an endogenous PPAR\u03b3 ligand and reports reduced amounts of 15-keto-PGE2 in Cftr-deficient tissues, consistent with decreased conversion from PGE2. Together, these support the mechanistic claim that reduced conversion of PGE2 to 15-keto-PGE2 lowers the PPAR\u03b3 ligand and leads to relative accumulation of PGE2. Note: while PGE2 accumulation is inferred from reduced catabolism, direct measurement of increased PGE2 in these abstracts is not shown."
    },
    "overthinking_doc_ids": [
      "21181273",
      "25817686",
      "16086778",
      "22478394",
      "24150328"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.8,
      "justification": "Of the provided papers, only Paper 1 mentions the PPAR\u03b3 ligand 15-keto-PGE2, reporting reduced levels in Cftr-deficient tissues. However, it does not demonstrate decreased conversion from PGE2, nor does it provide data on PGE2 accumulation. The other papers are unrelated to PGE2/15-keto-PGE2 metabolism. Therefore, the evidence set does not confirm that decreased conversion of PGE2 to 15-keto-PGE2 causes PGE2 accumulation."
    },
    "posthoc_doc_ids": [
      "712078",
      "31564409",
      "3127341",
      "13573143",
      "597790"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1278",
    "claim": "The treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Evidence indicates that blocking co-inhibitory receptors can precipitate autoimmune phenomena and clinically meaningful toxicities. In mice, genetic loss/blockade of the checkpoint VISTA leads to heightened T-cell activation, multiorgan inflammation, and increased frequency/intensity of autoimmunity under susceptible conditions (Paper 2), demonstrating autoimmune risk from checkpoint disruption. In cancer patients, PD-1 blockade with pembrolizumab caused notable treatment-related adverse events (grade 3\u20134 in 14%; serious AEs in 9%) (Paper 6), inconsistent with the claim of no adverse autoimmune events. No paper supports the assertion that co-inhibitory receptor blockade is free of autoimmune adverse effects."
    },
    "naive_doc_ids": [
      "4468861",
      "23912923",
      "3559136",
      "25589047",
      "52180874"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "Only Paper 4 is relevant to co-inhibitory receptor (PD-1) blockade in cancer and it reports treatment-related adverse events, but it does not specify whether these were autoimmune (immune-related) events. The other papers address MDR-TB therapy, acute coronary syndromes, kidney transplant induction with MSCs, and glucosamine for back pain, which are not relevant to co-IR blockade in cancer. Therefore, the provided evidence does not contain explicit information about autoimmune adverse events from co-IR blockade to confirm or refute the claim."
    },
    "overthinking_doc_ids": [
      "11254040",
      "29253460",
      "10582939",
      "3471191",
      "14724693"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.6,
      "justification": "Paper 5 shows that blocking a co-inhibitory immune checkpoint (VISTA) in mice leads to a proinflammatory phenotype with multiorgan chronic inflammation and a heightened predisposition to autoimmune disease under susceptible conditions. This contradicts the claim that co-inhibitory receptor (co-IR) blockade does not cause any adverse autoimmune events. While Papers 4 and 7 discuss PD-1/CTLA-4 blockade in cancer, they do not report autoimmune adverse events; however, the mechanistic and in vivo evidence in Paper 5 indicates that checkpoint blockade can precipitate autoimmunity, opposing the claim's absolute statement."
    },
    "posthoc_doc_ids": [
      "6334188",
      "20454006",
      "21382907",
      "4468861",
      "23912923"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1280",
    "claim": "The ureABIEFGH gene cluster encodes urease maturation proteins : UreD/UreH, UreE, UreF, and UreG.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.74,
      "justification": "Paper 1 identifies ureD, ureE, ureF, and ureG adjacent to the urease structural genes and shows that deletions in these genes prevent proper nickel metallocenter incorporation, establishing them as accessory (maturation) proteins. Papers 2 and 3 further demonstrate that UreD, UreF, and UreG form complexes with urease apoprotein essential for in vivo activation, with UreE facilitating the process. Together, these data confirm that the urease gene cluster includes genes encoding the maturation proteins UreD (UreH homolog in some species), UreE, UreF, and UreG. While the specific ureABIEFGH arrangement and the UreH name are not explicitly discussed, the functional claim about these maturation proteins is strongly supported."
    },
    "naive_doc_ids": [
      "29214508",
      "37768883",
      "36233757"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.84,
      "justification": "Paper 1 demonstrates experimentally that ureD, ureE, ureF, and ureG are accessory genes required for nickel metallocenter biosynthesis and full urease activity, i.e., maturation proteins. Papers 4 and 5 further show UreD/UreF/UreG form complexes with urease apoprotein that are activation-competent, reinforcing their roles in maturation. Paper 2 describes UreI as a urea channel (consistent with the ureABIEFGH cluster composition in organisms like H. pylori) but does not affect the conclusion about maturation proteins. Papers 3 and 6 are not relevant. Overall, the evidence confirms that within the urease gene cluster, the maturation proteins are UreD (or its homolog UreH), UreE, UreF, and UreG."
    },
    "overthinking_doc_ids": [
      "29214508",
      "4387784",
      "13965483",
      "37768883",
      "36233757"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 shows that ureD, ureE, ureF, and ureG within the urease gene region are accessory genes required for nickel metallocenter biosynthesis; deletions in these genes impair urease activity in a manner correlating with nickel content, establishing their maturation roles. Papers 2 and 3 further demonstrate that UreD, UreF, and UreG (with UreE facilitating) form activation-competent apoprotein complexes essential for in vivo urease activation. Although UreH is not specifically discussed, the evidence confirms that the cluster encodes the maturation proteins UreD/E/F/G, aligning with the claim."
    },
    "posthoc_doc_ids": [
      "29214508",
      "37768883",
      "36233757",
      "29367554",
      "15425958"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "378",
    "claim": "Energy balance requires hypothalamic glutamate neurotransmission.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Multiple studies show hypothalamic glutamatergic signaling is necessary for normal feeding and weight regulation. Paper 7 demonstrates that glutamatergic NMDA receptor signaling on hypothalamic AgRP neurons is required for their fasting-induced activation; NMDAR deletion reduces food intake, body fat, and weight, indicating a necessary role in energy homeostasis. Paper 5 shows that genetic ablation of lateral hypothalamic glutamatergic neurons increases caloric intake and weight gain, and pathway-specific optogenetic modulation of LHA\u2192LHb glutamatergic fibers bidirectionally regulates feeding, supporting a causal role in energy balance. Paper 8 further implicates NMDA receptor-mediated glutamatergic signaling in the lateral hypothalamus as critical for feeding responses. Together, these data support the claim that hypothalamic glutamate neurotransmission is required for maintaining energy balance."
    },
    "naive_doc_ids": [
      "15535511",
      "11201004",
      "11742219",
      "22545779",
      "23869951"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Paper 1 shows that selectively disrupting glutamate release from hypothalamic PVH (Sim1) neurons abolishes MC4R-mediated anti-obesity effects and that disrupting glutamate release from adult PVH neurons alone rapidly causes obesity via hyperphagia and reduced energy expenditure\u2014demonstrating hypothalamic glutamate transmission is necessary for normal energy balance. Paper 4 shows that ablation of lateral hypothalamic area glutamatergic neurons increases caloric intake and body weight, further indicating hypothalamic glutamatergic signaling is required to maintain energy balance. Other papers are not directly about hypothalamic glutamate and do not contradict this."
    },
    "overthinking_doc_ids": [
      "45154987",
      "4353857",
      "5839365",
      "23869951",
      "26902591"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.88,
      "justification": "Direct loss-of-function studies in hypothalamus show that glutamate release is necessary for normal energy balance. Paper 7 demonstrates that selectively disrupting glutamate release from Sim1/PVH neurons abolishes the anti-obesity effect of restoring MC4R and, independently, that blocking glutamate release from adult PVH neurons causes rapid obesity via hyperphagia and reduced energy expenditure. Paper 4 shows that deleting VGLUT2 in VMH (SF1) neurons impairs counterregulatory responses, leading to fasting hypoglycemia, indicating glutamatergic neurotransmission is required for glucose homeostasis. Additional supportive context includes Paper 10 (LHA NMDA/glutamate activation triggers feeding) and Paper 1 (metabolic signals like leptin regulate hypothalamic astrocyte glutamate transporters influencing neuronal activity), reinforcing the role of hypothalamic glutamatergic signaling in energy regulation."
    },
    "posthoc_doc_ids": [
      "17150648",
      "11742219",
      "16398827",
      "11886686",
      "15535511"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1207",
    "claim": "The composition of myosin-II isoform switches from the polarizable B isoform to the more homogenous A isoform during hematopoietic differentiation.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.93,
      "justification": "None of the provided papers investigate myosin-II isoform composition (A vs B) during hematopoietic differentiation. The hematopoietic-focused papers address metabolic regulation (PTPMT1), self-renewal/differentiation mechanisms, and microRNA roles, but do not mention myosin-II isoforms. The myosin-related paper (Paper 9) concerns Myosin II in Drosophila wing compartment boundaries, not hematopoiesis or isoform switching, and Paper 5 discusses smooth-muscle differentiation with myosin heavy chain expression but not the A/B non-muscle isoforms or hematopoietic cells. Therefore, the evidence set does not confirm or refute the claim."
    },
    "naive_doc_ids": [
      "11289247",
      "13116880",
      "14581009",
      "23727313",
      "11840194"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Among the provided references, Paper 7 directly examines nonmuscle myosin-II isoforms in hematopoiesis. It reports that MIIB (myosin IIB) is the major isoform in HSC/progenitors and is strongly polarized, and that MIIB is downregulated upon differentiation via asymmetric division. In contrast, MIIA (myosin IIA) is constitutively expressed and becomes activated during cytokine-triggered differentiation (particularly on stiff, endosteum-like matrix). These data indicate a shift in isoform composition from polarized MIIB in stem/progenitors to predominance/activation of MIIA in differentiated cells, aligning with the claim. The other papers do not provide relevant information on myosin-II isoform switching and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "23727313",
      "12315072",
      "11289247",
      "14581009",
      "2151983"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 5 directly reports that in human hematopoiesis, nonmuscle myosin-II isoform B (MIIB) is the major, strongly polarized isoform in hematopoietic stem/progenitor cells and is downregulated in differentiated cells via asymmetric division, whereas myosin-IIA (MIIA) is constitutively present and becomes activated during differentiation. This supports a shift in myosin-II composition from a polarized MIIB-dominant state in HSC/progenitors to a more MIIA-dominant, less polarized (more homogeneous) state upon differentiation. The other papers do not address myosin-II isoform dynamics in hematopoiesis."
    },
    "posthoc_doc_ids": [
      "11289247",
      "13116880",
      "14581009",
      "735130",
      "18909530"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.78,
      "need_refinement": false,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "482",
    "claim": "Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 2 directly shows that tensile force applied to integrins activates the RhoA-specific GEFs LARG and GEF-H1 and recruits them to adhesion complexes via distinct signaling pathways (Fyn for LARG, ERK downstream of FAK/Ras for GEF-H1). Since LARG and GEF-H1 are GEFs for RhoA, their force-induced activation mediates RhoA activation in response to integrin tension. Papers 5 and 6 further support that Rho signaling is required for integrin-mediated mechanotransduction and reinforcement under applied force. While the abstracts do not explicitly state fibronectin-binding integrins, the evidence clearly links integrin-applied tension to activation of RhoA via specific GEFs."
    },
    "naive_doc_ids": [
      "8093935",
      "10991183",
      "33076846",
      "10530014",
      "9507605"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 directly shows that applying tensional force to integrins activates the Rho-specific GEFs LARG and GEF-H1 and recruits them to adhesion complexes via Fyn- and ERK-dependent pathways. These GEFs are known activators of RhoA, thereby providing mechanistic evidence that GEFs mediate RhoA activation in response to force on integrins engaged with the extracellular matrix. Paper 3 further supports the role of Rho signaling in force-induced adhesion maturation, consistent with RhoA activation downstream of integrin mechanotransduction. Papers 2 and 4 are not relevant to the claim. Overall, the evidence aligns with the claim that GEFs mediate RhoA activation in response to tensile forces on integrins (commonly fibronectin-binding in such assays)."
    },
    "overthinking_doc_ids": [
      "10991183",
      "30041895",
      "9507605",
      "20943272"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.87,
      "justification": "Paper 1 shows that applying tensional force to integrins activates the RhoA-specific GEFs LARG and GEF-H1 and recruits them to adhesion complexes via Fyn and FAK/Ras/ERK pathways, thereby mediating the RhoA-dependent mechanical reinforcement response. Paper 6 further supports that integrin-applied mechanical stress elicits adaptive responses that require Rho signaling. Together, these data support that GEFs mediate RhoA activation downstream of tensional forces on integrins, consistent with the claim about fibronectin-binding integrins."
    },
    "posthoc_doc_ids": [
      "10991183",
      "33076846",
      "8093935",
      "5821617",
      "20943272"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "764",
    "claim": "Medications to treat obesity are highly effective.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 (meta-analysis of long-term RCTs of approved anti-obesity drugs) found only modest weight loss vs placebo: orlistat \u22122.9 kg, sibutramine \u22124.2 kg, rimonabant \u22124.7 kg over 1\u20134 years, with 30\u201340% attrition, and explicitly concluded these drugs modestly reduce weight. Paper 4 (oral semaglutide in type 2 diabetes) showed dose-dependent weight loss (\u22122.1 to \u22126.9 kg over 26 weeks vs \u22121.2 kg placebo), indicating some efficacy but not clearly \u201chighly\u201d effective and not an obesity-specific population. Other papers are not directly relevant to obesity pharmacotherapy efficacy. Overall, the provided evidence does not support the claim that obesity medications are highly effective; it suggests modest effectiveness."
    },
    "naive_doc_ids": [
      "7552215",
      "5402581",
      "4515975",
      "3654468",
      "7098463"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 (updated meta-analysis of long-term anti-obesity drugs) found only modest weight loss vs placebo over 1\u20134 years: orlistat \u22122.9 kg, sibutramine \u22124.2 kg, rimonabant \u22124.7 kg, with 30\u201340% attrition and notable adverse effects; authors conclude these drugs modestly reduce weight, not highly. Paper 6 shows semaglutide (in type 2 diabetes, not an obesity trial) produces weight loss over 26 weeks (\u22122.1 to \u22126.9 kg), suggesting some efficacy but not establishing that obesity medications are highly effective. Other papers are not relevant to obesity pharmacotherapy. Overall, the provided evidence does not support the claim of high effectiveness and instead indicates modest effects."
    },
    "overthinking_doc_ids": [
      "7552215",
      "1831916",
      "21958900",
      "7098463",
      "22467585"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.82,
      "justification": "The provided evidence indicates that approved anti-obesity medications generally produce modest, not highly effective, weight loss. A meta-analysis of long-term pharmacotherapy (Paper 3) found average weight reductions vs placebo of only 2.9 kg (orlistat), 4.2 kg (sibutramine), and 4.7 kg (rimonabant) over 1\u20134 years, with substantial attrition (30\u201340%) and notable adverse effects. A review (Paper 2) emphasizes historical limitations and failures in anti-obesity drug development, noting that while GLP-1 agonists show promise, achieving surgery-like efficacy remains uncertain. A trial of oral semaglutide in type 2 diabetes (Paper 8) showed moderate weight loss over 26 weeks (difference vs placebo up to ~5.7 kg), not clearly \u201chighly effective.\u201d Papers on bariatric surgery (Papers 1 and 4) show large effects but are not medications, and other papers are not relevant. Overall, the evidence contradicts the claim that obesity medications are highly effective."
    },
    "posthoc_doc_ids": [
      "5824985",
      "5839365",
      "7552215",
      "40949706",
      "1831916"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "565",
    "claim": "In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that disrupting RNA surveillance in S. cerevisiae leads to iron sensitivity: RNase III (Rnt1p)-deficient cells accumulate aberrant iron-uptake mRNAs in iron-replete conditions and are hypersensitive to high iron, indicating RNA surveillance prevents iron toxicity. It also implicates multiple ribonucleases (Rrp6p, Xrn1p, Rat1p) in degrading aberrant transcripts, supporting the role of multiple surveillance pathways in iron homeostasis. The other papers do not address iron sensitivity from RNA surveillance and neither support nor contradict the claim."
    },
    "naive_doc_ids": [
      "16120395",
      "365896",
      "8247597",
      "30261663",
      "10300888"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that disrupting RNA surveillance in S. cerevisiae (e.g., loss of the RNase III ortholog Rnt1p) leads to aberrant expression of iron uptake mRNAs under iron-replete conditions and causes hypersensitivity to high iron, indicating RNA surveillance is required to prevent iron toxicity. It also implicates other surveillance components (Rrp6p, Xrn1p, Rat1p) in preventing accumulation of aberrant transcripts. The remaining papers are unrelated to this claim."
    },
    "overthinking_doc_ids": [
      "16120395",
      "13398997",
      "12383365",
      "10874408",
      "16686383"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 directly shows that loss of the RNA surveillance factor Rnt1p (RNase III) leads to hypersensitivity to high iron, and demonstrates that multiple RNA degradation/surveillance pathways (involving Rnt1p, Xrn1p, Rat1p, and Rrp6p) regulate iron uptake mRNAs to prevent iron toxicity. This aligns with the claim that absence of RNA surveillance pathways causes sensitivity to high iron conditions. The other papers do not address iron homeostasis or RNA surveillance in this context."
    },
    "posthoc_doc_ids": [
      "16120395",
      "365896",
      "26596106",
      "13398997",
      "12086599"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1212",
    "claim": "The deregulated and prolonged activation of monocytes has deleterious effects in chronic infectious conditions.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "Paper 1 shows that in persistent LCMV infection, chronic immune activation correlates with lymphoid tissue destruction and virus persistence, and that blocking IFN-I signaling reduces activation, restores lymphoid architecture, and improves viral control\u2014indicating prolonged immune activation is deleterious in chronic infection. Paper 5 demonstrates that the monocyte chemokine axis (CCL2/CCR2) enhances transmigration of HIV-infected leukocytes across the blood-brain barrier and disrupts barrier integrity via MMPs, a mechanism contributing to NeuroAIDS pathology. This supports that dysregulated/ongoing monocyte-related activation and trafficking cause harmful effects in chronic infectious conditions. The other papers are either about acute settings or non-infectious inflammation and do not contradict this claim."
    },
    "naive_doc_ids": [
      "2947124",
      "5511240",
      "5572127",
      "26124606",
      "27602752"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 2 provides direct evidence in a chronic infectious setting (HIV) that chronic hyperimmune activation upregulates PD-1 on monocytes, which upon engagement induces IL-10 production and leads to CD4+ T cell dysfunction. This demonstrates a deleterious consequence (impaired T cell activation) stemming from dysregulated, sustained monocyte activation. Other papers are not directly about monocytes in chronic infection (e.g., HBV therapy outcomes, TB IFN-\u03b3 dependency, post-MI macrophages), and none contradict the claim."
    },
    "overthinking_doc_ids": [
      "21700295",
      "10648422",
      "20261352",
      "1386103",
      "25134146"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.72,
      "justification": "Across the provided papers, none directly test or show that deregulated and prolonged activation of monocytes is deleterious specifically in chronic infectious conditions. Paper 1 examines TLR3 activation in macrophages in the context of HIV, but prolonged activation actually suppresses HIV transactivation and replication, and does not demonstrate host harm. Papers 2 and 7 link chronic infections (H. pylori, HBV) to deleterious outcomes via inflammation but do not identify monocyte-specific prolonged activation as the cause. Paper 8 shows regulated monocyte/macrophage responses aiding repair in bacterial infection (acute, not chronic). Other papers are reviews or focus on different cell types or non-infectious models. Therefore, there is insufficient direct evidence in these papers to confirm or refute the specific claim."
    },
    "posthoc_doc_ids": [
      "25606339",
      "24705390",
      "5572127",
      "15058155",
      "5035827"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1351",
    "claim": "Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.",
    "gold": "CONTRADICT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.64,
      "justification": "Paper 1 shows that dynein is required to maintain uniform plus-end-distal microtubule orientation in Drosophila axons; loss of dynein causes axons to contain minus-end-distal microtubules, which corresponds to more microtubule plus-ends growing toward the cell body. Thus, dynein activity suppresses soma-directed plus-ends in axons, implying that upregulation would not increase (and would likely reduce) soma-directed plus-ends\u2014opposite to the claim. Papers 2\u20135 do not provide relevant evidence on dynein upregulation or microtubule plus-end direction in Drosophila neurons."
    },
    "naive_doc_ids": [
      "28369117",
      "18126445",
      "36111909",
      "2727303",
      "1546650"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "None of the provided papers test dynein upregulation in Drosophila neurons or quantify microtubule plus-ends growing toward the soma. Paper 2 examines dynein loss-of-function and shows it is required for uniform plus-end-distal axonal polarity, but does not address dynein upregulation or increases in soma-directed plus-ends. Papers 1, 3, 4, and 5 are not about dynein-mediated changes in neuronal microtubule plus-end orientation in Drosophila."
    },
    "overthinking_doc_ids": [
      "18126445",
      "28369117",
      "36111909",
      "9217800",
      "1546650"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.88,
      "justification": "None of the cited papers examine dynein upregulation in Drosophila neurons or report an increase in the number of microtubule plus ends growing toward the soma. Paper 4 shows that dynein is required for polarized dendritic transport and for maintaining uniform plus-end-distal orientation in axons, but it addresses loss-of-function, not upregulation, and does not report increased proximal plus-end growth. The other papers concern different proteins (katanin, LL5\u03b1/\u03b2, HDAC6/STIM1) or in vitro/cell types other than Drosophila neurons, and do not provide relevant data about the claimed effect."
    },
    "posthoc_doc_ids": [
      "36111909",
      "18126445",
      "2727303",
      "28369117",
      "1546650"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "661",
    "claim": "JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 1 provides direct evidence that JMJD6 functions as an \u03b1-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that hydroxylates p53 predominantly at lysine 382, a C\u2011terminal lysine, and that this modification represses p53\u2019s transcriptional activity. The other papers do not address JMJD6 and are not relevant to the claim. Therefore, the evidence supports the claim."
    },
    "naive_doc_ids": [
      "37204802",
      "42314147",
      "2316374",
      "14367469",
      "4455466"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 reports that JMJD6 functions as an alpha-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that hydroxylates p53 predominantly at lysine 382, a C-terminal lysine. The study further shows that JMJD6 antagonizes p53 acetylation and represses p53 transcriptional activity. This directly supports both parts of the claim. The other papers do not address JMJD6 and are not relevant to this claim."
    },
    "overthinking_doc_ids": [
      "37204802",
      "2316374",
      "14367469",
      "25606339",
      "40901687"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 directly shows that JMJD6 functions as an alpha-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase that hydroxylates p53 primarily at lysine 382, a residue in the C-terminal region, and that JMJD6 represses p53\u2019s transcriptional activity (with depletion enhancing p53 transactivation). The other papers do not address JMJD6 and provide no conflicting information."
    },
    "posthoc_doc_ids": [
      "37204802",
      "2316374",
      "14367469",
      "29125354",
      "9199796"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.5,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1072",
    "claim": "Sepsis related mortality has remained stable between 2009-2014.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (US, 2009\u20132014) reports that in-hospital sepsis mortality declined significantly by 3.3% per year using EHR-based clinical criteria, and claims-based mortality declined by 7.0% per year. Although the combined outcome of death or discharge to hospice showed no significant change, the claim specifically states mortality remained stable, which is contradicted by both clinical and claims mortality trends. Other papers are not directly relevant to sepsis mortality trends in 2009\u20132014."
    },
    "naive_doc_ids": [
      "4824840",
      "27240667",
      "12224536",
      "3776162",
      "52827184"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.88,
      "justification": "Paper 1 directly examines US sepsis trends from 2009\u20132014 and shows that in-hospital mortality declined significantly using clinical criteria (\u22123.3% per year; P=0.004) and also declined using claims data (\u22127.0% per year; P<0.001). While the combined outcome of death or discharge to hospice did not change significantly, mortality itself decreased rather than remained stable. The other papers do not provide relevant mortality trend data for sepsis in 2009\u20132014."
    },
    "overthinking_doc_ids": [
      "4824840",
      "3878434",
      "4791384",
      "27240667",
      "12224536"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Paper 1 directly examines US sepsis outcomes from 2009\u20132014 using EHR-based clinical criteria and reports no significant change in the combined outcome of death or discharge to hospice (\u22121.3% per year; 95% CI, \u22123.2% to 0.6%; P=0.19). The authors explicitly conclude that the combined outcome did not change significantly over this period, consistent with mortality remaining stable. Note that in-hospital mortality alone declined (\u22123.3%/y, P=0.004), but the broader mortality-related outcome (death or hospice) was stable. The other papers are not relevant to sepsis mortality trends."
    },
    "posthoc_doc_ids": [
      "4824840",
      "27240667",
      "12224536",
      "663464",
      "1456068"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "756",
    "claim": "Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 5 explicitly describes lysine acetylation as a reversible post-translational modification governed by KATs/KDACs, notes proteomic evidence, and emphasizes its broad roles across many metabolic proteins\u2014indicating that numerous human proteins are acetylated on lysines. Papers 1, 4, and 6 provide concrete examples of lysine acetylation on histone H3 (e.g., H3K56ac) in human cells and the involvement of acetyltransferases (CBP/p300, Tip60), demonstrating the mechanism and occurrence of lysine acetylation. Paper 7 further supports the prevalence of acetyl-lysine marks by discussing bromodomains as readers of lysine acetylation central to chromatin regulation. Together, these papers substantiate that lysine acetylation is a common PTM affecting many proteins in human cells."
    },
    "naive_doc_ids": [
      "3052213",
      "11784947",
      "29851836",
      "502591",
      "2831620"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.58,
      "justification": "Among the provided papers, only Papers 3 and 5 directly address lysine acetylation, showing acetylation of histone H3 (e.g., H3K56ac) and its regulatory roles; Paper 4 discusses histone acetylation more generally. These support that lysine acetylation occurs on histones in human cells. However, none of the papers present evidence that many different proteins (beyond histones) in human cells are acetylated on lysine residues. The remaining papers (1, 2, 6) are unrelated. Therefore, the provided evidence does not substantiate the broader claim that many proteins are lysine-acetylated in human cells."
    },
    "overthinking_doc_ids": [
      "11026600",
      "1044552",
      "3052213",
      "1243475",
      "12588500"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Multiple papers indicate lysine acetylation is a common post-translational modification in human cells. Paper 1 reviews proteome-wide mass spectrometry revealing extensive lysine acetylation across many proteins and processes. Paper 4 highlights acetylation on both histone and non-histone proteins. Papers 2 and 6 provide experimental data for acetylation at histone H3 lysines (e.g., K56) in human cells and its functional roles. Paper 3 describes bromodomains that recognize acetyl-lysine on diverse proteins, implying broad occurrence. Together, these support that many human proteins can be acetylated on lysines."
    },
    "posthoc_doc_ids": [
      "27134527",
      "3052213",
      "12172346",
      "17919731",
      "1243475"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "946",
    "claim": "Physical activity level is associated with the difference in maximal oxygen consumption between black and white youth.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Paper 2 reports that African-American children have ~15% lower VO2max than Caucasian children and that this difference persists after adjustment for objectively measured activity energy expenditure (AEE) and total energy expenditure (TEE) via doubly labeled water, indicating the VO2max gap is independent of physical activity level. Paper 1 suggests the lower VO2max in black children could be partly due to a more sedentary lifestyle, but activity was assessed by questionnaire and this inference is not as strong as Paper 2\u2019s objective adjustment. Paper 3 shows racial differences in fitness but does not link them to activity; Paper 4 shows racial differences in activity but not VO2max; Paper 5 supports hemoglobin differences as a contributor. Overall, the strongest evidence contradicts that physical activity level is associated with the VO2max difference between black and white youth."
    },
    "naive_doc_ids": [
      "18537148",
      "26112696",
      "13230773",
      "8428935",
      "4449524"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.8,
      "justification": "Paper 1 directly compared black and white prepubertal and pubertal children and found lower VO2max in black youth; the authors assessed activity levels and concluded the VO2max difference could be attributed at least in part to a more sedentary lifestyle (and lower hemoglobin) among black children. Papers 2 and 4 show that non-Hispanic black adolescents/children engage in less moderate-to-vigorous activity and watch more television than peers, supporting racial differences in activity levels. Paper 7 reports lower estimated VO2max (fitness) among non-Hispanic blacks vs whites in a national sample. Together, these findings support that physical activity level is associated with the observed racial difference in maximal oxygen consumption among youth."
    },
    "overthinking_doc_ids": [
      "18537148",
      "13083189",
      "4449524",
      "8428935",
      "21274919"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Paper 2 directly measured activity energy expenditure (AEE) and total energy expenditure (TEE) via doubly labeled water and found that the approximately 15% lower VO2max in African-American vs Caucasian prepubertal children persisted after adjustment for AEE and TEE, indicating the ethnic difference in VO2max was independent of physical activity level. Paper 1 suggested the difference could be partly due to a more sedentary lifestyle based on questionnaire data, but did not demonstrate that activity explained the VO2max difference when rigorously controlled. Papers 3 and 4 show racial differences in fitness and activity patterns but do not link activity levels to the VO2max difference directly. Overall, the strongest evidence contradicts the claim that physical activity level is associated with the VO2max difference between black and white youth."
    },
    "posthoc_doc_ids": [
      "18537148",
      "26112696",
      "13230773",
      "8428935",
      "3222187"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.45,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1030",
    "claim": "Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 shows that inhibiting the H3K4 methyltransferase MLL1 with MM-401 reprograms mouse epiblast stem cells to naive pluripotency with high efficiency (>50% within 3 days), including functional validation (X reactivation and chimera contribution). MLL1 primarily catalyzes H3K4me3 at active promoters; its inhibition constitutes a reduction/perturbation of H3K4 methylation consistent with reduced H3K4me3 driving reprogramming. Papers 2\u20134 discuss pluripotent states and other regulators but do not contradict this finding."
    },
    "naive_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "3882374"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 directly shows that inhibiting the H3K4 methyltransferase MLL1 (which primarily catalyzes H3K4me3 at promoters) reprograms mouse epiblast stem cells to naive pluripotency with high efficiency (>50% within 3 days), including X reactivation and chimera contribution. This indicates that reducing H3K4 methylation (consistent with reduced H3K4me3) is sufficient to induce naive pluripotency efficiently. The other papers are not directly relevant to H3K4me3 reduction in mouse EpiSCs and do not contradict this finding."
    },
    "overthinking_doc_ids": [
      "6441369",
      "4462419",
      "3882374",
      "13955536",
      "4547102"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.74,
      "justification": "Paper 1 shows that inhibiting the H3K4 methyltransferase MLL1 with MM-401 reprograms mouse epiblast stem cells to a naive ESC-like state with high efficiency (>50% within 3 days), and concludes that perturbation of H3K4 methylation is sufficient to drive reprogramming. While the summary emphasizes redistribution of H3K4me1 at enhancers, inhibition of an H3K4 methyltransferase implies reduced H3K4 methylation marks, including H3K4me3 at MLL1 targets. Other papers provided discuss related pluripotency regulation (Wnt signaling, DNA demethylation, LIN28, WDR5) but do not contradict the central finding that lowering H3K4 methylation can efficiently induce naive pluripotency from EpiSCs."
    },
    "posthoc_doc_ids": [
      "6441369",
      "4462419",
      "23418635",
      "14923462",
      "3882374"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.62,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "14",
    "claim": "5'-nucleotidase metabolizes 6MP.",
    "gold": "NOINFO",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.85,
      "justification": "Papers 1 and 2 identify activating mutations in NT5C2, which encodes a cytosolic 5'-nucleotidase, and show that these mutations increase nucleotidase activity and confer resistance to 6-mercaptopurine (6MP) and 6-thioguanine in ALL cells. This indicates that 5'-nucleotidase metabolizes/inactivates thiopurine nucleotides derived from 6MP, aligning with the claim. Papers 3\u20135 do not provide relevant information."
    },
    "naive_doc_ids": [
      "6421792",
      "641786",
      "1373287",
      "5702790",
      "6588614"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Papers 2 and 3 show that activating mutations in the cytosolic 5'-nucleotidase NT5C2 increase its enzymatic activity and confer resistance to 6-mercaptopurine (6MP) and 6-thioguanine in ALL. Paper 2 explicitly states NT5C2 is responsible for inactivation (metabolism) of nucleoside-analog chemotherapy drugs and that mutant NT5C2 confers resistance to 6MP. Paper 3 similarly finds relapse-specific NT5C2 mutations that increase nucleotidase activity and resistance to nucleoside analog therapies. These findings support that a 5'-nucleotidase metabolizes/inactivates 6MP (via its nucleotide metabolites). Paper 1 is about dose intensity/TPMT and Paper 4 is unrelated to 6MP metabolism."
    },
    "overthinking_doc_ids": [
      "1373287",
      "6421792",
      "641786",
      "13106686"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Papers 1 and 4 identify activating mutations in NT5C2, a 5'-nucleotidase, that increase nucleotidase activity and confer resistance to 6-mercaptopurine (6MP) and 6-thioguanine in ALL cells, indicating NT5C2-mediated inactivation (metabolism) of thiopurine metabolites. Paper 3 shows 5'-nucleotidase activity toward IMP/GMP, consistent with dephosphorylation of thiopurine nucleotide analogs derived from 6MP. Other papers are not relevant. Together, this supports that a 5'-nucleotidase (NT5C2) metabolizes 6MP\u2019s active nucleotide forms, leading to drug resistance."
    },
    "posthoc_doc_ids": [
      "6421792",
      "293661",
      "393001",
      "641786",
      "6157371"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "264",
    "claim": "Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.86,
      "justification": "Paper 1 shows that NETs contain citrullinated histone H4 which is specifically recognized by anti-citrullinated protein antibodies (ACPAs) in RA sera, indicating NET-derived citrullinated proteins serve as autoantigens. Paper 2 demonstrates that NETs externalize citrullinated autoantigens, NETosis correlates with ACPA levels, ACPAs (e.g., anti-citrullinated vimentin) can trigger further NETosis, and NETs stimulate inflammatory cytokine/chemokine production by synovial fibroblasts\u2014together supporting a feedback loop that perpetuates inflammation involving autoantibodies. Paper 3 (review) further supports the concept that NETs provide nuclear autoantigens driving autoimmunity. Thus, the evidence supports that citrullinated proteins exposed in NETs contribute indirectly to sustaining inflammation by serving as targets that induce/maintain autoantibody responses."
    },
    "naive_doc_ids": [
      "30041340",
      "11328820",
      "14853989",
      "21578627",
      "1996292"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.75,
      "justification": "Paper 1 demonstrates that citrullinated histone H4 within NETs is a target of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) sera and concludes that NETosis can generate antigens for ACPA, linking innate and adaptive immunity. Paper 2 shows that NETs externalize citrullinated autoantigens, NETosis correlates with ACPA levels, and RA autoantibodies (including anti-citrullinated vimentin) can further induce NETosis, creating a feedback loop that perpetuates inflammation; NETs also directly amplify inflammatory cytokine production by synovial fibroblasts. Paper 3 conceptually supports NETs as sources of autoantigens driving autoimmunity. While direct de novo induction of autoantibodies by NETs is not formally proven, the evidence aligns with the claim that citrullinated proteins externalized in NETs contribute indirectly to sustaining inflammation via autoantibody responses."
    },
    "overthinking_doc_ids": [
      "30041340",
      "11328820",
      "14853989",
      "1191830",
      "20977638"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.82,
      "justification": "Paper 1 shows that citrullinated histone H4 present in NETs is recognized by RA autoantibodies (ACPAs) and concludes that NETosis can generate antigens for ACPA, linking NET-derived citrullinated proteins to autoantibody responses. Paper 4 demonstrates that NETs externalize citrullinated autoantigens, NETosis correlates with ACPA presence/levels, RA autoantibodies can drive further NETosis, and NETs stimulate inflammatory cytokine production in synovial fibroblasts\u2014together supporting a feed\u2011forward inflammatory cycle involving autoantibodies. Paper 3 further supports the concept that NETs provide extracellular nuclear antigens that can induce autoimmunity. Other papers are not relevant. Overall, the evidence supports that citrullinated proteins externalized in NETs contribute indirectly to perpetuating inflammation via autoantibody induction."
    },
    "posthoc_doc_ids": [
      "30041340",
      "1800734",
      "14853989",
      "11328820",
      "1191830"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "226",
    "claim": "Cancer-associated fibroblasts (CAFs) interact with cancer cells to mediate formation and activation of CAFs.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Several papers show bidirectional interactions in the tumor microenvironment, including CAFs influencing cancer cells (e.g., IL6/CXCR7 in ESCC in Paper 1; SDF-1/CXCR4 in NSCLC in Paper 3; chemokines driving HCC metastasis in Paper 8). However, none provide direct experimental evidence that interactions between cancer cells and fibroblasts mediate the formation or activation of CAFs from normal fibroblasts. Paper 7 discusses cancer cells inducing oxidative stress in existing CAFs and proposes a model of tumor\u2013stroma co-evolution, but does not demonstrate CAF formation/activation from non-CAF fibroblasts. Other papers address tumor effects on neutrophils (Paper 4), MSC reprogramming (Paper 5), and endothelial crosstalk (Paper 6), which are not specific to CAF activation. Therefore, the provided evidence does not directly support the specific claim about CAF formation/activation being mediated by tumor\u2013CAF interactions."
    },
    "naive_doc_ids": [
      "3376731",
      "22401720",
      "9648896",
      "52925737",
      "14768471"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.7,
      "justification": "Paper 4 provides mechanistic evidence from a co-culture context that cancer cells induce oxidative stress in adjacent fibroblasts/CAFs, driving their metabolic reprogramming and functional activation (e.g., Reverse Warburg Effect), indicating cancer cell\u2013CAF interaction that activates CAFs. Paper 5 (review) explicitly states that crosstalk between cancer cells and CAFs is key in tumor progression, consistent with cancer cells mediating CAF activation/formation. The other papers are not relevant to CAFs and do not contradict this claim."
    },
    "overthinking_doc_ids": [
      "22401720",
      "25915873",
      "2825380",
      "24349992",
      "952111"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "Paper 9 provides direct experimental evidence of cancer cell\u2013CAF crosstalk where tumor cell\u2013derived CSF1 modulates (i.e., functionally activates/reprograms) CAFs via HDAC2-mediated changes in chemokine expression, demonstrating cancer cells influence CAF activity. Paper 8 shows CAFs secrete chemokines that activate signaling pathways (Hedgehog, TGF-\u03b2) in cancer cells, evidencing bidirectional interaction. Paper 7 (review) explicitly states that crosstalk between cancer cells and CAFs is key in tumor progression. While explicit induction of CAF formation by cancer cells is not directly shown in these papers, the activation/modulation of CAF function by tumor-derived signals is supported, aligning with the claim\u2019s core premise of interaction-driven CAF activation."
    },
    "posthoc_doc_ids": [
      "25915873",
      "25050969",
      "33397197",
      "31682248",
      "52925737"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.35,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "759",
    "claim": "Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.76,
      "justification": "Paper 1\u2019s mathematical model predicts that ACTs can substantially reduce transmission in low-transmission settings (e.g., ~53% reduction in prevalence with full ACT replacement), but only modestly in high-transmission settings (~11%). Critically, the model also predicts that a non-gametocytocidal regimen with long prophylaxis could outperform a short-acting ACT in high-transmission areas, undermining a general claim of ACT superiority over nongametocytocidal drugs. Paper 2\u2019s empirical data further temper expectations, finding that ACTs had only a moderate effect on transmission\u2014no significant reduction in the proportion of infectious children, with effects limited to reducing the proportion of infected mosquitoes\u2014contrary to a \u2018dramatic\u2019 impact. Paper 3 does not provide specific support for a dramatic, ACT-specific advantage over nongametocytocidal drugs. Overall, the evidence indicates context-dependent and often moderate effects rather than a universally dramatic, superior impact of ACTs over nongametocytocidal treatments."
    },
    "naive_doc_ids": [
      "1805641",
      "10617916",
      "18074797"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.7,
      "justification": "Paper 1 (modeling) predicts that switching from non-gametocytocidal SP to ACT can substantially reduce transmission in low-transmission settings (e.g., ~53% reduction in prevalence), but only modestly in high-transmission settings (~11%). It also predicts that a long-prophylactic, non-gametocytocidal regimen could outperform a short-acting ACT in the highest-transmission setting. Thus, models do not universally predict a dramatic impact of ACT over nongametocytocidal drugs. Paper 2 (clinical) further indicates that ACT\u2019s effect on transmission is moderate and short-lived, not dramatic. Paper 3 shows significant individual-level reductions in infectiousness with ACT, but does not establish dramatic population-level impact across settings. Overall, the evidence indicates context-dependent and sometimes modest effects, contradicting the claim\u2019s broad framing."
    },
    "overthinking_doc_ids": [
      "1805641",
      "10617916",
      "12409683",
      "10072941",
      "12994780"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.72,
      "justification": "Two mathematical modeling studies predict substantial transmission reductions with ACT. Paper 1 projects large population-level impacts from switching to ACT (e.g., up to a 53% reduction in infection prevalence in low-transmission settings, approaching the effect of insecticide-treated nets), though it notes smaller effects in very high-transmission settings and that long-acting non-gametocytocidal regimens could outperform short-acting ACT there. Paper 4\u2019s fitted model indicates high coverage with ACT can drive long-term declines toward elimination, enhanced by primaquine. Empirical studies provide mixed context: Paper 3 shows ACT significantly reduces gametocytemia and mosquito infection versus non-artemisinin regimens, while Paper 2 finds only moderate transmission effects, underscoring setting dependence. Overall, the modeling evidence supports the claim that models predict a dramatic impact of ACT on transmission, especially in lower-transmission contexts, with important caveats."
    },
    "posthoc_doc_ids": [
      "1805641",
      "10617916",
      "12409683",
      "3929361"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.6,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "153",
    "claim": "B3-Galectin decreases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 3 shows that an integrin \u03b1v\u03b23\u2013KRAS\u2013RalB complex activates TBK1/NF-\u03baB and drives tumour stemness and resistance to EGFR tyrosine kinase inhibitors; pharmacologic targeting of this pathway reverses resistance. Thus, engaging the KRAS\u2013RalB pathway increases, rather than decreases, resistance, and it functions as an alternate bypass rather than downstream of EGFR. Additionally, none of the provided papers mention B3-Galectin, so there is no support for the specific molecule named in the claim."
    },
    "naive_doc_ids": [
      "9929089",
      "40710501",
      "4702639",
      "17648235",
      "7736860"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 shows that integrin \u03b1v\u03b23 recruits a KRAS\u2013RalB complex that activates TBK1/NF-\u03baB and drives resistance to EGFR tyrosine kinase inhibitors (e.g., erlotinib), not decreased resistance. This pathway functions as an alternative bypass rather than downstream of EGFR signaling. None of the provided papers present data on a 'B3-Galectin' reducing TKI resistance via KRAS\u2013RalB; in fact, the relevant evidence indicates the opposite effect for \u03b23 integrin. Papers 2\u20135 discuss other resistance mechanisms (\u03b21 integrin/EGFR targeting inefficacy in spheres, NF1 loss maintaining RAS-ERK, PTEN/PI3K-Akt\u2013mediated resistance, anti-angiogenic RTK inhibitors) and do not support the claim."
    },
    "overthinking_doc_ids": [
      "4702639",
      "4688340",
      "2272614",
      "34016944",
      "23420807"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 shows that integrin \u03b1v\u03b23 recruits a KRAS\u2013RalB complex that activates TBK1/NF-\u03baB and drives resistance to EGFR TKIs (e.g., erlotinib). Thus, engaging the KRAS\u2013RalB pathway increases, rather than decreases, TKI resistance, and this mechanism is tied to integrin \u03b23, not a galectin. The other papers discuss different resistance mechanisms (NF1 loss, EGFR C797S, PTEN loss/PI3K-Akt, matrix stiffness/YAP-TAZ, GNB1 mutations) and do not support a role for a \u201cB3-Galectin\u201d reducing TKI resistance via KRAS\u2013RalB. Therefore, the claim is contradicted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "4702639",
      "2272614",
      "9505402",
      "34016944",
      "9929089"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "434",
    "claim": "Foxp3 enables the expression of transcriptional regulators implicated in memory T cell development.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers show that Foxp3 enables expression of transcriptional regulators involved in memory T cell development within T cells. Paper 1 shows Foxp3+ Tregs upregulate KLF2 in endothelial cells, not T cells. Paper 4 discusses KLF2 in dendritic cells. Paper 5 covers IL-2/inflammation effects on Eomes, T-bet, and perforin in CTLs without involving Foxp3. Paper 7 shows an inverse correlation between Foxp3 and IL-7Ralpha (CD127) in human T cells, a memory-associated receptor, not a transcription factor. Paper 8 examines Blimp-1\u2019s repression of ifng, tbx21, and bcl6, again without Foxp3 involvement. Other papers are unrelated to T cells or memory development. Therefore, the evidence set does not address the claim."
    },
    "naive_doc_ids": [
      "30908508",
      "20179918",
      "29429111",
      "5979056",
      "10359591"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers show that Foxp3 enables the expression of transcriptional regulators implicated in memory T cell development. Paper 1 separates Foxo1-driven programs from Foxp3 regulation in Treg cells, and the other papers discuss memory T cell biology, KLF2 roles in myeloid, endothelial, or dendritic cells, or Treg-mediated regulatory memory without linking Foxp3 to inducing memory-related transcription factors. There is no direct evidence supporting or refuting the specific claim."
    },
    "overthinking_doc_ids": [
      "4418070",
      "5508750",
      "7399084",
      "6493422",
      "30908508"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers present data showing that Foxp3 enables (positively regulates) the expression of transcriptional regulators implicated in memory T cell development. Paper 4 shows Foxo1 controls key Treg programs and that many Foxo1 target genes are not directly regulated by Foxp3, but does not indicate Foxp3 induces Foxo1 or other memory-related regulators. Papers 1, 2, 5, 6, and 7 discuss regulators such as Blimp-1, Bcl-6, T-bet, and Eomes in T cell differentiation and memory, yet do not link their expression to Foxp3. The remaining papers are not directly relevant to Foxp3\u2019s regulation of memory-associated transcription factors. Therefore, the claim is not supported or refuted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "7399084",
      "21363424",
      "464511",
      "4418070",
      "13636631"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.15,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "975",
    "claim": "Primary pro-inflammatory cytokines induce secondary pro- and anti-inflammatory mediators.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.54,
      "justification": "The provided papers offer evidence that primary pro-inflammatory cytokines can induce secondary pro-inflammatory mediators, but do not show induction of anti-inflammatory mediators by these cytokines. Specifically: Paper 2 shows TNF-alpha upregulates ICAM-1, VCAM-1, and MCP-1 (pro-inflammatory mediators). Paper 7 shows IL-6 upregulates soluble MD-2, an acute-phase protein that enhances TLR4 signaling and phagocytosis (pro-inflammatory). None of the papers demonstrate that primary pro-inflammatory cytokines induce anti-inflammatory mediators (e.g., IL-10, IL-1Ra, TGF-beta). Paper 6 shows CRP (an acute-phase protein, not a primary cytokine) decreases IL-10. Therefore, the claim that primary pro-inflammatory cytokines induce both pro- and anti-inflammatory mediators is not fully supported by the provided evidence."
    },
    "naive_doc_ids": [
      "36386637",
      "22889972",
      "38023457",
      "40963697",
      "7735859"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "None of the provided papers directly examine or report that primary pro-inflammatory cytokines (e.g., TNF-\u03b1, IL-1\u03b2) induce secondary pro- or anti-inflammatory mediators. The studies address dendritic cell motility via CLEC-2 (Paper 1), antihypertensive mechanisms (Paper 2), beta-adrenergic receptor polymorphisms in heart failure (Paper 3), aromatase inhibitors for ovulation induction (Paper 4), cyclosporine A\u2013induced renal apoptosis mechanisms (Paper 5), and statin effects on inflammatory markers around cardiopulmonary bypass (Paper 6). Although Paper 6 reports changes in cytokines and hsCRP, it does not provide causal evidence that primary cytokines induce secondary mediators, nor does any paper show induction of anti-inflammatory mediators by primary cytokines."
    },
    "overthinking_doc_ids": [
      "7370282",
      "14584755",
      "24586989",
      "14827874",
      "238409"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Paper 5 shows that the primary pro-inflammatory cytokine IL-1\u03b2 induces secondary inflammatory mediators in human synovial fibroblasts, specifically increasing PGE2 production, COX-2 expression, and MMP secretion\u2014classic downstream pro-inflammatory mediators. Paper 2 demonstrates that factors produced by activated T cells (a pro-inflammatory cytokine milieu) up-regulate both RANK (pro-osteoclastogenic, stimulatory) and osteoprotegerin (OPG; a decoy receptor with inhibitory effects), indicating induction of both stimulatory (pro-inflammatory/osteoclastogenic) and inhibitory (counter-regulatory) mediators. Together these data support the claim that primary pro-inflammatory cytokines can induce secondary pro- and anti-(counter-regulatory) mediators."
    },
    "posthoc_doc_ids": [
      "2391552",
      "43619625",
      "3973445",
      "26731863",
      "343052"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.3,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "181",
    "claim": "Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "The only relevant paper (Paper 7) shows that TDP-43 accumulates in mitochondria, binds ND3 and ND6 mRNAs (not the proteins), impairs their expression, and that inhibiting TDP-43 mitochondrial localization abolishes its mitochondrial dysfunction and neuronal toxicity. There is no evidence provided that directly tests or demonstrates that blocking a physical interaction between TDP-43 and the ND3/ND6 proteins prevents neuronal loss. Other papers are unrelated to TDP-43 or ND3/ND6 in this context. Therefore, the specific claim about blocking TDP-43\u2013ND3/ND6 protein interaction preventing neuronal loss is not supported by the provided evidence."
    },
    "naive_doc_ids": [
      "6386930",
      "25479072",
      "4270992",
      "8065561",
      "45875990"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "Paper 7 reports that TDP-43 accumulates in mitochondria and preferentially binds the mitochondrially transcribed mRNAs for respiratory complex I subunits ND3 and ND6, reducing their expression and causing complex I disassembly. Critically, inhibiting TDP-43 mitochondrial localization\u2014which blocks its interaction with these ND3/ND6 transcripts\u2014abolishes TDP-43-induced mitochondrial dysfunction and neuronal loss, and improves phenotypes in TDP-43 transgenic mice. While the paper demonstrates interaction with ND3/ND6 mRNAs rather than the proteins directly, the findings support the claim that preventing this interaction rescues neurons from TDP-43-induced toxicity."
    },
    "overthinking_doc_ids": [
      "3127341",
      "6386930",
      "6492658",
      "39929509",
      "935538"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.74,
      "justification": "Paper 4 reports that mitochondrial TDP-43 binds mitochondria-encoded ND3 and ND6 mRNAs, impairing their expression and causing complex I disassembly, which leads to neuronal loss. Critically, suppressing TDP-43 mitochondrial localization\u2014thereby blocking its interaction with ND3/ND6 transcripts\u2014abolished TDP-43\u2013induced mitochondrial dysfunction and neuronal loss, and improved phenotypes in TDP-43 transgenic mice. While the paper specifies interaction with ND3/ND6 mRNAs rather than the proteins per se, preventing this interaction via blocking mitochondrial localization prevented neuronal loss, aligning with the claim\u2019s core premise."
    },
    "posthoc_doc_ids": [
      "25479072",
      "13242763",
      "13380011",
      "16966326",
      "10698739"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "672",
    "claim": "L3MBTL2 binds to H2AK119Ub marked chromatin to form a PRC1 complex.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "Paper 1 shows that L3mbtl2 assembles an atypical PRC1-family complex (including Ring1B) and that its presence at target genes is associated with H2AK119 ubiquitination. However, it explicitly notes that H2AK119Ub is neither dependent on L3mbtl2 nor sufficient for repression, and provides no evidence that L3MBTL2 binds H2AK119Ub-marked chromatin or is recruited by this mark. Papers 2\u20138 do not address L3MBTL2 or H2AK119Ub binding. Thus, while PRC1 association is supported, the specific claim that L3MBTL2 binds H2AK119Ub-marked chromatin is not supported by the provided evidence."
    },
    "naive_doc_ids": [
      "15635366",
      "23244529",
      "14581009",
      "21557055",
      "25682129"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Only Paper 4 is relevant to L3MBTL2/PRC1. It shows that L3mbtl2 assembles an atypical PRC1-family complex and that its presence correlates with H2AK119 ubiquitination at target genes. However, it does not demonstrate that L3MBTL2 binds to H2AK119Ub-marked chromatin or uses that mark for recruitment. It also states H2AK119Ub is neither dependent on L3mbtl2 nor sufficient for repression. The other papers are unrelated to the claim. Therefore, the provided evidence does not confirm the specific binding mechanism asserted in the claim."
    },
    "overthinking_doc_ids": [
      "140874",
      "169264",
      "799586",
      "15635366",
      "8331432"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "Paper 1 shows that L3mbtl2 recruits an atypical PRC1-related complex (including Ring1b) and that L3mbtl2 occupancy correlates with H3K9me2, low acetylation, and H2AK119 ubiquitination at target genes. However, it does not show that L3MBTL2 binds to H2AK119Ub-marked chromatin, nor that such binding mediates complex formation; in fact, it notes H2AK119Ub is neither dependent on L3mbtl2 nor sufficient for repression. The other papers do not address L3MBTL2 or H2AK119Ub binding. Thus, the specific claim about L3MBTL2 binding to H2AK119Ub-marked chromatin is not supported or refuted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "15635366",
      "140874",
      "17240457",
      "24311787",
      "41620295"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.2,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "71",
    "claim": "Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.",
    "gold": "SUPPORT",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.61,
      "justification": "Paper 1 shows that SRGP-1 is a GAP for CED-10 (Rac1) and that loss of srgp-1 enhances engulfment, promoting clearance of dead and sublethally injured cells. It implies increased CED-10 activity in engulfing cells but does not directly demonstrate that activation of CED-10 kills otherwise viable cells in srgp-1 mutants. The other papers are unrelated to this claim. Therefore, the provided evidence does not explicitly confirm or refute the specific claim."
    },
    "naive_doc_ids": [
      "1127562",
      "7036529",
      "7042304",
      "5798227",
      "10582939"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "Paper 1 shows that SRGP-1 is a GAP for CED-10 (Rac1) and that loss of srgp-1 enhances CED-10\u2013dependent engulfment activity. This increased engulfment in srgp-1 mutants leads not only to improved clearance of apoptotic corpses but also to removal of cells subjected to sublethal (i.e., still viable) apoptotic, necrotic, or cytotoxic insults. Moreover, when engulfment is impaired, these damaged cells can escape clearance and survive long-term. Together, this supports that elevated CED-10 activity in the srgp-1 mutant background can drive engulfment-mediated killing of cells that remain viable. Other provided papers are irrelevant to the claim."
    },
    "overthinking_doc_ids": [
      "1127562",
      "7036529",
      "2686003",
      "10582939",
      "5002665"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.78,
      "justification": "Paper 1 shows that SRGP-1 is a GAP for CED-10 (Rac1) and acts in engulfing cells to negatively regulate cell clearance. Loss of srgp-1 (which would increase CED-10 activity) enhances engulfment not only of apoptotic corpses but also of cells subjected to sublethal insults ('brought to the verge of death'). Importantly, when engulfment is impaired, these damaged cells escape clearance and show increased long-term survival, implying that enhanced CED-10\u2013dependent engulfment in srgp-1 mutants removes (and thus kills) otherwise viable or salvageable cells. Other papers provided are unrelated to this claim."
    },
    "posthoc_doc_ids": [
      "1127562",
      "7036529",
      "7042304",
      "10648422",
      "34436231"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "935",
    "claim": "Peroxynitrite is required for induction of T cell tolerance.",
    "gold": "SUPPORT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.86,
      "justification": "Paper 1 shows that peroxynitrite produced by MDSCs can induce antigen-specific CD8+ T cell tolerance via nitration of the TCR\u2013CD8 complex in cancer, indicating involvement in that context. However, Paper 8 demonstrates that T cell anergy can be induced by Schistosoma mansoni via PD-L1 on macrophages through a mechanism explicitly independent of nitric oxide (and thus not dependent on peroxynitrite), showing that peroxynitrite is not universally required for T cell tolerance. Additionally, Paper 2 shows IL-10-mediated suppression of antigen-specific T cell responses via effects on APCs, further illustrating peroxynitrite-independent tolerance/suppression pathways. Therefore, the broad claim that peroxynitrite is required for induction of T cell tolerance is contradicted by evidence of peroxynitrite-independent tolerance mechanisms."
    },
    "naive_doc_ids": [
      "5483793",
      "8639034",
      "1196631",
      "15435343",
      "25726838"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.68,
      "justification": "Paper 1 reports that myeloid-derived suppressor cells induce antigen-specific CD8+ T-cell tolerance via nitration of the TCR\u2013CD8 complex, and that this nitration is induced through hyperproduction of reactive oxygen species and peroxynitrite during direct cell\u2013cell contact. This identifies peroxynitrite as a causal mediator in the induction of T-cell tolerance in this cancer model. The other papers do not address peroxynitrite in T-cell tolerance and neither contradict nor add to this point. While the claim is broad, the provided evidence supports it in the context examined."
    },
    "overthinking_doc_ids": [
      "5483793",
      "37182501",
      "1744097",
      "994800",
      "19510470"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.66,
      "justification": "Paper 1 shows that myeloid-derived suppressor cells induce antigen-specific CD8+ T-cell tolerance via peroxynitrite-driven nitration of the TCR\u2013CD8 complex, which disrupts pMHC binding and renders T cells unresponsive to specific peptide. This identifies peroxynitrite as a necessary mediator in this tolerance mechanism. The other papers do not address peroxynitrite in T cell tolerance. Thus, the provided evidence supports the claim in the MDSC-induced tumor context."
    },
    "posthoc_doc_ids": [
      "5483793",
      "26495128",
      "37182501",
      "26886351",
      "10993232"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1141",
    "claim": "Taking 400mg of \u03b1-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.",
    "gold": "CONTRADICT",
    "naive_label": "CONTRADICT",
    "naive_result": {
      "label": "CONTRADICT",
      "confidence": 0.87,
      "justification": "Paper 1 (Physicians' Health Study II), a large randomized, double-blind, placebo-controlled factorial trial in 14,641 men, tested vitamin E (400 IU every other day, commonly \u03b1-tocopheryl acetate) and vitamin C (500 mg daily). It found no reduction in prostate cancer incidence with vitamin E (HR 0.97, 95% CI 0.85\u20131.09) or vitamin C (HR 1.02, 95% CI 0.90\u20131.15), and concluded neither supplement reduced prostate or total cancer risk. While the claim specifies 400 mg \u03b1-tocopheryl acetate and combination use, this high-quality evidence directly refutes a protective effect of these supplements on prostate cancer risk. The other papers are unrelated to vitamin E/C and prostate cancer."
    },
    "naive_doc_ids": [
      "12009265",
      "20454006",
      "32423829",
      "1759213",
      "7639744"
    ],
    "overthinking_label": "CONTRADICT",
    "overthinking_result": {
      "label": "CONTRADICT",
      "confidence": 0.78,
      "justification": "Paper 1 (Physicians' Health Study II), a large randomized, double-blind, placebo-controlled factorial trial in 14,641 men, tested vitamin E (400 IU of \u03b1-tocopheryl acetate every other day) and vitamin C (500 mg daily) and found no reduction in prostate cancer risk (vitamin E HR 0.97, 95% CI 0.85\u20131.09; vitamin C HR 1.02, 95% CI 0.90\u20131.15). Although the claim specifies 400 mg and a combination, this trial used a similar form of vitamin E and included a combination arm within its factorial design; no benefit or interaction suggesting a reduction was reported. Papers 2\u20135 are not relevant to prostate cancer risk from vitamins E and C. Therefore, the provided evidence contradicts the claim."
    },
    "overthinking_doc_ids": [
      "12009265",
      "520579",
      "15648443",
      "3222187",
      "32421068"
    ],
    "posthoc_label": "CONTRADICT",
    "posthoc_result": {
      "label": "CONTRADICT",
      "confidence": 0.9,
      "justification": "Paper 1 (Physicians' Health Study II), a large randomized, double-blind, placebo-controlled trial in 14,641 men, tested vitamin E (400 IU \u03b1-tocopheryl acetate every other day) and vitamin C (500 mg/day). It found no reduction in prostate cancer incidence with vitamin E (HR 0.97, 95% CI 0.85\u20131.09) or vitamin C (HR 1.02, 0.90\u20131.15). In this factorial design there was no evidence that either supplement, alone or together, reduced prostate cancer risk. The other papers are not relevant to prostate cancer prevention with vitamins E and C."
    },
    "posthoc_doc_ids": [
      "12009265",
      "24396137",
      "39903312",
      "3222187",
      "32534305"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "154",
    "claim": "B3-Galectin increases cell resistance to tyrosine kinase inhibitors (TKIs) by engaging the alternate KRAS-RalB signaling complex downstream of EGFR.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.86,
      "justification": "None of the provided papers mention B3-Galectin (Galectin-3) or evaluate its effect on TKI resistance. Paper 4 shows that integrin \u03b1v\u03b23, not galectin, recruits KRAS and RalB to drive resistance to EGFR inhibition via TBK1/NF-\u03baB, which aligns with the KRAS\u2013RalB complex aspect but attributes it to integrin \u03b23. The other papers discuss different resistance mechanisms (PTEN/Akt, YAP/TAZ mechanotransduction, GNB1/2 mutations, PI3K/mTOR signaling, WNT\u2013EGFR transactivation) and do not provide data about galectins. Therefore, the specific claim about B3-Galectin cannot be verified with the given evidence."
    },
    "naive_doc_ids": [
      "40710501",
      "9929089",
      "1065627",
      "4702639",
      "33387953"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.72,
      "justification": "Among the provided papers, only Paper 1 shows that integrin \u03b1v\u03b23 recruits KRAS and RalB to drive TBK1/NF-\u03baB activation and resistance to EGFR TKIs, implicating an \u03b1v\u03b23\u2013KRAS\u2013RalB complex. None of the papers examine or mention Galectin-3 (or any 'B3-Galectin') as the factor increasing TKI resistance or engaging the KRAS\u2013RalB complex. The remaining papers address other resistance mechanisms (NF1 loss, PTEN loss, matrix stiffness/YAP-TAZ, clinical biomarkers) and do not involve galectins. Therefore, the specific claim about B3-Galectin cannot be verified with the provided evidence."
    },
    "overthinking_doc_ids": [
      "4702639",
      "9929089",
      "1065627",
      "21164071",
      "4688340"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.85,
      "justification": "Among the provided papers, only Paper 1 describes resistance to EGFR TKIs via an alternate KRAS\u2013RalB signaling complex, but this mechanism is driven by integrin \u03b1v\u03b23 (not galectin) leading to TBK1/NF-\u03baB activation. The other papers discuss distinct resistance mechanisms (e.g., NF1 loss, EGFR mutations like C797S, PTEN/PI3K/Akt pathway alterations, WNT/VEGF signaling). None of the papers provide data that B3-Galectin (Galectin-3) increases TKI resistance by engaging a KRAS\u2013RalB complex downstream of EGFR. Therefore, the specific claim about B3-Galectin is not supported or refuted by the provided evidence."
    },
    "posthoc_doc_ids": [
      "4702639",
      "2272614",
      "9505402",
      "17648235",
      "17844478"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.25,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "361",
    "claim": "During the primary early antibody response activated B cells migrate toward the inner-and outer follicular areas where oxysterol accumulation is generated by stromal cells.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.7,
      "justification": "The provided papers support that during early antibody responses, activated B cells are guided by EBI2 to inter/outer follicular or extrafollicular niches (Papers 1 and 2), and that EBI2\u2019s ligand is the oxysterol 7\u03b1,25-dihydroxycholesterol and its gradient regulates B cell migration (Paper 3). However, none of the excerpts explicitly state that oxysterol accumulation in the inner/outer follicular areas is generated by stromal cells. Thus, the specific claim about stromal cells producing the oxysterol gradient at those sites is not directly supported by the provided text."
    },
    "naive_doc_ids": [
      "15488881",
      "38587347",
      "15058155",
      "11020556",
      "35256900"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.65,
      "justification": "The provided papers support that activated B cells migrate to inter/outer follicular areas during early responses and that EBI2 guides this movement (Papers 2 and 7). They also identify the oxysterol 7\u03b1,25-dihydroxycholesterol as an EBI2 ligand and note that an in vivo gradient guides migration (Paper 3). However, none of the excerpts explicitly state that stromal cells generate the oxysterol accumulation/gradient in those follicular regions. Thus, the specific claim that stromal cells produce the oxysterol accumulation is not directly supported by the provided evidence."
    },
    "overthinking_doc_ids": [
      "11721286",
      "38587347",
      "15058155",
      "11020556",
      "35256900"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.62,
      "justification": "Paper 1 states that EBI2 guides activated B cells to inter- and outer-follicular niches during early T-dependent responses, not to inner follicular areas; in fact, EBI2 downregulation is required for organizing cells into germinal centers in the follicle center. Paper 4 identifies the oxysterol 7\u03b1,25-dihydroxycholesterol as the EBI2 ligand and notes that an in vivo gradient regulates B cell migration, but the abstracts provided do not explicitly state that stromal cells generate this oxysterol accumulation. Thus, the claim is contradicted on the location (inner vs inter/outer), and the stromal cell source of oxysterols is not supported by the provided abstracts."
    },
    "posthoc_doc_ids": [
      "38587347",
      "30369606",
      "7736860",
      "15058155",
      "7370282"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.55,
      "need_refinement": true,
      "refinement_triggered": true
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "19",
    "claim": "7-day-old adult Caenorhabditis elegans exhibit approximately 5% of the learning capacity seen in 1-day old adults.",
    "gold": "NOINFO",
    "naive_label": "NOINFO",
    "naive_result": {
      "label": "NOINFO",
      "confidence": 0.73,
      "justification": "Among the provided papers, only Paper 4 addresses learning and memory with age in C. elegans, but the excerpt contains no quantitative data or specific age-day comparisons. None of the excerpts report that 7\u2011day\u2011old adults retain ~5% of the learning capacity of 1\u2011day\u2011old adults, nor do they present comparable percentages or learning indices at those ages. The other papers focus on protein aggregation, neuronal morphology, and lifespan/endocrine signaling without quantifying learning capacity. Therefore, the specific 5% figure cannot be verified from the supplied evidence."
    },
    "naive_doc_ids": [
      "7042304",
      "13072113",
      "16267205",
      "3202143",
      "11414664"
    ],
    "overthinking_label": "NOINFO",
    "overthinking_result": {
      "label": "NOINFO",
      "confidence": 0.84,
      "justification": "Among the provided papers, only Paper 1 addresses learning/memory across age in C. elegans, but its summary does not report quantitative values comparing 7-day-old adults to 1-day-old adults (e.g., ~5%). Paper 6 discusses age-related neuronal morphology decline but provides no behavioral learning metrics. The remaining papers are unrelated to age-dependent learning capacity. Therefore, the specific claim that 7-day-old adults retain ~5% of 1-day-old adult learning capacity is not supported or refuted by the supplied evidence."
    },
    "overthinking_doc_ids": [
      "3202143",
      "7042304",
      "6333347",
      "17050065",
      "36558211"
    ],
    "posthoc_label": "NOINFO",
    "posthoc_result": {
      "label": "NOINFO",
      "confidence": 0.78,
      "justification": "Among the provided papers, only Paper 4 addresses learning and memory decline with age in C. elegans, but the excerpt provides no quantitative values comparing 7-day-old to 1-day-old adults, nor does it state an approximate 5% residual learning capacity. The other papers focus on neuronal morphology, apoptosis/engulfment, insulin signaling effects on lifespan and reproduction, polyglutamine toxicity, sex-specific aging, or human clinical studies, none of which quantify age-dependent learning capacity in C. elegans. Therefore, the specific claim (7-day adults at ~5% of day-1 learning) is not supported or refuted by the provided text."
    },
    "posthoc_doc_ids": [
      "13072113",
      "1127562",
      "1576955",
      "3202143",
      "602760"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.4,
      "need_refinement": true,
      "refinement_triggered": false
    }
  },
  {
    "model": "gpt-5",
    "claim_id": "1390",
    "claim": "mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.",
    "gold": "SUPPORT",
    "naive_label": "SUPPORT",
    "naive_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 1 explicitly states that the wobble modification mcm5s2U is required for proper decoding of NNR codons in eukaryotes and provides mechanistic rationale (2-thio group rigidifies U34 to ensure stable and accurate codon\u2013anticodon pairing). Paper 2 shows that tRNAs for Gln, Lys, and Glu, which decode A/G-ending codons (NNR), normally carry mcm5s2U; removing these modifications in yeast leads to lethality that can be rescued by overexpressing the unmodified tRNAs, indicating the modification is needed for efficient, proper decoding in vivo. Other papers are unrelated to the claim."
    },
    "naive_doc_ids": [
      "2890952",
      "34498325",
      "8126244",
      "365896",
      "1256116"
    ],
    "overthinking_label": "SUPPORT",
    "overthinking_result": {
      "label": "SUPPORT",
      "confidence": 0.95,
      "justification": "Paper 2 explicitly states that the wobble modification mcm5s2U is required for proper decoding of NNR (purine-ending) codons in eukaryotes and provides mechanistic evidence by identifying the genes necessary for 2-thiolation and reconstituting the reaction in vitro. Paper 1 shows that removing the mcm5 and s2 components from wobble U34 in eukaryotic tRNAs for Gln, Lys, and Glu (which decode A/G-ending codons) severely impairs decoding efficiency and is lethal unless compensated by overexpression of unmodified tRNAs, indicating the modification is critical for proper (efficient/accurate) decoding of these NNR codons. Papers 3 and 4 are unrelated to this claim."
    },
    "overthinking_doc_ids": [
      "34498325",
      "2890952",
      "236204",
      "4313478"
    ],
    "posthoc_label": "SUPPORT",
    "posthoc_result": {
      "label": "SUPPORT",
      "confidence": 0.9,
      "justification": "Paper 2 explicitly states that the wobble modification mcm5s2U is required for proper decoding of NNR (A/G-ending) codons in eukaryotes and provides mechanistic insights into the 2-thiouridine biogenesis pathway. Paper 1 shows that removal of both the mcm5 and s2 components from wobble U34 in tRNAs for Gln, Lys, and Glu (which decode NNR codons) is lethal in yeast and that the modification primarily improves efficiency of reading cognate A/G-ending codons, supporting the necessity of mcm5s2U for proper decoding. Other papers are unrelated."
    },
    "posthoc_doc_ids": [
      "34498325",
      "2890952",
      "4313478",
      "16927286",
      "24974080"
    ],
    "posthoc_metadata": {
      "initial_confidence": 0.65,
      "need_refinement": true,
      "refinement_triggered": true
    }
  }
]